,assay_id,doi,year,volume,issue,assay_description,compound_smiles,compound_name,value,unit,relation,log_value,classification_label,scaffold_smiles
0,1366626,10.1021/jm500535j,,,,Inhibition of human ERG,Nc1nc2ccc(OC3CCOC3)nc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl,"rac-2-(2-Amino-5-((tetrahydrofuran-3-yl)oxy)-3H-imidazo[4,5-b]-pyridin-3-yl)-1-(2-chloro-4-(trifluoromethyl)phenyl)ethanol",16.6,uM,=,1.2201080880400552,1,c1ccc(CCn2cnc3ccc(OC4CCOC4)nc32)cc1
1,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(C(O)CC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(+)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-2-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.3,uM,=,0.1139433523068367,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2,1924512,10.1021/acsmedchemlett.6b00122,,,,Displacement of [35S]MK-499 from human ERG,Cc1c(CCN2CCN(CC(O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,"US9018211, 12",5.2,uM,=,0.7160033436347992,1,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21
3,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,CCOC(=O)c1cncc([C@@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)c1,"Ethyl5-((1S,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)nicotinate",2.52,uM,=,0.4014005407815441,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cccnc4)(c4cn[nH]c4)N3)n2)cc1
4,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=c1c2ccccc2nc(-c2ccc(OCCCN3CCCCC3)cc2)n1Cc1ccccc1,3-benzyl-2-(4-(3-(piperidin-1-yl)propoxy)phenyl)quinazolin-4(3H)-one,0.17,uM,=,-0.7695510786217261,0,O=c1c2ccccc2nc(-c2ccc(OCCCN3CCCCC3)cc2)n1Cc1ccccc1
5,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3cccnc3cc2OC)[nH]1,(S)-N-((S)-1-(5-(7-methoxyquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,51.0,uM,=,1.7075701760979365,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)[nH]1)[C@H]1CC12CCNCC2
6,2112211,10.1016/j.bmcl.2021.127909,,,,Inhibition of human ERG by automated patch method relative to control,Fc1ccc2c(C3CCN(CCCOc4ccc(CCN5CCCCC5)cc4)CC3)noc2c1,6-fluoro-3-(1-(4-(4-(3-(piperidin-1-yl)propyl)phenoxy)butyl)piperidin-4-yl)benzo[d]isoxazole,2.2902,uM,=,0.3598734103327424,1,c1ccc2c(C3CCN(CCCOc4ccc(CCN5CCCCC5)cc4)CC3)noc2c1
7,1853420,10.1016/j.ejmech.2019.06.037,,,,Inhibition of human ERG,O=C1OCCN1CCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,"N-(3-Bromo-4-fluorophenyl)-N'-hydroxy-4-((2-(2-oxooxazolidin-3yl)ethyl)amino)-1,2,5-oxadiazole-3-carboximidamide",31.12,uM,=,1.4930395883176513,1,N=C(Nc1ccccc1)c1nonc1NCCN1CCOC1=O
8,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCOC(=O)[C@H]1CC[C@@H](N2CC(NC(=O)CNc3nn(C4CCCC4)c4ccc(C(F)(F)F)cc34)C2)CC1,cis-ethyl 4-(3-(2-(1-cyclopentyl-5-(trifluoromethyl)-1H-indazol-3-ylamino)acetamido)azetidin-1-yl)cyclohexanecarboxylate,4.1,uM,=,0.6127838567197355,1,O=C(CNc1nn(C2CCCC2)c2ccccc12)NC1CN(C2CCCCC2)C1
9,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CSc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-5-(2,2,2-trifluoroethyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4(5H)-one",4.75,uM,=,0.6766936096248666,1,O=C1Nc2ccccc2SCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
10,969290,10.1016/j.bmcl.2013.05.068,,,,Inhibition of human ERG transfected in CHO cells by patch clamp assay,Cc1cc(N2CC[C@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C,"5-fluoro-2-methyl-N-(2-methyl-4-((2S,3'S)-2-methyl-1,3'-bipyrrolidin-1'-yl)phenyl)benzamide",1.1,uM,=,0.041392685158225,1,O=C(Nc1ccc(N2CC[C@H](N3CCCC3)C2)cc1)c1ccccc1
11,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,COc1nc2ccc(CO)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,4-(dimethylamino)-1-(6-(hydroxymethyl)-2-methoxyquinolin-3-yl)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol,10.0,uM,=,1.0,1,c1ccc(C(Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
12,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc(C(CC(=O)N(C)C)C(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)cc1,"2-(4-ethylsulfonylphenyl)-N',N'-dimethyl-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]butanediamide",8.0,uM,=,0.9030899869919436,1,O=C(Cc1ccccc1)Nc1ccccc1
13,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CC4(CCOC4)C3)cc2)C1,"US8685958, 7::US8685958, 8",16.0,uM,=,1.2041199826559248,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CC4(CCOC4)C3)cc2)C1
14,1881829,10.1016/j.ejmech.2018.09.067,,,,Displacement of [3H]-Dofetilide from recombinant human ERG after 60 mins by scintillation counting analysis,O=C(NNC(=S)Nc1ccc(Cl)c(Cl)c1)c1ccccc1O,"4-(3,4-Dichlorophenyl)-1-(2-hydroxybenzoyl)-3-thiosemicarbazide",0.08,uM,=,-1.0969100130080565,0,O=C(NNC(=S)Nc1ccccc1)c1ccccc1
15,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,Cc1noc(-c2ccc(CCN3CC[C@@H](Nc4nc5ccccc5n4Cc4ccc(C#N)cc4)C3)cc2)n1,"(R)-4-((2-(1-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenethyl)pyrrolidin-3-ylamino)-1H-benzo[d]imidazol-1-yl)methyl)benzonitrile",0.13,uM,=,-0.8860566476931633,0,c1ccc(Cn2c(N[C@@H]3CCN(CCc4ccc(-c5ncno5)cc4)C3)nc3ccccc32)cc1
16,2234939,10.1021/acs.jmedchem.2c00608,,,,Inhibition of human ERG potassium channel by manual patch-clamp electrophysiology,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.0312,uM,=,-1.5058454059815571,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
17,2130441,10.1021/acs.jmedchem.1c00904,,,,Inhibition of human ERG,COc1nc(C2=NOC(C3CC3)C(c3ccc(Cl)cc3)N2)ccc1-n1cnc(C)c1,"5-(4-chlorophenyl)-6-cyclopropyl-3-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-5,6-dihydro-4H-1,2,4-oxadiazine",12.0,uM,=,1.0791812460476249,1,c1ccc(C2NC(c3ccc(-n4ccnc4)cn3)=NOC2C2CC2)cc1
18,948139,10.1016/j.bmcl.2013.01.019,,,,Inhibition of human ERG,COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@@H](C)O[C@@H](C)C4)nc3n2)cc1CNCCO,"2-(5-(2-((2R,6S)-2,6-dimethylmorpholino)-4-morpholinopyrido[2,3-d]pyrimidin-7-yl)-2-methoxybenzylamino)ethanol",27.5,uM,=,1.4393326938302626,1,c1ccc(-c2ccc3c(N4CCOCC4)nc(N4CCOCC4)nc3n2)cc1
19,541583,10.1021/jm801236n,,,,Inhibition of wild-type human ERG expressed in HEK293 cells by whole cell patch clamp method,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1.Cl.Cl,N-(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide dihydrochloride,0.02,uM,=,-1.6989700043360187,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
20,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C1CN(C(=O)COc2ccc3cc(Oc4ccc(C(F)(F)F)cn4)ccc3n2)CCN1,4-[2-[[6-[[5-(trifluoromethyl)-2-pyridyl]oxy]-2-quinolyl]oxy]acetyl]piperazin-2-one,30.0,uM,=,1.4771212547196624,1,O=C1CN(C(=O)COc2ccc3cc(Oc4ccccn4)ccc3n2)CCN1
21,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,FC(F)(F)Oc1ccccc1CC(c1ccccc1)N1CCNCC1,1-(1-phenyl-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine,10.9,uM,=,1.0374264979406236,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
22,820353,10.1021/jm300138g,,,,Displacement of [3H]astemizole from human Erg expressed in HEK293 cells after 75 mins,CCN[C@H]1CC[C@@H](c2c[nH]c3ccc(NC(=N)c4cccs4)cc32)CC1.Cl,cis-N-(3-(4-(ethylamino)cyclohexyl)-1H-indol-5-yl)thiophene-2-carboximidamide hydrochloride,23.0,uM,=,1.3617278360175928,1,N=C(Nc1ccc2[nH]cc(C3CCCCC3)c2c1)c1cccs1
23,755452,10.1016/j.bmcl.2010.05.026,,,,Inhibition of human hERG,COC1CN(c2nnc(C)c3c(C)n(-c4ccc(Cl)cc4OC(F)(F)F)nc23)C1,"2-(4-chloro-2-(trifluoromethoxy)phenyl)-7-(3-methoxyazetidin-1-yl)-3,4-dimethyl-2H-pyrazolo[4,3-d]pyridazine",4.0,uM,=,0.6020599913279624,1,c1ccc(-n2cc3cnnc(N4CCC4)c3n2)cc1
24,2241386,10.1016/j.ejmech.2021.113981,,,,Inhibition of hERG channel expressed in CHO cells at holding potential of -80 mV by whole cell patch clamp method,COC[C@H](Cc1ccccc1)NC[C@@H](O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12,"(S)-1-(2,8-Bis(trifluoromethyl)quinolin-4-yl)-2-(((S)-1-methoxy-3-phenylpropan-2-yl)amino)ethan-1-ol",17.3,uM,=,1.2380461031287957,1,c1ccc(CCNCCc2ccnc3ccccc23)cc1
25,1973140,10.1021/acs.jmedchem.0c00245,,,,Inhibition of human ERG,Cc1cc(Cl)cc(-c2ccnc3cc(CN4C(=O)C5C(C4=O)C5(C)C)sc23)c1C[C@@H]1CNCCO1,"3-((7-(5-Chloro-3-methyl-2-(((R)-morpholin-2-yl)methyl)phenyl)thieno[3,2-b]pyridin-2-yl)methyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione",4.2,uM,=,0.6232492903979004,1,O=C1C2CC2C(=O)N1Cc1cc2nccc(-c3ccccc3C[C@@H]3CNCCO3)c2s1
26,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,COCCOc1cc(NC(=O)N2CCCc3cc(CN(CCN(C)C)S(C)(=O)=O)c(C=O)nc32)ncc1C#N,"N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-6-((N-(2-(dimethylamino)ethyl)methylsulfonamido)methyl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide",20.0,uM,=,1.3010299956639813,1,O=C(Nc1ccccn1)N1CCCc2cccnc21
27,1802839,10.1016/j.ejmech.2018.08.020,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current at -80 holding potential after 100 to 200 secs by whole cell automated patch-clamp electrophysiology assay,O=C1S/C(=C\c2ccc(Oc3ccc([N+](=O)[O-])cc3)cc2)C(=O)N1c1ccc(OCCCCN2CCN(CC3CC3)CC2)cc1,"(Z)-3-(4-(4-(4-(Cyclopropylmethyl)piperazin-1-yl)butoxy)phenyl)-5-(4-(4-nitrophenoxy)benzylidene)thiazolidine-2,4-dione",55.3,uM,=,1.7427251313046983,1,O=C1S/C(=C\c2ccc(Oc3ccccc3)cc2)C(=O)N1c1ccc(OCCCCN2CCN(CC3CC3)CC2)cc1
28,1783529,10.1016/j.ejmech.2017.12.075,,,,Inhibition of human ERG by [3H]dofetilide binding displacement assay,Cc1c(CN2CCOCC2)cc(-c2ccc(C(C)C)cc2)n1CC(C)C,4-((1-Isobutyl-5-(4-isopropylphenyl)-2-methyl-1H-pyrrol-3-yl)methyl)morpholine,16.0,uM,=,1.2041199826559248,1,c1ccc(-c2cc(CN3CCOCC3)c[nH]2)cc1
29,2163947,10.1021/acs.jmedchem.1c01564,,,,Inhibition of human ERG by [3H]]Astemizole binding assay,NCCCCN(C[C@H]1Cc2cccnc2CN1)[C@H]1CCCc2cccnc21,"N1-(((R)-5,6,7,8-tetrahydro-1,7-naphthyridin-6-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",5.4,uM,=,0.7323937598229685,1,c1cnc2c(c1)C[C@H](CN[C@H]1CCCc3cccnc31)NC2
30,938758,10.1016/j.bmcl.2013.01.033,,,,Inhibition of human hERG by automated patch clamp assay,N#CC=C1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1,"(R)-2-(1-(4-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperidin-4-ylidene)acetonitrile",49.5,uM,=,1.6946051989335686,1,C=C1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2)CC1
31,445439,10.1021/jm0705408,,,,Inhibition of hERG,CN(C(=O)CC[C@@H](C1CCCCC1)N1Cc2cc(Oc3ccccc3)ccc2N=C1N)C1CCCCC1,"4-(2-amino-6-phenoxy-4H-quinazolin-3-yl)-4-(S)-,N-dicyclohexyl-N-methylbutyramide",0.14,uM,=,-0.8538719643217619,0,O=C(CC[C@@H](C1CCCCC1)N1C=Nc2ccc(Oc3ccccc3)cc2C1)NC1CCCCC1
32,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2cc(F)c(Cl)cc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-chloro-6-fluoro-4-oxo-4H-chromene-2-carboxamide",0.0105,uM,=,-1.978810700930062,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
33,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,NCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-(2-aminoethoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",17.5,uM,=,1.2430380486862944,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
34,2100973,10.1021/acs.jmedchem.1c00375,,,,Displacement of [3H]-dofetilide from human ERG after 60 mins by scintillation counting method,Cc1c(N2CCC(C3(N)CC3)C2)c(F)cc2c(-c3noc(=S)[nH]3)cc(=O)n(C3CC3)c12,"7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)quinolin-2(1H)-one",18.0,uM,=,1.255272505103306,1,O=c1cc(-c2noc(=S)[nH]2)c2ccc(N3CCC(C4CC4)C3)cc2n1C1CC1
35,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,N#Cc1cncc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)c1,"5-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridin-6-yl)nicotinonitrile",1.235955056,uM,=,0.0920026784501421,1,c1cncc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)c1
36,675212,10.1016/j.bmcl.2010.09.016,,,,Inhibition of human ERG channel,O=C(NO)c1cnc(N2C[C@H]3CN(Cc4ccc5ccccc5c4)C[C@H]3C2)nc1,"N-hydroxy-2-((3aR,6aS)-5-(naphthalen-2-ylmethyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidine-5-carboxamide",4.1,uM,=,0.6127838567197355,1,c1cnc(N2C[C@H]3CN(Cc4ccc5ccccc5c4)C[C@H]3C2)nc1
37,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,Cc1cc(Nc2nccc(-c3sc(C4CCNCC4)nc3C3CC3)n2)ccn1,4-(4-Cyclopropyl-2-(piperidin-4-yl)thiazol-5-yl)-N-(2-methylpyridin-4-yl)pyrimidin-2-amine,4.2,uM,=,0.6232492903979004,1,c1cc(Nc2nccc(-c3sc(C4CCNCC4)nc3C3CC3)n2)ccn1
38,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,COc1ccc(/C=C/CN(C)Cc2ccc3c(c2)OCCC3)c(F)c1.Cl,(E)-N-(Chroman-7-methyl)-N-methyl-3-(2-fluoro-4-methoxylphenyl)prop-2-en-1amine Hydrochloride,3.1,uM,=,0.4913616938342727,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)OCCC2
39,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,COc1cnc2c(c1)CN(C(=O)[C@@]13CCC[C@@H]1C[C@@H](NC1CCOCC1OC)C3)CC2,"(3-methoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)((2R,3aR,6aR)-2-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)methanone",46.6,uM,=,1.66838591669,1,O=C(N1CCc2ncccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
40,793275,10.1016/j.bmcl.2011.09.117,,,,Displacement of [3H]dofetilide from human ERG by liquid scintillation counting,COc1ccc2ncc(F)c(CCN3CC[C@@H](NCc4cc5c(cn4)OCCO5)[C@H](O)C3)c2n1,"(3R,4R)-4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)piperidin-3-ol",29.5,uM,=,1.469822015978163,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
41,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)nn2)ccc1-n1cnc(C)c1,"1-(3,5-bis(trifluoromethyl)benzyl)-4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazole",0.39,uM,=,-0.4089353929735008,0,c1ccc(Cn2cc(-c3ccc(-n4ccnc4)cc3)nn2)cc1
42,2203568,10.1016/j.bmcl.2022.128824,,,,Inhibition of human ERG,CNCC[C@@](O)(c1cccc2ccccc12)[C@H](c1ccccc1)c1ccc(-c2ccc(Cl)cc2)nc1OC,"(1R,2S)-1-(6-(4-chlorophenyl)-2-methoxypyridin-3-yl)-4-(methylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol",1.89,uM,=,0.2764618041732441,1,c1ccc(-c2ccc([C@H](Cc3cccc4ccccc34)c3ccccc3)cn2)cc1
43,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1ccc(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)cn1,(R)-2-(6-methylpyridin-3-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,26.4,uM,=,1.421603926869831,1,c1cncc(-c2ccc3cc(CCN4CCCC4)ccc3n2)c1
44,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,Cc1c(OCF)ccc2c1C(=O)N(Cc1ccccc1-c1ccccc1)C2C(=O)NC(C)(C)C,(rac)-2-(biphenyl-2-ylmethyl)-N-tert-butyl-5-(fluoromethoxy)-4-methyl-3-oxoisoindoline-1-carboxamide,27.0,uM,=,1.4313637641589874,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
45,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H]3CNC[C@H]3O2)cc1,"(4aR,7aS)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-4,4a,5,6,7,7a-hexahydropyrrolo[3,4-e][1,3]oxazine",5.1,uM,=,0.7075701760979364,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H]3CNC[C@H]3O2)cc1
46,612186,10.1016/j.bmcl.2009.12.071,,,,Inhibition of human ERG by patch clamp study,CCN1C[C@H]2C[C@@H](N(Cc3ccc(F)c(C(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1,(exo)-N-(2-ethyloctahydrocyclopenta[c]pyrrol-5-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide,1.54,uM,=,0.1875207208364631,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)[C@H]1C[C@H]2CNC[C@H]2C1
47,804235,10.1016/j.bmcl.2011.12.032,,,,Inhibition of human ERG,O=C(N1CCCCC1)N1CC(O[C@@H](c2ccc(Cl)cc2)c2cccnc2Cl)C1,(S)-{3-[(4-Chlorophenyl)-(2-chloropyridin-3-yl)methoxy]azetidin-1-yl}piperidin-1-ylmethanone,30.8,uM,=,1.4885507165004443,1,O=C(N1CCCCC1)N1CC(O[C@@H](c2ccccc2)c2cccnc2)C1
48,420606,10.1016/j.bmcl.2006.11.061,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C1COc2cc3c(cc2N1)C(N1CCC(NC(=O)c2cc(=O)c4ccc(F)cc4o2)CC1)CC3,"7-fluoro-4-oxo-N-(1-(3-oxo-2,3,4,6,7,8-hexahydroindeno[5,6-b][1,4]oxazin-6-yl)piperidin-4-yl)-4H-chromene-2-carboxamide",14.6,uM,=,1.1643528557844371,1,O=C1COc2cc3c(cc2N1)C(N1CCC(NC(=O)c2cc(=O)c4ccccc4o2)CC1)CC3
49,820353,10.1021/jm300138g,,,,Displacement of [3H]astemizole from human Erg expressed in HEK293 cells after 75 mins,CN[C@H]1CC[C@@H](c2c[nH]c3ccc(NC(=N)c4cccs4)cc32)CC1.Cl,cis-N-(3-(4-(methylamino)cyclohexyl)-1H-indol-5-yl)thiophene-2-carboximidamide hydrochloride,39.0,uM,=,1.591064607026499,1,N=C(Nc1ccc2[nH]cc(C3CCCCC3)c2c1)c1cccs1
50,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3nc(C(F)(F)F)cs3)CC2)(C(C)C)C1,"cis-((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxytetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(4-(trifluoromethyl)thiazol-2-yl)piperazin-1-yl)methanone",3900.0,uM,=,3.591064607026499,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2nccs2)CC1
51,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,CN1CCN(C(=O)c2ccc3cc(Oc4ccccn4)ccc3n2)CC1,"US9452986, 77",16.8,uM,=,1.2253092817258628,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
52,1805877,10.1021/acs.jmedchem.9b00335,,,,Inhibition of human ERG expressed in CHOK1 cells by Q-patch electrophysiology method,Cc1ccc(-c2cc(S(C)(=O)=O)cc(S(=O)(=O)c3ccc(CN)s3)c2)cc1,"(5-((4'-Methyl-5-(methylsulfonyl)-[1,1'-biphenyl]-3-yl)sulfonyl)thiophen-2-yl)methanamine",4.6,uM,=,0.6627578316815741,1,O=S(=O)(c1cccc(-c2ccccc2)c1)c1cccs1
53,1783291,10.1016/j.ejmech.2017.12.099,,,,Inhibition of human ERG by auomated patch clamp assay,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,"7-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-quinolin-2-one",3.86,uM,=,0.5865873046717549,1,O=C1CCc2ccc(OCCCCN3CCN(c4ccccc4)CC3)cc2N1
54,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,COc1ccc2c(ccc(=O)n2CCN2CCC(NCc3cnc(C)c(C#N)c3)CC2)n1,"5-((1-(2-(6-Methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)-piperidin-4-ylamino)methyl)-2-methylnicotinonitrile",10.0,uM,=,1.0,1,O=c1ccc2ncccc2n1CCN1CCC(NCc2cccnc2)CC1
55,1446841,10.1021/jm500715u,,,,Inhibition of human ERG,Cc1ccc(Nc2nc3ccc(N4CCN(C)CC4)cc3[nH]2)nc1,6-(4-Methylpiperazin-1-yl)-N-(5-methylpyridin-2-yl)-1H-benzo[d]-imidazol-2-amine,12.7,uM,=,1.1038037209559568,1,c1ccc(Nc2nc3ccc(N4CCNCC4)cc3[nH]2)nc1
56,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cnc(-c2cnc(N)c(O[C@H]3CN(C(=O)Cc4ccc(OC(F)(F)F)cc4)CC3(F)F)c2)c1,"(S)-1-(4-((2-Amino-5-(1-methyl-1H-imidazol-4-yl)pyridin-3-yl)oxy)-3,3-difluoropyrrolidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)ethan-1-one",11.0,uM,=,1.0413926851582251,1,O=C(Cc1ccccc1)N1CC[C@@H](Oc2cncc(-c3c[nH]cn3)c2)C1
57,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)C1CCN(Cc2ccc(C(F)(F)F)cn2)CC1,2-(4-(1H-tetrazol-1-yl)phenyl)-N-methyl-N-(1-((5-(trifluoromethyl)pyridin-2-yl)methyl)piperidin-4-yl)acetamide,4.2,uM,=,0.6232492903979004,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2ccccn2)CC1
58,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C)cc(NC(=O)c2cncc(-c3cc(C)cc(C)c3)c2N2CCC(N)CC2)c1,"4-(4-aminopiperidin-1-yl)-N,5-bis(3,5-dimethylphenyl)nicotinamide",0.8,uM,=,-0.0969100130080563,0,O=C(Nc1ccccc1)c1cncc(-c2ccccc2)c1N1CCCCC1
59,2232935,10.1016/j.bmcl.2022.128666,,,,Inhibition of hERG,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1ccc2c(c1)OC1(CCOCC1)NC2=O,"N-(4-Methyl-3-(4-oxo-2',3,3',4,5',6'-hexahydrospiro[benzo[e][1,3]oxazine-2,4'-pyran]-7-yl)phenyl)-2-(trifluoromethyl)isonicotinamide",5.9,uM,=,0.7708520116421442,1,O=C(Nc1cccc(-c2ccc3c(c2)OC2(CCOCC2)NC3=O)c1)c1ccncc1
60,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COc1cccc(CN2CCC(C#N)(CNC(=O)c3cc(CC(C)C)n(-c4ccccc4)n3)CC2)c1,N-((4-cyano-1-(3-methoxybenzyl)piperidin-4-yl)methyl)-5-isobutyl-1-phenyl-1H-pyrazole-3-carboxamide,1.5,uM,=,0.1760912590556812,1,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccn(-c2ccccc2)n1
61,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,OCCN1CC[C@@]2(CN=C(N3CCc4ccccc4[C@@H]3c3ccc(F)cc3)O2)C1,"2-[(5S)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-1-oxa-3,7-diazaspiro[4.4]non-2-en-7-yl]ethanol",4.4,uM,=,0.6434526764861874,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@]3(CCNC3)O2)cc1
62,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N3C[C@H](O)C[C@@H]3Cc3ccc(Cl)cc3)CC2)n1,"(3R,5S)-1-(1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)-5-(4-chlorobenzyl)pyrrolidin-3-ol",55.0,uM,=,1.740362689494244,1,c1ccc(C[C@H]2CCCN2C2CCN(c3ncn[nH]3)CC2)cc1
63,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,NC(=O)c1cnc(N[C@H]2CCCNC2)c2cc(-c3cccc(F)c3)sc12,"2-(3-Fluorophenyl)-4-[(3S)-piperidin-3-ylamino]thieno[3,2-c]pyridine-7-carboxamide",14.2,uM,=,1.1522883443830565,1,c1ccc(-c2cc3c(N[C@H]4CCCNC4)nccc3s2)cc1
64,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,CN(C)CCC1=C(Cc2cnccn2)c2ccc(Cl)cc2C1,"2-(6-chloro-3-(pyrazin-2-ylmethyl)-1H-inden-2-yl)-N,N-dimethylethanamine",0.11,uM,=,-0.958607314841775,0,C1=C(Cc2cnccn2)c2ccccc2C1
65,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,CN1CCC(c2nc(-c3ccc(F)cc3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1,4-(4-(4-fluorophenyl)-2-(1-methylpiperidin-4-yl)thiazol-5-yl)-N-(4-(piperazin-1-yl)phenyl)pyrimidin-2-amine,28.2,uM,=,1.4502491083193612,1,c1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
66,728505,10.1016/j.bmcl.2011.01.113,,,,Inhibition of human ERG by patch clamp assay,Cc1c(C(=O)Nc2ccn(C)n2)ncn1Cc1cccc(C(F)(F)F)c1,5-methyl-N-(1-methyl-1H-pyrazol-3-yl)-1-(3-(trifluoromethyl)benzyl)-1H-imidazole-4-carboxamide,28.9,uM,=,1.4608978427565478,1,O=C(Nc1cc[nH]n1)c1cn(Cc2ccccc2)cn1
67,471260,10.1016/j.bmc.2007.12.045,,,,Inhibition of human ERG channel,COC1OC2(CCN(Cc3ccccc3)CC2)c2cnn(-c3ccccc3)c21,"1'-benzyl-3-methoxy-4-phenyl-3,4-dihydrospiro[furo[3,4-c]pyrazole-1,4'-piperidine]",0.00041,uM,=,-3.3872161432802645,0,c1ccc(CN2CCC3(CC2)OCc2c3cnn2-c2ccccc2)cc1
68,2112211,10.1016/j.bmcl.2021.127909,,,,Inhibition of human ERG by automated patch method relative to control,Fc1ccc2c(C3CCN(CCCOc4ccc(CCN5CCOCC5)cc4)CC3)noc2c1,6-fluoro-3-(1-(3-(4-(2-morpholinoethyl)phenoxy)propyl)piperidin-4-yl)benzo[d]isoxazole,2.4101,uM,=,0.3820350627189303,1,c1ccc2c(C3CCN(CCCOc4ccc(CCN5CCOCC5)cc4)CC3)noc2c1
69,2048818,10.1016/j.bmc.2020.115776,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,CNc1cc(F)cc2cc(C(=O)Nc3ccc(CO)cc3CN(CCO)C3CCCCC3)c(=O)[nH]c12,N-[2-[[cyclohexyl(2-hydroxyethyl)amino]methyl]-4-(hydroxymethyl)phenyl]-6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carboxamide,2.39,uM,=,0.3783979009481377,1,O=C(Nc1ccccc1CNC1CCCCC1)c1cc2ccccc2[nH]c1=O
70,633190,10.1021/jm100262j,,,,Inhibition of human ERG,Cc1cc(CN2CCN(c3c(Cl)cnc4[nH]c(N5CCN(C)CC5)nc34)CC2)no1,"3-((4-(6-Chloro-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole",2.3,uM,=,0.3617278360175928,1,c1cc(N2CCN(Cc3ccon3)CC2)c2nc(N3CCNCC3)[nH]c2n1
71,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,COC[C@H](N)CNc1cnc(C(N)=O)c(Nc2cc(C)cc(C)n2)c1,"(R)-5-((2-amino-3-methoxypropyl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide",1.6,uM,=,0.2041199826559248,1,c1ccc(Nc2cccnc2)nc1
72,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,"8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine",3.2,uM,=,0.505149978319906,1,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2
73,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3nccnc3C)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1,"2-Methyl-4'-[1-(3-methyl-pyrazin-2-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",7.8,uM,=,0.8920946026904804,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1cnccn1
74,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,CN1CC=CC[C@H](c2ccc(Cl)c(Cl)c2)C1,"(R)-3-(3,4-dichlorophenyl)-1-methyl-2,3,4,7-tetrahydro-1H-azepine",10.0,uM,=,1.0,1,C1=CC[C@H](c2ccccc2)CNC1
75,1463730,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"6-((1-((3-fluoro-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",30.0,uM,=,1.4771212547196624,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
76,877362,10.1021/jm301048a,,,,Inhibition of human ERG expressed in CHO cells by whole cell voltage clamp assay,O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc2ccccc2o1,"N-((2S,3R)-2-(pyridin-3-ylmethyl)quinuclidin-3-yl)benzofuran-2-carboxamide",54.0,uM,=,1.7323937598229686,1,O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc2ccccc2o1
77,345010,10.1016/j.bmcl.2005.12.094,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CN(C)C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1cccc(O)c1,"(S)-4-(2,5-difluorophenyl)-2-(3-hydroxyphenyl)-N,N-dimethyl-2H-pyrrole-1(5H)-carboxamide",33.0,uM,=,1.5185139398778875,1,C1=C(c2ccccc2)CN[C@@H]1c1ccccc1
78,1926979,10.1021/acsmedchemlett.6b00119,,,,Displacement of [3H]dofetilide from recombinant human ERG transfected in HEK293 cell membranes after 60 mins by scintillation counting,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cc1OC,"(3-(6-(3,4-dimethoxyphenyl)quinazolin-4-yl)phenyl)(4-methylpiperazin-1-yl)methanone",1.9,uM,=,0.2787536009528289,1,O=C(c1cccc(-c2ncnc3ccc(-c4ccccc4)cc23)c1)N1CCNCC1
79,2246303,10.1021/acs.jmedchem.1c01670,,,,Inhibition of MK-499 binding to hERG,O=C(Nc1ccc(F)cc1)C1(c2ccc(-c3cnc(C(F)(F)F)cc3CO)cc2)CCC1,N-(4-Fluorophenyl)-1-(4-(4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-3-yl)phenyl)cyclobutane-1-carboxamide,11910.0,uM,=,4.075911761482778,1,O=C(Nc1ccccc1)C1(c2ccc(-c3cccnc3)cc2)CCC1
80,1871838,10.1016/j.bmcl.2018.12.015,,,,Inhibition of human ERG,COC(C)(C)CC#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1,"(S)-3,4-dichloro-2-(4-methoxy-4-methylpent-1-ynyl)-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",0.004,uM,=,-2.397940008672037,0,c1cnc2c(c1)ccn2[C@H]1CCCNC1
81,1361026,10.1021/jm401895u,,,,Inhibition of human cloned ERG expressed in CHO cells assessed as inhibition of potassium channel current by automated patch clamp assay,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,1-(2-{4-[5-Chloro-1-(4-fluoro-phenyl)-1H-indol-3-yl]-piperidin-1-yl}-ethyl)-imidazolidin-2-one,0.0027,uM,=,-2.5686362358410126,0,O=C1NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccccc23)CC1
82,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(CCOCC#Cc2cccc(C#CCOCCc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis(3-(4-methylphenethoxy)prop-1-ynyl)pyridinium",14.426,uM,=,1.1591459278540472,1,C(#Cc1cccc(C#CCOCCc2ccccc2)[nH+]1)COCCc1ccccc1
83,1435893,10.1016/j.bmc.2014.10.020,,,,Inhibition of human ERG expressed in CHO cells by Rb efflux assay,COc1cc(CN2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc(OC)c1OC,"1-(6,6-bis(4-fluorophenyl)hexyl)-4-(3,4,5-trimethoxybenzyl)piperazine",3.4,uM,=,0.5314789170422551,1,c1ccc(CN2CCN(CCCCCC(c3ccccc3)c3ccccc3)CC2)cc1
84,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,c1ccc(-c2ccc(-c3c[nH]c([C@H]4Cc5c([nH]c6ccccc56)[C@@H](C5CCOCC5)N4)n3)cc2)cc1,"(1R,3R)-3-(4-(biphenyl-4-yl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.017,uM,=,-1.769551078621726,0,c1ccc(-c2ccc(-c3c[nH]c([C@H]4Cc5c([nH]c6ccccc56)[C@@H](C5CCOCC5)N4)n3)cc2)cc1
85,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,COC(=O)c1ccc2c(c1)nc(NC1CCN(CCc3ccc(-c4nc(C)no4)cc3)CC1)n2C,"methyl 1-methyl-2-(1-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenethyl)piperidin-4-ylamino)-1H-benzo[d]imidazole-5-carboxylate",0.49,uM,=,-0.3098039199714864,0,c1ccc2[nH]c(NC3CCN(CCc4ccc(-c5ncno5)cc4)CC3)nc2c1
86,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,Clc1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2,"8-Chloro-11-piperazin-1-yl-5H-dibenzo[b,e][1,4]diazepine",4.49,uM,=,0.6522463410033232,1,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2
87,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC(F)F)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(6-(difluoromethoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.7,uM,=,-0.1549019599857432,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
88,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,COc1ccc(CN(C)C)c(Oc2ccc(Cl)c(Cl)c2)c1,"1-(2-(3,4-dichlorophenoxy)-4-methoxyphenyl)-N,N-dimethylmethanamine",0.234,uM,=,-0.6307841425898572,0,c1ccc(Oc2ccccc2)cc1
89,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,CCOc1ccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,cis-N-({1-[4-(6-Ethoxy-pyridin-3-yl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,14.5,uM,=,1.1613680022349748,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccnc3)CC2)C1
90,1679756,10.1016/j.bmcl.2017.03.086,,,,Inhibition of human ERG by Qpatch electrophysiology method,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(S(C)(=O)=O)cn2)C3)ccc2c1COC2=O,"(R)-5-(1-hydroxy-2-(2-(5-(methylsulfonyl)pyridin-2-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",11.7,uM,=,1.0681858617461617,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccccn3)C4)ccc21
91,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2cncc(C#N)c2)C3)ccc2c1COC2=O,"(R)-5-(8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-2-yl)nicotinonitrile",2.4,uM,=,0.380211241711606,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cccnc3)C4)ccc21
92,1665706,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by flux assay,NS(=O)(=O)c1ncccc1-c1nc(NCc2ccccn2)c2c(-c3ccccc3)cccc2n1,3-(5-phenyl-4-((pyridin-2-ylmethyl)amino)quinazolin-2-yl)pyridine-2-sulfonamide,36.0,uM,=,1.5563025007672873,1,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1
93,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,O=C(CSc1nc2cc([N+](=O)[O-])ccc2[nH]1)Nc1ccc(Oc2ccccc2)cc1,2-(5-nitro-1H-benzo[d]imidazol-2-ylthio)-N-(4-phenoxyphenyl)acetamide,8.24,uM,=,0.9159272116971158,1,O=C(CSc1nc2ccccc2[nH]1)Nc1ccc(Oc2ccccc2)cc1
94,2089285,10.1016/j.ejmech.2020.112395,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,COc1ccc(-c2ccccc2N2CCN(CCCCOc3ccc4c(c3)NC(=O)C(C)O4)CC2)cc1,"6-{4-{4-[2-(4-Methoxyphenyl)phenyl]piperazin-1-yl}butoxy}-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one",0.4479999999999999,uM,=,-0.348721986001856,0,O=C1COc2ccc(OCCCCN3CCN(c4ccccc4-c4ccccc4)CC3)cc2N1
95,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CC2CCCCC2)c1,endo-3-(8-(cyclohexylmethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.002,uM,=,-2.6989700043360187,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CC2CCCCC2)cc1
96,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(Br)c3n2CCN1Cc1ccc(Cl)cc1F,"6-Bromo-2-[(4-Chloro-2-fluorophenyl)methyl]-3,4-dihydropyrazino(1,2-a)henzimidazol-1(2H)-one",5.6,uM,=,0.7481880270062004,1,O=C1c2nc3ccccc3n2CCN1Cc1ccccc1
97,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide,0.01,uM,=,-2.0,0,c1ccc(CCNCCOc2ccccc2)cc1
98,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)c(F)c4)CC3)ccc21,5-(2-(4-(2-(3-fluoro-4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,27.0,uM,=,1.4313637641589874,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
99,1986145,10.1021/acs.jmedchem.0c00347,,,,Inhibition of human ERG expressed in CHOK1 cells measured for 10 mins by QPatch automated patch-clamp assay,Cc1c(N2CC3CC3(N)C2)c(F)cc2c(CN)c(F)c(=O)n(C3CC3)c12,"7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-cyclopropyl-3,6-difluoro-8-methylquinolin-2(1H)-one",114.0,uM,=,2.0569048513364727,1,O=c1ccc2ccc(N3CC4CC4C3)cc2n1C1CC1
100,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2cccc(F)c2)cc1,"N,N-Diethyl-4-[(3-fluoro-phenyl)-piperidin-4-ylidene-methyl]-benzamide",3.0,uM,=,0.4771212547196624,1,c1ccc(C(=C2CCNCC2)c2ccccc2)cc1
101,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,Cc1cc(C(=O)O)ccc1-c1ccc(Cl)c(-c2ccc(C(F)(F)F)cc2CN2C(=O)O[C@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H]2C)c1,"2''-[(4S,5R)-5-(3,5-Bis-trifluoromethyl-phenyl)-4-methyl-2-oxo-oxazolidin-3-ylmethyl]-4'-chloro-2-methyl-4''-trifluoromethyl-[1,1';3',1'']terphenyl-4-carboxylic acid",5.0,uM,=,0.6989700043360189,1,O=C1O[C@H](c2ccccc2)CN1Cc1ccccc1-c1cccc(-c2ccccc2)c1
102,2164773,10.1021/acs.jmedchem.1c02131,,,,Inhibition of human ERG by patch clamp assay,CC(C)C[C@](C)(N)COc1ccc(-c2ccnc(C(F)F)c2)nc1C(F)F,"(S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2ccncc2)nc1
103,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ncccc2F)C1=O,"4-(3-fluoro-2-pyridyl)-2-methyl-9-(2-phenylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",1.2,uM,=,0.0791812460476248,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccn1
104,1810686,10.1021/acs.jmedchem.8b01333,,,,Inhibition of human ERG by patch clamp electrophysiology,FC(F)(F)c1cccc(Nc2cc3[nH]c(Nc4ccc(N5CCNCC5)cn4)nc3cn2)c1,"N-(5-(Piperazin-1-yl)pyridin-2-yl)-2-(3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]pyridin-6-amine",30.0,uM,=,1.4771212547196624,1,c1ccc(Nc2cc3[nH]c(Nc4ccc(N5CCNCC5)cn4)nc3cn2)cc1
105,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(OC2CCNCC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)-N-(2-methoxy-4-(piperidin-4-yloxy)phenyl)pyrimidin-2-amine",4.8,uM,=,0.6812412373755872,1,c1ccn2c(-c3ccnc(Nc4ccc(OC5CCNCC5)cc4)n3)cnc2c1
106,2147833,10.1021/acs.jmedchem.1c01299,,,,Inhibition of human ERG by patch clamp assay,CCCC(N)C(=O)NCCc1ccc(-c2ccc(Cl)c(Cl)c2)cc1.Cl,"Rac-2-amino-N-(2-(3',4'-dichlorobiphenyl-4-yl)ethyl)pentanamide hydrochloride",39.502,uM,=,1.5966190846638009,1,c1ccc(-c2ccccc2)cc1
107,804952,10.1021/jm201407j,,,,Inhibition of human ERG by cell based voltage clamp assay,COc1cc(/C=C2\CCCN3C2=NOC[C@@H]3c2cc(F)c(F)c(F)c2)ccc1-n1cnc(C)c1,"(S,E)-9-(3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)-benzylidene)-4-(3,4,5-trifluorophenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]oxadiazine",1.0,uM,=,0.0,0,C(=C1\CCCN2C1=NOC[C@@H]2c1ccccc1)\c1ccc(-n2ccnc2)cc1
108,75160,10.1021/jm00014a008,,,,Blockade of the delayed rectifier K+ current (IKr) of guinea pig myocytes,CSc1ccc([C@H]2N=C(OCc3ccc(NS(C)(=O)=O)cc3)N(C)Cc3ccccc32)cc1.Cl,"N-{4-[2-Methyl-5-(4-methylsulfanyl-phenyl)-2,5-dihydro-1H-benzo[e][1,3]diazepin-3-yloxymethyl]-phenyl}-methanesulfonamide hydrochloride",21.0,uM,=,1.3222192947339193,1,c1ccc(COC2=N[C@H](c3ccccc3)c3ccccc3CN2)cc1
109,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,Cc1noc(C)c1-c1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,"(E)-3-[4-({2-[2-(3,5-Dimethyl-isoxazol-4-yl)-1H-indol-3-yl]-ethylamino}-methyl)-phenyl]-N-hydroxy-acrylamide",31.24,uM,=,1.4947110252052629,1,c1ccc(CNCCc2c(-c3cnoc3)[nH]c3ccccc23)cc1
110,804476,10.1016/j.bmcl.2012.01.026,,,,Inhibition of human Erg by patch clamp assay,O=c1ccc(-c2ccc(OC3CCN(C4CCC4)CC3)nc2)n[nH]1,6-(6-(1-cyclobutylpiperidin-4-yloxy)pyridin-3-yl)pyridazin-3(2H)-one,9.0,uM,=,0.9542425094393248,1,O=c1ccc(-c2ccc(OC3CCN(C4CCC4)CC3)nc2)n[nH]1
111,1648277,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG,CC(C)c1noc(N2CCC([C@H]3C[C@H]3CCOc3ccc(CC(=O)N4CCC4)c(F)c3)CC2)n1,"(cis)-1-(azetidin-1-yl)-2-(2-fluoro-4-(2-((1S,2R)-2-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)cyclopropyl)ethoxy)phenyl)ethanone",7.0,uM,=,0.8450980400142568,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncno3)CC2)cc1)N1CCC1
112,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3ccc(C)nc3)cc12,4-[(2-Ethylbutyl)amino]-6-(6-methyl-3-pyridinyl)-3-quinolinecarboxamide,3.3,uM,=,0.5185139398778875,1,c1cncc(-c2ccc3ncccc3c2)c1
113,1446841,10.1021/jm500715u,,,,Inhibition of human ERG,CN1CCN(c2ccc3nc(Nc4ccc(Br)cn4)[nH]c3c2)CC1,N-(5-Bromopyridin-2-yl)-6-(4-methylpiperazin-1-yl)-1H-benzo[d]-imidazol-2-amine,3.5,uM,=,0.5440680443502757,1,c1ccc(Nc2nc3ccc(N4CCNCC4)cc3[nH]2)nc1
114,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1,"US9145392, 7",3.5,uM,=,0.5440680443502757,1,c1ccc(-c2c[nH]c(C3CCN(c4ccncn4)CC3)n2)cc1
115,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,CC(C)c1ccccc1C(=O)N(CC1CCCC1)[C@H]1CCNC1,(S)-N-(cyclopentylmethyl)-2-isopropyl-N-(pyrrolidin-3-yl)benzamide,2.35,uM,=,0.3710678622717362,1,O=C(c1ccccc1)N(CC1CCCC1)[C@H]1CCNC1
116,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)[C@H]1CCN(Cc2ccc(C(F)(F)F)cc2)C[C@H]1F,"2-(4-(1H-tetrazol-1-yl)phenyl)-N-((3R,4S)-3-fluoro-1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)-N-methylacetamide",3.6,uM,=,0.5563025007672873,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2ccccc2)CC1
117,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4ccccc4N(Cc4ccccn4)C3=O)nn2)ccc1-n1cnc(C)c1,"rac-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(pyridin-2-ylmethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",7.57,uM,=,0.8790958795000727,1,O=C1C(n2cc(-c3ccc(-n4ccnc4)cc3)nn2)CCc2ccccc2N1Cc1ccccn1
118,2079104,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes measured after 60 mins by microbeta liquid scintillation counting method,N#Cc1cncc(NC(=O)COc2ccc(C(=O)c3cc(Cl)ccc3Br)cc2)c1,2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)-N-(5-cyanopyridin-3-yl)acetamide,2.7,uM,=,0.4313637641589873,1,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1cccnc1
119,699317,10.1016/j.bmc.2010.10.034,,,,Inhibition of human ERG,CN[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1,"trans-(2S,4R)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",2.32,uM,=,0.3654879848908996,1,c1ccc([C@H]2CCCc3ccccc32)cc1
120,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,O[C@H]1C[C@H](CN2CC[C@H](c3ccc(F)cc3Cl)[C@@H](O)C2)CCc2cccnc21,"(7R,9S)-7-(((3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxypiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",13.0,uM,=,1.1139433523068367,1,c1ccc(C2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
121,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cn1c(-c2ccc(OCCCN3CCCC3)cc2)nc2ccccc2c1=O,3-methyl-2-(4-(3-(pyrrolidin-1-yl)propoxy)phenyl)quinazolin-4(3H)-one,2.9,uM,=,0.4623979978989561,1,O=c1[nH]c(-c2ccc(OCCCN3CCCC3)cc2)nc2ccccc12
122,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)C3)ccc2c1COC2=O,"(R)-6-(8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-2-yl)-2-methylpyridazin-3(2H)-one",4.5,uM,=,0.6532125137753437,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccc(=O)[nH]n3)C4)ccc21
123,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)OCCN1CCC(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1,"N-{[1-(2-tert-butoxyethyl)piperidin-4-yl]methyl}-3,5-dichlorobenzamide",1.26,uM,=,0.1003705451175629,1,O=C(NCC1CCNCC1)c1ccccc1
124,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(C#N)cc2)[C@@H]3C)n1,"US9422299, 29",59.0,uM,=,1.7708520116421442,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
125,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,O=C(NC1CCCC1)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1,"N-Cyclopentyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide",8.2,uM,=,0.9138138523837168,1,O=C(NC1CCCC1)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1
126,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,C[S+]([O-])c1ccc(-c2cnc3ccc(NC4CCN(S(C)(=O)=O)CC4)nn23)cc1,"3-(4-(methylsulfinyl)phenyl)-N-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-b]pyridazin-6-amine",25.9,uM,=,1.413299764081252,1,c1ccc(-c2cnc3ccc(NC4CCNCC4)nn23)cc1
127,1996654,10.1021/acs.jmedchem.0c00446,,,,Inhibition of MK499 binding to human ERG,COc1cc(C2=CC3=NO[C@H](c4cc(F)c(F)c(F)c4)CN3CCC2)ccc1-n1cnc(C)c1,"(R)-9-(3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-3-(3,4,5-trifluorophenyl)-3,4,7,8-tetrahydro-6H-[1,2,4]oxadiazino[4,3-a]azepine",3.352,uM,=,0.5253040099582389,1,C1=C(c2ccc(-n3ccnc3)cc2)CCCN2C[C@@H](c3ccccc3)ON=C12
128,2222127,10.1016/j.ejmech.2022.114246,,,,Inhibition of hERG potassium channel expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CN1CCC(N(Cc2ccc(F)cn2)C(=O)NCc2ccc3c(c2)CC(C)(C)O3)CC1,"3-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-1-((5-fluoropyridin-2-yl)methyl)-1-(1-methylpiperidin-4-yl)urea",3.61,uM,=,0.557507201905658,1,O=C(NCc1ccc2c(c1)CCO2)N(Cc1ccccn1)C1CCNCC1
129,959401,10.1016/j.bmcl.2013.04.006,,,,Inhibition of human ERG by IonWorks assay,C[C@@H]1CN(C(=O)OCC(F)(F)F)CCN1c1ncc(OCc2ccncc2C#N)cn1,"2,2,2-Trifluoroethyl-(3R)-4-{5-[(3-Cyanopyridin-4-yl)-methoxy]pyrimidin-2-yl}-3-methylpiperazine-1-carboxylate",12.0,uM,=,1.0791812460476249,1,c1cc(COc2cnc(N3CCNCC3)nc2)ccn1
130,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCNC(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1,"N-Ethyl-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide",11.989,uM,=,1.0787829601969634,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
131,1288300,10.1016/j.bmcl.2013.12.078,,,,Inhibition of human ERG by whole-cell patch clamp method,COC(=O)C(CCCN1CC=C(c2ccccc2OC)CC1)(c1ccc(Br)cc1)C(C)C,"methyl 2-(4-bromophenyl)-2-isopropyl-5-(4-(2-methoxyphenyl)-5,6-dihydropyridin-1(2H)-yl)pentanoate",1.26,uM,=,0.1003705451175629,1,C1=C(c2ccccc2)CCN(CCCCc2ccccc2)C1
132,489010,10.1021/jm8003834,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide from human ERG in HEK293 cells",Cc1nc2ccccc2c(=O)n1-c1ccc(OCCCN2CCC(C)C2)cc1,2-Methyl-3-(4-{[3-(3-methyl-1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,6.4,uM,=,0.8061799739838872,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
133,1924512,10.1021/acsmedchemlett.6b00122,,,,Displacement of [35S]MK-499 from human ERG,Cc1c(C(O)CN2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC2)ccc2c1COC2=O,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)-1-hydroxyethyl)-4-methylisobenzofuran-1(3H)-one,100.0,uM,=,2.0,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
134,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",O=c1cc(OCc2ccc(Cl)cc2)ccn1-c1ccc(OCCN2CCCC2)cc1,4-[(4-Chlorobenzyl)oxy]-1-{4-[2-(pyrrolidin-1-yl)ethoxy]-phenyl}pyridin-2(1H)-one,0.0017,uM,=,-2.7695510786217263,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCN2CCCC2)cc1
135,2298259,10.1016/j.bmc.2023.117276,,,,Inhibition of hERG expressed in CHO cells by automated patch clamp method,NCCc1cc2cc(CN3CCOCC3)cc3c(=O)c(C(=O)NCc4ccc(Cl)cc4)cn1c23,"2-(2-Aminoethyl)-N-[(4-chlorophenyl)methyl]-8-[(morpholin-4-yl)methyl]-6-oxo-6H-pyrrolo[3,2,1-ij]quinoline-5-carboxamide",8.6,uM,=,0.9344984512435676,1,O=C(NCc1ccccc1)c1cn2ccc3cc(CN4CCOCC4)cc(c1=O)c32
136,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3ccn4ncnc4n3)ccc2c1,"(R)-2-([1,2,4]triazolo[1,5-a]pyrimidin-5-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline",20.8,uM,=,1.3180633349627615,1,c1nc2nc(-c3ccc4cc(CCN5CCCC5)ccc4n3)ccn2n1
137,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CC[C@H]3OC[C@H](NCc4ccc5c(n4)NC(=O)CS5)CO3)c2c1,"6-(((2-(2-(6-methoxyquinolin-4-yl)ethyl)-trans-1,3-dioxan-5-yl)amino)methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one",1.3,uM,=,0.1139433523068367,1,O=C1CSc2ccc(CN[C@H]3CO[C@H](CCc4ccnc5ccccc45)OC3)nc2N1
138,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,Cc1ccncc1-c1cc2c(N[C@@H]3CC[C@](C)(N)C3(C)C)c(C(N)=O)cnn2c1,"US8921368, 195",18.0,uM,=,1.255272505103306,1,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1
139,77051,10.1021/jm970517u,,,,Inhibition of Ikr current in isolated guinea pig myocytes during a 0.5 s voltage clamp step from -50 to -10 mV.,Cc1cccc(NC(=O)N[C@H]2N=C(c3ccccc3)c3ccccc3N(C)C2=O)c1,"(S)-1-(1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-m-tolyl-urea",10.0,uM,=,1.0,1,O=C(Nc1ccccc1)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O
140,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)o1,endo-3-(8-((5-methylfuran-2-yl)methyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0028,uM,=,-2.552841968657781,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccco2)cc1
141,1642194,,,,,Fast Patch Assay: Representative compounds were tested for hERG activity using the Fast Patch assay available from WuXiApptec (Shanghai China).,O[C@H]1CC[C@H](Nc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,"US9416132, 8-1",16.0,uM,=,1.2041199826559248,1,c1ccc(-c2cnc3ccc(NC4CCCCC4)nn23)cc1
142,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,Cc1ccccc1-c1nc2cn(-c3cccc(Cl)c3)nc2c(=O)n1CC1CCCN(C(C)C)C1,"rac-2-(3-Chlorophenyl)-6-((1-isopropylpiperidin-3-yl)methyl)-5-o-tolyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",10.0,uM,=,1.0,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2ccccc2)n1CC1CCCNC1
143,535682,10.1016/j.bmcl.2008.08.067,,,,Displacement of [3H]dofetilide from human ERG in HEK293 cells,CNC(=O)c1c(NCC2CCC3(CCC3)CC2)nc(C#N)nc1OCC1CCN(C)CC1,2-cyano-N-methyl-4-((1-methylpiperidin-4-yl)methoxy)-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide,0.71,uM,=,-0.1487416512809247,0,c1nc(NCC2CCC3(CCC3)CC2)cc(OCC2CCNCC2)n1
144,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=N[C@H](C3(F)CNC3)CO2)cc1,"(4S)-4-(3-fluoroazetidin-3-yl)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-4,5-dihydrooxazole",3.1,uM,=,0.4913616938342727,1,c1ccc([C@H]2c3ccccc3CCN2C2=N[C@H](C3CNC3)CO2)cc1
145,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CC(C)n1nc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)oc1=O,"5-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3-isopropyl-1,3,4-oxadiazol-2(3H)-one",27.9,uM,=,1.4456042032735976,1,O=c1[nH]nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
146,1288300,10.1016/j.bmcl.2013.12.078,,,,Inhibition of human ERG by whole-cell patch clamp method,CC(C)C(CCCN(C)CCCc1nc2ccccc2[nH]1)(C(=O)O)c1ccc(Br)cc1,5-((3-(1H-benzo[d]imidazol-2-yl)propyl)(methyl)amino)-2-(4-bromophenyl)-2-isopropylpentanoic acid,2.34,uM,=,0.3692158574101428,1,c1ccc(CCCCNCCCc2nc3ccccc3[nH]2)cc1
147,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,NCC(=O)N1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc([N+](=O)[O-])c4)c3c2)CC1,2-amino-1-(4-(5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinolin-3-yl)piperazin-1-yl)ethanone,18.3,uM,=,1.2624510897304295,1,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
148,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COC(=O)N1CC(Oc2ccc(F)cc2)CC1C(=O)N1CCCN(C2CCC2)CC1,"methyl-2-(4-cyclobutyl-1,4-diazepane-1-carbonyl)-4-(4-fluorophenoxy)pyrrolidine-1-carboxylate",10.0,uM,=,1.0,1,O=C(C1CC(Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
149,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,COCc1ccncc1-c1ccc2[nH]nc(C(=O)NCC3CCOCC3)c2c1,5-(4-(Methoxymethyl)pyridin-3-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-3-carboxamide,47.1,uM,=,1.6730209071288962,1,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cccnc3)cc12
150,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,COc1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCN(C)CC2)n1,2-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-6-methoxy-4-(trifluoromethyl)pyridine,9.9,uM,=,0.99563519459755,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
151,629699,10.1016/j.bmcl.2010.03.084,,,,Inhibition of human ERG,O=C(CN1CCCN(Cc2nc3ccccc3[nH]2)CC1)Nc1ccc(C(F)(F)F)cc1,"2-(4-((1H-benzo[d]imidazol-2-yl)methyl)-1,4-diazepan-1-yl)-N-(4-(trifluoromethyl)phenyl)acetamide",4.97,uM,=,0.6963563887333322,1,O=C(CN1CCCN(Cc2nc3ccccc3[nH]2)CC1)Nc1ccccc1
152,501618,10.1021/jm8016199,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,COc1cc(-n2ccnc(NCCc3ccccc3)c2=O)ccc1OCCN1CCCC1,1-[3-Methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-3-phenethylamino-1H-pyrazin-2-one,6.2,uM,=,0.7923916894982539,1,O=c1c(NCCc2ccccc2)nccn1-c1ccc(OCCN2CCCC2)cc1
153,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(Cl)cnc56)(CC3)OC4)nc2N1,"6-((1-(2-(7-chloro-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00327,uM,=,-2.485452247339714,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
154,1904027,10.1021/acs.jmedchem.9b01392,,,,Inhibition of human ERG,COc1nn(C)cc1Nc1ncc(Br)c(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1,(2R)-N-[3-[5-bromo-2-[(3-methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide,15.0,uM,=,1.1760912590556811,1,O=C(CN1CCNCC1)Nc1cccc2c(-c3ccnc(Nc4cn[nH]c4)n3)c[nH]c12
155,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,OCCCN1CC[C@@]2(CN=C(N3CCc4ccccc4[C@@H]3c3ccc(F)cc3)O2)C1,"3-[(5S)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-1-oxa-3,7-diazaspiro[4.4]non-2-en-7-yl]propan-1-ol",4.8,uM,=,0.6812412373755872,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@]3(CCNC3)O2)cc1
156,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,Cc1c(N2CCC(C3(N)CC3)C2)c(F)cc2cc(C(=O)O)c(=O)n(C3CC3)c12,"7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid",109.0,uM,=,2.037426497940624,1,O=c1ccc2ccc(N3CCC(C4CC4)C3)cc2n1C1CC1
157,570979,10.1016/j.bmcl.2009.04.035,,,,Inhibition human ERG expressed in HEK293 cells assessed as blockade of membrane current by patch clamp method,CN1C[C@@H]2[C@H](C1)[C@H]2CN(Cc1cccc(OC(F)(F)F)c1)C(=O)c1cn(C)cn1,1-Methyl-1H-imidazole-4-carboxylic acid(3-methyl-3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-(3-trifluoromethoxy-benzyl)-amide,3.8,uM,=,0.5797835966168101,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)C[C@H]1[C@@H]2CNC[C@@H]21
158,541589,10.1021/jm801236n,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp method,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,4-Amino-5-chloro-2-ethoxy-N-[4-(4-fluoro-benzyl)-morpholin-2-ylmethyl]-benzamide,4.8,uM,=,0.6812412373755872,1,O=C(NCC1CN(Cc2ccccc2)CCO1)c1ccccc1
159,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,COC(=O)[C@@H]1C[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(cis)-methyl 2-((7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)methyl)cyclopropanecarboxylate",0.6,uM,=,-0.2218487496163563,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7CC7)nc56)(CC3)OC4)nc2N1
160,949743,10.1021/jm301720p,,,,Inhibition of human ERG channel,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCC(O)CO)c4ccc(OC(F)F)cc34)nc12,"N-tert-butyl-2-(5-(difluoromethoxy)-1-(3,4-dihydroxybutyl)-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",4.15,uM,=,0.6180480967120927,1,c1ccc2c(-c3cnc4[nH]ccc4n3)n[nH]c2c1
161,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,"5-[2-Ethoxy-5-(4-methyl-piperazine-1-sulfonyl)-phenyl]-1-methyl-3-propyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one",3.3,uM,=,0.5185139398778875,1,O=c1[nH]c(-c2cccc(S(=O)(=O)N3CCNCC3)c2)nc2cn[nH]c12
162,2014372,10.1021/acsmedchemlett.9b00123,,,,Displacement of Tracer Red from human ERG incubated for 2 hrs by fluorescence polarization assay,CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(C(F)(F)F)cc2)cc1,"(-)-2-(4-(Dimethylamino)phenyl)-N-((3S,4R)-4-(4-(trifluoromethyl)phenyl)pyrrolidin-3-yl)acetamide",5.91,uM,=,0.7715874808812554,1,O=C(Cc1ccccc1)N[C@@H]1CNC[C@H]1c1ccccc1
163,2047203,10.1021/acs.jmedchem.0c01170,,,,Inhibition of human ERG by Q-patch assay,CC1(CN)CCN(c2cnc(Sc3cccc(Cl)c3Cl)c(N)n2)CC1,"6-(4-(aminomethyl)-4-methylpiperidin-1-yl)-3-((2,3-dichlorophenyl)thio)pyrazin-2-amine",2.4,uM,=,0.380211241711606,1,c1ccc(Sc2cnc(N3CCCCC3)cn2)cc1
164,1911375,10.1021/acs.jmedchem.8b01296,,,,Inhibition of human ERG after 4 hrs by fluorescence polarization assay,CC(C)N1CCN(c2ccc(/C(=C(/CCCO)c3ccccc3)c3ccc(O)cc3)cc2)CC1.Cl.Cl,(E)-4-(5-hydroxy-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylpent-1-enyl)phenol dihydrochloride,18.7,uM,=,1.271841606536499,1,C(=C(c1ccccc1)c1ccc(N2CCNCC2)cc1)c1ccccc1
165,359863,10.1016/j.bmcl.2006.03.040,,,,Inhibition of hERG expressed in HEK cells by radioligand binding assay,CC(=O)N1N=C(c2cc(F)ccc2F)C[C@H]1c1cccc(O)c1,"1-[(S)-3-(2,5-Difluoro-phenyl)-5-(3-hydroxy-phenyl)-4,5-dihydro-pyrazol-1-yl]-ethanone",26.4,uM,=,1.421603926869831,1,c1ccc(C2=NN[C@H](c3ccccc3)C2)cc1
166,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2c1OC(c1ccc(OCCCN3CCCCC3)cc1)C(C)S2(=O)=O,"(+/-)-1-{3-[4-(8-Methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-piperidine",4.8,uM,=,0.6812412373755872,1,O=S1(=O)CC(c2ccc(OCCCN3CCCCC3)cc2)Oc2ccccc21
167,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2ccccc2)N2CCN(S(=O)(=O)C(F)(F)F)CC2)CC1,(S)-N-ethyl-2-(4-(methylsulfonyl)phenyl)-N-(1-(3-phenyl-3-(4-(trifluoromethylsulfonyl)piperazin-1-yl)propyl)piperidin-4-yl)acetamide,3.2,uM,=,0.505149978319906,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)N2CCNCC2)CC1
168,807853,10.1016/j.bmcl.2012.01.074,,,,Displacement of [3H]-astemizole from human ERG expressed in CHO-K1 cells membrane,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1,"4-(6-(1H-indazol-4-yl)-2-((4-(methylsulfonyl)piperazin-1-yl)methyl)imidazo[1,2-a]pyrazin-8-yl)morpholine",100.0,uM,=,2.0,1,c1cc(-c2cn3cc(CN4CCNCC4)nc3c(N3CCOCC3)n2)c2cn[nH]c2c1
169,980797,10.1021/jm4006324,,,,Inhibition of human ERG channel by electrophysiological method,Cn1cc(-c2ccnc(C3COCCN3)c2)c(-c2ccc(F)cc2)n1,(-)3-(4-(3-(4-Fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-pyridin-2-yl)morpholine,4.43,uM,=,0.6464037262230695,1,c1ccc(-c2n[nH]cc2-c2ccnc(C3COCCN3)c2)cc1
170,2023649,10.1016/j.bmcl.2020.127681,,,,Inhibition of human ERG by Qpatch method,C[C@H]1CN(CC[C@H]2CC[C@H](NC(=O)N(C)C)CC2)CCc2ccc(Cl)cc21,"3-(trans-4-(2-((R)-8-chloro-1-methyl-4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)ethyl)cyclohexyl)-1,1-dimethylurea",1.23,uM,=,0.0899051114393979,1,c1ccc2c(c1)CCN(CCC1CCCCC1)CC2
171,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4cncs4)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-N-[1-(4-Hydroxy-4-thiazol-5-yl-cyclohexyl)-azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,44.0,uM,=,1.6434526764861874,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3cncs3)CC2)C1
172,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@H](c2cc(OC)nc(N(C)C)c2)c2cc3cc(C#N)ccc3nc2OC)cc(OC)n1,"3-((1R,2S)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)-1-(2-(dimethylamino)-6-methoxypyridin-4-yl)-2-hydroxybutyl)-2-methoxyquinoline-6-carbonitrile",9.4,uM,=,0.9731278535996988,1,c1ccc2ncc([C@H](Cc3ccncc3)c3ccncc3)cc2c1
173,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CC(C)c1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCN(C)CC2)n1,2-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-6-isopropyl-4-(trifluoromethyl)pyridine,26.0,uM,=,1.414973347970818,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
174,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nn(CC4CC4)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"3-(cyclopropylmethyl)-5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,3,4-oxadiazol-2(3H)-one",5.5,uM,=,0.7403626894942439,1,O=c1oc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)nn1CC1CC1
175,1926979,10.1021/acsmedchemlett.6b00119,,,,Displacement of [3H]dofetilide from recombinant human ERG transfected in HEK293 cell membranes after 60 mins by scintillation counting,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cc1C#N,2-methoxy-5-(4-(3-(4-methylpiperazine-1-carbonyl)phenyl)quinazolin-6-yl)nicotinonitrile,11.0,uM,=,1.0413926851582251,1,O=C(c1cccc(-c2ncnc3ccc(-c4cccnc4)cc23)c1)N1CCNCC1
176,2208843,10.1016/j.bmc.2022.116657,,,,Inhibition of hERG channel expressed in CHO cells at -80 mV holding potential by Qpatch clamp method,COc1cc(OC)c(F)c(COc2cnc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)nc3)nc2)c1F,"5-[(2,6-Difluoro-3,5-dimethoxyphenyl)methoxy]-N-{6-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyridin-3-yl}pyrimidin-2-amine",14.0,uM,=,1.146128035678238,1,c1ccc(COc2cnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)nc3)nc2)cc1
177,1643768,10.1039/C6MD00281A,,,,Inhibition of Cy3B-labeled ligand binding to recombinant human ERG expressed in HEK293 cells by fluorescence polarization method,COC[C@@](C)(N)c1nc(-c2ccc(OC(F)(F)F)cc2)c[nH]1,(S)-1-methoxy-2-(4-(4-(trifluoromethoxy)phenyl)-1H-imidazol-2-yl)propan-2-amine,3.7,uM,=,0.568201724066995,1,c1ccc(-c2c[nH]cn2)cc1
178,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCOC4)N3)n2)cc1,"(3R)-3-(4-phenyl-1H-imidazol-2-yl)-1-(tetrahydrofuran-3-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.025,uM,=,-1.6020599913279625,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCOC4)N3)n2)cc1
179,1576971,10.1016/j.bmcl.2016.04.087,,,,Inhibition of human ERG after 10 mins,CNC(=O)c1cccc(OCCCCN2CCC(c3noc4cc(F)ccc34)CC2)c1,3-(4-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-N-methylbenza-mide,1.03,uM,=,0.0128372247051722,1,c1ccc(OCCCCN2CCC(c3noc4ccccc34)CC2)cc1
180,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,Fc1cccc(C(Cc2ccccc2OC(F)(F)F)N2CCNCC2)c1,1-(1-(3-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine,6.11,uM,=,0.7860412102425542,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
181,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,O=C(N1CCc2ncc(C(F)(F)F)cc2C1)[C@@]12CCC[C@@H]1C[C@@H](NCC1CCOCC1)C2,"((2R,3aR,6aR)-2-((tetrahydro-2H-pyran-4-yl)methylamino)octahydropentalen-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",47.0,uM,=,1.6720978579357175,1,O=C(N1CCc2ncccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NCC1CCOCC1)C2
182,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc(C(F)(F)F)cc1F)Cc1ccc2c(c1)OCCC2.Cl,(E)-N-(Chroman-7-methyl)-N-methyl-3-(2-fluoro-4-trifluoromethylphenyl)prop2-en-1-amine Hydrochloride,3.2,uM,=,0.505149978319906,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)OCCC2
183,876604,10.1021/jm301476b,,,,Inhibition of human ERG expressed in chinese hamster lung cells by IonWorks patch clamp electrophysiology assay,CN1CCN(C(=O)c2ccc(-c3cnc(N)c(-c4ccc(C(F)(F)F)cc4)c3)cc2)CC1,(4-(6-amino-5-(6-(trifluoromethyl)pyridin-3-yl)pyridin-3-yl)phenyl)(4-methylpiperazin-1-yl)methanone,16.3,uM,=,1.212187604403958,1,O=C(c1ccc(-c2cncc(-c3ccccc3)c2)cc1)N1CCNCC1
184,2152411,10.1021/acs.jmedchem.0c02254,,,,Inhibition of hERG expressed in CHO cells by whole-cell QPatch automated patch-clamp technique,C=CC(=O)N1C(=O)CC(c2ccc(F)cc2)Sc2ccccc21,"5-acryloyl-2-(4-fluorophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4(5H)-one",37.5,uM,=,1.5740312677277188,1,O=C1CC(c2ccccc2)Sc2ccccc2N1
185,1570074,10.1016/j.bmcl.2016.02.075,,,,Displacement of [3H]-dofetilide from human ERG channel expressed in HEK293 cells,Nc1ncnc2c1c(-c1cccc(OCC34CCC(CC3)O4)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,"5-(3-(7-oxabicyclo[2.2.1]heptan-1-ylmethoxy)phenyl)-7-((cis)-3-(azetidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",1.1,uM,=,0.041392685158225,1,c1cc(OCC23CCC(CC2)O3)cc(-c2cn([C@H]3C[C@@H](CN4CCC4)C3)c3ncncc23)c1
186,463271,10.1016/j.bmcl.2007.11.052,,,,Inhibition of human ERG,Cc1ccc(Oc2ccc(Nc3ncnc4cccc(O[C@@H](C)C(=O)N(C)C)c34)cc2C)cn1,"(S)-N,N-dimethyl-2-(4-(3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino)quinazolin-5-yloxy)propanamide",11.0,uM,=,1.0413926851582251,1,c1cncc(Oc2ccc(Nc3ncnc4ccccc34)cc2)c1
187,1498164,10.1021/ml500514w,,,,Inhibition of human ERG by Patchexpress patch clamp assay,Cc1nc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"3-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,2,4-oxadiazole",12.0,uM,=,1.0791812460476249,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)nc1
188,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(OC)cc(OC)c2)CCN(Cc2ccc(OC)cc2)CC1,"methyl 4-((3,5-dimethoxybenzamido)methyl)-1-(4-methoxybenzyl)piperidine-4-carboxylate",0.48,uM,=,-0.3187587626244128,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
189,490606,10.1016/j.bmcl.2008.06.027,,,,Inhibition of human ERG,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(S(=O)(=O)CCN(C)C)CC4)cc3)n2)n1C(C)C,N-(4-(4-(2-(dimethylamino)ethylsulfonyl)piperazin-1-yl)phenyl)-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-amine,18.0,uM,=,1.255272505103306,1,c1cc(-c2cnc[nH]2)nc(Nc2ccc(N3CCNCC3)cc2)n1
190,1637262,,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in tail current amplitude by whole cell patch clamp method,COc1ccc(-c2cc(=O)c3cc(Cl)ccc3o2)cc1,6-Chloro-2-(4-methoxy-phenyl)-chromen-4-one,13.0,uM,=,1.1139433523068367,1,O=c1cc(-c2ccccc2)oc2ccccc12
191,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,Cc1ccccc1[C@@H]1CCN(C[C@@H]2CCc3cccnc3[C@@H](O)C2)C[C@H]1O,"(7R,9S)-7-(((3S,4S)-3-hydroxy-4-o-tolylpiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",40.0,uM,=,1.6020599913279625,1,c1ccc(C2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
192,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,CCSc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2ccnc(OC)c2OC)cc(SCC)n1,"Rac-(1R,2S)-2-[2,6-bis(ethylsulfanyl)-4-pyridyl]-1-(6-bromo-2-methoxy-3-quinolyl)-1-(2,3-dimethoxy-4-pyridyl)-4-(dimethylamino)butan-2-ol",9.2,uM,=,0.9637878273455552,1,c1ccc2ncc([C@H](Cc3ccncc3)c3ccncc3)cc2c1
193,2045776,10.1039/d0md00174k,,,,Inhibition of human ERG,Cc1c(-c2cc(F)c(N)cc2F)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12,"7-(4-amino-2,5-difluorophenyl)-2-(aminomethyl)-5-cyclopropyl-6-methyloxazolo[4,5-c]quinolin-4-one",7.9,uM,=,0.8976270912904415,1,O=c1c2ncoc2c2ccc(-c3ccccc3)cc2n1C1CC1
194,793274,10.1016/j.bmcl.2011.09.117,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp electrophysiology,COc1ccc2ncc(C#N)c(CCN3CCC(NCc4cc5c(cn4)OCS5)CC3)c2c1,"4-(2-(4-([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile",2.0,uM,=,0.3010299956639812,1,c1ccc2c(CCN3CCC(NCc4cc5c(cn4)OCS5)CC3)ccnc2c1
195,2093859,10.1021/acs.jmedchem.0c00766,,,,Inhibition of human ERG,CC(C)n1c(=O)n(C)c2cnc3cc(F)c(-c4ccc(OCCCN5CCCCC5)nc4)cc3c21,AZD-1390,6.55,uM,=,0.8162412999917831,1,O=c1[nH]c2cnc3ccc(-c4ccc(OCCCN5CCCCC5)nc4)cc3c2[nH]1
196,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nn(C(C)C)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3-isopropyl-1,3,4-oxadiazol-2(3H)-one",7.7,uM,=,0.8864907251724818,1,O=c1[nH]nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
197,811994,10.1016/j.bmcl.2012.01.023,,,,Inhibition of human ERG by PatchXpress voltage patch clamp assay,Nc1ncnc(Nc2ccc(Oc3ccc(Cl)cc3)cc2)n1,"N2-(4-(4-chlorophenoxy)phenyl)-1,3,5-triazine-2,4-diamine",1.5,uM,=,0.1760912590556812,1,c1ccc(Oc2ccc(Nc3ncncn3)cc2)cc1
198,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc2occc12,"(1S,2S)-2-(benzofuran-4-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-1-(2,3-dimethoxypyridin-4-yl)-4-(dimethylamino)butan-2-ol",1.0,uM,=,0.0,0,c1ccc2cc([C@H](Cc3cccc4occc34)c3ccncc3)ccc2c1
199,1478735,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,CN(C)CCOC(c1ccccc1)c1ccccc1,(2-Benzhydryloxy-ethyl)-dimethyl-amine,5.2,uM,=,0.7160033436347992,1,c1ccc(Cc2ccccc2)cc1
200,1890282,10.1021/acs.jmedchem.8b01972,,,,Inhibition of Tracer Red binding to human ERG expressed in membranes by fluorescence polarization assay,CCN(CC)c1ccc(CNC(=O)[C@@H]2CNC[C@H]2c2ccc(C(F)(F)F)cc2)cc1,"(+/-)-(3S,4R)-N-{[4-(diethylamino)phenyl]methyl}-4-[4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide",4.74,uM,=,0.6757783416740851,1,O=C(NCc1ccccc1)[C@@H]1CNC[C@H]1c1ccccc1
201,2051795,10.1021/acs.jmedchem.6b00275,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1cc(NC2Cc3cc(F)c(F)cc3C2)n2nc(C(C)(F)F)nc2n1,"N-(5,6-Difluoro-2,3-dihydro-1H-inden-2-yl)-2-(1,1-difluoroethyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",1.7,uM,=,0.2304489213782739,1,c1ccc2c(c1)CC(Nc1ccnc3ncnn13)C2
202,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H](C3CN4CCC3CC4)O2)cc1,"(5S)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-5-quinuclidin-3-yl-4,5-dihydrooxazole",0.68,uM,=,-0.1674910872937636,0,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H](C3CN4CCC3CC4)O2)cc1
203,971921,10.1016/j.bmcl.2013.05.037,,,,Inhibition of human ERG,Cc1ccc(Cn2cnc(=O)c3cc(Oc4ncccc4C(F)(F)F)ccc32)cc1,1-(4-methylbenzyl)-6-(3-(trifluoromethyl)pyridin-2-yloxy)quinazolin-4(1H)-one,17.0,uM,=,1.230448921378274,1,O=c1ncn(Cc2ccccc2)c2ccc(Oc3ccccn3)cc12
204,2024332,10.1016/j.bmcl.2020.127710,,,,Inhibition of human ERG,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.27,uM,=,-0.5686362358410126,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
205,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CN(C)C(=O)c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2ccccn2)cc1,"N,N-dimethyl-4-(pyridin-2-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide",18.0,uM,=,1.255272505103306,1,c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2ccccn2)cc1
206,1619713,10.1021/acs.jmedchem.6b01156,,,,Inhibition of human ERG expressed in CHO cells assessed as reduction in channel currents at -80 mV holding potential by automated whole-cell patch clamp method,Cc1nc2cc(-n3ncc(C(=O)c4cc5ccc(CN6CCC(F)(F)CC6)cc5[nH]4)c3N)ccc2[nH]1,"US8829199, 196",8.6,uM,=,0.9344984512435676,1,O=C(c1cnn(-c2ccc3[nH]cnc3c2)c1)c1cc2ccc(CN3CCCCC3)cc2[nH]1
207,591827,10.1021/jm900729s,,,,Inhibition of human ERG by patch-clamp assay,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(C3CN(Cc4c(O)cnc5cccnc45)C3)C(=O)O[C@]12C,"3-Descladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl-(1-((3-hydroxy[1,5]naphthyridin-4-yl)methyl)azetidin-3-yl)imino)erythromycin A",67.0,uM,=,1.8260748027008264,1,O=C1CC(=O)OCC2OC(=O)N(C3CN(Cc4ccnc5cccnc45)C3)[C@@H]2CC(=O)CCC[C@H](O[C@H]2CCCCO2)C1
208,1452204,10.1021/ml500137b,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes incubated for 90 mins by beta-counting method,CCOC[C@@H](CC(C)C)NC(=O)[C@@H]1CNC[C@H](C(=O)N(c2ccc(C(C)C)c(OCCCOC)n2)C2CC2)C1.Cl,"(3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(5-isopropyl-6-(3-methoxypropoxy)pyridin-2-yl)piperidine-3,5-dicarboxamide hydrochloride",3.3,uM,=,0.5185139398778875,1,O=C([C@@H]1CCCNC1)N(c1ccccn1)C1CC1
209,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CN(c2ccns2)C(=O)O3)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-3-(isothiazol-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one",12.0,uM,=,1.0791812460476249,1,O=C1OCc2cc(CCN3CCC4(CC3)CN(c3ccns3)C(=O)O4)ccc21
210,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,O=C(O)c1cccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)c1,"3-(2-((1R,3R)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl)-1H-imidazol-4-yl)benzoic acid",0.839,uM,=,-0.0762380391712997,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
211,1927239,10.1016/j.bmc.2016.06.006,,,,Inhibition of human ERG expressed in CHO-K1 cells by whole cell patch clamp method,CC(C)Cc1cc(C(=O)NCC2C3CN(CCC(C)(C)C)CC23)nn1-c1ccccc1,"3-{2-[3-(3,3-Dimethylbutyl)-3-azabicyclo[3.1.0]hexane-6-yl]methyl}carbamoyl-5-isobutyl-1-phenyl-1H-pyrazole",3.13,uM,=,0.4955443375464484,1,O=C(NCC1C2CNCC21)c1ccn(-c2ccccc2)n1
212,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,O=C(NC1CCN(C2CCCCC2)CC1)c1cc(-c2ccc(F)cc2F)on1,"5-(2,4-Difluoro-phenyl)-isoxazole-3-carboxylic acid (1-cyclohexyl-piperidin-4-yl)-amide",1.5,uM,=,0.1760912590556812,1,O=C(NC1CCN(C2CCCCC2)CC1)c1cc(-c2ccccc2)on1
213,420606,10.1016/j.bmcl.2006.11.061,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(C2CCc3cc4oc(=O)[nH]c4cc32)CC1)c1cc(=O)c2ccc(F)cc2o1,"7-fluoro-4-oxo-N-(1-(2-oxo-3,5,6,7-tetrahydro-2H-indeno[5,6-d]oxazol-5-yl)piperidin-4-yl)-4H-chromene-2-carboxamide",25.0,uM,=,1.3979400086720375,1,O=C(NC1CCN(C2CCc3cc4oc(=O)[nH]c4cc32)CC1)c1cc(=O)c2ccccc2o1
214,591827,10.1021/jm900729s,,,,Inhibition of human ERG by patch-clamp assay,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(C3CN([C@H](C)c4ccnc5ncccc45)C3)C(=O)O[C@]12C,"3-Descladinosyl-11,12-dideoxy-6-Omethyl-3-oxo-12,11-(oxycarbonyl-(1-(1R-([1,8]naphthyridin-4-yl)-ethyl)azetidin-3-yl)imino)erythromycin A",43.0,uM,=,1.6334684555795866,1,O=C1CC(=O)OCC2OC(=O)N(C3CN(Cc4ccnc5ncccc45)C3)[C@@H]2CC(=O)CCC[C@H](O[C@H]2CCCCO2)C1
215,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,N#Cc1cccc(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC2)c1,3-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)benzonitrile,2.7,uM,=,0.4313637641589873,1,O=C(Cc1ccc(-n2cnnn2)cc1)N1CCN(CCc2ccccc2)CC1
216,570979,10.1016/j.bmcl.2009.04.035,,,,Inhibition human ERG expressed in HEK293 cells assessed as blockade of membrane current by patch clamp method,Cn1cnc(C(=O)N(Cc2ccc(F)c(Cl)c2)C[C@H]2[C@@H]3CNC[C@@H]32)c1,1-Methyl-1H-imidazole-4-carboxylic acid(3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-(3-chloro-4-fluoro-benzyl)-amide,14.6,uM,=,1.1643528557844371,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)C[C@H]1[C@@H]2CNC[C@@H]21
217,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1-c1ccc(F)cc1,"US9145392, 219",1.3,uM,=,0.1139433523068367,1,c1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncncc4-c4ccccc4)CC3)n2)cc1
218,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Nc1cnc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)cn1,"5-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridin-6-yl)pyrazin-2-amine",132.8571429,uM,=,2.1233849086797734,1,c1cnc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)cn1
219,1747135,10.1016/j.bmcl.2017.10.042,,,,Inhibition of human ERG,COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol",0.37,uM,=,-0.431798275933005,0,c1ccc([C@@H](Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
220,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(C1CCCCN1C(=O)CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCCC1,1-(2-(pyrrolidine-1-carbonyl)piperidin-1-yl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)ethanone,10.0,uM,=,1.0,1,O=C(C1CCCCN1C(=O)CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCCC1
221,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,N#Cc1ccc2c(=O)cc(C(=O)NC3CCN(Cc4ccc5c(c4)OCO5)CC3)oc2c1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-cyano-4-oxo-4H-chromene-2-carboxamide",0.005,uM,=,-2.3010299956639813,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
222,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2ncc(F)c([C@@H](O)CC[C@@H]3CCN(CCSc4cccs4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-4-((S)-3-(3-fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl)-1-(2-(thiophen-2-ylthio)ethyl)piperidine-3-carboxylic acid",23.6,uM,=,1.3729120029701067,1,c1csc(SCCN2CCC(CCCc3ccnc4ccccc34)CC2)c1
223,2220317,10.1016/j.ejmech.2021.114091,,,,Inhibition of human ERG potassium channel expressed in CHO-K1 cells by Qube-automated patch clamp assay,NC(=S)c1ccc(C(=O)NC2CCN(Cc3ccccc3)CC2)cc1,N-(1-benzylpiperidin-4-yl)-4-carbamothioylbenzamide,6.8,uM,=,0.8325089127062363,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1ccccc1
224,793274,10.1016/j.bmcl.2011.09.117,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp electrophysiology,COc1ccc2ncc(F)c([C@@H](O)CN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"(R)-2-(4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)-1-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethanol",5.0,uM,=,0.6989700043360189,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
225,577703,10.1016/j.bmcl.2009.06.001,,,,Inhibition of human ERG,C[C@@H](N[C@@H]1CCCc2c1[nH]c1ccc(Br)cc21)c1ccccc1,"(R)-6-bromo-N-((R)-1-phenylethyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine",1.7,uM,=,0.2304489213782739,1,c1ccc(CN[C@@H]2CCCc3c2[nH]c2ccccc32)cc1
226,627647,10.1016/j.bmcl.2009.12.065,,,,Inhibition of human ERG potassium channel,CC(C)(O)C(=O)c1oc2nc(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)cc2c1NC(=O)CO,"N-(6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-(2-hydroxy-2-methylpropanoyl)furo[2,3-b]pyridin-3-yl)-2-hydroxyacetamide",6.6,uM,=,0.8195439355418687,1,c1ccc(-c2cc3ccoc3nc2-c2ccccc2)cc1
227,1842230,10.1016/j.bmcl.2018.12.049,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2cc(NC(=O)c3ccc(OC(F)F)cn3)ccc2F)CO1,"N-(3-((6S,8aS)-2-amino-6-methyl-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-8a-yl)-4-fluorophenyl)-5-(difluoromethoxy)picolinamide",0.4,uM,=,-0.3979400086720376,0,O=C(Nc1cccc([C@]23COCC[C@H]2CSC=N3)c1)c1ccccn1
228,2025950,10.1021/acsmedchemlett.0c00575,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,Cc1ncnc(C2CC2)c1-c1ncc2nc(NCc3ccc(S(C)(=O)=O)cn3)c(=O)n([C@@H](C)C3CC3)c2n1,(S)-2-(4-cyclopropyl-6-methylpyrimidin-5-yl)-8-(1-cyclopropylethyl)-6-((5-(methylsulfonyl)pyridin-2-yl)methylamino)pteridin-7(8H)-one,16.0,uM,=,1.2041199826559248,1,O=c1c(NCc2ccccn2)nc2cnc(-c3cncnc3C3CC3)nc2n1CC1CC1
229,2075219,10.1021/acsmedchemlett.9b00395,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,7.7,uM,=,0.8864907251724818,1,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
230,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nn(CC(N)=O)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"2-(5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl)acetamide",34.5,uM,=,1.5378190950732742,1,O=c1[nH]nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
231,487847,10.1021/jm800386y,,,,Displacement of [35S]MK499 from human ERG expressed in HEL cells,CN(C)C(=O)N1CC(c2cc(F)ccc2F)=C[C@@]1(CC[C@@H](N)C(F)F)c1ccccc1,"(S)-2-((R)-3-amino-4,4-difluorobutyl)-4-(2,5-difluorophenyl)-N,N-dimethyl-2-phenyl-2H-pyrrole-1(5H)-carboxamide",15.9,uM,=,1.2013971243204515,1,C1=C(c2ccccc2)CNC1c1ccccc1
232,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(-c2cccs2)sc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-4-methyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-2-(thiophen-2-yl)thiazole,3.72,uM,=,0.5705429398818975,1,c1csc(-c2ncc(-c3ccc4cc(CCN5CCCC5)ccc4n3)s2)c1
233,534565,10.1016/j.bmc.2008.01.017,,,,Inhibition of human ERG potassium channel,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,N-[4-(Acridin-9-ylamino)-3-methoxy-phenyl]-methanesulfonamide,0.21,uM,=,-0.6777807052660807,0,c1ccc(Nc2c3ccccc3nc3ccccc23)cc1
234,2153149,10.1016/j.ejmech.2021.113827,,,,Inhibition of hERG expressed in CHO-K1 cells assessed as reduction in thallium influx incubated for 30 minutes by FLIPR,O=c1ccc2c([nH]1)CCC(NCCCCCCNc1c3c(nc4cc(Cl)ccc14)CCCC3)C2,"6-(6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexylamino)-5,6,7,8-tetrahydroquinolin-2(1H)-one",11.637,uM,=,1.0658410343197189,1,O=c1ccc2c([nH]1)CCC(NCCCCCCNc1c3c(nc4ccccc14)CCCC3)C2
235,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,CN1CCC(C(=O)Nc2nc(-c3ccc(F)cc3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1,"N-[4-(4-Fluorophenyl)-5-{2-[4-(piperazin-1-yl)anilino]pyrimidin-4-yl}-1,3-thiazol-2-yl]-1-methylpiperidine-4-carboxamide",50.1,uM,=,1.6998377258672457,1,O=C(Nc1nc(-c2ccccc2)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1)C1CCNCC1
236,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@]3(O)CC[C@H](NCc4ccc5c(c4)OCCO5)CC3)c2n1,"(1r,4s)-4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)-1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)cyclohexanol",2.3,uM,=,0.3617278360175928,1,c1cnc2c(CCC3CCC(NCc4ccc5c(c4)OCCO5)CC3)ccnc2c1
237,1760517,10.1021/acs.jmedchem.8b00372,,,,Inhibition of human ERG expressed in CHO cells at 10 nM to 10 uM at holding potential of -80 mV measured after 5 mins by QPatch automated patch clamp electrophysiology method,CS(=O)(=O)c1ccc(N2CCC(F)(F)CC2)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1,"3-{5-[2-(4,4-Difluoropiperidin-1-yl)-5-methanesulfonylbenzoyl]-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-2-yl}-5-fluoropyridine",6.7,uM,=,0.8260748027008264,1,O=C(c1ccccc1N1CCCCC1)N1Cc2cn(-c3cccnc3)nc2C1
238,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,CNC(=O)N1CCC(C2N[C@@H](c3nc(-c4ccccc4)c[nH]3)Cc3c2[nH]c2ccccc32)CC1,"N-methyl-4-((3R)-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)piperidine-1-carboxamide",0.24,uM,=,-0.619788758288394,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCNCC4)N3)n2)cc1
239,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(Cl)c3n2CCN1CC1CC1,"6-Chloro-2-(cyclopropylmethyl)-3,4-dihydropyrazino(1,2-a)benzimidazol-1(2H)-one",30.0,uM,=,1.4771212547196624,1,O=C1c2nc3ccccc3n2CCN1CC1CC1
240,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,Cc1ccn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2CCO)n1,1-((R)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-methylpyrazol-1-yl)-ethanone,0.005,uM,=,-2.3010299956639813,0,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
241,582986,10.1021/jm900933k,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp technique,CN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1,Dimethyl-[2-(3-pyrazin-2ylmethyl-1H-inden-2-yl)-ethyl]-amine,5.5,uM,=,0.7403626894942439,1,C1=C(Cc2cnccn2)c2ccccc2C1
242,2229351,10.1021/acsmedchemlett.2c00172,,,,Inhibition of hERG expressed in CHO cells by electrophysiological assay based automated patch clamp method,Cc1cc2ncccc2cc1Nc1ncc2c(n1)n([C@H]1CCN(CCO)C1)c(=O)n2C,(S)-9-(1-(2-hydroxyethyl)pyrrolidin-3-yl)-7-methyl-2-(7-methylquinolin-6-ylamino)-7H-purin-8(9H)-one,30.0,uM,=,1.4771212547196624,1,O=c1[nH]c2cnc(Nc3ccc4ncccc4c3)nc2n1[C@H]1CCNC1
243,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,C[C@@H]1CN(c2nnc(C(F)(F)F)o2)CCN1c1ncc(OCc2ccc(S(C)(=O)=O)cc2)cn1,"5-{[4-(Methylsulfonyl)benzyl]oxy}-2-{(2R)-2-methyl-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]piperazin-1-yl}pyrimidine",9.4,uM,=,0.9731278535996988,1,c1ccc(COc2cnc(N3CCN(c4nnco4)CC3)nc2)cc1
244,2157699,10.1021/acsmedchemlett.1c00549,,,,Inhibition of human ERG,O=C1COc2ccc(CNC3CCN(CCn4c(=O)ccc5ccc(Oc6ccccn6)nc54)CC3)nc2N1,"6-((1-(2-(2-oxo-7-(pyridin-2-yloxy)-1,8-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",155.0,uM,=,2.1903316981702914,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)ccc5ccc(Oc6ccccn6)nc54)CC3)nc2N1
245,1996654,10.1021/acs.jmedchem.0c00446,,,,Inhibition of MK499 binding to human ERG,COc1cc(/C=C2\CCCN3C2=NO[C@H](c2cc(F)cc(F)c2)[C@@H]3C)ccc1-n1cnc(C)c1,"(3R,4S)-3-(3,5-Difluorophenyl)-9-((E)-3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)-4-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]oxadiazine",2.007,uM,=,0.3025473724874856,1,C(=C1\CCCN2C[C@@H](c3ccccc3)ON=C12)\c1ccc(-n2ccnc2)cc1
246,1973585,10.1021/acs.jmedchem.9b02016,,,,Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay,O=C(CCCCCCC(=O)Nc1ccccc1)NOC(c1ccccc1)(c1ccccc1)c1ccccc1,N-Phenyl-N'-(trityloxy)octanediamide,96.22,uM,=,1.983265352566545,1,O=C(CCCCCCC(=O)Nc1ccccc1)NOC(c1ccccc1)(c1ccccc1)c1ccccc1
247,2264097,10.1021/acs.jmedchem.1c00703,,,,Inhibition of hERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp assay,COCCCN1CCC(c2noc(-c3nn(C(C)C)c4ccccc34)n2)CC1,"1-isopropyl-3-[5-[1-(3-methoxypropyl)-piperidin-4-yl]-[1,2,4]-oxadiazol-3-yl)-1H-indazole",0.95,uM,=,-0.0222763947111522,0,c1ccc2c(-c3nc(C4CCNCC4)no3)n[nH]c2c1
248,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,CCOc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2OC)cc(OCC)n1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-2-(2,6-diethoxypyridin-4-yl)-1-(2,3-dimethoxyphenyl)-4-(dimethylamino)butan-2-ol",5.5,uM,=,0.7403626894942439,1,c1ccc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)cc1
249,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1,"(R)-N-(1-(3-(3,5-difluorophenyl)-3-(1-(methylsulfonyl)piperidin-4-yl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide",24.0,uM,=,1.380211241711606,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
250,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(CC1CCCS1(=O)=O)C2=O,"2-[(2-{[3-(4-Fluorophenyl)-5-methyl-1,2-oxazol-4-yl]-methoxy}-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridin-6-yl)methyl]-1,6-thiolane-1,1-dione",1.8,uM,=,0.255272505103306,1,O=C1c2ccc(OCc3conc3-c3ccccc3)nc2CCN1CC1CCCS1(=O)=O
251,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,O=C(c1ccccc1Oc1ccccc1)N(C1CCC1)[C@H]1CCNC1,(S)-N-cyclobutyl-2-phenoxy-N-(pyrrolidin-3-yl)benzamide,2.95,uM,=,0.469822015978163,1,O=C(c1ccccc1Oc1ccccc1)N(C1CCC1)[C@H]1CCNC1
252,466094,10.1016/j.bmcl.2008.02.012,,,,Inhibition of human ERG,CCOC(=O)C(N)c1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1,amino-[4-(2-amino-5-thiophen-2-yl-phenylcarbamoyl)-phenyl]-acetic acid ethyl ester,5.7,uM,=,0.7558748556724915,1,O=C(Nc1cccc(-c2cccs2)c1)c1ccccc1
253,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2ccc(F)cc2F)CO1,"(4aR,6S,8aS)-8a-(2,4-Difluorophenyl)-6-methyl-4,4a,5,6,8,8ahexahydropyrano[3,4-d][1,3]thiazin-2-amine",15.8,uM,=,1.1986570869544226,1,C1=N[C@@]2(c3ccccc3)COCC[C@H]2CS1
254,1779901,10.1021/acs.jmedchem.8b00884,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1ccc2ncccc2c1NS(=O)(=O)c1ccc(CCCN2CCN3CCC[C@@H]3C2)cc1,"(R)-4-(3-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)propyl)-N-(6-isobutylquinolin-5-yl)benzenesulfonamide",1.3,uM,=,0.1139433523068367,1,O=S(=O)(Nc1cccc2ncccc12)c1ccc(CCCN2CCN3CCC[C@@H]3C2)cc1
255,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1nnc(-c2ccc(F)cc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1,"(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)(4-(4-(pyrrolidin-1-ylmethyl)phenoxy)piperidin-1-yl)methanone",6.2,uM,=,0.7923916894982539,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
256,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,Cc1cc(C2C[C@H]3[C@@H](C)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1,"(4R,4aR,8aS)-8a-(2,4-difluorophenyl)-4-methyl-6-(3-methylisoxazol-5-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",2.1,uM,=,0.3222192947339193,1,C1=N[C@@]2(c3ccccc3)COC(c3ccno3)C[C@H]2CS1
257,1783529,10.1016/j.ejmech.2017.12.075,,,,Inhibition of human ERG by [3H]dofetilide binding displacement assay,Cc1c(CN2CCOCC2)cc(-c2ccc(C(C)C)cc2)n1-c1ccc(F)cn1,4-((1-(5-Fluoropyridin-2-yl)-5-(4-isopropylphenyl)-2-methyl-1H-pyrrol-3-yl)methyl)morpholine,8.0,uM,=,0.9030899869919436,1,c1ccc(-c2cc(CN3CCOCC3)cn2-c2ccccn2)cc1
258,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN(C)C)c(F)c4)C3)o2)cc1,"(3-(4-((dimethylamino)methyl)-3-fluorophenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone",15.0,uM,=,1.1760912590556811,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccccc2)C1
259,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3c(O)ccnc3C(F)(F)F)ccc2c1,(R)-3-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-2-(trifluoromethyl)pyridin-4-ol,40.0,uM,=,1.6020599913279625,1,c1cncc(-c2ccc3cc(CCN4CCCC4)ccc3n2)c1
260,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cccc(C[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"exo-3-(((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)methyl)benzamide",0.25,uM,=,-0.6020599913279624,0,c1ccc(C[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)cc1
261,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,COc1ccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNc4n[nH]c5ccc(C(F)(F)F)cc45)C3)CC2)cn1,cis-N-{1-[4-Hydroxy-4-(6-methoxy-pyridin-3-yl)-cyclohexyl]-azetidin-3-yl}-2-(5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,32.0,uM,=,1.505149978319906,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCC(c3cccnc3)CC2)C1
262,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(OC(F)F)cc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-(difluoromethoxy)-4-oxo-4H-chromene-2-carboxamide",0.0036,uM,=,-2.4436974992327127,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
263,1736165,10.1021/acs.jmedchem.8b00300,,,,Inhibition of human ERG,O=S(=O)(CC1CC1)NCCOc1ccc2c(c1)[C@@H](Cc1ccccc1)[C@@H](N1CCC1)CC2,"N-(2-(((7S,8R)-7-(Azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)ethyl)-1-cyclopropylmethanesulfonamide",0.08,uM,=,-1.0969100130080565,0,O=S(=O)(CC1CC1)NCCOc1ccc2c(c1)[C@@H](Cc1ccccc1)[C@@H](N1CCC1)CC2
264,599953,10.1016/j.bmcl.2009.07.047,,,,Inhibition of human ERG in L929 cells by whole cell patch-clamp assay,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,0.312,uM,=,-0.5058454059815573,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
265,939638,10.1016/j.bmcl.2012.11.023,,,,Inhibition of human ERG,Nc1nc2cc3c(cc2s1)CCN(Cc1ccccc1)CC3,"7-Benzyl-6,7,8,9-tetrahydro-5H-1-thia-3,7-diaza-cyclohepta[f]inden-2-ylamine",7.8,uM,=,0.8920946026904804,1,c1ccc(CN2CCc3cc4ncsc4cc3CC2)cc1
266,2113604,10.1016/j.bmc.2021.116163,,,,Inhibition of human ERG,Cn1cc(-c2nc3c(-c4ccc5c(c4)CCC[C@H]5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cn1,"(R)-3-tert-butyl-N-(6-(2-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)-1,2,3,4-tetrahydronaphthalen-1-yl)-1,2,4-oxadiazole-5-carboxamide",6.3,uM,=,0.7993405494535817,1,O=C(N[C@@H]1CCCc2cc(-c3ccnc4[nH]c(-c5cn[nH]c5)nc34)ccc21)c1ncno1
267,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CCCCC(NC(=O)CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)c1ccc(OC)nc1,N-(1-(6-methoxypyridin-3-yl)pentyl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,1.0,uM,=,0.0,0,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NCc1cccnc1
268,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,Cc1ncc(CN[C@@H]2CCN(CCn3c(=O)ccc4ncc(F)cc43)C[C@@H]2F)cc1C#N,"5-(((3S,4R)-3-Fluoro-1-(2-(7-fluoro-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile",133.0,uM,=,2.123851640967086,1,O=c1ccc2ncccc2n1CCN1CCC(NCc2cccnc2)CC1
269,1792104,10.1016/j.bmcl.2018.09.018,,,,Inhibition of human ERG,C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4CCCCC4)nc3)n2)C1,(S)-6-(3-acrylamidopyrrolidin-1-yl)-2-(6-(piperidin-1-yl)pyridin-3-ylamino)nicotinamide,0.26,uM,=,-0.585026652029182,0,c1cc(Nc2ccc(N3CCCCC3)nc2)nc(N2CCCC2)c1
270,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,N#Cc1ccc2ccc(=O)n(CCN3CC[C@H](NCc4ccc5c(n4)NC(=O)CO5)[C@H](O)C3)c2c1,"cis-1-[2-((3R,4S)-3-Hydroxy-4-{[(3-oxo-3,4-dihydro-2H-pyrido-[3,2-b][1,4]oxazin-6-yl)methyl]amino}piperidin-1-yl)ethyl]-2-oxo-1,2-dihydroquinoline-7-carbonitrile",305.0,uM,=,2.484299839346786,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)ccc5ccccc54)CC3)nc2N1
271,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(C#N)cc2cc1[C@@H](c1cccc(F)c1)[C@@](O)(CCN(C)C)c1cc2ccccc2o1,"7-((1R,2S)-2-(benzofuran-2-yl)-4-(dimethylamino)-1-(3-fluorophenyl)-2-hydroxybutyl)-6-methoxy-2-naphthonitrile",0.9,uM,=,-0.0457574905606751,0,c1ccc([C@@H](Cc2cc3ccccc3o2)c2ccc3ccccc3c2)cc1
272,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1cccc(Cl)c1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1,(S)-N-(3-chlorophenyl)-4-((1-cyclopropylpiperidin-3-yl)methyl)piperazine-1-carboxamide,28.0,uM,=,1.4471580313422192,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
273,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=C1\S/C(=C2\SC(C(=O)Nc3ccccc3)=NN2c2ccccc2)C(=O)N1c1ccccc1,"5-(2-((3-Cyano-4,6-diphenylpyridin-2-yl)imino)-4-oxo-3-phenylthiazolidin-5-ylidene)-N,4-diphenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxamide",3.4,uM,=,0.5314789170422551,1,O=C(Nc1ccccc1)C1=NN(c2ccccc2)/C(=C2/S/C(=N\c3cc(-c4ccccc4)cc(-c4ccccc4)n3)N(c3ccccc3)C2=O)S1
274,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,NC(=O)c1ccc(N[C@H]2CCCNC2)c2cc(-c3ccc(Cl)cc3)[nH]c12,2-(4-Chlorophenyl)-4-[(3S)-piperidin-3-ylamino]-1H-indole-7-carboxamide,4.1,uM,=,0.6127838567197355,1,c1ccc(-c2cc3c(N[C@H]4CCCNC4)cccc3[nH]2)cc1
275,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,Cc1cc2[nH]c(C3CCN(CCn4c(=O)ccc5ncc(F)cc54)CC3)nc2cc1Cl,"1-(2-(4-(5-chloro-6-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)-7-fluoro-1,5-naphthyridin-2(1H)-one",1.2,uM,=,0.0791812460476248,1,O=c1ccc2ncccc2n1CCN1CCC(c2nc3ccccc3[nH]2)CC1
276,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc(C(NC(C)=O)C(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)nc1,"2-acetamido-2-(5-ethylsulfonyl-2-pyridyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide",16.0,uM,=,1.2041199826559248,1,O=C(Cc1ccccn1)Nc1ccccc1
277,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1nc(-n2cnnn2)ccc1[C@@H](O)CN1CCC2(CC1)CCN(c1ccc(=O)n(C)n1)C2=O,"(R)-8-(2-hydroxy-2-(2-methyl-6-(1H-tetrazol-1-yl)pyridin-3-yl)ethyl)-2-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one",17.2,uM,=,1.235528446907549,1,O=C1N(c2ccc(=O)[nH]n2)CCC12CCN(CCc1ccc(-n3cnnn3)nc1)CC2
278,1924902,10.1016/j.bmcl.2016.07.048,,,,Inhibition of MK499 binding to human ERG,Cn1cc(NC(=O)c2ccnc(-c3ccnc(NCC4CC4)c3)n2)c(C(N)=O)n1,N-(3-carbamoyl-1-methyl-1H-pyrazol-4-yl)-2-(2-(cyclopropylmethylamino)pyridin-4-yl)pyrimidine-4-carboxamide,1.9,uM,=,0.2787536009528289,1,O=C(Nc1cn[nH]c1)c1ccnc(-c2ccnc(NCC3CC3)c2)n1
279,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(Cl)c(Cl)cc43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(5,6-dichloro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",9.6,uM,=,0.9822712330395684,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
280,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@H](c2cc(OC)nc(OC(C)C)c2)c2cc3cc(C#N)ccc3nc2OC)cc(OC)n1,"3-((1R,2S)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)-2-hydroxy-1-(2-isopropoxy-6-methoxypyridin-4-yl)butyl)-2-methoxyquinoline-6-carbonitrile",10.6,uM,=,1.0253058652647702,1,c1ccc2ncc([C@H](Cc3ccncc3)c3ccncc3)cc2c1
281,535682,10.1016/j.bmcl.2008.08.067,,,,Displacement of [3H]dofetilide from human ERG in HEK293 cells,CNC(=O)c1c(NCC2CCC3(CCC3)CC2)nc(C#N)nc1OCC1CCN(CCO)CC1,2-cyano-4-((1-(2-hydroxyethyl)piperidin-4-yl)methoxy)-N-methyl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide,0.89,uM,=,-0.0506099933550872,0,c1nc(NCC2CCC3(CCC3)CC2)cc(OCC2CCNCC2)n1
282,1736165,10.1021/acs.jmedchem.8b00300,,,,Inhibition of human ERG,Cn1cnc(S(=O)(=O)NCCOc2ccc3c(c2)[C@@H](Cc2ccccc2)[C@@H](N2CCC2)CC3)c1,"N-(2-(((7S,8R)-7-(Azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)ethyl)-1-methyl-1H-imidazole-4-sulfonamide",15.0,uM,=,1.1760912590556811,1,O=S(=O)(NCCOc1ccc2c(c1)[C@@H](Cc1ccccc1)[C@@H](N1CCC1)CC2)c1c[nH]cn1
283,465697,10.1021/jm701187w,,,,Inhibition of human ERG potassium current expressed in HEK293 cells by patch-clamp technique,Cc1cc(C)n(-c2cc(NC(=O)CN3CCN(C)CC3)nc(-c3ccc(C)o3)n2)n1,"N-[6-(3,5-dimethylpyrazol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl]-2-(4-methylpiperazin-1-yl)acetamide",0.95,uM,=,-0.0222763947111522,0,O=C(CN1CCNCC1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
284,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CCN3CCC(NCc4ccc(Cl)c(Cl)c4)CC3)c2c1,"N-(3,4-dichlorobenzyl)-1-(2-(6-methoxyquinolin-4-yl)ethyl)piperidin-4-amine",1.0,uM,=,0.0,0,c1ccc(CNC2CCN(CCc3ccnc4ccccc34)CC2)cc1
285,744146,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG,O=C(NC1CC1)c1ccc(OCCC2CC2C2CCN(c3ncc(Cl)cn3)CC2)cc1F,(rac)-cis-4-(2-(2-(1-(5-chloropyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)-N-cyclopropyl-2-fluorobenzamide,2.6,uM,=,0.414973347970818,1,O=C(NC1CC1)c1ccc(OCCC2CC2C2CCN(c3ncccn3)CC2)cc1
286,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2OC)cc(OC)n1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-1-(2,3-dimethoxyphenyl)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)butan-2-ol",2.2,uM,=,0.3424226808222063,1,c1ccc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)cc1
287,540677,10.1016/j.bmcl.2008.12.083,,,,Inhibition of human ERG,Nc1ccc(-c2ccsc2)cc1NC(=O)c1ccc(CN2CCC3(CCCN3)CC2)cc1,"4-(1,8-diazaspiro[4.5]decan-8-ylmethyl)-N-(2-amino-5-(thiophen-3-yl)phenyl)benzamide",1.492,uM,=,0.17376882313665,1,O=C(Nc1cccc(-c2ccsc2)c1)c1ccc(CN2CCC3(CCCN3)CC2)cc1
288,755452,10.1016/j.bmcl.2010.05.026,,,,Inhibition of human hERG,Cc1nnc(N2CC[C@@H](F)C2)c2nn(-c3ccc(OCC(F)(F)F)cc3)c(C)c12,"(R)-7-(3-fluoropyrrolidin-1-yl)-3,4-dimethyl-2-(4-(2,2,2-trifluoroethoxy)phenyl)-2H-pyrazolo[4,3-d]pyridazine",0.316,uM,=,-0.5003129173815962,0,c1ccc(-n2cc3cnnc(N4CCCC4)c3n2)cc1
289,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3ccccc3[nH]c2=O)[nH]1,"(S)-6-methyl-N-((S)-7-oxo-1-(5-(2-oxo-1,2-dihydroquinolin-3-yl)-1H-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide",28.0,uM,=,1.4471580313422192,1,O=C(NCc1ncc(-c2cc3ccccc3[nH]c2=O)[nH]1)[C@H]1CC12CCNCC2
290,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,C[C@H](C(=O)N1CCC(Oc2ccc(-c3cn(C)cn3)cc2C(N)=O)CC1)c1ccc(OC(F)(F)F)cc1,(S)-5-(1-Methyl-1H-imidazol-4-yl)-2-((1-(2-(4-(trifluoromethoxy)-phenyl)propanoyl)piperidin-4-yl)oxy)benzamide,6.5,uM,=,0.8129133566428556,1,O=C(Cc1ccccc1)N1CCC(Oc2ccc(-c3c[nH]cn3)cc2)CC1
291,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,N#Cc1ccc2ccc(=O)n(CCN3CC[C@H](NCc4cc5c(cn4)OCCO5)[C@H](F)C3)c2c1,"cis-1-(2-{(3R,4S)-4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-3-fluoropiperidin-1-yl}ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",233.0,uM,=,2.367355921026019,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
292,1911678,10.1021/acs.jmedchem.8b01725,,,,Inhibition of human ERG by Q-patch assay,C[C@@H]1OCC2(CCN(c3nc4[nH]nc(-c5ccnc(NC6CCC6)c5Cl)c4c(=O)n3C)CC2)[C@@H]1N,"6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(3-chloro-2-(cyclobutylamino)pyridin-4-yl)-5-methyl-2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one",1.9,uM,=,0.2787536009528289,1,O=c1[nH]c(N2CCC3(CCOC3)CC2)nc2[nH]nc(-c3ccnc(NC4CCC4)c3)c12
293,2293467,10.1021/acs.jmedchem.7b00463,,,,Inhibition of hERG potassium channel by Q-patch clamp assay,COc1cc(NC(=O)c2nnn(Cc3ccc(CN4CCOCC4)cc3)c2N)nc(OC)n1,"5-amino-N-(2,6-dimethoxypyrimidin-4-yl)-1-(4-(morpholinomethyl)benzyl)-1H-1,2,3-triazole-4-carboxamide",113.0,uM,=,2.05307844348342,1,O=C(Nc1ccncn1)c1cn(Cc2ccc(CN3CCOCC3)cc2)nn1
294,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(-c4ccn[nH]4)cc3)cc1)C(=O)N2c1cc(O)ncn1,"1-(6-Hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-3-[4'-(2H-pyrazol-3-yl)-biphenyl-4-yl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione",8.1,uM,=,0.9084850188786496,1,O=C1N(c2ccc(-c3ccc(-c4ccn[nH]4)cc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
295,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3cnc4cccnc43)[C@H](C)C2)cn1,"1-{(R)-4-[4-(2-Ethoxy-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-2-imidazo[4,5-b]pyridin-3-yl-ethanone",13.0,uM,=,1.1139433523068367,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2cncnc2)CC1
296,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,C[C@@H](NC(=O)c1ccc(Cl)cc1)c1ccc2c(c1)CCCN2C(=O)c1cccc(Cl)c1,"(R)-4-chloro-N-(1-(1-(3-chlorobenzoyl)-1,2,3,4-tetrahydroquinolin-6-yl)ethyl)benzamide",1.0,uM,=,0.0,0,O=C(NCc1ccc2c(c1)CCCN2C(=O)c1ccccc1)c1ccccc1
297,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1nccc2c(=O)n(C)c(-c3ccc(OC4CCN(C5CCC5)CC4)cc3)nc12,"2-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-8-methoxy-3-methylpyrido[3,4-d]pyrimidin-4(3H)-one",10.0,uM,=,1.0,1,O=c1[nH]c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2cnccc12
298,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(=O)Nc1ccc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)cn1,"N-(5-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridin-6-yl)pyridin-2-yl)acetamide",8.518518518999999,uM,=,0.9303640718831526,1,c1cncc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)c1
299,534565,10.1016/j.bmc.2008.01.017,,,,Inhibition of human ERG potassium channel,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,glyburide,74.0,uM,=,1.869231719730976,1,O=C(NC1CCCCC1)NS(=O)(=O)c1ccc(CCNC(=O)c2ccccc2)cc1
300,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CS(=O)(=O)Nc1ccc(OC[C@@H](O)CN(CCc2ccc(Cl)c(Cl)c2)Cc2cccc(O)c2)cc1,"(S)-1-(4-Methanesulfonamidophenoxy)-3-(N-(3-hydroxybenzyl)-3,4-dichlorophenylethylamino)-2-propanol",0.78,uM,=,-0.1079053973095195,0,c1ccc(CCN(CCCOc2ccccc2)Cc2ccccc2)cc1
301,1822313,10.1021/acs.jmedchem.8b01891,,,,Inhibition of human ERG,O=C1OCc2cc(C3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)cc5)CC4CO3)ccc21,"5-(8-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)isobenzofuran-1(3H)-one",21.1,uM,=,1.3242824552976926,1,O=C1OCc2cc(C3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)cc5)CC4CO3)ccc21
302,591458,10.1021/jm900563e,,,,Inhibition of human ERG,CCOC(=O)CCc1ccc(OC[C@H](O)CNC(C)(C)Cc2ccc3ccccc3c2)c(C#N)c1.Cl,"Ethyl 3-{3-Cyano-4-[((2R)-3-{[1,1-dimethyl-2-(2-naphthalenyl)-ethyl]amino}-2-hydroxypropyl)oxy]phenyl}propanoate Hydrochloride",0.0017,uM,=,-2.7695510786217263,0,c1ccc(OCCCNCCc2ccc3ccccc3c2)cc1
303,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(C[C@@H]2CCCN(CCCc3ccccc3)C2)CC1,"(R)-N-(3,4-dichlorophenyl)-4-((1-(3-phenylpropyl)piperidin-3-yl)methyl)piperazine-1-carboxamide",0.4,uM,=,-0.3979400086720376,0,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(CCCc3ccccc3)C2)CC1
304,875808,10.1021/jm201710f,,,,Displacement of [3H]dofetilide to human ERG expressed in HEK293 cells,Cc1cn(-c2ccc(Nc3cccc4c3nc(-c3ccc(F)cc3)n4C)nc2)cn1,[2-(4-Fluoro-phenyl)-1-methyl-1H-benzoimidazol-4-yl]-[5-(4-methyl-imidazol-1-yl)-pyridin-2-yl]-amine,5.2,uM,=,0.7160033436347992,1,c1ccc(-c2nc3c(Nc4ccc(-n5ccnc5)cn4)cccc3[nH]2)cc1
305,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4ccccc4N(CC4(C)COC4)C3=O)nn2)ccc1-n1cnc(C)c1,"rac-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-((3-methyloxetan-3-yl)methyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",18.1,uM,=,1.2576785748691846,1,O=C1C(n2cc(-c3ccc(-n4ccnc4)cc3)nn2)CCc2ccccc2N1CC1COC1
306,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2ccccc2)CO1,"(4aR,6S,8aS)-6-Methyl-8a-phenyl-4,4a,5,6,8,8a-Hexahydropyrano[3,4-d][1,3]thiazin-2-amine",85.7,uM,=,1.932980821923198,1,C1=N[C@@]2(c3ccccc3)COCC[C@H]2CS1
307,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Clc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1,"(1R,3R)-3-(4-(4-chlorophenyl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.144,uM,=,-0.8416375079047503,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
308,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(C/C(=N\O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(E)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-(hydroxyimino)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.6,uM,=,0.2041199826559248,1,N=C(Cc1ccnc2cccnc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
309,749792,10.1016/j.bmcl.2009.04.093,,,,Inhibition of human ERG by cell based by patch clamp assay,CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F,"N4-((1R,2R)-2-(dimethylamino)cyclopentyl)-N2-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl)pyrimidine-2,4-diamine",4.7,uM,=,0.6720978579357175,1,c1ccc(Nc2nccc(NC3CCCC3)n2)cc1
310,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CCCC56COC6)cc4)C3)o2)cc1,"US8685958, 12",12.0,uM,=,1.0791812460476249,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CCCC34COC4)cc2)C1
311,1518195,10.1016/j.bmcl.2015.09.018,,,,Inhibition of human ERG by flux assay,O=c1c2cc(-c3ccc(Cl)cc3)cn2ncn1-c1ccc(N2CCC(N3CC(O)C3)C2)nc1,"6-(4-chlorophenyl)-3-(6-(3-(3-hydroxyazetidin-1-yl)pyrrolidin-1-yl)pyridin-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one",2.0,uM,=,0.3010299956639812,1,O=c1c2cc(-c3ccccc3)cn2ncn1-c1ccc(N2CCC(N3CCC3)C2)nc1
312,1928829,10.1021/acs.jmedchem.6b00698,,,,Inhibition of human ERG in membranes incubated for 2 hrs by fluorescence polarization assay,O=c1c(O)c(-c2cccc(O)c2)oc2ccc(O)cc12,"3,6-dihydroxy-2-(3-hydroxyphenyl)-4H-chromen-4-one",99.3,uM,=,1.9969492484953808,1,O=c1cc(-c2ccccc2)oc2ccccc12
313,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,CC(C)(C)NC(=O)C1c2ccccc2C(=O)N1Cc1ccccc1-c1ccccc1,(rac)-2-(biphenyl-2-ylmethyl)-N-tert-butyl-3-oxoisoindoline-1-carboxamide,62.0,uM,=,1.792391689498254,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
314,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cccc(Cl)c2)C2CCN(S(C)(=O)=O)CC2)CC1,(R)-N-(1-(3-(3-chlorophenyl)-3-(1-(methylsulfonyl)piperidin-4-yl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide,7.9,uM,=,0.8976270912904415,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
315,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CS(=O)(=O)Nc1ccc(OC[C@@H](O)CN(CCc2ccc(Cl)c(Cl)c2)Cc2ccccc2F)cc1,"(S)-1-(4-Methanesulfonamidophenoxy)-3-(N-(2-fluorobenzyl)-3,4-dichlorophenylethylamino)-2-propanol",1.2,uM,=,0.0791812460476248,1,c1ccc(CCN(CCCOc2ccccc2)Cc2ccccc2)cc1
316,2222127,10.1016/j.ejmech.2022.114246,,,,Inhibition of hERG potassium channel expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CN1CCC(N(Cc2ccc(F)cn2)C(=O)NCc2ccc(OCC(F)(F)F)cc2)CC1,"3-(4-(2,2,2-trifluoroethoxy)benzyl)-1-((5-fluoropyridin-2-yl)methyl)-1-(1-methylpiperidin-4-yl)urea",1.1,uM,=,0.041392685158225,1,O=C(NCc1ccccc1)N(Cc1ccccn1)C1CCNCC1
317,2089285,10.1016/j.ejmech.2020.112395,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,COc1ccc(-c2ccccc2C2CCN(C[C@@H](O)COc3ccc(-c4cn5ccccc5n4)cc3)CC2)cc1,"(R)-[4-(Imidazo[1,2-a]pyridin-2-yl)phenoxy]-3-{4-[2-(4-methoxyphenyl)phenyl]piperidin-1-yl}propan-2-ol",1.863,uM,=,0.2702128548962427,1,c1ccc(-c2ccccc2C2CCN(CCCOc3ccc(-c4cn5ccccc5n4)cc3)CC2)cc1
318,1553512,10.1016/j.bmc.2016.02.006,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,CC1(C)CCc2cc(S(=O)(=O)N(CC(=O)O)Cc3cccc(-c4ccccc4)c3)ccc2O1,"2-(N-([1,1'-Biphenyl]-3-ylmethyl)-2,2-dimethylchroman-6-sulfonamido)acetic acid",20.0,uM,=,1.3010299956639813,1,O=S(=O)(NCc1cccc(-c2ccccc2)c1)c1ccc2c(c1)CCCO2
319,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4ccccc43)C[C@@H]21,"N-(1-((1R,3s,5S,6r)-3-(1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)-4-chlorobenzamide",0.78,uM,=,-0.1079053973095195,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
320,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,COc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)c(F)c1,N-[1-[(2-fluoro-4-methoxybenzyl)methyl]piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide,0.0147,uM,=,-1.832682665251824,0,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
321,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3ccc4c(c3)COCO4)ccc2c1,"(R)-2-(4H-benzo[d][1,3]dioxin-6-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline",3.6,uM,=,0.5563025007672873,1,c1cc2nc(-c3ccc4c(c3)COCO4)ccc2cc1CCN1CCCC1
322,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,O=c1ccc2cccc(OC[C@@H](O)CN3CCC4(CC3)Cc3cc(Cl)ccc3O4)c2[nH]1,"(S)-8-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)quinolin-2(1H)-one",0.6,uM,=,-0.2218487496163563,0,O=c1ccc2cccc(OCCCN3CCC4(CC3)Cc3ccccc3O4)c2[nH]1
323,1749929,10.1016/j.bmcl.2017.12.020,,,,Inhibition of human ERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp assay,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,"4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide (loperamide)",0.033,uM,=,-1.4814860601221125,0,c1ccc(C2CCN(CCC(c3ccccc3)c3ccccc3)CC2)cc1
324,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,COc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1,"2-(6-methoxy-3-(pyrazin-2-ylmethyl)-1H-inden-2-yl)-N,N-dimethylethanamine",2.1,uM,=,0.3222192947339193,1,C1=C(Cc2cnccn2)c2ccccc2C1
325,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,Cc1[nH]c2ccccc2c1C1CCN(Cc2ccc(/C=C/C(=O)NO)cc2)C1,(E)-N-Hydroxy-3-{4-[3-(2-methyl-1H-indol-3-yl)pyrrolidin-1-ylmethyl]phenyl}acrylamide,13.4,uM,=,1.1271047983648077,1,c1ccc(CN2CCC(c3c[nH]c4ccccc34)C2)cc1
326,1502030,10.1021/acs.jmedchem.5b00217,,,,Inhibition of human ERG,Cc1ncc(OC[C@@]2(c3ccc(F)cc3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1,"(1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(4-fluoro-phenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide",2.2,uM,=,0.3424226808222063,1,O=C(Nc1ccccn1)[C@@H]1C[C@@]1(COc1cncnc1)c1ccccc1
327,2049587,10.1016/j.bmcl.2020.127625,,,,Inhibition of human ERG by patch clamp assay,Cc1cn([C@H](C)[C@@H]2CCNC[C@H]2F)c2nc(C(N)=O)cc(Cl)c12,"Rac-4-chloro-1-[(1R)-1-[(3S,4S)-3-fluoro-4-piperidyl]ethyl]-3-methyl-pyrrolo[2,3-b]pyridine-6-carboxamide",6.0,uM,=,0.7781512503836436,1,c1cnc2c(c1)ccn2CC1CCNCC1
328,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N(C)[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)cnn3)CC2)(C(C)C)C1,"cis-((1S,3R)-1-isopropyl-3-(((3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl)(methyl)amino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone",52.8,uM,=,1.7226339225338123,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2cccnn2)CC1
329,804664,10.1016/j.bmcl.2011.12.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc(OC(C)C)cc(S(=O)(=O)c2ccc3c(c2)O[C@H]2CNCC[C@@H]32)c1.Cl,"cis-7-(3-isopropoxy-5-methoxyphenylsulfonyl)-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridine hydrochloride",3.3,uM,=,0.5185139398778875,1,O=S(=O)(c1ccccc1)c1ccc2c(c1)O[C@H]1CNCC[C@@H]21
330,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(S(=O)(=O)NC)ccc1Oc1ccc(Cl)c(Cl)c1,"4-(3,4-dichlorophenoxy)-N-methyl-3-((methylamino)methyl)benzenesulfonamide",4.8,uM,=,0.6812412373755872,1,c1ccc(Oc2ccccc2)cc1
331,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CS(=O)(=O)c1ccc(OCC2CC2)c(C(=O)N2CCN(c3ccc(C#N)cc3F)CC2)c1,4-(4-(2-(cyclopropylmethoxy)-5-(methylsulfonyl)benzoyl)piperazin-1-yl)-3-fluorobenzonitrile,0.6,uM,=,-0.2218487496163563,0,O=C(c1ccccc1OCC1CC1)N1CCN(c2ccccc2)CC1
332,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCCC1Cc1cccnc1,2-(pyridin-3-ylmethyl)-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)pyrrolidine-1-carboxamide,1.73,uM,=,0.2380461031287954,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCCC1Cc1cccnc1
333,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCc1ncc([C@H]2CC[C@@H](N3CC(NC(=O)CNc4nn(C)c5ccc(C(F)(F)F)cc45)C3)CC2)s1,cis-N-{1-[4-(2-Ethyl-thiazol-5-yl)-4-hydroxy-cyclohexyl]-azetidin-3-yl}-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,23.0,uM,=,1.3617278360175928,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3cncs3)CC2)C1
334,1972154,10.1021/acs.jmedchem.9b01624,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,O=C(Nc1cc(-c2cn(C3CCOCC3)c3cnccc23)ccn1)N1CCOCC1,"N-(4-(1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)morpholine-4-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C(Nc1cc(-c2cn(C3CCOCC3)c3cnccc23)ccn1)N1CCOCC1
335,1884876,10.1021/acs.jmedchem.9b00336,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current amplitude by automated patch-clamp method,CCC#CC[C@H](C)[C@H](O)/C=C/[C@H]1CC(F)(F)C(=O)N1CCCCCCC(=O)O,"US9180116, 2C",25.9,uM,=,1.413299764081252,1,O=C1CCCN1
336,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,0.204,uM,=,-0.6903698325741012,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
337,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CC#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCN(C)CC4)ccc2-3)cs1,"3-(5-ethynylthiophen-3-yl)-6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno[1,2-c]pyrazole",1.41,uM,=,0.1492191126553798,1,c1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1
338,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,"1-{1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one",0.018,uM,=,-1.744727494896694,0,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccccc2)c2ccccc2)CC1
339,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2ncc(OC)s2)=NC1c1ccc(F)cc1Br,"Ethyl 4-(2-bromo-4-fluorophenyl)-2-(5-methoxythiazol-2-yl)-6-(morpholinomethyl)-1,4-dihydropyrimidine-5-carboxylate",4.19,uM,=,0.6222140229662954,1,C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccccc1
340,949743,10.1021/jm301720p,,,,Inhibition of human ERG channel,CN(C)CCCn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)CO)c3n2)c2cc(OC(F)F)ccc21,"2-(5-(difluoromethoxy)-1-(3-(dimethylamino)propyl)-1H-indazol-3-yl)-N-(1-hydroxy-2-methylpropan-2-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",6.32,uM,=,0.800717078282385,1,c1ccc2c(-c3cnc4[nH]ccc4n3)n[nH]c2c1
341,1613479,10.1021/acs.jmedchem.6b00972,,,,Inhibition of human ERG transfected in HEK293 cells assessed as reduction in tail current by patch clamp assay,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccnc1,"rac-(1R,3S/1S,3R)-5-(3-{[4-Methyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluoromethyl)phenyl]-5azaspiro[2.4]-heptane",1.2,uM,=,0.0791812460476248,1,c1ccc([C@H]2C[C@]23CCN(CCCSc2nnc(-c4cccnc4)[nH]2)C3)cc1
342,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,COc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC2)ccc2c1COC2=O,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-4-methoxyisobenzofuran-1(3H)-one,40.0,uM,=,1.6020599913279625,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
343,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2ccc3nc(CC)ccc3c2)[nH]1,(S)-N-((S)-1-(5-(2-ethylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,19.0,uM,=,1.2787536009528289,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)[nH]1)[C@H]1CC12CCNCC2
344,1510552,10.1016/j.bmcl.2015.06.057,,,,Inhibition of human ERG expressed in CHO cells measured for 5 mins by automated patch clamp assay,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(c(C)c5C)OCC(=O)N6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-7,8-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",4.6,uM,=,0.6627578316815741,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
345,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,N#Cc1ccc(-c2ccc3c(ccc(=O)n3CC(=O)N3CCCCC3)c2)cc1,4-[2-oxo-1-[2-oxo-2-(1-piperidyl)ethyl]-6-quinolyl]benzonitrile,17.0,uM,=,1.230448921378274,1,O=C(Cn1c(=O)ccc2cc(-c3ccccc3)ccc21)N1CCCCC1
346,744146,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG,Cc1cnc(N2CCC(C3CCN(c4cc(C)nc(C#N)n4)CC3)CC2)cn1,"4-methyl-6-(1'-(5-methylpyrazin-2-yl)-4,4'-bipiperidin-1-yl)pyrimidine-2-carbonitrile",10.6,uM,=,1.0253058652647702,1,c1cc(N2CCC(C3CCN(c4cnccn4)CC3)CC2)ncn1
347,421810,10.1016/j.bmcl.2006.10.053,,,,Inhibition of binding to hERG,CN(C)Cc1ccc2c(c1)CC[C@H](N(C)C(=O)c1ccc(-c3ccccn3)cc1)C2,"(S)-N-(6-((dimethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methyl-4-(pyridin-2-yl)benzamide",30.0,uM,=,1.4771212547196624,1,O=C(N[C@H]1CCc2ccccc2C1)c1ccc(-c2ccccn2)cc1
348,857606,10.1021/ml2002604,,,,Inhibition of human recombinant hERG expressed in CHO cells by automated patch clamp assay,CNC(=O)N(Cc1ccsc1)C1CCN([C@H](C)CCNC(=O)c2c(C)cc(Cl)nc2C)CC1,"(R)-6-chloro-2,4-dimethyl-N-(3-(4-(3-methyl-1-(thiophen-3-ylmethyl)ureido)piperidin-1-yl)butyl)nicotinamide",1.6,uM,=,0.2041199826559248,1,O=C(NCCCN1CCC(NCc2ccsc2)CC1)c1cccnc1
349,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,FC(F)Oc1ccccc1CC(c1ccccc1)N1CCNCC1,1-(2-(2-(difluoromethoxy)phenyl)-1-phenylethyl)piperazine,15.3,uM,=,1.1846914308175989,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
350,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(C(=O)N2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1C(C)(C)C,"(4-(6,6-bis(4-fluorophenyl)hexyl)piperazin-1-yl)(3,5-di-tert-butyl-4-methoxyphenyl)methanone",0.66,uM,=,-0.1804560644581313,0,O=C(c1ccccc1)N1CCN(CCCCCC(c2ccccc2)c2ccccc2)CC1
351,1728697,10.1021/acsmedchemlett.7b00312,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,CC(OC(=O)N1C[C@@H]2[C@@H](CNC(=O)c3ccc4[nH]c(=O)oc4c3)[C@@H]2C1)c1cc(Cl)cc(Cl)c1,"(1R,5S,6s)-1-(3,5-dichlorophenyl)ethyl 6-((2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxamido)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate",8.5,uM,=,0.9294189257142929,1,O=C(NC[C@@H]1[C@H]2CN(C(=O)OCc3ccccc3)C[C@@H]12)c1ccc2[nH]c(=O)oc2c1
352,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)NC3CCOCC3)cc2)cc1,4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic Acid(Tetrahydro-pyran-4-yl)-amide,12.78947368,uM,=,1.1068526725025056,1,O=S(=O)(NC1CCOCC1)c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
353,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3cccnc3)CC2)C1,"N-(3,5-bis(trifluoromethyl)benzyl)-1-isopropyl-3-(4-(pyridin-3-yl)piperidin-1-yl)cyclopentanecarboxamide",0.224,uM,=,-0.6497519816658371,0,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3cccnc3)CC2)C1
354,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,O=C(N1CCc2ncc(C(F)(F)F)cc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCCC1)C2,"((2R,3aR,6aR)-2-(cyclopentylamino)octahydropentalen-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",33.5,uM,=,1.5250448070368452,1,O=C(N1CCc2ncccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCCC1)C2
355,2021863,10.1016/j.bmcl.2020.127433,,,,Inhibition of human ERG by plate-based planar patch clamp method,CNC(=O)c1nc(C)n2ccc(Nc3nccc(-n4cc([C@@H]5C[C@H](O)CN5C)cn4)n3)cc12,"7-(4-(4-((2S,4S)-4-hydroxy-1-methylpyrrolidin-2-yl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-N,3-dimethylimidazo[1,5-a]pyridine-1-carboxamide",14.0,uM,=,1.146128035678238,1,c1cc(-n2cc([C@@H]3CCCN3)cn2)nc(Nc2ccn3cncc3c2)n1
356,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,COc1nc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cc(SC)nc(SC)c1,"Rac-(1R,2S)-2-[2,6-bis(methylsulfanyl)-4-pyridyl]-1-(6-bromo-2-methoxy-3-quinolyl)-1-(2,3-dimethoxy-4-pyridyl)-4-(dimethylamino)butan-2-ol",2.8,uM,=,0.4471580313422192,1,c1ccc2ncc([C@H](Cc3ccncc3)c3ccncc3)cc2c1
357,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCCc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3cnc4cccnc43)[C@H](C)C2)cn1,"2-imidazo[4,5-b]pyridin-3-yl-1-{(R)-2-methyl-4-[4-(2-propyl-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-piperazin-1-yl}-ethanone",5.9,uM,=,0.7708520116421442,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2cncnc2)CC1
358,1455475,10.1016/j.bmcl.2014.06.026,,,,Inhibition of human ERG expressed in CHO-K1 cells by patch-clamp electrophysiology method,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1,3-(2-(4-chloro-3-fluorophenyl)-2-(3-fluorophenoxy)ethyl)azetidine,1.46,uM,=,0.1643528557844371,1,c1ccc(OC(CC2CNC2)c2ccccc2)cc1
359,2229351,10.1021/acsmedchemlett.2c00172,,,,Inhibition of hERG expressed in CHO cells by electrophysiological assay based automated patch clamp method,Cc1cc2ncccc2cc1Nc1ncc2c(n1)n(C1CCN(C)CC1)c(=O)n2C,7-methyl-9-(1-methylpiperidin-4-yl)-2-(7-methylquinolin-6-ylamino)-7H-purin-8(9H)-one,9.7,uM,=,0.9867717342662448,1,O=c1[nH]c2cnc(Nc3ccc4ncccc4c3)nc2n1C1CCNCC1
360,606311,10.1016/j.bmcl.2009.10.133,,,,Inhibition of human ERG channel,Cc1cc(Nc2ccccc2)nc(NCc2ccccn2)n1,"6-methyl-N4-phenyl-N2-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine",15.8,uM,=,1.1986570869544226,1,c1ccc(Nc2ccnc(NCc3ccccn3)n2)cc1
361,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(C)c1,"N,N-Diethyl-3-methyl-4-(spiro[chromene-2,4'-piperidine]-4-yl)-benzamide",4.243,uM,=,0.6276730317666159,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
362,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,COc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1,N-[1-[(4-methoxybenzyl)methyl]piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide,0.0054,uM,=,-2.2676062401770314,0,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
363,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C(O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"5-(7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)pentanoic acid",43.5,uM,=,1.6384892569546374,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
364,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N(C)C)nc1CN1C(=O)O[C@H](c2cccc(OC(F)(F)F)c2)[C@@H]1C,"3'-(2-(Dimethylamino)-4-(((4S,5R)-4-methyl-2-oxo-5-(3-(trifluoromethoxy)phenyl)oxazolidin-3-yl)methyl)pyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic Acid",17.0,uM,=,1.230448921378274,1,O=C1O[C@H](c2ccccc2)CN1Cc1ncncc1-c1cccc(-c2ccccc2)c1
365,1858719,10.1021/acs.jmedchem.0c00117,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell electrophysiology assay,Cc1cc(C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2ccsc12,"4-((4-((4-(4-Cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenesulfonamide",0.13,uM,=,-0.8860566476931633,0,c1ccc(CN2CCC(Nc3nc(Oc4ccccc4)c4sccc4n3)CC2)cc1
366,1541704,10.1016/j.ejmech.2015.10.036,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,O=C(c1ccc(Cl)c(C(F)(F)F)c1)N1CCN(c2cc(=O)[nH]c(=O)n2Cc2ccc(OS(=O)(=O)c3cccc4cnccc34)cc2)CC1,"4-((6-(4-(4-chloro-3-(trifluoromethyl)benzoyl)piperazin-1-yl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)phenyl isoquinoline-5-sulfonate",47.8,uM,=,1.6794278966121188,1,O=C(c1ccccc1)N1CCN(c2cc(=O)[nH]c(=O)n2Cc2ccc(OS(=O)(=O)c3cccc4cnccc34)cc2)CC1
367,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,COc1ccc(Cn2c(=O)n3ncnc3c3c4c(sc32)CN(CC2CCOCC2)CC4)c(F)c1,"6-(2-Fluoro-4-methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)-methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]-triazolo[1,5-c]pyrimidin-5(6H)-one",2.7,uM,=,0.4313637641589873,1,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCN(CC1CCOCC1)C3
368,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,C[C@@H](Nc1c(C(N)=O)cnc2ccc(-c3cccnc3)cc12)C1CCOCC1,6-(3-Pyridinyl)-4-{[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide,4.3,uM,=,0.6334684555795865,1,c1cncc(-c2ccc3nccc(NCC4CCOCC4)c3c2)c1
369,853148,10.1021/ml300074j,,,,Inhibition of human ERG,CC(C)Oc1cc(-n2cnc3ccc(N[C@@H](CO)c4ccc(F)cn4)nc32)n[nH]1,"(R)-2-(5-fluoropyridin-2-yl)-2-(3-(5-isopropoxy-1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridin-5-ylamino)ethanol",52.0,uM,=,1.7160033436347992,1,c1ccc(CNc2ccc3ncn(-c4cc[nH]n4)c3n2)nc1
370,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COc1cc(OC)cc(C(=O)NCC2(C#N)CCN(Cc3ccccc3OC)CC2)c1,"N-((4-cyano-1-(2-methoxybenzyl)piperidin-4-yl)methyl)-3,5-dimethoxybenzamide",0.92,uM,=,-0.0362121726544447,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
371,701152,10.1016/j.bmcl.2010.11.074,,,,Inhibition of human ERG,O=C(O)CCNC(=O)c1ccc(Cn2nc(-c3cc(Cl)cc(Cl)c3)cc2-c2ccc(OC(F)(F)F)cc2)cc1,"3-(4-((3-(3,5-dichlorophenyl)-5-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)methyl)benzamido)propanoic acid",5.1,uM,=,0.7075701760979364,1,c1ccc(Cn2nc(-c3ccccc3)cc2-c2ccccc2)cc1
372,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,COc1cccc(NC(=O)c2cnc([C@]34CO[C@@H](C)C[C@H]3CSC(N)=N4)s2)c1,"2-((4aR,6S,8aR)-2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano-[3,4-d][1,3]thiazin-8a(8H)-yl)-N-(3-methoxyphenyl)thiazole-5-carboxamide",6.2,uM,=,0.7923916894982539,1,O=C(Nc1ccccc1)c1cnc([C@]23COCC[C@H]2CSC=N3)s1
373,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,CC(=O)NCCc1ccccc1-c1ccc([C@@H](CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)c(C)c1.Cl,"(S)-N-(2-(4'-(1-amino-3-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)propan-2-yl)-3'-methylbiphenyl-2-yl)ethyl)acetamide hydrochloride",0.006,uM,=,-2.2218487496163566,0,c1ccc(OCCOc2ccc(CCc3ccc(-c4ccccc4)cc3)cc2)cc1
374,804280,10.1016/j.bmcl.2011.12.124,,,,Inhibition of human Erg by voltage ion flux electrophysiological assay,CCS(=O)(=O)n1c2c(c3cc(C(=O)N4CCC(C)CC4)ccc31)CN(C1CCOC1)CC2,"(5-(ethylsulfonyl)-2-(tetrahydrofuran-3-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)(4-methylpiperidin-1-yl)methanone",25.0,uM,=,1.3979400086720375,1,O=C(c1ccc2[nH]c3c(c2c1)CN(C1CCOC1)CC3)N1CCCCC1
375,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Nc1ccc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)cn1,"5-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridin-6-yl)pyridin-2-amine",190.0,uM,=,2.278753600952829,1,c1cncc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)c1
376,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,CC(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1,"4-(3-((R)-4-acetylmorpholin-2-yl)-8-aminoimidazo[1,5-a]pyrazin-1-yl)-3-fluoro-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",19.0,uM,=,1.2787536009528289,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@H]3CNCCO3)n3ccncc23)cc1
377,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(CNC(C)C)c1,N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methyl)propan-2-amine,6.67,uM,=,0.8241258339165489,1,c1ccc(-c2cccnc2)cc1
378,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(COc1cccc(Cl)c1)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,2-(3-chlorophenoxy)-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,0.56,uM,=,-0.2518119729937995,0,O=C(COc1ccccc1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
379,1463730,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(S)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",18.0,uM,=,1.255272505103306,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
380,1336040,10.1021/jm500118j,,,,Binding affinity to human ERG,Fc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12,"9-Cyclopentyl-8-fluoro-N-(5-(1-piperazinyl)-2-pyridinyl)-9Hpyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidin-2-amine",0.72,uM,=,-0.1426675035687315,0,c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2cn1
381,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCOC(=O)[C@H]1CC[C@@H](N2CC(NC(=O)CNc3nn(S(C)(=O)=O)c4ccc(C(F)(F)F)cc34)C2)CC1,cis-4-{3-[2-(1-Methanesulfonyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetylamino]-azetidin-1-yl}-cyclohexane carboxylic acid ethyl ester,25.0,uM,=,1.3979400086720375,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
382,463083,10.1016/j.bmcl.2008.02.032,,,,Inhibition of human ERG by patch clamp assay,Cc1cc(C)n(-c2cc(NC(=O)COc3cccc(CN(C)C)c3)nc(-c3ccc(C)o3)n2)n1,"N-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl)-2-(3-((dimethylamino)methyl)phenoxy)acetamide",1.2,uM,=,0.0791812460476248,1,O=C(COc1ccccc1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
383,304886,10.1016/j.bmcl.2004.07.056,,,,Inhibition of human Potassium channel HERG,NC(CC(=O)N1CCC[C@H]1C(=O)NCc1ccc(C(F)(F)F)cc1)Cc1ccccc1F.O=C(O)C(F)(F)F,Trifluoro-acetate1-(2-fluoro-benzyl)-3-oxo-3-[(S)-2-(4-trifluoromethyl-benzylcarbamoyl)-pyrrolidin-1-yl]-propyl-ammonium,0.87,uM,=,-0.0604807473813814,0,O=C(NCc1ccccc1)[C@@H]1CCCN1C(=O)CCCc1ccccc1
384,744146,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG,O=C(NC1CC1)c1ccc(OCC2CC2C2CCN(c3ncc(Cl)cn3)CC2)cc1F,(rac)-cis-4-((2-(1-(5-chloropyrimidin-2-yl)piperidin-4-yl)cyclopropyl)methoxy)-N-cyclopropyl-2-fluorobenzamide,1.9,uM,=,0.2787536009528289,1,O=C(NC1CC1)c1ccc(OCC2CC2C2CCN(c3ncccn3)CC2)cc1
385,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(C3CC3)n2)(c2cccc(F)c2)CC1,2-cyclopropyl-6-(((4-(3-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,9.0,uM,=,0.9542425094393248,1,c1ccc(C2(COCc3cccc(C4CC4)n3)CCNCC2)cc1
386,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(C(C)(C)C)ccc2c1,(R)-2-tert-butyl-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,6.8,uM,=,0.8325089127062363,1,c1cnc2ccc(CCN3CCCC3)cc2c1
387,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,COCCN1CC=CC[C@H](c2ccc(Cl)c(Cl)c2)C1,"(R)-3-(3,4-dichlorophenyl)-1-(2-methoxyethyl)azepane",5.3,uM,=,0.724275869600789,1,C1=CC[C@H](c2ccccc2)CNC1
388,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1.Cl,(E)-5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol hydrochloride,0.22,uM,=,-0.6575773191777937,0,c1ccc(/N=N/c2ccccn2)cc1
389,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,CS(=O)(=O)CCNC(=O)c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1,"US9452986, 251",30.0,uM,=,1.4771212547196624,1,c1ccc(Oc2ccc3ncccc3c2)nc1
390,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2cc(-c4ccccc4)ns2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(3-phenylisothiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",0.0095,uM,=,-2.0222763947111524,0,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cc(-c5ccccc5)ns3)C4=O)ccc21
391,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,Fc1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(Nc3nncs3)n2)cc1,"N-(4-(4-(4-Fluorophenyl)-2-(piperidin-4-yl)thiazol-5-yl)-pyrimidin-2-yl)-1,3,4-thiadiazol-2-amine",2.5,uM,=,0.3979400086720376,1,c1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(Nc3nncs3)n2)cc1
392,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N(CC(F)(F)F)c3ccc4c(c3)CCC4)nn2)ccc1-n1cnc(C)c1,"N-(2,3-dihydro-1H-inden-5-yl)-2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide",1.49,uM,=,0.173186268412274,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)Nc1ccc2c(c1)CCC2
393,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CO[C@H]1C[C@H](Cc2ccc(Cl)cc2)N(C2CCN(c3nc(N)n[nH]3)CC2)C1,"5-(4-((2S,4S)-2-(4-Chlorobenzyl)-4-methoxypyrrolidin-1-yl)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",19.0,uM,=,1.2787536009528289,1,c1ccc(C[C@H]2CCCN2C2CCN(c3ncn[nH]3)CC2)cc1
394,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Cl)cc1Oc1cccc(Cl)c1,1-(4-chloro-2-(3-chlorophenoxy)phenyl)-N-methylmethanamine,2.11,uM,=,0.3242824552976926,1,c1ccc(Oc2ccccc2)cc1
395,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(OC)cc(OC)c2)CCN(Cc2ccccc2C(F)(F)F)CC1,"methyl 4-((3,5-dimethoxybenzamido)methyl)-1-(2-(trifluoromethyl)benzyl)piperidine-4-carboxylate",4.98,uM,=,0.6972293427597176,1,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
396,1871838,10.1016/j.bmcl.2018.12.015,,,,Inhibition of human ERG,COCC(C)(C)C#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1,"(S)-3,4-dichloro-2-(4-methoxy-3,3-dimethylbut-1-ynyl)-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",0.0011,uM,=,-2.958607314841775,0,c1cnc2c(c1)ccn2[C@H]1CCCNC1
397,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=C1COc2cc(Cl)c(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"(R)-7-chloro-6-((1-((3-fluoro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",126.0,uM,=,2.100370545117563,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
398,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3ccc(CS(C)(=O)=O)nc3)cc12,4-[(2-Ethylbutyl)amino]-6-{6-[(methylsulfonyl)methyl]-3-pyridinyl}-3-quinolinecarboxamide,1.9,uM,=,0.2787536009528289,1,c1cncc(-c2ccc3ncccc3c2)c1
399,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,O=C(N[C@H]1CCN(CC2CCC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccc(F)cc2F)on1,"(3S,4S)-1-Cyclobutylmethyl-4-([5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino)piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide",1.4,uM,=,0.1461280356782379,1,O=C(N[C@H]1CCN(CC2CCC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccccc2)on1
400,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(C)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-methoxy-3-methyl-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",27.43,uM,=,1.4382258076045296,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
401,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3cnc(C(F)(F)F)cn3)ccc2n1)N1CCNCC1,"US9452986, 245",18.6,uM,=,1.2695129442179165,1,O=C(c1ccc2cc(Oc3cnccn3)ccc2n1)N1CCNCC1
402,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Fc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1F,"(1R,3R)-3-(4-(3,4-difluorophenyl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.35,uM,=,-0.4559319556497244,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
403,2021700,10.1021/acs.jmedchem.9b00069,,,,Inhibition of human ERG by thallium flux assay,CC(C)(CO)n1nc(-c2ccc3cc(OC4CC4)ccc3c2)c(C(N)=O)c1N,5-Amino-3-(6-cyclopropoxynaphthalen-2-yl)-1-(1-hydroxy-2-methylpropan-2-yl)-1H-pyrazole-4-carboxamide,30.0,uM,=,1.4771212547196624,1,c1cc(-c2ccc3cc(OC4CC4)ccc3c2)n[nH]1
404,1760517,10.1021/acs.jmedchem.8b00372,,,,Inhibition of human ERG expressed in CHO cells at 10 nM to 10 uM at holding potential of -80 mV measured after 5 mins by QPatch automated patch clamp electrophysiology method,N#Cc1ccc(-c2cccc(F)c2)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1,"4-(3-Fluorophenyl)-3-[2-(5-fluoropyridin-3-yl)-2H,4H,5H,6Hpyrrolo[3,4-c]pyrazole-5-carbonyl]benzonitrile",8.8,uM,=,0.9444826721501688,1,O=C(c1ccccc1-c1ccccc1)N1Cc2cn(-c3cccnc3)nc2C1
405,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,CC(C(O)c1ccc2c(c1)CN(C)C(=O)N2)N1CCC(O)(c2ccc(F)cc2)CC1,"6-(2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxypropyl)-3-methyl-3,4-dihydroquinazolin-2(1H)-one",3.1,uM,=,0.4913616938342727,1,O=C1NCc2cc(CCN3CCC(c4ccccc4)CC3)ccc2N1
406,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)O1,2-(8-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-8-azaspiro[4.5]decan-2-yl)acetic Acid,16.0,uM,=,1.2041199826559248,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCO5)CC4)nc3)nc2c1
407,640798,10.1016/j.bmcl.2010.05.041,,,,Inhibition of human ERG by patch clamp technique,O=C(c1ccc(Oc2ccc(Cl)cc2)nc1)N1CCCN(C2CCC2)CC1,"(6-(4-chlorophenoxy)pyridin-3-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methanone",1.4,uM,=,0.1461280356782379,1,O=C(c1ccc(Oc2ccccc2)nc1)N1CCCN(C2CCC2)CC1
408,1473398,10.1021/jm501920g,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,Fc1cccc(-n2cc(NCCN3CCCCC3)nn2)c1,"1-(3-fluorophenyl)-N-(2-(piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-amine",5.2,uM,=,0.7160033436347992,1,c1ccc(-n2cc(NCCN3CCCCC3)nn2)cc1
409,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CC[C@@H](NC(=O)C12CC(F)(C1)C2)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"N-((R)-1-((1R,3S,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)-3-fluorobicyclo[1.1.1]pentane-1-carboxamide",48.0,uM,=,1.6812412373755872,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)C12CC(C1)C2
410,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CCOC(=N)c1ccc(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)s1,(R)-ethyl 5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)thiophene-2-carbimidate,4.8,uM,=,0.6812412373755872,1,c1csc(-c2ccc3cc(CCN4CCCC4)ccc3n2)c1
411,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCCC(CO)C1,3-(hydroxymethyl)-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)piperidine-1-carboxamide,4.89,uM,=,0.6893088591236203,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCCCC1
412,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(NC(=O)CCCN(C)C)nc5)cc4c32)C1,"4-(Dimethylamino)-N-(5-[7-fluoro-3-methyl-2-oxo-1-[cis-3-methoxycyclobutyl]-1H,2H,3H-imidazo[4,5-c]quinolin-8-yl]pyridin-2-yl)butanamide",18.0,uM,=,1.255272505103306,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCC1
413,363727,10.1021/jm060015t,,,,Inhibition of hERG,CN(C)C(=O)[C@@H](c1ccc(-c2ccn3ncnc3c2)cc1)[C@H](N)C(=O)N1CCC(F)(F)C1.O=C(O)C(F)(F)F,"(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridin-7-ylphenyl)butanamide trifluoroacetate",16.0,uM,=,1.2041199826559248,1,O=C(CCc1ccc(-c2ccn3ncnc3c2)cc1)N1CCCC1
414,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)C1CCN(Cc2ccc(C(F)(F)F)nc2)CC1,2-(4-(1H-tetrazol-1-yl)phenyl)-N-methyl-N-(1-((6-(trifluoromethyl)pyridin-3-yl)methyl)piperidin-4-yl)acetamide,13.0,uM,=,1.1139433523068367,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2cccnc2)CC1
415,1622890,10.1021/acsmedchemlett.6b00433,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes after 90 mins by scintillation counting,FC(F)c1cc(-c2cnn(Cc3cc[nH]n3)c2)ccc1Cl,1-((1H-pyrazol-3-yl)methyl)-4-(4-chloro-3-(difluoromethyl)phenyl)-1H-pyrazole,4.75,uM,=,0.6766936096248666,1,c1ccc(-c2cnn(Cc3cc[nH]n3)c2)cc1
416,1496337,10.1021/ml500505q,,,,Inhibition of human ERG expressed in HEK293 cells by FLIPR based flux assay,CC(C)N(C)[C@@H]1CC[C@H](NC(=O)CNC(=O)c2cccc(C(F)(F)F)c2)[C@H](CCc2ccccc2)C1,"N-(2-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-phenethylcyclohexylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide",1.6,uM,=,0.2041199826559248,1,O=C(CNC(=O)c1ccccc1)N[C@H]1CCCC[C@H]1CCc1ccccc1
417,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1cc(=O)n(C)nc1N1CCC2(CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)C1=O,"(R)-2-(1,4-dimethyl-6-oxo-1,6-dihydropyridazin-3-yl)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one",21.0,uM,=,1.3222192947339193,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccc(=O)[nH]n3)C4=O)ccc21
418,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,Cc1cc(C)nc(Nc2cc(NCC3(N)CC3)cnc2C(N)=O)c1,"5-(((1-aminocyclopropyl)methyl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide",1.7,uM,=,0.2304489213782739,1,c1ccc(Nc2cncc(NCC3CC3)c2)nc1
419,674336,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human ERG expressed in HEK cells by patch clamp technique,COc1ccccc1-c1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1,(S)-2-(2-methoxyphenyl)-N-(quinuclidin-8-yl)benzo[d]oxazole-4-carboxamide,0.2,uM,=,-0.6989700043360187,0,O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(-c3ccccc3)nc12
420,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,O=C(CCCS(=O)(=O)c1ccccc1)NC1CCOC1=O,N-(2-oxotetrahydrofuran-3-yl)-4-(phenylsulfonyl)butanamide,109.01,uM,=,2.0374663396435,1,O=C(CCCS(=O)(=O)c1ccccc1)NC1CCOC1=O
421,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,CCNC(=O)c1cnc(N)c(O[C@H]2CN(C(=O)Cc3ccc(OC(F)(F)F)cc3)CC2(F)F)c1,"(S)-6-amino-5-(4,4-difluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)pyrrolidin-3-yloxy)-N-ethylnicotinamide",43.0,uM,=,1.6334684555795866,1,O=C(Cc1ccccc1)N1CC[C@@H](Oc2cccnc2)C1
422,964986,10.1016/j.bmcl.2013.04.047,,,,Inhibition of human ERG expressed in HEK cells by ion flux electrophysiology method,O=C(c1ccc(F)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2)N1CC[C@H](O)C1,"(2-((S)-3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-fluorophenyl)((S)-3-hydroxypyrrolidin-1-yl)methanone",0.7,uM,=,-0.1549019599857432,0,O=C(c1ccccc1OCCCN1CCC2(CC1)Cc1ccccc1O2)N1CCCC1
423,880571,10.1021/ml300280g,,,,Binding affinity to human ERG,N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N[C@H]3CCCC[C@@H]3O)c(=O)n3ccccc23)CC1,"1-((4-cyano-4-(pyridin-2-yl)piperidin-1-yl)methyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-oxo-4H-quinolizine-3-carboxamide",16.4,uM,=,1.214843848047698,1,O=C(NC1CCCCC1)c1cc(CN2CCC(c3ccccn3)CC2)c2ccccn2c1=O
424,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(C(F)(F)F)cc3)ccc2n1)N1CCNCC1,"US9452986, 249",5.91,uM,=,0.7715874808812554,1,O=C(c1ccc2cc(Oc3ccccc3)ccc2n1)N1CCNCC1
425,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2cc3c(cc2Cl)OCO3)CC1)c1cc(=O)c2ccc(F)cc2o1,"N-{1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]piperidin-4-yl}-7-fluoro-4-oxo-4H-chromene-2-carboxamide",0.0135,uM,=,-1.869666231504994,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
426,630097,10.1016/j.bmcl.2010.03.027,,,,Inhibition of human ERG channel by electrophysiology assay,COc1ccc(Cn2c(N3CC[C@@H](N(C)C)C3)nc3ccccc32)cc1,"(R)-1-(1-(4-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)-N,N-dimethylpyrrolidin-3-amine",0.492,uM,=,-0.3080348972326396,0,c1ccc(Cn2c(N3CCCC3)nc3ccccc32)cc1
427,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1,"US9145392, 230",1.6,uM,=,0.2041199826559248,1,c1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ccncn4)CC3)n2)cc1
428,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc(C#N)cn3)CC2)ccc2c1COC2=O,"6-((S)-1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)nicotinonitrile",18.0,uM,=,1.255272505103306,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
429,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Nc1cc(CN2CCC(N(C(=O)NCc3ccc(F)cc3)c3ccc(Cl)cc3)CC2)ccn1,1-(1-((2-aminopyridin-4-yl)methyl)piperidin-4-yl)-1-(4-chlorophenyl)-3-(4-fluorobenzyl)urea,0.384,uM,=,-0.4156687756324692,0,O=C(NCc1ccccc1)N(c1ccccc1)C1CCN(Cc2ccncc2)CC1
430,804280,10.1016/j.bmcl.2011.12.124,,,,Inhibition of human Erg by voltage ion flux electrophysiological assay,CC1CCN(C(=O)c2ccc3c(c2)c2c(n3C)CCN(C3CCOCC3)C2)CC1,"(5-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)(4-methylpiperidin-1-yl)methanone",2.6,uM,=,0.414973347970818,1,O=C(c1ccc2[nH]c3c(c2c1)CN(C1CCOCC1)CC3)N1CCCCC1
431,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CC[C@@H](NCc4cc5c(cn4)OCCO5)[C@@H](O)C3)c2c1,"cis-1-(2-{(3S,4R)-4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-3-hydroxypiperidin-1-yl}ethyl)-7-methoxyquinoxalin-2(1H)-one",15.0,uM,=,1.1760912590556811,1,O=c1cnc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
432,1813578,10.1021/acs.jmedchem.9b00510,,,,Inhibition of human ERG by patch-clamp method,Cc1ccc2oc(-c3c4c(N)n[nH]c(=O)c4nn3-c3ccc(NC(=O)/C=C/CN(C)C)cc3)c(C)c2c1,"(E)-N-(4-(4-Amino-3-(3,5-dimethylbenzofuran-2-yl)-7-oxo-6,7-dihydro-2H-pyrazolo[3,4-d]pyridazin-2-yl)phenyl)-4-(dimethylamino)but-2-enamide",32.85,uM,=,1.5165353738957996,1,O=c1[nH]ncc2c(-c3cc4ccccc4o3)n(-c3ccccc3)nc12
433,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)N3CCC(O)C3)cc2)cc1,1-(4'-(2-((R)-2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-ylsulfonyl)pyrrolidin-3-ol,7.0,uM,=,0.8450980400142568,1,O=S(=O)(c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1)N1CCCC1
434,2135920,10.1021/acsmedchemlett.1c00449,,,,Inhibition of human ERG by automated patch clamp method,CN1CCN(Nc2cccc3c2C[C@@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1,"(S)-N-methyl-N-(((R)-5-((4-methylpiperazin-1-yl)amino)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",6.8,uM,=,0.8325089127062363,1,c1cnc2c(c1)CCC[C@@H]2NC[C@@H]1Cc2c(cccc2NN2CCNCC2)CN1
435,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(C#Cc2ccccc2Cl)cccc1C#Cc1ccccc1Cl,"2,6-bis((2-chlorophenyl)ethynyl)-1-methylpyridinium",3.901,uM,=,0.5911759503117914,1,C(#Cc1cccc(C#Cc2ccccc2)[nH+]1)c1ccccc1
436,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,1.4,uM,=,0.1461280356782379,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
437,1553512,10.1016/j.bmc.2016.02.006,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,O=C(O)CN(Cc1cccc(-c2ccccc2OC(F)(F)F)c1)S(=O)(=O)c1ccc(OC(F)F)cc1,"2-(4-(Difluoromethoxy)-N-((2'-(trifluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)phenylsulfonamido)acetic acid",11.0,uM,=,1.0413926851582251,1,O=S(=O)(NCc1cccc(-c2ccccc2)c1)c1ccccc1
438,622012,10.1021/jm901319p,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1nc(C)c(-c2nnc(SCCCN3C[C@@H]4C[C@]4(c4ccc(C(F)(F)F)cc4)C3)n2C)s1,"(1S,5R)-3-(3-{[5-(2,4-Dimethyl-1,3-thiazol-5-yl)-4-methyl-4H-1,2,4-triazol-3-yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane",0.35,uM,=,-0.4559319556497244,0,c1ccc([C@]23C[C@H]2CN(CCCSc2nnc(-c4cncs4)[nH]2)C3)cc1
439,1744232,10.1021/acs.jmedchem.6b01703,,,,Displacement of [3H]dofetilide from recombinant human ERG expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting method,CCc1nn2c(C)cc(C)nc2c1Cc1ccc(CCC(O)C2CCNCC2)cc1,"3-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-1-(piperidin-4-yl)propan-1-ol",5.3,uM,=,0.724275869600789,1,c1cnc2c(Cc3ccc(CCCC4CCNCC4)cc3)cnn2c1
440,1578296,10.1016/j.bmcl.2016.04.020,,,,Inhibition of human ERG,Cc1ccn2nc3c(c2n1)CN([C@H]1CO[C@H](c2cc(F)ccc2F)[C@@H](N)C1)C3,"(2R,3S,5R)-2-(2,5-Difluoro-phenyl)-5-(5-methyl-1H,3H-2,4,7a,8-tetraaza-cyclopenta[a]inden-2-yl)-tetrahydro-pyran-3-ylamine",18.0,uM,=,1.255272505103306,1,c1ccc([C@@H]2CC[C@@H](N3Cc4nn5cccnc5c4C3)CO2)cc1
441,2219922,10.1016/j.bmcl.2021.128463,,,,Inhibition of human ERG expressed in HEK cells by voltage clamp assay,CN1C(N)=N[C@](C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS1(=O)=O,VERUBECESTAT,2.2,uM,=,0.3424226808222063,1,O=C(Nc1cccc(C2CS(=O)(=O)NC=N2)c1)c1ccccn1
442,1362192,10.1021/ml400473x,,,,Inhibition of human ERG,Cc1cc(-c2ccc3c(c2)CC[C@H]3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1,"2-(2-Methylimidazo[2,1-b][1,3]thiazol-6-yl)-1-{2-[(1R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-ylethanone",6.9,uM,=,0.8388490907372553,1,O=C(Cc1cn2ccsc2n1)N1CCC2(CC1)CN([C@@H]1CCc3cc(-c4ccncn4)ccc31)C2
443,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,N#Cc1ccc2ccc(=O)n(CCN3CC[C@@H](NCc4cc5c(cn4)OCCO5)[C@@H](F)C3)c2c1,"cis-1-(2-{(3S,4R)-4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-3-fluoropiperidin-1-yl}ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",199.0,uM,=,2.298853076409707,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
444,966756,10.1016/j.bmcl.2013.04.074,,,,Binding affinity to wild type human ERG expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization to -40 mV by patch clamp method,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23.C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23.O,"(S)-8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid",1100.0,uM,=,3.041392685158225,1,O=c1ccn2c3c(c(N4CCNCC4)ccc13)OCC2.O=c1ccn2c3c(c(N4CCNCC4)ccc13)OCC2
445,1448835,10.1016/j.ejmech.2014.07.108,,,,Inhibition of human ERG channel after 3 hrs by fluorescence assay,COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]c(C)c(C(=O)NCCN3CCCC3)c2C)c(F)c1,"N-(2-(Pyrrolidin-1-yl)ethyl)-5-((6-(3-(2-fluoro-4-methoxybenzoyl)ureido)-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide",9.67,uM,=,0.9854264740830015,1,O=C(NC(=O)c1ccccc1)Nc1ccc2c(c1)NC(=O)/C2=C\c1cc(C(=O)NCCN2CCCC2)c[nH]1
446,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CCC(CC)c1cn(-c2ccc(F)cc2)c2ccc(Cl)cc12,5-Chloro-3-(1-ethyl-propyl)-1-(4-fluoro-phenyl)-1H-indole,1.48,uM,=,0.1702617153949573,1,c1ccc(-n2ccc3ccccc32)cc1
447,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(CC2CCCNC2)CC1,"rac-N-(3,4-dichlorophenyl)-4-(piperidin-3-ylmethyl)piperazine-1-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(Nc1ccccc1)N1CCN(CC2CCCNC2)CC1
448,811343,10.1016/j.bmcl.2012.01.095,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1cc(O[C@H](CCCCNCc2ccc(F)cc2)C(=O)NO)cc(C)c1F,"(R)-2-(4-fluoro-3,5-dimethylphenoxy)-6-(4-fluorobenzylamino)-N-hydroxyhexanamide",0.79,uM,=,-0.1023729087095585,0,c1ccc(CNCCCCCOc2ccccc2)cc1
449,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3cc(C(F)(F)F)ccn3)ccc2n1)N1CCNCC1,"US9452986, 152",7.3,uM,=,0.8633228601204559,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
450,948139,10.1016/j.bmcl.2013.01.019,,,,Inhibition of human ERG,C[C@@H]1CN(c2nc(N3CCOCC3)c3ccc(-c4cccc(CNCCO)c4)nc3n2)C[C@H](C)O1,"2-(3-(2-((2R,6S)-2,6-dimethylmorpholino)-4-morpholinopyrido[2,3-d]pyrimidin-7-yl)benzylamino)ethanol",13.0,uM,=,1.1139433523068367,1,c1ccc(-c2ccc3c(N4CCOCC4)nc(N4CCOCC4)nc3n2)cc1
451,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCN(C)C(=O)c1ccc([C@H](c2cccnc2)N2CCN(Cc3ccccn3)CC2)cc1,(R)-N-ethyl-N-methyl-4-((4-(pyridin-2-ylmethyl)piperazin-1-yl)(pyridin-3-yl)methyl)benzamide,13.0,uM,=,1.1139433523068367,1,c1ccc([C@H](c2cccnc2)N2CCN(Cc3ccccn3)CC2)cc1
452,580515,10.1016/j.bmcl.2009.06.050,,,,Displacement of [35S]MK499 from human ERG potassium channel expressed in HEK293 cells,COc1ccc([C@@H](C)N[C@@H]2CC[C@@H](C(=O)N3CCC(c4ccccc4)(c4ccc(OC)nc4)CC3)C(C)(C)C2)cc1,"((1R,4R)-4-((R)-1-(4-methoxyphenyl)ethylamino)-2,2-dimethylcyclohexyl)(4-(6-methoxypyridin-3-yl)-4-phenylpiperidin-1-yl)methanone",0.52,uM,=,-0.2839966563652008,0,O=C([C@H]1CC[C@H](NCc2ccccc2)CC1)N1CCC(c2ccccc2)(c2cccnc2)CC1
453,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,COc1ccc2c(=O)cc(C(=O)NC3CCN(Cc4ccc5c(c4)OCO5)CC3)oc2c1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-oxo-4H-chromene-2-carboxamide",0.0115,uM,=,-1.9393021596463884,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
454,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CCN1CCC[C@@H](C(=O)N2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"(R)-N-(3,4-dichlorophenyl)-4-(1-ethylpiperidine-3-carbonyl)piperazine-1-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C(Nc1ccccc1)N1CCN(C(=O)[C@@H]2CCCNC2)CC1
455,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3cccnc3)ccc2c1,(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)-2-(pyridin-3-yl)quinoline,12.0,uM,=,1.0791812460476249,1,c1cncc(-c2ccc3cc(CCN4CCCC4)ccc3n2)c1
456,1973585,10.1021/acs.jmedchem.9b02016,,,,Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,Benzyl-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)-phenyl-amine,1.4,uM,=,0.1461280356782379,1,c1ccc(CN(CCN2CCCC2)c2ccccc2)cc1
457,1935939,10.1016/j.bmc.2019.02.025,,,,Inhibition of human ERG by manual patch clamp electrophysiology assay,COc1cnc(OC)c(C(O)(CCN(C)C)C(c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2F)c1,"rac-1-(6-bromo-2-methoxyquinolin-3-yl)-2-(2,5-dimethoxypyridin-3-yl)-4-(dimethylamino)-1-(2-fluoro-3-methoxyphenyl)butan-2-ol",2.9,uM,=,0.4623979978989561,1,c1ccc(C(Cc2cccnc2)c2cnc3ccccc3c2)cc1
458,876021,10.1021/jm3011838,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,CN1C[C@@H](C(=O)Nc2ccc(Cl)cc2)[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)C1,"(3S,4R)-4-(4-((E)-3-(2-aminophenylamino)-3-oxoprop-1-enyl)phenyl)-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C(/C=C/c1ccc([C@@H]2CNC[C@H]2C(=O)Nc2ccccc2)cc1)Nc1ccccc1
459,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,CC(=O)N1CCC(C2N[C@@H](c3nc(-c4ccccc4)c[nH]3)Cc3c2[nH]c2ccccc32)CC1,"1-(4-((3R)-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)piperidin-1-yl)ethanone",9.8,uM,=,0.9912260756924948,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCNCC4)N3)n2)cc1
460,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,O=C(c1ccccc1Oc1ccccc1)N(CC1CCC1)[C@H]1CCNC1,(S)-N-(cyclobutylmethyl)-2-phenoxy-N-(pyrrolidin-3-yl)benzamide,0.76,uM,=,-0.1191864077192086,0,O=C(c1ccccc1Oc1ccccc1)N(CC1CCC1)[C@H]1CCNC1
461,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,COc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1F,N-[1-[(3-fluoro-4-methoxybenzyl)methyl]piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide,8.3,uM,=,0.919078092376074,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
462,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3ccc(CO)nc3)cc12,4-[(2-Ethylbutyl)amino]-6-[6-(hydroxymethyl)-3-pyridinyl]-3-quinolinecarboxamide,3.1,uM,=,0.4913616938342727,1,c1cncc(-c2ccc3ncccc3c2)c1
463,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,Cc1cc(C)nc(Nc2cc(NC[C@@H](N)CC(F)F)cnc2C(N)=O)c1,"(S)-5-((2-amino-4,4-difluorobutyl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide",5.2,uM,=,0.7160033436347992,1,c1ccc(Nc2cccnc2)nc1
464,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,CN1CCC(c2nc(-c3ccc(F)c(NS(C)(=O)=O)c3)c(-c3ccnc(NCC4CC4)n3)s2)CC1,N-(5-(5-(2-(cyclopropylmethylamino)pyrimidin-4-yl)-2-(1-methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)methanesulfonamide,1.34,uM,=,0.1271047983648076,1,c1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(NCC3CC3)n2)cc1
465,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N(C)C)nc1CN1C(=O)O[C@H](c2cc(Cl)cc(C(F)(F)F)c2)[C@@H]1C,"3'-(4-(((4S,5R)-5-(3-Chloro-5-(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-2-(dimethylamino)pyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic Acid",20.0,uM,=,1.3010299956639813,1,O=C1O[C@H](c2ccccc2)CN1Cc1ncncc1-c1cccc(-c2ccccc2)c1
466,1570047,10.1016/j.bmcl.2016.02.074,,,,Inhibition of human ERG by dofetilide binding assay,Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,"3-(4-amino-7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol",0.42,uM,=,-0.3767507096020995,0,c1ccc(-c2cn([C@H]3C[C@@H](CN4CCC4)C3)c3ncncc23)cc1
467,1714647,10.1021/acs.jmedchem.8b00650,,,,Inhibition of human ERG by patch clamp method,CN(C)c1cncc(-c2ccc(C(=O)N(c3ncccc3Cl)[C@@H]3CCCNC3)cc2)n1,(R)-N-(3-Chloropyridin-2-yl)-4-(6-(dimethylamino)pyrazin-2-yl)-N-(piperidin-3-yl)benzamide,43.2,uM,=,1.6354837468149122,1,O=C(c1ccc(-c2cnccn2)cc1)N(c1ccccn1)[C@@H]1CCCNC1
468,465697,10.1021/jm701187w,,,,Inhibition of human ERG potassium current expressed in HEK293 cells by patch-clamp technique,Cc1cc(C)n(-c2cc(NC(=O)CC3CCN(C)CC3)nc(-c3ccc(C)o3)n2)n1,"N-[6-(3,5-dimethylpyrazol-1-yl)-2-(5-methyl furan-2-yl)pyrimidin-4-yl]-2-(1-methylpiperidin-4-yl)acetamide",4.17,uM,=,0.6201360549737576,1,O=C(CC1CCNCC1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
469,541742,10.1016/j.bmc.2009.01.061,,,,Inhibition of human ERG,CN(C)C(=O)[C@@H](c1ccc(C2=CN3N=CNC3C=C2)cc1)[C@H](N)C(=O)N1CC[C@H](F)C1,"(2S,3S)-3-amino-2-(4-(1,8a-dihydro-[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl)-4-((S)-3-fluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxobutanamide",86.0,uM,=,1.934498451243568,1,O=C(CCc1ccc(C2=CN3N=CNC3C=C2)cc1)N1CCCC1
470,471260,10.1016/j.bmc.2007.12.045,,,,Inhibition of human ERG channel,CCCCN1CCC2(CC1)OC(OC)c1c2cnn1-c1ccccc1,"1'-butyl-3-methoxy-4-phenyl-3,4-dihydrospiro[furo[3,4-c]pyrazole-1,4'-piperidine]",0.00065,uM,=,-3.1870866433571443,0,c1ccc(-n2ncc3c2COC32CCNCC2)cc1
471,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,CCOC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1,Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-carbamic acid ethyl ester,4.98,uM,=,0.6972293427597176,1,c1ccc(-c2ccccc2CN[C@H]2CCNC2)cc1
472,1648277,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncc(Cl)cn3)CC2)nc1)N1CCC1,"(cis)-1-(azetidin-1-yl)-2-(6-(2-((1S,2R)-2-(1-(5-chloropyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)pyridin-3-yl)ethanone",2.1,uM,=,0.3222192947339193,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)nc1)N1CCC1
473,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1c(C#N)cnc3ccccc13)c(=O)n2C,"4-((7-cyano-6-(1,4-diazepan-1-yl)-1-methyl-5-(3-methylbut-2-enyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)methyl)quinoline-3-carbonitrile",0.9,uM,=,-0.0457574905606751,0,O=c1[nH]c2cc(N3CCCNCC3)[nH]c2c(=O)n1Cc1ccnc2ccccc12
474,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CCC(O)(CN)C3)nn12,"3-(Aminomethyl)-1-(5-(4-fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)pyrrolidin-3-ol",21.9,uM,=,1.3404441148401185,1,c1ccc(-c2cnc3sc(N4CCCC4)nn23)cc1
475,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,CSc1cc(Nc2cnc(C#N)c(O[C@H](C)CN(C)C)n2)ncc1-c1cnn(C)c1,(R)-3-((1-(Dimethylamino)propan-2-yl)oxy)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylthio)pyridin-2-yl)amino)pyrazine-2-carbonitrile,8.0,uM,=,0.9030899869919436,1,c1cnc(Nc2ccc(-c3cn[nH]c3)cn2)cn1
476,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,(2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid,108.0,uM,=,2.03342375548695,1,c1ccc(C(c2ccccc2)N2CCNCC2)cc1
477,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,CC(C)Oc1ncc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)s1,cis-N-({1-[4-Hydroxy-4-(2-isopropoxy-thiazol-5-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,28.0,uM,=,1.4471580313422192,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cncs3)CC2)C1
478,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(C#CCOc2ccc(Cl)cc2)cccc1C#CCOc1ccc(Cl)cc1,"2,6-bis(3-(4-chlorophenoxy)prop-1-ynyl)-1-methylpyridinium",31.077,uM,=,1.4924390877887792,1,C(#Cc1cccc(C#CCOc2ccccc2)[nH+]1)COc1ccccc1
479,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,COC(=O)c1ccc(-n2cc(C3CCN(CCN4CCNC4=O)CC3)c3cc(Cl)ccc32)cc1,4-(5-Chloro-3-{1-[2-(2-oxo-imidazolidin-1-yl)-ethyl]-piperidin-4-yl}-indol-1-yl)-benzoic acid methyl ester,0.036,uM,=,-1.4436974992327127,0,O=C1NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccccc23)CC1
480,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Fc1ncccc1-c1cc2sc(N3CCC(N4CCCCC4)CC3)nc2cn1,"2-(1,4'-bipiperidin-1'-yl)-6-(2-fluoropyridin-3-yl)thiazolo[4,5-c]pyridine",1.363636364,uM,=,0.134698574013268,1,c1cncc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)c1
481,2130695,10.1021/acsmedchemlett.1c00334,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated Qpatch electrophysiological method,CNC(=O)c1cc(-n2ncc3cc(Oc4ccccc4Cl)ccc32)cs1,4-(5-(2-chlorophenoxy)-1H-indazol-1-yl)-N-methylthiophene-2-carboxamide,15.7,uM,=,1.1958996524092338,1,c1ccc(Oc2ccc3c(cnn3-c3ccsc3)c2)cc1
482,1663976,10.1021/acs.jmedchem.7b00140,,,,Inhibition of human ERG by fluorescence polarization assay,CCN(CC)Cc1cc(/C=N/N=C(\N)CC(O)c2cc3c(F)cc(F)cc3c3cc(C(F)(F)F)ccc23)ccc1O,"(Z)-N'-((E)-3-((Diethylamino)methyl)-4-hydroxybenzylidene)-3-(1,3-difluoro-6-(trifluoromethyl)-phenanthrene-9-yl)-3-hydroxypropanehydrazonamide",0.39,uM,=,-0.4089353929735008,0,C(CCc1cc2ccccc2c2ccccc12)=N/N=C/c1ccccc1
483,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,CN(C)[C@H]1C[C@@]2(CN=C(N3CCc4ccccc4[C@@H]3c3ccc(F)cc3)O2)C1,"(r)-6-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N,N-dimethyl-5-oxa-7-azaspiro[3.4]oct-6-en-2-amine",7.0,uM,=,0.8450980400142568,1,c1ccc([C@H]2c3ccccc3CCN2C2=NCC3(CCC3)O2)cc1
484,1456349,10.1021/jm401951t,,,,Inhibition of human ERG expressed in CHO cells by electrophysiology assay,CN(C)Cc1ccc2c(c1)CCN(C(=O)c1cc3cc(Br)ncc3n1C)C2,"(5-Bromo-1-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl){6-[(dimethylamino)methyl]-3,4-dihydroisoquinolin-2(1H)-yl}-methanone",31.2,uM,=,1.4941545940184429,1,O=C(c1cc2ccncc2[nH]1)N1CCc2ccccc2C1
485,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(S(C)(=O)=O)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-methoxy-3-(methylsulfonyl)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.55,uM,=,0.1903316981702915,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
486,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,"5-[2-Ethoxy-5-(4-methyl-piperazine-1-sulfonyl)-phenyl]-1-methyl-3-propyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one",100.0,uM,=,2.0,1,O=c1[nH]c(-c2cccc(S(=O)(=O)N3CCNCC3)c2)nc2cn[nH]c12
487,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NCc3ccc4c(c3)OC(F)(F)O4)(CC1)CO2,"(R)-4-((4-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",28.2,uM,=,1.4502491083193612,1,O=c1ccc2nccc3c2n1CC3CC12CCC(NCc3ccc4c(c3)OCO4)(CC1)CO2
488,983134,10.1016/j.bmcl.2013.07.013,,,,Inhibition of human ERG by patch clamp assay,O=c1c(F)cc2ncc(F)c3c2n1C[C@@]3(O)CN1CCC(NCc2cc3c(cn2)OCCO3)CC1,"(S)-4-((4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)methyl)-3,8-difluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",289.0,uM,=,2.460897842756548,1,O=c1ccc2nccc3c2n1CC3CN1CCC(NCc2cc3c(cn2)OCCO3)CC1
489,1666773,10.1021/acs.jmedchem.7b00618,,,,Inhibition of human ERG by patch clamp assay,CC(=O)N1CCN(c2cccc(-c3cc(-c4ccnn4CC(F)(F)F)c4c(N)ncnn34)c2)C(=O)C1(C)C,"4-Acetyl-1-(3-(4-amino-5-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)-3,3-dimethylpiperazin-2-one",17.0,uM,=,1.230448921378274,1,O=C1CNCCN1c1cccc(-c2cc(-c3ccn[nH]3)c3cncnn23)c1
490,761292,10.1021/jm101312a,,,,Inhibition of human ERG expressed in CHO cells by high throughput single cell planar patch clamp method,CN1C[C@@H]2CCC[C@]2(c2ccc(Cl)c(Cl)c2)C1,"cis-rac-(3aS,6aR)-3a-(3,4-dichlorophenyl)-2-methyloctahydrocyclopenta[c]pyrrole",5.64,uM,=,0.7512791039833423,1,c1ccc([C@]23CCC[C@H]2CNC3)cc1
491,1452362,10.1016/j.ejmech.2014.08.027,,,,Inhibition of human ERG expressed in CHO-K1 cells by whole cell patch-clamp assay,C#CCNc1ccnc2sc3c(=O)n(-c4ccc(OC)cc4)cnc3c12,"3-(4-Methoxy-phenyl)-9-prop-2-ynylamino-3H-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-one",31.0,uM,=,1.4913616938342726,1,O=c1c2sc3ncccc3c2ncn1-c1ccccc1
492,494878,10.1021/jm8012618,,,,Inhibition of human cloned ERG,CCN(CC)Cc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O,5-(7-Chloro-quinolin-4-ylamino)-2-diethylaminomethyl-phenol,3.9,uM,=,0.5910646070264992,1,c1ccc(Nc2ccnc3ccccc23)cc1
493,2266525,10.1021/acsmedchemlett.2c00454,,,,Displacement of E-4031 from hERG by fluorescence polarization assay,Nc1nccc(Sc2cnc3[nH]c(N4CCC5(CC4)Cc4ccccc4[C@H]5N)nc3n2)c1Cl,"(S)-1'-(5-((2-amino-3-chloropyridin-4-yl)thio)-1H-imidazo[4,5-b]pyrazin-2-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine",0.9,uM,=,-0.0457574905606751,0,c1ccc2c(c1)CC1(CCN(c3nc4nc(Sc5ccncc5)cnc4[nH]3)CC1)C2
494,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)ccc43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(5-fluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",0.18,uM,=,-0.744727494896694,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
495,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N(CC(F)(F)F)c3ccc4c(c3)OC(F)(F)O4)nn2)ccc1-n1cnc(C)c1,"N-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide",1.92,uM,=,0.2833012287035495,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)Nc1ccc2c(c1)OCO2
496,873269,10.1021/jm3009635,,,,Inhibition of human ERG,C[C@H](c1nc2c(cnn2C2CCCC2)c(=O)[nH]1)N1CC(c2ncccn2)C1,"1-Cyclopentyl-6-[(1R)-1-(3-pyrimidin-2-ylazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one",53.5,uM,=,1.7283537820212285,1,O=c1[nH]c(CN2CC(c3ncccn3)C2)nc2c1cnn2C1CCCC1
497,1924512,10.1021/acsmedchemlett.6b00122,,,,Displacement of [35S]MK-499 from human ERG,Cc1c(C(F)CN2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC2)ccc2c1COC2=O,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)-1-fluoroethyl)-4-methylisobenzofuran-1(3H)-one,68.0,uM,=,1.8325089127062364,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
498,990152,10.1016/j.bmc.2013.08.041,,,,Inhibition of human ERG channel expressed in CHO cells by whole cell patch clamp technique,CCCCOc1ccc(S(=O)(=O)NCCc2c[nH]c3ccccc23)cc1,N-(2-(1H-Indol-3-yl)ethyl)-4-butoxybenzenesulfonamide,3.18,uM,=,0.5024271199844327,1,O=S(=O)(NCCc1c[nH]c2ccccc12)c1ccccc1
499,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,Cc1cc(C2CC=CCN(C)C2)ccc1Cl,"3-(4-chloro-3-methylphenyl)-1-methyl-2,3,4,7-tetrahydro-1H-azepine",26.0,uM,=,1.414973347970818,1,C1=CCC(c2ccccc2)CNC1
500,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Fc1ccccc1-c1c[nH]c([C@H]2Cc3c([nH]c4ccccc34)[C@@H](C3CCOCC3)N2)n1,"(1R,3R)-3-(4-(2-fluorophenyl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.495,uM,=,-0.3053948010664313,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
501,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1onc(-c2ccccc2)c1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-5-methyl-4-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-3-phenylisoxazole,6.4,uM,=,0.8061799739838872,1,c1ccc(-c2nocc2-c2ccc3cc(CCN4CCCC4)ccc3n2)cc1
502,1446841,10.1021/jm500715u,,,,Inhibition of human ERG,CN1CCN(Cc2ccc3nc(Nc4ccc(C(F)(F)F)cn4)[nH]c3c2)CC1,6-((4-methylpiperazin-1-yl)methyl)-N-(5-(trifluoromethyl)pyridin-2-yl)-1H-benzo[d]imidazol-2-amine,21.5,uM,=,1.3324384599156054,1,c1ccc(Nc2nc3ccc(CN4CCNCC4)cc3[nH]2)nc1
503,1473398,10.1021/jm501920g,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,C[C@@H]1CCC[C@H](C)N1CCNc1cn(Cc2ccc(F)cc2)nn1,"N-(2-((2R,6S)-2,6-dimethylpiperidin-1-yl)ethyl)-1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-amine",0.6,uM,=,-0.2218487496163563,0,c1ccc(Cn2cc(NCCN3CCCCC3)nn2)cc1
504,580799,10.1016/j.bmcl.2009.06.095,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells overexpressing Ikr channel protein,CCc1c(CN[C@H]2CC[C@@H](F)C2)nc(-c2ncccc2Cl)n1-c1ccc(C)nc1,"(1S,3R)-N-((2-(3-chloropyridin-2-yl)-5-ethyl-1-(6-methylpyridin-3-yl)-1H-imidazol-4-yl)methyl)-3-fluorocyclopentanamine",15.0,uM,=,1.1760912590556811,1,c1ccc(-c2nc(CNC3CCCC3)cn2-c2cccnc2)nc1
505,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,C[C@H]1CCCN1C(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1,"6-(4-{[(2S)-2-Methylpyrrolidin-1-yl]carbonyl}phenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one",12.0,uM,=,1.0791812460476249,1,O=C(c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1)N1CCCC1
506,541084,10.1016/j.bmcl.2009.01.009,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,CC(C[C@H](NC(=O)C1CCC1)c1ccccc1)N1CCC(c2nnc(CN(C)C)o2)CC1,"N-((1S)-3-(4-(5-((dimethylamino)methyl)-1,3,4-oxadiazol-2-yl)piperidin-1-yl)-1-phenylbutyl)cyclobutanecarboxamide",3.1,uM,=,0.4913616938342727,1,O=C(N[C@@H](CCN1CCC(c2nnco2)CC1)c1ccccc1)C1CCC1
507,2266525,10.1021/acsmedchemlett.2c00454,,,,Displacement of E-4031 from hERG by fluorescence polarization assay,N[C@@H]1c2ccccc2CC12CCN(c1nc3nc(Sc4cccnc4C(F)(F)F)cnc3[nH]1)CC2,"(S)-1'-(5-((2-(trifluoromethyl)pyridin-3-yl)thio)-1H-imidazo[4,5-b]pyrazin-2-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine",1.8,uM,=,0.255272505103306,1,c1cncc(Sc2cnc3[nH]c(N4CCC5(CC4)Cc4ccccc4C5)nc3n2)c1
508,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(NCCc1ccccn1)C1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,N-(2-(pyridin-2-yl)ethyl)-1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidine-4-carboxamide,10.0,uM,=,1.0,1,O=C(NCCc1ccccn1)C1CCN(Cc2ccn(-c3ccccc3)c2)CC1
509,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N(C)C)nc1CN1C(=O)O[C@H](c2cc(F)cc(C(F)(F)F)c2)[C@@H]1C,"3'-(2-(Dimethylamino)-4-(((4 S,5R)-5-(3-fluoro-5-(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-pyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic Acid",25.0,uM,=,1.3979400086720375,1,O=C1O[C@H](c2ccccc2)CN1Cc1ncncc1-c1cccc(-c2ccccc2)c1
510,850453,10.1021/ml300146q,,,,Inhibition of recombinant human ERG channel IKr expressed in CHO cells by patch clamp assay,Cc1cc(C#N)ccc1-c1ccnc(NCc2cc(-c3ccccn3)[nH]n2)c1,3-Methyl-4-(2-((5-(pyridin-2-yl)-1H-pyrazol-3-yl)methylamino)pyridin-4-yl)benzonitrile,1.1,uM,=,0.041392685158225,1,c1ccc(-c2ccnc(NCc3cc(-c4ccccn4)[nH]n3)c2)cc1
511,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1nc(C)ccc1-c1cnc2sc(N3CCC(O)(CN)CC3)nn12,"4-(Aminomethyl)-1-(5-(2-methoxy-6-methylpyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-ol",27.5,uM,=,1.4393326938302626,1,c1cncc(-c2cnc3sc(N4CCCCC4)nn23)c1
512,1924853,10.1016/j.bmcl.2016.07.029,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells measured after 90 mins by scintillation proximity assay,NCc1ccc(C(=O)N2C[C@@H](n3cc(C4CC4)nn3)C[C@H]2C(=O)NCC(c2ccccc2)c2ccccc2)cc1,"(2S,4S)-1-(4-(aminomethyl)benzoyl)-4-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide",0.5,uM,=,-0.3010299956639812,0,O=C(NCC(c1ccccc1)c1ccccc1)[C@@H]1C[C@H](n2cc(C3CC3)nn2)CN1C(=O)c1ccccc1
513,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(NC1CCC1)c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1,"US9452986, 596",30.0,uM,=,1.4771212547196624,1,O=C(NC1CCC1)c1ccc2cc(Oc3ccccn3)ccc2n1
514,537242,10.1021/jm800569w,,,,"Antagonist activity at human ERG in HEK293 cells assessed as inhibition of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide binding",Cc1nc2ccccc2c(=O)n1-c1ccc(OC2CCC(N3CCCC3)C2)cc1,2-Methyl-3-[4-([3-(1-pyrrolidinyl)cyclopentyl]oxy)phenyl]-4(3H)-quinazolinone,10.0,uM,=,1.0,1,O=c1c2ccccc2ncn1-c1ccc(OC2CCC(N3CCCC3)C2)cc1
515,792666,10.1016/j.bmcl.2011.09.133,,,,Inhibition of human ERG,COc1ccc(N(Cc2cnccc2C)C2CCN([C@H](C)CCNC(=O)c3c(C)cc(Cl)nc3C)CC2)cc1,"(R)-6-chloro-N-(3-(4-((4-methoxyphenyl)((4-methylpyridin-3-yl)methyl)amino)piperidin-1-yl)butyl)-2,4-dimethylnicotinamide",0.25,uM,=,-0.6020599913279624,0,O=C(NCCCN1CCC(N(Cc2cccnc2)c2ccccc2)CC1)c1cccnc1
516,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4cc(F)c(F)cc43)C[C@@H]12)c1ccc(Cl)cc1,"4-chloro-N-(((1R,3s,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)methyl)benzamide",4.8,uM,=,0.6812412373755872,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
517,716794,10.1016/j.bmcl.2010.12.123,,,,Inhibition of human ERG expressed in CHO cells,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(Cl)c1,"(S)-3-chloro-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)benzoic acid",7.8,uM,=,0.8920946026904804,1,O=C(Nc1ccccc1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
518,1890282,10.1021/acs.jmedchem.8b01972,,,,Inhibition of Tracer Red binding to human ERG expressed in membranes by fluorescence polarization assay,CN(C)c1ccc(CNC(=O)[C@@H]2CNC[C@H]2c2ccc(C(F)(F)F)c(Cl)c2)cc1,"(+/-)-(3S,4R)-4-[3-chloro-4-(trifluoromethyl)phenyl]-N-{[4-(dimethylamino)phenyl]methyl}pyrrolidine-3-carboxamide",7.56,uM,=,0.8785217955012066,1,O=C(NCc1ccccc1)[C@@H]1CNC[C@H]1c1ccccc1
519,1882359,10.1016/j.ejmech.2018.10.057,,,,Inhibition of red tracer binding to human ERG expressed in membranes preincubated for 10 to 15 mins followed by tracer addition measured after 3 hrs by fluorescence polarization assay,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1.Cl.Cl,N-(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide dihydrochloride,0.01,uM,=,-2.0,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
520,755804,10.1021/jm2003359,,,,Inhibition of human ERG expressed in CHO cells by Q-patch assay,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)cc2)C1,"2-amino-1-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one",5.6,uM,=,0.7481880270062004,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
521,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,C[C@@H](NC(=O)c1ccc(Cl)cc1)c1ccc2c(n1)CCCN2C(=O)c1cccc(Cl)c1,"(R)-4-chloro-N-(1-(5-(3-chlorobenzoyl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)benzamide",8.7,uM,=,0.9395192526186184,1,O=C(NCc1ccc2c(n1)CCCN2C(=O)c1ccccc1)c1ccccc1
522,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3ccc(C)nc3cc2F)o1,(S)-N-((S)-1-(5-(7-fluoro-2-methylquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,30.0,uM,=,1.4771212547196624,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)o1)[C@H]1CC12CCNCC2
523,1613479,10.1021/acs.jmedchem.6b00972,,,,Inhibition of human ERG transfected in HEK293 cells assessed as reduction in tail current by patch clamp assay,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(F)cc3F)C2)nnc1-c1cccnc1,"(1S,3S)-1-(2,4-Difluorophenyl)-5-(3-{[4-methyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptane",2.8,uM,=,0.4471580313422192,1,c1ccc([C@H]2C[C@]23CCN(CCCSc2nnc(-c4cccnc4)[nH]2)C3)cc1
524,537242,10.1021/jm800569w,,,,"Antagonist activity at human ERG in HEK293 cells assessed as inhibition of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide binding",Cc1nc2ccccc2c(=O)n1-c1ccc(OC2CCCN(C3CCCC3)CC2)cc1,3-(4-[(1-Cyclopentyl-4-azepanyl)oxy]phenyl)-2-methyl-4(3H)-quinazolinone,6.8,uM,=,0.8325089127062363,1,O=c1c2ccccc2ncn1-c1ccc(OC2CCCN(C3CCCC3)CC2)cc1
525,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccns2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(isothiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",8.9,uM,=,0.9493900066449128,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccns3)C4=O)ccc21
526,2013230,10.1016/j.bmcl.2019.03.014,,,,Inhibition of human ERG by manual patch clamp assay,Cc1noc(C)c1-c1ccc2nc(-c3cnn(CC(C)(C)O)c3)nc(N3CCOC[C@@H]3c3ccccc3)c2c1,"(S)-1-(4-(6-(3,5-dimethylisoxazol-4-yl)-4-(3-phenylmorpholino)quinazolin-2-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-ol",6.5,uM,=,0.8129133566428556,1,c1ccc([C@H]2COCCN2c2nc(-c3cn[nH]c3)nc3ccc(-c4cnoc4)cc23)cc1
527,1973585,10.1021/acs.jmedchem.9b02016,,,,Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,1.2,uM,=,0.0791812460476248,1,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
528,793275,10.1016/j.bmcl.2011.09.117,,,,Displacement of [3H]dofetilide from human ERG by liquid scintillation counting,COc1ccc2ncc(C#N)c(CCN3CCC(NCc4cc5c(cn4)OCS5)CC3)c2c1,"4-(2-(4-([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile",0.5,uM,=,-0.3010299956639812,0,c1ccc2c(CCN3CCC(NCc4cc5c(cn4)OCS5)CC3)ccnc2c1
529,1682731,10.1021/acs.jmedchem.7b01135,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cell membranes,N#C[C@H]1C[C@@H](O)CC[C@@H]1n1cc(C(N)=O)c(Nc2ccc(Cl)cc2)n1,"US8962608, 33-2",26.0,uM,=,1.414973347970818,1,c1ccc(Nc2ccn(C3CCCCC3)n2)cc1
530,629418,10.1016/j.bmcl.2010.03.071,,,,Displacement of labeled dofetilide human ERG,N#Cc1ccc(O[C@@H]2CN[C@@H](C(=O)N3CCCN(C4CCCC4)CC3)C2)cc1,"4-((3S,5R)-5-(4-cyclopentyl-1,4-diazepane-1-carbonyl)pyrrolidin-3-yloxy)benzonitrile",2.9,uM,=,0.4623979978989561,1,O=C([C@H]1C[C@H](Oc2ccccc2)CN1)N1CCCN(C2CCCC2)CC1
531,941017,10.1021/jm301564f,,,,Inhibition of human ERG K+ channel expressed in HEK293 cells after 15 mins by patch clamp assay,Cc1ccc(OCCCc2cc(N)cc(CCCOc3ccc(C)cc3)n2)cc1,"2,6-bis(3-(p-tolyloxy)propyl)pyridin-4-amine",0.146,uM,=,-0.835647144215563,0,c1ccc(OCCCc2cccc(CCCOc3ccccc3)n2)cc1
532,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,C[C@@H]1CC[C@H](Nc2ncc(C(N)=O)c3sc(-c4ccccc4)cc23)CN1,"rac-4-(cis-6-Methylpiperidin-3-ylamino)-2-phenylthieno[3,2-c]-pyridine-7-carboxamide",2.45,uM,=,0.3891660843645325,1,c1ccc(-c2cc3c(N[C@H]4CCCNC4)nccc3s2)cc1
533,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21,2-Methanesulfinyl-10-[2-(1-methyl-piperidin-2-yl)-ethyl]-10H-phenothiazine,0.32,uM,=,-0.494850021680094,0,c1ccc2c(c1)Sc1ccccc1N2CCC1CCCCN1
534,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cn1c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2ccccc2c1=O,2-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-3-methylquinazolin-4(3H)-one,5.6,uM,=,0.7481880270062004,1,O=c1[nH]c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2ccccc12
535,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,N#Cc1cc(CC(=O)N2CCN(CCc3ccc4c(c3)COC4=O)CC2)ccc1-n1cnnn1,"5-(2-oxo-2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-2-(1H-tetrazol-1-yl)benzonitrile",7.1,uM,=,0.8512583487190752,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
536,1637262,,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in tail current amplitude by whole cell patch clamp method,COc1ccc(-c2cc(=O)c3cc(C)ccc3o2)cc1,2-(4-methoxyphenyl)-6-methyl-4H-chromen-4-one,57.9,uM,=,1.7626785637274365,1,O=c1cc(-c2ccccc2)oc2ccccc12
537,1655139,10.1016/j.bmcl.2016.12.054,,,,Displacement of [3H]-MK499 from human ERG IKr channel expressed in HEK293 cell membranes,OC(Cc1cccnc1-c1cccc(C(F)(F)F)c1)(c1cccnc1F)c1cccnc1F,"rac-1,1-bis(2-fluoropyridin-3-yl)-2-(2-(3-(trifluoromethyl)phenyl)pyridin-3-yl)ethanol",10.0,uM,=,1.0,1,c1ccc(-c2ncccc2CC(c2cccnc2)c2cccnc2)cc1
538,1901723,10.1021/acs.jmedchem.9b01684,,,,Inhibition of human ERG stably expressed in CHO cells at -90 mV holding potential by electrophysiological assay,Cc1cc2nccn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C,"7-Methyl-2-((7-methylimidazo[1,2-a]pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one",8.1,uM,=,0.9084850188786496,1,O=c1[nH]c2cnc(Nc3ccc4nccn4c3)nc2n1C1CCOCC1
539,1992475,10.1021/acs.jmedchem.0c01199,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by IonWorks barracuda patch clamp method,COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1F,"1-(4-(5-(4-Fluoro-3,5-dimethoxyphenyl)-4-methylpyridin-3-yl)phenyl)piperazine",2.5,uM,=,0.3979400086720376,1,c1ccc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2)cc1
540,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CC[C@@H](NC(=O)c1ccc(Cl)c(F)c1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)-3-fluorobenzamide",2.5,uM,=,0.3979400086720376,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
541,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(C)c(C)cc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-4,5-dimethylphenyl)-N-methylmethanamine",1.48,uM,=,0.1702617153949573,1,c1ccc(Oc2ccccc2)cc1
542,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Fc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)nc1,"(1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",1.742,uM,=,0.2410481506716444,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)nc1
543,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,OCCN1CC=CC[C@H](c2ccc(Cl)c(Cl)c2)C1,"2-[(R)-3-(3,4-Dichloro-phenyl)-2,3,4,7-tetrahydro-azepin-1-yl]-ethanol",10.0,uM,=,1.0,1,C1=CC[C@H](c2ccccc2)CNC1
544,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc(C2(c3nn(C)c(=O)o3)NC(c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"5-(1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one",27.1,uM,=,1.4329692908744058,1,O=c1[nH]nc(C2(c3cn[nH]c3)NC(c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
545,2084867,10.1021/acs.jmedchem.6b00943,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated Qpatch electrophysiological assay,Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C#Cc1nn([C@H]2CC[C@H](O)CC2)c2ncnc(N)c12,"N-(3-((4-Amino-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide",26.42,uM,=,1.4219328132785083,1,O=C(Nc1cccc(C#Cc2nn(C3CCCCC3)c3ncncc23)c1)c1ccccc1
546,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1.O=[N+]([O-])O,5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol nitrate,0.16,uM,=,-0.7958800173440752,0,c1ccc(/N=N/c2ccccn2)cc1
547,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cc2ccccc2o1,"(1S,2S)-2-(benzofuran-2-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-1-(2,3-dimethoxypyridin-4-yl)-4-(dimethylamino)butan-2-ol",0.8,uM,=,-0.0969100130080563,0,c1ccc2cc([C@H](Cc3cc4ccccc4o3)c3ccncc3)ccc2c1
548,1463729,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG by MK499 binding assay,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"6-((1-((3-fluoro-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",23.0,uM,=,1.3617278360175928,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
549,960793,10.1016/j.bmcl.2013.04.020,,,,Inhibition of human ERG channel by patch clamp technique,O=C(Nc1c[nH]c2ncc(-c3ccccc3F)cc12)c1cnn2ccc(NC[C@H]3CCNC[C@@H]3F)nc12,"rel-trans-N-(5-(2-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-((((3R,4R)-3-fluoropiperidin-4-yl)methyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C(Nc1c[nH]c2ncc(-c3ccccc3)cc12)c1cnn2ccc(NCC3CCNCC3)nc12
550,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,Cc1noc(-c2ccc(CCN3CCC(Nc4nc5ccccc5n4Cc4ccc(C#N)cc4)CC3)cc2)n1,"4-((2-(1-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenethyl)piperidin-4-ylamino)-1H-benzo[d]imidazol-1-yl)methyl)benzonitrile",0.1,uM,=,-1.0,0,c1ccc(Cn2c(NC3CCN(CCc4ccc(-c5ncno5)cc4)CC3)nc3ccccc32)cc1
551,1577972,10.1021/acsmedchemlett.5b00432,,,,Inhibition of human ERG by whole-cell patch clamp assay,COc1cnc(C(=O)Nc2cc(F)c(F)c([C@]3(C)C[C@@H](c4c(C)noc4C)SC(N)=N3)c2)cn1,"N-(3-((4S,6S)-2-amino-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-4-yl)-4,5-difluorophenyl)-3,5-dimethoxypyrazine-2-carboxamide",0.64,uM,=,-0.1938200260161128,0,O=C(Nc1cccc(C2C[C@@H](c3cnoc3)SC=N2)c1)c1cnccn1
552,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,CC(=O)Nc1cccc(N2CCN(CCCCNS(=O)(=O)c3ccc(C)cc3)CC2)c1,N-(3-{4-[4-(toluene-4-sulfonylamino)-butyl]-piperazin-1-yl}-phenyl)-acetamide,0.3,uM,=,-0.5228787452803376,0,O=S(=O)(NCCCCN1CCN(c2ccccc2)CC1)c1ccccc1
553,1972207,10.1021/acs.jmedchem.9b01624,,,,Inhibition of human ERG by Qpatch S8 assay,O=C(Nc1cc(-c2cn(-c3ccccc3)c3cnccc23)ccn1)NC1CC1,"1-Cyclopropyl-3-(4-(1-phenyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)urea",0.6,uM,=,-0.2218487496163563,0,O=C(Nc1cc(-c2cn(-c3ccccc3)c3cnccc23)ccn1)NC1CC1
554,1706671,10.1016/j.bmc.2017.07.008,,,,Inhibition of human ERG expressed in CHOK1 cells by whole cell patch clamp method,CC(C)c1cc(CN2Cc3ccccc3S2(=O)=O)nn1C(C)(C)C,"2-[{(1-t-butyl)-5-isobutyl-1H-pyrazol-3-yl-}methyl]2,3-dihydrobenzo[d]isothiazol-1,1-dioxide",19.3,uM,=,1.285557309007774,1,O=S1(=O)c2ccccc2CN1Cc1cc[nH]n1
555,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=C1\SCC(=O)N1c1ccccc1,"2-((4-Oxo-3-phenylthiazolidin-2-ylidene)amino)-4,6-diphenylnicotinonitrile",45.5,uM,=,1.6580113966571124,1,O=C1CS/C(=N\c2cc(-c3ccccc3)cc(-c3ccccc3)n2)N1c1ccccc1
556,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Cc1nc([C@@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"5-methyl-3-((1S,3R)-1-(1-methyl-1H-pyrazol-4-yl)-3-(4-(pyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,2,4-oxadiazole",4.895,uM,=,0.6897526961391566,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@](c4cn[nH]c4)(c4ncon4)N3)n2)nc1
557,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CCCNS(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1,(R)-4'-(2-(2-methylpyrrolidin-1-yl)ethyl)-N-propylbiphenyl-4-sulfonamide,1.411764706,uM,=,0.1497623203695233,1,c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
558,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC1=C(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc2S1(=O)=O,"1-{3-[4-(3-Methyl-4,4-dioxo-4H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",0.47,uM,=,-0.3279021420642826,0,O=S1(=O)C=C(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
559,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,COc1ccc(Cn2c(=O)n3ncnc3c3c4c(sc32)CN(CC2CCOCC2)CC4(F)F)cc1,"11,11-Difluoro-6-(4-methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]-triazolo[1,5-c]pyrimidin-5(6H)-one",9.2,uM,=,0.9637878273455552,1,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCN(CC1CCOCC1)C3
560,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,C[C@@H]1NCCC[C@@H]1Nc1ncc(C(N)=O)c2sc(-c3ccccc3)cc12,"4-((2S,3S)-2-Methylpiperidin-3-ylamino)-2-phenylthieno-[3,2-c]pyridine-7-carboxamide",5.9,uM,=,0.7708520116421442,1,c1ccc(-c2cc3c(N[C@H]4CCCNC4)nccc3s2)cc1
561,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,CN1CCC(COc2cc(NC(=O)N3CCCc4cc(C(F)F)c(C=O)nc43)ncc2C#N)CC1,"N-(5-cyano-4-((1-methylpiperidin-4-yl)methoxy)pyridin-2-yl)-6-(difluoromethyl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide",10.0,uM,=,1.0,1,O=C(Nc1cc(OCC2CCNCC2)ccn1)N1CCCc2cccnc21
562,439396,10.1016/j.bmcl.2007.05.087,,,,Inhibition of human ERG potassium channel,Cc1cc(=O)n2nc(N3CC[C@H](c4cc(F)c(F)cc4F)[C@@H](N)C3)ccc2n1.O=C(O)C(F)(F)F,"(3R,4R)-1-(2-methyl-4-oxo-4H-pyrimido[1,2-b]pyridazin-7-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium 2,2,2-trifluoroacetate",33.2,uM,=,1.5211380837040362,1,O=c1ccnc2ccc(N3CCC(c4ccccc4)CC3)nn12
563,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CCn1cc([C@]2(c3cccc(C#CC4CC4)c3)N=C(N)c3c(F)cccc32)cc(C)c1=O,(R)-5-(3-Amino-1-(3-(cyclopropylethynyl)phenyl)-4-fluoro-1H-isoindol-1-yl)-1-ethyl-3-methylpyridin-2(1H)-one,8.5,uM,=,0.9294189257142929,1,O=c1ccc([C@]2(c3cccc(C#CC4CC4)c3)N=Cc3ccccc32)c[nH]1
564,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COC(=O)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"methyl 7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridine-2-carboxylate",0.00875,uM,=,-2.057991946977687,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
565,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3ccc(C)nc3cc2F)[nH]1,(S)-N-((S)-1-(5-(7-fluoro-2-methylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,24.0,uM,=,1.380211241711606,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)[nH]1)[C@H]1CC12CCNCC2
566,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,C[C@H]1C=C(C2=Nc3cc(Cl)ccc3Nc3ccc(C#N)cc32)CCN1C,"(S)-8-chloro-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepine-2-carbonitrile",0.6,uM,=,-0.2218487496163563,0,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
567,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(Br)c3n2CCN1CC1CC1,"6-Bromo-2-(cyclopropylmethyl)-3,4-dihydropyrazino(1,2-a)benzimidazol-1(2H)-one",30.0,uM,=,1.4771212547196624,1,O=C1c2nc3ccccc3n2CCN1CC1CC1
568,1478745,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,"1-{1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one",0.02,uM,=,-1.6989700043360187,0,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccccc2)c2ccccc2)CC1
569,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COc1cccc(-n2cc3nc(-c4ccccc4C)n(CC4CCCN(C(C)C)C4)c(=O)c3n2)c1,"rac-6-((1-Isopropylpiperidin-3-yl)methyl)-2-(3-methoxyphenyl)-5-o-tolyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",15.0,uM,=,1.1760912590556811,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2ccccc2)n1CC1CCCNC1
570,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,Cc1c(O)ccc2c1C(=O)N(Cc1ccccc1-c1ccc(F)c(F)c1)C2C(=O)NC(C)(C)C,"N-tert-butyl-2-((3',4'-difluorobiphenyl-2-yl)methyl)-5-hydroxy-4-methyl-3-oxoisoindoline-1-carboxamide",27.0,uM,=,1.4313637641589874,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
571,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cncc(C(F)(F)F)c3)CC2)(C(C)C)C1,"cis-((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxytetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridin-3-yl)piperazin-1-yl)methanone",2.1,uM,=,0.3222192947339193,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2cccnc2)CC1
572,1570074,10.1016/j.bmcl.2016.02.075,,,,Displacement of [3H]-dofetilide from human ERG channel expressed in HEK293 cells,CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cccc(OCC56CCC(CC5)O6)c4)c4c(N)ncnc43)C2)CC1,"1-(4-((cis)-3-(5-(3-(7-oxabicyclo[2.2.1]heptan-1-ylmethoxy)phenyl)-4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclobutyl)piperazin-1-yl)ethanone",15.0,uM,=,1.1760912590556811,1,c1cc(OCC23CCC(CC2)O3)cc(-c2cn([C@H]3C[C@@H](N4CCNCC4)C3)c3ncncc23)c1
573,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2,"8-[4,4-Bis-(4-fluoro-phenyl)-butyl]-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one",2.3,uM,=,0.3617278360175928,1,O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccccc1)c1ccccc1)CC2
574,489010,10.1021/jm8003834,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide from human ERG in HEK293 cells",Cc1nc2ccccc2c(=O)n1-c1ccc(OCCCN2CCCCC2)cc1,2-methyl-3-(4-(3-(piperidin-1-yl)propoxy)phenyl)quinazolin-4(3H)-one,8.6,uM,=,0.9344984512435676,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCCC2)cc1
575,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,Nc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCN(CCO)CC7)ncc6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1,"2-(4-(7-(4-((4-(5-(6-aminopyridin-3-yl)-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-6-phenylpyrido[2,3-d]pyrimidin-2-yl)piperazin-1-yl)ethanol",7.4,uM,=,0.8692317197309762,1,c1ccc(-c2cc3cnc(N4CCNCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5cccnc5)[nH]4)CC3)cc2)cc1
576,1865158,10.1021/acsmedchemlett.9b00186,,,,Inhibition of human ERG,COCc1nnc(N2C[C@@H]3C[C@]3(c3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1,"(1S,5R)-1-(2-chloro-4-fluorophenyl)-3-(5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-azabicyclo[3.1.0]hexane",16.0,uM,=,1.2041199826559248,1,c1ccc([C@]23C[C@H]2CN(c2nncn2-c2cccnc2)C3)cc1
577,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(OC)cc(OC)c2)CCN(CC2=Cc3ccccc3OC2(C)C)CC1,"methyl 4-((3,5-dimethoxybenzamido)methyl)-1-(2,2-dimethyl-2H-chromen-3-yl)piperidine-4-carboxylate",1.29,uM,=,0.1105897102992489,1,O=C(NCC1CCN(CC2=Cc3ccccc3OC2)CC1)c1ccccc1
578,1613239,10.1021/acs.jmedchem.6b00703,,,,Inhibition of human ERG,CN1CCN(c2ccccc2CNC(=O)c2ccc(F)c(NC(=O)c3cnc4cc(-c5ccnn5C)ccn34)c2)CC1,"N-(2-Fluoro-5-((2-(4-methylpiperazin-1-yl)benzyl)carbamoyl)-phenyl)-7-(1-methyl-1H-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide",4.0,uM,=,0.6020599913279624,1,O=C(NCc1ccccc1N1CCNCC1)c1cccc(NC(=O)c2cnc3cc(-c4ccn[nH]4)ccn23)c1
579,883359,10.1021/jm300952s,,,,Inhibition of human ERG by cell-based electrophysiology assay,Cc1nc(CN2CCN(c3c(Cl)cnc4[nH]c(-c5cn(C)nc5C)nc34)CC2)no1,"3-((4-(6-Chloro-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methyl-1,2,4-oxadiazole",9.5,uM,=,0.9777236052888478,1,c1cc(N2CCN(Cc3ncon3)CC2)c2nc(-c3cn[nH]c3)[nH]c2n1
580,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,Fc1ccc(C(Cc2ccccc2OC(F)(F)F)N2CCNCC2)cc1,1-(1-(4-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine,9.64,uM,=,0.9840770339028307,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
581,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CCCn1c(-c2ccc(OCCCN3CCCCC3)cc2)nc2ccccc2c1=O,2-(4-(3-(piperidin-1-yl)propoxy)phenyl)-3-propylquinazolin-4(3H)-one,1.8,uM,=,0.255272505103306,1,O=c1[nH]c(-c2ccc(OCCCN3CCCCC3)cc2)nc2ccccc12
582,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1cc2ncn(Cc3ccc(Cl)cc3)c2cc1C,"1-(4-chlorobenzyl)-5,6-dimethyl-1H-benzo[d]imidazole",7.0,uM,=,0.8450980400142568,1,c1ccc(Cn2cnc3ccccc32)cc1
583,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1,"1-[(1S,2S)-2-Hydroxy-2-(4-hydroxy-phenyl)-1-methyl-ethyl]-4-phenyl-piperidin-4-ol",10.0,uM,=,1.0,1,c1ccc(CCN2CCC(c3ccccc3)CC2)cc1
584,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CC(C)COc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ccc(C#N)cc2F)CC1,3-Fluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-1-yl]-benzonitrile,0.7,uM,=,-0.1549019599857432,0,O=C(c1ccccc1)N1CCN(c2ccccc2)CC1
585,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,FC(F)(F)Oc1cccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)c1,"(1R,3R)-1-(tetrahydro-2H-pyran-4-yl)-3-(4-(3-(trifluoromethoxy)phenyl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.058,uM,=,-1.2365720064370629,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
586,498774,10.1021/jm900110t,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",N#Cc1ccnc(C2=NC(c3ccc(F)cc3)(c3ccc(F)cc3)CN2)c1,"2-(4,4-bis(4-fluorophenyl)-4,5-dihydro-1H-imidazol-2-yl)isonicotinonitrile",0.101,uM,=,-0.9956786262173574,0,c1ccc(C2(c3ccccc3)CNC(c3ccccn3)=N2)cc1
587,1437941,10.1021/jm5016022,,,,Inhibition of human ERG channel by patch-clamp assay,Cc1nc2ccc(C(=O)N3CCC4(CC3)CC(=O)c3c(cnn3C(C)C)C4)cc2[nH]1,"1-Isopropyl-1'-(2-methyl-1H-benzo[d]imidazole-6-carbonyl)-1,4-dihydrospiro[indazole-5,4'-piperidin]-7(6H)-one",141.0,uM,=,2.14921911265538,1,O=C1CC2(CCN(C(=O)c3ccc4nc[nH]c4c3)CC2)Cc2cn[nH]c21
588,2153986,10.1021/acsmedchemlett.1c00660,,,,Inhibition on hERG expressed in HEK293 cells by Qpatch method,CCN(CC)CCNC(=O)c1cccn2c(=O)c3ccc4ccccc4c3nc12,"N-(2-(diethylamino)ethyl)-7-oxo-7H-benzo[h]pyrido[2,1-b]quinazoline-12-carboxamide",3.8,uM,=,0.5797835966168101,1,O=c1c2ccc3ccccc3c2nc2ccccn12
589,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3ccns3)CC2)C1,cis-N-{[1-(4-Hydroxy-4-isothiazol-5-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide,24.0,uM,=,1.380211241711606,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccns3)CC2)C1
590,357755,10.1021/jm0508641,,,,Inhibition of hERG potassium channel in HEK293 cells by patch clamp assay,CC(=O)Nc1cccc(N2CCN(CCCCNS(=O)(=O)CC(C)C)CC2)c1,N-(3-{4-[4-(2-methyl-propane-1-sulfonylamino)-butyl]-piperazin-1-yl}-phenyl)-acetamide,3.0,uM,=,0.4771212547196624,1,c1ccc(N2CCNCC2)cc1
591,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,O=C(CCCS(=O)(=O)c1ccccc1)Nc1nc(=O)[nH]cc1F,"N-(5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)-4-(phenylsulfonyl)butanamide",40.477,uM,=,1.6072083167831537,1,O=C(CCCS(=O)(=O)c1ccccc1)Nc1cc[nH]c(=O)n1
592,1364610,10.1021/ml500069w,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp assay,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1.Cl,"6-((1-(2-(3-Fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one hydrochloride",0.6,uM,=,-0.2218487496163563,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
593,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,CC(C)(CO)Oc1ccc(C(N)=O)c(O[C@@H]2CCN(C(=O)Cc3ccc(OC(F)(F)F)cc3)C[C@@H]2F)c1,"2-(((3S,4R)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)-piperidin-4-yl)oxy)-4-((1-hydroxy-2-methylpropan-2-yl)oxy)-benzamide",35.0,uM,=,1.5440680443502757,1,O=C(Cc1ccccc1)N1CCC(Oc2ccccc2)CC1
594,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,c1ccc(CCc2cccc(CCc3ccccc3)n2)cc1,"2,6-diphenethylpyridine",1.608,uM,=,0.2062860444124324,1,c1ccc(CCc2cccc(CCc3ccccc3)n2)cc1
595,606311,10.1016/j.bmcl.2009.10.133,,,,Inhibition of human ERG channel,FC(F)(F)c1cc(Nc2ccncc2)nc(NCc2ccc3c(c2)OCO3)n1,"N2-(benzo[d][1,3]dioxol-5-ylmethyl)-N4-(pyridin-4-yl)-6-(trifluoromethyl)pyrimidine-2,4-diamine",135.0,uM,=,2.130333768495006,1,c1cc(Nc2ccnc(NCc3ccc4c(c3)OCO4)n2)ccn1
596,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(C)N1CCN(C(=O)N2CC=C(c3ccccc3)CC2)CC1,"(4-isopropylpiperazin-1-yl)(4-phenyl-5,6-dihydropyridin-1(2H)-yl)methanone",22.25806452,uM,=,1.3474873969785122,1,O=C(N1CC=C(c2ccccc2)CC1)N1CCNCC1
597,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(NC1CC(F)(F)C1)c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1,"US9452986, 59",30.0,uM,=,1.4771212547196624,1,O=C(NC1CCC1)c1ccc2cc(Oc3ccccn3)ccc2n1
598,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(CCCOc2ccccc2Cl)cccc1CCCOc1ccccc1Cl,"2,6-bis(3-(2-chlorophenoxy)propyl)-1-methylpyridinium",0.074,uM,=,-1.1307682802690238,0,c1ccc(OCCCc2cccc(CCCOc3ccccc3)[nH+]2)cc1
599,1640440,,,,,"hERG Patch Clamp Assay: All testing was carried out in CHO cells transfected with the hERG gene purchased from Millipore (PrecisION hERG-CHO Recombinant Cell Line CYL3038). The cell line was grown in DMEM/F-12, GlutaMAX with 10% fetal bovine serum, 1% Penicillin-Streptomycin, 1% Geneticin and 1% of 1M HEPES buffer solution, and maintained at approximately 37 °C. in a humidified atmosphere containing 5% carbon dioxide. The cells were passaged every 3-5 days based on confluency. On the day of the experiment, 50%-80% confluent cells were harvested from a 175 cm2 culture flask using Detachin. After 10 minutes of exposure to Detachin at 37 °C., the cells were centrifuged for 1 minute at 1000 RPM. The supernatant was removed and the cell pellet was reconstituted in 5-8 mL of serum free media with 2.5% of 1M HEPES, placed on the Qstirrer, and allowed to recover. After a 30 minute recovery period, experiments were initiated.",C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3ccc(OC(F)F)cn3)ccc2F)CO1,"US9315520, Comparator 2::US9315520, Comparator 3",0.4,uM,=,-0.3979400086720376,0,O=C(Nc1cccc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccn1
600,580799,10.1016/j.bmcl.2009.06.095,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells overexpressing Ikr channel protein,COCCc1nc(CN[C@H]2CC[C@@H](F)C2)n(C(C)C)c1-c1ccc(Cl)cc1,"(1S,3R)-N-((5-(4-chlorophenyl)-1-isopropyl-4-(2-methoxyethyl)-1H-imidazol-2-yl)methyl)-3-fluorocyclopentanamine",16.0,uM,=,1.2041199826559248,1,c1ccc(-c2cnc(CNC3CCCC3)[nH]2)cc1
601,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(C)c(-c2ccc3cc(CCN4CCCC4C)ccc3n2)cc1C#N,"2,6-dimethyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)nicotinonitrile",8.4,uM,=,0.9242792860618816,1,c1cncc(-c2ccc3cc(CCN4CCCC4)ccc3n2)c1
602,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,"1-{1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one",1.7,uM,=,0.2304489213782739,1,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccccc2)c2ccccc2)CC1
603,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC7(CO)CC7)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-((1-(hydroxymethyl)cyclopropyl)methoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.7,uM,=,0.4313637641589873,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7CC7)nc56)(CC3)OC4)nc2N1
604,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3CCO)n1,"(R)-(4-Fluorophenyl)(8-(2-hydroxyethyl)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",50.0,uM,=,1.6989700043360187,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
605,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,COCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-(2-methoxyethoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",17.3,uM,=,1.2380461031287957,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
606,634333,10.1021/jm100053t,,,,Inhibition of human ERG,CNC[C@@H](O)CCN1c2ccccc2N(c2cc(F)ccc2F)S1(=O)=O,"(2S)-(4-[3-(2,5-Difluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ol",13.0,uM,=,1.1139433523068367,1,O=S1(=O)Nc2ccccc2N1c1ccccc1
607,1926979,10.1021/acsmedchemlett.6b00119,,,,Displacement of [3H]dofetilide from recombinant human ERG transfected in HEK293 cell membranes after 60 mins by scintillation counting,CN1CCN(C(=O)c2cccc(-c3ncnc4ccc(-c5cnc6ccccc6c5)cc34)c2)CC1,(4-methylpiperazin-1-yl)(3-(6-(quinoline-3-yl)quinazolin-4-yl)phenyl)methanone,2.6,uM,=,0.414973347970818,1,O=C(c1cccc(-c2ncnc3ccc(-c4cnc5ccccc5c4)cc23)c1)N1CCNCC1
608,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)(O)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3cc(Cl)ncn3)CC2)C1,"N-(3,5-bis(trifluoromethyl)benzyl)-3-(4-(6-chloropyrimidin-4-yl)piperidin-1-yl)-1-(2-hydroxypropan-2-yl)cyclopentanecarboxamide",0.186,uM,=,-0.7304870557820837,0,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3ccncn3)CC2)C1
609,1840679,10.1016/j.ejmech.2019.02.022,,,,Inhibition of human ERG incubated for 1 hr by Fluorescence polarization binding assay,COc1cc(NCC2CCNCC2)nc2c1nnn2-c1cccc(OC(F)(F)F)c1,"7-methoxy-N-(piperidin-4-ylmethyl)-3-(3-(trifluoromethoxy)phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",2.1,uM,=,0.3222192947339193,1,c1ccc(-n2nnc3ccc(NCC4CCNCC4)nc32)cc1
610,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3cccnc3)cc12,4-[(2-Ethylbutyl)amino]-6-(3-pyridinyl)-3-quinolinecarboxamide,0.67,uM,=,-0.1739251972991735,0,c1cncc(-c2ccc3ncccc3c2)c1
611,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,Fc1ccccc1C(Cc1ccccc1OC(F)F)N1CCNCC1,1-(2-(2-(difluoromethoxy)phenyl)-1-(2-fluorophenyl)ethyl)piperazine,6.5,uM,=,0.8129133566428556,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
612,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,CN(CC1(O)CCCCC1)C(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,1-((1-hydroxycyclohexyl)methyl)-1-methyl-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,2.16,uM,=,0.3344537511509309,1,O=C(NCC1CCCCC1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
613,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,CSc1ncc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)s1,cis-N-({1-[4-Hydroxy-4-(2-methylsulfanyl-thiazol-5-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,6.0,uM,=,0.7781512503836436,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cncs3)CC2)C1
614,1682731,10.1021/acs.jmedchem.7b01135,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cell membranes,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccc(F)cc2)n1,"1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-3-(4-fluorophenylamino)-1H-pyrazole-4-carboxamide",40.0,uM,=,1.6020599913279625,1,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1
615,2150697,10.1021/acs.jmedchem.1c00712,,,,Inhibition of human ERG,O=C1NC2(CC2)COc2ncc(F)cc2[C@H]2COCCN2c2ccn3ncc1c3n2,"(S,3'E,4'E)-5'-Fluorospiro[cyclopropane-1,6'-4-oxa-7-oxa-2(4,3)-morpholina-1(5,3)-pyrazolol[1,5-a]pyrimidina-3(3,2)-pyridinacyclooctaphan]-8'-one",13.0,uM,=,1.1139433523068367,1,O=C1NC2(CC2)COc2ncccc2[C@H]2COCCN2c2ccn3ncc1c3n2
616,622012,10.1021/jm901319p,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(C(F)(F)F)cc3F)C2)n1C,"(1R,5S/1S,5R)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}-propyl)-3-azabicyclo[3.1.0]hexane",0.46,uM,=,-0.3372421683184259,0,c1ccc(C23CC2CN(CCCSc2nnc(-c4cnco4)[nH]2)C3)cc1
617,2217382,10.1021/acs.jmedchem.1c02141,,,,Inhibition of hERG,C[C@@H](N)c1cc(Cl)ccc1Cn1c(=S)[nH]c(=O)c2[nH]cnc21,"(R)-3-(2-(1-aminoethyl)-4-chlorobenzyl)-2-thioxo-2,3-dihydro-1H-purin-6-(7H)-one",23.0,uM,=,1.3617278360175928,1,O=c1[nH]c(=S)n(Cc2ccccc2)c2nc[nH]c12
618,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CCn1cc([C@]2(c3cccc(NC(=O)c4ccc(Cl)cn4)c3)N=C(N)c3c(F)cccc32)cc(C)c1=O,"(R)-N-(3-(3-Amino-1-(1-ethyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-fluoro-1H-isoindol-1-yl)phenyl)-5-chloropicolinamide",1.3,uM,=,0.1139433523068367,1,O=C(Nc1cccc([C@@]2(c3ccc(=O)[nH]c3)N=Cc3ccccc32)c1)c1ccccn1
619,1973040,10.1021/acsmedchemlett.0c00015,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,COc1ccc(-c2cnn3c(N)c(-c4ccccc4)c(NC4CC(C)(C)N(C)C(C)(C)C4)nc23)cc1OC,"3-(3,4-dimethoxyphenyl)-N5-(1,2,2,6,6-pentamethylpiperidin-4-yl)-6-phenylpyrazolo[1,5-a]pyrimidine-5,7-diamine",1.2,uM,=,0.0791812460476248,1,c1ccc(-c2cn3ncc(-c4ccccc4)c3nc2NC2CCNCC2)cc1
620,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(CCOCc2cccc(COCCc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis((4-methylphenethoxy)methyl)pyridinium",0.135,uM,=,-0.8696662315049939,0,c1ccc(CCOCc2cccc(COCCc3ccccc3)[nH+]2)cc1
621,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1,(R)-1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine,6.95,uM,=,0.8419848045901139,1,c1ccc(C[C@H](c2ccccc2)N2CCNCC2)cc1
622,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCO)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-(4-hydroxybutoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.4,uM,=,0.380211241711606,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
623,1786751,10.1039/C7MD00568G,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by automated planar patch clamp method,CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC12CC2,"(R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile",120.0,uM,=,2.0791812460476247,1,c1nc(N[C@H]2CNCC23CC3)c2cc[nH]c2n1
624,420606,10.1016/j.bmcl.2006.11.061,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2cc(F)ccc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-6-fluoro-4-oxo-4H-chromene-2-carboxamide",15.0,uM,=,1.1760912590556811,1,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
625,1840679,10.1016/j.ejmech.2019.02.022,,,,Inhibition of human ERG incubated for 1 hr by Fluorescence polarization binding assay,CN1CCOc2c1cnn1c(-c3ccc4ccnc(NC5CCCCC5)c4c3)nnc21,"N-cyclohexyl-7-(7-methyl-8,9-dihydro-7H-[1,4]oxazino[2,3-d][1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoquinolin-1-amine",4.0,uM,=,0.6020599913279624,1,c1cc2ccc(-c3nnc4c5c(cnn34)NCCO5)cc2c(NC2CCCCC2)n1
626,624297,10.1016/j.bmcl.2010.01.134,,,,Inhibition of human ERG expressed in HEK cells assessed as blockade of potassium tail current by standard patch clamp analysis,C[C@H](c1cccnc1F)c1c(CCN(C)C)sc2ccccc12,"(-)-(R)-2-(3-(1-(2-fluoropyridin-3-yl)ethyl)benzo[b]thiophen-2-yl)-N,N-dimethylethanamine",2.3,uM,=,0.3617278360175928,1,c1cncc(Cc2csc3ccccc23)c1
627,158543,10.1021/jm0205651,,,,Inhibitory activity against Potassium channel HERG,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,10-[2-(1-Methyl-piperidin-2-yl)-ethyl]-2-methylsulfanyl-10H-phenothiazine,0.191,uM,=,-0.7189666327522725,0,c1ccc2c(c1)Sc1ccccc1N2CCC1CCCCN1
628,1747272,10.1021/acs.jmedchem.7b01236,,,,Inhibition of human ERG by patch clamp method,N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1,N-(1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)phenyl)acetamide,5.5,uM,=,0.7403626894942439,1,O=C(Cc1ccc(C2CC2)cc1)Nc1ccn(Cc2ccccn2)n1
629,1672389,10.1016/j.bmcl.2017.05.018,,,,Inhibition of human ERG by patch clamp assay,Cc1ccc(-c2ncc(OC[C@H]3CCNC3)cc2-c2ccc(C#N)cc2)cc1,(S)-4-(5-(pyrrolidin-3-ylmethoxy)-2-p-tolylpyridin-3-yl)benzonitrile,3.0,uM,=,0.4771212547196624,1,c1ccc(-c2cc(OC[C@H]3CCNC3)cnc2-c2ccccc2)cc1
630,872803,10.1021/jm300991n,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CC#Cc1cncc(-c2cccc(C3(C4CC4)N=C(C)C(N)=N3)c2)c1,2-Cyclopropyl-5-methyl-2-(3-(5-(prop-1-ynyl)pyridin-3-yl)-phenyl)-2H-imidazol-4-amine,14.4,uM,=,1.1583624920952498,1,C1=NC(c2cccc(-c3cccnc3)c2)(C2CC2)N=C1
631,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCCC[C@@H](CCO)Nc1nc(N)nc2cc(F)ccc12,(S)-3-((2-Amino-7-fluoroquinazolin-4-yl)amino)heptan-1-ol,4.9,uM,=,0.6901960800285137,1,c1ccc2ncncc2c1
632,598887,10.1016/j.bmcl.2009.07.136,,,,Inhibition of human ERG,C[C@@H]1CNCCN1c1ccc(=O)n(CCOc2ccccc2C(F)(F)F)n1,(R)-6-(2-methylpiperazin-1-yl)-2-(2-(2-(trifluoromethyl)phenoxy)ethyl)pyridazin-3(2H)-one,3.7,uM,=,0.568201724066995,1,O=c1ccc(N2CCNCC2)nn1CCOc1ccccc1
633,632197,10.1016/j.bmcl.2010.03.111,,,,Inhibition of human ERG by patch clamp electrophysiology,CCOCCn1nc(C)c2nc(NC3CCNCC3)nc(Nc3cc(C)ccn3)c21,"1-(2-ethoxyethyl)-3-methyl-N7-(4-methylpyridin-2-yl)-N5-(piperidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine",2.8,uM,=,0.4471580313422192,1,c1ccc(Nc2nc(NC3CCNCC3)nc3cn[nH]c23)nc1
634,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(C(F)(F)F)c3n2CCN1CC1CC1,"2-(Cyclopropylmethyl)-6-(trifluoromethyl)-3,4-dihydropyrazino-(1,2-a)benzimidazol-1(2H)-one",30.0,uM,=,1.4771212547196624,1,O=C1c2nc3ccccc3n2CCN1CC1CC1
635,1682731,10.1021/acs.jmedchem.7b01135,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cell membranes,CN([C@H]1CC[C@H](n2cc(C(N)=O)c(Nc3ccc(Cl)cc3)n2)[C@@H](C#N)C1)C1(C)COC1,"3-(4-chlorophenylamino)-1-((1S,2S,4S)-2-cyano-4-(methyl(3-methyloxetan-3-yl)amino)cyclohexyl)-1H-pyrazole-4-carboxamide",46.0,uM,=,1.662757831681574,1,c1ccc(Nc2ccn([C@H]3CC[C@H](NC4COC4)CC3)n2)cc1
636,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,CCOC(=O)c1nn(-c2ccc(C)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1,"Ethyl 5-((3-cyano-4,6-diphenylpyridin-2-yl)imino)-4-(p-tolyl)-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate",9.3,uM,=,0.9684829485539352,1,c1ccc(-c2cc(/N=c3\scnn3-c3ccccc3)nc(-c3ccccc3)c2)cc1
637,1721264,10.1021/acsmedchemlett.7b00164,,,,Inhibition of human ERG,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,"(Z)-3-[(4-{Methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino}-phenylamino)-methylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid Methyl Ester",0.0026,uM,=,-2.5850266520291822,0,O=C(CN1CCNCC1)Nc1ccc(N/C(=C2\C(=O)Nc3ccccc32)c2ccccc2)cc1
638,863340,10.1016/j.bmcl.2012.05.036,,,,Inhibition of human recombinant ERG channel expressed in HEK297 cells after 3 to 8 mins by voltage clamp assay,CNc1nn2c3c(cnc2c1S(=O)(=O)c1ccccc1)CN(C)CC3,"N,7-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[3,4-e]pyrimidin-2-amine",54.2,uM,=,1.7339992865383869,1,O=S(=O)(c1ccccc1)c1cnn2c3c(cnc12)CNCC3
639,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,Cc1cc(F)cnc1C(=O)Nc1csc([C@]23CO[C@@H](C)C[C@H]2CSC(N)=N3)n1,"US9315520, 13",17.9,uM,=,1.252853030979893,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccn1
640,598542,10.1016/j.bmcl.2009.07.023,,,,Inhibition of human ERG potassium channel 1,CCCNCc1ccc(CCn2ccc(OCc3ccc(F)cc3)cc2=O)cc1,4-(4-fluorobenzyloxy)-1-(4-((propylamino)methyl)phenethyl)pyridin-2(1H)-one,4.2,uM,=,0.6232492903979004,1,O=c1cc(OCc2ccccc2)ccn1CCc1ccccc1
641,345010,10.1016/j.bmcl.2005.12.094,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,N[C@H](C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1cccc(O)c1)C1CC1,"(S)-2-amino-2-cyclopropyl-1-((S)-4-(2,5-difluorophenyl)-2-(3-hydroxyphenyl)-2H-pyrrol-1(5H)-yl)ethanone",5.6,uM,=,0.7481880270062004,1,O=C(CC1CC1)N1CC(c2ccccc2)=C[C@H]1c1ccccc1
642,1366626,10.1021/jm500535j,,,,Inhibition of human ERG,CN1CCN(c2ccc3nc(N)n(CC(O)c4ccc(C(F)(F)F)cc4Cl)c3n2)CC1,"rac-2-(2-Amino-5-(4-methylpiperazin-1-yl)-3H-imidazo[4,5-b]-pyridin-3-yl)-1-(2-chloro-4-(trifluoromethyl)phenyl)ethan-1-ol",12.2,uM,=,1.0863598306747482,1,c1ccc(CCn2cnc3ccc(N4CCNCC4)nc32)cc1
643,1298306,10.1016/j.ejmech.2014.01.021,,,,Inhibition of human ERG expressed in CHO-ZG cells after 20 mins by FluxOR thallium assay,N#C[C@@H]1C[C@H](F)CN1C(=O)[C@@H](N)Cc1cc2c(cc1Br)OCO2,"(2S,4S)-1-[(2S)-2-Amino-3-(6-bromobenzo[d][1,3]dioxol-5-yl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile",48.0,uM,=,1.6812412373755872,1,O=C(CCc1ccc2c(c1)OCO2)N1CCCC1
644,989986,10.1016/j.bmc.2013.09.004,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp technique,O=C(OCC1CCN(Cc2ccc(-c3ccccc3-c3nnn[nH]3)cc2)CC1)c1c2n(c3ccccc13)CCCO2,"(1-((2'-(1H-Tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)piperidin-4-yl)methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate",27.5,uM,=,1.4393326938302626,1,O=C(OCC1CCN(Cc2ccc(-c3ccccc3-c3nnn[nH]3)cc2)CC1)c1c2n(c3ccccc13)CCCO2
645,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=C1COc2cc(OC(=O)c3ccccc3)c(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"(R)-6-((1-((3-fluoro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl benzoate",30.5,uM,=,1.484299839346786,1,O=C1COc2cc(OC(=O)c3ccccc3)c(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
646,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCN(c2cc(C(F)(F)F)cc(COCC3(c4ccccc4)CCNCC3)n2)CC1,1-methyl-4-(6-(((4-phenylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)piperazine,16.0,uM,=,1.2041199826559248,1,c1ccc(C2(COCc3cccc(N4CCNCC4)n3)CCNCC2)cc1
647,2244060,10.1016/j.ejmech.2022.114145,,,,Inhibition of hERG,COC(=O)NC(=O)c1ccsc1NC(=O)c1ccc(S(=O)(=O)N2CCC(OC)CC2)cc1,Methyl (2-(4-((4-methoxypiperidin-1-yl)sulfonyl)benzamido)thiophene-3-carbonyl)carbamate,8.9,uM,=,0.9493900066449128,1,O=C(Nc1cccs1)c1ccc(S(=O)(=O)N2CCCCC2)cc1
648,971477,10.1021/jm400402q,,,,Inhibition of human ERG by dofetilide binding assay,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(C)CC1,"5-Chloro-N2-(2-isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)-phenyl)pyrimidine-2,4-diamine",3.35,uM,=,0.5250448070368452,1,c1ccc(Nc2ccnc(Nc3ccc(C4CCNCC4)cc3)n2)cc1
649,1348051,10.1016/j.bmcl.2014.03.075,,,,Inhibition of human ERG by Q-patch assay,N[C@H]1CCCC[C@H]1Nc1cc2nc[nH]c(=O)c2c(Nc2cccc3c(Cl)c[nH]c23)n1,"7-((1R,2S)-2-aminocyclohexylamino)-5-(3-chloro-1H-indol-7-ylamino)pyrido[4,3-d]pyrimidin-4(3H)-one",20.0,uM,=,1.3010299956639813,1,O=c1[nH]cnc2cc(NC3CCCCC3)nc(Nc3cccc4cc[nH]c34)c12
650,1992475,10.1021/acs.jmedchem.0c01199,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by IonWorks barracuda patch clamp method,COc1cc(-c2cncc(-c3ccc(OC4CCNCC4)cc3)c2C)cc(OC)c1OC,"4-Methyl-3-(4-(piperidin-4-yloxy)phenyl)-5-(3,4,5-trimethoxyphenyl)pyridine",8.1,uM,=,0.9084850188786496,1,c1ccc(-c2cncc(-c3ccc(OC4CCNCC4)cc3)c2)cc1
651,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,O=C(CCCS(=O)(=O)c1ccccc1)Nc1cc[nH]c(=O)n1,"N-(2-oxo-1,2-dihydropyrimidin-4-yl)-4-(phenylsulfonyl)butanamide",67.8,uM,=,1.831229693867064,1,O=C(CCCS(=O)(=O)c1ccccc1)Nc1cc[nH]c(=O)n1
652,1698436,10.1021/acs.jmedchem.8b00190,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,CCc1ccn2ccnc2c1N1CCCN(CC2CCN(C(=O)[C@H]3C[C@@H]4CC[C@H]3O4)CC2)CC1,"((rac-exo)-7-Oxabicyclo[2.2.1]heptan-2-yl)(4-((4-(7-ethylimidazo-[1,2-a]pyridin-8-yl)-1,4-diazepan-1-yl)methyl)piperidin-1-yl)-methanone",1.3,uM,=,0.1139433523068367,1,O=C([C@H]1C[C@@H]2CC[C@H]1O2)N1CCC(CN2CCCN(c3cccn4ccnc34)CC2)CC1
653,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-2-methoxy-piperidin-4-yl}-2-methoxy-benzamide,0.0065,uM,=,-2.1870866433571443,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
654,2278023,10.1021/acs.jmedchem.2c01517,,,,Inhibition of human ERG channel expressed in HEK293 cells clamped at -80 mV stimulated +20 mV for 2 sec followed by repolarized to -50 mV for 5 secs by electrophysiological analysis,Cc1nc(N[C@H](C)c2cccc(C(F)F)c2F)c2cc3c(cc2n1)OC[C@H]1CN(C(=O)[C@H]2CCOC2)CCN31,"((R)-11-(((R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-9-methyl-1,2,4a,5-tetrahydropyrazino[1',2':4,5][1,4]oxazino[3,2-g]quinazolin-3(4H)-yl)((S)-tetrahydrofuran-3-yl)methanone",2.2,uM,=,0.3424226808222063,1,O=C([C@H]1CCOC1)N1CCN2c3cc4c(NCc5ccccc5)ncnc4cc3OC[C@H]2C1
655,699317,10.1016/j.bmc.2010.10.034,,,,Inhibition of human ERG,CNC[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1,"trans-1-((2R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylmethanamine",1.61,uM,=,0.2068258760318497,1,c1ccc([C@@H]2CCCc3ccccc32)cc1
656,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(Cl)cc(Cl)c2)CCN(Cc2ccc(C(F)(F)F)cc2)CC1,"methyl 4-((3,5-dichlorobenzamido)methyl)-1-(4-(trifluoromethyl)benzyl)piperidine-4-carboxylate",0.29,uM,=,-0.5376020021010439,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
657,819957,10.1021/ml200199c,,,,Displacement of [3H]dofetilide from human ERG,O=C(NCC(=O)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4cccnc4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1,"(S)-N-(2-{3-[trans-4-(3,3'-Bipyridin-6-yl)-4-hydroxycyclohexylamino]pyrrolidin-1-yl}-2-oxoethyl)-3-(trifluoromethyl)benzamide",30.0,uM,=,1.4771212547196624,1,O=C(NCC(=O)N1CC[C@H](NC2CCC(c3ccc(-c4cccnc4)cn3)CC2)C1)c1ccccc1
658,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,NC1CCN(c2c(-c3cc(F)cc(Cl)c3)cncc2-c2nc3cc(F)ccc3[nH]2)CC1,1-(3-(3-chloro-5-fluorophenyl)-5-(5-fluoro-1H-benzo[d]imidazol-2-yl)pyridin-4-yl)piperidin-4-amine,4.9,uM,=,0.6901960800285137,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
659,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3ccc(C4CC4)nc3cc2F)o1,(S)-N-((S)-1-(5-(2-cyclopropyl-7-fluoroquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,3.3,uM,=,0.5185139398778875,1,O=C(NCc1ncc(-c2ccc3nc(C4CC4)ccc3c2)o1)[C@H]1CC12CCNCC2
660,490606,10.1016/j.bmcl.2008.06.027,,,,Inhibition of human ERG,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)n2)n1C(C)C,4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrimidin-2-amine,5.5,uM,=,0.7403626894942439,1,c1cc(-c2cnc[nH]2)nc(Nc2ccc(N3CCNCC3)cc2)n1
661,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCN(CC)C(=O)c1ccc([C@H](c2cccc(NC(=O)C3CC3)c2)N2CCN(Cc3ccc(F)cc3)CC2)cc1,"(R)-4-((3-(cyclopropanecarboxamido)phenyl)(4-(4-fluorobenzyl)piperazin-1-yl)methyl)-N,N-diethylbenzamide",11.0,uM,=,1.0413926851582251,1,O=C(Nc1cccc([C@@H](c2ccccc2)N2CCN(Cc3ccccc3)CC2)c1)C1CC1
662,1473398,10.1021/jm501920g,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,Clc1ccc(-n2cc(NCCN3CCCCC3)nn2)cc1,"1-(4-chlorophenyl)-N-(2-(piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-amine",3.1,uM,=,0.4913616938342727,1,c1ccc(-n2cc(NCCN3CCCCC3)nn2)cc1
663,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3cncnc3)CC2)C1,"N-(3,5-bis(trifluoromethyl)benzyl)-1-isopropyl-3-(4-(pyrimidin-5-yl)piperidin-1-yl)cyclopentanecarboxamide",1.413,uM,=,0.1501421618485586,1,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3cncnc3)CC2)C1
664,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,N#Cc1cc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)ccc1F,"5-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridin-6-yl)-2-fluorobenzonitrile",0.101010101,uM,=,-0.9956351946409794,0,c1ccc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cc1
665,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,CC(=O)Nc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1,N-[1-N-[1-{4-[(4-aminopiperidin-1-yl)methyl]phenyl}ethanonyl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide,0.0477,uM,=,-1.321481620959886,0,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
666,498774,10.1021/jm900110t,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",C[C@@H]1NC(c2cccc(C#N)n2)=N[C@@]1(c1ccc(F)cc1)c1ccc(F)nc1,"6-[(4S,5S)-4-(4-Fluorophenyl)-4-(6-fluoro-3-pyridyl)-5-methyl-4,5-dihydro-1H-imidazol-2-yl]-2-pyridinecarbonitrile",6.93,uM,=,0.8407332346118067,1,c1ccc([C@]2(c3cccnc3)CNC(c3ccccn3)=N2)cc1
667,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCN(C(=O)[C@H](C)O)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"(2S)-1-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)piperazin-1-yl)-2-hydroxypropan-1-one",8.1,uM,=,0.9084850188786496,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
668,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3nccs3)ccc2c1,(R)-2-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)thiazole,11.6,uM,=,1.0644579892269186,1,c1csc(-c2ccc3cc(CCN4CCCC4)ccc3n2)n1
669,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2cccc(Cl)c2)[C@@H]3C)n1,"US9422299, 16",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
670,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Clc1cc2sc(N3CCC(N4CCCCC4)CC3)nc2cn1,"2-(1,4'-bipiperidin-1'-yl)-6-chlorothiazolo[4,5-c]pyridine",6.949152542,uM,=,0.8419318450542878,1,c1cc2sc(N3CCC(N4CCCCC4)CC3)nc2cn1
671,2074272,10.1016/j.bmcl.2020.127506,,,,Inhibition of human ERG by patch-clamp method,CC(=O)Nc1ccc(OCCCN2CCC(c3noc4cc(F)ccc34)CC2)cc1,N-(4-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propoxy)phenyl)acetamide,2.98,uM,=,0.4742162640762553,1,c1ccc(OCCCN2CCC(c3noc4ccccc34)CC2)cc1
672,1518195,10.1016/j.bmcl.2015.09.018,,,,Inhibition of human ERG by flux assay,CNC1CCN(c2ccc(-n3cnn4cc(-c5ccc(Cl)cc5)cc4c3=O)cn2)C1,"6-(4-chlorophenyl)-3-(6-(3-(methylamino)pyrrolidin-1-yl)pyridin-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one",3.0,uM,=,0.4771212547196624,1,O=c1c2cc(-c3ccccc3)cn2ncn1-c1ccc(N2CCCC2)nc1
673,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3ccc(C)nc3cc2OC)[nH]1,(S)-N-((S)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,16.0,uM,=,1.2041199826559248,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)[nH]1)[C@H]1CC12CCNCC2
674,766531,10.1016/j.bmcl.2011.06.126,,,,Inhibition of human ERG by electrophysiological assay,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccc(Cl)cc54)CC3)nc2N1,"6-((1-(2-(6-chloro-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.0,uM,=,0.4771212547196624,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccccc54)CC3)nc2N1
675,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,Cc1ccn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2C)n1,2-(3-Methyl-pyrazol-1-yl)-1-((R)-2-methyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)ethanone,0.0050999999999999,uM,=,-2.292429823902064,0,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
676,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1,"US9145392, 8",1.6,uM,=,0.2041199826559248,1,c1ccc(-c2c[nH]c(C3CCN(c4ccncn4)CC3)n2)cc1
677,1293759,10.1016/j.bmcl.2014.01.061,,,,Inhibition of human ERG channel by patch clamp technique,O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@@H]2C[C@H]12,"(-)-(1S,6R)-5-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-3,4-diazabicyclo[4.1.0]hept-4-en-2-one",6.0,uM,=,0.7781512503836436,1,O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@@H]2C[C@H]12
678,1633794,10.1016/j.bmc.2016.11.018,,,,Inhibition of human ERG by patch clamp method,FC(F)(F)c1c(OC[C@H]2C[C@@H]2c2ccc(Cl)cc2)ccn2c(CC3CC3)nnc12,"(+)-3-(Cyclopropylmethyl)-7-(((1S,2S)-2-(4-chlorophenyl)cyclopropyl)methoxy)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine",0.38,uM,=,-0.4202164033831898,0,c1ccc([C@H]2C[C@@H]2COc2ccn3c(CC4CC4)nnc3c2)cc1
679,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-2-methoxy-piperidin-4-yl}-2-methoxy-benzamide,0.045,uM,=,-1.3467874862246565,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
680,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1ccc(C(=O)N2CCOCC2)cc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"(3-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)(morpholino)methanone",1.3,uM,=,0.1139433523068367,1,O=C(c1cccc(Nc2nccc(-c3cnc4ccccn34)n2)c1)N1CCOCC1
681,1637594,,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in outward tail current after 5 mins at -80 mV holding potential by patch clamp assay,COc1ccc2c(c1)CN(C(=O)CCN1CCC(Cc3ccccc3)CC1)CCS2.Cl,"3-(4-benzylpiperidin-1-yl)-1-(7-methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)propan-1-one hydrochloride",0.463,uM,=,-0.3344190089820468,0,O=C(CCN1CCC(Cc2ccccc2)CC1)N1CCSc2ccccc2C1
682,811994,10.1016/j.bmcl.2012.01.023,,,,Inhibition of human ERG by PatchXpress voltage patch clamp assay,Nc1cncc(Nc2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)n1,"N2-(4-(4-(trifluoromethoxy)phenoxy)phenyl)pyrazine-2,6-diamine",8.5,uM,=,0.9294189257142929,1,c1ccc(Oc2ccc(Nc3cnccn3)cc2)cc1
683,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2C(=O)OC1CC1,"cyclopropyl (R)-6-(1-(4-fluorobenzamido)ethyl)-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate",20.0,uM,=,1.3010299956639813,1,O=C(NCc1ccc2c(n1)CCCN2C(=O)OC1CC1)c1ccccc1
684,455097,10.1016/j.bmcl.2007.02.066,,,,Inhibition of cardiac hERG,CN(C)C(=O)[C@@H](c1ccc(-c2ccc(F)cc2)cc1)[C@H](N)C(=O)N1CC[C@H](F)C1.O=C(O)C(F)(F)F,"Trifluoro-acetate(1S,2S)-2-dimethylcarbamoyl-2-(4'-fluoro-biphenyl-4-yl)-1-((S)-3-fluoro-pyrrolidine-1-carbonyl)-ethyl-ammonium",4.6,uM,=,0.6627578316815741,1,O=C(CCc1ccc(-c2ccccc2)cc1)N1CCCC1
685,726745,10.1016/j.bmcl.2011.01.036,,,,Inhibition of human ERG,C[C@@H](C[C@@H](CS(=O)(=O)N1CCC(OCc2ccc(Cl)cc2Cl)CC1)N(O)C=O)c1ncc(F)cn1,"N-((2S,4S)-1-(4-(2,4-dichlorobenzyloxy)piperidin-1-ylsulfonyl)-4-(5-fluoropyrimidin-2-yl)pentan-2-yl)-N-hydroxyformamide",5.0,uM,=,0.6989700043360189,1,O=S(=O)(CCCCc1ncccn1)N1CCC(OCc2ccccc2)CC1
686,1655139,10.1016/j.bmcl.2016.12.054,,,,Displacement of [3H]-MK499 from human ERG IKr channel expressed in HEK293 cell membranes,c1cncc(C(Cc2ccccc2-c2ccncc2)c2cccnc2)c1,"3,3'-(2-(2-(pyridin-4-yl)phenyl)ethane-1,1-diyl)dipyridine",22.1,uM,=,1.3443922736851108,1,c1cncc(C(Cc2ccccc2-c2ccncc2)c2cccnc2)c1
687,755804,10.1021/jm2003359,,,,Inhibition of human ERG expressed in CHO cells by Q-patch assay,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(Cl)c(F)c2)C1,"2-amino-1-(3-(4-chloro-3-fluorophenylamino)-2-(4-fluorophenyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one",5.6,uM,=,0.7481880270062004,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
688,1545989,10.1021/acs.jmedchem.5b01227,,,,Inhibition of human ERG channel by automated Q-patch assay,C[C@H]1Cc2c(ncnc2Oc2ccc3c(ccn3C(=O)Nc3cc(C4(C)CC4)[nH]n3)c2)CN1,"5-((S)-6-Methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)-indole-1-carboxylic Acid [5-(1-Methyl-cyclopropyl)-2H-pyrazol-3-yl]-amide",27.4,uM,=,1.437750562820388,1,O=C(Nc1cc(C2CC2)[nH]n1)n1ccc2cc(Oc3ncnc4c3CCNC4)ccc21
689,1926457,10.1016/j.bmc.2016.08.007,,,,Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assay,N#Cc1ccc(N2CCC(Nc3c(C(N)=O)cnc4[nH]ccc34)CC2)nc1,"4-{[1-(5-Cyanopyridin-2-yl)piperidin-4-yl]amino}-1Hpyrrolo[2,3-b]pyridine-5-carboxamide",13.4,uM,=,1.1271047983648077,1,c1ccc(N2CCC(Nc3ccnc4[nH]ccc34)CC2)nc1
690,1655139,10.1016/j.bmcl.2016.12.054,,,,Displacement of [3H]-MK499 from human ERG IKr channel expressed in HEK293 cell membranes,FC(F)(F)Oc1cccc(-c2ncccc2CC(c2cccnc2)c2cccnc2)c1,"3,3'-(2-(2-(3-(trifluoromethoxy)phenyl)pyridin-3-yl)ethane-1,1-diyl)dipyridine",12.7,uM,=,1.1038037209559568,1,c1ccc(-c2ncccc2CC(c2cccnc2)c2cccnc2)cc1
691,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,Cc1[nH]c(-c2ccccc2)cc1C(=O)NCCCN1CCN(c2cccc(Cl)c2Cl)CC1,"N-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide",0.1,uM,=,-1.0,0,O=C(NCCCN1CCN(c2ccccc2)CC1)c1c[nH]c(-c2ccccc2)c1
692,2014372,10.1021/acsmedchemlett.9b00123,,,,Displacement of Tracer Red from human ERG incubated for 2 hrs by fluorescence polarization assay,CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(C(C)(F)F)cc2)cc1,"(-)-N-[(3S,4R)-4-[4-(1,1-difluoroethyl)phenyl]pyrrolidin-3-yl]-2-[4-(dimethylamino)phenyl]acetamide",2.809,uM,=,0.4485517392015781,1,O=C(Cc1ccccc1)N[C@@H]1CNC[C@H]1c1ccccc1
693,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(C[C@@H]2CCCN(CC3CC3)C2)CC1,"(R)-4-((1-(cyclopropylmethyl)piperidin-3-yl)methyl)-N-(3,4-dichlorophenyl)piperazine-1-carboxamide",0.93,uM,=,-0.0315170514460648,0,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(CC3CC3)C2)CC1
694,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CC(C)(O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,4-[4-(Hydroxy-diphenyl-methyl)-piperidin-1-yl]-1-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-butan-1-ol,0.46,uM,=,-0.3372421683184259,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
695,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,CCOC(=O)C(CC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2)c1c(F)cnc2ccc(OC)nc12,"(rac)-ethyl 2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-3-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)propanoate",8.4,uM,=,0.9242792860618816,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
696,1329649,10.1039/C1MD00015B,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch clamp assay,CC(=O)Nc1cccc(C2CCN(Cc3ccc(C(=O)c4nc5ccccc5n4-c4ccc(Cl)cc4)cc3)CC2)c1,N-(3-(1-(4-(1-(4-chlorophenyl)-1H-benzo[d]imidazole-2-carbonyl)benzyl)piperidin-4-yl)phenyl)acetamide,1.7,uM,=,0.2304489213782739,1,O=C(c1ccc(CN2CCC(c3ccccc3)CC2)cc1)c1nc2ccccc2n1-c1ccccc1
697,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,O=C(Nc1cccc([C@@H](c2ccc(C(=O)N3CCC3)cc2)N2CCN(Cc3ccc(F)cc3)CC2)c1)C1CC1,(R)-N-(3-((4-(azetidine-1-carbonyl)phenyl)(4-(4-fluorobenzyl)piperazin-1-yl)methyl)phenyl)cyclopropanecarboxamide,3.6,uM,=,0.5563025007672873,1,O=C(Nc1cccc([C@@H](c2ccc(C(=O)N3CCC3)cc2)N2CCN(Cc3ccccc3)CC2)c1)C1CC1
698,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,Cc1c(N2CC[C@@H](C3(N)CC3)C2)c(F)cc2cc(C(=O)O)c(=O)n(C3CC3)c12,"(R)-7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid",136.0,uM,=,2.133538908370217,1,O=c1ccc2ccc(N3CC[C@@H](C4CC4)C3)cc2n1C1CC1
699,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,NC(=O)n1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4ccc5c(c4)OCO5)CC3)C2)c2cc(C(F)(F)F)ccc21,"cis-3-((2-((1-(4-(benzo[d][1,3]dioxol-5-yl)cyclohexyl)azetidin-3-yl)amino)-2-oxoethyl)amino)-5-(trifluoromethyl)-1H-indazole-1-carboxamide",12.0,uM,=,1.0791812460476249,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccc4c(c3)OCO4)CC2)C1
700,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCOC[C@H]1CC[C@@H](N2CC(NC(=O)CNc3nn(C)c4ccc(C(F)(F)F)cc34)C2)CC1,cis-N-(1-(4-(ethoxymethyl)cyclohexyl)azetidin-3-yl)-2-(1-methyl-5-(trifluoromethyl)-1H-indazol-3-ylamino)acetamide,5.6,uM,=,0.7481880270062004,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
701,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,CC(C)(O)COc1ccc(C(N)=O)c(O[C@H]2CCN(C(=O)Cc3ccc(OC(F)(F)F)cc3)C[C@H]2F)c1,"2-(((3R,4S)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)-piperidin-4-yl)oxy)-4-(2-hydroxy-2-methylpropoxy)benzamide",42.0,uM,=,1.6232492903979006,1,O=C(Cc1ccccc1)N1CCC(Oc2ccccc2)CC1
702,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,CO[C@@H]1CN(CCn2c(=O)ccc3ccc(C#N)cc32)CC[C@H]1NCc1ccc2c(n1)NC(=O)CO2,"trans-1-[2-(3-Methoxy-4-{[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b]-[1,4]oxazin-6-yl)methyl]amino}piperidin-1-yl)ethyl]-2-oxo-1,2-dihydroquinoline-7-carbonitrile",124.0,uM,=,2.093421685162235,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)ccc5ccccc54)CC3)nc2N1
703,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(Br)cc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-bromo-4-oxo-4H-chromene-2-carboxamide",0.0025,uM,=,-2.6020599913279625,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
704,2084867,10.1021/acs.jmedchem.6b00943,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated Qpatch electrophysiological assay,Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C#Cc1nn(CC2CCN(C)C2)c2ncnc(N)c12,"N-(3-((4-Amino-1-((1-methylpyrrolidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide",2.38,uM,=,0.3765769570565119,1,O=C(Nc1cccc(C#Cc2nn(CC3CCNC3)c3ncncc23)c1)c1ccccc1
705,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,OC(CNc1nccc(-c2sc(C3CCNCC3)nc2-c2ccc(F)cc2)n1)c1ccncc1,"2-({4-[4-(4-Fluorophenyl)-2-(piperidin-4-yl)-1,3-thiazol-5-yl]-pyrimidin-2-yl}amino)-1-(pyridin-4-yl)ethanol",28.2,uM,=,1.4502491083193612,1,c1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(NCCc3ccncc3)n2)cc1
706,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,CO/N=C/c1ccc2nc(OC)c([C@@H](c3ccccc3)[C@](O)(CCN(C)C)c3cccc4ccccc34)cc2c1,"3-((1R,2R)-4-(dimethylamino)-2-hydroxy-2-(naphthalen-1-yl)-1-phenylbutyl)-2-methoxyquinoline-6-carbaldehyde O-methyl oxime",2.2,uM,=,0.3424226808222063,1,c1ccc([C@@H](Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
707,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1,2-(4-(1H-tetrazol-1-yl)phenyl)-N-methyl-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)acetamide,1.2,uM,=,0.0791812460476248,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2ccccc2)CC1
708,2240601,10.1021/acs.jmedchem.2c01497,,,,Inhibition of human ERG at -90 mV holding potential,CN(C)CCC=C1c2ccccc2CCc2ccccc21,"[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine",3.2,uM,=,0.505149978319906,1,C=C1c2ccccc2CCc2ccccc21
709,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,CS(=O)(=O)N1CCN(Cc2ccc3c(c2)CC[C@H](N2CCN(CCc4ccc(F)cc4)CC2=O)C3)CC1,"(S)-4-(4-fluorophenethyl)-1-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)piperazin-2-one",13.0,uM,=,1.1139433523068367,1,O=C1CN(CCc2ccccc2)CCN1[C@H]1CCc2cc(CN3CCNCC3)ccc2C1
710,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,CCCCNC(=O)C1c2ccccc2C(=O)N1CC(C)c1ccc(Cl)cc1,(rac)-N-butyl-2-(2-(4-chlorophenyl)propyl)-3-oxoisoindoline-1-carboxamide,32.0,uM,=,1.505149978319906,1,O=C1c2ccccc2CN1CCc1ccccc1
711,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1c(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)cnn1-c1ccc(N(C)C)nn1,"(R)-N,N-dimethyl-6-(5-methyl-4-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-1H-pyrazol-1-yl)pyridazin-3-amine",18.0,uM,=,1.255272505103306,1,c1cnnc(-n2cc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cn2)c1
712,1637594,,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in outward tail current after 5 mins at -80 mV holding potential by patch clamp assay,COc1ccc2c(c1)CNCCS2,"7-methoxy-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine",7.029,uM,=,0.8468935433166253,1,c1ccc2c(c1)CNCCS2
713,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(NCc1c(O)cc(Cl)cc1Cl)C1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,"N-(2,4-dichloro-6-hydroxybenzyl)-1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidine-4-carboxamide",4.2,uM,=,0.6232492903979004,1,O=C(NCc1ccccc1)C1CCN(Cc2ccn(-c3ccccc3)c2)CC1
714,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,Cc1ncc(-c2nc(Nc3ccc(C(N)=O)cc3)ncc2F)n1C(C)C,4-(5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)benzamide,20.0,uM,=,1.3010299956639813,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
715,980797,10.1021/jm4006324,,,,Inhibition of human ERG channel by electrophysiological method,CNCc1cc(-c2cn(C)nc2-c2ccc(F)cc2)ccn1,1-(4-(3-(4-Fluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine-2-yl)-N-methylmethanamine,3.99,uM,=,0.6009728956867483,1,c1ccc(-c2n[nH]cc2-c2ccncc2)cc1
716,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,CN1CCCCC(c2ccc(Cl)c(Cl)c2)C1,"rac-3-(3,4-Dichlorophenyl)-1-methylazepane",10.0,uM,=,1.0,1,c1ccc(C2CCCCNC2)cc1
717,988281,10.1021/jm401101p,,,,Inhibition of human recombinant ERG expressed in CHO cells by patch-clamp technique,Cc1nc(Oc2ccc(C(N)=O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1,(R)-4-((6-Methyl-5-((4-(2-oxo-5-phenyl-3-(tetrahydro-2Hpyran-4-yl)imidazolidin-1-yl)piperidin-1-yl)methyl)pyridin-2-yl)oxy)benzamide,18.0,uM,=,1.255272505103306,1,O=C1N(C2CCOCC2)C[C@@H](c2ccccc2)N1C1CCN(Cc2ccc(Oc3ccccc3)nc2)CC1
718,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1nnn(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(CCS(C)(=O)=O)C2=O,"2-((1-(4-fluorophenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-6-(2-(methylsulfonyl)ethyl)-7,8-dihydro-1,6-naphthyridin-5(6H)-one",30.0,uM,=,1.4771212547196624,1,O=C1NCCc2nc(OCc3cnnn3-c3ccccc3)ccc21
719,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H]([C@@H]3CCNC3)O2)cc1,"(5S)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-5-[(3R)-pyrrolidin-3-yl]-4,5-dihydrooxazole",6.7,uM,=,0.8260748027008264,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H]([C@@H]3CCNC3)O2)cc1
720,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(Cl)ccc5[nH]4)CC3)c2c1,"1-(2-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)-7-methoxy-1,5-naphthyridin-2(1H)-one",1.0,uM,=,0.0,0,O=c1ccc2ncccc2n1CCN1CCC(c2nc3ccccc3[nH]2)CC1
721,1435055,10.1021/jm500809c,,,,Inhibition of human ERG,Cc1nn(C)c(C)c1N(C(F)F)S(=O)(=O)c1c(Cl)cc(CCCC2CCN(C)CC2)cc1Cl,"2,6-Dichloro-N-(difluoromethyl)-4-(3-(1-methylpiperidin-4-yl)propyl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide",0.6,uM,=,-0.2218487496163563,0,O=S(=O)(Nc1cn[nH]c1)c1ccc(CCCC2CCNCC2)cc1
722,886196,10.1016/j.bmcl.2012.10.036,,,,Inhibition of dofetilide binding to human ERG by patch clamp assay,NC(=O)C1CCN(Cc2ccc(Oc3nc4ncccc4s3)cc2)CC1,"1-(4-(thiazolo[4,5-b]pyridin-2-yloxy)benzyl)piperidine-4-carboxamide",8.9,uM,=,0.9493900066449128,1,c1cnc2nc(Oc3ccc(CN4CCCCC4)cc3)sc2c1
723,1278259,10.1021/jm4010434,,,,Inhibition of human ERG channel expressed in HEK293 cells after 15 mins by whole-cell patch clamp technique,CCCCCCCN(CC)CC#CCc1ccc(Cl)cc1,N-Ethyl-4-(4-chlorophenyl)-N-heptylbut-2-yn-1-amine,0.0049,uM,=,-2.309803919971486,0,c1ccccc1
724,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,Cc1cc(C)nc(Nc2cc(N[C@@H]3CS(=O)(=O)CC[C@@H]3N)cnc2C(N)=O)c1,"5-(((3S,4S)-4-amino-1,1-dioxidotetrahydro-2H-thiopyran-3-yl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide",29.0,uM,=,1.462397997898956,1,O=S1(=O)CCC[C@H](Nc2cncc(Nc3ccccn3)c2)C1
725,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(OCCCN(C)C)nc5F)cc4c32)C1,"US9428503, 19",22.0,uM,=,1.3424226808222062,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCC1
726,1513054,10.1021/ml500531p,,,,Inhibition of human ERG by IonWorks assay,O=C1COc2ccc(CNC3CCN(CCn4c(=O)ccc5ncc(Oc6cncc(F)c6)cc54)CC3)nc2N1,"6-((1-(2-(7-(5-fluoropyridin-3-yloxy)-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",79.0,uM,=,1.8976270912904407,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)ccc5ncc(Oc6cccnc6)cc54)CC3)nc2N1
727,1648277,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG,COCc1cnc(N2CCC([C@H]3C[C@H]3CCOc3cc(F)c(CC(=O)N4CCC4)c(F)c3)CC2)nc1,"(cis)-1-(azetidin-1-yl)-2-(2,6-difluoro-4-(2-((1S,2R)-2-(1-(5-(methoxymethyl)pyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)phenyl)ethanone",9.1,uM,=,0.9590413923210936,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)cc1)N1CCC1
728,1892808,10.1016/j.ejmech.2019.03.062,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated patch clamp assay,COc1cccc(OCCCN)c1-c1cc(Nc2cnc(C#N)cn2)n[nH]1,PREXASERTIB,20.0,uM,=,1.3010299956639813,1,c1ccc(-c2cc(Nc3cnccn3)n[nH]2)cc1
729,492219,10.1021/jm800419w,,,,Antagonist activity at human ERG by voltage-clamp electrophysiology assay,CC(C)(C)CCN1CCC(F)(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1,"3,5-Dichloro-N-[1-(3,3-dimethyl-butyl)-4-fluoro-piperidin-4-ylmethyl]-benzamide",2.22,uM,=,0.3463529744506387,1,O=C(NCC1CCNCC1)c1ccccc1
730,1893595,10.1016/j.ejmech.2019.04.037,,,,Inhibition of fluorescently labeled tracer binding to human ERG by competitive binding assay,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide,0.00782,uM,=,-2.106793246940152,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
731,2051795,10.1021/acs.jmedchem.6b00275,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1cc(NC2CCc3cc(F)ccc3C2)n2nc(C(C)(F)F)nc2n1,"2-(1,1-Difluoroethyl)-N-(6-fluoro-1,2,3,4-tetrahydronaphthalen-2-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",0.7,uM,=,-0.1549019599857432,0,c1ccc2c(c1)CCC(Nc1ccnc3ncnn13)C2
732,880571,10.1021/ml300280g,,,,Binding affinity to human ERG,O=C(N[C@H]1CCCC[C@@H]1O)c1cc(CN2CCN(c3cc4ccccc4cn3)CC2)c2ccccn2c1=O,"N-((1S,2S)-2-hydroxycyclohexyl)-1-((4-(isoquinolin-3-yl)piperazin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxamide",2.0,uM,=,0.3010299956639812,1,O=C(NC1CCCCC1)c1cc(CN2CCN(c3cc4ccccc4cn3)CC2)c2ccccn2c1=O
733,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,CCOc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1N1CCCN(C)CC1,"4-(2,4-difluorophenylamino)-7-ethoxy-6-(4-methyl-1,4-diazepan-1-yl)quinoline-3-carboxamide",6.0,uM,=,0.7781512503836436,1,c1ccc(Nc2ccnc3ccc(N4CCCNCC4)cc23)cc1
734,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)(O)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3ccc(F)cc3)CC2)C1,"(1S,3R)-N-(3,5-bis(trifluoromethyl)benzyl)-3-(4-(4-fluorophenyl)piperidin-1-yl)-1-(2-hydroxypropan-2-yl)cyclopentanecarboxamide",0.054,uM,=,-1.2676062401770316,0,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3ccccc3)CC2)C1
735,1475773,10.1021/jm5017413,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch-clamp assay,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3)cs1,"(3-(2-Methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]-pyrazin-7(8H)-yl)(4-(thiophen-2yl)phenyl)methanone",27.0,uM,=,1.4313637641589874,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2cscn2)C1
736,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN(C)C)CC1,"US9145392, 82",1.3,uM,=,0.1139433523068367,1,c1ccc(-c2c[nH]c(C3CCN(c4ccncn4)CC3)n2)cc1
737,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CC[C@H](NCc4ccc5c(n4)NC(=O)CO5)[C@H](O)C3)c2c1,"cis-6-[({(3R,4S)-3-Hydroxy-1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b]-[1,4]oxazin-3(4H)-one",172.0,uM,=,2.2355284469075487,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)cnc5ccccc54)CC3)nc2N1
738,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,COc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1,"(1R,3R)-3-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.069,uM,=,-1.1611509092627446,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
739,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-ethoxy-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.4,uM,=,-0.3979400086720376,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
740,1576909,10.1021/acs.jmedchem.5b01416,,,,Inhibition of human ERG expressed in HEK293 cells assessed as tail current at -50 mV holding potential by whole-cell patch clamp method,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccc(Cl)cc1,2-(4-Chlorophenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H)-one,1.45,uM,=,0.1613680022349748,1,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccccc1
741,963062,10.1021/jm400408r,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,Cc1c(C)c2ccc(OCCCCN3CCC(c4noc5cc(F)ccc45)CC3)cc2oc1=O,"7-(4-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-3,4-dimethyl-2H-chromen-2-one",0.195,uM,=,-0.7099653886374819,0,O=c1ccc2ccc(OCCCCN3CCC(c4noc5ccccc45)CC3)cc2o1
742,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,Fc1ccc(-c2nc(N3CCOCC3)sc2-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,"4-[4-(4-Fluorophenyl)-2-(morpholin-4-yl)-1,3-thiazol-5-yl]-N-[4-(piperazin-1-yl)phenyl]pyrimidin-2-amine",5.4,uM,=,0.7323937598229685,1,c1ccc(-c2nc(N3CCOCC3)sc2-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
743,498774,10.1021/jm900110t,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",C[C@@H]1NC(c2cc(C#N)ccn2)=NC1(c1ccc(F)cc1)c1ccc(F)cc1,"2-[(5S)-4,4-Bis(4-fluorophenyl)-5-methyl-4,5-dihydro-1H-imidazol-2-yl]-4-pyridinecarbonitrile",1.73,uM,=,0.2380461031287954,1,c1ccc(C2(c3ccccc3)CNC(c3ccccn3)=N2)cc1
744,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc5[nH]ncc5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"3-[4-(1H-Indazol-5-yl)-phenyl]-1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",4.7,uM,=,0.6720978579357175,1,O=C1N(c2ccc(-c3ccc4[nH]ncc4c3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
745,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3ccc(C)nc3cc2CC)[nH]1,(S)-N-((S)-1-(5-(7-ethyl-2-methylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,21.0,uM,=,1.3222192947339193,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)[nH]1)[C@H]1CC12CCNCC2
746,1972831,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,"3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide",0.77,uM,=,-0.1135092748275181,0,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(C#Cc2cnc3cccnn23)c1
747,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3cccc(F)c32)CC1,"4-{3-[4-(7-Fluoro-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-4H-benzo[1,4]oxazin-3-one",6.3,uM,=,0.7993405494535817,1,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
748,357755,10.1021/jm0508641,,,,Inhibition of hERG potassium channel in HEK293 cells by patch clamp assay,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,0.0009,uM,=,-3.0457574905606752,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
749,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(C(=O)NC[C@H]2CCN(C(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc1C(C)(C)C,"(R)-N-((1-(6,6-bis(4-fluorophenyl)hexanoyl)pyrrolidin-3-yl)methyl)-3,5-di-tert-butyl-4-methoxybenzamide",5.0,uM,=,0.6989700043360189,1,O=C(NC[C@H]1CCN(C(=O)CCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
750,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CC(=O)N(c2ccns2)C3)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(isothiazol-5-yl)-2,8-diazaspiro[4.5]decan-3-one",8.0,uM,=,0.9030899869919436,1,O=C1OCc2cc(CCN3CCC4(CC3)CC(=O)N(c3ccns3)C4)ccc21
751,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(C(F)(F)F)cc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1,(S)-4-((1-cyclopropylpiperidin-3-yl)methyl)-N-(4-(trifluoromethyl)phenyl)piperazine-1-carboxamide,6.3,uM,=,0.7993405494535817,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
752,2234749,10.1021/acs.jmedchem.2c00165,,,,Inhibition of hERG by patch clamp assay,CC(C)(O)c1ccc(-c2cccc(N(CC34CCC(c5noc(C(C)(C)F)n5)(CC3)CC4)C(=O)[C@H]3C[C@](O)(C(F)(F)F)C3)c2)cc1,"(cis)-N-((4-(5-(2-Fluoropropan-2-yl)-1,2,4-oxadiazol-3-yl)bicyclo-(2.2.2)octan-1-yl)methyl)-3-hydroxy-N-(4'-(2-hydroxypropan-2-yl)-[1,1'-biphenyl]-3-yl)-3-(trifluoromethyl)cyclobutane-1-carboxamide",4.5,uM,=,0.6532125137753437,1,O=C(C1CCC1)N(CC12CCC(c3ncon3)(CC1)CC2)c1cccc(-c2ccccc2)c1
753,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(Cl)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"3-Chloro-4'-[1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",5.7,uM,=,0.7558748556724915,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
754,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=c1c2ccccc2nc(-c2ccccc2)n1-c1ccc(OCCCN2CCCC2)cc1,2-Phenyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,1.1,uM,=,0.041392685158225,1,O=c1c2ccccc2nc(-c2ccccc2)n1-c1ccc(OCCCN2CCCC2)cc1
755,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(C3CC3)n2)(c2cccc(Cl)c2)CC1,2-(((4-(3-chlorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-6-cyclopropyl-4-(trifluoromethyl)pyridine,9.2,uM,=,0.9637878273455552,1,c1ccc(C2(COCc3cccc(C4CC4)n3)CCNCC2)cc1
756,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1.O=S(=O)(O)c1ccccc1,(E)-5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol benzenesulfonate,0.21,uM,=,-0.6777807052660807,0,c1ccc(/N=N/c2ccccn2)cc1.c1ccccc1
757,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C,"(S)-6-(3-aminopiperidin-1-yl)-3-(isoquinolin-1-ylmethyl)-1-methyl-5-(3-methylbut-2-enyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",9.0,uM,=,0.9542425094393248,1,O=c1[nH]c2cc(N3CCCCC3)[nH]c2c(=O)n1Cc1nccc2ccccc12
758,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CC[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",2.4,uM,=,0.380211241711606,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
759,1654955,10.1016/j.bmcl.2016.10.032,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(S(C)(=O)=O)nc2)C3)ccc2c1COC2=O,"(R)-5-(1-hydroxy-2-(2-(6-(methylsulfonyl)pyridin-3-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",29.6,uM,=,1.4712917110589383,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cccnc3)C4)ccc21
760,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,COc1cccc([C@H](c2cc3cc(C#N)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cc(SC)nc(SC)c2)c1F,"Rac-[(1S,2S)-3-(2-(2,6-bis(methylthio)pyridin-4-yl)-4-(dimethylamino)-1-(2-fluoro-3-methoxyphenyl)-2-hydroxybutyl)-2-methoxyquinoline-6-carbonitrile",5.1,uM,=,0.7075701760979364,1,c1ccc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)cc1
761,541084,10.1016/j.bmcl.2009.01.009,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,CC(C[C@H](NC(=O)C1CCC1)c1ccccc1)N1CCC(n2cc(-c3ccccc3)[nH]c2=O)CC1,"N-((1S)-3-(4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidin-1-yl)-1-phenylbutyl)cyclobutanecarboxamide",0.0047,uM,=,-2.3279021420642825,0,O=C(N[C@@H](CCN1CCC(n2cc(-c3ccccc3)[nH]c2=O)CC1)c1ccccc1)C1CCC1
762,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@H](c2cc(OC(C)C)cnc2OC)c2cc3cc(C#N)ccc3nc2OC)cc(OC)n1,"3-((1S,2S)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)-2-hydroxy-1-(5-isopropoxy-2-methoxypyridin-3-yl)butyl)-2-methoxyquinoline-6-carbonitrile",2.4,uM,=,0.380211241711606,1,c1cncc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)c1
763,624297,10.1016/j.bmcl.2010.01.134,,,,Inhibition of human ERG expressed in HEK cells assessed as blockade of potassium tail current by standard patch clamp analysis,C[C@H](c1cccnc1Cl)c1c(CCN(C)C)sc2ccccc12,"(-)-(S)-2-(3-(1-(2-chloropyridin-3-yl)ethyl)benzo[b]thiophen-2-yl)-N,N-dimethylethanamine",1.5,uM,=,0.1760912590556812,1,c1cncc(Cc2csc3ccccc23)c1
764,1442903,10.1016/j.bmcl.2014.08.008,,,,Inhibition of human ERG by patch clamp assay,O=C(NOCCO)c1ncc2cncn2c1Nc1ccc(I)cc1F,"5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyrazine-6-carboxamide",3.3,uM,=,0.5185139398778875,1,c1ccc(Nc2cncc3cncn23)cc1
765,2125318,10.1021/acs.jmedchem.0c01955,,,,Displacement of [3H]dofetilide from recombinant human ERG stably expressed in HEK293 cell membranes measured after 90 mins by microbeta liquid scintillation counting method,NCCCn1nnc(-c2ccc(Oc3ccc(Cl)cc3)cc2)n1,3-(5-(4-(4-Chlorophenoxy)phenyl)-2H-tetrazol-2-yl)propan-1-amine,4.8,uM,=,0.6812412373755872,1,c1ccc(Oc2ccc(-c3nn[nH]n3)cc2)cc1
766,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)nc(C)c1C#N,"6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-methoxy-2-methylnicotinonitrile",16.0,uM,=,1.2041199826559248,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
767,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4ccccc4N(CCF)C3=O)nn2)ccc1-n1cnc(C)c1,"1-(2-fluoroethyl)-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",3.22,uM,=,0.5078558716958309,1,O=C1Nc2ccccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
768,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,CN1CCN(C(=O)COc2ccc3cc(Oc4ccccn4)ccc3n2)CC1,1-(4-methylpiperazin-1-yl)-2-[[6-(2-pyridyloxy)-2-quinolyl]oxy]ethanone,30.0,uM,=,1.4771212547196624,1,O=C(COc1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
769,1290262,10.1016/j.bmcl.2013.05.024,,,,Binding affinity to human ERG,CCN1C[C@@H]2C[C@@H](NC3CCOCC3OC)C[C@]2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1,"((3aR,5R,6aR)-2-ethyl-5-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydrocyclopenta[c]pyrrol-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",42.6,uM,=,1.6294095991027189,1,O=C(N1CCc2ncccc2C1)[C@@]12CNC[C@@H]1C[C@@H](NC1CCOCC1)C2
770,2089285,10.1016/j.ejmech.2020.112395,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide,1.46,uM,=,0.1643528557844371,1,c1ccc(CCNCCOc2ccccc2)cc1
771,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,NC(=O)CNC(=O)COc1ccc2cc(Oc3ccccn3)ccc2n1,2-[[2-[[6-(2-pyridyloxy)-2-quinolyl]oxy]acetyl]amino]acetamide,30.0,uM,=,1.4771212547196624,1,c1ccc(Oc2ccc3ncccc3c2)nc1
772,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cnc(-c2cnc(O[C@H]3CCN(C(=O)Cc4ccc(OC(F)(F)F)cc4)C[C@@H]3F)c(C(N)=O)c2)c1,"2-(((3S,4S)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)-piperidin-4-yl)oxy)-5-(1-methyl-1H-imidazol-4-yl)nicotinamide",24.0,uM,=,1.380211241711606,1,O=C(Cc1ccccc1)N1CCC(Oc2ccc(-c3c[nH]cn3)cn2)CC1
773,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,CCCOc1cccc(-n2cc3nc(-c4cccnc4C)n(C[C@H]4CCCN(C[C@H]5CCCO5)C4)c(=O)c3n2)c1,"5-(2-Methylpyridin-3-yl)-2-(3-propoxyphenyl)-6-(((S)-1-(((R)-tetrahydrofuran-2-yl)methyl)piperidin-3-yl)methyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",7.3,uM,=,0.8633228601204559,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2cccnc2)n1C[C@H]1CCCN(C[C@H]2CCCO2)C1
774,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,CS(=O)(=O)c1ccc(-c2noc(C3CCN(C(=O)NC4CC4c4ccccc4)CC3)n2)cc1,"4-(3-(4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide",9.0,uM,=,0.9542425094393248,1,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccc3)no2)CC1
775,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,CC(C)CC(=O)N1CCCc2cc(CNC(=O)c3ccc(Cl)cc3)ccc21,"4-chloro-N-((1-(3-methylbutanoyl)-1,2,3,4-tetrahydroquinolin-6-yl)methyl)benzamide",22.0,uM,=,1.3424226808222062,1,O=C(NCc1ccc2c(c1)CCCN2)c1ccccc1
776,745085,10.1016/j.bmcl.2011.02.049,,,,Displacement of [35S]MK499 from human ERG expressed in HEK cells,CC(C)c1cc(C#N)cc2nc(-c3ccc(C(=O)NC[C@H]4CN(c5ccc(-c6ccccc6OC(F)(F)F)cn5)C(=O)O4)cc3)oc12,(S)-4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((2-oxo-3-(5-(2-(trifluoromethoxy)phenyl)pyridin-2-yl)oxazolidin-5-yl)methyl)benzamide,3.58,uM,=,0.5538830266438743,1,O=C(NC[C@H]1CN(c2ccc(-c3ccccc3)cn2)C(=O)O1)c1ccc(-c2nc3ccccc3o2)cc1
777,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,N#Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridine-2-carbonitrile",0.00387,uM,=,-2.4122890349810886,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
778,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,CN(C)CC(C)(O)CNc1cc(NC(=O)N2CCCc3cc(CO)c(C=O)nc32)ncc1C#N,"US9266883, 87",25.0,uM,=,1.3979400086720375,1,O=C(Nc1ccccn1)N1CCCc2cccnc21
779,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5ccn[nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-3-[4'-(2H-pyrazol-3-yl)-biphenyl-4-yl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione",2.0,uM,=,0.3010299956639812,1,O=C1N(c2ccc(-c3ccc(-c4ccn[nH]4)cc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
780,1990506,10.1016/j.bmc.2020.115548,,,,Inhibition of human ERG,N[C@@H]1CC[C@@H](n2cc(-c3ccc4cc[nH]c4c3)c(C(F)(F)F)n2)C1,"(1R,3R)-3-[4-(1H-indol-6-yl)-3-(trifluoromethyl)pyrazol-1-yl]cyclopentanamine",17.0,uM,=,1.230448921378274,1,c1cc2ccc(-c3cnn(C4CCCC4)c3)cc2[nH]1
781,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(C)c6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-8-methyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.3,uM,=,-0.5228787452803376,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
782,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(C)N1CCN(C(=O)N2CCC(NC(=O)C3CCCC3)CC2)CC1,N-(1-(1-isopropylpiperazine-4-carbonyl)piperidin-4-yl)cyclopentanecarboxamide,156.6666667,uM,=,2.1949766033084583,1,O=C(NC1CCN(C(=O)N2CCNCC2)CC1)C1CCCC1
783,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCOC(C)(C)C1)c1cccc(C(F)(F)F)n1,"N-((4-(4-benzylpiperazin-1-yl)-2,2-dimethyltetrahydro-2H-pyran-4-yl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)propionamide",3.2,uM,=,0.505149978319906,1,c1ccc(CN2CCN(C3(CNc4ccccn4)CCOCC3)CC2)cc1
784,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(C3(F)CC3)n2)(c2ccccc2)CC1,2-(1-fluorocyclopropyl)-6-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,12.0,uM,=,1.0791812460476249,1,c1ccc(C2(COCc3cccc(C4CC4)n3)CCNCC2)cc1
785,1573161,10.1016/j.bmcl.2016.03.034,,,,Inhibition of human ERG,CN(C)C(=O)c1cc(CN2CCOc3c(F)cccc32)c2oc(N3CCOCC3)cc(=O)c2c1,"8-((8-fluoro-2H-benzo[b][1,4]oxazin-4(3H)-yl)methyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide",94.0,uM,=,1.9731278535996988,1,O=c1cc(N2CCOCC2)oc2c(CN3CCOc4ccccc43)cccc12
786,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1,(-)-Dimethyl-{2-[3-((R)-1-pyrazin-2-yl-ethyl)-1H-inden-2-yl]-ethyl}-amine,1.4,uM,=,0.1461280356782379,1,C1=C(Cc2cnccn2)c2ccccc2C1
787,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C)cc(-c2cncc(-c3nc4cc(C)cc(C)c4[nH]3)c2N2CCC(N)CC2)c1,"1-(3-(5,7-dimethyl-1H-benzo[d]imidazol-2-yl)-5-(3,5-dimethylphenyl)pyridin-4-yl)piperidin-4-amine",2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
788,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N(CCc3ccc(Cl)cc3)CC3CCCO3)CC2)n1,"1-(3-Amino-1H-1,2,4-triazol-5-yl)-N-(4-chlorophenethyl)-N-((tetrahydrofuran-2-yl)methyl)piperidin-4-amine",15.0,uM,=,1.1760912590556811,1,c1ccc(CCN(CC2CCCO2)C2CCN(c3ncn[nH]3)CC2)cc1
789,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1c(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)cnn1C,"(R)-2-(1,5-dimethyl-1H-pyrazol-4-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline",40.0,uM,=,1.6020599913279625,1,c1cc2nc(-c3cn[nH]c3)ccc2cc1CCN1CCCC1
790,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,COc1cccnc1Cn1ccc2nc(N)nc(NCc3cc(C)on3)c21,"5-((3-Methoxypyridin-2-yl)methyl)-4-((5-methylisoxazol-3-yl)methoxy)-5H-pyrrolo[3,2-d]pyrimidin-2-amine",1.6,uM,=,0.2041199826559248,1,c1ccc(Cn2ccc3ncnc(NCc4ccon4)c32)nc1
791,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,Cc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1,"N,N-dimethyl-2-(6-methyl-3-(pyrazin-2-ylmethyl)-1H-inden-2-yl)ethanamine",0.52,uM,=,-0.2839966563652008,0,C1=C(Cc2cnccn2)c2ccccc2C1
792,1549436,10.1021/acsmedchemlett.5b00215,,,,Inhibition of human ERG transfected in HEK293 cells,Nc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cn1,"5-(4-Chlorophenyl)-[3,3'-bipyridine]-6,6'-diamine",1.8,uM,=,0.255272505103306,1,c1ccc(-c2cncc(-c3cccnc3)c2)cc1
793,580515,10.1016/j.bmcl.2009.06.050,,,,Displacement of [35S]MK499 from human ERG potassium channel expressed in HEK293 cells,COc1ccc([C@@H](C)N[C@@H]2CC[C@@H](C(=O)N3CCC(c4ccccc4)(c4cccnc4)CC3)C(C)(C)C2)cc1,"((1R,4R)-4-((R)-1-(4-methoxyphenyl)ethylamino)-2,2-dimethylcyclohexyl)(4-phenyl-4-(pyridin-3-yl)piperidin-1-yl)methanone",9.6,uM,=,0.9822712330395684,1,O=C([C@H]1CC[C@H](NCc2ccccc2)CC1)N1CCC(c2ccccc2)(c2cccnc2)CC1
794,839832,10.1021/jm300310c,,,,Inhibition of human hERG,CC(C)c1nc(N2CCN(c3ncc(OCc4ccncc4C#N)cn3)[C@H](C)C2)no1,"4-{[(2-{(2R)-2-Methyl-4-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]piperazin-1-yl}pyrimidin-5-yl)oxy]methyl}pyridine-3-carbonitrile",10.0,uM,=,1.0,1,c1cc(COc2cnc(N3CCN(c4ncon4)CC3)nc2)ccn1
795,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,C[C@@H](NC(=O)c1ccc(Cl)cc1)c1cc2c(cn1)N(C(=O)c1cccc(Cl)c1)CCC2,"(R)-4-chloro-N-(1-(1-(3-chlorobenzoyl)-1,2,3,4-tetrahydro-1,7-naphthyridin-6-yl)ethyl)benzamide",16.0,uM,=,1.2041199826559248,1,O=C(NCc1cc2c(cn1)N(C(=O)c1ccccc1)CCC2)c1ccccc1
796,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1ccc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)cn1,"2-(1,4'-bipiperidin-1'-yl)-6-(6-methylpyridin-3-yl)thiazolo[4,5-c]pyridine",8.181818182,uM,=,0.9128498242907508,1,c1cncc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)c1
797,1623141,10.1021/acsmedchemlett.6b00314,,,,Inhibition of human ERG,Cc1nccn1-c1ccc(-c2cn(CC(=O)Nc3cccc(Cl)c3Cl)nn2)cc1,"N-(2,3-dichlorophenyl)-2-(4-(4-(2-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)acetamide",2.2,uM,=,0.3424226808222063,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)Nc1ccccc1
798,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,N#Cc1ccc(OC2CNC(C(=O)N3CCCN(C4CCC4)CC3)C2)cc1,"4-(5-(4-cyclobutyl-1,4-diazepane-1-carbonyl)pyrrolidin-3-yloxy)benzonitrile",10.0,uM,=,1.0,1,O=C(C1CC(Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
799,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(C)N1CCN(C(=O)N2CCC(C(C)(C)C)CC2)CC1,(4-tert-butylpiperidin-1-yl)(4-isopropylpiperazin-1-yl)methanone,66.92307692,uM,=,1.8255759002918144,1,O=C(N1CCCCC1)N1CCNCC1
800,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,CC(C)C(Cn1ccnc1)NC(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,1-(1-(1H-imidazol-1-yl)-3-methylbutan-2-yl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,20.9,uM,=,1.320146286111054,1,O=C(NCCn1ccnc1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
801,820353,10.1021/jm300138g,,,,Displacement of [3H]astemizole from human Erg expressed in HEK293 cells after 75 mins,CNC1CCCC(c2c[nH]c3ccc(NC(=N)c4cccs4)cc23)C1.Cl,cis-(+)-N-(3-(3-(methylamino)cyclohexyl)-1H-indol-5-yl)thiophene-2-carboximidamide hydrochloride,33.0,uM,=,1.5185139398778875,1,N=C(Nc1ccc2[nH]cc(C3CCCCC3)c2c1)c1cccs1
802,2122463,10.1021/acs.jmedchem.1c00263,,,,Inhibition of human ERG,CCOC(=O)NC(=O)c1ccsc1NC(=O)c1ccc(C(=O)N2CCCCC2)s1,Ethyl (2-(5-(Piperidine-1-carbonyl)thiophene-2-carboxamido)thiophene-3-carbonyl)carbamate,65.04367560962571,uM,=,1.813205075204,1,O=C(Nc1cccs1)c1ccc(C(=O)N2CCCCC2)s1
803,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CC[C@H](NCc4ccc5c(n4)NC(=O)CO5)[C@@H](F)C3)c2c1,"trans-6-[({3-Fluoro-1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)-ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]-oxazin-3(4H)-one",19.0,uM,=,1.2787536009528289,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)cnc5ccccc54)CC3)nc2N1
804,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,Cc1ccc(/C=C/CN(C)Cc2ccc3c(c2)OCCC3)cc1.Cl,(E)-N-(Chroman-7-methyl)-N-methyl-3-(4-methylphenyl)prop-2-en-1-amine Hydrochloride,3.8,uM,=,0.5797835966168101,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)OCCC2
805,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(NCc1ccc(F)cc1)N(c1ccc(Cl)cc1)C1CCN(CCO)CC1,1-(4-chlorophenyl)-3-(4-fluorobenzyl)-1-(1-(2-hydroxyethyl)piperidin-4-yl)urea,12.7,uM,=,1.1038037209559568,1,O=C(NCc1ccccc1)N(c1ccccc1)C1CCNCC1
806,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,CN(C)C(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1,"N,N-Dimethyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide",11.0,uM,=,1.0413926851582251,1,O=C1c2ccc(-c3ccccc3)cc2CCN1CCN1CCCC1
807,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c([C@@H](O)[C@H](O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-((1S,2R)-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1,2-dihydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",60.0,uM,=,1.7781512503836436,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
808,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,CC(C(O)c1ccc2[nH]c(=O)oc2c1)N1CCC(O)(c2ccc(F)cc2)CC1,6-(2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxypropyl)benzo[d]oxazol-2(3H)-one,2.6,uM,=,0.414973347970818,1,O=c1[nH]c2ccc(CCN3CCC(c4ccccc4)CC3)cc2o1
809,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1ccc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cn1,"2-(1,4'-bipiperidin-1'-yl)-6-(6-methoxypyridin-3-yl)thiazolo[4,5-b]pyridine",0.101010101,uM,=,-0.9956351946409794,0,c1cncc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)c1
810,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3cccnn3)cc12,4-[(2-Ethylbutyl)amino]-6-(3-pyridazinyl)-3-quinolinecarboxamide,2.3,uM,=,0.3617278360175928,1,c1cnnc(-c2ccc3ncccc3c2)c1
811,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,"6-(1,4-diazepan-1-yl)-1-methyl-5-(3-methylbut-2-enyl)-3-((4-methylquinazolin-2-yl)methyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",2.0,uM,=,0.3010299956639812,1,O=c1[nH]c2cc(N3CCCNCC3)[nH]c2c(=O)n1Cc1ncc2ccccc2n1
812,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1C,"N,N-Diethyl-2-methyl-4-(spiro[chromene-2,4'-piperidine]-4-yl)-benzamide",4.485,uM,=,0.6517624473801109,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
813,79532,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12,"1H-Indole-3-carboxylic acid (3S,7S)-10-oxo-8-aza-tricyclo[5.3.1.0*3,8*]undec-5-yl ester",5.95,uM,=,0.7745169657285496,1,O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12
814,1760517,10.1021/acs.jmedchem.8b00372,,,,Inhibition of human ERG expressed in CHO cells at 10 nM to 10 uM at holding potential of -80 mV measured after 5 mins by QPatch automated patch clamp electrophysiology method,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2O[C@@H](C)C(F)(F)F)C3)ccn1,"3-[2-(2-Methylpyridin-4-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]-pyrazole-5-carbonyl]-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}-benzonitrile",10.0,uM,=,1.0,1,O=C(c1ccccc1)N1Cc2cn(-c3ccncc3)nc2C1
815,1440048,10.1021/jm500887k,,,,Inhibition of human ERG channel by patch clamp technique,C[S+]([O-])c1cccc(-c2ccc3ncc(-c4ccc(S(C)(=O)=O)cc4)n3n2)c1,"6-(3-(methylsulfinyl)phenyl)-3-(4-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine",4.0,uM,=,0.6020599913279624,1,c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1
816,1779901,10.1021/acs.jmedchem.8b00884,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1ccc2nn(C)cc2c1NS(=O)(=O)c1ccc(CCCOC[C@H]2CN(C)CCO2)cc1,(R)-N-(5-isobutyl-2-methyl-2H-indazol-4-yl)-4-(3-((4-methylmorpholin-2-yl)methoxy)propyl)benzenesulfonamide,6.7,uM,=,0.8260748027008264,1,O=S(=O)(Nc1cccc2n[nH]cc12)c1ccc(CCCOC[C@H]2CNCCO2)cc1
817,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,O=C1C(COCc2ccccc2)OC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1,"2-(benzyloxymethyl)-4-phenyl-9-(2-phenylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.1,uM,=,-1.0,0,O=C1C(COCc2ccccc2)OC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
818,2046362,10.1021/acs.jmedchem.0c00746,,,,Inhibition of human ERG,FC(F)Oc1ccc(-c2nnc3cncc(OCCC45C6C7C8C6C4C8C75)n23)cc1,"5-(2-(Cuban-1-yl)ethoxy)-3-(4-(difluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyrazine",4.26,uM,=,0.6294095991027189,1,c1ccc(-c2nnc3cncc(OCCC45C6C7C8C6C4C8C75)n23)cc1
819,1832209,10.1016/j.bmcl.2018.12.024,,,,Inhibition of human ERG by patch clamp method,CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1,"1-(4-fluorophenyl)-N-(1-(2-(methylsulfonyl)pyridin-4-yl)cyclopropyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxamide",68.0,uM,=,1.8325089127062364,1,O=C(NC1(c2ccncc2)CC1)c1cncc2c1cnn2-c1ccccc1
820,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1,"6-(4-methylpiperazin-1-yl)-2-phenyl-3-(4-((4-(5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)pyrido[3,2-b]pyrazine",9.1,uM,=,0.9590413923210936,1,c1ccc(-c2nc3ccc(N4CCNCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1
821,629418,10.1016/j.bmcl.2010.03.071,,,,Displacement of labeled dofetilide human ERG,O=C([C@H]1C[C@H](Oc2ccc(F)cc2)CN1)N1CCCN(C2CCCC2)CC1,"(4-cyclopentyl-1,4-diazepan-1-yl)((2R,4S)-4-(4-fluorophenoxy)pyrrolidin-2-yl)methanone",4.6,uM,=,0.6627578316815741,1,O=C([C@H]1C[C@H](Oc2ccccc2)CN1)N1CCCN(C2CCCC2)CC1
822,971475,10.1021/jm400402q,,,,Inhibition of human ERG by patch-clamp technique,Cc1cc(Nc2ncc(C)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(C)CC1,"N2-(2-Isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-5-methylpyrimidine-2,4-diamine",20.0,uM,=,1.3010299956639813,1,c1ccc(Nc2ccnc(Nc3ccc(C4CCNCC4)cc3)n2)cc1
823,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,C[C@H]1CCc2c(N3CC[C@@H](C4(N)CC4)C3)c(F)cc3cc(C(=O)O)c(=O)n1c23,"(S)-8-((R)-3-(1-aminocyclopropyl)pyrrolidin-1-yl)-9-fluoro-5-methyl-3-oxo-3,5,6,7-tetrahydropyrido[3,2,1-ij]quinoline-2-carboxylic acid",297.0,uM,=,2.4727564493172123,1,O=c1ccc2ccc(N3CC[C@@H](C4CC4)C3)c3c2n1CCC3
824,2052279,10.1021/acs.jmedchem.7b01465,,,,Inhibition of human ERG by fluorescence polarization assay,COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,FIMEPINOSTAT,79.5,uM,=,1.9003671286564705,1,c1cnc(NCc2cc3nc(-c4cccnc4)nc(N4CCOCC4)c3s2)nc1
825,863322,10.1021/jm3008294,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp technique,Cl.c1ccc(OC(c2ccc3ccccc3c2)C2CNC2)cc1,3-(Naphthalen-2-yl(phenoxy)methyl)azetidine hydrochloride,0.83,uM,=,-0.0809219076239261,0,c1ccc(OC(c2ccc3ccccc3c2)C2CNC2)cc1
826,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,O=C(Nc1cc(Cl)c(O)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2)NC1CC1,"(S)-1-(5-chloro-2-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-hydroxyphenyl)-3-cyclopropylurea",1.0,uM,=,0.0,0,O=C(Nc1ccccc1OCCCN1CCC2(CC1)Cc1ccccc1O2)NC1CC1
827,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,C[C@@H]1CN(c2nc(C(F)(F)F)no2)CCN1c1ncc(OCc2ccc(C[S+](C)[O-])cc2F)cn1,"5-({2-Fluoro-4-[(methylsulfinyl)methyl]benzyl}oxy)-2-{(2R)-2-methyl-4-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]piperazin-1-yl}-pyrimidine",28.0,uM,=,1.4471580313422192,1,c1ccc(COc2cnc(N3CCN(c4ncno4)CC3)nc2)cc1
828,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,COC(=O)N(C)c1c(N)nc(-n2nc(Cc3cccc(F)c3F)c3ccccc32)nc1N,"methyl N-[4,6-diamino-2-[3-[(2,3-difluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methyl-carbamate",7.2,uM,=,0.8573324964312685,1,c1ccc(Cc2nn(-c3ncccn3)c3ccccc23)cc1
829,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CC1(C)CC(Oc2ccc(-c3ccc(-c4cn[nH]c4)cc3O)nn2)CC(C)(C)N1,"5-(1H-pyrazol-4-yl)-2-(6-(2,2,6,6-tetramethylpiperidin-4-yloxy)pyridazin-3-yl)phenol; Branaplam",6.3,uM,=,0.7993405494535817,1,c1cc(-c2ccc(OC3CCNCC3)nn2)ccc1-c1cn[nH]c1
830,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4nccs4)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-N-[1-(4-Hydroxy-4-thiazol-2-yl-cyclohexyl)-azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,27.0,uM,=,1.4313637641589874,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3nccs3)CC2)C1
831,2264097,10.1021/acs.jmedchem.1c00703,,,,Inhibition of hERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp assay,COCC(C)(C)CN1CCC(c2nnc(-c3nn(C(C)C)c4ccccc34)o2)CC1.O=C(O)C(=O)O,"1-Isopropyl-3-{5-[1-(3-methoxy-2,2-dimethyl-propyl)-piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate",1.4,uM,=,0.1461280356782379,1,c1ccc2c(-c3nnc(C4CCNCC4)o3)n[nH]c2c1
832,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1,"3-Methyl-4-{5-[8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrazin-2-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-pyridin-2-yl}-benzoic acid",2.5,uM,=,0.3979400086720376,1,O=C1N(c2ccc(-c3ccccc3)nc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1cnccn1
833,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=C1COc2ccc(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)cc2N1,"(R)-6-((1-((3-fluoro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",7.3,uM,=,0.8633228601204559,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)cc2N1
834,883359,10.1021/jm300952s,,,,Inhibition of human ERG by cell-based electrophysiology assay,Cc1cc(CN2CCN(c3c(Cl)cnc4[nH]c(-c5cn(C)nc5C)nc34)CC2)no1,"6-Chloro-2-(1,3-dimethylpyrazol-4-yl)-7-(4-(5-methylisoxazol-3-ylmethyl)piperazin-1-yl)-3H-imidazo[4,5-b]pyridine",6.3,uM,=,0.7993405494535817,1,c1cc(N2CCN(Cc3ccon3)CC2)c2nc(-c3cn[nH]c3)[nH]c2n1
835,1636974,,,,,Inhibition of human ERG expressed in HEK cells by patch clamp method,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC.Cl,VERNAKALANT HYDROCHLORIDE,7.0,uM,=,0.8450980400142568,1,c1ccc(CCO[C@@H]2CCCC[C@H]2N2CCCC2)cc1
836,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,C[C@@H](c1ccccc1)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,endo-3-(8-((S)-1-phenylethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0018,uM,=,-2.744727494896694,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
837,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COc1cccc(CN2CCC(C#N)(CNC(=O)c3cc(OC)cc(OC)c3)CC2)c1,"N-((4-cyano-1-(3-methoxybenzyl)piperidin-4-yl)methyl)-3,5-dimethoxybenzamide",1.5,uM,=,0.1760912590556812,1,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
838,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(Cl)cc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-chloro-4-oxo-4H-chromene-2-carboxamide",0.0036,uM,=,-2.4436974992327127,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
839,498774,10.1021/jm900110t,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",C[C@@H]1NC(c2cc(Cl)ccn2)=N[C@@]1(c1ccc(F)cc1)c1ccc(F)nc1.Cl,"4-Chloro-2-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridyl)-5-methyl-4,5-dihydro-1H-imidazol-2-yl]pyridine Hydrochloride",7.8,uM,=,0.8920946026904804,1,c1ccc([C@]2(c3cccnc3)CNC(c3ccccn3)=N2)cc1
840,990689,10.1016/j.bmcl.2013.09.006,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp technique,Cc1cc(N2CC[C@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)C1CCOCC1,"N-(2-methyl-4-((2S,3'S)-2-methyl-1,3'-bipyrrolidin-1'-yl)phenyl)tetrahydro-2H-pyran-4-carboxamide",18.9,uM,=,1.276461804173244,1,O=C(Nc1ccc(N2CC[C@H](N3CCCC3)C2)cc1)C1CCOCC1
841,1275662,10.1021/jm400856t,,,,Inhibition of human ERG,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,"1-(3-Dimethylamino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile",0.01,uM,=,-2.0,0,c1ccc(C2OCc3ccccc32)cc1
842,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](C#N)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-N-[1-(4-Cyano-cyclohexyl)-azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,24.0,uM,=,1.380211241711606,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
843,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(C#N)c(CC(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(+)-4-(2-hydroxy-2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-6-methoxy-1,5-naphthyridine-3-carbonitrile",0.00258,uM,=,-2.58838029403677,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
844,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCOC(=O)Nc1ccccc1[C@@H](c1ccc(C(=O)N(CC)CC)cc1)N1CCN(Cc2ccccn2)CC1,(R)-ethyl 2-((4-(diethylcarbamoyl)phenyl)(4-(pyridin-2-ylmethyl)piperazin-1-yl)methyl)phenylcarbamate,9.9,uM,=,0.99563519459755,1,c1ccc(C(c2ccccc2)N2CCN(Cc3ccccn3)CC2)cc1
845,1783529,10.1016/j.ejmech.2017.12.075,,,,Inhibition of human ERG by [3H]dofetilide binding displacement assay,Cc1c(CN2CCOCC2)cc(-c2ccc(C(C)C)cc2)n1C1CCC1,4-((1-Cyclobutyl-5-(4-isopropylphenyl)-2-methyl-1H-pyrrol-3-yl)methyl)morpholine,8.0,uM,=,0.9030899869919436,1,c1ccc(-c2cc(CN3CCOCC3)cn2C2CCC2)cc1
846,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3cccn3)[C@H](C)C2)cn1,1-{(R)-4-(4-(2-Ethoxy-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-2-pyrazol-1-yl-ethanone,19.0,uM,=,1.2787536009528289,1,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
847,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccc(F)cc32)CC1,"4-{3-[4-(6-Fluoro-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-4H-benzo[1,4]oxazin-3-one",4.4,uM,=,0.6434526764861874,1,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
848,1734340,10.1021/acsmedchemlett.8b00080,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in peak tail current after 2 to 5 mins by patch clamp based electrophysiology assay,Cc1ccc(CN2CC[C@@H](N3CC[C@H](c4ccc(O)cc4)[C@H](F)C3)C2=O)cc1,"(R)-3-((3S,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrolrolidin-2-one",7.8,uM,=,0.8920946026904804,1,O=C1[C@H](N2CCC(c3ccccc3)CC2)CCN1Cc1ccccc1
849,1809217,10.1021/acsmedchemlett.9b00204,,,,Inhibition of human ERG,C[Si]1(C)CCN(Cc2cc(-c3ccc(C(F)(F)F)cc3)n(C3CCCCC3)n2)CC1,"1-((1-Cyclohexyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl)-4,4-dimethyl-1,4-azasilinane",2.5,uM,=,0.3979400086720376,1,c1ccc(-c2cc(CN3CC[SiH2]CC3)nn2C2CCCCC2)cc1
850,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(N(C)CCN(C)C)nc5)cc4c32)C1,"8-(6-[[2-(Dimethylamino)ethyl](methyl)amino]pyridin-3-yl)-7-fluoro-3-methyl-1-[cis-3-methoxycyclobutyl]-1H,2H,3H-imidazo[4,5-c]quinolin-2-one",5.7,uM,=,0.7558748556724915,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCC1
851,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3ccncn3)CC2)C1,"N-(3,5-bis(trifluoromethyl)benzyl)-1-isopropyl-3-(4-(pyrimidin-4-yl)piperidin-1-yl)cyclopentanecarboxamide",0.13,uM,=,-0.8860566476931633,0,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3ccncn3)CC2)C1
852,2025950,10.1021/acsmedchemlett.0c00575,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,CCS(=O)(=O)c1ccc(CNc2nc3cnc(-c4c(C)ncnc4C4CC4)nc3n([C@@H](C)C3CC3)c2=O)nc1,(S)-2-(4-cyclopropyl-6-methylpyrimidin-5-yl)-8-(1-cyclopropylethyl)-6-((5-(ethylsulfonyl)pyridin-2-yl)methylamino)pteridin-7(8H)-one,10.0,uM,=,1.0,1,O=c1c(NCc2ccccn2)nc2cnc(-c3cncnc3C3CC3)nc2n1CC1CC1
853,809877,10.1021/ml200143c,,,,Inhibition of human ERG expressed in CHOK1 cells by whole cell voltage clamp assay,Cc1nc2c(OC(F)F)cccc2n1-c1ccc(C(=O)NC2CC2)s1,N-Cyclopropyl-5-(4-(difluoromethoxy)-2-methyl-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,28.8,uM,=,1.4593924877592308,1,O=C(NC1CC1)c1ccc(-n2cnc3ccccc32)s1
854,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1cc2nc(C(C)Cc3ccncc3)n(Cc3ccc(Cl)cc3)c2cc1C,"US8975247, EBP461",8.8,uM,=,0.9444826721501688,1,c1ccc(Cn2c(CCc3ccncc3)nc3ccccc32)cc1
855,964765,10.1016/j.bmcl.2013.03.081,,,,Inhibition of human ERG channel,Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)c1ccccc1F,"2-fluoro-N-(2-methyl-4-(2-methyl-1,3'-bipyrrolidin-1'-yl)phenyl)benzamide",1.0,uM,=,0.0,0,O=C(Nc1ccc(N2CCC(N3CCCC3)C2)cc1)c1ccccc1
856,458756,10.1016/j.bmcl.2007.10.063,,,,Inhibition of hERG by patch clamp assay,Cc1cc(CN2C[C@H](N)[C@H](C(=O)C3CCC[C@H]3C#N)C2)cc(C)c1C#N,"4-(((3R,4R)-3-amino-4-((2R)-2-cyanocyclopentanecarbonyl)pyrrolidin-1-yl)methyl)-2,6-dimethylbenzonitrile",28.9,uM,=,1.4608978427565478,1,O=C(C1CCCC1)[C@H]1CCN(Cc2ccccc2)C1
857,1887243,10.1016/j.bmcl.2019.05.023,,,,Inhibition of human ERG by receptor binding assay,COc1c(C#N)ccc2[nH]c(-c3cn4c(n3)[C@H](c3cccc(F)c3C)OCC4)cc12,"(S)-2-[8-(3-fluoro-2-methyl-phenyl)-6,8-dihydro-5H-imidazo[2,1-c][1,4]oxazin-2-yl]-4-methoxy-1H-indole-5-carbonitrile",5.29,uM,=,0.7234556720351858,1,c1ccc([C@@H]2OCCn3cc(-c4cc5ccccc5[nH]4)nc32)cc1
858,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(CCCOc2ccccc2)cccc1CCCOc1ccccc1,"1-methyl-2,6-bis(3-phenoxypropyl)pyridinium",0.208,uM,=,-0.6819366650372385,0,c1ccc(OCCCc2cccc(CCCOc3ccccc3)[nH+]2)cc1
859,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2ncc(F)c(CCN3CCC(NCc4ccc5c(n4)NC(=O)CO5)CC3)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",4.0,uM,=,0.6020599913279624,1,O=C1COc2ccc(CNC3CCN(CCc4ccnc5cccnc45)CC3)nc2N1
860,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(-n4cnnn4)cn2)C3)ccc2c1COC2=O,"(R)-5-(2-(2-(5-(1H-tetrazol-1-yl)pyridin-2-yl)-2,8-diazaspiro[4.5]decan-8-yl)-1-hydroxyethyl)-4-methylisobenzofuran-1(3H)-one",3.29,uM,=,0.5171958979499743,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccc(-n5cnnn5)cn3)C4)ccc21
861,1780273,10.1039/C6MD00406G,,,,Inhibition of human ERG expressed in CHOK1 cells by QPatch automated patch-clamp method,Cc1cn(-c2ccc3n(c2=O)CCN(C[C@@]24C[C@@H]2C(C)(C)Oc2ccc(C(F)(F)F)cc24)C3=O)cn1,"2-(((1aS,7bS)-2,2-dimethyl-6-(trifluoromethyl)-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7b-yl)methyl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-1H-pyrido[1,2-a]pyrazine-1,6(2H)-dione",15.6,uM,=,1.1931245983544616,1,O=C1c2ccc(-n3ccnc3)c(=O)n2CCN1C[C@@]12C[C@@H]1COc1ccccc12
862,2196932,10.1016/j.bmcl.2022.128911,,,,Inhibition of hERG,CC(c1ccc(N2C[C@@H]3C[C@H]2CN3C)cc1)c1ccc2c(c1)Nc1ccccc1S2,"2-(1-(4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)ethyl)-10H-phenothiazine",1.98,uM,=,0.2966651902615311,1,c1ccc2c(c1)Nc1cc(Cc3ccc(N4C[C@@H]5C[C@H]4CN5)cc3)ccc1S2
863,1641577,,,,,"In Vitro Assay: The in vitro effects of the selected compounds on the hERG (human ether-á-go-go-related gene) potassium channel current (a surrogate for IKr, the rapidly activating, delayed rectifier cardiac potassium current) expressed in mammalian cells were evaluated at room temperature using the PatchXpress 7000A (Molecular Devices), an automatic parallel patch clamp system. Each compound was evaluated at varying concentrations in duplicate up to 10 μM, and the duration of exposure to each test article concentration was 5 minutes.",OCCn1c2ccccc2c2ccnc(CN(CCCN3CCNCC3)C3CCCc4cccnc43)c21,"US9314468, Table 8, Compound 14::US9314468, Table 9, Compound 13",2.4,uM,=,0.380211241711606,1,c1cnc2c(c1)CCCC2N(CCCN1CCNCC1)Cc1nccc2c1[nH]c1ccccc12
864,454299,10.1016/j.bmcl.2007.01.020,,,,Inhibition of hERG,Cc1c(CN(C2CCOCC2)[C@H]2CCNC2)cccc1C(F)(F)F,(S)-N-(2-methyl-3-(trifluoromethyl)benzyl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amine,2.9,uM,=,0.4623979978989561,1,c1ccc(CN(C2CCOCC2)[C@H]2CCNC2)cc1
865,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CNC(=O)NCCN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"1-(2-((1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)(4-chlorophenethyl)amino)ethyl)-3-methylurea",1.8,uM,=,0.255272505103306,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
866,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCCOc5ccccc5)c4)n[nH]c2-3)CC1,"6-((4-methylpiperazin-1-yl)methyl)-3-(5-(4-phenoxybut-1-ynyl)thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole",0.45,uM,=,-0.3467874862246563,0,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)CCOc1ccccc1
867,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,Benzyl-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)-phenyl-amine,0.43,uM,=,-0.3665315444204134,0,c1ccc(CN(CCN2CCCC2)c2ccccc2)cc1
868,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc(C(O)(CCn2ccnc2)C(c2cc3cc(Br)ccc3nc2OC)c2ccnc(OC)c2OC)cc(OC)n1,"1-(6-bromo-2-methoxyquinolin-3-yl)-1-(2,3-dimethoxypyridin-4-yl)-2-(2,6-dimethoxypyridin-4-yl)-4-(1H-imidazol-1-yl)butan-2-ol",5.8,uM,=,0.7634279935629373,1,c1ccc2ncc(C(c3ccncc3)C(CCn3ccnc3)c3ccncc3)cc2c1
869,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3cccc(O)c3)CC2)C1,"N-(3,5-bis(trifluoromethyl)benzyl)-3-(4-(3-hydroxyphenyl)piperidin-1-yl)-1-isopropylcyclopentanecarboxamide",0.067,uM,=,-1.1739251972991736,0,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3ccccc3)CC2)C1
870,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCN(CC1CCOCC1)C3,"6-(Benzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]-pyrimidin-5(6H)-one",0.57,uM,=,-0.2441251443275086,0,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCN(CC1CCOCC1)C3
871,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,Cc1ccc2c(c1)N=C(C1=C[C@H](C)N(C)CC1)c1cc(F)ccc1N2,"(S)-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-fluoro-8-methyl-5H-dibenzo[b,e][1,4]diazepine",1.6,uM,=,0.2041199826559248,1,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
872,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2cc3c(cc2F)ncc2c3n([C@H]3CC[C@H](OC)CC3)c(=O)n2C)cn1,"7-Fluoro-1-(trans-4-methoxycyclohexyl)-8-(6-(methoxymethyl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one",27.0,uM,=,1.4313637641589874,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCCCC1
873,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",6.4,uM,=,0.8061799739838872,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
874,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CC[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4ccc(Cl)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(6-chloro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",2.3,uM,=,0.3617278360175928,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
875,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,CC(C)(C)c1cc(CNCC2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc(C(C)(C)C)c1O,"4-(((1-(6,6-bis(4-fluorophenyl)hexyl)pyrrolidin-3-yl)methylamino)methyl)-2,6-di-tert-butylphenol",0.87,uM,=,-0.0604807473813814,0,c1ccc(CNCC2CCN(CCCCCC(c3ccccc3)c3ccccc3)C2)cc1
876,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,FC(F)(F)c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1,"(1R,3R)-1-(tetrahydro-2H-pyran-4-yl)-3-(4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.158,uM,=,-0.8013429130455774,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
877,1456349,10.1021/jm401951t,,,,Inhibition of human ERG expressed in CHO cells by electrophysiology assay,Cc1cc2c(cc1CN(C)C)CCN(C(=O)c1cc3cc(Cl)ccc3n1C)C2,"(+)-(5-chloro-1-methyl-1H-indol-2-yl)(6-((dimethylamino)methyl)-7-methyl-3,4-dihydroisoquinolin-2(1H)-yl)methanone",12.9,uM,=,1.110589710299249,1,O=C(c1cc2ccccc2[nH]1)N1CCc2ccccc2C1
878,2071698,10.1016/j.bmcl.2020.127412,,,,Inhibition of human ERG,CNCCOc1ccccc1C(C)(C)Nc1nccn(-c2cc(C(=O)NC3CC3)ccc2C)c1=O,N-cyclopropyl-4-methyl-3-(3-(2-(2-(2-(methylamino)ethoxy)phenyl)propan-2-ylamino)-2-oxopyrazin-1(2H)-yl)benzamide,27.0,uM,=,1.4313637641589874,1,O=C(NC1CC1)c1cccc(-n2ccnc(NCc3ccccc3)c2=O)c1
879,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1,"(S)-4-((1-cyclopropylpiperidin-3-yl)methyl)-N-(3,4-dichlorophenyl)piperazine-1-carboxamide",2.0,uM,=,0.3010299956639812,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
880,749224,10.1016/j.bmcl.2011.04.029,,,,Inhibition of human ERG by patch clamp method,CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,"(R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one",79.6,uM,=,1.900913067737669,1,O=C1CN(C(=O)CCCc2ccccc2)CCN1
881,1679756,10.1016/j.bmcl.2017.03.086,,,,Inhibition of human ERG by Qpatch electrophysiology method,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccns2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(isothiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",5.0,uM,=,0.6989700043360189,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccns3)C4=O)ccc21
882,498774,10.1021/jm900110t,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",N#Cc1ccnc(C2=NC(c3ccc(F)cc3)(c3ccc(F)cc3)[C@H](CO)N2)c1,"2-[(5R)-4,4-Bis(4-fluorophenyl)-5-(hydroxymethyl)-4,5-dihydro-1H-imidazol-2-yl]-4-pyridinecarbonitrile",6.1,uM,=,0.785329835010767,1,c1ccc(C2(c3ccccc3)CNC(c3ccccn3)=N2)cc1
883,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1cc(CCC23CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC2)CO3)c2nc(OC)ccc2n1,"6-((1-(2-(2,6-dimethoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00421,uM,=,-2.375717904164332,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
884,405656,10.1016/j.bmcl.2006.06.045,,,,Inhibition of HERG potassium channel expressed in HEK cells by whole cell patch clamp method,CN(C(=O)c1ccc(-c2ccc(C(F)(F)F)cc2)cc1)[C@H]1CCN(C(=O)N2CC[C@@H](NCCC(C)(C)c3ccc(Cl)cc3)C2)C1,4'-trifluoromethyl-biphenyl-4-carboxylic acid ((S)-1-{(R)-3-[3-(4-chloro-phenyl)-3-methyl-butylamino]-pyrrolidine-1-carbonyl}-pyrrolidin-3-yl)-methyl-amide,2.6,uM,=,0.414973347970818,1,O=C(N[C@H]1CCN(C(=O)N2CC[C@@H](NCCCc3ccccc3)C2)C1)c1ccc(-c2ccccc2)cc1
885,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,CCCn1c(-c2ccccc2)cc(C(=O)N(C)CCCN2CCN(c3cccc(C)c3C)CC2)c1C,"N-(3-(4-(2,3-dimethylphenyl)piperazin-1-yl)propyl)-N,2-dimethyl-5-phenyl-1-propyl-1H-pyrrole-3-carboxamide",0.7,uM,=,-0.1549019599857432,0,O=C(NCCCN1CCN(c2ccccc2)CC1)c1c[nH]c(-c2ccccc2)c1
886,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,N[C@@H]1C(=O)NC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-((3R,4S)-4-amino-5-oxopyrrolidin-3-yloxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",39.9,uM,=,1.6009728956867482,1,O=C1C[C@H](Oc2ccc3nccc(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CN1
887,2015639,10.1016/j.bmcl.2020.127393,,,,Inhibition of human ERG,Cc1nn(-c2ccnc3[nH]c(-c4cccc5c4ccn5C)nc23)cc1CN1CC[C@H](O)C1,"(S)-1-((3-methyl-1-(2-(1-methyl-1H-indol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-4-yl)methyl)pyrrolidin-3-ol",27.0,uM,=,1.4313637641589874,1,c1cc(-c2nc3c(-n4cc(CN5CCCC5)cn4)ccnc3[nH]2)c2cc[nH]c2c1
888,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(CC1CCN(Cc2ccc(-c3ccc(Cl)cc3)o2)CC1)N1CCCC(CO)C1,2-(1-((5-(4-chlorophenyl)furan-2-yl)methyl)piperidin-4-yl)-1-(3-(hydroxymethyl)piperidin-1-yl)ethanone,2.34,uM,=,0.3692158574101428,1,O=C(CC1CCN(Cc2ccc(-c3ccccc3)o2)CC1)N1CCCCC1
889,948139,10.1016/j.bmcl.2013.01.019,,,,Inhibition of human ERG,CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,"3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide",47.5,uM,=,1.6766936096248666,1,c1ccc(-c2ccc3c(N4CCOCC4)nc(N4CCOCC4)nc3n2)cc1
890,556966,10.1021/jm801065q,,,,Displacement of [3H]dofetilide from human recombinant ERG expressed in HEK293 cells,CC1(C)CN2C(CS/C(=N\C3CCCCC3)NC3CCCCC3)=CSC2=N1,"1,3-dicyclohexyl-2-((6,6-dimethyl-5,6-dihydroimidazo[2,1-b]thiazol-3-yl)methyl)isothiourea",13.24,uM,=,1.1218879851036812,1,C1=C(CS/C(=N\C2CCCCC2)NC2CCCCC2)N2CCN=C2S1
891,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(CC)CC2)c1ncc(-c2ccc3ccncc3c2)[nH]1,(S)-6-ethyl-N-((S)-1-(5-(isoquinolin-7-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide,16.0,uM,=,1.2041199826559248,1,O=C(NCc1ncc(-c2ccc3ccncc3c2)[nH]1)[C@H]1CC12CCNCC2
892,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc2cc(F)ccc2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,7-Fluoro-2-methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,6.0,uM,=,0.7781512503836436,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
893,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CC6(COC6)C5)cc4)C3)o2)cc1,"3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)-azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)-methanone",22.0,uM,=,1.3424226808222062,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CC4(COC4)C3)cc2)C1
894,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOc5cccc(Cl)c5)c4)n[nH]c2-3)CC1,"3-(5-(3-(3-chlorophenoxy)prop-1-ynyl)thiophen-3-yl)-6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno[1,2-c]pyrazole",2.59,uM,=,0.4132997640812518,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)COc1ccccc1
895,1696477,10.1016/j.bmcl.2017.08.068,,,,Inhibition of human ERG by patch clamp assay,NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n([C@@H]3CCCNC3)c2n1,"(R)-3,4-dichloro-2-cyclopropyl-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",1.5,uM,=,0.1760912590556812,1,c1cnc2c(c1)cc(C1CC1)n2[C@@H]1CCCNC1
896,1637262,,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in tail current amplitude by whole cell patch clamp method,COc1ccc(C(=O)Oc2cc(O)cc3oc(-c4ccc(OC)cc4)cc(=O)c23)cc1,7-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-5-yl 4-methoxybenzoate,4.1,uM,=,0.6127838567197355,1,O=C(Oc1cccc2oc(-c3ccccc3)cc(=O)c12)c1ccccc1
897,1924512,10.1021/acsmedchemlett.6b00122,,,,Displacement of [35S]MK-499 from human ERG,Cc1c(C(F)CN2CCN(CC(F)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,"5,5'-(2,2'-(piperazine-1,4-diyl)bis(1-fluoroethane-2,1-diyl))bis(4-methylisobenzofuran-1(3H)-one)",40.0,uM,=,1.6020599913279625,1,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21
898,1517213,10.1021/acs.jmedchem.5b01156,,,,Inhibition of human ERG expressed in CHO cells by patch clamp electrophysiology assay,Nc1nc(NC2CCNCC2)c2sc(-c3ccc(C(F)(F)F)cc3)cc2n1,"N4-(piperidin-4-yl)-6-(4-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine",0.9,uM,=,-0.0457574905606751,0,c1ccc(-c2cc3ncnc(NC4CCNCC4)c3s2)cc1
899,2083683,10.1016/j.bmc.2021.116116,,,,Inhibition of recombinant human ERG expressed in CHO cells incubated for 12 mins by whole cell voltage clamp method,N=C(N)NC(=O)c1nc(-c2cc3ccccc3o2)c(N)nc1N,"3,5-diamino-6-(benzofuran-2-yl)-N-carbamimidoylpyrazine-2-carboxamide",6.9,uM,=,0.8388490907372553,1,c1ccc2oc(-c3cnccn3)cc2c1
900,1840679,10.1016/j.ejmech.2019.02.022,,,,Inhibition of human ERG incubated for 1 hr by Fluorescence polarization binding assay,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,"N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine",0.511,uM,=,-0.2915790998652872,0,c1ccc(-c2cnc3ccc(NCC4CCNCC4)nn23)cc1
901,49082,10.1021/jm0208875,,,,K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.1,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine,1.47,uM,=,0.1673173347481761,1,c1ccc2c(c1)Nc1ccccc1S2
902,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)c(C)nc2ccc(-c3cccnc3)cc12,4-[(2-Ethylbutyl)amino]-2-methyl-6-(pyridin-3-yl)quinoline-3-carboxamide,0.68,uM,=,-0.1674910872937636,0,c1cncc(-c2ccc3ncccc3c2)c1
903,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cnc(-c2cnc(N)c(O[C@H]3CN(C(=O)Cc4ccc(OC(F)(F)F)cc4)C[C@@H]3F)c2)c1,"1-((3S,4S)-3-((2-Amino-5-(1-methyl-1H-imidazol-4-yl)pyridin-3-yl)oxy)-4-fluoropyrrolidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)-ethan-1-one",16.0,uM,=,1.2041199826559248,1,O=C(Cc1ccccc1)N1CC[C@@H](Oc2cncc(-c3c[nH]cn3)c2)C1
904,2153149,10.1016/j.ejmech.2021.113827,,,,Inhibition of hERG expressed in CHO-K1 cells assessed as reduction in thallium influx incubated for 30 minutes by FLIPR,O=c1ccc2c([nH]1)CCC(NCCCCNc1c3c(nc4cc(Cl)ccc14)CCCC3)C2,"6-(4-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)butylamino)-5,6,7,8-tetrahydroquinolin-2(1H)-one",8.069,uM,=,0.9068197154665456,1,O=c1ccc2c([nH]1)CCC(NCCCCNc1c3c(nc4ccccc14)CCCC3)C2
905,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1,"Cis-(1R,3R)-3-(5-phenyl-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-beta-carboline",0.38,uM,=,-0.4202164033831898,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
906,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC[C@@H]1CCCC[C@H]1O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,"1-(((1S,2R)-2-hydroxycyclohexyl)methyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea",7.33,uM,=,0.865103974641128,1,O=C(NCC1CCCCC1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
907,963062,10.1021/jm400408r,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,Cc1cc(=O)oc2c(Cl)c(OCCCCN3CCC(c4noc5cc(F)ccc45)CC3)ccc12,7-(4-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-4-methyl-8-chloro-2H-chromen-2-one,1.591,uM,=,0.2016701796465815,1,O=c1ccc2ccc(OCCCCN3CCC(c4noc5ccccc45)CC3)cc2o1
908,627338,10.1016/j.bmcl.2010.03.005,,,,Inhibition of human ERG,CC(C)C(N1CCOCC1)C(O)(c1cccnc1)c1cccnc1,"3-methyl-2-morpholino-1,1-di(pyridin-3-yl)butan-1-ol",75.0,uM,=,1.8750612633917,1,c1cncc(C(CN2CCOCC2)c2cccnc2)c1
909,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNC3)Oc3ccccc32)cc1,"N,N-Diethyl-4-(spiro[chromene-2,3'-pyrrolidine]-4-yl)benzamide",6.429,uM,=,0.8081434257614911,1,C1=C(c2ccccc2)c2ccccc2OC12CCNC2
910,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOC(CO)C2)NC(c2nccs2)=NC1c1ccc(F)cc1Br,"Ethyl 4-(2-Bromo-4-fluorophenyl)-6-((2-(hydroxymethyl)-morpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",7.33,uM,=,0.865103974641128,1,C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccccc1
911,1290262,10.1016/j.bmcl.2013.05.024,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CN(C(=O)/C=C/c3ccccc3)C[C@@]2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1,"1-((3aR,5R,6aR)-5-(3-methoxytetrahydro-2H-pyran-4-ylamino)-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-phenylprop-2-en-1-one",24.1,uM,=,1.3820170425748683,1,O=C(/C=C/c1ccccc1)N1C[C@@H]2C[C@@H](NC3CCOCC3)C[C@]2(C(=O)N2CCc3ncccc3C2)C1
912,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2c(c1)N(CCN1CCC(NCc3cc4c(cn3)OCCO4)CC1)C(=O)CO2,"4-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]piperidin-1-yl}ethyl)-6-methoxy-2H-1,4-benzoxazin-3(4H)-one",13.0,uM,=,1.1139433523068367,1,O=C1COc2ccccc2N1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
913,585577,10.1016/j.bmcl.2009.06.081,,,,Inhibition of human ERG by whole cell patch clamp assay,CN1CC[C@@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,(R)-2-chloro-4-((1-methylpyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,0.78,uM,=,-0.1079053973095195,0,c1ccc(CN(c2ccccc2)[C@@H]2CCNC2)cc1
914,612186,10.1016/j.bmcl.2009.12.071,,,,Inhibition of human ERG by patch clamp study,CN1C[C@H]2C[C@@H](N(Cc3ccc(F)c(C(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1,"(exo)-1-Methyl-1H-imidazole-4-carboxylic acid(3-trifluoromethyl, 4-fluorobenzyl)-(2-methyl-octahydro-cyclopenta[c]pyrrol-5-yl)-amide",1.72,uM,=,0.2355284469075489,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)[C@H]1C[C@H]2CNC[C@H]2C1
915,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,CSc1ccccc1C(=O)N(C1CCCCC1)[C@H]1CCNC1,(S)-N-cyclohexyl-2-(methylthio)-N-(pyrrolidin-3-yl)benzamide,2.27,uM,=,0.3560258571931227,1,O=C(c1ccccc1)N(C1CCCCC1)[C@H]1CCNC1
916,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=N[C@@](c2cccc(-c3cncnc3)c2)(c2ccnc(C(F)F)c2)c2cccc(F)c21,(S)-1-(2-(Difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine,4.8,uM,=,0.6812412373755872,1,C1=N[C@](c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
917,2253561,10.1021/acs.jmedchem.1c02071,,,,Inhibition of hERG expressed in HEK293 cells by automated patch clamp assay,O=c1nc2n(c3c1CN(Cc1ccccc1)CC3)CCN2Cc1ccc(F)c(Br)c1,"7-benzyl-3-(3-bromo-4-fluorobenzyl)-2,3,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one",4.91,uM,=,0.6910814921229685,1,O=c1nc2n(c3c1CN(Cc1ccccc1)CC3)CCN2Cc1ccccc1
918,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COCc1nc(-c2ccc(N3C(=O)N(c4cc(O)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)no1,"1-(6-Hydroxy-pyrimidin-4-yl)-3-[4-(5-methoxymethyl-[1,2,4]oxadiazol-3-yl)-phenyl]-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",7.7,uM,=,0.8864907251724818,1,O=C1N(c2ccc(-c3ncon3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
919,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,COc1cccc([C@@H](C)N2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)c1,endo-3-(8-((R)-1-(3-methoxyphenyl)ethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0046,uM,=,-2.337242168318426,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
920,880571,10.1021/ml300280g,,,,Binding affinity to human ERG,Cc1ccc(N2CCN(Cc3cc(C(=O)N[C@H]4CCCC[C@@H]4O)c(=O)n4ccccc34)CC2)nc1,"N-((1S,2S)-2-hydroxycyclohexyl)-1-((4-(5-methylpyridin-2-yl)piperazin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxamide",11.5,uM,=,1.0606978403536118,1,O=C(NC1CCCCC1)c1cc(CN2CCN(c3ccccn3)CC2)c2ccccn2c1=O
921,1973140,10.1021/acs.jmedchem.0c00245,,,,Inhibition of human ERG,Cc1cc(Cl)cc(-c2ccnc3cc(CN4C(=O)C5C(C4=O)C5(C)C)sc23)c1O[C@@H]1CCNC[C@@H]1C,"3-((7-(5-Chloro-3-methyl-2-(((3S,4R)-3-methylpiperidin-4-yl)oxy)phenyl)thieno[3,2-b]pyridin-2-yl)methyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione",0.4,uM,=,-0.3979400086720376,0,O=C1C2CC2C(=O)N1Cc1cc2nccc(-c3ccccc3OC3CCNCC3)c2s1
922,1292641,10.1021/jm401760c,,,,Binding affinity to full length human ERG expressed in CHO cells after 6 to 7 mins by IonWorks assay,CNc1nc(NCCCN(C)C)c2sc(-c3ccc(OC(F)(F)F)cc3)cc2n1,"N4-(3-(dimethylamino)propyl)-N2-methyl-6-(4-(trifluoromethoxy)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine",2.8,uM,=,0.4471580313422192,1,c1ccc(-c2cc3ncncc3s2)cc1
923,946025,10.1016/j.bmcl.2012.10.128,,,,Inhibition of human ERG,Cc1cn([C@H]2CCCN(S(=O)(=O)c3ccc(O)c(Oc4cccc(Cl)c4)c3)C2)c(=O)[nH]c1=O,"(S)-1-(1-(3-(3-chlorophenoxy)-4-hydroxyphenylsulfonyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione",27.0,uM,=,1.4313637641589874,1,O=c1ccn([C@H]2CCCN(S(=O)(=O)c3cccc(Oc4ccccc4)c3)C2)c(=O)[nH]1
924,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,CNCCCN1c2ccccc2CCc2ccccc21,"[3-(10,11-Dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-methyl-amine",1.39,uM,=,0.143014800254095,1,c1ccc2c(c1)CCc1ccccc1N2
925,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,O=C(CNc1n[nH]c2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](O)CC2)C1,cis-N-(1-(4-hydroxycyclohexyl)azetidin-3-yl)-2-(5-(trifluoromethyl)-1H-indazol-3-ylamino)acetamide,30.0,uM,=,1.4771212547196624,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
926,1871973,10.1021/acs.jmedchem.8b01769,,,,Inhibition of human ERG expressed in CHO cells assessed as reduction in peak channel current by IonWork patch-clamp electrophysiology method,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC.Cl,"[4-Cyano-4-(3,4-dimethoxy-phenyl)-5-methyl-hexyl]-[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-ammonium chloride",0.2,uM,=,-0.6989700043360187,0,c1ccc(CCCCNCCc2ccccc2)cc1
927,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ncc(-c2ccc(C(=O)O)cc2C)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C,"4-(5-(2-(((4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4-(trifluoromethyl)phenyl)-6-methoxypyridin-3-yl)-3-methylbenzoic Acid",0.44,uM,=,-0.3565473235138126,0,O=C1O[C@H](c2ccccc2)CN1Cc1ccccc1-c1cncc(-c2ccccc2)c1
928,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ncc(-c2ccc(C(=O)O)cc2C)cc1-c1ccc(C(F)(F)F)nc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C,"4-(2'-(((4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-2-methoxy-6'-(trifluoromethyl)-[3,3'-bipyridin]-5-yl)-3-methylbenzoic Acid",2.5,uM,=,0.3979400086720376,1,O=C1O[C@H](c2ccccc2)CN1Cc1ncccc1-c1cncc(-c2ccccc2)c1
929,2298259,10.1016/j.bmc.2023.117276,,,,Inhibition of hERG expressed in CHO cells by automated patch clamp method,Cc1c(CN(C)CC(O)c2ccc(O)cc2)sc2c(=O)c(C(=O)NCc3ccc(Cl)cc3)cn(C)c12,"N-(4-chlorobenzyl)-2-(((2-hydroxy-2-(4-hydroxyphenyl)ethyl)(methyl)amino)methyl)-3,4-dimethyl-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(NCc1ccccc1)c1c[nH]c2cc(CNCCc3ccccc3)sc2c1=O
930,1630280,10.1016/j.ejmech.2016.07.032,,,,Inhibition of human ERG expressed in CHOK1 cells by whole-cell patch clamp method,CC(C)Cc1cc(CNS(=O)(=O)c2ccc(CCc3ccccc3)cc2)nn1-c1ccccc1,N-[(5-isobutyl-1-phenyl-1H-pyrazol-3-yl)methyl]-2-phenylethanesulfonamide,8.73,uM,=,0.9410142437055696,1,O=S(=O)(NCc1ccn(-c2ccccc2)n1)c1ccc(CCc2ccccc2)cc1
931,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Clc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)nc1,"(1R,3R)-3-(4-(5-chloropyridin-2-yl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.465,uM,=,-0.332547047110046,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)nc1
932,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CC(C)N1CCN[C@@H](CN2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"(S)-N-(3,4-dichlorophenyl)-4-((4-isopropylpiperazin-2-yl)methyl)piperazine-1-carboxamide",5.6,uM,=,0.7481880270062004,1,O=C(Nc1ccccc1)N1CCN(C[C@H]2CNCCN2)CC1
933,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,O=c1n(Cc2ccc(Cl)cc2F)c2sc3c(c2c2ncnn12)CCN(CC1CCOCC1)C3,"6-(4-Chloro-2-fluorobenzyl)-9-((tetrahydro-2H-pyran-4-yl)-methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]-triazolo[1,5-c]pyrimidin-5(6H)-one",0.61,uM,=,-0.2146701649892329,0,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCN(CC1CCOCC1)C3
934,2293467,10.1021/acs.jmedchem.7b00463,,,,Inhibition of hERG potassium channel by Q-patch clamp assay,Cc1noc(C)c1-c1noc(-c2nnn(Cc3ccc(CN4CCOCC4)cc3)c2N)n1,"4-(3-(3,5-dimethylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl)-1-(4-(morpholinomethyl)benzyl)-1H-1,2,3-triazol-5-amine",6.0,uM,=,0.7781512503836436,1,c1cc(Cn2cc(-c3nc(-c4cnoc4)no3)nn2)ccc1CN1CCOCC1
935,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(C1CC(Oc2ccc(F)cc2)CN1)N1CCCN(C2CCCC2)CC1,"(4-cyclopentyl-1,4-diazepan-1-yl)(4-(4-fluorophenoxy)pyrrolidin-2-yl)methanone",4.6,uM,=,0.6627578316815741,1,O=C(C1CC(Oc2ccccc2)CN1)N1CCCN(C2CCCC2)CC1
936,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,COc1ccc(C2(c3cccc(-c4cncnc4)c3)N=C(N)c3c(F)cccc32)cc1,4-Fluoro-1-(4-methoxyphenyl)-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine,0.5,uM,=,-0.3010299956639812,0,C1=NC(c2ccccc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
937,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(C#CCOc2ccccc2)cccc1C#CCOc1ccccc1,"1-methyl-2,6-bis(3-phenoxyprop-1-ynyl)pyridinium",14.014,uM,=,1.1465621131575567,1,C(#Cc1cccc(C#CCOc2ccccc2)[nH+]1)COc1ccccc1
938,824789,10.1021/jm2015952,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,CC(C)(C)Oc1cccc2nc(N)nc(N)c12,"5-tert-Butoxyquinazoline-2,4-diamine",20.2,uM,=,1.305351369446624,1,c1ccc2ncncc2c1
939,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,CNC(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1F,2-fluoro-4-(4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)-N-methylbenzamide,16.0,uM,=,1.2041199826559248,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
940,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C(Cc1ccc([N+](=O)[O-])cc1)N1CCN(CCc2ccc([N+](=O)[O-])cc2)CC1,1-(4-(4-nitrophenethyl)piperazin-1-yl)-2-(4-nitrophenyl)ethanone,0.046,uM,=,-1.337242168318426,0,O=C(Cc1ccccc1)N1CCN(CCc2ccccc2)CC1
941,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,COCC(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1,"4-(8-amino-3-((R)-4-(2-methoxyacetyl)morpholin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-3-fluoro-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",24.0,uM,=,1.380211241711606,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@H]3CNCCO3)n3ccncc23)cc1
942,745085,10.1016/j.bmcl.2011.02.049,,,,Displacement of [35S]MK499 from human ERG expressed in HEK cells,Cc1ccc(-c2ccc(N3CC(CNC(=O)c4ccc(-c5nc6cc(C#N)cc(C(C)C)c6o5)cc4)OC3=O)nc2)s1,rac-4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((3-(5-(5-methylthiophen-2-yl)pyridin-2-yl)-2-oxooxazolidin-5-yl)methyl)benzamide,12.65,uM,=,1.1020905255118367,1,O=C(NCC1CN(c2ccc(-c3cccs3)cn2)C(=O)O1)c1ccc(-c2nc3ccccc3o2)cc1
943,540677,10.1016/j.bmcl.2008.12.083,,,,Inhibition of human ERG,Nc1ccc(-c2cccs2)cc1NC(=O)c1ccc(CN2CCC3(CCCN3)CC2)cc1,"4-(1,8-diazaspiro[4.5]decan-8-ylmethyl)-N-(2-amino-5-(thiophen-2-yl)phenyl)benzamide",1.597,uM,=,0.2033049161384829,1,O=C(Nc1cccc(-c2cccs2)c1)c1ccc(CN2CCC3(CCCN3)CC2)cc1
944,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(F)ccc3OC[C@H]2[C@@]1(CCCN)c1ccccc1,"1-[(3R,3aR)-3-(3-amino-propyl)-8-fluoro-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-2-yl]-ethanone",0.94,uM,=,-0.0268721464003013,0,C1=NN2c3ccccc3OC[C@H]2C1c1ccccc1
945,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,COc1cnc(C(=O)Nc2csc([C@]34CO[C@@H](C)C[C@H]3CSC(N)=N4)n2)cn1,"US9315520, 10",43.0,uM,=,1.6334684555795866,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1cnccn1
946,761736,10.1021/jm200401v,,,,Inhibition of recombinant human ERG channel expressed in human HEK 293 cells by patch clamp assay,C[C@@H]1CCCN1CCCOc1ccc(-c2cn[nH]c(=O)c2)cc1,5-[4-[3-((R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-2Hpyridazin-3-one,9.5,uM,=,0.9777236052888478,1,O=c1cc(-c2ccc(OCCCN3CCCC3)cc2)cn[nH]1
947,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2c1CCN2C,"(1R,2S)-1-(7-bromo-3-methoxynaphthalen-2-yl)-4-(dimethylamino)-2-(1-methylindolin-4-yl)-1-phenylbutan-2-ol",1.3,uM,=,0.1139433523068367,1,c1ccc([C@@H](Cc2cccc3c2CCN3)c2ccc3ccccc3c2)cc1
948,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1cc(C(F)(F)F)cc(-n2ncc(-c3ccc4cc(CCN5CCC[C@H]5C)ccc4n3)c2C)n1,(R)-2-(5-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,16.8,uM,=,1.2253092817258628,1,c1ccc(-n2cc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cn2)nc1
949,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1cnc(OC)c(OC)c1)[C@@](O)(CCN(C)C)c1cccc2ccoc12,"(1R,2S)-2-(benzofuran-7-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-1-(5,6-dimethoxypyridin-3-yl)-4-(dimethylamino)butan-2-ol",1.0,uM,=,0.0,0,c1cncc([C@@H](Cc2cccc3ccoc23)c2ccc3ccccc3c2)c1
950,958294,10.1016/j.bmcl.2013.03.047,,,,Inhibition of human ERG channel in HEK293 cells by voltage-gated patch clamp technique,COc1ccc2nccc([C@@H](O)CC[C@@H]3CCN(C4CC(c5ccccc5F)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-1-(3-(2-fluorophenyl)cyclobutyl)-4-((S)-3-hydroxy-3-(6-methoxyquinolin-4-yl)propyl)piperidine-3-carboxylic acid",12.2,uM,=,1.0863598306747482,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
951,2153986,10.1021/acsmedchemlett.1c00660,,,,Inhibition on hERG expressed in HEK293 cells by Qpatch method,O=C(NCCCN1CCCC1)c1cccn2c(=O)c3ccc4ccccc4c3nc12,"7-oxo-N-(3-(pyrrolidin-1-yl)propyl)-7H-benzo[h]pyrido[2,1-b]quinazoline-12-carboxamide",4.44,uM,=,0.6473829701146199,1,O=C(NCCCN1CCCC1)c1cccn2c(=O)c3ccc4ccccc4c3nc12
952,876021,10.1021/jm3011838,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,CN1C[C@H](C(=O)Nc2ccc(Cl)cc2)[C@@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)C1,"(3R,4S)-4-{4-[(E)-2-(2-Amino-phenylcarbamoyl)-vinyl]-phenyl}-1-methyl-pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-amide",10.0,uM,=,1.0,1,O=C(/C=C/c1ccc([C@H]2CNC[C@@H]2C(=O)Nc2ccccc2)cc1)Nc1ccccc1
953,1760517,10.1021/acs.jmedchem.8b00372,,,,Inhibition of human ERG expressed in CHO cells at 10 nM to 10 uM at holding potential of -80 mV measured after 5 mins by QPatch automated patch clamp electrophysiology method,CS(=O)(=O)c1ccc(N2CCC(F)(F)CC2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1,"4,4-Difluoro-1-{2-[2-(2-fluorophenyl)-2H,4H,5H,6H-pyrrolo-[3,4-c]pyrazole-5-carbonyl]-4-methanesulfonylphenyl}-piperidine",4.3,uM,=,0.6334684555795865,1,O=C(c1ccccc1N1CCCCC1)N1Cc2cn(-c3ccccc3)nc2C1
954,438968,10.1021/jm0700565,,,,Blockade of hERG expressed in HEK293 cells by whole-cell patch clamp method,CC1(C)C2=C3CC4C5=[N+](CCC4OC3CCN2c2ccc(CC(=O)NCCCCCCN(CCOc3ccc(NS(C)(=O)=O)cc3)CCc3ccc(NS(C)(=O)=O)cc3)cc21)c1ccc(S(=O)(=O)[O-])cc1C5(C)C,"24-{[(6-{[2-(4-methanesulfonamidophenoxy)ethyl][2-(4-methanesulfonamidophenyl)ethyl]amino}hexyl)carbamoyl]methyl}-5,5,27,27-tetramethyl-16-oxa-12,20-diazaheptacyclo[15.11.0.0^{3,15}.0^{4,12}.0^{6,11}.0^{20,28}.0^{21,26}]octacosa-1(28),4(12),6(11),7,9,21(26),22,24-octaen-12-ylium-8-sulfonate",0.31,uM,=,-0.5086383061657274,0,O=C(Cc1ccc2c(c1)CC1=C3CC4C5=[N+](CCC4OC3CCN12)c1ccccc1C5)NCCCCCCN(CCOc1ccccc1)CCc1ccccc1
955,876604,10.1021/jm301476b,,,,Inhibition of human ERG expressed in chinese hamster lung cells by IonWorks patch clamp electrophysiology assay,CN1CCN(C(=O)c2ccc(-c3cnc(N)c(-c4ccc(C(F)(F)F)nc4)c3)cc2)CC1,(4-(6-Amino-5-(6-(trifluoromethyl)pyridin-3-yl)pyridin-3-yl)phenyl)(4-methylpiperazin-1-yl)methanone,8.2,uM,=,0.9138138523837168,1,O=C(c1ccc(-c2cncc(-c3cccnc3)c2)cc1)N1CCNCC1
956,755804,10.1021/jm2003359,,,,Inhibition of human ERG expressed in CHO cells by Q-patch assay,NCC(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(Cl)c(F)c2)C1,"2-amino-1-(3-(4-chloro-3-fluorophenylamino)-2-(4-fluorophenyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone",21.0,uM,=,1.3222192947339193,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
957,2208843,10.1016/j.bmc.2022.116657,,,,Inhibition of hERG channel expressed in CHO cells at -80 mV holding potential by Qpatch clamp method,COc1cc(OC)c(F)c(COc2cnc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)c(F)c3)nc2)c1F,"5-[(2,6-Difluoro-3,5-dimethoxyphenyl)methoxy]-N-{3-fluoro-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine",7.6,uM,=,0.8808135922807914,1,c1ccc(COc2cnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)nc2)cc1
958,966756,10.1016/j.bmcl.2013.04.074,,,,Binding affinity to wild type human ERG expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization to -40 mV by patch clamp method,C[C@@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@H](C)N1,"5-Amino-1-cyclopropyl-7-(3,5-dimethyl-piperazin-1-yl)-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid",21.7,uM,=,1.3364597338485296,1,O=c1ccn(C2CC2)c2cc(N3CCNCC3)ccc12
959,2021700,10.1021/acs.jmedchem.9b00069,,,,Inhibition of human ERG by thallium flux assay,CCOc1ccc2cc(-c3nn(CC(C)(C)CO)c(N)c3C(N)=O)ccc2c1,"5-Amino-3-(6-ethoxynaphthalen-2-yl)-1-(3-hydroxy-2,2-dimethylpropyl)-1H-pyrazole-4-carboxamide",30.0,uM,=,1.4771212547196624,1,c1ccc2cc(-c3cc[nH]n3)ccc2c1
960,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCCC(C(=O)N2CCCC2)C1,1-(3-(pyrrolidine-1-carbonyl)piperidin-1-yl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)ethanone,31.0,uM,=,1.4913616938342726,1,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCCC(C(=O)N2CCCC2)C1
961,1990506,10.1016/j.bmc.2020.115548,,,,Inhibition of human ERG,NCc1ccc(-n2cc(-c3ccc4cc[nH]c4c3)c(C(F)(F)F)n2)cc1,[4-[4-(1H-indol-6-yl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]methanamine,4.0,uM,=,0.6020599913279624,1,c1ccc(-n2cc(-c3ccc4cc[nH]c4c3)cn2)cc1
962,1525287,10.1016/j.bmcl.2015.09.045,,,,Inhibition of human ERG expressed in HEK293 cells by whole-cell patch clamp method,CC(c1ccc(OCCCN2CCC(c3noc4cc(F)ccc34)CC2)cc1)c1nc2ccccc2o1,3-(1-(3-(4-(1-(benzo[d]oxazol-2-yl)ethyl)phenoxy)propyl)piperidin-4-yl)-6-fluorobenzo[d]isoxazole,1.01,uM,=,0.0043213737826425,1,c1ccc2oc(Cc3ccc(OCCCN4CCC(c5noc6ccccc56)CC4)cc3)nc2c1
963,1760517,10.1021/acs.jmedchem.8b00372,,,,Inhibition of human ERG expressed in CHO cells at 10 nM to 10 uM at holding potential of -80 mV measured after 5 mins by QPatch automated patch clamp electrophysiology method,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2-c2cccc(F)c2)C3)ccn1,"4-(3-Fluorophenyl)-3-[2-(2-methylpyridin-4-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole-5-carbonyl]benzonitrile",10.0,uM,=,1.0,1,O=C(c1ccccc1-c1ccccc1)N1Cc2cn(-c3ccncc3)nc2C1
964,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(Cl)cc(Cl)c2)CCN(Cc2ccccc2OC)CC1,"methyl 4-((3,5-dichlorobenzamido)methyl)-1-(2-methoxybenzyl)piperidine-4-carboxylate",0.16,uM,=,-0.7958800173440752,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
965,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4ccccc4N(CC4CC4)C3=O)nn2)ccc1-n1cnc(C)c1,"1-(cyclopropylmethyl)-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",1.58,uM,=,0.1986570869544226,1,O=C1C(n2cc(-c3ccc(-n4ccnc4)cc3)nn2)CCc2ccccc2N1CC1CC1
966,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CCc1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2CCO)n1,"2-(3-Ethyl-[1,2,4]triazol-1-yl)-1-((R)-2-(2-hydroxy-ethyl)-4-(2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl)-piperazin-1-yl)-ethanone",0.0098,uM,=,-2.008773924307505,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
967,1713882,10.1016/j.bmcl.2018.05.030,,,,Inhibition of human ERG expressed in CHO-K1 cells at -90 mV holding potential by Qpatch clamp assay,O=C(CCCCc1c[nH]nn1)NC1CCN(C(=O)OCc2cc(Cl)cc(Cl)c2)CC1,"US9409895, 20",9.3,uM,=,0.9684829485539352,1,O=C(CCCCc1c[nH]nn1)NC1CCN(C(=O)OCc2ccccc2)CC1
968,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CSc1ccc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2)cn1,"(R)-5-(1-hydroxy-2-(2-(6-(methylthio)pyridin-3-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",4.6,uM,=,0.6627578316815741,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cccnc3)C4)ccc21
969,1622464,10.1016/j.bmcl.2016.09.067,,,,Inhibition of radiolabeled dofetilide binding to human ERG expressed in HEK293 cells,C[C@@H]1C[C@H](N)CN(c2ccncc2Nc2ncc3ccc(-c4ncccc4F)nn23)C1,"N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(3-fluoropyridin-2-yl)imidazo[1,5-b]pyridazin-7-amine",1.2,uM,=,0.0791812460476248,1,c1ccc(-c2ccc3cnc(Nc4cnccc4N4CCCCC4)n3n2)nc1
970,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Fc1ncccc1-c1cnc2nc(N3CCC(N4CCCCC4)CC3)sc2c1,"2-(1,4'-bipiperidin-1'-yl)-6-(2-fluoropyridin-3-yl)thiazolo[4,5-b]pyridine",2.658227848,uM,=,0.4245922034269333,1,c1cncc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)c1
971,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@H]3CO2)ccc2c1COC2=O,"5-((3R,9aS)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-4-methylisobenzofuran-1(3H)-one",19.7,uM,=,1.294466226161593,1,O=C1OCc2cc([C@@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@H]4CO3)ccc21
972,876021,10.1021/jm3011838,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,CN1C[C@H](C(=O)Nc2ccc(Cl)cc2)[C@@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2F)C1,"rac-(trans-3,4)-4-{4-[2-(2-Amino-phenylcarbamoyl)-vinyl]-2-fluoro-phenyl}-1-methyl-pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-amide",7.0,uM,=,0.8450980400142568,1,O=C(/C=C/c1ccc([C@H]2CNC[C@@H]2C(=O)Nc2ccccc2)cc1)Nc1ccccc1
973,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCNCC2)c1,4-(benzyloxy)-1-(1-(2-(piperazin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,16.4,uM,=,1.214843848047698,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCNCC2)c1
974,1972154,10.1021/acs.jmedchem.9b01624,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,O=C(Nc1cc(-c2cn(C3CCOCC3)c3cnccc23)ccn1)NC1CC1,"1-Cyclopropyl-3-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)urea",4.6,uM,=,0.6627578316815741,1,O=C(Nc1cc(-c2cn(C3CCOCC3)c3cnccc23)ccn1)NC1CC1
975,420606,10.1016/j.bmcl.2006.11.061,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(C2CCc3c2ccc2c3OCO2)CC1)c1cc(=O)c2cc(F)ccc2o1,"N-(1-(7,8-dihydro-6H-indeno[5,4-d][1,3]dioxol-6-yl)piperidin-4-yl)-6-fluoro-4-oxo-4H-chromene-2-carboxamide",5.86,uM,=,0.7678976160180907,1,O=C(NC1CCN(C2CCc3c2ccc2c3OCO2)CC1)c1cc(=O)c2ccccc2o1
976,1294319,10.1021/jm401278d,,,,Inhibition of human ERG by patch clamp electrophysiology,CS(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc(C(F)(F)F)nc3)n2)cc1,5-(4-(Methylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine,8.1,uM,=,0.9084850188786496,1,c1ccc(-c2cncc(-c3cccnc3)n2)cc1
977,812136,10.1016/j.bmcl.2012.01.015,,,,Inhibition of human ERG by patchXpress assay,c1ccc(Cn2ccc3c(OC4CCN(Cc5cscn5)CC4)ncnc32)cc1,"4-((4-(7-benzyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)piperidin-1-yl)methyl)thiazole",0.76,uM,=,-0.1191864077192086,0,c1ccc(Cn2ccc3c(OC4CCN(Cc5cscn5)CC4)ncnc32)cc1
978,834187,10.1021/jm2013248,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,c1ccc(-c2nnc(CN3CCN(Cc4nc5ccccc5s4)CC3)o2)cc1,"2-((4-(benzo[d]thiazol-2-ylmethyl)piperazin-1-yl)methyl)-5-phenyl-1,3,4-oxadiazole",30.0,uM,=,1.4771212547196624,1,c1ccc(-c2nnc(CN3CCN(Cc4nc5ccccc5s4)CC3)o2)cc1
979,1809217,10.1021/acsmedchemlett.9b00204,,,,Inhibition of human ERG,C[Si]1(C)CCN(Cc2cc(-c3ccc(C(F)(F)F)cc3)n(-c3ccc(F)cc3)n2)CC1,"1-((1-(4-Fluorophenyl)-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl)-4,4-dimethyl-1,4-azasilinane",1.26,uM,=,0.1003705451175629,1,c1ccc(-c2cc(CN3CC[SiH2]CC3)nn2-c2ccccc2)cc1
980,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1,"2-(1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-yl)-6-methyl-1H-benzo[d]imidazole-5-carbonitrile",10.0,uM,=,1.0,1,O=c1ccc2ncccc2n1CCN1CCC(c2nc3ccccc3[nH]2)CC1
981,492219,10.1021/jm800419w,,,,Antagonist activity at human ERG by voltage-clamp electrophysiology assay,CC1(C)C[C@H](CN2CCC(F)(CNC(=O)c3cc(Cl)cc(Cl)c3)CC2)CCO1,"(R)-3,5-Dichloro-N-[1-(2,2-dimethyl-tetrahydro-pyran-4-ylmethyl)-4-fluoro-piperidin-4-ylmethyl]-benzamide",5.01,uM,=,0.6998377258672457,1,O=C(NCC1CCN(CC2CCOCC2)CC1)c1ccccc1
982,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@@H]3CO2)ccc2c1COC2=O,"5-((3R,9aR)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-4-methylisobenzofuran-1(3H)-one",74.9,uM,=,1.8744818176994664,1,O=C1OCc2cc([C@@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@@H]4CO3)ccc21
983,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,Cc1c(O)ccc2c1C(=O)N(Cc1ccccc1-c1ccccc1)C2C(=O)NC(C)(C)C,(rac)-2-(biphenyl-2-ylmethyl)-N-tert-butyl-5-hydroxy-4-methyl-3-oxoisoindoline-1-carboxamide,46.0,uM,=,1.662757831681574,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
984,1348051,10.1016/j.bmcl.2014.03.075,,,,Inhibition of human ERG by Q-patch assay,NC(=O)c1cnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc(-n2nccn2)c1,"4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide",8.6,uM,=,0.9344984512435676,1,c1cc(Nc2ccnc(NC3CCCCC3)n2)cc(-n2nccn2)c1
985,815278,10.1016/j.ejmech.2012.02.049,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cells after 45 mins by scintillation counting method,NS(=O)(=O)c1ccc(OCCN2CCCCC2)cc1,4-[(2-(piperidin-1-yl)ethoxy)]benzenesulfonamide,24.0,uM,=,1.380211241711606,1,c1ccc(OCCN2CCCCC2)cc1
986,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)cnc43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(6-fluoro-3H-imidazo[4,5-b]pyridin-3-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",2.1,uM,=,0.3222192947339193,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4cccnc43)C[C@@H]12)c1ccccc1
987,1436764,10.1021/ml500187a,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated whole-cell patch-clamp electrophysiology method,CC(C)N(Cc1ccc(Cl)c(Cl)c1)CC1CNC1.Cl,"N-(azetidin-3-ylmethyl)-N-(3,4-dichlorobenzyl)propan-2-amine hydrochloride",5.5,uM,=,0.7403626894942439,1,c1ccc(CNCC2CNC2)cc1
988,952825,10.1016/j.bmc.2013.02.009,,,,Inhibition of human ERG,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO,"(8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one",20.0,uM,=,1.3010299956639813,1,O=C1C=CC2C(=C1)CC[C@@H]1C2=CCC2CCC[C@H]21
989,1924853,10.1016/j.bmcl.2016.07.029,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells measured after 90 mins by scintillation proximity assay,CNC(=O)[C@@H]1C[C@H](N2CCc3c(cccc3OCCc3ccccc3)C2)CN1C(=O)c1ccc(CN)c(OC)c1,"(2S,4S)-1-(4-(aminomethyl)-3-methoxybenzoyl)-N-methyl-4-(5-phenethoxy-3,4-dihydroisoquinolin-2(1H)-yl)pyrrolidine-2-carboxamide",4.0,uM,=,0.6020599913279624,1,O=C(c1ccccc1)N1CC[C@H](N2CCc3c(cccc3OCCc3ccccc3)C2)C1
990,1545989,10.1021/acs.jmedchem.5b01227,,,,Inhibition of human ERG channel by automated Q-patch assay,O=C(Nc1cccc(C(F)(F)F)c1)n1ccc2cc(Oc3ncnc4c3CNC4)ccc21,"5-((6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1H-indole-1-carboxamide",15.6,uM,=,1.1931245983544616,1,O=C(Nc1ccccc1)n1ccc2cc(Oc3ncnc4c3CNC4)ccc21
991,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,COC(=O)[C@H]1C[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(trans)-methyl 2-((7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)methyl)cyclopropanecarboxylate",0.5,uM,=,-0.3010299956639812,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7CC7)nc56)(CC3)OC4)nc2N1
992,2298259,10.1016/j.bmc.2023.117276,,,,Inhibition of hERG expressed in CHO cells by automated patch clamp method,NS(=O)(=O)NCCc1cc2cc(CN3CCOCC3)cc3c(=O)c(C(=O)NCc4ccc(Cl)cc4)cn1c23,"N-[(4-Chlorophenyl)methyl]-8-[(morpholin-4-yl)methyl]-6-oxo-2-[2-(sulfamoylamino)ethyl]-6H-pyrrolo[3,2,1-ij]quinoline-5-carboxamide",12.0,uM,=,1.0791812460476249,1,O=C(NCc1ccccc1)c1cn2ccc3cc(CN4CCOCC4)cc(c1=O)c32
993,1502030,10.1021/acs.jmedchem.5b00217,,,,Inhibition of human ERG,Cc1ncc(OC[C@@]2(c3ccc(F)c(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1,"(1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,4-difluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide",2.2,uM,=,0.3424226808222063,1,O=C(Nc1ccccn1)[C@@H]1C[C@@]1(COc1cncnc1)c1ccccc1
994,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)CC2c2ccc(C(F)(F)F)cc2)cc1,1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-trifluoromethyl-phenyl)-2-imidazolidinone,9.1,uM,=,0.9590413923210936,1,O=C1NCC(c2ccccc2)N1CCc1ccccc1
995,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CS(=O)(=O)N[C@H]1CC[C@@H](N2CC(NC(=O)CNc3n[nH]c4ccc(C(F)(F)F)cc34)C2)CC1,cis-N-(1-(4-(methylsulfonamido)cyclohexyl)azetidin-3-yl)-2-(5-(trifluoromethyl)-1H-indazol-3-ylamino)acetamide,23.0,uM,=,1.3617278360175928,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
996,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc2c(c1)CN(C(C)=O)[C@H]2C(=O)Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,"(1R)-2-acetyl-5-ethylsulfonyl-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]isoindoline-1-carboxamide",40.0,uM,=,1.6020599913279625,1,O=C(Nc1ccccc1)[C@@H]1NCc2ccccc21
997,687332,10.1016/j.bmcl.2010.10.042,,,,Displacement of [3H]-dofetilide from human ERG,N#Cc1ccc(CNC(=O)N(c2cccc(F)c2)C2CCN(CCC3(c4cccc(F)c4)CCN(C(=O)c4cccc(C(N)=O)c4)CC3)CC2)cc1,3-(4-(2-(4-(3-(4-cyanobenzyl)-1-(3-fluorophenyl)ureido)piperidin-1-yl)ethyl)-4-(3-fluorophenyl)piperidine-1-carbonyl)benzamide,20.0,uM,=,1.3010299956639813,1,O=C(c1ccccc1)N1CCC(CCN2CCC(N(C(=O)NCc3ccccc3)c3ccccc3)CC2)(c2ccccc2)CC1
998,1865114,10.1021/acsmedchemlett.9b00086,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp method,CNC(C(=O)N[C@](Cc1ccccc1)(c1ccc(F)cc1)c1cc(F)cc(C(F)(F)F)c1)C(O)(C(F)(F)F)C(F)(F)F,"4,4,4-trifluoro-N-((R)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-hydroxy-2-(methylamino)-3-(trifluoromethyl)butanamide",13.0,uM,=,1.1139433523068367,1,c1ccc(CC(c2ccccc2)c2ccccc2)cc1
999,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,Oc1ccc2ccccc2c1/N=N/c1nccs1,DNDI1417016,0.31,uM,=,-0.5086383061657274,0,c1ccc2c(/N=N/c3nccs3)cccc2c1
1000,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,Cn1c(=O)c2c(c(C#N)c(N3CCC[C@H](N)C3)n2Cc2ccccc2)n(C)c1=O,"(S)-6-(3-aminopiperidin-1-yl)-5-benzyl-1,3-dimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",4.3,uM,=,0.6334684555795865,1,O=c1[nH]c(=O)c2c(cc(N3CCCCC3)n2Cc2ccccc2)[nH]1
1001,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,COC(=O)N1CCC(C2N[C@@H](c3nc(-c4ccccc4)c[nH]3)Cc3c2[nH]c2ccccc32)CC1,"methyl 4-((3R)-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)piperidine-1-carboxylate",0.7,uM,=,-0.1549019599857432,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCNCC4)N3)n2)cc1
1002,815278,10.1016/j.ejmech.2012.02.049,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cells after 45 mins by scintillation counting method,NS(=O)(=O)c1ccc(OCCCN2CCCCC2)cc1,4-[(3-(piperidin-1-yl)propoxy)]benzenesulfonamide,93.2,uM,=,1.9694159123539807,1,c1ccc(OCCCN2CCCCC2)cc1
1003,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"4-{5-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-pyridin-2-yl}-benzoic acid",46.0,uM,=,1.662757831681574,1,O=C1N(c2ccc(-c3ccccc3)nc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
1004,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CCNS(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1,4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic Acid Ethylamide,3.3829787230000004,uM,=,0.5292992663328373,1,c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
1005,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCN2C(=O)N(NS(=O)(=O)CC#N)C[C@@H]2c2ccc(OC)cc2)cc1,1-(Cyanomethylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-[(4-methoxy)-phenyl]-2-imidazolidinone,33.0,uM,=,1.5185139398778875,1,O=C1NC[C@H](c2ccccc2)N1CCc1ccccc1
1006,1436559,10.1016/j.bmcl.2014.09.089,,,,Inhibition of human ERG by patch clam assay,O=C(NCCN1CCC(O)(Cc2ccc(F)cc2)CC1)Nc1ccnc2ccsc12,"1-[2-[4-(4-Fluorobenzyl)-4-hydroxypiperidin-1-yl]ethyl]-3-(thieno[3,2-b]pyridin-7-yl)urea",5.0,uM,=,0.6989700043360189,1,O=C(NCCN1CCC(Cc2ccccc2)CC1)Nc1ccnc2ccsc12
1007,674336,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human ERG expressed in HEK cells by patch clamp technique,O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(N3CCOCC3)nc12,(S)-2-morpholino-N-(quinuclidin-3-yl)benzo[d]oxazole-4-carboxamide,3.2,uM,=,0.505149978319906,1,O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(N3CCOCC3)nc12
1008,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Oc1ccc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)cn1,"5-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridin-6-yl)pyridin-2-ol",190.0,uM,=,2.278753600952829,1,c1cncc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)c1
1009,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(F)ccc1Oc1ccc(Cl)c(F)c1,1-(2-(4-chloro-3-fluorophenoxy)-5-fluorophenyl)-N-methylmethanamine,4.67,uM,=,0.6693168805661122,1,c1ccc(Oc2ccccc2)cc1
1010,879307,10.1021/jm1013693,,,,Inhibition of human ERG,CN(C)CCCCc1ccc(C2(C)COC2)cc1,"N,N-dimethyl-4-(4-(3-methyloxetan-3-yl)phenyl)butan-1-amine",35.0,uM,=,1.5440680443502757,1,c1ccc(C2COC2)cc1
1011,1627127,10.1016/j.bmcl.2016.10.064,,,,Displacement of 35S-MK499 from human ERG expressed in HEK293 cell membranes,Cc1c([C@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@@H]3CN2)ccc2c1COC2=O,"5-((3S,9aS)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydro-1H-pyrazino[1,2-a]pyrazin-3-yl)-4-methylisobenzofuran-1(3H)-one",22.0,uM,=,1.3424226808222062,1,O=C1OCc2cc([C@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@@H]4CN3)ccc21
1012,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2ccccc2NC(=O)OC)cc1,methyl 2-((4-(diethylcarbamoyl)phenyl)(1-(4-fluorobenzyl)piperidin-4-ylidene)methyl)phenylcarbamate,4.7,uM,=,0.6720978579357175,1,c1ccc(CN2CCC(=C(c3ccccc3)c3ccccc3)CC2)cc1
1013,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,CC(C)Oc1ccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,cis-N-({1-[4-Hydroxy-4-(6-isopropoxy-pyridin-3-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,11.2,uM,=,1.0492180226701815,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccnc3)CC2)C1
1014,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1cc(C2=CC3(CCNCC3)Oc3ccccc32)cs1,"N,N-Diethyl-4-(spiro[chromene-2,4'-piperidine]-4-yl)thiophene-2-carboxamide",3.463,uM,=,0.5394524915494608,1,C1=C(c2ccsc2)c2ccccc2OC12CCNCC2
1015,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2c(c1)N(CCN1CCC(NCc3cc4c(cn3)OCCO4)CC1)C(=O)CS2,"4-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]piperidin-1-yl}ethyl)-6-methoxy-2H-1,4-benzothiazin-3(4H)-one",6.0,uM,=,0.7781512503836436,1,O=C1CSc2ccccc2N1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
1016,938571,10.1021/jm3014597,,,,Inhibition of human ERG channel expressed in CHO cells by Ionworks HT assay,COc1ccc(C(CCCN)(c2ccccc2)c2ccccc2)cc1,"4-(4-methoxyphenyl)-4,4-diphenylbutan-1-amine",6.6,uM,=,0.8195439355418687,1,c1ccc(C(c2ccccc2)c2ccccc2)cc1
1017,1688709,10.1021/acs.jmedchem.7b00410,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp assay,Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1,N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide,73.6,uM,=,1.8668778143374989,1,O=C(Nc1ccccn1)c1cc(Oc2cncnc2)ccn1
1018,613538,10.1021/jm901781q,,,,Inhibition of human ERG by patch-clamp method,CCCOCCn1c(=O)c(N2CCNCC2)nc2cnc(-c3ccc(OC)nc3)cc21,"3-(2-(2-hydroxyethylamino)ethylamino)-1-(2-propoxyethyl)-7-(6-methoxypyridin-3-yl)-1,2-dihydropyrido[3,4-b]pyrazin-2-ol",0.67,uM,=,-0.1739251972991735,0,O=c1[nH]c2cc(-c3cccnc3)ncc2nc1N1CCNCC1
1019,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,O=C(CNc1noc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3ccc4c(c3)OCO4)CC2)C1,"cis-N-[1-(4-Benzo[1,3]dioxol-5-yl-cyclohexyl)-azetidin-3-yl]-2-(5-trifluoromethyl-benzo[d]isoxazol-3-ylamino)-acetamide",1.9,uM,=,0.2787536009528289,1,O=C(CNc1noc2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccc4c(c3)OCO4)CC2)C1
1020,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,NC1CCN(c2c(NC(=O)c3cn4ccccc4n3)cncc2-c2cc(Cl)cc(Cl)c2)CC1,"N-[4-(4-aminopiperidin-1-yl)-5-(3,5-dichlorophenyl)pyridin-3-yl]imidazo[1,2-a]pyridine-2-carboxamide",1.9,uM,=,0.2787536009528289,1,O=C(Nc1cncc(-c2ccccc2)c1N1CCCCC1)c1cn2ccccc2n1
1021,830253,10.1021/jm300041e,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,CC(C)[C@@H]1c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)c(Cl)c3)n2CCN1C(=O)CN,"(R)-2-Amino-1-(3-(4-chloro-3-fluorophenylamino)-2-(4-fluorophenyl)-8-isopropyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone",13.4,uM,=,1.1271047983648077,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
1022,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,CS(=O)(=O)N1CCC(C2N[C@@H](c3nc(-c4ccccc4)c[nH]3)Cc3c2[nH]c2ccccc32)CC1,"(3R)-1-(1-(methylsulfonyl)piperidin-4-yl)-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",3.5,uM,=,0.5440680443502757,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCNCC4)N3)n2)cc1
1023,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CS(=O)(=O)Nc1ccc(OC[C@@H](O)CNCCc2ccc(Cl)c(F)c2)cc1,(S)-1-(4-Methanesulfonamidophenoxy)-3-(3-fluoro-4-chorophenylethylamino)-2-propanol,1.91,uM,=,0.2810333672477275,1,c1ccc(CCNCCCOc2ccccc2)cc1
1024,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,COc1ccc(/C=C/CN(C)Cc2ccc3c(c2)CCCCC3)cc1.Cl,"(E)-3-(4-methoxyphenyl)-N-methyl-N-((6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)methyl)prop-2-en-1-amine Hydrochloride",3.2,uM,=,0.505149978319906,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)CCCCC2
1025,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CC1(C)CC(NC(=O)CC(O)C(F)(F)F)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1,"N-[6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-4,4,4-trifluoro-3-hydroxybutanamide",2.47,uM,=,0.3926969532596658,1,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
1026,2253561,10.1021/acs.jmedchem.1c02071,,,,Inhibition of hERG expressed in HEK293 cells by automated patch clamp assay,CN(C)CCC=C1c2ccccc2CCc2ccccc21,"[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine",1.81,uM,=,0.2576785748691845,1,C=C1c2ccccc2CCc2ccccc21
1027,1537932,10.1016/j.bmcl.2015.10.070,,,,Inhibition of human ERG assessed as reduction in IKr current,CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,OMARIGLIPTIN,39.0,uM,=,1.591064607026499,1,c1ccc([C@@H]2CC[C@@H](N3Cc4c[nH]nc4C3)CO2)cc1
1028,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"6-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione",39.0,uM,=,1.591064607026499,1,O=C1CCCCOC(=O)C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CCC1
1029,1935939,10.1016/j.bmc.2019.02.025,,,,Inhibition of human ERG by manual patch clamp electrophysiology assay,CCOc1cc(C(O)(CCN(C)C)C(c2cc3cc(Br)ccc3nc2OC)c2ccnc(OC)c2OC)cc(OC(C)C)n1,"rac-1-(6-bromo-2-methoxyquinolin-3-yl)-1-(2,3-dimethoxypyridin-4-yl)-4-(dimethylamino)-2-(2-ethoxy-6-isopropoxypyridin-4-yl)butan-2-ol",7.8,uM,=,0.8920946026904804,1,c1ccc2ncc(C(Cc3ccncc3)c3ccncc3)cc2c1
1030,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=NC(c2cccc(-c3cncnc3)c2)(c2ccnc(C(F)F)c2)c2cccc(F)c21,rac-1-(2-(Difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine,7.2,uM,=,0.8573324964312685,1,C1=NC(c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
1031,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=C1COc2cnc(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"(R)-2-((1-((3-fluoro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one",30.0,uM,=,1.4771212547196624,1,O=C1COc2cnc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
1032,2129860,10.1021/acsmedchemlett.1c00328,,,,Inhibition of human ERG stably expressed in CHO-K1 cells at -90 mV holding potential by automated Q-patch clamp method,N#Cc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(C#N)c(F)c3)CC2)cc1,4-((2-((1-(4-cyanophenethyl)piperidin-4-yl)amino)-1H-benzo[d]imidazol-1-yl)methyl)-2-fluorobenzonitrile,0.05,uM,=,-1.3010299956639813,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
1033,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCC[C@@H](CCO)Nc1nc(N)nc2cccc(C)c12,(S)-3-((2-Amino-5-methylquinazolin-4-yl)amino)hexan-1-ol,5.5,uM,=,0.7403626894942439,1,c1ccc2ncncc2c1
1034,1658369,10.1016/j.ejmech.2016.12.038,,,,Inhibition of human ERG expressed in CHO cells by Qpatch assay,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,"5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide",0.5,uM,=,-0.3010299956639812,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1
1035,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2cccc3c2OCO3)cc(OC)n1,"3-((1R,2S)-1-(benzo[d][1,3]dioxol-4-yl)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)-2-hydroxybutyl)-2-methoxyquinoline-6-carbonitrile",1.6,uM,=,0.2041199826559248,1,c1cc2c(c([C@@H](Cc3ccncc3)c3cnc4ccccc4c3)c1)OCO2
1036,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)N1CCOCC1)C2,"(2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)(morpholino)methanone",9.1,uM,=,0.9590413923210936,1,O=C(N1CCOCC1)N1CCc2nc(OCc3conc3-c3ccccc3)ccc2C1
1037,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(CC)CC2)c1ncc(-c2cc3cccnc3nc2OC)o1,"(S)-6-ethyl-N-((S)-1-(5-(2-methoxy-1,8-naphthyridin-3-yl)oxazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide",12.0,uM,=,1.0791812460476249,1,O=C(NCc1ncc(-c2cnc3ncccc3c2)o1)[C@H]1CC12CCNCC2
1038,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,Cc1ccccc1[C@@H]1CCN(C[C@@H]2CCc3cccnc3[C@@H](O)C2)C[C@H]1C,"(7R,9S)-7-(((3S,4R)-3-methyl-4-o-tolylpiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",9.2,uM,=,0.9637878273455552,1,c1ccc(C2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
1039,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,COc1ccc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3cnc4cccnc43)[C@H](C)C2)cc1,"2-imidazo[4,5-b]pyridin-3-yl-1-{(R)-4-[4-(4-methoxy-phenyl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-ethanone",8.8,uM,=,0.9444826721501688,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2ccccc2)CC1
1040,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,Cc1noc(-c2ccc(CCN3CCC(Nc4nc5ccccc5n4C)CC3)cc2)n1,"1-methyl-N-(1-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine",0.35,uM,=,-0.4559319556497244,0,c1ccc2[nH]c(NC3CCN(CCc4ccc(-c5ncno5)cc4)CC3)nc2c1
1041,611802,10.1021/jm9015075,,,,Inhibition of human ERG,Brc1cnc2nc(N3CCN4CCC3CC4)oc2c1,"4-(6-Bromooxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]-nonane",2.3,uM,=,0.3617278360175928,1,c1cnc2nc(N3CCN4CCC3CC4)oc2c1
1042,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CN1CCC(Cn2nc(-c3ccc4nc(OC5CC5)ccc4c3)c3c(N)ncnc32)CC1,"3-(2-Cyclopropoxyquinolin-6-yl)-1-((1-methylpiperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",1.7,uM,=,0.2304489213782739,1,c1ncc2c(-c3ccc4nc(OC5CC5)ccc4c3)nn(CC3CCNCC3)c2n1
1043,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,O=C(/C=C/c1ccc(CNCCc2c(-c3cccs3)[nH]c3ccccc23)cc1)NO,(E)-N-hydroxy-3-(4-((2-(2-(thiophen-2-yl)-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide,0.48,uM,=,-0.3187587626244128,0,c1ccc(CNCCc2c(-c3cccs3)[nH]c3ccccc23)cc1
1044,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1ccc2c(c1)S(=O)(=O)C(C)C(c1ccc(OCCCN3CCCC3)cc1)O2,"(+/-)-1-{3-[4-(6-Methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",1.0,uM,=,0.0,0,O=S1(=O)CC(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
1045,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C)cc(CNc2cncc(-c3cc(C)cc(C)c3)c2N2CCC(N)CC2)c1,"4-(4-aminopiperidin-1-yl)-N-(3,5-dimethylbenzyl)-5-(3,5-dimethylphenyl)pyridin-3-amine",1.7,uM,=,0.2304489213782739,1,c1ccc(CNc2cncc(-c3ccccc3)c2N2CCCCC2)cc1
1046,440956,10.1016/j.bmcl.2006.10.091,,,,Inhibition of hERG,CCN(CC)C(C)CCCNc1nccc(NCc2ccc(Cl)cc2Cl)n1.N,"N4-(2,4-dichlorobenzyl)-N2-(4-(diethylamino)pentyl)pyrimidine-2,4-diamine",0.3,uM,=,-0.5228787452803376,0,c1ccc(CNc2ccncn2)cc1
1047,464747,10.1016/j.bmcl.2008.01.126,,,,Inhibition of human ERG by FLIPR assay,Cc1oc(-c2cccc(Cl)c2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1,"(2S,3S)-3-(3-(2-(2-(3-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",1.8,uM,=,0.255272505103306,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
1048,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCOC(=O)[C@H]1CC[C@@H](N2CC(NC(=O)CNc3nn(CC(F)(F)F)c4ccc(C(F)(F)F)cc34)C2)CC1,"cis-4-(3-{2-[1-(2,2,2-Trifluoro-ethyl)-5-trifluoromethyl-1H-indazol-3-ylamino]-acetylamino}-azetidin-1-yl)-cyclohexane carboxylic acid ethyl ester",2.5,uM,=,0.3979400086720376,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
1049,463271,10.1016/j.bmcl.2007.11.052,,,,Inhibition of human ERG,C[C@H](Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12)C(=O)N(C)C,"(S)-2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)-N,N-dimethylpropanamide",10.0,uM,=,1.0,1,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
1050,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",CC[C@@H]1c2nnc(-c3nc(C)ns3)n2CCN1C(=O)c1ccc(F)cc1,"US9422299, 22",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
1051,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,COc1cnc2ccc(=O)n(CCN3CCC(NCc4cnc(C)c(C#N)n4)CC3)c2c1,"6-((1-(2-(7-Methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)-piperidin-4-ylamino)methyl)-3-methylpyrazine-2-carbonitrile",69.0,uM,=,1.8388490907372552,1,O=c1ccc2ncccc2n1CCN1CCC(NCc2cnccn2)CC1
1052,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(OC)cc(OC)c2)CCN(Cc2ccccc2OC)CC1,"methyl 4-((3,5-dimethoxybenzamido)methyl)-1-(2-methoxybenzyl)piperidine-4-carboxylate",1.9,uM,=,0.2787536009528289,1,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
1053,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(O)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-hydroxy-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.96,uM,=,0.292256071356476,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1054,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccc(F)cc4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(4-fluorophenyl)pyrrolo[1,2-b]pyridazine-3-carboxamide",10.2,uM,=,1.0086001717619175,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
1055,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1nc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2)ccc1S(C)(=O)=O,"(R)-5-(1-hydroxy-2-(2-(6-methyl-5-(methylsulfonyl)pyridin-2-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",7.9,uM,=,0.8976270912904415,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccccn3)C4)ccc21
1056,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(N1CCN(C2CC2)CC1)N1Cc2ccccc2C1,(4-cyclopropylpiperazin-1-yl)(isoindolin-2-yl)methanone,52.5,uM,=,1.7201593034059568,1,O=C(N1CCN(C2CC2)CC1)N1Cc2ccccc2C1
1057,699317,10.1016/j.bmc.2010.10.034,,,,Inhibition of human ERG,NCC[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1,"cis-2-((2R,4R)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine",1.51,uM,=,0.1789769472931694,1,c1ccc([C@H]2CCCc3ccccc32)cc1
1058,2241986,10.1016/j.ejmech.2021.114028,,,,Inhibition of hERG,CN(C)C(=O)[C@]1(C)CC[C@@](CF)(c2cc(-c3ccc(F)cn3)ccc2F)N=C1N,"(3R,6S)-2-amino-6-(2-fluoro-5-(5-fluoropyridin-2-yl)phenyl)-6-(fluoromethyl)-N,N,3-trimethyl-3,4,5,6-tetrahydropyridine-3-carboxamide",8.32,uM,=,0.920123326290724,1,C1=NC(c2cccc(-c3ccccn3)c2)CCC1
1059,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cnc2cc(F)c(-c3cccnc3)cc2c1NC1CCOCC1,7-Fluoro-6-(3-pyridinyl)-4-(tetrahydro-2H-pyran-4-ylamino)-3-quinolinecarboxamide,2.0,uM,=,0.3010299956639812,1,c1cncc(-c2ccc3nccc(NC4CCOCC4)c3c2)c1
1060,2024332,10.1016/j.bmcl.2020.127710,,,,Inhibition of human ERG,NC(=O)c1cc(Cl)c2cc(-c3cc4c(s3)CNCC4)cnn12,"5-chloro-3-(4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)pyrrolo[1,2-b]pyridazine-7-carboxamide",11.31,uM,=,1.0534626049254554,1,c1cc2cc(-c3cc4c(s3)CNCC4)cnn2c1
1061,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c([C@@H]3OC(=O)O[C@H]3C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-((4R,5S)-5-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-1,3-dioxolan-4-yl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",4.9,uM,=,0.6901960800285137,1,O=C1COc2ccc(CNC34CCC([C@@H]5OC(=O)O[C@H]5c5ccnc6cccnc56)(CC3)OC4)nc2N1
1062,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(=O)Nc1cccc(-c2ccc([C@H]3CN(C)C[C@@H]3NS(=O)(=O)C(C)C)cc2)c1,"N-(4'-((3R,4R)-1-methyl-4-(1-methylethylsulfonamido)pyrrolidin-3-yl)biphenyl-3-yl)acetamide",12.6,uM,=,1.100370545117563,1,c1ccc(-c2ccc([C@@H]3CCNC3)cc2)cc1
1063,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCN2CCCCC2)cc1,4-(Benzyloxy)-1-{4-[2-(piperidin-1-yl)ethoxy]phenyl}-pyridin-2(1H)-one,0.0058,uM,=,-2.2365720064370627,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCN2CCCCC2)cc1
1064,1779901,10.1021/acs.jmedchem.8b00884,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1ccc2nn(C)cc2c1NS(=O)(=O)c1ccc(CCCOC[C@@H]2CN(C)CCO2)cc1,(S)-N-(5-isobutyl-2-methyl-2H-indazol-4-yl)-4-(3-((4-methylmorpholin-2-yl)methoxy)propyl)benzenesulfonamide,5.6,uM,=,0.7481880270062004,1,O=S(=O)(Nc1cccc2n[nH]cc12)c1ccc(CCCOC[C@@H]2CNCCO2)cc1
1065,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)C1CCOC1)C2,"(2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)(tetrahydrofuran-3-yl)methanone",3.6,uM,=,0.5563025007672873,1,O=C(C1CCOC1)N1CCc2nc(OCc3conc3-c3ccccc3)ccc2C1
1066,460777,10.1021/jm070637u,,,,Inhibition of hERG potassium channel expressed in CHO cells by isotope efflux assay,Cc1cccc(NC(=O)c2ccc(-c3ccc(Cl)cc3)o2)c1,5-(4-chlorophenyl)-N-(3-methylphenyl)furan-2-carboxamide,27.0,uM,=,1.4313637641589874,1,O=C(Nc1ccccc1)c1ccc(-c2ccccc2)o1
1067,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(N[C@H]1C[C@@H](O)C1)c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1,"US9452986, 34",20.0,uM,=,1.3010299956639813,1,O=C(NC1CCC1)c1ccc2cc(Oc3ccccn3)ccc2n1
1068,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,CC(=O)N1CCN(Cc2ccc3c(c2)CC[C@H](N2CCN(CCc4ccc(F)cc4)CC2=O)C3)CC1,"(S)-1-(6-((4-acetylpiperazin-1-yl)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-4-(4-fluorophenethyl)piperazin-2-one",25.0,uM,=,1.3979400086720375,1,O=C1CN(CCc2ccccc2)CCN1[C@H]1CCc2cc(CN3CCNCC3)ccc2C1
1069,649407,10.1021/jm100479q,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cn1cc(Cl)c(C(=O)N2CCN(CC(=O)c3ccc(F)cc3)CC2)n1,2-[4-(4-Chloro-1-methyl-1H-pyrazole-3-carbonyl)piperazin-1-yl]-1-(4-fluorophenyl)ethanone,30.0,uM,=,1.4771212547196624,1,O=C(CN1CCN(C(=O)c2cc[nH]n2)CC1)c1ccccc1
1070,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4ccccc4)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-N-[1-(4-Hydroxy-4-phenyl-cyclohexyl)-azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,10.0,uM,=,1.0,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccccc3)CC2)C1
1071,1879326,10.1021/acs.jmedchem.9b01172,,,,Inhibition of human ERG assessed as reduction in channel tail current by plate-based planar patch clamp assay,CCCCCOc1cccc(CCNCC(=O)N(C)C)c1.Cl,"2-((3-Pentoxyphenethyl)amino)-N,N-dimethylacetamide Hydrochloride",1.8,uM,=,0.255272505103306,1,c1ccccc1
1072,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccccc23)CC1,1-(2-{4-[1-(4-Fluoro-phenyl)-1H-indol-3-yl]-piperidin-1-yl}-ethyl)-imidazolidin-2-one,0.007,uM,=,-2.154901959985743,0,O=C1NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccccc23)CC1
1073,1840679,10.1016/j.ejmech.2019.02.022,,,,Inhibition of human ERG incubated for 1 hr by Fluorescence polarization binding assay,CN1CCOc2c1cnn1c(-c3ccc4cccc(NCC5(F)CCNCC5)c4n3)nnc21,"(4-Fluoro-piperidin-4-ylmethyl)-[2-(6-methyl-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalen-3-yl)-quinolin-8-yl]-amine",19.7,uM,=,1.294466226161593,1,c1cc(NCC2CCNCC2)c2nc(-c3nnc4c5c(cnn34)NCCO5)ccc2c1
1074,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1nnn(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)NC1CCOC1)C2,"2-((1-(4-fluorophenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-N-(tetrahydrofuran-3-yl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxamide",21.0,uM,=,1.3222192947339193,1,O=C(NC1CCOC1)N1CCc2nc(OCc3cnnn3-c3ccccc3)ccc2C1
1075,990152,10.1016/j.bmc.2013.08.041,,,,Inhibition of human ERG channel expressed in CHO cells by whole cell patch clamp technique,COc1ccc(NC(=O)Cn2cc(CCNS(=O)(=O)c3ccc(OC)cc3)c3ccccc32)cc1,N-(4-Methoxyphenyl)-2-(3-(2-(4-methoxyphenylsulfonamido)ethyl)-1H-indol-1-yl)acetamide,10.23,uM,=,1.0098756337121602,1,O=C(Cn1cc(CCNS(=O)(=O)c2ccccc2)c2ccccc21)Nc1ccccc1
1076,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2c1S(=O)(=O)C(C)C(c1ccc(OCCCN3CCCC3)cc1)O2,"(+/-)-1-{3-[4-(5-Methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",6.3,uM,=,0.7993405494535817,1,O=S1(=O)CC(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
1077,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)nc1,"N,N-Diethyl-6-(spiro[chromene-2,4'-piperidine]-4-yl)nicotinamide",71.666,uM,=,1.855313165228484,1,C1=C(c2ccccn2)c2ccccc2OC12CCNCC2
1078,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Cl)cc1Oc1ccc(C)c(Cl)c1,1-(4-chloro-2-(3-chloro-4-methylphenoxy)phenyl)-N-methylmethanamine,1.06,uM,=,0.0253058652647702,1,c1ccc(Oc2ccccc2)cc1
1079,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1ccc2c(=O)n(-c3ccc(OCCCN4CCCC4)cc3)c(C)nc2c1,"2,7-Dimethyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone",6.7,uM,=,0.8260748027008264,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
1080,2047203,10.1021/acs.jmedchem.0c01170,,,,Inhibition of human ERG by Q-patch assay,Nc1nc(N2CCC3(CCC[C@H]3N)CC2)cnc1Sc1cccnc1C(F)(F)F,(R)-8-(6-amino-5-(2-(trifluoromethyl)pyridin-3-ylthio)pyrazin-2-yl)-8-azaspiro[4.5]decan-1-amine,6.0,uM,=,0.7781512503836436,1,c1cncc(Sc2cnc(N3CCC4(CCCC4)CC3)cn2)c1
1081,2048454,10.1016/j.bmc.2020.115734,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,COc1nc(-c2csc(Nc3c4c(nn3C)CCC4)n2)ccc1-n1cnc(C)c1,"4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-N-(2-methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)thiazol-2-amine",0.92,uM,=,-0.0362121726544447,0,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCC5)n3)nc2)cn1
1082,2293467,10.1021/acs.jmedchem.7b00463,,,,Inhibition of hERG potassium channel by Q-patch clamp assay,COc1cc(NC(=O)c2nnn(Cc3ccc(CN4CCOCC4)cc3)c2N)ncn1,"5-amino-N-(6-methoxypyrimidin-4-yl)-1-(4-(morpholinomethyl)benzyl)-1H-1,2,3-triazole-4-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C(Nc1ccncn1)c1cn(Cc2ccc(CN3CCOCC3)cc2)nn1
1083,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(C3CC3)n2)(c2ccc(F)cc2)CC1,2-cyclopropyl-6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,13.0,uM,=,1.1139433523068367,1,c1ccc(C2(COCc3cccc(C4CC4)n3)CCNCC2)cc1
1084,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1nc(C(C)C)ccc1-c1cnc2sc(N3CCC(O)(CN)CC3)nn12,"4-(aminomethyl)-1-(5-(6-isopropyl-2-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-ol",23.0,uM,=,1.3617278360175928,1,c1cncc(-c2cnc3sc(N4CCCCC4)nn23)c1
1085,963062,10.1021/jm400408r,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,COc1ccccc1N1CCN(CCCCOc2ccc3c(C)cc(=O)oc3c2)CC1,7-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butoxy)-4-methyl-2Hchromen-2-one,0.031,uM,=,-1.5086383061657274,0,O=c1ccc2ccc(OCCCCN3CCN(c4ccccc4)CC3)cc2o1
1086,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cc(CNC2CCCC2)ccn1,N-((2-(4-fluoro-2-methoxyphenyl)pyridin-4-yl)methyl)cyclopentanamine,3.85,uM,=,0.5854607295085007,1,c1ccc(-c2cc(CNC3CCCC3)ccn2)cc1
1087,579539,10.1016/j.bmcl.2009.05.101,,,,Inhibition of [35S]MK499 binding to human ERG transfected in HEK293 cells by microscintillation counting,C[C@@H]1[C@@H](c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc2S1(=O)=O,"trans-1-{3-[4-(3-Methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",1.3,uM,=,0.1139433523068367,1,O=S1(=O)C[C@@H](c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
1088,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCc3ccc(OC)c(OC)c3)C[C@@H]2CC(=O)NCc2cccc(Cl)c2)cc1,"rac-N-(3-chlorobenzyl)-2-((3R,4S)-1-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)acetamide",0.034,uM,=,-1.4685210829577449,0,O=C(C[C@H]1CN(CCc2ccccc2)C[C@@H]1c1ccccc1)NCc1ccccc1
1089,535682,10.1016/j.bmcl.2008.08.067,,,,Displacement of [3H]dofetilide from human ERG in HEK293 cells,CNC(=O)c1c(NCCC2CCCC2)nc(C#N)nc1OCC1CCN(C)CC1,2-cyano-4-(2-cyclopentylethylamino)-N-methyl-6-((1-methylpiperidin-4-yl)methoxy)pyrimidine-5-carboxamide,0.36,uM,=,-0.4436974992327127,0,c1nc(NCCC2CCCC2)cc(OCC2CCNCC2)n1
1090,1703610,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by patch clamp method,COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(6-methoxypyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide",3.0,uM,=,0.4771212547196624,1,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1
1091,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)N3CCCCC3)cc2)cc1,1-{4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine,1.109589041,uM,=,0.0451621587206622,1,O=S(=O)(c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1)N1CCCCC1
1092,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCN(C(=O)N(C)C)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)-N,N-dimethylpiperazine-1-carboxamide",16.0,uM,=,1.2041199826559248,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
1093,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,NC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1,"6-((1-(2-(6-((1-aminocyclopropyl)methoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.7,uM,=,0.568201724066995,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7CC7)nc56)(CC3)OC4)nc2N1
1094,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,CS(=O)(=O)c1cccc(-c2ccc3ncc(-c4cccc(S(C)(=O)=O)c4)n3n2)c1,"3,6-bis(3-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine",2.35,uM,=,0.3710678622717362,1,c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1
1095,2203304,10.1016/j.bmcl.2022.128807,,,,Inhibition of hERG by patch clamp assay,Cc1ccc(F)c2[nH]c(-c3cncc(-c4cc(F)cc(C#N)c4)c3N3CC[C@H](N)C3)nc12,(S)-3-(4-(3-aminopyrrolidin-1-yl)-5-(7-fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-3-yl)-5-fluorobenzonitrile,0.28,uM,=,-0.5528419686577808,0,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCC2)cc1
1096,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CCOc1ccc2cc(-c3nn(CC4CN(C)C4)c4ncnc(N)c34)ccc2c1,"3-(6-ethoxynaphthalen-2-yl)-1-((1-methylazetidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",1.4,uM,=,0.1461280356782379,1,c1ccc2cc(-c3nn(CC4CNC4)c4ncncc34)ccc2c1
1097,2266525,10.1021/acsmedchemlett.2c00454,,,,Displacement of E-4031 from hERG by fluorescence polarization assay,CNc1nccc(Sc2cnc3[nH]c(N4CCC5(CC4)Cc4ccccc4[C@H]5N)nc3n2)c1Cl,"(S)-1'-(5-((3-chloro-2-(methylamino)pyridin-4-yl)thio)-1H-imidazo[4,5-b]pyrazin-2-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine",4.2,uM,=,0.6232492903979004,1,c1ccc2c(c1)CC1(CCN(c3nc4nc(Sc5ccncc5)cnc4[nH]3)CC1)C2
1098,2082050,10.1021/acs.jmedchem.1c00034,,,,Inhibition of human ERG incubated for 4 hrs by fluorescene microplate reader assay,N[C@@H](C(=O)N1CC(CNc2ccc(F)cc2)C2(C1)CN(c1cc(F)cc(F)c1)C2)c1ccc(O)cc1,"Rac-(2R)-2-amino-1-[2-(3,5-difluorophenyl)-5-[(4-fluoroanilino)methyl]-2,7-diazaspiro[3.4]octan-7-yl]-2-(4-hydroxyphenyl)ethanone",1.6,uM,=,0.2041199826559248,1,O=C(Cc1ccccc1)N1CC(CNc2ccccc2)C2(C1)CN(c1ccccc1)C2
1099,1972154,10.1021/acs.jmedchem.9b01624,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,Nc1cc(-c2cn(-c3ccccc3)c3cnccc23)ccn1,"4-(1-Phenyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-amine",0.59,uM,=,-0.2291479883578558,0,c1ccc(-n2cc(-c3ccncc3)c3ccncc32)cc1
1100,1473874,10.1021/jm5018863,,,,Inhibition of human ERG expressed in CHO cells by automated Qpatch clamp assay,NC(=O)c1ncc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc2cc[nH]c12,"3-(1H-indol-7-ylamino)-5-((1R,2S)-2-aminocyclohexylamino)pyrazine-2-carboxamide",8.1,uM,=,0.9084850188786496,1,c1cc(Nc2cncc(NC3CCCCC3)n2)c2[nH]ccc2c1
1101,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2ncc(F)c([C@@H](O)CC[C@@H]3CCN(C4CC(c5c(F)cccc5F)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-1-(3-(2,6-difluorophenyl)cyclobutyl)-4-((S)-3-(3-fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl)piperidine-3-carboxylic acid",45.3,uM,=,1.656098202012832,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
1102,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CC[C@@H](N)[C@@H](F)C3)nn12,"(3S,4R)-3-Fluoro-1-(5-(4-fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-amine",8.8,uM,=,0.9444826721501688,1,c1ccc(-c2cnc3sc(N4CCCCC4)nn23)cc1
1103,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1cccc2c(=O)n(-c3ccc(OCCCN4CCCC4)cc3)c(C)nc12,"2,8-Dimethyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone",1.6,uM,=,0.2041199826559248,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
1104,421810,10.1016/j.bmcl.2006.10.053,,,,Inhibition of binding to hERG,CN(C)Cc1ccc2c(c1)CC[C@H](N(C)C(=O)c1ccc(-c3ccc(F)cc3)cn1)C2,"(S)-N-(6-((dimethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-5-(4-fluorophenyl)-N-methylpicolinamide",5.2,uM,=,0.7160033436347992,1,O=C(N[C@H]1CCc2ccccc2C1)c1ccc(-c2ccccc2)cn1
1105,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,COC(=O)CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,"methyl 2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)acetate",0.2,uM,=,-0.6989700043360187,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
1106,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3ccc(OC(F)F)cn3)cs2)CO1,"US9315520, 1::US9315520, Comparator 1::US9315520, Example 1::US9315520, Example 2",9.9,uM,=,0.99563519459755,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccn1
1107,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,COCCC(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1,"(R)-4-(8-amino-3-(4-(3-methoxypropanoyl)morpholin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",5.8,uM,=,0.7634279935629373,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@H]3CNCCO3)n3ccncc23)cc1
1108,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(OCCCN6CCCCC6)nc5)cc4c32)C1,"US9428503, 33",14.0,uM,=,1.146128035678238,1,O=c1[nH]c2cnc3ccc(-c4ccc(OCCCN5CCCCC5)nc4)cc3c2n1C1CCC1
1109,1576909,10.1021/acs.jmedchem.5b01416,,,,Inhibition of human ERG expressed in HEK293 cells assessed as tail current at -50 mV holding potential by whole-cell patch clamp method,CC1CCN(CCCOc2ccc(=O)n(-c3ccc(F)c(F)c3)n2)CC1,"2-(3,4-Difluorophenyl)-6-(3-(4-methylpiperidin-1-yl)-propoxy)pyridazin-3(2H)-one",2.68,uM,=,0.4281347940287888,1,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccccc1
1110,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,NC(=O)c1cnc(O[C@H]2CCCNC2)c2cc(-c3ccccc3)sc12,"2-Phenyl-4-[(3S)-piperidin-3-yloxy]thieno[3,2-c]pyridine-7-carboxamide",3.8,uM,=,0.5797835966168101,1,c1ccc(-c2cc3c(O[C@H]4CCCNC4)nccc3s2)cc1
1111,1504613,10.1021/acs.jmedchem.5b00518,,,,Inhibition of human Kv11.1 expressed in HEK293 cells assessed as inhibition of channel tail current at holding potential -80 mV by whole cell voltage clamp assay,CCCCCCCN(CC)CC#CC(c1ccccc1)c1ccccc1,"N-(4,4-Diphenylbut-2-yn-1-yl)-N-ethylheptan-1-amine",0.182,uM,=,-0.7399286120149252,0,c1ccc(Cc2ccccc2)cc1
1112,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CN(c1ccc(-c2cc3cnccc3cc2O)nn1)C1CC(C)(C)NC(C)(C)C1,"7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)isoquinolin-6-ol",14.0,uM,=,1.146128035678238,1,c1cc2ccc(-c3ccc(NC4CCNCC4)nn3)cc2cn1
1113,541084,10.1016/j.bmcl.2009.01.009,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,CC(C)c1noc(C2CCN(C(C)C[C@H](NC(=O)C3CCC3)c3ccccc3)CC2)n1,"N-((1S)-3-(4-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-1-phenylbutyl)cyclobutanecarboxamide",1.65,uM,=,0.2174839442139062,1,O=C(N[C@@H](CCN1CCC(c2ncno2)CC1)c1ccccc1)C1CCC1
1114,1824184,10.1021/acs.jmedchem.9b01348,,,,Inhibition of human ERG,Cc1cnc(Nc2ccc(N3CCC(N(C)CCO)CC3)c(F)c2)nc1-c1cnn(C(C)C)c1,2-((1-(2-Fluoro-4-((4-(1-isopropyl-1H-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)phenyl)piperidin-4-yl)(methyl)-amino)ethan-1-ol,28.0,uM,=,1.4471580313422192,1,c1cc(-c2cn[nH]c2)nc(Nc2ccc(N3CCCCC3)cc2)n1
1115,1744232,10.1021/acs.jmedchem.6b01703,,,,Displacement of [3H]dofetilide from recombinant human ERG expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting method,CCc1nc2c(C)cc(C)nn2c1Cc1ccc(/C=C/CN2CCN(C(C)C)CC2)cc1,"(E)-2-ethyl-3-(4-(3-(4-isopropylpiperazin-1-yl)prop-1-enyl)benzyl)-6,8-dimethylimidazo[1,2-b]pyridazine",2.3,uM,=,0.3617278360175928,1,C(=C/c1ccc(Cc2cnc3cccnn23)cc1)\CN1CCNCC1
1116,1672277,10.1016/j.bmcl.2017.05.026,,,,Inhibition of recombinant human ERG expressed in HEK293 cells after 9 mins by patch clamp method,COc1ccc(/C=C/C(=O)N2CCN(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1,(E)-N-(2-aminophenyl)-4-(4-(3-(4-methoxyphenyl)acryloyl)piperazin-1-yl)benzamide,25.1,uM,=,1.3996737214810382,1,O=C(Nc1ccccc1)c1ccc(N2CCN(C(=O)/C=C/c3ccccc3)CC2)cc1
1117,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC1COCC(C)N1S(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1,"3,5-Dimethyl-4-{4'-[2-((R)-2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-morpholine",1.166666667,uM,=,0.0669467897546973,1,O=S(=O)(c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1)N1CCOCC1
1118,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2nccc([C@@H](O)CC[C@@H]3CCN(C4CC(c5cc(F)ccc5F)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-1-(3-(2,5-difluorophenyl)cyclobutyl)-4-((S)-3-hydroxy-3-(6-methoxyquinolin-4-yl)propyl)piperidine-3-carboxylic acid",9.97,uM,=,0.9986951583116558,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
1119,1676692,10.1021/acs.jmedchem.7b01039,,,,Inhibition of human ERG by fluorescently labeled tracer binding method,Cc1ccc(Oc2ccnc3cc(-c4cnn(C5CCNCC5)c4)ccc23)cc1,7-(1-(Piperidin-4-yl)-1H-pyrazol-4-yl)-4-(p-tolyloxy)quinoline,3.12,uM,=,0.4941545940184428,1,c1ccc(Oc2ccnc3cc(-c4cnn(C5CCNCC5)c4)ccc23)cc1
1120,1749583,10.1016/j.bmcl.2017.10.040,,,,Inhibition of human ERG,CCc1cc(C(=O)NC[C@H](C)N(CC)CC)cc(-c2cnn3ccc(-c4cccs4)nc23)n1,"(S)-N-(2-(diethylamino)propyl)-2-ethyl-6-(5-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)isonicotinamide",3.28,uM,=,0.5158738437116791,1,c1ccc(-c2cnn3ccc(-c4cccs4)nc23)nc1
1121,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC(C)C1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,"2-isopropyl-4-phenyl-9-(2-phenylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",1.2,uM,=,0.0791812460476248,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
1122,879386,10.1021/jm200939b,,,,Inhibition of human Erg expressed in human HEK293 cells,c1cc([C@H]2C[C@@H](CN3CCOCC3)C2)ccc1CN1CCCC1,4-({cis-3-[4-(Pyrrolidin-1-ylmethyl)phenyl]cyclobutyl}-methyl)morpholine,300.0,uM,=,2.4771212547196626,1,c1cc([C@H]2C[C@@H](CN3CCOCC3)C2)ccc1CN1CCCC1
1123,379068,10.1016/j.bmcl.2006.05.049,,,,Binding affinity to hERG,CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1.Cl,(R)-1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine hydrochloride,16.0,uM,=,1.2041199826559248,1,c1ccc(C[C@H](c2ccccc2)N2CCNCC2)cc1
1124,1743006,10.1021/acs.jmedchem.8b01183,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp assay,CCOC(=O)C[C@H]1Cc2ccccc2C2(CCC(N3CCN(C4CCCCC4)CC3)CC2)O1,"ethyl cis-2-{4'-(4-cyclohexylpiperazin-1-yl)-3,4-dihydrospiro[[2]benzo-pyran-1,1'-cyclohexan]-3-yl}acetate",1.753,uM,=,0.2437819160937949,1,c1ccc2c(c1)CCOC21CCC(N2CCN(C3CCCCC3)CC2)CC1
1125,2246303,10.1021/acs.jmedchem.1c01670,,,,Inhibition of MK-499 binding to hERG,O=C(Nc1ccc(F)cc1)C1(c2ccc(-c3cnc(C(F)(F)F)cc3CO)cc2)CC(F)(F)C1,"3,3-Difluoro-N-(4-fluorophenyl)-1-(4-(4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-3-yl)phenyl)cyclobutane-1-carboxamide",6096.0,uM,=,3.785044958331544,1,O=C(Nc1ccccc1)C1(c2ccc(-c3cccnc3)cc2)CCC1
1126,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,O=C(NCC1CCOC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,"5-(2,3-Difluorophenyl)-N-((tetrahydrofuran-3-yl)methyl)-1H-indazole-3-carboxamide",4.3,uM,=,0.6334684555795865,1,O=C(NCC1CCOC1)c1n[nH]c2ccc(-c3ccccc3)cc12
1127,629417,10.1016/j.bmcl.2010.03.071,,,,Inhibition of human ERG by patch clamp assay,CC(=O)N1C[C@@H](Oc2cccc(F)c2)C[C@@H]1C(=O)N1CCCN(C2CCC2)CC1,"1-((2R,4S)-2-(4-cyclobutyl-1,4-diazepane-1-carbonyl)-4-(3-fluorophenoxy)pyrrolidin-1-yl)ethanone",6.0,uM,=,0.7781512503836436,1,O=C([C@H]1C[C@H](Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
1128,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4ccccc4N(Cc4ccncc4)C3=O)nn2)ccc1-n1cnc(C)c1,"rac-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(pyridin-4-ylmethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",6.22,uM,=,0.7937903846908188,1,O=C1C(n2cc(-c3ccc(-n4ccnc4)cc3)nn2)CCc2ccccc2N1Cc1ccncc1
1129,1749583,10.1016/j.bmcl.2017.10.040,,,,Inhibition of human ERG,CCN(CC)[C@@H](C)CNC(=O)c1cc(-c2cnn3ccc(-c4cccs4)nc23)nc(N2CC(OC)C2)c1,"(S)-N-(2-(diethylamino)propyl)-2-(3-methoxyazetidin-1-yl)-6-(5-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)isonicotinamide",4.16,uM,=,0.6190933306267428,1,c1cc(-c2cnn3ccc(-c4cccs4)nc23)nc(N2CCC2)c1
1130,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,"5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-1,3-dihydro-indol-2-one",0.125,uM,=,-0.9030899869919436,0,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)ccc2N1
1131,464747,10.1016/j.bmcl.2008.01.126,,,,Inhibition of human ERG by FLIPR assay,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1,"(2S,3S)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",6.2,uM,=,0.7923916894982539,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
1132,945538,10.1016/j.bmcl.2012.10.140,,,,Inhibition of human ERG expressed in CHO cells by IONWORKS assay,CC(C)(C)NC(=O)NCCN1CCC(CNC(=O)c2cc(Cl)cc(Cl)c2)C1,"N-((1-(2-(3-tert-butylureido)ethyl)pyrrolidin-3-yl)methyl)-3,5-dichlorobenzamide",5.8,uM,=,0.7634279935629373,1,O=C(NCC1CCNC1)c1ccccc1
1133,790372,10.1016/j.bmcl.2011.09.105,,,,Displacement of [35S]-MK-499 from human ERG expressed in HEK cells,CCCCC[C@@H](Cc1ccc(C(=O)NCCC(=O)O)cc1)C(=O)c1cc2cc(Cl)ccc2n1-c1cccc(C(F)(F)F)c1,(S)-3-(4-(2-(5-chloro-1-(3-(trifluoromethyl)phenyl)-1H-indole-2-carbonyl)heptyl)benzamido)propanoic acid,3.7,uM,=,0.568201724066995,1,O=C(CCc1ccccc1)c1cc2ccccc2n1-c1ccccc1
1134,494878,10.1021/jm8012618,,,,Inhibition of human cloned ERG,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl,4-(7-Chloro-quinolin-4-ylamino)-2-diethylaminomethyl-phenol (Amodiaquin),2.4,uM,=,0.380211241711606,1,c1ccc(Nc2ccnc3ccccc23)cc1
1135,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CNC(=O)c1ccc(CC(=O)N(C)C2CCN(Cc3ccc(C(F)(F)F)cc3)CC2)cc1,N-methyl-4-(2-(methyl(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)amino)-2-oxoethyl)benzamide,2.1,uM,=,0.3222192947339193,1,O=C(Cc1ccccc1)NC1CCN(Cc2ccccc2)CC1
1136,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2ccc(NC(C)=O)cc2)cc1,"4-((4-acetamidophenyl)(1-(4-fluorobenzyl)piperidin-4-ylidene)methyl)-N,N-diethylbenzamide",1.3,uM,=,0.1139433523068367,1,c1ccc(CN2CCC(=C(c3ccccc3)c3ccccc3)CC2)cc1
1137,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCCC3CCNCC3)C[C@@H]2CNC(=O)c2cccc(Cl)c2)cc1,"rac-3-chloro-N-(((3S,4S)-4-(4-methoxyphenyl)-1-(3-(piperidin-4-yl)propyl)pyrrolidin-3-yl)methyl)benzamide",20.3,uM,=,1.307496037913213,1,O=C(NC[C@H]1CN(CCCC2CCNCC2)C[C@@H]1c1ccccc1)c1ccccc1
1138,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,O=C(c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1)N1CCCC1,"Pyrrolidin-1-yl(4-(spiro[chromene-2,4'-piperidine]-4-yl)phenyl)methanone",10.566,uM,=,1.0239106063509205,1,O=C(c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1)N1CCCC1
1139,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,CS(=O)(=O)c1ccc(-c2ccc3ncc(-c4cccc(S(C)(=O)=O)c4)n3n2)cc1,"3-(3-(methylsulfonyl)phenyl)-6-(4-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine",4.0,uM,=,0.6020599913279624,1,c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1
1140,2061618,10.1016/j.bmcl.2015.11.049,,,,Inhibition of human ERG by dofetilide binding assay,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCNCC1,"N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",1.1,uM,=,0.041392685158225,1,c1ccc(Nc2nc(Nc3ccc(C4CCNCC4)cc3)nc3[nH]ccc23)cc1
1141,2238137,10.1021/acs.jmedchem.1c01012,,,,Inhibition of human ERG,O=c1[nH]c(CCCN2CCN(c3ccc(F)cc3F)CC2)nc2c(Cl)cccc12,"8-chloro-2-(3-(4-(2,4-difluorophenyl)piperazin-1-yl)propyl)quinazolin-4(3H)-one",1.4,uM,=,0.1461280356782379,1,O=c1[nH]c(CCCN2CCN(c3ccccc3)CC2)nc2ccccc12
1142,2123077,10.1016/j.ejmech.2021.113674,,,,Inhibition of human ERG incubated for 3 hrs by competitive fluorescence tracer binding based assay,c1ccc(COc2cccc(-c3nc4sccn4c3-c3ccncn3)c2)cc1,"6-(3-(Benzyloxy)phenyl)-5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole",12.83,uM,=,1.1082266563749286,1,c1ccc(COc2cccc(-c3nc4sccn4c3-c3ccncn3)c2)cc1
1143,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCCN2C(=O)N(NS(C)(=O)=O)C[C@@H]2c2ccc(OC)cc2)cc1,(S)-1-(Methylsulfonylamino)-3-[3-(4-methoxyphenyl)propyl]-4-[(4-methoxy)-phenyl]-2-imidazolidinone,14.1,uM,=,1.14921911265538,1,O=C1NC[C@H](c2ccccc2)N1CCCc1ccccc1
1144,345010,10.1016/j.bmcl.2005.12.094,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CC(C)(C)C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1cccc(O)c1,"(S)-1-(4-(2,5-difluorophenyl)-2-(3-hydroxyphenyl)-2H-pyrrol-1(5H)-yl)-2,2-dimethylpropan-1-one",7.8,uM,=,0.8920946026904804,1,C1=C(c2ccccc2)CN[C@@H]1c1ccccc1
1145,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cn1c(-c2ccc(OCCCN3CCCCC3)cc2)nc2ccccc2c1=O,3-methyl-2-(4-(3-(piperidin-1-yl)propoxy)phenyl)quinazolin-4(3H)-one,2.8,uM,=,0.4471580313422192,1,O=c1[nH]c(-c2ccc(OCCCN3CCCCC3)cc2)nc2ccccc12
1146,762093,10.1021/jm200018k,,,,Inhibition of human Erg expressed in human HEK293 cells by patch-clamp electrophysiological assay,CC(=O)Nc1cccc(Nc2ncnc(N3CCC(OCc4ccc(C)cc4)CC3)n2)c1C,"N-(2-Methyl-3-(4-(4-(4-methylbenzyloxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide",1.93,uM,=,0.2855573090077737,1,c1ccc(COC2CCN(c3ncnc(Nc4ccccc4)n3)CC2)cc1
1147,1809217,10.1021/acsmedchemlett.9b00204,,,,Inhibition of human ERG,CC(C)c1ccc(-c2cc(CN3CC[Si](C)(C)CC3)nn2C2CCCCC2)cc1,"1-((1-Cyclohexyl-5-(4-isopropylphenyl)-1H-pyrazol-3-yl)methyl)-4,4-dimethyl-1,4-azasilinane",8.0,uM,=,0.9030899869919436,1,c1ccc(-c2cc(CN3CC[SiH2]CC3)nn2C2CCCCC2)cc1
1148,2246303,10.1021/acs.jmedchem.1c01670,,,,Inhibition of MK-499 binding to hERG,Cc1cc(C2CC2)ncc1-c1ccc(C2(C(=O)Nc3ccc(F)cc3)COC2)cc1,3-(4-(6-Cyclopropyl-4-methylpyridin-3-yl)phenyl)-N-(4-fluorophenyl)oxetane-3-carboxamide,15890.0,uM,=,4.201123897207379,1,O=C(Nc1ccccc1)C1(c2ccc(-c3ccc(C4CC4)nc3)cc2)COC1
1149,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(N3CCC(C#N)C3)n2)(c2ccc(F)cc2)CC1,1-(6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)pyrrolidine-3-carbonitrile,8.3,uM,=,0.919078092376074,1,c1ccc(C2(COCc3cccc(N4CCCC4)n3)CCNCC2)cc1
1150,75467,10.1021/jm00014a008,,,,Blockade of the delayed rectifier K+ current (IKr) of guinea pig myocytes,CN1Cc2ccccc2[C@@H](c2ccccc2)N=C1OCc1ccc(NS(C)(=O)=O)cc1.O=C(O)/C=C/C(=O)O,"N-[4-(2-Methyl-5-phenyl-2,5-dihydro-1H-benzo[e][1,3]diazepin-3-yloxymethyl)-phenyl]-methanesulfonamide; compound with (E)-but-2-enedioic acid",38.0,uM,=,1.57978359661681,1,c1ccc(COC2=N[C@H](c3ccccc3)c3ccccc3CN2)cc1
1151,793464,10.1016/j.bmcl.2011.09.114,,,,Inhibition of human ERG by whole cell patch clamp assay,COc1ccc2nccc(NC(=O)[C@]3(O)CC[C@@H](NCc4cc5c(cn4)OCCO5)CC3)c2c1,"4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-1-hydroxy-N-(6-methoxyquinolin-4-yl)cyclohexanecarboxamide",200.0,uM,=,2.3010299956639813,1,O=C(Nc1ccnc2ccccc12)C1CCC(NCc2cc3c(cn2)OCCO3)CC1
1152,804280,10.1016/j.bmcl.2011.12.124,,,,Inhibition of human Erg by voltage ion flux electrophysiological assay,CCCS(=O)(=O)n1c2c(c3cc(C(=O)N4CCC(C)CC4)ccc31)CN(C1CCOC1)CC2,"(4-methylpiperidin-1-yl)(5-(propylsulfonyl)-2-(tetrahydrofuran-3-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)methanone",13.0,uM,=,1.1139433523068367,1,O=C(c1ccc2[nH]c3c(c2c1)CN(C1CCOC1)CC3)N1CCCCC1
1153,1640440,,,,,"hERG Patch Clamp Assay: All testing was carried out in CHO cells transfected with the hERG gene purchased from Millipore (PrecisION hERG-CHO Recombinant Cell Line CYL3038). The cell line was grown in DMEM/F-12, GlutaMAX with 10% fetal bovine serum, 1% Penicillin-Streptomycin, 1% Geneticin and 1% of 1M HEPES buffer solution, and maintained at approximately 37 °C. in a humidified atmosphere containing 5% carbon dioxide. The cells were passaged every 3-5 days based on confluency. On the day of the experiment, 50%-80% confluent cells were harvested from a 175 cm2 culture flask using Detachin. After 10 minutes of exposure to Detachin at 37 °C., the cells were centrifuged for 1 minute at 1000 RPM. The supernatant was removed and the cell pellet was reconstituted in 5-8 mL of serum free media with 2.5% of 1M HEPES, placed on the Qstirrer, and allowed to recover. After a 30 minute recovery period, experiments were initiated.",C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CO1,"US9315520, Comparator 7",0.2,uM,=,-0.6989700043360187,0,O=C(Nc1cccc([C@]23COCC[C@H]2CSC=N3)c1)c1ccccn1
1154,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1ncc3ccccc3c1C#N)c(=O)n2C,"3-((7-cyano-6-(1,4-diazepan-1-yl)-1-methyl-5-(3-methylbut-2-enyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)methyl)isoquinoline-4-carbonitrile",1.8,uM,=,0.255272505103306,1,O=c1[nH]c2cc(N3CCCNCC3)[nH]c2c(=O)n1Cc1cc2ccccc2cn1
1155,1566930,10.1021/acs.jmedchem.5b01633,,,,Inhibition of dofetilide binding to human ERG,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3[nH]ccc23)c1,"N-(3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide",1.0,uM,=,0.0,0,c1ccc(Oc2nc(Nc3ccc(N4CCNCC4)cc3)nc3[nH]ccc23)cc1
1156,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CCN(CCOc3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,N-((4-(4-(2-phenoxyethyl)piperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)propionamide,2.3,uM,=,0.3617278360175928,1,c1ccc(OCCN2CCN(C3(CNc4ccccn4)CCOCC3)CC2)cc1
1157,1362933,10.1016/j.bmcl.2014.04.083,,,,Inhibition of human ERG tail current after 5 mins by patch-clamp method,COC(=O)N1CCC(C)(CN2CCC3(CC2)CN(S(C)(=O)=O)c2ncccc23)CC1,"methyl 4-methyl-4-((1'-(methylsulfonyl)-1',2'-dihydrospiro[piperidine-4,3'-pyrrolo[2,3-b]pyridine]-1-yl)methyl)piperidine-1-carboxylate",17.0,uM,=,1.230448921378274,1,c1cnc2c(c1)C1(CCN(CC3CCNCC3)CC1)CN2
1158,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nn(C)cc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,"(R)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline",24.8,uM,=,1.3944516808262164,1,c1cc2nc(-c3cn[nH]c3)ccc2cc1CCN1CCCC1
1159,1435893,10.1016/j.bmc.2014.10.020,,,,Inhibition of human ERG expressed in CHO cells by Rb efflux assay,O=C(CNCC1(O)CCCCC1)N1CCc2ccccc2C1C1CCCCC1,"(1-Cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-{[(1-hydroxycyclohexyl)methyl]amino}ethanone",46.1,uM,=,1.6637009253896482,1,O=C(CNCC1CCCCC1)N1CCc2ccccc2C1C1CCCCC1
1160,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c(C#N)cccc1[C@@H]1CN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)C[C@@H]2CO1,"3-((3R,9aR)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-2-methylbenzonitrile",14.8,uM,=,1.1702617153949575,1,O=C(Cc1ccc(-n2cnnn2)nc1)N1CCN2C[C@@H](c3ccccc3)OC[C@H]2C1
1161,2048818,10.1016/j.bmc.2020.115776,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,CCCCCN(CCCCC)Cc1cc(C(=O)O)ccc1NC(=O)c1cc2cc(F)cc(NC)c2[nH]c1=O,3-[(dipentylamino)methyl]-4-[[6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid,11.9,uM,=,1.0755469613925308,1,O=C(Nc1ccccc1)c1cc2ccccc2[nH]c1=O
1162,2047203,10.1021/acs.jmedchem.0c01170,,,,Inhibition of human ERG by Q-patch assay,CC1(N)CCN(c2cnc(-c3cccc(Cl)c3Cl)c(N)n2)CC1,"6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine",5.9,uM,=,0.7708520116421442,1,c1ccc(-c2cnc(N3CCCCC3)cn2)cc1
1163,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCNC(=O)Nc5ccccc5)c4)n[nH]c2-3)CC1,"1-(3-(4-(6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno-[1,2-c]pyrazol-3-yl)thiophen-2-yl)prop-2-ynyl)-3-phenylurea",7.91,uM,=,0.8981764834976765,1,O=C(NCC#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)Nc1ccccc1
1164,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,CC(C)N(CCc1c[nH]c2ccccc12)Cc1ccc(/C=C/C(=O)NO)cc1,(E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide,5.87,uM,=,0.7686381012476144,1,c1ccc(CNCCc2c[nH]c3ccccc23)cc1
1165,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,COCC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,"2-(methoxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",1.9,uM,=,0.2787536009528289,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
1166,1923311,10.1021/acs.jmedchem.6b00373,,,,Inhibition of human ERG by patch clamp method,O=C(O)C[C@H]1CCCN(C[C@@H](O)c2ccc(-c3noc(-c4onc(-c5ccccc5)c4C(F)(F)F)n3)cc2)C1,"2-((R)-1-((S)-2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)-isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)-acetic Acid",4.1,uM,=,0.6127838567197355,1,c1ccc(-c2cc(-c3nc(-c4ccc(CCN5CCCCC5)cc4)no3)on2)cc1
1167,1512965,10.1021/acsmedchemlett.5b00117,,,,Inhibition of human ERG,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",8.0,uM,=,0.9030899869919436,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2ncns2)C1
1168,1513054,10.1021/ml500531p,,,,Inhibition of human ERG by IonWorks assay,COc1ccc2ccc(=O)n(CCN3CCC(NCc4ccc5c(n4)NC(=O)CO5)CC3)c2n1,"6-((1-(2-(7-methoxy-2-oxo-1,8-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",23.0,uM,=,1.3617278360175928,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)ccc5cccnc54)CC3)nc2N1
1169,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2ccccc2)C2CCN(S(C)(=O)=O)CC2)CC1,(R)-N-ethyl-2-(4-(methylsulfonyl)phenyl)-N-(1-(3-(1-(methylsulfonyl)piperidin-4-yl)-3-phenylpropyl)piperidin-4-yl)acetamide,25.0,uM,=,1.3979400086720375,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
1170,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,CCCOc1ccccc1CC(c1ccccc1)N1CCNCC1,1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine,5.84,uM,=,0.7664128471123994,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
1171,1766690,10.1021/acs.jmedchem.8b01147,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method,Nc1nc(Nc2cnn(C3CC3)c2)nc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)n1,"2-(3-{4-Amino-6-[(1-cyclopropyl-1H-pyrazol-4-yl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2H)-one",9.5,uM,=,0.9777236052888478,1,O=c1c2ccc(C3CC3)cc2ccn1-c1cccc(-c2ncnc(Nc3cnn(C4CC4)c3)n2)c1
1172,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(S)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.026,uM,=,-1.585026652029182,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1173,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,NC(=O)c1cnc(SC2CCCNC2)c2cc(-c3ccccc3)sc12,"rac-2-Phenyl-4-(piperidin-3-ylthio)thieno[3,2-c]pyridine-7-carboxamide",4.9,uM,=,0.6901960800285137,1,c1ccc(-c2cc3c(SC4CCCNC4)nccc3s2)cc1
1174,963062,10.1021/jm400408r,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,O=c1cc(-c2ccccc2)c2ccc(OCCCCN3CCC(c4noc5cc(F)ccc45)CC3)cc2o1,7-(4-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-4-phenyl-2H-chromen-2-one,0.82,uM,=,-0.0861861476162833,0,O=c1cc(-c2ccccc2)c2ccc(OCCCCN3CCC(c4noc5ccccc45)CC3)cc2o1
1175,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,CC(C)(O)COc1ccc(C(N)=O)c(O[C@@H]2CCN(C(=O)Cc3ccc(OC(F)(F)F)cc3)C[C@H]2F)c1,"2-(((3R,4R)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)-piperidin-4-yl)oxy)-4-(2-hydroxy-2-methylpropoxy)benzamide",29.0,uM,=,1.462397997898956,1,O=C(Cc1ccccc1)N1CCC(Oc2ccccc2)CC1
1176,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,C[C@@H]1CN(c2sc(C(F)(F)F)nc2-c2cnc(C(F)(F)F)nc2)CCN1C(=O)Cn1cnc(C#N)n1,"1-(2-((R)-2-Methyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-oxo-ethyl)-1H-(1,2,4)-triazole-3-carbonitrile",0.0026,uM,=,-2.5850266520291822,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
1177,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,CCCNC(=O)C1(c2ccc(NC(=O)c3cccc(Cl)c3)cc2)CCC1,3-chloro-N-(4-(1-(propylcarbamoyl)cyclobutyl)phenyl)benzamide,60.0,uM,=,1.7781512503836436,1,O=C(Nc1ccc(C2CCC2)cc1)c1ccccc1
1178,1911678,10.1021/acs.jmedchem.8b01725,,,,Inhibition of human ERG by Q-patch assay,C[C@@H]1OCC2(CCN(c3cnc4c(-c5cccc(Cl)c5Cl)c[nH]c4n3)CC2)[C@@H]1N,"(3S,4S)-8-(7-(2,3-dichlorophenyl)-5H-pyrrolo[2,3-b]pyrazin-3-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine",0.007,uM,=,-2.154901959985743,0,c1ccc(-c2c[nH]c3nc(N4CCC5(CCOC5)CC4)cnc23)cc1
1179,1972831,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,Cc1ccc(C(=O)Nc2ccc(CN3CCC4C=NNC4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12,"N-[3-chloro-4-(1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-ylmethyl)phenyl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",5.02,uM,=,0.7007037171450193,1,O=C(Nc1ccc(CN2CCC3C=NNC3C2)cc1)c1cccc(C#Cc2cnc3cccnn23)c1
1180,2100970,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by long incubation protocol based Qpatch clamp method,C[C@H]1COc2c(N3C[C@H]4CCC[C@@H](N)[C@H]4C3)c(F)cc3cc(C(=O)O)c(=O)n1c23,"(3S)-10-((4R,7aR)-4-amino-1H-isoindol-2(3H,3aH,4H,5H,6H,7H,7aH)-yl)-9-fluoro-3-methyl-5-oxo-3,5-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid",127.0,uM,=,2.103803720955957,1,O=c1ccc2ccc(N3C[C@H]4CCCC[C@H]4C3)c3c2n1CCO3
1181,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1,"US9145392, 38",4.0,uM,=,0.6020599913279624,1,c1ccc(-c2c[nH]c(C3CCN(c4ccncn4)CC3)n2)cc1
1182,872803,10.1021/jm300991n,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,COc1ccc(C2(c3cccc(-c4cncnc4)c3)N=C(N)C(C(C)C)=N2)cc1,5-Isopropyl-2-(4-methoxyphenyl)-2-(3-(pyrimidin-5-yl)-phenyl)-2H-imidazol-4-amine,26.8,uM,=,1.428134794028789,1,C1=NC(c2ccccc2)(c2cccc(-c3cncnc3)c2)N=C1
1183,627338,10.1016/j.bmcl.2010.03.005,,,,Inhibition of human ERG,CCCCCCC(N1CCOCC1)C(O)(c1cccnc1)c1cccnc1,"2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol",27.5,uM,=,1.4393326938302626,1,c1cncc(C(CN2CCOCC2)c2cccnc2)c1
1184,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,10-[2-(1-Methyl-piperidin-2-yl)-ethyl]-2-methylsulfanyl-10H-phenothiazine,0.0332,uM,=,-1.4788619162959638,0,c1ccc2c(c1)Sc1ccccc1N2CCC1CCCCN1
1185,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,O=C(N[C@H]1CCN(C2CCCCC2)C[C@@H]1C(=O)N[C@H](CO)c1ccccc1)c1cc(-c2ccc(F)cc2F)on1,"(3S,4S)-1-Cyclohexyl-4-([5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino)piperidine-3-carboxylic acid ((S)-2-hydroxy-1-phenyl-ethyl)-amide",7.2,uM,=,0.8573324964312685,1,O=C(N[C@H]1CCN(C2CCCCC2)C[C@@H]1C(=O)NCc1ccccc1)c1cc(-c2ccccc2)on1
1186,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,COC(=O)N(C)c1c(N)nc(-c2nc(Cc3ccccc3F)n3ncccc23)nc1N,"methyl N-[4,6-diamino-2-[7-[(2-fluorophenyl)methyl]imidazo[1,5-b]pyridazin-5-yl]pyrimidin-5-yl]-N-methyl-carbamate",16.1,uM,=,1.2068258760318498,1,c1ccc(Cc2nc(-c3ncccn3)c3cccnn23)cc1
1187,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CN(Cc1ccccc1)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1,"N-Benzyl-N-methyl-4-(spiro[chromene-2,4'-piperidine]-4-yl)-benzamide",1.571,uM,=,0.1961761850399733,1,O=C(NCc1ccccc1)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1
1188,2153149,10.1016/j.ejmech.2021.113827,,,,Inhibition of hERG expressed in CHO-K1 cells assessed as reduction in thallium influx incubated for 30 minutes by FLIPR,Nc1c2c(nc3ccccc13)CCCC2,"1,2,3,4-Tetrahydro-acridin-9-ylamine",14.312,uM,=,1.1557003275593165,1,c1ccc2nc3c(cc2c1)CCCC3
1189,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CC[C@@H](O)[C@@H](N)C3)nn12,"(3S,4R)-3-Amino-1-(5-(4-fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-o",9.2,uM,=,0.9637878273455552,1,c1ccc(-c2cnc3sc(N4CCCCC4)nn23)cc1
1190,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(CNC(=O)C2CCC2)c1,N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methyl)cyclobutanecarboxamide,18.6,uM,=,1.2695129442179165,1,O=C(NCc1cncc(-c2ccccc2)c1)C1CCC1
1191,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc2c(F)cccc2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,8-Fluoro-2-methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,10.0,uM,=,1.0,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
1192,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,CC1(c2ccccc2)CCN(C[C@@H]2CCc3cccnc3[C@@H](O)C2)CC1,"(7R,9S)-7-((4-methyl-4-phenylpiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",11.0,uM,=,1.0413926851582251,1,c1ccc(C2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
1193,1924512,10.1021/acsmedchemlett.6b00122,,,,Displacement of [35S]MK-499 from human ERG,Cc1c([C@H](O)CN2CCN(C[C@@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,"US9018211, 2B",47.0,uM,=,1.6720978579357175,1,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21
1194,1623141,10.1021/acsmedchemlett.6b00314,,,,Inhibition of human ERG,Cc1nccn1-c1ccc(-c2cn(CC(=O)Nc3cccc(Cl)c3Cl)nn2)cn1,"N-(2,3-dichlorophenyl)-2-(4-(6-(2-methyl-1H-imidazol-1-yl)pyridin-3-yl)-1H-1,2,3-triazol-1-yl)acetamide",4.5,uM,=,0.6532125137753437,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)nc2)nn1)Nc1ccccc1
1195,2025950,10.1021/acsmedchemlett.0c00575,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,CC[C@@H](C)n1c(=O)c(NCc2ccc(S(=O)(=O)CC)cn2)nc2cnc(-c3c(OC)ncnc3C3CC3)nc21,(R)-8-sec-butyl-2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-6-((5-(ethylsulfonyl)pyridin-2-yl)methylamino)pteridin-7(8H)-one,4.8,uM,=,0.6812412373755872,1,O=c1[nH]c2nc(-c3cncnc3C3CC3)ncc2nc1NCc1ccccn1
1196,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CCN1CCOC(C(=O)N2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"rac-N-(3,4-dichlorophenyl)-4-(4-ethylmorpholine-2-carbonyl)piperazine-1-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C(Nc1ccccc1)N1CCN(C(=O)C2CNCCO2)CC1
1197,872803,10.1021/jm300991n,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,COc1cccc(-c2cccc(C3(C4CCOCC4)N=C(C)C(N)=N3)c2)c1,2-(3'-Methoxybiphenyl-3-yl)-5-methyl-2-(tetrahydro-2Hpyran-4-yl)-2H-imidazol-4-amine,21.0,uM,=,1.3222192947339193,1,C1=NC(c2cccc(-c3ccccc3)c2)(C2CCOCC2)N=C1
1198,1924512,10.1021/acsmedchemlett.6b00122,,,,Displacement of [35S]MK-499 from human ERG,Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,"US9018211, 2A",23.0,uM,=,1.3617278360175928,1,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21
1199,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,COc1nccc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)n1,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(2-methoxypyrimidin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",7.9,uM,=,0.8976270912904415,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccncn3)C4=O)ccc21
1200,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine,3.1,uM,=,0.4913616938342727,1,c1ccc(COc2ccccc2)cc1
1201,766531,10.1016/j.bmcl.2011.06.126,,,,Inhibition of human ERG by electrophysiological assay,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccc(Br)cc54)CC3)nc2N1,"6-((1-(2-(6-bromo-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.8,uM,=,0.4471580313422192,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccccc54)CC3)nc2N1
1202,575209,10.1016/j.bmcl.2009.03.090,,,,Inhibition of human ERG channel,Clc1cccc(OC(c2ccccn2)[C@H]2CCNC2)c1Cl,"2-((2,3-dichlorophenoxy)((S)-pyrrolidin-3-yl)methyl)pyridine",10.0,uM,=,1.0,1,c1ccc(OC(c2ccccn2)[C@H]2CCNC2)cc1
1203,340115,10.1016/j.bmcl.2005.11.083,,,,Inhibition of hERG potassium channel expressed in CHO cells by whole cell patch clamp method,C[C@@H]1CNC[C@H]2Cc3ccc(Cl)nc3N21,"(4R,9aR)-6-chloro-4-methyl-1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene",40.0,uM,=,1.6020599913279625,1,c1cnc2c(c1)C[C@@H]1CNCCN21
1204,793275,10.1016/j.bmcl.2011.09.117,,,,Displacement of [3H]dofetilide from human ERG by liquid scintillation counting,COc1ccc2ncc(F)c(CCN3CC[C@H](NCc4cc5c(cn4)OCCO5)[C@H](O)C3)c2n1,"(3R,4S)-4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)piperidin-3-ol",7.9,uM,=,0.8976270912904415,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
1205,939638,10.1016/j.bmcl.2012.11.023,,,,Inhibition of human ERG,Nc1nc2cc3c(cc2s1)CCN(Cc1cccnc1)CC3,"7-Pyridin-3-ylmethyl-6,7,8,9-tetrahydro-5H-1-thia-3,7-diaza-cyclohepta[f]inden-2-ylamine",21.0,uM,=,1.3222192947339193,1,c1cncc(CN2CCc3cc4ncsc4cc3CC2)c1
1206,2234011,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by manual electrophysiology method,O=C(c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CCNCC1,"US9452986, 1",20.0,uM,=,1.3010299956639813,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
1207,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(/C=C/c1ccc(C(F)(F)F)cc1)N1CCC[C@H]1CN1CCCC1,(S)-1-(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-one,3.698630137,uM,=,0.56804090404014,1,O=C(/C=C/c1ccccc1)N1CCC[C@H]1CN1CCCC1
1208,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(N2CCOCC2)sc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-4-(4-methyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)thiazol-2-yl)morpholine,20.4,uM,=,1.3096301674258988,1,c1cc2nc(-c3cnc(N4CCOCC4)s3)ccc2cc1CCN1CCCC1
1209,2274261,10.1016/j.ejmech.2020.112290,,,,Inhibition of human ERG,N#Cc1ccc(Cn2cncc2CC[C@H]2CCN(Cc3cccc(Cl)c3)C2=O)cc1,(S)-4-((5-(2-(1-(3-chlorobenzyl)-2-oxopyrrolidin-3-yl)ethyl)-1H-imidazol-1-yl)methyl)benzonitrile,0.44,uM,=,-0.3565473235138126,0,O=C1[C@@H](CCc2cncn2Cc2ccccc2)CCN1Cc1ccccc1
1210,1696477,10.1016/j.bmcl.2017.08.068,,,,Inhibition of human ERG by patch clamp assay,NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n(C3CCCNC3)c2n1,"rac-3,4-dichloro-2-cyclopropyl-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",2.9,uM,=,0.4623979978989561,1,c1cnc2c(c1)cc(C1CC1)n2C1CCCNC1
1211,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,CC(C)CN(C(=O)c1ccccc1C(C)C)[C@H]1CCNC1,(S)-N-isobutyl-2-isopropyl-N-(pyrrolidin-3-yl)benzamide,12.9,uM,=,1.110589710299249,1,O=C(N[C@H]1CCNC1)c1ccccc1
1212,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,CCCCc1nn(-c2nc(N)c3c(n2)NC(=O)C3(C)C)c2ccc(Cl)cc12,"4-amino-2-(3-butyl-5-chloro-indazol-1-yl)-5,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-6-one",12.3,uM,=,1.089905111439398,1,O=C1Cc2cnc(-n3ncc4ccccc43)nc2N1
1213,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,N#Cc1ccccc1[C@H]1CC[C@@H](N2CC(NC(=O)CNc3ncnc4ccc(C(F)(F)F)cc34)C2)CC1,Cis-N-(1-(4-(2-cyanophenyl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,2.1,uM,=,0.3222192947339193,1,O=C(CNc1ncnc2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccccc3)CC2)C1
1214,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CC1(C)CC(NC(=O)C2(O)CC2)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1,"N-[6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-1-hydroxycyclopropanecarboxamide",0.3,uM,=,-0.5228787452803376,0,O=C(NC1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)C1CC1
1215,2130588,10.1021/acs.jmedchem.1c01250,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(C(O)C[C@H]3OC[C@H](NCc4ccc5c(c4)OCCO5)CO3)c2c1,"Rac-2-((2r,5r)-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)-1,3-dioxan-2-yl)-1-(3-fluoro-6-methoxyquinolin-4-yl)ethanol",8.0,uM,=,0.9030899869919436,1,c1ccc2c(CC[C@H]3OC[C@H](NCc4ccc5c(c4)OCCO5)CO3)ccnc2c1
1216,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C)cc(-c2cncc(-c3nc4cc(Cl)ccc4[nH]3)c2N2CCC(N)CC2)c1,"1-(3-(5-chloro-1H-benzo[d]imidazol-2-yl)-5-(3,5-dimethylphenyl)pyridin-4-yl)piperidin-4-amine",1.7,uM,=,0.2304489213782739,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
1217,2054847,10.1016/j.ejmech.2020.112709,,,,Inhibition of human ERG expressed in HEK293 cells by whole-cell patch clamp method,CN1CCc2ccc(OCCCN3CCC(c4noc5cc(F)ccc45)CC3)cc2C1=O,"7-(3-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propoxy)-2-methyl-3,4-dihydroisoquinolin-1(2H)-one",2.312,uM,=,0.3639878297484914,1,O=C1NCCc2ccc(OCCCN3CCC(c4noc5ccccc45)CC3)cc21
1218,2153149,10.1016/j.ejmech.2021.113827,,,,Inhibition of hERG expressed in CHO-K1 cells assessed as reduction in thallium influx incubated for 30 minutes by FLIPR,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,"2-(1-Benzyl-piperidin-4-ylmethyl)-5,6-dimethoxy-indan-1-one",8.718,uM,=,0.9404168646816652,1,O=C1c2ccccc2CC1CC1CCN(Cc2ccccc2)CC1
1219,1736165,10.1021/acs.jmedchem.8b00300,,,,Inhibition of human ERG,O=S(=O)(CC1CC1)NC1CN(c2ccc3c(c2)[C@@H](Cc2ccccc2)[C@@H](N2CCC2)CO3)C1,N-(1-(cis-3-(Azetidin-1-yl)-4-benzylchroman-6-yl)azetidin-3-yl)-1-cyclopropylmethanesulfonamide,11.4,uM,=,1.0569048513364727,1,O=S(=O)(CC1CC1)NC1CN(c2ccc3c(c2)[C@@H](Cc2ccccc2)[C@@H](N2CCC2)CO3)C1
1220,1677359,10.1021/acs.jmedchem.7b01454,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK cells after 180 mins by scintillation counting method,CN(C)CCN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2,"2-(3alpha-(Bis(4-fluorophenyl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-N,N-dimethylethanamine",8.23,uM,=,0.91539983521227,1,c1ccc(C(OC2CC3CCC(C2)N3)c2ccccc2)cc1
1221,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,C[S+]([O-])c1ccc(-c2cnc3ccc(Nc4cnccn4)nn23)cc1,"3-(4-(methylsulfinyl)phenyl)-N-(pyrazin-2-yl)imidazo[1,2-b]pyridazin-6-amine",7.84,uM,=,0.8943160626844384,1,c1ccc(-c2cnc3ccc(Nc4cnccn4)nn23)cc1
1222,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CC3COCC(C2)N3)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"N-(4-(3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl)-2-methoxyphenyl)-5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-amine",10.0,uM,=,1.0,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CC6COCC(C5)N6)cc4)n3)cnc2c1
1223,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1ccc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cn1,"2-(1,4'-bipiperidin-1'-yl)-6-(6-methylpyridin-3-yl)thiazolo[4,5-b]pyridine",7.543859649,uM,=,0.8775935999000252,1,c1cncc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)c1
1224,304652,10.1016/j.bmcl.2005.02.030,,,,Inhibitory activity against human Potassium channel HERG,O=C(O)[C@@H](CC1CCC1)N1C[C@H](CN2CCC(c3cnc4ccccn34)CC2)[C@@H](c2cccc(F)c2)C1,"(R)-3-Cyclobutyl-2-[(3S,4S)-3-(4-imidazo[1,2-a]pyridin-3-yl-piperidin-1-ylmethyl)-4-phenyl-pyrrolidin-1-yl]-propionic acid",2.7,uM,=,0.4313637641589873,1,c1ccc([C@H]2CN(CCC3CCC3)C[C@@H]2CN2CCC(c3cnc4ccccn34)CC2)cc1
1225,1438951,10.1021/jm501175v,,,,Inhibition of human ERG by patch clamp assay,CS(=O)(=O)c1ccc(-n2cc(Cl)c(OC3CCN(c4ncc(Cl)cn4)CC3)cc2=O)c(F)c1,5-Chloro-4-(1-(5-chloropyrimidin-2-yl)piperidin-4-yloxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one,1.4,uM,=,0.1461280356782379,1,O=c1cc(OC2CCN(c3ncccn3)CC2)ccn1-c1ccccc1
1226,1747135,10.1016/j.bmcl.2017.10.042,,,,Inhibition of human ERG,COc1nc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc(C)c1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-1-(2,3-dimethoxypyridin-4-yl)-4-(dimethylamino)-2-m-tolylbutan-2-ol",0.53,uM,=,-0.2757241303992109,0,c1ccc(C[C@H](c2ccncc2)c2cnc3ccccc3c2)cc1
1227,941017,10.1021/jm301564f,,,,Inhibition of human ERG K+ channel expressed in HEK293 cells after 15 mins by patch clamp assay,Cc1ccc(OCCCc2cccc(CCCOc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis(3-(p-tolyloxy)propyl)pyridinium",0.962,uM,=,-0.016824927962187,0,c1ccc(OCCCc2cccc(CCCOc3ccccc3)[nH+]2)cc1
1228,613538,10.1021/jm901781q,,,,Inhibition of human ERG by patch-clamp method,CCCOCCn1c(=O)c(N2CCN(C[C@@H](C)O)CC2)nc2cnc(-c3ccc(OC)nc3)cc21,"(R)-3-(4-(2-hydroxypropyl)piperazin-1-yl)-1-(2-isopropoxyethyl)-7-(6-methoxypyridin-3-yl)pyrido[3,4-b]pyrazin-2(1H)-one",0.23,uM,=,-0.6382721639824072,0,O=c1[nH]c2cc(-c3cccnc3)ncc2nc1N1CCNCC1
1229,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CS(=O)(=O)Nc1ccc2c(c1)[C@H](O)CC1(CCN([C@@H]3CCc4cc(C#N)ccc4C3)CC1)O2,"N-((R)-1'-((R)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl)-4-hydroxyspiro[chroman-2,4'-piperidine]-6-yl)methanesulfonamide",0.67,uM,=,-0.1739251972991735,0,c1ccc2c(c1)CC[C@@H](N1CCC3(CCc4ccccc4O3)CC1)C2
1230,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCN(C(=O)CN)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"2-amino-1-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)piperazin-1-yl)ethanone",16.0,uM,=,1.2041199826559248,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
1231,424195,10.1016/j.bmcl.2006.08.039,,,,Inhibition of human ERG potassium channel in HEK293 cells by patch clamp assay,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,56.0,uM,=,1.7481880270062005,1,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
1232,1706834,10.1016/j.bmcl.2017.07.031,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp method,CC(C)Cc1cc(CNS(=O)(=O)c2cccc3cccnc23)nn1-c1ccccc1,N-((5-isobutyl-1-phenyl-1H-pyrazol-3-yl)methyl)quinoline-8-sulfonamide,4.67,uM,=,0.6693168805661122,1,O=S(=O)(NCc1ccn(-c2ccccc2)n1)c1cccc2cccnc12
1233,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,CCOC(CN1CCN(CCc2ccc(C#N)c(OC)c2)CC1)c1ccc2c(c1C)COC2=O,"4-(2-(4-(2-ethoxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-2-methoxybenzonitrile",3.5,uM,=,0.5440680443502757,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
1234,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(C(CC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)C(=O)O)c2n1,"(rac)-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-3-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)propanoic acid",1.0,uM,=,0.0,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1235,1629116,10.1016/j.bmc.2016.10.009,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes,Cl.N=C(N)N/N=C/c1ccc(-c2ccc(/C=N/Nc3ccccc3Cl)cc2)cc1,2-((4'-((2-(2-chlorophenyl)hydrazono)methyl)biphenyl-4-yl)methylene)hydrazinecarboximidamide hydrochloride,1.14,uM,=,0.0569048513364725,1,C(=N/Nc1ccccc1)\c1ccc(-c2ccccc2)cc1
1236,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cccnc3)cc12,5-(Pyridin-3-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-3-carboxamide,49.3,uM,=,1.69284691927723,1,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cccnc3)cc12
1237,1980044,10.1021/acs.jmedchem.0c00711,,,,Inhibition of human ERG,C[C@@H](Nc1nc2c(cnn2C(C)(C)C)c(=O)n1Cc1ccc(F)cc1)c1ccc(Cl)cc1,"(R)-1-(tert-Butyl)-6-((1-(4-chlorophenyl)ethyl)amino)-5-(4-fluorobenzyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one",11.0,uM,=,1.0413926851582251,1,O=c1c2cn[nH]c2nc(NCc2ccccc2)n1Cc1ccccc1
1238,455097,10.1016/j.bmcl.2007.02.066,,,,Inhibition of cardiac hERG,Cl.N[C@H](C(=O)N1CC[C@H](F)C1)C1CCC(NS(=O)(=O)c2ccc(F)cc2F)CC1,"(S)-1-(4-(2,4-difluorophenylsulfonamido)cyclohexyl)-2-((S)-3-fluoropyrrolidin-1-yl)-2-oxoethanaminium chloride",49.0,uM,=,1.6901960800285136,1,O=C(CC1CCC(NS(=O)(=O)c2ccccc2)CC1)N1CCCC1
1239,964986,10.1016/j.bmcl.2013.04.047,,,,Inhibition of human ERG expressed in HEK cells by ion flux electrophysiology method,CC(=O)NCCNC(=O)c1ccc(O)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2,"(S)-N-(2-acetamidoethyl)-2-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-hydroxybenzamide",1.2,uM,=,0.0791812460476248,1,c1ccc(OCCCN2CCC3(CC2)Cc2ccccc2O3)cc1
1240,1278259,10.1021/jm4010434,,,,Inhibition of human ERG channel expressed in HEK293 cells after 15 mins by whole-cell patch clamp technique,CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1.Cc1ccc(S(=O)(=O)[O-])cc1,GNF-Pf-3889,0.05,uM,=,-1.3010299956639813,0,c1ccccc1.c1ccccc1
1241,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)[C@@H]1CCN(Cc2ccc(C(F)(F)F)nc2)C[C@@H]1F,"2-(4-(1H-tetrazol-1-yl)phenyl)-N-((3S,4R)-3-fluoro-1-((6-(trifluoromethyl)pyridin-3-yl)methyl)piperidin-4-yl)-N-methylacetamide",15.0,uM,=,1.1760912590556811,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2cccnc2)CC1
1242,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CN1CCN[C@@H](C(=O)N2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"(R)-N-(3,4-dichlorophenyl)-4-(4-methylpiperazine-2-carbonyl)piperazine-1-carboxamide",20.0,uM,=,1.3010299956639813,1,O=C(Nc1ccccc1)N1CCN(C(=O)[C@H]2CNCCN2)CC1
1243,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,Cc1cc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)ccn1,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(2-methylpyridin-4-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide",30.0,uM,=,1.4771212547196624,1,c1cc(-c2cc3c(NC4CCCC4)ccnn3c2)ccn1
1244,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc2cccc(Cl)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,5-Chloro-2-methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,8.1,uM,=,0.9084850188786496,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
1245,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CC3CNCC(C2)O3)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"N-(4-(9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-methoxyphenyl)-5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-amine",5.3,uM,=,0.724275869600789,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CC6CNCC(C5)O6)cc4)n3)cnc2c1
1246,421810,10.1016/j.bmcl.2006.10.053,,,,Inhibition of binding to hERG,CN(C)Cc1ccc2c(c1)CC[C@H](N(C)C(=O)c1ccc(-c3ccc(Cl)cc3)nc1)C2,"(S)-6-(4-chlorophenyl)-N-(6-((dimethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylnicotinamide",5.1,uM,=,0.7075701760979364,1,O=C(N[C@H]1CCc2ccccc2C1)c1ccc(-c2ccccc2)nc1
1247,1744232,10.1021/acs.jmedchem.6b01703,,,,Displacement of [3H]dofetilide from recombinant human ERG expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting method,CCc1nn2c(C)cc(C)nc2c1Cc1ccc(/C=C/CN2CCNCC2=O)cc1,"(E)-1-(3-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)allyl)piperazin-2-one",25.0,uM,=,1.3979400086720375,1,O=C1CNCCN1C/C=C/c1ccc(Cc2cnn3cccnc23)cc1
1248,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CCc1ncnn1CC(=O)N1CCN(c2sc(C(F)(F)F)nc2-c2cnc(C(F)(F)F)nc2)C[C@H]1C,"2-(5-Ethyl-[1,2,4]triazol-1-yl)-1-((R)-2-methyl-4-(2-trifiuoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl)-piperazin-1-yl)ethanone",0.013,uM,=,-1.8860566476931635,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
1249,465697,10.1021/jm701187w,,,,Inhibition of human ERG potassium current expressed in HEK293 cells by patch-clamp technique,Cc1cc(C)n(-c2cc(NC(=O)CCN3CC[C@H](N(C)C)C3)nc(-c3ccc(C)o3)n2)n1,"3-((S)-3-dimethylaminopyrrolidin-1-yl)-N-[6-(3,5-dimethylpy razol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl]propionamide",2.28,uM,=,0.3579348470004537,1,O=C(CCN1CCCC1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
1250,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CN1CCC(Cn2nc(-c3ccc4nc(OCC(F)(F)F)ccc4c3)c3c(N)ncnc32)CC1,"1-((1-Methylpiperidin-4-yl)methyl)-3-(2-(2,2,2-trifluoroethoxy)quinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.5,uM,=,-0.3010299956639812,0,c1cnc2ccc(-c3nn(CC4CCNCC4)c4ncncc34)cc2c1
1251,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,c1ccc(C(Cc2cccc3c2OCC3)N2CCNCC2)cc1,"1-(2-(2,3-dihydrobenzofuran-7-yl)-1-phenylethyl)piperazine",21.4,uM,=,1.3304137733491908,1,c1ccc(C(Cc2cccc3c2OCC3)N2CCNCC2)cc1
1252,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1ccc2nc(CN3CCCC3)n(Cc3ccc(Cl)cc3)c2c1,"US8975247, EBP425",0.65,uM,=,-0.1870866433571444,0,c1ccc(Cn2c(CN3CCCC3)nc3ccccc32)cc1
1253,1765514,10.1021/acs.jmedchem.8b01040,,,,Inhibition of human ERG by manual patch clamp assay,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cncnc2)c1,"US9278981, 170",5.0,uM,=,0.6989700043360189,1,O=C(Nc1ccccc1)c1cnc(N2CCCC2)c(-c2cncnc2)c1
1254,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1,"6-((1-(2-(7-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.0156199999999999,uM,=,-1.8063189704587184,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1255,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,CCOC(=O)c1ccc([C@@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)nc1,"ethyl6-((1R,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)nicotinate",2.845,uM,=,0.45408227073109,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@](c4cn[nH]c4)(c4ccccn4)N3)n2)cc1
1256,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,Cc1cc(F)ccc1[C@@H]1CCN(C[C@@H]2CCc3cccnc3[C@@H](O)C2)C[C@H]1O,"(7R,9S)-7-(((3S,4S)-4-(4-fluoro-2-methylphenyl)-3-hydroxypiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",13.0,uM,=,1.1139433523068367,1,c1ccc(C2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
1257,621155,10.1016/j.bmcl.2009.07.122,,,,Inhibition of human ERG,CCCC[C@H]1CN(CC2CCOCC2)C(=O)OC12CCN(C1(C)CCN(C(=O)c3c(C)ncnc3C)CC1)CC2,"(S)-5-butyl-9-(1-(4,6-dimethylpyrimidine-5-carbonyl)-4-methylpiperidin-4-yl)-3-((tetrahydro-2H-pyran-4-yl)methyl)-1-oxa-3,9-diazaspiro[5.5]undecan-2-one",11.9,uM,=,1.0755469613925308,1,O=C1OC2(CCN1CC1CCOCC1)CCN(C1CCN(C(=O)c3cncnc3)CC1)CC2
1258,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCNCC1,"2-Methyl-10-piperazin-1-yl-4H-3-thia-4,9-diaza-benzo[f]azulene",14.2,uM,=,1.1522883443830565,1,c1ccc2c(c1)N=C(N1CCNCC1)c1ccsc1N2
1259,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CCC(Oc4ccc(CN5CCC(O)C5)cc4)CC3)o2)cc1,"(4-(4-((3-hydroxypyrrolidin-1-yl)methyl)phenoxy)piperidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone",24.0,uM,=,1.380211241711606,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
1260,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,Cc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(6-methylpyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide",8.0,uM,=,0.9030899869919436,1,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1
1261,1461416,10.1016/j.bmcl.2014.12.068,,,,Inhibition of human ERG,CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(-c4cncc(O[C@H]5CNCCC56CC6)n4)c3c2)c(F)c1,(R)-N-(4-(3-(6-(6-azaspiro[2.5]octan-4-yloxy)pyrazin-2-yl)-1H-indazol-5-yl)-3-fluorophenyl)methanesulfonamide,2.3,uM,=,0.3617278360175928,1,c1ccc(-c2ccc3[nH]nc(-c4cncc(O[C@H]5CNCCC56CC6)n4)c3c2)cc1
1262,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Fc1ccc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cn1,"2-(1,4'-bipiperidin-1'-yl)-6-(6-fluoropyridin-3-yl)thiazolo[4,5-b]pyridine",0.3092783504999999,uM,=,-0.5096504795682972,0,c1cncc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)c1
1263,1996017,10.1021/acs.jmedchem.9b01803,,,,Inhibition of human ERG by Ionworks electrophysiology assay,CC(C)(C#N)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)(C)C#N)c1,"(S)-2-(3-Aminopiperidin-1-yl)-4-((3,5-bis(2-cyanopropan-2-yl)phenyl)amino)pyrimidine-5-carboxamide",7.1,uM,=,0.8512583487190752,1,c1ccc(Nc2ccnc(N3CCCCC3)n2)cc1
1264,744146,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG,O=C(NC1CC1)c1ccc(OCC2CC2CC2CCN(c3ncc(Cl)cn3)CC2)cc1F,(rac)-cis-4-((2-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)methyl)cyclopropyl)methoxy)-N-cyclopropyl-2-fluorobenzamide,1.2,uM,=,0.0791812460476248,1,O=C(NC1CC1)c1ccc(OCC2CC2CC2CCN(c3ncccn3)CC2)cc1
1265,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1ccc2nc(C)n(-c3ccc(OCCCN4CCCC4)cc3)c(=O)c2c1,"2,6-Dimethyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone",10.0,uM,=,1.0,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
1266,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CSc1ccc(Oc2ccccc2CN(C)C)cc1,"N,N-dimethyl-1-(2-(4-(methylthio)phenoxy)phenyl)methanamine",3.02,uM,=,0.4800069429571506,1,c1ccc(Oc2ccccc2)cc1
1267,2125084,10.1021/acsmedchemlett.1c00450,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell after 90 mins by microbeta liquid scintillation counting method,CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4ccc(Cl)c(N)c4)c4c(N)ncnc43)C2)CC1,"1-(4-((cis)-3-(4-amino-5-(3-amino-4-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclobutyl)piperazin-1-yl)ethan-1-one",19.0,uM,=,1.2787536009528289,1,c1ccc(-c2cn([C@H]3C[C@@H](N4CCNCC4)C3)c3ncncc23)cc1
1268,1512965,10.1021/acsmedchemlett.5b00117,,,,Inhibition of human ERG,C[C@@H]1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1,"[(8R)-3-[2-(2,4-Difluorophenyl)thiazol-4-yl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-[4-(2-thienyl)phenyl]-methanone",1.4,uM,=,0.1461280356782379,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2csc(-c3ccccc3)n2)C1
1269,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,N-{4-[4-(Ethyl-heptyl-amino)-1-hydroxy-butyl]-phenyl}-methanesulfonamide,0.02,uM,=,-1.6989700043360187,0,c1ccccc1
1270,1543580,10.1016/j.bmcl.2015.11.030,,,,Inhibition of human ERG by IKr binding assay,CCOC(=O)[C@H]1[C@@H]2CN(C(=O)c3ccc(C[C@@H]4CC[C@H]([C@H](O)c5ccccc5)N4)cc3)C[C@@H]21,"(1R,5S,6S)-ethyl 3-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)benzoyl)-3-azabicyclo[3.1.0]hexane-6-carboxylate",7.0,uM,=,0.8450980400142568,1,O=C(c1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)N1C[C@H]2C[C@H]2C1
1271,1362192,10.1021/ml400473x,,,,Inhibition of human ERG,COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5ncccn5)ccc42)C3)cc1,"2-(4-methoxyphenyl)-1-(2-((R)-5-(pyrimidin-2-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)ethanone",2.9,uM,=,0.4623979978989561,1,O=C(Cc1ccccc1)N1CCC2(CC1)CN([C@@H]1CCc3cc(-c4ncccn4)ccc31)C2
1272,304886,10.1016/j.bmcl.2004.07.056,,,,Inhibition of human Potassium channel HERG,NC(CC(=O)N1CCC[C@H]1C(=O)NCc1ccc(C(=O)O)cc1)Cc1ccc(F)c(F)c1.O=C(O)C(F)(F)F,"Trifluoro-acetate3-[(S)-2-(4-carboxy-benzylcarbamoyl)-pyrrolidin-1-yl]-1-(3,4-difluoro-benzyl)-3-oxo-propyl-ammonium",79.0,uM,=,1.8976270912904407,1,O=C(NCc1ccccc1)[C@@H]1CCCN1C(=O)CCCc1ccccc1
1273,2133680,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG expressed in CHO by QPatch assay,CC[C@@H](NC(=O)c1ccc(C#N)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4ccc(Cl)cc43)C[C@@H]21,"N-((R)-1-((1R,3S,5S,6r)-3-(6-chloro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)-4-cyanobenzamide",2.1,uM,=,0.3222192947339193,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
1274,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,C[C@@H]1CCCN1CCN1CCc2cc(-c3ccc(F)cc3)ccc2C1=O,"6-(4-Fluorophenyl)-2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-3,4-dihydroisoqui-nolin-1(2H)-one",0.3,uM,=,-0.5228787452803376,0,O=C1c2ccc(-c3ccccc3)cc2CCN1CCN1CCCC1
1275,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cn1c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2c(C(F)(F)F)cccc2c1=O,2-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-3-methyl-8-(trifluoromethyl)quinazolin-4(3H)-one,0.35,uM,=,-0.4559319556497244,0,O=c1[nH]c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2ccccc12
1276,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,14.0,uM,=,1.146128035678238,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
1277,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cccc(CNC2CCCC2)c1,N-((4'-fluoro-2'-methoxybiphenyl-3-yl)methyl)cyclopentanamine,2.15,uM,=,0.3324384599156053,1,c1ccc(-c2cccc(CNC3CCCC3)c2)cc1
1278,1927239,10.1016/j.bmc.2016.06.006,,,,Inhibition of human ERG expressed in CHO-K1 cells by whole cell patch clamp method,CC(C)Cc1cc(CNC(=O)C2C3CN(C(=O)Cc4ccccc4)CC32)nn1-c1ccccc1,5-Isobutyl-1-phenyl-3-[3-(2-phenylacetyl)-3-azabicyclo[3.1.0]hexane-6-carboxamido]methyl-1H-pyrazole,20.8,uM,=,1.3180633349627615,1,O=C(NCc1ccn(-c2ccccc2)n1)C1C2CN(C(=O)Cc3ccccc3)CC21
1279,434542,10.1021/jm061223o,,,,Inhibition of hERG expressed in HEK293 cells assessed as effect on ionic current by patch clamp assay,COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1,"3-(5-(3-(2-methoxyethoxy)prop-1-ynyl)thiophen-3-yl)-6-((4-methylpiperazin-1-yl)methyl)indeno[1,2-c]pyrazol-4(1H)-one",5.3,uM,=,0.724275869600789,1,O=C1c2cc(CN3CCNCC3)ccc2-c2[nH]nc(-c3ccsc3)c21
1280,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,CC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@H]2c2cccnc2)c(Cl)c1,"N-(2-(3'-chloro-4'-((3S,4S)-4-(pyridin-3-yl)piperidin-3-yl)biphenyl-2-yl)ethyl)acetamide",4.8,uM,=,0.6812412373755872,1,c1ccc(-c2ccc([C@H]3CNCC[C@@H]3c3cccnc3)cc2)cc1
1281,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2ccc3nc(N4CCCC4)ccc3c2)[nH]1,(S)-6-methyl-N-((S)-7-oxo-1-(5-(2-(pyrrolidin-1-yl)quinolin-6-yl)-1H-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide,28.0,uM,=,1.4471580313422192,1,O=C(NCc1ncc(-c2ccc3nc(N4CCCC4)ccc3c2)[nH]1)[C@H]1CC12CCNCC2
1282,814820,10.1016/j.bmcl.2012.03.074,,,,Inhibition of human ERG,CCOc1cc2nccc(Oc3cnc(CC(=O)Nc4n[nH]c(CC)c4C)c(OC)c3)c2cc1OC,2-(5-(7-ethoxy-6-methoxyquinolin-4-yloxy)-3-methoxypyridin-2-yl)-N-(5-ethyl-4-methyl-1H-pyrazol-3-yl)acetamide,76.0,uM,=,1.880813592280792,1,O=C(Cc1ccc(Oc2ccnc3ccccc23)cn1)Nc1cc[nH]n1
1283,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CC1(C)CC(NC(=O)C(F)(F)CO)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1,"N-[6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-2,2-difluoro-3-hydroxypropanamide",0.08,uM,=,-1.0969100130080565,0,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
1284,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,O=C(NC1CCN(Cc2ccc(OCCCN3CCCCC3)c(F)c2)CC1)c1cc(=O)c2ccc(F)cc2o1,N-(1-(3-fluoro-4-(3-(piperidin-1-yl)propoxy)benzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,42.0,uM,=,1.6232492903979006,1,O=C(NC1CCN(Cc2ccc(OCCCN3CCCCC3)cc2)CC1)c1cc(=O)c2ccccc2o1
1285,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(C#N)cn2)CC3)ccc2c1COC2=O,"6-(9-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-3,9-diazaspiro[5.5]undecan-3-yl)nicotinonitrile",0.193,uM,=,-0.7144426909922262,0,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccccn3)CC4)ccc21
1286,2238137,10.1021/acs.jmedchem.1c01012,,,,Inhibition of human ERG,O=c1[nH]c(CCCN2CC=C(c3ccc(F)cc3)CC2)nc2c(Cl)cccc12,"8-Chloro-2-{3-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-propyl}-3H-quinazolin-4-one",2.6,uM,=,0.414973347970818,1,O=c1[nH]c(CCCN2CC=C(c3ccccc3)CC2)nc2ccccc12
1287,2152616,10.1021/acs.jmedchem.1c00179,,,,Inhibition of hERG expressed in HEK293 cells,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.0130999999999999,uM,=,-1.882728704344236,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
1288,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3cccc(C(=O)O)c3)CC2)C1,"3-(1-((1R,3S)-3-((3,5-bis(trifluoromethyl)benzyl)carbamoyl)-3-isopropylcyclopentyl)piperidin-4-yl)benzoic acid",2.786,uM,=,0.4449811120879446,1,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3ccccc3)CC2)C1
1289,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(CCN2CCN(CC(OC)c3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"2-methoxy-4-(2-(4-(2-methoxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",9.0,uM,=,0.9542425094393248,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
1290,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)NCc3ccccc3)cc2)cc1,4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic Acid Benzylamide,0.5714285714,uM,=,-0.2430380487080091,0,O=S(=O)(NCc1ccccc1)c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
1291,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1,"N-(2-phenylcyclopropyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",2.6,uM,=,0.414973347970818,1,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
1292,1805877,10.1021/acs.jmedchem.9b00335,,,,Inhibition of human ERG expressed in CHOK1 cells by Q-patch electrophysiology method,CS(=O)(=O)c1cc(-c2ccccc2)cc(S(=O)(=O)c2ccc(CN)s2)c1,(5-(5-(methylsulfonyl)biphenyl-3-ylsulfonyl)thiophen-2-yl)methanamine,25.0,uM,=,1.3979400086720375,1,O=S(=O)(c1cccc(-c2ccccc2)c1)c1cccs1
1293,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",CCC[C@@H]1c2nnc(-c3nc(C)ns3)n2CCN1C(=O)c1ccc(F)cc1,"US9422299, 24",61.0,uM,=,1.7853298350107671,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
1294,1578287,10.1016/j.ejmech.2016.03.083,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as inhibition of tail current after 5 mins by automated whole-cell patch clamp assay,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide,0.024,uM,=,-1.619788758288394,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
1295,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,Cc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N,"2-methyl-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridine-3-carbonitrile",0.00087,uM,=,-3.0604807473813813,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1296,1677359,10.1021/acs.jmedchem.7b01454,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK cells after 180 mins by scintillation counting method,Fc1ccc(C(OC2CC3CCC(C2)N3CC2CC2)c2ccc(F)cc2)cc1,3-[Bis-(4-fluoro-phenyl)-methoxy]-8-cyclopropylmethyl-8-aza-bicyclo[3.2.1]octane,3.96,uM,=,0.5976951859255123,1,c1ccc(C(OC2CC3CCC(C2)N3CC2CC2)c2ccccc2)cc1
1297,802630,10.1016/j.bmcl.2011.12.092,,,,Inhibition of human ERG by patch clamp assay,COc1c(Nc2ccc(S(C)(=O)=O)nc2C)ncnc1OC1CCN(C(=O)OC(C)C)CC1,isopropyl 4-(5-methoxy-6-(2-methyl-6-(methylsulfonyl)pyridin-3-ylamino)pyrimidin-4-yloxy)piperidine-1-carboxylate,13.0,uM,=,1.1139433523068367,1,c1cncc(Nc2cc(OC3CCNCC3)ncn2)c1
1298,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)[C@@H]1CCN(Cc2nc3cc(F)ccc3s2)C[C@@H]1F,"N-((3S,4R)-3-fluoro-1-((5-fluorobenzo[d]thiazol-2-yl)methyl)piperidin-4-yl)-N-methyl-2-(4-(methylsulfonyl)phenyl)acetamide",7.0,uM,=,0.8450980400142568,1,O=C(Cc1ccccc1)NC1CCN(Cc2nc3ccccc3s2)CC1
1299,766531,10.1016/j.bmcl.2011.06.126,,,,Inhibition of human ERG by electrophysiological assay,COC(=O)c1ccc2c(c1)N(CCN1CCC(NCc3ccc4c(n3)NC(=O)CO4)CC1)C(=O)CO2,"methyl 3-oxo-4-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)piperidin-1-yl)ethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate",14.8,uM,=,1.1702617153949575,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccccc54)CC3)nc2N1
1300,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(F)ccc21,"(R)-2-(6-fluoro-3-(1-(3-methoxypyrazin-2-yl)ethyl)-1H-inden-2-yl)-N,N-dimethylethanamine",1.8,uM,=,0.255272505103306,1,C1=C(Cc2cnccn2)c2ccccc2C1
1301,1992475,10.1021/acs.jmedchem.0c01199,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by IonWorks barracuda patch clamp method,COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2Cl)cc(OC)c1OC,"1-(4-(4-Chloro-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine",2.7,uM,=,0.4313637641589873,1,c1ccc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2)cc1
1302,1627127,10.1016/j.bmcl.2016.10.064,,,,Displacement of 35S-MK499 from human ERG expressed in HEK293 cell membranes,Cc1c([C@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@@H]3CO2)ccc2c1COC2=O,"5-((3S,9aR)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-4-methylisobenzofuran-1(3H)-one",53.4,uM,=,1.7275412570285564,1,O=C1OCc2cc([C@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@@H]4CO3)ccc21
1303,687332,10.1016/j.bmcl.2010.10.042,,,,Displacement of [3H]-dofetilide from human ERG,N#Cc1ccc(CNC(=O)N(c2cccc(F)c2)C2CCN(CCC3(c4cccc(F)c4)CCN(C(=O)c4c(Cl)cccc4Cl)CC3)CC2)cc1,"3-(4-cyanobenzyl)-1-(1-(2-(1-(2,6-dichlorobenzoyl)-4-(3-fluorophenyl)piperidin-4-yl)ethyl)piperidin-4-yl)-1-(3-fluorophenyl)urea",1.0,uM,=,0.0,0,O=C(c1ccccc1)N1CCC(CCN2CCC(N(C(=O)NCc3ccccc3)c3ccccc3)CC2)(c2ccccc2)CC1
1304,766531,10.1016/j.bmcl.2011.06.126,,,,Inhibition of human ERG by electrophysiological assay,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccc([N+](=O)[O-])cc54)CC3)nc2N1,"6-((1-(2-(6-nitro-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",24.3,uM,=,1.385606273598312,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccccc54)CC3)nc2N1
1305,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3cccc(F)c3)nn2)ccc1-n1cnc(C)c1,"1-(3-fluorobenzyl)-4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazole",2.7,uM,=,0.4313637641589873,1,c1ccc(Cn2cc(-c3ccc(-n4ccnc4)cc3)nn2)cc1
1306,1682731,10.1021/acs.jmedchem.7b01135,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cell membranes,N#C[C@H]1C[C@@H](N2CCC2)CC[C@@H]1n1cc(C(N)=O)c(Nc2ccc([C@H](O)C(F)(F)F)cc2)n1,"US8962608, 28-47",32.0,uM,=,1.505149978319906,1,c1ccc(Nc2ccn([C@H]3CC[C@H](N4CCC4)CC3)n2)cc1
1307,1765499,10.1021/acs.jmedchem.8b01040,,,,Displacement of [3H]dofetilide from human ERG by high throughput assay,COc1ccc(C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1-c1cncnc1,"US9315489, 30",1.1,uM,=,0.041392685158225,1,O=C(Nc1ccccc1)c1cccc(-c2cncnc2)c1
1308,2117635,10.1016/j.ejmech.2021.113560,,,,Inhibition of human ERG channel expressed in CHO cells measured after 7 to 10 mins at -80 mV holding potential by whole cell patch clamp assay,Cc1ccc(CN2CCN(C(=O)C(=O)Nc3ccc4c(ccn4C)c3)CC2)cc1,N-(1-methyl-1H-indol-5-yl)-2-(4-[(4-methylphenyl)methyl]piperazin-1-yl)-2-oxoacetamide,7.5,uM,=,0.8750612633917001,1,O=C(Nc1ccc2[nH]ccc2c1)C(=O)N1CCN(Cc2ccccc2)CC1
1309,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(C)N1CCN(C(=O)N2Cc3ccccc3C2)CC1,isoindolin-2-yl(4-isopropylpiperazin-1-yl)methanone,19.41176471,uM,=,1.2880650185917366,1,O=C(N1CCNCC1)N1Cc2ccccc2C1
1310,1736165,10.1021/acs.jmedchem.8b00300,,,,Inhibition of human ERG,CCCS(=O)(=O)N[C@@H]1CCN(c2ccc3c(c2)[C@@H](Cc2ccccc2)[C@@H](N2CCC2)CC3)C1=O,"N-((R)-1-((7S,8R)-7-(Azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2-oxopyrrolidin-3-yl)propane-1-sulfonamide",4.5,uM,=,0.6532125137753437,1,O=C1CCCN1c1ccc2c(c1)[C@@H](Cc1ccccc1)[C@@H](N1CCC1)CC2
1311,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC#CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(CC(=O)c1cccc(OC)c1)c(=O)n2C,"(S)-6-(3-aminopiperidin-1-yl)-5-(but-2-ynyl)-3-(2-(3-methoxyphenyl)-2-oxoethyl)-1-methyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",1.3,uM,=,0.1139433523068367,1,O=C(Cn1c(=O)[nH]c2cc(N3CCCCC3)[nH]c2c1=O)c1ccccc1
1312,2129860,10.1021/acsmedchemlett.1c00328,,,,Inhibition of human ERG stably expressed in CHO-K1 cells at -90 mV holding potential by automated Q-patch clamp method,O=C(c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1)N1CCNCC1,(4-(2-(4-((1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)amino)piperidin-1-yl)ethyl)phenyl)(piperazin-1-yl)methanone,8.61,uM,=,0.9350031514536548,1,O=C(c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1)N1CCNCC1
1313,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC1(C)C[C@@H](CN2CCC(F)(CNC(=O)c3cc(Cl)cc(Cl)c3)CC2)CCO1,"(S)-3,5-Dichloro-N-[1-(2,2-dimethyl-tetrahydro-pyran-4-ylmethyl)-4-fluoro-piperidin-4-ylmethyl]-benzamide",3.79,uM,=,0.5786392099680724,1,O=C(NCC1CCN(CC2CCOCC2)CC1)c1ccccc1
1314,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,Cc1cc(N2CCCc3nc([C@@H](C)NC(=O)c4ccc(F)cc4)ccc32)ccn1,"(R)-4-fluoro-N-(1-(5-(2-methylpyridin-4-yl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)benzamide",0.73,uM,=,-0.1366771398795441,0,O=C(NCc1ccc2c(n1)CCCN2c1ccncc1)c1ccccc1
1315,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,CCOc1ccc2c(c1)C(C1=C[C@H](C)N(C)CC1)=Nc1cc(Cl)ccc1N2,"(S)-8-chloro-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-ethoxy-5H-dibenzo[b,e][1,4]diazepine",0.9,uM,=,-0.0457574905606751,0,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
1316,1361026,10.1021/jm401895u,,,,Inhibition of human cloned ERG expressed in CHO cells assessed as inhibition of potassium channel current by automated patch clamp assay,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1.Cl.Cl,N-(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide dihydrochloride,0.089,uM,=,-1.0506099933550872,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
1317,2192070,10.1016/j.ejmech.2020.112955,,,,Inhibition of human ERG,Cc1nc(Nc2ncc(N3CCN(C)[C@H](C)C3)c(Nc3cc(C)n(C)n3)n2)cc(C2CC2)c1F,"(R)-N2-(4-cyclopropyl-5-fluoro-6-methylpyridin-2-yl)-N4-(1,5-dimethyl-1H-pyrazol-3-yl)-5-(3,4-dimethylpiperazin-1-yl)pyrimidine-2,4-diamine",33.0,uM,=,1.5185139398778875,1,c1cc(C2CC2)cc(Nc2ncc(N3CCNCC3)c(Nc3cc[nH]n3)n2)n1
1318,518708,10.1016/j.bmcl.2008.12.017,,,,Inhibition of human ERG expressed in HEK cells by competitive radioligand binding assay,O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3ccccc3)cc12,"3-phenyl-2-(4-((4-(5-(pyridin-2-yl)-1H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-1,6-naphthyridin-5(6H)-one",5.61,uM,=,0.7489628612561614,1,O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3ccccc3)cc12
1319,1576909,10.1021/acs.jmedchem.5b01416,,,,Inhibition of human ERG expressed in HEK293 cells assessed as tail current at -50 mV holding potential by whole-cell patch clamp method,CC1CCN(CCCOc2ccc(=O)n(-c3ccc(F)c(Cl)c3)n2)CC1,2-(3-Chloro-4-fluorophenyl)-6-(3-(4-methylpiperidin-1-yl)-propoxy)pyridazin-3(2H)-one,2.16,uM,=,0.3344537511509309,1,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccccc1
1320,1330254,10.1039/C2MD20010D,,,,Inhibition of human ERG channel expressed in CHO cells by IonWorks assay,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CC[C@@H](NCCc3cncn3C2)C1=O,"(20R)-19,20,22,23-Tetrahydro-19-oxo-5H,21H-18,20-ethano-12,14-etheno-6,10-methenobenz[d]imidazo[4,3-l][l,6,9,13]oxatriazacyclononadecosine-9-carbonitrile",0.21,uM,=,-0.6777807052660807,0,O=C1[C@H]2CCN1c1cccc3ccc(cc13)Oc1cccc(c1)Cn1cncc1CCN2
1321,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,CC(C)(C)c1[nH]c2ccccc2c1C1CCCN(Cc2ccc(/C=C/C(=O)NO)cc2Cl)C1,(E)-3-{4-[3-(2-tert-Butyl-1H-indol-3-yl)piperidin-1-ylmethyl]-3-chlorophenyl}-N-hydroxyacrylamide,9.9,uM,=,0.99563519459755,1,c1ccc(CN2CCCC(c3c[nH]c4ccccc34)C2)cc1
1322,820353,10.1021/jm300138g,,,,Displacement of [3H]astemizole from human Erg expressed in HEK293 cells after 75 mins,CCN[C@H]1CCC[C@@H](c2c[nH]c3ccc(NC(=N)c4cccs4)cc23)C1.Cl,cis-(+/-)-N-(3-(3-(Ethylamino)cyclohexyl)-1H-indol-5-yl)thiophene-2-carboximidamide hydrochloride,16.3,uM,=,1.212187604403958,1,N=C(Nc1ccc2[nH]cc(C3CCCCC3)c2c1)c1cccs1
1323,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,C[S+]([O-])c1ccc(Nc2ccc3ncc(-c4ccc([S+](C)[O-])cc4)n3n2)cc1,"N,3-bis(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-amine",32.3,uM,=,1.509202522331103,1,c1ccc(Nc2ccc3ncc(-c4ccccc4)n3n2)cc1
1324,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(OC)cc(OC)c2)CCN(Cc2cccc(OC)c2)CC1,"methyl 4-((3,5-dimethoxybenzamido)methyl)-1-(3-methoxybenzyl)piperidine-4-carboxylate",0.31,uM,=,-0.5086383061657274,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
1325,2216859,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG by manual patch clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3nc(C)nc3C)[C@H](C)C2)cn1,"2-(3,5-Dimethyl-[1,2,4]triazol-1-yl)-1-{(R)-4-[4-(2-ethoxy-pyrimidin-5-yl)-2-trifluoromethylthiazol-5-yl]-2-methyl-piperazin-1-yl}-ethanone",44.0,uM,=,1.6434526764861874,1,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
1326,1570617,10.1016/j.bmcl.2016.03.106,,,,Inhibition of human ERG,O=c1ccc2ccc(F)c3c2n1C[C@H]3CN1CCC(NCc2cc3c(nn2)OCCO3)CC1,"(R)-1-((4-((6,7-dihydro-[1,4]dioxino[2,3-c]pyridazin-3-yl)methylamino)piperidin-1-yl)methyl)-9-fluoro-1H-pyrrolo[3,2,1-ij]quinolin-4(2H)-one",238.0,uM,=,2.376576957056512,1,O=c1ccc2cccc3c2n1C[C@H]3CN1CCC(NCc2cc3c(nn2)OCCO3)CC1
1327,2293467,10.1021/acs.jmedchem.7b00463,,,,Inhibition of hERG potassium channel by Q-patch clamp assay,COc1ccc(F)c(NC(=O)c2nnn(Cc3ccc(CN4CCOCC4)cc3)c2N)c1,"5-amino-N-(2-fluoro-5-methoxyphenyl)-1-(4-(morpholinomethyl)benzyl)-1H-1,2,3-triazole-4-carboxamide",36.0,uM,=,1.5563025007672873,1,O=C(Nc1ccccc1)c1cn(Cc2ccc(CN3CCOCC3)cc2)nn1
1328,814147,10.1016/j.bmcl.2012.03.019,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp assay,CC(=O)N1CCC(C(=O)N(CCCN2CCN(Cc3ccc(F)cc3)CC2)c2ccc(C)c(Cl)c2)CC1.Cl,1-acetyl-N-(3-chloro-4-methylphenyl)-N-(3-(4-(4-fluorobenzyl)piperazin-1-yl)propyl)piperidine-4-carboxamide hydrochloride,1.82,uM,=,0.2600713879850748,1,O=C(C1CCNCC1)N(CCCN1CCN(Cc2ccccc2)CC1)c1ccccc1
1329,2129860,10.1021/acsmedchemlett.1c00328,,,,Inhibition of human ERG stably expressed in CHO-K1 cells at -90 mV holding potential by automated Q-patch clamp method,N#Cc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(C(=O)O)cc3)CC2)cc1,4-((2-((1-(4-cyanophenethyl)piperidin-4-yl)amino)-1H-benzo[d]imidazol-1-yl)methyl)benzoicacid,4.16,uM,=,0.6190933306267428,1,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
1330,1990748,10.1016/j.bmcl.2020.127214,,,,Inhibition of human ERG expressed in CHO cells by electrophysiology QPatch assay,COc1c(S(C)(=O)=O)ccc(O[C@@H](C)C(F)(F)F)c1C(=O)N1CC(c2ccccc2)C1,"(S)-(2-methoxy-3-(methylsulfonyl)-6-(1,1,1-trifluoropropan-2-yloxy)phenyl)(3-phenylazetidin-1-yl)methanone",6.8,uM,=,0.8325089127062363,1,O=C(c1ccccc1)N1CC(c2ccccc2)C1
1331,2157068,10.1021/acsmedchemlett.1c00445,,,,Inhibition of hERG expressed in HEK293 cells at -80 mV holding potential by automated patch-clamp method,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)Cn2nc(C#N)cc2C(N)=N1,"(R)-N-(3-(4-amino-2-cyano-6-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-6-yl)-4-fluorophenyl)-5-cyanopicolinamide",4.6,uM,=,0.6627578316815741,1,O=C(Nc1cccc(C2Cn3nccc3C=N2)c1)c1ccccn1
1332,1545989,10.1021/acs.jmedchem.5b01227,,,,Inhibition of human ERG channel by automated Q-patch assay,CC(C)(C)c1cc(NC(=O)n2ccc3cc(Oc4ncnc5c4CNC5)ccc32)no1,"5-(6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yloxy)-indole-1-carboxylic Acid (5-tert-Butyl-isoxazol-3-yl)-amide",23.5,uM,=,1.3710678622717365,1,O=C(Nc1ccon1)n1ccc2cc(Oc3ncnc4c3CNC4)ccc21
1333,1642194,,,,,Fast Patch Assay: Representative compounds were tested for hERG activity using the Fast Patch assay available from WuXiApptec (Shanghai China).,O[C@H]1CC[C@H](Nc2ccc3ncc(-c4cccc(C(F)(F)F)c4)n3n2)CC1,"US9416132, 8-29",10.0,uM,=,1.0,1,c1ccc(-c2cnc3ccc(NC4CCCCC4)nn23)cc1
1334,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,COC(=O)N(C)c1c(N)nc(-n2nc(Cc3ccccc3Cl)c3ccccc32)nc1N,"methyl N-[4,6-diamino-2-[3-[(2-chlorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methyl-carbamate",10.9,uM,=,1.0374264979406236,1,c1ccc(Cc2nn(-c3ncccn3)c3ccccc23)cc1
1335,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1cccc2c(=O)n(C)c(-c3ccc(OC4CCN(C5CCC5)CC4)cc3)nc12,"2-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-3,8-dimethylquinazolin-4(3H)-one",2.0,uM,=,0.3010299956639812,1,O=c1[nH]c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2ccccc12
1336,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,NC(=O)c1cnc(N[C@H]2CCCNC2)c2cc(-c3ccsc3)sc12,"4-[(3S)-Piperidin-3-ylamino]-2-(3-thienyl)thieno[3,2-c]-pyridine-7-carboxamide",28.0,uM,=,1.4471580313422192,1,c1cc2sc(-c3ccsc3)cc2c(N[C@H]2CCCNC2)n1
1337,2089346,10.1016/j.ejmech.2020.112424,,,,Inhibition of fluorescently labeled tracer binding to human ERG by competitive binding assay,COc1cc(F)ccc1-c1nc(Nc2ccc3c(N4CCOCC4)c(C(C)=O)c(=O)oc3c2)ncc1F,3-Acetyl-7-((5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyrimidin-2-yl)amino)-4-morpholino-2H-chromen-2-one,10.08,uM,=,1.0034605321095065,1,O=c1cc(N2CCOCC2)c2ccc(Nc3nccc(-c4ccccc4)n3)cc2o1
1338,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,Cc1cc(CNc2nc(N)nc3ccn(Cc4cc(Cl)ccn4)c23)no1,"5-((4-Chloropyridin-2-yl)methyl)-N4-((5-methylisoxazol-3-yl)methyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine",0.5,uM,=,-0.3010299956639812,0,c1ccc(Cn2ccc3ncnc(NCc4ccon4)c32)nc1
1339,499728,10.1016/j.bmcl.2009.02.111,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp method,COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1,"N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide",8.9,uM,=,0.9493900066449128,1,O=C(Nc1ccccc1C(=O)Nc1ccccn1)c1ccccc1
1340,591827,10.1021/jm900729s,,,,Inhibition of human ERG by patch-clamp assay,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(C3CN(Cc4ccnc5cccnc45)C3)C(=O)O[C@]12C,"3-Descladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl-(1-(([1,5]naphthyridin-4-yl)methyl)azetidin-3-yl)imino)-erythromycin A",196.0,uM,=,2.292256071356476,1,O=C1CC(=O)OCC2OC(=O)N(C3CN(Cc4ccnc5cccnc45)C3)[C@@H]2CC(=O)CCC[C@H](O[C@H]2CCCCO2)C1
1341,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc2c(C(F)(F)F)cccc2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,2-Methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-8-(trifluoromethyl)-4(3H)-quinazolinone,0.35,uM,=,-0.4559319556497244,0,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
1342,1747135,10.1016/j.bmcl.2017.10.042,,,,Inhibition of human ERG,CCSc1ccc([C@H](c2cc3cc(Br)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cccc(F)c2)cn1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-1-(6-(ethylthio)pyridin-3-yl)-2-(3-fluorophenyl)butan-2-ol",0.46,uM,=,-0.3372421683184259,0,c1ccc(C[C@H](c2cccnc2)c2cnc3ccccc3c2)cc1
1343,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CC(C)CN(CCc1ccc(Cl)c(Cl)c1)C[C@H](O)COc1ccc(NS(C)(=O)=O)cc1,"(S)-1-(4-Methanesulfonamidophenoxy)-3-(N-isobutyl-3,4dichlorophenylethylamino)-2-propanol",0.73,uM,=,-0.1366771398795441,0,c1ccc(CCNCCCOc2ccccc2)cc1
1344,1924902,10.1016/j.bmcl.2016.07.048,,,,Inhibition of MK499 binding to human ERG,Cn1cc(NC(=O)c2cccc(-c3ccnc(NCC4CC4)c3)n2)c(C(N)=O)n1,"N-(3-carbamoyl-1-methyl-1H-pyrazol-4-yl)-2'-(cyclopropylmethylamino)-2,4'-bipyridine-6-carboxamide",2.9,uM,=,0.4623979978989561,1,O=C(Nc1cn[nH]c1)c1cccc(-c2ccnc(NCC3CC3)c2)n1
1345,1663976,10.1021/acs.jmedchem.7b00140,,,,Inhibition of human ERG by fluorescence polarization assay,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1,"2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol",0.377,uM,=,-0.4236586497942071,0,C(=C1c2ccccc2-c2ccccc21)c1ccccc1
1346,1913293,10.1021/acs.jmedchem.9b01032,,,,Inhibition of human ERG expressed in HEK293 cells by IonWorks barracuda patch clamp method,CN(Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1)C(C)(C)C,"4-((2-((tert-Butyl(methyl)amino)methyl)-6-fluorobenzyl)amino)-2,6-difluoro-N-(thiazol-4-yl)benzenesulfonamide",26.3,uM,=,1.4199557484897578,1,O=S(=O)(Nc1cscn1)c1ccc(NCc2ccccc2)cc1
1347,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COCCN1CCC[C@@H](Cn2c(-c3ccccc3C)nc3nc(-c4ccc(Cl)cc4)sc3c2=O)C1,"2-(4-Chlorophenyl)-6-{[(3R)-1-(2-methoxyethyl)piperidin-3-yl]methyl}-5-(2-methylphenyl)[1,3]thiazolo[4,5-d]pyrimidin-7(6H)-one",3.7,uM,=,0.568201724066995,1,O=c1c2sc(-c3ccccc3)nc2nc(-c2ccccc2)n1C[C@@H]1CCCNC1
1348,2079116,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 10 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),O=C(COc1ccc(C(=O)c2cc(Cl)ccc2Br)cc1)Nc1ccncc1,2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)-N-(pyridin-4-yl)acetamide,0.0437,uM,=,-1.359518563029578,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1ccncc1
1349,1685716,10.1016/j.bmc.2017.04.033,,,,Inhibition of human ERG,C[C@@H](c1ccc(Br)cc1)N1CC[C@](CCC(N)=O)(c2ccc(F)cc2)OC1=O,"3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)propanamide",6.3,uM,=,0.7993405494535817,1,O=C1OC(c2ccccc2)CCN1Cc1ccccc1
1350,1654660,10.1016/j.bmcl.2016.12.033,,,,Inhibition of human ERG,O=C(c1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)N1CCN(Cc2ncn(CC(F)F)n2)CC1,"(4-((1-(2,2-difluoroethyl)-1H-1,2,4-triazol-3-yl)methyl)piperazin-1-yl)(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)methanone",34.01,uM,=,1.5316066319327222,1,O=C(c1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)N1CCN(Cc2nc[nH]n2)CC1
1351,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CCCc1cn(-c2ccc(F)cc2)c2ccc(Cl)cc12,5-Chloro-1-(4-fluoro-phenyl)-3-propyl-1H-indole,26.0,uM,=,1.414973347970818,1,c1ccc(-n2ccc3ccccc32)cc1
1352,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,COCCN1CCN(c2cc3c(Nc4ccc(C)cc4F)c(C(N)=O)nnc3cc2OC)CC1,4-(2-fluoro-4-methylphenylamino)-7-methoxy-6-(4-(2-methoxyethyl)piperazin-1-yl)cinnoline-3-carboxamide,23.0,uM,=,1.3617278360175928,1,c1ccc(Nc2cnnc3ccc(N4CCNCC4)cc23)cc1
1353,1643779,10.1039/C6MD00281A,,,,Inhibition of recombinant human ERG expressed in HEK293 cells at holding potential of -120 mV by PatchXpress automated electrophysiology method,CC(C)(N)c1nc(-c2ccc(OC(F)(F)F)cc2)c[nH]1,2-(4-(4-(Trifluoromethoxy)phenyl)-1H-imidazol-2-yl)propan-2-amine,2.6,uM,=,0.414973347970818,1,c1ccc(-c2c[nH]cn2)cc1
1354,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,O=C(c1cccc(Cl)c1Cl)N(c1ccccc1)[C@H]1CCNC1,"(S)-2,3-dichloro-N-phenyl-N-(pyrrolidin-3-yl)benzamide",7.92,uM,=,0.8987251815894935,1,O=C(c1ccccc1)N(c1ccccc1)[C@H]1CCNC1
1355,1474497,10.1021/acs.jmedchem.5b00191,,,,Inhibition of human ERG expressed in CHO cells,Cn1cc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)cn1,"(4aR,6R,8aS)-8a-(2,4-difluorophenyl)-6-(1-methyl-1H-pyrazol-4-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",4.9,uM,=,0.6901960800285137,1,C1=N[C@@]2(c3ccccc3)CO[C@@H](c3cn[nH]c3)C[C@H]2CS1
1356,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cccnc43)C[C@@H]21,"N-(1-((1R,3s,5S,6r)-3-(3H-imidazo[4,5-b]pyridin-3-yl)bicyclo[3.1.0]hexan-6-yl)propyl)-4-chlorobenzamide",11.0,uM,=,1.0413926851582251,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4cccnc43)C[C@@H]12)c1ccccc1
1357,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,CCc1ccc2c(c1)C(C1=C[C@H](C)N(C)CC1)=Nc1ccccc1N2,"(S)-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-ethyl-5H-dibenzo[b,e][1,4]diazepine",0.6,uM,=,-0.2218487496163563,0,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
1358,1890282,10.1021/acs.jmedchem.8b01972,,,,Inhibition of Tracer Red binding to human ERG expressed in membranes by fluorescence polarization assay,CN(C)c1ccc(CNC(=O)[C@@H]2CNC[C@H]2c2ccc(Oc3ccccc3)cc2)cc1,"(+/-)-(3S,4R)-N-{[4-(dimethylamino)phenyl]methyl}-4-(4-phenoxyphenyl)pyrrolidine-3-carboxamide",2.11,uM,=,0.3242824552976926,1,O=C(NCc1ccccc1)[C@@H]1CNC[C@H]1c1ccc(Oc2ccccc2)cc1
1359,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,Cc1cccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)c1,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-m-tolylpyrrolo[1,2-b]pyridazine-3-carboxamide",7.7,uM,=,0.8864907251724818,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
1360,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,CO/N=C/COc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1F,N-(1-(3-fluoro-4-(2-(methoxyimino)ethoxy)benzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,3.2,uM,=,0.505149978319906,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
1361,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CC(Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(F)(F)F,"rac-4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl]-methanone",20.0,uM,=,1.3010299956639813,1,O=C(c1ccccc1)N1CCN(c2ccccn2)CC1
1362,439396,10.1016/j.bmcl.2007.05.087,,,,Inhibition of human ERG potassium channel,Cc1nnc2ccc(N3CC[C@H](c4cc(F)c(F)cc4F)[C@@H](N)C3)nn12.O=C(O)C(F)(F)F,"(3R,4R)-1-(3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium 2,2,2-trifluoroacetate",20.3,uM,=,1.307496037913213,1,c1ccc(C2CCN(c3ccc4nncn4n3)CC2)cc1
1363,2154547,10.1021/acs.jmedchem.0c02081,,,,Inhibition of human ERG,CC(=O)N1CCc2nc(N3CCC(Oc4ccc(F)cc4F)CC3)c(N[C@@H]3CCOC3)nc2C1,"(R)-1-(2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-((tetrahydrofuran-3-yl)amino)-7,8-dihydropyrido[3,4-b]pyrazin-6(5H)-yl)ethan-1-one",3.5,uM,=,0.5440680443502757,1,c1ccc(OC2CCN(c3nc4c(nc3N[C@@H]3CCOC3)CNCC4)CC2)cc1
1364,1929690,10.1021/acsmedchemlett.6b00149,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp assay,CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)C(C)(C)S(=O)(=O)C3)cc1,"(S)-1-(4-(7,7-dimethyl-4-(3-methylmorpholino)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)phenyl)-3-ethylurea",48.0,uM,=,1.6812412373755872,1,O=S1(=O)Cc2nc(-c3ccccc3)nc(N3CCOCC3)c2C1
1365,2049587,10.1016/j.bmcl.2020.127625,,,,Inhibition of human ERG by patch clamp assay,Cc1cn([C@@H](C)[C@]2(F)CCNC2)c2nc(C(N)=O)cc(Cl)c12,"Rac-4-chloro-1-[(1S)-1-[(3S)-3-fluoropyrrolidin-3-yl]ethyl]-3-methyl-pyrrolo[2,3-b]pyridine-6-carboxamide",22.0,uM,=,1.3424226808222062,1,c1cnc2c(c1)ccn2CC1CCNC1
1366,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,C[C@H](CN(C)C)Oc1nc(Nc2cc3cccc(Cl)c3cn2)cnc1C#N,(R)-5-(8-chloroisoquinolin-3-ylamino)-3-(1-(dimethylamino)propan-2-yloxy)pyrazine-2-carbonitrile,5.0,uM,=,0.6989700043360189,1,c1ccc2cc(Nc3cnccn3)ncc2c1
1367,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC#CCn1c(N2CCC[C@@H](N)C2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,"(R)-6-(3-aminopiperidin-1-yl)-5-(but-2-ynyl)-1-methyl-3-((4-methylquinazolin-2-yl)methyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",21.7,uM,=,1.3364597338485296,1,O=c1[nH]c2cc(N3CCCCC3)[nH]c2c(=O)n1Cc1ncc2ccccc2n1
1368,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Fc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1,"(1R,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.377,uM,=,-0.4236586497942071,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
1369,627338,10.1016/j.bmcl.2010.03.005,,,,Inhibition of human ERG,OC(c1cccnc1)(c1cccnc1)C(c1ccccc1)N1CCCOCC1,"2-(1,4-oxazepan-4-yl)-2-phenyl-1,1-di(pyridin-3-yl)ethanol",3.55,uM,=,0.5502283530550941,1,c1ccc(C(C(c2cccnc2)c2cccnc2)N2CCCOCC2)cc1
1370,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CC(C)N(C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1)C(C)C,"N,N-Diisopropyl-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide",6.809,uM,=,0.833083334178343,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
1371,804952,10.1021/jm201407j,,,,Inhibition of human ERG by cell based voltage clamp assay,COc1cc(/C=C2\CCCN3C2=NOC3(C)c2ccc(F)cc2)ccc1-n1cnc(C)c1,"(E)-3-(4-Fluorophenyl)-8-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)-3-methyl-5,6,7,8-tetrahydro-3H-[1,2,4]-oxadiazolo[4,3-a]pyridine",0.74,uM,=,-0.1307682802690238,0,C(=C1\CCCN2C1=NOC2c1ccccc1)\c1ccc(-n2ccnc2)cc1
1372,541084,10.1016/j.bmcl.2009.01.009,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,CC(C[C@H](NC(=O)C1CCC1)c1ccccc1)N1CCC(c2[nH]ncc2-c2ccncc2)CC1,N-((1S)-1-phenyl-3-(4-(4-(pyridin-4-yl)-1H-pyrazol-5-yl)piperidin-1-yl)butyl)cyclobutanecarboxamide,0.117,uM,=,-0.9318141382538384,0,O=C(N[C@@H](CCN1CCC(c2[nH]ncc2-c2ccncc2)CC1)c1ccccc1)C1CCC1
1373,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",CCc1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1,"US9422299, 13",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncno2)C1
1374,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,COc1cccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cnn(C)c4)(c4noc(C)n4)N3)n2)n1,"3-((1R,3R)-3-(4-(6-methoxypyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,2,4-oxadiazole",3.619,uM,=,0.5585885831081994,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)nc1
1375,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,COc1ccccc1CC(c1ccccc1F)N1CCNCC1,1-(1-(2-fluorophenyl)-2-(2-methoxyphenyl)ethyl)piperazine,40.1,uM,=,1.6031443726201824,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
1376,716794,10.1016/j.bmcl.2010.12.123,,,,Inhibition of human ERG expressed in CHO cells,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(Cl)cc21,"(S)-2-(6-chloro-2-(4-chlorophenyl)-5-fluoro-1H-benzo[d]imidazol-1-yl)-N,2-dicyclohexylacetamide",1.6,uM,=,0.2041199826559248,1,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
1377,345010,10.1016/j.bmcl.2005.12.094,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,O=C([C@@H](O)C1CC1)N1CC(c2cc(F)ccc2F)=C[C@H]1c1cccc(O)c1,"(S)-2-cyclopropyl-1-((S)-4-(2,5-difluorophenyl)-2-(3-hydroxyphenyl)-2H-pyrrol-1(5H)-yl)-2-hydroxyethanone",18.0,uM,=,1.255272505103306,1,O=C(CC1CC1)N1CC(c2ccccc2)=C[C@H]1c1ccccc1
1378,2245517,10.1021/acs.jmedchem.1c02156,,,,Inhibition of hERG potassium channel in CHO cells at -80 mV holding potential by QPatch automated patch clamp assay,O=S(=O)(c1ccccc1)N1CCc2cc(C3CC3NCC3CCNCC3)ccc21,trans-2-(1-(phenylsulfonyl)indolin-5-yl)-N-(piperidin-4-ylmethyl)cyclopropanamine,8.38,uM,=,0.9232440186302766,1,O=S(=O)(c1ccccc1)N1CCc2cc(C3CC3NCC3CCNCC3)ccc21
1379,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",CCc1noc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"US9422299, 30",32.0,uM,=,1.505149978319906,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2ncno2)C1
1380,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"exo-3-((1R,3s,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide",3.0,uM,=,0.4771212547196624,1,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
1381,980797,10.1021/jm4006324,,,,Inhibition of human ERG channel by electrophysiological method,Cn1cc(-c2ccnc3c2OCCNC3)c(-c2ccc(F)cc2)n1,"9-(3-(4-Fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepin",25.7,uM,=,1.4099331233312946,1,c1ccc(-c2n[nH]cc2-c2ccnc3c2OCCNC3)cc1
1382,1463730,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"6-((1-((3-fluoro-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",15.8,uM,=,1.1986570869544226,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
1383,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,Cc1ccccc1C1CCN(C[C@H]2CCc3cccnc3[C@@H](O)C2)CC1,"cis-(+)-7-((4-o-tolylpiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",0.31,uM,=,-0.5086383061657274,0,c1ccc(C2CCN(C[C@H]3CCc4cccnc4CC3)CC2)cc1
1384,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cnc(-c2cnc(N)c(O[C@@H]3CN(C(=O)Cc4ccc(OC(F)(F)F)cc4)C[C@H]3F)c2)c1,"1-((3R,4R)-3-((2-Amino-5-(1-methyl-1Himidazol-4-yl)pyridin-3-yl)oxy)-4-fluoropyrrolidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)ethan-1-one",15.0,uM,=,1.1760912590556811,1,O=C(Cc1ccccc1)N1CC[C@H](Oc2cncc(-c3c[nH]cn3)c2)C1
1385,1622464,10.1016/j.bmcl.2016.09.067,,,,Inhibition of radiolabeled dofetilide binding to human ERG expressed in HEK293 cells,N[C@H]1CCCN(c2ccncc2Nc2ncc3ccc(-c4ncccc4F)nn23)C1,"(S)-N-(4-(3-aminopiperidin-1-yl)pyridin-3-yl)-2-(3-fluoropyridin-2-yl)imidazo[1,5-b]pyridazin-7-amine",2.8,uM,=,0.4471580313422192,1,c1ccc(-c2ccc3cnc(Nc4cnccc4N4CCCCC4)n3n2)nc1
1386,2133680,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG expressed in CHO by QPatch assay,CC[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4ccc(C#N)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(6-cyano-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",5.6,uM,=,0.7481880270062004,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
1387,2165295,10.1021/acsmedchemlett.1c00666,,,,Inhibition of human ERG by patch-clamp assay,c1ccc2oc(-c3csc(C4CCN(Cc5nc6ncccc6[nH]5)CC4)n3)cc2c1,BAY-179,3.0,uM,=,0.4771212547196624,1,c1ccc2oc(-c3csc(C4CCN(Cc5nc6ncccc6[nH]5)CC4)n3)cc2c1
1388,534565,10.1016/j.bmc.2008.01.017,,,,Inhibition of human ERG potassium channel,CN(C)c1cn(-c2ccc(F)cc2)c2ccc(Cl)cc12,"5-chloro-1-(4-fluorophenyl)-N,N-dimethyl-1H-indol-3-amine",0.011,uM,=,-1.958607314841775,0,c1ccc(-n2ccc3ccccc32)cc1
1389,2059206,10.1021/acs.jmedchem.0c01489,,,,Inhibition of human ERG,O=C1CCC(N2Cc3cc(CNC(=O)C(F)(F)c4ccc(Cl)cc4)ccc3C2=O)C(=O)N1,"2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide",5.3,uM,=,0.724275869600789,1,O=C(Cc1ccccc1)NCc1ccc2c(c1)CN(C1CCC(=O)NC1=O)C2=O
1390,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,O=C(NC1CCN(C2CCCCC2)CC1)c1noc(-c2ccc(F)cc2F)n1,"5-(2,4-Difluoro-phenyl)-[1,2,4]oxadiazole-3-carboxylic acid (1-cyclohexyl-piperidin-4-yl)-amide",2.7,uM,=,0.4313637641589873,1,O=C(NC1CCN(C2CCCCC2)CC1)c1noc(-c2ccccc2)n1
1391,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nn(CCN(C)C)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"3-(2-(dimethylamino)ethyl)-5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,3,4-oxadiazol-2(3H)-one",3.4,uM,=,0.5314789170422551,1,O=c1[nH]nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
1392,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,CC1(c2nc(-c3ccccc3)c[nH]2)Cc2c([nH]c3ccccc23)C(C2CCOCC2)N1,"3-methyl-3-(4-phenyl-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",2.175,uM,=,0.3374592612906561,1,c1ccc(-c2c[nH]c(C3Cc4c([nH]c5ccccc45)C(C4CCOCC4)N3)n2)cc1
1393,634333,10.1021/jm100053t,,,,Inhibition of human ERG,CNC[C@@H](O)CCN1c2ccccc2N(c2ccccc2)S1(=O)=O,"(2S)-4-(2,2-Dioxido-3-phenyl-2,1,3-benzothiadiazol-1(3H)-yl)-1-(methylamino)butan-2-ol",8.0,uM,=,0.9030899869919436,1,O=S1(=O)Nc2ccccc2N1c1ccccc1
1394,1912248,10.1021/acs.jmedchem.9b00443,,,,Inhibition of human ERG by fluorescence polarization assay,CNC(=O)c1cnc(Nc2ccc(OC)cn2)cc1Nc1ccccc1S(C)(=O)=O,6-((5-Methoxypyridin-2-yl)amino)-N-methyl-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide,17.0,uM,=,1.230448921378274,1,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1
1395,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(Cl)cnc56)(CC3)OC4)nc2N1,"6-((1-(2-(7-chloro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.0049299999999999,uM,=,-2.3071530807227703,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1396,581929,10.1016/j.bmcl.2009.06.011,,,,Inhibition of human ERG,N[C@H]1Cn2c(nc3ncccc32)C[C@@H]1c1cc(F)c(F)cc1F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,"(11R,12R)-12-azaniumyl-11-(2,4,5-trifluorophenyl)-1,6,8-triazatricyclo[7.4.0.0^{2,7}]trideca-2(7),3,5,8-tetraen-6-ium; bis(2,2,2-trifluoroacetate)",90.0,uM,=,1.954242509439325,1,c1ccc([C@@H]2CCn3c(nc4ncccc43)C2)cc1
1397,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(C#Cc2ccc(Cl)cc2)cccc1C#Cc1ccc(Cl)cc1,"2,6-bis((4-chlorophenyl)ethynyl)-1-methylpyridinium",1.159,uM,=,0.064083435963596,1,C(#Cc1cccc(C#Cc2ccccc2)[nH+]1)c1ccccc1
1398,761292,10.1021/jm101312a,,,,Inhibition of human ERG expressed in CHO cells by high throughput single cell planar patch clamp method,CN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1,"cis-3a-(3,4-dichlorophenyl)-2-methyloctahydro-1H-isoindole",4.14,uM,=,0.617000341120899,1,c1ccc([C@@]23CCCC[C@@H]2CNC3)cc1
1399,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cc(F)cc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"endo-3-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)-5-fluorobenzamide",0.68,uM,=,-0.1674910872937636,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccc2)C3)cc1
1400,1911678,10.1021/acs.jmedchem.8b01725,,,,Inhibition of human ERG by Q-patch assay,C[C@@H]1OCC2(CCN(c3nc4[nH]nc(-c5ccnc(Cl)c5Cl)c4c(=O)n3C)CC2)[C@@H]1N,"6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichloropyridin-4-yl)-5-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one",1.2,uM,=,0.0791812460476248,1,O=c1[nH]c(N2CCC3(CCOC3)CC2)nc2[nH]nc(-c3ccncc3)c12
1401,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCC[C@@H](CCO)Nc1nc(N)nc2cc(F)ccc12,(S)-3-((2-Amino-7-fluoroquinazolin-4-yl)amino)hexan-1-ol,9.1,uM,=,0.9590413923210936,1,c1ccc2ncncc2c1
1402,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,CCOc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2cccc3c2OCCO3)cc(OCC)n1,"3-((1R,2S)-2-(2,6-diethoxypyridin-4-yl)-1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-4-(dimethylamino)-2-hydroxybutyl)-2-methoxyquinoline-6-carbonitrile",4.5,uM,=,0.6532125137753437,1,c1cc2c(c([C@@H](Cc3ccncc3)c3cnc4ccccc4c3)c1)OCCO2
1403,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,CN1CCN(C(=O)NC2CCN(Cc3ccn(-c4ccc(C(F)(F)F)cc4)c3)CC2)C(c2ccccc2)C1,4-methyl-2-phenyl-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)piperazine-1-carboxamide,4.7,uM,=,0.6720978579357175,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCNCC1c1ccccc1
1404,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CO[C@H]1CN(Cc2ccc(C(F)(F)F)cc2)CC[C@H]1N(C)C(=O)Cc1ccc(-n2cnnn2)cc1,"2-(4-(1H-tetrazol-1-yl)phenyl)-N-((3S,4R)-3-methoxy-1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)-N-methylacetamide",1.2,uM,=,0.0791812460476248,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2ccccc2)CC1
1405,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,CC#Cc1ccc2nc(OC)c(C(c3ccccc3)C(O)(CCN(C)C)c3cccc4ccccc34)cc2c1,4-(dimethylamino)-1-(2-methoxy-6-(prop-1-ynyl)quinolin-3-yl)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol,7.9,uM,=,0.8976270912904415,1,c1ccc(C(Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
1406,1444863,10.1021/ml500353p,,,,Inhibition of human ERG by automated whole cell electrophysiology,C[C@@H]1Cn2ncc(C3CCN(S(C)(=O)=O)CC3)c2CN1c1cc(Cl)nc2[nH]ccc12,"(R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-(methylsulfonyl)piperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine",12.5,uM,=,1.0969100130080565,1,c1cc(N2CCn3ncc(C4CCNCC4)c3C2)c2cc[nH]c2n1
1407,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)CC2c2ccc(C3CC3)cc2)cc1,1-[(Methylsulfonyl)amino]-3-[(4-methoxyphenyl)ethyl]-4-(4-cyclopropylphenyl)-2-imidazolidinone,8.4,uM,=,0.9242792860618816,1,O=C1NCC(c2ccc(C3CC3)cc2)N1CCc1ccccc1
1408,463271,10.1016/j.bmcl.2007.11.052,,,,Inhibition of human ERG,CNC(=O)[C@@H](C)Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,(R)-2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)-N-methylpropanamide,32.0,uM,=,1.505149978319906,1,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
1409,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,CCN(CCc1c[nH]c2ccccc12)Cc1ccc(/C=C/C(=O)NO)cc1,(E)-3-(4-(((2-(1H-indol-3-yl)ethyl)(ethyl)amino)methyl)phenyl)-N-hydroxyacrylamide,5.92,uM,=,0.7723217067229198,1,c1ccc(CNCCc2c[nH]c3ccccc23)cc1
1410,2209836,10.1016/j.bmc.2022.116729,,,,Inhibition of human ERG channel,C[C@H](F)Cn1ccc2nc(Nc3cnn(C4CC5(C4)CN(C)C5)c3)nc(NC3(C)CC3)c2c1=O,"(S)-6-(2-fluoropropyl)-2-((1-(2-methyl-2-azaspiro[3.3]heptan-6-yl)-1H-pyrazol-4-yl)amino)-4-((1-methylcyclopropyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one",4.2,uM,=,0.6232492903979004,1,O=c1[nH]ccc2nc(Nc3cnn(C4CC5(CNC5)C4)c3)nc(NC3CC3)c12
1411,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(NCC1(O)CCCCC1)C1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,N-((1-hydroxycyclohexyl)methyl)-1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidine-4-carboxamide,11.7,uM,=,1.0681858617461617,1,O=C(NCC1CCCCC1)C1CCN(Cc2ccn(-c3ccccc3)c2)CC1
1412,454299,10.1016/j.bmcl.2007.01.020,,,,Inhibition of hERG,Fc1ccc(CN(C2CCOCC2)[C@H]2CCNC2)c(F)c1F,"(S)-pyrrolidin-3-yl-(tetrahydro-pyran-4-yl)-(2,3,4-trifluoro-benzyl)-amine",1.2,uM,=,0.0791812460476248,1,c1ccc(CN(C2CCOCC2)[C@H]2CCNC2)cc1
1413,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCc1nc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"5-ethyl-3-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,2,4-oxadiazole",9.6,uM,=,0.9822712330395684,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)nc1
1414,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,COc1cc(C(=O)NCCN2CCCC2)ccc1CN1CCC(NC(=O)c2cc(=O)c3ccc(F)cc3o2)CC1,N-(1-(2-methoxy-4-((2-(pyrrolidin-1-yl)ethyl)carbamoyl)benzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,6.6,uM,=,0.8195439355418687,1,O=C(NCCN1CCCC1)c1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccccc4o3)CC2)cc1
1415,2015639,10.1016/j.bmcl.2020.127393,,,,Inhibition of human ERG,CN(c1cnn(-c2ccnc3[nH]c(-c4cccc5c4ccn5C)nc23)c1)[C@@H]1CCOC[C@@H]1N,"(3R,4R)-N4-methyl-N4-(1-(2-(1-methyl-1H-indol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-4-yl)tetrahydro-2H-pyran-3,4-diamine",9.2,uM,=,0.9637878273455552,1,c1cc(-c2nc3c(-n4cc(NC5CCOCC5)cn4)ccnc3[nH]2)c2cc[nH]c2c1
1416,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2c(C)cc(=O)n(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2c1,"1-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]piperidin-1-yl}ethyl)-7-methoxy-4-methylquinolin-2(1H)-one",23.0,uM,=,1.3617278360175928,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
1417,2118310,10.1021/acs.jmedchem.1c00847,,,,Inhibition of human ERG expressed in HEK293 cells incubated for 5 mins by patch clamp assay,C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO,GIREDESTRANT,6.1,uM,=,0.785329835010767,1,c1ccc2c3c([nH]c2c1)[C@@H](c1ccc(NC2CNC2)cc1)NCC3
1418,2298259,10.1016/j.bmc.2023.117276,,,,Inhibition of hERG expressed in CHO cells by automated patch clamp method,CC1(C)CN(C(=O)[C@H]2CC(=O)N(c3cccc(C#N)c3)C2)c2cc(Cl)c(Cn3ccnc3)cc21,"(S)-3-(4-(5-((1H-imidazol-1-yl)methyl)-6-chloro-3,3-dimethylindoline-1-carbonyl)-2-oxopyrrolidin-1-yl)benzonitrile",2.2,uM,=,0.3424226808222063,1,O=C1C[C@H](C(=O)N2CCc3cc(Cn4ccnc4)ccc32)CN1c1ccccc1
1419,814499,10.1016/j.bmcl.2012.03.050,,,,Inhibition of human ERG,Cc1nc(N2CCC(N3CCCC3=O)CC2)nc2ccc(NC(=O)COc3ccc(OC(F)(F)F)cc3)cc12,N-(4-methyl-2-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)quinazolin-6-yl)-2-(4-(trifluoromethoxy)phenoxy)acetamide,3.7,uM,=,0.568201724066995,1,O=C(COc1ccccc1)Nc1ccc2nc(N3CCC(N4CCCC4=O)CC3)ncc2c1
1420,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2ccccc2C(F)(F)F)CO1,"(4aR,6S,8aS)-6-methyl-8a-(2-(trifluoromethyl)phenyl)-4,4a,5,6,8,8ahexahydropyrano[3,4-d][1,3]thiazin-2-amine",55.4,uM,=,1.7435097647284297,1,C1=N[C@@]2(c3ccccc3)COCC[C@H]2CS1
1421,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CCC(Oc4ccc(CN5CCN(C)CC5)cc4)CC3)o2)cc1,"(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)(4-(4-((4-methylpiperazin-1-yl)methyl)phenoxy)piperidin-1-yl)methanone",15.0,uM,=,1.1760912590556811,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCNCC3)cc2)CC1
1422,938040,10.1016/j.bmcl.2012.11.013,,,,Inhibition of human ERG by patch clamp assay,COc1ccc(Cl)cc1-c1ccnc(Nc2ccc(N3CCOCC3)c(OC)c2)c1,4-(5-chloro-2-methoxyphenyl)-N-(3-methoxy-4-morpholinophenyl)pyridin-2-amine,20.0,uM,=,1.3010299956639813,1,c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)c2)cc1
1423,512417,10.1016/j.bmcl.2008.07.103,,,,Inhibition of human ERG,Cc1c(C(=O)c2ccc(Cl)cc2)c2ccc(OC(F)(F)F)cc2n1Cc1cccc(O[C@H](C)C(=O)O)c1,(R)-2-(3-((3-(4-chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl)methyl)phenoxy)propanoic acid,3.23,uM,=,0.5092025223311029,1,O=C(c1ccccc1)c1cn(Cc2ccccc2)c2ccccc12
1424,1617630,10.1021/acs.jmedchem.6b01217,,,,Inhibition of human ERG,COc1ccc2[nH]c3c(c2c1)CC1c2cc4c(cc2CCN1C3)OCO4,"2,3-Methylenedioxy-12-methoxy-5,8,14,14a-tetrahydro-6H-benzo[a]indolo[2,3-g]quinolizine",16.5,uM,=,1.2174839442139065,1,c1ccc2c3c([nH]c2c1)CN1CCc2cc4c(cc2C1C3)OCO4
1425,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,CCCCCCCc1[nH]c2ccc([N+](=O)[O-])cc2c(=O)c1CO,2-heptyl-3-(hydroxymethyl)-6-nitroquinolin-4(1H)-one,12.87,uM,=,1.1095785469043866,1,O=c1cc[nH]c2ccccc12
1426,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,COCC(=O)N1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1,"4-(8-amino-3-((R)-1-(2-methoxyacetyl)piperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-3-fluoro-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",4.5,uM,=,0.6532125137753437,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@@H]3CCCNC3)n3ccncc23)cc1
1427,2112211,10.1016/j.bmcl.2021.127909,,,,Inhibition of human ERG by automated patch method relative to control,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one",0.167,uM,=,-0.7772835288524167,0,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2
1428,2240601,10.1021/acs.jmedchem.2c01497,,,,Inhibition of human ERG at -90 mV holding potential,C[C@@H](c1cn(-c2ccc(Cl)cc2F)nn1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,"(2R,3S)-3-(1-(4-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol",11.33,uM,=,1.0542299098633974,1,c1ccc(C(Cc2cn(-c3ccccc3)nn2)Cn2cncn2)cc1
1429,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CCc1cn(-c2ccc(F)cc2)c2ccc(Cl)cc12,5-Chloro-3-ethyl-1-(4-fluoro-phenyl)-1H-indole,3.5,uM,=,0.5440680443502757,1,c1ccc(-n2ccc3ccccc32)cc1
1430,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,CC(C)(O)C#Cc1cnc(Nc2cnc(C#N)cn2)cc1NC[C@@H]1CNCCO1,(S)-5-((5-(3-Hydroxy-3-methylbut-1-yn-1-yl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,26.0,uM,=,1.414973347970818,1,c1cnc(Nc2cc(NC[C@@H]3CNCCO3)ccn2)cn1
1431,2163947,10.1021/acs.jmedchem.1c01564,,,,Inhibition of human ERG by [3H]]Astemizole binding assay,c1cnc2c(c1)CN[C@@H](CN(CCCCN1CCOCC1)[C@H]1CCCc3cccnc31)C2,"(S)-N-(4-morpholinobutyl)-N-(((R)-5,6,7,8-tetrahydro-1,6-naphthyridin-7-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",11.0,uM,=,1.0413926851582251,1,c1cnc2c(c1)CN[C@@H](CN(CCCCN1CCOCC1)[C@H]1CCCc3cccnc31)C2
1432,1853420,10.1016/j.ejmech.2019.06.037,,,,Inhibition of human ERG,O=S1(=O)CCCN1CCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,"N-(3-Bromo-4-fluorophenyl)-4-((2-(1,1-dioxidoisothiazolidin-2-yl)ethyl)amino)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide",17.27,uM,=,1.2372923375674587,1,N=C(Nc1ccccc1)c1nonc1NCCN1CCCS1(=O)=O
1433,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(N[C@@H]1CCOC1=O)c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1,"US9452986, 530",30.0,uM,=,1.4771212547196624,1,O=C(N[C@@H]1CCOC1=O)c1ccc2cc(Oc3ccccn3)ccc2n1
1434,1541589,10.1039/C4MD00578C,,,,Inhibition of human ERG,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one",0.778,uM,=,-0.109020403010311,0,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2
1435,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(C)N1CCN(C(=O)N2CCc3ccccc3C2)CC1,"(3,4-dihydroisoquinolin-2(1H)-yl)(4-isopropylpiperazin-1-yl)methanone",115.0,uM,=,2.060697840353612,1,O=C(N1CCNCC1)N1CCc2ccccc2C1
1436,1677359,10.1021/acs.jmedchem.7b01454,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK cells after 180 mins by scintillation counting method,CN(C)CCN1C2CCC1CC(NC(c1ccc(F)cc1)c1ccc(F)cc1)C2,N-(Bis(4-fluorophenyl)methyl)-8-(2-(dimethylamino)ethyl)-8-azabicyclo[3.2.1]octan-3alpha-amine,5.48,uM,=,0.7387805584843692,1,c1ccc(C(NC2CC3CCC(C2)N3)c2ccccc2)cc1
1437,2229210,10.1021/acs.jmedchem.2c00960,,,,Inhibition of hERG,Cc1cccnc1Nc1nc(-c2ccc(OC3CCN(C4CC4)CC3)cn2)ns1,"3-[5-[(1-cyclopropyl-4-piperidinyl)oxy]-2-pyridyl]-N-(3-methyl-2-pyridyl)-1,2,4-thiadiazol-5-amine",3.46,uM,=,0.5390760987927766,1,c1ccc(Nc2nc(-c3ccc(OC4CCN(C5CC5)CC4)cn3)ns2)nc1
1438,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3ncc4cccnc43)[C@H](C)C2)cn1,"1-{(R)-4-[4-(2-Ethoxy-pyrimidin-5-yl)-2-tritluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-2-pyrazolo[3,4-b]pyridin-1-yl-ethanone",15.0,uM,=,1.1760912590556811,1,O=C(Cn1ncc2cccnc21)N1CCN(c2scnc2-c2cncnc2)CC1
1439,1475693,10.1016/j.bmcl.2015.04.002,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,COc1ccc2ncc(C)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-methoxy-3-methyl-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.06,uM,=,0.0253058652647702,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1440,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,COc1cc(F)cc(-c2cncc(-c3nc4cc(F)ccc4[nH]3)c2N2CCC(N)CC2)c1,1-(3-(5-fluoro-1H-benzo[d]imidazol-2-yl)-5-(3-fluoro-5-methoxyphenyl)pyridin-4-yl)piperidin-4-amine,7.5,uM,=,0.8750612633917001,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
1441,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,O[C@H]1C[C@H](CN2CCC(c3ccccc3)CC2)CCc2cccnc21,"(7R,9S)-7-((4-phenylpiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",11.0,uM,=,1.0413926851582251,1,c1ccc(C2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
1442,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,CC(C)(C)c1[nH]c2ccccc2c1C1CCCN(Cc2ccc(/C=C/C(=O)NO)cc2F)C1,(E)-3-{4-[3-(2-tert-Butyl-1H-indol-3-yl)piperidin-1-ylmethyl]-3-fluorophenyl}-N-hydroxyacrylamide,30.0,uM,=,1.4771212547196624,1,c1ccc(CN2CCCC(c3c[nH]c4ccccc34)C2)cc1
1443,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc(C(F)F)cc1)Cc1ccc2c(c1)CCO2.Cl,(E)-N-(Coumaran-5-methyl)-N-methyl-3-(4-difluoromethylphenyl)prop-2-en-1-amine Hydrochloride,1.3,uM,=,0.1139433523068367,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)CCO2
1444,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,C=CCO[C@H]1CC[C@@H](N2CC(NC(=O)CNc3n[nH]c4ccc(C(F)(F)F)cc34)C2)CC1,cis-N-[1-(4-Allyloxy-cyclohexyl)-azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,7.4,uM,=,0.8692317197309762,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
1445,772749,10.1016/j.bmcl.2011.08.038,,,,Displacement of [3H]dofetilide from human ERG transfected in HEK293 cells by fluorescence polarization binding assay,CN1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1,"8-chloro-5-methyl-1-(1-(pyridin-2-yl)piperidin-4-yl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine",17.9,uM,=,1.252853030979893,1,c1ccc(N2CCC(c3nnc4n3-c3ccccc3CNC4)CC2)nc1
1446,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,CCOC(=O)c1c(OC)cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12,"ethyl 3-methoxy-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridine-4-carboxylate",0.00787,uM,=,-2.1040252676409352,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1447,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,N[C@@H]1COC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-((3S,4R)-4-aminotetrahydrofuran-3-yloxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",11.3,uM,=,1.0530784434834195,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(O[C@H]7CCOC7)nc56)(CC3)OC4)nc2N1
1448,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCOC(=O)Nc1cccc([C@@H](c2ccc(C(=O)N3CCC3)cc2)N2CCN(Cc3cccnc3)CC2)c1,(R)-ethyl 3-((4-(azetidine-1-carbonyl)phenyl)(4-(pyridin-3-ylmethyl)piperazin-1-yl)methyl)phenylcarbamate,11.0,uM,=,1.0413926851582251,1,O=C(c1ccc([C@H](c2ccccc2)N2CCN(Cc3cccnc3)CC2)cc1)N1CCC1
1449,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-2-methoxy-piperidin-4-yl}-2-methoxy-benzamide,0.0067,uM,=,-2.1739251972991736,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
1450,1525287,10.1016/j.bmcl.2015.09.045,,,,Inhibition of human ERG expressed in HEK293 cells by whole-cell patch clamp method,Fc1ccc2c(C3CCN(CCCOc4ccc(Cc5nc6ccccc6o5)cc4)CC3)noc2c1,3-(1-(3-(4-(benzo[d]oxazol-2-ylmethyl)phenoxy)propyl)piperidin-4-yl)-6-fluorobenzo[d]isoxazole,5.98,uM,=,0.7767011839884109,1,c1ccc2oc(Cc3ccc(OCCCN4CCC(c5noc6ccccc56)CC4)cc3)nc2c1
1451,1743006,10.1021/acs.jmedchem.8b01183,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp assay,FCC[C@@H]1Cc2ccccc2C2(CCC(N3CCN(C4CCCCC4)CC3)CC2)O1,"trans-1-cyclohexyl-4-[3-(2-fluoroethyl)-3,4-dihydrospiro[[2]benzopyran-1,1'-cyclohexan]-4'-yl]piperazine",2.62,uM,=,0.4183012913197454,1,c1ccc2c(c1)CCOC21CCC(N2CCN(C3CCCCC3)CC2)CC1
1452,464747,10.1016/j.bmcl.2008.01.126,,,,Inhibition of human ERG by FLIPR assay,COc1ccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)cc1,"(2S,3S)-3-(3-(2-(2-(4-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",3.2,uM,=,0.505149978319906,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
1453,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3csc(-c4ccc(OCC(F)(F)F)nc4)n3)ccc2c1,"(R)-4-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-2-(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)thiazole",1.52,uM,=,0.1818435879447725,1,c1cncc(-c2nc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cs2)c1
1454,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",3.56,uM,=,0.5514499979728752,1,O=C1Nc2ccccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
1455,2130695,10.1021/acsmedchemlett.1c00334,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated Qpatch electrophysiological method,CNC(=O)c1cc(-n2ncc3cc(Nc4c(F)cccc4Cl)cnc32)cs1,"4-(5-((2-chloro-6-fluorophenyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-N-methylthiophene-2-carboxamide",9.0,uM,=,0.9542425094393248,1,c1ccc(Nc2cnc3c(cnn3-c3ccsc3)c2)cc1
1456,629417,10.1016/j.bmcl.2010.03.071,,,,Inhibition of human ERG by patch clamp assay,O=C([C@H]1C[C@H](Oc2ccc(F)cc2)CN1)N1CCCN(C2CCC2)CC1,"(4-cyclobutyl-1,4-diazepan-1-yl)((2R,4S)-4-(4-fluorophenoxy)pyrrolidin-2-yl)methanone",7.8,uM,=,0.8920946026904804,1,O=C([C@H]1C[C@H](Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
1457,158543,10.1021/jm0205651,,,,Inhibitory activity against Potassium channel HERG,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-2-methoxy-piperidin-4-yl}-2-methoxy-benzamide,0.047,uM,=,-1.3279021420642825,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
1458,1298306,10.1016/j.ejmech.2014.01.021,,,,Inhibition of human ERG expressed in CHO-ZG cells after 20 mins by FluxOR thallium assay,N#C[C@@H]1C[C@H](F)CN1C(=O)[C@@H](N)Cc1cscn1,"(2S,4S)-1-[(2S)-2-Amino-3-(thiazol-4-yl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile",176.6,uM,=,2.24699069924155,1,O=C(CCc1cscn1)N1CCCC1
1459,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1cc2nc(/C=C/C3CCNC3)n(Cc3ccc(Cl)cc3)c2cc1C,"US8975247, EBP372",1.6,uM,=,0.2041199826559248,1,C(=C/C1CCNC1)\c1nc2ccccc2n1Cc1ccccc1
1460,624932,10.1016/j.bmcl.2010.02.047,,,,Inhibition of human ERG by patch clamp technique,CC(=O)N1CCC(c2[nH]nc(-c3ccc(F)cc3)c2-c2ccncc2)CC1,1-(4-(3-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-pyrazol-5-yl)piperidin-1-yl)ethanone,0.79,uM,=,-0.1023729087095585,0,c1ccc(-c2n[nH]c(C3CCNCC3)c2-c2ccncc2)cc1
1461,390361,10.1016/j.bmcl.2006.05.069,,,,Inhibition of hERG channel by voltage clamp assay,CN1CCN(CCCN(C(=O)Nc2ccc(F)c(C(F)(F)F)c2)[C@@H]2CC[C@]3(c4ccc5c(N)noc5c4)C[C@H]23)CC1,"1-((1S,2R,5S)-5-(3-aminobenzo[d]isoxazol-6-yl)bicyclo[3.1.0]hexan-2-yl)-3-(4-fluoro-3-(trifluoromethyl)phenyl)-1-(3-(4-methylpiperazin-1-yl)propyl)urea",0.69,uM,=,-0.1611509092627447,0,O=C(Nc1ccccc1)N(CCCN1CCNCC1)[C@@H]1CC[C@]2(c3ccc4cnoc4c3)C[C@H]12
1462,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,CN1CCN=C1Cn1ncc2cc(-n3ccc(OCc4ccccc4)cc3=O)ccc21,"4-(benzyloxy)-1-(1-((1-methyl-4,5-dihydro-1H-imidazol-2-yl)methyl)-1H-indazol-5-yl)pyridin-2(1H)-one",3.3,uM,=,0.5185139398778875,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CC2=NCCN2)c1
1463,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(O)CO)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(6-(2,3-dihydroxypropoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.3,uM,=,0.3617278360175928,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1464,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CCN1C[C@H](NS(=O)(=O)C(C)C)[C@@H](c2ccc(-c3ccc(C#N)cc3)cc2)C1,"N-((3R,4R)-4-(4'-cyanobiphenyl-4-yl)-1-ethylpyrrolidin-3-yl)propane-2-sulfonamide",0.4,uM,=,-0.3979400086720376,0,c1ccc(-c2ccc([C@@H]3CCNC3)cc2)cc1
1465,1783529,10.1016/j.ejmech.2017.12.075,,,,Inhibition of human ERG by [3H]dofetilide binding displacement assay,Cc1c(CN2CCOCC2)cc(-c2ccc(C(C)C)cc2)n1C1CCCCC1,4-((1-Cyclohexyl-5-(4-isopropylphenyl)-2-methyl-1H-pyrrol-3-yl)methyl)morpholine,50.0,uM,=,1.6989700043360187,1,c1ccc(-c2cc(CN3CCOCC3)cn2C2CCCCC2)cc1
1466,1464215,10.1016/j.bmcl.2015.02.044,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in tail current at membrane potential of +20 mV,Cl.c1ccc(C2CC3(N4CCCC4)CNCC2C(c2ccccc2)C3)cc1,"(6RS,9RS)-(+/-)-N-(6,9-Diphenyl-3-azabicyclo[3.2.2]nonan-1-yl)pyrrolidine hydrochloride",2.63,uM,=,0.4199557484897578,1,c1ccc(C2CC3(N4CCCC4)CNCC2C(c2ccccc2)C3)cc1
1467,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1nccc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)n1,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-1-(2-methyl-pyrimidin-4-yl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",22.0,uM,=,1.3424226808222062,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
1468,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2cc3c(N[C@@H](C)c4ccn(C)n4)c(C(N)=O)cnc3cc2F)cn1,(S)-7-fluoro-6-(6-(methoxymethyl)pyridin-3-yl)-4-(1-(1-methyl-1H-pyrazol-3-yl)ethylamino)quinoline-3-carboxamide,22.0,uM,=,1.3424226808222062,1,c1cncc(-c2ccc3nccc(NCc4cc[nH]n4)c3c2)c1
1469,2133640,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG by fluorescence polarization assay,CCC(c1nc2cc(Cl)ccc2[nH]1)[C@H]1[C@@H]2C[C@@H](c3ccnc4ccc(F)cc34)C[C@@H]21,"4-((1R,3s,5S,6r)-6-(1-(5-chloro-1H-benzo[d]imidazol-2-yl)propyl)bicyclo[3.1.0]hexan-3-yl)-6-fluoroquinoline",1.0,uM,=,0.0,0,c1ccc2[nH]c(C[C@@H]3[C@H]4C[C@H](c5ccnc6ccccc56)C[C@@H]34)nc2c1
1470,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cncnc3)CC2)C1,cis-N-{[1-(4-Hydroxy-4-pyrimidin-5-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide,43.8,uM,=,1.6414741105040995,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cncnc3)CC2)C1
1471,806244,10.1016/j.bmcl.2012.01.078,,,,Inhibition of human Erg by patch clamp assay,Cc1nc2ccc(Oc3ccc(F)cc3)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,6-(4-fluorophenoxy)-3-{[(3S)-1-isopropylpiperidin-3-yl]methyl}-2-methylquinazolin-4(3H)-one,1.6,uM,=,0.2041199826559248,1,O=c1c2cc(Oc3ccccc3)ccc2ncn1C[C@H]1CCCNC1
1472,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2c1ccc(CCN1CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC1)c2F,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-4-fluoroisobenzofuran-1(3H)-one,31.0,uM,=,1.4913616938342726,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
1473,2163947,10.1021/acs.jmedchem.1c01564,,,,Inhibition of human ERG by [3H]]Astemizole binding assay,NCCCCN(C[C@H]1Cc2ncccc2CN1)[C@H]1CCCc2cccnc21,"N1-(((R)-5,6,7,8-tetrahydro-1,6-naphthyridin-7-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",5.8,uM,=,0.7634279935629373,1,c1cnc2c(c1)CN[C@@H](CN[C@H]1CCCc3cccnc31)C2
1474,674336,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human ERG expressed in HEK cells by patch clamp technique,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3oc(C4CC4)nc13)C2,"endo-2-cyclopropyl-N-((1R,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzo[d]oxazole-4-carboxamide",0.2,uM,=,-0.6989700043360187,0,O=C(N[C@@H]1C[C@H]2CCC[C@@H](C1)N2)c1cccc2oc(C3CC3)nc12
1475,1682731,10.1021/acs.jmedchem.7b01135,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cell membranes,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccc(-n3ccnn3)cc2)n1,"3-(4-(1H-1,2,3-triazol-1-yl)phenylamino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide",13.2,uM,=,1.1205739312058498,1,c1cn(-c2ccc(Nc3ccn([C@@H]4CCCOC4)n3)cc2)nn1
1476,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,CN(C)c1ccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,cis-N-({1-[4-(6-Dimethylamino-pyridin-3-yl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,22.5,uM,=,1.3521825181113625,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccnc3)CC2)C1
1477,1930034,10.1016/j.bmc.2017.07.058,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by patch clamp method,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",0.53,uM,=,-0.2757241303992109,0,c1ccc(CCCCNCCc2ccccc2)cc1
1478,49075,10.1021/jm0208875,,,,K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.1,CN1CCN(CCCCN2C(=O)CN(/N=C/c3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,"1-{[1-[5-(4-Chloro-phenyl)-furan-2-yl]-meth-(E)-ylidene]-amino}-3-[3-(4-methyl-piperazin-1-yl)-propyl]-imidazolidine-2,4-dione",0.56,uM,=,-0.2518119729937995,0,O=C1CN(/N=C/c2ccc(-c3ccccc3)o2)C(=O)N1CCCCN1CCNCC1
1479,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CC(Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ccc(C(F)(F)F)cc2F)CC1)C(F)(F)F,"rac-[4-(2-Fluoro-4-trifluoromethyl-phenyl)-piperazin-1-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone",6.9,uM,=,0.8388490907372553,1,O=C(c1ccccc1)N1CCN(c2ccccc2)CC1
1480,1578296,10.1016/j.bmcl.2016.04.020,,,,Inhibition of human ERG,Cc1cc2ncc3c(n2n1)CN([C@H]1CO[C@H](c2cc(F)c(F)cc2F)[C@@H](N)C1)C3,"(2R,3S,5R)-5-(2-methyl-6H-pyrazolo[1,5-a]pyrrolo[3,4-e]pyrimidin-7(8H)-yl)-2-(2,4,5-trifluorophenyl)tetrahydro-2H-pyran-3-amine",6.4,uM,=,0.8061799739838872,1,c1ccc([C@@H]2CC[C@@H](N3Cc4cnc5ccnn5c4C3)CO2)cc1
1481,1926457,10.1016/j.bmc.2016.08.007,,,,Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assay,Cc1nc2cc(Nc3cc(NC4CCN(c5ccc(C#N)cn5)CC4)c(C(N)=O)cn3)ccc2o1,"4-{[1-(5-Cyanopyridin-2-yl)piperidin-4-yl]amino}-6-[(2-methyl-1,3-benzoxazol-5-yl)amino]nicotinamide",6.6,uM,=,0.8195439355418687,1,c1ccc(N2CCC(Nc3ccnc(Nc4ccc5ocnc5c4)c3)CC2)nc1
1482,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(N3CC=CC3)n2)(c2ccc(F)cc2)CC1,"2-(2,5-dihydro-1H-pyrrol-1-yl)-6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine",8.7,uM,=,0.9395192526186184,1,C1=CCN(c2cccc(COCC3(c4ccccc4)CCNCC3)n2)C1
1483,1986395,10.1016/j.bmcl.2020.127027,,,,Inhibition of human ERG,O=c1n(CCCCN2CCN(c3cccc4sccc34)CC2)nc2ccccn12,"2-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one",3.01,uM,=,0.4785664955938433,1,O=c1n(CCCCN2CCN(c3cccc4sccc34)CC2)nc2ccccn12
1484,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(C3CCCCC3)cc1)C(=O)N2c1cc(O)ncn1,"3-(4-Cyclohexyl-phenyl)-1-(6-hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",1.0,uM,=,0.0,0,O=C1N(c2ccc(C3CCCCC3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
1485,749792,10.1016/j.bmcl.2009.04.093,,,,Inhibition of human ERG by cell based by patch clamp assay,CN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1,"N4-((1R,2R)-2-(dimethylamino)cyclopentyl)-N2-(4-(N,S-dimethylsulfonimidoyl)phenyl)-5-(trifluoromethyl)pyrimidine-2,4-diamine",20.3,uM,=,1.307496037913213,1,c1ccc(Nc2nccc(NC3CCCC3)n2)cc1
1486,541583,10.1021/jm801236n,,,,Inhibition of wild-type human ERG expressed in HEK293 cells by whole cell patch clamp method,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-2-methoxy-piperidin-4-yl}-2-methoxy-benzamide,0.01,uM,=,-2.0,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
1487,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,c1ccc2c3c([nH]c2c1)[C@@H](C1CCOCC1)N[C@@H](c1nc(-c2csc4ccccc24)c[nH]1)C3,"(1R,3R)-3-(4-(benzo[b]thiophen-3-yl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.087,uM,=,-1.0604807473813815,0,c1ccc2c3c([nH]c2c1)[C@@H](C1CCOCC1)N[C@@H](c1nc(-c2csc4ccccc24)c[nH]1)C3
1488,793275,10.1016/j.bmcl.2011.09.117,,,,Displacement of [3H]dofetilide from human ERG by liquid scintillation counting,COc1ccc2nccc([C@@H](O)CN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"(R)-2-(4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)-1-(6-methoxy-1,5-naphthyridin-4-yl)ethanol",25.1,uM,=,1.3996737214810382,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
1489,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=C1CSc2ccc(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"(R)-6-((1-((3-fluoro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one",25.7,uM,=,1.4099331233312946,1,O=C1CSc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
1490,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,Cc1ncnn1CC(=O)N1CCN(c2sc(C(F)(F)F)nc2-c2cnc(C(F)(F)F)nc2)C[C@H]1C,"2-(5-Methyl-[1,2,4]triazol-1-y1)-1-((R)-2-methyl-4-(2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl)-piperazin-1-yl)-ethanone",0.016,uM,=,-1.7958800173440752,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
1491,1700906,10.1021/acs.jmedchem.7b00032,,,,Inhibition of human ERG by automated patch clamp assay,CCc1nc2ccc(C3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)c(C#N)s1,"2-[[2-Ethyl-6-[1-[2-(3-hydroxyazetidin-1-yl)-2-oxo-ethyl]-4-piperidyl]imidazo[1,2-a]pyridin-3-yl]-methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile",2.9,uM,=,0.4623979978989561,1,O=C(CN1CCC(c2ccc3ncc(Nc4nc(-c5ccccc5)cs4)n3c2)CC1)N1CCC1
1492,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(C(=O)[C@H]2CN(C3CC3)CCN2)CC1,"(R)-4-(4-cyclopropylpiperazine-2-carbonyl)-N-(3,4-dichlorophenyl)piperazine-1-carboxamide",19.0,uM,=,1.2787536009528289,1,O=C(Nc1ccccc1)N1CCN(C(=O)[C@H]2CN(C3CC3)CCN2)CC1
1493,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,Fc1ccc(-n2cc(C3CCNCC3)c3cc(Cl)ccc32)cc1,5-Chloro-1-(4-fluoro-phenyl)-3-piperidin-4-yl-1H-indole,0.204,uM,=,-0.6903698325741012,0,c1ccc(-n2cc(C3CCNCC3)c3ccccc32)cc1
1494,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,COc1ccccc1-c1cc2c(N[C@@H]3CC[C@](C)(N)C3(C)C)c(C(N)=O)cnn2c1,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(2-methoxyphenyl)pyrrolo[1,2-b]pyridazine-3-carboxamide",7.5,uM,=,0.8750612633917001,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
1495,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC(C)Oc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(6-isopropoxypyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide",5.3,uM,=,0.724275869600789,1,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1
1496,2049320,10.1021/acs.jmedchem.0c01179,,,,Inhibition of tracer red binding to human ERG expressed in HEK293 cell membranes measured after 2 to 6 hrs by fluorescence polarization assay,CC(C)C[C@H]1CN(C2CCN(c3nc(N)n[nH]3)CC2)[C@@H](Cc2ccc(Cl)cc2)CO1,"5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-isobutylmorpholino)-piperidin-1-yl)-4H-1,2,4-triazol-3-amine",8.5,uM,=,0.9294189257142929,1,c1ccc(C[C@H]2COCCN2C2CCN(c3ncn[nH]3)CC2)cc1
1497,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-methoxy-4-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridine-3-carbonitrile",0.37,uM,=,-0.431798275933005,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1498,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1,"US9145392, 37",1.9,uM,=,0.2787536009528289,1,c1ccc(-c2c[nH]c(C3CCN(c4ccncn4)CC3)n2)cc1
1499,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,COc1cccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)n1,"(1R,3R)-3-(4-(6-methoxypyridin-2-yl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",1.025,uM,=,0.010723865391773,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)nc1
1500,686871,10.1016/j.bmcl.2010.10.031,,,,Binding affinity to human ERG expressed in HEK cells by radioligand displacement assay,CC(C)[C@@H](Nc1nc2cc[nH]c(=O)c2c2cc(F)ccc12)C(F)(F)F,"(R)-9-fluoro-6-(1,1,1-trifluoro-3-methylbutan-2-ylamino)benzo[c][1,6]naphthyridin-1(2H)-one",3.5,uM,=,0.5440680443502757,1,O=c1[nH]ccc2ncc3ccccc3c12
1501,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1CCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21,"5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-2,3-dihydro-1H-inden-1-one",6.5,uM,=,0.8129133566428556,1,O=C1CCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
1502,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(NC1CCOC1)c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1,"US9452986, 149",8.8,uM,=,0.9444826721501688,1,O=C(NC1CCOC1)c1ccc2cc(Oc3ccccn3)ccc2n1
1503,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1cc(C(=O)N2CCC(CNC(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc(OC)c1OC,"6,6-bis(4-fluorophenyl)-N-((1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl)methyl)hexanamide",0.75,uM,=,-0.1249387366082999,0,O=C(CCCCC(c1ccccc1)c1ccccc1)NCC1CCN(C(=O)c2ccccc2)C1
1504,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(Cl)n2)(c2ccc(Cl)cc2)CC1,2-chloro-6-(((4-(4-chlorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,23.0,uM,=,1.3617278360175928,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
1505,582986,10.1021/jm900933k,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp technique,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1,Dimethyl-{2-[3-(1-pyridin-2-yl-ethyl)-1H-inden-2-yl]-ethyl}-amine,0.9,uM,=,-0.0457574905606751,0,C1=C(Cc2ccccn2)c2ccccc2C1
1506,1850954,10.1021/acs.jmedchem.9b00322,,,,Inhibition of human ERG by electrophysiology method,CCn1cnc2c(-c3ccc(F)c(-c4ccc(S(=O)(=O)CC)cc4OC)c3)cnnc21,"US8952008, 4",26.8,uM,=,1.428134794028789,1,c1ccc(-c2cccc(-c3cnnc4[nH]cnc34)c2)cc1
1507,2229351,10.1021/acsmedchemlett.2c00172,,,,Inhibition of hERG expressed in CHO cells by electrophysiological assay based automated patch clamp method,Cc1cc2ncccc2cc1Nc1ncc2c(n1)n([C@H]1CCN(C)C1)c(=O)n2C,(S)-7-methyl-9-(1-methylpyrrolidin-3-yl)-2-(7-methylquinolin-6-ylamino)-7H-purin-8(9H)-one,16.0,uM,=,1.2041199826559248,1,O=c1[nH]c2cnc(Nc3ccc4ncccc4c3)nc2n1[C@H]1CCNC1
1508,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,CCOC(=O)C1(C)Oc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)nc2NC1=O,"(+)-ethyl 6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2-methyl-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-2-carboxylate",3.6,uM,=,0.5563025007672873,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1509,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,COC(=O)N(C)c1c(N)nc(-c2nc(Cc3ccccc3F)n3ccccc23)nc1N,"methyl N-[4,6-diamino-2-[3-[(2-fluorophenyl)methyl]imidazo[1,5-a]pyridin-1-yl]pyrimidin-5-yl]-N-methyl-carbamate",0.4,uM,=,-0.3979400086720376,0,c1ccc(Cc2nc(-c3ncccn3)c3ccccn23)cc1
1510,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@H]1Sc2ccccc2O[C@@H]1c1ccc(OCCCN2CCCC2)cc1,"trans-1-(3-(4-(3-methyl-2,3-dihydrobenzo[b][1,4]oxathiin-2-yl)phenoxy)propyl)pyrrolidine",0.025,uM,=,-1.6020599913279625,0,c1ccc2c(c1)O[C@H](c1ccc(OCCCN3CCCC3)cc1)CS2
1511,2241386,10.1016/j.ejmech.2021.113981,,,,Inhibition of hERG channel expressed in CHO cells at holding potential of -80 mV by whole cell patch clamp method,O[C@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@@H]1CCCCN1,"(R)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((S)-piperidin-2-yl)methanol",13.6,uM,=,1.1335389083702174,1,c1ccc2c(C[C@@H]3CCCCN3)ccnc2c1
1512,1517213,10.1021/acs.jmedchem.5b01156,,,,Inhibition of human ERG expressed in CHO cells by patch clamp electrophysiology assay,Nc1nc(NC2CCOCC2)c2sc(-c3ccc(C(F)(F)F)cc3)cc2n1,"N4-(tetrahydro-2H-pyran-4-yl)-6-(4-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine",0.7,uM,=,-0.1549019599857432,0,c1ccc(-c2cc3ncnc(NC4CCOCC4)c3s2)cc1
1513,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,CCOc1cc(F)ccc1-c1cnc2sc(N3CCC(O)(CN)CC3)nn12,"4-(aminomethyl)-1-(5-(2-ethoxy-4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-ol",21.5,uM,=,1.3324384599156054,1,c1ccc(-c2cnc3sc(N4CCCCC4)nn23)cc1
1514,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,O=C(NC1CCOC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,"5-(2,3-Difluorophenyl)-N-(tetrahydrofuran-3-yl)-1H-indazole-3-carboxamide",13.3,uM,=,1.1238516409670858,1,O=C(NC1CCOC1)c1n[nH]c2ccc(-c3ccccc3)cc12
1515,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COc1cc(OC)cc(C(=O)NCC2(C(=O)O)CCN(Cc3ccc(C(F)(F)F)cc3)CC2)c1.Cl,"4-((3,5-dimethoxybenzamido)methyl)-1-(4-(trifluoromethyl)benzyl)piperidine-4-carboxylic acid hydrochloride",12.08,uM,=,1.082066934285113,1,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
1516,1541589,10.1039/C4MD00578C,,,,Inhibition of human ERG,O=[N+]([O-])c1ccc(S(=O)(=O)N2CCC(CN3CCC(c4noc5cc(F)ccc45)CC3)CC2)cc1,6-Fluoro-3-(1-((1-((4-nitrophenyl)sulfonyl)piperidin-4-yl)methyl)piperidin-4-yl)benzo[d]isoxazole,3.8102,uM,=,0.5809477726878763,1,O=S(=O)(c1ccccc1)N1CCC(CN2CCC(c3noc4ccccc34)CC2)CC1
1517,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1cc2nc(CC3CCCC3)n(Cc3ccc(Cl)cc3)c2cc1C,"US8975247, EBP271",1.3,uM,=,0.1139433523068367,1,c1ccc(Cn2c(CC3CCCC3)nc3ccccc32)cc1
1518,856089,10.1016/j.bmc.2012.08.050,,,,Inhibition of human ERG expressed in HEK293 cells by voltage-clamp method,CCN(CC)CCOc1cc(-c2nc(SCC(=O)NC)nc3[nH]cc(C#N)c23)c(Cl)cc1Cl,"2-{5-Cyano-4-[2,4-dichloro-5-(2-diethylamino-ethoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-2-ylsulfanyl}-N-methylacetamide",17.8,uM,=,1.250420002308894,1,c1ccc(-c2ncnc3[nH]ccc23)cc1
1519,1926979,10.1021/acsmedchemlett.6b00119,,,,Displacement of [3H]dofetilide from recombinant human ERG transfected in HEK293 cell membranes after 60 mins by scintillation counting,COc1ccc(-c2ccc3ncnc(N4CCC[C@H](C(=O)N5CCN(C)CC5)C4)c3c2)cn1,(S)-(1-(6-(6-methoxypyridin-3-yl)quinazolin-4-yl)piperidin-3-yl)(4-methylpiperazin-1-yl)methanone,1.5,uM,=,0.1760912590556812,1,O=C([C@H]1CCCN(c2ncnc3ccc(-c4cccnc4)cc23)C1)N1CCNCC1
1520,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-4-yl)acetic Acid,2.9,uM,=,0.4623979978989561,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCCO5)CC4)nc3)nc2c1
1521,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1,"(S)-2,3-dichloro-N-isobutyl-N-(pyrrolidin-3-yl)benzamide",20.0,uM,=,1.3010299956639813,1,O=C(N[C@H]1CCNC1)c1ccccc1
1522,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,C=CCOC[C@H]1CC[C@@H](N2CC(NC(=O)CNc3nn(C)c4ccc(C(F)(F)F)cc34)C2)CC1,cis-N-[1-(4-Allyloxymethyl-cyclohexyl)-azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,5.0,uM,=,0.6989700043360189,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
1523,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2cccnc2)n1C,"N-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propyl)-1,2-dimethyl-5-(pyridin-3-yl)-1H-pyrrole-3-carboxamide",6.8,uM,=,0.8325089127062363,1,O=C(NCCCN1CCN(c2ccccc2)CC1)c1c[nH]c(-c2cccnc2)c1
1524,958294,10.1016/j.bmcl.2013.03.047,,,,Inhibition of human ERG channel in HEK293 cells by voltage-gated patch clamp technique,COc1ccc2nccc([C@@H](O)CC[C@@H]3CCN(C4CC(c5cccc(F)c5)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-1-(3-(3-fluorophenyl)cyclobutyl)-4-((S)-3-hydroxy-3-(6-methoxyquinolin-4-yl)propyl)piperidine-3-carboxylic acid",10.3,uM,=,1.0128372247051722,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
1525,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,N#Cc1ccc2ccc(=O)n(CCN3CC[C@H](NCc4cc5c(cn4)OCCO5)[C@@H](F)C3)c2c1,"trans-1-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]-3-fluoropiperidin-1-yl}ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",122.0,uM,=,2.0863598306747484,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
1526,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,Nc1nccn2c([C@H]3CN(C4CCOCC4)CCO3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12,"4-(8-amino-3-((R)-4-(tetrahydro-2H-pyran-4-yl)morpholin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-3-fluoro-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",4.6,uM,=,0.6627578316815741,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@H]3CN(C4CCOCC4)CCO3)n3ccncc23)cc1
1527,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOC[C@H]2CO)NC(c2nccs2)=N[C@H]1c1ccc(F)cc1Br,"(R)-Ethyl 4-(2-Bromo-4-fluorophenyl)-6-(((R)-3-(hydroxymethyl)morpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",24.2,uM,=,1.383815365980431,1,C1=C(CN2CCOCC2)NC(c2nccs2)=N[C@H]1c1ccccc1
1528,2022324,10.1021/acs.jmedchem.0c01163,,,,Inhibition of human ERG by plate-based planar patch clamp technique,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(N[C@H]3CCN(CCCF)C3)cn2)N1CC(F)(F)F,"N-((S)-1-(3-Fluoropropyl)pyrrolidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine",13.0,uM,=,1.1139433523068367,1,c1cc([C@H]2NCCc3c2ccc2[nH]ncc32)ncc1N[C@H]1CCNC1
1529,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,"5,5-Diphenyl-imidazolidine-2,4-dione",240.0,uM,=,2.380211241711606,1,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
1530,1972831,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,Cc1ccc(C(=O)Nc2ccc(CN3Cc4cn[nH]c4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12,"N-[3-chloro-4-(4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-ylmethyl)phenyl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",12.1,uM,=,1.08278537031645,1,O=C(Nc1ccc(CN2Cc3cn[nH]c3C2)cc1)c1cccc(C#Cc2cnc3cccnn23)c1
1531,969290,10.1016/j.bmcl.2013.05.068,,,,Inhibition of human ERG transfected in CHO cells by patch clamp assay,Cc1cc(N2CC[C@@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C,"5-fluoro-2-methyl-N-(2-methyl-4-((2S,3'R)-2-methyl-1,3'-bipyrrolidin-1'-yl)phenyl)benzamide",1.8,uM,=,0.255272505103306,1,O=C(Nc1ccc(N2CC[C@@H](N3CCCC3)C2)cc1)c1ccccc1
1532,1478731,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,c1ccc(C2(c3ccccc3)CC2C2=NCCN2)cc1,"2-(2,2-Diphenyl-cyclopropyl)-4,5-dihydro-1H-imidazole",22.6,uM,=,1.354108439147401,1,c1ccc(C2(c3ccccc3)CC2C2=NCCN2)cc1
1533,340115,10.1016/j.bmcl.2005.11.083,,,,Inhibition of hERG potassium channel expressed in CHO cells by whole cell patch clamp method,Cc1ccc2c(n1)N1[C@@H](CNC[C@H]1C)C2,"(4R,9aR)-4,6-dimethyl-1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene",21.0,uM,=,1.3222192947339193,1,c1cnc2c(c1)C[C@@H]1CNCCN21
1534,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,C[C@@H]1CCCN1CCN1CCc2cc(-c3ccc(C#N)cc3)ccc2C1=O,"4-(2-{2-[(2R)-2-Methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzonitrile",0.14,uM,=,-0.8538719643217619,0,O=C1c2ccc(-c3ccccc3)cc2CCN1CCN1CCCC1
1535,1979587,10.1021/acs.jmedchem.0c00369,,,,Inhibition of recombinant human ERG stably expressed in HEK293 cells at -80 mV by whole cell voltage clamp method,CS(=O)(=O)c1ccc(-c2cc(N3CCOCC3)nc3c(-c4ccn[nH]4)nccc23)cc1,"4-[4-(Methylsulfonyl)phenyl]-2-(morpholin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine",5.8,uM,=,0.7634279935629373,1,c1ccc(-c2cc(N3CCOCC3)nc3c(-c4ccn[nH]4)nccc23)cc1
1536,812486,10.1016/j.bmcl.2012.02.010,,,,Inhibition of human ERG,N[C@H]1CN(c2ccc(-n3ccc(OCc4ccccc4)cc3=O)cn2)C[C@@H]1c1cc(F)c(F)cc1F,"1-(6-((3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl)pyridin-3-yl)-4-(benzyloxy)pyridin-2(1H)-one",6.1,uM,=,0.785329835010767,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc(N2CC[C@@H](c3ccccc3)C2)nc1
1537,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C,"N-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)-2-methyl-5-phenyl-1-propyl-1H-pyrrole-3-carboxamide",0.54,uM,=,-0.2676062401770315,0,O=C(NCCCN1CCN(c2ccccc2)CC1)c1c[nH]c(-c2ccccc2)c1
1538,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",CN1CCCC1COc1ccc(-n2ccc(OCc3ccccc3)cc2=O)cc1,4-(Benzyloxy)-1-{4-[(1-methylpyrrolidin-2-yl)methoxy]-phenyl}pyridin-2(1H)-one,0.0093,uM,=,-2.0315170514460648,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCC2CCCN2)cc1
1539,2229351,10.1021/acsmedchemlett.2c00172,,,,Inhibition of hERG expressed in CHO cells by electrophysiological assay based automated patch clamp method,Cc1cc2ncccc2cc1Nc1ncc2c(n1)n([C@@H]1CN(C)C[C@@H]1F)c(=O)n2C,"9-((3R,4S)-4-fluoro-1-methylpyrrolidin-3-yl)-7-methyl-2-(7-methylquinolin-6-ylamino)-7H-purin-8(9H)-one",24.0,uM,=,1.380211241711606,1,O=c1[nH]c2cnc(Nc3ccc4ncccc4c3)nc2n1[C@H]1CCNC1
1540,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(C)N1CCN(C(=O)N2CCC(c3ccccc3)CC2)CC1,(4-isopropylpiperazin-1-yl)(4-phenylpiperidin-1-yl)methanone,52.5,uM,=,1.7201593034059568,1,O=C(N1CCNCC1)N1CCC(c2ccccc2)CC1
1541,1927239,10.1016/j.bmc.2016.06.006,,,,Inhibition of human ERG expressed in CHO-K1 cells by whole cell patch clamp method,CC(C)Cc1cc(CNC(=O)C2C3CN(CCC(C)(C)C)CC32)nn1-c1ccccc1,"3-[3-(3,3-Dimethylbutyl)-3-azabicyclo[3.1.0]hexane-6-carboxamido]methyl-5-isobutyl-1-phenyl-1H-pyrazole",2.6,uM,=,0.414973347970818,1,O=C(NCc1ccn(-c2ccccc2)n1)C1C2CNCC21
1542,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2ccc3nc(-n4cccn4)ccc3c2)[nH]1,(S)-N-((S)-1-(5-(2-(1H-pyrazol-1-yl)quinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,1.2,uM,=,0.0791812460476248,1,O=C(NCc1ncc(-c2ccc3nc(-n4cccn4)ccc3c2)[nH]1)[C@H]1CC12CCNCC2
1543,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(Cc1ccco1)C2=O,"2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-6-(furan-2-ylmethyl)-7,8-dihydro-1,6-naphthyridin-5(6H)-one",3.5,uM,=,0.5440680443502757,1,O=C1c2ccc(OCc3conc3-c3ccccc3)nc2CCN1Cc1ccco1
1544,621608,10.1016/j.bmcl.2009.09.024,,,,Inhibition of human ERG expressed in CHO cells by patch clamp technique,CCOc1cc(CN2CCC(Nc3nc4cc(S(N)(=O)=O)ccc4o3)CC2)ccc1OC,2-(1-(3-ethoxy-4-methoxybenzyl)piperidin-4-ylamino)benzo[d]oxazole-5-sulfonamide,3.5,uM,=,0.5440680443502757,1,c1ccc(CN2CCC(Nc3nc4ccccc4o3)CC2)cc1
1545,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1ccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)nc1,"endo-6-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)nicotinamide",1.3,uM,=,0.1139433523068367,1,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccn2)C3)cc1
1546,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Cc1nc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccccc4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"5-methyl-3-((1R,3R)-1-(1-methyl-1H-pyrazol-4-yl)-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,2,4-oxadiazole",1.817,uM,=,0.2593549273080343,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)cc1
1547,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(CC(N)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(+)-6-((1-(1-amino-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",14.6,uM,=,1.1643528557844371,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1548,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,CC(C)(c1ccccc1)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,endo-3-(8-(2-phenylpropan-2-yl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0047,uM,=,-2.3279021420642825,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
1549,1897548,10.1021/acsmedchemlett.9b00134,,,,Inhibition of human ERG,Cc1cc(-c2ccnc3[nH]nc(C(F)(F)F)c23)cc(C2(CN)CCC2)c1,"(1-(3-Methyl-5-(3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)cyclobutyl)methanamine",0.7,uM,=,-0.1549019599857432,0,c1cc(-c2ccnc3[nH]ncc23)cc(C2CCC2)c1
1550,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,C[C@H]1COc2c(N3CC[C@@H](C4(N)CC4)C3)ccc3cc(C(=O)O)c(=O)n1c23,"(S)-10-((R)-3-(1-aminocyclopropyl)pyrrolidin-1-yl)-3-methyl-5-oxo-3,5-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid",90.0,uM,=,1.954242509439325,1,O=c1ccc2ccc(N3CC[C@@H](C4CC4)C3)c3c2n1CCO3
1551,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(-c2nc(-c3ccc4cc(CCN5CCC[C@H]5C)ccc4n3)cs2)cs1,"(R)-2'-methyl-4-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-2,4'-bithiazole",12.4,uM,=,1.0934216851622351,1,c1nc(-c2nc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cs2)cs1
1552,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CCc1nc(C)nn1CC(=O)N1CCN(c2sc(C(F)(F)F)nc2-c2cnc(C(F)(F)F)nc2)C[C@H]1C,"(R)-2-(5-Ethyl-3-methyl-1H-1,2,4-triazol-1-yl)-1-(2-methyl-4-(2-(trifluoromethyl)-4-(2-(trifluoromethyl)pyrimidin-5-yl)thiazol-5-yl)piperazin-1-yl)ethan-1-one",0.012,uM,=,-1.9208187539523751,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
1553,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,1-(2-{4-[5-Chloro-1-(4-fluoro-phenyl)-1H-indol-3-yl]-piperidin-1-yl}-ethyl)-imidazolidin-2-one,0.0147,uM,=,-1.832682665251824,0,O=C1NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccccc23)CC1
1554,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3nncc(C(F)(F)F)n3)CC2)(C(C)C)C1,"cis-((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxytetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)-1,2,4-triazin-3-yl)piperazin-1-yl)methanone",8.9,uM,=,0.9493900066449128,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2nccnn2)CC1
1555,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(C)ccc21,"(R)-2-(3-(1-(3-methoxypyrazin-2-yl)ethyl)-6-methyl-1H-inden-2-yl)-N,N-dimethylethanamine",3.8,uM,=,0.5797835966168101,1,C1=C(Cc2cnccn2)c2ccccc2C1
1556,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Cl)cc1Oc1ccc(Cl)cc1,1-(4-chloro-2-(4-chlorophenoxy)phenyl)-N-methylmethanamine,0.645,uM,=,-0.1904402853647322,0,c1ccc(Oc2ccccc2)cc1
1557,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2ccc(-c3ccncc3)cc2)[nH]1,(S)-6-methyl-N-((S)-7-oxo-1-(5-(4-(pyridin-4-yl)phenyl)-1H-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide,6.0,uM,=,0.7781512503836436,1,O=C(NCc1ncc(-c2ccc(-c3ccncc3)cc2)[nH]1)[C@H]1CC12CCNCC2
1558,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@@H]1COC[C@@H]1c1ccc(-c2ccc(F)nc2)cc1,"N-((3S,4S)-4-(4-(6-fluoropyridin-3-yl)phenyl)tetrahydrofuran-3-yl)propane-2-sulfonamide",12.6,uM,=,1.100370545117563,1,c1cncc(-c2ccc([C@@H]3CCOC3)cc2)c1
1559,787991,10.1021/jm2005546,,,,Inhibition of human cloned ERG channel expressed in chinese hamster CHO cells after 5 mins by patch clamp assay,Cc1ccc(N2CCN(CC(O)COc3ccccc3C(=O)CCc3ccccc3)CC2)cc1.Cl,rac-1-(2-(2-hydroxy-3-(4-p-tolylpiperazin-1-yl)propoxy)phenyl)-3-phenylpropan-1-one hydrochloride,4.31,uM,=,0.6344772701607315,1,O=C(CCc1ccccc1)c1ccccc1OCCCN1CCN(c2ccccc2)CC1
1560,1924512,10.1021/acsmedchemlett.6b00122,,,,Displacement of [35S]MK-499 from human ERG,Cc1c(C(C)CN2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC2)ccc2c1COC2=O,5-(1-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)propan-2-yl)-4-methylisobenzofuran-1(3H)-one,60.0,uM,=,1.7781512503836436,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
1561,2159402,10.1021/acs.jmedchem.1c01968,,,,Inhibition of human ERG by voltage clamp assay,FC1CN(C2CCOC2)CCC1c1cc2nc(Nc3cnn(C4CC4(F)F)c3Cl)ncc2cc1Cl,"6-chloro-N-(5-chloro-1-(2,2-difluorocyclopropyl)-1H-pyrazol-4-yl)-7-(3-fluoro-1-(tetrahydrofuran-3-yl)piperidin-4-yl)quinazolin-2-amine",35.0,uM,=,1.5440680443502757,1,c1nn(C2CC2)cc1Nc1ncc2ccc(C3CCN(C4CCOC4)CC3)cc2n1
1562,1868814,10.1021/acs.jmedchem.8b01218,,,,Inhibition of human ERG by patch clamp assay,COc1ccccc1-c1n[nH]c2nc(N[C@H]3CC[C@H](NS(=O)(=O)CCC(F)(F)F)CC3)nc(OC)c12,"3,3,3-Trifluoro-N-(trans-4-((4-methoxy-3-(2-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide",17.5,uM,=,1.2430380486862944,1,c1ccc(-c2n[nH]c3nc(NC4CCCCC4)ncc23)cc1
1563,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,NC(=O)Nc1ccccc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2,"(S)-1-(2-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)phenyl)urea",0.4,uM,=,-0.3979400086720376,0,c1ccc(OCCCN2CCC3(CC2)Cc2ccccc2O3)cc1
1564,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3ccccc3n(C)c2=O)[nH]1,"(S)-6-methyl-N-((S)-1-(5-(1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C(NCc1ncc(-c2cc3ccccc3[nH]c2=O)[nH]1)[C@H]1CC12CCNCC2
1565,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,CC(C)(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1,"(S)-2,3-dichloro-N-neopentyl-N-(pyrrolidin-3-yl)benzamide",16.8,uM,=,1.2253092817258628,1,O=C(N[C@H]1CCNC1)c1ccccc1
1566,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1,(S)-N-(4-chloro-3-(trifluoromethyl)phenyl)-4-((1-cyclopropylpiperidin-3-yl)methyl)piperazine-1-carboxamide,6.3,uM,=,0.7993405494535817,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
1567,465697,10.1021/jm701187w,,,,Inhibition of human ERG potassium current expressed in HEK293 cells by patch-clamp technique,Cc1cc(C)n(-c2cc(NC(=O)CN3CC[C@H](CN(C)C)C3)nc(-c3ccc(C)o3)n2)n1,"2-((R)-3-dimethylaminomethylpyrrolidin-1-yl)-N-[6-(3,5-di methylpyrazol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl]acetamide",1.86,uM,=,0.2695129442179163,1,O=C(CN1CCCC1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
1568,2021863,10.1016/j.bmcl.2020.127433,,,,Inhibition of human ERG by plate-based planar patch clamp method,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(CN(C)C)c(F)n4)n3)cc12,"5-(4-(4-((dimethylamino)methyl)-3-fluoro-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-N,1-dimethyl-1H-indazole-3-carboxamide",11.0,uM,=,1.0413926851582251,1,c1cnn(-c2ccnc(Nc3ccc4[nH]ncc4c3)n2)c1
1569,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,Cc1ncc(-c2nc(Nc3ccc(C(=O)N(C)C)c(F)c3)ncc2F)n1C(C)C,"2-fluoro-4-(5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)-N,N-dimethylbenzamide",6.0,uM,=,0.7781512503836436,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
1570,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1cc2nc(/C=C/c3ccccc3)n(Cc3ccc(Cl)cc3)c2cc1C,"US8975247, EBP101",4.0,uM,=,0.6020599913279624,1,C(=C/c1nc2ccccc2n1Cc1ccccc1)\c1ccccc1
1571,1352646,10.1021/jm4016284,,,,Inhibition of human ERG expressed in CHO cells by whole-cell patch clamp assay,C[C@@H](n1cnc2cc(Cl)ccc2c1=O)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,"7-Chloro-3-[(1R,2R)-2-(2,4-difluoro-phenyl)-2-hydroxy-1-methyl-3-[1,2,4]triazol-1-yl-propyl]-3H-quinazolin-4-one",34.86,uM,=,1.5423273827739743,1,O=c1c2ccccc2ncn1CC(Cn1cncn1)c1ccccc1
1572,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,COc1cc(CC(=O)N2CCN(CCc3ccc4c(c3)COC4=O)CC2)ccc1-n1cnnn1,5-(2-(4-(2-(3-methoxy-4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,8.2,uM,=,0.9138138523837168,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
1573,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,CCC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)c(Cl)c1,"N-(2-(3'-chloro-4'-((3S,4S)-4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidin-3-yl)biphenyl-2-yl)ethyl)propionamide",2.8,uM,=,0.4471580313422192,1,O=c1cc([C@H]2CCNC[C@@H]2c2ccc(-c3ccccc3)cc2)cc[nH]1
1574,2246303,10.1021/acs.jmedchem.1c01670,,,,Inhibition of MK-499 binding to hERG,O=C(Nc1ccc(F)cc1)C1(c2ccc(-c3ccc(C4CC4)nc3)cc2)COC1,3-(4-(6-Cyclopropylpyridin-3-yl)phenyl)-N-(4-fluorophenyl)oxetane-3-carboxamide,13450.0,uM,=,4.128722284338427,1,O=C(Nc1ccccc1)C1(c2ccc(-c3ccc(C4CC4)nc3)cc2)COC1
1575,1765499,10.1021/acs.jmedchem.8b01040,,,,Displacement of [3H]dofetilide from human ERG by high throughput assay,O=C(Nc1ccc(SC(F)(F)F)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cncnc2)c1,"US9278981, 186",10.5,uM,=,1.021189299069938,1,O=C(Nc1ccccc1)c1cnc(N2CCCC2)c(-c2cncnc2)c1
1576,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CC3CN(CCO)CC(C2)O3)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"2-(7-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl)ethanol",1.5,uM,=,0.1760912590556812,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CC6CNCC(C5)O6)cc4)n3)cnc2c1
1577,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CCn1c(-c2ccc(OCCCN3CCCCC3)cc2)nc2ccccc2c1=O,3-ethyl-2-(4-(3-(piperidin-1-yl)propoxy)phenyl)quinazolin-4(3H)-one,1.7,uM,=,0.2304489213782739,1,O=c1[nH]c(-c2ccc(OCCCN3CCCCC3)cc2)nc2ccccc12
1578,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NCc3cc4c(cn3)OCS4)(CC1)CO2,"(R)-4-((4-([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",33.6,uM,=,1.526339277389844,1,O=c1ccc2nccc3c2n1CC3CC12CCC(NCc3cc4c(cn3)OCS4)(CC1)CO2
1579,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,CC1(c2nc(-c3ccccc3)c[nH]2)Cc2c([nH]c3ccccc23)C(C2CCOCC2)N1,"3-methyl-3-(4-phenyl-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.53,uM,=,-0.2757241303992109,0,c1ccc(-c2c[nH]c(C3Cc4c([nH]c5ccccc45)C(C4CCOCC4)N3)n2)cc1
1580,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,COc1ccc(Cn2c(=O)n3ncnc3c3c4c(sc32)CN(C(=O)C2CC2(F)F)CC4)cc1,"(RS)-9-(2,2-Difluorocyclopropanecarbonyl)-6-(4-methoxybenzyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one",4.9,uM,=,0.6901960800285137,1,O=C(C1CC1)N1CCc2c(sc3c2c2ncnn2c(=O)n3Cc2ccccc2)C1
1581,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,Cn1c(=O)n(Cc2nccc3ccccc23)c(=O)c2c1c(C#N)c(N1CCC[C@H](N)C1)n2Cc1ccccc1,"(S)-6-(3-aminopiperidin-1-yl)-5-benzyl-3-(isoquinolin-1-ylmethyl)-1-methyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",2.8,uM,=,0.4471580313422192,1,O=c1[nH]c2cc(N3CCCCC3)n(Cc3ccccc3)c2c(=O)n1Cc1nccc2ccccc12
1582,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,Nc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1,"2-(4-((4-(5-(6-aminopyridin-3-yl)-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-3-phenyl-1,6-naphthyridin-5(6H)-one",10.0,uM,=,1.0,1,O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6cccnc6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12
1583,1669922,10.1021/acs.jmedchem.7b00462,,,,Inhibition of human hERG by patch clamp method,COc1ccc(CN(CC(=O)N2CCC(CN)CC2)c2ccc(C#N)cc2)cc1F,4-[[2-[4-(Aminomethyl)-1-piperidyl]-2-oxo-ethyl]-[(3-fluoro-4-methoxy-phenyl)methyl]amino]benzonitrile,12.4,uM,=,1.0934216851622351,1,O=C(CN(Cc1ccccc1)c1ccccc1)N1CCCCC1
1584,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCC[S+]([O-])CCCN(CC)CC(O)COc1ccc(C#N)cc1,4-(3-{Ethyl-[3-(propane-1-sulfinyl)-propyl]-amino}-2-hydroxy-propoxy)-benzonitrile,0.25,uM,=,-0.6020599913279624,0,c1ccccc1
1585,1926457,10.1016/j.bmc.2016.08.007,,,,Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assay,Cc1cncc(Nc2cc(NC3CCN(c4ccc(C#N)cn4)CC3)c(C(N)=O)cn2)n1,4-{[1-(5-Cyanopyridin-2-yl)piperidin-4-yl]amino}-6-[(6-methylpyrazin-2-yl)amino]nicotinamide,5.4,uM,=,0.7323937598229685,1,c1ccc(N2CCC(Nc3ccnc(Nc4cnccn4)c3)CC2)nc1
1586,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,O=C1OCc2nc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21,"2-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)furo[3,4-b]pyridin-5(7H)-one",26.0,uM,=,1.414973347970818,1,O=C1OCc2nc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
1587,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(F)ccc3OC[C@H]2[C@@]1(CCCN1CCN(C(C)=O)CC1)c1ccccc1,"1-{(3R,3aR)-3-[3-(4-acetyl-piperazin-1-yl)-propyl]-8-fluoro-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-2-yl}-ethanone",10.0,uM,=,1.0,1,C1=NN2c3ccccc3OC[C@H]2[C@@]1(CCCN1CCNCC1)c1ccccc1
1588,804476,10.1016/j.bmcl.2012.01.026,,,,Inhibition of human Erg by patch clamp assay,C[C@H]1CC(=O)NN=C1c1ccc(OC2CCN(C3CCC3)CC2)cc1,"(S)-6-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one",27.0,uM,=,1.4313637641589874,1,O=C1CCC(c2ccc(OC3CCN(C4CCC4)CC3)cc2)=NN1
1589,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,COc1c(F)cccc1CC(c1ccccc1)N1CCNCC1,1-(2-(3-fluoro-2-methoxyphenyl)-1-phenylethyl)piperazine,20.8,uM,=,1.3180633349627615,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
1590,1865114,10.1021/acsmedchemlett.9b00086,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp method,CC(C)Oc1cc([C@@](Cc2ccccc2)(NCC(O)C(O)(C(F)(F)F)C(F)(F)F)c2cc(F)cc(OC(F)(F)C(F)F)c2)ccc1F,"1,1,1-trifluoro-4-((R)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethylamino)-2-(trifluoromethyl)butane-2,3-diol",12.0,uM,=,1.0791812460476249,1,c1ccc(CC(c2ccccc2)c2ccccc2)cc1
1591,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CCOc1ccc2cc(-c3nn(CC4CCN(C(C)C)CC4)c4ncnc(N)c34)ccc2c1,"3-(6-ethoxynaphthalen-2-yl)-1-((1-isopropylpiperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.3,uM,=,-0.5228787452803376,0,c1ccc2cc(-c3nn(CC4CCNCC4)c4ncncc34)ccc2c1
1592,518708,10.1016/j.bmcl.2008.12.017,,,,Inhibition of human ERG expressed in HEK cells by competitive radioligand binding assay,ClCc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12,"3-(chloromethyl)-9-phenyl-8-(4-((4-(5-(pyridin-2-yl)-1H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-[1,2,4]triazolo[3,4-f][1,6]naphthyridine",2.018,uM,=,0.3049211619008917,1,c1ccc(-c2cc3c(ccn4cnnc34)nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1
1593,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(C1CC(Oc2cccc(Cl)c2)CN1)N1CCCN(C2CCC2)CC1,"(4-(3-chlorophenoxy)pyrrolidin-2-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methanone",7.2,uM,=,0.8573324964312685,1,O=C(C1CC(Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
1594,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)c1ccc2c(c1)C(=O)OC21CCN(c2ccc(-c3nc4cc(C(F)(F)F)ccc4[nH]3)cn2)CC1,"3-Oxo-1'-(5-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-pyridin-2-yl)-3H-spiro[isobenzofuran-1,4'-piperidine]-5-carboxylic Acid",0.56,uM,=,-0.2518119729937995,0,O=C1OC2(CCN(c3ccc(-c4nc5ccccc5[nH]4)cn3)CC2)c2ccccc21
1595,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,FC(F)(F)c1cc(Cl)nc(COCC2(c3ccccc3)CCNCC2)c1,2-chloro-6-(((4-phenylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,28.0,uM,=,1.4471580313422192,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
1596,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@H](c2ccc(S(C)(=O)=O)cc2)c2cc(F)cc(F)c2)CC1,"(R)-N-(1-(3-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide",7.3,uM,=,0.8633228601204559,1,O=C(Cc1ccccc1)NC1CCN(CCC(c2ccccc2)c2ccccc2)CC1
1597,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,Cc1ccn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@@H]2CO)n1,1-((R)-2-Hydroxymethyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-methyl-pyrazol-1-yl)-ethanone,0.021,uM,=,-1.6777807052660807,0,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
1598,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(C)c(-c2ccc3cc(CCN4CCCC4C)ccc3n2)cc1C(N)=O,"2,6-dimethyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)nicotinamide",40.0,uM,=,1.6020599913279625,1,c1cncc(-c2ccc3cc(CCN4CCCC4)ccc3n2)c1
1599,2047203,10.1021/acs.jmedchem.0c01170,,,,Inhibition of human ERG by Q-patch assay,CC1(CN)CCN(c2cnc(-c3cccc(Cl)c3Cl)c(N)n2)CC1,"6-(4-(aminomethyl)-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine",1.7,uM,=,0.2304489213782739,1,c1ccc(-c2cnc(N3CCCCC3)cn2)cc1
1600,340115,10.1016/j.bmcl.2005.11.083,,,,Inhibition of hERG potassium channel expressed in CHO cells by whole cell patch clamp method,Cc1c(Cl)ccc2c1N1[C@H](CNC[C@H]1C)C2,"(4R,10aS)-7-Chloro-4,6-dimethyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indole",2.5,uM,=,0.3979400086720376,1,c1ccc2c(c1)C[C@H]1CNCCN21
1601,489010,10.1021/jm8003834,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide from human ERG in HEK293 cells",Cc1nc2ccccc2c(=O)n1-c1ccc(OCCCN2CCC[C@@H]2C)cc1,2-Methyl-3-[4-({3-[(2S)-2-methyl-1-pyrrolidinyl]propyl}oxy)phenyl]-4(3H)-quinazolinone,6.0,uM,=,0.7781512503836436,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
1602,1992475,10.1021/acs.jmedchem.0c01199,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by IonWorks barracuda patch clamp method,COc1cc(-c2cncc(-c3ccc(C4CCN(C)CC4)cc3)c2C)cc(OC)c1OC,"4-Methyl-3-(4-(1-methylpiperidin-4-yl)phenyl)-5-(3,4,5-trimethoxyphenyl)pyridine",4.8,uM,=,0.6812412373755872,1,c1ccc(-c2cncc(-c3ccc(C4CCNCC4)cc3)c2)cc1
1603,2103369,10.1021/acs.jmedchem.0c01917,,,,Inhibition of human ERG expressed in HEK293 cells maintained at -80 mV membrane potential by manual patch-clamp technique,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=CSC(N)=N1,"US9270353, 17",0.5,uM,=,-0.3010299956639812,0,O=C(Nc1cccc(C2C=CSC=N2)c1)c1ccccn1
1604,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CC[C@H](NCc4cc5c(cn4)OCCO5)[C@@H](F)C3)c2c1,"trans-1-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]-3-fluoropiperidin-1-yl}ethyl)-7-methoxyquinoxalin-2(1H)-one",75.0,uM,=,1.8750612633917,1,O=c1cnc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
1605,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C(NC(c1ccc(Cl)cc1)c1ccncc1Cl)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1,"(1R,2R,4R)-2-(4-bromophenyl)-N-((4-chlorophenyl)(3-chloropyridin-4-yl)methyl)-4-morpholinocyclohexanecarboxamide",0.69,uM,=,-0.1611509092627447,0,O=C(NC(c1ccccc1)c1ccncc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
1606,1926457,10.1016/j.bmc.2016.08.007,,,,Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assay,N#Cc1ccc(N2CCC(Nc3cc(Nc4ccncn4)ncc3C(N)=O)CC2)nc1,4-{[1-(5-Cyanopyridin-2-yl)piperidin-4-yl]amino}-6-(pyrimidin-4-ylamino)nicotinamide,17.0,uM,=,1.230448921378274,1,c1ccc(N2CCC(Nc3ccnc(Nc4ccncn4)c3)CC2)nc1
1607,629417,10.1016/j.bmcl.2010.03.071,,,,Inhibition of human ERG by patch clamp assay,O=C([C@H]1C[C@H](Oc2cccc(F)c2)CN1)N1CCCN(C2CCC2)CC1,"(4-cyclobutyl-1,4-diazepan-1-yl)((2R,4S)-4-(3-fluorophenoxy)pyrrolidin-2-yl)methanone",3.0,uM,=,0.4771212547196624,1,O=C([C@H]1C[C@H](Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
1608,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=N[C@@H](C3(F)CNC3)CO2)cc1,"(4R)-4-(3-fluoroazetidin-3-yl)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-4,5-dihydrooxazole",10.0,uM,=,1.0,1,c1ccc([C@H]2c3ccccc3CCN2C2=N[C@@H](C3CNC3)CO2)cc1
1609,1474497,10.1021/acs.jmedchem.5b00191,,,,Inhibition of human ERG expressed in CHO cells,Cc1cc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1,"(4S,4aR,6R,8aS)-8a-(2,4-difluorophenyl)-4-(fluoromethyl)-6-(3-methylisoxazol-5-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",10.1,uM,=,1.0043213737826426,1,C1=N[C@@]2(c3ccccc3)CO[C@@H](c3ccno3)C[C@H]2CS1
1610,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,COc1cc2nnc(C(N)=O)c(Nc3ccc(C)cc3F)c2cc1C1CCN(CCO)CC1,4-(2-fluoro-4-methylphenylamino)-6-(1-(2-hydroxyethyl)piperidin-4-yl)-7-methoxycinnoline-3-carboxamide,14.0,uM,=,1.146128035678238,1,c1ccc(Nc2cnnc3ccc(C4CCNCC4)cc23)cc1
1611,793464,10.1016/j.bmcl.2011.09.114,,,,Inhibition of human ERG by whole cell patch clamp assay,COc1ccc2nccc(NC(=O)[C@H]3CC[C@H](NCc4cc5c(cn4)OCCO5)CC3)c2n1,"4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-N-(6-methoxy-1,5-naphthyridin-4-yl)cyclohexanecarboxamide",29.0,uM,=,1.462397997898956,1,O=C(Nc1ccnc2cccnc12)[C@H]1CC[C@H](NCc2cc3c(cn2)OCCO3)CC1
1612,983134,10.1016/j.bmcl.2013.07.013,,,,Inhibition of human ERG by patch clamp assay,O=c1ccc2ncc(F)c3c2n1C[C@@]3(F)CN1CCC(NCc2cc3c(cn2)OCCO3)CC1,"(S)-4-((4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)methyl)-3,4-difluoro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",16.0,uM,=,1.2041199826559248,1,O=c1ccc2nccc3c2n1CC3CN1CCC(NCc2cc3c(cn2)OCCO3)CC1
1613,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc2cccc(F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,5-Fluoro-2-methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,10.0,uM,=,1.0,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
1614,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(C2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"1-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)piperidin-1-yl)ethanone",12.0,uM,=,1.0791812460476249,1,c1ccn2c(-c3ccnc(Nc4ccc(C5CCNCC5)cc4)n3)cnc2c1
1615,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cc1ccc([C@H]2CC[C@@H](N3CC(NC(=O)CNc4n[nH]c5ccc(C(F)(F)F)cc45)C3)CC2)cn1,cis-N-{1-[4-Hydroxy-4-(6-methyl-pyridin-3-yl)-cyclohexyl]-azetidin-3-yl}-2-(5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,27.0,uM,=,1.4313637641589874,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3cccnc3)CC2)C1
1616,806244,10.1016/j.bmcl.2012.01.078,,,,Inhibition of human Erg by patch clamp assay,Cc1nc2cnc(Oc3ccc(F)cc3)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,"(S)-6-(4-fluorophenoxy)-3-((1-isopropylpiperidin-3-yl)methyl)-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one",1.3,uM,=,0.1139433523068367,1,O=c1c2cc(Oc3ccccc3)ncc2ncn1C[C@H]1CCCNC1
1617,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,COc1cc2nnc(C(N)=O)c(Nc3ccc(C)cc3F)c2cc1C1CCN(C(C)C)CC1,4-(2-fluoro-4-methylphenylamino)-6-(1-isopropylpiperidin-4-yl)-7-methoxycinnoline-3-carboxamide,11.0,uM,=,1.0413926851582251,1,c1ccc(Nc2cnnc3ccc(C4CCNCC4)cc23)cc1
1618,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(Cl)c2)C2CCN(S(C)(=O)=O)CC2)CC1,(R)-N-(1-(3-(3-chloro-5-fluorophenyl)-3-(1-(methylsulfonyl)piperidin-4-yl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide,14.0,uM,=,1.146128035678238,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
1619,458756,10.1016/j.bmcl.2007.10.063,,,,Inhibition of hERG by patch clamp assay,N#C[C@@H]1CCCN1C(=O)[C@@H]1CN(Cc2ccc(-n3cncn3)cc2)C[C@@H]1N,"(S)-1-((3R,4R)-1-(4-(1H-1,2,4-triazol-1-yl)benzyl)-3-aminopyrrolidine-4-carbonyl)pyrrolidine-2-carbonitrile",1.8,uM,=,0.255272505103306,1,O=C([C@H]1CCN(Cc2ccc(-n3cncn3)cc2)C1)N1CCCC1
1620,861902,10.1021/jm3007323,,,,Inhibition of human ERG transfected in HEK293 cell membranes by whole cell patch clamp assay,Cc1cc(OCCN2CCOCC2)nn1-c1ccc(Cl)c(Cl)c1,"4-(2-(1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl)morpholine",3.5,uM,=,0.5440680443502757,1,c1ccc(-n2ccc(OCCN3CCOCC3)n2)cc1
1621,833999,10.1016/j.bmcl.2012.06.094,,,,Inhibition of human ERG by patch clamp assay,O=C1CC(c2nc(-c3cccc(Cl)c3)no2)CN1c1ccc(F)cc1,"(-)-4-(3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl)-1-(4-fluorophenyl)pyrrolidin-2-one",3.0,uM,=,0.4771212547196624,1,O=C1CC(c2nc(-c3ccccc3)no2)CN1c1ccccc1
1622,1784292,10.1021/acsmedchemlett.7b00501,,,,Inhibition of recombinant human ERG expressed in CHO cells at -80 mV holding potential measured after 3 minutes by automated whole cell patch clamp Qpatch method,CN(C/C=C/C=C/C=C/c1ccc(C(F)(F)F)cc1)Cc1ccc2c(c1)OCCO2.Cl,"(2E,4E,6E)-N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-N-methyl-7-(4-(trifluoromethyl)phenyl)hepta-2,4,6-trien-1-amine Hydrochloride",8.7,uM,=,0.9395192526186184,1,C(=C/C=C/c1ccccc1)\C=C\CNCc1ccc2c(c1)OCCO2
1623,1760223,10.1021/acs.jmedchem.8b00002,,,,Inhibition of human ERG expressed in HEK293 cells by manual patch clamp assay,CC1=C[C@@](CF)(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)N=C(N)O1,"(S)-N-(3-(2-amino-4-(fluoromethyl)-6-methyl-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide",3.9,uM,=,0.5910646070264992,1,O=C(Nc1cccc(C2C=COC=N2)c1)c1ccccn1
1624,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NCc3ccc4c(c3)OCCO4)(CC1)CO2,"(R)-4-((4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",16.5,uM,=,1.2174839442139065,1,O=c1ccc2nccc3c2n1CC3CC12CCC(NCc3ccc4c(c3)OCCO4)(CC1)CO2
1625,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1,(S)-N-(3-chloro-4-(trifluoromethyl)phenyl)-4-((1-cyclopropylpiperidin-3-yl)methyl)piperazine-1-carboxamide,0.89,uM,=,-0.0506099933550872,0,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
1626,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,CN1CCN(c2ccc(Nc3nccc(-c4sc(C5CCNCC5)nc4-c4ccc(F)cc4)n3)cc2)CC1,4-(4-(4-fluorophenyl)-2-(piperidin-4-yl)thiazol-5-yl)-N-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidin-2-amine,13.2,uM,=,1.1205739312058498,1,c1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1627,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CO[C@@H]1CN(Cc2ccc(C(F)(F)F)cc2)CC[C@@H]1N(C)C(=O)Cc1ccc(-n2cnnn2)cc1,"2-(4-(1H-tetrazol-1-yl)phenyl)-N-((3R,4S)-3-methoxy-1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)-N-methylacetamide",2.0,uM,=,0.3010299956639812,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2ccccc2)CC1
1628,2219922,10.1016/j.bmcl.2021.128463,,,,Inhibition of human ERG expressed in HEK cells by voltage clamp assay,COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C(C)(C)C(N)=N3)c2)cn1,"US9273042, 7",8.1,uM,=,0.9084850188786496,1,O=C(Nc1cccc(C2CS(=O)(=O)CC=N2)c1)c1cnccn1
1629,1474497,10.1021/acs.jmedchem.5b00191,,,,Inhibition of human ERG expressed in CHO cells,NC1=N[C@@]2(c3ccc(F)cc3F)CO[C@@H](c3ncco3)C[C@H]2CS1,"(4aR,6R,8aS)-8a-(2,4-difluorophenyl)-6-(oxazol-2-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",10.6,uM,=,1.0253058652647702,1,C1=N[C@@]2(c3ccccc3)CO[C@@H](c3ncco3)C[C@H]2CS1
1630,1462544,10.1016/j.bmcl.2015.01.035,,,,Inhibition of human ERG,Cc1c(-c2ccc(F)cc2F)noc1-c1ccc2c(c1)CN(C(C)C)C2=O,"5-(3-(2,4-difluorophenyl)-4-methylisoxazol-5-yl)-2-isopropylisoindolin-1-one",1.06,uM,=,0.0253058652647702,1,O=C1NCc2cc(-c3cc(-c4ccccc4)no3)ccc21
1631,1682731,10.1021/acs.jmedchem.7b01135,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cell membranes,CN(C)[C@H]1CC[C@H](n2cc(C(N)=O)c(Nc3ccc(Cl)cc3)n2)[C@@H](C#N)C1,"US8962608, 28-117",12.2,uM,=,1.0863598306747482,1,c1ccc(Nc2ccn(C3CCCCC3)n2)cc1
1632,1290262,10.1016/j.bmcl.2013.05.024,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CN(C(=O)C#CC3CC3)C[C@@]2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1,"3-cyclopropyl-1-((3aR,5R,6aR)-5-(3-methoxytetrahydro-2H-pyran-4-ylamino)-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)prop-2-yn-1-one",49.6,uM,=,1.6954816764901974,1,O=C(C#CC1CC1)N1C[C@@H]2C[C@@H](NC3CCOCC3)C[C@]2(C(=O)N2CCc3ncccc3C2)C1
1633,2083683,10.1016/j.bmc.2021.116116,,,,Inhibition of recombinant human ERG expressed in CHO cells incubated for 12 mins by whole cell voltage clamp method,N=C(N)NC(=O)c1nc(Cl)c(N2CCCCCC2)nc1N,3-amino-5-(azepan-1-yl)-6-chloro-N-(diaminomethylene)pyrazine-2-carboxamide,3.3,uM,=,0.5185139398778875,1,c1cnc(N2CCCCCC2)cn1
1634,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,O=C(NC1CCOCC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,"5-(2,3-Difluorophenyl)-N-(tetrahydro-2H-pyran-4-yl)-1H-indazole-3-carboxamide",1.8,uM,=,0.255272505103306,1,O=C(NC1CCOCC1)c1n[nH]c2ccc(-c3ccccc3)cc12
1635,2049587,10.1016/j.bmcl.2020.127625,,,,Inhibition of human ERG by patch clamp assay,Cc1cn([C@H](C)[C@H]2CCNC[C@@H]2F)c2nc(C(N)=O)cc(Cl)c12,"Rac-4-chloro-1-[(1R)-1-[(3R,4R)-3-fluoro-4-piperidyl]ethyl]-3-methyl-pyrrolo[2,3-b]pyridine-6-carboxamide",7.0,uM,=,0.8450980400142568,1,c1cnc2c(c1)ccn2CC1CCNCC1
1636,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc2cc(C(F)(F)F)ccc2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,2-Methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-7-(trifluoromethyl)-4(3H)-quinazolinone,2.6,uM,=,0.414973347970818,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
1637,2229210,10.1021/acs.jmedchem.2c00960,,,,Inhibition of hERG,Cc1cccnc1Nc1nc(-c2ccc(OC3CC4(C3)CN(C3CC3)C4)cn2)ns1,"3-[5-[(2-Cyclopropyl-2-azaspiro[3.3]heptan-6-yl)oxy]-2-pyridyl]-N-(3-methyl-2-pyridyl)-1,2,4-thiadiazol-5-amine",0.203,uM,=,-0.6925039620867871,0,c1ccc(Nc2nc(-c3ccc(OC4CC5(C4)CN(C4CC4)C5)cn3)ns2)nc1
1638,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(OC)cc(OC)c2)CCN(Cc2ccc(C(F)(F)F)cc2)CC1,"methyl 4-((3,5-dimethoxybenzamido)methyl)-1-(4-(trifluoromethyl)benzyl)piperidine-4-carboxylate",2.35,uM,=,0.3710678622717362,1,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
1639,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,O=C1COc2ccccc2N1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1,"4-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]piperidin-1-yl}ethy)-2H-1,4-benzoxazin-3(4H)-one",20.0,uM,=,1.3010299956639813,1,O=C1COc2ccccc2N1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
1640,983133,10.1016/j.bmcl.2013.07.013,,,,Inhibition of human ERG transfected in HEK293 cells by patch clamp assay,O=c1ccc2ncc(F)c3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCO3)CC1,"(R)-4-((4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)methyl)-3-fluoro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",122.0,uM,=,2.0863598306747484,1,O=c1ccc2nccc3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCO3)CC1
1641,2021698,10.1021/acs.jmedchem.9b00069,,,,Inhibition of human ERG by Qpatch assay,CC(C)(CO)Cn1nc(-c2ccc3cc(OC4CC4)ccc3c2)c(C(N)=O)c1N,"5-Amino-3-(6-cyclopropoxynaphthalen-2-yl)-1-(3-hydroxy-2,2-dimethylpropyl)-1H-pyrazole-4-carboxamide",12.3,uM,=,1.089905111439398,1,c1cc(-c2ccc3cc(OC4CC4)ccc3c2)n[nH]1
1642,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,CN(C)CCC1=C(Cc2cnccn2)c2ccc(F)cc2C1,"2-(6-fluoro-3-(pyrazin-2-ylmethyl)-1H-inden-2-yl)-N,N-dimethylethanamine",0.59,uM,=,-0.2291479883578558,0,C1=C(Cc2cnccn2)c2ccccc2C1
1643,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(C(N)=O)ccc1Oc1ccc(Cl)c(Cl)c1,"4-(3,4-dichlorophenoxy)-3-((methylamino)methyl)benzamide",5.44,uM,=,0.7355988996981799,1,c1ccc(Oc2ccccc2)cc1
1644,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCN(CC(O)c3cc(C4CC4)c(C#N)cn3)CC2)ccc2c1COC2=O,"4-cyclopropyl-6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)nicotinonitrile",10.0,uM,=,1.0,1,O=C1OCc2cc(CCN3CCN(CCc4cc(C5CC5)ccn4)CC3)ccc21
1645,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(OCCCc2cc(N)cc(CCCOc3ccc(C)cc3)n2)cc1,"2,6-bis(3-(p-tolyloxy)propyl)pyridin-4-amine",0.17,uM,=,-0.7695510786217261,0,c1ccc(OCCCc2cccc(CCCOc3ccccc3)n2)cc1
1646,2022324,10.1021/acs.jmedchem.0c01163,,,,Inhibition of human ERG by plate-based planar patch clamp technique,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(N(C)C3CN(CCCF)C3)cn2)N1CC(F)(F)F,"N-(1-(3-Fluoropropyl)azetidin-3-yl)-N-methyl-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine",7.7,uM,=,0.8864907251724818,1,c1cc([C@H]2NCCc3c2ccc2[nH]ncc32)ncc1NC1CNC1
1647,2163947,10.1021/acs.jmedchem.1c01564,,,,Inhibition of human ERG by [3H]]Astemizole binding assay,NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21,"N1-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",8.9,uM,=,0.9493900066449128,1,c1ccc2c(c1)CN[C@@H](CN[C@H]1CCCc3cccnc31)C2
1648,2185846,10.1021/acs.jmedchem.1c00621,,,,Inhibition of hERG potassium channel assessed as maximum inhibition rate at -80 mV holding potential incubated for 120 seconds by whole cell-automated voltage clamp analysis assay,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC.O,Cisapride Monohydrate,0.04,uM,=,-1.3979400086720375,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
1649,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2cc(F)c(F)c(F)c2)[C@@H]3C)n1,"US9422299, 7",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
1650,379391,10.1016/j.bmcl.2006.05.063,,,,Inhibition of hERG potassium channel expressed in CHO cells by whole cell patch clamp method,O=C1NCC(c2ccc(F)cc2)C12CCN(C1(c3ccc(F)cc3)CCCCC1)CC2,"rac-4-(4-fluoro-phenyl)-8-[1-(4-fluoro-phenyl)-cyclohexyl]-2,8-diaza-spiro[4.5]decan-1-one",1.3,uM,=,0.1139433523068367,1,O=C1NCC(c2ccccc2)C12CCN(C1(c3ccccc3)CCCCC1)CC2
1651,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"endo-3-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide",0.61,uM,=,-0.2146701649892329,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccc2)C3)cc1
1652,2100973,10.1021/acs.jmedchem.1c00375,,,,Displacement of [3H]-dofetilide from human ERG after 60 mins by scintillation counting method,Cc1c(N2CC[C@@H](C3(N)CC3)C2)c(F)cc2cc(-c3nnco3)c(=O)n(C3CC3)c12,"(R)-7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-3-(1,3,4-oxadiazol-2-yl)quinolin-2(1H)-one",8.0,uM,=,0.9030899869919436,1,O=c1c(-c2nnco2)cc2ccc(N3CC[C@@H](C4CC4)C3)cc2n1C1CC1
1653,1475693,10.1016/j.bmcl.2015.04.002,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.3,uM,=,0.1139433523068367,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1654,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,COC(=O)N1CCCc2nc([C@@H](C)NC(=O)c3ccc(F)cc3)ccc21,"(R)-methyl 6-(1-(4-fluorobenzamido)ethyl)-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate",60.0,uM,=,1.7781512503836436,1,O=C(NCc1ccc2c(n1)CCCN2)c1ccccc1
1655,1467033,10.1021/jm501629p,,,,Inhibition of human ERG channel,C[C@H](c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12)N(C)c1cc(F)cc(F)c1,"(R)-8-(1-((3,5-Difluorophenyl)(methyl)amino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide",19.0,uM,=,1.2787536009528289,1,O=c1cc(N2CCOCC2)oc2c(CNc3ccccc3)cccc12
1656,2125085,10.1021/acsmedchemlett.1c00450,,,,Inhibition of human ERG expressed in CHO cells by manual patch clamp assay,CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4ccc(Cl)c(N)c4)c4c(N)ncnc43)C2)CC1,"1-(4-((cis)-3-(4-amino-5-(3-amino-4-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclobutyl)piperazin-1-yl)ethan-1-one",7.9,uM,=,0.8976270912904415,1,c1ccc(-c2cn([C@H]3C[C@@H](N4CCNCC4)C3)c3ncncc23)cc1
1657,1478748,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,CC(C)NCC(O)COc1cccc2ccccc12,1-Isopropylamino-3-(naphthalen-1-yloxy)-propan-2-ol,2.828,uM,=,0.4514794051248617,1,c1ccc2ccccc2c1
1658,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2F)cc(OC)n1,"(1S,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)-1-(2-fluoro-3-methoxyphenyl)butan-2-ol",13.0,uM,=,1.1139433523068367,1,c1ccc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)cc1
1659,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,COc1ccc2ccc(=O)n(CCN3CCC(NCc4ccc5c(n4)NC(=O)CO5)CC3)c2n1,"6-((1-(2-(7-methoxy-2-oxo-1,8-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",21.0,uM,=,1.3222192947339193,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)ccc5cccnc54)CC3)nc2N1
1660,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(C#N)cc12,6-Cyano-4-[(2-ethylbutyl)amino]-3-quinolinecarboxamide,2.3,uM,=,0.3617278360175928,1,c1ccc2ncccc2c1
1661,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,C/C=C/c1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCN(C)CC2)n1,2-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-6-(prop-1-enyl)-4-(trifluoromethyl)pyridine,13.0,uM,=,1.1139433523068367,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
1662,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,CC(C(O)c1ccc2c(c1)OCC(=O)N2)N1CCC(O)(c2ccc(F)cc2)CC1,"7-(2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxypropyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",1.6,uM,=,0.2041199826559248,1,O=C1COc2cc(CCN3CCC(c4ccccc4)CC3)ccc2N1
1663,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1cnsc1N1CCC2(CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)C1=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(4-methylisothiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",7.9,uM,=,0.8976270912904415,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccns3)C4=O)ccc21
1664,2238137,10.1021/acs.jmedchem.1c01012,,,,Inhibition of human ERG,Cc1cnc(N2CCN(Cc3ccc4c5c(c(=O)[nH]c4c3)CCCN5)CC2)n1C,"8-((4-(1,5-dimethyl-1H-imidazol-2-yl)piperazin-1-yl)methyl)-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridin-5(6H)-one",30.0,uM,=,1.4771212547196624,1,O=c1[nH]c2cc(CN3CCN(c4ncc[nH]4)CC3)ccc2c2c1CCCN2
1665,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CC(C)N1CCO[C@@H](CN2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"(S)-N-(3,4-dichlorophenyl)-4-((4-isopropylmorpholin-2-yl)methyl)piperazine-1-carboxamide",6.3,uM,=,0.7993405494535817,1,O=C(Nc1ccccc1)N1CCN(C[C@H]2CNCCO2)CC1
1666,1543580,10.1016/j.bmcl.2015.11.030,,,,Inhibition of human ERG by IKr binding assay,Cn1nnc([C@H]2[C@@H]3CN(C(=O)c4ccc(C[C@@H]5CC[C@H]([C@H](O)c6ccccc6)N5)cc4)C[C@@H]32)n1,"(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)((1R,5S,6S)-6-(2-methyl-2H-tetrazol-5-yl)-3-azabicyclo[3.1.0]hexan-3-yl)methanone",17.0,uM,=,1.230448921378274,1,O=C(c1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)N1C[C@@H]2[C@H](C1)[C@H]2c1nn[nH]n1
1667,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2cc3c(cc2F)ncc2c3n([C@H]3C[C@@H](OC)C3)c(=O)n2C)cn1,"7-Fluoro-1-(cis-3-methoxycyclobutyl)-8-(6-(methoxymethyl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one",9.0,uM,=,0.9542425094393248,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCC1
1668,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,Cc1[nH]c2ccccc2c1CCN(CCF)Cc1ccc(/C=C/C(=O)NO)cc1,(E)-3-[4-({(2-Fluoro-ethyl)-[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino}-methyl)-phenyl]-N-hydroxy-acrylamide,5.77,uM,=,0.7611758131557314,1,c1ccc(CNCCc2c[nH]c3ccccc23)cc1
1669,2208843,10.1016/j.bmc.2022.116657,,,,Inhibition of hERG channel expressed in CHO cells at -80 mV holding potential by Qpatch clamp method,COc1cc(Nc2ncc(CCc3c(F)c(OC)cc(OC)c3F)cn2)ccc1N1CCN(C2CCN(C)CC2)CC1,"5-[2-(2,6-Difluoro-3,5-dimethoxyphenyl)ethyl]-N-{3-methoxy-4-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]phenyl}pyrimidin-2-amine",4.5,uM,=,0.6532125137753437,1,c1ccc(CCc2cnc(Nc3ccc(N4CCN(C5CCNCC5)CC4)cc3)nc2)cc1
1670,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOc5cccnc5)c4)n[nH]c2-3)CC1,"6-((4-methylpiperazin-1-yl)methyl)-3-(5-(3-(pyridin-3-yloxy)-prop-1-ynyl)thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole",3.39,uM,=,0.5301996982030822,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)COc1cccnc1
1671,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccncn2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(pyrimidin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",21.9,uM,=,1.3404441148401185,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccncn3)C4=O)ccc21
1672,1472977,10.1021/jm5019274,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp method,Cl.NC[C@H]1C[C@@H]1c1cc(Cl)ccc1OCCF,"(+)-((1S,2S)-2-(5-chloro-2-(2-fluoroethoxy)phenyl)cyclopropyl)methanamine hydrochloride",2.0,uM,=,0.3010299956639812,1,c1ccc(C2CC2)cc1
1673,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,CC(C)N(CCc1c(-c2ccccc2)nn2ccccc12)Cc1ccc(/C=C/C(=O)NO)cc1,"(E)-N-Hydroxy-3-[4-({isopropyl-[2-(2-phenyl-pyrazolo[1,5-a]pyridin-3-yl)-ethyl]-amino}-methyl)-phenyl]-acrylamide",8.16,uM,=,0.9116901587538612,1,c1ccc(CNCCc2c(-c3ccccc3)nn3ccccc23)cc1
1674,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,COc1cccc2[nH]c(-c3nc(N[C@@H]4CCOC[C@@H]4N)cnc3C(N)=O)cc12,"5-(((3R,4R)-3-aminotetrahydro-2H-pyran-4-yl)amino)-3-(4-methoxy-1H-indol-2-yl)pyrazine-2-carboxamide",22.0,uM,=,1.3424226808222062,1,c1ccc2[nH]c(-c3cncc(NC4CCOCC4)n3)cc2c1
1675,1935939,10.1016/j.bmc.2019.02.025,,,,Inhibition of human ERG by manual patch clamp electrophysiology assay,COc1cc(C(O)(CCN(C)C)C(c2cc3cc(Br)ccc3nc2OC)c2ccnc(OC)c2OC)c(OC)nc1OC,"rac-1-(6-bromo-2-methoxyquinolin-3-yl)-1-(2,3-dimethoxypyridin-4-yl)-4-(dimethylamino)-2-(2,5,6-trimethoxypyridin-3-yl)butan-2-ol",2.7,uM,=,0.4313637641589873,1,c1cncc(CC(c2ccncc2)c2cnc3ccccc3c2)c1
1676,1478726,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)c5ccccc5[C@]45C[C@@H]([C@@H]2[C@H]5O)N3[C@@H]1O,"3-Ethyl-13-methyl-1,3,4,7,8,13,13a,13b-octahydro-2H,6H-2,7-cyclo-6,8a-methano-pyrido[1',2':1,2]azepino[3,4-b]indole-4,8-diol",1.04,uM,=,0.0170333392987803,1,c1ccc2c(c1)N[C@H]1[C@@H]3C[C@H]4CCN3[C@H]3C[C@@]21C[C@H]43
1677,421810,10.1016/j.bmcl.2006.10.053,,,,Inhibition of binding to hERG,CN(C)Cc1ccc2c(c1)CC[C@H](N(C)C(=O)c1ccc(-c3ccccc3)cn1)C2,"(S)-N-(6-((dimethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methyl-5-phenylpicolinamide",20.0,uM,=,1.3010299956639813,1,O=C(N[C@H]1CCc2ccccc2C1)c1ccc(-c2ccccc2)cn1
1678,420606,10.1016/j.bmcl.2006.11.061,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(C2CCc3cc4c(cc32)OCO4)CC1)c1cc(=O)c2cc(F)ccc2o1,"N-(1-(6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-5-yl)piperidin-4-yl)-6-fluoro-4-oxo-4H-chromene-2-carboxamide",7.87,uM,=,0.8959747323590646,1,O=C(NC1CCN(C2CCc3cc4c(cc32)OCO4)CC1)c1cc(=O)c2ccccc2o1
1679,1474497,10.1021/acs.jmedchem.5b00191,,,,Inhibition of human ERG expressed in CHO cells,Cc1coc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1,"(4aR,6R,8aS)-8a-(2,4-difluorophenyl)-6-(4-methyloxazol-2-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",2.3,uM,=,0.3617278360175928,1,C1=N[C@@]2(c3ccccc3)CO[C@@H](c3ncco3)C[C@H]2CS1
1680,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N2CCOCC2)nc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C,"3'-(4-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-2-morpholinopyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic acid",11.0,uM,=,1.0413926851582251,1,O=C1O[C@H](c2ccccc2)CN1Cc1nc(N2CCOCC2)ncc1-c1cccc(-c2ccccc2)c1
1681,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1.O=C(O)c1cc(O)ccc1O,"5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol 2,5-dihydroxybenzoate",0.24,uM,=,-0.619788758288394,0,c1ccc(/N=N/c2ccccn2)cc1.c1ccccc1
1682,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,Cn1cc([C@@]2(c3cncc(C(=O)O)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"5-((1R,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)nicotinicacid",11.99,uM,=,1.0788191830988487,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@](c4cccnc4)(c4cn[nH]c4)N3)n2)cc1
1683,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc2c(c1)CN(C(C)=O)C2C(=O)Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,"rac-2-acetyl-5-ethylsulfonyl-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]isoindoline-1-carboxamide",34.0,uM,=,1.5314789170422551,1,O=C(Nc1ccccc1)C1NCc2ccccc21
1684,1463729,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG by MK499 binding assay,CO[C@@]1(CC23CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC2)CO3)Cn2c(=O)ccc3ncc(F)c1c32,"(R)-6-((1-((3-fluoro-4-methoxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",7.3,uM,=,0.8633228601204559,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
1685,1463729,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG by MK499 binding assay,O=C1COc2ccc(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(Cl)c5c76)(CC3)OC4)nc2N1,"(R)-6-((1-((3-chloro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",53.3,uM,=,1.7267272090265722,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
1686,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,Cc1nc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)cnc2C(N)=O)cc(OCC(C)(C)O)n1,"5-(((1R,2S)-2-aminocyclohexyl)amino)-3-((6-(2-hydroxy-2-methylpropoxy)-2-methylpyrimidin-4-yl)amino)picolinamide",18.0,uM,=,1.255272505103306,1,c1cc(Nc2cncc(NC3CCCCC3)c2)ncn1
1687,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3cncnc3)ccc2c1,(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)-2-(pyrimidin-5-yl)quinoline,40.0,uM,=,1.6020599913279625,1,c1ncc(-c2ccc3cc(CCN4CCCC4)ccc3n2)cn1
1688,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CC#Cc1cncc(-c2cccc([C@@]3(c4cc(C)c(=O)n(CC)c4)N=C(N)c4c(F)cc(F)cc43)c2)c1,"(R)-5-(3-Amino-4,6-difluoro-1-(3-(5-(prop-1-ynyl)pyridin-3-yl)phenyl)-1H-isoindol-1-yl)-1-ethyl-3-methylpyridin-2(1H)-one",3.1,uM,=,0.4913616938342727,1,O=c1ccc([C@]2(c3cccc(-c4cccnc4)c3)N=Cc3ccccc32)c[nH]1
1689,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,CN1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc(C#N)c4)c3c2)CC1,3-((3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinolin-5-ylamino)methyl)benzonitrile,0.174,uM,=,-0.7594507517174003,0,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
1690,1872220,10.1016/j.bmcl.2018.12.029,,,,Inhibition of human ERG expressed in HEK293 cells by Qpatch method,COc1cc(F)cc2c1nnc1c2c(-c2ccncc2C)nn1C,"8-fluoro-6-methoxy-3-methyl-1-(3-methylpyridin-4-yl)-3H-pyrazolo[3,4-c]cinnoline",17.3,uM,=,1.2380461031287957,1,c1ccc2c(c1)nnc1[nH]nc(-c3ccncc3)c12
1691,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cccs3)CC2)C1,cis-N-{[1-(4-Hydroxy-4-thiophen-2-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide,27.0,uM,=,1.4313637641589874,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccs3)CC2)C1
1692,874106,10.1021/jm300118s,,,,Inhibition of human ERG,CO[C@H](C)C(=O)N[C@@H](Cc1ccc2c(c1)OCO2)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21,"(R)-N-((2S,3R)-1-(Benzo[d][1,3]dioxol-5-yl)-3-hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)butan-2-yl)-2-methoxypropanamide",23.7,uM,=,1.374748346010104,1,c1cnc2c(c1)[C@@H](NCCCCc1ccc3c(c1)OCO3)CC1(CCC1)O2
1693,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C(NC(c1ccccc1)c1ccccc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1,"(1R,2R,4R)-N-benzhydryl-2-(4-bromophenyl)-4-morpholinocyclohexanecarboxamide",0.53,uM,=,-0.2757241303992109,0,O=C(NC(c1ccccc1)c1ccccc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
1694,649965,10.1021/jm100505n,,,,Displacement of [3H]dofetilide from human ERG at 10 uM,N#Cc1ccc(N2N=C(c3ccc4[nH]c(=O)oc4c3)C[C@@H]2c2ccc(F)cc2)cc1,"4-[(5R)-5-(4-Fluorophenyl)-3-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-4,5-dihydro-1H-pyrazol-1-yl]benzonitrile",0.029,uM,=,-1.537602002101044,0,O=c1[nH]c2ccc(C3=NN(c4ccccc4)[C@@H](c4ccccc4)C3)cc2o1
1695,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc12,"6-((1-(2-(3-fluoro-8-methyl-6-(methylsulfonyl)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.01238,uM,=,-1.9072793553159009,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1696,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,CCOc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1N1CCN(C)CC1,"4-(2,4-difluorophenylamino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide",23.0,uM,=,1.3617278360175928,1,c1ccc(Nc2ccnc3ccc(N4CCNCC4)cc23)cc1
1697,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Fc1cc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)ccn1,"2-(1,4'-bipiperidin-1'-yl)-6-(2-fluoropyridin-4-yl)thiazolo[4,5-c]pyridine",1.764705882,uM,=,0.2466723332545295,1,c1cc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)ccn1
1698,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N3C[C@@H](O)C[C@@H]3Cc3ccc(Cl)cc3)CC2)n1,"(3S,5S)-1-(1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)-5-(4-chlorobenzyl)pyrrolidin-3-ol",13.2,uM,=,1.1205739312058498,1,c1ccc(C[C@H]2CCCN2C2CCN(c3ncn[nH]3)CC2)cc1
1699,2157068,10.1021/acsmedchemlett.1c00445,,,,Inhibition of hERG expressed in HEK293 cells at -80 mV holding potential by automated patch-clamp method,C[C@@]1(c2cc(NC(=O)c3ccc(OC(F)F)cn3)ccc2F)Cn2nc(C#N)cc2C(N)=N1,"(R)-N-(3-(4-amino-2-cyano-6-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-6-yl)-4-fluorophenyl)-5-(difluoromethoxy)picolinamide",6.6,uM,=,0.8195439355418687,1,O=C(Nc1cccc(C2Cn3nccc3C=N2)c1)c1ccccn1
1700,943930,10.1021/ml300277t,,,,Inhibition of human ERG,CCNc1nc2c(c(C(N)=O)n1)CN(C(=O)CCc1ccc(OC(F)(F)F)cc1)CC2,"2-(ethylamino)-6-(3-(4-(trifluoromethoxy)phenyl)propanoyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-4-carboxamide",4.6,uM,=,0.6627578316815741,1,O=C(CCc1ccccc1)N1CCc2ncncc2C1
1701,850164,10.1021/jm3001289,,,,Inhibition of human ERG,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,"N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine",0.98,uM,=,-0.0087739243075051,0,c1ccc(-c2cnc3ccc(NCC4CCNCC4)nn23)cc1
1702,1472977,10.1021/jm5019274,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp method,C=CCOc1ccc(Cl)cc1[C@H]1C[C@@H]1CN.O=C(O)C(F)(F)F,"(+)-((1S,2S)-2-(2-(allyloxy)-5-chlorophenyl)cyclopropyl)methanamine trifluoroacetate",0.27,uM,=,-0.5686362358410126,0,c1ccc(C2CC2)cc1
1703,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,NC(=O)Cc1ccc([C@H]2CC[C@@H](N3CC(NC(=O)CNc4n[nH]c5ccc(C(F)(F)F)cc45)C3)CC2)cc1,cis-2-[4-(4-{3-[2-(5-Trifluoromethyl-1H-indazol-3-ylamino)-acetylamino]-azetidin-1-yl}-cyclohexyl)-phenyl]-acetamide,9.5,uM,=,0.9777236052888478,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccccc3)CC2)C1
1704,1642442,,,,,"Binding Assay: Predictor hERG Assay test kits were obtained from Invitrogen (Carlsbad, Calif.). The binding assay was carried out according to the kit instructions. Fluorescence polarization measurements were made using EnVision Microplate Reader from Perkin-Elmer Instruments.",CNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21,"US9453031, 11",4000.0,uM,=,3.6020599913279625,1,c1ccc2c(c1)ncn2-c1ncc2c(n1)N1CCOC[C@H]1CO2
1705,2238137,10.1021/acs.jmedchem.1c01012,,,,Inhibition of human ERG,Cc1cnc(N2CCN(Cc3ccc4c5c(c(=O)[nH]c4c3)CCCC5)CC2)n1C,"3-((4-(1,5-dimethyl-1H-imidazol-2-yl)piperazin-1-yl)methyl)-7,8,9,10-tetrahydrophenanthridin-6(5H)-one",3.8,uM,=,0.5797835966168101,1,O=c1[nH]c2cc(CN3CCN(c4ncc[nH]4)CC3)ccc2c2c1CCCC2
1706,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccsc12,"(1R,2S)-2-(benzo[b]thiophen-7-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-4-(dimethylamino)-1-phenylbutan-2-ol",12.0,uM,=,1.0791812460476249,1,c1ccc([C@@H](Cc2cccc3ccsc23)c2ccc3ccccc3c2)cc1
1707,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(OC2CNC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"N-(4-(azetidin-3-yloxy)-2-methoxyphenyl)-5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-amine",5.9,uM,=,0.7708520116421442,1,c1ccn2c(-c3ccnc(Nc4ccc(OC5CNC5)cc4)n3)cnc2c1
1708,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)nc1,"(1R,3R)-3-(4-(pyridin-2-yl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",4.026,uM,=,0.6048737705526357,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)nc1
1709,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@H]2CN3CCN(C(=O)Cc4cnc(-n5cnnn5)nc4)C[C@H]3CO2)ccc(F)c1C#N,"3-((3S,9aS)-8-(2-(2-(1H-tetrazol-1-yl)pyrimidin-5-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-6-fluoro-2-methylbenzonitrile",25.2,uM,=,1.4014005407815442,1,O=C(Cc1cnc(-n2cnnn2)nc1)N1CCN2C[C@H](c3ccccc3)OC[C@@H]2C1
1710,794861,10.1016/j.bmcl.2011.11.075,,,,Inhibition of human ERG by patch-clamp assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)CCO)cc2)cc1,2-{4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-ethanol,7.7,uM,=,0.8864907251724818,1,c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
1711,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CC[C@H]3OC[C@H](NCc4ccc(Cl)cc4)CO3)c2c1,"N-(4-chlorobenzyl)-2-(2-(6-methoxyquinolin-4-yl)ethyl)-trans-1,3-dioxan-5-amine",2.0,uM,=,0.3010299956639812,1,c1ccc(CN[C@H]2CO[C@H](CCc3ccnc4ccccc34)OC2)cc1
1712,434542,10.1021/jm061223o,,,,Inhibition of hERG expressed in HEK293 cells assessed as effect on ionic current by patch clamp assay,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(Cn4cncn4)ccc2-3)cs1)COc1ccccc1,"6-((1H-1,2,4-triazol-1-yl)methyl)-3-(5-(3-phenoxyprop-1-ynyl)-thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole",1.7,uM,=,0.2304489213782739,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(Cn4cncn4)ccc2-3)cs1)COc1ccccc1
1713,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn([C@H]3C[C@@H](c4ccccc4)CCN(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"(3S,5S)-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-5-phenyl-1-(2,2,2-trifluoroethyl)azepan-2-one",2.22,uM,=,0.3463529744506387,1,O=C1NCC[C@H](c2ccccc2)C[C@@H]1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
1714,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,CCN(CC)Cc1ccc2c(c1)CC[C@H](N1CCN(CCC3CCCCC3)CC1=O)C2,"(S)-4-(2-cyclohexylethyl)-1-(6-((diethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)piperazin-2-one",3.3,uM,=,0.5185139398778875,1,O=C1CN(CCC2CCCCC2)CCN1[C@H]1CCc2ccccc2C1
1715,1463729,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG by MK499 binding assay,CO[C@]1(CC23CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC2)CO3)Cn2c(=O)ccc3ncc(F)c1c32,"(S)-6-((1-((3-fluoro-4-methoxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",24.5,uM,=,1.3891660843645326,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
1716,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCc3ccc(OC)c(OC)c3)C[C@@H]2CCNC(=O)c2cccc(Cl)c2)cc1,"rac-3-chloro-N-(2-((3R,4S)-1-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)ethyl)benzamide",0.056,uM,=,-1.2518119729937995,0,O=C(NCC[C@H]1CN(CCc2ccccc2)C[C@@H]1c1ccccc1)c1ccccc1
1717,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N[C@H](CO)c1ccccc1,(S)-1-(2-hydroxy-1-phenylethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,23.9,uM,=,1.3783979009481375,1,O=C(NCc1ccccc1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
1718,1642194,,,,,Fast Patch Assay: Representative compounds were tested for hERG activity using the Fast Patch assay available from WuXiApptec (Shanghai China).,O=S1(=O)CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,"US9416132, 8-13",10.0,uM,=,1.0,1,O=S1(=O)CCC(CNc2ccc3ncc(-c4ccccc4)n3n2)CC1
1719,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(F)ccc3OC[C@H]2[C@@]1(CCCN1CCNC(=O)CC1)c1ccccc1,"1-[3-((3R,3aR)-2-acetyl-8-fluoro-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-3-yl)-propyl]-[1,4]diazepan-5-one",17.0,uM,=,1.230448921378274,1,O=C1CCN(CCC[C@]2(c3ccccc3)C=NN3c4ccccc4OC[C@H]32)CCN1
1720,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CC[C@H]3CC[C@H](NCc4ccc5c(n4)NC(=O)CO5)CC3)c2c1,"6-((trans-4-(2-(6-methoxyquinolin-4-yl)ethyl)cyclohexylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.41,uM,=,-0.3872161432802645,0,O=C1COc2ccc(CN[C@H]3CC[C@H](CCc4ccnc5ccccc45)CC3)nc2N1
1721,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,O=C(c1cn(CCCNCc2ccc(Oc3ccc(Cl)cc3)cc2)nn1)N1CCOCC1,"(1-(3-((4-(4-chlorophenoxy)benzyl)amino)propyl)-1H-1,2,3-triazol-4-yl)(morpholino)methanone",0.678,uM,=,-0.1687703061329366,0,O=C(c1cn(CCCNCc2ccc(Oc3ccccc3)cc2)nn1)N1CCOCC1
1722,945538,10.1016/j.bmcl.2012.10.140,,,,Inhibition of human ERG expressed in CHO cells by IONWORKS assay,CC(C)(C)NC(=O)NCCN1CCCC(NC(=O)c2cc(Cl)cc(Cl)c2)C1,"N-(1-(2-(3-tert-butylureido)ethyl)piperidin-3-yl)-3,5-dichlorobenzamide",4.1,uM,=,0.6127838567197355,1,O=C(NC1CCCNC1)c1ccccc1
1723,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1CCc2ccccc2N1CCCN1CCC(c2ccc3[nH]ccc3c2)CC1,"1-(3-(4-(1H-indol-5-yl)piperidin-1-yl)propyl)-3,4-dihydroquinolin-2(1H)-one",4.4,uM,=,0.6434526764861874,1,O=C1CCc2ccccc2N1CCCN1CCC(c2ccc3[nH]ccc3c2)CC1
1724,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,N[C@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-(((2R,3S)-3-aminooxetan-2-yl)methoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",23.9,uM,=,1.3783979009481375,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OC[C@H]7CCO7)nc56)(CC3)OC4)nc2N1
1725,1289670,10.1016/j.bmcl.2013.12.118,,,,Inhibition of human ERG by dofetilide binding assay,NC[C@]1(c2cccc(Cl)c2)CC[C@H](N2CCc3c(nc(C(F)(F)F)nc3C3CC3)C2=O)CC1,"7-(syn-4-(aminomethyl)-4-(3-chlorophenyl)cyclohexyl)-4-cyclopropyl-2-(trifluoromethyl)-6,7-dihydropyrido[3,4-d]pyrimidin-8(5H)-one",0.26,uM,=,-0.585026652029182,0,O=C1c2ncnc(C3CC3)c2CCN1C1CCC(c2ccccc2)CC1
1726,2185846,10.1021/acs.jmedchem.1c00621,,,,Inhibition of hERG potassium channel assessed as maximum inhibition rate at -80 mV holding potential incubated for 120 seconds by whole cell-automated voltage clamp analysis assay,CNc1cc(F)cc2c1[nH]c1nc(Oc3cnc(C)nc3)nc(N3CC4CCNC4C3)c12,"rac-6-fluoro-4-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-N-methyl-2-((2-methylpyrimidin-5-yl)oxy)-9H-pyrimido[4,5-b]indol-8-amine",12.3,uM,=,1.089905111439398,1,c1ccc2c(c1)[nH]c1nc(Oc3cncnc3)nc(N3CC4CCNC4C3)c12
1727,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(Cc2ccc3[nH]ccc3c2)CC1)c1cc(=O)c2ccc(F)cc2o1,N-(1-((1H-indol-5-yl)methyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,6.08,uM,=,0.7839035792727349,1,O=C(NC1CCN(Cc2ccc3[nH]ccc3c2)CC1)c1cc(=O)c2ccccc2o1
1728,2163947,10.1021/acs.jmedchem.1c01564,,,,Inhibition of human ERG by [3H]]Astemizole binding assay,NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21,"(S)-N-((1H-benzo[d]imidazol-2-yl)methyl)-N-(4-aminobutyl)-5,6,7,8-tetrahydroquinolin-8-amine",5.2,uM,=,0.7160033436347992,1,c1cnc2c(c1)CCC[C@@H]2NCc1nc2ccccc2[nH]1
1729,1509182,10.1016/j.bmcl.2015.05.065,,,,Inhibition of human ERG by patch clamp assay,COc1ccc(COc2cnn(CC(=O)c3ccc(CN(C)C)cc3C)c(=O)c2)nc1,2-(2-(4-((dimethylamino)methyl)-2-methylphenyl)-2-oxoethyl)-5-((5-methoxypyridin-2-yl)methoxy)pyridazin-3(2H)-one,16.0,uM,=,1.2041199826559248,1,O=C(Cn1ncc(OCc2ccccn2)cc1=O)c1ccccc1
1730,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",CCN(CC)CCOc1ccc(-n2ccc(OCc3ccccc3)cc2=O)cc1,4-(Benzyloxy)-1-{4-[2-(diethylamino)ethoxy]phenyl}-pyridin-2(1H)-one,0.0098,uM,=,-2.008773924307505,0,O=c1cc(OCc2ccccc2)ccn1-c1ccccc1
1731,1985700,10.1021/acsmedchemlett.0c00109,,,,Inhibition of human ERG,Cc1cc(N2C[C@H]3CC[C@@H](C2)[C@@H]3Nc2nc3n(n2)CCCC[C@H]3c2ccc(F)c(F)c2F)ncn1,"(S)-N-((1R,5S,8s)-3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[1,5-a]azepin-2-amine",1.4,uM,=,0.1461280356782379,1,c1ccc([C@@H]2CCCCn3nc(N[C@@H]4[C@@H]5CC[C@H]4CN(c4ccncn4)C5)nc32)cc1
1732,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(C(=O)CC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-2-oxoethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.2,uM,=,0.0791812460476248,1,O=C1COc2ccc(CNC34CCC(CC(=O)c5ccnc6cccnc56)(CC3)OC4)nc2N1
1733,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",O=c1ccc(-c2nc3cc(Cl)c(Cl)cc3n2Cc2ccc(Cl)c(Cl)c2)c[nH]1,"US8975247, EBP106",5.0,uM,=,0.6989700043360189,1,O=c1ccc(-c2nc3ccccc3n2Cc2ccccc2)c[nH]1
1734,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,Cc1c(OC(F)F)ccc2c1C(=O)N(Cc1ccccc1-c1ccccc1)C2C(=O)NC(C)(C)C,(rac)-2-(biphenyl-2-ylmethyl)-N-tert-butyl-5-(difluoromethoxy)-4-methyl-3-oxoisoindoline-1-carboxamide,22.0,uM,=,1.3424226808222062,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
1735,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,c1ccc2c3c([nH]c2c1)[C@@H](C1CCOCC1)N[C@@H](c1nc(-c2ccncc2)c[nH]1)C3,"(1R,3R)-3-(4-(pyridin-4-yl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",7.518,uM,=,0.8761023213777936,1,c1ccc2c3c([nH]c2c1)[C@@H](C1CCOCC1)N[C@@H](c1nc(-c2ccncc2)c[nH]1)C3
1736,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,C[S+]([O-])c1ccc(-c2ccc3ncc(-c4cccc([S+](C)[O-])c4)n3n2)cc1,"3-(3-(methylsulfinyl)phenyl)-6-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine",21.1,uM,=,1.3242824552976926,1,c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1
1737,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CC4(COC4)C3)cc2)C1,"(3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone",28.0,uM,=,1.4471580313422192,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CC4(COC4)C3)cc2)C1
1738,1665800,10.1021/acs.jmedchem.7b00328,,,,Inhibition of human ERG by thallium flux assay,CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ncccn5)CC4)ccc3C)c(F)c12,4-Fluoro-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide,24.0,uM,=,1.380211241711606,1,O=C(NC1(c2ncccn2)CC1)c1cccc(-c2ccc3oc(-c4ccccc4)cc3c2)c1
1739,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,COc1ccc(Cn2c(=O)n3ncnc3c3c4c(sc32)CN(CC2CCOCC2)CC4)cc1,"6-(4-Methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one",2.2,uM,=,0.3424226808222063,1,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCN(CC1CCOCC1)C3
1740,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,Cc1cc2c(cc1CCN1CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC1)COC2=O,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-6-methylisobenzofuran-1(3H)-one,14.0,uM,=,1.146128035678238,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
1741,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,c1cncc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)c1,"(1R,3R)-3-(4-(pyridin-3-yl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",2.701,uM,=,0.4315245841874509,1,c1cncc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)c1
1742,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,CN1CC[C@]2(CN=C(N3CCc4ccccc4[C@@H]3c3ccc(F)cc3)O2)C1,"(5R)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-7-methyl-1-oxa-3,7-diazaspiro[4.4]non-2-ene",0.51,uM,=,-0.2924298239020636,0,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@]3(CCNC3)O2)cc1
1743,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CC[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3c(C)nc4ccc(F)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(6-fluoro-2-methyl-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",2.05,uM,=,0.3117538610557542,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
1744,490606,10.1016/j.bmcl.2008.06.027,,,,Inhibition of human ERG,Cc1ncc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2F)n1C(C)C,5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-morpholinophenyl)pyrimidin-2-amine,11.0,uM,=,1.0413926851582251,1,c1cc(-c2cnc[nH]2)nc(Nc2ccc(N3CCOCC3)cc2)n1
1745,1992475,10.1021/acs.jmedchem.0c01199,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by IonWorks barracuda patch clamp method,COc1cc(-c2cncc(-c3ccc(N4C[C@@H](C)N[C@@H](C)C4)cc3)c2C)cc(OC)c1OC,"(3S,5R)-3,5-Dimethyl-1-(4-(4-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine",5.9,uM,=,0.7708520116421442,1,c1ccc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2)cc1
1746,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,Fc1ccccc1C(Cc1ccccc1OC(F)(F)F)N1CCNCC1,1-(1-(2-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine,2.05,uM,=,0.3117538610557542,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
1747,949743,10.1021/jm301720p,,,,Inhibition of human ERG channel,CN1CC(Cn2nc(-c3cnc4[nH]cc(C(=O)NC(C)(C)C)c4n3)c3cc(OC(F)F)ccc32)C1,"N-tert-butyl-2-(5-(difluoromethoxy)-1-((1-methylazetidin-3-yl)methyl)-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",0.293,uM,=,-0.5331323796458906,0,c1ccc2c(c1)c(-c1cnc3[nH]ccc3n1)nn2CC1CNC1
1748,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CC(=O)Nc2ccccc2)c1,endo-3-(8-(2-oxo-2-(phenylamino)ethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0007199999999999,uM,=,-3.1426675035687315,0,O=C(CN1[C@@H]2CC[C@H]1C[C@H](Oc1ccccc1)C2)Nc1ccccc1
1749,834187,10.1021/jm2013248,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,C[C@@H](Oc1nnc(-c2ccncc2)n1C)c1nnc(-c2cccc(Cl)c2)o1,"(R)-2-(3-chlorophenyl)-5-(1-(4-methyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yloxy)ethyl)-1,3,4-oxadiazole",21.5,uM,=,1.3324384599156054,1,c1ccc(-c2nnc(COc3nnc(-c4ccncc4)[nH]3)o2)cc1
1750,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1n[nH]cc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-2-(3-methyl-1H-pyrazol-4-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,17.6,uM,=,1.24551266781415,1,c1cc2nc(-c3cn[nH]c3)ccc2cc1CCN1CCCC1
1751,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(C(=O)N2CCN(C(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C[C@@H]2C)cc1C(C)(C)C,"(S)-1-(4-(3,5-di-tert-butyl-4-methoxybenzoyl)-3-methylpiperazin-1-yl)-6,6-bis(4-fluorophenyl)hexan-1-one",4.9,uM,=,0.6901960800285137,1,O=C(CCCCC(c1ccccc1)c1ccccc1)N1CCN(C(=O)c2ccccc2)CC1
1752,1728697,10.1021/acsmedchemlett.7b00312,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,O=C(CCN1CCN(C(=O)OCc2cc(Cl)cc(Cl)c2)CC1)c1ccc2[nH]c(=O)oc2c1,SID174006268,0.48,uM,=,-0.3187587626244128,0,O=C(CCN1CCN(C(=O)OCc2ccccc2)CC1)c1ccc2[nH]c(=O)oc2c1
1753,2066476,10.1016/j.ejmech.2018.04.062,,,,Inhibition of human ERG transfected in HEK293 cells assessed as reduction in channel current at -80 mV holding potential by whole-cell patch clamp method,NC[C@H](NC(=O)c1ccc(-c2ccc(C(F)(F)F)c(F)c2)[nH]1)c1nc(CO)cs1,(S)-N-(2-amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(3-fluoro-4-(trifluoromethyl)phenyl)-1H-pyrrole-2-carboxamide,3.0,uM,=,0.4771212547196624,1,O=C(NCc1nccs1)c1ccc(-c2ccccc2)[nH]1
1754,2241386,10.1016/j.ejmech.2021.113981,,,,Inhibition of hERG channel expressed in CHO cells at holding potential of -80 mV by whole cell patch clamp method,CCCCCNC[C@@H](O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12,"(1S)-1-[2,8-bis(trifluoromethyl)-4-quinolyl]-2-(pentylamino)ethanol",8.8,uM,=,0.9444826721501688,1,c1ccc2ncccc2c1
1755,963062,10.1021/jm400408r,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,"8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine",0.65,uM,=,-0.1870866433571444,0,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2
1756,1290262,10.1016/j.bmcl.2013.05.024,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CN(C3CC3)C[C@@]2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1,"((3aR,5R,6aR)-2-cyclopropyl-5-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydrocyclopenta[c]pyrrol-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",42.1,uM,=,1.6242820958356683,1,O=C(N1CCc2ncccc2C1)[C@]12C[C@H](NC3CCOCC3)C[C@H]1CN(C1CC1)C2
1757,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,O=C(Cn1cnc(C2CC2)n1)N1CCN(c2sc(C(F)(F)F)nc2-c2cnc(C(F)(F)F)nc2)C[C@H]1CO,"2-(3-Cyclopropyl-[1,2,4]triazol-1-yl)-1-((S)-2-hydroxymethyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]piperazin-1-yl)-ethanone",0.031,uM,=,-1.5086383061657274,0,O=C(Cn1cnc(C2CC2)n1)N1CCN(c2scnc2-c2cncnc2)CC1
1758,855975,10.1021/jm2002124,,,,Inhibition of human ERG,COc1ccc2nccc([C@@H](O)CC[C@@H]3CCN(CCSc4cccs4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-4-((S)-3-hydroxy-3-(6-methoxyquinolin-4-yl)propyl)-1-(2-(thiophen-2-ylthio)ethyl)piperidine-3-carboxylic acid",21.0,uM,=,1.3222192947339193,1,c1csc(SCCN2CCC(CCCc3ccnc4ccccc34)CC2)c1
1759,958294,10.1016/j.bmcl.2013.03.047,,,,Inhibition of human ERG channel in HEK293 cells by voltage-gated patch clamp technique,COc1ccc2nccc([C@@H](O)CC[C@@H]3CCN(C4CC(c5cc(F)cc(F)c5F)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-4-((S)-3-hydroxy-3-(6-methoxyquinolin-4-yl)propyl)-1-(3-(2,3,5-trifluorophenyl)cyclobutyl)piperidine-3-carboxylic acid",30.9,uM,=,1.4899584794248346,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
1760,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1,(S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide,15.0,uM,=,1.1760912590556811,1,O=C(N[C@H]1CCCNC1)c1ccc(-c2ccccc2)s1
1761,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CC(C)N1CCC[C@@H](CN2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"(S)-N-(3,4-dichlorophenyl)-4-((1-isopropylpiperidin-3-yl)methyl)piperazine-1-carboxamide",1.3,uM,=,0.1139433523068367,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCNC2)CC1
1762,465697,10.1021/jm701187w,,,,Inhibition of human ERG potassium current expressed in HEK293 cells by patch-clamp technique,Cc1cc(C)n(-c2cc(NC(=O)CN3CCCN(C)CC3)nc(-c3ccc(C)o3)n2)n1,"N-[6-(3,5-dimethylpyrazol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl]-2-(4-methyl[1,4]diazepan-1-yl)acetamide",0.285,uM,=,-0.5451551399914898,0,O=C(CN1CCCNCC1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
1763,1650772,10.1016/j.bmcl.2016.11.079,,,,Inhibition of human ERG,C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1,"4-(8-amino-3-((3R,6S)-1-(cyclopropanecarbonyl)-6-methylpiperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-3-fluoro-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",4.3,uM,=,0.6334684555795865,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@@H]3CCCN(C(=O)C4CC4)C3)n3ccncc23)cc1
1764,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,Cc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC2)ccc2c1COC2=O,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-4-methylisobenzofuran-1(3H)-one,20.0,uM,=,1.3010299956639813,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
1765,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3cccc(OC(F)(F)F)c3)nn2)ccc1-n1cnc(C)c1,"4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1-(3-(trifluoromethoxy)benzyl)-1H-1,2,3-triazole",0.72,uM,=,-0.1426675035687315,0,c1ccc(Cn2cc(-c3ccc(-n4ccnc4)cc3)nn2)cc1
1766,872803,10.1021/jm300991n,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,COc1ccc(C2(c3cccc(-c4cccnc4)c3)N=C(C)C(N)=N2)cc1,2-(4-Methoxyphenyl)-5-methyl-2-(3-(pyridin-3-yl)phenyl)-2H-imidazol-4-amine,19.0,uM,=,1.2787536009528289,1,C1=NC(c2ccccc2)(c2cccc(-c3cccnc3)c2)N=C1
1767,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CN(CCO)C(=O)c1ccc([C@H](c2cccc(NC(=O)C3CC3)c2)N2CCN(Cc3ccc(F)cc3)CC2)cc1,(R)-4-((3-(cyclopropanecarboxamido)phenyl)(4-(4-fluorobenzyl)piperazin-1-yl)methyl)-N-(2-hydroxyethyl)-N-methylbenzamide,15.0,uM,=,1.1760912590556811,1,O=C(Nc1cccc([C@@H](c2ccccc2)N2CCN(Cc3ccccc3)CC2)c1)C1CC1
1768,2033688,10.1016/j.bmc.2020.115724,,,,Inhibition of human ERG,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,"N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine",1.0,uM,=,0.0,0,c1ccc(-c2cnc3ccc(NCC4CCNCC4)nn23)cc1
1769,1552682,10.1016/j.bmcl.2015.12.058,,,,Inhibition of human ERG by FLIPR assay,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)CC(C)C)cc21,,16.6,uM,=,1.2201080880400552,1,O=C(N1C2CCC1CNC2)[C@]12C[C@H]1c1ccccc1-c1c(C3CCCCC3)c3ccccc3n1C2
1770,581929,10.1016/j.bmcl.2009.06.011,,,,Inhibition of human ERG,N[C@H]1Cn2c(nc3cnc(C(F)(F)F)cc32)C[C@@H]1c1cc(F)c(F)cc1F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,"(11R,12R)-12-azaniumyl-4-(trifluoromethyl)-11-(2,4,5-trifluorophenyl)-1,5,8-triazatricyclo[7.4.0.0^{2,7}]trideca-2(7),3,5,8-tetraen-5-ium; bis(2,2,2-trifluoroacetate)",57.0,uM,=,1.7558748556724917,1,c1ccc([C@@H]2CCn3c(nc4cnccc43)C2)cc1
1771,794861,10.1016/j.bmcl.2011.11.075,,,,Inhibition of human ERG by patch-clamp assay,COCCS(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1,(R)-1-{2-[4'-(2-Methoxy-ethanesulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine,7.4,uM,=,0.8692317197309762,1,c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
1772,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(C1CC(Oc2cccc(F)c2)CN1)N1CCCN(C2CCC2)CC1,"(4-cyclobutyl-1,4-diazepan-1-yl)(4-(3-fluorophenoxy)pyrrolidin-2-yl)methanone",10.0,uM,=,1.0,1,O=C(C1CC(Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
1773,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,C=Cc1c(CNC23CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC2)OC3)nc2c(c1C)OCC(=O)N2,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-8-methyl-7-vinyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.5,uM,=,-0.3010299956639812,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1774,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)COC1)c1ccccc1,N-((3-(4-benzylpiperazin-1-yl)oxetan-3-yl)methyl)-N-phenylpropionamide,2.9,uM,=,0.4623979978989561,1,c1ccc(CN2CCN(C3(CNc4ccccc4)COC3)CC2)cc1
1775,2054254,10.1016/j.ejmech.2020.112501,,,,Inhibition of human ERG by fluorescence polarization assay,CC(C)N1CCC(c2ccc(/C(=C(/CCCO)c3ccc(F)cc3)c3ccc(O)cc3)cc2)CC1.Cl,4-(2-(4-fluorophenyl)-5-hydroxy-1-(4-(1-isopropylpiperidin-4-yl)phenyl)pent-1-enyl)phenol hydrochloride,11.9,uM,=,1.0755469613925308,1,C(=C(c1ccccc1)c1ccc(C2CCNCC2)cc1)c1ccccc1
1776,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CC4(CCCO4)C3)cc2)C1,"(3-(4-(5-oxa-2-azaspiro[3.4]octan-2-ylmethyl)phenoxy)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone",8.9,uM,=,0.9493900066449128,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CC4(CCCO4)C3)cc2)C1
1777,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(CNC(=O)c2ccccn2)c1,N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methyl)picolinamide,27.0,uM,=,1.4313637641589874,1,O=C(NCc1cncc(-c2ccccc2)c1)c1ccccn1
1778,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,O=C(/C=C/c1ccc(CN2CCCC(c3c(-c4ccccc4)[nH]c4ccccc34)C2)c(F)c1)NO,(E)-3-{3-Fluoro-4-[3-(2-phenyl-1H-indol-3-yl)piperidin-1-ylmethyl]phenyl}-N-hydroxyacrylamide,19.3,uM,=,1.285557309007774,1,c1ccc(CN2CCCC(c3c(-c4ccccc4)[nH]c4ccccc34)C2)cc1
1779,1363584,10.1021/jm500109z,,,,Inhibition of human ERG tail current by patch clamp method,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1.Cl.Cl,N-(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide dihydrochloride,0.024,uM,=,-1.619788758288394,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
1780,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,O=C(NCC1CCCO1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,"5-(2,3-Difluorophenyl)-N-((tetrahydrofuran-2-yl)methyl)-1H-indazole-3-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C(NCC1CCCO1)c1n[nH]c2ccc(-c3ccccc3)cc12
1781,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,O=C1CN(CCc2ccc(F)cc2)CCN1[C@H]1CCc2cc(Cn3ccnc3)ccc2C1,"(S)-1-(6-((1H-imidazol-1-yl)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-4-(4-fluorophenethyl)piperazin-2-one",4.0,uM,=,0.6020599913279624,1,O=C1CN(CCc2ccccc2)CCN1[C@H]1CCc2cc(Cn3ccnc3)ccc2C1
1782,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(Cl)c(C)cc5[nH]4)CC3)c2c1,"1-(2-(4-(5-chloro-6-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)-7-methoxy-1,5-naphthyridin-2(1H)-one",1.4,uM,=,0.1461280356782379,1,O=c1ccc2ncccc2n1CCN1CCC(c2nc3ccccc3[nH]2)CC1
1783,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(CO)CO)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-(3-hydroxy-2-(hydroxymethyl)propoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",10.5,uM,=,1.021189299069938,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1784,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,COc1cc2nnc(C(N)=O)c(Nc3ccc(C)cc3F)c2cc1N1CCS(=O)(=O)CC1,"6-(1,1-Dioxo-1lambda*6*-thiomorpholin-4-yl)-4-(2-fluoro-4-methyl-phenylamino)-7-methoxy-cinnoline-3-carboxylic acid amide",16.0,uM,=,1.2041199826559248,1,O=S1(=O)CCN(c2ccc3nncc(Nc4ccccc4)c3c2)CC1
1785,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N(Cc3ccc(F)cc3)C3C4CC5CC(C4)CC3C5)nn2)ccc1-n1cnc(C)c1,"N-Adamantan-2-yl-N-(4-fluoro-benzyl)-2-{4-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[1,2,3]triazol-1-yl}-acetamide",0.25,uM,=,-0.6020599913279624,0,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)N(Cc1ccccc1)C1C2CC3CC(C2)CC1C3
1786,420606,10.1016/j.bmcl.2006.11.061,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(C2CCc3cc4c(cc32)OCO4)CC1)c1cc(=O)c2cc(F)ccc2o1,"N-(1-(6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-5-yl)piperidin-4-yl)-6-fluoro-4-oxo-4H-chromene-2-carboxamide",9.31,uM,=,0.9689496809813428,1,O=C(NC1CCN(C2CCc3cc4c(cc32)OCO4)CC1)c1cc(=O)c2ccccc2o1
1787,1972154,10.1021/acs.jmedchem.9b01624,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,CC1(C)CN(C(=O)Nc2cc(-c3cn(C4CCOCC4)c4cnccc34)ccn2)C1,"3,3-Dimethyl-N-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)azetidine-1-carboxamide",3.8,uM,=,0.5797835966168101,1,O=C(Nc1cc(-c2cn(C3CCOCC3)c3cnccc23)ccn1)N1CCC1
1788,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)c(F)c2)[C@@H]3C)n1,"US9422299, 9",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
1789,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3ccc(C#N)s3)ccc2c1,(R)-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)thiophene-2-carbonitrile,2.0,uM,=,0.3010299956639812,1,c1csc(-c2ccc3cc(CCN4CCCC4)ccc3n2)c1
1790,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H]([C@H]3CCNC3)O2)cc1,"(5R)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-5-[(3S)-pyrrolidin-3-yl]-4,5-dihydrooxazole",3.9,uM,=,0.5910646070264992,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H]([C@H]3CCNC3)O2)cc1
1791,1637594,,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in outward tail current after 5 mins at -80 mV holding potential by patch clamp assay,O=C(N1CCN(Cc2ccc3c(c2)OCO3)CC1)N1CCSc2ccccc2C1,"(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)(2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methanone",4.406,uM,=,0.6440444928147487,1,O=C(N1CCN(Cc2ccc3c(c2)OCO3)CC1)N1CCSc2ccccc2C1
1792,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c[nH]nc1C(=O)N[C@@H]1CC(C)(C)Oc2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc21,"N-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-4-methyl-1H-pyrazole-3-carboxamide",5.3,uM,=,0.724275869600789,1,O=C(N[C@@H]1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)c1cc[nH]n1
1793,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),0.0281,uM,=,-1.5512936800949202,0,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1
1794,834187,10.1021/jm2013248,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,c1cncc(-c2ccc(-c3nnc(C4CN5CCC4CC5)o3)o2)c1,"2-(5-(pyridin-3-yl)furan-2-yl)-5-(quinuclidin-3-yl)-1,3,4-oxadiazole",20.2,uM,=,1.305351369446624,1,c1cncc(-c2ccc(-c3nnc(C4CN5CCC4CC5)o3)o2)c1
1795,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,0.0015,uM,=,-2.8239087409443187,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
1796,1813578,10.1021/acs.jmedchem.9b00510,,,,Inhibition of human ERG by patch-clamp method,Cc1ccc2oc(-c3c4c(N)n[nH]c(=O)c4nn3-c3ccccc3)c(C)c2c1,"4-Amino-3-(3,5-dimethylbenzofuran-2-yl)-2-phenyl-2,6-dihydro-7H-pyrazolo[3,4-d]pyridazin-7-one",19.53,uM,=,1.2907022432878543,1,O=c1[nH]ncc2c(-c3cc4ccccc4o3)n(-c3ccccc3)nc12
1797,802877,10.1016/j.bmcl.2011.12.127,,,,Inhibition of human ERG by whole-cell patch clamp electrophysiology assay,CCCOc1sc(C(=O)N2CCC(c3cccc(CN)c3)CC2)c(C)c1Br,(4-(3-(aminomethyl)phenyl)piperidin-1-yl)(4-bromo-3-methyl-5-propoxythiophen-2-yl)methanone,1.0,uM,=,0.0,0,O=C(c1cccs1)N1CCC(c2ccccc2)CC1
1798,2079116,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 10 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),O=C(COc1ccc(C(=O)c2ccccc2Br)cc1)Nc1cccnc1,2-[4-(2-Bromobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide,0.0356,uM,=,-1.448550002027125,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1cccnc1
1799,535682,10.1016/j.bmcl.2008.08.067,,,,Displacement of [3H]dofetilide from human ERG in HEK293 cells,CNC(=O)c1c(NCC2CCC3(CC2)OCCO3)nc(C#N)nc1OCC1CCN(C)CC1,"4-(1,4-dioxaspiro[4.5]decan-8-ylmethylamino)-2-cyano-N-methyl-6-((1-methylpiperidin-4-yl)methoxy)pyrimidine-5-carboxamide",5.77,uM,=,0.7611758131557314,1,c1nc(NCC2CCC3(CC2)OCCO3)cc(OCC2CCNCC2)n1
1800,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccc(F)cc2o1,N-[1-benzylpiperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide,0.0198999999999999,uM,=,-1.7011469235902934,0,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
1801,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,O=C(N1CCc2ncc(C(F)(F)F)cc2C1)[C@@]12CCCC[C@@H]1C[C@@H](NC1CCOCC1)C2,"((2R,3aR)-2-(tetrahydro-2H-pyran-4-ylamino)octahydro-1H-inden-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",38.9,uM,=,1.5899496013257075,1,O=C(N1CCc2ncccc2C1)[C@@]12CCCC[C@@H]1C[C@@H](NC1CCOCC1)C2
1802,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(F)cn3)ccc2n1)N1CCNCC1,"US9452986, 229",17.0,uM,=,1.230448921378274,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
1803,498774,10.1021/jm900110t,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",CCC[C@@H]1NC(c2cc(C#N)ccn2)=NC1(c1ccc(F)cc1)c1ccc(F)cc1,"2-[(5S)-4,4-Bis(4-fluorophenyl)-5-propyl-4,5-dihydro-1H-imidazol-2-yl]-4-pyridinecarbonitrile",0.49,uM,=,-0.3098039199714864,0,c1ccc(C2(c3ccccc3)CNC(c3ccccn3)=N2)cc1
1804,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1cc(OC)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6,8-dimethoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00178,uM,=,-2.749579997691106,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1805,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(C(C)(C)O)nc2)C3)ccc2c1COC2=O,"(R)-5-(1-hydroxy-2-(2-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",29.0,uM,=,1.462397997898956,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cccnc3)C4)ccc21
1806,1924853,10.1016/j.bmcl.2016.07.029,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells measured after 90 mins by scintillation proximity assay,COc1cc(C(=O)N2C[C@@H](n3cc(C4CC4)nn3)C[C@H]2C(=O)NCC(c2ccccc2)c2ccccc2)ccc1CN,"(2S,4S)-1-(4-(aminomethyl)-3-methoxybenzoyl)-4-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide",2.4,uM,=,0.380211241711606,1,O=C(NCC(c1ccccc1)c1ccccc1)[C@@H]1C[C@H](n2cc(C3CC3)nn2)CN1C(=O)c1ccccc1
1807,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNC(C)c1cc(C)ccc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-5-methylphenyl)-N-methylethanamine",2.69,uM,=,0.4297522800024079,1,c1ccc(Oc2ccccc2)cc1
1808,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",1.4,uM,=,0.1461280356782379,1,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
1809,559360,10.1021/jm8012932,,,,Inhibition of human ERG,Clc1ccc(-n2c(-c3ccc(Cl)cc3Cl)nc3c(NN4CCCCC4)ncnc32)cc1,"9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-9H-purin-6-amine",2.7,uM,=,0.4313637641589873,1,c1ccc(-c2nc3c(NN4CCCCC4)ncnc3n2-c2ccccc2)cc1
1810,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,Oc1cc(-n2cccn2)ccc1-c1ccc(OC2CCNCC2)nn1,2-(6-(piperidin-4-yloxy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol,6.0,uM,=,0.7781512503836436,1,c1cnn(-c2ccc(-c3ccc(OC4CCNCC4)nn3)cc2)c1
1811,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,COc1ncc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cc1C,cis-N-({1-[4-Hydroxy-4-(6-methoxy-5-methyl-pyridin-3-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,21.6,uM,=,1.334453751150931,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccnc3)CC2)C1
1812,1622464,10.1016/j.bmcl.2016.09.067,,,,Inhibition of radiolabeled dofetilide binding to human ERG expressed in HEK293 cells,N[C@@H]1CN(c2ccncc2Nc2ncc3ccc(-c4ncccc4F)nn23)C[C@H](N)[C@H]1O,"(3S,4r,5R)-3,5-diamino-1-(3-(2-(3-fluoropyridin-2-yl)imidazo[1,5-b]pyridazin-7-ylamino)pyridin-4-yl)piperidin-4-ol",11.5,uM,=,1.0606978403536118,1,c1ccc(-c2ccc3cnc(Nc4cnccc4N4CCCCC4)n3n2)nc1
1813,1677359,10.1021/acs.jmedchem.7b01454,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK cells after 180 mins by scintillation counting method,Fc1ccc(C(OC2CC3CCC(C2)N3CCN2CCCCC2)c2ccc(F)cc2)cc1,3alpha-(Bis(4-fluorophenyl)methoxy)-8-(2-(piperidin-1-yl)ethyl)-8-azabicyclo[3.2.1]octane,5.15,uM,=,0.7118072290411911,1,c1ccc(C(OC2CC3CCC(C2)N3CCN2CCCCC2)c2ccccc2)cc1
1814,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"exo-3-((1R,3s,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide",0.00061,uM,=,-3.214670164989233,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
1815,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ncccn1,"4'-[8-(3-Methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrimidin-2-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",19.0,uM,=,1.2787536009528289,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ncccn1
1816,579539,10.1016/j.bmcl.2009.05.101,,,,Inhibition of [35S]MK499 binding to human ERG transfected in HEK293 cells by microscintillation counting,C[C@H]1[C@@H](c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc2S1(=O)=O,"cis-1-{3-[4-(3-Methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",0.44,uM,=,-0.3565473235138126,0,O=S1(=O)C[C@@H](c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
1817,763235,10.1016/j.ejmech.2011.05.015,,,,Inhibition of wild-type human ERG channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl,SID26748842,32.0,uM,=,1.505149978319906,1,O=C(Nc1ccccc1)C1CCCCN1
1818,1504613,10.1021/acs.jmedchem.5b00518,,,,Inhibition of human Kv11.1 expressed in HEK293 cells assessed as inhibition of channel tail current at holding potential -80 mV by whole cell voltage clamp assay,C[n+]1c(C#Cc2ccc(-c3ccccc3)cc2)cccc1C#Cc1ccc(-c2ccccc2)cc1,"2,6-bis(biphenyl-4-ylethynyl)-1-methylpyridinium",0.107,uM,=,-0.9706162223147904,0,C(#Cc1cccc(C#Cc2ccc(-c3ccccc3)cc2)[nH+]1)c1ccc(-c2ccccc2)cc1
1819,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=c1\sc(C(=O)Nc2ccccc2)nn1-c1ccccc1,"5-((3-Cyano-4,6-diphenylpyridin-2-yl)imino)-N,4-diphenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxamide",8.4,uM,=,0.9242792860618816,1,O=C(Nc1ccccc1)c1nn(-c2ccccc2)/c(=N/c2cc(-c3ccccc3)cc(-c3ccccc3)n2)s1
1820,439396,10.1016/j.bmcl.2007.05.087,,,,Inhibition of human ERG potassium channel,N[C@H]1CN(c2ccncn2)CC[C@@H]1c1cc(F)c(F)cc1F.O=C(O)C(F)(F)F,"(3R,4R)-1-(pyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium 2,2,2-trifluoroacetate",26.1,uM,=,1.416640507338281,1,c1ccc(C2CCN(c3ccncn3)CC2)cc1
1821,815278,10.1016/j.ejmech.2012.02.049,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cells after 45 mins by scintillation counting method,CCOC(=O)C1CCN(CCCOc2ccc(S(N)(=O)=O)cc2)CC1,4-{3-[(4-ethoxycarbonyl)piperidin-1-yl]propoxy}benzenesulfonamide,76.5,uM,=,1.8836614351536176,1,c1ccc(OCCCN2CCCCC2)cc1
1822,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CCCC[C@@]2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1,"((2R,3aR)-2-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydro-1H-inden-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",40.9,uM,=,1.611723308007342,1,O=C(N1CCc2ncccc2C1)[C@@]12CCCC[C@@H]1C[C@@H](NC1CCOCC1)C2
1823,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,N#Cc1ccc(Oc2ccc3nc(C(=O)N4CCNCC4)ccc3c2)cc1,"US9452986, 112",5.2,uM,=,0.7160033436347992,1,O=C(c1ccc2cc(Oc3ccccc3)ccc2n1)N1CCNCC1
1824,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1,"N,N-dimethyl-2-(4-(6-phenyl-7-(4-((4-(5-(pyrimidin-2-yl)-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)pyrido[2,3-d]pyrimidin-2-yl)piperazin-1-yl)ethanamine",4.8,uM,=,0.6812412373755872,1,c1ccc(-c2cc3cnc(N4CCNCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ncccn5)[nH]4)CC3)cc2)cc1
1825,762537,10.1016/j.bmcl.2011.06.017,,,,Inhibition of human ERG expressed in HEK293 cells assessed as inhibition of potassium channel current after 5 mins by patch clamp assay,Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,"5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide",2.79,uM,=,0.4456042032735975,1,O=C(NN1CCCCC1)c1cc(-c2ccccc2)n(-c2ccccc2)n1
1826,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",CN(CCOc1ccc(-n2ccc(OCc3ccccc3)cc2=O)cc1)Cc1ccccc1,1-(4-{2-[Benzyl(methyl)amino]ethoxy}phenyl)-4-(benzyloxy)pyridin-2(1H)-one,0.00081,uM,=,-3.09151498112135,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCNCc2ccccc2)cc1
1827,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2cc3c(N[C@@H](C)c4nn(C)cc4C)c(C(N)=O)cnc3cc2F)cn1,"(S)-4-(1-(1,4-dimethyl-1H-pyrazol-3-yl)ethylamino)-7-fluoro-6-(6-(methoxymethyl)pyridin-3-yl)quinoline-3-carboxamide",17.0,uM,=,1.230448921378274,1,c1cncc(-c2ccc3nccc(NCc4cc[nH]n4)c3c2)c1
1828,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3ccc(Cl)nc3)ccc2c1,(R)-2-(6-chloropyridin-3-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,3.6,uM,=,0.5563025007672873,1,c1cncc(-c2ccc3cc(CCN4CCCC4)ccc3n2)c1
1829,804952,10.1021/jm201407j,,,,Inhibition of human ERG by cell based voltage clamp assay,COc1cc(/C=C2\CCCN3C2=NO[C@]3(CO)c2ccc(F)cc2)ccc1-n1cnc(C)c1,"(S,E)-(3-(4-Fluorophenyl)-8-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)-5,6,7,8-tetrahydro-3H-[1,2,4]-oxadiazolo[4,3-a]pyridin-3-yl)methanol",3.3,uM,=,0.5185139398778875,1,C(=C1\CCCN2C1=NOC2c1ccccc1)\c1ccc(-n2ccnc2)cc1
1830,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,O=c1ccc2ncc(=O)n3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1,"(R)-2-{4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)-amino]-piperidin-1-ylmethyl}-1,2-dihydro-2a,5,8a-triaza-acenaphthylene-3,8-dione",1311.8490863806444,uM,=,3.117883877172367,1,O=c1ccc2ncc(=O)n3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1
1831,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,N[C@H]1C(=O)N[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-(((2S,3R)-3-amino-4-oxoazetidin-2-yl)methoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",29.1,uM,=,1.4638929889859074,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OC[C@@H]7CC(=O)N7)nc56)(CC3)OC4)nc2N1
1832,1973140,10.1021/acs.jmedchem.0c00245,,,,Inhibition of human ERG,Cc1cc(Cl)cc(-c2ccnc3cc(CN4C(=O)C5CC5C4=O)sc23)c1C[C@@H]1CNCCO1,"3-((7-(5-Chloro-3-methyl-2-(((R)-morpholin-2-yl)methyl)phenyl)thieno[3,2-b]pyridin-2-yl)methyl)-3-azabicyclo[3.1.0]hexane-2,4-dione",8.0,uM,=,0.9030899869919436,1,O=C1C2CC2C(=O)N1Cc1cc2nccc(-c3ccccc3C[C@@H]3CNCCO3)c2s1
1833,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2cnn(C)c(=O)c2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",12.0,uM,=,1.0791812460476249,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cn[nH]c(=O)c3)C4=O)ccc21
1834,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(NCc1ccc(O)cc1Cl)C1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,N-(2-chloro-4-hydroxybenzyl)-1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidine-4-carboxamide,1.55,uM,=,0.1903316981702915,1,O=C(NCc1ccccc1)C1CCN(Cc2ccn(-c3ccccc3)c2)CC1
1835,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,CC(=O)C1=NN(c2ccccc2)/C(=C2/S/C(=N\c3nc(-c4ccccc4)cc(-c4ccccc4)c3C#N)N(c3ccccc3)C2=O)S1,"2-[(5-(5-Acetyl-3-phenyl-1,3,4-thiadiazol-2(3H)-ylidene)-4-oxo-3-phenylthiazolidin-2-ylidene)amino]-4,6-diphenylnicotinonitrile",5.7,uM,=,0.7558748556724915,1,O=C1/C(=C2/SC=NN2c2ccccc2)S/C(=N\c2cc(-c3ccccc3)cc(-c3ccccc3)n2)N1c1ccccc1
1836,1779901,10.1021/acs.jmedchem.8b00884,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1ccc2nn(C)cc2c1NS(=O)(=O)c1ccc(CCCOC[C@H]2COCCN2C)cc1,(S)-N-(5-isobutyl-2-methyl-2H-indazol-4-yl)-4-(3-((4-methylmorpholin-3-yl)methoxy)propyl)benzenesulfonamide,3.1,uM,=,0.4913616938342727,1,O=S(=O)(Nc1cccc2n[nH]cc12)c1ccc(CCCOC[C@H]2COCCN2)cc1
1837,1973040,10.1021/acsmedchemlett.0c00015,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,CN1C(C)(C)CC(Nc2nc3c(-c4ccc(C(=O)N5C[C@@H]6C[C@H]5CO6)cc4)cnn3c(N)c2-c2ccccc2)CC1(C)C,"(4-(7-amino-5-((1,2,2,6,6-pentamethylpiperidin-4-yl)amino)-6-phenylpyrazolo[1,5-a]pyrimidin-3-yl)phenyl)((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methanone",4.7,uM,=,0.6720978579357175,1,O=C(c1ccc(-c2cnn3cc(-c4ccccc4)c(NC4CCNCC4)nc23)cc1)N1C[C@@H]2C[C@H]1CO2
1838,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN(C)c1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCNCC2)n1,"6-(((4-(4-fluorophenyl)piperidin-4-yl)methoxy)methyl)-N,N-dimethyl-4-(trifluoromethyl)pyridin-2-amine",8.4,uM,=,0.9242792860618816,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
1839,1579492,10.1021/acsmedchemlett.5b00452,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)CCN(C)C,"N-(5-(3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acetamide",4.0,uM,=,0.6020599913279624,1,c1ccc(Nc2cc(NC3CC3)n3nccc3n2)cc1
1840,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,CN1CC[C@@]2(CN=C(N3CCc4ccccc4[C@@H]3c3ccc(F)cc3)O2)C1,"(5S)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-7-methyl-1-oxa-3,7-diazaspiro[4.4]non-2-ene",1.7,uM,=,0.2304489213782739,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@]3(CCNC3)O2)cc1
1841,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(N2CCCC2)ncc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,6-{2-[(2R)-2-methyl-pyrrolidin-1-yl]ethyl}-2-(4-methyl-2-pyrrolidin-1-ylpyrimidin-5-yl)quinoline,10.4,uM,=,1.0170333392987805,1,c1cc2nc(-c3cnc(N4CCCC4)nc3)ccc2cc1CCN1CCCC1
1842,537242,10.1021/jm800569w,,,,"Antagonist activity at human ERG in HEK293 cells assessed as inhibition of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide binding",Cc1nc2ccccc2c(=O)n1-c1ccc(O[C@H]2CC[C@@H](N3CCCC3)CC2)cc1,cis-2-Methyl-3-(4-([4-(1-pyrrolidinyl)cyclohexyl]oxy)phenyl)-4(3H)-quinazolinone,8.0,uM,=,0.9030899869919436,1,O=c1c2ccccc2ncn1-c1ccc(O[C@H]2CC[C@@H](N3CCCC3)CC2)cc1
1843,699709,10.1016/j.bmcl.2010.11.111,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells,CCOC(=O)c1sc2nc(/C=C/c3ccc(-n4cnc(C)c4)c(OC)c3)nc(N)c2c1C,"ethyl 4-amino-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)styryl)-5-methylthieno[2,3-d]pyrimidine-6-carboxylate",0.98,uM,=,-0.0087739243075051,0,C(=C/c1ncc2ccsc2n1)\c1ccc(-n2ccnc2)cc1
1844,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,CCOc1cc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N,"4-ethoxy-6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)nicotinonitrile",7.7,uM,=,0.8864907251724818,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
1845,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CC(Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ccc(C#N)cc2)CC1)C(F)(F)F,"rac-4-{4-[5-Methanesulfonyl-2-(2,2,2-trifluoro-1-methyl-ethoxy)-benzoyl]-piperazin-1-yl}-benzonitrile",1.2,uM,=,0.0791812460476248,1,O=C(c1ccccc1)N1CCN(c2ccccc2)CC1
1846,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN(C)CC5(C)COC5)cc4)C3)o2)cc1,"(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)(3-(4-((methyl((3-methyloxetan-3-yl)methyl)amino)methyl)phenoxy)azetidin-1-yl)methanone",16.0,uM,=,1.2041199826559248,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CNCC3COC3)cc2)C1
1847,518708,10.1016/j.bmcl.2008.12.017,,,,Inhibition of human ERG expressed in HEK cells by competitive radioligand binding assay,Oc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12,"9-phenyl-8-(4-((4-(5-(pyridin-2-yl)-1H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-ol",5.312,uM,=,0.725258066359961,1,c1ccc(-c2cc3c(ccn4cnnc34)nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1
1848,1577772,10.1021/acsmedchemlett.5b00360,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cell membranes incubated for 2 hrs by scintillation counting analysis,CCN(CC)c1ccc2cc(C(=O)NCCCCN3CCC(Nc4nc5ccccc5n4Cc4ccc(F)cc4)CC3)c(=O)oc2c1,7-(diethylamino)-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-ylamino)piperidin-1-yl)butyl)-2-oxo-2H-chromene-3-carboxamide,0.434,uM,=,-0.3625102704874893,0,O=C(NCCCCN1CCC(Nc2nc3ccccc3n2Cc2ccccc2)CC1)c1cc2ccccc2oc1=O
1849,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)o1,"N,N-Diethyl-5-(spiro[chromene-2,4'-piperidine]-4-yl)furan-2-carboxamide",5.132,uM,=,0.7102866477028908,1,C1=C(c2ccco2)c2ccccc2OC12CCNCC2
1850,446746,10.1016/j.bmcl.2006.12.007,,,,Inhibition of hERG by patch clamp assay,CS(=O)(=O)O.NC[C@H]1CC[C@]2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3,"dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1''-cyclohexane]-4''-ylmethanamine; methanesulfonate",1.8,uM,=,0.255272505103306,1,C1CCC2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3
1851,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1CCc2c(F)cccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1,"5-Fluoro-1-{3-[4-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-3,4-dihydro-1H-quinolin-2-one",5.3,uM,=,0.724275869600789,1,O=C1CCc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
1852,2133680,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG expressed in CHO by QPatch assay,CC[C@H](NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@@H]2C[C@@H](n3cnc4ccc(F)cc43)C[C@@H]21,"4-chloro-N-((S)-1-((1R,3S,5S,6r)-3-(6-fluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide.",14.0,uM,=,1.146128035678238,1,O=C(NC[C@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
1853,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CCC(O)(CN)C3)nn12,"3-(Aminomethyl)-1-(5-(4-fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)pyrrolidin-3-ol",17.8,uM,=,1.250420002308894,1,c1ccc(-c2cnc3sc(N4CCCC4)nn23)cc1
1854,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,Cc1ccccc1-c1nc2cc(-c3ccc(Cl)cc3)sc2c(=O)n1CC1CCCN(C(C)C)C1,"rac-6-(4-Chlorophenyl)-3-((1-isopropylpiperidin-3-yl)methyl)-2-o-tolylthieno[3,2-d]pyrimidin-4(3H)-one",2.1,uM,=,0.3222192947339193,1,O=c1c2sc(-c3ccccc3)cc2nc(-c2ccccc2)n1CC1CCCNC1
1855,1364610,10.1021/ml500069w,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp assay,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1.Cl,"(S)-6-((1-(2-(3-Fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one hydrochloride",18.0,uM,=,1.255272505103306,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1856,806244,10.1016/j.bmcl.2012.01.078,,,,Inhibition of human Erg by patch clamp assay,Cc1nc2cnc(Oc3ccc(F)c4cccnc34)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,"(S)-6-(5-fluoroquinolin-8-yloxy)-3-((1-isopropylpiperidin-3-yl)methyl)-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one",9.4,uM,=,0.9731278535996988,1,O=c1c2cc(Oc3cccc4cccnc34)ncc2ncn1C[C@H]1CCCNC1
1857,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-3-yl)acetic Acid,1.2,uM,=,0.0791812460476248,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCCO5)CC4)nc3)nc2c1
1858,2125085,10.1021/acsmedchemlett.1c00450,,,,Inhibition of human ERG expressed in CHO cells by manual patch clamp assay,COC(=O)N[C@H]1CC[C@@H](n2cc(-c3ccc(Cl)c(N)c3)c3c(N)ncnc32)CC1,"methyl ((cis)-4-(4-amino-5-(3-amino-4-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)carbamate",5.3,uM,=,0.724275869600789,1,c1ccc(-c2cn(C3CCCCC3)c3ncncc23)cc1
1859,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CN(c1ccc(-c2cc3cccnc3cc2O)nn1)C1CC(C)(C)NC(C)(C)C1,"6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-7-ol",4.5,uM,=,0.6532125137753437,1,c1cnc2ccc(-c3ccc(NC4CCNCC4)nn3)cc2c1
1860,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CC2CC2)c1,endo-3-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0073,uM,=,-2.136677139879544,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CC2CC2)cc1
1861,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,Cn1cc2cc(-c3cnc(Nc4cnc(C#N)cn4)cc3NC[C@H]3CNCCO3)ccc2n1,(R)-5-((5-(2-Methyl-2H-indazol-6-yl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,16.0,uM,=,1.2041199826559248,1,c1cnc(Nc2cc(NC[C@H]3CNCCO3)c(-c3ccc4n[nH]cc4c3)cn2)cn1
1862,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CCN(C)c1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCN(C)CC2)n1,N-ethyl-6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-N-methyl-4-(trifluoromethyl)pyridin-2-amine,6.1,uM,=,0.785329835010767,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
1863,755804,10.1021/jm2003359,,,,Inhibition of human ERG expressed in CHO cells by Q-patch assay,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)c(F)c2)C1,"2-amino-1-(3-(3,4-difluorophenylamino)-2-(4-fluorophenyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one",4.8,uM,=,0.6812412373755872,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
1864,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c(CCN2CCN(C(=O)Cc3cnc(-n4cnnn4)cn3)CC2)ccc2c1COC2=O,5-(2-(4-(2-(5-(1H-tetrazol-1-yl)pyrazin-2-yl)acetyl)piperazin-1-yl)ethyl)-4-methylisobenzofuran-1(3H)-one,12.0,uM,=,1.0791812460476249,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4cnc(-n5cnnn5)cn4)CC3)ccc21
1865,1366626,10.1021/jm500535j,,,,Inhibition of human ERG,Nc1nc2ccccc2n1CC(O)c1ccc(Cl)cc1Cl,"rac-2-(2-Amino-1H-benzo[d]imidazol-1-yl)-1-(2,4-dichlorophenyl)-ethanol",10.3,uM,=,1.0128372247051722,1,c1ccc(CCn2cnc3ccccc32)cc1
1866,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2ncccc2c1,(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,40.0,uM,=,1.6020599913279625,1,c1cnc2ccc(CCN3CCCC3)cc2c1
1867,1792104,10.1016/j.bmcl.2018.09.018,,,,Inhibition of human ERG,C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4CCCCC4)cc3)n2)C1,(S)-6-(3-acrylamidopyrrolidin-1-yl)-2-(4-(piperidin-1-yl)phenylamino)nicotinamide,3.3,uM,=,0.5185139398778875,1,c1cc(Nc2ccc(N3CCCCC3)cc2)nc(N2CCCC2)c1
1868,1446841,10.1021/jm500715u,,,,Inhibition of human ERG,CN1CCN(c2cc(Cl)c3nc(Nc4ccc(Br)cn4)[nH]c3c2)CC1,N-(5-Bromopyridin-2-yl)-4-chloro-6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-amine,7.3,uM,=,0.8633228601204559,1,c1ccc(Nc2nc3ccc(N4CCNCC4)cc3[nH]2)nc1
1869,2117143,10.1021/acs.jmedchem.0c01938,,,,Inhibition of human ERG expressed in HEK cells at -80 mV holding potential by patch clamp assay relative to control,CS(=O)(=O)c1nc(Nc2ccc(F)c(Cl)c2)cc(NC2CCC(N)CC2)n1,6-(4-Aminopiperidin-1-yl)-N-(3-chloro-4-fluorophenyl)-2-(methylsulfonyl)pyrimidin-4-amine,19.8,uM,=,1.2966651902615312,1,c1ccc(Nc2cc(NC3CCCCC3)ncn2)cc1
1870,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,N#Cc1cnc(Nc2cc(NC[C@@H]3CNCCO3)c(C3CC3)cn2)cn1,(S)-5-((5-Cyclopropyl-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,6.6,uM,=,0.8195439355418687,1,c1cnc(Nc2cc(NC[C@@H]3CNCCO3)c(C3CC3)cn2)cn1
1871,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3nccc4ccccc34)no2)CC1,"4-(3-(isoquinolin-1-yl)-1,2,4-oxadiazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide",7.0,uM,=,0.8450980400142568,1,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3nccc4ccccc34)no2)CC1
1872,1694220,10.1016/j.bmc.2017.07.040,,,,Inhibition of human ERG,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one",1.33,uM,=,0.1238516409670858,1,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2
1873,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C1CN(C(=O)COc2ccc3cc(Oc4ccccn4)ccc3n2)CCN1,4-[2-[[6-(2-pyridyloxy)-2-quinolyl]oxy]acetyl]piperazin-2-one,30.0,uM,=,1.4771212547196624,1,O=C1CN(C(=O)COc2ccc3cc(Oc4ccccn4)ccc3n2)CCN1
1874,876604,10.1021/jm301476b,,,,Inhibition of human ERG expressed in chinese hamster lung cells by IonWorks patch clamp electrophysiology assay,Nc1ncc(-c2ccc(C(=O)N3CCOCC3)cc2)cc1-c1ccc(C(F)(F)F)nc1,(4-(6-Amino-5-(6-(trifluoromethyl)pyridin-3-yl)pyridin-3-yl)phenyl)-(morpholino)methanone,20.2,uM,=,1.305351369446624,1,O=C(c1ccc(-c2cncc(-c3cccnc3)c2)cc1)N1CCOCC1
1875,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,C#Cc1cnc(Nc2cnc(C#N)cn2)cc1NC[C@@H]1CNCCO1,(S)-5-((5-Ethynyl-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,8.2,uM,=,0.9138138523837168,1,c1cnc(Nc2cc(NC[C@@H]3CNCCO3)ccn2)cn1
1876,674336,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human ERG expressed in HEK cells by patch clamp technique,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3oc(N4CCOCC4)nc13)C2,"endo-N-((1R,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-morpholinobenzo[d]oxazole-4-carboxamide",1.4,uM,=,0.1461280356782379,1,O=C(N[C@@H]1C[C@H]2CCC[C@@H](C1)N2)c1cccc2oc(N3CCOCC3)nc12
1877,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CCN1CCC[C@@H](CN2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"(R)-N-(3,4-dichlorophenyl)-4-((1-ethylpiperidin-3-yl)methyl)piperazine-1-carboxamide",2.1,uM,=,0.3222192947339193,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCNC2)CC1
1878,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(O)cc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-hydroxy-4-oxo-4H-chromene-2-carboxamide",0.0637,uM,=,-1.1958605676646494,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
1879,1760517,10.1021/acs.jmedchem.8b00372,,,,Inhibition of human ERG expressed in CHO cells at 10 nM to 10 uM at holding potential of -80 mV measured after 5 mins by QPatch automated patch clamp electrophysiology method,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2N2CCC(F)(F)CC2)C3)ccn1,"4-(4,4-Difluoropiperidin-1-yl)-3-[2-(2-methylpyridin-4-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole-5-carbonyl]benzonitrile",6.9,uM,=,0.8388490907372553,1,O=C(c1ccccc1N1CCCCC1)N1Cc2cn(-c3ccncc3)nc2C1
1880,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Fc1cccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)c1,"(1R,3R)-3-(4-(3-fluorophenyl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.258,uM,=,-0.5883802940367698,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
1881,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(-c4ccc(Cl)cc4)c3n2CCN1CC1CC1,"2-(Cyclopropylmethyl)-6-(4-chlorophenyl)-3,4-dihydropyrazino-(1,2-a)bendmidazol-1(2H)-one",9.5,uM,=,0.9777236052888478,1,O=C1c2nc3cccc(-c4ccccc4)c3n2CCN1CC1CC1
1882,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,CC(C)(NC(=O)[C@H]1CN(C2CCCCC2)CC[C@@H]1NC(=O)c1cc(-c2ccc(F)cc2F)on1)c1ccccn1,"(3S,4S)-1-Cyclohexyl-4-([5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino)piperidine-3-carboxylic acid (1-methyl-1-pyridin-2-yl-ethyl)-amide",1.5,uM,=,0.1760912590556812,1,O=C(N[C@H]1CCN(C2CCCCC2)C[C@@H]1C(=O)NCc1ccccn1)c1cc(-c2ccccc2)on1
1883,1655139,10.1016/j.bmcl.2016.12.054,,,,Displacement of [3H]-MK499 from human ERG IKr channel expressed in HEK293 cell membranes,Nc1cccc(C(Cc2cccnc2-c2cc(Cl)cc(Cl)c2)c2cccnc2)n1,"6-(2-(2-(3,5-dichlorophenyl)pyridin-3-yl)-1-(pyridin-3-yl)ethyl)pyridin-2-amine",10.2,uM,=,1.0086001717619175,1,c1ccc(-c2ncccc2CC(c2cccnc2)c2ccccn2)cc1
1884,875808,10.1021/jm201710f,,,,Displacement of [3H]dofetilide to human ERG expressed in HEK293 cells,COc1cc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1,2-(4-fluorophenyl)-N-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1-methyl-1H-benzo[d]imidazol-4-amine,2.0,uM,=,0.3010299956639812,1,c1ccc(-c2nc3c(Nc4ccc(-n5ccnc5)cc4)cccc3[nH]2)cc1
1885,2129860,10.1021/acsmedchemlett.1c00328,,,,Inhibition of human ERG stably expressed in CHO-K1 cells at -90 mV holding potential by automated Q-patch clamp method,N#Cc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(C#N)cc3)CC2)cc1,4-(2-(4-((1-(4-cyanobenzyl)-1H-benzo[d]imidazol-2-yl)amino)piperidin-1-yl)ethyl)benzonitrile,0.05,uM,=,-1.3010299956639813,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
1886,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ccc(=O)n(CCN3CCC(c4c[nH]c5cc(C(F)(F)F)ccc45)CC3)c2c1,"7-methoxy-1-(2-(4-(6-(trifluoromethyl)-1H-indol-3-yl)piperidin-1-yl)ethyl)-1,5-naphthyridin-2(1H)-one",1.8,uM,=,0.255272505103306,1,O=c1ccc2ncccc2n1CCN1CCC(c2c[nH]c3ccccc23)CC1
1887,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@H](C4CCOCC4)N3)n2)cc1,"trans-(1S,3R)-3-(4-phenyl-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.73,uM,=,-0.1366771398795441,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@H](C4CCOCC4)N3)n2)cc1
1888,2253561,10.1021/acs.jmedchem.1c02071,,,,Inhibition of hERG expressed in HEK293 cells by automated patch clamp assay,Cc1ccccc1CN1C(=O)C2=C(CCN(Cc3ccccc3)C2)N2CCN=C12,DORDAVIPRONE,3.71,uM,=,0.5693739096150459,1,O=C1C2=C(CCN(Cc3ccccc3)C2)N2CCN=C2N1Cc1ccccc1
1889,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,COc1cccc(N2CC3(CCN(CCc4ccccc4)CC3)OC(C)C2=O)c1,"4-(3-methoxyphenyl)-2-methyl-9-(2-phenylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",1.0,uM,=,0.0,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
1890,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,CC(=O)N1CCc2nc(OCc3c(-c4ccc(F)cc4)noc3C)ccc2C1,"1-(2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)ethanone",5.3,uM,=,0.724275869600789,1,c1ccc(-c2nocc2COc2ccc3c(n2)CCNC3)cc1
1891,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@H]2CCCOC2)c(=O)n4C)cn1,"US9428503, 17",27.0,uM,=,1.4313637641589874,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1[C@H]1CCCOC1
1892,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3(C)CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-3-methyl-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",6.0,uM,=,0.7781512503836436,1,O=C1Nc2ccccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
1893,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrazin-2-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",7.2,uM,=,0.8573324964312685,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1cnccn1
1894,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ccc(F)cc3C2)C1,"(7-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)((2R,3aR,6aR)-2-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)methanone",23.5,uM,=,1.3710678622717365,1,O=C(N1CCc2ccccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
1895,1741067,10.1021/acs.jmedchem.8b00450,,,,Displacement of [3H]astemizole from human ERG expressed in HEK cell membranes,CN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21,"(S)-N-methyl-N-(((R)-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",20.3,uM,=,1.307496037913213,1,c1cnc2c(c1)CCC[C@@H]2NC[C@H]1Cc2c(cccc2N2CCNCC2)CN1
1896,611802,10.1021/jm9015075,,,,Inhibition of human ERG,Fc1cnc2nc(N3CCN4CCC3CC4)oc2c1,"4-(6-Fluorooxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]-nonane",8.7,uM,=,0.9395192526186184,1,c1cnc2nc(N3CCN4CCC3CC4)oc2c1
1897,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)CCN1CCC(CNC(=O)c2cccc(Cl)c2)CC1,"3-chloro-N-{[1-(3,3-dimethylbutyl)piperidin-4-yl]methyl}benzamide",4.823,uM,=,0.6833172619218827,1,O=C(NCC1CCNCC1)c1ccccc1
1898,640798,10.1016/j.bmcl.2010.05.041,,,,Inhibition of human ERG by patch clamp technique,O=C(c1ccc(Oc2ccc(F)cc2)cn1)N1CCCN(C2CCC2)CC1,"(4-cyclobutyl-1,4-diazepan-1-yl)(5-(4-fluorophenoxy)pyridin-2-yl)methanone",0.9,uM,=,-0.0457574905606751,0,O=C(c1ccc(Oc2ccccc2)cn1)N1CCCN(C2CCC2)CC1
1899,811343,10.1016/j.bmcl.2012.01.095,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1cc(C[C@H](CCCCNCc2ccc(F)cc2)C(=O)NO)cc(C)c1F,"(S)-2-(4-fluoro-3,5-dimethylbenzyl)-6-(4-fluorobenzylamino)-N-hydroxyhexanamide",4.65,uM,=,0.667452952889954,1,c1ccc(CCCCCCNCc2ccccc2)cc1
1900,1912248,10.1021/acs.jmedchem.9b00443,,,,Inhibition of human ERG by fluorescence polarization assay,CNC(=O)c1cnc(Nc2cc(C)ccn2)cc1Nc1ccccc1S(C)(=O)=O,N-Methyl-6-((4-methylpyridin-2-yl)amino)-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide,16.0,uM,=,1.2041199826559248,1,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1
1901,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ncccc32)CC1,"4-{3-[4-(2-Oxo-2,3-dihydro-imidazo[4,5-b]pyridin-1-yl)-piperidin-1-yl]-propyl}-4H-benzo[1,4]oxazin-3-one",22.0,uM,=,1.3424226808222062,1,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ncccc32)CC1
1902,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-7-(trifluoromethyl)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00089,uM,=,-3.050609993355087,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
1903,421810,10.1016/j.bmcl.2006.10.053,,,,Inhibition of binding to hERG,CN(C(=O)c1ccc(-c2ccc(F)cc2)cc1)[C@H]1CCc2cc(CN3CCN(C(N)=O)CC3)ccc2C1,"(S)-4-((6-(4'-fluoro-N-methylbiphenyl-4-ylcarboxamido)-5,6,7,8-tetrahydronaphthalen-2-yl)methyl)piperazine-1-carboxamide",6.7,uM,=,0.8260748027008264,1,O=C(N[C@H]1CCc2cc(CN3CCNCC3)ccc2C1)c1ccc(-c2ccccc2)cc1
1904,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4ccccc4N(Cc4cccnc4)C3=O)nn2)ccc1-n1cnc(C)c1,"rac-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(pyridin-3-ylmethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",4.45,uM,=,0.6483600109809317,1,O=C1C(n2cc(-c3ccc(-n4ccnc4)cc3)nn2)CCc2ccccc2N1Cc1cccnc1
1905,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccns2)C3)ccc2c1COC2=O,"(R)-5-(1-hydroxy-2-(2-(isothiazol-5-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",1.4,uM,=,0.1461280356782379,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccns3)C4)ccc21
1906,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc(C(NC(=O)Cc2nccs2)C(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)nc1,"2-(5-ethylsulfonyl-2-pyridyl)-2-[(2-thiazol-2-ylacetyl)amino]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide",5.5,uM,=,0.7403626894942439,1,O=C(Cc1nccs1)NC(C(=O)Nc1ccccc1)c1ccccn1
1907,1515505,10.1021/ml500440u,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc(C#N)cn3)CC2)ccc2c1COC2=O,"6-((S)-1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)nicotinonitrile",12.0,uM,=,1.0791812460476249,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
1908,804952,10.1021/jm201407j,,,,Inhibition of human ERG by cell based voltage clamp assay,COc1cc(/C=C2\CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1,"(S,E)-1-(1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)piperidin-2-one",1.2,uM,=,0.0791812460476248,1,O=C1/C(=C/c2ccc(-n3ccnc3)cc2)CCCN1Cc1ccccc1
1909,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CCNC(C(F)(F)F)C1,"US9452986, 20",30.0,uM,=,1.4771212547196624,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
1910,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CC[C@H]3OC[C@H](NCc4ccc5c(n4)NC(=O)CO5)CO3)c2c1,"6-(((2-(2-(6-methoxyquinolin-4-yl)ethyl)-trans-1,3-dioxan-5-yl)amino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.5,uM,=,0.3979400086720376,1,O=C1COc2ccc(CN[C@H]3CO[C@H](CCc4ccnc5ccccc45)OC3)nc2N1
1911,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,O=C(C1CC1)N1CCc2c(sc3c2c2ncnn2c(=O)n3Cc2ccc(Cl)cc2)C1,"6-(4-Chlorobenzyl)-9-(cyclopropanecarbonyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]-pyrimidin-5(6H)-one",0.49,uM,=,-0.3098039199714864,0,O=C(C1CC1)N1CCc2c(sc3c2c2ncnn2c(=O)n3Cc2ccccc2)C1
1912,541084,10.1016/j.bmcl.2009.01.009,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,Cc1nnc(C)n1C1CCN(C(C)C[C@H](NC(=O)C2CCC2)c2ccccc2)CC1,"N-((1S)-3-(4-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl)-1-phenylbutyl)cyclobutanecarboxamide",0.849,uM,=,-0.0710923097560473,0,O=C(N[C@@H](CCN1CCC(n2cnnc2)CC1)c1ccccc1)C1CCC1
1913,390361,10.1016/j.bmcl.2006.05.069,,,,Inhibition of hERG channel by voltage clamp assay,CN1CCN(CCCN(C(=O)Nc2ccc(F)c(C(F)(F)F)c2)[C@@H]2CC[C@]3(c4ccc(C#N)cc4)C[C@H]23)CC1,N-[trans-5-(4-cyanophenyl)bicyclo[3.1.0]hex-2-yl]-N'-[4-fluoro-3-(trifluoromethyl)phenyl)-N-[3-(4-methyl-1-piperazinyl)propyl]-urea,0.052,uM,=,-1.2839966563652008,0,O=C(Nc1ccccc1)N(CCCN1CCNCC1)[C@@H]1CC[C@]2(c3ccccc3)C[C@H]12
1914,2052512,10.1016/j.ejmech.2019.111914,,,,Inhibition of human ERG stably expressed in CHO cells after 4 mins,Cc1nc(CN(C)[C@H]2CCCc3cccnc32)cc(N2CCN(C)CC2)n1,"(S)-N-Methyl-N-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",8.0,uM,=,0.9030899869919436,1,c1cnc2c(c1)CCC[C@@H]2NCc1cc(N2CCNCC2)ncn1
1915,2025950,10.1021/acsmedchemlett.0c00575,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,CCS(=O)(=O)c1ccc(CNc2nc3cnc(-c4c(OC)ncnc4C4CC4)nc3n([C@@H](C)C(F)(F)F)c2=O)nc1,"(S)-2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-6-((5-(ethylsulfonyl)pyridin-2-yl)methylamino)-8-(1,1,1-trifluoropropan-2-yl)pteridin-7(8H)-one",4.7,uM,=,0.6720978579357175,1,O=c1[nH]c2nc(-c3cncnc3C3CC3)ncc2nc1NCc1ccccn1
1916,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(F)ccc1Oc1ccc(C)c(C)c1,"1-(2-(3,4-dimethylphenoxy)-5-fluorophenyl)-N-methylmethanamine",20.0,uM,=,1.3010299956639813,1,c1ccc(Oc2ccccc2)cc1
1917,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC1CCCN1CCc1ccc2nc(-c3ccoc3)ccc2c1,2-(furan-3-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,8.4,uM,=,0.9242792860618816,1,c1cc(-c2ccc3cc(CCN4CCCC4)ccc3n2)co1
1918,1452204,10.1021/ml500137b,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes incubated for 90 mins by beta-counting method,CCOC[C@@H](CC(C)C)NC(=O)[C@@H]1CNC[C@H](C(=O)N(c2cc(OCCCOC)c(C(C)C)cc2F)C2CC2)C1.Cl,"(3R,5S)-N3-cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(2-fluoro-4-isopropyl-5-(3-methoxypropoxy)phenyl)piperidine-3,5-dicarboxamide hydrochloride",5.5,uM,=,0.7403626894942439,1,O=C([C@@H]1CCCNC1)N(c1ccccc1)C1CC1
1919,1623141,10.1021/acsmedchemlett.6b00314,,,,Inhibition of human ERG,Cc1cn(-c2ccc(-c3cn(CC(=O)Nc4cccc(Cl)c4Cl)nn3)cc2F)cn1,"N-(2,3-dichlorophenyl)-2-(4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)acetamide",3.4,uM,=,0.5314789170422551,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)Nc1ccccc1
1920,1294654,10.1021/jm4016894,,,,Inhibition of human ERG by patch-clamp assay,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,"(8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-({3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl}carbonyl)-12-azapentacyclo[10.7.0.0^{2,7}.0^{8,10}.0^{13,18}]nonadeca-1(19),2(7),3,5,13,15,17-heptaene-15-carboxamide",12.4,uM,=,1.0934216851622351,1,O=C(N1C2CCC1CNC2)[C@]12C[C@H]1c1ccccc1-c1c(C3CCCCC3)c3ccccc3n1C2
1921,1728697,10.1021/acsmedchemlett.7b00312,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,O=C(NC[C@@H]1[C@H]2CN(C(=O)/C=C/c3cc(Cl)cc(Cl)c3)C[C@@H]12)c1ccc2[nH]c(=O)oc2c1,"N-(((1R,5S,6s)-3-((E)-3-(3,5-dichlorophenyl)acryloyl)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxamide",4.2,uM,=,0.6232492903979004,1,O=C(NC[C@@H]1[C@H]2CN(C(=O)/C=C/c3ccccc3)C[C@@H]12)c1ccc2[nH]c(=O)oc2c1
1922,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2cccc3c2CCC3)cc(OC)n1,"3-((1R,2S)-1-(2,3-dihydro-1H-inden-4-yl)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)-2-hydroxybutyl)-2-methoxyquinoline-6-carbonitrile",4.5,uM,=,0.6532125137753437,1,c1cc2c(c([C@@H](Cc3ccncc3)c3cnc4ccccc4c3)c1)CCC2
1923,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(C(F)F)cn3)ccc2n1)N1CCNCC1,"US9452986, 14",29.5,uM,=,1.469822015978163,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
1924,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,CC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)c(Cl)c1,"N-(2-(3'-chloro-4'-((3S,4S)-4-(3,4-difluorophenyl)piperidin-3-yl)biphenyl-2-yl)ethyl)acetamide",1.1,uM,=,0.041392685158225,1,c1ccc(-c2ccc([C@H]3CNCC[C@@H]3c3ccccc3)cc2)cc1
1925,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(C#Cc2cccc(Cl)c2)cccc1C#Cc1cccc(Cl)c1,"2,6-bis((3-chlorophenyl)ethynyl)-1-methylpyridinium",4.019,uM,=,0.6041180061920349,1,C(#Cc1cccc(C#Cc2ccccc2)[nH+]1)c1ccccc1
1926,1714647,10.1021/acs.jmedchem.8b00650,,,,Inhibition of human ERG by patch clamp method,Cc1cnc2c(c1)nnn2-c1ccc(C(=O)N(c2ncccc2Cl)[C@@H]2CCCNC2)nc1,"US9227956, 9",3.6,uM,=,0.5563025007672873,1,O=C(c1ccc(-n2nnc3cccnc32)cn1)N(c1ccccn1)[C@@H]1CCCNC1
1927,1677359,10.1021/acs.jmedchem.7b01454,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK cells after 180 mins by scintillation counting method,CCOC(=O)[C@@H]1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2CCc1c[nH]c2ccccc12,(+/-)-N-(2-(1H-Indol-3-yl))ethyl-2beta-carboethoxy-3alpha-[bis(4-fluorophenyl)methoxy]tropane,14.0,uM,=,1.146128035678238,1,c1ccc(C(OC2CC3CCC(C2)N3CCc2c[nH]c3ccccc23)c2ccccc2)cc1
1928,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,COCCOc1cc(NC(=O)N2CCCc3cc(CN4CC[C@@H](N(C)C)C4=O)c(C=O)nc32)ncc1C#N,"(R)-N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-6-((3-(dimethylamino)-2-oxopyrrolidin-1-yl)methyl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide",8.5,uM,=,0.9294189257142929,1,O=C1CCCN1Cc1cnc2c(c1)CCCN2C(=O)Nc1ccccn1
1929,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1ccc(CCN(C)CCCN(C(=O)c2ccc([N+](=O)[O-])cc2)c2ccc(OC)c(OC)c2)cc1OC,"N-(3,4-Dimethoxy-phenyl)-N-(3-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-propyl)-4-nitro-benzamide",0.02,uM,=,-1.6989700043360187,0,O=C(c1ccccc1)N(CCCNCCc1ccccc1)c1ccccc1
1930,1339285,10.1016/j.bmcl.2014.02.013,,,,Inhibition of human ERG by FLIPR assay,CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](NC(=O)c3cccc(C(F)(F)F)c3)C2=O)[C@H](CS(=O)(=O)c2ccccc2)C1,"N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-3-(trifluoromethyl)benzamide",30.0,uM,=,1.4771212547196624,1,O=C(N[C@H]1CCN([C@H]2CCCC[C@H]2CS(=O)(=O)c2ccccc2)C1=O)c1ccccc1
1931,855975,10.1021/jm2002124,,,,Inhibition of human ERG,COc1ccc2ncc(F)c([C@@H](O)CC[C@@H]3CCN(CCSc4cccs4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-4-((S)-3-(3-fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl)-1-(2-(thiophen-2-ylthio)ethyl)piperidine-3-carboxylic acid",124.0,uM,=,2.093421685162235,1,c1csc(SCCN2CCC(CCCc3ccnc4ccccc34)CC2)c1
1932,1977735,10.1016/j.bmc.2019.115227,,,,Inhibition of human ERG,Cc1ncc(-c2cc(NC(=O)c3ccc(OCc4ccccn4)cc3)c(C)cc2C)[nH]1,"N-[5-(l,2-dimethyl-lH-imidazol-5-yl)-2,4-dimethylphenyl]-4-(pyridin-2-ylmethoxy)benzamide",12.0,uM,=,1.0791812460476249,1,O=C(Nc1cccc(-c2cnc[nH]2)c1)c1ccc(OCc2ccccn2)cc1
1933,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(C2CCCN2)c1,3-(4-fluoro-2-methoxyphenyl)-5-(pyrrolidin-2-yl)pyridine,8.62,uM,=,0.9355072658247128,1,c1ccc(-c2cncc(C3CCCN3)c2)cc1
1934,2238137,10.1021/acs.jmedchem.1c01012,,,,Inhibition of human ERG,CCc1cc2ccc(CN3CCN(c4ccc(F)cc4F)CC3)cc2[nH]c1=O,"7-((4-(2,4-difluorophenyl)piperazin-1-yl)methyl)-3-ethylquinolin-2(1H)-one",2.3,uM,=,0.3617278360175928,1,O=c1ccc2ccc(CN3CCN(c4ccccc4)CC3)cc2[nH]1
1935,1276748,10.1016/j.bmcl.2013.09.081,,,,Inhibition of human ERG current transfected in CHO cells by patch clamp assay,Cc1cc(N2CC[C@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1c(C)noc1C,"3,5-dimethyl-N-(2-methyl-4-((2S,3'S)-2-methyl-1,3'-bipyrrolidin-1'-yl)phenyl)isoxazole-4-carboxamide",37.0,uM,=,1.568201724066995,1,O=C(Nc1ccc(N2CC[C@H](N3CCCC3)C2)cc1)c1cnoc1
1936,1275662,10.1021/jm400856t,,,,Inhibition of human ERG,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine,0.01,uM,=,-2.0,0,c1ccc(COc2ccccc2)cc1
1937,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,CCN(CC)Cc1ccc2c(c1)CC[C@H](N1CCN(CCc3ccc(Cl)cc3)CC1=O)C2,"(S)-4-(4-chlorophenethyl)-1-(6-((diethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)piperazin-2-one",3.3,uM,=,0.5185139398778875,1,O=C1CN(CCc2ccccc2)CCN1[C@H]1CCc2ccccc2C1
1938,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CS(=O)(=O)c1ccc(OCC(F)(F)F)c(C(=O)N2CCN(c3ccc(C#N)cc3F)CC2)c1,"3-Fluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-ethoxy)-benzoyl]-piperazin-1-yl}-benzonitrile",2.0,uM,=,0.3010299956639812,1,O=C(c1ccccc1)N1CCN(c2ccccc2)CC1
1939,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,CCOC(=O)C1=NN(c2ccccc2)/C(=C2/S/C(=N\c3nc(-c4ccccc4)cc(-c4ccccc4)c3C#N)N(c3ccccc3)C2=O)S1,"Ethyl5-(2-((3-cyano-4,6-diphenylpyridin-2-yl)imino)-4-oxo-3-phenylthiazolidin-5-ylidene)-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate",4.6,uM,=,0.6627578316815741,1,O=C1/C(=C2/SC=NN2c2ccccc2)S/C(=N\c2cc(-c3ccccc3)cc(-c3ccccc3)n2)N1c1ccccc1
1940,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,C#Cc1cnc(Nc2cnc(C#N)c(O[C@H](C)CN(C)C)n2)cc1NC,(R)-3-((1-(Dimethylamino)propan-2-yl)oxy)-5-((5-ethynyl-4-(methylamino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,8.0,uM,=,0.9030899869919436,1,c1ccc(Nc2cnccn2)nc1
1941,540677,10.1016/j.bmcl.2008.12.083,,,,Inhibition of human ERG,Nc1ccc(-c2ccccc2F)cc1NC(=O)c1ccc(CN2CCC3(CCCN3)CC2)cc1,"4-(1,8-diazaspiro[4.5]decan-8-ylmethyl)-N-(4-amino-2'-fluorobiphenyl-3-yl)benzamide",0.183,uM,=,-0.7375489102695706,0,O=C(Nc1cccc(-c2ccccc2)c1)c1ccc(CN2CCC3(CCCN3)CC2)cc1
1942,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1nnc(-c2ccc(OC(F)F)cc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1,"(5-(4-(difluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)(4-(4-(pyrrolidin-1-ylmethyl)phenoxy)piperidin-1-yl)methanone",4.2,uM,=,0.6232492903979004,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
1943,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(Cc2ccc3ncoc3c2)CC1)c1cc(=O)c2ccc(F)cc2o1,N-(1-(benzo[d]oxazol-6-ylmethyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,34.6,uM,=,1.5390760987927767,1,O=C(NC1CCN(Cc2ccc3ncoc3c2)CC1)c1cc(=O)c2ccccc2o1
1944,624362,10.1016/j.bmcl.2010.01.121,,,,Inhibition of human ERG by ion works assay,O=C(NCc1cc(Cl)cc(Cl)c1)N(c1ccc(Br)cc1)C1CCN(C2CCCC2)CC1,"1-(4-bromophenyl)-1-(1-cyclopentylpiperidin-4-yl)-3-(3,5-dichlorobenzyl)urea",0.061,uM,=,-1.214670164989233,0,O=C(NCc1ccccc1)N(c1ccccc1)C1CCN(C2CCCC2)CC1
1945,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,NC(=O)c1cnc(N[C@H]2CCCNC2)c2cc(-c3ccccc3)sc12,"(S)-2-phenyl-4-(piperidin-3-ylamino)thieno[3,2-c]pyridine-7-carboxamide",19.7,uM,=,1.294466226161593,1,c1ccc(-c2cc3c(N[C@H]4CCCNC4)nccc3s2)cc1
1946,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(Cn4ccnc4)ccc2-3)cs1)COc1ccccc1,"6-((1H-imidazol-1-yl)methyl)-3-(5-(3-phenoxyprop-1-ynyl)thiophen-3-yl)-1, 4-dihydroindeno[1,2-c]pyrazole",1.43,uM,=,0.1553360374650617,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(Cn4ccnc4)ccc2-3)cs1)COc1ccccc1
1947,2233472,10.1016/j.ejmech.2022.114315,,,,Inhibition of hERG channel expressed in HEK293 cells at -80 mV holding potential by automated patch clamp method,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.017,uM,=,-1.769551078621726,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
1948,2066476,10.1016/j.ejmech.2018.04.062,,,,Inhibition of human ERG transfected in HEK293 cells assessed as reduction in channel current at -80 mV holding potential by whole-cell patch clamp method,NC[C@H](NC(=O)c1ccc(-c2cc(F)c(Cl)c(F)c2)[nH]1)c1nc(CO)cs1,"(S)-N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(4-chloro-3,5-difluorophenyl)-1H-pyrrole-2-carboxamide",0.9,uM,=,-0.0457574905606751,0,O=C(NCc1nccs1)c1ccc(-c2ccccc2)[nH]1
1949,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1,"N,N-Diethyl-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide",7.9,uM,=,0.8976270912904415,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
1950,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CCC(=O)c1cn(-c2ccc(F)cc2)c2ccc(Cl)cc12,1-[5-Chloro-1-(4-fluoro-phenyl)-1H-indol-3-yl]-propan-1-one,1.947,uM,=,0.2893659515200317,1,c1ccc(-n2ccc3ccccc32)cc1
1951,699317,10.1016/j.bmc.2010.10.034,,,,Inhibition of human ERG,CN[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1,"cis-(2R,4R)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",1.6,uM,=,0.2041199826559248,1,c1ccc([C@H]2CCCc3ccccc32)cc1
1952,2049320,10.1021/acs.jmedchem.0c01179,,,,Inhibition of tracer red binding to human ERG expressed in HEK293 cell membranes measured after 2 to 6 hrs by fluorescence polarization assay,COC[C@H]1CN(C2CCN(c3nc(N)n[nH]3)CC2)[C@@H](Cc2ccc(Cl)cc2)CO1,"5-(4-((2R,5S)-5-(4-Chlorobenzyl)-2-(methoxymethyl)-morpholino)piperidin-1-yl)-4H-1,2,4-triazol-3-amine",100.0,uM,=,2.0,1,c1ccc(C[C@H]2COCCN2C2CCN(c3ncn[nH]3)CC2)cc1
1953,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(C)N1CCN(C(=O)N2CCC(Cc3ccccc3)CC2)CC1,(4-benzylpiperidin-1-yl)(4-isopropylpiperazin-1-yl)methanone,37.61904762,uM,=,1.5754077965675168,1,O=C(N1CCNCC1)N1CCC(Cc2ccccc2)CC1
1954,2021700,10.1021/acs.jmedchem.9b00069,,,,Inhibition of human ERG by thallium flux assay,CCOc1ccc2cc(-c3nn(CC4CC4)c(N)c3C(N)=O)ccc2c1,5-Amino-1-(cyclopropylmethyl)-3-(6-ethoxynaphthalen-2-yl)-1H-pyrazole-4-carboxamide,15.7,uM,=,1.1958996524092338,1,c1ccc2cc(-c3ccn(CC4CC4)n3)ccc2c1
1955,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,COCc1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2C)n1,"(R)-2-(3-(Methoxymethyl)-1H-1,2,4-triazol-1-yl)-1-(2-methyl-4-(2-(trifluoromethyl)-4-(2-(trifluoromethyl)pyrimidin-5-yl)thiazol-5-yl)piperazin-1-yl)ethan-1-on",0.018,uM,=,-1.744727494896694,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
1956,1989034,10.1021/acsmedchemlett.0c00249,,,,Inhibition of human ERG by automated patch clamp assay,Cn1cc(-c2cc(F)cc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@@H]2C[C@@H]2F)c1=O,"(1S,2S)-N-[5-[3-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-yl)-5-fluoro-2-(hydroxymethyl)phenyl]-1-methyl-2-oxo-3-pyridyl]-2-fluoro-cyclopropanecarboxamide",1.6,uM,=,0.2041199826559248,1,O=C(Nc1cc(-c2cccc(-n3ncc4ccccc4c3=O)c2)c[nH]c1=O)C1CC1
1957,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(CCc2ccccc2)cccc1CCc1ccccc1,"1-methyl-2,6-diphenethylpyridinium",0.466,uM,=,-0.3316140833099998,0,c1ccc(CCc2cccc(CCc3ccccc3)[nH+]2)cc1
1958,1760517,10.1021/acs.jmedchem.8b00372,,,,Inhibition of human ERG expressed in CHO cells at 10 nM to 10 uM at holding potential of -80 mV measured after 5 mins by QPatch automated patch clamp electrophysiology method,CS(=O)(=O)c1ccc(OCC2CC2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1,"5-[2-(Cyclopropylmethoxy)-5-methanesulfonylbenzoyl]-2-(2-fluorophenyl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole",9.9,uM,=,0.99563519459755,1,O=C(c1ccccc1OCC1CC1)N1Cc2cn(-c3ccccc3)nc2C1
1959,1473874,10.1021/jm5018863,,,,Inhibition of human ERG expressed in CHO cells by automated Qpatch clamp assay,NC(=O)c1ncc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc(-n2nccn2)c1,"3-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-5-((1R,2S)-2-aminocyclohexylamino)pyrazine-2-carboxamide",10.0,uM,=,1.0,1,c1cc(Nc2cncc(NC3CCCCC3)n2)cc(-n2nccn2)c1
1960,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,O=C1OCc2cc(CCC3(F)CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21,5-(2-(1-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)-4-fluoropiperidin-4-yl)ethyl)isobenzofuran-1(3H)-one,2.1,uM,=,0.3222192947339193,1,O=C1OCc2cc(CCC3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
1961,1764419,10.1021/acsmedchemlett.8b00095,,,,Inhibition of human ERG,O=c1c2cc(Cc3ccc(Cl)nc3)c3ccccc3c2ncn1[C@H]1CCCC[C@@H]1O,"6-(6-Chloropyridin-3-yl)methyl-3-(1S,2S)-2-hydroxycyclohexylbenzo[h]quinazolin-4(3H)-one",13.0,uM,=,1.1139433523068367,1,O=c1c2cc(Cc3cccnc3)c3ccccc3c2ncn1C1CCCCC1
1962,964765,10.1016/j.bmcl.2013.03.081,,,,Inhibition of human ERG channel,Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)c1cc(F)ccc1C,"5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl-[1,3']bipyrrolidinyl-10-yl)phenyl]benzamide",0.48,uM,=,-0.3187587626244128,0,O=C(Nc1ccc(N2CCC(N3CCCC3)C2)cc1)c1ccccc1
1963,422070,10.1016/j.bmcl.2006.08.057,,,,Inhibition of hERG expressed in HEK cells by whole cell patch clamp assay,CCc1c(C)[nH]c2c1/C(=N/NC(=O)Nc1ccccc1)CCC2,"(E)-2-(3-ethyl-2-methyl-6,7-dihydro-1H-indol-4(5H)-ylidene)-N-phenylhydrazinecarboxamide",21.0,uM,=,1.3222192947339193,1,O=C(N/N=C1\CCCc2[nH]ccc21)Nc1ccccc1
1964,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2c(c1)N(CCN1CCC(NCc3ccc4c(n3)NC(=O)CO4)CC1)C(=O)CO2,"6-((1-(2-(6-methoxy-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",13.0,uM,=,1.1139433523068367,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccccc54)CC3)nc2N1
1965,1972154,10.1021/acs.jmedchem.9b01624,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,CC(C)Cn1cc(-c2ccncc2)c2ccncc21,"1-Isobutyl-3-(pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridine",30.0,uM,=,1.4771212547196624,1,c1cc(-c2c[nH]c3cnccc23)ccn1
1966,1474497,10.1021/acs.jmedchem.5b00191,,,,Inhibition of human ERG expressed in CHO cells,C[C@H]1SC(N)=N[C@@]2(c3ccc(F)cc3F)CO[C@@H](c3cnn(C)c3)C[C@@H]12,"(4R,4aR,6R,8aS)-8a-(2,4-difluorophenyl)-4-methyl-6-(1-methyl-1H-pyrazol-4-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",4.8,uM,=,0.6812412373755872,1,C1=N[C@@]2(c3ccccc3)CO[C@@H](c3cn[nH]c3)C[C@H]2CS1
1967,581929,10.1016/j.bmcl.2009.06.011,,,,Inhibition of human ERG,CS(=O)(=O)Nc1ccc2c(c1)nc1n2C[C@H](N)[C@@H](c2cc(F)c(F)cc2F)C1.O=C(O)C(F)(F)F,"Trifluoro-acetate(2R,3R)-7-methanesulfonylamino-3-(2,4,5-trifluoro-phenyl)-1,2,3,4-tetrahydro-benzo[4,5]imidazo[1,2-a]pyridin-2-yl-ammonium",2.5,uM,=,0.3979400086720376,1,c1ccc([C@@H]2CCn3c(nc4ccccc43)C2)cc1
1968,2123621,10.1021/acs.jmedchem.1c01015,,,,Inhibition of human ERG expressed in CHO cells by manual patch clamp technique,Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2ccsc12,"(E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenesulfonamide",0.18,uM,=,-0.744727494896694,0,c1ccc(CN2CCC(Nc3nc(Oc4ccccc4)c4sccc4n3)CC2)cc1
1969,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,O=c1n(Cc2ccc(Cl)cc2)c2sc3c(c2c2ncnn12)CCN(CC1CCOCC1)C3,"6-(4-Chlorobenzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one",0.35,uM,=,-0.4559319556497244,0,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCN(CC1CCOCC1)C3
1970,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(CNCC2CC2)n1,1-cyclopropyl-N-((6-(4-fluoro-2-methoxyphenyl)pyrazin-2-yl)methyl)methanamine,1.89,uM,=,0.2764618041732441,1,c1ccc(-c2cncc(CNCC3CC3)n2)cc1
1971,1783529,10.1016/j.ejmech.2017.12.075,,,,Inhibition of human ERG by [3H]dofetilide binding displacement assay,Cc1c(CN2CCOCC2)cc(-c2ccc(C(C)C)cc2)n1Cc1ccc(F)cc1,2-Methyl-3-[(morpholino)-methyl]-5-[4-(i-propyl)phenyl]-1-(4-fluorobenzyl)-1H-pyrrole,5.0,uM,=,0.6989700043360189,1,c1ccc(Cn2cc(CN3CCOCC3)cc2-c2ccccc2)cc1
1972,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,CC(C)(C)c1cc(C(=O)NCC2CCN(C(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc(C(C)(C)C)c1,"N-((1-(6,6-bis(4-fluorophenyl)hexanoyl)pyrrolidin-3-yl)methyl)-3,5-di-tert-butylbenzamide",2.8,uM,=,0.4471580313422192,1,O=C(NCC1CCN(C(=O)CCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
1973,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CCOc1ccc2cc(-c3nn(CC4CNC4)c4ncnc(N)c34)ccc2c1,"1-(azetidin-3-ylmethyl)-3-(6-ethoxynaphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",1.7,uM,=,0.2304489213782739,1,c1ccc2cc(-c3nn(CC4CNC4)c4ncncc34)ccc2c1
1974,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3csc(-c4cc(Cl)nc(Cl)c4)n3)ccc2c1,"(R)-2-(2,6-dichloropyridin-4-yl)-4-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)thiazole",20.4,uM,=,1.3096301674258988,1,c1cc(-c2nc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cs2)ccn1
1975,1898259,10.1016/j.bmcl.2019.126643,,,,Inhibition of human ERG,C[C@H]1CCCN1CCCOc1ccc2c(c1)CC[C@H]1[C@@H]3[C@H](C(=O)N4CCCC4)CC(=O)[C@@]3(C)CC[C@H]21,"(8R,9S,13S,14R,15R)-13-methyl-3-(3-((S)-2-methylpyrrolidin-1-yl)propoxy)-15-(pyrrolidine-1-carbonyl)-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one",80.0,uM,=,1.9030899869919435,1,O=C1C[C@@H](C(=O)N2CCCC2)[C@@H]2C1CC[C@@H]1c3ccc(OCCCN4CCCC4)cc3CC[C@@H]21
1976,1924902,10.1016/j.bmcl.2016.07.048,,,,Inhibition of MK499 binding to human ERG,Cn1cc(NC(=O)c2cncc(-c3ccnc(NCC4CC4)c3)c2)c(C(N)=O)n1,"N-(3-carbamoyl-1-methyl-1H-pyrazol-4-yl)-2'-(cyclopropylmethylamino)-3,4'-bipyridine-5-carboxamide",5.2,uM,=,0.7160033436347992,1,O=C(Nc1cn[nH]c1)c1cncc(-c2ccnc(NCC3CC3)c2)c1
1977,2153986,10.1021/acsmedchemlett.1c00660,,,,Inhibition on hERG expressed in HEK293 cells by Qpatch method,O=C(NCCN1CCCC1)c1cccn2c(=O)c3ccc4ccccc4c3nc12,"7-oxo-N-(2-(pyrrolidin-1-yl)ethyl)-7H-benzo[h]pyrido[2,1-b]quinazoline-12-carboxamide",3.64,uM,=,0.561101383649056,1,O=C(NCCN1CCCC1)c1cccn2c(=O)c3ccc4ccccc4c3nc12
1978,499833,10.1016/j.bmcl.2009.04.022,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(SC4(C)CCC(NC(=O)OC)C4)nc3cc2Cl)CC1,(+/-)-methyl 3-(5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazol-2-ylthio)-3-methylcyclopentylcarbamate,2.0,uM,=,0.3010299956639812,1,c1cc2nc(SC3CCCC3)[nH]c2cc1N1CCNCC1
1979,964237,10.1016/j.ejmech.2013.03.061,,,,Displacement of [3H]astemizole from human ERG channel transfected in HEK293 cells after 60 mins by liquid scintillation counting analysis,O=C(/C=C/c1ccc2c(c1)C(=O)CC1(CCN(Cc3ccccc3)CC1)O2)NO,"(E)-N-Hydroxy-3-{1'-benzyl-4-oxospiro[chromane-2,4-piperidine]-6-yl}acrylamide",3.81,uM,=,0.5809249756756193,1,O=C1CC2(CCN(Cc3ccccc3)CC2)Oc2ccccc21
1980,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)CC2c2ccc(OC(C)C)cc2)cc1,1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-[(4-isopropyloxy)-phenyl]-2-imidazolidinone,17.0,uM,=,1.230448921378274,1,O=C1NCC(c2ccccc2)N1CCc1ccccc1
1981,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2cccc3c2OCCO3)cc(OC)n1,"3-((1R,2S)-1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)-2-hydroxybutyl)-2-methoxyquinoline-6-carbonitrile",4.4,uM,=,0.6434526764861874,1,c1cc2c(c([C@@H](Cc3ccncc3)c3cnc4ccccc4c3)c1)OCCO2
1982,2100973,10.1021/acs.jmedchem.1c00375,,,,Displacement of [3H]-dofetilide from human ERG after 60 mins by scintillation counting method,Cc1c(N2CC[C@@H](C3(N)CC3)C2)c(F)cc2cc(-c3noc(=O)[nH]3)c(=O)n(C3CC3)c12,"(R)-3-(7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-1,2,4-oxadiazol-5(4H)-one",29.0,uM,=,1.462397997898956,1,O=c1[nH]c(-c2cc3ccc(N4CC[C@@H](C5CC5)C4)cc3n(C3CC3)c2=O)no1
1983,1583749,10.1016/j.bmcl.2016.05.058,,,,Inhibition of recombinant human ERG flux expressed in HEK293 cells by patch clamp assay,CC(C)Oc1cc([C@@](Cc2ccccc2)(NC[C@H](O)CC(F)(F)F)c2cc(F)cc(OC(F)(F)C(F)F)c2)ccc1F,"(R)-4,4,4-trifluoro-1-((R)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethylamino)butan-2-ol",28.0,uM,=,1.4471580313422192,1,c1ccc(CC(c2ccccc2)c2ccccc2)cc1
1984,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,O=C(N[C@H](C1CC1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21)c1ccc(Cl)cc1,"4-chloro-N-((R)-cyclopropyl((1R,3S,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)methyl)benzamide",0.56,uM,=,-0.2518119729937995,0,O=C(N[C@H](C1CC1)[C@H]1[C@@H]2C[C@@H](n3cnc4ccccc43)C[C@@H]21)c1ccccc1
1985,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2cccc3c2OCO3)cc(OC(F)F)n1,"Rac-3-[(1R,2S)-1-(1,3-benzodioxol-4-yl)-2-[2-(difluoromethoxy)-6-methoxy-4-pyridyl]-4-(dimethylamino)-2-hydroxy-butyl]-2-methoxy-quinoline-6-carbonitrile",4.8,uM,=,0.6812412373755872,1,c1cc2c(c([C@@H](Cc3ccncc3)c3cnc4ccccc4c3)c1)OCO2
1986,2133994,10.1021/acs.jmedchem.1c00959,,,,Inhibition of human ERG,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C,"2''-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4'-methoxy-2-methyl-4''-(trifluoromethyl)-[1,1':3',1''-terphenyl]-4-carboxylic acid",10.0,uM,=,1.0,1,O=C1O[C@H](c2ccccc2)CN1Cc1ccccc1-c1cccc(-c2ccccc2)c1
1987,1517213,10.1021/acs.jmedchem.5b01156,,,,Inhibition of human ERG expressed in CHO cells by patch clamp electrophysiology assay,CNc1nc(NCCN2CCNCC2)c2sc(-c3ccc(C(F)(F)F)cc3)cc2n1,"N2-methyl-N4-(2-(piperazin-1-yl)ethyl)-6-(4-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2cc3ncnc(NCCN4CCNCC4)c3s2)cc1
1988,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CC(C)c1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2CO)n1,"1-((S)-2-Hydroxymethyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-isopropyl-[1,2,4]triazol-1-yl)-ethanone",0.029,uM,=,-1.537602002101044,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
1989,876604,10.1021/jm301476b,,,,Inhibition of human ERG expressed in chinese hamster lung cells by IonWorks patch clamp electrophysiology assay,COc1ccc(-c2cc(-c3ccc(S(=O)(=O)N4CCN(C)CC4)cc3)cnc2N)cn1,3-(6-methoxypyridin-3-yl)-5-[4-(4-methyl-1-piperazinyl)sulfonyl]phenyl)pyridin-2-amine,10.4,uM,=,1.0170333392987805,1,O=S(=O)(c1ccc(-c2cncc(-c3cccnc3)c2)cc1)N1CCNCC1
1990,304886,10.1016/j.bmcl.2004.07.056,,,,Inhibition of human Potassium channel HERG,COC(=O)Cc1ccc(CNC(=O)[C@@H]2CSCN2C(=O)CC(N)Cc2ccccc2F)cc1.O=C(O)C(F)(F)F,Trifluoro-acetate1-(2-fluoro-benzyl)-3-[(R)-4-(4-methoxycarbonylmethyl-benzylcarbamoyl)-thiazolidin-3-yl]-3-oxo-propyl-ammonium,9.7,uM,=,0.9867717342662448,1,O=C(NCc1ccccc1)[C@@H]1CSCN1C(=O)CCCc1ccccc1
1991,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(NCc2ccccc2)c1,N-benzyl-5-(4-fluoro-2-methoxyphenyl)pyridin-3-amine,5.2,uM,=,0.7160033436347992,1,c1ccc(CNc2cncc(-c3ccccc3)c2)cc1
1992,744146,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG,Cc1cnc(N2CCC(C3CCN(c4cc(C#N)nc(C)n4)CC3)CC2)nc1,"2-methyl-6-(1'-(5-methylpyrimidin-2-yl)-4,4'-bipiperidin-1-yl)pyrimidine-4-carbonitrile",1.8,uM,=,0.255272505103306,1,c1cnc(N2CCC(C3CCN(c4ccncn4)CC3)CC2)nc1
1993,1972831,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(CCO)CC3)c(C3CC3)c2)cc1C#Cc1cnc2cccnn12,"N-[3-cyclopropyl-4-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]phenyl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",0.34,uM,=,-0.4685210829577448,0,O=C(Nc1ccc(CN2CCNCC2)c(C2CC2)c1)c1cccc(C#Cc2cnc3cccnn23)c1
1994,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCc3cccc(OC)c3)C[C@@H]2CNC(=O)c2cccc(Cl)c2)cc1,"rac-3-chloro-N-(((3S,4S)-1-(3-methoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)methyl)benzamide",0.047,uM,=,-1.3279021420642825,0,O=C(NC[C@H]1CN(CCc2ccccc2)C[C@@H]1c1ccccc1)c1ccccc1
1995,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,Cc1noc(-c2ccc(CCN3CCC(Nc4nc5cc(F)ccc5n4C)CC3)cc2)n1,"5-fluoro-1-methyl-N-(1-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine",28.7,uM,=,1.4578818967339924,1,c1ccc2[nH]c(NC3CCN(CCc4ccc(-c5ncno5)cc4)CC3)nc2c1
1996,939638,10.1016/j.bmcl.2012.11.023,,,,Inhibition of human ERG,CN(C)C(=O)c1ccc(CN2CCc3cc4nc(N)sc4cc3CC2)cc1,"4-(2-Amino-5,6,8,9-tetrahydro-1-thia-3,7-diaza-cyclohepta[f]inden-7-ylmethyl)-N,N-dimethyl-benzamide",12.0,uM,=,1.0791812460476249,1,c1ccc(CN2CCc3cc4ncsc4cc3CC2)cc1
1997,1924902,10.1016/j.bmcl.2016.07.048,,,,Inhibition of MK499 binding to human ERG,Cn1cc(NC(=O)c2cccc(-c3ccnc(NCC4CC4)c3)c2)c(C(N)=O)n1,4-(3-(2-(cyclopropylmethylamino)pyridin-4-yl)benzamido)-1-methyl-1H-pyrazole-3-carboxamide,6.1,uM,=,0.785329835010767,1,O=C(Nc1cn[nH]c1)c1cccc(-c2ccnc(NCC3CC3)c2)c1
1998,2298259,10.1016/j.bmc.2023.117276,,,,Inhibition of hERG expressed in CHO cells by automated patch clamp method,CC(=O)NCc1cc2cc(CN3CCOCC3)cc3c(=O)c(C(=O)NCc4ccc(Cl)cc4)cn1c23,"2-(acetamidomethyl)-N-(4-chlorobenzyl)-8-(morpholinomethyl)-6-oxo-6H-pyrrolo[3,2,1-ij]quinoline-5-carboxamide",4.5,uM,=,0.6532125137753437,1,O=C(NCc1ccccc1)c1cn2ccc3cc(CN4CCOCC4)cc(c1=O)c32
1999,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,C[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)ethyl)benzamide",0.52,uM,=,-0.2839966563652008,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
2000,591827,10.1021/jm900729s,,,,Inhibition of human ERG by patch-clamp assay,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,"10-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-4-ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-(4-pyridin-3-yl-4H-imidazol-1-yl)-butyl]-octahydro-3,5-dioxa-1-aza-cyclopentacyclotetradecene-2,6,8,14-tetraone",40.0,uM,=,1.6020599913279625,1,O=C1CC(=O)OCC2OC(=O)N(CCCCn3cnc(-c4cccnc4)c3)[C@@H]2CC(=O)CCC[C@H](O[C@H]2CCCCO2)C1
2001,1642373,,,,,"Inhibition Assay: hERG study was conducted with an automated patch clamp machine, Qpatch-48HT (Sophion Biosciences, Denmark). Cultured CHO cells stably expressing hERG channels (provided by Sophion Biosciences, Denmark) were harvested from culture flasks of 70-90% cell confluence rate and prepared as cell suspension with a cell density of 3-8&timse;10^6 cells/mL in serum-free media (CHO-S-SFM II, cat#12052 Invitrogen; 25 mM HEPES). Cells in such condition were placed into a Qpatch cell stir chamber and used within 4 hours. For each run, cells were first spun down by the built-in Qpatch centrifuge and re-suspended in an extracellular solution (in mM, 2 CaCl2, 1 MgCl2, 4 KCl, 145 NaCl, 10 Glucose, 10 HEPES, pH 7.4, osmolarity ~305 mOsm). Qplate-48 that holds one cell in each of its 48 channels for the later voltage-clamped assay were primed with the extracellular solution and intracellular solution (in mM, 5.4 CaCl2, 1.75 MgCl2, 120 KCl, 10 HEPES, 5 EGTA, 4 NaATP, pH 7.25, Osmolarity ~280-295 mOsm). Cells were dispatched by Qpatch robotic dispensing guns into each Qplate channel and went through the process of giga-ohm sealing and whole cell configuration. Whole-cell recordings were performed in voltage-clamp mode at a holding potential of −80 mV. The hERG current was activated by depolarizing at +20 mV for 5 sec, after which the current was taken back to −50 mV for 5 sec to remove the inactivation and observe the deactivating tail current. The maximum amount of tail current size was used to determine the hERG current amplitude. The above voltage protocol was applied to the cells every 15 sec throughout the whole procedure. External solution containing 0.1% DMSO (vehicle) was applied to the cells to establish the baseline. Compound solution was added, and the cells were kept in the test solution until the compound's effect reached a steady state or for a maximum of 4 min. For dose response assays (0.1, 0.3, 1, 3, 10 and 30 μM), the compound was applied to the cells accumulatively from low to high concentrations. Washout with extracellular solution was performed after compound testing. Positive control cisapride 0.1 μM was used on each cell after compound testing to ensure the normal response and the good quality of the cell.",Cc1cc(Cl)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1,"US9434724, 65",2.43,uM,=,0.3856062735983122,1,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccccc12
2002,1749929,10.1016/j.bmcl.2017.12.020,,,,Inhibition of human ERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp assay,CNC(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,"4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-N-methyl-2,2-diphenylbutanamide",0.245,uM,=,-0.6108339156354675,0,c1ccc(C2CCN(CCC(c3ccccc3)c3ccccc3)CC2)cc1
2003,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,N#Cc1ccc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cc1,"4-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridin-6-yl)benzonitrile",1.111111111,uM,=,0.0457574905172456,1,c1ccc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cc1
2004,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3cncnc3)cc12,4-[(2-Ethylbutyl)amino]-6-(5-pyrimidinyl)-3-quinolinecarboxamide,0.76,uM,=,-0.1191864077192086,0,c1cnc2ccc(-c3cncnc3)cc2c1
2005,2293467,10.1021/acs.jmedchem.7b00463,,,,Inhibition of hERG potassium channel by Q-patch clamp assay,Nc1c(C(=O)Nc2cccc(F)c2)nnn1Cc1ccc(CN2CCOCC2)cc1,"5-amino-N-(3-fluorophenyl)-1-(4-(morpholinomethyl)benzyl)-1H-1,2,3-triazole-4-carboxamide",7.0,uM,=,0.8450980400142568,1,O=C(Nc1ccccc1)c1cn(Cc2ccc(CN3CCOCC3)cc2)nn1
2006,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2ccccn2)cc1,"N,N-diethyl-4-(piperidin-4-ylidene(pyridin-2-yl)methyl)benzamide",33.0,uM,=,1.5185139398778875,1,c1ccc(C(=C2CCNCC2)c2ccccn2)cc1
2007,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,"N-(4-Methoxy-benzyl)-N',N'-dimethyl-N-pyridin-2-yl-ethane-1,2-diamine (mepyramine)",1.1,uM,=,0.041392685158225,1,c1ccc(CNc2ccccn2)cc1
2008,487380,10.1021/jm800199h,,,,Displacement of MK-499 from human ERG channel in HEK293 cells,O=C(NCCCN1CCCCC1)Nc1ccc(S(=O)(=O)Nc2ccccc2C(=O)c2ccccc2)cc1,N-(2-Benzoyl-phenyl)-4-[3-(3-piperidin-1-yl-propyl)-ureido]-benzenesulfonamide,1.0,uM,=,0.0,0,O=C(NCCCN1CCCCC1)Nc1ccc(S(=O)(=O)Nc2ccccc2C(=O)c2ccccc2)cc1
2009,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-8-methyl-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.0029,uM,=,-2.537602002101044,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2010,219494,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,"8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine",0.191,uM,=,-0.7189666327522725,0,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2
2011,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,Cc1ccc(NC(=O)N2CCN(C[C@@H]3CCCN(C4CC4)C3)CC2)cc1Cl,(S)-N-(3-chloro-4-methylphenyl)-4-((1-cyclopropylpiperidin-3-yl)methyl)piperazine-1-carboxamide,7.1,uM,=,0.8512583487190752,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
2012,1286728,10.1021/ml4003953,,,,Inhibition of human ERG,COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@H]5F)c4n3)cnc2c1,"8-(((3R,4R)-3-fluoropiperidin-4-yl)oxy)-2-(7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl)quinolone",3.9,uM,=,0.5910646070264992,1,c1cc(OC2CCNCC2)c2nc(-c3cnc4ccccn34)ccc2c1
2013,439396,10.1016/j.bmcl.2007.05.087,,,,Inhibition of human ERG potassium channel,N[C@H]1CN(c2ccn3cnnc3n2)CC[C@@H]1c1cc(F)c(F)cc1F.O=C(O)C(F)(F)F,"(3R,4R)-1-([1,2,4]triazolo[4,3-a]pyrimidin-7-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium 2,2,2-trifluoroacetate",100.0,uM,=,2.0,1,c1ccc(C2CCN(c3ccn4cnnc4n3)CC2)cc1
2014,806244,10.1016/j.bmcl.2012.01.078,,,,Inhibition of human Erg by patch clamp assay,Cc1nc2cnc(Oc3cccc4cccnc34)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,"(S)-3-((1-isopropylpiperidin-3-yl)methyl)-2-methyl-6-(quinolin-8-yloxy)pyrido[3,4-d]pyrimidin-4(3H)-one",25.1,uM,=,1.3996737214810382,1,O=c1c2cc(Oc3cccc4cccnc34)ncc2ncn1C[C@H]1CCCNC1
2015,1542591,10.1021/acs.jmedchem.5b00928,,,,Displacement of doferilide from human ERG,O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1,"1-(4-((3,4-Dichlorobenzyl)oxy)benzyl)azetidine-3-carboxylic Acid",77.0,uM,=,1.8864907251724816,1,c1ccc(COc2ccc(CN3CCC3)cc2)cc1
2016,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3ccc(COC)nc3)cc12,4-[(2-Ethylbutyl)amino]-6-[6-(methoxymethyl)-3-pyridinyl]-3-quinolinecarboxamide,2.5,uM,=,0.3979400086720376,1,c1cncc(-c2ccc3ncccc3c2)c1
2017,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1ccc(C(=O)N2CCN(c3ccc4c(c3)CCC(=O)N4)CC2)cc1OC,"6-[4-(3,4-Dimethoxy-benzoyl)-piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one",18.0,uM,=,1.255272505103306,1,O=C1CCc2cc(N3CCN(C(=O)c4ccccc4)CC3)ccc2N1
2018,1926457,10.1016/j.bmc.2016.08.007,,,,Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assay,Cc1cnc(Nc2cc(NC3CCN(c4ccc(C#N)cn4)CC3)c(C(N)=O)cn2)cn1,4-{[1-(5-Cyanopyridin-2-yl)piperidin-4-yl]amino}-6-[(5-methylpyrazin-2-yl)amino]nicotinamide,4.8,uM,=,0.6812412373755872,1,c1ccc(N2CCC(Nc3ccnc(Nc4cnccn4)c3)CC2)nc1
2019,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CCC(O)(CC)c1cn(-c2ccc(F)cc2)c2ccc(Cl)cc12,3-[5-Chloro-1-(4-fluoro-phenyl)-1H-indol-3-yl]-pentan-3-ol,15.7,uM,=,1.1958996524092338,1,c1ccc(-n2ccc3ccccc32)cc1
2020,1446331,10.1021/ml500387y,,,,Inhibition of human ERG channel expressed in recombinant HEK293 cells by whole cell patch-clamp technique,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O,"1,1,1-trifluoro-4-methyl-4-(2-(methylsulfonyl)phenyl)-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",20.0,uM,=,1.3010299956639813,1,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
2021,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",5.0,uM,=,0.6989700043360189,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
2022,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1.O=S(=O)(O)CCS(=O)(=O)O,"5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol ethane-1,2-disulfonate",0.16,uM,=,-0.7958800173440752,0,c1ccc(/N=N/c2ccccn2)cc1
2023,1685716,10.1016/j.bmc.2017.04.033,,,,Inhibition of human ERG,C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CCC(N)=O)(c2ccc(F)cc2)OC1=O,"3-((R)-3-((S)-1-(4-(difluoromethoxy)phenyl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)propanamide",5.3,uM,=,0.724275869600789,1,O=C1OC(c2ccccc2)CCN1Cc1ccccc1
2024,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(F)cc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-4-fluorophenyl)-N-methylmethanamine",3.01,uM,=,0.4785664955938433,1,c1ccc(Oc2ccccc2)cc1
2025,2025950,10.1021/acsmedchemlett.0c00575,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,CCS(=O)(=O)c1ccc(CNc2nc3cnc(-c4c(OC)ncnc4C4CC4)nc3n([C@@H](C)C3CC3)c2=O)nc1,(S)-2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-8-(1-cyclopropylethyl)-6-((5-(ethylsulfonyl)pyridin-2-yl)methylamino)pteridin-7(8H)-one,3.1,uM,=,0.4913616938342727,1,O=c1c(NCc2ccccn2)nc2cnc(-c3cncnc3C3CC3)nc2n1CC1CC1
2026,815278,10.1016/j.ejmech.2012.02.049,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cells after 45 mins by scintillation counting method,O=C(Nc1ccccc1)NS(=O)(=O)c1ccc(OCCN2CCCCC2)cc1,1-Phenyl-3-[4-(2-piperidin-1-ylethoxy)benzene]sulfonylurea,27.6,uM,=,1.4409090820652175,1,O=C(Nc1ccccc1)NS(=O)(=O)c1ccc(OCCN2CCCCC2)cc1
2027,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C(Cc1ccc(-n2cnnn2)cc1)N1CCN(CCc2ccc([N+](=O)[O-])cc2)CC1,2-(4-(1H-tetrazol-1-yl)phenyl)-1-(4-(4-nitrophenethyl)piperazin-1-yl)ethanone,0.16,uM,=,-0.7958800173440752,0,O=C(Cc1ccc(-n2cnnn2)cc1)N1CCN(CCc2ccccc2)CC1
2028,514034,10.1016/j.bmcl.2008.06.096,,,,Displacement of radiolabeled dofetilide from human ERG,Fc1ccc(-c2noc(C3CCN(c4cnc5ccc(Cl)cc5c4)CC3)n2)c(Cl)c1,"6-chloro-3-(4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)quinoline",0.5,uM,=,-0.3010299956639812,0,c1ccc(-c2noc(C3CCN(c4cnc5ccccc5c4)CC3)n2)cc1
2029,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,NC(=O)c1ccc(N[C@H]2CCCNC2)c2cc(-c3cccc(F)c3)[nH]c12,2-(3-Fluorophenyl)-4-[(3S)-piperidin-3-ylamino]-1H-indole-7-carboxamide,7.7,uM,=,0.8864907251724818,1,c1ccc(-c2cc3c(N[C@H]4CCCNC4)cccc3[nH]2)cc1
2030,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COc1ccccc1CN1CCC(C#N)(CNC(=O)c2cc(CC(C)C)n(-c3ccccc3)n2)CC1,N-((4-cyano-1-(2-methoxybenzyl)piperidin-4-yl)methyl)-5-isobutyl-1-phenyl-1H-pyrazole-3-carboxamide,0.92,uM,=,-0.0362121726544447,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccn(-c2ccccc2)n1
2031,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,O=C(O)Cc1ccc(-n2cc(C3CCN(CCN4CCNC4=O)CC3)c3cc(Cl)ccc32)cc1,[4-(5-Chloro-3-{1-[2-(2-oxo-imidazolidin-1-yl)-ethyl]-piperidin-4-yl}-indol-1-yl)-phenyl]-acetic acid,0.579,uM,=,-0.2373214362725638,0,O=C1NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccccc23)CC1
2032,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nn(CC(=O)O)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"2-(5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl)acetic acid",30.5,uM,=,1.484299839346786,1,O=c1[nH]nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
2033,958105,10.1016/j.bmcl.2013.03.125,,,,Inhibition of human ERG by patch clamp assay,CC(C)CN1CCC(COc2ccc(NC(=O)Nc3cccnc3Oc3ccccc3C(C)(C)C)c(F)c2)CC1,1-(2-(2-tert-butylphenoxy)pyridin-3-yl)-3-(2-fluoro-4-((1-isobutylpiperidin-4-yl)methoxy)phenyl)urea,3.7,uM,=,0.568201724066995,1,O=C(Nc1ccc(OCC2CCNCC2)cc1)Nc1cccnc1Oc1ccccc1
2034,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N(C)C)nc1CN1C(=O)O[C@H](c2cccc(Cl)c2)[C@@H]1C,"3'-(4-(((4S,5R)-5-(3-Chlorophenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-2-(dimethylamino)pyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic Acid",15.0,uM,=,1.1760912590556811,1,O=C1O[C@H](c2ccccc2)CN1Cc1ncncc1-c1cccc(-c2ccccc2)c1
2035,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)(O)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3cccc(C(=O)O)c3)CC2)C1,"3-(1-(3-((3,5-bis(trifluoromethyl)benzyl)carbamoyl)-3-(2-hydroxypropan-2-yl)cyclopentyl)piperidin-4-yl)benzoic acid",19.72,uM,=,1.2949069106051925,1,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3ccccc3)CC2)C1
2036,1978265,10.1016/j.bmcl.2019.126928,,,,Inhibition of human ERG expressed in HEK293 cells by semi-automatic patch clamp assay,Cc1cnc(-c2ccc(-c3ccco3)cc2)n1Cc1ccccc1OCCCCCC(=O)O,6-(2-((2-(4-(furan-2-yl)phenyl)-5-methyl-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid,5.5,uM,=,0.7403626894942439,1,c1ccc(Cn2ccnc2-c2ccc(-c3ccco3)cc2)cc1
2037,77051,10.1021/jm970517u,,,,Inhibition of Ikr current in isolated guinea pig myocytes during a 0.5 s voltage clamp step from -50 to -10 mV.,CN1C(=O)[C@H](NC(=O)C(N)Cc2ccccc2)N=C(c2ccccc2)c2ccccc21,"2-Amino-N-((R)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-propionamide",8.8,uM,=,0.9444826721501688,1,O=C(CCc1ccccc1)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O
2038,1552682,10.1016/j.bmcl.2015.12.058,,,,Inhibition of human ERG by FLIPR assay,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,"(8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-({3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl}carbonyl)-12-azapentacyclo[10.7.0.0^{2,7}.0^{8,10}.0^{13,18}]nonadeca-1(19),2(7),3,5,13,15,17-heptaene-15-carboxamide",26.0,uM,=,1.414973347970818,1,O=C(N1C2CCC1CNC2)[C@]12C[C@H]1c1ccccc1-c1c(C3CCCCC3)c3ccccc3n1C2
2039,513130,10.1016/j.bmcl.2008.07.079,,,,Inhibition of human ERG expressed in CHO cells by Patch clamp assay,O=C(COc1cccc(Cl)c1)NC1CCN(Cc2ccn(-c3ccc(OC(F)(F)F)cc3)c2)CC1,2-(3-chlorophenoxy)-N-(1-((1-(4-(trifluoromethoxy)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,0.49,uM,=,-0.3098039199714864,0,O=C(COc1ccccc1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
2040,1973040,10.1021/acsmedchemlett.0c00015,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,CN1C(C)(C)CC(Nc2nc3c(-c4ccc(C(=O)N5CCN(S(C)(=O)=O)CC5)cc4)cnn3c(N)c2-c2ccccc2)CC1(C)C,"(4-(7-amino-5-((1,2,2,6,6-pentamethylpiperidin-4-yl)amino)-6-phenylpyrazolo[1,5-a]pyrimidin-3-yl)phenyl)(4-(methylsulfonyl)piperazin-1-yl)methanone",14.0,uM,=,1.146128035678238,1,O=C(c1ccc(-c2cnn3cc(-c4ccccc4)c(NC4CCNCC4)nc23)cc1)N1CCNCC1
2041,630097,10.1016/j.bmcl.2010.03.027,,,,Inhibition of human ERG channel by electrophysiology assay,CCOCCn1c(N2CC[C@H](N(C)C)C2)nc2ccccc21,"(S)-1-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)-N,N-dimethylpyrrolidin-3-amine",0.233,uM,=,-0.632644078973981,0,c1ccc2[nH]c(N3CCCC3)nc2c1
2042,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)CC2c2ccc(Cl)cc2)cc1,1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-chlorophenyl)-2-imidazolidinone,8.7,uM,=,0.9395192526186184,1,O=C1NCC(c2ccccc2)N1CCc1ccccc1
2043,493016,10.1021/jm800851u,,,,Inhibition of human ERG by electrophysiology assay,COc1cncc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1,"N-(2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-methoxypyridin-3-yl)pyrimidin-4-yl)acetamide",24.0,uM,=,1.380211241711606,1,c1cncc(-c2ccnc(-n3cccn3)n2)c1
2044,883359,10.1021/jm300952s,,,,Inhibition of human ERG by cell-based electrophysiology assay,Cc1cc(CN2CCN(c3c(Cl)cnc4[nH]c(-c5ccc(N6CCN(C)CC6)cc5)nc34)CC2)no1,"3-((4-(6-chloro-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole",2.3,uM,=,0.3617278360175928,1,c1cc(N2CCN(Cc3ccon3)CC2)c2nc(-c3ccc(N4CCNCC4)cc3)[nH]c2n1
2045,2075219,10.1021/acsmedchemlett.9b00395,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1,"(R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one",5.6,uM,=,0.7481880270062004,1,O=c1[nH]ncc2c(-c3ccc(Oc4ccccc4)cc3)nn([C@@H]3CCCNC3)c12
2046,2133640,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG by fluorescence polarization assay,CC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"N-(4-Chlorophenyl)-2-((1R,3s,5S,6r)-3-(5,6-difluoro-1H-benzo[d]-imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propanamide",3.6,uM,=,0.5563025007672873,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
2047,882784,10.1016/j.ejmech.2012.07.006,,,,Displacement of [3H]astemizole from human recombinant ERG expressed in HEK293 cells,N=C(Nc1ccc2c(c1)CCN2C1CCNCC1)c1cccs1,N-(1-(Piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide,160.0,uM,=,2.204119982655925,1,N=C(Nc1ccc2c(c1)CCN2C1CCNCC1)c1cccs1
2048,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CN1CCCC(CN2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"N-(3,4-dichlorophenyl)-4-((1-methylpiperidin-3-yl)methyl)piperazine-1-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(Nc1ccccc1)N1CCN(CC2CCCNC2)CC1
2049,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,Cc1cc(C(NC(=O)[C@@H]2CC[C@@H](N3CCOCC3)C[C@H]2c2ccc(Br)cc2)c2ccc(Cl)cc2)ccn1,"(1R,2R,4R)-2-(4-bromophenyl)-N-((4-chlorophenyl)(2-methylpyridin-4-yl)methyl)-4-morpholinocyclohexanecarboxamide",1.5,uM,=,0.1760912590556812,1,O=C(NC(c1ccccc1)c1ccncc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
2050,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cncc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"endo-5-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)nicotinamide",1.5,uM,=,0.1760912590556812,1,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2cccnc2)C3)cc1
2051,755804,10.1021/jm2003359,,,,Inhibition of human ERG expressed in CHO cells by Q-patch assay,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(Cl)cc2)C1,"2-amino-1-(3-(4-chlorophenylamino)-2-(4-fluorophenyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one",2.3,uM,=,0.3617278360175928,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
2052,1478736,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide,0.005,uM,=,-2.3010299956639813,0,c1ccc(CCNCCOc2ccccc2)cc1
2053,850453,10.1021/ml300146q,,,,Inhibition of recombinant human ERG channel IKr expressed in CHO cells by patch clamp assay,Cc1cc(C#N)ccc1-c1ccnc(NCc2n[nH]c3nc(F)ccc23)c1,"4-(2-((6-Fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)methylamino)pyridin-4-yl)-3-methylbenzonitrile",2.7,uM,=,0.4313637641589873,1,c1ccc(-c2ccnc(NCc3n[nH]c4ncccc34)c2)cc1
2054,1832115,10.1016/j.bmcl.2018.12.043,,,,Inhibition of human ERG by automated patch clamp method,CCCCc1nc(C(C)C)c(CC(=O)OCC)c(=O)n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,"ethyl 2-(2-butyl-4-isopropyl-6-oxo-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1,6-dihydropyrimidin-5-yl)acetate",8.1,uM,=,0.9084850188786496,1,O=c1[nH]c(-c2ccccc2-c2ccc(Cn3cnccc3=O)cc2)no1
2055,624297,10.1016/j.bmcl.2010.01.134,,,,Inhibition of human ERG expressed in HEK cells assessed as blockade of potassium tail current by standard patch clamp analysis,C[C@@H](c1ccc(F)cn1)c1c(CCN(C)C)sc2ccccc12,"(-)-(R)-2-(3-(1-(5-fluoropyridin-2-yl)ethyl)benzo[b]thiophen-2-yl)-N,N-dimethylethanamine",0.24,uM,=,-0.619788758288394,0,c1ccc(Cc2csc3ccccc23)nc1
2056,2153986,10.1021/acsmedchemlett.1c00660,,,,Inhibition on hERG expressed in HEK293 cells by Qpatch method,CN1CCC(NC(=O)c2cccn3c(=O)c4ccc5ccccc5c4nc23)CC1,"N-(1-methylpiperidin-4-yl)-7-oxo-7H-benzo[h]pyrido[2,1-b]quinazoline-12-carboxamide",7.39,uM,=,0.8686444383948257,1,O=C(NC1CCNCC1)c1cccn2c(=O)c3ccc4ccccc4c3nc12
2057,1578296,10.1016/j.bmcl.2016.04.020,,,,Inhibition of human ERG,N[C@H]1C[C@@H](N2Cc3nn4nccnc4c3C2)CO[C@@H]1c1cc(F)ccc1F,"(2R,3S,5R)-2-(2,5-Difluoro-phenyl)-5-(1H,3H-2,4,7,7a,8-pentaaza-cyclopenta[a]inden-2-yl)-tetrahydro-pyran-3-ylamine",23.0,uM,=,1.3617278360175928,1,c1ccc([C@@H]2CC[C@@H](N3Cc4nn5nccnc5c4C3)CO2)cc1
2058,763235,10.1016/j.ejmech.2011.05.015,,,,Inhibition of wild-type human ERG channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl,LEVOBUPIVACAINE HYDROCHLORIDE,13.0,uM,=,1.1139433523068367,1,O=C(Nc1ccccc1)[C@@H]1CCCCN1
2059,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",COc1cccc(C(=O)N2CCn3c(-c4nc(C)ns4)nnc3[C@H]2C)c1,"US9422299, 27",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
2060,1543580,10.1016/j.bmcl.2015.11.030,,,,Inhibition of human ERG by IKr binding assay,CCOC(=O)[C@@H]1[C@@H]2CN(C(=O)c3ccc(C[C@@H]4CC[C@H]([C@H](O)c5ccccc5)N4)cc3)C[C@@H]21,"(1R,5S,6R)-ethyl 3-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)benzoyl)-3-azabicyclo[3.1.0]hexane-6-carboxylate",12.0,uM,=,1.0791812460476249,1,O=C(c1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)N1C[C@H]2C[C@H]2C1
2061,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC1CCCN1CCc1ccc2nc(-c3cccs3)ccc2c1,6-(2-(2-methylpyrrolidin-1-yl)ethyl)-2-(thiophen-2-yl)quinoline,2.48,uM,=,0.3944516808262163,1,c1csc(-c2ccc3cc(CCN4CCCC4)ccc3n2)c1
2062,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,CC(C)CN(C(=O)c1ccccc1Oc1ccccc1)[C@H]1CCNC1,(S)-N-isobutyl-2-phenoxy-N-(pyrrolidin-3-yl)benzamide,1.08,uM,=,0.0334237554869497,1,O=C(N[C@H]1CCNC1)c1ccccc1Oc1ccccc1
2063,812486,10.1016/j.bmcl.2012.02.010,,,,Inhibition of human ERG,N[C@H]1CN(c2ccc(-n3ccc(OCc4ccccc4)cc3=O)cn2)C[C@@H]1c1cc(F)ccc1F,"1-(6-((3R,4S)-3-amino-4-(2,5-difluorophenyl)pyrrolidin-1-yl)pyridin-3-yl)-4-(benzyloxy)pyridin-2(1H)-one",8.8,uM,=,0.9444826721501688,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc(N2CC[C@@H](c3ccccc3)C2)nc1
2064,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,O=C(/C=C/c1ccc(CN2CCCC(c3c[nH]c4ccccc34)C2)c(F)c1)NO,(E)-3-{3-Fluoro-4-[3-(1H-indol-3-yl)piperidin-1-ylmethyl]-phenyl}-N-hydroxyacrylamide,15.3,uM,=,1.1846914308175989,1,c1ccc(CN2CCCC(c3c[nH]c4ccccc34)C2)cc1
2065,1510552,10.1016/j.bmcl.2015.06.057,,,,Inhibition of human ERG expressed in CHO cells measured for 5 mins by automated patch clamp assay,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(C)c6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-8-methyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.0,uM,=,0.3010299956639812,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2066,1442903,10.1016/j.bmcl.2014.08.008,,,,Inhibition of human ERG by patch clamp assay,O=C(NOCCO)c1ccn2cncc2c1Nc1ccc(I)cc1F,"8-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-7-carboxamide",2.1,uM,=,0.3222192947339193,1,c1ccc(Nc2cccn3cncc23)cc1
2067,2254299,10.1021/acs.jmedchem.1c01856,,,,Inhibition of hERG ion channel by patch-clamp method,Cn1c(CN2CCC(c3nc(OCc4ccc(Cl)cc4F)ncc3F)CC2)nc2ccccc21,2-((4-(2-(4-chloro-2-fluorobenzyloxy)-5-fluoropyrimidin-4-yl)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole,5.4,uM,=,0.7323937598229685,1,c1ccc(COc2nccc(C3CCN(Cc4nc5ccccc5[nH]4)CC3)n2)cc1
2068,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,CC1(C)C(=O)Nc2nc(-n3nc(CCCC(F)(F)F)c4cc(Cl)ccc43)nc(N)c21,"4-amino-2-[5-chloro-3-(4,4,4-trifluorobutyl)indazol-1-yl]-5,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-6-one",4.1,uM,=,0.6127838567197355,1,O=C1Cc2cnc(-n3ncc4ccccc43)nc2N1
2069,815278,10.1016/j.ejmech.2012.02.049,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cells after 45 mins by scintillation counting method,CCOC(=O)C1CCN(CCCOc2ccc(S(=O)(=O)NC(=O)Nc3ccccc3)cc2)CC1,1-Phenyl-3-[4-(3-(4-ethoxycarbonylpiperidin-1-yl)propoxy)benzene]sulfonylurea,78.7,uM,=,1.8959747323590648,1,O=C(Nc1ccccc1)NS(=O)(=O)c1ccc(OCCCN2CCCCC2)cc1
2070,2164004,10.1021/acs.jmedchem.1c02110,,,,Inhibition of hERG by patch clamp method,CCOP(=O)(Cn1ccc(NC(=O)c2cc(Oc3ccc(S(C)(=O)=O)cc3)cc(OC(CF)CF)c2)n1)OCC,"Diethyl ((3-(3-((1,3-Difluoropropan-2-yl)oxy)-5-(4-(methylsulfonyl)phenoxy)benzamido)-1H-pyrazol-1-yl)methyl)phosphonate",44.0,uM,=,1.6434526764861874,1,O=C(Nc1cc[nH]n1)c1cccc(Oc2ccccc2)c1
2071,885330,10.1016/j.bmcl.2012.10.090,,,,Inhibition of human ERG,COCC[C@H](Oc1ncnc2c1cnn2-c1ccccc1C(F)(F)F)C(=O)Nc1ccc(C)cn1,"(2S)-4-methoxy-N-(5-methylpyridin-2-yl)-2-(1-(2-(trifluoromethyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)butanamide",26.0,uM,=,1.414973347970818,1,O=C(COc1ncnc2c1cnn2-c1ccccc1)Nc1ccccn1
2072,1992475,10.1021/acs.jmedchem.0c01199,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by IonWorks barracuda patch clamp method,COc1cc(-c2cncc(-c3ccc(N4CCN(C(C)C)CC4)cc3)c2C)cc(OC)c1OC,"1-Isopropyl-4-(4-(4-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine",3.1,uM,=,0.4913616938342727,1,c1ccc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2)cc1
2073,1438341,10.1016/j.ejmech.2014.09.010,,,,Inhibition of human ERG,O=C1NC(=O)/C(=C\c2ccccc2OCc2nnc(-c3ccccc3)o2)S1,"5-[2-{(5-Phenyl-1,3,4-oxadiazol-2-yl)methoxy}benzylidene]thiazolidine-2,4-dione",41.0,uM,=,1.6127838567197357,1,O=C1NC(=O)/C(=C\c2ccccc2OCc2nnc(-c3ccccc3)o2)S1
2074,2123621,10.1021/acs.jmedchem.1c01015,,,,Inhibition of human ERG expressed in CHO cells by manual patch clamp technique,Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc2c1CSCC2,"(E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenoxy)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-ylamino)benzonitrile",19.84,uM,=,1.29754166781816,1,c1ccc(Nc2nc3c(c(Oc4ccccc4)n2)CSCC3)cc1
2075,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(C[C@@H]2CCCN(Cc3ccccc3)C2)CC1,"(R)-4-((1-benzylpiperidin-3-yl)methyl)-N-(3,4-dichlorophenyl)piperazine-1-carboxamide",0.56,uM,=,-0.2518119729937995,0,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(Cc3ccccc3)C2)CC1
2076,2169260,10.1021/acs.jmedchem.1c00625,,,,Inhibition of human ERG by patch-clamp assay,Cc1nnn(C)c1-c1cnc2c3ccc(C(C)(C)O)cc3n([C@H](c3ccccc3)C3CCOCC3)c2c1,EZOBRESIB,28.0,uM,=,1.4471580313422192,1,c1ccc([C@H](C2CCOCC2)n2c3ccccc3c3ncc(-c4cnn[nH]4)cc32)cc1
2077,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COCCN1CCC[C@@H](Cn2c(-c3ccccc3C)nc3cn(-c4ccc(Cl)cc4)nc3c2=O)C1,"2-(4-Chlorophenyl)-6-{[(3R)-1-(2-methoxyethyl)piperidin-3-yl]methyl}-5-(2-methylphenyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one",2.5,uM,=,0.3979400086720376,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2ccccc2)n1C[C@@H]1CCCNC1
2078,1557379,10.1021/acs.jmedchem.5b01153,,,,Inhibition of human ERG channel,C=CCOc1cc(F)c(F)cc1C1CC1CN.Cl,"(-)-[2-[2-(Allyloxy)-4,5-difluorophenyl]cyclopropyl]methanamine Hydrochloride",9.1,uM,=,0.9590413923210936,1,c1ccc(C2CC2)cc1
2079,1642335,,,,,"Cell-Based Electrophysiology Assays: All hERG percentage inhibitions at 10 uM compound concentration were determined by Millipore in a high-throughput cell-based electrophysiology assay for inhibition of hERG tail current41, and values are reported as a mean of multiple determinations. 0.3% DMSO aqueous vehicle negative control gave 7-16% inhibition. Cisapride (1 uM) positive control gave 96-104% inhibition. All hERG IC50 values were determined by Millipore,41 and the hERG IC50 for Example 1 was also determined by Cyprotex plc measuring hERG tail-currents by whole-cell voltage-clamping.",Cn1cc(-c2nc3c(N4CCN(Cc5cccnc5)CC4)c(Br)cnc3[nH]2)cn1,"US9447092, Comparator 1, Example 56",5.5,uM,=,0.7403626894942439,1,c1cncc(CN2CCN(c3ccnc4[nH]c(-c5cn[nH]c5)nc34)CC2)c1
2080,580515,10.1016/j.bmcl.2009.06.050,,,,Displacement of [35S]MK499 from human ERG potassium channel expressed in HEK293 cells,COc1ccc([C@@H](C)N[C@@H]2CC[C@@H](C(=O)N3CCC(c4ccccc4)(N4CCCCC4)CC3)C(C)(C)C2)cc1,"((1R,4R)-4-((R)-1-(4-methoxyphenyl)ethylamino)-2,2-dimethylcyclohexyl)(4'-phenyl-1,4'-bipiperidin-1'-yl)methanone",6.7,uM,=,0.8260748027008264,1,O=C([C@H]1CC[C@H](NCc2ccccc2)CC1)N1CCC(c2ccccc2)(N2CCCCC2)CC1
2081,2153149,10.1016/j.ejmech.2021.113827,,,,Inhibition of hERG expressed in CHO-K1 cells assessed as reduction in thallium influx incubated for 30 minutes by FLIPR,O=c1ccc2c([nH]1)CCC(NCCCCCCCCNc1c3c(nc4cc(Cl)ccc14)CCCC3)C2,"6-(8-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)octylamino)-5,6,7,8-tetrahydroquinolin-2(1H)-one",2.191,uM,=,0.3406423775607052,1,O=c1ccc2c([nH]1)CCC(NCCCCCCCCNc1c3c(nc4ccccc14)CCCC3)C2
2082,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(CCN2CCN(CC(C)c3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"2-methoxy-4-(2-(4-(2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)propyl)piperazin-1-yl)ethyl)benzonitrile",2.8,uM,=,0.4471580313422192,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
2083,420606,10.1016/j.bmcl.2006.11.061,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,CC(=O)Nc1ccc2c(c1)C(N1CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC1)CC2,"N-(1-(6-acetamido-2,3-dihydro-1H-inden-1-yl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide",34.8,uM,=,1.541579243946581,1,O=C(NC1CCN(C2CCc3ccccc32)CC1)c1cc(=O)c2ccccc2o1
2084,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,O=C(N1CCc2ncc(C(F)(F)F)cc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCCCC1)C2,"((2R,3aR,6aR)-2-(cyclohexylamino)octahydropentalen-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",33.6,uM,=,1.526339277389844,1,O=C(N1CCc2ncccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCCCC1)C2
2085,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,CN(C)CC(O)Cn1ncc2cc(-n3ccc(OCc4ccccc4)cc3=O)ccc21,4-(benzyloxy)-1-(1-(3-(dimethylamino)-2-hydroxypropyl)-1H-indazol-5-yl)pyridin-2(1H)-one,12.1,uM,=,1.08278537031645,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2[nH]ncc2c1
2086,421810,10.1016/j.bmcl.2006.10.053,,,,Inhibition of binding to hERG,CN(C)Cc1ccc2c(c1)CC[C@H](N(C)C(=O)c1ccc(-c3ccc(Cl)cc3)cn1)C2,"(S)-5-(4-chlorophenyl)-N-(6-((dimethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylpicolinamide",2.6,uM,=,0.414973347970818,1,O=C(N[C@H]1CCc2ccccc2C1)c1ccc(-c2ccccc2)cn1
2087,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,Cc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1cnccn1,"(R)-N,N-dimethyl-2-(6-methyl-3-(1-(pyrazin-2-yl)ethyl)-1H-inden-2-yl)ethanamine",0.36,uM,=,-0.4436974992327127,0,C1=C(Cc2cnccn2)c2ccccc2C1
2088,1461416,10.1016/j.bmcl.2014.12.068,,,,Inhibition of human ERG,CS(=O)(=O)c1ccc(-c2ccc3[nH]nc(-c4cncc(O[C@H]5CNCCC56CC6)n4)c3c2)c(F)c1,(R)-3-(6-(6-azaspiro[2.5]octan-4-yloxy)pyrazin-2-yl)-5-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-indazole,2.0,uM,=,0.3010299956639812,1,c1ccc(-c2ccc3[nH]nc(-c4cncc(O[C@H]5CNCCC56CC6)n4)c3c2)cc1
2089,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,COc1cccc(F)c1CC(c1ccccc1)N1CCNCC1,1-(2-(2-fluoro-6-methoxyphenyl)-1-phenylethyl)piperazine,8.55,uM,=,0.9319661147281728,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
2090,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,COc1ccc(NC(=O)NC2CC2)c(OC[C@@H](O)CN2CCC3(CC2)Cc2cc(Cl)ccc2O3)c1,"(S)-1-(2-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-methoxyphenyl)-3-cyclopropylurea",0.7,uM,=,-0.1549019599857432,0,O=C(Nc1ccccc1OCCCN1CCC2(CC1)Cc1ccccc1O2)NC1CC1
2091,965438,10.1016/j.bmcl.2013.01.025,,,,Displacement of [3H]Astemizole from human recombinant ERG expressed in HEK293 cells at after 60 mins,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,0.0026,uM,=,-2.5850266520291822,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
2092,1990087,10.1021/acs.jmedchem.0c00259,,,,Inhibition of human ERG by Ionworks high-throughput electrophysiology method,Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1F,"rac-2,5-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy]-N-(1,3-thiazol-4-yl)benzene-1-sulfonamide",94.0,uM,=,1.9731278535996988,1,O=S(=O)(Nc1cscn1)c1ccc(O[C@H]2CCCC[C@@H]2c2ccn[nH]2)cc1
2093,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)CCN1CCC(CNC(=O)Nc2cccc(Cl)c2)(c2ccccc2)CC1,"1-(3-Chloro-phenyl)-3-[1-(3,3-dimethyl-butyl)-4-phenyl-piperidin-4-ylmethyl]-urea",0.088,uM,=,-1.055517327849831,0,O=C(NCC1(c2ccccc2)CCNCC1)Nc1ccccc1
2094,2112211,10.1016/j.bmcl.2021.127909,,,,Inhibition of human ERG by automated patch method relative to control,CN1CCN(Cc2ccc(OCCCCN3CCC(c4noc5cc(F)ccc45)CC3)cc2)CC1,6-fluoro-3-(1-(4-(4-((4-methylpiperazin-1-yl)methyl)phenoxy)butyl)piperidin-4-yl)benzo[d]isoxazole,1.0565,uM,=,0.0238695013883321,1,c1ccc2c(C3CCN(CCCCOc4ccc(CN5CCNCC5)cc4)CC3)noc2c1
2095,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)-N-(2-methoxy-4-(piperidin-4-yl)phenyl)pyrimidin-2-amine",9.1,uM,=,0.9590413923210936,1,c1ccn2c(-c3ccnc(Nc4ccc(C5CCNCC5)cc4)n3)cnc2c1
2096,1669922,10.1021/acs.jmedchem.7b00462,,,,Inhibition of human hERG by patch clamp method,Cc1ccc(-c2ncc(OC[C@H]3CCNC3)cc2-c2ccc(C#N)cc2)cc1,(S)-4-(5-(pyrrolidin-3-ylmethoxy)-2-p-tolylpyridin-3-yl)benzonitrile,3.2,uM,=,0.505149978319906,1,c1ccc(-c2cc(OC[C@H]3CCNC3)cnc2-c2ccccc2)cc1
2097,2226047,10.1021/acs.jmedchem.2c00227,,,,Inhibition of hERG transfected in T-REX-CHO cells incubated for 30 mins by BTC-AM dye based fluorescence assay,CNC(=O)c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CCCCC3)c12,5-hydroxy-2-(4-hydroxyphenyl)-N-methyl-4-(1-piperidylmethyl)benzofuran-3-carboxamide,21.0,uM,=,1.3222192947339193,1,c1ccc(-c2cc3c(CN4CCCCC4)cccc3o2)cc1
2098,806244,10.1016/j.bmcl.2012.01.078,,,,Inhibition of human Erg by patch clamp assay,Cc1nc2cnc(Oc3ccc(Cl)cc3F)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,"(S)-6-(4-chloro-2-fluorophenoxy)-3-((1-isopropylpiperidin-3-yl)methyl)-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one",0.13,uM,=,-0.8860566476931633,0,O=c1c2cc(Oc3ccccc3)ncc2ncn1C[C@H]1CCCNC1
2099,2244060,10.1016/j.ejmech.2022.114145,,,,Inhibition of hERG,COC(=O)NC(=O)c1ccsc1NC(=O)c1ccc(S(=O)(=O)N2CCCCC2)cc1,Methyl (2-(4-(piperidin-1-ylsulfonyl)benzamido)thiophene-3-carbonyl)carbamate,3.3,uM,=,0.5185139398778875,1,O=C(Nc1cccs1)c1ccc(S(=O)(=O)N2CCCCC2)cc1
2100,1505208,10.1016/j.bmc.2015.05.034,,,,Inhibition of human ERG expressed in CHOK1 cells incubated for 10 mins by Rb efflux assay,C[C@H]1CN(c2ccc(C#N)cn2)CC[C@H]1Nc1c(C(N)=O)cnc2[nH]ccc12,"cis-4-{[1-(5-Cyanopyridin-2-yl)-3-methylpiperidin-4-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide",28.7,uM,=,1.4578818967339924,1,c1ccc(N2CCC(Nc3ccnc4[nH]ccc34)CC2)nc1
2101,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(N3CCCC3)n2)(c2ccccc2)CC1,2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-6-(pyrrolidin-1-yl)-4-(trifluoromethyl)pyridine,7.4,uM,=,0.8692317197309762,1,c1ccc(C2(COCc3cccc(N4CCCC4)n3)CCNCC2)cc1
2102,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccc(C#N)cc4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(4-cyanophenyl)pyrrolo[1,2-b]pyridazine-3-carboxamide",12.0,uM,=,1.0791812460476249,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
2103,538846,10.1021/jm800830n,,,,Inhibition of human ERG,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",0.806,uM,=,-0.0936649581949093,0,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
2104,2049320,10.1021/acs.jmedchem.0c01179,,,,Inhibition of tracer red binding to human ERG expressed in HEK293 cell membranes measured after 2 to 6 hrs by fluorescence polarization assay,C[C@H]1CN(C2CCN(c3nc(N)n[nH]3)CC2)[C@@H](Cc2ccc(Cl)cc2)CO1,"5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-methylmorpholino)-piperidin-1-yl)-4H-1,2,4-triazol-3-amine",23.0,uM,=,1.3617278360175928,1,c1ccc(C[C@H]2COCCN2C2CCN(c3ncn[nH]3)CC2)cc1
2105,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,O=C1OCCc2cc([C@@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@H]4CO3)ccc21,"6-((3R,9aS)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)isochroman-1-one",75.9,uM,=,1.8802417758954804,1,O=C1OCCc2cc([C@@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@H]4CO3)ccc21
2106,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@H]1CN(C)C[C@@H]1c1ccc(-c2ccsc2)cc1,"N-((3R,4R)-1-methyl-4-(4-(thiophen-3-yl)phenyl)pyrrolidin-3-yl)propane-2-sulfonamide",4.0,uM,=,0.6020599913279624,1,c1cc(-c2ccc([C@@H]3CCNC3)cc2)cs1
2107,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,CNc1cc(Nc2cnc(C#N)c(O[C@@H]3CCNC3)n2)ncc1C(=O)OC,(R)-Methyl 6-((5-cyano-6-(pyrrolidin-3-yloxy)pyrazin-2-yl)amino)-4-(methylamino)nicotinate,16.0,uM,=,1.2041199826559248,1,c1ccc(Nc2cncc(O[C@@H]3CCNC3)n2)nc1
2108,990152,10.1016/j.bmc.2013.08.041,,,,Inhibition of human ERG channel expressed in CHO cells by whole cell patch clamp technique,Cc1ccc(S(=O)(=O)N/N=C/c2cn(CC(=O)Nc3ccccc3)c3ccccc23)cc1,N-Phenyl-2-(3-((2-tosylhydrazono)methyl)-1H-indol-1-yl)acetamide,43.62,uM,=,1.6396856612426816,1,O=C(Cn1cc(/C=N/NS(=O)(=O)c2ccccc2)c2ccccc21)Nc1ccccc1
2109,1336040,10.1021/jm500118j,,,,Binding affinity to human ERG,C[C@@H](O)CN(C)C1CCN(c2ccc(Nc3ncc4c5ccncc5n([C@H]5CC[C@H](C)CC5)c4n3)nn2)CC1,"(R)-1-(Methyl(1-(6-((9-((trans)-4-methylcyclohexyl)-9H-pyrido-[4',3':4,5]pyrrolo[2,3-d]pyrimidin-2-yl)amino)pyridazin-3-yl)-piperidin-4-yl)amino)propan-2-ol",0.92,uM,=,-0.0362121726544447,0,c1cc2c3cnc(Nc4ccc(N5CCCCC5)nn4)nc3n(C3CCCCC3)c2cn1
2110,1784292,10.1021/acsmedchemlett.7b00501,,,,Inhibition of recombinant human ERG expressed in CHO cells at -80 mV holding potential measured after 3 minutes by automated whole cell patch clamp Qpatch method,Cc1ccc(/C=C/CN(C)Cc2ccc3c(c2)OCCO3)cc1.Cl,"(E)-N-(1,4-Benzodioxine-7-methyl)-N-methyl-3-(4-methylphenyl)prop-2-en-1-amine Hydrochloride",4.6,uM,=,0.6627578316815741,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)OCCO2
2111,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCOC(=O)[C@H]1CC[C@@H](N2CC(NC(=O)CNc3nn(C(N)=O)c4ccc(C(F)(F)F)cc34)C2)CC1,cis-ethyl 4-(3-(2-(1-carbamoyl-5-(trifluoromethyl)-1H-indazol-3-ylamino)acetamido)azetidin-1-yl)cyclohexanecarboxylate,20.0,uM,=,1.3010299956639813,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
2112,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCCCC4)N3)n2)nc1,"(3R)-1-cyclohexyl-3-(4-(pyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.2,uM,=,-0.6989700043360187,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCCCC4)N3)n2)nc1
2113,624297,10.1016/j.bmcl.2010.01.134,,,,Inhibition of human ERG expressed in HEK cells assessed as blockade of potassium tail current by standard patch clamp analysis,C[C@H](c1c(CCN(C)C)sc2ccccc12)n1cccn1,"(-)-(R)-2-(3-(1-(1H-pyrazol-1-yl)ethyl)benzo[b]thiophen-2-yl)-N,N-dimethylethanamine",2.0,uM,=,0.3010299956639812,1,c1ccc2c(Cn3cccn3)csc2c1
2114,1332040,10.1039/C1MD00092F,,,,Inhibition of human ERG,COC[C@H](C)Oc1cc(Oc2ccc(S(C)(=O)=O)cc2)cc(C(=O)Nc2nccs2)c1,(S)-3-(1-methoxypropan-2-yloxy)-5-(4-(methylsulfonyl)phenoxy)-N-(thiazol-2-yl)benzamide,6.9,uM,=,0.8388490907372553,1,O=C(Nc1nccs1)c1cccc(Oc2ccccc2)c1
2115,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CC[C@@H](NCc4ccc5c(n4)NC(=O)CO5)[C@H](OC)C3)c2c1,"trans-6-[({3-Methoxy-1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)-ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]-oxazin-3(4H)-one",27.0,uM,=,1.4313637641589874,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)cnc5ccccc54)CC3)nc2N1
2116,1813578,10.1021/acs.jmedchem.9b00510,,,,Inhibition of human ERG by patch-clamp method,Cc1c(C(=O)CC#N)oc2ccc(Cl)cc12,3-(5-Chloro-3-methylbenzofuran-2-yl)-3-oxopropanenitrile,0.03,uM,=,-1.5228787452803376,0,c1ccc2occc2c1
2117,2111972,10.1021/acs.jmedchem.0c01992,,,,Inhibition of human ERG by patch-clamp assay,CC(C)(O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,"N-((3R,3aS,9bS)-9b-(4-fluorophenylsulfonyl)-7-(perfluoropropan-2-yl)-2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[a]naphthalen-3-yl)-2-hydroxy-2-methylpropanamide",19.0,uM,=,1.2787536009528289,1,O=S(=O)(c1ccccc1)[C@@]12CCC[C@@H]1CCc1ccccc12
2118,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3ccc(F)cc3)CC2)C1,"(1S,3R)-N-(3,5-bis(trifluoromethyl)benzyl)-3-(4-(4-fluorophenyl)piperidin-1-yl)-1-isopropylcyclopentanecarboxamide",0.016,uM,=,-1.7958800173440752,0,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3ccccc3)CC2)C1
2119,2196932,10.1016/j.bmcl.2022.128911,,,,Inhibition of hERG,C=C(c1ccc(NC(C)=O)cc1)c1ccc2c(c1)Nc1ccccc1S2,N-(4-(1-(10H-phenothiazin-2-yl)vinyl)phenyl)acetamide,21.97,uM,=,1.3418300569205104,1,C=C(c1ccccc1)c1ccc2c(c1)Nc1ccccc1S2
2120,559360,10.1021/jm8012932,,,,Inhibition of human ERG,CN1CCN(c2ncnc3c2nc(-c2ccccc2Cl)n3-c2ccc(Cl)cc2)CC1,8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-(4-methylpiperazin-1-yl)-9H-purine,0.63,uM,=,-0.2006594505464183,0,c1ccc(-c2nc3c(N4CCNCC4)ncnc3n2-c2ccccc2)cc1
2121,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,NC(=O)Nc1ccc(F)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2,"(S)-1-(2-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-fluorophenyl)urea",0.4,uM,=,-0.3979400086720376,0,c1ccc(OCCCN2CCC3(CC2)Cc2ccccc2O3)cc1
2122,1648277,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG,CC1(OC(=O)N2CCC([C@H]3C[C@H]3CCOc3ccc(CC(=O)N4CCC4)c(F)c3)CC2)CC1,"(cis)-1-methylcyclopropyl 4-((1R,2S)-2-(2-(4-(2-(azetidin-1-yl)-2-oxoethyl)-3-fluorophenoxy)ethyl)cyclopropyl)piperidine-1-carboxylate",23.0,uM,=,1.3617278360175928,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(C(=O)OC3CC3)CC2)cc1)N1CCC1
2123,1362933,10.1016/j.bmcl.2014.04.083,,,,Inhibition of human ERG tail current after 5 mins by patch-clamp method,CC(C)OC(=O)N1CCC(C)(CN2CCC3(CC2)CN(S(C)(=O)=O)c2ncccc23)CC1,"isopropyl 4-methyl-4-((1'-(methylsulfonyl)-1',2'-dihydrospiro[piperidine-4,3'-pyrrolo[2,3-b]pyridine]-1-yl)methyl)piperidine-1-carboxylate",2.75,uM,=,0.4393326938302626,1,c1cnc2c(c1)C1(CCN(CC3CCNCC3)CC1)CN2
2124,853148,10.1021/ml300074j,,,,Inhibition of human ERG,CCOc1cc(Nc2nc3c(cc2F)ncn3[C@@H](CO)c2ccc(F)cn2)n[nH]1,"(R)-2-(5-(5-ethoxy-1H-pyrazol-3-ylamino)-6-fluoro-3H-imidazo[4,5-b]pyridin-3-yl)-2-(5-fluoropyridin-2-yl)ethanol",32.0,uM,=,1.505149978319906,1,c1ccc(Cn2cnc3ccc(Nc4cc[nH]n4)nc32)nc1
2125,1765257,10.1021/acsmedchemlett.8b00200,,,,Inhibition of recombinant human ERG expressed in CHOK1 cells at -70 mV holding potential by patch clamp electrophysiology method,CNC(=O)c1nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc2c1N[C@@H](C)C1CCOCC1,6-{6-[3-(Dimethylamino)propoxy]-3-pyridinyl}-N-methyl-4-{[(1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-cinnolinecarboxamide,15.0,uM,=,1.1760912590556811,1,c1cncc(-c2ccc3nncc(NCC4CCOCC4)c3c2)c1
2126,768149,10.1016/j.bmcl.2011.07.020,,,,Inhibition of human ERG,CN1CC(c2c[nH]c3cc(-n4ccc(OCc5ccccc5)cc4=O)ccc23)C1,4-(benzyloxy)-1-(3-(1-methylazetidin-3-yl)-1H-indol-6-yl)pyridin-2(1H)-one,12.0,uM,=,1.0791812460476249,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(C3CNC3)c[nH]c2c1
2127,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1cc(C(=O)NCC2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc(OC)c1OC,"N-((1-(6,6-bis(4-fluorophenyl)hexyl)pyrrolidin-3-yl)methyl)-3,4,5-trimethoxybenzamide",0.1,uM,=,-1.0,0,O=C(NCC1CCN(CCCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
2128,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1nccc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)n1,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(2-methylpyrimidin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",17.6,uM,=,1.24551266781415,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccncn3)C4=O)ccc21
2129,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,C[C@@H]1CC[C@H](Nc2ncc(C(N)=O)c3sc(-c4ccccc4)cc23)[C@H](C)N1,"rac-4-[(cis-2,6-Dimethylpiperidin-3-yl)amino]-2-phenylthieno-[3,2-c]pyridine-7-carboxamide",8.4,uM,=,0.9242792860618816,1,c1ccc(-c2cc3c(N[C@H]4CCCNC4)nccc3s2)cc1
2130,2015654,10.1016/j.bmcl.2020.127417,,,,Inhibition of human ERG by QPatch HTX automated patch clamp system,Clc1ccc2c(c1)CCc1nnc([C@H]3CC[C@H](Oc4ccccn4)CC3)n1-2,"7-chloro-1-((1r,4r)-4-(pyridin-2-yloxy)cyclohexyl)-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline",7.2,uM,=,0.8573324964312685,1,c1ccc(O[C@H]2CC[C@H](c3nnc4n3-c3ccccc3CC4)CC2)nc1
2131,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,O=C1OCc2cc(CCC3CCN(C(=O)Cc4ccc(-n5cnnn5)cn4)CC3)ccc21,5-(2-(1-(2-(5-(1H-tetrazol-1-yl)pyridin-2-yl)acetyl)piperidin-4-yl)ethyl)isobenzofuran-1(3H)-one,7.9,uM,=,0.8976270912904415,1,O=C1OCc2cc(CCC3CCN(C(=O)Cc4ccc(-n5cnnn5)cn4)CC3)ccc21
2132,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CN1CCN(C)C(C(=O)N2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"rac-N-(3,4-dichlorophenyl)-4-(1,4-dimethylpiperazine-2-carbonyl)piperazine-1-carboxamide",13.0,uM,=,1.1139433523068367,1,O=C(Nc1ccccc1)N1CCN(C(=O)C2CNCCN2)CC1
2133,1990748,10.1016/j.bmcl.2020.127214,,,,Inhibition of human ERG expressed in CHO cells by electrophysiology QPatch assay,COc1c(S(C)(=O)=O)ccc(O[C@@H](C)C(F)(F)F)c1C(=O)N1CC(c2ccc(C(F)(F)F)cc2)C1,"(S)-(2-methoxy-3-(methylsulfonyl)-6-(1,1,1-trifluoropropan-2-yloxy)phenyl)(3-(4-(trifluoromethyl)phenyl)azetidin-1-yl)methanone",2.4,uM,=,0.380211241711606,1,O=C(c1ccccc1)N1CC(c2ccccc2)C1
2134,830253,10.1021/jm300041e,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN,"2-Amino-1-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone",13.4,uM,=,1.1271047983648077,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
2135,938758,10.1016/j.bmcl.2013.01.033,,,,Inhibition of human hERG by automated patch clamp assay,CC(C#N)=C1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1,"(R)-2-(1-(4-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperidin-4-ylidene)propanenitrile",213.32,uM,=,2.329031575010839,1,C=C1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2)CC1
2136,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(Br)cc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1,(S)-N-(4-bromophenyl)-4-((1-cyclopropylpiperidin-3-yl)methyl)piperazine-1-carboxamide,7.1,uM,=,0.8512583487190752,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
2137,579352,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG activation expressed in CHO cells by rubidium efflux assay,O=C(NCc1ccc(Cl)cc1Cl)C1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cn3)c2)CC1,"N-(2,4-dichlorobenzyl)-1-((1-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrol-3-yl)methyl)piperidine-4-carboxamide",3.5,uM,=,0.5440680443502757,1,O=C(NCc1ccccc1)C1CCN(Cc2ccn(-c3ccccn3)c2)CC1
2138,2229351,10.1021/acsmedchemlett.2c00172,,,,Inhibition of hERG expressed in CHO cells by electrophysiological assay based automated patch clamp method,Cc1cc2ncccc2cc1Nc1ncc2c(n1)n([C@@H]1CNC[C@H]1F)c(=O)n2C,"9-((3R,4R)-4-fluoropyrrolidin-3-yl)-7-methyl-2-(7-methylquinolin-6-ylamino)-7H-purin-8(9H)-one",75.0,uM,=,1.8750612633917,1,O=c1[nH]c2cnc(Nc3ccc4ncccc4c3)nc2n1[C@H]1CCNC1
2139,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cnc(-c2cnc(OC3CCN(C(=O)Cc4ccc(OC(F)(F)F)cc4)CC3)c(C(N)=O)c2)c1,5-(1-Methyl-1H-imidazol-4-yl)-2-((1-(2-(4-(trifluoromethoxy)-phenyl)acetyl)piperidin-4-yl)oxy)nicotinamide,4.5,uM,=,0.6532125137753437,1,O=C(Cc1ccccc1)N1CCC(Oc2ccc(-c3c[nH]cn3)cn2)CC1
2140,1716395,10.1016/j.ejmech.2017.07.015,,,,Displacement of [3H]astemizole from human ERG,O=C1S/C(=C\c2ccc3c(cnn3Cc3ccc(Cl)cc3C(F)(F)F)c2)C(=O)N1[C@@H]1CCNC[C@H]1F,"(5Z)-5-({1-[4-Chloro-2-(trifluoromethyl)benzyl]-1H-indazol-5-yl}methylidene)-3-(trans-3-fluoropiperidin-4-yl)-1,3-thiazolidine-2,4-dione",21.0,uM,=,1.3222192947339193,1,O=C1S/C(=C\c2ccc3c(cnn3Cc3ccccc3)c2)C(=O)N1C1CCNCC1
2141,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CS(=O)(=O)Nc1ccc(OC[C@@H](O)CNCCc2ccc(Cl)c(Cl)c2)cc1,"(S)-1-(4-Methanesulfonamidephenoxy)-3-(3,4-dichlorophenylethylamino)-2-propanol",0.73,uM,=,-0.1366771398795441,0,c1ccc(CCNCCCOc2ccccc2)cc1
2142,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(NCc1ccccc1)N(c1ccc(Br)cc1)C1CCN(Cc2ccncc2)CC1,3-benzyl-1-(4-bromophenyl)-1-(1-(pyridin-4-ylmethyl)piperidin-4-yl)urea,2.31,uM,=,0.3636119798921443,1,O=C(NCc1ccccc1)N(c1ccccc1)C1CCN(Cc2ccncc2)CC1
2143,2021700,10.1021/acs.jmedchem.9b00069,,,,Inhibition of human ERG by thallium flux assay,CC(C)(CCO)n1nc(-c2ccc3cc(OC4CC4)ccc3c2)c(C(N)=O)c1N,5-Amino-3-(6-cyclopropoxynaphthalen-2-yl)-1-(4-hydroxy-2-methylbutan-2-yl)-1H-pyrazole-4-carboxamide,4.5,uM,=,0.6532125137753437,1,c1cc(-c2ccc3cc(OC4CC4)ccc3c2)n[nH]1
2144,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,COCC(O)CN(Cc1ccc(F)cc1)C(=O)CC1CCN(Cc2ccc(-c3ccc(Cl)cc3)o2)CC1,2-(1-((5-(4-chlorophenyl)furan-2-yl)methyl)piperidin-4-yl)-N-(4-fluorobenzyl)-N-(2-hydroxy-3-methoxypropyl)acetamide,1.09,uM,=,0.0374264979406236,1,O=C(CC1CCN(Cc2ccc(-c3ccccc3)o2)CC1)NCc1ccccc1
2145,1672277,10.1016/j.bmcl.2017.05.026,,,,Inhibition of recombinant human ERG expressed in HEK293 cells after 9 mins by patch clamp method,Cc1ccc(/C=C/C(=O)N2CCN(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1,(E)-N-(2-aminophenyl)-4-(4-(3-(p-tolyl)acryloyl)piperazin-1-yl)benzamide,27.1,uM,=,1.4329692908744058,1,O=C(Nc1ccccc1)c1ccc(N2CCN(C(=O)/C=C/c3ccccc3)CC2)cc1
2146,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,Cc1cc(C2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1,"(4S,4aR,8aS)-8a-(2,4-difluorophenyl)-4-(fluoromethyl)-6-(3-methylisoxazol-5-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",2.1,uM,=,0.3222192947339193,1,C1=N[C@@]2(c3ccccc3)COC(c3ccno3)C[C@H]2CS1
2147,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCC[C@@H](CCO)Nc1nc(N)nc2cccc(F)c12,(S)-3-((2-Amino-5-fluoroquinazolin-4-yl)amino)hexan-1-ol,8.9,uM,=,0.9493900066449128,1,c1ccc2ncncc2c1
2148,1453433,10.1016/j.bmc.2014.07.040,,,,Inhibition of human ERG by cell-based patch clamp method,N[C@@H](Cn1c(=O)cnc2ccc(F)cc21)[C@H]1CC[C@H](NCc2ccc3c(n2)NC(=O)CO3)CC1,"(R)-trans-6-((4-(1-Amino-2-(7-fluoro-2-oxoquinoxalin-1(2H)-yl)ethyl)cyclohexylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",174.0,uM,=,2.2405492482826,1,O=C1COc2ccc(CN[C@H]3CC[C@H](CCn4c(=O)cnc5ccccc54)CC3)nc2N1
2149,1924512,10.1021/acsmedchemlett.6b00122,,,,Displacement of [35S]MK-499 from human ERG,Cc1c(CCN2CCN(CCc3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,"5,5'-(2,2'-(piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-methylisobenzofuran-1(3H)-one)",3.0,uM,=,0.4771212547196624,1,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21
2150,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,O=C(/C=C/c1ccc(CNCCc2c(-c3ccccn3)[nH]c3ccccc23)cc1)NO,(E)-N-hydroxy-3-(4-((2-(2-(pyridin-2-yl)-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide,1.54,uM,=,0.1875207208364631,1,c1ccc(CNCCc2c(-c3ccccn3)[nH]c3ccccc23)cc1
2151,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,CNC(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)c(F)c1,"3-Fluoro-N-methyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]benzamide",3.7,uM,=,0.568201724066995,1,O=C1c2ccc(-c3ccccc3)cc2CCN1CCN1CCCC1
2152,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCN2C(=O)N(NS(=O)(=O)Cc3ccccc3)C[C@@H]2c2ccc(OC)cc2)cc1,1-[(Phenylmethyl)sulfonylamino]-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone,4.4,uM,=,0.6434526764861874,1,O=C1N(NS(=O)(=O)Cc2ccccc2)C[C@H](c2ccccc2)N1CCc1ccccc1
2153,304899,10.1016/j.bmcl.2005.03.055,,,,Inhibitory concentration against Potassium channel HERG was determined,C[C@@H](c1ccc(-c2cccc(-c3nn[nH]n3)c2)cc1)[C@H](N)C(=O)N1CC[C@H](F)C1.O=C(O)C(F)(F)F,"Trifluoro-acetate(1S,2S)-1-((S)-3-fluoro-pyrrolidine-1-carbonyl)-2-[3'-(1H-tetrazol-5-yl)-biphenyl-4-yl]-propyl-ammonium",59.0,uM,=,1.7708520116421442,1,O=C(CCc1ccc(-c2cccc(-c3nn[nH]n3)c2)cc1)N1CCCC1
2154,1764419,10.1021/acsmedchemlett.8b00095,,,,Inhibition of human ERG,Cc1ccc(Cc2cc3c(=O)n([C@H]4CCCC[C@@H]4O)cnc3c3ccccc23)cn1,"3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-methylpyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one",60.0,uM,=,1.7781512503836436,1,O=c1c2cc(Cc3cccnc3)c3ccccc3c2ncn1C1CCCCC1
2155,1785994,10.1039/C7MD00131B,,,,Inhibition of human ERG,O=C(NCc1ccc(OC(F)(F)F)c(Cl)c1)c1ccc(S(=O)(=O)Nc2nccs2)c(F)c1,N-(3-chloro-4-(trifluoromethoxy)benzyl)-3-fluoro-4-(N-thiazol-2-ylsulfamoyl)benzamide,17.7,uM,=,1.2479732663618066,1,O=C(NCc1ccccc1)c1ccc(S(=O)(=O)Nc2nccs2)cc1
2156,1629116,10.1016/j.bmc.2016.10.009,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes,Cl.N=C(N)N/N=C/c1ccc(-c2ccc(/C=N/Nc3ccc(F)cc3)cc2)cc1,2-((4'-((2-(4-fluorophenyl)hydrazono)methyl)biphenyl-4-yl)methylene)hydrazinecarboximidamide hydrochloride,3.29,uM,=,0.5171958979499743,1,C(=N/Nc1ccccc1)\c1ccc(-c2ccccc2)cc1
2157,1728697,10.1021/acsmedchemlett.7b00312,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,O=C(NC[C@@H]1[C@H]2CN(C(=O)CCc3cc(Cl)cc(Cl)c3)C[C@@H]12)c1ccc2[nH]c(=O)oc2c1,"N-(((1R,5S,6s)-3-(3-(3,5-dichlorophenyl)propanoyl)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxamide",8.1,uM,=,0.9084850188786496,1,O=C(NC[C@@H]1[C@H]2CN(C(=O)CCc3ccccc3)C[C@@H]12)c1ccc2[nH]c(=O)oc2c1
2158,821302,10.1021/jm201454n,,,,Displacement of dofetilide from human ERG,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(s2)COC/1,"15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12-dioxa-25-thia-19,21,24-triazatetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14-(26),15,17,20,22-nonaene",7.2,uM,=,0.8573324964312685,1,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(s2)COC/1
2159,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCc3ccc(OC)c(OC)c3)C[C@@H]2CNC(=O)c2cccc(Cl)c2)cc1,"rac-3-cyano-N-(((3S,4S)-1-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)methyl)benzamide",0.16,uM,=,-0.7958800173440752,0,O=C(NC[C@H]1CN(CCc2ccccc2)C[C@@H]1c1ccccc1)c1ccccc1
2160,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCc3ccc(OC)c(OC)c3)C[C@@H]2CC(=O)Nc2cccc(Cl)c2)cc1,"rac-N-(3-chlorophenyl)-2-((3R,4S)-1-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)acetamide",0.066,uM,=,-1.1804560644581312,0,O=C(C[C@H]1CN(CCc2ccccc2)C[C@@H]1c1ccccc1)Nc1ccccc1
2161,2034159,10.1021/acs.jmedchem.0c01732,,,,Inhibition of human ERG by patch clamp assay,Cc1nc2cc(F)c(-c3cnc(C(C)(C)O)nc3)nc2c(N[C@H](C)c2cc(C#N)ccc2F)c1Cl,"(R)-3-(1-((3-Chloro-7-fluoro-6-(2-(2-hydroxypropan-2-yl)-pyrimidin-5-yl)-2-methyl-1,5-naphthyridin-4-yl)amino)ethyl)-4-fluorobenzonitrile",5.6,uM,=,0.7481880270062004,1,c1ccc(CNc2ccnc3ccc(-c4cncnc4)nc23)cc1
2162,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(C3CC3)n2)(c2ccc(Cl)cc2)CC1,2-(((4-(4-chlorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-6-cyclopropyl-4-(trifluoromethyl)pyridine,3.1,uM,=,0.4913616938342727,1,c1ccc(C2(COCc3cccc(C4CC4)n3)CCNCC2)cc1
2163,687332,10.1016/j.bmcl.2010.10.042,,,,Displacement of [3H]-dofetilide from human ERG,N#Cc1ccc(CNC(=O)N(c2cccc(F)c2)C2CCN(CCC3(c4cccc(F)c4)CCN(C(=O)c4c(F)cccc4F)CC3)CC2)cc1,"3-(4-cyanobenzyl)-1-(1-(2-(1-(2,6-difluorobenzoyl)-4-(3-fluorophenyl)piperidin-4-yl)ethyl)piperidin-4-yl)-1-(3-fluorophenyl)urea",1.2,uM,=,0.0791812460476248,1,O=C(c1ccccc1)N1CCC(CCN2CCC(N(C(=O)NCc3ccccc3)c3ccccc3)CC2)(c2ccccc2)CC1
2164,811343,10.1016/j.bmcl.2012.01.095,,,,Inhibition of human ERG by fluorescence polarization assay,CCC(NCCCC[C@@H](C[C@@H](OC)c1ccc(F)cc1)C(=O)NO)c1ccc(F)cc1,rac-(2S)-2-((R)-2-(4-fluorophenyl)-2-methoxyethyl)-6-(1-(4-fluorophenyl)propylamino)-N-hydroxyhexanamide,10.0,uM,=,1.0,1,c1ccc(CCCCCCCNCc2ccccc2)cc1
2165,1278259,10.1021/jm4010434,,,,Inhibition of human ERG channel expressed in HEK293 cells after 15 mins by whole-cell patch clamp technique,CCCCN(CC)CC#CC#Cc1ccc(Cl)cc1,"N-Butyl-5-(4-chlorophenyl)-N-ethylpenta-2,4-diyn-1-amine",0.473,uM,=,-0.3251388592621884,0,c1ccccc1
2166,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N3CCC[C@@H]3Cc3ccc(Cl)cc3)CC2)n1,"(R)-5-(4-(2-(4-chlorobenzyl)pyrrolidin-1-yl)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",4.0,uM,=,0.6020599913279624,1,c1ccc(C[C@H]2CCCN2C2CCN(c3ncn[nH]3)CC2)cc1
2167,2291203,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG K+ currents by GLP assay,Cc1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2CCO)n1,"1-((R)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-methyl-[1,2,4]triazol-1-yl)-ethanone",15.450797591093847,uM,=,1.188950903208761,1,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
2168,983134,10.1016/j.bmcl.2013.07.013,,,,Inhibition of human ERG by patch clamp assay,O=c1ccc2ncc(F)c3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCO3)CC1,"(R)-4-((4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)methyl)-3-fluoro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",58.0,uM,=,1.7634279935629371,1,O=c1ccc2nccc3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCO3)CC1
2169,2266240,10.1021/acsmedchemlett.2c00441,,,,Inhibition of human ERG,O=C(N1CCN2CCC1CC2)n1nc(-c2ccc(F)cc2)c2c1COCC2,"1,4-diazabicyclo[3.2.2]nonan-4-yl(3-(4-fluorophenyl)-4,5-dihydropyrano[3,4-c]pyrazol-1(7H)-yl)methanone",2.0,uM,=,0.3010299956639812,1,O=C(N1CCN2CCC1CC2)n1nc(-c2ccccc2)c2c1COCC2
2170,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(C3CC3)ccc2c1,(R)-2-cyclopropyl-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,44.0,uM,=,1.6434526764861874,1,c1cc2nc(C3CC3)ccc2cc1CCN1CCCC1
2171,1433959,10.1021/jm5010682,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by scintillation counting method,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,0.13,uM,=,-0.8860566476931633,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
2172,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1cc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)sn1,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(3-methylisothiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",7.4,uM,=,0.8692317197309762,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccns3)C4=O)ccc21
2173,1879147,10.1021/acs.jmedchem.9b01460,,,,Inhibition of human ERG,C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1,"1-(4-{(1R)-1-[2-({6-[6-(Dimethylamino)pyrimidin-4-yl]-1H-benzimidazol-2-yl}amino)pyridin-4-yl]ethyl}piperazin-1-yl)-3,3,3-trifluoropropan-1-one",4.7,uM,=,0.6720978579357175,1,c1cc(-c2ccc3nc(Nc4cc(CN5CCNCC5)ccn4)[nH]c3c2)ncn1
2174,2294517,10.1016/j.bmc.2023.117202,,,,Binding affinity to human ERG,C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,POZIOTINIB,0.915,uM,=,-0.0385789059335517,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
2175,938758,10.1016/j.bmcl.2013.01.033,,,,Inhibition of human hERG by automated patch clamp assay,CC(C#N)=C1CCN(c2ccc(N3C[C@H](Cn4cc(F)nn4)OC3=O)cc2F)CC1,"(R)-2-(1-(2-fluoro-4-(5-((4-fluoro-1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)phenyl)piperidin-4-ylidene)propanenitrile",21.0,uM,=,1.3222192947339193,1,C=C1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2)CC1
2176,880571,10.1021/ml300280g,,,,Binding affinity to human ERG,O=C(N[C@H]1CCCC[C@@H]1O)c1cc(CN2CCN(c3cc4scnc4cn3)CC2)c2ccccn2c1=O,"N-((1S,2S)-2-hydroxycyclohexyl)-4-oxo-1-((4-(thiazolo[4,5-c]pyridin-6-yl)piperazin-1-yl)methyl)-4H-quinolizine-3-carboxamide",13.1,uM,=,1.1172712956557642,1,O=C(NC1CCCCC1)c1cc(CN2CCN(c3cc4scnc4cn3)CC2)c2ccccn2c1=O
2177,2164004,10.1021/acs.jmedchem.1c02110,,,,Inhibition of hERG by patch clamp method,CCOP(=O)(Cc1csc(NC(=O)c2cc(Oc3ccc(S(C)(=O)=O)cc3)cc(O[C@@H](C)COC)c2)n1)OCC,diethyl (S)-(2-(3-(1-methoxypropan-2-yloxy)-5-(4-(methylsulfonyl)phenoxy)benzamido)thiazol-4-yl)methylphosphonate,50.0,uM,=,1.6989700043360187,1,O=C(Nc1nccs1)c1cccc(Oc2ccccc2)c1
2178,698202,10.1016/j.bmcl.2010.11.033,,,,Inhibition of human hERG,COC(=O)c1coc(CN2CCN(C(=O)CC(c3ccc(F)cc3)c3ccc(Br)cc3)CC2)n1,methyl 2-((4-(3-(4-bromophenyl)-3-(4-fluorophenyl)propanoyl)piperazin-1-yl)methyl)oxazole-4-carboxylate,2.23,uM,=,0.3483048630481606,1,O=C(CC(c1ccccc1)c1ccccc1)N1CCN(Cc2ncco2)CC1
2179,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(C(F)(F)F)ccc5[nH]4)CC3)c2c1,"7-methoxy-1-(2-(4-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)-1,5-naphthyridin-2(1H)-one",1.0,uM,=,0.0,0,O=c1ccc2ncccc2n1CCN1CCC(c2nc3ccccc3[nH]2)CC1
2180,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CC(Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ccc(C(F)(F)F)cn2)CC1)C(F)(F)F,"rac-[5-Methanesulfonyl-2-(2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-[4-(5-trifluoromethylpyridin-2-yl)-piperazin-1-yl]-methanone",20.0,uM,=,1.3010299956639813,1,O=C(c1ccccc1)N1CCN(c2ccccn2)CC1
2181,816515,10.1021/jm201195m,,,,Inhibition of human ERG,Cc1cccc(C(CCCN)(c2ccccc2)c2ccccc2)c1,"4-(3-Methylphenyl)-4,4-diphenylbutan-1-amine",6.48,uM,=,0.8115750058705934,1,c1ccc(C(c2ccccc2)c2ccccc2)cc1
2182,1700805,10.1021/acs.jmedchem.6b01831,,,,Inhibition of human ERG assessed as reduction of K+ current,COc1ccc2ncc(F)c(C[C@H](N)[C@@H]3CC[C@@H](NCc4ccc5c(n4)NC(=O)CO5)CO3)c2n1,"6-((((3R,6S)-6-((1S)-1-Amino-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)tetrahydro-2H-pyran-3-yl)amino)methyl)-2Hpyrido[3,2-b][1,4]oxazin-3(4H)-one",5.0,uM,=,0.6989700043360189,1,O=C1COc2ccc(CN[C@@H]3CC[C@@H](CCc4ccnc5cccnc45)OC3)nc2N1
2183,219494,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,"5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-1,3-dihydro-indol-2-one",0.152,uM,=,-0.8181564120552275,0,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)ccc2N1
2184,826732,10.1021/jm201194q,,,,Inhibition of human ERG expressed in HEK cells by patch clamp assay,c1ccc(CCCNCCN(c2ccccc2)c2ccccc2)cc1,"N1,N1-diphenyl-N2-(3-phenylpropyl)ethane-1,2-diamine",0.58,uM,=,-0.2365720064370627,0,c1ccc(CCCNCCN(c2ccccc2)c2ccccc2)cc1
2185,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,c1ccc(OCc2cccc(COc3ccccc3)n2)cc1,"2,6-bis(phenoxymethyl)pyridine",0.074,uM,=,-1.1307682802690238,0,c1ccc(OCc2cccc(COc3ccccc3)n2)cc1
2186,990152,10.1016/j.bmc.2013.08.041,,,,Inhibition of human ERG channel expressed in CHO cells by whole cell patch clamp technique,COc1ccc(S(=O)(=O)NCCc2cn(CC(=O)Nc3ccc(Cl)cc3)c3ccccc23)cc1,N-(4-Chlorophenyl)-2-(3-(2-(4-methoxyphenylsulfonamido)ethyl)-1H-indol-1-yl)acetamide,11.49,uM,=,1.0603200286882852,1,O=C(Cn1cc(CCNS(=O)(=O)c2ccccc2)c2ccccc21)Nc1ccccc1
2187,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cccc(CNC2CCCC2)n1,N-((6-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)methyl)cyclopentanamine,6.23,uM,=,0.7944880466591696,1,c1ccc(-c2cccc(CNC3CCCC3)n2)cc1
2188,535682,10.1016/j.bmcl.2008.08.067,,,,Displacement of [3H]dofetilide from human ERG in HEK293 cells,CNC(=O)c1c(NCC2CCC3(CCC3)CC2)nc(C#N)nc1OCCC1CCN(C)CC1,2-cyano-N-methyl-4-(2-(1-methylpiperidin-4-yl)ethoxy)-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide,0.42,uM,=,-0.3767507096020995,0,c1nc(NCC2CCC3(CCC3)CC2)cc(OCCC2CCNCC2)n1
2189,2125085,10.1021/acsmedchemlett.1c00450,,,,Inhibition of human ERG expressed in CHO cells by manual patch clamp assay,COC(=O)NC12CCC(n3cc(-c4ccc(Cl)c(N)c4)c4c(N)ncnc43)(CC1)CC2,"methyl (4-(4-amino-5-(3-amino-4-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octan-1-yl)carbamate",3.0,uM,=,0.4771212547196624,1,c1ccc(-c2cn(C34CCC(CC3)CC4)c3ncncc23)cc1
2190,941017,10.1021/jm301564f,,,,Inhibition of human ERG K+ channel expressed in HEK293 cells after 15 mins by patch clamp assay,Cc1ccc(CCCOCc2cccc(COCCCc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis((3-p-tolylpropoxy)methyl)pyridinium",0.194,uM,=,-0.712198270069774,0,c1ccc(CCCOCc2cccc(COCCCc3ccccc3)[nH+]2)cc1
2191,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(CC)CC2)c1ncc(-c2cc3nccnc3cc2OC)[nH]1,(S)-6-ethyl-N-((S)-1-(5-(7-methoxyquinoxalin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide,25.0,uM,=,1.3979400086720375,1,O=C(NCc1ncc(-c2ccc3nccnc3c2)[nH]1)[C@H]1CC12CCNCC2
2192,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(Cl)ccc1Oc1ccc(Cl)c(Cl)c1,"1-(5-chloro-2-(3,4-dichlorophenoxy)phenyl)-N-methylmethanamine",3.12,uM,=,0.4941545940184428,1,c1ccc(Oc2ccccc2)cc1
2193,2051795,10.1021/acs.jmedchem.6b00275,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1cc(NC2CCc3cc(Cl)ccc3C2)n2nc(C(C)(F)F)nc2n1,"2-(1,1-Difluoroethyl)-N-(6-chloro-1,2,3,4-tetrahydronaphthalen-2-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",1.4,uM,=,0.1461280356782379,1,c1ccc2c(c1)CCC(Nc1ccnc3ncnn13)C2
2194,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ncc2ncc(=O)n(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"8-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]piperidin-1-yl}ethyl)-2-methoxypteridin-7(8H)-one",81.0,uM,=,1.9084850188786493,1,O=c1cnc2cncnc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
2195,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N(C3CCCCC3)C3CCCCC3)nn2)ccc1-n1cnc(C)c1,"N,N-dicyclohexyl-2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)acetamide",1.39,uM,=,0.143014800254095,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)N(C1CCCCC1)C1CCCCC1
2196,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCCNCC(O)COc1ccc(O)cc1C(=O)CCc1ccccc1,1-[5-Hydroxy-2-(2-hydroxy-3-propylamino-propoxy)-phenyl]-3-phenyl-propan-1-one,40.0,uM,=,1.6020599913279625,1,O=C(CCc1ccccc1)c1ccccc1
2197,1911375,10.1021/acs.jmedchem.8b01296,,,,Inhibition of human ERG after 4 hrs by fluorescence polarization assay,CC(C)N1CCN(c2ccc(/C(=C(/CCCO)c3ccccc3)c3cccc(O)c3)cc2)CC1.Cl.Cl,(E)-3-(5-hydroxy-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylpent-1-enyl)phenol dihydrochloride,24.6,uM,=,1.390935107103379,1,C(=C(c1ccccc1)c1ccc(N2CCNCC2)cc1)c1ccccc1
2198,581929,10.1016/j.bmcl.2009.06.011,,,,Inhibition of human ERG,N[C@H]1Cn2c(nc3cnccc32)C[C@@H]1c1cc(F)c(F)cc1F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,"(11R,12R)-12-azaniumyl-11-(2,4,5-trifluorophenyl)-1,5,8-triazatricyclo[7.4.0.0^{2,7}]trideca-2(7),3,5,8-tetraen-5-ium; bis(2,2,2-trifluoroacetate)",89.0,uM,=,1.9493900066449128,1,c1ccc([C@@H]2CCn3c(nc4cnccc43)C2)cc1
2199,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c([O-])c1.[Na+],5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol sodium salt,0.11,uM,=,-0.958607314841775,0,c1ccc(/N=N/c2ccccn2)cc1
2200,304709,10.1016/j.bmcl.2005.03.025,,,,Mean inhibitory concentration against potassium channel HERG,COc1cc2c(cc1OC)[C@H](C[C@H](O)c1ccc(Cl)cc1)N(C)CC2,"(S)-1-(4-Chloro-phenyl)-2-((S)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethanol",0.4,uM,=,-0.3979400086720376,0,c1ccc(CC[C@@H]2NCCc3ccccc32)cc1
2201,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,Fc1cccc(C(Cc2ccccc2OC(F)F)N2CCNCC2)c1,1-(2-(2-(difluoromethoxy)phenyl)-1-(3-fluorophenyl)ethyl)piperazine,8.24,uM,=,0.9159272116971158,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
2202,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CN(CCc1ccc(Cl)c(Cl)c1)C[C@H](O)COc1ccc(NS(C)(=O)=O)cc1,"(S)-1-(4-Methanesulfonamidophenoxy)-3-(N-methyl-3,4-dichlorophenylethylamino)-2-propanol",0.37,uM,=,-0.431798275933005,0,c1ccc(CCNCCCOc2ccccc2)cc1
2203,2250952,10.1016/j.ejmech.2022.114347,,,,Inhibition of hERG transfected in CHO cells by manual patch-clamp assay,CCCCc1sc(C2CCN(CCCCc3cn(C)c4ccc(C#N)cc34)CC2)nc1-c1ccc(Oc2ccc(Cl)cc2)cc1,3-(4-(4-(5-Butyl-4-(4-(4-chlorophenoxy)phenyl)thiazol-2-yl)piperidin-1-yl)butyl)-1-methyl-1H-indole-5-carbonitrile,7.2,uM,=,0.8573324964312685,1,c1ccc(Oc2ccc(-c3csc(C4CCN(CCCCc5c[nH]c6ccccc56)CC4)n3)cc2)cc1
2204,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@H]7C[C@@H]7C(=O)O)nc56)(CC3)OC4)nc2N1,"(trans)-2-((7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)methyl)cyclopropanecarboxylic acid",43.4,uM,=,1.6374897295125108,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7CC7)nc56)(CC3)OC4)nc2N1
2205,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CN(Cc1ccc(-c2ccccc2)cc1)C(=O)N1CCC[C@H]1CN1CCCC1,(S)-2-pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid biphenyl-4-ylmethyl-methyl-amide,5.151515152,uM,=,0.7119349815412612,1,O=C(NCc1ccc(-c2ccccc2)cc1)N1CCC[C@H]1CN1CCCC1
2206,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,Cc1c(C(=O)N(C)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C,"N-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propyl)-N,1,2-trimethyl-5-phenyl-1H-pyrrole-3-carboxamide",0.5,uM,=,-0.3010299956639812,0,O=C(NCCCN1CCN(c2ccccc2)CC1)c1c[nH]c(-c2ccccc2)c1
2207,1694220,10.1016/j.bmc.2017.07.040,,,,Inhibition of human ERG,Cc1nc2n(c(=O)c1CCN1CCN(c3cccc4sccc34)CC1)CCCC2F,"3-(2-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-9-fluoro-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one",6.13,uM,=,0.787460474518415,1,O=c1c(CCN2CCN(c3cccc4sccc34)CC2)cnc2n1CCCC2
2208,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,c1cncc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCCCC4)N3)n2)c1,"(3R)-1-cyclohexyl-3-(4-(pyridin-3-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.19,uM,=,-0.721246399047171,0,c1cncc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCCCC4)N3)n2)c1
2209,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2Cl)C1=O,"4-(2-chlorophenyl)-2-methyl-9-(2-phenylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",1.0,uM,=,0.0,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
2210,2159402,10.1021/acs.jmedchem.1c01968,,,,Inhibition of human ERG by voltage clamp assay,O[C@H]1COC[C@H]1N1CC[C@@H](c2cc3nc(Nc4cnn([C@@H]5CC5(F)F)c4Cl)ncc3cc2Cl)[C@H](F)C1,"(3R,4R)-4-((3S,4S)-4-(6-chloro-2-(5-chloro-1-((R)-2,2-difluorocyclopropyl)-1H-pyrazol-4-ylamino)quinazolin-7-yl)-3-fluoropiperidin-1-yl)tetrahydrofuran-3-ol",9.7,uM,=,0.9867717342662448,1,c1nn(C2CC2)cc1Nc1ncc2ccc(C3CCN([C@H]4CCOC4)CC3)cc2n1
2211,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CCC(CO)NS(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1,N-(1-hydroxybutan-2-yl)-4'-(2-((R)-2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-sulfonamide,5.108108108000001,uM,=,0.7082600800970578,1,c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
2212,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cnc2ccc(-c3cccnc3)c(F)c2c1NC1CCOCC1,5-Fluoro-6-(3-pyridinyl)-4-(tetrahydro-2H-pyran-4-ylamino)-3-quinolinecarboxamide,13.0,uM,=,1.1139433523068367,1,c1cncc(-c2ccc3nccc(NC4CCOCC4)c3c2)c1
2213,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-2-methyl-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,216.0,uM,=,2.334453751150931,1,c1cnc2ccc(CCN3CCCC3)cc2c1
2214,537242,10.1021/jm800569w,,,,"Antagonist activity at human ERG in HEK293 cells assessed as inhibition of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide binding",Cc1nc2ccc(Cl)cc2c(=O)n1-c1ccc(OC2CCN(C3CCC3)CC2)cc1,6-Chloro-3-(4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl)-2-methyl-4(3H)-quinazolinone,5.4,uM,=,0.7323937598229685,1,O=c1c2ccccc2ncn1-c1ccc(OC2CCN(C3CCC3)CC2)cc1
2215,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ncc(Br)cc3C2)C1,"(3-bromo-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)((2R,3aR,6aR)-2-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)methanone",48.9,uM,=,1.6893088591236205,1,O=C(N1CCc2ncccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
2216,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CC[C@H]3OC[C@H](NCc4ccc5c(c4)OCCO5)CO3)c2c1,"N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-(2-(6-methoxyquinolin-4-yl)ethyl)-trans-1,3-dioxan-5-amine",5.1,uM,=,0.7075701760979364,1,c1ccc2c(CC[C@H]3OC[C@H](NCc4ccc5c(c4)OCCO5)CO3)ccnc2c1
2217,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C#N,"3-methoxy-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridine-2-carbonitrile",0.00196,uM,=,-2.707743928643524,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2218,1294319,10.1021/jm401278d,,,,Inhibition of human ERG by patch clamp electrophysiology,CCS(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc(C(F)(F)F)nc3)n2)cc1,5-(4-(Ethylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine,3.7,uM,=,0.568201724066995,1,c1ccc(-c2cncc(-c3cccnc3)n2)cc1
2219,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1cc(CNCC2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc(OC)c1OC,"1-(1-(6,6-bis(4-fluorophenyl)hexyl)pyrrolidin-3-yl)-N-(3,4,5-trimethoxybenzyl)methanamine",0.04,uM,=,-1.3979400086720375,0,c1ccc(CNCC2CCN(CCCCCC(c3ccccc3)c3ccccc3)C2)cc1
2220,940937,10.1021/jm301859s,,,,Inhibition of human ERG by whole-cell electrophysiology assay,C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1,4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)-cyclopropyl]pyrimidi-2-yl}-1H-indole,50.0,uM,=,1.6989700043360187,1,c1cc(-c2nc(C3CC3)cc(N3CCOCC3)n2)c2cc[nH]c2c1
2221,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,Cc1ccc(NC(=O)c2ccc3c(c2)CC(c2ccc(Cl)cc2)OC3=O)cc1C,"3-(4-chlorophenyl)-N-(3,4-dimethylphenyl)-1-oxoisochromane-6-carboxamide",6.77,uM,=,0.8305886686851442,1,O=C(Nc1ccccc1)c1ccc2c(c1)CC(c1ccccc1)OC2=O
2222,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccncc3)no2)CC1,"N-(2-phenylcyclopropyl)-4-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",10.0,uM,=,1.0,1,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccncc3)no2)CC1
2223,2051795,10.1021/acs.jmedchem.6b00275,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1cc(N[C@H]2CCc3ccc(Cl)cc3C2)n2nc(C(C)(F)F)nc2n1,"(S)-N-(7-Chloro-1,2,3,4-tetrahydronaphthalen-2-yl)-2-(1,1-difluoroethyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",1.5,uM,=,0.1760912590556812,1,c1ccc2c(c1)CC[C@H](Nc1ccnc3ncnn13)C2
2224,2298259,10.1016/j.bmc.2023.117276,,,,Inhibition of hERG expressed in CHO cells by automated patch clamp method,NCc1cc2cc(CN3CCOCC3)cc3c(=O)c(C(=O)NCc4ccc(Cl)cc4)cn1c23,"2-(Aminomethyl)-N-[(4-chlorophenyl)methyl]-8-[(morpholin-4-y1)methyl]-6-oxo-6H-pyrrolo[3,2,1-ij]quinoline-5-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C(NCc1ccccc1)c1cn2ccc3cc(CN4CCOCC4)cc(c1=O)c32
2225,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,CNc1cc(Nc2cnc(C#N)c(O[C@H](C)CN(C)C)n2)ncc1C(F)(F)F,(R)-3-((1-(Dimethylamino)propan-2-yl)oxy)-5-((4-(methylamino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile,1.0,uM,=,0.0,0,c1ccc(Nc2cnccn2)nc1
2226,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,Cn1cc([C@@]2(c3nnc(N)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"5-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,3,4-oxadiazol-2-amine",35.4,uM,=,1.549003262025788,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4nnco4)N3)n2)nc1
2227,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-],"2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-isobutyl ester 5-methyl ester",23.0,uM,=,1.3617278360175928,1,C1=CC(c2ccccc2)C=CN1
2228,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CC1(C)CC(NC(=O)CC(O)C(F)(F)F)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1,"N-[6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-4,4,4-trifluoro-3-hydroxybutanamide",1.46,uM,=,0.1643528557844371,1,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
2229,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,Cc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3cnc4cccnc43)[C@H](C)C2)cn1,"2-imidazo[4,5-blpyridin-3-yl-1-{(R)-2-methyl-4-[4-(2-methyl-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-piperazin-1-yl}-ethanone",15.0,uM,=,1.1760912590556811,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2cncnc2)CC1
2230,830902,10.1021/ml200257n,,,,Inhibition of human Erg,CC(=O)Nc1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,"N-(1-(3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl)-1H-indol-6-yl)acetamide",8.6,uM,=,0.9344984512435676,1,c1ccc2c(c1)ccn2-c1cc(NC2CC2)n2nccc2n1
2231,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N(C)C)nc1CN1C(=O)O[C@H](c2cc(Cl)cc(Cl)c2)[C@@H]1C,"3'-(4-(((4S,5R)-5-(3,5-Dichlorophenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-2-(dimethylamino)pyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic Acid",16.0,uM,=,1.2041199826559248,1,O=C1O[C@H](c2ccccc2)CN1Cc1ncncc1-c1cccc(-c2ccccc2)c1
2232,964986,10.1016/j.bmcl.2013.04.047,,,,Inhibition of human ERG expressed in HEK cells by ion flux electrophysiology method,O=C(c1ccc(O)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2)N1CC[C@H](O)C1,"(2-((S)-3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-hydroxyphenyl)((S)-3-hydroxypyrrolidin-1-yl)methanone",22.7,uM,=,1.3560258571931227,1,O=C(c1ccccc1OCCCN1CCC2(CC1)Cc1ccccc1O2)N1CCCC1
2233,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,Cc1[nH]c2ccccc2c1CCN1CCc2cc(/C=C/C(=O)NO)ccc2C1,"N-hydroxy-3-(2-(2-(2-methyl-1H-indol-3-yl)ethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)acrylamide",14.8,uM,=,1.1702617153949575,1,c1ccc2c(c1)CCN(CCc1c[nH]c3ccccc13)C2
2234,774852,10.1016/j.bmcl.2011.09.074,,,,Inhibition of human ERG,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)NCc1cccnc1)C2=O,"(+)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-7-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N-(pyridin-3-ylmethyl)acetamide",80.0,uM,=,1.9030899869919435,1,O=C(CN1Cc2c(-c3ccccc3)ccnc2C1=O)NCc1cccnc1
2235,535682,10.1016/j.bmcl.2008.08.067,,,,Displacement of [3H]dofetilide from human ERG in HEK293 cells,CNC(=O)c1c(NCC2CCC3(CCC3)CC2)nc(C#N)nc1OC1CC(C)(C)NC(C)(C)C1,"2-cyano-N-methyl-4-(spiro[3.5]nonan-7-ylmethylamino)-6-(2,2,6,6-tetramethylpiperidin-4-yloxy)pyrimidine-5-carboxamide",5.04,uM,=,0.7024305364455253,1,c1nc(NCC2CCC3(CCC3)CC2)cc(OC2CCNCC2)n1
2236,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC1=C(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc2S1,"1-(3-(4-(3-methylbenzo[b][1,4]oxathiin-2-yl)phenoxy)propyl)pyrrolidine",0.0044,uM,=,-2.356547323513813,0,C1=C(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc2S1
2237,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C(=O)O,"3-methoxy-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridine-2-carboxylic acid",0.01309,uM,=,-1.8830603534492445,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2238,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,CCOC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"ethyl 2,2-difluoro-4-(7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)butanoate",25.4,uM,=,1.404833716619938,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2239,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,Cc1ccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,cis-N-({1-[4-Hydroxy-4-(6-methyl-pyridin-3-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,35.0,uM,=,1.5440680443502757,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccnc3)CC2)C1
2240,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1onc(-c2ccc(Cl)cc2)c1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-3-(4-chlorophenyl)-5-methyl-4-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)isoxazole,1.6,uM,=,0.2041199826559248,1,c1ccc(-c2nocc2-c2ccc3cc(CCN4CCCC4)ccc3n2)cc1
2241,1714647,10.1021/acs.jmedchem.8b00650,,,,Inhibition of human ERG by patch clamp method,O=C(c1ccc(-n2nnc3cccnc32)cc1)N(c1ncccc1Cl)[C@@H]1CCCNC1,"US9227956, 16",8.5,uM,=,0.9294189257142929,1,O=C(c1ccc(-n2nnc3cccnc32)cc1)N(c1ccccn1)[C@@H]1CCCNC1
2242,1619713,10.1021/acs.jmedchem.6b01156,,,,Inhibition of human ERG expressed in CHO cells assessed as reduction in channel currents at -80 mV holding potential by automated whole-cell patch clamp method,Cc1ccc2cc(C(=O)c3cnn(-c4ccc5nc(C)[nH]c5c4)c3N)[nH]c2c1,[5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(6-methyl-1H-indol-2-yl)methanone,6.9,uM,=,0.8388490907372553,1,O=C(c1cnn(-c2ccc3nc[nH]c3c2)c1)c1cc2ccccc2[nH]1
2243,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(C(CO)CC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(rac)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-3-hydroxypropyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",11.0,uM,=,1.0413926851582251,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2244,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,O[C@H]1C[C@H](CN2CCC(c3ccccc3Cl)CC2)CCc2cccnc21,"(7R,9S)-7-((4-(2-chlorophenyl)piperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",1.5,uM,=,0.1760912590556812,1,c1ccc(C2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
2245,1468603,10.1016/j.ejmech.2014.12.045,,,,Inhibition of human ERG expressed in CHO cells assessed as reduction in channel current at holding potential of 0 mV by electrophysiological method,NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1,2-(3-(4-(1-(phenylsulfonyl)-1H-indol-4-yl)piperazin-1-yl)propoxy)benzamide,6.2,uM,=,0.7923916894982539,1,O=S(=O)(c1ccccc1)n1ccc2c(N3CCN(CCCOc4ccccc4)CC3)cccc21
2246,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2ncc(F)c([C@@H](O)CC[C@@H]3CCN(C4CC(c5cc(F)ccc5F)C4)C[C@@H]3C(=O)O)c2n1,"(3R,4R)-1-(3-(2,5-difluorophenyl)cyclobutyl)-4-((S)-3-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-3-hydroxypropyl)piperidine-3-carboxylic acid",45.0,uM,=,1.6532125137753435,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5cccnc45)CC3)C2)cc1
2247,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(-c2ccncc2)sc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-4-methyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-2-(pyridin-4-yl)thiazole,4.8,uM,=,0.6812412373755872,1,c1cc(-c2ncc(-c3ccc4cc(CCN5CCCC5)ccc4n3)s2)ccn1
2248,726964,10.1016/j.bmcl.2011.01.019,,,,Inhibition of human ERG,CC(N(C)C)C1(c2ccc3ccccc3c2)CCCCC1.Cl,"N,N-dimethyl-1-(1-(naphthalen-2-yl)cyclohexyl)ethanamine hydrochloride",4.3,uM,=,0.6334684555795865,1,c1ccc2cc(C3CCCCC3)ccc2c1
2249,2015639,10.1016/j.bmcl.2020.127393,,,,Inhibition of human ERG,CN(C)Cc1cnn(-c2ccnc3[nH]c(-c4cccc5c4ccn5C)nc23)c1,"N,N-dimethyl-1-(1-(2-(1-methyl-1H-indol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-4-yl)methanamine",8.9,uM,=,0.9493900066449128,1,c1cc(-c2nc3c(-n4cccn4)ccnc3[nH]2)c2cc[nH]c2c1
2250,872803,10.1021/jm300991n,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CC1=NC(c2cccc(-c3cncc(Cl)c3)c2)(C2CC2)N=C1N,2-(3-(5-Chloropyridin-3-yl)phenyl)-2-cyclopropyl-5-methyl-2H-imidazol-4-amine,12.4,uM,=,1.0934216851622351,1,C1=NC(c2cccc(-c3cccnc3)c2)(C2CC2)N=C1
2251,834187,10.1021/jm2013248,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,c1ccc(CN2CCN(Cc3nnc(-c4ccccc4)o3)CC2)cc1,SID24815875,27.3,uM,=,1.436162647040756,1,c1ccc(CN2CCN(Cc3nnc(-c4ccccc4)o3)CC2)cc1
2252,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(NCc1ccccc1)N(c1ccc(Br)cc1)C1CCN(Cc2ccnnc2)CC1,3-benzyl-1-(4-bromophenyl)-1-(1-(pyridazin-4-ylmethyl)piperidin-4-yl)urea,13.8,uM,=,1.1398790864012365,1,O=C(NCc1ccccc1)N(c1ccccc1)C1CCN(Cc2ccnnc2)CC1
2253,591415,10.1021/jm901107f,,,,Inhibition of human ERG expressed in HEK cells,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@H](OCC(=O)NC)[C@H](C)[C@@H](O)[C@]1(C)O,"2-((2R,3S,4R,5R,6S,7R,9R,10R,11S,12S,13R)-2-ethyl-3,4,9-trihydroxy-10-((2S,3R,4S,6R)-3-hydroxy-4-(isopropyl(methyl)amino)-6-methyltetrahydro-2H-pyran-2-yloxy)-12-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-14-oxooxacyclotetradecan-6-yloxy)-N-methylacetamide",0.411,uM,=,-0.3861581781239308,0,O=C1C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CCCCCCCCO1
2254,1567467,10.1039/C5MD00479A,,,,Inhibition of human ERG,CCCC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1,"(1R)-2-[(5S)-5-{[5-Chloro-2-(1H-tetrazol-1-yl)benzyl]carbamoyl}-4,5-dihydro-1H-pyrazol-1-yl]-1-(4-fluorophenyl)-2-oxoethyl butanoate",15.0,uM,=,1.1760912590556811,1,O=C(NCc1ccccc1-n1cnnn1)[C@@H]1CC=NN1C(=O)Cc1ccccc1
2255,816614,10.1016/j.bmcl.2012.03.032,,,,Inhibition of human ERG by electrophysiology assay,COc1ccc2c(-c3cnn(-c4ccccc4)c3)ccnc2c1,7-methoxy-4-(1-phenyl-1H-pyrazol-4-yl)quinoline,2.5,uM,=,0.3979400086720376,1,c1ccc(-n2cc(-c3ccnc4ccccc34)cn2)cc1
2256,1648277,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncc(Cl)cn3)CC2)cc1)N1CCC1,"(cis)-1-(azetidin-1-yl)-2-(4-(2-((1S,2R)-2-(1-(5-chloropyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)phenyl)ethanone",7.4,uM,=,0.8692317197309762,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)cc1)N1CCC1
2257,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,1-(2-{4-[5-Chloro-1-(4-fluoro-phenyl)-1H-indol-3-yl]-piperidin-1-yl}-ethyl)-imidazolidin-2-one,0.014,uM,=,-1.853871964321762,0,O=C1NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccccc23)CC1
2258,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,1-[2-(2-Hydroxy-3-propylamino-propoxy)-phenyl]-3-phenyl-propan-1-one,0.8,uM,=,-0.0969100130080563,0,O=C(CCc1ccccc1)c1ccccc1
2259,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CN(c1ccc(-c2ccc(F)cc2O)nn1)C1CC(C)(C)NC(C)(C)C1,"5-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenol",2.2,uM,=,0.3424226808222063,1,c1ccc(-c2ccc(NC3CCNCC3)nn2)cc1
2260,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(C3CCCC(C(C)(C)C)NC3=O)nn2)ccc1-n1cnc(C)c1,"rac-7-tert-butyl-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)azepan-2-one",44.2,uM,=,1.645422269349092,1,O=C1NCCCCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
2261,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccoc12,"(1R,2S)-2-(benzofuran-7-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-4-(dimethylamino)-1-phenylbutan-2-ol",0.8,uM,=,-0.0969100130080563,0,c1ccc([C@@H](Cc2cccc3ccoc23)c2ccc3ccccc3c2)cc1
2262,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cc1cnccn1)c1ccccc1,1-(1-phenyl-2-(pyrazin-2-yl)ethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,5.34,uM,=,0.7275412570285564,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(Cc1cnccn1)c1ccccc1
2263,1630280,10.1016/j.ejmech.2016.07.032,,,,Inhibition of human ERG expressed in CHOK1 cells by whole-cell patch clamp method,CC(C)Cc1cc(CNS(=O)(=O)c2ccccc2)nn1-c1ccccc1,N-[(5-Isobutyl-1-phenyl-1H-pyrazol-3-yl)methyl]benzenesulfonamide,21.0,uM,=,1.3222192947339193,1,O=S(=O)(NCc1ccn(-c2ccccc2)n1)c1ccccc1
2264,1911678,10.1021/acs.jmedchem.8b01725,,,,Inhibition of human ERG by Q-patch assay,Cn1c(N2CCC3(CCC[C@H]3N)CC2)nc2[nH]nc(-c3cccc(Cl)c3Cl)c2c1=O,"(R)-6-(1-amino-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-5-methyl-2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one",0.25,uM,=,-0.6020599913279624,0,O=c1[nH]c(N2CCC3(CCCC3)CC2)nc2[nH]nc(-c3ccccc3)c12
2265,2130588,10.1021/acs.jmedchem.1c01250,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@H]3OC[C@H](NCc4ccc5c(c4)OCCO5)CO3)c2n1,"(2r,5r)-N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-1,3-dioxan-5-amine",23.0,uM,=,1.3617278360175928,1,c1cnc2c(CC[C@H]3OC[C@H](NCc4ccc5c(c4)OCCO5)CO3)ccnc2c1
2266,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN(C)C)CC1,"US9145392, 73",1.1,uM,=,0.041392685158225,1,c1ccc(-c2c[nH]c(C3CCN(c4ccncn4)CC3)n2)cc1
2267,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,O=C(NC[C@H]1CCN(C(=O)CCCCC(c2ccc(F)cc2)c2ccc(F)cc2)C1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"(R)-N-((1-(6,6-bis(4-fluorophenyl)hexanoyl)pyrrolidin-3-yl)methyl)-3,5-bis(trifluoromethyl)benzamide",0.75,uM,=,-0.1249387366082999,0,O=C(NC[C@H]1CCN(C(=O)CCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
2268,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CC[C@@H](NC(=O)c1ccc(C#N)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-cyano-N-((R)-1-((1R,3S,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",1.1,uM,=,0.041392685158225,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
2269,761292,10.1021/jm101312a,,,,Inhibition of human ERG expressed in CHO cells by high throughput single cell planar patch clamp method,Clc1ccc([C@]23CCCC[C@H]2CNC3)cc1Cl,"cis-rac-3a-(3,4-dichlorophenyl)octahydro-1H-isoindole",6.48,uM,=,0.8115750058705934,1,c1ccc([C@]23CCCC[C@H]2CNC3)cc1
2270,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,CC(C)C(=O)N1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1,"4-(8-amino-3-((R)-1-isobutyrylpiperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-3-fluoro-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",2.8,uM,=,0.4471580313422192,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@@H]3CCCNC3)n3ccncc23)cc1
2271,1576909,10.1021/acs.jmedchem.5b01416,,,,Inhibition of human ERG expressed in HEK293 cells assessed as tail current at -50 mV holding potential by whole-cell patch clamp method,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccc(F)c(F)c1,"2-(3,4-Difluorophenyl)-6-(3-(piperidin-1-yl)propoxy)-pyridazin-3(2H)-one",1.89,uM,=,0.2764618041732441,1,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccccc1
2272,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide,0.015,uM,=,-1.8239087409443189,0,c1ccc(CCNCCOc2ccccc2)cc1
2273,490606,10.1016/j.bmcl.2008.06.027,,,,Inhibition of human ERG,COCCS(=O)(=O)N1CCN(c2ccc(Nc3nccc(-c4cnc(C)n4C(C)C)n3)cc2)CC1,4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(4-(2-methoxyethylsulfonyl)piperazin-1-yl)phenyl)pyrimidin-2-amine,8.4,uM,=,0.9242792860618816,1,c1cc(-c2cnc[nH]2)nc(Nc2ccc(N3CCNCC3)cc2)n1
2274,158543,10.1021/jm0205651,,,,Inhibitory activity against Potassium channel HERG,Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1,"1-Cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid",50.0,uM,=,1.6989700043360187,1,O=c1ccn(C2CC2)c2cc(N3CCNCC3)ccc12
2275,2293467,10.1021/acs.jmedchem.7b00463,,,,Inhibition of hERG potassium channel by Q-patch clamp assay,Nc1c(C(=O)Nc2cccc(Cl)c2)nnn1Cc1ccc(CN2CCOCC2)cc1,"5-amino-N-(3-chlorophenyl)-1-(4-(morpholinomethyl)benzyl)-1H-1,2,3-triazole-4-carboxamide",18.0,uM,=,1.255272505103306,1,O=C(Nc1ccccc1)c1cn(Cc2ccc(CN3CCOCC3)cc2)nn1
2276,2220911,10.1016/j.bmcl.2022.128587,,,,Inhibition of human ERG,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.03155,uM,=,-1.501000636419847,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
2277,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCN(CCO)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"2-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)piperazin-1-yl)ethanol",3.7,uM,=,0.568201724066995,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
2278,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(CO)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-(hydroxymethyl)-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.44,uM,=,0.1583624920952496,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2279,990152,10.1016/j.bmc.2013.08.041,,,,Inhibition of human ERG channel expressed in CHO cells by whole cell patch clamp technique,Cc1ccc(S(=O)(=O)N/N=C/c2cn(CC(=O)Nc3ccccc3Cl)c3ccccc23)cc1,N-(2-Chlorophenyl)-2-(3-((2-tosylhydrazono)methyl)-1H-indol-1-yl)acetamide,18.66,uM,=,1.2709116394104811,1,O=C(Cn1cc(/C=N/NS(=O)(=O)c2ccccc2)c2ccccc21)Nc1ccccc1
2280,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=C1COc2cc(F)c(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"(R)-7-fluoro-6-((1-((3-fluoro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",333.0,uM,=,2.52244423350632,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
2281,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=N[C@@](c2cccc(-c3cncnc3)c2)(c2ccnc(C(F)F)c2)c2cc(F)cc(F)c21,"(S)-1-[2-(Difluoromethyl)pyridin-4-yl]-4,6-difluoro-1-(3-pyrimidin-5-ylphenyl)-1H-isoindol-3-amine",19.0,uM,=,1.2787536009528289,1,C1=N[C@](c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
2282,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,COc1cccc(NC(=O)c2cnc([C@]34CO[C@@H](C)C[C@H]3CSC(N)=N4)s2)n1,"2-((4aR,6S,8aR)-2-amino-6-methyl-4,4a,5,6-tetrahydropyrano-[3,4-d][1,3]thiazin-8a(8H)-yl)-N-(6-methoxypyridin-2-yl)thiazole-5-carboxamide",4.8,uM,=,0.6812412373755872,1,O=C(Nc1ccccn1)c1cnc([C@]23COCC[C@H]2CSC=N3)s1
2283,2199820,10.1021/acs.jmedchem.2c00668,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp assay,Cc1nc(N(C)C(=O)Cc2ccc(-c3ccccn3)cc2)sc1S(N)(=O)=O,Pritelivir; N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide,160.0,uM,=,2.204119982655925,1,O=C(Cc1ccc(-c2ccccn2)cc1)Nc1nccs1
2284,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,CC(C)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1,"US9145392, 114",1.8,uM,=,0.255272505103306,1,c1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ccncn4)CC3)n2)cc1
2285,983133,10.1016/j.bmcl.2013.07.013,,,,Inhibition of human ERG transfected in HEK293 cells by patch clamp assay,O=c1cnc2ccc(F)c3c2n1C[C@@]3(O)CN1CCC(NCc2cc3c(cn2)OCCO3)CC1,"(S)-6-((4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)methyl)-7-fluoro-6-hydroxy-5,6-dihydro-3H-pyrrolo[1,2,3-de]quinoxalin-3-one",206.0,uM,=,2.3138672203691533,1,O=c1cnc2cccc3c2n1CC3CN1CCC(NCc2cc3c(cn2)OCCO3)CC1
2286,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CC(C)c1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@@H]2CO)n1,"1-((R)-2-Hydroxymethyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-isopropyl-[1,2,4]triazol-1-yl)-ethanone",0.017,uM,=,-1.769551078621726,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
2287,861902,10.1021/jm3007323,,,,Inhibition of human ERG transfected in HEK293 cell membranes by whole cell patch clamp assay,Cc1cc(OCCN2CCN(C)CC2)nn1-c1ccc(Cl)c(Cl)c1,"1-(2-(1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl)-4-methylpiperazine",7.4,uM,=,0.8692317197309762,1,c1ccc(-n2ccc(OCCN3CCNCC3)n2)cc1
2288,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1cc(-n2cnnn2)ncc1CC(=O)N1CCN(CCc2ccc3c(c2C)COC3=O)CC1,4-methyl-5-(2-(4-(2-(4-methyl-6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,9.1,uM,=,0.9590413923210936,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
2289,806244,10.1016/j.bmcl.2012.01.078,,,,Inhibition of human Erg by patch clamp assay,Cc1nc2ccc(Oc3ccc(Cl)cc3F)nc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,"6-(4-Chloro-2-fluorophenoxy)-3-((S)-1-isopropylpiperidin-3-ylmethyl)-2-methyl-3H-pyrido[3,2-d]pyrimidin-4-one",1.3,uM,=,0.1139433523068367,1,O=c1c2nc(Oc3ccccc3)ccc2ncn1C[C@H]1CCCNC1
2290,1790683,10.1039/C7MD00106A,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by PatchXpress automated electrophysiology method,NC1=N[C@@]2(CO1)c1cc(NC(=O)c3ccc(Cl)cn3)ccc1Oc1cnc(C3=CCCOC3)cc12,"(S)-N-(2'-amino-3-(5,6-dihydro-2H-pyran-3-yl)-5'H-spiro[chromeno[2,3-c]pyridine-5,4'-oxazole]-7-yl)-5-chloropicolinamide",0.9,uM,=,-0.0457574905606751,0,O=C(Nc1ccc2c(c1)[C@@]1(COC=N1)c1cc(C3=CCCOC3)ncc1O2)c1ccccn1
2291,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,Cn1nc(C(=O)N2CCC(Oc3ccc(CN4CCCC4)cc3)CC2)cc1-c1ccccc1,(1-methyl-5-phenyl-1H-pyrazol-3-yl)(4-(4-(pyrrolidin-1-ylmethyl)phenoxy)piperidin-1-yl)methanone,7.4,uM,=,0.8692317197309762,1,O=C(c1cc(-c2ccccc2)[nH]n1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
2292,971475,10.1021/jm400402q,,,,Inhibition of human ERG by patch-clamp technique,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine",46.0,uM,=,1.662757831681574,1,c1ccc(Nc2ccnc(Nc3ccc(C4CCNCC4)cc3)n2)cc1
2293,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@H]3CO2)ccc(F)c1C#N,"3-((3S,9aS)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-6-fluoro-2-methylbenzonitrile",12.5,uM,=,1.0969100130080565,1,O=C(Cc1ccc(-n2cnnn2)nc1)N1CCN2C[C@H](c3ccccc3)OC[C@@H]2C1
2294,591415,10.1021/jm901107f,,,,Inhibition of human ERG expressed in HEK cells,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"6-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione",0.039,uM,=,-1.408935392973501,0,O=C1CCCCOC(=O)C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CCC1
2295,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1cc(-c2nc(-c3ccc4cc(CCN5CCC[C@H]5C)ccc4n3)cs2)no1,(R)-5-methyl-3-(4-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)thiazol-2-yl)isoxazole,2.84,uM,=,0.4533183400470376,1,c1cc(-c2nc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cs2)no1
2296,1635871,10.1016/j.ejmech.2016.11.017,,,,Inhibition of human ERG expressed in CHOK1 cells by automated patch clamp method,CN(C)CCCNC(=O)c1ccc(Cn2c(Cc3c(Cl)cccc3Cl)nc3ccccc32)cc1,"4-((2-(2,6-Dichlorobenzyl)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-(dimethylamino)propyl)benzamide",4.53,uM,=,0.6560982020128319,1,c1ccc(Cc2nc3ccccc3n2Cc2ccccc2)cc1
2297,2021700,10.1021/acs.jmedchem.9b00069,,,,Inhibition of human ERG by thallium flux assay,CC(C)(C)n1nc(-c2ccc3cc(OC4CC4)ccc3c2)c(C(N)=O)c1N,5-Amino-1-(tert-butyl)-3-(6-cyclopropoxynaphthalen-2-yl)-1H-pyrazole-4-carboxamide,27.0,uM,=,1.4313637641589874,1,c1cc(-c2ccc3cc(OC4CC4)ccc3c2)n[nH]1
2298,624296,10.1016/j.bmcl.2010.01.134,,,,Displacement of [3H]Dofetilide from human ERG,C[C@@H](c1ccccn1)c1c(CCN2CCC2)sc2ccccc12,(-)-(R)-2-(1-(2-(2-(azetidin-1-yl)ethyl)benzo[b]thiophen-3-yl)ethyl)pyridine,4.2,uM,=,0.6232492903979004,1,c1ccc(Cc2c(CCN3CCC3)sc3ccccc23)nc1
2299,2061618,10.1016/j.bmcl.2015.11.049,,,,Inhibition of human ERG by dofetilide binding assay,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cn[nH]c3n2)c(OC(C)C)cc1C1CCN(C)CC1,"N6-(2-isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine",1.0,uM,=,0.0,0,c1ccc(Nc2nc(Nc3ccc(C4CCNCC4)cc3)nc3[nH]ncc23)cc1
2300,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(C#N)c(CC(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(+)-4-(2-hydroxy-2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-6-methoxy-1,5-naphthyridine-3-carbonitrile",0.00213,uM,=,-2.6716203965612624,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2301,1509543,10.1021/acs.jmedchem.5b00810,,,,Inhibition of human ERG by radioligand binding assay,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCNC(=O)C4)CC3)cc1)C(=O)C2,"(trans)-(S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(3-oxo-piperazin-1-yl)-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one",16.0,uM,=,1.2041199826559248,1,O=C1CN([C@H]2CC[C@H](CNc3ccc(N4C(=O)Cc5ccccc5[C@@H]4c4ccccc4)cc3)CC2)CCN1
2302,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(N(C)Cc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-(((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-yl)(methyl)amino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.2,uM,=,0.0791812460476248,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2303,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,CCN(CC)Cc1ccc2c(c1)CC[C@H](N1CCN(CCC3CCCS3)CC1=O)C2,"1-((S)-6-((diethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-4-(2-(tetrahydrothiophen-2-yl)ethyl)piperazin-2-one",13.2,uM,=,1.1205739312058498,1,O=C1CN(CCC2CCCS2)CCN1[C@H]1CCc2ccccc2C1
2304,1789492,10.1021/acs.jmedchem.8b01533,,,,Inhibition of human ERG expressed in CHO-S1 cells by Qpatch clamp assay,Brc1ccc(Nc2ccc(CN3CCC4(CC3)OCCc3sccc34)cc2)cc1,"4-Bromo-N-(4-((6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran]-1-yl)methyl)phenyl)aniline",2.3,uM,=,0.3617278360175928,1,c1ccc(Nc2ccc(CN3CCC4(CC3)OCCc3sccc34)cc2)cc1
2305,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,O=C(N1CCc2ncc(C(F)(F)F)cc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCCCCC1)C2,"((2R,3aR,6aR)-2-(cycloheptylamino)octahydropentalen-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",14.7,uM,=,1.167317334748176,1,O=C(N1CCc2ncccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCCCCC1)C2
2306,1461416,10.1016/j.bmcl.2014.12.068,,,,Inhibition of human ERG,Oc1ccc(-c2ccc3[nH]nc(-c4cncc(O[C@H]5CNCCC56CC6)n4)c3c2)c(F)c1,(R)-4-(3-(6-(6-azaspiro[2.5]octan-4-yloxy)pyrazin-2-yl)-1H-indazol-5-yl)-3-fluorophenol,0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2ccc3[nH]nc(-c4cncc(O[C@H]5CNCCC56CC6)n4)c3c2)cc1
2307,1824533,10.1021/acs.jmedchem.9b01295,,,,Inhibition of human ERG,Cc1cnc(Nc2ccnn2C)nc1-c1cn2c(n1)C(=O)N(Cc1ccc(F)c(F)c1)CC2,"7-(3,4-Difluorobenzyl)-2-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5H)-one",23.0,uM,=,1.3617278360175928,1,O=C1c2nc(-c3ccnc(Nc4ccn[nH]4)n3)cn2CCN1Cc1ccccc1
2308,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,Cc1cc(-n2cnnn2)ccc1CC(=O)N1CCN(CCc2ccc3c(c2)COC3=O)CC1,5-(2-(4-(2-(2-methyl-4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,1.4,uM,=,0.1461280356782379,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
2309,815278,10.1016/j.ejmech.2012.02.049,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cells after 45 mins by scintillation counting method,CC(C)NC(=O)NS(=O)(=O)c1ccc(OCCN2CCCCC2)cc1,1-Isopropyl-3-[4-(2-piperidin-1-ylethoxy)benzene]sulfonylurea,26.1,uM,=,1.416640507338281,1,c1ccc(OCCN2CCCCC2)cc1
2310,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(OCC#Cc2cccc(CCCOc3ccc(C)cc3)[n+]2C)cc1,1-methyl-2-(3-(p-tolyloxy)prop-1-ynyl)-6-(3-(p-tolyloxy)propyl)pyridinium,2.908,uM,=,0.4635944021870002,1,C(#Cc1cccc(CCCOc2ccccc2)[nH+]1)COc1ccccc1
2311,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCN(C)C(=O)c1ccc([C@H](c2cccc(NC(=O)C3CCC3)c2)N2CCN(Cc3cccnc3)CC2)cc1,(R)-4-((3-(cyclobutanecarboxamido)phenyl)(4-(pyridin-3-ylmethyl)piperazin-1-yl)methyl)-N-ethyl-N-methylbenzamide,28.0,uM,=,1.4471580313422192,1,O=C(Nc1cccc([C@@H](c2ccccc2)N2CCN(Cc3cccnc3)CC2)c1)C1CCC1
2312,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,O=C(c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1)N1CCOCC1,"Morpholino(4-(spiro[chromene-2,4'-piperidine]-4-yl)phenyl)-methanone",54.256,uM,=,1.734447772434011,1,O=C(c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1)N1CCOCC1
2313,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1.O=C(O)C(=O)O,(E)-5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol hemioxalate,0.15,uM,=,-0.8239087409443188,0,c1ccc(/N=N/c2ccccn2)cc1
2314,460777,10.1021/jm070637u,,,,Inhibition of hERG potassium channel expressed in CHO cells by isotope efflux assay,Cc1cccc(NC(=O)c2ccc(-c3ccc(C#N)cc3)o2)c1,5-(4-cyanophenyl)-N-(3-methylphenyl)furan-2-carboxamide,5.8,uM,=,0.7634279935629373,1,O=C(Nc1ccccc1)c1ccc(-c2ccccc2)o1
2315,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H]3CNCC[C@H]3O2)cc1,"(4aS,8aR)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-4a,5,6,7,8,8a-hexahydro-4H-pyrido[3,4-e][1,3]oxazine",3.1,uM,=,0.4913616938342727,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H]3CNCC[C@H]3O2)cc1
2316,2298259,10.1016/j.bmc.2023.117276,,,,Inhibition of hERG expressed in CHO cells by automated patch clamp method,CC1(C)CN(C(=O)Cn2c(=O)c(C(=O)NCc3ccc(Cl)cc3)cc3cccnc32)C1,"N-(4-chlorobenzyl)-1-(2-(3,3-dimethylazetidin-1-yl)-2-oxoethyl)-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide",5.2,uM,=,0.7160033436347992,1,O=C(NCc1ccccc1)c1cc2cccnc2n(CC(=O)N2CCC2)c1=O
2317,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccn2C)=NC1c1ccc(F)cc1Br,"Ethyl 4-(2-bromo-4-fluorophenyl)-2-(1-methyl-1H-imidazol-2-yl)-6-(morpholinomethyl)-1,4-dihydropyrimidine-5-carboxylate",0.17,uM,=,-0.7695510786217261,0,C1=C(CN2CCOCC2)NC(c2ncc[nH]2)=NC1c1ccccc1
2318,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,CCOc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1C1CCN(C)CC1,"4-(2,4-difluorophenylamino)-7-ethoxy-6-(1-methylpiperidin-4-yl)quinoline-3-carboxamide",11.0,uM,=,1.0413926851582251,1,c1ccc(Nc2ccnc3ccc(C4CCNCC4)cc23)cc1
2319,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3nccc(C(F)(F)F)n3)CC2)(C(C)C)C1,"((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(4-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)methanone",4.9,uM,=,0.6901960800285137,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2ncccn2)CC1
2320,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,C[C@@H](Nc1c(C(N)=O)cnc2ccc(-c3cccnc3)cc12)c1ccn(C)n1,4-{[(1R)-1-(1-Methyl-1H-pyrazol-3-yl)ethyl]amino}-6-(3-pyridinyl)-3-quinolinecarboxamide,2.8,uM,=,0.4471580313422192,1,c1cncc(-c2ccc3nccc(NCc4cc[nH]n4)c3c2)c1
2321,2249200,10.1021/acs.jmedchem.2c00008,,,,Inhibition of human ERG potassium channel expressed in CHO cells by patch-clamp assay,CC(C)(F)c1cc(F)ccc1-c1sc2c(ccc3[nH]ncc32)c1Oc1ccc(NC2CN(CCCF)C2)cc1,"N-[4-[[2-[4-fluoro-2-(1-fluoro-1-methyl-ethyl)phenyl]-6H-thieno[2,3-e]indazol-3-yl]oxy]phenyl]-1-(3-fluoropropyl)azetidin-3-amine",6.2,uM,=,0.7923916894982539,1,c1ccc(-c2sc3c(ccc4[nH]ncc43)c2Oc2ccc(NC3CNC3)cc2)cc1
2322,1696561,10.1016/j.bmcl.2017.08.052,,,,Inhibition of human ERG expressed in CHO cells by Ionworks electrophysiology method,Cc1ccc([C@@H]2CN(C(=O)[C@H]3CC[C@H](CN)CC3)C[C@H]2c2ccc(C#N)cc2)cc1,4-(trans-1-(trans-4-(Aminomethyl)cyclohexane-1-carbonyl)-4-(p-tolyl)pyrrolidin-3-yl)benzonitrile,12.1,uM,=,1.08278537031645,1,O=C(C1CCCCC1)N1C[C@@H](c2ccccc2)[C@H](c2ccccc2)C1
2323,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)N1CCCC1)C2,"(2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)(pyrrolidin-1-yl)methanone",10.0,uM,=,1.0,1,O=C(N1CCCC1)N1CCc2nc(OCc3conc3-c3ccccc3)ccc2C1
2324,1744232,10.1021/acs.jmedchem.6b01703,,,,Displacement of [3H]dofetilide from recombinant human ERG expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting method,CCc1nn2c(C)cc(C)nc2c1Cc1ccc(CCCN2CCN(C(C)C)CC2)cc1,"US8748435, 39",4.5,uM,=,0.6532125137753437,1,c1cnc2c(Cc3ccc(CCCN4CCNCC4)cc3)cnn2c1
2325,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCC[C@H](N)C4)n3CC=C(C)C)n(C)c2=O)c1,"(S)-6-(3-aminopiperidin-1-yl)-3-(2-(3-methoxyphenyl)-2-oxoethyl)-1-methyl-5-(3-methylbut-2-enyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",1.6,uM,=,0.2041199826559248,1,O=C(Cn1c(=O)[nH]c2cc(N3CCCCC3)[nH]c2c1=O)c1ccccc1
2326,1366626,10.1021/jm500535j,,,,Inhibition of human ERG,Nc1nc(C2CC2)cn1CC(O)c1ccc(Cl)cc1Cl,"rac-2-(2-Amino-4-cyclopropyl-1H-imidazol-1-yl)-1-(2,4-dichlorophenyl)ethanol",4.5,uM,=,0.6532125137753437,1,c1ccc(CCn2cnc(C3CC3)c2)cc1
2327,1297426,10.1016/j.bmcl.2014.01.067,,,,Inhibition of human ERG,CN1C(=O)CC[C@H]1CN(Cc1ccc(Cl)cc1)S(=O)(=O)c1cccc(C#N)c1,(S)-N-(4-chlorobenzyl)-3-cyano-N-((1-methyl-5-oxopyrrolidin-2-yl)methyl)benzenesulfonamide,30.0,uM,=,1.4771212547196624,1,O=C1CC[C@@H](CN(Cc2ccccc2)S(=O)(=O)c2ccccc2)N1
2328,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCN2C(=O)N(NS(=O)(=O)CF)C[C@@H]2c2ccc(OC)cc2)cc1,1-(Fluoromethylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxy-phenyl)-2-imidazolidinone,28.3,uM,=,1.4517864355242902,1,O=C1NC[C@H](c2ccccc2)N1CCc1ccccc1
2329,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,CC(C)C(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1,N-Biphenyl-2-ylmethyl-N-(S)-pyrrolidin-3-yl-isobutyramide,3.02,uM,=,0.4800069429571506,1,c1ccc(-c2ccccc2CN[C@H]2CCNC2)cc1
2330,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3c(-c4ccccc4)nn(C)c3Cl)ccc2c1,(R)-2-(5-chloro-1-methyl-3-phenyl-1H-pyrazol-4-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,6.0,uM,=,0.7781512503836436,1,c1ccc(-c2n[nH]cc2-c2ccc3cc(CCN4CCCC4)ccc3n2)cc1
2331,1741807,10.1021/acs.jmedchem.8b00900,,,,Inhibition of human ERG expressed in CHOK1 cells incubated for 600 secs at -80 mV holding potential by automated patch clamp assay,C[C@@H]1CN(CC(=O)N2CC(C)(C)c3ncc(Cc4ccc(F)cc4)cc32)[C@@H](CN2CCOC[C@H]2C)CN1,"1-{6-[(4-Fluorophenyl)methyl]-3,3-dimethyl-1H,2H,3Hpyrrolo[3,2-b]pyridin-1-yl}-2-[(2R,5R)-5-methyl-2-{[(3R)-3-methylmorpholin-4-yl]methyl}piperazin-1-yl]ethan-1-one",9.0,uM,=,0.9542425094393248,1,O=C(CN1CCNC[C@@H]1CN1CCOCC1)N1CCc2ncc(Cc3ccccc3)cc21
2332,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,Cc1ncc(CNC2CCN(CCn3c(=O)ccc4c3ccc(=O)n4C)CC2)cc1C#N,"2-Methyl-5-((1-(2-(5-methyl-2,6-dioxo-5,6-dihydro-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-nicotinonitrile",33.0,uM,=,1.5185139398778875,1,O=c1ccc2c(ccc(=O)n2CCN2CCC(NCc3cccnc3)CC2)[nH]1
2333,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CN1CCC(Cn2nc(-c3ccc4cc(OCC5CC5)ccc4c3)c3c(N)ncnc32)CC1,"3-(6-(Cyclopropylmethoxy)naphthalen-2-yl)-1-((1-methylpiperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.9,uM,=,-0.0457574905606751,0,c1ncc2c(-c3ccc4cc(OCC5CC5)ccc4c3)nn(CC3CCNCC3)c2n1
2334,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)c(C(F)(F)F)c4)CC3)ccc21,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)-3-(trifluoromethyl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,5.1,uM,=,0.7075701760979364,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
2335,560248,10.1016/j.bmcl.2008.11.002,,,,Inhibition of human ERG by calcium-flux based assay,CN1CC(C)(NC(=O)Nc2cccc(-c3nnnn3C)c2)C(CN2CCC[C@@H](Cc3ccc(F)cc3)C2)OC1=O.Cl,"1-(6-(((S)-3-(4-fluorobenzyl)piperidin-1-yl)methyl)-3,5-dimethyl-2-oxo-1,3-oxazinan-5-yl)-3-(3-(1-methyl-1H-tetrazol-5-yl)phenyl)urea",15.7,uM,=,1.1958996524092338,1,O=C(Nc1cccc(-c2nnn[nH]2)c1)NC1CNC(=O)OC1CN1CCC[C@@H](Cc2ccccc2)C1
2336,875808,10.1021/jm201710f,,,,Displacement of [3H]dofetilide to human ERG expressed in HEK293 cells,COc1cc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)cnc1-n1cnc(C)c1,[2-(4-Fluoro-phenyl)-1-methyl-1H-benzoimidazol-4-yl]-[5-methoxy-6-(4-methyl-imidazol-1-yl)-pyridin-3-yl]-amine,1.8,uM,=,0.255272505103306,1,c1ccc(-c2nc3c(Nc4ccc(-n5ccnc5)nc4)cccc3[nH]2)cc1
2337,584296,10.1016/j.bmcl.2009.05.086,,,,Inhibition of human ERG channel expressed in HEK293 cells by patch clamp assay,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,2-({1-[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-piperidin-4-yl}-methyl-amino)-3H-pyrimidin-4-one,0.441,uM,=,-0.3555614105321614,0,O=c1ccnc(NC2CCN(c3nc4ccccc4n3Cc3ccccc3)CC2)[nH]1
2338,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCOC(=O)[C@H]1CC[C@@H](N2CC(NC(=O)CNc3n[nH]c4ccc(C(F)(F)F)cc34)C2)CC1,cis-4-{3-[2-(5-Trifluoromethyl-1H-indazol-3-ylamino)-acetylamino]-azetidin-1-yl}-cyclohexane carboxylic acid ethyl ester,9.1,uM,=,0.9590413923210936,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
2339,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCC[C@H](N)C4)n3Cc3ccccc3)n(C)c2=O)c1,"(S)-6-(3-aminopiperidin-1-yl)-5-benzyl-3-(2-(3-methoxyphenyl)-2-oxoethyl)-1-methyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",0.1,uM,=,-1.0,0,O=C(Cn1c(=O)[nH]c2cc(N3CCCCC3)n(Cc3ccccc3)c2c1=O)c1ccccc1
2340,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nnc(N(C)C)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-N,N-dimethyl-1,3,4-oxadiazol-2-amine",5.5,uM,=,0.7403626894942439,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4nnco4)N3)n2)nc1
2341,1765499,10.1021/acs.jmedchem.8b01040,,,,Displacement of [3H]dofetilide from human ERG by high throughput assay,O=C(Nc1ccc(OC(F)(F)F)cc1)c1cccc(CN2CCOCC2)c1,3-(Morpholinomethyl)-N-(4-(trifluoromethoxy)phenyl)benzamide,3.7,uM,=,0.568201724066995,1,O=C(Nc1ccccc1)c1cccc(CN2CCOCC2)c1
2342,1339285,10.1016/j.bmcl.2014.02.013,,,,Inhibition of human ERG by FLIPR assay,CCS(=O)(=O)C[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1CC[C@H](NC(=O)c2cccc(-c3ccccc3)c2)C1=O,"N-((S)-1-((1S,2R,4R)-2-(ethylsulfonylmethyl)-4-(isopropyl(methyl)amino)cyclohexyl)-2-oxopyrrolidin-3-yl)biphenyl-3-carboxamide",60.0,uM,=,1.7781512503836436,1,O=C(N[C@H]1CCN(C2CCCCC2)C1=O)c1cccc(-c2ccccc2)c1
2343,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,C[C@@H]1CN(c2nnc(C(F)(F)F)o2)CCN1c1ncc(OCc2ccc(-n3cnnn3)cc2F)cn1,"5-{[2-fluoro-4-(1H-tetrazol-1-yl)benzyl]oxy}-2-{(2R)-2-methyl-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]piperazin-1-yl}pyrimidine",5.7,uM,=,0.7558748556724915,1,c1nnc(N2CCN(c3ncc(OCc4ccc(-n5cnnn5)cc4)cn3)CC2)o1
2344,591458,10.1021/jm900563e,,,,Inhibition of human ERG,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N,"2-Chloro-6-[(R)-3-(1,1-dimethyl-2-naphthalen-2-yl-ethylamino)-2-hydroxy-propoxy]-benzonitrile",0.003,uM,=,-2.5228787452803374,0,c1ccc(OCCCNCCc2ccc3ccccc3c2)cc1
2345,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@H]3OC[C@H](NCc4ccc5c(n4)NC(=O)CO5)CO3)c2n1,"6-(((2r,5r)-2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-1,3-dioxan-5-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.4,uM,=,0.1461280356782379,1,O=C1COc2ccc(CN[C@H]3CO[C@H](CCc4ccnc5cccnc45)OC3)nc2N1
2346,1442903,10.1016/j.bmcl.2014.08.008,,,,Inhibition of human ERG by patch clamp assay,C[C@H](O)CONC(=O)c1ncc2cncn2c1Nc1ccc(I)cc1F,"(S)-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxypropoxy)imidazo[1,5-a]pyrazine-6-carboxamide",3.3,uM,=,0.5185139398778875,1,c1ccc(Nc2cncc3cncn23)cc1
2347,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,Cc1nc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"3-((1R,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,2,4-oxadiazole",1.74,uM,=,0.2405492482825997,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)cc1
2348,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,O=C(NC1CCN(Cc2ccc(OCC(F)(F)F)c(F)c2)CC1)c1cc(=O)c2ccc(F)cc2o1,"N-(1-(3-fluoro-4-(2,2,2-trifluoroethoxy)benzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
2349,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)CCN1CCC(CNC(=O)Cc2ccc(C(C)(C)C)cc2)CC1,"2-(4-tert-butylphenyl)-N-{[1-(3,3-dimethylbutyl)piperidin-4-yl]methyl}acetamide",1.021,uM,=,0.0090257420869102,1,O=C(Cc1ccccc1)NCC1CCNCC1
2350,1784292,10.1021/acsmedchemlett.7b00501,,,,Inhibition of recombinant human ERG expressed in CHO cells at -80 mV holding potential measured after 3 minutes by automated whole cell patch clamp Qpatch method,CN(C/C=C/c1ccc(C(F)(F)F)cc1)Cc1ccc2c(c1)OCCO2.Cl,"(E)-N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-N-methyl-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-amine Hydrochloride",3.9,uM,=,0.5910646070264992,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)OCCO2
2351,854484,10.1021/jm300579z,,,,Binding affinity to human ERG,COc1ccc2cc(-c3cc(-c4cc(Cl)ccc4Cl)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1,"N-[(4-{(1S)-1-[3-(2,5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)-carbonyl]-beta-alanine",9.7,uM,=,0.9867717342662448,1,c1ccc(Cn2nc(-c3ccccc3)cc2-c2ccc3ccccc3c2)cc1
2352,627338,10.1016/j.bmcl.2010.03.005,,,,Inhibition of human ERG,OC(c1cccnc1)(c1cccnc1)C(c1ccccc1)N1CCCC1,"2-phenyl-1,1-di(pyridin-3-yl)-2-(pyrrolidin-1-yl)ethanol",20.0,uM,=,1.3010299956639813,1,c1ccc(C(C(c2cccnc2)c2cccnc2)N2CCCC2)cc1
2353,1906723,10.1016/j.ejmech.2019.111674,,,,Inhibition of human ERG expressed in HEK293 cells incubated for 72 hrs by patch clamp assay,Cc1cc(C(N)=O)c(-c2cccc(OC(=O)NCCN3CCN(c4ccccc4)CC3)c2)s1,3-(3-Carbamoyl-5-methylthiophen-2-yl)phenyl (2-(4-phenylpiperazin-1-yl)ethyl)carbamate,0.28,uM,=,-0.5528419686577808,0,O=C(NCCN1CCN(c2ccccc2)CC1)Oc1cccc(-c2cccs2)c1
2354,1713882,10.1016/j.bmcl.2018.05.030,,,,Inhibition of human ERG expressed in CHO-K1 cells at -90 mV holding potential by Qpatch clamp assay,O=C(CCc1c[nH]nn1)NC1CCN(C(=O)OCc2cc(Cl)cc(Cl)c2)CC1,"US9409895, 19",8.8,uM,=,0.9444826721501688,1,O=C(CCc1c[nH]nn1)NC1CCN(C(=O)OCc2ccccc2)CC1
2355,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC[C@H]1CCCC[C@H]1O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,"1-(((1R,2R)-2-hydroxycyclohexyl)methyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea",3.96,uM,=,0.5976951859255123,1,O=C(NCC1CCCCC1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
2356,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,C[C@H]1COc2c(N3CC[C@@H](C4(N)CC4)C3)c(F)c(Cl)c3cc(C(=O)O)c(=O)n1c23,"(S)-10-((R)-3-(1-aminocyclopropyl)pyrrolidin-1-yl)-8-chloro-9-fluoro-3-methyl-5-oxo-3,5-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid",150.0,uM,=,2.1760912590556813,1,O=c1ccc2ccc(N3CC[C@@H](C4CC4)C3)c3c2n1CCO3
2357,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cc1ccc([C@H]2CC[C@@H](N3CC(NC(=O)CNc4nn(C)c5ccc(C(F)(F)F)cc45)C3)CC2)cn1,cis-N-{1-[4-Hydroxy-4-(6-methyl-pyridin-3-yl)-cyclohexyl]-azetidin-3-yl}-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,18.0,uM,=,1.255272505103306,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3cccnc3)CC2)C1
2358,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(C)cc(C)c2)C2CCN(S(C)(=O)=O)CC2)CC1,"(R)-N-(1-(3-(3,5-dimethylphenyl)-3-(1-(methylsulfonyl)piperidin-4-yl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide",4.0,uM,=,0.6020599913279624,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
2359,2293467,10.1021/acs.jmedchem.7b00463,,,,Inhibition of hERG potassium channel by Q-patch clamp assay,COc1cc(NC(=O)c2nnn(Cc3ccc(CN4CCOCC4)cc3)c2N)cc(OC)c1,"5-amino-N-(3,5-dimethoxyphenyl)-1-(4-(morpholinomethyl)benzyl)-1H-1,2,3-triazole-4-carboxamide",23.0,uM,=,1.3617278360175928,1,O=C(Nc1ccccc1)c1cn(Cc2ccc(CN3CCOCC3)cc2)nn1
2360,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(C/C(=N/O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(Z)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-(hydroxyimino)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",5.4,uM,=,0.7323937598229685,1,N=C(Cc1ccnc2cccnc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
2361,1440048,10.1021/jm500887k,,,,Inhibition of human ERG channel by patch clamp technique,C[S+]([O-])c1ccc(-c2cnc3ccc(-c4cccc(S(C)(=O)=O)c4)nn23)cc1,"3-(4-(Methylsulfinyl)phenyl)-6-(3-(methylsulfonyl)phenyl)-imidazo[1,2-b]pyridazine",4.0,uM,=,0.6020599913279624,1,c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1
2362,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CC[C@@H](NCc4cc5c(cn4)OCCO5)[C@@H](OC)C3)c2c1,"cis-1-(2-{(3S,4R)-4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-3-methoxypiperidin-1-yl}ethyl)-7-methoxyquinoxalin-2(1H)-one",75.0,uM,=,1.8750612633917,1,O=c1cnc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
2363,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CC[C@H]3OC[C@H](NCc4ccc(Cl)c(Cl)c4)CO3)c2c1,"N-(3,4-dichlorobenzyl)-2-(2-(6-methoxyquinolin-4-yl)ethyl)-trans-1,3-dioxan-5-amine",4.8,uM,=,0.6812412373755872,1,c1ccc(CN[C@H]2CO[C@H](CCc3ccnc4ccccc34)OC2)cc1
2364,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3nccs3)CC2)C1,cis-N-{[1-(4-Hydroxy-4-thiazol-2-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide,32.0,uM,=,1.505149978319906,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3nccs3)CC2)C1
2365,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@H]1CN(c2ccccc2)C[C@@H]1c1ccc(-c2cccc(NS(C)(=O)=O)c2)cc1,"N-((3R,4R)-4-(3'-(methylsulfonamido)biphenyl-4-yl)-1-phenylpyrrolidin-3-yl)propane-2-sulfonamide",1.3,uM,=,0.1139433523068367,1,c1ccc(-c2ccc([C@@H]3CCN(c4ccccc4)C3)cc2)cc1
2366,761292,10.1021/jm101312a,,,,Inhibition of human ERG expressed in CHO cells by high throughput single cell planar patch clamp method,CCN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1,"cis-(3aR,7aS)-3a-(3,4-dichlorophenyl)-2-ethyloctahydro-1H-isoindole",4.73,uM,=,0.6748611407378116,1,c1ccc([C@@]23CCCC[C@@H]2CNC3)cc1
2367,1474497,10.1021/acs.jmedchem.5b00191,,,,Inhibition of human ERG expressed in CHO cells,Cc1coc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1,"(4S,4aR,6R,8aS)-8a-(2,4-difluorophenyl)-4-(fluoromethyl)-6-(4-methyloxazol-2-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",19.6,uM,=,1.292256071356476,1,C1=N[C@@]2(c3ccccc3)CO[C@@H](c3ncco3)C[C@H]2CS1
2368,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,Cc1c(N2CC[C@@H]([C@H](C)N)C2)c(F)cc2cc(C(=O)O)c(=O)n(C3CC3)c12,"7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic Acid",214.0,uM,=,2.330413773349191,1,O=c1ccc2ccc(N3CCCC3)cc2n1C1CC1
2369,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,c1ccc(C(Cc2ccccc2OC2CC2)N2CCNCC2)cc1,1-(2-(2-cyclopropoxyphenyl)-1-phenylethyl)piperazine,6.4,uM,=,0.8061799739838872,1,c1ccc(C(Cc2ccccc2OC2CC2)N2CCNCC2)cc1
2370,963062,10.1021/jm400408r,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,Cc1cc(=O)oc2cc(OCCCCN3CCC(c4noc5cc(F)ccc45)CC3)ccc12,7-(4-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-4-methyl-2H-chromen-2-one,0.159,uM,=,-0.7986028756795485,0,O=c1ccc2ccc(OCCCCN3CCC(c4noc5ccccc45)CC3)cc2o1
2371,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,Br.CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1,(E)-5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol hydrobromide,0.24,uM,=,-0.619788758288394,0,c1ccc(/N=N/c2ccccn2)cc1
2372,1990506,10.1016/j.bmc.2020.115548,,,,Inhibition of human ERG,CN(C)Cc1ccc(-n2cc(-c3ccc4cc[nH]c4c3)c3c(Cl)ccnc32)cc1,"1-[4-[4-chloro-3-(1H-indol-6-yl)pyrrolo[2,3-b]pyridin-1-yl]phenyl]-N,N-dimethyl-methanamine",1.7,uM,=,0.2304489213782739,1,c1ccc(-n2cc(-c3ccc4cc[nH]c4c3)c3cccnc32)cc1
2373,1669922,10.1021/acs.jmedchem.7b00462,,,,Inhibition of human hERG by patch clamp method,COc1ccc(CN(CC(=O)N2CCC3(CC2)CNC3)c2ccc(C#N)cc2)cc1F,"4-[[2-(2,7-Diazaspiro[3.5]nonan-7-yl)-2-oxo-ethyl]-[(3-fluoro-4-methoxy-phenyl)methyl]amino]benzonitrile",20.1,uM,=,1.3031960574204888,1,O=C(CN(Cc1ccccc1)c1ccccc1)N1CCC2(CC1)CNC2
2374,304964,10.1016/j.bmcl.2004.09.065,,,,Inhibitory activity against human Potassium channel HERG,NCc1ccc(F)c(C2CCN(C(=O)c3cccc(-c4nc(-c5cccs5)no4)c3)CC2)c1,"[4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[3-(3-thiophen-2-yl-[1,2,4]oxadiazol-5-yl)-phenyl]-methanone",0.8,uM,=,-0.0969100130080563,0,O=C(c1cccc(-c2nc(-c3cccs3)no2)c1)N1CCC(c2ccccc2)CC1
2375,988936,10.1021/jm401094t,,,,Inhibition of human ERG tail current transfected in HEK293 cells by patch clamp assay,CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1,"3-(1H-Indol-5-yl)-5-(4-((4-methylpiperazin-1-yl)methyl)-phenyl)-1H-pyrrolo[2,3-b]pyridine",21.0,uM,=,1.3222192947339193,1,c1cc2cc(-c3c[nH]c4ncc(-c5ccc(CN6CCNCC6)cc5)cc34)ccc2[nH]1
2376,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CCCC#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCN(C)CC4)ccc2-3)cs1,"6-((4-methylpiperazin-1-yl)methyl)-3-(5-(pent-1-ynyl)thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole",1.8,uM,=,0.255272505103306,1,c1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1
2377,826732,10.1021/jm201194q,,,,Inhibition of human ERG expressed in HEK cells by patch clamp assay,O=C(Cc1ccccc1)NCCN(c1ccccc1)c1ccccc1,N-(2-(diphenylamino)ethyl)-2-phenylacetamide,7.86,uM,=,0.895422546039408,1,O=C(Cc1ccccc1)NCCN(c1ccccc1)c1ccccc1
2378,1637262,,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in tail current amplitude by whole cell patch clamp method,COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1,"5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one",32.4,uM,=,1.510545010206612,1,O=c1cc(-c2ccccc2)oc2ccccc12
2379,493421,10.1016/j.bmcl.2008.10.025,,,,Inhibition of human ERG expressed in CHO cells,c1ccc(CC2(c3ccc4sccc4c3)CCNC2)cc1,3-(benzo[b]thiophen-5-yl)-3-benzylpyrrolidine,11.0,uM,=,1.0413926851582251,1,c1ccc(CC2(c3ccc4sccc4c3)CCNC2)cc1
2380,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)CC1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,2-(8-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-8-azaspiro[4.5]decan-3-yl)acetic Acid,19.5,uM,=,1.290034611362518,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCO5)CC4)nc3)nc2c1
2381,1988642,10.1021/acs.jmedchem.0c00909,,,,Inhibition of human ERG,Cc1cc(N2C[C@H]3CC[C@@H](C2)[C@@H]3Nc2nc3c(OCC(F)F)ccc(C(F)(F)F)n3n2)ncn1,"8-(2,2-Difluoroethoxy)-N-[(1R,5S,8r)-3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-5-(trifluoromethyl)-[1,2,4]triazolo-[1,5-a]pyridin-2-amine",4.5,uM,=,0.6532125137753437,1,c1ccn2nc(N[C@@H]3[C@@H]4CC[C@H]3CN(c3ccncn3)C4)nc2c1
2382,1680139,10.1021/acs.jmedchem.6b01647,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc([S+](C)[O-])n2C)ccn1,rac-N-(4-(4-(4-fluorophenyl)-1-methyl-2-(methylsulfinyl)-1H-imidazol-5-yl)pyridin-2-yl)acetamide,213.0,uM,=,2.3283796034387376,1,c1ccc(-c2nc[nH]c2-c2ccncc2)cc1
2383,2120447,10.1016/j.ejmech.2021.113718,,,,Inhibition of human ERG,COc1cc2c(cc1OCC(F)(F)F)CCN1CC(CC(C)C)C(O)CC21,"3-Isobutyl-10-methoxy-9-(2,2,2-trifluoroethoxy)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol",6.51,uM,=,0.8135809885681919,1,c1ccc2c(c1)CCN1CCCCC21
2384,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,CC1(C)C(=O)Nc2nc(-n3nc(Cc4c(F)ccc(F)c4F)c4cc(Cl)ccc43)nc(N)c21,"4-amino-2-[5-chloro-3-[(2,3,6-trifluorophenyl)methyl]indazol-1-yl]-5,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-6-one",1.4,uM,=,0.1461280356782379,1,O=C1Cc2cnc(-n3nc(Cc4ccccc4)c4ccccc43)nc2N1
2385,2021698,10.1021/acs.jmedchem.9b00069,,,,Inhibition of human ERG by Qpatch assay,CC(C)(CO)Cn1nc(-c2ccc3nc(OC4CC4)ccc3c2)c(C(N)=O)c1N,"5-Amino-3-(2-cyclopropoxyquinolin-6-yl)-1-(3-hydroxy-2,2-dimethylpropyl)-1H-pyrazole-4-carboxamide",3.2,uM,=,0.505149978319906,1,c1cc(-c2ccc3nc(OC4CC4)ccc3c2)n[nH]1
2386,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,N#Cc1ccc2ccc(=O)n(CCN3CC[C@H](NCc4cc5c(cn4)OCCO5)[C@H](O)C3)c2c1,"cis-1-(2-{(3R,4S)-4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-3-hydroxypiperidin-1-yl}ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",156.0,uM,=,2.1931245983544616,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
2387,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(CCCOc2ccc(Cl)cc2)cccc1CCCOc1ccc(Cl)cc1,"2,6-bis(3-(4-chlorophenoxy)propyl)-1-methylpyridinium",0.014,uM,=,-1.853871964321762,0,c1ccc(OCCCc2cccc(CCCOc3ccccc3)[nH+]2)cc1
2388,632197,10.1016/j.bmcl.2010.03.111,,,,Inhibition of human ERG by patch clamp electrophysiology,CCOCCn1nc(CC)c2nc(N3CCC(C(=O)O)CC3)nc(Nc3cc(C)ccn3)c21,"1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid",1.1,uM,=,0.041392685158225,1,c1ccc(Nc2nc(N3CCCCC3)nc3cn[nH]c23)nc1
2389,2057776,10.1016/j.ejmech.2020.113103,,,,Inhibition of fluorescence tracer red binding to human ERG measured after 4 hrs by fluorescence polarization assay,O=S(=O)(/C=C/c1ncccc1Cl)c1ccccc1Cl,(E)-3-chloro-2-(2-(2-chlorophenylsulfonyl)vinyl)pyridine,110.0,uM,=,2.041392685158225,1,O=S(=O)(/C=C/c1ccccn1)c1ccccc1
2390,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1cccc2nc(C)n(-c3ccc(OCCCN4CCCC4)cc3)c(=O)c12,"2,5-Dimethyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone",6.6,uM,=,0.8195439355418687,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
2391,2125318,10.1021/acs.jmedchem.0c01955,,,,Displacement of [3H]dofetilide from recombinant human ERG stably expressed in HEK293 cell membranes measured after 90 mins by microbeta liquid scintillation counting method,Cc1ccc(Oc2ccc(-c3nnn(CCN)n3)cc2)cc1,2-(5-(4-(p-Tolyloxy)phenyl)-2H-tetrazol-2-yl)ethan-1-amine,5.8,uM,=,0.7634279935629373,1,c1ccc(Oc2ccc(-c3nn[nH]n3)cc2)cc1
2392,748955,10.1016/j.bmcl.2011.04.078,,,,Inhibition of human ERG,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@H](OCC(=O)NC)[C@H](C)[C@@H](O)[C@]1(C)O,"2-((2R,3S,4R,5R,6S,7R,9R,10R,11S,12S,13R)-2-ethyl-3,4,9-trihydroxy-10-((2S,3R,4S,6R)-3-hydroxy-4-(isopropyl(methyl)amino)-6-methyltetrahydro-2H-pyran-2-yloxy)-12-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-14-oxooxacyclotetradecan-6-yloxy)-N-methylacetamide",411.0,uM,=,2.6138418218760693,1,O=C1C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CCCCCCCCO1
2393,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1-c1ccc(F)cc1,"US9145392, 57",1.5,uM,=,0.1760912590556812,1,c1ccc(-c2cn(CCN3CCCC3)c(C3CCN(c4ncncc4-c4ccccc4)CC3)n2)cc1
2394,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCOC(=O)[C@H]1CC[C@@H](N2CC(NC(=O)CNc3noc4ccc(C(F)(F)F)cc34)C2)CC1,cis-4-{3-[2-(5-Trifluoromethyl-benzo[d]isoxazol-3-ylamino)-acetylamino]-azetidin-1-yl}-cyclohexanecarboxylic acid ethyl ester,5.6,uM,=,0.7481880270062004,1,O=C(CNc1noc2ccccc12)NC1CN(C2CCCCC2)C1
2395,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC7(O)COC7)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-((3-hydroxyoxetan-3-yl)methoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",12.2,uM,=,1.0863598306747482,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7COC7)nc56)(CC3)OC4)nc2N1
2396,1275662,10.1021/jm400856t,,,,Inhibition of human ERG,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",0.01,uM,=,-2.0,0,c1ccc(CCCCNCCc2ccccc2)cc1
2397,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,O=C(NC1CC1c1ccccc1)N1CCC(c2nc3ccccc3o2)CC1,4-(benzo[d]oxazol-2-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide,8.2,uM,=,0.9138138523837168,1,O=C(NC1CC1c1ccccc1)N1CCC(c2nc3ccccc3o2)CC1
2398,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,CNC(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1,"N-Methyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide",29.0,uM,=,1.462397997898956,1,O=C1c2ccc(-c3ccccc3)cc2CCN1CCN1CCCC1
2399,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,CN1CCc2c(sc3c2c2ncnn2c(=O)n3Cc2ccc(Cl)cc2)C1,"6-(4-Chlorobenzyl)-9-methyl-8,9,10,11-tetrahydropyrido-[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one",0.069,uM,=,-1.1611509092627446,0,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCNC3
2400,793274,10.1016/j.bmcl.2011.09.117,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp electrophysiology,COc1ccc2nccc([C@@H](O)CN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"(R)-2-(4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)-1-(6-methoxy-1,5-naphthyridin-4-yl)ethanol",4.0,uM,=,0.6020599913279624,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
2401,1513054,10.1021/ml500531p,,,,Inhibition of human ERG by IonWorks assay,O=C1COc2ccc(CN[C@@H]3CCN(CCn4c(=O)ccc5ncc(Oc6cccnc6)cc54)C[C@@H]3F)nc2N1,"6-(((3S,4R)-3-fluoro-1-(2-(2-oxo-7-(pyridin-3-yloxy)-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",75.0,uM,=,1.8750612633917,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)ccc5ncc(Oc6cccnc6)cc54)CC3)nc2N1
2402,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,Cc1nnc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1,"2-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,3,4-oxadiazole",3.2,uM,=,0.505149978319906,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4nnco4)N3)n2)nc1
2403,1501722,10.1021/acs.jmedchem.5b00742,,,,Inhibition of [3H]-astemizole binding to human ERG expressed in HEK293 cells,COc1ccc(-n2nccn2)c(C(=O)N2C[C@@H]3CN(c4nc(C)cc(C)n4)C[C@@H]3C2)c1,"((3aR,6aS)-5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone",8.1,uM,=,0.9084850188786496,1,O=C(c1ccccc1-n1nccn1)N1C[C@@H]2CN(c3ncccn3)C[C@@H]2C1
2404,833999,10.1016/j.bmcl.2012.06.094,,,,Inhibition of human ERG by patch clamp assay,Cc1cccc(-c2noc(C3CC(=O)N(c4ccc(F)cc4)C3)n2)c1,"(-)-1-(4-fluorophenyl)-4-(3-m-tolyl-1,2,4-oxadiazol-5-yl)pyrrolidin-2-one",6.0,uM,=,0.7781512503836436,1,O=C1CC(c2nc(-c3ccccc3)no2)CN1c1ccccc1
2405,1545989,10.1021/acs.jmedchem.5b01227,,,,Inhibition of human ERG channel by automated Q-patch assay,O=C(Nc1cccc(C(F)(F)F)c1)n1ccc2cc(Oc3ncnc4c3CCNC4)ccc21,"5-((5,6,7,8-Tetrahydropyrido[3,4-d]pyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1H-indole-1-carboxamide",8.9,uM,=,0.9493900066449128,1,O=C(Nc1ccccc1)n1ccc2cc(Oc3ncnc4c3CCNC4)ccc21
2406,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(C3C(=O)NC4CCC3C4)nn2)ccc1-n1cnc(C)c1,"rac-4-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-2-azabicyclo[3.2.1]octan-3-one",5.35,uM,=,0.7283537820212285,1,O=C1NC2CCC(C2)C1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
2407,2159402,10.1021/acs.jmedchem.1c01968,,,,Inhibition of human ERG by voltage clamp assay,Clc1cc2cnc(Nc3cnn(C4CC4)c3Cl)nc2cc1N1CCN(C2COC2)CC1,6-chloro-N-(5-chloro-1-cyclopropyl-1H-pyrazol-4-yl)-7-(4-(oxetan-3-yl)piperazin-1-yl)quinazolin-2-amine,24.0,uM,=,1.380211241711606,1,c1nn(C2CC2)cc1Nc1ncc2ccc(N3CCN(C4COC4)CC3)cc2n1
2408,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N(C)C)nc1CN1C(=O)O[C@H](c2cccc(C(F)(F)F)n2)[C@@H]1C,"3'-(2-(dimethylamino)-4-(((4S,5S)-4-methyl-2-oxo-5-(6-(trifluoromethyl)pyridin-2-yl)oxazolidin-3-yl)-methyl)pyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic Acid",22.0,uM,=,1.3424226808222062,1,O=C1O[C@H](c2ccccn2)CN1Cc1ncncc1-c1cccc(-c2ccccc2)c1
2409,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(Cl)ccc3OC[C@H]2[C@@]1(CCCN1CCN(C(C)=O)CC1)c1ccccc1,"1-{(3R,3aR)-3-[3-(4-acetyl-piperazin-1-yl)-propyl]-8-chloro-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-2-yl}-ethanone",5.6,uM,=,0.7481880270062004,1,C1=NN2c3ccccc3OC[C@H]2[C@@]1(CCCN1CCNCC1)c1ccccc1
2410,886194,10.1016/j.bmcl.2012.10.036,,,,Inhibition of human ERG by patch clamp assay,CC(=O)NC1CC2CCC(C1)N2CCc1ccc(Oc2nc3ncccc3s2)cc1,"N-(8-(4-(thiazolo[4,5-b]pyridin-2-yloxy)phenethyl)-8-azabicyclo[3.2.1]octan-3-yl)acetamide",4.3,uM,=,0.6334684555795865,1,c1cnc2nc(Oc3ccc(CCN4C5CCCC4CC5)cc3)sc2c1
2411,1857806,10.1021/acs.jmedchem.9b01916,,,,Inhibition of human ERG by Qpatch clamp method,C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C,Remibrutinib; N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide,1.4,uM,=,0.1461280356782379,1,O=C(Nc1cccc(-c2ccncn2)c1)c1ccc(C2CC2)cc1
2412,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCCC[C@@H](CCO)Nc1nc(N)nc2ccc(C)cc12,(S)-3-((2-Amino-6-methylquinazolin-4-yl)amino)heptan-1-ol,5.4,uM,=,0.7323937598229685,1,c1ccc2ncncc2c1
2413,1637262,,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in tail current amplitude by whole cell patch clamp method,COc1ccc(-c2cc(=O)c3ccccc3o2)cc1,2-(4-Methoxy-phenyl)-chromen-4-one,21.9,uM,=,1.3404441148401185,1,O=c1cc(-c2ccccc2)oc2ccccc12
2414,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3ccc(OC(F)(F)F)cn3)cs2)CO1,"US9315520, 20",10.1,uM,=,1.0043213737826426,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccn1
2415,1512965,10.1021/acsmedchemlett.5b00117,,,,Inhibition of human ERG,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3)n1,"(4-Fluorophenyl)(3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",50.0,uM,=,1.6989700043360187,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
2416,2081968,10.1016/j.ejmech.2021.113248,,,,Inhibition of human ERG expressed in CHO cells,O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3o1)CC2,"8-(3-(Benzofuran-2-yl)-5-chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",10.9,uM,=,1.0374264979406236,1,O=C1NCCC12CCN(c1ccncc1-c1cc3ccccc3o1)CC2
2417,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,NC1COCC1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-(4-aminotetrahydrofuran-3-yloxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.6,uM,=,0.5563025007672873,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OC7CCOC7)nc56)(CC3)OC4)nc2N1
2418,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCc1cc(C(=O)N[C@@H]2CC(C)(C)Oc3nc(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)cc32)n[nH]1,"N-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-5-ethyl-1H-pyrazole-3-carboxamide",1.2,uM,=,0.0791812460476248,1,O=C(N[C@@H]1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)c1cc[nH]n1
2419,1972207,10.1021/acs.jmedchem.9b01624,,,,Inhibition of human ERG by Qpatch S8 assay,C[C@@H]1CN(C(=O)Nc2cc(-c3cn(C4CCOCC4)c4cnccc34)ccn2)C[C@H](C)O1,"(2S,6R)-2,6-Dimethyl-N-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)morpholine-4-carboxamide",6.6,uM,=,0.8195439355418687,1,O=C(Nc1cc(-c2cn(C3CCOCC3)c3cnccc23)ccn1)N1CCOCC1
2420,1294319,10.1021/jm401278d,,,,Inhibition of human ERG by patch clamp electrophysiology,Nc1ncc(-c2ccc(C(=O)N3CCOCC3)cc2)nc1-c1ccc(C(F)(F)F)nc1,(4-(5-Amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2yl)phenyl)(morpholino)methanone,20.2,uM,=,1.305351369446624,1,O=C(c1ccc(-c2cncc(-c3cccnc3)n2)cc1)N1CCOCC1
2421,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=NC(c2cccc(-c3cncnc3)c2)(c2ccnc(C3CC3)c2)c2cccc(F)c21,1-(2-Cyclopropylpyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine,3.5,uM,=,0.5440680443502757,1,C1=NC(c2cccc(-c3cncnc3)c2)(c2ccnc(C3CC3)c2)c2ccccc21
2422,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCN(C)C(=O)c1ccc([C@H](c2cccc(NC(=O)C3CC3)c2)N2CCN(Cc3nc(C)cs3)CC2)cc1,(R)-4-((3-(cyclopropanecarboxamido)phenyl)(4-((4-methylthiazol-2-yl)methyl)piperazin-1-yl)methyl)-N-ethyl-N-methylbenzamide,18.0,uM,=,1.255272505103306,1,O=C(Nc1cccc([C@@H](c2ccccc2)N2CCN(Cc3nccs3)CC2)c1)C1CC1
2423,2159402,10.1021/acs.jmedchem.1c01968,,,,Inhibition of human ERG by voltage clamp assay,Cc1c(Nc2ncc3cc(Cl)c(C4CCN([C@@H]5COC[C@@H]5O)CC4)cc3n2)cnn1[C@@H]1CC1(F)F,"(3R,4R)-4-(4-(6-chloro-2-(1-((R)-2,2-difluorocyclopropyl)-5-methyl-1H-pyrazol-4-ylamino)quinazolin-7-yl)piperidin-1-yl)-4-methyltetrahydrofuran-3-ol",6.2,uM,=,0.7923916894982539,1,c1nn(C2CC2)cc1Nc1ncc2ccc(C3CCN([C@H]4CCOC4)CC3)cc2n1
2424,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1noc(-c2ccccc2)n1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1,"(5-phenyl-1,2,4-oxadiazol-3-yl)(4-(4-(pyrrolidin-1-ylmethyl)phenoxy)piperidin-1-yl)methanone",7.5,uM,=,0.8750612633917001,1,O=C(c1noc(-c2ccccc2)n1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
2425,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,COc1cccc(C2(O)CCN(C(C)C(O)c3ccc4c(c3)CCC(=O)N4)CC2)c1,"6-(1-hydroxy-2-(4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)propyl)-3,4-dihydroquinolin-2(1H)-one",11.0,uM,=,1.0413926851582251,1,O=C1CCc2cc(CCN3CCC(c4ccccc4)CC3)ccc2N1
2426,1478750,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,(6-Methoxy-quinolin-4-yl)-(5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol,0.3,uM,=,-0.5228787452803376,0,c1ccc2c(C[C@H]3CC4CCN3CC4)ccnc2c1
2427,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2ncc(=O)n(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2c1,"1-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]piperidin-1-yl}ethyl)-7-methoxyquinoxalin-2(1H)-one",19.0,uM,=,1.2787536009528289,1,O=c1cnc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
2428,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O,"US9056859, 72",29.0,uM,=,1.462397997898956,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
2429,1329649,10.1039/C1MD00015B,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch clamp assay,CC(=O)Nc1cccc(C2CCN(Cc3ccc(C(=O)c4nc5ccccc5n4-c4ccc(F)cc4)cc3)CC2)c1,N-(3-(1-(4-(1-(4-fluorophenyl)-1H-benzo[d]imidazole-2-carbonyl)benzyl)piperidin-4-yl)phenyl)acetamide,1.97,uM,=,0.2944662261615929,1,O=C(c1ccc(CN2CCC(c3ccccc3)CC2)cc1)c1nc2ccccc2n1-c1ccccc1
2430,796063,10.1016/j.bmcl.2011.11.050,,,,Inhibition of human ERG by patch express assay,O=S(=O)(c1cccc(F)c1)c1ccc2c3c(oc2c1)CNCC3,"7-(3-fluorophenylsulfonyl)-1,2,3,4-tetrahydrobenzofuro[2,3-c]pyridine",1.0,uM,=,0.0,0,O=S(=O)(c1ccccc1)c1ccc2c3c(oc2c1)CNCC3
2431,716794,10.1016/j.bmcl.2010.12.123,,,,Inhibition of human ERG expressed in CHO cells,O=C(N[C@H]1CC[C@H](C(=O)O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,"trans-4-((S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)cyclohexanecarboxylic acid",7.6,uM,=,0.8808135922807914,1,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
2432,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,Cc1c(Cl)cccc1C(=O)N(CC(C)C)[C@H]1CCNC1,(S)-3-chloro-N-isobutyl-2-methyl-N-(pyrrolidin-3-yl)benzamide,52.4,uM,=,1.7193312869837267,1,O=C(N[C@H]1CCNC1)c1ccccc1
2433,1464215,10.1016/j.bmcl.2015.02.044,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in tail current at membrane potential of +20 mV,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,"(S)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((R)-piperidin-2-yl)methanol",2.6,uM,=,0.414973347970818,1,c1ccc2c(C[C@H]3CCCCN3)ccnc2c1
2434,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2cnsc2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(isothiazol-4-yl)-2,8-diazaspiro[4.5]decan-1-one",4.9,uM,=,0.6901960800285137,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cnsc3)C4=O)ccc21
2435,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(Cl)cc(Cl)c2)CCN(Cc2cccc(OC)c2)CC1,"methyl 4-((3,5-dichlorobenzamido)methyl)-1-(3-methoxybenzyl)piperidine-4-carboxylate",0.36,uM,=,-0.4436974992327127,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
2436,842172,10.1021/jm300247y,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,COc1ccc(-c2cc(NC(=O)CCCCN3CCCN(C(C)=O)CC3)[nH]n2)cc1,"5-(4-Acetyl-[1,4]diazepan-1-yl)pentanoic Acid[5-(4-Methoxyphenyl)-2H-pyrazol-3-yl]Amide",24.2,uM,=,1.383815365980431,1,O=C(CCCCN1CCCNCC1)Nc1cc(-c2ccccc2)n[nH]1
2437,1831533,10.1016/j.ejmech.2018.11.018,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 2.5 mins by Qpatch clamp assay,Oc1ccc(Cn2c(-c3cscn3)nc3ccccc32)c2cccnc12,1-((8-hydroxy-quinolin-5-yl)methyl)-2-(thiazol-4-yl)-1H-benzimidazol,18.0,uM,=,1.255272505103306,1,c1cc(Cn2c(-c3cscn3)nc3ccccc32)c2cccnc2c1
2438,1935939,10.1016/j.bmc.2019.02.025,,,,Inhibition of human ERG by manual patch clamp electrophysiology assay,COc1cccc(C(c2cc3cc(Br)ccc3nc2OC)C(O)(CCN(C)C)c2cc(C)cnc2C)c1OC,"rac-1-(6-bromo-2-methoxyquinolin-3-yl)-1-(2,3-dimethoxyphenyl)-4-(dimethylamino)-2-(2,5-dimethylpyridin-3-yl)butan-2-ol",1.1,uM,=,0.041392685158225,1,c1ccc(C(Cc2cccnc2)c2cnc3ccccc3c2)cc1
2439,1912248,10.1021/acs.jmedchem.9b00443,,,,Inhibition of human ERG by fluorescence polarization assay,CNC(=O)c1cnc(Nc2ccccn2)cc1Nc1ccccc1S(C)(=O)=O,N-Methyl-4-((2-(methylsulfonyl)phenyl)amino)-6-(pyridin-2-ylamino)nicotinamide,36.0,uM,=,1.5563025007672873,1,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1
2440,2133681,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG expressed in CHO by manual patch clamp method,CC[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3c(C)nc4ccc(F)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(6-fluoro-2-methyl-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",1.1,uM,=,0.041392685158225,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
2441,2274261,10.1016/j.ejmech.2020.112290,,,,Inhibition of human ERG,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CCC3)N1CC[C@H](C1)NCc1cncn1-2,,7.0,uM,=,0.8450980400142568,1,c1cc2cc(c1)-n1cncc1CN[C@@H]1CCN(C1)[C@@H]1CCCc3ccc(cc31)O2
2442,1293874,10.1021/jm401836p,,,,Inhibition of human ERG by whole cell patch clamp assay,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C,daclatasvir,29.2,uM,=,1.4653828514484184,1,c1cc(-c2cnc([C@@H]3CCCN3)[nH]2)ccc1-c1ccc(-c2cnc([C@@H]3CCCN3)[nH]2)cc1
2443,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)cc1,endo-3-(8-(4-methylbenzyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.00014,uM,=,-3.853871964321762,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
2444,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,N[C@H](COc1cccc2c1NC(=O)CO2)CN1CCC2(CC1)Cc1cc(F)ccc1O2,"(S)-5-(2-amino-3-(5-fluoro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)propoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one",1.1,uM,=,0.041392685158225,1,O=C1COc2cccc(OCCCN3CCC4(CC3)Cc3ccccc3O4)c2N1
2445,2048454,10.1016/j.bmc.2020.115734,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCC2,"N-(2-ethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",1.19,uM,=,0.0755469613925307,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCC5)n3)nc2)cn1
2446,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2cccnc2)cc1,"N,N-diethyl-4-((1-(4-fluorobenzyl)piperidin-4-ylidene)(pyridin-3-yl)methyl)benzamide",1.3,uM,=,0.1139433523068367,1,c1ccc(CN2CCC(=C(c3ccccc3)c3cccnc3)CC2)cc1
2447,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCCC3CCOCC3)C[C@@H]2CC(=O)Nc2cccc(Cl)c2)cc1,"N-(3-chlorophenyl)-2-((3R,4S)-4-(4-methoxyphenyl)-1-(3-(tetrahydro-2H-pyran-4-yl)propyl)pyrrolidin-3-yl)acetamide",0.37,uM,=,-0.431798275933005,0,O=C(C[C@H]1CN(CCCC2CCOCC2)C[C@@H]1c1ccccc1)Nc1ccccc1
2448,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,CC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@]23OC(=O)c2cc(F)c(F)cc23)c(C)c1,"N-(2-(4'-((1R,3'S)-5,6-difluoro-3-oxo-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-yl)-3'-methylbiphenyl-2-yl)ethyl)acetamide",12.9,uM,=,1.110589710299249,1,O=C1O[C@@]2(CCNC[C@@H]2c2ccc(-c3ccccc3)cc2)c2ccccc21
2449,2264097,10.1021/acs.jmedchem.1c00703,,,,Inhibition of hERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp assay,CC(C)n1nc(-c2nnc(C3CCN(C4CCC4)CC3)o2)c2ccccc21.O=C(O)C(=O)O,"3-[5-(1-Cyclobutyl-piperidin-4-yl)-[1,3,4]oxadiazol-2-yl]-1-isopropyl-1H-indazoleoxalate",2.4,uM,=,0.380211241711606,1,c1ccc2c(-c3nnc(C4CCN(C5CCC5)CC4)o3)n[nH]c2c1
2450,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(6-(((1r,3R,4S)-3,4-dihydroxycyclopentyl)methoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.7,uM,=,0.4313637641589873,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7CCCC7)nc56)(CC3)OC4)nc2N1
2451,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cnc(OC)c([C@H](c2cc3cc(Br)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cc(OC)nc(OC)c2)c1,"(1S,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-1-(2,5-dimethoxypyridin-3-yl)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)butan-2-ol",2.2,uM,=,0.3424226808222063,1,c1cncc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)c1
2452,1682333,10.1021/acs.jmedchem.7b01347,,,,Inhibition of full length human ERG expressed in CHO cells at -70 mV holding potential by patch clamp assay,CN(Cc1ccc(C(F)(F)F)cc1)c1cc(C(=O)Nc2ccccc2)ncn1,6-(Methyl(4-(trifluoromethyl)benzyl)amino)-N-phenylpyrimidine-4-carboxamide,3.3,uM,=,0.5185139398778875,1,O=C(Nc1ccccc1)c1cc(NCc2ccccc2)ncn1
2453,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(COc1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1,1-piperazin-1-yl-2-[[6-(2-pyridyloxy)-2-quinolyl]oxy]ethanone,30.0,uM,=,1.4771212547196624,1,O=C(COc1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
2454,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,O=S1(=O)CCC(C2N[C@@H](c3nc(-c4ccccc4)c[nH]3)Cc3c2[nH]c2ccccc32)CC1,"(R)-1-(1,1-Dioxo-hexahydro-1lambda*6*-thiopyran-4-yl)-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-beta-carboline",0.1,uM,=,-1.0,0,O=S1(=O)CCC(C2N[C@@H](c3nc(-c4ccccc4)c[nH]3)Cc3c2[nH]c2ccccc32)CC1
2455,77051,10.1021/jm970517u,,,,Inhibition of Ikr current in isolated guinea pig myocytes during a 0.5 s voltage clamp step from -50 to -10 mV.,O=C(Cc1cc(Cl)cc(Cl)c1)N[C@@H]1N=C(c2ccccc2)c2ccccc2N(CC(F)(F)F)C1=O,"2-(3,5-Dichloro-phenyl)-N-[(R)-2-oxo-5-phenyl-1-(2,2,2-trifluoro-ethyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-acetamide",4.0,uM,=,0.6020599913279624,1,O=C(Cc1ccccc1)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O
2456,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,O=C(NC1CCN(C2CCCCC2)CC1)c1nnc(-c2ccc(F)cc2F)o1,"5-(2,4-Difluoro-phenyl)-[1,3,4]oxadiazole-2-carboxylic acid (1-cyclohexyl-piperidin-4-yl)-amide",2.7,uM,=,0.4313637641589873,1,O=C(NC1CCN(C2CCCCC2)CC1)c1nnc(-c2ccccc2)o1
2457,622012,10.1021/jm901319p,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(Cl)cc3)C2)n1C,"(1S,5R/1R,5S)-1-(4-Chlorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo-[3.1.0]hexane",0.11,uM,=,-0.958607314841775,0,c1ccc(C23CC2CN(CCCSc2nnc(-c4cnco4)[nH]2)C3)cc1
2458,1979419,10.1021/acs.jmedchem.0c00456,,,,Inhibition of human ERG stably expressed in HEK293 cells,CCS(=O)(=O)Nc1cc(-c2cn(C)c3c(=O)[nH]ccc23)cc2c1ccn2C(C)(c1ccccn1)c1ccccn1.Cl,"N-(1-(1,1-Di(pyridin-2-yl)ethyl)-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl)-ethanesulfonamide Hydrochloride",29.258,uM,=,1.4662446355743104,1,O=c1[nH]ccc2c(-c3ccc4ccn(C(c5ccccn5)c5ccccn5)c4c3)c[nH]c12
2459,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cncc(C(F)(F)F)n3)CC2)(C(C)C)C1,"cis-((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxytetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(6-(trifluoromethyl)pyrazin-2-yl)piperazin-1-yl)methanone",7.6,uM,=,0.8808135922807914,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2cnccn2)CC1
2460,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3nc4ccccc4s3)ccc2c1,(R)-2-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)benzo[d]thiazole,2.0,uM,=,0.3010299956639812,1,c1ccc2sc(-c3ccc4cc(CCN5CCCC5)ccc4n3)nc2c1
2461,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(Br)c3n2CCN1Cc1ccc(Cl)cc1,"6-Bromo-2-[(4-Chlorophenyl)methyl]-3,4-dihydropyrazino(1,2-a)henzimidazol-1(2H)-one",4.7,uM,=,0.6720978579357175,1,O=C1c2nc3ccccc3n2CCN1Cc1ccccc1
2462,1912277,10.1021/acs.jmedchem.9b00443,,,,Inhibition of human ERG by patch clamp assay,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccccc1S(C)(=O)=O,6-((5-Fluoropyridin-2-yl)amino)-N-methyl-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide,2.5,uM,=,0.3979400086720376,1,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1
2463,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(Br)c3n2CCN1Cc1ccc(F)cc1,"6-Bromo-2-[(4-fluorophenyl)methyl]-3,4-dihydropyrazino(1,2-a)henzimidazol-1(2H)-one",8.6,uM,=,0.9344984512435676,1,O=C1c2nc3ccccc3n2CCN1Cc1ccccc1
2464,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,O=C(CNc1n[nH]c2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3cccnc3)CC2)C1,cis-N-[1-(4-Hydroxy-4-pyridin-3-yl-cyclohexyl)-azetidin-3-yl]-2-(5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,36.0,uM,=,1.5563025007672873,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3cccnc3)CC2)C1
2465,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,C[N+]1([O-])CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,Clozapine-N-oxide,133.3,uM,=,2.12483014941386,1,c1ccc2c(c1)N=C(N1CC[NH2+]CC1)c1ccccc1N2
2466,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCCN(C)S(=O)(=O)c3ccccc3)C[C@@H]2CC(=O)Nc2cccc(Cl)c2)cc1,"N-(3-chlorophenyl)-2-((3R,4S)-4-(4-methoxyphenyl)-1-(3-(N-methylphenylsulfonamido)propyl)pyrrolidin-3-yl)acetamide",0.14,uM,=,-0.8538719643217619,0,O=C(C[C@H]1CN(CCCNS(=O)(=O)c2ccccc2)C[C@@H]1c1ccccc1)Nc1ccccc1
2467,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2ccc(=O)n(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"1-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]piperidine-1-yl}ethyl)-7-methoxy-1,8-naphthyridin-2(1H)-one",40.0,uM,=,1.6020599913279625,1,O=c1ccc2cccnc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
2468,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1nc(-n2cnnn2)ccc1C(C)C(=O)N1CCN(CCc2ccc3c(c2C)COC3=O)CC1,4-methyl-5-(2-(4-(2-(2-methyl-6-(1H-tetrazol-1-yl)pyridin-3-yl)propanoyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,3.4,uM,=,0.5314789170422551,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
2469,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,C[C@H]1CN(c2scnc2-c2nc3ccccc3[nH]2)CCN1C(=O)Cn1cnc2cccnc21,"US9266876, 47",0.63,uM,=,-0.2006594505464183,0,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2nc3ccccc3[nH]2)CC1
2470,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,CCCCOc1cc(Cl)cc(OCCCC)c1/N=N/c1c(O)ccc2ccccc12,"1-((2,6-dibutoxy-4-chlorophenyl)diazenyl)naphthalen-2-ol",0.4,uM,=,-0.3979400086720376,0,c1ccc(/N=N/c2cccc3ccccc23)cc1
2471,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Cl)cc1Oc1ccc(C)c(C)c1,"1-(4-chloro-2-(3,4-dimethylphenoxy)phenyl)-N-methylmethanamine",1.74,uM,=,0.2405492482825997,1,c1ccc(Oc2ccccc2)cc1
2472,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CC[S+]([O-])CC2)NC(c2nccs2)=NC1c1ccc(F)cc1Br,"Ethyl 4-(2-Bromo-4-fluorophenyl)-6-((1-oxidothiomorpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",5.74,uM,=,0.7589118923979735,1,C1=C(CN2CC[SH+]CC2)NC(c2nccs2)=NC1c1ccccc1
2473,983133,10.1016/j.bmcl.2013.07.013,,,,Inhibition of human ERG transfected in HEK293 cells by patch clamp assay,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CN1CCC(NCc2cc3c(cn2)OCCO3)CC1,"(S)-4-((4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",310.0,uM,=,2.4913616938342726,1,O=c1ccc2nccc3c2n1CC3CN1CCC(NCc2cc3c(cn2)OCCO3)CC1
2474,1788775,10.1016/j.bmcl.2018.10.007,,,,Inhibition of human ERG,COc1ccccc1-n1nc(C2CC(C)(C)OC(C)(C)C2)cc1-c1csc(Cl)c1,"5-(5-chlorothiophen-3-yl)-1-(2-methoxyphenyl)-3-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazole",26.0,uM,=,1.414973347970818,1,c1ccc(-n2nc(C3CCOCC3)cc2-c2ccsc2)cc1
2475,1760517,10.1021/acs.jmedchem.8b00372,,,,Inhibition of human ERG expressed in CHO cells at 10 nM to 10 uM at holding potential of -80 mV measured after 5 mins by QPatch automated patch clamp electrophysiology method,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2OC(C)C)C3)ccn1,"3-[2-(2-Methylpyridin-4-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]-pyrazole-5-carbonyl]-4-(propan-2-yloxy)benzonitrile",10.0,uM,=,1.0,1,O=C(c1ccccc1)N1Cc2cn(-c3ccncc3)nc2C1
2476,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,N#Cc1ccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,cis-N-({1-[4-(6-Cyano-pyridin-3-yl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,12.5,uM,=,1.0969100130080565,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccnc3)CC2)C1
2477,2229247,10.1021/acs.jmedchem.2c00960,,,,Inhibition of hERG potassium channel expressed in HEK293 cells,CC(C)Oc1ccc(-c2nsc(Nc3ncccc3N(C)C)n2)nc1,"N2-(3-(5-isopropoxypyridin-2-yl)-1,2,4-thiadiazol-5-yl)-N3,N3-dimethylpyridine-2,3-diamine",11.4,uM,=,1.0569048513364727,1,c1ccc(Nc2nc(-c3ccccn3)ns2)nc1
2478,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,1-(2-{4-[5-Chloro-1-(4-fluoro-phenyl)-1H-indol-3-yl]-piperidin-1-yl}-ethyl)-imidazolidin-2-one,0.003,uM,=,-2.5228787452803374,0,O=C1NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccccc23)CC1
2479,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4cccnc4)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-N-[1-(4-Hydroxy-4-pyridin-3-yl-cyclohexyl)-azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,24.0,uM,=,1.380211241711606,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3cccnc3)CC2)C1
2480,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,CCOc1cc2ncc(C(N)=O)c(Nc3ccc(C)cc3F)c2cc1N1CCN(C)CC1,7-ethoxy-4-(2-fluoro-4-methylphenylamino)-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide,15.0,uM,=,1.1760912590556811,1,c1ccc(Nc2ccnc3ccc(N4CCNCC4)cc23)cc1
2481,2064218,10.1021/acs.jmedchem.6b01265,,,,Inhibition of human ERG by IonWorks patch clamp electrophysiology method,Nc1ncc(-c2ccc(C(=O)N3CCC(N)C3)cc2)nc1-c1ccc(C(F)(F)F)cc1,(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-aminopyrrolidin-1-yl)methanone,10.0,uM,=,1.0,1,O=C(c1ccc(-c2cncc(-c3ccccc3)n2)cc1)N1CCCC1
2482,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1nnn(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)C1CC(=O)N(C)C1)C2,"4-(2-((1-(4-fluorophenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)-1-methylpyrrolidin-2-one",30.0,uM,=,1.4771212547196624,1,O=C1CC(C(=O)N2CCc3nc(OCc4cnnn4-c4ccccc4)ccc3C2)CN1
2483,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cnc2ccc(-c3cccnc3)cc2c1NC1CCCC1,4-(Cyclopentylamino)-6-(3-pyridinyl)-3-quinolinecarboxamide,0.57,uM,=,-0.2441251443275086,0,c1cncc(-c2ccc3nccc(NC4CCCC4)c3c2)c1
2484,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,Cc1ccccc1C(C)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,endo-3-(8-(1-o-tolylethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0049,uM,=,-2.309803919971486,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
2485,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,O=C1NCCc2nc(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc21,"3-phenyl-2-(4-((4-(5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-7,8-dihydro-1,6-naphthyridin-5(6H)-one",2.5,uM,=,0.3979400086720376,1,O=C1NCCc2nc(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc21
2486,454299,10.1016/j.bmcl.2007.01.020,,,,Inhibition of hERG,Fc1cccc(CN(C2CCOCC2)[C@H]2CCNC2)c1C(F)(F)F,(S)-N-(3-fluoro-2-(trifluoromethyl)benzyl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amine,1.6,uM,=,0.2041199826559248,1,c1ccc(CN(C2CCOCC2)[C@H]2CCNC2)cc1
2487,1779901,10.1021/acs.jmedchem.8b00884,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1ccc2nn(C)cc2c1N(C(F)F)S(=O)(=O)c1ccc(CCCCC2CCN(C)CC2)cc1,N-(difluoromethyl)-N-(5-isobutyl-2-methyl-indazol-4-yl)-4-[4-(1-methyl-4-piperidyl)butyl]benzenesulfonamide,6.0,uM,=,0.7781512503836436,1,O=S(=O)(Nc1cccc2n[nH]cc12)c1ccc(CCCCC2CCNCC2)cc1
2488,1460449,10.1016/j.bmcl.2014.06.083,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by patch clamp method,O=C(OCC1CCN(CC(O)CO)CC1)c1c2n(c3ccccc13)CCCO2,"[1-(2,3-dihydroxypropyl)-4-piperidinyl]methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate",81.0,uM,=,1.9084850188786493,1,O=C(OCC1CCNCC1)c1c2n(c3ccccc13)CCCO2
2489,1435893,10.1016/j.bmc.2014.10.020,,,,Inhibition of human ERG expressed in CHO cells by Rb efflux assay,O=C(CNCCc1c(Cl)cccc1Cl)N1CCc2ccccc2C1C1CCCCC1,"1-(1-Cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-{[2-(2,6-dichlorophenyl)ethyl]amino}ethanone",54.7,uM,=,1.737987326333431,1,O=C(CNCCc1ccccc1)N1CCc2ccccc2C1C1CCCCC1
2490,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,CN(C)CCCOc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1F,N-(1-(4-(3-(dimethylamino)propoxy)-3-fluorobenzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,65.0,uM,=,1.812913356642856,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
2491,591827,10.1021/jm900729s,,,,Inhibition of human ERG by patch-clamp assay,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(C3CN(Cc4c(O)cnc5ncccc45)C3)C(=O)O[C@]12C,"3-Descladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl-(1-((3-hydroxy[1,8]naphthyridin-4-yl)methyl)azetidin-3-yl)imino)erythromycin A",140.0,uM,=,2.146128035678238,1,O=C1CC(=O)OCC2OC(=O)N(C3CN(Cc4ccnc5ncccc45)C3)[C@@H]2CC(=O)CCC[C@H](O[C@H]2CCCCO2)C1
2492,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1-(9H-Carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol,0.35,uM,=,-0.4559319556497244,0,c1ccc(OCCNCCCOc2cccc3[nH]c4ccccc4c23)cc1
2493,1574698,10.1021/acs.jmedchem.5b01995,,,,Inhibition of human ERG,COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(F)cc3F)C2)nc(C)c1F,"US8541427, 1",1.9,uM,=,0.2787536009528289,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2ccccc2)N1
2494,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(F)cc2)CC1,"US9145392, 10",1.8,uM,=,0.255272505103306,1,c1ccc(-c2c[nH]c(C3CCN(c4ncncc4-c4ccccc4)CC3)n2)cc1
2495,606311,10.1016/j.bmcl.2009.10.133,,,,Inhibition of human ERG channel,FC(F)(F)c1cc(Nc2ccccc2)nc(NCc2ccccn2)n1,"N4-phenyl-N2-(pyridin-2-ylmethyl)-6-(trifluoromethyl)pyrimidine-2,4-diamine",40.1,uM,=,1.6031443726201824,1,c1ccc(Nc2ccnc(NCc3ccccn3)n2)cc1
2496,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(C(F)(F)F)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(6-(trifluoromethyl)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00099,uM,=,-3.0043648054024503,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2497,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(NCc1ccc(Cl)cc1O)C1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,N-(4-chloro-2-hydroxybenzyl)-1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidine-4-carboxamide,1.55,uM,=,0.1903316981702915,1,O=C(NCc1ccccc1)C1CCN(Cc2ccn(-c3ccccc3)c2)CC1
2498,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCN(CCS(C)(=O)=O)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)-N-(2-methoxy-4-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)phenyl)pyrimidin-2-amine",9.4,uM,=,0.9731278535996988,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
2499,1513054,10.1021/ml500531p,,,,Inhibition of human ERG by IonWorks assay,Cc1ncc(CNC2CCN(CCn3c(=O)ccc4ncc(Oc5ccc(S(N)(=O)=O)cc5)cc43)CC2)cc1Cl,"4-(5-(2-(4-((5-chloro-6-methylpyridin-3-yl)methylamino)piperidin-1-yl)ethyl)-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yloxy)benzenesulfonamide",82.0,uM,=,1.9138138523837167,1,O=c1ccc2ncc(Oc3ccccc3)cc2n1CCN1CCC(NCc2cccnc2)CC1
2500,1972831,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,Cc1ccc(C(=O)Nc2ccc(CN3Cc4ccc(O)cc4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12,"N-(3-chloro-4-((5-hydroxyisoindolin-2-yl)methyl)phenyl)-3-(imidazo [1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",0.78,uM,=,-0.1079053973095195,0,O=C(Nc1ccc(CN2Cc3ccccc3C2)cc1)c1cccc(C#Cc2cnc3cccnn23)c1
2501,971921,10.1016/j.bmcl.2013.05.037,,,,Inhibition of human ERG,O=c1ncn(Cc2c(F)cc(F)cc2F)c2ccc(Oc3ccccc3)cc12,"6-phenoxy-1-(2,4,6-trifluorobenzyl)quinazolin-4(1H)-one",3.7,uM,=,0.568201724066995,1,O=c1ncn(Cc2ccccc2)c2ccc(Oc3ccccc3)cc12
2502,1973140,10.1021/acs.jmedchem.0c00245,,,,Inhibition of human ERG,Cc1cc(Cl)cc(-c2ccnc3cc(CN4C(=O)CCC4=O)sc23)c1CN1[C@@H](C)CNC[C@@H]1C,"1-((7-(5-Chloro-2-(((2S,6S)-2,6-dimethylpiperazin-1-yl)methyl)-3-methylphenyl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione",2.7,uM,=,0.4313637641589873,1,O=C1CCC(=O)N1Cc1cc2nccc(-c3ccccc3CN3CCNCC3)c2s1
2503,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,COc1cc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)ccn1,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(2-methoxypyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",3.8,uM,=,0.5797835966168101,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccncc3)C4=O)ccc21
2504,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,COc1nc2ccc(/C=N/O)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,3-(4-(dimethylamino)-2-hydroxy-2-(naphthalen-1-yl)-1-phenylbutyl)-2-methoxyquinoline-6-carbaldehyde oxime,3.5,uM,=,0.5440680443502757,1,c1ccc(C(Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
2505,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,O=C1OCc2cc(CCC3C4CN(C(=O)Cc5ccc(-n6cnnn6)cc5)CC34)ccc21,5-(2-(3-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)-3-azabicyclo[3.1.0]hexan-6-yl)ethyl)isobenzofuran-1(3H)-one,5.0,uM,=,0.6989700043360189,1,O=C1OCc2cc(CCC3C4CN(C(=O)Cc5ccc(-n6cnnn6)cc5)CC34)ccc21
2506,1972154,10.1021/acs.jmedchem.9b01624,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,c1cc(-c2cn(CC3CC3)c3cnccc23)ccn1,"1-(Cyclopropylmethyl)-3-(pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridine",15.5,uM,=,1.1903316981702914,1,c1cc(-c2cn(CC3CC3)c3cnccc23)ccn1
2507,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)C1CCOCC1)C2,"(2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)(tetrahydro-2H-pyran-4-yl)methanone",5.7,uM,=,0.7558748556724915,1,O=C(C1CCOCC1)N1CCc2nc(OCc3conc3-c3ccccc3)ccc2C1
2508,572595,10.1021/jm900581g,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells coexpressing IKr channel protein,Cl.O=c1n(C[C@@H](O)CO)c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1,"4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine hydrochloride",25.0,uM,=,1.3979400086720375,1,O=c1[nH]c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1
2509,1824533,10.1021/acs.jmedchem.9b01295,,,,Inhibition of human ERG,COC[C@H]1Cn2cc(-c3nc(Nc4ccnn4C)ncc3C)cc2C(=O)N1Cc1cccc(C)n1,"(3R)-3-(methoxymethyl)-7-[5-methyl-2[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-2-[(6-methyl-2-pyridyl)methyl]-3,4 dihydropyrrolo[1,2-a]pyrazin-1-one",20.0,uM,=,1.3010299956639813,1,O=C1c2cc(-c3ccnc(Nc4ccn[nH]4)n3)cn2CCN1Cc1ccccn1
2510,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,O=C1OCc2cc(CCC3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21,5-(2-(1-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperidin-4-yl)ethyl)isobenzofuran-1(3H)-one,5.4,uM,=,0.7323937598229685,1,O=C1OCc2cc(CCC3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
2511,1713882,10.1016/j.bmcl.2018.05.030,,,,Inhibition of human ERG expressed in CHO-K1 cells at -90 mV holding potential by Qpatch clamp assay,O=C(CCCc1c[nH]nn1)NC1CCN(C(=O)OCc2cc(Cl)cc(Cl)c2)CC1,"3,5-dichlorobenzyl 4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate",20.9,uM,=,1.320146286111054,1,O=C(CCCc1c[nH]nn1)NC1CCN(C(=O)OCc2ccccc2)CC1
2512,611802,10.1021/jm9015075,,,,Inhibition of human ERG,Cc1ccc2oc(N3CCN4CCC3CC4)nc2n1,"4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]-nonane",40.0,uM,=,1.6020599913279625,1,c1cnc2nc(N3CCN4CCC3CC4)oc2c1
2513,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CC1CC1c1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCN(C)CC2)n1,2-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-6-(2-methylcyclopropyl)-4-(trifluoromethyl)pyridine,34.0,uM,=,1.5314789170422551,1,c1ccc(C2(COCc3cccc(C4CC4)n3)CCNCC2)cc1
2514,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCC[C@@H](CCO)Nc1nc(N)nc2cc(C)ccc12,(S)-3-((2-Amino-7-methylquinazolin-4-yl)amino)hexan-1-ol,8.1,uM,=,0.9084850188786496,1,c1ccc2ncncc2c1
2515,1802440,10.1016/j.ejmech.2018.07.068,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cell membranes after 1 hr by microbeta counting method,O=C(Nc1ccc(Cl)c(Cl)c1)Nc1nccnc1OCc1ccccc1,"1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea",11.3,uM,=,1.0530784434834195,1,O=C(Nc1ccccc1)Nc1nccnc1OCc1ccccc1
2516,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nn(C)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one",32.2,uM,=,1.507855871695831,1,O=c1[nH]nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
2517,1766690,10.1021/acs.jmedchem.8b01147,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method,Cn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N,"4-({4-Amino-6-[3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1H)-yl)-2-(hydroxymethyl)phenyl]-1,3,5-triazin-2-yl}amino)-1-methyl-1H-pyrrole-2-carbonitrile",2.6,uM,=,0.414973347970818,1,O=c1c2ccc(C3CC3)cc2ccn1-c1cccc(-c2ncnc(Nc3cc[nH]c3)n2)c1
2518,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nnc(C)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"2-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,3,4-oxadiazole",8.5,uM,=,0.9294189257142929,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4nnco4)N3)n2)nc1
2519,958294,10.1016/j.bmcl.2013.03.047,,,,Inhibition of human ERG channel in HEK293 cells by voltage-gated patch clamp technique,COc1ccc2nccc([C@@H](O)CC[C@@H]3CCN(C4CC(c5cc(F)cc(F)c5)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-1-(3-(3,5-difluorophenyl)cyclobutyl)-4-((S)-3-hydroxy-3-(6-methoxyquinolin-4-yl)propyl)piperidine-3-carboxylic acid",7.18,uM,=,0.8561244442423004,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
2520,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cnc2cc(Cl)c(-c3cccnc3)cc2c1NC1CCOCC1,7-Chloro-6-(3-pyridinyl)-4-(tetrahydro-2H-pyran-4-ylamino)-3-quinolinecarboxamide,1.2,uM,=,0.0791812460476248,1,c1cncc(-c2ccc3nccc(NC4CCOCC4)c3c2)c1
2521,948139,10.1016/j.bmcl.2013.01.019,,,,Inhibition of human ERG,C[C@@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ncc(-c4ccccc4)nc3n2)C[C@H](C)O1,"(2R,6S)-2,6-dimethyl-4-(4-((S)-3-methylmorpholino)-7-phenylpteridin-2-yl)morpholine",13.2,uM,=,1.1205739312058498,1,c1ccc(-c2cnc3c(N4CCOCC4)nc(N4CCOCC4)nc3n2)cc1
2522,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H]3CNCC[C@@H]3O2)cc1,"(4aS,8aS)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-4a,5,6,7,8,8a-hexahydro-4H-pyrido[3,4-e][1,3]oxazine",21.0,uM,=,1.3222192947339193,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H]3CNCC[C@@H]3O2)cc1
2523,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,Cc1ncccc1-c1nc2cn(-c3ccccc3)nc2c(=O)n1C[C@H]1CCCN(C[C@H]2CCCO2)C1,"5-(2-Methylpyridin-3-yl)-2-phenyl-6-(((S)-1-(((R)-tetrahydrofuran-2-yl)methyl)piperidin-3-yl)methyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",12.0,uM,=,1.0791812460476249,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2cccnc2)n1C[C@H]1CCCN(C[C@H]2CCCO2)C1
2524,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C(Cc1ccc(-n2cnnn2)cc1)N1CCN(CCc2ccc3c(c2)COC3)CC1,"2-(4-(1H-tetrazol-1-yl)phenyl)-1-(4-(2-(1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethanone",2.5,uM,=,0.3979400086720376,1,O=C(Cc1ccc(-n2cnnn2)cc1)N1CCN(CCc2ccc3c(c2)COC3)CC1
2525,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,N#Cc1ccc2c(c1)N(CCN1CCC(NCc3ccc4c(n3)NC(=O)CO4)CC1)C(=O)CO2,"3-oxo-4-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)piperidin-1-yl)ethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonitrile",41.0,uM,=,1.6127838567197357,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccccc54)CC3)nc2N1
2526,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc(-c2ccccc2)cc1)Cc1ccc2c(c1)OCCC2.Cl,(E)-N-(Chroman-7-methyl)-N-methyl-3-(4-biphenyl)prop-2-en-1-amine Hydrochloride,32.1,uM,=,1.506505032404872,1,C(=C/c1ccc(-c2ccccc2)cc1)\CNCc1ccc2c(c1)OCCC2
2527,2153986,10.1021/acsmedchemlett.1c00660,,,,Inhibition on hERG expressed in HEK293 cells by Qpatch method,O=C(NCCN1CCCCC1)c1cccn2c(=O)c3ccc4ccccc4c3nc12,"7-oxo-N-(2-(piperidin-1-yl)ethyl)-7H-benzo[h]pyrido[2,1-b]quinazoline-12-carboxamide",3.72,uM,=,0.5705429398818975,1,O=C(NCCN1CCCCC1)c1cccn2c(=O)c3ccc4ccccc4c3nc12
2528,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,COC(=O)N1Cc2cc(S(C)(=O)=O)ccc2C1C(=O)Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,"methyl 5-methylsulfonyl-1-[[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]carbamoyl]isoindoline-2-carboxylate",14.7,uM,=,1.167317334748176,1,O=C(Nc1ccccc1)C1NCc2ccccc21
2529,876604,10.1021/jm301476b,,,,Inhibition of human ERG expressed in chinese hamster lung cells by IonWorks patch clamp electrophysiology assay,COc1ccc(-c2cc(-c3ccc(S(=O)(=O)NC4CC4)cc3)cnc2N)cn1,3-(6-methoxypyridin-3-yl)-5-(4-N-(cyclopropylsulfonamide)phenyl)pyridin-2-amine,2.1,uM,=,0.3222192947339193,1,O=S(=O)(NC1CC1)c1ccc(-c2cncc(-c3cccnc3)c2)cc1
2530,1640440,,,,,"hERG Patch Clamp Assay: All testing was carried out in CHO cells transfected with the hERG gene purchased from Millipore (PrecisION hERG-CHO Recombinant Cell Line CYL3038). The cell line was grown in DMEM/F-12, GlutaMAX with 10% fetal bovine serum, 1% Penicillin-Streptomycin, 1% Geneticin and 1% of 1M HEPES buffer solution, and maintained at approximately 37 °C. in a humidified atmosphere containing 5% carbon dioxide. The cells were passaged every 3-5 days based on confluency. On the day of the experiment, 50%-80% confluent cells were harvested from a 175 cm2 culture flask using Detachin. After 10 minutes of exposure to Detachin at 37 °C., the cells were centrifuged for 1 minute at 1000 RPM. The supernatant was removed and the cell pellet was reconstituted in 5-8 mL of serum free media with 2.5% of 1M HEPES, placed on the Qstirrer, and allowed to recover. After a 30 minute recovery period, experiments were initiated.",C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3ccc(OC(F)F)cn3)cs2)CO1,"US9315520, 1::US9315520, Comparator 1::US9315520, Example 1::US9315520, Example 2",23.6,uM,=,1.3729120029701067,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccn1
2531,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,Cc1ccccc1CN1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,endo-3-(8-(2-methylbenzyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.00062,uM,=,-3.207608310501746,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
2532,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,NC(=O)c1ccc(N[C@H]2CCCNC2)c2cc(-c3ccc(F)cc3)[nH]c12,2-(4-Fluorophenyl)-4-[(3S)-piperidin-3-ylamino]-1H-indole-7-carboxamide,6.7,uM,=,0.8260748027008264,1,c1ccc(-c2cc3c(N[C@H]4CCCNC4)cccc3[nH]2)cc1
2533,795949,10.1016/j.bmcl.2011.10.125,,,,Inhibition of human ERG by rubidium [86Rb] efflux assay,CC(=O)N[C@@H]1CC2(CCN(Cc3ccc4c(c3)c3ccccc3n4C(N)=O)CC2)c2ccccc21,"(R)-3-((3-acetamido-2,3-dihydrospiro[indene-1,4'-piperidine]-1'-yl)methyl)-9H-carbazole-9-carboxamide",2.0,uM,=,0.3010299956639812,1,c1ccc2c(c1)CCC21CCN(Cc2ccc3[nH]c4ccccc4c3c2)CC1
2534,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,O=C(Cn1cnc(C2CC2)n1)N1CCN(c2sc(C(F)(F)F)nc2-c2cnc(C(F)(F)F)nc2)C[C@H]1CCO,"2-(3-Cyclopropyl-[1,2,4]triazol-1-yl)-1-((R)-2-(2-hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-ethanone",0.0073,uM,=,-2.136677139879544,0,O=C(Cn1cnc(C2CC2)n1)N1CCN(c2scnc2-c2cncnc2)CC1
2535,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C(NC(c1ccccc1)c1ccccc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1,"(1R,2R,4R)-N-benzhydryl-4-morpholino-2-phenylcyclohexanecarboxamide",0.17,uM,=,-0.7695510786217261,0,O=C(NC(c1ccccc1)c1ccccc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
2536,540677,10.1016/j.bmcl.2008.12.083,,,,Inhibition of human ERG,Nc1ccc(-c2cccs2)cc1NC(=O)c1ccc(C(=O)N2CCC3(CCCN3)CC2)cc1,"N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(1,8-diazaspiro[4.5]decane-8-carbonyl)benzamide",25.09,uM,=,1.3995006613146106,1,O=C(Nc1cccc(-c2cccs2)c1)c1ccc(C(=O)N2CCC3(CCCN3)CC2)cc1
2537,580799,10.1016/j.bmcl.2009.06.095,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells overexpressing Ikr channel protein,Cc1ccc(-n2c(-c3ncccc3Cl)nc(CNC3CCCC3)c2C)cn1,N-((2-(3-chloropyridin-2-yl)-5-methyl-1-(6-methylpyridin-3-yl)-1H-imidazol-4-yl)methyl)cyclopentanamine,19.0,uM,=,1.2787536009528289,1,c1ccc(-c2nc(CNC3CCCC3)cn2-c2cccnc2)nc1
2538,1912248,10.1021/acs.jmedchem.9b00443,,,,Inhibition of human ERG by fluorescence polarization assay,CNC(=O)c1cnc(Nc2ccc(N3CCOCC3)cn2)cc1Nc1ccccc1S(C)(=O)=O,N-Methyl-4-((2-(methylsulfonyl)phenyl)amino)-6-((5-morpholinopyridin-2-yl)amino)nicotinamide,40.0,uM,=,1.6020599913279625,1,c1ccc(Nc2ccnc(Nc3ccc(N4CCOCC4)cn3)c2)cc1
2539,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C(=O)Nc2cncc(-c3cc(Cl)cc(Cl)c3)c2N2CCC(N)CC2)n(C)n1,"N-(4-(4-aminopiperidin-1-yl)-5-(3,5-dichlorophenyl)pyridin-3-yl)-1,3-dimethyl-1H-pyrazole-5-carboxamide",4.9,uM,=,0.6901960800285137,1,O=C(Nc1cncc(-c2ccccc2)c1N1CCCCC1)c1ccn[nH]1
2540,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3ccc(C(C)(C)C)cc3)nn2)ccc1-n1cnc(C)c1,"1-(4-tert-butylbenzyl)-4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazole",0.39,uM,=,-0.4089353929735008,0,c1ccc(Cn2cc(-c3ccc(-n4ccnc4)cc3)nn2)cc1
2541,1515505,10.1021/ml500440u,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,[2H]C([2H])([2H])Oc1cc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N,"6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-(methoxy-d3)nicotinonitrile",30.0,uM,=,1.4771212547196624,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
2542,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Fc1cc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)ccn1,"2-(1,4'-bipiperidin-1'-yl)-6-(2-fluoropyridin-4-yl)thiazolo[4,5-b]pyridine",0.2040816327,uM,=,-0.690196079928626,0,c1cc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)ccn1
2543,1992475,10.1021/acs.jmedchem.0c01199,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by IonWorks barracuda patch clamp method,COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1OC,"1-[4-[4-methyl-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenyl]piperazine",8.3,uM,=,0.919078092376074,1,c1ccc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2)cc1
2544,2219922,10.1016/j.bmcl.2021.128463,,,,Inhibition of human ERG expressed in HEK cells by voltage clamp assay,CC1(C)C(=N)N[C@](C)(c2nc(NC(=O)c3ccc(C#N)cn3)ccc2F)CS1(=O)=O,"(R)-5-cyano-N-(5-fluoro-6-(5-imino-3,6,6-trimethyl-1,1-dioxidothiomorpholin-3-yl)pyridin-2-yl)picolinamide",5.8,uM,=,0.7634279935629373,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3ccccn3)n2)N1
2545,1972154,10.1021/acs.jmedchem.9b01624,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,c1ccc(Cn2cc(-c3ccncc3)c3ccncc32)cc1,"1-Benzyl-3-(pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridine",5.7,uM,=,0.7558748556724915,1,c1ccc(Cn2cc(-c3ccncc3)c3ccncc32)cc1
2546,804280,10.1016/j.bmcl.2011.12.124,,,,Inhibition of human Erg by voltage ion flux electrophysiological assay,Cn1c2c(c3cc(C(=O)N4CCCCC4)ccc31)CN(C1CCOCC1)CC2,"(5-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)(piperidin-1-yl)methanone",18.0,uM,=,1.255272505103306,1,O=C(c1ccc2[nH]c3c(c2c1)CN(C1CCOCC1)CC3)N1CCCCC1
2547,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CN(C)Cc1ccccc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)phenyl)-N,N-dimethylmethanamine",2.12,uM,=,0.3263358609287514,1,c1ccc(Oc2ccccc2)cc1
2548,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,Cc1cc(CC(C)(C)O)cc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)cnc2C(N)=O)n1,"5-(((1R,2S)-2-aminocyclohexyl)amino)-3-((4-(2-hydroxy-2-methylpropyl)-6-methylpyridin-2-yl)amino)picolinamide",5.9,uM,=,0.7708520116421442,1,c1ccc(Nc2cncc(NC3CCCCC3)c2)nc1
2549,763235,10.1016/j.ejmech.2011.05.015,,,,Inhibition of wild-type human ERG channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique,CCCCN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C.Cl,Dextro-(R)-bupivacaine hydrochloride,84.0,uM,=,1.9242792860618816,1,O=C(Nc1ccccc1)[C@H]1CCCCN1
2550,1935939,10.1016/j.bmc.2019.02.025,,,,Inhibition of human ERG by manual patch clamp electrophysiology assay,COc1cccc(C(c2cc3cc(Br)ccc3nc2OC)C(O)(CCN(C)C)c2cnc(C)cc2C)c1OC,"rac-1-(6-bromo-2-methoxyquinolin-3-yl)-1-(2,3-dimethoxyphenyl)-4-(dimethylamino)-2-(4,6-dimethylpyridin-3-yl)butan-2-ol",3.9,uM,=,0.5910646070264992,1,c1ccc(C(Cc2cccnc2)c2cnc3ccccc3c2)cc1
2551,621608,10.1016/j.bmcl.2009.09.024,,,,Inhibition of human ERG expressed in CHO cells by patch clamp technique,CCOc1cc(CN2CCC(Nc3nc4cc(S(=O)(=O)CC)ccc4o3)CC2)ccc1OC,N-(1-(3-ethoxy-4-methoxybenzyl)piperidin-4-yl)-5-(ethylsulfonyl)benzo[d]oxazol-2-amine,0.18,uM,=,-0.744727494896694,0,c1ccc(CN2CCC(Nc3nc4ccccc4o3)CC2)cc1
2552,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,Cc1cc(CNc2nc(N)nc3ccn(Cc4ccccn4)c23)no1,"N4-((5-Methylisoxazol-3-yl)methyl)-5-(pyridin-2-ylmethyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine",1.2,uM,=,0.0791812460476248,1,c1ccc(Cn2ccc3ncnc(NCc4ccon4)c32)nc1
2553,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,Cc1ncc(-c2ccnc(Nc3ccc(C(N)=O)c(F)c3)n2)n1C(C)C,2-fluoro-4-(4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)benzamide,10.0,uM,=,1.0,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
2554,1501722,10.1021/acs.jmedchem.5b00742,,,,Inhibition of [3H]-astemizole binding to human ERG expressed in HEK293 cells,Cc1cc(C)nc(N2C[C@H]3CN(C(=O)c4cccc(F)c4-n4nccn4)C[C@H]3C2)n1,"((3aR,6aS)-5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone",6.0,uM,=,0.7781512503836436,1,O=C(c1ccccc1-n1nccn1)N1C[C@@H]2CN(c3ncccn3)C[C@@H]2C1
2555,1522961,10.1016/j.bmcl.2015.04.057,,,,Inhibition of human ERG,Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4c(C)cc(Cl)cc4[nH]3)c(Cl)c2)n1,"(R)-2,6-dichloro-N-(2-(6-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-(3-fluorophenyl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",3.051,uM,=,0.4844422076424071,1,O=C(NC[C@@H](c1ccccc1)c1nc2ccccc2[nH]1)c1ccc(-n2cncn2)cc1
2556,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,CC(C)CN(C(=O)c1cccc(C(F)(F)F)c1Cl)[C@H]1CCNC1,(S)-2-chloro-N-isobutyl-N-(pyrrolidin-3-yl)-3-(trifluoromethyl)benzamide,4.12,uM,=,0.6148972160331346,1,O=C(N[C@H]1CCNC1)c1ccccc1
2557,537242,10.1021/jm800569w,,,,"Antagonist activity at human ERG in HEK293 cells assessed as inhibition of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide binding",Cc1nc2cc(Cl)ccc2c(=O)n1-c1ccc(OC2CCN(C3CCC3)CC2)cc1,7-Chloro-3-(4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl)-2-methyl-4(3H)-quinazolinone,3.9,uM,=,0.5910646070264992,1,O=c1c2ccccc2ncn1-c1ccc(OC2CCN(C3CCC3)CC2)cc1
2558,1992475,10.1021/acs.jmedchem.0c01199,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by IonWorks barracuda patch clamp method,COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C#N)cc(OC)c1OC,"3-(4-(Piperazin-1-yl)phenyl)-5-(3,4,5-trimethoxyphenyl)isonicotinonitrile",6.0,uM,=,0.7781512503836436,1,c1ccc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2)cc1
2559,1990506,10.1016/j.bmc.2020.115548,,,,Inhibition of human ERG,Nc1ncnc2c1c(-c1ccc3cc[nH]c3c1)cn2-c1ccc(OCCNCCO)cc1,"2-[2-[4-[4-amino-5-(1H-indol-6-yl)pyrrolo[2,3-d]pyrimidin-7-yl]phenoxy]ethylamino]ethanol",2.8,uM,=,0.4471580313422192,1,c1ccc(-n2cc(-c3ccc4cc[nH]c4c3)c3cncnc32)cc1
2560,1622464,10.1016/j.bmcl.2016.09.067,,,,Inhibition of radiolabeled dofetilide binding to human ERG expressed in HEK293 cells,C[C@@H]1CC[C@H](N)CN1c1ccncc1Nc1ncc2ccc(-c3c(F)cccc3F)nn12,"N-(4-((2R,5S)-5-amino-2-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-amine",19.7,uM,=,1.294466226161593,1,c1ccc(-c2ccc3cnc(Nc4cnccc4N4CCCCC4)n3n2)cc1
2561,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1(C)OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,"2,2-dimethyl-4-phenyl-9-(2-phenylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.1,uM,=,-1.0,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
2562,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(Cc2cc[n+](C)c(COc3ccc(C)cc3)c2)cc1.O=S(=O)([O-])C(F)(F)F,1-methyl-4-(4-methylbenzyl)-2-(p-tolyloxymethyl)pyridinium trifluoromethanesulfonate,0.346,uM,=,-0.4609239012072234,0,c1ccc(Cc2cc[nH+]c(COc3ccccc3)c2)cc1
2563,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,COc1ccc(C(NC(=O)CC2CCN(Cc3ccn(-c4ccc(C(F)(F)F)cc4)c3)CC2)c2ccc(F)cc2)cn1,N-((4-fluorophenyl)(6-methoxypyridin-3-yl)methyl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,1.75,uM,=,0.2430380486862944,1,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(c1ccccc1)c1cccnc1
2564,2048454,10.1016/j.bmc.2020.115734,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,COc1nc(-c2csc(Nc3c4c(nn3CCF)CCC4)n2)ccc1-n1cnc(C)c1,"N-(2-(2-fluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",2.88,uM,=,0.4593924877592308,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCC5)n3)nc2)cn1
2565,2022324,10.1021/acs.jmedchem.0c01163,,,,Inhibition of human ERG by plate-based planar patch clamp technique,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F,CAMIZESTRANT,22.0,uM,=,1.3424226808222062,1,c1cc([C@H]2NCCc3c2ccc2[nH]ncc32)ncc1NC1CNC1
2566,2026986,10.1021/acs.jmedchem.6b01099,,,,Inhibition of human ERG by patch clamp assay,O=C(O)C1CN(Cc2ccc3c(c2)CCc2c-3noc2-c2onc(-c3ccccc3)c2C(F)(F)F)C1,"US9216972, 7",2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cc(-c3onc4c3CCc3cc(CN5CCC5)ccc3-4)on2)cc1
2567,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3ccc(CS(C)(=O)=O)cc3)cc12,4-[(2-Ethylbutyl)amino]-6-{4-[(methylsulfonyl)methyl]phenyl}-3-quinolinecarboxamide,2.1,uM,=,0.3222192947339193,1,c1ccc(-c2ccc3ncccc3c2)cc1
2568,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ncccc2C(F)(F)F)C1=O,"2-methyl-9-(2-phenylethyl)-4-[3-(trifluoromethyl)-2-pyridyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",8.2,uM,=,0.9138138523837168,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccn1
2569,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C(F)(F)F,"6-((1-(2-(6-(dimethylamino)-7-(trifluoromethyl)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00229,uM,=,-2.640164517660112,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2570,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc([C@H]2CN(NS(C)(=O)=O)C(=O)N2CCc2ccc(OC(F)(F)F)cc2)cc1,1-(Methylsulfonylamino)-3-[2-(4-trifluoromethoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone,5.6,uM,=,0.7481880270062004,1,O=C1NC[C@H](c2ccccc2)N1CCc1ccccc1
2571,1525287,10.1016/j.bmcl.2015.09.045,,,,Inhibition of human ERG expressed in HEK293 cells by whole-cell patch clamp method,O=C(c1ccc(F)cc1F)C1CCN(CCCOc2ccc(-c3nc4ccccc4o3)cc2)CC1,"(1-(3-(4-(benzo[d]oxazol-2-yl)phenoxy)propyl)piperidin-4-yl)(2,4-difluorophenyl)methanone",0.85,uM,=,-0.0705810742857072,0,O=C(c1ccccc1)C1CCN(CCCOc2ccc(-c3nc4ccccc4o3)cc2)CC1
2572,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,Cc1ccccc1C1CCN(C[C@@H]2CCc3c(C)cccc3[C@@H](O)C2)CC1,"cis-1-methyl-7-((4-o-tolylpiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol",0.086,uM,=,-1.0655015487564323,0,c1ccc(C2CCN(CC3CCc4ccccc4CC3)CC2)cc1
2573,609460,10.1016/j.bmcl.2009.12.026,,,,Inhibition of human ERG,O=C(c1cc(Cc2c[nH]c(=O)c3cc(Cl)c(Cl)n23)ccc1F)N1CCC(N2CCCC2)CC1,"6,7-dichloro-4-(4-fluoro-3-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)benzyl)pyrrolo[1,2-a]pyrazin-1(2H)-one",8.0,uM,=,0.9030899869919436,1,O=C(c1cccc(Cc2c[nH]c(=O)c3cccn23)c1)N1CCC(N2CCCC2)CC1
2574,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,O=C(N1CCc2ncc(C(F)(F)F)cc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2,"((2R,3aR,6aR)-2-(tetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",25.7,uM,=,1.4099331233312946,1,O=C(N1CCc2ncccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
2575,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,NC(=O)N1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOc5ccccc5)c4)n[nH]c2-3)CC1,"4-((3-(5-(3-phenoxyprop-1-ynyl)thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)methyl)piperazine-1-carbaldehyde",5.36,uM,=,0.72916478969277,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)COc1ccccc1
2576,1654660,10.1016/j.bmcl.2016.12.033,,,,Inhibition of human ERG,O=C(c1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)N1CCN(Cc2nnn(CC3CC3)n2)CC1,"(4-((2-(cyclopropylmethyl)-2H-tetrazol-5-yl)methyl)piperazin-1-yl)(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)methanone",39.38,uM,=,1.5952757118020997,1,O=C(c1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)N1CCN(Cc2nnn(CC3CC3)n2)CC1
2577,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,CN(C)CCn1ncc2cc(-n3ccc(OCc4ccccc4)cc3=O)ccc21,4-(benzyloxy)-1-(1-(2-(dimethylamino)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,1.8,uM,=,0.255272505103306,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2[nH]ncc2c1
2578,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1.O=S(=O)(O)O,(E)-5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol sulfate,0.26,uM,=,-0.585026652029182,0,c1ccc(/N=N/c2ccccn2)cc1
2579,304709,10.1016/j.bmcl.2005.03.025,,,,Mean inhibitory concentration against potassium channel HERG,COc1ccc([C@@H](O)C[C@H]2c3cc(OC)c(OC)cc3CCN2C)cc1,"(S)-2-((S)-6,7-Dimethoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)-1-(4-methoxy-phenyl)-ethanol",0.79,uM,=,-0.1023729087095585,0,c1ccc(CC[C@@H]2NCCc3ccccc32)cc1
2580,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,Cc1cc(C)nc(Nc2cc(NC[C@@H](N)CCS(C)(=O)=O)cnc2C(N)=O)c1,"(S)-5-((2-amino-4-(methylsulfonyl)butyl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide",14.0,uM,=,1.146128035678238,1,c1ccc(Nc2cccnc2)nc1
2581,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(CC(F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(rac)-6-((1-(1-fluoro-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.2,uM,=,0.505149978319906,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2582,1694220,10.1016/j.bmc.2017.07.040,,,,Inhibition of human ERG,Cc1nc2n(c(=O)c1CCN1CCN(c3cccc4sccc34)CC1)CCCC2,"3-(2-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one",2.67,uM,=,0.4265112613645752,1,O=c1c(CCN2CCN(c3cccc4sccc34)CC2)cnc2n1CCCC2
2583,1288300,10.1016/j.bmcl.2013.12.078,,,,Inhibition of human ERG by whole-cell patch clamp method,COC(=O)C(CCC(=O)N1CCN(c2ccccc2OC)CC1)(c1ccc(Br)cc1)C(C)C,methyl 2-(4-bromophenyl)-2-isopropyl-5-(4-(2-methoxyphenyl)piperazin-1-yl)-5-oxopentanoate,16.8,uM,=,1.2253092817258628,1,O=C(CCCc1ccccc1)N1CCN(c2ccccc2)CC1
2584,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(NCc1ccc(F)cc1)N(c1ccc(Br)cc1)C1CCN(C2CCCC2)CC1,1-(4-bromophenyl)-1-(1-cyclopentylpiperidin-4-yl)-3-(4-fluorobenzyl)urea,0.202,uM,=,-0.6946486305533762,0,O=C(NCc1ccccc1)N(c1ccccc1)C1CCN(C2CCCC2)CC1
2585,558278,10.1016/j.bmcl.2008.10.034,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1nc2ccccc2c(=O)n1-c1ccc(OCCCN2CCCCC2)cc1,2-methyl-3-(4-(3-(piperidin-1-yl)propoxy)phenyl)quinazolin-4(3H)-one,7.9,uM,=,0.8976270912904415,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCCC2)cc1
2586,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,N#Cc1cnc(Nc2cc(NC[C@H]3CNCCO3)c(C(F)(F)F)cn2)cn1,(R)-5-(4-(morpholin-2-ylmethylamino)-5-(trifluoromethyl)pyridin-2-ylamino)pyrazine-2-carbonitrile,6.2,uM,=,0.7923916894982539,1,c1cnc(Nc2cc(NC[C@H]3CNCCO3)ccn2)cn1
2587,2193908,10.1016/j.ejmech.2022.114611,,,,Inhibition of hERG,C=CC(=O)N1CC=C(c2c[nH]c3ncnc(-c4ccc(CNC(=O)c5ccccc5)c(F)c4)c23)CC1,"N-(4-(5-(1-acryloyl-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-fluorobenzyl)benzamide",4.38,uM,=,0.6414741105040995,1,O=C(NCc1ccc(-c2ncnc3[nH]cc(C4=CCNCC4)c23)cc1)c1ccccc1
2588,2051562,10.1021/acs.jmedchem.0c01573,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,C[C@@H](c1cc(OCC(F)F)ccn1)n1cnc2c(N)nc(Cl)nc21,"(S)-2-chloro-9-(1-(4-(2,2-difluoroethoxy)pyridin-2-yl)ethyl)-9H-purin-6-amine",18.0,uM,=,1.255272505103306,1,c1ccc(Cn2cnc3cncnc32)nc1
2589,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(C(=O)NCC2CCN(C(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc1C(C)(C)C,"N-((1-(6,6-bis(4-fluorophenyl)hexanoyl)pyrrolidin-3-yl)methyl)-3,5-di-tert-butyl-4-methoxybenzamide",1.9,uM,=,0.2787536009528289,1,O=C(NCC1CCN(C(=O)CCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
2590,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1n[nH]c(C)c1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,"(R)-2-(3,5-dimethyl-1H-pyrazol-4-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline",40.0,uM,=,1.6020599913279625,1,c1cc2nc(-c3cn[nH]c3)ccc2cc1CCN1CCCC1
2591,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn([C@H]3CC[C@H](c4ccccc4)CN(Cc4ccccc4)C3=O)nn2)ccc1-n1cnc(C)c1,"(3S,6R)-1-benzyl-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-6-phenylazepan-2-one",0.2,uM,=,-0.6989700043360187,0,O=C1[C@@H](n2cc(-c3ccc(-n4ccnc4)cc3)nn2)CC[C@H](c2ccccc2)CN1Cc1ccccc1
2592,1364766,10.1021/jm4014746,,,,Inhibition of human ERG,CC1CN(CC(=O)N[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)S(=O)(=O)N(c2c(Cl)cc(Cl)cc2Cl)C1,"rac-(E)-4-{2-[4-Methyl-1,1-dioxidoo-6-(2,4,6-trichlorophenyl)-1,2,6-thiadiazinan-2-yl]-acetamido}-adamantane-1-carboxamide",37.0,uM,=,1.568201724066995,1,O=C(CN1CCCN(c2ccccc2)S1(=O)=O)NC1C2CC3CC(C2)CC1C3
2593,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C(Cc1ccc(-n2cnnn2)cc1)N1CCN(CCc2ccc3nonc3c2)CC1,"2-(4-(1H-tetrazol-1-yl)phenyl)-1-(4-(2-(benzo[c][1,2,5]oxadiazol-5-yl)ethyl)piperazin-1-yl)ethanone",1.3,uM,=,0.1139433523068367,1,O=C(Cc1ccc(-n2cnnn2)cc1)N1CCN(CCc2ccc3nonc3c2)CC1
2594,1831533,10.1016/j.ejmech.2018.11.018,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 2.5 mins by Qpatch clamp assay,O=[N+]([O-])c1ccc2c(c1)ncn2Cc1ccc(O)c2ncccc12,5-(1H-5-Nitro-benzimidazol-1-ylmethyl)-8-quinolinol,22.0,uM,=,1.3424226808222062,1,c1cc(Cn2cnc3ccccc32)c2cccnc2c1
2595,872803,10.1021/jm300991n,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CC1=NC(c2cccc(-c3cccnc3)c2)(C2CCCCC2)N=C1N,2-Cyclohexyl-5-methyl-2-(3-(pyridin-3-yl)phenyl)-2H-imidazol-4-amine,28.8,uM,=,1.4593924877592308,1,C1=NC(c2cccc(-c3cccnc3)c2)(C2CCCCC2)N=C1
2596,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCCC[C@@H](CCO)Nc1nc(N)nc2cc(OC)ccc12,(S)-3-((2-Amino-7-methoxyquinazolin-4-yl)amino)heptan-1-ol,3.2,uM,=,0.505149978319906,1,c1ccc2ncncc2c1
2597,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4csc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"4-{4-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-phenyl}-thiophene-2-carboxylic acid",8.0,uM,=,0.9030899869919436,1,O=C1N(c2ccc(-c3ccsc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
2598,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2C(=O)c1cccc(Cl)c1,"(R)-N-(1-(5-(3-chlorobenzoyl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)-4-fluorobenzamide",23.0,uM,=,1.3617278360175928,1,O=C(NCc1ccc2c(n1)CCCN2C(=O)c1ccccc1)c1ccccc1
2599,726964,10.1016/j.bmcl.2011.01.019,,,,Inhibition of human ERG,CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1.Cl,"1-(1-(3,4-dichlorophenyl)cyclohexyl)-N,N-dimethylethanamine hydrochloride",40.0,uM,=,1.6020599913279625,1,c1ccc(C2CCCCC2)cc1
2600,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CC(C)(O)CN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"1-((1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)(4-chlorophenethyl)amino)-2-methylpropan-2-ol",19.0,uM,=,1.2787536009528289,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
2601,1348051,10.1016/j.bmcl.2014.03.075,,,,Inhibition of human ERG by Q-patch assay,Cc1c[nH]c2c(Nc3nc(N[C@@H]4CCCC[C@@H]4N)cc4cc[nH]c(=O)c34)cccc12,"6-((1R,2S)-2-aminocyclohexylamino)-8-(3-methyl-1H-indol-7-ylamino)-2,7-naphthyridin-1(2H)-one",8.2,uM,=,0.9138138523837168,1,O=c1[nH]ccc2cc(NC3CCCCC3)nc(Nc3cccc4cc[nH]c34)c12
2602,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,COc1ccc2ncc(=O)n(CCN3CCC(NCc4cnc(C)c(C#N)c4)CC3)c2n1,"5-((1-(2-(6-Methoxy-3-oxopyrido[3,2-b]pyrazin-4(3H)-yl)-ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile",13.0,uM,=,1.1139433523068367,1,O=c1cnc2cccnc2n1CCN1CCC(NCc2cccnc2)CC1
2603,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,COC[C@H]1CCCN1CCn1ncc2cc(-n3ccc(OCc4ccccc4)cc3=O)ccc21,(R)-4-(benzyloxy)-1-(1-(2-(2-(methoxymethyl)pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,0.8,uM,=,-0.0969100130080563,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
2604,443485,10.1016/j.bmcl.2007.03.006,,,,Inhibition of hERG expressed in CHO cells by cell voltage clamp assay,CN(C)C(=O)N1CC(c2cc(F)ccc2F)=C[C@@]1(CCCN)c1ccccc1,"(S)-2-(3-aminopropyl)-4-(2,5-difluorophenyl)-N,N-dimethyl-2-phenyl-2H-pyrrole-1(5H)-carboxamide",7.1,uM,=,0.8512583487190752,1,C1=C(c2ccccc2)CNC1c1ccccc1
2605,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCNS(=O)(=O)c5ccccc5)c4)n[nH]c2-3)CC1,"N-(3-(4-(6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno-[1,2-c]pyrazol-3-yl)thiophen-2-yl)prop-2-ynyl)benzenesulfonamide",4.87,uM,=,0.6875289612146344,1,O=S(=O)(NCC#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)c1ccccc1
2606,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2F)C1=O,"4-(2-Fluorophenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",1.2,uM,=,0.0791812460476248,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
2607,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CCC(Oc4ccc(CN5CCCC5)nc4)CC3)o2)cc1,"(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)(4-(6-(pyrrolidin-1-ylmethyl)pyridin-3-yloxy)piperidin-1-yl)methanone",25.0,uM,=,1.3979400086720375,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCCC3)nc2)CC1
2608,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2cc3c(cc2F)ncc2c3n([C@@H](C)C3CCOCC3)c(=O)n2C)cn1,"(S)-7-Fluoro-8-(6-(methoxymethyl)pyridin-3-yl)-3-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",15.0,uM,=,1.1760912590556811,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1CC1CCOCC1
2609,498774,10.1021/jm900110t,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",Fc1ccc(C2(c3ccc(F)cc3)CNC(c3cnccn3)=N2)cc1,"2-(4,4-bis(4-fluorophenyl)-4,5-dihydro-1H-imidazol-2-yl)pyrazine",3.4,uM,=,0.5314789170422551,1,c1ccc(C2(c3ccccc3)CNC(c3cnccn3)=N2)cc1
2610,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc2ccccc2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,2-Methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,10.0,uM,=,1.0,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
2611,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc(C(F)F)cc1)Cc1ccc2c(c1)OCCC2.Cl,(E)-N-(Chroman-7-methyl)-N-methyl-3-(4-difluoromethylphenyl)prop-2-en-1-amine Hydrochloride,1.9,uM,=,0.2787536009528289,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)OCCC2
2612,304964,10.1016/j.bmcl.2004.09.065,,,,Inhibitory activity against human Potassium channel HERG,NCc1ccc(F)c(C2CCN(C(=O)c3cc(C(=O)O)cc(-c4nc(-c5cccs5)no4)c3)CC2)c1,"3-[4-(5-Aminomethyl-2-fluoro-phenyl)-piperidine-1-carbonyl]-5-(3-thiophen-2-yl-[1,2,4]oxadiazol-5-yl)-benzoic acid",76.8,uM,=,1.885361220031512,1,O=C(c1cccc(-c2nc(-c3cccs3)no2)c1)N1CCC(c2ccccc2)CC1
2613,538846,10.1021/jm800830n,,,,Inhibition of human ERG,O=C(NCC1CCN(Cc2ccc(Br)nc2)CC1)c1cc(Cl)cc(Cl)c1,"N-({1-[(6-bromopyridin-3-yl)methyl]piperidin-4-yl}methyl)-3,5-dichlorobenzamide",0.655,uM,=,-0.1837587000082169,0,O=C(NCC1CCN(Cc2cccnc2)CC1)c1ccccc1
2614,2194946,10.1021/acs.jmedchem.2c01064,,,,Inhibition of hERG expressed in CHO cells Qpatch-clamp electrophysiology assay,O=c1oc2cc(O)ccc2c2oc3ccc4c(c3c12)CN(C1CCCC1)CO4,"2-Cyclopentyl-10-hydroxy-2,3-dihydro-1H,13H-chromeno-[4',3':2,3]benzofuro[4,5-e][1,3]oxazin-13-one",0.52,uM,=,-0.2839966563652008,0,O=c1oc2ccccc2c2oc3ccc4c(c3c12)CN(C1CCCC1)CO4
2615,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2ncc(F)c([C@@H](O)CC[C@@H]3CCN(C4CC(c5cc(F)ccc5F)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-1-(3-(2,5-difluorophenyl)cyclobutyl)-4-((S)-3-(3-fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl)piperidine-3-carboxylic acid",85.9,uM,=,1.9339931638312424,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
2616,2135561,10.1021/acs.jmedchem.1c01067,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by patch clamp assay,NC(=O)c1ccn(-c2ccc(NCC3(c4ncccc4F)CCC3)nn2)c1,1-(6-((1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyridazin-3-yl)-1H-pyrrole-3-carboxamide,97.0,uM,=,1.9867717342662448,1,c1ccc(C2(CNc3ccc(-n4cccc4)nn3)CCC2)nc1
2617,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CC(=O)N[C@H]1CC(C)(C)Oc2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc21,"N-[(4S)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]acetamide",2.66,uM,=,0.424881636631067,1,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
2618,1643768,10.1039/C6MD00281A,,,,Inhibition of Cy3B-labeled ligand binding to recombinant human ERG expressed in HEK293 cells by fluorescence polarization method,NC(CF)(CF)c1nc(-c2ccc(OC(F)(F)F)cc2)c[nH]1,"1,3-difluoro-2-(4-(4-(trifluoromethoxy)phenyl)-1H-imidazol-2-yl)propan-2-amine",15.0,uM,=,1.1760912590556811,1,c1ccc(-c2c[nH]cn2)cc1
2619,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,"2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene",0.2313,uM,=,-0.6358243672293806,0,c1ccc2c(c1)N=C(N1CCNCC1)c1ccsc1N2
2620,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1nc(C)c(-c2ccc(N3C(=O)N(c4cc(O)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)s1,"3-[4-(2,4-Dimethyl-thiazol-5-yl)-phenyl]-1-(6-hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",0.95,uM,=,-0.0222763947111522,0,O=C1N(c2ccc(-c3cncs3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
2621,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)N(C)C)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid dimethylamide",8.9,uM,=,0.9493900066449128,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
2622,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Oc1ccc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cn1,"5-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridin-6-yl)pyridin-2-ol",323.3333333,uM,=,2.50965047950181,1,c1cncc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)c1
2623,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CC1(C)CC(NC(=O)C(C)(C)O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1,"N-[6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-2-hydroxy-2-methylpropanamide",0.38,uM,=,-0.4202164033831898,0,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
2624,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,O=[N+]([O-])c1cccc(CNc2cc(C(F)(F)F)cc3ncc(N4CCN(CCO)CC4)cc23)c1,2-(4-(5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinolin-3-yl)piperazin-1-yl)ethanol,0.037,uM,=,-1.431798275933005,0,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
2625,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,2-({1-[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-piperidin-4-yl}-methyl-amino)-3H-pyrimidin-4-one,0.35,uM,=,-0.4559319556497244,0,O=c1ccnc(NC2CCN(c3nc4ccccc4n3Cc3ccccc3)CC2)[nH]1
2626,1521346,10.1016/j.bmcl.2015.09.011,,,,Inhibition of human ERG by manual patch clamp assay,Cc1nn(-c2ccnc(Nc3ccc4c(c3)c(C)c(C)n4C)n2)cc1CN1CC(O)C1,"1-((3-methyl-1-(2-(1,2,3-trimethyl-1H-indol-5-ylamino)pyrimidin-4-yl)-1H-pyrazol-4-yl)methyl)azetidin-3-ol",12.5,uM,=,1.0969100130080565,1,c1cc(-n2cc(CN3CCC3)cn2)nc(Nc2ccc3[nH]ccc3c2)n1
2627,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CCc1ccn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2CO)n1,2-(3-Ethyl-pyrazol-1-yl)-1-((S)-2-hydroxymethyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-ethanone,0.0086,uM,=,-2.065501548756432,0,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
2628,2129860,10.1021/acsmedchemlett.1c00328,,,,Inhibition of human ERG stably expressed in CHO-K1 cells at -90 mV holding potential by automated Q-patch clamp method,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",0.2,uM,=,-0.6989700043360187,0,c1ccc(CCCCNCCc2ccccc2)cc1
2629,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(Nc1ccc(Cl)cc1CO)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,1-(4-chloro-2-(hydroxymethyl)phenyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,3.33,uM,=,0.5224442335063199,1,O=C(Nc1ccccc1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
2630,1680139,10.1021/acs.jmedchem.6b01647,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)=O)c2)n1C,N-{4-[5-(4-Fluoro-phenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide,28.6,uM,=,1.4563660331290431,1,c1ccc(-c2nc[nH]c2-c2ccncc2)cc1
2631,1696477,10.1016/j.bmcl.2017.08.068,,,,Inhibition of human ERG by patch clamp assay,NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n([C@H]3CCCNC3)c2n1,"(S)-3,4-dichloro-2-cyclopropyl-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",2.9,uM,=,0.4623979978989561,1,c1cnc2c(c1)cc(C1CC1)n2[C@H]1CCCNC1
2632,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCCC1c1ccc(F)cc1,2-(4-fluorophenyl)-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)pyrrolidine-1-carboxamide,1.81,uM,=,0.2576785748691845,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCCC1c1ccccc1
2633,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CS(=O)(=O)Nc1ccc2c(c1)C(=O)CC1(CCN(CCc3ccc4nonc4c3)CC1)O2,"N-[1''-(2-benzo[c][1,2,5]oxadiazol-5-ylethyl)-4-oxospiro[3,4-dihydro-2H-chromene-2,4''-(hexahydropyridine)]-6-yl]methanesulfonamide",0.008,uM,=,-2.096910013008056,0,O=C1CC2(CCN(CCc3ccc4nonc4c3)CC2)Oc2ccccc21
2634,880571,10.1021/ml300280g,,,,Binding affinity to human ERG,N#CC1(c2ccccc2)CCN(Cc2cc(C(=O)N[C@H]3CCCC[C@@H]3O)c(=O)n3ccccc23)CC1,"1-((4-cyano-4-phenylpiperidin-1-yl)methyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-oxo-4H-quinolizine-3-carboxamide",5.1,uM,=,0.7075701760979364,1,O=C(NC1CCCCC1)c1cc(CN2CCC(c3ccccc3)CC2)c2ccccn2c1=O
2635,1452362,10.1016/j.ejmech.2014.08.027,,,,Inhibition of human ERG expressed in CHO-K1 cells by whole cell patch-clamp assay,COc1ccc(-n2cnc3c(-c4ccccc4C)csc3c2=O)cc1,"3-(4-Methoxyphenyl)-7-(o-tolyl)thieno[3,2-d]pyrimidin-4(3H)-one",9.87,uM,=,0.9943171526696368,1,O=c1c2scc(-c3ccccc3)c2ncn1-c1ccccc1
2636,1327812,10.1039/C1MD00116G,,,,Inhibition of dofetilide binding to human ERG,Cc1cnc(NC(=O)c2cc(Oc3ccc(C#N)cc3)c3cc(C)oc3c2)cn1,4-(4-Cyanophenoxy)-2-methyl-N-(5-methylpyrazin-2-yl)benzofuran-6-carboxamide,4.0,uM,=,0.6020599913279624,1,O=C(Nc1cnccn1)c1cc(Oc2ccccc2)c2ccoc2c1
2637,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,Fc1ccc(C(Cc2ccccc2OC(F)F)N2CCNCC2)cc1,1-(2-(2-(difluoromethoxy)phenyl)-1-(4-fluorophenyl)ethyl)piperazine,9.12,uM,=,0.959994838328416,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
2638,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCNC(=O)Oc5ccccc5)c4)n[nH]c2-3)CC1,"phenyl 3-(4-(6-((4-Methylpiperazin-1-yl)methyl)-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)thiophen-2-yl)prop-2-ynylcarbamate",2.75,uM,=,0.4393326938302626,1,O=C(NCC#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)Oc1ccccc1
2639,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2c1ncccn1,"(R)-4-fluoro-N-(1-(5-(pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)benzamide",20.0,uM,=,1.3010299956639813,1,O=C(NCc1ccc2c(n1)CCCN2c1ncccn1)c1ccccc1
2640,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCOC(=O)Nc1cccc([C@@H](c2ccc(C(=O)N(CC)CC)cc2)N2CCN(Cc3cscn3)CC2)c1,(R)-ethyl 3-((4-(diethylcarbamoyl)phenyl)(4-(thiazol-4-ylmethyl)piperazin-1-yl)methyl)phenylcarbamate,5.4,uM,=,0.7323937598229685,1,c1ccc(C(c2ccccc2)N2CCN(Cc3cscn3)CC2)cc1
2641,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,CN1CC=CCC(c2cc3ccccc3o2)C1,"3-(Benzofuran-2-yl)-1-methyl-2,3,4,7-tetrahydro-1H-azepine",15.0,uM,=,1.1760912590556811,1,C1=CCC(c2cc3ccccc3o2)CNC1
2642,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cn1c(-c2ccc(OC3CCN(C4CCCC4)CC3)cc2)nc2ccccc2c1=O,2-(4-(1-cyclopentylpiperidin-4-yloxy)phenyl)-3-methylquinazolin-4(3H)-one,2.9,uM,=,0.4623979978989561,1,O=c1[nH]c(-c2ccc(OC3CCN(C4CCCC4)CC3)cc2)nc2ccccc12
2643,2260412,10.1021/acs.jmedchem.0c01744,,,,Inhibition of hERG by fluorescence polarization assay,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C\c1ccc(Cl)cc1,Lumefantrine,0.38,uM,=,-0.4202164033831898,0,C(=C1c2ccccc2-c2ccccc21)c1ccccc1
2644,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,C[C@@H](NC(=O)c1ccc(Cl)cc1)c1ccc2c(c1)OCCN2C(=O)c1cccc(Cl)c1,"(R)-4-chloro-N-(1-(4-(3-chlorobenzoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)ethyl)benzamide",6.9,uM,=,0.8388490907372553,1,O=C(NCc1ccc2c(c1)OCCN2C(=O)c1ccccc1)c1ccccc1
2645,812136,10.1016/j.bmcl.2012.01.015,,,,Inhibition of human ERG by patchXpress assay,Cc1c(C)n(Cc2ccccc2)c2ncnc(OC3CCN(Cc4cscn4)CC3)c12,"4-((4-(7-benzyl-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)piperidin-1-yl)methyl)thiazole",0.51,uM,=,-0.2924298239020636,0,c1ccc(Cn2ccc3c(OC4CCN(Cc5cscn5)CC4)ncnc32)cc1
2646,1871838,10.1016/j.bmcl.2018.12.015,,,,Inhibition of human ERG,CC(C)(C#N)CC#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1,"(S)-3,4-dichloro-2-(4-cyano-4-methylpent-1-ynyl)-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",0.003,uM,=,-2.5228787452803374,0,c1cnc2c(c1)ccn2[C@H]1CCCNC1
2647,948139,10.1016/j.bmcl.2013.01.019,,,,Inhibition of human ERG,C[C@@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccccc4)nc3n2)C[C@H](C)O1,"(2R,6S)-2,6-dimethyl-4-(4-((S)-3-methylmorpholino)-7-phenylpyrido[2,3-d]pyrimidin-2-yl)morpholine",4.0,uM,=,0.6020599913279624,1,c1ccc(-c2ccc3c(N4CCOCC4)nc(N4CCOCC4)nc3n2)cc1
2648,1474497,10.1021/acs.jmedchem.5b00191,,,,Inhibition of human ERG expressed in CHO cells,Cn1cc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)cn1,"(4S,4aR,6R,8aS)-8a-(2,4-difluorophenyl)-4-(fluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",13.8,uM,=,1.1398790864012365,1,C1=N[C@@]2(c3ccccc3)CO[C@@H](c3cn[nH]c3)C[C@H]2CS1
2649,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CC(N2CCCOCC2)C1,"3-(1,4-oxazepan-4-yl)-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)azetidine-1-carboxamide",3.0,uM,=,0.4771212547196624,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CC(N2CCCOCC2)C1
2650,219494,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,CN(C)CCC=C1c2ccccc2CCc2ccccc21,"[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine",10.0,uM,=,1.0,1,C=C1c2ccccc2CCc2ccccc21
2651,479556,10.1016/j.bmcl.2008.03.057,,,,Inhibition of human ERG by patch clamp method,Cc1cc2cc(Nc3ncnn4cc(-c5nnc(C)o5)c(C(C)C)c34)cnc2[nH]1,"5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine",6.6,uM,=,0.8195439355418687,1,c1nc(Nc2cnc3[nH]ccc3c2)c2cc(-c3nnco3)cn2n1
2652,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CCC(Oc4ccc(CN5CC(O)C(C)(C)C5)cc4)CC3)o2)cc1,"(4-(4-((4-hydroxy-3,3-dimethylpyrrolidin-1-yl)methyl)phenoxy)piperidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone",10.0,uM,=,1.0,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
2653,2247004,10.1021/acs.jmedchem.1c02132,,,,Inhibition of human ERG by patch clamp assay,COC(=O)Nc1cc(-c2ccc(OC[C@@](C)(N)CC(C)C)c(C)n2)ccn1,"(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-6-methyl-[2,4'-bipyridin]-2'-yl)carbamate",5.9,uM,=,0.7708520116421442,1,c1ccc(-c2ccncc2)nc1
2654,1810686,10.1021/acs.jmedchem.8b01333,,,,Inhibition of human ERG by patch clamp electrophysiology,C[C@@H]1CN(C(=O)c2ccnc(Nc3nc4cnc(Nc5ccc(F)c(C(F)(F)F)c5)cc4[nH]3)c2)C[C@H](C)N1,"((3S,5R)-3,5-Dimethylpiperazin-1-yl)(2-((2-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)-pyridin-4-yl)methanone",13.0,uM,=,1.1139433523068367,1,O=C(c1ccnc(Nc2nc3cnc(Nc4ccccc4)cc3[nH]2)c1)N1CCNCC1
2655,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3ccc(Cl)cn3)cs2)CO1,"US9315520, 7::US9315520, Example 7",9.0,uM,=,0.9542425094393248,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccn1
2656,1521007,10.1021/acs.jmedchem.5b01073,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCOCC1,N-(3-Chloro-2-fluorophenyl)-7-methoxy-6-(morpholinomethyl)-quinazolin-4-amine,17.0,uM,=,1.230448921378274,1,c1ccc(Nc2ncnc3ccc(CN4CCOCC4)cc23)cc1
2657,2129860,10.1021/acsmedchemlett.1c00328,,,,Inhibition of human ERG stably expressed in CHO-K1 cells at -90 mV holding potential by automated Q-patch clamp method,N#Cc1ccc(CCN2CCC(Nc3nc4ccccc4[nH]3)CC2)cc1,4-(2-(4-((1H-benzo[d]imidazol-2-yl)amino)piperidin-1-yl)ethyl)benzonitrile,0.09,uM,=,-1.0457574905606752,0,c1ccc(CCN2CCC(Nc3nc4ccccc4[nH]3)CC2)cc1
2658,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NCc3cc4c(c(Cl)c3Cl)OCCO4)(CC1)CO2,"(R)-4-((4-((7,8-dichloro-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",31.6,uM,=,1.499687082618404,1,O=c1ccc2nccc3c2n1CC3CC12CCC(NCc3ccc4c(c3)OCCO4)(CC1)CO2
2659,2229351,10.1021/acsmedchemlett.2c00172,,,,Inhibition of hERG expressed in CHO cells by electrophysiological assay based automated patch clamp method,COCCN1CC[C@H](n2c(=O)n(C)c3cnc(Nc4cc5cccnc5cc4C)nc32)C1,(S)-9-(1-(2-methoxyethyl)pyrrolidin-3-yl)-7-methyl-2-(7-methylquinolin-6-ylamino)-7H-purin-8(9H)-one,20.0,uM,=,1.3010299956639813,1,O=c1[nH]c2cnc(Nc3ccc4ncccc4c3)nc2n1[C@H]1CCNC1
2660,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,O[C@H]1C[C@H](CN2CCC(c3c(Cl)cccc3Cl)CC2)CCc2cccnc21,"(7R,9S)-7-((4-(2,6-dichlorophenyl)piperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",0.94,uM,=,-0.0268721464003013,0,c1ccc(C2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
2661,1327425,10.1039/C2MD20054F,,,,Inhibition of human ERG,C[C@@H]1CN(c2nc(C(F)(F)F)no2)CCN1c1ncc(OCc2ccncc2C#N)cn1,"4-{[(2-{(2R)-2-Methyl-4-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]piperazin-1-yl}pyrimidin-5-yl)oxy]methyl}pyridine-3-carbonitrile",5.9,uM,=,0.7708520116421442,1,c1cc(COc2cnc(N3CCN(c4ncno4)CC3)nc2)ccn1
2662,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CC(=O)N(c2ccc(S(C)(=O)=O)cn2)C3)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(5-(methylsulfonyl)pyridin-2-yl)-2,8-diazaspiro[4.5]decan-3-one",17.4,uM,=,1.2405492482825995,1,O=C1OCc2cc(CCN3CCC4(CC3)CC(=O)N(c3ccccn3)C4)ccc21
2663,2165295,10.1021/acsmedchemlett.1c00666,,,,Inhibition of human ERG by patch-clamp assay,c1ccc2oc(-c3csc(C4CCN(Cc5nc6cnccc6[nH]5)CC4)n3)cc2c1,"2-({4-[4-(1-Benzofuran-2-yl)-1,3-thiazol-2-yl]piperidin-1-yl}methyl)-1H-imidazo-[4,5-c]-pyridine",1.8,uM,=,0.255272505103306,1,c1ccc2oc(-c3csc(C4CCN(Cc5nc6cnccc6[nH]5)CC4)n3)cc2c1
2664,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CCN1CC2(CCN(CCc3ccccc3)CC2)OC(C)C1=O,"4-ethyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",3.1,uM,=,0.4913616938342727,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1
2665,1696477,10.1016/j.bmcl.2017.08.068,,,,Inhibition of human ERG by patch clamp assay,NC(=O)c1cc(Cl)c2c(Cl)c(C#CC3CC3)n(C3CCCNC3)c2n1,"rac-3,4-dichloro-2-(cyclopropylethynyl)-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",1.0,uM,=,0.0,0,C(#CC1CC1)c1cc2cccnc2n1C1CCCNC1
2666,1478743,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1,"(Nitrendipine) 2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester",10.0,uM,=,1.0,1,C1=CC(c2ccccc2)C=CN1
2667,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CN(c2ccc(C#N)cn2)C3)ccc2c1COC2=O,"6-(7-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,7-diazaspiro[3.5]nonan-2-yl)nicotinonitrile",10.5,uM,=,1.021189299069938,1,O=C1OCc2cc(CCN3CCC4(CC3)CN(c3ccccn3)C4)ccc21
2668,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(-c2ccccn2)sc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-4-methyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-2-(pyridin-2-yl)thiazole,11.2,uM,=,1.0492180226701815,1,c1ccc(-c2ncc(-c3ccc4cc(CCN5CCCC5)ccc4n3)s2)nc1
2669,2159402,10.1021/acs.jmedchem.1c01968,,,,Inhibition of human ERG by voltage clamp assay,FC1CN(C2COC2)CCC1c1cc2nc(Nc3cnn(C4CC4)c3Cl)ncc2cc1Cl,6-chloro-N-(5-chloro-1-cyclopropyl-1H-pyrazol-4-yl)-7-(3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)quinazolin-2-amine,14.0,uM,=,1.146128035678238,1,c1nn(C2CC2)cc1Nc1ncc2ccc(C3CCN(C4COC4)CC3)cc2n1
2670,1654955,10.1016/j.bmcl.2016.10.032,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@@H](O)CN2CCC3(CC2)CC(=O)N(c2cnc(S(C)(=O)=O)cn2)C3)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(5-(methylsulfonyl)pyrazin-2-yl)-2,8-diazaspiro[4.5]decan-3-one",27.8,uM,=,1.4440447959180762,1,O=C1OCc2cc(CCN3CCC4(CC3)CC(=O)N(c3cnccn3)C4)ccc21
2671,1461436,10.1016/j.bmcl.2014.12.044,,,,Inhibition of human ERG by Q-patch assay,COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5s4)s3)cc2)[nH]1)C(C)C,"methyl N-[(2S)-1-[(2S,4S)-2-{5-[5-(4-{2-[(2S,4S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]-4-methylpyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)thiophen-2-yl]-1H-thieno[2,3-d]imidazol-2-yl}-4-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate",25.1,uM,=,1.3996737214810382,1,c1cc(-c2ccc(-c3cc4[nH]c([C@@H]5CCCN5)nc4s3)s2)ccc1-c1cnc([C@@H]2CCCN2)[nH]1
2672,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,Cc1[nH]c2ccccc2c1C1CCCN(Cc2ccc(/C=C/C(=O)NO)cc2)C1,(E)-N-Hydroxy-3-{4-[3-(2-methyl-1H-indol-3-yl)piperidin-1-ylmethyl]-phenyl}acrylamide,27.6,uM,=,1.4409090820652175,1,c1ccc(CN2CCCC(c3c[nH]c4ccccc34)C2)cc1
2673,2049587,10.1016/j.bmcl.2020.127625,,,,Inhibition of human ERG by patch clamp assay,Cc1cn([C@H](C)[C@]2(F)CCNC2)c2nc(C(N)=O)cc(Cl)c12,"Rac-4-chloro-1-[(1R)-1-[(3S)-3-fluoropyrrolidin-3-yl]ethyl]-3-methyl-pyrrolo[2,3-b]pyridine-6-carboxamide",30.0,uM,=,1.4771212547196624,1,c1cnc2c(c1)ccn2CC1CCNC1
2674,876604,10.1021/jm301476b,,,,Inhibition of human ERG expressed in chinese hamster lung cells by IonWorks patch clamp electrophysiology assay,COc1ccc(-c2cc(-c3ccc(S(=O)(=O)N(C)C)cc3)cnc2N)cn1,"3-(6-methoxypyridin-3-yl)-5-(3-N,N-(dimethylsulfonamide)phenyl)pyridin-2-amine",9.7,uM,=,0.9867717342662448,1,c1ccc(-c2cncc(-c3cccnc3)c2)cc1
2675,831501,10.1021/np3000987,,,,Inhibition of human ERG expressed in HEK293 cells coexpressing Kir2.3 after 30 mins by FluxOR based FLIPR assay,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,0.008,uM,=,-2.096910013008056,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
2676,634333,10.1021/jm100053t,,,,Inhibition of human ERG,CNC[C@@H](O)CCN1c2ccccc2N(c2c(F)cccc2F)S1(=O)=O,"(2S)-(4-[3-(2,6-Difluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ol",20.0,uM,=,1.3010299956639813,1,O=S1(=O)Nc2ccccc2N1c1ccccc1
2677,699709,10.1016/j.bmcl.2010.11.111,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells,COc1cc(/C=C/c2nc(N)c3c4c(sc3n2)CCCCC4)ccc1-n1cnc(C)c1,"2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-vinyl}-6,7,8,9-tetrahydro-5H-10-thia-1,3-diaza-benzo[a]azulen-4-ylamine",0.39,uM,=,-0.4089353929735008,0,C(=C/c1ncc2c3c(sc2n1)CCCCC3)\c1ccc(-n2ccnc2)cc1
2678,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C(NC(c1ccc(Cl)cc1)c1ccc(Cl)cc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1,"(1R,2R,4R)-N-(bis(4-chlorophenyl)methyl)-2-(4-bromophenyl)-4-morpholinocyclohexanecarboxamide",0.039,uM,=,-1.408935392973501,0,O=C(NC(c1ccccc1)c1ccccc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
2679,2260412,10.1021/acs.jmedchem.0c01744,,,,Inhibition of hERG by fluorescence polarization assay,N/C(CC(O)c1cc2c(F)cc(F)cc2c2cc(C(F)(F)F)ccc12)=N\N=C\c1ccc(F)cc1,"(Z)-3-(1,3-Difluoro-6-(trifluoromethyl)phenanthren-9-yl)-N'-((E)-4-fluorobenzylidene)-3-hydroxypropanehydrazonamide",0.07,uM,=,-1.154901959985743,0,C(CCc1cc2ccccc2c2ccccc12)=N/N=C/c1ccccc1
2680,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCN(CC(=O)N(C)C)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"2-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)piperazin-1-yl)-N,N-dimethylacetamide",12.0,uM,=,1.0791812460476249,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
2681,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,CC(C)CN(C(=O)c1ccc(Cl)c(Cl)c1)[C@H]1CCNC1,"(S)-3,4-dichloro-N-isobutyl-N-(pyrrolidin-3-yl)benzamide",17.2,uM,=,1.235528446907549,1,O=C(N[C@H]1CCNC1)c1ccccc1
2682,2112211,10.1016/j.bmcl.2021.127909,,,,Inhibition of human ERG by automated patch method relative to control,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,"7-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-quinolin-2-one",0.8965,uM,=,-0.0474497061017983,0,O=C1CCc2ccc(OCCCCN3CCN(c4ccccc4)CC3)cc2N1
2683,1898259,10.1016/j.bmcl.2019.126643,,,,Inhibition of human ERG,C[C@@H]1CCCN1CCCOc1ccc2c(c1)CC[C@H]1[C@@H]3[C@@H](C(=O)NCC4CC4)CC[C@@]3(C)CC[C@H]21,"(8R,9S,13R,14R,15S)-N-(cyclopropylmethyl)-13-methyl-3-(3-((R)-2-methylpyrrolidin-1-yl)propoxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-15-carboxamide",4.1,uM,=,0.6127838567197355,1,O=C(NCC1CC1)[C@H]1CCC2CC[C@@H]3c4ccc(OCCCN5CCCC5)cc4CC[C@H]3[C@@H]21
2684,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCCC[C@@H](CCO)Nc1nc(N)nc2ccc(OC)cc12,(S)-3-((2-Amino-6-methoxyquinazolin-4-yl)amino)heptan-1-ol,6.0,uM,=,0.7781512503836436,1,c1ccc2ncncc2c1
2685,938040,10.1016/j.bmcl.2012.11.013,,,,Inhibition of human ERG by patch clamp assay,COc1cc(Nc2cc(-c3cccc(C#N)c3)ccn2)ccc1N1CCN(C)CC1,3-(2-(3-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyridin-4-yl)benzonitrile,1.3,uM,=,0.1139433523068367,1,c1ccc(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)c2)cc1
2686,830253,10.1021/jm300041e,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)cc2)C1(C)C,"2-Amino-1-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one",21.9,uM,=,1.3404441148401185,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
2687,2217382,10.1021/acs.jmedchem.1c02141,,,,Inhibition of hERG,CNCc1cc(Cl)ccc1Cn1c(=S)[nH]c(=O)c2[nH]ccc21,"1-(4-Chloro-2-((methylamino)methyl)benzyl)-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one",10.0,uM,=,1.0,1,O=c1[nH]c(=S)n(Cc2ccccc2)c2cc[nH]c12
2688,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1ccnc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"endo-2-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)isonicotinamide",1.0,uM,=,0.0,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccn2)C3)cc1
2689,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CN(C)Cc1cn(-c2ccc(F)cc2)c2ccc(Cl)cc12,[5-Chloro-1-(4-fluoro-phenyl)-1H-indol-3-ylmethyl]-dimethyl-amine,0.011,uM,=,-1.958607314841775,0,c1ccc(-n2ccc3ccccc32)cc1
2690,2241986,10.1016/j.ejmech.2021.114028,,,,Inhibition of hERG,CC1CC[C@@](CF)(c2cc(-c3cc4c(cn3)OC(F)(F)O4)ccc2F)N=C1N,"(6S)-6-(5-(2,2-difluoro-[1,3]dioxolo[4,5-c]pyridin-6-yl)-2-fluorophenyl)-6-(fluoromethyl)-3-methyl-3,4,5,6-tetrahydropyridin-2-amine",5.25,uM,=,0.7201593034059569,1,C1=NC(c2cccc(-c3cc4c(cn3)OCO4)c2)CCC1
2691,1475693,10.1016/j.bmcl.2015.04.002,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,COc1ccc2ncc(S(C)(=O)=O)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-methoxy-3-(methylsulfonyl)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.41,uM,=,0.3820170425748684,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2692,498774,10.1021/jm900110t,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",COc1ccc([C@]2(c3ccc(F)cc3)N=C(c3cc(C#N)ccn3)N[C@H]2C)cn1.Cl,"2-{(4S,5S)-4-(4-Fluorophenyl)-5-methyl-4-[6-(methyloxy)-3-pyridyl]-4,5-dihydro-1H-imidazol-2-yl}-4-pyridinecarbonitrile Hydrochloride",6.3,uM,=,0.7993405494535817,1,c1ccc([C@]2(c3cccnc3)CNC(c3ccccn3)=N2)cc1
2693,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(C)c(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)o1,"(R)-2,4-dimethyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)oxazole",40.0,uM,=,1.6020599913279625,1,c1ncc(-c2ccc3cc(CCN4CCCC4)ccc3n2)o1
2694,463271,10.1016/j.bmcl.2007.11.052,,,,Inhibition of human ERG,CN1CCC(Oc2cccc3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,[3-Chloro-4-(pyridin-2-ylmethoxy)-phenyl]-[5-(1-methyl-piperidin-4-yloxy)-quinazolin-4-yl]-amine,5.0,uM,=,0.6989700043360189,1,c1ccc(COc2ccc(Nc3ncnc4cccc(OC5CCNCC5)c34)cc2)nc1
2695,1667133,10.1021/acs.jmedchem.7b00437,,,,Inhibition of human ERG after 3.5 hrs by fluorescence polarization assay,COc1cncc(Cc2cc(-c3ccccc3)no2)c1,5-((5-Methoxypyridin-3-yl)methyl)-3-phenylisoxazole,23.0,uM,=,1.3617278360175928,1,c1ccc(-c2cc(Cc3cccnc3)on2)cc1
2696,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,0.0042,uM,=,-2.3767507096021,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
2697,1648277,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncc(Cl)cn3)CC2)c(F)c1)N1CCC1,"(cis)-1-(azetidin-1-yl)-2-(4-(2-((1S,2R)-2-(1-(5-chloropyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)-3-fluorophenyl)ethanone",3.5,uM,=,0.5440680443502757,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)cc1)N1CCC1
2698,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,C[S+]([O-])c1ccc(-c2cnc3ccc(NC4CCS(=O)(=O)CC4)nn23)cc1,"4-((3-(4-(Methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)tetrahydro-2Hthiopyran-1,1-dioxide",28.8,uM,=,1.4593924877592308,1,O=S1(=O)CCC(Nc2ccc3ncc(-c4ccccc4)n3n2)CC1
2699,990152,10.1016/j.bmc.2013.08.041,,,,Inhibition of human ERG channel expressed in CHO cells by whole cell patch clamp technique,COc1ccc2c(c1)c(/C=N/NS(=O)(=O)c1ccc(C)cc1)cn2CC(=O)Nc1ccc(Cl)cc1,N-(4-Chlorophenyl)-2-(5-methoxy-3-((2-tosylhydrazono)methyl)-1H-indol-1-yl)acetamide,418.35,uM,=,2.621539773321731,1,O=C(Cn1cc(/C=N/NS(=O)(=O)c2ccccc2)c2ccccc21)Nc1ccccc1
2700,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ncc(OC(C)C)cc3C2)C1,"(3-isopropoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)((2R,3aR,6aR)-2-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)methanone",46.9,uM,=,1.6711728427150834,1,O=C(N1CCc2ncccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
2701,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,O=C(N[C@H]1CCN(C2CCCCC2)C[C@@H]1C(=O)NCCc1ccccn1)c1cc(-c2ccc(F)cc2F)on1,"(3S,4S)-1-Cyclohexyl-4-([5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino)piperidine-3-carboxylic acid (2-pyridin-2-yl-ethyl)-amide",0.96,uM,=,-0.0177287669604316,0,O=C(N[C@H]1CCN(C2CCCCC2)C[C@@H]1C(=O)NCCc1ccccn1)c1cc(-c2ccccc2)on1
2702,1463729,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG by MK499 binding assay,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"6-((1-((3-fluoro-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",15.2,uM,=,1.1818435879447726,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
2703,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(Cc2ccc3occc3c2)CC1)c1cc(=O)c2ccc(F)cc2o1,N-(1-(benzofuran-5-ylmethyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,5.28,uM,=,0.7226339225338123,1,O=C(NC1CCN(Cc2ccc3occc3c2)CC1)c1cc(=O)c2ccccc2o1
2704,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1CCc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1,"1-{3-[4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-3,4-dihydro-1H-quinolin-2-one",7.3,uM,=,0.8633228601204559,1,O=C1CCc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
2705,1641577,,,,,"In Vitro Assay: The in vitro effects of the selected compounds on the hERG (human ether-á-go-go-related gene) potassium channel current (a surrogate for IKr, the rapidly activating, delayed rectifier cardiac potassium current) expressed in mammalian cells were evaluated at room temperature using the PatchXpress 7000A (Molecular Devices), an automatic parallel patch clamp system. Each compound was evaluated at varying concentrations in duplicate up to 10 μM, and the duration of exposure to each test article concentration was 5 minutes.",NCCCCN(Cc1nccc2c3ccccc3n(CC(=O)O)c12)[C@H]1CCCc2cccnc21,"US9314468, Table 7, Compound 56::US9314468, Table 9, Compound 2",2.7,uM,=,0.4313637641589873,1,c1cnc2c(c1)CCC[C@@H]2NCc1nccc2c1[nH]c1ccccc12
2706,1433959,10.1021/jm5010682,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by scintillation counting method,OC(c1ccccc1)(c1ccccc1)C1CCN(CCCOc2ccc(-c3ccccc3)cc2)CC1,"(1-(3-([1,1'-Biphenyl]-4-yloxy)propyl)piperidin-4-yl)-diphenylmethanol",0.14,uM,=,-0.8538719643217619,0,c1ccc(-c2ccc(OCCCN3CCC(C(c4ccccc4)c4ccccc4)CC3)cc2)cc1
2707,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,CN(Cc1ccc(OC2CN(C(=O)c3nnc(-c4ccccc4)o3)C2)cc1)CC1(C)COC1,"(3-(4-((methyl((3-methyloxetan-3-yl)methyl)amino)methyl)phenoxy)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone",14.0,uM,=,1.146128035678238,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CNCC3COC3)cc2)C1
2708,1518195,10.1016/j.bmcl.2015.09.018,,,,Inhibition of human ERG by flux assay,COc1cc(-n2cnn3cc(-c4ccc(Cl)cc4)cc3c2=O)ccc1OCCN1CCCC1,"6-(4-chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one",5.5,uM,=,0.7403626894942439,1,O=c1c2cc(-c3ccccc3)cn2ncn1-c1ccc(OCCN2CCCC2)cc1
2709,1686889,10.1021/acs.jmedchem.7b00925,,,,Displacement of Tracer Red from human ERG expressed in cell membranes by fluorescence polarization assay,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O,"4-[1,5,11,14-Tetrahydroxy-10-hydroxymethyl-13-methyl-3-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-hexadecahydro-cyclopenta[a]phenanthren-17-yl]-5H-furan-2-one (Ouabain)",5.8,uM,=,0.7634279935629373,1,O=C1C=C([C@H]2CCC3C2CC[C@@H]2C4CC[C@H](O[C@H]5CCCCO5)CC4CC[C@@H]32)CO1
2710,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=C1\S/C(=C2\SC(c3ccccc3)=NN2c2ccccc2)C(=O)N1c1ccccc1,"2-[(5-(3,5-Diphenyl-1,3,4-thiadiazol-2(3H)-ylidene)-4-oxo-3-phenylthiazolidin-2-ylidene)amino]-4,6-diphenylnicotinonitrile",2.5,uM,=,0.3979400086720376,1,O=C1/C(=C2/SC(c3ccccc3)=NN2c2ccccc2)S/C(=N\c2cc(-c3ccccc3)cc(-c3ccccc3)n2)N1c1ccccc1
2711,863322,10.1021/jm3008294,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp technique,CCCOC(c1ccc(Cl)c(Cl)c1)C1CNC1.Cl,"3-((3,4-Dichlorophenyl)(propoxy)methyl)azetidine hydrochloride",2.2,uM,=,0.3424226808222063,1,c1ccc(CC2CNC2)cc1
2712,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(C[C@H](OC)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(S)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-methoxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",6.0,uM,=,0.7781512503836436,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2713,1755294,10.1021/acs.jmedchem.8b00270,,,,Inhibition of human ERG,CS(=O)(=O)N1CCN(C(=O)c2cnc3ccc(F)cc3c2-c2ccc(C3(C#N)CC3)cc2)CC1,1-(4-(6-Fluoro-3-(4-(methylsulfonyl)piperazine-1-carbonyl)-quinolin-4-yl)phenyl)cyclopropanecarbonitrile,10.94,uM,=,1.039017321997412,1,O=C(c1cnc2ccccc2c1-c1ccc(C2CC2)cc1)N1CCNCC1
2714,879307,10.1021/jm1013693,,,,Inhibition of human ERG,CN(C)CCCCc1ccc(C(C)(C)C)cc1,"4-(4-tert-butylphenyl)-N,N-dimethylbutan-1-amine",7.5,uM,=,0.8750612633917001,1,c1ccccc1
2715,2241386,10.1016/j.ejmech.2021.113981,,,,Inhibition of hERG channel expressed in CHO cells at holding potential of -80 mV by whole cell patch clamp method,CCCCCNC[C@H](O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12,"(1R)-1-[2,8-bis(trifluoromethyl)-4-quinolyl]-2-(pentylamino)ethanol",5.6,uM,=,0.7481880270062004,1,c1ccc2ncccc2c1
2716,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3ccc(C)n3)[C@H](C)C2)cn1,1-{(R)-4-[4-(2-Ethoxy-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-2-(3-methyl-pyrazol-1-yl)-ethanone,13.0,uM,=,1.1139433523068367,1,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
2717,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,Cc1ccc2c(c1)N=C(C1=C[C@H](C)N(C)CC1)c1cc(Cl)ccc1N2,"(S)-2-chloro-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-8-methyl-5H-dibenzo[b,e][1,4]diazepine",1.1,uM,=,0.041392685158225,1,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
2718,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CC(O)c1cn(-c2ccc(F)cc2)c2ccc(Cl)cc12,1-[5-Chloro-1-(4-fluoro-phenyl)-1H-indol-3-yl]-ethanol,4.55,uM,=,0.6580113966571124,1,c1ccc(-n2ccc3ccccc32)cc1
2719,2082050,10.1021/acs.jmedchem.1c00034,,,,Inhibition of human ERG incubated for 4 hrs by fluorescene microplate reader assay,Oc1ccc(CN2CC(CNc3ccccc3)C3(C2)CN(c2ccccc2)C3)cc1,"4-((2-Phenyl-8-((phenylamino)methyl)-2,6-diazaspiro[3.4]octan-6-yl)methyl)phenol",2.2,uM,=,0.3424226808222063,1,c1ccc(CN2CC(CNc3ccccc3)C3(C2)CN(c2ccccc2)C3)cc1
2720,439396,10.1016/j.bmcl.2007.05.087,,,,Inhibition of human ERG potassium channel,N[C@H]1CN(c2cnc3nccnc3n2)CC[C@@H]1c1cc(F)c(F)cc1F.O=C(O)C(F)(F)F,"(3R,4R)-1-(pyrazino[2,3-b]pyrazin-2-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium 2,2,2-trifluoroacetate",9.9,uM,=,0.99563519459755,1,c1ccc(C2CCN(c3cnc4nccnc4n3)CC2)cc1
2721,1728849,10.1021/acsmedchemlett.7b00391,,,,Inhibition of human ERG,O[C@H]1CNCCC[C@@H]1n1c2ccc(C(F)(F)F)cc2c2cc(C(F)(F)F)ccc21,"(3S,4S)-4-(3,6-bis(trifluoromethyl)-9H-carbazol-9-yl)azepan-3-ol",1.18,uM,=,0.0718820073061253,1,c1ccc2c(c1)c1ccccc1n2[C@H]1CCCNCC1
2722,627338,10.1016/j.bmcl.2010.03.005,,,,Inhibition of human ERG,OC(c1cccnc1)(c1cccnc1)C(c1ccccc1)N1CCC1,"2-(azetidin-1-yl)-2-phenyl-1,1-di(pyridin-3-yl)ethanol",15.0,uM,=,1.1760912590556811,1,c1ccc(C(C(c2cccnc2)c2cccnc2)N2CCC2)cc1
2723,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4c(ccc5ccccc45)N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-5-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-naphtho[2,1-b]azepin-4(5H)-one",0.9,uM,=,-0.0457574905606751,0,O=C1Nc2ccc3ccccc3c2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
2724,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,O=C(NC1CCN(Cc2ccc(OCCCN3C(=O)CSC3=O)c(F)c2)CC1)c1cc(=O)c2ccc(F)cc2o1,"N-(1-(4-(3-(2,4-dioxothiazolidin-3-yl)propoxy)-3-fluorobenzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide",8.5,uM,=,0.9294189257142929,1,O=C(NC1CCN(Cc2ccc(OCCCN3C(=O)CSC3=O)cc2)CC1)c1cc(=O)c2ccccc2o1
2725,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,CCCN1CC[C@H](NC(=O)c2cc(-c3ccc(F)cc3F)on2)[C@@H](C(=O)NC2(c3ncccn3)CC2)C1,"(3S,4S)-4-([5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]-amino)-1-propyl-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide",4.4,uM,=,0.6434526764861874,1,O=C(N[C@H]1CCNC[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccccc2)on1
2726,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,N#Cc1cncc(-c2cccc(C3(c4ccnc(C(F)(F)F)c4)N=C(N)c4c(F)cccc43)c2)c1,5-(3-(3-amino-4-fluoro-1-(2-(trifluoromethyl)pyridin-4-yl)-1H-isoindol-1-yl)phenyl)nicotinonitrile,1.7,uM,=,0.2304489213782739,1,C1=NC(c2ccncc2)(c2cccc(-c3cccnc3)c2)c2ccccc21
2727,819957,10.1021/ml200199c,,,,Displacement of [3H]dofetilide from human ERG,O=C(C1CCN(c2cccc(C(F)(F)F)n2)CC1)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ncccn4)cn3)CC2)C1,(S)-(3-{trans-4-Hydroxy-4-[5-(pyrimidin-2-yl)pyridin-2-yl]cyclohexylamino}pyrrolidin-1-yl){1-[6-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methanone,10.0,uM,=,1.0,1,O=C(C1CCN(c2ccccn2)CC1)N1CC[C@H](NC2CCC(c3ccc(-c4ncccn4)cn3)CC2)C1
2728,2298259,10.1016/j.bmc.2023.117276,,,,Inhibition of hERG expressed in CHO cells by automated patch clamp method,O=C(NCc1ccc(Cl)cc1)c1cn2c(CCO)cc3cc(CN4CCOCC4)cc(c1=O)c32,"N-(4-chlorobenzyl)-2-(2-hydroxyethyl)-8-(morpholinomethyl)-6-oxo-6H-pyrrolo[3,2,1-ij]quinoline-5-carboxamide",2.1,uM,=,0.3222192947339193,1,O=C(NCc1ccccc1)c1cn2ccc3cc(CN4CCOCC4)cc(c1=O)c32
2729,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CCc1cc(Oc2ccc(F)cc2CNC)ccc1Cl,1-(2-(4-chloro-3-ethylphenoxy)-5-fluorophenyl)-N-methylmethanamine,4.56,uM,=,0.658964842664435,1,c1ccc(Oc2ccccc2)cc1
2730,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,Cc1cc(CN(C)C)ccc1OC1CN(C(=O)c2nnc(-c3ccccc3)o2)C1,"(3-{4-[(Dimethylamino)methyl]-2-methyl-phenoxy}azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone",8.6,uM,=,0.9344984512435676,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccccc2)C1
2731,2286943,10.1021/acs.jmedchem.1c01215,,,,Inhibition of hERG channel,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(B3C=CC=CN3)cc2)CC1,"4-(1,2-azaborinin-2(1H)-yl)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)benzamide",0.17,uM,=,-0.7695510786217261,0,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc(B2C=CC=CN2)cc1
2732,1747135,10.1016/j.bmcl.2017.10.042,,,,Inhibition of human ERG,COc1nc2ccc(Br)cc2cc1[C@@H](c1cc(C)c(C)s1)[C@@](O)(CCN(C)C)c1cccc(F)c1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-1-(4,5-dimethylthiophen-2-yl)-2-(3-fluorophenyl)butan-2-ol",0.88,uM,=,-0.0555173278498313,0,c1ccc(C[C@@H](c2cnc3ccccc3c2)c2cccs2)cc1
2733,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1,"US9145392, 74",0.7,uM,=,-0.1549019599857432,0,c1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ccncn4)CC3)n2)cc1
2734,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4cncc(F)c4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(5-fluoropyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide",5.0,uM,=,0.6989700043360189,1,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1
2735,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CO[C@@H]1C[C@H](Cc2ccc(Cl)cc2)N(C2CCN(c3nc(N)n[nH]3)CC2)C1,"5-(4-((2S,4R)-2-(4-Chlorobenzyl)-4-methoxypyrrolidin-1-yl)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",15.8,uM,=,1.1986570869544226,1,c1ccc(C[C@H]2CCCN2C2CCN(c3ncn[nH]3)CC2)cc1
2736,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,COc1cc2nnc(C(N)=O)c(Nc3ccc(C)cc3F)c2cc1N1CCCN(CCO)CC1,"4-(2-fluoro-4-methylphenylamino)-6-(4-(2-hydroxyethyl)-1,4-diazepan-1-yl)-7-methoxycinnoline-3-carboxamide",14.0,uM,=,1.146128035678238,1,c1ccc(Nc2cnnc3ccc(N4CCCNCC4)cc23)cc1
2737,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",O=c1cc(OCc2ccc(F)cc2)ccn1-c1ccc(OCCN2CCCC2)cc1,4-(4-fluorobenzyloxy)-1-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyridin-2(1H)-one,0.009,uM,=,-2.0457574905606752,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCN2CCCC2)cc1
2738,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,CC(C)(C)c1ccc(C(=O)NCC2CCN(C(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc1,"N-((1-(6,6-bis(4-fluorophenyl)hexanoyl)pyrrolidin-3-yl)methyl)-4-tert-butylbenzamide",0.82,uM,=,-0.0861861476162833,0,O=C(NCC1CCN(C(=O)CCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
2739,357755,10.1021/jm0508641,,,,Inhibition of hERG potassium channel in HEK293 cells by patch clamp assay,O=C(Nc1cccc(N2CCN(CCCCNS(=O)(=O)CC3CCCCC3)CC2)c1)C1CC1,cyclopropanecarboxylic acid {3-[4-(4-cyclohexylmethanesulfonylamino-butyl)-piperazin-1-yl]-phenyl}-amide,1.5,uM,=,0.1760912590556812,1,O=C(Nc1cccc(N2CCN(CCCCNS(=O)(=O)CC3CCCCC3)CC2)c1)C1CC1
2740,1839450,10.1021/acsmedchemlett.8b00542,,,,Displacement of [3H]dofetilide from recombinant human ERG expressed in HEK293 cell membranes measured after 80 mins by TopCount scintillation analysis,O=C(Cn1ccc2ncc(-c3cccc(C(F)(F)F)c3)cc21)N1CCC1,"1-(azetidin-1-yl)-2-(6-(3-(trifluoromethyl)phenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)ethanone",5.3,uM,=,0.724275869600789,1,O=C(Cn1ccc2ncc(-c3ccccc3)cc21)N1CCC1
2741,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1n[nH]c(C)c1C(=O)N[C@@H]1CC(C)(C)Oc2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc21,"N-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-3,5-dimethyl-1H-pyrazole-4-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(N[C@@H]1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)c1cn[nH]c1
2742,2238137,10.1021/acs.jmedchem.1c01012,,,,Inhibition of human ERG,Cc1cnc(N2CCN(CCCc3nc4c(Cl)cccc4c(=O)[nH]3)CC2)n1C,"8-chloro-2-(3-(4-(1,5-dimethyl-1H-imidazol-2-yl)piperazin-1-yl)propyl)quinazolin-4(3H)-one",1.5,uM,=,0.1760912590556812,1,O=c1[nH]c(CCCN2CCN(c3ncc[nH]3)CC2)nc2ccccc12
2743,1515505,10.1021/ml500440u,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,4.5,uM,=,0.6532125137753437,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
2744,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc2ccoc12,"(1S,2S)-2-(benzofuran-7-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-1-(2,3-dimethoxypyridin-4-yl)-4-(dimethylamino)butan-2-ol",0.9,uM,=,-0.0457574905606751,0,c1ccc2cc([C@H](Cc3cccc4ccoc34)c3ccncc3)ccc2c1
2745,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,COC(=O)N(C)c1c(N)nc(-n2nc(Cc3cc(F)ccc3F)c3ccccc32)nc1N,"methyl N-[4,6-diamino-2-[3-[(2,5-difluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methyl-carbamate",3.4,uM,=,0.5314789170422551,1,c1ccc(Cc2nn(-c3ncccn3)c3ccccc23)cc1
2746,2063573,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by IonWorks patch-clamp electrophysiology assay,CCOc1ccccc1-c1cc2c(N[C@H](CCO)c3ccccc3)ncnc2[nH]1,"(R)-3-((6-(2-Ethoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-3-phenylpropan-1-ol",11.0,uM,=,1.0413926851582251,1,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
2747,1472876,10.1021/jm5018863,,,,Inhibition of human ERG by GLP study,NC(=O)c1nnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc2cc[nH]c12,"5-(1H-indol-7-ylamino)-3-((1R,2S)-2-aminocyclohexylamino)-1,2,4-triazine-6-carboxamide",5.0,uM,=,0.6989700043360189,1,c1cc(Nc2cnnc(NC3CCCCC3)n2)c2[nH]ccc2c1
2748,1765514,10.1021/acs.jmedchem.8b01040,,,,Inhibition of human ERG by manual patch clamp assay,O=C(Nc1ccc(OC(F)(F)F)cc1)c1cnc(N2CC[C@H](O)C2)c(-c2cncnc2)c1,"US9278981, 33",4.5,uM,=,0.6532125137753437,1,O=C(Nc1ccccc1)c1cnc(N2CCCC2)c(-c2cncnc2)c1
2749,463271,10.1016/j.bmcl.2007.11.052,,,,Inhibition of human ERG,C[C@@H](Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12)C(=O)N(C)C,"(R)-2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)-N,N-dimethylpropanamide",14.0,uM,=,1.146128035678238,1,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
2750,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.1,uM,=,0.3222192947339193,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2751,2294517,10.1016/j.bmc.2023.117202,,,,Binding affinity to human ERG,C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2O[C@H]2CCOC2)CC1,"(S)-1-(4-((4-((3,4-diChloro-2-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one",1.135,uM,=,0.0549958615291415,1,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(OC4CCNCC4)cc23)cc1
2752,988976,10.1021/jm400732v,,,,Inhibition of human ERG,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl,"(S)-N-((3S,4S)-5-Acetyl-7-cyano-4-methyl-1-((2-methylnaphthalen-1-yl)methyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-diazepin-3-yl)-2-(methylamino)propanamide Hydrochloride",35.3,uM,=,1.5477747053878226,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
2753,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C2CC2)CC1,"US9145392, 91",0.83,uM,=,-0.0809219076239261,0,c1ccc(-c2c[nH]c(C3CCN(c4ncncc4C4CC4)CC3)n2)cc1
2754,463271,10.1016/j.bmcl.2007.11.052,,,,Inhibition of human ERG,Cc1ccc(Oc2ccc(Nc3ncnc4cccc(O[C@H](C)C(=O)N(C)C)c34)cc2C)cn1,"(R)-N,N-dimethyl-2-(4-(3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino)quinazolin-5-yloxy)propanamide",8.0,uM,=,0.9030899869919436,1,c1cncc(Oc2ccc(Nc3ncnc4ccccc34)cc2)c1
2755,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,Cc1ccc(CCNC[C@H](O)COc2ccc(NS(C)(=O)=O)cc2)cc1C,"(S)-1-(4-Methanesulfonamidophenoxy)-3-(3,4-dimethylphenylethylamino)-2-propanol",2.4,uM,=,0.380211241711606,1,c1ccc(CCNCCCOc2ccccc2)cc1
2756,2049320,10.1021/acs.jmedchem.0c01179,,,,Inhibition of tracer red binding to human ERG expressed in HEK293 cell membranes measured after 2 to 6 hrs by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N3CC(=O)NC[C@@H]3Cc3ccc(Cl)cc3)CC2)n1,"(S)-4-(1-(5-Amino-4H-1,2,4-triazol-3-yl)piperidin-4-yl)-5-(4-chlorobenzyl)piperazin-2-one",80.0,uM,=,1.9030899869919435,1,O=C1CN(C2CCN(c3ncn[nH]3)CC2)[C@@H](Cc2ccccc2)CN1
2757,1328170,10.1039/C3MD20368A,,,,Inhibition of human ERG by electrophysiological analysis,Cc1cnc(NC(=O)[C@H](CN2CC(O)C2)Oc2ncnc3c2cnn3-c2c(Cl)cccc2Cl)cn1,"(S)-2-(1-(2,6-dichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)-3-(3-hydroxyazetidin-1-yl)-N-(5-methylpyrazin-2-yl)propanamide",62.0,uM,=,1.792391689498254,1,O=C(Nc1cnccn1)[C@H](CN1CCC1)Oc1ncnc2c1cnn2-c1ccccc1
2758,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COc1cccc(-n2cc3nc(-c4cccnc4C)n(C[C@H]4CCCN(C[C@H]5CCCO5)C4)c(=O)c3n2)c1,"2-(3-Methoxyphenyl)-5-(2-methylpyridin-3-yl)-6-(((S)-1-(((R)-tetrahydrofuran-2-yl)methyl)piperidin-3-yl)methyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",44.0,uM,=,1.6434526764861874,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2cccnc2)n1C[C@H]1CCCN(C[C@H]2CCCO2)C1
2759,2249200,10.1021/acs.jmedchem.2c00008,,,,Inhibition of human ERG potassium channel expressed in CHO cells by patch-clamp assay,COc1cc(Oc2c(-c3ccc(F)cc3C(C)(F)F)sc3c2ccc2[nH]ncc23)ccc1NC1CN(CCCF)C1,"N-[4-[[2-[2-(1,1-difluoroethyl)-4-fluoro-phenyl]-6H-thieno[2,3-e]indazol-3-yl]oxy]-2-methoxy-phenyl]-1-(3-fluoropropyl)azetidin-3-amine",11.5,uM,=,1.0606978403536118,1,c1ccc(-c2sc3c(ccc4[nH]ncc43)c2Oc2ccc(NC3CNC3)cc2)cc1
2760,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),0.0268,uM,=,-1.5718652059712113,0,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1
2761,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2cnc(S(C)(=O)=O)cn2)C3)ccc2c1COC2=O,"(R)-5-(1-hydroxy-2-(2-(5-(methylsulfonyl)pyrazin-2-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",8.9,uM,=,0.9493900066449128,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cnccn3)C4)ccc21
2762,1760223,10.1021/acs.jmedchem.8b00002,,,,Inhibition of human ERG expressed in HEK293 cells by manual patch clamp assay,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=C(CF)OC(N)=N1,"(S)-N-(3-(2-Amino-6-(fluoromethyl)-4-methyl-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide",2.0,uM,=,0.3010299956639812,1,O=C(Nc1cccc(C2C=COC=N2)c1)c1ccccn1
2763,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4ccc5c(c4)OCO5)CC3)C2)c2cc(C(F)(F)F)ccc21,"cis-N-(1-(4-(benzo[d][1,3]dioxol-5-yl)cyclohexyl)azetidin-3-yl)-2-(1-methyl-5-(trifluoromethyl)-1H-indazol-3-ylamino)acetamide",0.84,uM,=,-0.0757207139381183,0,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccc4c(c3)OCO4)CC2)C1
2764,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2sncc2Cl)C3=O)ccc2c1COC2=O,"(R)-2-(4-chloroisothiazol-5-yl)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one",1.5,uM,=,0.1760912590556812,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccns3)C4=O)ccc21
2765,582986,10.1021/jm900933k,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp technique,C[C@@H](c1ccccn1)c1c(CCN(C)C)oc2ccccc12,(-)-Dimethyl-{2-[3-((R)-1-pyridin-2-yl-ethyl)-benzofuran-2-yl]-ethyl}-amine,1.2,uM,=,0.0791812460476248,1,c1ccc(Cc2coc3ccccc23)nc1
2766,499332,10.1016/j.bmcl.2009.04.023,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(C(=O)[C@]4(C)CC[C@@](C)(O)CC4)nc3cc2Cl)CC1,"trans-(5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)(4-hydroxy-1,4-dimethylcyclohexyl)methanone",20.0,uM,=,1.3010299956639813,1,O=C(c1nc2ccc(N3CCNCC3)cc2[nH]1)C1CCCCC1
2767,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4C(F)(F)F)CC3)ccc21,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)-2-(trifluoromethyl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,6.9,uM,=,0.8388490907372553,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
2768,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,CO[C@H]1CN(CCn2c(=O)ccc3ccc(C#N)cc32)CC[C@H]1NCc1ccc2c(n1)NC(=O)CO2,"cis-1-[2-((3S,4R)-3-Methoxy-4-{[(3-oxo-3,4-dihydro-2H-pyrido-[3,2-b][1,4]oxazin-6-yl)methyl]amino}piperidin-1-yl)ethyl]-2-oxo-1,2-dihydroquinoline-7-carbonitrile",189.0,uM,=,2.2764618041732443,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)ccc5ccccc54)CC3)nc2N1
2769,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CC(C)[C@]1(C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)CC[C@@H](NC2C3CCCC2COC3)C1,"cis-((1S,3R)-3-(3-oxabicyclo[3.3.1]nonan-9-ylamino)-1-isopropylcyclopentyl)(4-(4-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methanone",1.2,uM,=,0.0791812460476248,1,O=C(C1CC[C@@H](NC2C3CCCC2COC3)C1)N1CCN(c2ccccn2)CC1
2770,651867,10.1016/j.bmc.2010.07.013,,,,Inhibition of human ERG at holding potential of -80 mV to +40 mV,C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1,"N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide",14.2,uM,=,1.1522883443830565,1,O=C(COc1ccccn1)NC[C@@H](Cc1ccccc1)c1ccccc1
2771,1926457,10.1016/j.bmc.2016.08.007,,,,Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assay,Cc1nccc(Nc2cc(NC3CCN(c4ccc(C#N)cn4)CC3)c(C(N)=O)cn2)n1,4-{[1-(5-Cyanopyridin-2-yl)piperidin-4-yl]amino}-6-[(2-methylpyrimidin-4-yl)amino]nicotinamide,8.1,uM,=,0.9084850188786496,1,c1ccc(N2CCC(Nc3ccnc(Nc4ccncn4)c3)CC2)nc1
2772,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2cccc(NC(C)=O)c2)cc1,"4-((3-acetamidophenyl)(1-(4-fluorobenzyl)piperidin-4-ylidene)methyl)-N,N-diethylbenzamide",3.0,uM,=,0.4771212547196624,1,c1ccc(CN2CCC(=C(c3ccccc3)c3ccccc3)CC2)cc1
2773,1278259,10.1021/jm4010434,,,,Inhibition of human ERG channel expressed in HEK293 cells after 15 mins by whole-cell patch clamp technique,CCCCCCCN(CC)CC#CCCc1ccc(Cl)cc1,N-(5-(4-Chlorophenyl)pent-2-yn-1-yl)-N-ethylheptan-1-amine,0.053,uM,=,-1.275724130399211,0,c1ccccc1
2774,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(c1ccncc1)c1ccc(Cl)cc1,N-((4-chlorophenyl)(pyridin-4-yl)methyl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,1.7,uM,=,0.2304489213782739,1,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(c1ccccc1)c1ccncc1
2775,1473930,10.1021/jm5018863,,,,Inhibition of human ERG by manual patch clamp assay,NC(=O)c1cnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc(-n2nccn2)c1,"4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide",10.0,uM,=,1.0,1,c1cc(Nc2ccnc(NC3CCCCC3)n2)cc(-n2nccn2)c1
2776,1813578,10.1021/acs.jmedchem.9b00510,,,,Inhibition of human ERG by patch-clamp method,Cc1c(C(=O)CC#N)oc2ccc(Br)cc12,3-(5-Bromo-3-methylbenzofuran-2-yl)-3-oxopropanenitrile,0.03,uM,=,-1.5228787452803376,0,c1ccc2occc2c1
2777,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1C1CCC1,6-(4-(1-(2-(azetidin-1-yl)ethyl)-4-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)piperidin-1-yl)-5-cyclobutylpyrimidin-4-amine,1.3,uM,=,0.1139433523068367,1,c1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncncc4C4CCC4)CC3)n2)cc1
2778,1824533,10.1021/acs.jmedchem.9b01295,,,,Inhibition of human ERG,COC[C@H]1Cn2cc(-c3nc(Nc4ccnn4C)ncc3C)nc2C(=O)N1Cc1ccc(F)c(F)c1,"(R)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5H)-one",11.0,uM,=,1.0413926851582251,1,O=C1c2nc(-c3ccnc(Nc4ccn[nH]4)n3)cn2CCN1Cc1ccccc1
2779,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](C(=O)O)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-4-(3-(2-(1-methyl-5-(trifluoromethyl)-1H-indazol-3-ylamino)acetamido)azetidin-1-yl)cyclohexanecarboxylic acid,25.0,uM,=,1.3979400086720375,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
2780,1473398,10.1021/jm501920g,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,Clc1ccc(Cn2cc(NCCN3CCCCC3)nn2)cc1Cl,"1-(3,4-dichlorobenzyl)-N-(2-(piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-amine",2.2,uM,=,0.3424226808222063,1,c1ccc(Cn2cc(NCCN3CCCCC3)nn2)cc1
2781,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,NC(=O)c1ccc(N[C@H]2CCCNC2)c2cc(-c3ccccc3)[nH]c12,2-Phenyl-4-[(3S)-piperidin-3-ylamino]-1H-indole-7-carboxamide,11.6,uM,=,1.0644579892269186,1,c1ccc(-c2cc3c(N[C@H]4CCCNC4)cccc3[nH]2)cc1
2782,2054254,10.1016/j.ejmech.2020.112501,,,,Inhibition of human ERG by fluorescence polarization assay,Cl.OCCC/C(=C(\c1ccc(O)cc1)c1ccc(C2CCN(C3CC3)C2)cc1)c1ccccc1,4-(1-(4-(1-cyclopropylpyrrolidin-3-yl)phenyl)-5-hydroxy-2-phenylpent-1-enyl)phenol hydrochloride,4.3,uM,=,0.6334684555795865,1,C(=C(c1ccccc1)c1ccc(C2CCN(C3CC3)C2)cc1)c1ccccc1
2783,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccc3c(c2)OCO3)c1,"endo-3-(8-(benzo[d][1,3]dioxol-5-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide",0.00062,uM,=,-3.207608310501746,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccc3c(c2)OCO3)cc1
2784,1577772,10.1021/acsmedchemlett.5b00360,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cell membranes incubated for 2 hrs by scintillation counting analysis,CC(=O)Nc1ccc2c3c(cccc13)C(=O)N(CCCCN1CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC1)C2=O,"N-(2-(4-(4-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-ylamino)piperidin-1-yl)butyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)acetamide",0.182,uM,=,-0.7399286120149252,0,O=C1c2cccc3cccc(c23)C(=O)N1CCCCN1CCC(Nc2nc3ccccc3n2Cc2ccccc2)CC1
2785,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,COc1cnc2ccc(=O)n(CCN3CCC(NCc4cnc(OC)c(C#N)c4)CC3)c2c1,"2-Methoxy-5-((1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)nicotinonitrile",12.0,uM,=,1.0791812460476249,1,O=c1ccc2ncccc2n1CCN1CCC(NCc2cccnc2)CC1
2786,2153149,10.1016/j.ejmech.2021.113827,,,,Inhibition of hERG expressed in CHO-K1 cells assessed as reduction in thallium influx incubated for 30 minutes by FLIPR,O=c1ccc2c([nH]1)CCC(NCCCCCNc1c3c(nc4cc(Cl)ccc14)CCCC3)C2,"6-(5-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)pentylamino)-5,6,7,8-tetrahydroquinolin-2(1H)-one",7.657,uM,=,0.8840586470939384,1,O=c1ccc2c([nH]1)CCC(NCCCCCNc1c3c(nc4ccccc14)CCCC3)C2
2787,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CC(C)[C@]1(C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)CC[C@@H](N[C@H]2CCOC[C@H]2O)C1,"cis-((1S,3R)-3-((3S,4S)-3-hydroxytetrahydro-2H-pyran-4-ylamino)-1-isopropylcyclopentyl)(4-(4-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methanone",0.3,uM,=,-0.5228787452803376,0,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2ccccn2)CC1
2788,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,"5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one",0.162,uM,=,-0.790484985457369,0,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
2789,761292,10.1021/jm101312a,,,,Inhibition of human ERG expressed in CHO cells by high throughput single cell planar patch clamp method,CCN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1,"cis-3a-(3,4-dichlorophenyl)-2-ethyloctahydro-1H-isoindole",4.33,uM,=,0.6364878963533654,1,c1ccc([C@]23CCCC[C@H]2CNC3)cc1
2790,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccc(F)cc1-c1ccccc1,"Ethyl 4-(5-fluoro-[1,1'-biphenyl]-2-yl)-6-(morpholinomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",4.96,uM,=,0.6954816764901974,1,C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccccc1-c1ccccc1
2791,2125084,10.1021/acsmedchemlett.1c00450,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell after 90 mins by microbeta liquid scintillation counting method,COC(=O)NC12CCC(n3cc(-c4ccc(Cl)c(N)c4)c4c(N)ncnc43)(CC1)CC2,"methyl (4-(4-amino-5-(3-amino-4-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octan-1-yl)carbamate",9.9,uM,=,0.99563519459755,1,c1ccc(-c2cn(C34CCC(CC3)CC4)c3ncncc23)cc1
2792,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn([C@H]3C[C@@H](C(F)(F)F)CCN(Cc4ccccc4)C3=O)nn2)ccc1-n1cnc(C)c1,"(3S,5S)-1-benzyl-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)azepan-2-one",5.48,uM,=,0.7387805584843692,1,O=C1[C@@H](n2cc(-c3ccc(-n4ccnc4)cc3)nn2)CCCCN1Cc1ccccc1
2793,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COc1ccc(CN2CCC(C#N)(CNC(=O)c3cc(OC)cc(OC)c3)CC2)cc1,"N-((4-cyano-1-(4-methoxybenzyl)piperidin-4-yl)methyl)-3,5-dimethoxybenzamide",3.21,uM,=,0.5065050324048721,1,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
2794,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(CC(=O)N2CCOCC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"2-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)-1-morpholinoethanone",8.8,uM,=,0.9444826721501688,1,O=C(Cc1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1)N1CCOCC1
2795,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccc(F)cc54)CC3)nc2N1,"6-((1-(2-(6-fluoro-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",9.0,uM,=,0.9542425094393248,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccccc54)CC3)nc2N1
2796,493421,10.1016/j.bmcl.2008.10.025,,,,Inhibition of human ERG expressed in CHO cells,N#Cc1cc2cc(C3(Cc4ccccc4)CCNC3)ccc2[nH]1,5-(3-benzylpyrrolidin-3-yl)-1H-indole-2-carbonitrile,1.4,uM,=,0.1461280356782379,1,c1ccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)cc1
2797,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2nccc([C@@H](O)CC[C@@H]3CCN(C4CC(c5c(F)cccc5F)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-1-(3-(2,6-difluorophenyl)cyclobutyl)-4-((S)-3-hydroxy-3-(6-methoxyquinolin-4-yl)propyl)piperidine-3-carboxylic acid",47.6,uM,=,1.677606952720493,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
2798,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CN(C)CC(C)(C)Cn1nc(-c2ccc3nc(OC4CC4)ccc3c2)c2c(N)ncnc21,"3-(2-Cyclopropoxyquinolin-6-yl)-1-(3-(dimethylamino)-2,2-dimethylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.082,uM,=,-1.0861861476162833,0,c1ncc2c(-c3ccc4nc(OC5CC5)ccc4c3)n[nH]c2n1
2799,1293759,10.1016/j.bmcl.2014.01.061,,,,Inhibition of human ERG channel by patch clamp technique,O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@H]2C[C@@H]12,"(+)-(1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one",14.0,uM,=,1.146128035678238,1,O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@H]2C[C@@H]12
2800,2081968,10.1016/j.ejmech.2021.113248,,,,Inhibition of human ERG expressed in CHO cells,O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3s1)CC2,"8-(3-(Benzo[b]thiophen-2-yl)-5-chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",14.7,uM,=,1.167317334748176,1,O=C1NCCC12CCN(c1ccncc1-c1cc3ccccc3s1)CC2
2801,1640436,,,,,"hERG Inhibition Assay: The effect of compounds of the formula I on the cloned human cardiac hERG channel was evaluated in an in vitro model using a whole-cell patch-clamping technique. CHO (Chinese hamster ovary) cells stably expressing hERG, the potassium channel underlying IKr currents in human hearts, were grown in HAM's F-12 media supplemented with 10% fetal bovine serum, 1x penicillin/streptomycin and 500 ug/ml G418 (Invitrogen, Carlsbad, Calif., USA) in an atmosphere of 95% air and 5% carbon dioxide. Cells used for patch-clamping were seeded on glass or plastic coverslips 12 to 36 hours before use. hERG channel currents were recorded at room temperature using the whole-cell configuration of the patch clamp technique with an Axopatch 200B amplifier (Axon Instruments, Foster City, Calif., USA). Briefly, electrodes (3 to 6 MΩ resistance) were fashioned from TW150F glass capillary tubes (World Precision Instruments, Sarasota, Fla., USA) and filled with pipette solution (containing 120 mM potassium aspartate, 20 mM potassium chloride, 4 mM adenosine triphosphate disodium salt, 5 mM HEPES, 1 mM magnesium chloride; pH adjusted to 7.2 with potassium hydroxide). hERG currents were initiated by a positive voltage pulse (20 mV) followed by a negative pulse (-40 mV) and were recorded for off-line analyses. Once hERG current from a cell perfused with external solution (containing 130 mM sodium chloride, 5 mM potassium chloride, 2.8 mM sodium acetate, 1 mM magnesium chloride, 10 mM HEPES, 10 mM glucose, 1 mM calcium chloride; pH adjusted to 7.4 with sodium hydroxide) without the test compound, i.e. control solution, was stabilized, the cell was perfused with external solution containing the test compound at specific concentrations.",CC[C@@H](NC(=O)c1cc(C(=O)N2CCC[C@@H]2C)n2c1COCC2)c1ccc(Cl)c(Cl)c1,"US9284333, 16ci",10.0,uM,=,1.0,1,O=C(NCc1ccccc1)c1cc(C(=O)N2CCCC2)n2c1COCC2
2802,761292,10.1021/jm101312a,,,,Inhibition of human ERG expressed in CHO cells by high throughput single cell planar patch clamp method,Clc1ccc([C@@]23CCCC[C@@H]2CNC3)cc1Cl,"(3aR,7aS)-3a-(3,4-dichlorophenyl)octahydro-1H-isoindole",3.64,uM,=,0.561101383649056,1,c1ccc([C@@]23CCCC[C@@H]2CNC3)cc1
2803,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1nc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)oc1=O,"3-ethyl-5-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,3,4-oxadiazol-2(3H)-one",51.5,uM,=,1.711807229041191,1,O=c1[nH]nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
2804,1973041,10.1021/acsmedchemlett.0c00015,,,,Inhibition of human ERG expressed in human embryonic kidney cells by manual patch clamp assay,COc1ccc(-c2cnn3c(N)c(-c4ccccc4)c(NC4CC(C)(C)N(C)C(C)(C)C4)nc23)cc1OC,"3-(3,4-dimethoxyphenyl)-N5-(1,2,2,6,6-pentamethylpiperidin-4-yl)-6-phenylpyrazolo[1,5-a]pyrimidine-5,7-diamine",0.5,uM,=,-0.3010299956639812,0,c1ccc(-c2cn3ncc(-c4ccccc4)c3nc2NC2CCNCC2)cc1
2805,1809217,10.1021/acsmedchemlett.9b00204,,,,Inhibition of human ERG,CC(C)c1ccc(-c2cc(CN3CCN(c4ccccn4)CC3)nn2-c2ccc(F)cc2)cc1,1-((1-(4-Fluorophenyl)-5-(4-isopropylphenyl)-1H-pyrazol-3-yl)methyl)-4-(pyridin-2-yl)piperazine,25.1,uM,=,1.3996737214810382,1,c1ccc(-c2cc(CN3CCN(c4ccccn4)CC3)nn2-c2ccccc2)cc1
2806,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1c(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)cnn1-c1ccc(Cl)c(Cl)c1,"(R)-2-(1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-4-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline",0.6,uM,=,-0.2218487496163563,0,c1ccc(-n2cc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cn2)cc1
2807,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CC[C@@H](NCc4ccc5c(n4)NC(=O)CO5)[C@@H](O)C3)c2c1,"cis-6-[({(3S,4R)-3-Hydroxy-1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b]-[1,4]oxazin-3(4H)-one",152.0,uM,=,2.1818435879447726,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)cnc5ccccc54)CC3)nc2N1
2808,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)ccn1,"2-(1,4'-bipiperidin-1'-yl)-6-(2-methoxypyridin-4-yl)thiazolo[4,5-b]pyridine",0.2040816327,uM,=,-0.690196079928626,0,c1cc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)ccn1
2809,1578296,10.1016/j.bmcl.2016.04.020,,,,Inhibition of human ERG,Cc1ccnc2c3c(nn12)CN([C@H]1CO[C@H](c2cc(F)ccc2F)[C@@H](N)C1)C3,"(2R,3S,5R)-2-(2,5-Difluoro-phenyl)-5-(7-methyl-1H,3H-2,4,7a,8-tetraaza-cyclopenta[a]inden-2-yl)-tetrahydro-pyran-3-ylamine",97.0,uM,=,1.9867717342662448,1,c1ccc([C@@H]2CC[C@@H](N3Cc4nn5cccnc5c4C3)CO2)cc1
2810,2249200,10.1021/acs.jmedchem.2c00008,,,,Inhibition of human ERG potassium channel expressed in CHO cells by patch-clamp assay,CC(F)(F)c1cc(F)c(F)cc1-c1sc2c(ccc3[nH]ncc32)c1Oc1ccc(NC2CN(CCCF)C2)cc1,"N-[4-[[2-[2-(1,1-difluoroethyl)-4,5-difluoro-phenyl]-6H-thieno[2,3-e]indazol-3-yl]oxy]phenyl]-1-(3-fluoropropyl)azetidin-3-amine",7.4,uM,=,0.8692317197309762,1,c1ccc(-c2sc3c(ccc4[nH]ncc43)c2Oc2ccc(NC3CNC3)cc2)cc1
2811,455097,10.1016/j.bmcl.2007.02.066,,,,Inhibition of cardiac hERG,C[C@@H](C1CCC(N(C)C(=O)c2cccc(F)c2)CC1)[C@H](N)C(=O)N1CC[C@H](F)C1.Cl,"(2S,3S)-3-(4-(3-fluoro-N-methylbenzamido)cyclohexyl)-1-((S)-3-fluoropyrrolidin-1-yl)-1-oxobutan-2-aminium chloride",78.0,uM,=,1.8920946026904804,1,O=C(NC1CCC(CCC(=O)N2CCCC2)CC1)c1ccccc1
2812,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(c1ccccc1)c1cnc[nH]1,N-((1H-imidazol-5-yl)(phenyl)methyl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,11.4,uM,=,1.0569048513364727,1,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(c1ccccc1)c1cnc[nH]1
2813,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,CC(=O)Nc1cccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)c1,N-(1-(3-acetamidobenzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,60.7,uM,=,1.7831886910752577,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
2814,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@H]1CN(C)C[C@@H]1c1ccc(-c2cccnc2)cc1,"N-((3R,4R)-1-methyl-4-(4-(pyridin-3-yl)phenyl)pyrrolidin-3-yl)propane-2-sulfonamide",31.6,uM,=,1.499687082618404,1,c1cncc(-c2ccc([C@@H]3CCNC3)cc2)c1
2815,1581796,10.1021/acsmedchemlett.6b00027,,,,Displacement of [35S]MK499 from human ERG,CN1C(=O)Cn2c1nc1nc(N3CCC[C@@H](N)C3)n(Cc3cc(F)ccc3C#N)c1c2=O,"US9051329, Example 1",40.0,uM,=,1.6020599913279625,1,O=C1Cn2c(nc3nc(N4CCCCC4)n(Cc4ccccc4)c3c2=O)N1
2816,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,CN(C)CCCn1ncc2cc(-n3ccc(OCc4ccccc4)cc3=O)ccc21,4-(benzyloxy)-1-(1-(3-(dimethylamino)propyl)-1H-indazol-5-yl)pyridin-2(1H)-one,1.4,uM,=,0.1461280356782379,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2[nH]ncc2c1
2817,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,O=C1CCc2cc(C(O)CN3CCC(O)(c4cccc(F)c4)CC3)ccc2N1,"6-(2-(4-(3-fluorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxyethyl)-3,4-dihydroquinolin-2(1H)-one",13.0,uM,=,1.1139433523068367,1,O=C1CCc2cc(CCN3CCC(c4ccccc4)CC3)ccc2N1
2818,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,Cc1c(N2CCC(C3(N)CC3)C2)c(F)cc2c(Cc3n[nH]c(=O)o3)cc(=O)n(C3CC3)c12,"5-((7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-4-yl)methyl)-1,3,4-oxadiazol-2(3H)-one",188.0,uM,=,2.27415784926368,1,O=c1[nH]nc(Cc2cc(=O)n(C3CC3)c3cc(N4CCC(C5CC5)C4)ccc23)o1
2819,1640014,,,,,Inhibition of human ERG expressed in CHO cells using voltage step to -50 mV for 300 ms from -80 mV holding potential by automated patch clamp assay,O=C1c2cc(-c3ccc(OC(F)(F)F)cc3)ccc2OCCN1Cc1ncccn1,ELECLAZINE,5.7,uM,=,0.7558748556724915,1,O=C1c2cc(-c3ccccc3)ccc2OCCN1Cc1ncccn1
2820,1474497,10.1021/acs.jmedchem.5b00191,,,,Inhibition of human ERG expressed in CHO cells,Cc1coc([C@H]2C[C@H]3[C@@H](C)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1,"(4R,4aR,6R,8aS)-8a-(2,4-difluorophenyl)-4-methyl-6-(4-methyloxazol-2-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",4.8,uM,=,0.6812412373755872,1,C1=N[C@@]2(c3ccccc3)CO[C@@H](c3ncco3)C[C@H]2CS1
2821,1865114,10.1021/acsmedchemlett.9b00086,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp method,CC(C)Oc1cc([C@@](Cc2ccccc2)(NC(=O)C(O)C(O)(C(F)(F)F)C(F)(F)F)c2cc(F)cc(OC(F)(F)C(F)F)c2)ccc1F,"4,4,4-trifluoro-N-((R)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-2,3-dihydroxy-3-(trifluoromethyl)butanamide",11.0,uM,=,1.0413926851582251,1,c1ccc(CC(c2ccccc2)c2ccccc2)cc1
2822,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,2-(4-{1-Hydroxy-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butyl}-phenyl)-2-methyl-propionic acid,23.0,uM,=,1.3617278360175928,1,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
2823,499728,10.1016/j.bmcl.2009.02.111,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp method,CN(C)C(=N)c1ccc(C(=O)Nc2ccc(Cl)cc2C(=O)Nc2ccc(Cl)cn2)cc1,"5-chloro-N-(5-chloro-pyridin-2-yl)-2-[4-(N,N-dimethyl-carbamimidoyl)-benzoylamino]-benzamide",0.33,uM,=,-0.4814860601221125,0,O=C(Nc1ccccc1C(=O)Nc1ccccn1)c1ccccc1
2824,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COc1cc(OC)cc(C(=O)NCC2(C#N)CCN(CCc3ccccc3)CC2)c1,"N-((4-cyano-1-phenethylpiperidin-4-yl)methyl)-3,5-dimethoxybenzamide",1.57,uM,=,0.1958996524092337,1,O=C(NCC1CCN(CCc2ccccc2)CC1)c1ccccc1
2825,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,Cc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccs1,"(R)-N,N-dimethyl-2-(6-methyl-3-(1-(thiazol-2-yl)ethyl)-1H-inden-2-yl)ethanamine",0.62,uM,=,-0.2076083105017461,0,C1=C(Cc2nccs2)c2ccccc2C1
2826,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1,"(R)-(4-Fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
2827,872803,10.1021/jm300991n,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CC#Cc1cncc(-c2cccc(C3(c4cc(C)c(OC)c(C)c4)N=C(C)C(N)=N3)c2)c1,"2-(4-Methoxy-3,5-dimethylphenyl)-5-methyl-2-{3-[5-(prop-1-yn-1-yl)pyridin-3-yl]phenyl}-2H-imidazol-4-amine",17.5,uM,=,1.2430380486862944,1,C1=NC(c2ccccc2)(c2cccc(-c3cccnc3)c2)N=C1
2828,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3cnc4ccccc43)[C@H](C)C2)cn1,2-Benzoimidazol-1-yl-1-{(R)-4-[4-(2-ethoxy-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-ethanone,4.7,uM,=,0.6720978579357175,1,O=C(Cn1cnc2ccccc21)N1CCN(c2scnc2-c2cncnc2)CC1
2829,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3cnc(OC(F)F)cn3)cs2)CO1,"N-{2-[(4aR,6S,8aR)-2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyrazine-2-carboxamide",23.6,uM,=,1.3729120029701067,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1cnccn1
2830,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1ccc2c(=O)n(-c3ccc(OCCCN4CCCC4)cc3)c(C)nc2c1,7-Methoxy-2-methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,10.0,uM,=,1.0,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
2831,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CS(=O)(=O)Nc1ccc(OC[C@@H](O)CNCCc2ccc(Cl)cc2)cc1,(S)-1-(4-Methanesulfonamidophenoxy)-3-(4-chlorophenylethylamino)-2-propanol,1.39,uM,=,0.143014800254095,1,c1ccc(CCNCCCOc2ccccc2)cc1
2832,1749583,10.1016/j.bmcl.2017.10.040,,,,Inhibition of human ERG,CCN(CC)[C@@H](C)CNC(=O)c1ccnc(-c2cnn3ccc(-c4cccs4)nc23)c1,"(S)-N-(2-(diethylamino)propyl)-2-(5-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)isonicotinamide",0.718,uM,=,-0.1438755557576996,0,c1ccc(-c2cnn3ccc(-c4cccs4)nc23)nc1
2833,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,NC(=O)c1ncc(N[C@@H]2CCCC[C@@H]2N)cc1Nc1cccc(C(F)(F)F)n1,"5-(((1R,2S)-2-aminocyclohexyl)amino)-3-((6-(trifluoromethyl)pyridin-2-yl)amino)picolinamide",0.6,uM,=,-0.2218487496163563,0,c1ccc(Nc2cncc(NC3CCCCC3)c2)nc1
2834,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc(C(F)(F)F)cc1)Cc1ccc2c(c1)CCO2.Cl,(E)-N-(Coumaran-5-methyl)-N-methyl-3-(4-trifluoromethylphenyl)prop-2-en-1-amine Hydrochloride,2.2,uM,=,0.3424226808222063,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)CCO2
2835,1832936,10.1016/j.bmcl.2018.12.058,,,,Binding affinity to human ERG,O=C(c1ccc(-c2ccc(F)c(F)c2)o1)N1CCN(Cc2ccc(OC3CCNCC3)c(Cl)c2)CC1,"(4-(3-chloro-4-(piperidin-4-yloxy)benzyl)piperazin-1-yl)-5-(3,4-difluorophenyl)-furan-2-carboxamide",4.0,uM,=,0.6020599913279624,1,O=C(c1ccc(-c2ccccc2)o1)N1CCN(Cc2ccc(OC3CCNCC3)cc2)CC1
2836,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,CC(C)CN(C(=O)c1cc(Cl)ccc1Cl)[C@H]1CCNC1,"(S)-2,5-dichloro-N-isobutyl-N-(pyrrolidin-3-yl)benzamide",19.8,uM,=,1.2966651902615312,1,O=C(N[C@H]1CCNC1)c1ccccc1
2837,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)C[C@@H]2c2ccc(OC)cc2)cc1,(S)-1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxy-phenyl)-2-imidazolidinone,26.7,uM,=,1.4265112613645752,1,O=C1NC[C@H](c2ccccc2)N1CCc1ccccc1
2838,1972831,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide,0.45,uM,=,-0.3467874862246563,0,O=C(Nc1cccc(-n2ccnc2)c1)c1cccc(Nc2nccc(-c3cccnc3)n2)c1
2839,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)CC2c2ccc(C)c(C)c2)cc1,"1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(3,4-dimethylphenyl)-2-imidazolidinone",15.8,uM,=,1.1986570869544226,1,O=C1NCC(c2ccccc2)N1CCc1ccccc1
2840,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1cnccn1,"4'-[8-(3-Methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrazin-2-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",16.0,uM,=,1.2041199826559248,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1cnccn1
2841,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(Cl)ccc3OC[C@H]2[C@@]1(CCCN(C)C)c1ccccc1,"1-[(3R,3aR)-8-chloro-3-(3-dimethylamino-propyl)-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-2-yl]-ethanone",2.0,uM,=,0.3010299956639812,1,C1=NN2c3ccccc3OC[C@H]2C1c1ccccc1
2842,1911375,10.1021/acs.jmedchem.8b01296,,,,Inhibition of human ERG after 4 hrs by fluorescence polarization assay,CC(C)N1CCN(c2ccc(/C(=C(/CCCO)c3ccccc3)c3ccc(Br)cc3)cc2)CC1.Cl.Cl,(E)-5-(4-bromophenyl)-5-(4-(4-isopropylpiperazin-1-yl)phenyl)-4-phenylpent-4-en-1-ol dihydrochloride,15.3,uM,=,1.1846914308175989,1,C(=C(c1ccccc1)c1ccc(N2CCNCC2)cc1)c1ccccc1
2843,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,[3-(4-Chloro-phenyl)-3-pyridin-2-yl-propyl]-dimethyl-amine,1.1,uM,=,0.041392685158225,1,c1ccc(Cc2ccccn2)cc1
2844,1635871,10.1016/j.ejmech.2016.11.017,,,,Inhibition of human ERG expressed in CHOK1 cells by automated patch clamp method,CCN1CCCC1CNC(=O)c1ccc(Cn2c(Cc3c(Cl)cccc3Cl)nc3ccccc32)cc1,"4-((2-(2,6-Dichlorobenzyl)-1H-benzo[d]imidazol-1-yl)methyl)-N-((1-ethylpyrrolidin-2-yl)methyl)benzamide",1.57,uM,=,0.1958996524092337,1,O=C(NCC1CCCN1)c1ccc(Cn2c(Cc3ccccc3)nc3ccccc32)cc1
2845,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,COc1ccc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3cnc4cccnc43)[C@H](C)C2)cn1,"2-imidazo[4,5-b]pyridin-3-yl-1-{(R)-4-[4-(6-methoxy-pyridin-3-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-ethanone",8.9,uM,=,0.9493900066449128,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2cccnc2)CC1
2846,971477,10.1021/jm400402q,,,,Inhibition of human ERG by dofetilide binding assay,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(C(=O)CN(C)C)CC1,1-(4-(4-((5-Chloro-4-((2-(isopropylsulfonyl)-phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-2-(dimethylamino)ethanone,24.5,uM,=,1.3891660843645326,1,c1ccc(Nc2ccnc(Nc3ccc(C4CCNCC4)cc3)n2)cc1
2847,591415,10.1021/jm901107f,,,,Inhibition of human ERG expressed in HEK cells,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@]1(C)O,3 9-dihydro-N-desmethyl-N-isopropylerythromycin A,0.01,uM,=,-2.0,0,O=C1C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CCCCCCCCO1
2848,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CN(C)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1,"N,N-Dimethyl-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide",23.07,uM,=,1.3630475945210936,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
2849,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CCCCN(CCc1ccc(Cl)c(Cl)c1)C[C@H](O)COc1ccc(NS(C)(=O)=O)cc1,"(S)-1-(4-Methanesulfonamidophenoxy)-3-(N-butyl-3,4-dichlorophenylethylamino)-2-propanol",0.07,uM,=,-1.154901959985743,0,c1ccc(CCNCCCOc2ccccc2)cc1
2850,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)N1C[C@H](NS(=O)(=O)C(C)C)[C@@H](c2ccc(-c3cccc(NS(C)(=O)=O)c3)cc2)C1,"N-((3R,4R)-1-isopropyl-4-(3'-(methylsulfonamido)biphenyl-4-yl)pyrrolidin-3-yl)propane-2-sulfonamide",6.3,uM,=,0.7993405494535817,1,c1ccc(-c2ccc([C@@H]3CCNC3)cc2)cc1
2851,2051310,10.1021/acs.jmedchem.0c01575,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CC(=O)N1CCN(CCCOCc2cc(C)n(-c3ccc(Cl)c(Cl)c3)n2)CC1,"1-(4-(3-((1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone",4.084,uM,=,0.6110857334148726,1,c1ccc(-n2ccc(COCCCN3CCNCC3)n2)cc1
2852,1288300,10.1016/j.bmcl.2013.12.078,,,,Inhibition of human ERG by whole-cell patch clamp method,COC(=O)C(CCCN1CCN(c2ccccc2OC)CC1)(c1ccc(Br)cc1)C(C)C,methyl 2-(4-bromophenyl)-2-isopropyl-5-(4-(2-methoxyphenyl)piperazin-1-yl)pentanoate,1.38,uM,=,0.1398790864012364,1,c1ccc(CCCCN2CCN(c3ccccc3)CC2)cc1
2853,487847,10.1021/jm800386y,,,,Displacement of [35S]MK499 from human ERG expressed in HEL cells,CN1CCC(N(C)C(=O)N2CC(c3cc(F)ccc3F)=C[C@@]2(CO)c2ccccc2)CC1,"(2S)-4-(2,5-Difluorophenyl)-2-(hydroxymethyl)-N-methyl-N-(1-methylpiperidin-4-yl)-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide",14.6,uM,=,1.1643528557844371,1,O=C(NC1CCNCC1)N1CC(c2ccccc2)=CC1c1ccccc1
2854,1351560,10.1016/j.bmcl.2014.03.036,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells,O=C(O)c1cccc(C2CCN([C@@H]3C[C@H]4OCC[C@@]4(C(=O)N4COc5ccc(C(F)(F)F)cc5C4)C3)CC2)c1,"3-(1-((3aS,5S,6aR)-3a-(6-(trifluoromethyl)-3,4-dihydro-2H-benzo[e][1,3]oxazine-3-carbonyl)hexahydro-2H-cyclopenta[b]furan-5-yl)piperidin-4-yl)benzoic acid",29.0,uM,=,1.462397997898956,1,O=C(N1COc2ccccc2C1)[C@@]12CCO[C@@H]1C[C@@H](N1CCC(c3ccccc3)CC1)C2
2855,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4ncc(C#N)cc43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(6-cyano-1H-imidazo[4,5-b]pyridin-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",5.2,uM,=,0.7160033436347992,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ncccc43)C[C@@H]12)c1ccccc1
2856,1700805,10.1021/acs.jmedchem.6b01831,,,,Inhibition of human ERG assessed as reduction of K+ current,COc1ccc2ccc(=O)n(C[C@H](O)[C@@H]3CC[C@@H](NCc4ccc5c(n4)NC(=O)CO5)CO3)c2n1,"6-((((3R,6S)-6-((1S)-1-Hydroxy-2-(7-methoxy-2-oxo-1,8-naphthyridin-1(2H)-yl)ethyl)tetrahydro-2H-pyran-3-yl)amino)methyl)-2Hpyrido[3,2-b][1,4]oxazin-3(4H)-one",15.0,uM,=,1.1760912590556811,1,O=C1COc2ccc(CN[C@@H]3CC[C@@H](CCn4c(=O)ccc5cccnc54)OC3)nc2N1
2857,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3nc4ccccc4s3)CC2)C1,cis-N-{[1-(4-Benzothiazol-2-yl-4-hydroxy-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide,6.2,uM,=,0.7923916894982539,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3nc4ccccc4s3)CC2)C1
2858,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cn1ncc(C(=O)Nc2cncc(-c3cc(Cl)cc(Cl)c3)c2N2CCC(N)CC2)c1C(F)(F)F,"N-(4-(4-aminopiperidin-1-yl)-5-(3,5-dichlorophenyl)pyridin-3-yl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide",7.3,uM,=,0.8633228601204559,1,O=C(Nc1cncc(-c2ccccc2)c1N1CCCCC1)c1cn[nH]c1
2859,1986137,10.1021/acs.jmedchem.0c00347,,,,Inhibition of human ERG expressed in HEK293 cells measured after 10 mins by manual patch clamp electrophysiology method,Cc1c(N2CC[C@@H]([C@H](C)N)C2)c(F)cc2ccc(=O)n(C3CC3)c12,7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methylquinolin-2(1H)-one,48.8,uM,=,1.688419822002711,1,O=c1ccc2ccc(N3CCCC3)cc2n1C1CC1
2860,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc(C2(c3nn(C)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"(3R)-3-(4-(5-Fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-ethyl-pyrazol-4-yl)-1-(2-hydroxy-1,3,4-oxadiazol-5-yl)-2,3,4,9-tetrahydro-1H-beta-carboline",39.9,uM,=,1.6009728956867482,1,O=c1[nH]nc(C2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
2861,858346,10.1016/j.bmcl.2012.08.100,,,,Inhibition of human ERG by IonWorks assay,N#Cc1ccc(-c2noc(-c3cc(F)cc(C#N)c3)n2)nc1,"6-(5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazol-3-yl)nicotinonitrile",6.35,uM,=,0.8027737252919757,1,c1ccc(-c2nc(-c3ccccn3)no2)cc1
2862,1437797,10.1021/jm501119j,,,,Inhibition of human ERG by whole cell based electrophysiology assay,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc2ncccc2c1,N-(4-(4-Phenylpiperazin-1-yl)butyl)quinoline-6-carboxamide,10.0,uM,=,1.0,1,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc2ncccc2c1
2863,2021863,10.1016/j.bmcl.2020.127433,,,,Inhibition of human ERG by plate-based planar patch clamp method,CNC(=O)c1ncn2ccc(Nc3nccc(-n4cc(CN(C)C)cn4)n3)cc12,"7-(4-(4-((dimethylamino)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-N-methylimidazo[1,5-a]pyridine-1-carboxamide",7.3,uM,=,0.8633228601204559,1,c1cnn(-c2ccnc(Nc3ccn4cncc4c3)n2)c1
2864,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CCNCC1,"US9452986, 1",12.9,uM,=,1.110589710299249,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
2865,499332,10.1016/j.bmcl.2009.04.023,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(C(=O)[C@]4(CC)CC[C@@](C)(O)CC4)nc3cc2Cl)CC1,trans-(5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)(1-ethyl-4-hydroxy-4-methylcyclohexyl)methanone,11.0,uM,=,1.0413926851582251,1,O=C(c1nc2ccc(N3CCNCC3)cc2[nH]1)C1CCCCC1
2866,796063,10.1016/j.bmcl.2011.11.050,,,,Inhibition of human ERG by patch express assay,CC1(C)NCCc2c1oc1cc(S(=O)(=O)c3cccc(F)c3)ccc21,"7-(3-fluorophenylsulfonyl)-1,1-dimethyl-1,2,3,4-tetrahydrobenzofuro[2,3-c]pyridine",1.0,uM,=,0.0,0,O=S(=O)(c1ccccc1)c1ccc2c3c(oc2c1)CNCC3
2867,948139,10.1016/j.bmcl.2013.01.019,,,,Inhibition of human ERG,COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO,"(5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol",30.4,uM,=,1.4828735836087537,1,c1ccc(-c2ccc3c(N4CCOCC4)nc(N4CCOCC4)nc3n2)cc1
2868,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N(Cc3ccccc3)CC(F)(F)F)nn2)ccc1-n1cnc(C)c1,"N-benzyl-2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide",2.87,uM,=,0.4578818967339924,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)NCc1ccccc1
2869,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,O=C1N(c2ccccc2)CC2(CCN(CCc3ccccc3)CC2)OC12CC2,"8-Phenethyl-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one",1.2,uM,=,0.0791812460476248,1,O=C1N(c2ccccc2)CC2(CCN(CCc3ccccc3)CC2)OC12CC2
2870,1583746,10.1016/j.bmcl.2016.05.058,,,,Inhibition of recombinant human ERG expressed in HEK293 cells assessed as inhibition of peak tail current by patch clamp assay,CC(C)Oc1cc([C@@](Cc2ccccc2)(NC[C@H](O)CC(F)(F)F)c2cc(F)cc(OC(F)(F)C(F)F)c2)ccc1F,"(R)-4,4,4-trifluoro-1-((R)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethylamino)butan-2-ol",25.6,uM,=,1.4082399653118496,1,c1ccc(CC(c2ccccc2)c2ccccc2)cc1
2871,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2c(C)cc(-c3cccnc3)cc12,4-[(2-Ethylbutyl)amino]-8-methyl-6-(3-pyridinyl)-3-quinolinecarboxamide,0.36,uM,=,-0.4436974992327127,0,c1cncc(-c2ccc3ncccc3c2)c1
2872,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(C(F)(F)F)ccc1Oc1ccc(C)cc1,N-methyl-1-(2-(p-tolyloxy)-5-(trifluoromethyl)phenyl)methanamine,10.4,uM,=,1.0170333392987805,1,c1ccc(Oc2ccccc2)cc1
2873,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(CC)CC2)c1ncc(-c2ccc(-c3ccccc3)[nH]c2=O)[nH]1,"(S)-6-ethyl-N-((S)-7-oxo-1-(5-(2-oxo-6-phenyl-1,2-dihydropyridin-3-yl)-1H-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide",3.0,uM,=,0.4771212547196624,1,O=C(NCc1ncc(-c2ccc(-c3ccccc3)[nH]c2=O)[nH]1)[C@H]1CC12CCNCC2
2874,2092876,10.1016/j.ejmech.2020.112677,,,,Inhibition of human ERG,O=C(CCCCCCC(=O)Nc1ccccc1)NO,Octanedioic acid hydroxyamide phenylamide,0.322,uM,=,-0.4921441283041691,0,c1ccccc1
2875,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(N)=O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid amide",0.65,uM,=,-0.1870866433571444,0,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
2876,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CCN1CC2(CCN(CCc3ccccc3)CC2)O[C@H](C)C1=O,"(R)-4-Ethyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one",4.7,uM,=,0.6720978579357175,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1
2877,1563076,10.1016/j.ejmech.2016.02.008,,,,Inhibition of human ERG by QPatch assay,Cc1cc(C)n(Cc2ccc(C(=O)NCC3(c4nc(-c5ccccc5)cs4)CCOCC3)cc2)n1,"4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)-N-((4-(4-phenylthiazol-2-yl)tetrahydro-2H-pyran-4-yl)methyl)benzamide",44.9,uM,=,1.6522463410033232,1,O=C(NCC1(c2nc(-c3ccccc3)cs2)CCOCC1)c1ccc(Cn2cccn2)cc1
2878,2046076,10.1021/acsmedchemlett.8b00541,,,,Inhibition of human ERG by patch clamp method,CNc1nc(Nc2ccc(-n3cnc(C)n3)c(OC)c2)nc2c1CC[C@H]2c1ccc(F)cc1,"(S)-7-(4-fluorophenyl)-N2-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine",1.2,uM,=,0.0791812460476248,1,c1ccc([C@@H]2CCc3cnc(Nc4ccc(-n5cncn5)cc4)nc32)cc1
2879,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(C3CC([Si](C)(C)C)CCNC3=O)nn2)ccc1-n1cnc(C)c1,"rac-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-5-(trimethylsilyl)azepan-2-one",6.27,uM,=,0.7972675408307164,1,O=C1NCCCCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
2880,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2ccccn2)cc1,"N,N-diethyl-4-((1-(4-fluorobenzyl)piperidin-4-ylidene)(pyridin-2-yl)methyl)benzamide",3.9,uM,=,0.5910646070264992,1,c1ccc(CN2CCC(=C(c3ccccc3)c3ccccn3)CC2)cc1
2881,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,CC(C)(C)NC(=O)C1c2ccc(NS(C)(=O)=O)cc2C(=O)N1Cc1ccccc1-c1ccccc1,(rac)-2-(biphenyl-2-ylmethyl)-N-tert-butyl-5-(methylsulfonamido)-3-oxoisoindoline-1-carboxamide,15.0,uM,=,1.1760912590556811,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
2882,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1cccc(OC)c1F)[C@@](O)(CCN(C)C)c1cccc2c1CCC2,"(1S,2S)-1-(7-bromo-3-methoxynaphthalen-2-yl)-2-(2,3-dihydro-1H-inden-4-yl)-4-(dimethylamino)-1-(2-fluoro-3-methoxyphenyl)butan-2-ol",3.0,uM,=,0.4771212547196624,1,c1ccc([C@@H](Cc2cccc3c2CCC3)c2ccc3ccccc3c2)cc1
2883,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1.O=C(O)CCC(=O)O,5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol hemisuccinate,0.22,uM,=,-0.6575773191777937,0,c1ccc(/N=N/c2ccccn2)cc1
2884,493421,10.1016/j.bmcl.2008.10.025,,,,Inhibition of human ERG expressed in CHO cells,Fc1ccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)cc1,5-(3-(4-fluorobenzyl)pyrrolidin-3-yl)-1H-indole,9.0,uM,=,0.9542425094393248,1,c1ccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)cc1
2885,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide,0.0077,uM,=,-2.113509274827518,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
2886,49075,10.1021/jm0208875,,,,K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.1,Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1,"1-Cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid",104.0,uM,=,2.0170333392987803,1,O=c1ccn(C2CC2)c2cc(N3CCNCC3)ccc12
2887,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N(C)C)cc3)n2)n1C(C)C,"4-(4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)-N,N-dimethylbenzamide",18.0,uM,=,1.255272505103306,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
2888,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CC[C@H](F)C1,"US9452986, 51",22.9,uM,=,1.359835482339888,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCCC1
2889,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccnc1OC,"(R)-2-(6-methoxy-3-(1-(3-methoxypyrazin-2-yl)ethyl)-1H-inden-2-yl)-N,N-dimethylethanamine",5.0,uM,=,0.6989700043360189,1,C1=C(Cc2cnccn2)c2ccccc2C1
2890,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,CCOC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)c(Cl)c1,"ethyl 2-(3'-chloro-4'-((3S,4S)-4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidin-3-yl)biphenyl-2-yl)ethylcarbamate",3.2,uM,=,0.505149978319906,1,O=c1cc([C@H]2CCNC[C@@H]2c2ccc(-c3ccccc3)cc2)cc[nH]1
2891,579352,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG activation expressed in CHO cells by rubidium efflux assay,O=C(NCc1ccc(Cl)cc1Cl)N1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,"N-(2,4-dichlorobenzyl)-4-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperazine-1-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(NCc1ccccc1)N1CCN(Cc2ccn(-c3ccccc3)c2)CC1
2892,609460,10.1016/j.bmcl.2009.12.026,,,,Inhibition of human ERG,CNC(C)(C)C(=O)N1CCN(C(=O)c2cc(Cc3c[nH]c(=O)c4cc(Cl)c(Cl)n34)ccc2F)CC1,"6,7-dichloro-4-(4-fluoro-3-(4-(2-methyl-2-(methylamino)propanoyl)piperazine-1-carbonyl)benzyl)pyrrolo[1,2-a]pyrazin-1(2H)-one",11.0,uM,=,1.0413926851582251,1,O=C(c1cccc(Cc2c[nH]c(=O)c3cccn23)c1)N1CCNCC1
2893,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine,3.2,uM,=,0.505149978319906,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
2894,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CCc1cc(Oc2cc(Cl)ccc2CNC)ccc1Cl,1-(4-chloro-2-(4-chloro-3-ethylphenoxy)phenyl)-N-methylmethanamine,1.15,uM,=,0.0606978403536116,1,c1ccc(Oc2ccccc2)cc1
2895,446746,10.1016/j.bmcl.2006.12.007,,,,Inhibition of hERG by patch clamp assay,NC(=O)CNC[C@H]1CC[C@]2(CC1)OO[C@]1(O2)C2CC3CC(C2)CC1C3,"2-({dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1''-cyclohexane]-4''-ylmethyl}amino)acetamide",2.7,uM,=,0.4313637641589873,1,C1CC[C@]2(CC1)OO[C@]1(O2)C2CC3CC(C2)CC1C3
2896,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1,4-(benzyloxy)-1-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,2.5,uM,=,0.3979400086720376,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
2897,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(NCc1ccc(F)cc1)N(c1ccc(Cl)cc1)C1CCN(Cc2ccnnc2)CC1,1-(4-chlorophenyl)-3-(4-fluorobenzyl)-1-(1-(pyridazin-4-ylmethyl)piperidin-4-yl)urea,12.0,uM,=,1.0791812460476249,1,O=C(NCc1ccccc1)N(c1ccccc1)C1CCN(Cc2ccnnc2)CC1
2898,699709,10.1016/j.bmcl.2010.11.111,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells,COc1cc(/C=C/c2nc(N)nc(Nc3ccccc3)n2)ccc1-n1cnc(C)c1,"6-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)styryl)-N2-phenyl-1,3,5-triazine-2,4-diamine",0.3,uM,=,-0.5228787452803376,0,C(=C/c1ncnc(Nc2ccccc2)n1)\c1ccc(-n2ccnc2)cc1
2899,1924853,10.1016/j.bmcl.2016.07.029,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells measured after 90 mins by scintillation proximity assay,COc1cc(C(=O)N2C[C@@H](n3cc(C4CC4)nn3)C[C@H]2C(=O)N2CC[C@H](c3ccccc3)C2)ccc1CN,"((2S,4S)-1-(4-(aminomethyl)-3-methoxybenzoyl)-4-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)pyrrolidin-2-yl)((R)-3-phenylpyrrolidin-1-yl)methanone",14.0,uM,=,1.146128035678238,1,O=C([C@@H]1C[C@H](n2cc(C3CC3)nn2)CN1C(=O)c1ccccc1)N1CC[C@H](c2ccccc2)C1
2900,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cn3)c2)CC1)NC(c1ccc(F)cc1)c1ccc(F)cc1,N-(bis(4-fluorophenyl)methyl)-2-(1-((1-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,0.8,uM,=,-0.0969100130080563,0,O=C(CC1CCN(Cc2ccn(-c3ccccn3)c2)CC1)NC(c1ccccc1)c1ccccc1
2901,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)cn3)CC2)ccc2c1COC2=O,5-(2-(4-(2-(5-(1H-tetrazol-1-yl)pyridin-2-yl)acetyl)piperazin-1-yl)ethyl)-4-methylisobenzofuran-1(3H)-one,33.0,uM,=,1.5185139398778875,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cn4)CC3)ccc21
2902,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1nnc(-c2ccc(Cl)cc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1,"(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)(4-(4-(pyrrolidin-1-ylmethyl)phenoxy)piperidin-1-yl)methanone",5.5,uM,=,0.7403626894942439,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
2903,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ccc(=O)n(CCN3CCN(c4nc5ccccc5[nH]4)CC3)c2c1,"1-(2-(4-(1H-benzo[d]imidazol-2-yl)piperazin-1-yl)ethyl)-7-methoxy-1,5-naphthyridin-2(1H)-one",7.0,uM,=,0.8450980400142568,1,O=c1ccc2ncccc2n1CCN1CCN(c2nc3ccccc3[nH]2)CC1
2904,755452,10.1016/j.bmcl.2010.05.026,,,,Inhibition of human hERG,CCOc1ccc(-n2nc3c(N4CC(OC)C4)nnc(C)c3c2C)c(F)c1,"2-(4-ethoxy-2-fluorophenyl)-7-(3-methoxyazetidin-1-yl)-3,4-dimethyl-2H-pyrazolo[4,3-d]pyridazine",6.0,uM,=,0.7781512503836436,1,c1ccc(-n2cc3cnnc(N4CCC4)c3n2)cc1
2905,698202,10.1016/j.bmcl.2010.11.033,,,,Inhibition of human hERG,COC(=O)c1coc(CN2CCN(C(=O)CC(c3ccc(F)cc3)c3ccc(C(F)(F)F)cc3)CC2)n1,methyl 2-((4-(3-(4-fluorophenyl)-3-(4-(trifluoromethyl)phenyl)propanoyl)piperazin-1-yl)methyl)oxazole-4-carboxylate,3.83,uM,=,0.5831987739686227,1,O=C(CC(c1ccccc1)c1ccccc1)N1CCN(Cc2ncco2)CC1
2906,534565,10.1016/j.bmc.2008.01.017,,,,Inhibition of human ERG potassium channel,Cc1nccn1C[C@H]1CCc2c(c3ccccc3n2C)C1=O,"(R)-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-2,3-dihydro-1H-carbazol-4(9H)-one",0.81,uM,=,-0.0915149811213502,0,O=C1c2c([nH]c3ccccc23)CC[C@@H]1Cn1ccnc1
2907,1435893,10.1016/j.bmc.2014.10.020,,,,Inhibition of human ERG expressed in CHO cells by Rb efflux assay,COc1ccccc1CCNCC(=O)N1CCc2ccccc2C1C1CCCCC1,"1-(1-Cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-{[2-(2-methoxyphenyl)ethyl]amino}ethanone",8.3,uM,=,0.919078092376074,1,O=C(CNCCc1ccccc1)N1CCc2ccccc2C1C1CCCCC1
2908,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,CC(C)(C)c1c[nH]c(C2Cc3c([nH]c4ccccc34)C(C3CCOCC3)N2)n1,"3-(4-tert-butyl-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",2.944,uM,=,0.4689378056654612,1,c1ccc2c3c([nH]c2c1)C(C1CCOCC1)NC(c1ncc[nH]1)C3
2909,2035346,10.1021/acsmedchemlett.0c00660,,,,Inhibition of human ERG,CC1(C)OC(=O)c2ccc(Nc3ncc(-c4nc(C56CCN(CC5)CC6)no4)c(N[C@H](CO)c4ccccc4)n3)cc21,"(S)-5-((4-((2-Hydroxy-1-phenylethyl)amino)-5-(3-(quinuclidin-4-yl)-1,2,4-oxadiazol-5-yl)pyrimidin-2-yl)amino)-3,3-dimethylisobenzofuran-1(3H)-one",0.57,uM,=,-0.2441251443275086,0,O=C1OCc2cc(Nc3ncc(-c4nc(C56CCN(CC5)CC6)no4)c(NCc4ccccc4)n3)ccc21
2910,1655138,10.1016/j.bmcl.2016.12.054,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in rapidly activating delayed rectifier cardiac potassium current by whole-cell voltage-patch clamp assay,CS(=O)(=O)Nc1cccc([C@H](c2ccc(F)cc2)C(c2cccnc2)c2cccnc2)n1,"(S)-N-(6-(1-(4-fluorophenyl)-2,2-di(pyridin-3-yl)ethyl)pyridin-2-yl)methanesulfonamide",110.0,uM,=,2.041392685158225,1,c1ccc([C@@H](c2ccccn2)C(c2cccnc2)c2cccnc2)cc1
2911,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(CN2CCOCC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)-N-(2-methoxy-4-(morpholinomethyl)phenyl)pyrimidin-2-amine",9.9,uM,=,0.99563519459755,1,c1ccn2c(-c3ccnc(Nc4ccc(CN5CCOCC5)cc4)n3)cnc2c1
2912,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(Cl)n2)(c2ccccc2F)CC1,2-chloro-6-(((4-(2-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,43.0,uM,=,1.6334684555795866,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
2913,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,O=C1NCCN1CCN1CCC(C2CN(c3ccc(F)cc3)c3ccccc32)CC1,"1-(2-{4-[1-(4-Fluoro-phenyl)-2,3-dihydro-1H-indol-3-yl]-piperidin-1-yl}-ethyl)-imidazolidin-2-one",0.0235,uM,=,-1.6289321377282635,0,O=C1NCCN1CCN1CCC(C2CN(c3ccccc3)c3ccccc32)CC1
2914,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CCN3CCC(NCc4ccc5c(c4)OCCO5)CC3)c2c1,"N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1-(2-(6-methoxyquinolin-4-yl)ethyl)piperidin-4-amine",0.81,uM,=,-0.0915149811213502,0,c1ccc2c(CCN3CCC(NCc4ccc5c(c4)OCCO5)CC3)ccnc2c1
2915,2260412,10.1021/acs.jmedchem.0c01744,,,,Inhibition of hERG by fluorescence polarization assay,COc1ccc(/N=C(\N)CC(O)c2cc3c(F)cc(F)cc3c3cc(C(F)(F)F)ccc23)cc1.Cl,"(Z)-3-(1,3-Difluoro-6-(trifluoromethyl)phenanthrene-9-yl)-3-hydroxy-N'-(4-methoxyphenyl)propanimidamide Hydrochloride",0.19,uM,=,-0.721246399047171,0,C(CCc1cc2ccccc2c2ccccc12)=Nc1ccccc1
2916,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,Nc1nccn2c([C@@H]3CCCN(C4CCOCC4)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12,"4-(8-amino-3-((R)-1-(tetrahydro-2H-pyran-4-yl)piperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-3-fluoro-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",0.1,uM,=,-1.0,0,O=C(Nc1ccccn1)c1ccc(-c2nc([C@@H]3CCCN(C4CCOCC4)C3)n3ccncc23)cc1
2917,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2c1OC(c1ccc(OC3CCN(C4CCC4)CC3)cc1)C(C)S2(=O)=O,"(+/-)-1-Cyclobutyl-4-[4-(8-methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-piperidine",14.0,uM,=,1.146128035678238,1,O=S1(=O)CC(c2ccc(OC3CCN(C4CCC4)CC3)cc2)Oc2ccccc21
2918,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=C1COc2ccc(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"(R)-6-((1-((3-fluoro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",174.0,uM,=,2.2405492482826,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
2919,493421,10.1016/j.bmcl.2008.10.025,,,,Inhibition of human ERG expressed in CHO cells,c1ccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)cc1,5-(3-benzylpyrrolidin-3-yl)-1H-indole,9.0,uM,=,0.9542425094393248,1,c1ccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)cc1
2920,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,COc1c(C)cc(C2(c3cccc(-c4cncnc4)c3)N=C(N)c3c(F)cccc32)cc1C#N,5-(3-Amino-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-1-yl)-2-methoxy-3-methylbenzonitrile,2.1,uM,=,0.3222192947339193,1,C1=NC(c2ccccc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
2921,1672277,10.1016/j.bmcl.2017.05.026,,,,Inhibition of recombinant human ERG expressed in HEK293 cells after 9 mins by patch clamp method,Nc1ccccc1NC(=O)c1ccc(N2CCN(C(=O)/C=C/c3ccc(F)cc3)CC2)cc1,(E)-N-(2-aminophenyl)-4-(4-(3-(4-fluorophenyl)acryloyl)piperazin-1-yl)benzamide,32.6,uM,=,1.513217600067939,1,O=C(Nc1ccccc1)c1ccc(N2CCN(C(=O)/C=C/c3ccccc3)CC2)cc1
2922,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one",0.148,uM,=,-0.8297382846050426,0,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2
2923,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCC[C@@H](CCO)Nc1nc(N)nc2ccc(C)cc12,(S)-3-((2-Amino-6-methylquinazolin-4-yl)amino)hexan-1-ol,7.2,uM,=,0.8573324964312685,1,c1ccc2ncncc2c1
2924,2165730,10.1021/acsmedchemlett.1c00696,,,,Inhibition of human ERG,Cc1nccc(-c2cc3[nH]nc(NC4CCN(C)CC4)c3cc2C2CC2)c1F,5-cyclopropyl-6-(3-fluoro-2-methylpyridin-4-yl)-N-(1-methylpiperidin-4-yl)-1H-indazol-3-amine,11.0,uM,=,1.0413926851582251,1,c1cc(-c2cc3[nH]nc(NC4CCNCC4)c3cc2C2CC2)ccn1
2925,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,Cc1nn2ccccc2c1CCN(Cc1ccc(/C=C/C(=O)NO)cc1)C(C)C,"(E)-N-Hydroxy-3-[4-({isopropyl-[2-(2-methyl-pyrazolo[1,5-a]pyridin-3-yl)-ethyl]-amino}-methyl)-phenyl]-acrylamide",10.03,uM,=,1.001300933020418,1,c1ccc(CNCCc2cnn3ccccc23)cc1
2926,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,CC1(C(=O)N2CCO[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)C2)CCC1,"4-(8-amino-3-((R)-4-(1-methylcyclobutanecarbonyl)morpholin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-3-fluoro-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",14.0,uM,=,1.146128035678238,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@H]3CN(C(=O)C4CCC4)CCO3)n3ccncc23)cc1
2927,421810,10.1016/j.bmcl.2006.10.053,,,,Inhibition of binding to hERG,CN(C)Cc1ccc2c(c1)CC[C@H](N(C)C(=O)c1ccc(-c3ccc(F)cc3)nc1)C2,"(S)-N-(6-((dimethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-6-(4-fluorophenyl)-N-methylnicotinamide",10.0,uM,=,1.0,1,O=C(N[C@H]1CCc2ccccc2C1)c1ccc(-c2ccccc2)nc1
2928,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,"4-(8-Chloro-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-piperidine-1-carboxylic acid ethyl ester",0.173,uM,=,-0.7619538968712046,0,c1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
2929,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3cccc4cccnc34)nn2)ccc1-n1cnc(C)c1,"8-((4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)methyl)quinoline",5.43,uM,=,0.7347998295888469,1,c1cnc2c(Cn3cc(-c4ccc(-n5ccnc5)cc4)nn3)cccc2c1
2930,2025950,10.1021/acsmedchemlett.0c00575,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,CNS(=O)(=O)c1ccc(CNc2nc3cnc(-c4c(C)ncnc4C4CC4)nc3n([C@@H](C)C3CC3)c2=O)nc1,"(S)-6-((2-(4-cyclopropyl-6-methylpyrimidin-5-yl)-8-(1-cyclopropylethyl)-7-oxo-7,8-dihydropteridin-6-ylamino)methyl)-N-methylpyridine-3-sulfonamide",12.0,uM,=,1.0791812460476249,1,O=c1c(NCc2ccccn2)nc2cnc(-c3cncnc3C3CC3)nc2n1CC1CC1
2931,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=c1\scc(-c2ccccc2)n1-c1ccccc1,"2-((3,4-Diphenylthiazol-2(3H)-ylidene)amino)-4,6-diphenylnicotinonitrile",6.8,uM,=,0.8325089127062363,1,c1ccc(-c2cc(/N=c3\scc(-c4ccccc4)n3-c3ccccc3)nc(-c3ccccc3)c2)cc1
2932,1510552,10.1016/j.bmcl.2015.06.057,,,,Inhibition of human ERG expressed in CHO cells measured for 5 mins by automated patch clamp assay,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5C)OCC(=O)N6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-7-methyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",4.3,uM,=,0.6334684555795865,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2933,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,COC(=O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"methyl 5-(7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)pentanoate",0.4,uM,=,-0.3979400086720376,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
2934,2057776,10.1016/j.ejmech.2020.113103,,,,Inhibition of fluorescence tracer red binding to human ERG measured after 4 hrs by fluorescence polarization assay,COc1ccccc1S(=O)(=O)/C=C/c1ccccc1Cl,(E)-1-(2-((2-Methoxyphenyl)sulfonyl)vinyl)-2-chlorobenzene,12.0,uM,=,1.0791812460476249,1,O=S(=O)(/C=C/c1ccccc1)c1ccccc1
2935,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCN(CC(O)c3cc(C(F)(F)F)c(C#N)cn3)CC2)ccc2c1COC2=O,"6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-(trifluoromethyl)nicotinonitrile",10.0,uM,=,1.0,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
2936,2045815,10.1039/d0md00175a,,,,Inhibition of human ERG by patch clamp assay,Cc1nc2c(=O)n(C3CC3)c3c(Cl)c(N4CC[C@@H]([C@H](C)N)C4)c(F)cc3c2o1,"7-((R)-3-((S)-1-aminoethyl)pyrrolidin-1-yl)-6-chloro-5-cyclopropyl-8-fluoro-2-methyloxazolo[4,5-c]quinolin-4(5H)-one",28.7,uM,=,1.4578818967339924,1,O=c1c2ncoc2c2ccc(N3CCCC3)cc2n1C1CC1
2937,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@H]2CN3CCN(C(=O)Cc4cnc(-n5cnnn5)cn4)C[C@H]3CO2)ccc(F)c1C#N,"3-((3S,9aS)-8-(2-(5-(1H-tetrazol-1-yl)pyrazin-2-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-6-fluoro-2-methylbenzonitrile",12.3,uM,=,1.089905111439398,1,O=C(Cc1cnc(-n2cnnn2)cn1)N1CCN2C[C@H](c3ccccc3)OC[C@@H]2C1
2938,1713877,10.1016/j.bmcl.2018.05.030,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells after 45 mins by scintillation counting method,O=C(CCN1CCN(C(=O)OCc2cc(Cl)cc(Cl)c2)CC1)c1ccc2[nH]c(=O)oc2c1,SID174006268,2.7,uM,=,0.4313637641589873,1,O=C(CCN1CCN(C(=O)OCc2ccccc2)CC1)c1ccc2[nH]c(=O)oc2c1
2939,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CC1(C)CC(Cc2ccc(-c3ccc(-c4cn[nH]c4)cc3O)nn2)CC(C)(C)N1,"5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)methyl)pyridazin-3-yl)phenol",17.0,uM,=,1.230448921378274,1,c1cc(-c2ccc(CC3CCNCC3)nn2)ccc1-c1cn[nH]c1
2940,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CCN1CCC(N(C(=O)NCc2ccc(F)cc2)c2ccc(Cl)cc2)CC1,1-(4-chlorophenyl)-1-(1-ethylpiperidin-4-yl)-3-(4-fluorobenzyl)urea,6.65,uM,=,0.8228216453031046,1,O=C(NCc1ccccc1)N(c1ccccc1)C1CCNCC1
2941,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cnc(-c2ccc(OC3CCN(C(=O)Cc4ccc(OC(F)(F)F)cc4)CC3)c(C(N)=O)c2)c1,5-(1-methyl-1H-imidazol-4-yl)-2-(1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yloxy)benzamide,18.0,uM,=,1.255272505103306,1,O=C(Cc1ccccc1)N1CCC(Oc2ccc(-c3c[nH]cn3)cc2)CC1
2942,581929,10.1016/j.bmcl.2009.06.011,,,,Inhibition of human ERG,N[C@H]1Cn2c(nc3ccc(F)cc32)C[C@@H]1c1cc(F)c(F)cc1F.O=C(O)C(F)(F)F,"Trifluoro-acetate(2R,3R)-8-fluoro-3-(2,4,5-trifluoro-phenyl)-1,2,3,4-tetrahydro-benzo[4,5]imidazo[1,2-a]pyridin-2-yl-ammonium",17.0,uM,=,1.230448921378274,1,c1ccc([C@@H]2CCn3c(nc4ccccc43)C2)cc1
2943,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN(C)CCN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1,"N,N-dimethyl-2-(4-(2-phenyl-3-(4-((4-(5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)pyrido[3,2-b]pyrazin-6-yl)piperazin-1-yl)ethanamine",6.0,uM,=,0.7781512503836436,1,c1ccc(-c2nc3ccc(N4CCNCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1
2944,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1,N-ethyl-2-(4-(methylsulfonyl)phenyl)-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)acetamide,2.5,uM,=,0.3979400086720376,1,O=C(Cc1ccccc1)NC1CCN(Cc2ccccc2)CC1
2945,570979,10.1016/j.bmcl.2009.04.035,,,,Inhibition human ERG expressed in HEK293 cells assessed as blockade of membrane current by patch clamp method,Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)C[C@H]2[C@@H]3CN(CC4CC4)C[C@@H]32)c1,1-Methyl-1H-imidazole-4-carboxylic acid(3-cyclopropylmethyl-3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-(3-trifluoromethoxy-benzyl)-amide,0.53,uM,=,-0.2757241303992109,0,O=C(c1c[nH]cn1)N(Cc1ccccc1)C[C@H]1[C@@H]2CN(CC3CC3)C[C@@H]21
2946,763634,10.1016/j.bmcl.2011.06.035,,,,Inhibition of human ERG expressed in human HEK293 cells by patch-clamp electrophysiology,CC(C)CNc1nc(N2CCN(CC3CCCOC3)CC2)ncc1C(=O)NCc1ccccc1,N-benzyl-4-(isobutylamino)-2-(4-((tetrahydro-2H-pyran-3-yl)methyl)piperazin-1-yl)pyrimidine-5-carboxamide,0.58,uM,=,-0.2365720064370627,0,O=C(NCc1ccccc1)c1cnc(N2CCN(CC3CCCOC3)CC2)nc1
2947,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,CCC(C)c1ccc(OCCOc2ccc(Cl)cc2CNn2cnnc2)cc1,"1-(2-(2-(4-(sec-butyl)phenoxy)ethoxy)-5-chlorophenyl)-N-(4H-1,2,4-triazol-4-yl)methanimine",1.408,uM,=,0.1486026548060934,1,c1ccc(OCCOc2ccccc2CNn2cnnc2)cc1
2948,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,C[C@@H]1CN(c2sc(C3CC3)nc2-c2nc3ccccc3[nH]2)CCN1C(=O)Cn1cnc2cccnc21,"US9266876, 73",0.38,uM,=,-0.4202164033831898,0,O=C(Cn1cnc2cccnc21)N1CCN(c2sc(C3CC3)nc2-c2nc3ccccc3[nH]2)CC1
2949,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](C(N)=O)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-4-(3-(2-(1-methyl-5-(trifluoromethyl)-1H-indazol-3-ylamino)acetamido)azetidin-1-yl)cyclohexanecarboxamide,32.0,uM,=,1.505149978319906,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
2950,755804,10.1021/jm2003359,,,,Inhibition of human ERG expressed in CHO cells by Q-patch assay,Cc1ccc(Nc2c(-c3ccc(F)cc3)nc3n2CCN(C(=O)C(C)(C)N)C3)cc1,"2-amino-1-(2-(4-fluorophenyl)-3-(p-tolylamino)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one",1.5,uM,=,0.1760912590556812,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
2951,1871838,10.1016/j.bmcl.2018.12.015,,,,Inhibition of human ERG,NC(=O)c1cc(Cl)c2c(Cl)c(C#CC3CNCCO3)n([C@H]3CCCNC3)c2n1,"3,4-dichloro-2-(morpholin-2-ylethynyl)-1-((S)-piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",0.006,uM,=,-2.2218487496163566,0,C(#CC1CNCCO1)c1cc2cccnc2n1[C@H]1CCCNC1
2952,1496337,10.1021/ml500505q,,,,Inhibition of human ERG expressed in HEK293 cells by FLIPR based flux assay,CCC[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1NC(=O)CNC(=O)c1cccc(C(F)(F)F)c1,"N-(2-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-propylcyclohexylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide",32.0,uM,=,1.505149978319906,1,O=C(CNC(=O)c1ccccc1)NC1CCCCC1
2953,2112211,10.1016/j.bmcl.2021.127909,,,,Inhibition of human ERG by automated patch method relative to control,CN1CCN(Cc2ccc(OCCCN3CCC(c4noc5cc(F)ccc45)CC3)cc2)CC1,6-fluoro-3-(1-(3-(4-((4-methylpiperazin-1-yl)methyl)phenoxy)propyl)piperidin-4-yl)benzo[d]isoxazole,1.5604,uM,=,0.1932359416397537,1,c1ccc2c(C3CCN(CCCOc4ccc(CN5CCNCC5)cc4)CC3)noc2c1
2954,1930034,10.1016/j.bmc.2017.07.058,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by patch clamp method,O=C(O)C(=O)O.c1ccc(-c2ccc(OCCCCCN3CCCCC3)cc2)cc1,1-(5-(Biphenyl-4-yloxy)pentyl)piperidine hydrogen oxalate,1.75,uM,=,0.2430380486862944,1,c1ccc(-c2ccc(OCCCCCN3CCCCC3)cc2)cc1
2955,1574047,10.1039/C5MD00443H,,,,Inhibition of wild type human ERG channel expressed in Xenopus laevis oocytes assessed as use dependent suppression of K+ current at 1 Hz equilibrated for 5 mins by two-electrode voltage clamp method,O=C(CCc1ccccc1)c1ccccc1OCC(O)CN1CCN(C(c2ccccc2)(c2ccccc2)c2ccccc2)CC1,1-[2-(2-hydroxy-3-(4-tritylpiperazin-1-yl)-propoxy)phenyl]-3-phenylpropan-1-one,47.1,uM,=,1.6730209071288962,1,O=C(CCc1ccccc1)c1ccccc1OCCCN1CCN(C(c2ccccc2)(c2ccccc2)c2ccccc2)CC1
2956,458756,10.1016/j.bmcl.2007.10.063,,,,Inhibition of hERG by patch clamp assay,CC(c1ccc(C#N)cc1)N1C[C@H](N)[C@H](C(=O)N2CCC[C@H]2C#N)C1,"(S)-1-((3R,4R)-3-amino-1-(1-(4-cyanophenyl)ethyl)pyrrolidine-4-carbonyl)pyrrolidine-2-carbonitrile",10.0,uM,=,1.0,1,O=C([C@H]1CCN(Cc2ccccc2)C1)N1CCCC1
2957,1501722,10.1021/acs.jmedchem.5b00742,,,,Inhibition of [3H]-astemizole binding to human ERG expressed in HEK293 cells,Cc1cc(C)nc(N2C[C@H]3CN(C(=O)c4c(C)cccc4-n4nccn4)C[C@H]3C2)n1,"((3aR,6aS)-5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(2-methyl-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone",6.9,uM,=,0.8388490907372553,1,O=C(c1ccccc1-n1nccn1)N1C[C@@H]2CN(c3ncccn3)C[C@@H]2C1
2958,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)CCN1CC[C@@H](CNC(=O)c2cc(Cl)cc(Cl)c2)[C@H](F)C1,"trans 3,5-Dichloro-N-{[1-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}benzamide",3.034,uM,=,0.4820155764507117,1,O=C(NCC1CCNCC1)c1ccccc1
2959,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1cc(CN2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc(OC)c1OC,"1-(6,6-bis(4-fluorophenyl)hexyl)-4-(3,4,5-trimethoxybenzyl)piperazine",0.4,uM,=,-0.3979400086720376,0,c1ccc(CN2CCN(CCCCCC(c3ccccc3)c3ccccc3)CC2)cc1
2960,627338,10.1016/j.bmcl.2010.03.005,,,,Inhibition of human ERG,OC(c1cccnc1)(c1cccnc1)C(c1ccccc1)N1CCCCC1,"2-phenyl-2-(piperidin-1-yl)-1,1-di(pyridin-3-yl)ethanol",14.0,uM,=,1.146128035678238,1,c1ccc(C(C(c2cccnc2)c2cccnc2)N2CCCCC2)cc1
2961,1293874,10.1021/jm401836p,,,,Inhibition of human ERG by whole cell patch clamp assay,CCN(CC)[C@@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@H](C)NC(=O)OC)[nH]4)cc3)cc2)[nH]1)c1ccccc1,Methyl N-[(2S)-1-[(2S)-2-{5-[4-(4-{2-[(2S)-1-[(2R)-2-(diethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamate,9.1,uM,=,0.9590413923210936,1,O=C(Cc1ccccc1)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5)[nH]4)cc3)cc2)[nH]1
2962,971477,10.1021/jm400402q,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)Oc1nc(C2CCNCC2)ncc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,"5-Chloro-N2-(4-isopropoxy-2-(piperidin-4-yl)-pyrimidin-5-yl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine",0.4,uM,=,-0.3979400086720376,0,c1ccc(Nc2ccnc(Nc3cnc(C4CCNCC4)nc3)n2)cc1
2963,699709,10.1016/j.bmcl.2010.11.111,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells,COc1cc(/C=C/c2nc3ccccc3[nH]2)ccc1-n1cnc(C)c1,2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)styryl)-1H-benzo[d]imidazole,0.68,uM,=,-0.1674910872937636,0,C(=C/c1nc2ccccc2[nH]1)\c1ccc(-n2ccnc2)cc1
2964,2229351,10.1021/acsmedchemlett.2c00172,,,,Inhibition of hERG expressed in CHO cells by electrophysiological assay based automated patch clamp method,Cc1cc2nccnc2cc1Nc1ncc2c(n1)n(C1CCN(C)CC1)c(=O)n2C,7-methyl-9-(1-methylpiperidin-4-yl)-2-(7-methylquinoxalin-6-ylamino)-7H-purin-8(9H)-one,2.3,uM,=,0.3617278360175928,1,O=c1[nH]c2cnc(Nc3ccc4nccnc4c3)nc2n1C1CCNCC1
2965,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,COc1cccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)c1,"(1R,3R)-3-(4-(3-methoxyphenyl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.247,uM,=,-0.6073030467403343,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
2966,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2ccnc(OC)c2OC)cc(OC(F)F)n1,"Rac-3-[(1R,2S)-2-[2-(difluoromethoxy)-6-methoxy-4-pyridyl]-1-(2,3-dimethoxy-4-pyridyl)-4-(dimethylamino)-2-hydroxy-butyl]-2-methoxy-quinoline-6-carbonitrile",7.0,uM,=,0.8450980400142568,1,c1ccc2ncc([C@H](Cc3ccncc3)c3ccncc3)cc2c1
2967,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,C[S+]([O-])c1ccc(-c2cnc3ccc(Nc4cccc([S+](C)[O-])c4)nn23)cc1,"N-(3-(methylsulfinyl)phenyl)-3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-amine",18.2,uM,=,1.260071387985075,1,c1ccc(Nc2ccc3ncc(-c4ccccc4)n3n2)cc1
2968,988281,10.1021/jm401101p,,,,Inhibition of human recombinant ERG expressed in CHO cells by patch-clamp technique,Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2cccc(Cl)c2)CC1,(R)-4-((5-((4-(5-(3-Chlorophenyl)-2-oxo-3-(tetrahydro-2Hpyran-4-yl)imidazolidin-1-yl)piperidin-1-yl)methyl)-6-methylpyridin-2-yl)oxy)benzoic Acid,9.9,uM,=,0.99563519459755,1,O=C1N(C2CCOCC2)C[C@@H](c2ccccc2)N1C1CCN(Cc2ccc(Oc3ccccc3)nc2)CC1
2969,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(F)c(Cl)cc1Oc1ccc(Cl)c(Cl)c1,"1-(4-chloro-2-(3,4-dichlorophenoxy)-5-fluorophenyl)-N-methylmethanamine",3.21,uM,=,0.5065050324048721,1,c1ccc(Oc2ccccc2)cc1
2970,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,COc1nc2ccc(CN(C)C)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,4-(dimethylamino)-1-(6-((dimethylamino)methyl)-2-methoxyquinolin-3-yl)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol,4.8,uM,=,0.6812412373755872,1,c1ccc(C(Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
2971,1643768,10.1039/C6MD00281A,,,,Inhibition of Cy3B-labeled ligand binding to recombinant human ERG expressed in HEK293 cells by fluorescence polarization method,C[C@](N)(CF)c1nc(-c2ccc(OC(F)(F)F)cc2)c[nH]1,(R)-1-fluoro-2-(4-(4-(trifluoromethoxy)phenyl)-1H-imidazol-2-yl)propan-2-amine,14.0,uM,=,1.146128035678238,1,c1ccc(-c2c[nH]cn2)cc1
2972,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3CC2CCCCC2)c1,"3-((1R,3r,5S)-8-(cyclohexylmethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide",2.0,uM,=,0.3010299956639812,1,c1ccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3CC2CCCCC2)cc1
2973,1643768,10.1039/C6MD00281A,,,,Inhibition of Cy3B-labeled ligand binding to recombinant human ERG expressed in HEK293 cells by fluorescence polarization method,NC1(Cc2nc(-c3ccc(OC(F)(F)F)cc3)c[nH]2)COC1,3-((5-(4-(Trifluoromethoxy)phenyl)-1H-imidazol-2-yl)methyl)oxetan-3-amine,14.0,uM,=,1.146128035678238,1,c1ccc(-c2c[nH]c(CC3COC3)n2)cc1
2974,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N(CCO)CCc3ccc(Cl)cc3)CC2)n1,"2-((1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)(4-chlorophenethyl)amino)ethan-1-ol",6.3,uM,=,0.7993405494535817,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
2975,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,Cc1cc(CNc2nc(N)nc3ccn(Cc4ncccc4F)c23)no1,"5-((3-Fluoropyridin-2-yl)methyl)-N4-((5-methylisoxazol-3-yl)-methyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine",2.1,uM,=,0.3222192947339193,1,c1ccc(Cn2ccc3ncnc(NCc4ccon4)c32)nc1
2976,624297,10.1016/j.bmcl.2010.01.134,,,,Inhibition of human ERG expressed in HEK cells assessed as blockade of potassium tail current by standard patch clamp analysis,C[C@@H](c1ncccc1F)c1c(CCN(C)C)sc2ccccc12,"(-)-(R)-2-(3-(1-(3-fluoropyridin-2-yl)ethyl)benzo[b]thiophen-2-yl)-N,N-dimethylethanamine",0.33,uM,=,-0.4814860601221125,0,c1ccc(Cc2csc3ccccc23)nc1
2977,1583749,10.1016/j.bmcl.2016.05.058,,,,Inhibition of recombinant human ERG flux expressed in HEK293 cells by patch clamp assay,CC(C)Oc1cc([C@@](Cc2ccccc2)(NC[C@@H](O)CC(F)(F)F)c2cc(F)cc(OC(F)(F)C(F)F)c2)ccc1F,"(S)-4,4,4-trifluoro-1-((R)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethylamino)butan-2-ol",23.0,uM,=,1.3617278360175928,1,c1ccc(CC(c2ccccc2)c2ccccc2)cc1
2978,541742,10.1016/j.bmc.2009.01.061,,,,Inhibition of human ERG,CC(C)[C@H](Oc1ccc(CNC(=O)[C@@H]2CCCN2C(=O)C[C@H](N)Cc2cc(F)ccc2F)cc1)C(=O)O.O=C(O)C(F)(F)F,"(S)-2-(4-(((S)-1-((R)-3-amino-4-(2,5-difluorophenyl)butanoyl)pyrrolidine-2-carboxamido)methyl)phenoxy)-3-methylbutanoic acid 2,2,2-trifluoroacetic acid",76.0,uM,=,1.880813592280792,1,O=C(NCc1ccccc1)[C@@H]1CCCN1C(=O)CCCc1ccccc1
2979,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(N)nc7)[nH]6)CC5)cc4)nc3n2)CC1,"5-(5-(1-((4-(2-(4-methylpiperazin-1-yl)-6-phenylpyrido[2,3-d]pyrimidin-7-yl)phenyl)methyl)piperidin-4-yl)-4H-1,2,4-triazol-3-yl)pyridin-2-amine",6.1,uM,=,0.785329835010767,1,c1ccc(-c2cc3cnc(N4CCNCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5cccnc5)[nH]4)CC3)cc2)cc1
2980,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1ccc2occc2c1,"(1S,2S)-2-(benzofuran-5-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-1-(2,3-dimethoxypyridin-4-yl)-4-(dimethylamino)butan-2-ol",0.6,uM,=,-0.2218487496163563,0,c1ccc2cc([C@H](Cc3ccc4occc4c3)c3ccncc3)ccc2c1
2981,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(CC(C)N2CCN(CCc3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"2-methoxy-4-(2-(4-(2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)propyl)benzonitrile",1.3,uM,=,0.1139433523068367,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
2982,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(C#Cc2cccc(C#Cc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis(p-tolylethynyl)pyridinium",0.285,uM,=,-0.5451551399914898,0,C(#Cc1cccc(C#Cc2ccccc2)[nH+]1)c1ccccc1
2983,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3ccc(F)cc3)nn2)ccc1-n1cnc(C)c1,"1-(4-fluorobenzyl)-4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazole",2.19,uM,=,0.3404441148401183,1,c1ccc(Cn2cc(-c3ccc(-n4ccnc4)cc3)nn2)cc1
2984,748955,10.1016/j.bmcl.2011.04.078,,,,Inhibition of human ERG,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)C[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@H](OCC(=O)NC)[C@H](C)[C@@H](O)[C@]1(C)O,"2-((2R,3S,4R,5R,6S,7R,9R,10R,11S,12S,13R)-2-ethyl-3,4,9-trihydroxy-10-((2S,3R,4S,6R)-3-hydroxy-4-(isopropyl(methyl)amino)-6-methyltetrahydro-2H-pyran-2-yloxy)-12-((2S,4S,6S)-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-14-oxooxacyclotetradecan-6-yloxy)-N-methylacetamide",30.0,uM,=,1.4771212547196624,1,O=C1C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CCCCCCCCO1
2985,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,NC1CC1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-((2-aminocyclopropyl)methoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.2,uM,=,-0.6989700043360187,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7CC7)nc56)(CC3)OC4)nc2N1
2986,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,Cc1cc(C2CC=CCNC2)ccc1Cl,"3-(4-chloro-3-methylphenyl)-2,3,4,7-tetrahydro-1H-azepine",26.0,uM,=,1.414973347970818,1,C1=CCC(c2ccccc2)CNC1
2987,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,C[C@H](Nc1c(C(N)=O)cnc2ccc(-c3cccnc3)cc12)c1ccn(C)n1,4-{[(1S)-1-(1-Methyl-1H-pyrazol-3-yl)ethyl]amino}-6-(3-pyridinyl)-3-quinolinecarboxamide,11.0,uM,=,1.0413926851582251,1,c1cncc(-c2ccc3nccc(NCc4cc[nH]n4)c3c2)c1
2988,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CN(C)c1cccc([C@H]2CC[C@@H](N3CC(NC(=O)CNc4nn(C)c5ccc(C(F)(F)F)cc45)C3)CC2)c1,cis-N-{1-[4-(3-Dimethylamino-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-yl}-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,12.0,uM,=,1.0791812460476249,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccccc3)CC2)C1
2989,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCc3ccc(OC)c(OC)c3)C[C@@H]2CC(=O)Nc2cccc(Cl)c2)cc1,"rac-N-(3-chlorophenyl)-2-((3R,4S)-1-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)acetamide",0.002,uM,=,-2.6989700043360187,0,O=C(C[C@H]1CN(CCc2ccccc2)C[C@@H]1c1ccccc1)Nc1ccccc1
2990,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,COc1nc2ccc(C(=O)O)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,3-(4-(dimethylamino)-2-hydroxy-2-(naphthalen-1-yl)-1-phenylbutyl)-2-methoxyquinoline-6-carboxylic acid,10.0,uM,=,1.0,1,c1ccc(C(Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
2991,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(Cc1ccno1)C2=O,"2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-6-(isoxazol-5-ylmethyl)-7,8-dihydro-1,6-naphthyridin-5(6H)-one",2.5,uM,=,0.3979400086720376,1,O=C1c2ccc(OCc3conc3-c3ccccc3)nc2CCN1Cc1ccno1
2992,2156392,10.1016/j.ejmech.2021.114040,,,,Inhibition of human ERG,Cc1ccc(NC(=O)c2cc(C(F)(F)F)cnn2)cc1-c1ccc2c(c1)OC1(CCOCC1)CC(=O)N2,"N-(4-Methyl-3-(4-oxo-2',3',4,5,5',6'-hexahydro-3H-spiro[benzo[b][1,4]oxazepine-2,4'-pyran]-8-yl)phenyl)-5-(trifluoromethyl)pyridazine-3-carboxamide",19.4,uM,=,1.287801729930226,1,O=C1CC2(CCOCC2)Oc2cc(-c3cccc(NC(=O)c4cccnn4)c3)ccc2N1
2993,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,O=C(NC1CCN(Cc2ccc(OCCCN(C3CC3)C3CC3)c(F)c2)CC1)c1cc(=O)c2ccc(F)cc2o1,N-(1-(4-(3-(dicyclopropylamino)propoxy)-3-fluorobenzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,0.74,uM,=,-0.1307682802690238,0,O=C(NC1CCN(Cc2ccc(OCCCN(C3CC3)C3CC3)cc2)CC1)c1cc(=O)c2ccccc2o1
2994,304899,10.1016/j.bmcl.2005.03.055,,,,Inhibitory concentration against Potassium channel HERG was determined,C[C@@H](c1ccc(-c2cccc(-c3noc(O)n3)c2)cc1)[C@H](N)C(=O)N1CC[C@H](F)C1.O=C(O)C(F)(F)F,"Trifluoro-acetate(1S,2S)-1-((S)-3-fluoro-pyrrolidine-1-carbonyl)-2-[3'-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-biphenyl-4-yl]-propyl-ammonium",28.0,uM,=,1.4471580313422192,1,O=C(CCc1ccc(-c2cccc(-c3ncon3)c2)cc1)N1CCCC1
2995,1935939,10.1016/j.bmc.2019.02.025,,,,Inhibition of human ERG by manual patch clamp electrophysiology assay,COc1cc(C(O)(CCN(C)C)C(c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2F)c(OC)cn1,"rac-1-(6-bromo-2-methoxyquinolin-3-yl)-2-(2,5-dimethoxypyridin-4-yl)-4-(dimethylamino)-1-(2-fluoro-3-methoxyphenyl)butan-2-ol",1.7,uM,=,0.2304489213782739,1,c1ccc(C(Cc2ccncc2)c2cnc3ccccc3c2)cc1
2996,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CCOc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(6-ethoxypyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide",17.0,uM,=,1.230448921378274,1,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1
2997,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,CCc1ccc2c(=O)cc(C(=O)NC3CCN(Cc4ccc5c(c4)OCO5)CC3)oc2c1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-ethyl-4-oxo-4H-chromene-2-carboxamide",0.0074,uM,=,-2.130768280269024,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
2998,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn([C@H]3C[C@@H](C(C)(C)C)CCN(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"(3S,5S)-5-tert-butyl-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)azepan-2-one",5.4,uM,=,0.7323937598229685,1,O=C1NCCCC[C@@H]1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
2999,1865158,10.1021/acsmedchemlett.9b00186,,,,Inhibition of human ERG,CCOCc1nnc(N2C[C@@H]3C[C@]3(c3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1,"(1S,5R)-1-(2-chloro-4-fluorophenyl)-3-(5-(ethoxymethyl)-4-(6-methoxypyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-azabicyclo[3.1.0]hexane",6.1,uM,=,0.785329835010767,1,c1ccc([C@]23C[C@H]2CN(c2nncn2-c2cccnc2)C3)cc1
3000,1783529,10.1016/j.ejmech.2017.12.075,,,,Inhibition of human ERG by [3H]dofetilide binding displacement assay,Cc1c(CN2CCOCC2)cc(-c2ccc(C(C)C)cc2)n1C1CC1,4-((1-Cyclopropyl-5-(4-isopropylphenyl)-2-methyl-1H-pyrrol-3-yl)methyl)morpholine,8.0,uM,=,0.9030899869919436,1,c1ccc(-c2cc(CN3CCOCC3)cn2C2CC2)cc1
3001,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(Cl)c(Cl)c2)[C@@H]3C)n1,"US9422299, 1",42.0,uM,=,1.6232492903979006,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
3002,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCOC(=O)[C@H]1CC[C@@H](N2CC(NC(=O)CNc3nn(C)c4ccc(C(F)(F)F)cc34)C2)CC1,cis-4-{3-[2-(1-Methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetylamino]-azetidin-1-yl}-cyclohexane carboxylic acid ethyl ester,8.0,uM,=,0.9030899869919436,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
3003,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,O=C1NCCN1CCN1CCC(c2cn(C3CCCCC3)c3ccc(Cl)cc23)CC1,1-{2-[4-(5-Chloro-1-cyclohexyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-imidazolidin-2-one,0.137,uM,=,-0.8632794328435932,0,O=C1NCCN1CCN1CCC(c2cn(C3CCCCC3)c3ccccc23)CC1
3004,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,O=C(CCN1CCCCC1)Nc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1F,N-(1-(3-fluoro-4-(3-(piperidin-1-yl)propanamido)benzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,9.18,uM,=,0.9628426812012424,1,O=C(CCN1CCCCC1)Nc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccccc4o3)CC2)cc1
3005,2164004,10.1021/acs.jmedchem.1c02110,,,,Inhibition of hERG by patch clamp method,CCOP(=O)(Cn1ccc(NC(=O)c2cc(Oc3ccc(S(=O)(=O)C(C)C)cc3)cc(OC(C)C)c2)n1)OCC,Diethyl ((3-(3-Isopropoxy-5-(4-(isopropylsulfonyl)phenoxy)benzamido)-1H-pyrazol-1-yl)methyl)phosphonate,30.0,uM,=,1.4771212547196624,1,O=C(Nc1cc[nH]n1)c1cccc(Oc2ccccc2)c1
3006,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,COc1nccnc1CC1=C(CCN(C)C)Cc2ccccc21,"2-(3-((3-methoxypyrazin-2-yl)methyl)-1H-inden-2-yl)-N,N-dimethylethanamine",7.6,uM,=,0.8808135922807914,1,C1=C(Cc2cnccn2)c2ccccc2C1
3007,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,O=C1C(CO)OC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1,"2-(Hydroxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",1.1,uM,=,0.041392685158225,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
3008,2045776,10.1039/d0md00174k,,,,Inhibition of human ERG,Cc1c(-c2cnc3[nH]ncc3c2)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12,"2-(aminomethyl)-5-cyclopropyl-6-methyl-7-(1H-pyrazolo[3,4-b]pyridin-5-yl)oxazolo[4,5-c]quinolin-4-one",45.08,uM,=,1.653983907374069,1,O=c1c2ncoc2c2ccc(-c3cnc4[nH]ncc4c3)cc2n1C1CC1
3009,1502294,10.1021/jm501512b,,,,Inhibition of human ERG by PatchXpress assay,O=C(NCC[C@@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1,"(R)-N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide",0.38,uM,=,-0.4202164033831898,0,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1cc2ccccc2[nH]1
3010,2046899,10.1016/j.bmcl.2020.127521,,,,Inhibition of human ERG by patch clamp assay,C[C@H]1C[C@H](C(=O)O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccccc3)c3cc(F)c(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,"(1R,3S,4R)-4-((3aR,9bR)-8-fluoro-7-(perfluoropropan-2-yl)-9b-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole-3-carbonyl)-3-methylcyclohexanecarboxylic acid",18.0,uM,=,1.255272505103306,1,O=C(C1CCCCC1)N1CC[C@@]2(S(=O)(=O)c3ccccc3)c3ccccc3CC[C@@H]12
3011,1788775,10.1016/j.bmcl.2018.10.007,,,,Inhibition of human ERG,COc1ccccc1-n1nc(C2CC(C)(C)OC(C)(C)C2)cc1-c1ccc(Cl)cc1,"5-(4-chlorophenyl)-1-(2-methoxyphenyl)-3-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazole",20.0,uM,=,1.3010299956639813,1,c1ccc(-c2cc(C3CCOCC3)nn2-c2ccccc2)cc1
3012,2163947,10.1021/acs.jmedchem.1c01564,,,,Inhibition of human ERG by [3H]]Astemizole binding assay,c1cnc2c(c1)CN[C@@H](CN(CCCCNC1COC1)[C@H]1CCCc3cccnc31)C2,"N1-(oxetan-3-yl)-N4-(((R)-5,6,7,8-tetrahydro-1,6-naphthyridin-7-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",11.0,uM,=,1.0413926851582251,1,c1cnc2c(c1)CN[C@@H](CN(CCCCNC1COC1)[C@H]1CCCc3cccnc31)C2
3013,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,Cc1ccccc1-c1nc2cn(-c3cccc(C#N)c3)nc2c(=O)n1CC1CCCN(C(C)C)C1,"rac-3-(6-((1-Isopropylpiperidin-3-yl)methyl)-7-oxo-5-o-tolyl-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-2-yl)benzonitrile",22.0,uM,=,1.3424226808222062,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2ccccc2)n1CC1CCCNC1
3014,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c([C@H]3OC(=O)O[C@@H]3C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-((4S,5R)-5-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-1,3-dioxolan-4-yl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",11.2,uM,=,1.0492180226701815,1,O=C1COc2ccc(CNC34CCC([C@H]5OC(=O)O[C@@H]5c5ccnc6cccnc56)(CC3)OC4)nc2N1
3015,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,O=C(c1ccccc1Oc1ccccc1)N(c1ccccc1)[C@H]1CCNC1,(S)-2-phenoxy-N-phenyl-N-(pyrrolidin-3-yl)benzamide,2.81,uM,=,0.4487063199050799,1,O=C(c1ccccc1Oc1ccccc1)N(c1ccccc1)[C@H]1CCNC1
3016,421810,10.1016/j.bmcl.2006.10.053,,,,Inhibition of binding to hERG,CN(CC(=O)N(C)C)Cc1ccc2c(c1)CC[C@H](N(C)C(=O)c1ccc(-c3ccc(F)cc3)cc1)C2,"(S)-N-(6-(((2-(dimethylamino)-2-oxoethyl)(methyl)amino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-4'-fluoro-N-methylbiphenyl-4-carboxamide",1.8,uM,=,0.255272505103306,1,O=C(N[C@H]1CCc2ccccc2C1)c1ccc(-c2ccccc2)cc1
3017,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,COc1cc2c(cc1CCN1CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC1)COC2=O,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-6-methoxyisobenzofuran-1(3H)-one,5.6,uM,=,0.7481880270062004,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
3018,1622464,10.1016/j.bmcl.2016.09.067,,,,Inhibition of radiolabeled dofetilide binding to human ERG expressed in HEK293 cells,N[C@H]1CCCN(c2ccncc2Nc2ncc3ccc(-c4c(F)cccc4F)nn23)C1,"(S)-N-(4-(3-aminopiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-amine",3.6,uM,=,0.5563025007672873,1,c1ccc(-c2ccc3cnc(Nc4cnccc4N4CCCCC4)n3n2)cc1
3019,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(C)n1c(-c2ccc(OCCCN3CCCCC3)cc2)nc2ccccc2c1=O,3-isopropyl-2-(4-(3-(piperidin-1-yl)propoxy)phenyl)quinazolin-4(3H)-one,3.0,uM,=,0.4771212547196624,1,O=c1[nH]c(-c2ccc(OCCCN3CCCCC3)cc2)nc2ccccc12
3020,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,Fc1ccc(C(Cc2ccccc2OC(F)(F)F)N2CCNCC2)cc1,1-(1-(4-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine,4.95,uM,=,0.6946051989335688,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
3021,674336,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human ERG expressed in HEK cells by patch clamp technique,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O,"5-Methyl-2-(5-methyl-1H-imidazol-4-ylmethyl)-2,3,4,5-tetrahydro-pyrido[4,3-b]indol-1-one",2.3,uM,=,0.3617278360175928,1,O=C1c2c([nH]c3ccccc23)CCN1Cc1c[nH]cn1
3022,1760801,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by patch express assay,Cn1cnc(-c2cnc(N)c(O[C@H]3CN(C(=O)Cc4ccc(OC(F)(F)F)cc4)CC3(F)F)c2)c1,"(S)-1-(4-((2-Amino-5-(1-methyl-1H-imidazol-4-yl)pyridin-3-yl)oxy)-3,3-difluoropyrrolidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)ethan-1-one",7.7,uM,=,0.8864907251724818,1,O=C(Cc1ccccc1)N1CC[C@@H](Oc2cncc(-c3c[nH]cn3)c2)C1
3023,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(Br)c3n2CCN1Cc1ccccc1F,"6-Bromo-2[(2-fluorophenyl)methyl]-3,4-dihydropyrazino(1,2-a)benzimidazol-1(2H)-one",16.0,uM,=,1.2041199826559248,1,O=C1c2nc3ccccc3n2CCN1Cc1ccccc1
3024,1766690,10.1021/acs.jmedchem.8b01147,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method,CCn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N,"4-({4-Amino-6-[3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1H)-yl)-2-(hydroxymethyl)phenyl]-1,3,5-triazin-2-yl}amino)-1-ethyl-1H-pyrrole-2-carbonitrile",7.8,uM,=,0.8920946026904804,1,O=c1c2ccc(C3CC3)cc2ccn1-c1cccc(-c2ncnc(Nc3cc[nH]c3)n2)c1
3025,321319,10.1021/jm050598r,,,,Inhibition of human potassium channel HERG,O=c1cc(NC2CCN(Cc3ccc4c(c3)OCO4)CC2)c2cc(Cl)ccc2o1,"4-(1-Benzo[1,3]dioxol-5-ylmethyl-piperidin-4-ylamino)-6-chloro-chromen-2-one",2.25,uM,=,0.3521825181113625,1,O=c1cc(NC2CCN(Cc3ccc4c(c3)OCO4)CC2)c2ccccc2o1
3026,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,O=C(CNc1n[nH]c2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3ccccc3)CC2)C1,N-(1-(4-phenylcyclohexyl)azetidin-3-yl)-2-(5-(trifluoromethyl)-1H-indazol-3-ylamino)acetamide,1.2,uM,=,0.0791812460476248,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccccc3)CC2)C1
3027,1622890,10.1021/acsmedchemlett.6b00433,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes after 90 mins by scintillation counting,CCc1[nH]ncc1Cn1cc(-c2ccc(Cl)c(OC(F)F)c2)cn1,4-(4-chloro-3-(difluoromethoxy)phenyl)-1-((5-ethyl-1H-pyrazol-4-yl)methyl)-1H-pyrazole,35.0,uM,=,1.5440680443502757,1,c1ccc(-c2cnn(Cc3cn[nH]c3)c2)cc1
3028,494878,10.1021/jm8012618,,,,Inhibition of human cloned ERG,CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O,2-(tert-Butylamino-methyl)-5-(7-chloro-quinolin-4-ylamino)-phenol,7.5,uM,=,0.8750612633917001,1,c1ccc(Nc2ccnc3ccccc23)cc1
3029,1622464,10.1016/j.bmcl.2016.09.067,,,,Inhibition of radiolabeled dofetilide binding to human ERG expressed in HEK293 cells,N[C@@H]1CN(c2ccncc2Nc2ncc3ccc(-c4c(F)cccc4F)nn23)C[C@H](N)[C@H]1O,"(3S,4r,5R)-3,5-diamino-1-(3-(2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-ylamino)pyridin-4-yl)piperidin-4-ol",10.4,uM,=,1.0170333392987805,1,c1ccc(-c2ccc3cnc(Nc4cnccc4N4CCCCC4)n3n2)cc1
3030,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,Cn1nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)oc1=O,"5-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one",21.5,uM,=,1.3324384599156054,1,O=c1[nH]nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
3031,2208843,10.1016/j.bmc.2022.116657,,,,Inhibition of hERG channel expressed in CHO cells at -80 mV holding potential by Qpatch clamp method,COc1cc(Nc2ncc(OCc3c(F)c(OC)cc(OC)c3F)cn2)cnc1N1CCC(N2CCN(C)CC2)CC1,"5-[(2,6-Difluoro-3,5-dimethoxyphenyl)methoxy]-N-{5-methoxy-6-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyridin-3-yl}pyrimidin-2-amine",8.1,uM,=,0.9084850188786496,1,c1ccc(COc2cnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)nc3)nc2)cc1
3032,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,Cc1noc(-c2ccc(CCN3CCC(Nc4nc5ccccc5n4CC4CCCCC4)CC3)cc2)n1,"1-(cyclohexylmethyl)-N-(1-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine",0.89,uM,=,-0.0506099933550872,0,c1ccc2c(c1)nc(NC1CCN(CCc3ccc(-c4ncno4)cc3)CC1)n2CC1CCCCC1
3033,535682,10.1016/j.bmcl.2008.08.067,,,,Displacement of [3H]dofetilide from human ERG in HEK293 cells,CNC(=O)c1c(NCC2CCC3(CCC3)CC2)nc(C#N)nc1OCC1CCN(C(C)C)CC1,2-cyano-4-((1-isopropylpiperidin-4-yl)methoxy)-N-methyl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide,0.54,uM,=,-0.2676062401770315,0,c1nc(NCC2CCC3(CCC3)CC2)cc(OCC2CCNCC2)n1
3034,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,Fc1ccc(C2CC=CCNC2)cc1Cl,"3-(3-Chloro-4-fluoro-phenyl)-2,3,4,7-tetrahydro-1H-azepine",23.0,uM,=,1.3617278360175928,1,C1=CCC(c2ccccc2)CNC1
3035,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),1.4,uM,=,0.1461280356782379,1,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1
3036,1838858,10.1021/acsmedchemlett.9b00550,,,,Inhibition of human ERG expressed in human HEK293 cells by patch clamp assay,Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1cc(F)c(F)c(F)c1,"2-amino-4-fluoro-5-((4-hydroxypiperidin-1-yl)sulfonyl)-N-(3,4,5-trifluorophenyl)benzamide",8.78,uM,=,0.9434945159061026,1,O=C(Nc1ccccc1)c1cccc(S(=O)(=O)N2CCCCC2)c1
3037,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cnccn2)C1=O,"2-methyl-9-(2-phenylethyl)-4-pyrazin-2-yl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.1,uM,=,-1.0,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1cnccn1
3038,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCCC3CCOCC3)C[C@@H]2CNC(=O)c2cccc(Cl)c2)cc1,"rac-3-chloro-N-(((3S,4S)-4-(4-methoxyphenyl)-1-(3-(tetrahydro-2H-pyran-4-yl)propyl)pyrrolidin-3-yl)methyl)benzamide",1.03,uM,=,0.0128372247051722,1,O=C(NC[C@H]1CN(CCCC2CCOCC2)C[C@@H]1c1ccccc1)c1ccccc1
3039,1525287,10.1016/j.bmcl.2015.09.045,,,,Inhibition of human ERG expressed in HEK293 cells by whole-cell patch clamp method,Fc1ccc2c(C3CCN(CCCOc4ccc(CCc5nc6ccccc6o5)cc4)CC3)noc2c1,3-(1-(3-(4-(2-(benzo[d]oxazol-2-yl)ethyl)phenoxy)propyl)piperidin-4-yl)-6-fluorobenzo[d]isoxazole,0.63,uM,=,-0.2006594505464183,0,c1ccc2oc(CCc3ccc(OCCCN4CCC(c5noc6ccccc56)CC4)cc3)nc2c1
3040,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c(C(C)CN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O,(rac)-5-(1-(4-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperazin-1-yl)propan-2-yl)-4-methylisobenzofuran-1(3H)-one,49.0,uM,=,1.6901960800285136,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
3041,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4cccc(F)c4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(3-fluorophenyl)pyrrolo[1,2-b]pyridazine-3-carboxamide",7.6,uM,=,0.8808135922807914,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
3042,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C(NC(c1ccncc1)c1ccc(Cl)cc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1,"(1R,2R,4R)-2-(4-bromophenyl)-N-((4-chlorophenyl)(pyridin-4-yl)methyl)-4-morpholinocyclohexanecarboxamide",1.9,uM,=,0.2787536009528289,1,O=C(NC(c1ccccc1)c1ccncc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
3043,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(COc1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CCCCC1,1-(1-piperidyl)-2-[[6-[[5-(trifluoromethyl)-2-pyridyl]oxy]-2-quinolyl]oxy]ethanone,22.0,uM,=,1.3424226808222062,1,O=C(COc1ccc2cc(Oc3ccccn3)ccc2n1)N1CCCCC1
3044,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(Cl)cc(C(F)(F)F)n2)(c2ccccc2)CC1,4-chloro-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-6-(trifluoromethyl)pyridine,12.0,uM,=,1.0791812460476249,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
3045,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",0.143,uM,=,-0.8446639625349383,0,c1ccc(CCCCNCCc2ccccc2)cc1
3046,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CC(C)c1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2CCO)n1,"1-((R)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-isopropyl-[1,2,4]triazol-1-yl)-ethanone",0.0058,uM,=,-2.2365720064370627,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
3047,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2c1ccc(CCN1CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC1)c2C1CC1,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-4-cyclopropylisobenzofuran-1(3H)-one,12.0,uM,=,1.0791812460476249,1,O=C1OCc2c1ccc(CCN1CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC1)c2C1CC1
3048,945538,10.1016/j.bmcl.2012.10.140,,,,Inhibition of human ERG expressed in CHO cells by IONWORKS assay,CC(C)(C)NC(=O)NCCN1CCC(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1,"N-((1-(2-(3-tert-butylureido)ethyl)piperidin-4-yl)methyl)-3,5-dichlorobenzamide",13.0,uM,=,1.1139433523068367,1,O=C(NCC1CCNCC1)c1ccccc1
3049,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,CC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)c(Cl)c1,"N-(2-(3'-chloro-4'-((3S,4S)-4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidin-3-yl)biphenyl-2-yl)ethyl)acetamide",5.8,uM,=,0.7634279935629373,1,O=c1cc([C@H]2CCNC[C@@H]2c2ccc(-c3ccccc3)cc2)cc[nH]1
3050,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(C)C2=O)c1,"1-((R)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-m-tolyl-urea",5.0,uM,=,0.6989700043360189,1,O=C(Nc1ccccc1)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O
3051,420234,10.1016/j.bmcl.2006.11.092,,,,Inhibition of hERG in patch-clamp assay,Cc1nc(N2CCCC2)nc2ccc(NC(=O)COc3ccc(Cl)cc3)cc12,2-(4-chlorophenoxy)-N-(4-methyl-2-(pyrrolidin-1-yl)quinazolin-6-yl)acetamide,10.0,uM,=,1.0,1,O=C(COc1ccccc1)Nc1ccc2nc(N3CCCC3)ncc2c1
3052,793274,10.1016/j.bmcl.2011.09.117,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp electrophysiology,COc1ccc2ncc(F)c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2c1,"N-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methyl)-1-(2-(3-fluoro-6-methoxyquinolin-4-yl)ethyl)piperidin-4-amine",6.0,uM,=,0.7781512503836436,1,c1ccc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
3053,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@@H]1COC[C@@H]1c1ccc(-c2ccc(C#N)cc2)cc1,"N-((3S,4S)-4-(4'-cyanobiphenyl-4-yl)tetrahydrofuran-3-yl)propane-2-sulfonamide",12.6,uM,=,1.100370545117563,1,c1ccc(-c2ccc([C@@H]3CCOC3)cc2)cc1
3054,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,COCC(F)(F)COCc1ccc([C@@]2(O)CCNC[C@@H]2c2ccc(-c3ccccc3CCNC(C)=O)cc2C)cc1,"N-(2-(4'-((3S,4R)-4-(4-((2,2-difluoro-3-methoxypropoxy)methyl)phenyl)-4-hydroxypiperidin-3-yl)-3'-methylbiphenyl-2-yl)ethyl)acetamide",9.8,uM,=,0.9912260756924948,1,c1ccc(-c2ccc([C@H]3CNCCC3c3ccccc3)cc2)cc1
3055,487847,10.1021/jm800386y,,,,Displacement of [35S]MK499 from human ERG expressed in HEL cells,CN1CCC(N(C)C(=O)N2CC(c3cc(F)ccc3F)=C[C@H]2c2ccccc2)CC1,"(S)-4-(2,5-difluorophenyl)-N-methyl-N-(1-methylpiperidin-4-yl)-2-phenyl-2H-pyrrole-1(5H)-carboxamide",1.2,uM,=,0.0791812460476248,1,O=C(NC1CCNCC1)N1CC(c2ccccc2)=C[C@H]1c1ccccc1
3056,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(C#N)n2)(c2ccccc2)CC1,6-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)picolinonitrile,33.0,uM,=,1.5185139398778875,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
3057,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(CN2CCN(C(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1C(C)(C)C,"1-(4-(3,5-di-tert-butyl-4-methoxybenzyl)piperazin-1-yl)-6,6-bis(4-fluorophenyl)hexan-1-one",0.13,uM,=,-0.8860566476931633,0,O=C(CCCCC(c1ccccc1)c1ccccc1)N1CCN(Cc2ccccc2)CC1
3058,537242,10.1021/jm800569w,,,,"Antagonist activity at human ERG in HEK293 cells assessed as inhibition of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide binding",Cc1nc2c(Cl)cccc2c(=O)n1-c1ccc(OC2CCN(C3CCC3)CC2)cc1,8-Chloro-3-(4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl)-2-methyl-4(3H)-quinazolinone,3.3,uM,=,0.5185139398778875,1,O=c1c2ccccc2ncn1-c1ccc(OC2CCN(C3CCC3)CC2)cc1
3059,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COCCOc1ccc(C2CN(NS(C)(=O)=O)C(=O)N2CCc2ccc(OC)cc2)cc1,1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-(2-methoxyethoxy)phenyl)-2-imidazolidinone,33.0,uM,=,1.5185139398778875,1,O=C1NCC(c2ccccc2)N1CCc1ccccc1
3060,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CCN1CC2(CCN(CCc3cccc(F)c3)CC2)O[C@H](C)C1=O,"(R)-4-ethyl-9-(3-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",6.6,uM,=,0.8195439355418687,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1
3061,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CC[C@@H](NC(=O)c1ccc(C#N)cc1)[C@@H]1[C@@H]2C[C@@H](n3cnc4ccc(C#N)cc43)C[C@@H]21,"4-cyano-N-((R)-1-((1R,3S,5S,6r)-3-(6-cyano-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",1.2,uM,=,0.0791812460476248,1,O=C(NC[C@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
3062,1478747,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,1-[2-(2-Hydroxy-3-propylamino-propoxy)-phenyl]-3-phenyl-propan-1-one,0.44,uM,=,-0.3565473235138126,0,O=C(CCc1ccccc1)c1ccccc1
3063,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,COc1cccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)n1,cis-N-({1-[4-Hydroxy-4-(6-methoxy-pyridin-2-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,17.5,uM,=,1.2430380486862944,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccccn3)CC2)C1
3064,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(COc2ccccc2)cccc1COc1ccccc1,"1-methyl-2,6-bis(phenoxymethyl)pyridinium",0.767,uM,=,-0.115204636051019,0,c1ccc(OCc2cccc(COc3ccccc3)[nH+]2)cc1
3065,611802,10.1021/jm9015075,,,,Inhibition of human ERG,Clc1cnc2nc(N3CCN4CCC3CC4)oc2c1,"4-(6-Chlorooxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]-nonane",3.3,uM,=,0.5185139398778875,1,c1cnc2nc(N3CCN4CCC3CC4)oc2c1
3066,716794,10.1016/j.bmcl.2010.12.123,,,,Inhibition of human ERG expressed in CHO cells,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,"(S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-N,2-dicyclohexylacetamide",1.4,uM,=,0.1461280356782379,1,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
3067,1667858,10.1016/j.bmcl.2017.03.030,,,,Inhibition of human ERG,N=C(NCCCOc1ccc(F)cc1)Nc1ccc(Cl)cc1,1-(4-chlorophenyl)-3-(3-(4-fluorophenoxy)propyl)guanidine,0.216,uM,=,-0.6655462488490691,0,N=C(NCCCOc1ccccc1)Nc1ccccc1
3068,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,CCOc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3Cl)c2cc1N1CCN(C)CC1,"4-(2,3-dichlorophenylamino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide",8.0,uM,=,0.9030899869919436,1,c1ccc(Nc2ccnc3ccc(N4CCNCC4)cc23)cc1
3069,1760517,10.1021/acs.jmedchem.8b00372,,,,Inhibition of human ERG expressed in CHO cells at 10 nM to 10 uM at holding potential of -80 mV measured after 5 mins by QPatch automated patch clamp electrophysiology method,CC(C)(C)Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1,"5-[2-(2,2-Dimethylpropoxy)-5-methanesulfonylbenzoyl]-2-(2-fluorophenyl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole",8.1,uM,=,0.9084850188786496,1,O=C(c1ccccc1)N1Cc2cn(-c3ccccc3)nc2C1
3070,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CCOc1ccc2cc(-c3nn(CC4CCN(C)CC4)c4ncnc(N)c34)ccc2c1,"3-(6-ethoxynaphthalen-2-yl)-1-((1-methylpiperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.4,uM,=,-0.3979400086720376,0,c1ccc2cc(-c3nn(CC4CCNCC4)c4ncncc34)ccc2c1
3071,554780,10.1016/j.bmcl.2008.05.036,,,,Displacement of [35S]MK499 from human ERG in HEK293 cell membrane,Cc1nn(-c2c(Cl)cccc2NS(C)(=O)=O)cc1CN1CCC2(CC1)OCc1ccccc12,"1'-{[1-(3-chloropyridin-2-yl)-1H-pyrazol-4-yl]methyl}-3H-spiro[2-benzofuran-1,4'-piperidine]",17.0,uM,=,1.230448921378274,1,c1ccc(-n2cc(CN3CCC4(CC3)OCc3ccccc34)cn2)cc1
3072,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NCc3cc4c(cn3)OCCO4)(CC1)CO2,"(R)-4-((4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",764.0,uM,=,2.88309335857569,1,O=c1ccc2nccc3c2n1CC3CC12CCC(NCc3cc4c(cn3)OCCO4)(CC1)CO2
3073,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCCc5ccccc5)c4)n[nH]c2-3)CC1,"6-((4-methylpiperazin-1-yl)methyl)-3-(5-(4-phenylbut-1-ynyl)-thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole",4.8,uM,=,0.6812412373755872,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)CCc1ccccc1
3074,1643768,10.1039/C6MD00281A,,,,Inhibition of Cy3B-labeled ligand binding to recombinant human ERG expressed in HEK293 cells by fluorescence polarization method,CC(C)(N)c1nc(-c2cccc(OC(F)(F)F)c2)c[nH]1,2-(4-(3-(trifluoromethoxy)phenyl)-1H-imidazol-2-yl)propan-2-amine,9.0,uM,=,0.9542425094393248,1,c1ccc(-c2c[nH]cn2)cc1
3075,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(-c4cccc(F)c4)c3n2CCN1CC1CC1,"2-(Cyclopropylmethyl)-6-(2-fluorophenyl)-3,4-dihydropyrazino-(1,2-a)bendmidazol-1(2H)-one",9.1,uM,=,0.9590413923210936,1,O=C1c2nc3cccc(-c4ccccc4)c3n2CCN1CC1CC1
3076,983483,10.1016/j.bmcl.2013.07.061,,,,Inhibition of human ERG channel,N[C@H]1C[C@@H](N2Cc3cnc(C(F)(F)F)nc3C2)CC[C@@H]1c1cc(F)c(F)cc1F,"(1S,2R,5S)-5-(2-(trifluoromethyl)-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)-2-(2,4,5-trifluorophenyl)cyclohexanamine",4.8,uM,=,0.6812412373755872,1,c1ccc([C@H]2CC[C@H](N3Cc4cncnc4C3)CC2)cc1
3077,581929,10.1016/j.bmcl.2009.06.011,,,,Inhibition of human ERG,N[C@H]1Cn2c(nc3cnc(F)cc32)C[C@@H]1c1cc(F)c(F)cc1F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,"(11R,12R)-12-azaniumyl-4-fluoro-11-(2,4,5-trifluorophenyl)-1,5,8-triazatricyclo[7.4.0.0^{2,7}]trideca-2(7),3,5,8-tetraen-5-ium; bis(2,2,2-trifluoroacetate)",81.0,uM,=,1.9084850188786493,1,c1ccc([C@@H]2CCn3c(nc4cnccc43)C2)cc1
3078,2022383,10.1021/acs.jmedchem.0c01076,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel inward tail current by whole cell voltage clamp assay,CC1N(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(=O)NCc3ccccc3Cl)cc2C12CCNCC2,,1.1,uM,=,0.041392685158225,1,O=C(NCc1ccccc1)c1ccc2c(c1)C1(CCNCC1)CN2S(=O)(=O)c1ccccc1
3079,886196,10.1016/j.bmcl.2012.10.036,,,,Inhibition of dofetilide binding to human ERG by patch clamp assay,O=C(CO)NC1CCN(Cc2ccc(Oc3nc4ccccc4s3)cc2)CC1,N-{1-[4-(Benzothiazol-2-yloxy)benzyl]piperidin-4-yl}-2-hydroxyacetamide,9.9,uM,=,0.99563519459755,1,c1ccc2sc(Oc3ccc(CN4CCCCC4)cc3)nc2c1
3080,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(Cc2ccc3oc(=O)[nH]c3c2)CC1)c1cc(=O)c2ccc(F)cc2o1,"7-fluoro-4-oxo-N-(1-((2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)methyl)piperidin-4-yl)-4H-chromene-2-carboxamide",25.0,uM,=,1.3979400086720375,1,O=C(NC1CCN(Cc2ccc3oc(=O)[nH]c3c2)CC1)c1cc(=O)c2ccccc2o1
3081,2159402,10.1021/acs.jmedchem.1c01968,,,,Inhibition of human ERG by voltage clamp assay,FC1CN(C2COCC2F)CCC1c1cc2nc(Nc3cnn(C4CC4(F)F)c3Cl)ncc2cc1Cl,"6-chloro-N-(5-chloro-1-(2,2-difluorocyclopropyl)-1H-pyrazol-4-yl)-7-(3-fluoro-1-(4-fluorotetrahydrofuran-3-yl)piperidin-4-yl)quinazolin-2-amine",8.6,uM,=,0.9344984512435676,1,c1nn(C2CC2)cc1Nc1ncc2ccc(C3CCN(C4CCOC4)CC3)cc2n1
3082,304829,10.1021/jm049478u,,,,Inhibition of Potassium channel HERG,CN(C)CCCn1nc(C2=C(c3cn(-c4ccc5ccccc5c4)c4ccccc34)C(=O)NC2=O)c2ccccc21,"3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione",0.028,uM,=,-1.5528419686577808,0,O=C1NC(=O)C(c2cn(-c3ccc4ccccc4c3)c3ccccc23)=C1c1n[nH]c2ccccc12
3083,1721264,10.1021/acsmedchemlett.7b00164,,,,Inhibition of human ERG,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N2C(=O)CC[C@@H]2CN2CCN(C)CC2)cc1)c1ccccc1,"(R,Z)-3-((4-(2-((4-methylpiperazine-1-yl)methyl)-5-carbonylpyrrolidine-1-yl)(phenyl)amide)methylene)-2-carbonylindole-6-carboxylate",0.0014,uM,=,-2.853871964321762,0,O=C1Nc2ccccc2/C1=C(/Nc1ccc(N2C(=O)CC[C@@H]2CN2CCNCC2)cc1)c1ccccc1
3084,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,CCc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC2)ccc2c1COC2=O,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-4-ethylisobenzofuran-1(3H)-one,27.0,uM,=,1.4313637641589874,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
3085,983134,10.1016/j.bmcl.2013.07.013,,,,Inhibition of human ERG by patch clamp assay,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CN1CCC(NCc2cc3c(cn2)OCCO3)CC1,"(S)-4-((4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",239.0,uM,=,2.378397900948137,1,O=c1ccc2nccc3c2n1CC3CN1CCC(NCc2cc3c(cn2)OCCO3)CC1
3086,2066476,10.1016/j.ejmech.2018.04.062,,,,Inhibition of human ERG transfected in HEK293 cells assessed as reduction in channel current at -80 mV holding potential by whole-cell patch clamp method,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12,TEMSAVIR,21.9,uM,=,1.3404441148401185,1,O=C(C(=O)N1CCN(C(=O)c2ccccc2)CC1)c1c[nH]c2c(-n3cncn3)nccc12
3087,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],"2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester",280.0,uM,=,2.4471580313422194,1,C1=CC(c2ccccc2)C=CN1
3088,990152,10.1016/j.bmc.2013.08.041,,,,Inhibition of human ERG channel expressed in CHO cells by whole cell patch clamp technique,Cc1ccc(S(=O)(=O)N/N=C/c2cn(CC(=O)Nc3ccc(F)cc3F)c3ccccc23)cc1,"N-(2,4-Difluorophenyl)-2-(3-((2-tosylhydrazono)methyl)-1H-indol-1-yl)acetamide",42.97,uM,=,1.6331653536839033,1,O=C(Cn1cc(/C=N/NS(=O)(=O)c2ccccc2)c2ccccc21)Nc1ccccc1
3089,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,COCCOc1cc(NC(=O)N2CCCc3cc(C4CCN(C5COC5)CC4)c(C=O)nc32)ncc1C#N,"N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-(1-(oxetan-3-yl)piperidin-4-yl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide",28.0,uM,=,1.4471580313422192,1,O=C(Nc1ccccn1)N1CCCc2cc(C3CCN(C4COC4)CC3)cnc21
3090,1277482,10.1016/j.bmcl.2013.10.009,,,,Inhibition of human ERG flux,CC(C)(C)CN1CCC(c2ccccc2Oc2ncccc2NC(=O)Nc2ccc(OC(F)(F)F)cc2)CC1,1-(2-(2-(1-neopentylpiperidin-4-yl)phenoxy)pyridin-3-yl)-3-(4-(trifluoromethoxy)phenyl)urea,4.6,uM,=,0.6627578316815741,1,O=C(Nc1ccccc1)Nc1cccnc1Oc1ccccc1C1CCNCC1
3091,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(C3CC[C@H]4CCCC[C@@H]4NC3=O)nn2)ccc1-n1cnc(C)c1,"rac-(5aR,9aS)-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)octahydro-1H-benzo[b]azepin-2(3H)-one",20.8,uM,=,1.3180633349627615,1,O=C1N[C@H]2CCCC[C@@H]2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
3092,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-chloro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.32,uM,=,-0.494850021680094,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3093,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(Cl)cc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1,(S)-N-(4-chlorophenyl)-4-((1-cyclopropylpiperidin-3-yl)methyl)piperazine-1-carboxamide,14.0,uM,=,1.146128035678238,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
3094,1789491,10.1021/acs.jmedchem.8b01533,,,,Inhibition of human ERG expressed in CHO-S1 cells by automated planar chip-based electrophysiology,Brc1ccc(Nc2ccc(CN3CCC4(CC3)OCCc3sccc34)cc2)cc1,"4-Bromo-N-(4-((6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran]-1-yl)methyl)phenyl)aniline",7.9,uM,=,0.8976270912904415,1,c1ccc(Nc2ccc(CN3CCC4(CC3)OCCc3sccc34)cc2)cc1
3095,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,COc1cccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)c1,N-[1-[(3-methoxybenzyl)methyl]piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide,0.0104,uM,=,-1.98296666070122,0,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
3096,2054254,10.1016/j.ejmech.2020.112501,,,,Inhibition of human ERG by fluorescence polarization assay,CC(C)N1CC=C(c2ccc(/C(=C(/CCCO)c3ccccc3)c3ccc(O)cc3)cc2)CC1.Cl,"4-(5-hydroxy-1-(4-(1-isopropyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-2-phenylpent-1-enyl)phenol hydrochloride",8.2,uM,=,0.9138138523837168,1,C1=C(c2ccc(C(=Cc3ccccc3)c3ccccc3)cc2)CCNC1
3097,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,CN(C)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-(dimethylamino)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00835,uM,=,-2.078313524516398,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3098,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,COC[C@H](C)COCc1ccc([C@@]2(O)CCNC[C@@H]2c2ccc(-c3ccccc3CCNC(C)=O)cc2C)cc1,"N-(2-(4'-((3S,4R)-4-hydroxy-4-(4-(((S)-3-methoxy-2-methylpropoxy)methyl)phenyl)piperidin-3-yl)-3'-methylbiphenyl-2-yl)ethyl)acetamide",9.0,uM,=,0.9542425094393248,1,c1ccc(-c2ccc([C@H]3CNCCC3c3ccccc3)cc2)cc1
3099,1619713,10.1021/acs.jmedchem.6b01156,,,,Inhibition of human ERG expressed in CHO cells assessed as reduction in channel currents at -80 mV holding potential by automated whole-cell patch clamp method,Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1,[5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone,6.9,uM,=,0.8388490907372553,1,O=C(c1cnn(-c2ccc3nc[nH]c3c2)c1)c1cc2ccccc2[nH]1
3100,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CC(Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ccc(C#N)cc2F)CC1)C(F)(F)F,"rac-Fluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-1-methyl-ethoxy)-benzoyl]-piperazin-1-yl}-benzonitrile",3.0,uM,=,0.4771212547196624,1,O=C(c1ccccc1)N1CCN(c2ccccc2)CC1
3101,2194946,10.1021/acs.jmedchem.2c01064,,,,Inhibition of hERG expressed in CHO cells Qpatch-clamp electrophysiology assay,O=c1oc2cc(O)ccc2c2oc3ccc(O)c(CN4CCC(F)CC4)c3c12,"7-((4-Fluoropiperidin-1-yl)methyl)-3,8-dihydroxy-6H-benzofuro-[3,2-c]chromen-6-one",2.46,uM,=,0.3909351071033791,1,O=c1oc2ccccc2c2oc3cccc(CN4CCCCC4)c3c12
3102,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2ccnc(OC)c2OC)cc(OC(C)C)n1,"Rac-(1R,2S)-1-(6-bromo-2-methoxy-3-quinolyl)-1-(2,3-dimethoxy-4-pyridyl)-4-(dimethylamino)-2-(2-isopropoxy-6-methoxy-4-pyridyl)butan-2-ol",17.0,uM,=,1.230448921378274,1,c1ccc2ncc([C@H](Cc3ccncc3)c3ccncc3)cc2c1
3103,716794,10.1016/j.bmcl.2010.12.123,,,,Inhibition of human ERG expressed in CHO cells,Cc1cc(C(=O)O)ccc1NC(=O)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-methylbenzoic acid",0.7,uM,=,-0.1549019599857432,0,O=C(Nc1ccccc1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
3104,575209,10.1016/j.bmcl.2009.03.090,,,,Inhibition of human ERG channel,Clc1cccc(OC(c2cccnc2)C2CCNCC2)c1Cl,"rac-3-((2,3-dichlorophenoxy)(piperidin-4-yl)methyl)pyridine",5.18,uM,=,0.714329759745233,1,c1ccc(OC(c2cccnc2)C2CCNCC2)cc1
3105,580515,10.1016/j.bmcl.2009.06.050,,,,Displacement of [35S]MK499 from human ERG potassium channel expressed in HEK293 cells,COc1ccc([C@@H](C)N[C@@H]2CC[C@@H](C(=O)N3CCC(c4ccccc4)(c4ccccc4)CC3)C(C)(C)C2)cc1,"(4,4-diphenylpiperidin-1-yl)((1R,4R)-4-((R)-1-(4-methoxyphenyl)ethylamino)-2,2-dimethylcyclohexyl)methanone",0.53,uM,=,-0.2757241303992109,0,O=C([C@H]1CC[C@H](NCc2ccccc2)CC1)N1CCC(c2ccccc2)(c2ccccc2)CC1
3106,1744232,10.1021/acs.jmedchem.6b01703,,,,Displacement of [3H]dofetilide from recombinant human ERG expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting method,CCc1nn2c(C)cc(C)nc2c1Cc1ccc(CCCC2(O)CCN(C(C)C)CC2)cc1,"4-(3-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)propyl)-1-isopropylpiperidin-4-ol",5.7,uM,=,0.7558748556724915,1,c1cnc2c(Cc3ccc(CCCC4CCNCC4)cc3)cnn2c1
3107,1474497,10.1021/acs.jmedchem.5b00191,,,,Inhibition of human ERG expressed in CHO cells,Cc1cc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1,"(4aR,6R,8aS)-8a-(2,4-difluorophenyl)-6-(3-methylisoxazol-5-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",1.6,uM,=,0.2041199826559248,1,C1=N[C@@]2(c3ccccc3)CO[C@@H](c3ccno3)C[C@H]2CS1
3108,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3noc(C)n3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"3-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,2,4-oxadiazole",7.3,uM,=,0.8633228601204559,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)nc1
3109,2192070,10.1016/j.ejmech.2020.112955,,,,Inhibition of human ERG,Cc1cc(Nc2ccc(S(F)(F)(F)(F)F)cc2)n2nc(C(C)(F)F)nc2n1,"2-(1,1-Difluoroethyl)-5-methyl-N-[4-(pentafluoro-lambda6-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",1.6623695460951993,uM,=,0.2207275741953245,1,c1ccc(Nc2ccnc3ncnn23)cc1
3110,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCC[C@@H](CCO)Nc1nc(N)nc2ccc(F)cc12,(S)-3-((2-Amino-6-fluoroquinazolin-4-yl)amino)hexan-1-ol,9.3,uM,=,0.9684829485539352,1,c1ccc2ncncc2c1
3111,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn([C@H]3C[C@H](C)c4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"(3S,5S)-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-5-methyl-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",6.68,uM,=,0.8247764624755457,1,O=C1Nc2ccccc2CC[C@@H]1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
3112,554780,10.1016/j.bmcl.2008.05.036,,,,Displacement of [35S]MK499 from human ERG in HEK293 cell membrane,Cc1nn(-c2ncccc2Cl)cc1CN1CCC2(CC1)OCc1ccccc12,"1'-{[1-(3-chloropyridin-2-yl)-3-methyl-1H-pyrazol-4-yl]methyl}-3H-spiro[2-benzofuran-1,4'-piperidine]",7.8,uM,=,0.8920946026904804,1,c1ccc(-n2cc(CN3CCC4(CC3)OCc3ccccc34)cn2)nc1
3113,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,Cc1cc(CNc2nc(N)nc3ccn(Cc4ncccc4Cl)c23)no1,"5-((3-Chloropyridin-2-yl)methyl)-N4-((5-methylisoxazol-3-yl)methyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine",0.9,uM,=,-0.0457574905606751,0,c1ccc(Cn2ccc3ncnc(NCc4ccon4)c32)nc1
3114,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(C(F)(F)F)c3n2CCN1Cc1ccc(Cl)cc1,"2-[(4-Chlorophenyl)methyl]-6-(trifluoromethyl)-3,4-dihydropyrazino(1,2-a)benzimidazol-1(2H)-one",3.0,uM,=,0.4771212547196624,1,O=C1c2nc3ccccc3n2CCN1Cc1ccccc1
3115,2159402,10.1021/acs.jmedchem.1c01968,,,,Inhibition of human ERG by voltage clamp assay,Cc1c(Nc2ncc3cc(Cl)c(C4CCN(C5COC5)CC4)cc3n2)cnn1C1CC1,6-chloro-N-(1-cyclopropyl-5-methyl-1H-pyrazol-4-yl)-7-(1-(oxetan-3-yl)piperidin-4-yl)quinazolin-2-amine,15.0,uM,=,1.1760912590556811,1,c1nn(C2CC2)cc1Nc1ncc2ccc(C3CCN(C4COC4)CC3)cc2n1
3116,1880008,10.1021/acs.jmedchem.9b01769,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2F)nc2sccc12,"(E)-4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[2,3-d]pyrimidin-2-yl)amino)-3-fluorobenzonitrile",0.18,uM,=,-0.744727494896694,0,c1ccc(Nc2nc(Oc3ccccc3)c3ccsc3n2)cc1
3117,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CCOc1ccc(-n2ncc(-c3ccc4cc(CCN5CCC[C@H]5C)ccc4n3)c2C)nn1,2-[1-(6-ethoxypyridazin-3-yl)-5-methyl-1H-pyrazol-4-yl]-6-[2-(2-(R)-methylpyrrolidin-1-yl)ethyl]quinoline,10.4,uM,=,1.0170333392987805,1,c1cnnc(-n2cc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cn2)c1
3118,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3ccnnc3)cc12,4-[(2-Ethylbutyl)amino]-6-(4-pyridazinyl)-3-quinolinecarboxamide,1.6,uM,=,0.2041199826559248,1,c1cnc2ccc(-c3ccnnc3)cc2c1
3119,942909,10.1016/j.bmcl.2013.01.053,,,,Inhibition of human ERG,COc1cc(N2Cc3ccc(Sc4ccc(F)cc4)nc3C2=O)ccc1OCCN1CCCC1,"6-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-2-[(4-fluorophenyl)thio]-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",25.0,uM,=,1.3979400086720375,1,O=C1c2nc(Sc3ccccc3)ccc2CN1c1ccc(OCCN2CCCC2)cc1
3120,787991,10.1021/jm2005546,,,,Inhibition of human cloned ERG channel expressed in chinese hamster CHO cells after 5 mins by patch clamp assay,Cl.O=C(CCc1ccccc1)c1ccccc1OCC(O)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,rac-1-(2-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy)phenyl)-3-phenylpropan-1-one hydrochloride,2.6,uM,=,0.414973347970818,1,O=C(CCc1ccccc1)c1ccccc1OCCCN1CCN(C(c2ccccc2)c2ccccc2)CC1
3121,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,COc1ccc(OC2CN(C(=O)NC3CCN(Cc4ccn(-c5ccc(C(F)(F)F)cc5)c4)CC3)C2)cc1,3-(4-methoxyphenoxy)-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)azetidine-1-carboxamide,2.03,uM,=,0.3074960379132129,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CC(Oc2ccccc2)C1
3122,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(NCc1ccc(C(F)(F)F)cc1)N1CCC[C@H]1CN1CCCC1,(S)-N-(4-(trifluoromethyl)benzyl)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carboxamide,40.0,uM,=,1.6020599913279625,1,O=C(NCc1ccccc1)N1CCC[C@H]1CN1CCCC1
3123,875808,10.1021/jm201710f,,,,Displacement of [3H]dofetilide to human ERG expressed in HEK293 cells,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1,2-(4-fluorophenyl)-N-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-1-methyl-1H-benzo[d]imidazol-4-amine,8.5,uM,=,0.9294189257142929,1,c1ccc(-c2nc3c(Nc4ccc(-n5ccnc5)cn4)cccc3[nH]2)cc1
3124,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)c(F)c2F)[C@@H]3C)n1,"US9422299, 8",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
3125,575209,10.1016/j.bmcl.2009.03.090,,,,Inhibition of human ERG channel,Clc1cccc(OC(c2cccnc2)C2CCNCC2)c1Cl,"rac-3-((2,3-dichlorophenoxy)(piperidin-4-yl)methyl)pyridine",1.97,uM,=,0.2944662261615929,1,c1ccc(OC(c2cccnc2)C2CCNCC2)cc1
3126,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1,3-(4-{[3-(1-Pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,0.71,uM,=,-0.1487416512809247,0,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
3127,1728697,10.1021/acsmedchemlett.7b00312,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,O=C(NC[C@@H]1[C@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@@H]12)c1ccc2[nH]c(=O)oc2c1,"(1R,5S,6s)-3,5-bis(trifluoromethyl)benzyl 6-((2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxamido)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate",5.2,uM,=,0.7160033436347992,1,O=C(NC[C@@H]1[C@H]2CN(C(=O)OCc3ccccc3)C[C@@H]12)c1ccc2[nH]c(=O)oc2c1
3128,815278,10.1016/j.ejmech.2012.02.049,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cells after 45 mins by scintillation counting method,O=C(Nc1ccc(C(F)(F)F)cc1)NS(=O)(=O)c1ccc(OCCCCN2CCCC2)cc1,1-(4-trifluoromethylphenyl)-3-[4-(4-pyrrolidin-1-ylbutoxy)benzene]sulfonylurea,49.1,uM,=,1.6910814921229684,1,O=C(Nc1ccccc1)NS(=O)(=O)c1ccc(OCCCCN2CCCC2)cc1
3129,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc(C#N)cn3)CC2)ccc2c1COC2=O,"6-((S)-1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)nicotinonitrile",28.0,uM,=,1.4471580313422192,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
3130,2241986,10.1016/j.ejmech.2021.114028,,,,Inhibition of hERG,CN(C)S(=O)(=O)[C@]1(C)CC[C@@](CF)(c2cc(-c3ccc(F)cn3)ccc2F)N=C1N,"(3R,6S)-2-amino-6-(2-fluoro-5-(5-fluoropyridin-2-yl)phenyl)-6-(fluoromethyl)-N,N,3-trimethyl-3,4,5,6-tetrahydropyridine-3-sulfonamide",6.92,uM,=,0.8401060944567578,1,C1=NC(c2cccc(-c3ccccn3)c2)CCC1
3131,1478729,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,Benzyl-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)-phenyl-amine,0.033,uM,=,-1.4814860601221125,0,c1ccc(CN(CCN2CCCC2)c2ccccc2)cc1
3132,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(C(=O)N2CCN(C(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1C(C)(C)C,"1-(4-(3,5-di-tert-butyl-4-methoxybenzoyl)piperazin-1-yl)-6,6-bis(4-fluorophenyl)hexan-1-one",9.0,uM,=,0.9542425094393248,1,O=C(CCCCC(c1ccccc1)c1ccccc1)N1CCN(C(=O)c2ccccc2)CC1
3133,2049320,10.1021/acs.jmedchem.0c01179,,,,Inhibition of tracer red binding to human ERG expressed in HEK293 cell membranes measured after 2 to 6 hrs by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N3C[C@H](CO)OC[C@@H]3Cc3ccc(Cl)cc3)CC2)n1,"((2R,5S)-4-(1-(5-Amino-4H-1,2,4-triazol-3-yl)piperidin-4-yl)-5-(4-chlorobenzyl)morpholin-2-yl)methanol",72.0,uM,=,1.8573324964312683,1,c1ccc(C[C@H]2COCCN2C2CCN(c3ncn[nH]3)CC2)cc1
3134,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)(C)O6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.0,uM,=,0.4771212547196624,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3135,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2c1OC(c1ccc(OCCCN3CCCC3)cc1)C(C)S2(=O)=O,"(+/-)-1-{3-[4-(8-Methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",7.0,uM,=,0.8450980400142568,1,O=S1(=O)CC(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
3136,818370,10.1016/j.bmcl.2012.04.001,,,,Inhibition of human ERG by patch clamp assay,O=C1CC2CCc3cc(OC4CCN(C5CCC5)CC4)ccc3C2=NN1,"(+/-)-8-(1-cyclobutylpiperidin-4-yloxy)-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one",18.0,uM,=,1.255272505103306,1,O=C1CC2CCc3cc(OC4CCN(C5CCC5)CC4)ccc3C2=NN1
3137,939638,10.1016/j.bmcl.2012.11.023,,,,Inhibition of human ERG,Nc1nc2cc3c(cc2s1)CCN(C1CC1)CC3,"7-Cyclopropyl-6,7,8,9-tetrahydro-5H-1-thia-3,7-diaza-cyclohepta[f]inden-2-ylamine",13.0,uM,=,1.1139433523068367,1,c1nc2cc3c(cc2s1)CCN(C1CC1)CC3
3138,1886560,10.1021/acs.jmedchem.8b02021,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,COC(=O)c1ccc(COc2ccc3nc(N)sc3c2)cc1,Methyl 4-(((2-Aminobenzo[d]thiazol-6-yl)oxy)methyl)benzoate,10.0,uM,=,1.0,1,c1ccc(COc2ccc3ncsc3c2)cc1
3139,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CC(=O)N1Cc2cc(S(=O)(=O)CC3CC3)ccc2C1C(=O)Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,"2-acetyl-5-(cyclopropylmethylsulfonyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]isoindoline-1-carboxamide",18.0,uM,=,1.255272505103306,1,O=C(Nc1ccccc1)C1NCc2cc(S(=O)(=O)CC3CC3)ccc21
3140,698202,10.1016/j.bmcl.2010.11.033,,,,Inhibition of human hERG,Cc1ccc2nc(CN3CCN(C(=O)CC(c4ccccc4)c4ccc(F)cc4)CC3)oc2c1,3-(4-fluorophenyl)-1-(4-((6-methylbenzo[d]oxazol-2-yl)methyl)piperazin-1-yl)-3-phenylpropan-1-one,2.27,uM,=,0.3560258571931227,1,O=C(CC(c1ccccc1)c1ccccc1)N1CCN(Cc2nc3ccccc3o2)CC1
3141,1667858,10.1016/j.bmcl.2017.03.030,,,,Inhibition of human ERG,N=C(Nc1ccc(I)cc1)NC12CC3CC(CC(C3)C1)C2,N-Adamantan-1-yl-N'-(4-iodo-phenyl)-guanidine,0.4914,uM,=,-0.3085648478559379,0,N=C(Nc1ccccc1)NC12CC3CC(CC(C3)C1)C2
3142,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN(C)C)c(C)c4)C3)o2)cc1,"(3-(4-((dimethylamino)methyl)-3-methylphenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone",10.0,uM,=,1.0,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccccc2)C1
3143,1682333,10.1021/acs.jmedchem.7b01347,,,,Inhibition of full length human ERG expressed in CHO cells at -70 mV holding potential by patch clamp assay,CN(Cc1ccc(C(F)(F)F)nc1)c1cc(C(=O)Nc2nncs2)ncn1,"6-(Methyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-N-(1,3,4-thiadiazol-2-yl)pyrimidine-4-carboxamide",14.0,uM,=,1.146128035678238,1,O=C(Nc1nncs1)c1cc(NCc2cccnc2)ncn1
3144,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CC[C@H](NCc4cc5c(cn4)OCCO5)[C@@H](OC)C3)c2c1,"trans-1-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]-3-methoxypiperidin-1-yl}ethyl)-7-methoxyquinoxalin-2(1H)-one",93.0,uM,=,1.9684829485539352,1,O=c1cnc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
3145,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1Sc2ccccc2O[C@@H]1c1ccc(OCCCN2CCCC2)cc1,"cis-1-(3-(4-(3-methyl-2,3-dihydrobenzo[b][1,4]oxathiin-2-yl)phenoxy)propyl)pyrrolidine",0.005,uM,=,-2.3010299956639813,0,c1ccc2c(c1)O[C@H](c1ccc(OCCCN3CCCC3)cc1)CS2
3146,1911375,10.1021/acs.jmedchem.8b01296,,,,Inhibition of human ERG after 4 hrs by fluorescence polarization assay,Cc1ccc(/C(=C(\CCCO)c2ccccc2)c2ccc(N3CCNCC3)cc2)cc1.Cl.Cl,(Z)-4-phenyl-5-(4-(piperazin-1-yl)phenyl)-5-p-tolylpent-4-en-1-ol dihydrochloride,7.1,uM,=,0.8512583487190752,1,C(=C(c1ccccc1)c1ccc(N2CCNCC2)cc1)c1ccccc1
3147,834187,10.1021/jm2013248,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,CCOC(=O)N1CCN(Cc2noc(-c3cc(Cl)ccc3F)n2)CC1,"ethyl 4-((5-(5-chloro-2-fluorophenyl)-1,2,4-oxadiazol-3-yl)methyl)piperazine-1-carboxylate",31.0,uM,=,1.4913616938342726,1,c1ccc(-c2nc(CN3CCNCC3)no2)cc1
3148,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,COc1ccccc1CC(c1ccccc1)N1CCNCC1,1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine,41.0,uM,=,1.6127838567197357,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
3149,973417,10.1016/j.bmcl.2013.05.089,,,,Inhibition of human ERG channel by electrophysiological assay,C[C@]1(CS(=O)(=O)N2CCN(c3ncc(OCc4ccc(C(F)(F)F)o4)cn3)CC2)NC(=O)NC1=O,"(5S)-5-methyl-5-({[4-(5-{[5-(trifluoromethyl)-2-furyl]methoxy}pyrimidin-2-yl)piperazin-1-yl]sulfonyl}methyl)imidazolidine-2,4-dione",44.0,uM,=,1.6434526764861874,1,O=C1NC(=O)C(CS(=O)(=O)N2CCN(c3ncc(OCc4ccco4)cn3)CC2)N1
3150,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=[N+]([O-])c1ccc(CCN2CCN(CCc3ccc(-n4cnnn4)cc3)CC2)cc1,1-(4-(1H-tetrazol-1-yl)phenethyl)-4-(4-nitrophenethyl)piperazine,0.011,uM,=,-1.958607314841775,0,c1ccc(CCN2CCN(CCc3ccc(-n4cnnn4)cc3)CC2)cc1
3151,2133643,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG by manual patch clamp method,C[C@H](C(=O)Nc1ccc(Cl)cc1)[C@H]1CC[C@@H](c2ccnc3ccc(F)cc32)CC1,"(S)-N-(4-chlorophenyl)-2-((1s,4R)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide",2.4,uM,=,0.380211241711606,1,O=C(C[C@H]1CC[C@@H](c2ccnc3ccccc32)CC1)Nc1ccccc1
3152,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,CC(C)(C)c1cc(C(=O)NC[C@H]2CCN(C(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc(C(C)(C)C)c1,"(R)-N-((1-(6,6-bis(4-fluorophenyl)hexanoyl)pyrrolidin-3-yl)methyl)-3,5-di-tert-butylbenzamide",5.0,uM,=,0.6989700043360189,1,O=C(NC[C@H]1CCN(C(=O)CCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
3153,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CC1(C)C[C@@H](NC(=O)c2ccc3[nH]ncc3c2)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1,"N-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-1H-indazole-5-carboxamide",0.63,uM,=,-0.2006594505464183,0,O=C(N[C@@H]1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)c1ccc2[nH]ncc2c1
3154,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(CC(OCC(=O)O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(rac)-2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid",3.0,uM,=,0.4771212547196624,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3155,816393,10.1016/j.bmcl.2012.03.035,,,,Inhibition of human Erg by patch clamp assay in absence of plasma protein,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,SID103904272,1.0,uM,=,0.0,0,O=C(Nc1ccccc1)Nc1ccc(-c2csc3c(-c4cn[nH]c4)cncc23)cc1
3156,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1CCc2cc(F)ccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1,"6-Fluoro-1-{3-[4-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-3,4-dihydro-1H-quinolin-2-one",3.4,uM,=,0.5314789170422551,1,O=C1CCc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
3157,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,Cc1ccccc1N1CCN(C[C@@H]2CCc3cccnc3[C@@H](O)C2)CC1,"(7R,9S)-7-((4-o-tolylpiperazin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",2.3,uM,=,0.3617278360175928,1,c1ccc(N2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
3158,1906723,10.1016/j.ejmech.2019.111674,,,,Inhibition of human ERG expressed in HEK293 cells incubated for 72 hrs by patch clamp assay,Cn1c(C(N)=O)ccc1-c1cccc(OC(=O)NCCN2CCN(c3ccccc3)CC2)c1,3-(5-Carbamoyl-1-methyl-1H-pyrrol-2-yl)phenyl (2-(4-phenylpiperazin-1-yl)ethyl)carbamate,6.4,uM,=,0.8061799739838872,1,O=C(NCCN1CCN(c2ccccc2)CC1)Oc1cccc(-c2ccc[nH]2)c1
3159,1543580,10.1016/j.bmcl.2015.11.030,,,,Inhibition of human ERG by IKr binding assay,O=C(c1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)N1CCC2(CCOC2=O)CC1,"8-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)benzoyl)-2-oxa-8-azaspiro[4.5]decan-1-one",46.0,uM,=,1.662757831681574,1,O=C(c1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)N1CCC2(CCOC2=O)CC1
3160,796063,10.1016/j.bmcl.2011.11.050,,,,Inhibition of human ERG by patch express assay,O=S(=O)(c1cccc(F)c1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3,"(+/-)-7-(3-fluorophenylsulfonyl)-2',3,4,4',5',6'-hexahydro-2H-spiro[benzofuro[2,3-c]pyridine-1,3'-pyran]",9.6,uM,=,0.9822712330395684,1,O=S(=O)(c1ccccc1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3
3161,1809217,10.1021/acsmedchemlett.9b00204,,,,Inhibition of human ERG,CC(C)c1ccc(-c2cc(CN3CCOCC3)nn2C2CCC2)cc1,4-((1-Cyclobutyl-5-(4-isopropylphenyl)-1H-pyrazol-3-yl)methyl)morpholine,32.0,uM,=,1.505149978319906,1,c1ccc(-c2cc(CN3CCOCC3)nn2C2CCC2)cc1
3162,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(OC)cc(OC)c2)CCN(Cc2cccc(C(F)(F)F)c2)CC1,"methyl 4-((3,5-dimethoxybenzamido)methyl)-1-(3-(trifluoromethyl)benzyl)piperidine-4-carboxylate",2.8,uM,=,0.4471580313422192,1,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
3163,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,CCc1ccc2c(c1)C(C1=C[C@H](C)N(C)CC1)=Nc1cc(Cl)ccc1N2,"(S)-8-chloro-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-ethyl-5H-dibenzo[b,e][1,4]diazepine",1.1,uM,=,0.041392685158225,1,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
3164,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccn2)c1,endo-3-(8-(pyridin-2-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0019,uM,=,-2.721246399047171,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccn2)cc1
3165,1677014,10.1021/acs.jmedchem.7b01537,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp method,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC.Cl,"[4-Cyano-4-(3,4-dimethoxy-phenyl)-5-methyl-hexyl]-[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-ammonium chloride",0.56,uM,=,-0.2518119729937995,0,c1ccc(CCCCNCCc2ccccc2)cc1
3166,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1cc2nc(CC3CCCNC3)n(Cc3ccc(Cl)cc3)c2cc1C,"US8975247, EBP660",0.49,uM,=,-0.3098039199714864,0,c1ccc(Cn2c(CC3CCCNC3)nc3ccccc32)cc1
3167,1924512,10.1021/acsmedchemlett.6b00122,,,,Displacement of [35S]MK-499 from human ERG,Cc1c([C@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,"US9018211, 2C",100.0,uM,=,2.0,1,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21
3168,1553512,10.1016/j.bmc.2016.02.006,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,O=C(O)CN(C1(c2ccc(-c3ccccc3OC(F)(F)F)cc2)CCC1)S(=O)(=O)c1ccc(OC(F)F)cc1,2-(4-(Difluoromethoxy)-N-(1-(2'-(trifluoromethoxy)biphenyl-4-yl)cyclobutyl)phenylsulfonamido)acetic acid,15.0,uM,=,1.1760912590556811,1,O=S(=O)(NC1(c2ccc(-c3ccccc3)cc2)CCC1)c1ccccc1
3169,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1c(C#N)cnc3ccccc13)c(=O)n2C,"4-((5-(but-2-ynyl)-7-cyano-6-(1,4-diazepan-1-yl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)methyl)quinoline-3-carbonitrile",4.4,uM,=,0.6434526764861874,1,O=c1[nH]c2cc(N3CCCNCC3)[nH]c2c(=O)n1Cc1ccnc2ccccc12
3170,2294517,10.1016/j.bmc.2023.117202,,,,Binding affinity to human ERG,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,2.206,uM,=,0.3436055081041718,1,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
3171,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccc(F)cc1Br,"ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholinomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",0.86,uM,=,-0.0655015487564322,0,C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccccc1
3172,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",O=C1CCCN1Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,"US8975247, EBP144",7.0,uM,=,0.8450980400142568,1,O=C1CCCN1Cc1nc2ccccc2n1Cc1ccccc1
3173,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1ccc(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)c(C)n1,"(R)-2-(2,6-dimethylpyridin-3-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline",20.0,uM,=,1.3010299956639813,1,c1cncc(-c2ccc3cc(CCN4CCCC4)ccc3n2)c1
3174,806244,10.1016/j.bmcl.2012.01.078,,,,Inhibition of human Erg by patch clamp assay,COc1ccc2cccc(Oc3ccc4nc(C)n(C[C@H]5CCCN(C(C)C)C5)c(=O)c4n3)c2n1,"(S)-3-((1-isopropylpiperidin-3-yl)methyl)-6-(2-methoxyquinolin-8-yloxy)-2-methylpyrido[3,2-d]pyrimidin-4(3H)-one",13.6,uM,=,1.1335389083702174,1,O=c1c2nc(Oc3cccc4cccnc34)ccc2ncn1C[C@H]1CCCNC1
3175,1753764,10.1016/j.bmcl.2017.12.068,,,,Inhibition of human ERG,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,ABEMACICLIB,10.9,uM,=,1.0374264979406236,1,c1cc(-c2ccc3nc[nH]c3c2)nc(Nc2ccc(CN3CCNCC3)cn2)n1
3176,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CCN1CCNC(CN2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"rac-N-(3,4-dichlorophenyl)-4-((4-ethylpiperazin-2-yl)methyl)piperazine-1-carboxamide",8.9,uM,=,0.9493900066449128,1,O=C(Nc1ccccc1)N1CCN(CC2CNCCN2)CC1
3177,1879326,10.1021/acs.jmedchem.9b01172,,,,Inhibition of human ERG assessed as reduction in channel tail current by plate-based planar patch clamp assay,CCCCOc1cccc(CCNCC(=O)N(C)C)c1.Cl,"2-(3-butoxyphenethylamino)-N,N-dimethylacetamide Hydrochloride",9.4,uM,=,0.9731278535996988,1,c1ccccc1
3178,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@H]1CN(C)C[C@@H]1c1ccc(-c2cccc(NS(C)(=O)=O)c2)cc1,"N-((3R,4R)-1-methyl-4-(3'-(methylsulfonamido)biphenyl-4-yl)pyrrolidin-3-yl)propane-2-sulfonamide",31.6,uM,=,1.499687082618404,1,c1ccc(-c2ccc([C@@H]3CCNC3)cc2)cc1
3179,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3cccc(F)c3)CC2)C1,"N-(3,5-bis(trifluoromethyl)benzyl)-3-(4-(3-fluorophenyl)piperidin-1-yl)-1-isopropylcyclopentanecarboxamide",0.045,uM,=,-1.3467874862246565,0,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3ccccc3)CC2)C1
3180,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,Cc1c(O)ccc2c1C(=O)N(Cc1ccccc1-c1ccccc1)C2C(=O)NC(C)(C)C,(rac)-2-(biphenyl-2-ylmethyl)-N-tert-butyl-5-hydroxy-4-methyl-3-oxoisoindoline-1-carboxamide,26.0,uM,=,1.414973347970818,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
3181,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(CCc2cccc(CCc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis(4-methylphenethyl)pyridinium",0.024,uM,=,-1.619788758288394,0,c1ccc(CCc2cccc(CCc3ccccc3)[nH+]2)cc1
3182,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",CCN(CC)CCN(C)c1ccc(-n2ccc(OCc3ccccc3)cc2=O)cc1,4-(Benzyloxy)-1-(4-{[2-(diethylamino)ethyl](methyl)-amino}phenyl)pyridin-2(1H)-one,0.0017,uM,=,-2.7695510786217263,0,O=c1cc(OCc2ccccc2)ccn1-c1ccccc1
3183,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",CCN(CC)CCNc1ccc(-n2ccc(OCc3ccccc3)cc2=O)cc1,4-(Benzyloxy)-1-(4-{[2-(diethylamino)ethyl]amino}-phenyl)pyridin-2(1H)-one,0.007,uM,=,-2.154901959985743,0,O=c1cc(OCc2ccccc2)ccn1-c1ccccc1
3184,2238137,10.1021/acs.jmedchem.1c01012,,,,Inhibition of human ERG,CCc1cc2ccc(CN3CCN(c4ccc(C(=O)NC)nc4)CC3)cc2[nH]c1=O,"5-(4-((3-ethyl-2-oxo-1,2-dihydroquinolin-7-yl)methyl)piperazin-1-yl)-N-methylpicolinamide",21.0,uM,=,1.3222192947339193,1,O=c1ccc2ccc(CN3CCN(c4cccnc4)CC3)cc2[nH]1
3185,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2c1CCC2,"(1R,2S)-1-(7-bromo-3-methoxynaphthalen-2-yl)-2-(2,3-dihydro-1H-inden-4-yl)-4-(dimethylamino)-1-phenylbutan-2-ol",3.8,uM,=,0.5797835966168101,1,c1ccc([C@@H](Cc2cccc3c2CCC3)c2ccc3ccccc3c2)cc1
3186,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,CN1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc([N+](=O)[O-])c4)c3c2)CC1,3-(4-Methylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinoline,0.049,uM,=,-1.3098039199714864,0,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
3187,1779901,10.1021/acs.jmedchem.8b00884,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1ccc2nn(C)cc2c1NS(=O)(=O)c1ccc(CCCOC[C@@H]2CCCN2C)cc1,(S)-N-(5-isobutyl-2-methyl-2H-indazol-4-yl)-4-(3-((1-methylpyrrolidin-2-yl)methoxy)propyl)benzenesulfonamide,3.0,uM,=,0.4771212547196624,1,O=S(=O)(Nc1cccc2n[nH]cc12)c1ccc(CCCOC[C@@H]2CCCN2)cc1
3188,2054847,10.1016/j.ejmech.2020.112709,,,,Inhibition of human ERG expressed in HEK293 cells by whole-cell patch clamp method,Cn1ccc2ccc(OCCCN3CCC(c4noc5cc(F)ccc45)CC3)cc2c1=O,7-(3-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propoxy)-2-methylisoquinolin-1(2H)-one,0.598,uM,=,-0.2232988160115891,0,O=c1[nH]ccc2ccc(OCCCN3CCC(c4noc5ccccc45)CC3)cc12
3189,1722009,10.1021/acs.jmedchem.8b00304,,,,Inhibition of human ERG expressed in HEK293 cell membranes by radioligand binding assay,C[C@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)N=C(N)CO[C@@H]1F,"N-{3-[(2R,3R)-5-Amino-2-fluoro-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide",8.0,uM,=,0.9030899869919436,1,O=C(Nc1cccc(C2COCC=N2)c1)c1ccccn1
3190,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C=C(N(C)Cc1ccc(-c2ccccc2)cc1)N1CCN(C(C)C)CC1,N-(biphenyl-4-ylmethyl)-1-(4-isopropylpiperazin-1-yl)-N-methylethenamine,8.181818182,uM,=,0.9128498242907508,1,C=C(NCc1ccc(-c2ccccc2)cc1)N1CCNCC1
3191,1478749,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,"2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)-ethoxy]-ethanol",5.8,uM,=,0.7634279935629373,1,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1S2
3192,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,Cc1ncccc1-c1nc2cn(-c3cccc(OC(C)C)c3)nc2c(=O)n1C[C@H]1CCCN(C[C@H]2CCCO2)C1,"2-(3-Isopropoxyphenyl)-5-(2-methylpyridin-3-yl)-6-(((S)-1-(((R)-tetrahydrofuran-2-yl)methyl)piperidin-3-yl)methyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",6.8,uM,=,0.8325089127062363,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2cccnc2)n1C[C@H]1CCCN(C[C@H]2CCCO2)C1
3193,499332,10.1016/j.bmcl.2009.04.023,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(C(=O)C4(C)CCC(=O)CC4)nc3cc2Cl)CC1,4-(5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazole-2-carbonyl)-4-methylcyclohexanone,8.5,uM,=,0.9294189257142929,1,O=C1CCC(C(=O)c2nc3ccc(N4CCNCC4)cc3[nH]2)CC1
3194,755804,10.1021/jm2003359,,,,Inhibition of human ERG expressed in CHO cells by Q-patch assay,Cc1ccc(Nc2c(-c3ccc(F)cc3)nc3n2CCN(C(=O)CN)C3)cc1,"2-amino-1-(2-(4-fluorophenyl)-3-(p-tolylamino)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone",11.1,uM,=,1.0453229787866574,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
3195,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOc5ccccc5Cl)c4)n[nH]c2-3)CC1,"3-(5-(3-(2-chlorophenoxy)prop-1-ynyl)thiophen-3-yl)-6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno[1,2-c]pyrazole",0.79,uM,=,-0.1023729087095585,0,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)COc1ccccc1
3196,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,CN(C)C(=O)C(CO)N(C)Cc1ccc2c(c1)CC[C@H](N1CCN(CCc3ccc(F)cc3)CC1=O)C2,"2-((((S)-6-(4-(4-fluorophenethyl)-2-oxopiperazin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl)methyl)(methyl)amino)-3-hydroxy-N,N-dimethylpropanamide",25.0,uM,=,1.3979400086720375,1,O=C1CN(CCc2ccccc2)CCN1[C@H]1CCc2ccccc2C1
3197,793275,10.1016/j.bmcl.2011.09.117,,,,Displacement of [3H]dofetilide from human ERG by liquid scintillation counting,COc1ccc2ncc(F)c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"N-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methyl)-1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)piperidin-4-amine",15.1,uM,=,1.1789769472931697,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
3198,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N(C)C)nc1CN1C(=O)O[C@H](c2ccc(OC(F)(F)F)cc2)[C@@H]1C,"3'-(2-(Dimethylamino)-4-(((4S,5R)-4-methyl-2-oxo-5-(4-(trifluoromethoxy)phenyl)oxazolidin-3-yl)methyl)pyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic Acid",3.8,uM,=,0.5797835966168101,1,O=C1O[C@H](c2ccccc2)CN1Cc1ncncc1-c1cccc(-c2ccccc2)c1
3199,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4F)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(2-fluorophenyl)pyrrolo[1,2-b]pyridazine-3-carboxamide",9.6,uM,=,0.9822712330395684,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
3200,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc2c(c1)CN(C(C)=O)[C@@H]2C(=O)Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,"(1S)-2-acetyl-5-ethylsulfonyl-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]isoindoline-1-carboxamide",15.0,uM,=,1.1760912590556811,1,O=C(Nc1ccccc1)[C@H]1NCc2ccccc21
3201,834187,10.1021/jm2013248,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,CCOC(=O)N1CCN(Cc2nc(-c3cccc(Cl)c3)no2)CC1,SID24799236,15.5,uM,=,1.1903316981702914,1,c1ccc(-c2noc(CN3CCNCC3)n2)cc1
3202,983483,10.1016/j.bmcl.2013.07.061,,,,Inhibition of human ERG channel,N[C@H]1C[C@@H](N2Cc3cnc(C(F)(F)F)nc3C2)CO[C@@H]1c1cc(F)c(F)cc1F,"(2R,3S,5R)-5-(2-(trifluoromethyl)-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)-2-(2,4,5-trifluorophenyl)tetrahydro-2H-pyran-3-amine",23.0,uM,=,1.3617278360175928,1,c1ccc([C@@H]2CC[C@@H](N3Cc4cncnc4C3)CO2)cc1
3203,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ccc(Br)cc3C2)C1,"(7-bromo-3,4-dihydroisoquinolin-2(1H)-yl)((2R,3aR,6aR)-2-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)methanone",20.3,uM,=,1.307496037913213,1,O=C(N1CCc2ccccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
3204,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc2ccccc2c1)Cc1ccc2c(c1)OCCC2.Cl,(E)-N-(Chroman-7-methyl)-N-methyl-3-(naphth-2-yl)prop-2-en-1-amine Hydrochloride,16.2,uM,=,1.209515014542631,1,C(=C/c1ccc2ccccc2c1)\CNCc1ccc2c(c1)OCCC2
3205,420606,10.1016/j.bmcl.2006.11.061,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,CC(=O)Nc1ccc2c(c1)C(N1CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC1)CC2,"N-(1-(6-acetamido-2,3-dihydro-1H-inden-1-yl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide",15.6,uM,=,1.1931245983544616,1,O=C(NC1CCN(C2CCc3ccccc32)CC1)c1cc(=O)c2ccccc2o1
3206,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)(C(C)C)C1,"((3S,4S)-N-[(1R,3S)-3-isopropyl-3-({4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)cyclopentyl]-3-methoxytetrahydro-2H-pyran-4-amine",1.7,uM,=,0.2304489213782739,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2ccccn2)CC1
3207,1512016,10.1016/j.bmcl.2015.06.067,,,,Inhibition of dofetilide binding to human ERG,CN(C)C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,"(2S,3S)-3-Dimethylaminomethyl-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-[(7-tert-butyl-4,5-dihydrobenzo[1,2-d:3,4-d']bisthiazol-2-yl)-amide]",5.7,uM,=,0.7558748556724915,1,O=C(Nc1nc2c(s1)-c1ncsc1CC2)N1CCCC1
3208,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CC(Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ccc(C(F)(F)F)cc2)CC1)C(F)(F)F,"rac-[5-Methanesulfonyl-2-(2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-[4-(4-trifluoromethylphenyl)-piperazin-1-yl]-methanone",10.0,uM,=,1.0,1,O=C(c1ccccc1)N1CCN(c2ccccc2)CC1
3209,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,COc1ccccc1CC(c1ccc(F)cc1)N1CCNCC1,1-(1-(4-fluorophenyl)-2-(2-methoxyphenyl)ethyl)piperazine,16.0,uM,=,1.2041199826559248,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
3210,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,CC(C)(O)COc1ccc(C(N)=O)c(O[C@@H]2CCN(C(=O)Cc3ccc(OC(F)(F)F)cc3)C[C@@H]2F)c1,"2-(((3S,4R)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)-piperidin-4-yl)oxy)-4-(2-hydroxy-2-methylpropoxy)benzamide",38.0,uM,=,1.57978359661681,1,O=C(Cc1ccccc1)N1CCC(Oc2ccccc2)CC1
3211,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2ccc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)cc21,6-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,32.0,uM,=,1.505149978319906,1,O=C1OCc2ccc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)cc21
3212,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5F)OCC(=O)N6)(CC3)CO4)c2n1,"7-fluoro-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.3,uM,=,0.1139433523068367,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3213,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,CC(C)c1noc(N2CCN(c3ncc(OCc4ccc(S(C)(=O)=O)cc4F)cn3)[C@H](C)C2)n1,"5-{[2-Fluoro-4-(methylsulfonyl)benzyl]oxy}-2-{(2R)-2-methyl-4-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]piperazin-1-yl}pyrimidine",7.4,uM,=,0.8692317197309762,1,c1ccc(COc2cnc(N3CCN(c4ncno4)CC3)nc2)cc1
3214,1498164,10.1021/ml500514w,,,,Inhibition of human ERG by Patchexpress patch clamp assay,CCn1cc([C@@]2(c3nn(C)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one",27.0,uM,=,1.4313637641589874,1,O=c1[nH]nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
3215,1440048,10.1021/jm500887k,,,,Inhibition of human ERG channel by patch clamp technique,CS(=O)(=O)c1ccc(-c2cnc3ccc(-c4cccc(S(=O)(=O)C5CC5)c4)nn23)cc1,"6-(3-(Cyclopropylsulfonyl)phenyl)-3-(4-(methylsulfonyl)-phenyl)imidazo[1,2-b]pyridazine",0.4,uM,=,-0.3979400086720376,0,O=S(=O)(c1cccc(-c2ccc3ncc(-c4ccccc4)n3n2)c1)C1CC1
3216,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C)cc(C(=O)Nc2cncc(-c3cc(C)cc(C)c3)c2N2CCC(N)CC2)c1,"N-(4-(4-aminopiperidin-1-yl)-5-(3,5-dimethylphenyl)pyridin-3-yl)-3,5-dimethylbenzamide",1.7,uM,=,0.2304489213782739,1,O=C(Nc1cncc(-c2ccccc2)c1N1CCCCC1)c1ccccc1
3217,1881576,10.1021/acs.jmedchem.8b00741,,,,Inhibition of human ERG at 37 degC,CCc1nc(C)cn2nc(-c3cc(=O)n4cc(C5CCN(C)CC5)cc(C)c4n3)cc12,"2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one",1.8,uM,=,0.255272505103306,1,O=c1cc(-c2cc3cnccn3n2)nc2ccc(C3CCNCC3)cn12
3218,1543580,10.1016/j.bmcl.2015.11.030,,,,Inhibition of human ERG by IKr binding assay,O=C(c1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)N1C[C@@H]2[C@H](C1)[C@H]2c1nnco1,"((1R,5S,6S)-6-(1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.1.0]hexan-3-yl)(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)methanone",55.0,uM,=,1.740362689494244,1,O=C(c1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)N1C[C@@H]2[C@H](C1)[C@H]2c1nnco1
3219,2244060,10.1016/j.ejmech.2022.114145,,,,Inhibition of hERG,Cc1ccnc(NC(=O)c2ccsc2NC(=O)c2ccc(S(=O)(=O)N3CCCCC3)cc2)n1,N-(4-Methylpyrimidin-2-yl)-2-(4-(piperidin-1-ylsulfonyl)benzamido)thiophene-3-carboxamide,1.7,uM,=,0.2304489213782739,1,O=C(Nc1sccc1C(=O)Nc1ncccn1)c1ccc(S(=O)(=O)N2CCCCC2)cc1
3220,606274,10.1016/j.bmcl.2009.10.112,,,,Inhibition of human ERG channel,Cc1ccc(F)cc1CO[C@H]1CCc2ccc(N3CCNC[C@H]3C)nc21,"(S)-7-(5-fluoro-2-methylbenzyloxy)-2-((R)-2-methylpiperazin-1-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine",3.9,uM,=,0.5910646070264992,1,c1ccc(CO[C@H]2CCc3ccc(N4CCNCC4)nc32)cc1
3221,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccs1,"(R)-2-(6-methoxy-3-(1-(thiazol-2-yl)ethyl)-1H-inden-2-yl)-N,N-dimethylethanamine",22.0,uM,=,1.3424226808222062,1,C1=C(Cc2nccs2)c2ccccc2C1
3222,1475773,10.1021/jm5017413,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch-clamp assay,CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)co1,"(R)-(3-(2-Isopropyloxazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",7.3,uM,=,0.8633228601204559,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2cocn2)C1
3223,1817309,10.1021/acs.jmedchem.8b01750,,,,Inhibition of human ERG expressed in CHO cells in at -80 mV holding potential by automated Qpatch clamp assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.19,uM,=,-0.721246399047171,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
3224,640798,10.1016/j.bmcl.2010.05.041,,,,Inhibition of human ERG by patch clamp technique,N#Cc1cccc(Oc2ccc(C(=O)N3CCCN(C4CCC4)CC3)cn2)c1,"3-(5-(4-cyclobutyl-1,4-diazepane-1-carbonyl)pyridin-2-yloxy)benzonitrile",5.4,uM,=,0.7323937598229685,1,O=C(c1ccc(Oc2ccccc2)nc1)N1CCCN(C2CCC2)CC1
3225,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CC(C)c1nc(-c2nc3ccccc3[nH]2)c(N2CCN(C(=O)Cn3cnc4cccnc43)[C@H](C)C2)s1,"US9266876, 50",1.3,uM,=,0.1139433523068367,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2nc3ccccc3[nH]2)CC1
3226,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,COc1cccc(Cn2ccc3nc(N)nc(NCc4cc(C)on4)c32)n1,"5-((6-Methoxypyridin-2-yl)methyl)-N4-((5-methylisoxazol-3-yl)methyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine",2.3,uM,=,0.3617278360175928,1,c1ccc(Cn2ccc3ncnc(NCc4ccon4)c32)nc1
3227,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,O=C(/C=C/c1ccc(CN2CCCC(c3c(-c4ccccc4)[nH]c4ccccc34)C2)cc1)NO,(E)-N-Hydroxy-3-{4-[3-(2-phenyl-1H-indol-3-yl)piperidin-1-ylmethyl]phenyl}acrylamide,28.4,uM,=,1.4533183400470375,1,c1ccc(CN2CCCC(c3c(-c4ccccc4)[nH]c4ccccc34)C2)cc1
3228,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1cc(C(=O)NCC2(C#N)CCN(Cc3ccccc3C(F)(F)F)CC2)nn1-c1ccccc1,N-((4-cyano-1-(2-(trifluoromethyl)benzyl)piperidin-4-yl)methyl)-5-isobutyl-1-phenyl-1H-pyrazole-3-carboxamide,4.76,uM,=,0.6776069527204931,1,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccn(-c2ccccc2)n1
3229,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,c1ccc(C(Cc2ccccc2OCC2CC2)N2CCNCC2)cc1,1-(2-(2-(cyclopropylmethoxy)phenyl)-1-phenylethyl)piperazine,2.96,uM,=,0.4712917110589386,1,c1ccc(C(Cc2ccccc2OCC2CC2)N2CCNCC2)cc1
3230,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",O=c1cc(OCc2ccc(C(F)(F)F)cc2)ccn1-c1ccc(OCCN2CCCC2)cc1,1-{4-[2-(Pyrrolidin-1-yl)ethoxy]phenyl}-4-{[4-(trifluoromethyl)benzyl]oxy}pyridin-2(1H)-one,0.0024,uM,=,-2.619788758288394,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCN2CCCC2)cc1
3231,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,CC(C)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-(isopentyloxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.5,uM,=,0.5440680443502757,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3232,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",CCc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1,"US9422299, 2",32.0,uM,=,1.505149978319906,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
3233,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOc5ccc(Cl)cc5)c4)n[nH]c2-3)CC1,"3-(5-(3-(4-chlorophenoxy)prop-1-ynyl)thiophen-3-yl)-6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno[1,2-c]pyrazole",3.59,uM,=,0.5550944485783191,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)COc1ccccc1
3234,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ccc(OC(F)(F)F)cc3C2)C1,"((2R,3aR,6aR)-2-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)(7-(trifluoromethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone",7.4,uM,=,0.8692317197309762,1,O=C(N1CCc2ccccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
3235,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,COc1cc(F)cc(-c2cncc(-c3nc4cc(C)ccc4[nH]3)c2N2CCC(N)CC2)c1,1-(3-(3-fluoro-5-methoxyphenyl)-5-(5-methyl-1H-benzo[d]imidazol-2-yl)pyridin-4-yl)piperidin-4-amine,8.3,uM,=,0.919078092376074,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
3236,580515,10.1016/j.bmcl.2009.06.050,,,,Displacement of [35S]MK499 from human ERG potassium channel expressed in HEK293 cells,COc1ccc(CN[C@@H]2CC[C@@H](C(=O)N3CCC(C(=O)N4CCCC4)(c4ccccc4)CC3)C(C)(C)C2)cc1,"(1-((1R,4R)-4-(4-methoxybenzylamino)-2,2-dimethylcyclohexanecarbonyl)-4-phenylpiperidin-4-yl)(pyrrolidin-1-yl)methanone",0.9,uM,=,-0.0457574905606751,0,O=C(N1CCCC1)C1(c2ccccc2)CCN(C(=O)[C@H]2CC[C@H](NCc3ccccc3)CC2)CC1
3237,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,CCOC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"ethyl 2-(7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)acetate",8.5,uM,=,0.9294189257142929,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3238,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCC(c2ccccc2O)CC1,4-(2-hydroxyphenyl)-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)piperidine-1-carboxamide,4.12,uM,=,0.6148972160331346,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCC(c2ccccc2)CC1
3239,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cn1,"N,N-Diethyl-5-(spiro[chromene-2,4'-piperidine]-4-yl)picolinamide",44.113,uM,=,1.644566593918557,1,C1=C(c2cccnc2)c2ccccc2OC12CCNCC2
3240,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(CS(C)(=O)=O)nc5)cc4c32)C1,"7-Fluoro-8-[6-(methanesulfonylmethyl)pyridin-3-yl]-3-methyl-1-[cis-3-methoxycyclobutyl]-1H,2H,3H-imidazo[4,5-c]quinolin-2-one",14.0,uM,=,1.146128035678238,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCC1
3241,2286943,10.1021/acs.jmedchem.1c01215,,,,Inhibition of hERG channel,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1,Biphenyl-4-carboxylic acid {4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-butyl}-amide,0.042,uM,=,-1.3767507096020994,0,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc(-c2ccccc2)cc1
3242,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,N#Cc1cnc(Nc2cc(NC[C@H]3CNCCO3)c(Cl)cn2)cn1,(R)-5-(5-Chloro-4-(morpholin-2-ylmethylamino)pyridin-2-ylamino)pyrazine-2-carbonitrile,6.1,uM,=,0.785329835010767,1,c1cnc(Nc2cc(NC[C@H]3CNCCO3)ccn2)cn1
3243,1744232,10.1021/acs.jmedchem.6b01703,,,,Displacement of [3H]dofetilide from recombinant human ERG expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting method,CCc1nn2c(C)cc(C)nc2c1Cc1ccc(/C=C/CN2CCN(C(C)C)CC2)cc1,"(E)-2-ethyl-3-(4-(3-(4-isopropylpiperazin-1-yl)prop-1-enyl)benzyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine",2.1,uM,=,0.3222192947339193,1,C(=C/c1ccc(Cc2cnn3cccnc23)cc1)\CN1CCNCC1
3244,2048454,10.1016/j.bmc.2020.115734,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,COc1nc(-c2csc(Nc3c4c(nn3CC(C)(C)O)CCCC4)n2)ccc1-n1cnc(C)c1,"1-(3-((4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-yl)amino)-4,5,6,7-tetrahydro-2H-indazol-2-yl)-2-methylpropan-2-ol",5.8,uM,=,0.7634279935629373,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCC5)n3)nc2)cn1
3245,787991,10.1021/jm2005546,,,,Inhibition of human cloned ERG channel expressed in chinese hamster CHO cells after 5 mins by patch clamp assay,Cl.O=C(CCc1ccccc1)c1ccccc1OCC(O)CN1CCC(c2ccccc2)CC1,rac-1-(2-(2-hydroxy-3-(4-phenylpiperidin-1-yl)propoxy)phenyl)-3-phenylpropan-1-one hydrochloride,3.46,uM,=,0.5390760987927766,1,O=C(CCc1ccccc1)c1ccccc1OCCCN1CCC(c2ccccc2)CC1
3246,1682333,10.1021/acs.jmedchem.7b01347,,,,Inhibition of full length human ERG expressed in CHO cells at -70 mV holding potential by patch clamp assay,CC(C)Oc1ccc(NC(=O)c2cc(N(C)Cc3ccc(F)cc3)ncn2)cc1,6-((4-Fluorobenzyl)(methyl)amino)-N-(4-isopropoxyphenyl)pyrimidine-4-carboxamide,4.1,uM,=,0.6127838567197355,1,O=C(Nc1ccccc1)c1cc(NCc2ccccc2)ncn1
3247,1622464,10.1016/j.bmcl.2016.09.067,,,,Inhibition of radiolabeled dofetilide binding to human ERG expressed in HEK293 cells,C[C@@H]1C[C@H](N)CN(c2ccncc2Nc2ncc3ccc(-c4c(F)cccc4F)nn23)C1,"N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-amine",1.0,uM,=,0.0,0,c1ccc(-c2ccc3cnc(Nc4cnccc4N4CCCCC4)n3n2)cc1
3248,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1nsc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2)n1,"(R)-5-(1-hydroxy-2-(2-(3-methyl-1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",4.2,uM,=,0.6232492903979004,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ncns3)C4)ccc21
3249,489010,10.1021/jm8003834,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide from human ERG in HEK293 cells",Cc1nc2ccccc2c(=O)n1-c1ccc(OCCCN2CCCCCC2)cc1,3-(4-{[3-(1-Azepanyl)propyl]oxy}phenyl)-2-methyl-4(3H)-quinazolinone,6.6,uM,=,0.8195439355418687,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCCCC2)cc1
3250,2084737,10.1021/acs.jmedchem.6b00939,,,,Inhibition of human ERG expressed stably in CHO cells by manual patch clamp technique,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,"N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide",12.0,uM,=,1.0791812460476249,1,O=C(CN1CCN(CCCOc2ccccc2)CC1)Nc1ccccc1
3251,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cccc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1,(R)-N-ethyl-N-(1-(3-(3-fluorophenyl)-3-(1-(methylsulfonyl)piperidin-4-yl)propyl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)acetamide,35.0,uM,=,1.5440680443502757,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
3252,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,N-((4-(4-benzylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)propionamide,6.8,uM,=,0.8325089127062363,1,c1ccc(CN2CCN(C3(CNc4ccccn4)CCOCC3)CC2)cc1
3253,649407,10.1021/jm100479q,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cn1cc(Br)c(C(=O)N2CCN(CC(=O)c3ccc(F)cc3)CC2)n1,2-[4-(4-Bromo-1-methyl-1H-pyrazole-3-carbonyl)piperazin-1-yl]-1-(4-fluorophenyl)ethanone,19.0,uM,=,1.2787536009528289,1,O=C(CN1CCN(C(=O)c2cc[nH]n2)CC1)c1ccccc1
3254,1642194,,,,,Fast Patch Assay: Representative compounds were tested for hERG activity using the Fast Patch assay available from WuXiApptec (Shanghai China).,O[C@H]1CC[C@H](Nc2ccc3ncc(-c4cccc(Cl)c4)n3n2)CC1,"US9416132, 8-35",30.0,uM,=,1.4771212547196624,1,c1ccc(-c2cnc3ccc(NC4CCCCC4)nn23)cc1
3255,1442903,10.1016/j.bmcl.2014.08.008,,,,Inhibition of human ERG by patch clamp assay,O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F,"5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide",4.4,uM,=,0.6434526764861874,1,c1ccc(Nc2cccc3cncn23)cc1
3256,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,c1ccc2c3c([nH]c2c1)C(C1CCOCC1)NC(c1nc(C24CC5CC(CC(C5)C2)C4)c[nH]1)C3,"3-(4-Adamantan-1-yl-1H-imidazol-2-yl)-1-(tetrahydro-pyran-4-yl)-2,3,4,9-tetrahydro-1H-beta-carboline",0.506,uM,=,-0.2958494831602009,0,c1ccc2c3c([nH]c2c1)C(C1CCOCC1)NC(c1nc(C24CC5CC(CC(C5)C2)C4)c[nH]1)C3
3257,465697,10.1021/jm701187w,,,,Inhibition of human ERG potassium current expressed in HEK293 cells by patch-clamp technique,Cc1cc(C)n(-c2cc(NC(=O)CN3CCC(CN(C)C)CC3)nc(-c3ccc(C)o3)n2)n1,"2-(4-dimethylaminomethylpiperidin-1-yl)-N-[6-(3,5-dimethylpyrazol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl]acetamide",1.67,uM,=,0.2227164711475832,1,O=C(CN1CCCCC1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
3258,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(CCN2CCN(CCc3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"2-methoxy-4-(2-(4-(2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",2.1,uM,=,0.3222192947339193,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
3259,1654660,10.1016/j.bmcl.2016.12.033,,,,Inhibition of human ERG,O=C(c1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)N1CCN(Cc2nnn(CC(F)(F)F)n2)CC1,"(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)(4-((2-(2,2,2-trifluoroethyl)-2H-tetrazol-5-yl)methyl)piperazin-1-yl)methanone",29.89,uM,=,1.4755259150392808,1,O=C(c1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)N1CCN(Cc2nn[nH]n2)CC1
3260,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2ccnc(OC)c2OC)cc(OC)n1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-1-(2,3-dimethoxypyridin-4-yl)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)butan-2-ol",2.6,uM,=,0.414973347970818,1,c1ccc2ncc([C@H](Cc3ccncc3)c3ccncc3)cc2c1
3261,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CCC(c2ccccc2)N2CCN(S(C)(=O)=O)CC2)CC1,rac-N-ethyl-2-(4-(methylsulfonyl)phenyl)-N-(1-(3-(4-(methylsulfonyl)piperazin-1-yl)-3-phenylpropyl)piperidin-4-yl)acetamide,25.0,uM,=,1.3979400086720375,1,O=C(Cc1ccccc1)NC1CCN(CCC(c2ccccc2)N2CCNCC2)CC1
3262,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,N#Cc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridine-2,7-dicarbonitrile",0.00166,uM,=,-2.779891911959945,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3263,793274,10.1016/j.bmcl.2011.09.117,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp electrophysiology,COc1ccc2ncc(Cl)c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"1-(2-(3-chloro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-N-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methyl)piperidin-4-amine",2.0,uM,=,0.3010299956639812,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
3264,2156555,10.1021/acs.jmedchem.1c01570,,,,Inhibition of human ERG by PatchXpress assay,CC(C)C[C@@H]1NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@@H](N)Cc3ccc(O)cc3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@H]3CSSC[C@H](NC(=O)[C@H](C(C)C)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(N)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC3=O)C(=O)N2,,0.78,uM,=,-0.1079053973095195,0,O=C(CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CSSC[C@@H]2NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]3CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)CCc4ccccc4)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc4ccccc4)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N3)NC2=O)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1)NCCc1c[nH]c2ccccc12
3265,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CN(c1ccc(-c2ccc(-n3ccc(N)n3)cc2O)nn1)C1CC(C)(C)NC(C)(C)C1,"5-(3-amino-1H-pyrazol-1-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenol",16.0,uM,=,1.2041199826559248,1,c1cnn(-c2ccc(-c3ccc(NC4CCNCC4)nn3)cc2)c1
3266,1897548,10.1021/acsmedchemlett.9b00134,,,,Inhibition of human ERG,NCC1(c2cccc(-c3ccnc4[nH]nc(C(F)(F)F)c34)c2)CCC1,"(1-(3-(3-(Trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)cyclobutyl)methanamine",3.0,uM,=,0.4771212547196624,1,c1cc(-c2ccnc3[nH]ncc23)cc(C2CCC2)c1
3267,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Cl)cc1Oc1ccc(F)c(C(F)(F)F)c1,1-(4-chloro-2-(4-fluoro-3-(trifluoromethyl)phenoxy)phenyl)-N-methylmethanamine,0.873,uM,=,-0.0589857562944302,0,c1ccc(Oc2ccccc2)cc1
3268,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,CC(C(O)c1ccc2c(c1)CCC(=O)N2)N1CCC(O)(c2ccc3c(c2)COCC3)CC1,"6-(2-(4-(3,4-dihydro-1H-isochromen-7-yl)-4-hydroxypiperidin-1-yl)-1-hydroxypropyl)-3,4-dihydroquinolin-2(1H)-one",16.0,uM,=,1.2041199826559248,1,O=C1CCc2cc(CCN3CCC(c4ccc5c(c4)COCC5)CC3)ccc2N1
3269,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3ccn[nH]3)ccc2c1,(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)-2-(1H-pyrazol-5-yl)quinoline,40.0,uM,=,1.6020599913279625,1,c1cc(-c2ccc3cc(CCN4CCCC4)ccc3n2)[nH]n1
3270,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1cc(C(=O)NCC2(C#N)CCN(CCc3ccccc3)CC2)nn1-c1ccccc1,N-((4-cyano-1-phenethylpiperidin-4-yl)methyl)-5-isobutyl-1-phenyl-1H-pyrazole-3-carboxamide,1.57,uM,=,0.1958996524092337,1,O=C(NCC1CCN(CCc2ccccc2)CC1)c1ccn(-c2ccccc2)n1
3271,2232935,10.1016/j.bmcl.2022.128666,,,,Inhibition of hERG,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1ccc2c(c1)OC1(CCOCC1)CC2=O,"N-(4-Methyl-3-(4-oxo-2',3',5',6'-tetrahydrospiro[chromane-2,4'-pyran]-7-yl)phenyl)-2-(trifluoromethyl)isonicotinamide",3.4,uM,=,0.5314789170422551,1,O=C(Nc1cccc(-c2ccc3c(c2)OC2(CCOCC2)CC3=O)c1)c1ccncc1
3272,964266,10.1016/j.ejmech.2013.03.060,,,,Inhibition of human ERG expressed in HEK293 cells by whole-cell patch-clamp technique,CC(C)(C(=O)O)c1ccc(CN2CCC(COC(=O)c3c4n(c5ccccc35)CCCO4)CC2)cc1,"2-[4-[[4-(3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyloxymethyl)-1-piperidinyl]methyl]phenyl]-2-methylpropanoic acid",69.0,uM,=,1.8388490907372552,1,O=C(OCC1CCN(Cc2ccccc2)CC1)c1c2n(c3ccccc13)CCCO2
3273,540677,10.1016/j.bmcl.2008.12.083,,,,Inhibition of human ERG,Nc1ccc(-c2ccsc2)cc1N,"4-(3-thienyl)benzene-1,2-diamine)",1.5,uM,=,0.1760912590556812,1,c1ccc(-c2ccsc2)cc1
3274,1753764,10.1016/j.bmcl.2017.12.068,,,,Inhibition of human ERG,CN(C)CCC=C1c2ccccc2CCc2ccccc21,"[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine",3.29,uM,=,0.5171958979499743,1,C=C1c2ccccc2CCc2ccccc21
3275,520038,10.1021/jm900364m,,,,Binding affinity to human ERG,COc1ccc(CC(C)(C)NCC(O)COc2ccccc2C#N)cc1,"(+/-)-2-([3-((1,1-Dimethyl-2-[4-(methyloxy)phenyl]ethyl)amino)-2-hydroxypropyl]oxy)benzonitrile",3.5,uM,=,0.5440680443502757,1,c1ccc(CCNCCCOc2ccccc2)cc1
3276,1463522,10.1016/j.bmcl.2015.01.019,,,,Inhibition of human ERG by patch clamp cellular assay,COc1cc([C@H]2CCN(CCO)C[C@@H]2O)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1,"(trans)-1-(2-hydroxyethyl)-4-(3-methoxy-4-(7-(2-methoxyphenyl)pyrrolo[1,2-f][1,2,4]triazin-2-ylamino)phenyl)piperidin-3-ol",6.8,uM,=,0.8325089127062363,1,c1ccc(-c2ccc3cnc(Nc4ccc(C5CCNCC5)cc4)nn23)cc1
3277,2264495,10.1016/j.bmcl.2022.128808,,,,Inhibition of human ERG,O=c1ccc2ncc(=O)n3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1,"(R)-2-{4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)-amino]-piperidin-1-ylmethyl}-1,2-dihydro-2a,5,8a-triaza-acenaphthylene-3,8-dione",1.4,uM,=,0.1461280356782379,1,O=c1ccc2ncc(=O)n3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1
3278,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@@]3(O)CO[C@@H]4[C@@H](NCc5ccc6c(c5)OCCO6)CO[C@@H]43)c2n1,"(3R,3aS,6S,6aR)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)-3-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)hexahydrofuro[3,2-b]furan-3-ol",20.0,uM,=,1.3010299956639813,1,c1cnc2c(CCC3CO[C@@H]4[C@@H](NCc5ccc6c(c5)OCCO6)CO[C@H]34)ccnc2c1
3279,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=C1COc2cnc(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)cc2N1,"(R)-7-((1-((3-fluoro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-1H-pyrido[3,4-b][1,4]oxazin-2(3H)-one",30.0,uM,=,1.4771212547196624,1,O=C1COc2cnc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)cc2N1
3280,465697,10.1021/jm701187w,,,,Inhibition of human ERG potassium current expressed in HEK293 cells by patch-clamp technique,CCN[C@H]1CCN(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)C1,"N-[6-(3,5-dimethylpyrazol-1-yl)-2-(5-methylfuran-2-yl)pyri midin-4-yl]-2-((S)-3-ethylaminopyrrolidin-1-yl)acetamide",0.42,uM,=,-0.3767507096020995,0,O=C(CN1CCCC1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
3281,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccs2)c1,endo-3-(8-(thiophen-2-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.00043,uM,=,-3.3665315444204134,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccs2)cc1
3282,1682333,10.1021/acs.jmedchem.7b01347,,,,Inhibition of full length human ERG expressed in CHO cells at -70 mV holding potential by patch clamp assay,CN(Cc1ccc(C(F)(F)F)nc1)c1cc(C(=O)Nc2ccccc2)ncn1,6-(Methyl((6-(trifluoromethyl)pyridin-3-yl)methyl)amino)-N-phenylpyrimidine-4-carboxamide,5.6,uM,=,0.7481880270062004,1,O=C(Nc1ccccc1)c1cc(NCc2cccnc2)ncn1
3283,1789491,10.1021/acs.jmedchem.8b01533,,,,Inhibition of human ERG expressed in CHO-S1 cells by automated planar chip-based electrophysiology,FC(F)(F)Oc1ccc(Oc2ccc(CN3CCC4(CCCCO4)CC3)cc2)cc1,9-(4-(4-(Trifluoromethoxy)phenoxy)benzyl)-1-oxa-9-azaspiro[5.5]undecane,2.5,uM,=,0.3979400086720376,1,c1ccc(Oc2ccc(CN3CCC4(CCCCO4)CC3)cc2)cc1
3284,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,O=C(CCNC(=O)c1cccc([N+](=O)[O-])c1)Nc1nc(=O)[nH]cc1F,"N-(3-((5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)amino)-3-oxopropyl)-3-nitrobenzamide",356.18,uM,=,2.55166952957558,1,O=C(CCNC(=O)c1ccccc1)Nc1cc[nH]c(=O)n1
3285,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,O=c1n(Cc2ccc(Cl)cc2)c2sc3c(c2c2ncnn12)CCN(CC1CC1)C3,"6-(4-Chlorobenzyl)-9-(cyclopropylmethyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]-pyrimidin-5(6H)-one",0.16,uM,=,-0.7958800173440752,0,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCN(CC1CC1)C3
3286,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,COc1ccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNc4ncnc5ccc(C(F)(F)F)cc45)C3)CC2)cn1,Cis-N-(1-(4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,28.5,uM,=,1.4548448600085102,1,O=C(CNc1ncnc2ccccc12)NC1CN(C2CCC(c3cccnc3)CC2)C1
3287,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2cc3c(cc2F)ncc2c3n([C@H]3C[C@@H](O)C3)c(=O)n2C)cn1,"7-Fluoro-1-(cis-3-hydroxycyclobutyl)-8-(6-(methoxymethyl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one",15.0,uM,=,1.1760912590556811,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCC1
3288,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(CNC2CCCC2)c1,N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methyl)cyclopentanamine,1.89,uM,=,0.2764618041732441,1,c1ccc(-c2cncc(CNC3CCCC3)c2)cc1
3289,878181,10.1021/jm301190s,,,,Displacement of dofetilide from human ERG,C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc(C(=O)Nc4ccc(C(C)C)c(C)c4)c3)c3c(N)ncnc32)C1,"(R)-3-(1-(1-acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4-isopropyl-3-methylphenyl)benzamide",0.3,uM,=,-0.5228787452803376,0,O=C(Nc1ccccc1)c1cccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)c1
3290,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CCc1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2C)n1,"2-(3-Ethyl-[1,2,4]triazol-1-yl)-1-((R)-2-methyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)ethanone",0.012,uM,=,-1.9208187539523751,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
3291,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,Cc1cnc(-c2cnc(Nc3cnc(C#N)cn3)cc2NC[C@H]2CNCCO2)s1,(R)-5-((5-(5-Methylthiazol-2-yl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)-pyrazine-2-carbonitrile,56.0,uM,=,1.7481880270062005,1,c1cnc(Nc2cc(NC[C@H]3CNCCO3)c(-c3nccs3)cn2)cn1
3292,1501656,10.1021/acs.jmedchem.5b00626,,,,Inhibition of human ERG,CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1,ONATASERTIB,33.0,uM,=,1.5185139398778875,1,O=C1CNc2ncc(-c3cccnc3)nc2N1C1CCCCC1
3293,699709,10.1016/j.bmcl.2010.11.111,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells,COc1cc(/C=C/c2nc3cc(C(F)(F)F)ccc3c(=O)[nH]2)ccc1-n1cnc(C)c1,2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)styryl)-7-(trifluoromethyl)quinazolin-4(3H)-one,0.87,uM,=,-0.0604807473813814,0,O=c1[nH]c(/C=C/c2ccc(-n3ccnc3)cc2)nc2ccccc12
3294,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,O=C(NCC1CCN(CCCCCC(c2ccc(F)cc2)c2ccc(F)cc2)C1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"N-((1-(6,6-bis(4-fluorophenyl)hexyl)pyrrolidin-3-yl)methyl)-3,5-bis(trifluoromethyl)benzamide",0.1,uM,=,-1.0,0,O=C(NCC1CCN(CCCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
3295,1779901,10.1021/acs.jmedchem.8b00884,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1ccc2ncccc2c1NS(=O)(=O)c1ccc(CCCO[C@@H]2C[C@H]3CC[C@@H](C2)N3C)cc1,"N-(6-isobutylquinolin-5-yl)-4-(3-(((1R,3s,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)oxy)propyl)benzenesulfonamide",1.6,uM,=,0.2041199826559248,1,O=S(=O)(Nc1cccc2ncccc12)c1ccc(CCCO[C@@H]2C[C@H]3CC[C@@H](C2)N3)cc1
3296,1622890,10.1021/acsmedchemlett.6b00433,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes after 90 mins by scintillation counting,Cn1ccc(Cn2cc(-c3ccc(Cl)c(C(F)(F)F)c3)cn2)n1,4-(4-chloro-3-(trifluoromethyl)phenyl)-1-((1-methyl-1H-pyrazol-3-yl)methyl)-1H-pyrazole,3.47,uM,=,0.5403294747908738,1,c1ccc(-c2cnn(Cc3cc[nH]n3)c2)cc1
3297,960977,10.1021/ml4000996,,,,Inhibition of human ERG,CN(C)C(=O)[C@H]1C[C@@H]1c1ccc(-c2ncn(C)c2Sc2ccc(Cl)cn2)cc1,"(1S,2S)-2-(4-(5-((5-Chloropyridin-2-yl)thio)-1-methyl-1H-imidazol-4-yl)phenyl)-N,N-dimethylcyclopropanecarboxamide",37.0,uM,=,1.568201724066995,1,c1ccc(Sc2[nH]cnc2-c2ccc(C3CC3)cc2)nc1
3298,1973585,10.1021/acs.jmedchem.9b02016,,,,Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),1.16,uM,=,0.0644579892269184,1,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1
3299,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCN(CC(O)c3ncc(C#N)cc3Cl)CC2)ccc2c1COC2=O,"5-chloro-6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)nicotinonitrile",5.7,uM,=,0.7558748556724915,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
3300,964986,10.1016/j.bmcl.2013.04.047,,,,Inhibition of human ERG expressed in HEK cells by ion flux electrophysiology method,O=C(c1cc(Cl)c(O)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2)N1CC[C@H](O)C1,"(5-chloro-2-((S)-3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-hydroxyphenyl)((S)-3-hydroxypyrrolidin-1-yl)methanone",8.3,uM,=,0.919078092376074,1,O=C(c1ccccc1OCCCN1CCC2(CC1)Cc1ccccc1O2)N1CCCC1
3301,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,"rac-2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.4,uM,=,-0.3979400086720376,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
3302,886196,10.1016/j.bmcl.2012.10.036,,,,Inhibition of dofetilide binding to human ERG by patch clamp assay,Cc1ccnc2nc(Oc3ccc(CN4CCCCC4)cc3)sc12,"7-methyl-2-(4-(piperidin-1-ylmethyl)phenoxy)thiazolo[4,5-b]pyridine",8.1,uM,=,0.9084850188786496,1,c1cnc2nc(Oc3ccc(CN4CCCCC4)cc3)sc2c1
3303,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2ccccc2)C2CCN(S(=O)(=O)C(F)(F)F)CC2)CC1,(R)-N-ethyl-2-(4-(methylsulfonyl)phenyl)-N-(1-(3-phenyl-3-(1-(trifluoromethylsulfonyl)piperidin-4-yl)propyl)piperidin-4-yl)acetamide,1.2,uM,=,0.0791812460476248,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
3304,1764419,10.1021/acsmedchemlett.8b00095,,,,Inhibition of human ERG,COc1ccc(Cc2cc3c(=O)n([C@H]4CCCC[C@@H]4O)cnc3c3ccccc23)cn1,"3-((1S,2S)-2-Hydroxycyclohexyl)-6-((6-methoxypyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one",6.4,uM,=,0.8061799739838872,1,O=c1c2cc(Cc3cccnc3)c3ccccc3c2ncn1C1CCCCC1
3305,1983390,10.1021/acs.jmedchem.9b00167,,,,Inhibition of human ERG by patch clamp assay,CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1,BRANEBRUTINIB,11.0,uM,=,1.0413926851582251,1,c1cc(N2CCCCC2)c2cc[nH]c2c1
3306,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,C[C@H]1C=C(C2=Nc3cc(Cl)ccc3Nc3ccc(F)cc32)CCN1C,"(S)-8-chloro-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-fluoro-5H-dibenzo[b,e][1,4]diazepine",1.2,uM,=,0.0791812460476248,1,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
3307,613772,10.1021/jm901818u,,,,Inhibition of human ERG assessed as blockade of channel current by electrophysiology assay,CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1,"exo-rac-1-(3,4-dichlorophenyl)-6-(ethoxymethyl)-3-azabicyclo[3.1.0]hexane",4.2,uM,=,0.6232492903979004,1,c1ccc([C@]23CNC[C@H]2C3)cc1
3308,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CC#Cc1cncc(-c2cccc(C3(c4ccnc(C(F)F)c4)N=C(N)c4c(F)cccc43)c2)c1,1-(2-(Difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(5-(prop-1-ynyl)pyridin-3-yl)phenyl)-1H-isoindol-3-amine,2.9,uM,=,0.4623979978989561,1,C1=NC(c2ccncc2)(c2cccc(-c3cccnc3)c2)c2ccccc21
3309,1650772,10.1016/j.bmcl.2016.11.079,,,,Inhibition of human ERG,C[C@]1(C(=O)O)CC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1,"(1S,3R)-3-(8-amino-1-(4-(4-(trifluoromethyl)pyridin-2-ylcarbamoyl)phenyl)imidazo[1,5-a]pyrazin-3-yl)-1,3-dimethylcyclopentanecarboxylic acid",54.0,uM,=,1.7323937598229686,1,O=C(Nc1ccccn1)c1ccc(-c2nc(C3CCCC3)n3ccncc23)cc1
3310,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2C[C@@H]2CCCN2)c1,(S)-4-(benzyloxy)-1-(1-(pyrrolidin-2-ylmethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,2.0,uM,=,0.3010299956639812,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2C[C@@H]2CCCN2)c1
3311,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,Cc1[nH]c2ccccc2c1CCN1CCc2ccc(/C=C/C(=O)NO)cc2C1,"N-hydroxy-3-(2-(2-(2-methyl-1H-indol-3-yl)ethyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)acrylamide",2.7,uM,=,0.4313637641589873,1,c1ccc2c(c1)CCN(CCc1c[nH]c3ccccc13)C2
3312,938040,10.1016/j.bmcl.2012.11.013,,,,Inhibition of human ERG by patch clamp assay,COc1ccc(C#N)cc1-c1ccnc(Nc2ccc(N3CCOCC3)c(OC)c2)c1,4-methoxy-3-(2-(3-methoxy-4-morpholinophenylamino)pyridin-4-yl)benzonitrile,4.7,uM,=,0.6720978579357175,1,c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)c2)cc1
3313,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CC[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4ccc(C#N)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(6-cyano-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",5.3,uM,=,0.724275869600789,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
3314,2195638,10.1039/D1MD00097G,,,,Inhibition of human ERG tail current in cells at -80 mV holding potential by PatchXpress automated patch clamp assay,Cn1cc(-c2cccc(C(=O)Nc3cc(N4CC[C@@H](C(C)(C)O)C4)ncc3C(F)(F)F)n2)cn1,(R)-N-(2-(3-(2-hydroxypropan-2-yl)pyrrolidin-1-yl)-5-(trifluoromethyl)pyridin-4-yl)-6-(1-methyl-1H-pyrazol-4-yl)picolinamide,7.6,uM,=,0.8808135922807914,1,O=C(Nc1ccnc(N2CCCC2)c1)c1cccc(-c2cn[nH]c2)n1
3315,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,Fc1ccccc1C(Cc1ccccc1OC(F)(F)F)N1CCNCC1,1-(1-(2-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine,7.6,uM,=,0.8808135922807914,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
3316,1977735,10.1016/j.bmc.2019.115227,,,,Inhibition of human ERG,Cc1cc(C)c(-c2cn(C)cn2)cc1NC(=O)c1ccc(OCc2ccccn2)cc1,"N-[2,4-dimethyl-5-(l-methyl-lH-imidazol-4-yl)phenyl]-4-(pyr-idin-2-ylmethoxy)benzamide",21.0,uM,=,1.3222192947339193,1,O=C(Nc1cccc(-c2c[nH]cn2)c1)c1ccc(OCc2ccccn2)cc1
3317,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,CCOc1cc([C@H](c2cc3cc(Br)ccc3cc2OC)[C@@](O)(CCN(C)C)c2cccc3ccoc23)cc(OC)n1,"(1R,2S)-2-(benzofuran-7-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-4-(dimethylamino)-1-(2-ethoxy-6-methoxypyridin-4-yl)butan-2-ol",7.5,uM,=,0.8750612633917001,1,c1ccc2cc([C@H](Cc3cccc4ccoc34)c3ccncc3)ccc2c1
3318,2226080,10.1021/acs.jmedchem.2c00227,,,,Inhibition of hERG,FC(F)(F)Oc1ccc(Oc2ccc(CN3CCC4(CC3)OCCc3sccc34)cc2)cc1,,1.5,uM,=,0.1760912590556812,1,c1ccc(Oc2ccc(CN3CCC4(CC3)OCCc3sccc34)cc2)cc1
3319,580515,10.1016/j.bmcl.2009.06.050,,,,Displacement of [35S]MK499 from human ERG potassium channel expressed in HEK293 cells,COc1ccc([C@H](C)N[C@@H]2CC[C@@H](C(=O)N3CCC(C(=O)N4CCCC4)(c4ccccc4)CC3)C(C)(C)C2)cc1,"(1-((1R,4R)-4-((S)-1-(4-methoxyphenyl)ethylamino)-2,2-dimethylcyclohexanecarbonyl)-4-phenylpiperidin-4-yl)(pyrrolidin-1-yl)methanone",4.7,uM,=,0.6720978579357175,1,O=C(N1CCCC1)C1(c2ccccc2)CCN(C(=O)[C@H]2CC[C@H](NCc3ccccc3)CC2)CC1
3320,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CC(=O)Nc1ccc(CC(=O)N(C)C2CCN(Cc3ccc(C(F)(F)F)cc3)CC2)cc1,2-(4-acetamidophenyl)-N-methyl-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)acetamide,4.5,uM,=,0.6532125137753437,1,O=C(Cc1ccccc1)NC1CCN(Cc2ccccc2)CC1
3321,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1.Cc1ccc(S(=O)(=O)O)cc1,(E)-5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol 4-methylbenzenesulfonate,0.24,uM,=,-0.619788758288394,0,c1ccc(/N=N/c2ccccn2)cc1.c1ccccc1
3322,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4cc(F)ccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"7-fluoro-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",2.68,uM,=,0.4281347940287888,1,O=C1Nc2ccccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
3323,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(Br)c3n2CCN1CC1CCC1,"6-Bromo-2-(cyclobutylmethyl)-3,4-dihydropyrazino(1,2-a)benzimidazol-1(2H)-one",30.0,uM,=,1.4771212547196624,1,O=C1c2nc3ccccc3n2CCN1CC1CCC1
3324,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3ccccn3)ccc2c1,(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)-2-(pyridin-2-yl)quinoline,18.0,uM,=,1.255272505103306,1,c1ccc(-c2ccc3cc(CCN4CCCC4)ccc3n2)nc1
3325,2254299,10.1021/acs.jmedchem.1c01856,,,,Inhibition of hERG ion channel by patch-clamp method,Cn1c(CN2CCC(c3cccc(OCc4ccc(Cl)cc4F)n3)CC2)nc2ccncc21,"2-((4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)piperidin-1-yl)methyl)-3-methyl-3H-imidazo[4,5-c]pyridine",5.6,uM,=,0.7481880270062004,1,c1ccc(COc2cccc(C3CCN(Cc4nc5ccncc5[nH]4)CC3)n2)cc1
3326,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,c1ccc2c3c([nH]c2c1)[C@@H](C1CCOCC1)N[C@@H](c1nc(-c2cscn2)c[nH]1)C3,"4-(2-((1R,3R)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl)-1H-imidazol-4-yl)thiazole",4.393,uM,=,0.6427612032653204,1,c1ccc2c3c([nH]c2c1)[C@@H](C1CCOCC1)N[C@@H](c1nc(-c2cscn2)c[nH]1)C3
3327,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1C(F)(F)F,"6-((1-(2-(3-fluoro-6-methoxy-7-(trifluoromethyl)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.0017,uM,=,-2.7695510786217263,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3328,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1.CS(=O)(=O)O,5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol methanesulfonate,0.13,uM,=,-0.8860566476931633,0,c1ccc(/N=N/c2ccccn2)cc1
3329,857606,10.1021/ml2002604,,,,Inhibition of human recombinant hERG expressed in CHO cells by automated patch clamp assay,CONC(=O)N(Cc1ccsc1)C1CCN([C@H](C)CCNC(=O)c2c(C)cc(Cl)nc2C)CC1,"(R)-6-Chloro-N-(3-(4-(3-methoxy-1-(thiophen-3-ylmethyl)ureido)piperidin-1-yl)butyl)-2,4-dimethylnicotinamide",5.5,uM,=,0.7403626894942439,1,O=C(NCCCN1CCC(NCc2ccsc2)CC1)c1cccnc1
3330,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,COc1nc2ccc(C#N)cc2cc1[C@@H](c1cccc2c1OCO2)[C@@](O)(CCN(C)C)c1cc(SC)nc(SC)c1,"Rac-3-[(1R,2S)-1-(1,3-benzodioxol-4-yl)-2-[2,6-bis(methylsulfanyl)-4-pyridyl]-4-(dimethylamino)-2-hydroxy-butyl]-2-methoxy-quinoline-6-carbonitrile",5.9,uM,=,0.7708520116421442,1,c1cc2c(c([C@@H](Cc3ccncc3)c3cnc4ccccc4c3)c1)OCO2
3331,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",1.34,uM,=,0.1271047983648076,1,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
3332,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCN(C)C(=O)c1ccc([C@H](c2cccc(NC(=O)C3CC3)c2)N2CCN(CCCOC)CC2)cc1,(R)-4-((3-(cyclopropanecarboxamido)phenyl)(4-(3-methoxypropyl)piperazin-1-yl)methyl)-N-ethyl-N-methylbenzamide,13.0,uM,=,1.1139433523068367,1,O=C(Nc1cccc([C@@H](c2ccccc2)N2CCNCC2)c1)C1CC1
3333,1629116,10.1016/j.bmc.2016.10.009,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes,Cl.N=C(N)N/N=C/c1ccc(-c2ccc(/C=N/Nc3ccc(F)cc3F)cc2)cc1,"2-((4'-((2-(2,4-difluorophenyl)hydrazono)methyl)biphenyl-4-yl)methylene)hydrazinecarboximidamide hydrochloride",2.24,uM,=,0.3502480183341628,1,C(=N/Nc1ccccc1)\c1ccc(-c2ccccc2)cc1
3334,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,c1ccc2c3c([nH]c2c1)C(C1CCCCC1)N[C@@H](c1nc(-c2cnccn2)c[nH]1)C3,"(3R)-1-cyclohexyl-3-(4-(pyrazin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.34,uM,=,-0.4685210829577448,0,c1ccc2c3c([nH]c2c1)C(C1CCCCC1)N[C@@H](c1nc(-c2cnccn2)c[nH]1)C3
3335,421810,10.1016/j.bmcl.2006.10.053,,,,Inhibition of binding to hERG,CN(C)C(=O)[C@@H]1CCCN1Cc1ccc2c(c1)CC[C@H](N(C)C(=O)c1ccc(-c3ccc(F)cc3)cc1)C2,"(S)-1-(((S)-6-(4'-fluoro-N-methylbiphenyl-4-ylcarboxamido)-5,6,7,8-tetrahydronaphthalen-2-yl)methyl)-N,N-dimethylpyrrolidine-2-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C(N[C@H]1CCc2cc(CN3CCCC3)ccc2C1)c1ccc(-c2ccccc2)cc1
3336,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)CC2c2ccc(C)cc2)cc1,1-(Methylsulfonylamino)-3-[(4-methoxyphenyl)ethyl]-4-(4-methylphenyl)-2-imidazolidinone,11.2,uM,=,1.0492180226701815,1,O=C1NCC(c2ccccc2)N1CCc1ccccc1
3337,635425,10.1016/j.bmcl.2010.04.071,,,,Inhibition of human ERG,CC1(C)CC(NC(=O)CCO)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1,"N-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl)-3-hydroxypropanamide",0.38,uM,=,-0.4202164033831898,0,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
3338,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(C(F)(F)F)ccc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-5-(trifluoromethyl)phenyl)-N-methylmethanamine",1.31,uM,=,0.1172712956557642,1,c1ccc(Oc2ccccc2)cc1
3339,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc(C(F)(F)F)cc1F)Cc1ccc2c(c1)CCO2.Cl,(E)-N-(Coumaran-5-methyl)-N-methyl-3-(2-fluoro-4-trifluoromethylphenyl)prop-2-en-1-amine Hydrochloride,2.9,uM,=,0.4623979978989561,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)CCO2
3340,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CCC(Oc4ccc(CN5CCOCC5)cc4)CC3)o2)cc1,"(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)(4-(4-(morpholinomethyl)phenoxy)piperidin-1-yl)methanone",16.0,uM,=,1.2041199826559248,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCOCC3)cc2)CC1
3341,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,COc1ccc(C(=O)Nc2csc([C@]34CO[C@@H](C)C[C@H]3CSC(N)=N4)n2)nc1,"US9315520, 19",13.1,uM,=,1.1172712956557642,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccn1
3342,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CC(C)[C@]1(C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)CC[C@@H](NC2C3CCCC2COC3)C1,"cis-((1S,3R)-3-(3-oxabicyclo[3.3.1]nonan-9-ylamino)-1-isopropylcyclopentyl)(4-(4-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methanone",1.3,uM,=,0.1139433523068367,1,O=C(C1CC[C@@H](NC2C3CCCC2COC3)C1)N1CCN(c2ccccn2)CC1
3343,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCCCC1CCO,2-(2-hydroxyethyl)-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)piperidine-1-carboxamide,3.08,uM,=,0.4885507165004443,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCCCC1
3344,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N(CCCO)Cc1ccc(F)cc1,N-(4-fluorobenzyl)-N-(3-hydroxypropyl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,0.63,uM,=,-0.2006594505464183,0,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NCc1ccccc1
3345,1329649,10.1039/C1MD00015B,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch clamp assay,CC(=O)Nc1cccc(C2CCN(Cc3ccc(C(=O)c4nc(C)c(C)n4-c4ccc(F)cc4)cc3)CC2)c1,"N-(3-(1-(4-(1-(4-fluorophenyl)-4,5-dimethyl-1H-imidazole-2-carbonyl)benzyl)piperidin-4-yl)phenyl)acetamide",1.7,uM,=,0.2304489213782739,1,O=C(c1ccc(CN2CCC(c3ccccc3)CC2)cc1)c1nccn1-c1ccccc1
3346,2133680,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG expressed in CHO by QPatch assay,CC[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",11.0,uM,=,1.0413926851582251,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
3347,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(C(F)(F)F)c3n2CCN1CC1CCC1,"2-(Cyclobutylmethyl)-6-(trifluoromethyl)-3,4-dihydropyrazino-(1,2-a)benzimidazol-1(2H)-one",25.0,uM,=,1.3979400086720375,1,O=C1c2nc3ccccc3n2CCN1CC1CCC1
3348,857606,10.1021/ml2002604,,,,Inhibition of human recombinant hERG expressed in CHO cells by automated patch clamp assay,CONC(=O)N(Cc1ccsc1)C1CCN([C@H](C)CCNC(=O)c2c(C)cc(Cl)nc2Cl)CC1,"(R)-2,6-Dichloro-N-(3-(4-(3-methoxy-1-(thiophen-3-ylmethyl)ureido)piperidin-1-yl)butyl)-4-methylnicotinamide",0.3,uM,=,-0.5228787452803376,0,O=C(NCCCN1CCC(NCc2ccsc2)CC1)c1cccnc1
3349,1665800,10.1021/acs.jmedchem.7b00328,,,,Inhibition of human ERG by thallium flux assay,CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ncccn5)CC4)ccc3C)cc12,2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyrimidin-2-yl)-cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide,4.8,uM,=,0.6812412373755872,1,O=C(NC1(c2ncccn2)CC1)c1cccc(-c2ccc3oc(-c4ccccc4)cc3c2)c1
3350,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nncs2)=NC1c1ccc(F)cc1Br,"Ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholinomethyl)-2-(1,3,4-thiadiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",3.49,uM,=,0.5428254269591799,1,C1=C(CN2CCOCC2)NC(c2nncs2)=NC1c1ccccc1
3351,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1nccs1,"(R)-N,N-dimethyl-2-(3-(1-(thiazol-2-yl)ethyl)-1H-inden-2-yl)ethanamine",3.7,uM,=,0.568201724066995,1,C1=C(Cc2nccs2)c2ccccc2C1
3352,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(CC(NOC(C)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(rac)-6-((1-(1-(acetoxyamino)-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",18.2,uM,=,1.260071387985075,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3353,2229019,10.1021/acs.jmedchem.2c00632,,,,Inhibition of human ERG by patch-clamp assay,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@H](CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)OC(=O)OC(OC(=O)[C@H](N)C(C)C)C(C)C)C(C)(C)C,"(2R)-(5S,10S)-5-(tert-Butyl)-10-((S)-1-((S)-2-((methoxycarbonyl)amino)-3,3-dimethylbutanamido)-2-phenylethyl)-15-methyl-3,6,12-trioxo-8-(4-(pyridin-2-yl)benzyl)-2,11,13-trioxa-4,7,8-triazahexadecan-14-yl 2-amino-3-methylbutanoate",8.8,uM,=,0.9444826721501688,1,c1ccc(CCCCNCc2ccc(-c3ccccn3)cc2)cc1
3354,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,CN(C)C(=O)[C@H]1CN(C2CCCCC2)CC[C@@H]1NC(=O)c1cc(-c2ccc(F)cc2F)on1,"(trans,rac)-(3S*,4S*)-1-Cyclohexyl-4-([5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino)piperidine-3-carboxylic acid dimethylamide",5.5,uM,=,0.7403626894942439,1,O=C(NC1CCN(C2CCCCC2)CC1)c1cc(-c2ccccc2)on1
3355,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,NC(=O)c1cnc(N(CCc2ccccc2)[C@H]2CCCNC2)c2cc(-c3ccccc3)sc12,"2-Phenyl-4-{(2-phenylethyl)[(3S)-piperidin-3-yl]amino}-thieno[3,2-c]pyridine-7-carboxamide",2.1,uM,=,0.3222192947339193,1,c1ccc(CCN(c2nccc3sc(-c4ccccc4)cc23)[C@H]2CCCNC2)cc1
3356,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2ccccn2)cc1,"N,N-diethyl-4-(pyridin-2-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide",16.0,uM,=,1.2041199826559248,1,c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2ccccn2)cc1
3357,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,Cc1cc(OC(F)F)cnc1C(=O)Nc1csc([C@]23CO[C@@H](C)C[C@H]2CSC(N)=N3)n1,"US9315520, 45::US9315520, Example 45",9.6,uM,=,0.9822712330395684,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccn1
3358,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O,"3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one",1.3,uM,=,0.1139433523068367,1,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2
3359,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,CNC(=O)Nc1ccc(O)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2,"(S)-1-(2-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-hydroxyphenyl)-3-methylurea",4.6,uM,=,0.6627578316815741,1,c1ccc(OCCCN2CCC3(CC2)Cc2ccccc2O3)cc1
3360,1553512,10.1016/j.bmc.2016.02.006,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,CC1(C)CCc2cc(S(=O)(=O)N(CC(=O)O)C3(c4cccc(-c5cc(Cl)cc(Cl)c5)c4)CCC3)ccc2O1,"2-(N-(1-(3',5'-Dichlorobiphenyl-3-yl)cyclobutyl)-2,2-dimethylchroman-6-sulfonamido)acetic acid",40.0,uM,=,1.6020599913279625,1,O=S(=O)(NC1(c2cccc(-c3ccccc3)c2)CCC1)c1ccc2c(c1)CCCO2
3361,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(C#Cc2ccccc2)cccc1C#Cc1ccccc1,"1-methyl-2,6-bis(phenylethynyl)pyridinium",0.554,uM,=,-0.2564902352715702,0,C(#Cc1cccc(C#Cc2ccccc2)[nH+]1)c1ccccc1
3362,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(Cc2ccc3cc[nH]c3c2)CC1)c1cc(=O)c2ccc(F)cc2o1,N-(1-((1H-indol-6-yl)methyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,2.53,uM,=,0.4031205211758178,1,O=C(NC1CCN(Cc2ccc3cc[nH]c3c2)CC1)c1cc(=O)c2ccccc2o1
3363,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCCCC4)N3)n2)cc1,"(3R)-1-cyclohexyl-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.077,uM,=,-1.1135092748275182,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCCCC4)N3)n2)cc1
3364,493421,10.1016/j.bmcl.2008.10.025,,,,Inhibition of human ERG expressed in CHO cells,Clc1ccc(C23CNCC2C3)cc1Cl,"1-(3,4-dichlorophenyl)-3-aza-bicyclo[3.1.0]hexane",10.0,uM,=,1.0,1,c1ccc(C23CNCC2C3)cc1
3365,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(F)c1,"N,N-Diethyl-3-fluoro-4-(spiro[chromene-2,4'-piperidine]-4-yl)-benzamide",0.418,uM,=,-0.3788237182249648,0,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
3366,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1cc(Cl)ccc1-c1nc2c(cc1-c1ccc(Cl)cc1)C(NC(=O)C(O)C(F)(F)F)CC(C)(C)O2,"N-[6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-3,3,3-trifluoro-2-hydroxypropanamide",0.26,uM,=,-0.585026652029182,0,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
3367,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,CN(C)[C@H]1CC[C@@]2(CN=C(N3CCc4ccccc4[C@@H]3c3ccc(F)cc3)O2)C1,"(5S,8S)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N,N-dimethyl-1-oxa-3-azaspiro[4.4]non-2-en-8-amine",3.6,uM,=,0.5563025007672873,1,c1ccc([C@H]2c3ccccc3CCN2C2=NCC3(CCCC3)O2)cc1
3368,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,COc1nc2ccc(CN)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,1-(6-(aminomethyl)-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol,1.7,uM,=,0.2304489213782739,1,c1ccc(C(Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
3369,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,CC(C)(C)Oc1ccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,cis-N-({1-[4-(6-tert-Butoxy-pyridin-3-yl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,5.5,uM,=,0.7403626894942439,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccnc3)CC2)C1
3370,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(CC)CC2)c1ncc(-c2ccc3cnccc3c2)[nH]1,(S)-6-ethyl-N-((S)-1-(5-(isoquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide,12.0,uM,=,1.0791812460476249,1,O=C(NCc1ncc(-c2ccc3cnccc3c2)[nH]1)[C@H]1CC12CCNCC2
3371,487847,10.1021/jm800386y,,,,Displacement of [35S]MK499 from human ERG expressed in HEL cells,CN1CC[C@H](N(C)C(=O)N2CC(c3cc(F)ccc3F)=C[C@@]2(CO)c2ccccc2)[C@H](F)C1,"(S)-4-(2,5-difluorophenyl)-N-((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)-2-(hydroxymethyl)-N-methyl-2-phenyl-2H-pyrrole-1(5H)-carboxamide",20.5,uM,=,1.3117538610557542,1,O=C(NC1CCNCC1)N1CC(c2ccccc2)=CC1c1ccccc1
3372,1352646,10.1021/jm4016284,,,,Inhibition of human ERG expressed in CHO cells by whole-cell patch clamp assay,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-2-methoxy-piperidin-4-yl}-2-methoxy-benzamide,0.08,uM,=,-1.0969100130080565,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
3373,627338,10.1016/j.bmcl.2010.03.005,,,,Inhibition of human ERG,OC(c1cccnc1)(c1cccnc1)C(Cc1ccccc1)N1CCOCC1,"2-morpholino-3-phenyl-1,1-di(pyridin-3-yl)propan-1-ol",15.19,uM,=,1.1815577738627865,1,c1ccc(CC(C(c2cccnc2)c2cccnc2)N2CCOCC2)cc1
3374,861902,10.1021/jm3007323,,,,Inhibition of human ERG transfected in HEK293 cell membranes by whole cell patch clamp assay,CCOC(=O)N1CCN(CCOc2cc(C)n(-c3ccc(Cl)c(Cl)c3)n2)CC1,"ethyl 4-(2-(1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl)piperazine-1-carboxylate",4.1,uM,=,0.6127838567197355,1,c1ccc(-n2ccc(OCCN3CCNCC3)n2)cc1
3375,825853,10.1021/ml100095k,,,,Inhibition of human ERG,O=C(O)c1cc(CN2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2ccccn2c1=O,4-oxo-1-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)-4H-quinolizine-3-carboxylic acid,0.1,uM,=,-1.0,0,O=c1ccc(CN2CCN(c3ccccc3)CC2)c2ccccn12
3376,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNC(C)c1cc(C(F)(F)F)ccc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-5-(trifluoromethyl)phenyl)-N-methylethanamine",3.03,uM,=,0.481442628502305,1,c1ccc(Oc2ccccc2)cc1
3377,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CC1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOc5ccccc5)c4)n[nH]c2-3)CC1,"6-((4-methylpiperidin-1-yl)methyl)-3-(5-(3-phenoxyprop-1-ynyl)thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole",0.08,uM,=,-1.0969100130080565,0,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCCCC4)ccc2-3)cs1)COc1ccccc1
3378,1744232,10.1021/acs.jmedchem.6b01703,,,,Displacement of [3H]dofetilide from recombinant human ERG expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting method,CCc1nc2c(C)cc(C)nc2n1Cc1ccc(/C=C/CN2CCN(C(C)C)CC2)cc1,"US8748435, 40",1.0,uM,=,0.0,0,C(=C/c1ccc(Cn2cnc3cccnc32)cc1)\CN1CCNCC1
3379,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Br)cc1Oc1ccc(Cl)c(Cl)c1,"1-(4-bromo-2-(3,4-dichlorophenoxy)phenyl)-N-methylmethanamine",0.974,uM,=,-0.0114410431213844,0,c1ccc(Oc2ccccc2)cc1
3380,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,CC(=O)N1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1,"4-(3-((R)-1-acetylpiperidin-3-yl)-8-aminoimidazo[1,5-a]pyrazin-1-yl)-3-fluoro-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",2.4,uM,=,0.380211241711606,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@@H]3CCCNC3)n3ccncc23)cc1
3381,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,Cn1cc(-c2cnc(Nc3cnc(C#N)cn3)cc2NC[C@H]2CNCCO2)cn1,(R)-5-((5-(1-Methyl-1H-pyrazol-4-yl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,8.6,uM,=,0.9344984512435676,1,c1cnc(Nc2cc(NC[C@H]3CNCCO3)c(-c3cn[nH]c3)cn2)cn1
3382,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,Cc1nccn1CC(NC(=O)CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)c1ccccc1,N-(2-(2-methyl-1H-imidazol-1-yl)-1-phenylethyl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,26.6,uM,=,1.424881636631067,1,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(Cn1ccnc1)c1ccccc1
3383,1810686,10.1021/acs.jmedchem.8b01333,,,,Inhibition of human ERG by patch clamp electrophysiology,FC(F)(F)c1cccc(Nc2cc3[nH]c(Nc4ccc(N5CCOCC5)cn4)nc3cn2)c1,"N-(5-morpholinopyridin-2-yl)-2-(3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]pyridin-6-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2cc3[nH]c(Nc4ccc(N5CCOCC5)cn4)nc3cn2)cc1
3384,1783291,10.1016/j.ejmech.2017.12.099,,,,Inhibition of human ERG by auomated patch clamp assay,CCC1(C)CC(=O)N(CCCCN2CCN(c3cccc4sccc34)CC2)C(=O)C1,"1-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-4-ethyl-4-methylpiperidine-2,6-dione",6.21,uM,=,0.7930916001765802,1,O=C1CCCC(=O)N1CCCCN1CCN(c2cccc3sccc23)CC1
3385,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1,N-{2-Butyl-3-[4-(3-dibutylamino-propoxy)-benzoyl]-benzofuran-5-yl}-methanesulfonamide,3.0,uM,=,0.4771212547196624,1,O=C(c1ccccc1)c1coc2ccccc12
3386,755804,10.1021/jm2003359,,,,Inhibition of human ERG expressed in CHO cells by Q-patch assay,CC(C)(N)C(=O)N1CCn2c(nc(-c3cccc(F)c3)c2Nc2ccc(F)cc2)C1,"2-amino-1-(2-(3-fluorophenyl)-3-(4-fluorophenylamino)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one",5.7,uM,=,0.7558748556724915,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
3387,1567467,10.1039/C5MD00479A,,,,Inhibition of human ERG,O=C(O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1)c1ccccc1,"[(1R)-2-[(5S)-5-[[5-Chloro-2-(tetrazol-1-yl)phenyl]methylcarbamoyl]-4,5-dihydropyrazol-1-yl]-1-(4-fluorophenyl)-2-oxo-ethyl]benzoate",5.6,uM,=,0.7481880270062004,1,O=C(O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1ccccc1-n1cnnn1)c1ccccc1)c1ccccc1
3388,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,CNc1cc(Nc2cnc(C#N)c(O[C@H](C)CN(C)C)n2)ncc1C1CC1,(R)-5-((5-Cyclopropyl-4-(methylamino)pyridin-2-yl)amino)-3-((1-(dimethylamino)propan-2-yl)oxy)pyrazine-2-carbonitrile,6.0,uM,=,0.7781512503836436,1,c1cnc(Nc2ccc(C3CC3)cn2)cn1
3389,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,C[C@@H]1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,"(2S)-2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.3,uM,=,-0.5228787452803376,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
3390,2248659,10.1016/j.ejmech.2022.114271,,,,Inhibition of human ERG expressed in CHO cells with holding potential of -80 mV by whole cell patch clamp assay,CCOc1ccc(-c2cncnc2-c2cc(OC)c(OC)c(OC)c2)cc1Cl,"5-(3-chloro-4-ethoxyphenyl)-4-(3,4,5-trimethoxyphenyl)pyrimidine",22.3,uM,=,1.3483048630481609,1,c1ccc(-c2cncnc2-c2ccccc2)cc1
3391,345010,10.1016/j.bmcl.2005.12.094,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CC(C)(C)[C@H](O)C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1cccc(O)c1,"(S)-1-((S)-4-(2,5-difluorophenyl)-2-(3-hydroxyphenyl)-2H-pyrrol-1(5H)-yl)-2-hydroxy-3,3-dimethylbutan-1-one",7.8,uM,=,0.8920946026904804,1,C1=C(c2ccccc2)CN[C@@H]1c1ccccc1
3392,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COC(=O)N1CC(Oc2cccc(F)c2)CC1C(=O)N1CCCN(C2CCC2)CC1,"methyl-2-(4-cyclobutyl-1,4-diazepane-1-carbonyl)-4-(3-fluorophenoxy)pyrrolidine-1-carboxylate",10.0,uM,=,1.0,1,O=C(C1CC(Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
3393,1475773,10.1021/jm5017413,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch-clamp assay,Cc1cncc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(6-methylpyrazin-2-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",4.7,uM,=,0.6720978579357175,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2cnccn2)C1
3394,2203304,10.1016/j.bmcl.2022.128807,,,,Inhibition of hERG by patch clamp assay,Cc1cccc2[nH]c(-c3cncc(-c4cc(F)cc(C#N)c4)c3N3CC[C@H](N)C3)nc12,(S)-3-(4-(3-aminopyrrolidin-1-yl)-5-(4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-3-yl)-5-fluorobenzonitrile,2.1,uM,=,0.3222192947339193,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCC2)cc1
3395,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CCN1CCN[C@@H](C(=O)N2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"(R)-N-(3,4-dichlorophenyl)-4-(4-ethylpiperazine-2-carbonyl)piperazine-1-carboxamide",10.0,uM,=,1.0,1,O=C(Nc1ccccc1)N1CCN(C(=O)[C@H]2CNCCN2)CC1
3396,1521783,10.1016/j.bmcl.2015.08.037,,,,Inhibition of human ERG by automated patch clamp assay,NC(=O)c1nnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc2cc[nH]c12,"5-(1H-indol-7-ylamino)-3-((1R,2S)-2-aminocyclohexylamino)-1,2,4-triazine-6-carboxamide",28.0,uM,=,1.4471580313422192,1,c1cc(Nc2cnnc(NC3CCCCC3)n2)c2[nH]ccc2c1
3397,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CCN(CCc1ccc(Cl)c(Cl)c1)C[C@H](O)COc1ccc(NS(C)(=O)=O)cc1,"(S)-1-(4-Methanesulfonamidophenoxy)-3-(N-ethyl-3,4-dichlorophenylethylamino)-2-propanol",0.17,uM,=,-0.7695510786217261,0,c1ccc(CCNCCCOc2ccccc2)cc1
3398,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1cc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1OC,"6-((1-(2-(3-fluoro-6,7-dimethoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.01391,uM,=,-1.8566728700079536,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3399,1924853,10.1016/j.bmcl.2016.07.029,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells measured after 90 mins by scintillation proximity assay,CNC(=O)[C@@H]1C[C@H](N2CCc3c(cccc3OCCC3CC3)C2)CN1C(=O)c1ccc(CN)c(OC)c1,"(2S,4S)-1-(4-(aminomethyl)-3-methoxybenzoyl)-4-(5-(2-cyclopropylethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methylpyrrolidine-2-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C(c1ccccc1)N1CC[C@H](N2CCc3c(cccc3OCCC3CC3)C2)C1
3400,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)C[C@@H]1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,(R)-2-(8-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-8-azaspiro[4.5]decan-3-yl)acetic Acid,4.4,uM,=,0.6434526764861874,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCO5)CC4)nc3)nc2c1
3401,1622890,10.1021/acsmedchemlett.6b00433,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes after 90 mins by scintillation counting,Cn1cc(Cn2cc(-c3ccc(Cl)c(OC(F)F)c3)cn2)cn1,4-(4-chloro-3-(difluoromethoxy)phenyl)-1-((1-methyl-1H-pyrazol-4-yl)methyl)-1H-pyrazole,52.4,uM,=,1.7193312869837267,1,c1ccc(-c2cnn(Cc3cn[nH]c3)c2)cc1
3402,538846,10.1021/jm800830n,,,,Inhibition of human ERG,Cc1ccc(CN2CCC(CNC(=O)c3cc(Cl)cc(Cl)c3)CC2)cc1,"3,5-Dichloro-N-[1-(4-methyl-benzyl)-piperidin-4-ylmethyl]-benzamide",0.135,uM,=,-0.8696662315049939,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
3403,826732,10.1021/jm201194q,,,,Inhibition of human ERG expressed in HEK cells by patch clamp assay,c1ccc(CCNCCC(c2ccccc2)c2ccccc2)cc1,"N-phenethyl-3,3-diphenylpropan-1-amine",2.79,uM,=,0.4456042032735975,1,c1ccc(CCNCCC(c2ccccc2)c2ccccc2)cc1
3404,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CN1CCN(CCCCN2C(=O)CN(/N=C/c3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,"1-{[1-[5-(4-Chloro-phenyl)-furan-2-yl]-meth-(E)-ylidene]-amino}-3-[3-(4-methyl-piperazin-1-yl)-propyl]-imidazolidine-2,4-dione",0.4,uM,=,-0.3979400086720376,0,O=C1CN(/N=C/c2ccc(-c3ccccc3)o2)C(=O)N1CCCCN1CCNCC1
3405,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,"5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione",22800.0,uM,=,4.357934847000454,1,O=C1CC(=O)NC(=O)N1
3406,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(N4CCOCC4)cc3)cc1)C(=O)N2c1cc(O)ncn1,"1-(6-hydroxypyrimidin-4-yl)-8-((3-methylpyridin-2-yl)methyl)-3-(4'-morpholinobiphenyl-4-yl)-1,3,8-triazaspiro[4.5]decane-2,4-dione",13.0,uM,=,1.1139433523068367,1,O=C1N(c2ccc(-c3ccc(N4CCOCC4)cc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
3407,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cccc([S+]([O-])[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"endo-3-((R)-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)sulfinyl)benzamide",20.0,uM,=,1.3010299956639813,1,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H]([SH+]c2ccccc2)C3)cc1
3408,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)CCN1CCC(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1,"3,5-Dichloro-N-[1-(3,3-dimethyl-butyl)-piperidin-4-ylmethyl]-benzamide",1.934,uM,=,0.2864564697469828,1,O=C(NCC1CCNCC1)c1ccccc1
3409,1627127,10.1016/j.bmcl.2016.10.064,,,,Displacement of 35S-MK499 from human ERG expressed in HEK293 cell membranes,Cc1c([C@@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@H]3CO2)ccc2c1COC2=O,"5-((3R,9aS)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-4-methylisobenzofuran-1(3H)-one",21.1,uM,=,1.3242824552976926,1,O=C1OCc2cc([C@@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@H]4CO3)ccc21
3410,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,Nc1cnccc1[C@H]1CC[C@@H](N2CC(NC(=O)CNc3ncnc4ccc(C(F)(F)F)cc34)C2)CC1,Cis-N-(1-(4-(3-aminopyridin-4-yl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,46.0,uM,=,1.662757831681574,1,O=C(CNc1ncnc2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccncc3)CC2)C1
3411,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,CN(C)C(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)c(F)c1,"3-Fluoro-N,N-dimethyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]benzamide",32.5,uM,=,1.5118833609788744,1,O=C1c2ccc(-c3ccccc3)cc2CCN1CCN1CCCC1
3412,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C([C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1)N1CC(c2ccccc2)(c2ccccc2)C1,"((1R,2R,4R)-2-(4-bromophenyl)-4-morpholinocyclohexyl)(3,3-diphenylazetidin-1-yl)methanone",0.29,uM,=,-0.5376020021010439,0,O=C([C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1)N1CC(c2ccccc2)(c2ccccc2)C1
3413,1805877,10.1021/acs.jmedchem.9b00335,,,,Inhibition of human ERG expressed in CHOK1 cells by Q-patch electrophysiology method,Cc1ccc(-c2cc(S(=O)(=O)c3ccc(CN)s3)ccc2S(C)(=O)=O)cc1.Cl,"(5-((4'-Methyl-6-(methylsulfonyl)-[1,1'-biphenyl]-3-yl)sulfonyl)thiophen-2-yl)methanamine Hydrochloride",68.0,uM,=,1.8325089127062364,1,O=S(=O)(c1cccc(-c2ccccc2)c1)c1cccs1
3414,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)CN1CCC2(CC1)CCN(c1ccc(-c3nc4cc(C(F)(F)F)ccc4[nH]3)cn1)CC2,"2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-3,9-diazaspiro[5.5]undecan-3-yl)acetic Acid",4.8,uM,=,0.6812412373755872,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCNCC5)CC4)nc3)nc2c1
3415,420606,10.1016/j.bmcl.2006.11.061,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(C2CCc3cc4c(cc32)OCO4)CC1)c1cc(=O)c2cc(F)ccc2o1,"N-(1-(6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-5-yl)piperidin-4-yl)-6-fluoro-4-oxo-4H-chromene-2-carboxamide",11.2,uM,=,1.0492180226701815,1,O=C(NC1CCN(C2CCc3cc4c(cc32)OCO4)CC1)c1cc(=O)c2ccccc2o1
3416,1277482,10.1016/j.bmcl.2013.10.009,,,,Inhibition of human ERG flux,CC(C)CN1CCC(c2ccccc2Oc2ncccc2NC(=O)Nc2ccc(OC(F)(F)F)cc2)CC1,1-(2-(2-(1-isobutylpiperidin-4-yl)phenoxy)pyridin-3-yl)-3-(4-(trifluoromethoxy)phenyl)urea,6.0,uM,=,0.7781512503836436,1,O=C(Nc1ccccc1)Nc1cccnc1Oc1ccccc1C1CCNCC1
3417,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,Fc1cccc(OC(F)F)c1CC(c1ccccc1)N1CCNCC1,1-(2-(2-(difluoromethoxy)-6-fluorophenyl)-1-phenylethyl)piperazine,10.4,uM,=,1.0170333392987805,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
3418,2192070,10.1016/j.ejmech.2020.112955,,,,Inhibition of human ERG,C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12,"(1R,3S)-5',7-Dichloro-6-fluoro-3-methyl-2,3,4,9-tetrahydrospiro-[beta-carboline-1,3'-indol]-2'(1'H)-one",30.44,uM,=,1.4834446480985353,1,O=C1Nc2ccccc2[C@]12NCCc1c2[nH]c2ccccc12
3419,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1O,"N,N-Diethyl-2-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide",21.079,uM,=,1.3238500038468026,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
3420,1282784,10.1016/j.bmcl.2013.10.045,,,,Inhibition of human ERG,COc1ccc(CNC(=O)c2cc(-c3cc(Cl)cc(Cl)c3)cnc2-c2cccnc2)cc1OC,"5-(3,5-dichlorophenyl)-N-(3,4-dimethoxybenzyl)-2,3'-bipyridine-3-carboxamide",6.95,uM,=,0.8419848045901139,1,O=C(NCc1ccccc1)c1cc(-c2ccccc2)cnc1-c1cccnc1
3421,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)[C@@H]1CCN(Cc2ccc(C(F)(F)F)cc2)C[C@@H]1F,"2-(4-(1H-tetrazol-1-yl)phenyl)-N-((3S,4R)-3-fluoro-1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)-N-methylacetamide",2.0,uM,=,0.3010299956639812,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2ccccc2)CC1
3422,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@H]3CO2)ccc2c1COC2=O,"5-((3S,9aS)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-4-methylisobenzofuran-1(3H)-one",56.5,uM,=,1.7520484478194385,1,O=C1OCc2cc([C@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@H]4CO3)ccc21
3423,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CC(C)N1CCN[C@@H](C(=O)N2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"(R)-N-(3,4-dichlorophenyl)-4-(4-isopropylpiperazine-2-carbonyl)piperazine-1-carboxamide",17.0,uM,=,1.230448921378274,1,O=C(Nc1ccccc1)N1CCN(C(=O)[C@H]2CNCCN2)CC1
3424,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CCN1CC2(CCN(CCc3ccc(F)cc3F)CC2)O[C@H](C)C1=O,"(R)-9-(2,4-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",2.5,uM,=,0.3979400086720376,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1
3425,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,CCOc1cc([C@H](c2cc3cc(C#N)ccc3cc2OC)[C@@](O)(CCN(C)C)c2cccc3ccoc23)cc(OCC)n1,"7-((1R,2S)-2-(benzofuran-7-yl)-1-(2,6-diethoxypyridin-4-yl)-4-(dimethylamino)-2-hydroxybutyl)-6-methoxy-2-naphthonitrile",3.3,uM,=,0.5185139398778875,1,c1ccc2cc([C@H](Cc3cccc4ccoc34)c3ccncc3)ccc2c1
3426,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CC[C@@H]1CN(c2scnc2-c2nc3ccccc3[nH]2)CCN1C(=O)Cn1cnc2cccnc21,"US9266876, 49",0.75,uM,=,-0.1249387366082999,0,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2nc3ccccc3[nH]2)CC1
3427,606908,10.1016/j.bmcl.2009.10.092,,,,Inhibition of human ERG by patch clamp technique,CN1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,(S)-2-chloro-4-((1-methylpyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,0.78,uM,=,-0.1079053973095195,0,c1ccc(CN(c2ccccc2)[C@H]2CCNC2)cc1
3428,1461416,10.1016/j.bmcl.2014.12.068,,,,Inhibition of human ERG,Fc1cccc(F)c1-c1ccc2[nH]nc(-c3cncc(O[C@H]4CNCCC45CC5)n3)c2c1,"(R)-3-(6-(6-azaspiro[2.5]octan-4-yloxy)pyrazin-2-yl)-5-(2,6-difluorophenyl)-1H-indazole",3.7,uM,=,0.568201724066995,1,c1ccc(-c2ccc3[nH]nc(-c4cncc(O[C@H]5CNCCC56CC6)n4)c3c2)cc1
3429,833999,10.1016/j.bmcl.2012.06.094,,,,Inhibition of human ERG by patch clamp assay,O=C1CC(c2nc(-c3cccc(Cl)c3)no2)CN1c1ccc(F)cc1,"(-)-4-(3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl)-1-(4-fluorophenyl)pyrrolidin-2-one",4.0,uM,=,0.6020599913279624,1,O=C1CC(c2nc(-c3ccccc3)no2)CN1c1ccccc1
3430,1458367,10.1016/j.bmcl.2014.06.053,,,,Inhibition of human ERG,O=c1ccc2ncc(=O)n3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1,"(R)-2-{4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)-amino]-piperidin-1-ylmethyl}-1,2-dihydro-2a,5,8a-triaza-acenaphthylene-3,8-dione",1400.0,uM,=,3.146128035678238,1,O=c1ccc2ncc(=O)n3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1
3431,1361026,10.1021/jm401895u,,,,Inhibition of human cloned ERG expressed in CHO cells assessed as inhibition of potassium channel current by automated patch clamp assay,O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2ccccc2s1,N-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butyl)benzo[b]thiophene-2-sulfonamide,4.0,uM,=,0.6020599913279624,1,O=S(=O)(NCCCCN1CCC(c2noc3ccccc23)CC1)c1cc2ccccc2s1
3432,878181,10.1021/jm301190s,,,,Displacement of dofetilide from human ERG,C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc(C(=O)NCc4ccc(C(C)(C)C)cc4)c3)c3c(N)ncnc32)C1,"(R)-3-(1-(1-Acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)-N-(4-tert-butylbenzyl)benzamide",1.8,uM,=,0.255272505103306,1,O=C(NCc1ccccc1)c1cccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)c1
3433,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,CNC(=O)c1ccc(-c2ccc(N3C(=O)N(c4cc(OC)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)cc1,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid methylamide",8.5,uM,=,0.9294189257142929,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
3434,2021863,10.1016/j.bmcl.2020.127433,,,,Inhibition of human ERG by plate-based planar patch clamp method,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(CN(C)C)c(OC)n4)n3)cc12,"5-(4-(4-((dimethylamino)methyl)-3-methoxy-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-N,1-dimethyl-1H-indazole-3-carboxamide",3.6,uM,=,0.5563025007672873,1,c1cnn(-c2ccnc(Nc3ccc4[nH]ncc4c3)n2)c1
3435,863340,10.1016/j.bmcl.2012.05.036,,,,Inhibition of human recombinant ERG channel expressed in HEK297 cells after 3 to 8 mins by voltage clamp assay,CNc1nn2cc3c(nc2c1S(=O)(=O)c1ccccc1)CCN(C)C3,"N,7-dimethyl-3-(phenylsulfonyl)-5,6,7,8-tetrahydropyrazolo[1,5-a]pyrido[4,3-d]pyrimidin-2-amine",0.5,uM,=,-0.3010299956639812,0,O=S(=O)(c1ccccc1)c1cnn2cc3c(nc12)CCNC3
3436,2264097,10.1021/acs.jmedchem.1c00703,,,,Inhibition of hERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp assay,CC(C)n1nc(-c2nnc(C3CCN(CC4CCOCC4)CC3)o2)c2ccccc21.O=C(O)C(=O)O,"1-Isopropyl-3-{5-[1-(tetrahydro-pyran-4-ylmethyl)-piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate",8.5,uM,=,0.9294189257142929,1,c1ccc2c(-c3nnc(C4CCN(CC5CCOCC5)CC4)o3)n[nH]c2c1
3437,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc(C(NC(=O)OC)C(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)nc1,"Methyl (1-[5-(ethylsulfonyl)pyridin-2-yl]-2-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]amino}-2-oxoethyl)carbamate",9.3,uM,=,0.9684829485539352,1,O=C(Cc1ccccn1)Nc1ccccc1
3438,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,COc1ccc(OCCCc2cccc(CCCOc3ccc(OC)cc3)[n+]2C)cc1,"2,6-bis(3-(4-methoxyphenoxy)propyl)-1-methylpyridinium",0.158,uM,=,-0.8013429130455774,0,c1ccc(OCCCc2cccc(CCCOc3ccccc3)[nH+]2)cc1
3439,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCc3ccc(OC)c(OC)c3)C[C@@H]2CNC(=O)c2cccc(Cl)c2)cc1,"rac-3-cyano-N-(((3S,4S)-1-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)methyl)benzamide",0.11,uM,=,-0.958607314841775,0,O=C(NC[C@H]1CN(CCc2ccccc2)C[C@@H]1c1ccccc1)c1ccccc1
3440,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CN(C)Cc1ccc(C(F)(F)F)cc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-4-(trifluoromethyl)phenyl)-N,N-dimethylmethanamine",1.12,uM,=,0.0492180226701816,1,c1ccc(Oc2ccccc2)cc1
3441,2085165,10.1021/acs.jmedchem.6b01242,,,,Inhibition of human ERG,COc1ccc(C(NC(=O)c2cnc(-n3cccn3)nc2O)c2ccc(OC)cc2)cc1,N-(bis(4-methoxyphenyl)methyl)-4-hydroxy-2-(1H-pyrazol-1-yl)pyrimidine-5-carboxamide,0.9,uM,=,-0.0457574905606751,0,O=C(NC(c1ccccc1)c1ccccc1)c1cnc(-n2cccn2)nc1
3442,2123077,10.1016/j.ejmech.2021.113674,,,,Inhibition of human ERG incubated for 3 hrs by competitive fluorescence tracer binding based assay,CS(=O)(=O)c1nccc(-c2c(-c3cccc(OCc4ccccc4)c3)nc3sccn23)n1,"6-(3-(Benzyloxy)phenyl)-5-(2-(methylsulfonyl)pyrimidin-4-yl)imidazo[2,1-b]thiazole",12.41,uM,=,1.0937717814987298,1,c1ccc(COc2cccc(-c3nc4sccn4c3-c3ccncn3)c2)cc1
3443,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C)cc(-c2cncc(-c3nc4cc(C#N)ccc4[nH]3)c2N2CCC(N)CC2)c1,"2-(4-(4-aminopiperidin-1-yl)-5-(3,5-dimethylphenyl)pyridin-3-yl)-1H-benzo[d]imidazole-5-carbonitrile",2.2,uM,=,0.3424226808222063,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
3444,863322,10.1021/jm3008294,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp technique,CCCOC(c1ccc2ccccc2c1)C1CNC1.Cl,3-(Naphthalen-2-yl(propoxy)methyl)azetidine hydrochloride,0.98,uM,=,-0.0087739243075051,0,c1ccc2cc(CC3CNC3)ccc2c1
3445,939638,10.1016/j.bmcl.2012.11.023,,,,Inhibition of human ERG,Nc1nc2cc3c(cc2s1)CCN(Cc1ccccn1)CC3,"7-Pyridin-2-ylmethyl-6,7,8,9-tetrahydro-5H-1-thia-3,7-diaza-cyclohepta[f]inden-2-ylamine",13.0,uM,=,1.1139433523068367,1,c1ccc(CN2CCc3cc4ncsc4cc3CC2)nc1
3446,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,C[C@H]1COc2c(N3CC[C@@H](C4(N)CC4)C3)cc(Cl)c3cc(C(=O)O)c(=O)n1c23,"(S)-10-((R)-3-(1-aminocyclopropyl)pyrrolidin-1-yl)-8-chloro-3-methyl-5-oxo-3,5-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid",42.0,uM,=,1.6232492903979006,1,O=c1ccc2ccc(N3CC[C@@H](C4CC4)C3)c3c2n1CCO3
3447,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc([C@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N,"6-((R)-1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-methoxynicotinonitrile",18.0,uM,=,1.255272505103306,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
3448,2264495,10.1016/j.bmcl.2022.128808,,,,Inhibition of human ERG,O=C1COc2ccc(CNC34CCC(CCc5c(Cl)cnc6ccc(=O)n(CCO)c56)(CC3)OC4)nc2N1,"6-(((1-(2-(3-chloro-5-(2-hydroxyethyl)-6-oxo-5,6-dihydro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-yl)amino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.8,uM,=,0.5797835966168101,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(=O)[nH]c56)(CC3)OC4)nc2N1
3449,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CC[C@@H](N)[C@H](O)C3)nn12,"(3R,4R)-4-Amino-1-(5-(4-fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-3-ol",21.3,uM,=,1.3283796034387378,1,c1ccc(-c2cnc3sc(N4CCCCC4)nn23)cc1
3450,794861,10.1016/j.bmcl.2011.11.075,,,,Inhibition of human ERG by patch-clamp assay,COCCCS(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1,(R)-1-{2-[4'-(3-Methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine,11.0,uM,=,1.0413926851582251,1,c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
3451,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn([C@H]3C[C@@H](C(C)(C)C)CCN(CC(C)(C)C)C3=O)nn2)ccc1-n1cnc(C)c1,"(3S,5S)-5-tert-butyl-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-neopentylazepan-2-one",2.1,uM,=,0.3222192947339193,1,O=C1NCCCC[C@@H]1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
3452,492219,10.1021/jm800419w,,,,Antagonist activity at human ERG by voltage-clamp electrophysiology assay,CC1(C)CC(CN2CCC(F)(CNC(=O)c3cc(Cl)cc(Cl)c3)CC2)CCO1,"rac-3,5-Dichloro-N-[1-(2,2-dimethyl-tetrahydro-pyran-4-ylmethyl)-4-fluoro-piperidin-4-ylmethyl]-benzamide",8.41,uM,=,0.9247959957979122,1,O=C(NCC1CCN(CC2CCOCC2)CC1)c1ccccc1
3453,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(Cc2ccc3sccc3c2)CC1)c1cc(=O)c2ccc(F)cc2o1,N-(1-(benzo[b]thiophen-5-ylmethyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,1.37,uM,=,0.1367205671564068,1,O=C(NC1CCN(Cc2ccc3sccc3c2)CC1)c1cc(=O)c2ccccc2o1
3454,1741807,10.1021/acs.jmedchem.8b00900,,,,Inhibition of human ERG expressed in CHOK1 cells incubated for 600 secs at -80 mV holding potential by automated patch clamp assay,C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc32)[C@@H](CN2CCOC[C@H]2C)CN1,"1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl)-2-[(2R,5R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one",69.0,uM,=,1.8388490907372552,1,O=C(CN1CCNC[C@@H]1CN1CCOCC1)N1CCc2ncc(Cc3ccccc3)cc21
3455,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CC(Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2Cl)CC1)C(F)(F)F,"rac-[4-(3-Chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone",10.0,uM,=,1.0,1,O=C(c1ccccc1)N1CCN(c2ccccn2)CC1
3456,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccc3C(F)(F)F)no2)CC1,"N-(2-phenylcyclopropyl)-4-(3-(2-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",6.0,uM,=,0.7781512503836436,1,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccc3)no2)CC1
3457,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",COc1ccc2nc(CN3CCC[C@H]3CO)n(Cc3ccc(Cl)cc3)c2c1,"US8975247, EBP484",5.0,uM,=,0.6989700043360189,1,c1ccc(Cn2c(CN3CCCC3)nc3ccccc32)cc1
3458,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N[C@@H](CO)c1ccccc1,(R)-1-(2-hydroxy-1-phenylethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,25.8,uM,=,1.4116197059632305,1,O=C(NCc1ccccc1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
3459,770623,10.1016/j.bmcl.2011.07.061,,,,Inhibition of human ERG,Cc1nc2ccccc2n1-c1ccc(C(=O)N(C)[C@@H]2CCN(C(C)C)C2)cc1,(R)-N-(1-isopropylpyrrolidin-3-yl)-N-methyl-4-(2-methyl-1H-benzo[d]imidazol-1-yl)benzamide,45.0,uM,=,1.6532125137753435,1,O=C(N[C@@H]1CCNC1)c1ccc(-n2cnc3ccccc32)cc1
3460,770623,10.1016/j.bmcl.2011.07.061,,,,Inhibition of human ERG,CN(C(=O)c1ccc(-n2cccn2)cc1)[C@@H]1CCN(C2CCC2)C1,(R)-N-(1-cyclobutylpyrrolidin-3-yl)-N-methyl-4-(1H-pyrazol-1-yl)benzamide,25.0,uM,=,1.3979400086720375,1,O=C(N[C@@H]1CCN(C2CCC2)C1)c1ccc(-n2cccn2)cc1
3461,826732,10.1021/jm201194q,,,,Inhibition of human ERG expressed in HEK cells by patch clamp assay,c1ccc(CCNCCN(c2ccccc2)c2ccccc2)cc1,"N1-phenethyl-N2,N2-diphenylethane-1,2-diamine",0.062,uM,=,-1.207608310501746,0,c1ccc(CCNCCN(c2ccccc2)c2ccccc2)cc1
3462,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3cnc(-c4ccccc4)s3)ccc2c1,(R)-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-2-phenylthiazole,1.36,uM,=,0.1335389083702175,1,c1ccc(-c2ncc(-c3ccc4cc(CCN5CCCC5)ccc4n3)s2)cc1
3463,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,Cc1[nH]c2ccccc2c1CCN1CCc2ccc(/C=C/C(=O)NO)cc2CC1,"N-hydroxy-3-(3-(2-(2-methyl-1H-indol-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)acrylamide",3.2,uM,=,0.505149978319906,1,c1ccc2c(c1)CCN(CCc1c[nH]c3ccccc13)CC2
3464,1578296,10.1016/j.bmcl.2016.04.020,,,,Inhibition of human ERG,N[C@H]1C[C@@H](N2Cc3cnc4nnc(C5CC5)n4c3C2)CC[C@@H]1c1cc(F)c(F)cc1F,"(1S,2R,5S)-5-(1-cyclopropyl-6H-pyrrolo[3,4-e][1,2,4]triazolo[4,3-a]pyrimidin-7(8H)-yl)-2-(2,4,5-trifluorophenyl)cyclohexanamine",0.6,uM,=,-0.2218487496163563,0,c1ccc([C@H]2CC[C@H](N3Cc4cnc5nnc(C6CC6)n5c4C3)CC2)cc1
3465,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,CS(=O)(=O)C1CN(C(=O)c2ccc3cc(Oc4ccc(C(F)(F)F)cn4)ccc3n2)C1,"US9452986, 29",23.6,uM,=,1.3729120029701067,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCC1
3466,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cccnc2C(F)(F)F)C1=O,"2-methyl-9-(2-phenylethyl)-4-[2-(trifluoromethyl)-3-pyridyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",3.8,uM,=,0.5797835966168101,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1cccnc1
3467,1461416,10.1016/j.bmcl.2014.12.068,,,,Inhibition of human ERG,NC(=O)c1ccc(-c2ccc3[nH]nc(-c4cncc(O[C@H]5CNCCC56CC6)n4)c3c2)c(F)c1,(R)-4-(3-(6-(6-azaspiro[2.5]octan-4-yloxy)pyrazin-2-yl)-1H-indazol-5-yl)-3-fluorobenzamide,1.1,uM,=,0.041392685158225,1,c1ccc(-c2ccc3[nH]nc(-c4cncc(O[C@H]5CNCCC56CC6)n4)c3c2)cc1
3468,2251877,10.1021/acs.jmedchem.1c01756,,,,Inhibition of human ERG,CN1CCN(c2ncc(NC(=O)c3cc(C(=O)c4c(Cl)ccc(Cl)c4F)c[nH]3)cn2)CC1,"4-(3,6-dichloro-2-fluorobenzoyl)-N-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-1H-pyrrole-2-carboxamide",2.63,uM,=,0.4199557484897578,1,O=C(c1ccccc1)c1c[nH]c(C(=O)Nc2cnc(N3CCNCC3)nc2)c1
3469,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2ccc3nc(-c4ncco4)ccc3c2)[nH]1,(S)-6-methyl-N-((S)-1-(5-(2-(oxazol-2-yl)quinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide,15.0,uM,=,1.1760912590556811,1,O=C(NCc1ncc(-c2ccc3nc(-c4ncco4)ccc3c2)[nH]1)[C@H]1CC12CCNCC2
3470,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(S)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",26.0,uM,=,1.414973347970818,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3471,1540295,10.1016/j.bmcl.2015.10.097,,,,Inhibition of human ERG by patch clamp technique,CCOC[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCN(S(=O)(=O)c1ccc(C(F)(F)F)cc1)C2,"(R)-4a-(ethoxymethyl)-1-(4-fluorophenyl)-6-(4-(trifluoromethyl)phenylsulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinoline",0.8,uM,=,-0.0969100130080563,0,O=S(=O)(c1ccccc1)N1CCC2=Cc3c(cnn3-c3ccccc3)CC2C1
3472,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,N#Cc1ccc(Oc2ccc3nc(OCC(=O)N4CCOCC4)ccc3c2)cc1,4-[[2-(2-morpholino-2-oxo-ethoxy)-6-quinolyl]oxy]benzonitrile,6.7,uM,=,0.8260748027008264,1,O=C(COc1ccc2cc(Oc3ccccc3)ccc2n1)N1CCOCC1
3473,1351560,10.1016/j.bmcl.2014.03.036,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells,O=C(N1CCc2ncc(C(F)(F)F)cc2C1)[C@@]12CCO[C@@H]1C[C@@H](N1CCC(c3ccccc3)CC1)C2,"((3aS,5S,6aR)-5-(4-phenylpiperidin-1-yl)hexahydro-2H-cyclopenta[b]furan-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",5.8,uM,=,0.7634279935629373,1,O=C(N1CCc2ncccc2C1)[C@@]12CCO[C@@H]1C[C@@H](N1CCC(c3ccccc3)CC1)C2
3474,1802839,10.1016/j.ejmech.2018.08.020,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current at -80 holding potential after 100 to 200 secs by whole cell automated patch-clamp electrophysiology assay,O=C1S/C(=C\c2ccc(Oc3ccc(F)cc3)cc2)C(=O)N1c1ccc(OCCCCN2CCN(CC3CC3)CC2)cc1,"(Z)-3-(4-(4-(4-(Cyclopropylmethyl)piperazin-1-yl)butoxy)phenyl)-5-(4-(4-fluorophenoxy)benzylidene)thiazolidine-2,4-dione",3.4,uM,=,0.5314789170422551,1,O=C1S/C(=C\c2ccc(Oc3ccccc3)cc2)C(=O)N1c1ccc(OCCCCN2CCN(CC3CC3)CC2)cc1
3475,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(CCN2CCN(CC(O)c3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"4-(2-(4-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-2-methoxybenzonitrile",9.0,uM,=,0.9542425094393248,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
3476,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CC(=O)N(c2ccc(=O)n(C)n2)C3)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2,8-diazaspiro[4.5]decan-3-one",36.4,uM,=,1.561101383649056,1,O=C1OCc2cc(CCN3CCC4(CC3)CC(=O)N(c3ccc(=O)[nH]n3)C4)ccc21
3477,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,O=c1n(Cc2ccc(Cl)cc2)c2sc3c(c2c2ncnn12)CCCC3,SID4265052,6.3,uM,=,0.7993405494535817,1,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCCC3
3478,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1cnccn1,"(R)-2-(6-methoxy-3-(1-(pyrazin-2-yl)ethyl)-1H-inden-2-yl)-N,N-dimethylethanamine",3.4,uM,=,0.5314789170422551,1,C1=C(Cc2cnccn2)c2ccccc2C1
3479,1511129,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG expressed in CHO cells by patch express method based electrophysiology assay,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-(2-hydroxyethoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.9,uM,=,0.4623979978989561,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3480,819957,10.1021/ml200199c,,,,Displacement of [3H]dofetilide from human ERG,O=C(C1CCN(c2cc(C(F)(F)F)ccn2)CC1)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ncccn4)cn3)CC2)C1,(S)-(3-{trans-4-Hydroxy-4-[5-(pyrimidin-2-yl)pyridin-2-yl]cyclohexylamino}pyrrolidin-1-yl){1-[4-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methanone,28.0,uM,=,1.4471580313422192,1,O=C(C1CCN(c2ccccn2)CC1)N1CC[C@H](NC2CCC(c3ccc(-c4ncccn4)cn3)CC2)C1
3481,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@H]3OC[C@H](NCc4cc5c(cn4)OCCO5)CO3)c2n1,"(2r,5r)-N-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methyl)-2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-1,3-dioxan-5-amine",15.0,uM,=,1.1760912590556811,1,c1cnc2c(CC[C@H]3OC[C@H](NCc4cc5c(cn4)OCCO5)CO3)ccnc2c1
3482,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,COc1cccnc1Cn1ccc2nc(N)nc(OCc3ncc(C)o3)c21,"5-((3-Methoxypyridin-2-yl)methyl)-4-((5-methyloxazol-2-yl)-methoxy)-5H-pyrrolo[3,2-d]pyrimidin-2-amine",2.2,uM,=,0.3424226808222063,1,c1ccc(Cn2ccc3ncnc(OCc4ncco4)c32)nc1
3483,1627127,10.1016/j.bmcl.2016.10.064,,,,Displacement of 35S-MK499 from human ERG expressed in HEK293 cell membranes,Cc1c([C@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@H]3CO2)ccc2c1COC2=O,"5-((3S,9aS)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-4-methylisobenzofuran-1(3H)-one",26.8,uM,=,1.428134794028789,1,O=C1OCc2cc([C@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@H]4CO3)ccc21
3484,674336,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human ERG expressed in HEK cells by patch clamp technique,C[C@H]1CNC[C@H](C)N1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1,"endo-2-((2S,6S)-2,6-dimethylpiperazin-1-yl)-N-((1R,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzo[d]oxazole-4-carboxamide",6.4,uM,=,0.8061799739838872,1,O=C(N[C@@H]1C[C@H]2CCC[C@@H](C1)N2)c1cccc2oc(N3CCNCC3)nc12
3485,1696561,10.1016/j.bmcl.2017.08.052,,,,Inhibition of human ERG expressed in CHO cells by Ionworks electrophysiology method,Cc1ccc(-c2ncc(OC[C@@H]3CCNC3)cc2-c2ccc(C#N)cc2)cc1,(R)-4-(5-(pyrrolidin-3-ylmethoxy)-2-p-tolylpyridin-3-yl)benzonitrile,3.2,uM,=,0.505149978319906,1,c1ccc(-c2cc(OC[C@@H]3CCNC3)cnc2-c2ccccc2)cc1
3486,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Cl)cc1Oc1ccc(Cl)c(F)c1,1-(4-chloro-2-(4-chloro-3-fluorophenoxy)phenyl)-N-methylmethanamine,1.23,uM,=,0.0899051114393979,1,c1ccc(Oc2ccccc2)cc1
3487,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CC(C)Cn1nc(-c2ccc3nc(OC4CC4)ccc3c2)c2c(N)ncnc21,"3-(2-Cyclopropoxyquinolin-6-yl)-1-isobutyl-1H-pyrazolo-[3,4-d]pyrimidin-4-amine",10.0,uM,=,1.0,1,c1ncc2c(-c3ccc4nc(OC5CC5)ccc4c3)n[nH]c2n1
3488,2129860,10.1021/acsmedchemlett.1c00328,,,,Inhibition of human ERG stably expressed in CHO-K1 cells at -90 mV holding potential by automated Q-patch clamp method,CS(=O)(=O)c1ccc(Cn2c(NC3CCN(CCc4ccc(C#N)cc4)CC3)nc3ccccc32)cc1,4-(2-(4-((1-(4-(methylsulfonyl)benzyl)-1H-benzo[d]imidazol-2-yl)amino)piperidin-1-yl)ethyl)benzonitrile,0.11,uM,=,-0.958607314841775,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
3489,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCCC[C@@H](CCO)Nc1nc(N)nc2cc(C)ccc12,(S)-3-((2-Amino-7-methylquinazolin-4-yl)amino)heptan-1-ol,1.8,uM,=,0.255272505103306,1,c1ccc2ncncc2c1
3490,1583749,10.1016/j.bmcl.2016.05.058,,,,Inhibition of recombinant human ERG flux expressed in HEK293 cells by patch clamp assay,CC(C)Oc1cc([C@@](Cc2ccccc2)(NC[C@@H](O)C(F)(F)F)c2cc(F)cc(OC(F)(F)C(F)F)c2)ccc1F,"(R)-1,1,1-trifluoro-3-((R)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethylamino)propan-2-ol",21.0,uM,=,1.3222192947339193,1,c1ccc(CC(c2ccccc2)c2ccccc2)cc1
3491,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Clc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)s1,"(1R,3R)-3-(4-(5-chlorothiophen-2-yl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.522,uM,=,-0.2823294969977378,0,c1csc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)c1
3492,1648277,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncc(Cl)cn3)CC2)cc1F)N1CCC1,"(cis)-1-(azetidin-1-yl)-2-(4-(2-((1S,2R)-2-(1-(5-chloropyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)-2-fluorophenyl)ethanone",3.3,uM,=,0.5185139398778875,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)cc1)N1CCC1
3493,77051,10.1021/jm970517u,,,,Inhibition of Ikr current in isolated guinea pig myocytes during a 0.5 s voltage clamp step from -50 to -10 mV.,CN1C(=O)[C@H](NC(=O)CCC2CCCCC2)N=C(c2ccccc2)c2ccccc21,"3-Cyclohexyl-N-((R)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide",1.0,uM,=,0.0,0,O=C(CCC1CCCCC1)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O
3494,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,Cc1nc(-c2nc3ccccc3[nH]2)c(N2CCN(C(=O)Cn3cnc4cccnc43)[C@H](C)C2)s1,"US9266876, 144",2.6,uM,=,0.414973347970818,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2nc3ccccc3[nH]2)CC1
3495,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COc1cc(OC)cc(C(=O)NCC2(C#N)CCN(Cc3ccccc3C(F)(F)F)CC2)c1,"N-((4-cyano-1-(2-(trifluoromethyl)benzyl)piperidin-4-yl)methyl)-3,5-dimethoxybenzamide",4.76,uM,=,0.6776069527204931,1,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
3496,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1,"US9145392, 220",0.93,uM,=,-0.0315170514460648,0,c1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ccncn4)CC3)n2)cc1
3497,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(C(=O)N2CCC(CNC(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc1C(C)(C)C,"N-((1-(3,5-di-tert-butyl-4-methoxybenzoyl)pyrrolidin-3-yl)methyl)-6,6-bis(4-fluorophenyl)hexanamide",0.65,uM,=,-0.1870866433571444,0,O=C(CCCCC(c1ccccc1)c1ccccc1)NCC1CCN(C(=O)c2ccccc2)C1
3498,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,CN1CCN(C(=O)COc2ccc3cc(Oc4ccc(C#N)cc4)ccc3n2)CC1,4-[[2-[2-(4-methylpiperazin-1-yl)-2-oxo-ethoxy]-6-quinolyl]oxy]benzonitrile,4.9,uM,=,0.6901960800285137,1,O=C(COc1ccc2cc(Oc3ccccc3)ccc2n1)N1CCNCC1
3499,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(Nc1ccccc1)N(c1ccc(Br)cc1)C1CCN(C2CCCC2)CC1,1-(4-bromophenyl)-1-(1-cyclopentylpiperidin-4-yl)-3-phenylurea,0.188,uM,=,-0.7258421507363202,0,O=C(Nc1ccccc1)N(c1ccccc1)C1CCN(C2CCCC2)CC1
3500,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COc1cccc(-n2cc3nc(C)n(C[C@H]4CCCN(C[C@H]5CCCO5)C4)c(=O)c3n2)c1,"2-(3-Methoxyphenyl)-5-methyl-6-(((S)-1-(((R)-tetrahydrofuran-2-yl)methyl)piperidin-3-yl)methyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",2.9,uM,=,0.4623979978989561,1,O=c1c2nn(-c3ccccc3)cc2ncn1C[C@H]1CCCN(C[C@H]2CCCO2)C1
3501,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COC(=O)c1cc(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)on1,(R)-methyl 5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)isoxazole-3-carboxylate,16.8,uM,=,1.2253092817258628,1,c1cc(-c2ccc3cc(CCN4CCCC4)ccc3n2)on1
3502,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccn3)CC2)CN(c2ccccc2)C1=O,"2-methyl-4-phenyl-9-[2-(2-pyridyl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",2.0,uM,=,0.3010299956639812,1,O=C1COC2(CCN(CCc3ccccn3)CC2)CN1c1ccccc1
3503,378763,10.1016/j.bmcl.2006.05.058,,,,Inhibition of hERG potassium channel expressed in CHO cells by whole cell patch clamp method,O=C1NCC(c2ccccc2)C12CCN(C1CCCCC1(O)c1ccc(F)cc1)CC2,"8-[2-(4-fluoro-phenyl)-2-hydroxy-cyclohexyl]-4-phenyl-2,8-diaza-spiro[4.5]decan-1-one",1.8,uM,=,0.255272505103306,1,O=C1NCC(c2ccccc2)C12CCN(C1CCCCC1c1ccccc1)CC2
3504,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)C1CC1)C2,"6-cyclopropanecarbonyl-2-{[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy}-5,6,7,8-tetrahydro-1,6-naphthyridine",5.8,uM,=,0.7634279935629373,1,O=C(C1CC1)N1CCc2nc(OCc3conc3-c3ccccc3)ccc2C1
3505,1906723,10.1016/j.ejmech.2019.111674,,,,Inhibition of human ERG expressed in HEK293 cells incubated for 72 hrs by patch clamp assay,NC(=O)c1ccn(-c2cccc(OC(=O)NCCCN3CCN(c4ccccc4)CC3)c2)c1,3-(3-Carbamoyl-1H-pyrrol-1-yl)phenyl (3-(4-phenylpiperazin-1-yl)propyl)carbamate,3.5,uM,=,0.5440680443502757,1,O=C(NCCCN1CCN(c2ccccc2)CC1)Oc1cccc(-n2cccc2)c1
3506,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1CCc2ccc(F)cc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1,"7-Fluoro-1-{3-[4-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-3,4-dihydro-1H-quinolin-2-one",5.7,uM,=,0.7558748556724915,1,O=C1CCc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
3507,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)NCC3CC3)cc2)cc1,4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic Acid Cyclopropylmethyl-amide,2.555555556,uM,=,0.4074853266537974,1,O=S(=O)(NCC1CC1)c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
3508,962470,10.1021/jm4004895,,,,Inhibition of human ERG channel expressed in HEK293 cells by patch clamp assay,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CCC#N)CC1,"3-(trans-4-(2-((R)-1-Hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)propanenitrile",20.0,uM,=,1.3010299956639813,1,c1cc2c(ncc3ncn(C4CCCCC4)c32)[nH]1
3509,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,CN1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4ccc5cccnc5c4)c3c2)CC1,3-(4-methylpiperazin-1-yl)-N-(quinolin-7-ylmethyl)-7-(trifluoromethyl)quinolin-5-amine,75.8,uM,=,1.8796692056320536,1,c1cnc2cc(CNc3cccc4ncc(N5CCNCC5)cc34)ccc2c1
3510,580515,10.1016/j.bmcl.2009.06.050,,,,Displacement of [35S]MK499 from human ERG potassium channel expressed in HEK293 cells,COc1ccc([C@H](N[C@@H]2CC[C@@H](C(=O)N3CCC(C(=O)N4CCCC4)(c4ccccc4)CC3)C(C)(C)C2)C(F)(F)F)cc1,"(1-((1R,4R)-2,2-dimethyl-4-((S)-2,2,2-trifluoro-1-(4-methoxyphenyl)ethylamino)cyclohexanecarbonyl)-4-phenylpiperidin-4-yl)(pyrrolidin-1-yl)methanone",7.4,uM,=,0.8692317197309762,1,O=C(N1CCCC1)C1(c2ccccc2)CCN(C(=O)[C@H]2CC[C@H](NCc3ccccc3)CC2)CC1
3511,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(C2=CC3OC=NC3C=C2)[nH]1,"(S)-N-[(1S)-1-[5-(3a,7a-dihydro-1,3-benzoxazol-6-yl)-1H-imidazol-2-yl]-7-oxo-nonyl]-6-methyl-6-azaspiro[2.5]octane-2-carboxamide",58.0,uM,=,1.7634279935629371,1,O=C(NCc1ncc(C2=CC3OC=NC3C=C2)[nH]1)[C@H]1CC12CCNCC2
3512,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2ccc3nc(C4CC4)ccc3c2)[nH]1,(S)-N-((S)-1-(5-(2-cyclopropylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,4.8,uM,=,0.6812412373755872,1,O=C(NCc1ncc(-c2ccc3nc(C4CC4)ccc3c2)[nH]1)[C@H]1CC12CCNCC2
3513,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N(Cc3ccccc3)[C@H](C)c3ccccc3)nn2)ccc1-n1cnc(C)c1,"(R)-N-benzyl-2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-N-(1-phenylethyl)acetamide",0.43,uM,=,-0.3665315444204134,0,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)N(Cc1ccccc1)Cc1ccccc1
3514,1447392,10.1016/j.bmcl.2014.04.085,,,,Inhibition of human ERG channel,CCOC(=O)N1CCC(CN2CCC3(CC2)CN(C(=O)NC)c2ncccc23)CC1,"ethyl 4-((1'-(methylcarbamoyl)-1',2'-dihydrospiro[piperidine-4,3'-pyrrolo[2,3-b]pyridine]-1-yl)methyl)piperidine-1-carboxylate",0.3,uM,=,-0.5228787452803376,0,c1cnc2c(c1)C1(CCN(CC3CCNCC3)CC1)CN2
3515,793275,10.1016/j.bmcl.2011.09.117,,,,Displacement of [3H]dofetilide from human ERG by liquid scintillation counting,COc1ccc2ncc(F)c(CCN3CC[C@@H](NCc4cc5c(cn4)OCCO5)[C@@H](O)C3)c2n1,"(3S,4R)-4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)piperidin-3-ol",4.9,uM,=,0.6901960800285137,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
3516,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,"8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine",0.32,uM,=,-0.494850021680094,0,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2
3517,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(CC1CC1)CC2)c1ncc(-c2cc3ccc(C)nc3cc2OC)[nH]1,(S)-6-(cyclopropylmethyl)-N-((S)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide,8.4,uM,=,0.9242792860618816,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)[nH]1)[C@H]1CC12CCN(CC1CC1)CC2
3518,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-4-yl)acetic Acid,6.6,uM,=,0.8195439355418687,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCCO5)CC4)nc3)nc2c1
3519,2015654,10.1016/j.bmcl.2020.127417,,,,Inhibition of human ERG by QPatch HTX automated patch clamp system,Clc1ccc2c(c1)CCCc1nnc([C@H]3CC[C@H](Oc4ccccn4)CC3)n1-2,"(S)-8-chloro-1-((1r,4r)-4-(pyridin-2-yloxy)cyclohexyl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a]azepine",14.0,uM,=,1.146128035678238,1,c1ccc(O[C@H]2CC[C@H](c3nnc4n3-c3ccccc3CCC4)CC2)nc1
3520,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,C[S+]([O-])c1ccc(-c2ccc3ncc(-c4ccc(S(C)(=O)=O)cc4)n3n2)cc1,"6-(4-(methylsulfinyl)phenyl)-3-(4-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine",17.9,uM,=,1.252853030979893,1,c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1
3521,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3cccnc32)CC1,"4-{3-[4-(2-Oxo-1,2-dihydro-imidazo[4,5-b]pyridin-3-yl)-piperidin-1-yl]-propyl}-4H-benzo[1,4]oxazin-3-one",13.0,uM,=,1.1139433523068367,1,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3cccnc32)CC1
3522,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,10-[2-(1-Methyl-piperidin-2-yl)-ethyl]-2-methylsulfanyl-10H-phenothiazine,0.0357,uM,=,-1.4473317838878068,0,c1ccc2c(c1)Sc1ccccc1N2CCC1CCCCN1
3523,1972154,10.1021/acs.jmedchem.9b01624,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,C[C@@H]1CN(C(=O)Nc2cc(-c3cn(C4CCOCC4)c4cnccc34)ccn2)C[C@H](C)O1,"(2S,6R)-2,6-Dimethyl-N-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)morpholine-4-carboxamide",24.0,uM,=,1.380211241711606,1,O=C(Nc1cc(-c2cn(C3CCOCC3)c3cnccc23)ccn1)N1CCOCC1
3524,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCCC[C@@H](CCO)Nc1nc(N)nc2ccccc12,(S)-3-((2-Aminoquinazolin-4-yl)amino)heptan-1-ol,2.7,uM,=,0.4313637641589873,1,c1ccc2ncncc2c1
3525,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,Cc1ccccc1C1CCN(C[C@@H]2CCc3cccnc3[C@@H](O)C2)CC1,"trans-(+)-7-((4-o-tolylpiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",2.7,uM,=,0.4313637641589873,1,c1ccc(C2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
3526,1783291,10.1016/j.ejmech.2017.12.099,,,,Inhibition of human ERG by auomated patch clamp assay,O=C1[C@@H]2[C@H](C(=O)N1CCCCN1CCN(c3cccc4sccc34)CC1)[C@H]1C=C[C@@H]2C1,"(3aR,4R,7S,7aS)-2-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione",7.85,uM,=,0.8948696567452525,1,O=C1[C@@H]2[C@H](C(=O)N1CCCCN1CCN(c3cccc4sccc34)CC1)[C@H]1C=C[C@@H]2C1
3527,1537932,10.1016/j.bmcl.2015.10.070,,,,Inhibition of human ERG assessed as reduction in IKr current,N[C@H]1C[C@@H](N2Cc3cn(S(=O)(=O)C4CC4)nc3C2)CO[C@@H]1c1cc(F)ccc1F,"(2R,3S,5R)-5-(2-(cyclopropylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)-2-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-amine",21.0,uM,=,1.3222192947339193,1,O=S(=O)(C1CC1)n1cc2c(n1)CN([C@@H]1CC[C@@H](c3ccccc3)OC1)C2
3528,983134,10.1016/j.bmcl.2013.07.013,,,,Inhibition of human ERG by patch clamp assay,O=c1cnc2ccc(F)c3c2n1C[C@@]3(O)CN1CCC(NCc2cc3c(cn2)OCCO3)CC1,"(S)-6-((4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)methyl)-7-fluoro-6-hydroxy-5,6-dihydro-3H-pyrrolo[1,2,3-de]quinoxalin-3-one",101.0,uM,=,2.004321373782642,1,O=c1cnc2cccc3c2n1CC3CN1CCC(NCc2cc3c(cn2)OCCO3)CC1
3529,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cnc(OC)c([C@H](c2cc3cc(C#N)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cc(OC)nc(OC)c2)c1,"3-((1S,2S)-1-(2,5-dimethoxypyridin-3-yl)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)-2-hydroxybutyl)-2-methoxyquinoline-6-carbonitrile",3.1,uM,=,0.4913616938342727,1,c1cncc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)c1
3530,1924902,10.1016/j.bmcl.2016.07.048,,,,Inhibition of MK499 binding to human ERG,Cn1cc(NC(=O)c2cccc(-c3ccnc(N)c3)n2)c(C(N)=O)n1,"2'-amino-N-(3-carbamoyl-1-methyl-1H-pyrazol-4-yl)-2,4'-bipyridine-6-carboxamide",25.0,uM,=,1.3979400086720375,1,O=C(Nc1cn[nH]c1)c1cccc(-c2ccncc2)n1
3531,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,"1-{1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one",0.0322,uM,=,-1.4921441283041692,0,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccccc1
3532,1365396,10.1016/j.ejmech.2014.05.051,,,,Inhibition of human ERG,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)CCN1CCN(C)CC1,"(Z)-N-(5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)-3-(4-methylpiperazin-1-yl)propanamide",18.83,uM,=,1.2748503200166648,1,O=C(CCN1CCNCC1)Nc1c[nH]c(/C=C2\C(=O)Nc3ccccc32)c1
3533,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,CO/N=C(/Cc1c(F)cnc2ccc(OC)nc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2,"(Z)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-(methoxyimino)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.5,uM,=,0.3979400086720376,1,N=C(Cc1ccnc2cccnc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
3534,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,NC1CCN(c2c(NC(=O)c3ccccc3)cncc2-c2cc(Cl)cc(Cl)c2)CC1,"N-[4-(4-amino-1-piperidyl)-5-(3,5-dichlorophenyl)-3-pyridyl]benzamide",0.9,uM,=,-0.0457574905606751,0,O=C(Nc1cncc(-c2ccccc2)c1N1CCCCC1)c1ccccc1
3535,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,Cc1csc([C@H](C)C2=C(CCN(C)C)Cc3ccccc32)n1,"(R)-N,N-dimethyl-2-(3-(1-(4-methylthiazol-2-yl)ethyl)-1H-inden-2-yl)ethanamine",1.9,uM,=,0.2787536009528289,1,C1=C(Cc2nccs2)c2ccccc2C1
3536,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,CC(C)CN(C(=O)c1ccccc1-c1ccccc1)[C@H]1CCNC1,(S)-N-isobutyl-N-(pyrrolidin-3-yl)biphenyl-2-carboxamide,1.44,uM,=,0.1583624920952496,1,O=C(N[C@H]1CCNC1)c1ccccc1-c1ccccc1
3537,1473398,10.1021/jm501920g,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,Clc1ccc(-n2cc(NCCN3CCCCC3)nn2)c(Cl)c1,"1-(2,4-dichlorophenyl)-N-(2-(piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-amine",4.9,uM,=,0.6901960800285137,1,c1ccc(-n2cc(NCCN3CCCCC3)nn2)cc1
3538,493421,10.1016/j.bmcl.2008.10.025,,,,Inhibition of human ERG expressed in CHO cells,Cn1ccc2cc(C3(Cc4ccccc4)CCNC3)ccc21,5-(3-benzylpyrrolidin-3-yl)-1-methyl-1H-indole,7.0,uM,=,0.8450980400142568,1,c1ccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)cc1
3539,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NCc1nc2ccccc2[nH]1)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,1-((1H-benzo[d]imidazol-2-yl)methyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,14.7,uM,=,1.167317334748176,1,O=C(NCc1nc2ccccc2[nH]1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
3540,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,C[S+]([O-])c1ccc(-c2cnc3ccc(Nc4cccc(S(C)(=O)=O)c4)nn23)cc1,"3-(4-(methylsulfinyl)phenyl)-N-(3-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazin-6-amine",2.36,uM,=,0.3729120029701065,1,c1ccc(Nc2ccc3ncc(-c4ccccc4)n3n2)cc1
3541,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,CC(C)Oc1cncc(-c2ccc3[nH]nc(C(=O)NCC4CCOCC4)c3c2)c1,5-(5-Isopropoxypyridin-3-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-3-carboxamide,0.86,uM,=,-0.0655015487564322,0,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cccnc3)cc12
3542,464747,10.1016/j.bmcl.2008.01.126,,,,Inhibition of human ERG by FLIPR assay,Cc1oc(-c2ccc(Cl)cc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1,"(2S,3S)-3-(3-(2-(2-(4-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",1.3,uM,=,0.1139433523068367,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
3543,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(C#N)ccc1Oc1ccc(Cl)c(Cl)c1,"4-(3,4-dichlorophenoxy)-3-((methylamino)methyl)benzonitrile",4.56,uM,=,0.658964842664435,1,c1ccc(Oc2ccccc2)cc1
3544,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@H]3OC[C@H](NCc4ccc5c(c4)OCCO5)CO3)c2n1,"(2r,5r)-N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-1,3-dioxan-5-amine",8.0,uM,=,0.9030899869919436,1,c1cnc2c(CC[C@H]3OC[C@H](NCc4ccc5c(c4)OCCO5)CO3)ccnc2c1
3545,2145772,10.1021/acs.jmedchem.1c01524,,,,Inhibition of human ERG,C[C@H]1CC[C@H](Cn2c(N3CCO[C@@H]4CCC[C@H]43)nc3cc(-c4noc(=O)[nH]4)nc(-c4cncc(Cl)c4)c32)CC1,"US8846657, 3.2",12.0,uM,=,1.0791812460476249,1,O=c1[nH]c(-c2cc3nc(N4CCO[C@@H]5CCC[C@H]54)n(CC4CCCCC4)c3c(-c3cccnc3)n2)no1
3546,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCCNC3)Oc3ccccc32)cc1,"N,N-Diethyl-4-(spiro[chromene-2,3'-piperidine]-4-yl)benzamide",12.653,uM,=,1.1021935080397438,1,C1=C(c2ccccc2)c2ccccc2OC12CCCNC2
3547,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,Cc1[nH]c(-c2ccccn2)cc1C(=O)NCCCN1CCN(c2cccc(Cl)c2Cl)CC1.Cl.Cl.Cl.Cl,"N-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propyl)-2-methyl-5-(pyridin-2-yl)-1H-pyrrole-3-carboxamide dihydrochloride",0.9,uM,=,-0.0457574905606751,0,O=C(NCCCN1CCN(c2ccccc2)CC1)c1c[nH]c(-c2ccccn2)c1
3548,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1,"N,N-dimethyl-2-(4-(6-phenyl-7-(4-((4-(5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)pyrido[2,3-d]pyrimidin-2-yl)piperazin-1-yl)ethanamine",2.1,uM,=,0.3222192947339193,1,c1ccc(-c2cc3cnc(N4CCNCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1
3549,872803,10.1021/jm300991n,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CC#Cc1cncc(-c2cc(C3(C4CC4)N=C(C)C(N)=N3)ccc2O)c1,4-(4-Amino-2-cyclopropyl-5-methyl-2H-imidazol-2-yl)-2-(5-(prop-1-ynyl)pyridin-3-yl)phenol,24.5,uM,=,1.3891660843645326,1,C1=NC(c2cccc(-c3cccnc3)c2)(C2CC2)N=C1
3550,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1cc(C(=O)NCC2(C#N)CCN(CC3=Cc4ccccc4OC3(C)C)CC2)nn1-c1ccccc1,"N-((4-cyano-1-((2,2-dimethyl-2H-chromen-3-yl)methyl)piperidin-4-yl)methyl)-5-isobutyl-1-phenyl-1H-pyrazole-3-carboxamide",4.73,uM,=,0.6748611407378116,1,O=C(NCC1CCN(CC2=Cc3ccccc3OC2)CC1)c1ccn(-c2ccccc2)n1
3551,1992475,10.1021/acs.jmedchem.0c01199,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by IonWorks barracuda patch clamp method,COc1cc(-c2cncc(-c3ccc(C4=CCNCC4)cc3)c2C)cc(OC)c1OC,"4-Methyl-3-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-5-(3,4,5-trimethoxyphenyl)pyridine",3.4,uM,=,0.5314789170422551,1,C1=C(c2ccc(-c3cncc(-c4ccccc4)c3)cc2)CCNC1
3552,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCN(C(=O)N2CCCC2)CC1,1-(4-(pyrrolidine-1-carbonyl)piperazin-1-yl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)ethanone,14.0,uM,=,1.146128035678238,1,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCN(C(=O)N2CCCC2)CC1
3553,1871838,10.1016/j.bmcl.2018.12.015,,,,Inhibition of human ERG,CC1(CC#Cc2c(Cl)c3c(Cl)cc(C(N)=O)nc3n2[C@H]2CCCNC2)COC1,"(S)-3,4-dichloro-2-(3-(3-methyloxetan-3-yl)prop-1-ynyl)-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",0.005,uM,=,-2.3010299956639813,0,C(#Cc1cc2cccnc2n1[C@H]1CCCNC1)CC1COC1
3554,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccnnc2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(pyridazin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",27.0,uM,=,1.4313637641589874,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccnnc3)C4=O)ccc21
3555,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)s4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"5-{4-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-phenyl}-thiophene-2-carboxylic acid",12.0,uM,=,1.0791812460476249,1,O=C1N(c2ccc(-c3cccs3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
3556,794861,10.1016/j.bmcl.2011.11.075,,,,Inhibition of human ERG by patch-clamp assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)CC3CCOCC3)cc2)cc1,(R)-2-Methyl-1-{2-[4'-(tetrahydro-pyran-4-ylmethanesulfonyl)-biphenyl-4-yl]-ethyl}-pyrrolidine,3.1,uM,=,0.4913616938342727,1,O=S(=O)(CC1CCOCC1)c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
3557,1858719,10.1021/acs.jmedchem.0c00117,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell electrophysiology assay,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,"4-{4-[4-((E)-2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-pyrimidin-2-ylamino}-benzonitrile",0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
3558,2125085,10.1021/acsmedchemlett.1c00450,,,,Inhibition of human ERG expressed in CHO cells by manual patch clamp assay,COC(=O)NC12CCC(n3cc(-c4cc(N)c(Cl)cc4F)c4c(N)ncnc43)(CC1)CC2,"methyl 4-(4-amino-5-(5-amino-4-chloro-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octan-1-ylcarbamate",6.0,uM,=,0.7781512503836436,1,c1ccc(-c2cn(C34CCC(CC3)CC4)c3ncncc23)cc1
3559,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(CC1CCN(Cc2ccc(-c3ccc(Cl)cc3)o2)CC1)NCC(O)C(F)(F)F,"2-(1-((5-(4-chlorophenyl)furan-2-yl)methyl)piperidin-4-yl)-N-(3,3,3-trifluoro-2-hydroxypropyl)acetamide",1.02,uM,=,0.0086001717619175,1,c1ccc(-c2ccc(CN3CCCCC3)o2)cc1
3560,1985700,10.1021/acsmedchemlett.0c00109,,,,Inhibition of human ERG,COc1cc(N2C[C@H]3CC[C@@H](C2)[C@@H]3Nc2nc3n(n2)CCCCC3c2ccc(F)c(F)c2F)ncn1,"rac-N-((1R,5S,8s)-3-(6-methoxypyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[1,5-a]azepin-2-amine",0.55,uM,=,-0.2596373105057561,0,c1ccc(C2CCCCn3nc(N[C@@H]4[C@@H]5CC[C@H]4CN(c4ccncn4)C5)nc32)cc1
3561,1498164,10.1021/ml500514w,,,,Inhibition of human ERG by Patchexpress patch clamp assay,Cc1nc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"3-((1R,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,2,4-oxadiazole",3.4,uM,=,0.5314789170422551,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)cc1
3562,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,CCN(CC)Cc1ccc(-c2ccc3ncc(-c4ccc(S(C)(=O)=O)cc4)n3n2)cc1F,"N-ethyl-N-(2-fluoro-4-(3-(4-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)benzyl)ethanamine",5.2,uM,=,0.7160033436347992,1,c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1
3563,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1.Cl.Cl,N-(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide dihydrochloride,0.0181,uM,=,-1.7423214251308154,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
3564,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one",0.26,uM,=,-0.585026652029182,0,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2
3565,2048454,10.1016/j.bmc.2020.115734,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,CCn1nc(C(F)(F)F)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(OC)n2)cs1,N-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine,18.9,uM,=,1.276461804173244,1,c1cn(-c2ccc(-c3csc(Nc4ccn[nH]4)n3)nc2)cn1
3566,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,C[C@@H]1CN(c2nnc(C(F)(F)F)o2)CCN1c1ncc(OCc2ccc(C#N)cc2C#N)cn1,"4-{[(2-{(2R)-2-Methyl-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-piperazin-1-yl}pyrimidin-5-yl)oxy]methyl}benzene-1,3-dicarbonitrile",3.6,uM,=,0.5563025007672873,1,c1ccc(COc2cnc(N3CCN(c4nnco4)CC3)nc2)cc1
3567,1924512,10.1021/acsmedchemlett.6b00122,,,,Displacement of [35S]MK-499 from human ERG,Cc1c(C(O)CN2CCN(CC(O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,"5,5'-(2,2'-(piperazine-1,4-diyl)bis(1-hydroxyethane-2,1-diyl))bis(4-methylisobenzofuran-1(3H)-one)",23.0,uM,=,1.3617278360175928,1,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21
3568,2084088,,,,,Inhibition of human ERG,CC(=O)N1CCc2nc(N3CCC(Oc4ccc(F)cc4F)CC3)c(N[C@@H]3CCOC3)nc2C1,"(R)-1-(2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-((tetrahydrofuran-3-yl)amino)-7,8-dihydropyrido[3,4-b]pyrazin-6(5H)-yl)ethan-1-one",1.97,uM,=,0.2944662261615929,1,c1ccc(OC2CCN(c3nc4c(nc3N[C@@H]3CCOC3)CNCC4)CC2)cc1
3569,1809217,10.1021/acsmedchemlett.9b00204,,,,Inhibition of human ERG,CC(C)c1ccc(-c2cc(CN3CC[Si](C)(C)CC3)nn2-c2ccc(F)cc2)cc1,"1-((1-(4-Fluorophenyl)-5-(4-isopropylphenyl)-1H-pyrazol-3-yl)methyl)-4,4-dimethyl-1,4-azasilinane",2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cc(CN3CC[SiH2]CC3)nn2-c2ccccc2)cc1
3570,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(S(=O)(=O)C(F)(F)F)cc3)ccc2n1)N1CCNCC1,"US9452986, 215",4.27,uM,=,0.6304278750250238,1,O=C(c1ccc2cc(Oc3ccccc3)ccc2n1)N1CCNCC1
3571,1972154,10.1021/acs.jmedchem.9b01624,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,O=C(Nc1cc(-c2cn(-c3ccccc3)c3cnccc23)ccn1)NC1CC1,"1-Cyclopropyl-3-(4-(1-phenyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)urea",1.2,uM,=,0.0791812460476248,1,O=C(Nc1cc(-c2cn(-c3ccccc3)c3cnccc23)ccn1)NC1CC1
3572,1543580,10.1016/j.bmcl.2015.11.030,,,,Inhibition of human ERG by IKr binding assay,CC1(C)CC2(CCN(C(=O)c3ccc(C[C@@H]4CC[C@H]([C@H](O)c5ccccc5)N4)cc3)CC2)C(=O)O1,"8-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)benzoyl)-3,3-dimethyl-2-oxa-8-azaspiro[4.5]decan-1-one",31.0,uM,=,1.4913616938342726,1,O=C(c1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)N1CCC2(CCOC2=O)CC1
3573,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)cn4)C[C@H]3CO2)ccc(F)c1C#N,"3-((3R,9aS)-8-(2-(5-(1H-tetrazol-1-yl)pyridin-2-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-6-fluoro-2-methylbenzonitrile",20.3,uM,=,1.307496037913213,1,O=C(Cc1ccc(-n2cnnn2)cn1)N1CCN2C[C@@H](c3ccccc3)OC[C@@H]2C1
3574,2246303,10.1021/acs.jmedchem.1c01670,,,,Inhibition of MK-499 binding to hERG,CC(C)(O)c1cc(C(F)(F)F)ncc1-c1ccc(C2(C(=O)Nc3ccc(F)cc3)COC2)cc1,N-(4-Fluorophenyl)-3-(4-(4-(2-hydroxypropan-2-yl)-6-(trifluoromethyl)pyridin-3-yl)phenyl)oxetane-3-carboxamide,21310.0,uM,=,4.328583449714202,1,O=C(Nc1ccccc1)C1(c2ccc(-c3cccnc3)cc2)COC1
3575,2048454,10.1016/j.bmc.2020.115734,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,COc1nc(-c2csc(Nc3c4c(nn3CCO)CCCC4)n2)ccc1-n1cnc(C)c1,"2-(3-((4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-yl)amino)-4,5,6,7-tetrahydro-2H-indazol-2-yl)ethanol",2.63,uM,=,0.4199557484897578,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCC5)n3)nc2)cn1
3576,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1cccc(F)c1,N-((1-(4-benzylpiperazin-1-yl)cyclopropyl)methyl)-N-(3-fluorophenyl)propionamide,1.2,uM,=,0.0791812460476248,1,c1ccc(CN2CCN(C3(CNc4ccccc4)CC3)CC2)cc1
3577,1292641,10.1021/jm401760c,,,,Binding affinity to full length human ERG expressed in CHO cells after 6 to 7 mins by IonWorks assay,CNc1nc(NCCCN(C)C)c2sc(-c3ccccc3)cc2n1,"N4-[3-(Dimethylamino)propyl]-N2-methyl-6-phenylthieno[3,2-d]-pyrimidine-2,4-diamine",8.5,uM,=,0.9294189257142929,1,c1ccc(-c2cc3ncncc3s2)cc1
3578,1792104,10.1016/j.bmcl.2018.09.018,,,,Inhibition of human ERG,C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4CCOCC4)nc3)n2)C1,(S)-6-(3-acrylamidopyrrolidin-1-yl)-2-(6-morpholinopyridin-3-ylamino)nicotinamide,1.5,uM,=,0.1760912590556812,1,c1cc(Nc2ccc(N3CCOCC3)nc2)nc(N2CCCC2)c1
3579,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCOC(=O)Nc1ccc([C@@H](c2ccc(C(=O)N(CC)CC)cc2)N2CCN(Cc3cscn3)CC2)cc1,(R)-ethyl 4-((4-(diethylcarbamoyl)phenyl)(4-(thiazol-4-ylmethyl)piperazin-1-yl)methyl)phenylcarbamate,7.3,uM,=,0.8633228601204559,1,c1ccc(C(c2ccccc2)N2CCN(Cc3cscn3)CC2)cc1
3580,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CN(c1ccc(-c2cc3ccccc3cc2O)nn1)C1CC(C)(C)NC(C)(C)C1,"3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)naphthalen-2-ol",0.08,uM,=,-1.0969100130080565,0,c1ccc2cc(-c3ccc(NC4CCNCC4)nn3)ccc2c1
3581,789985,10.1016/j.bmcl.2011.10.013,,,,Inhibition of human ERG,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)C2CC2)cc(OCCOC)c1,"rac-(3S,4R)-N-cyclopropyl-4-(3,4-difluorophenyl)-4-hydroxy-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)piperidine-3-carboxamide",4.5,uM,=,0.6532125137753437,1,O=C([C@H]1CNCCC1c1ccccc1)N(Cc1ccccc1)C1CC1
3582,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1F,"6-((1-(2-(3,7-difluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00073,uM,=,-3.136677139879544,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3583,1329251,10.1039/C1MD00164G,,,,Inhibition of human ERG by [3H]dofetilide binding assay,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CCCC3(O)CCCCC3)C[C@@H]21,"N-(3-((1R,5S)-6-ethyl-3-(3-(1-hydroxycyclohexyl)propyl)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)methanesulfonamide",0.71,uM,=,-0.1487416512809247,0,c1ccc(C2[C@H]3CN(CCCC4CCCCC4)C[C@@H]23)cc1
3584,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,Fc1ccc(-c2nc(N3CCCC3)sc2-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,"4-[4-(4-Fluorophenyl)-2-(pyrrolidin-1-yl)-1,3-thiazol-5-yl]-N-[4-(piperazin-1-yl)phenyl]pyrimidin-2-amine",5.6,uM,=,0.7481880270062004,1,c1ccc(-c2nc(N3CCCC3)sc2-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3585,1348027,10.1021/jm5004599,,,,Inhibition of human ERG by whole-cell voltage clamp assay,COc1ccc(NC(=O)N2CCNC[C@@H]2COc2cccnc2)cc1.Cl,(R)-N-(4-Methoxyphenyl)-2-((pyridin-3-yloxy)methyl)piperazine-1-carboxamide Dihydrochloride,31.0,uM,=,1.4913616938342726,1,O=C(Nc1ccccc1)N1CCNC[C@@H]1COc1cccnc1
3586,978839,10.1021/jm400915j,,,,Inhibition of human ERG expressed in cisapride treated CHO cells by Ion Works assay,O=c1cc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12,8-Dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one,14.0,uM,=,1.146128035678238,1,O=c1cc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12
3587,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,COc1ccc(-n2nc(C(C)=O)s/c2=N\c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)cc1,"2-((5-Acetyl-3-(4-methoxyphenyl)-1,3,4-thiadiazol-2(3H)-ylidene)amino)-4,6-diphenyl-nicotinonitrile",17.6,uM,=,1.24551266781415,1,c1ccc(-c2cc(/N=c3\scnn3-c3ccccc3)nc(-c3ccccc3)c2)cc1
3588,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,COC(=O)N(C)c1c(N)nc(-n2nc(Cc3ccccc3F)c3cc(C#N)ccc32)nc1N,"methyl N-[4,6-diamino-2-[5-cyano-3-[(2-fluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methyl-carbamate",7.4,uM,=,0.8692317197309762,1,c1ccc(Cc2nn(-c3ncccn3)c3ccccc23)cc1
3589,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,COCCOc1cc(NC(=O)N2CCCc3cc(CN4CC[C@H](N(C)C)C4=O)c(C=O)nc32)ncc1C#N,"(S)-N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-6-((3-(dimethylamino)-2-oxopyrrolidin-1-yl)methyl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide",18.0,uM,=,1.255272505103306,1,O=C1CCCN1Cc1cnc2c(c1)CCCN2C(=O)Nc1ccccn1
3590,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc(C(F)(F)F)c(F)c1)Cc1ccc2c(c1)OCCC2.Cl,(E)-N-(Chroman-7-methyl)-N-methyl-3-(3-fluoro-4-trifluoromethylphenyl)prop2-en-1-amine Hydrochloride,0.2,uM,=,-0.6989700043360187,0,C(=C/c1ccccc1)\CNCc1ccc2c(c1)OCCC2
3591,831501,10.1021/np3000987,,,,Inhibition of human ERG expressed in HEK293 cells coexpressing Kir2.3 after 30 mins by FluxOR based FLIPR assay,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),0.23,uM,=,-0.6382721639824072,0,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1
3592,49075,10.1021/jm0208875,,,,K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.1,CN(C)CCCN1c2ccccc2CCc2ccccc21,"[3-(10,11-Dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-dimethyl-amine",3.4,uM,=,0.5314789170422551,1,c1ccc2c(c1)CCc1ccccc1N2
3593,1783291,10.1016/j.ejmech.2017.12.099,,,,Inhibition of human ERG by auomated patch clamp assay,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1CCCCN1CCN(c2cccc3sccc23)CC1,"(3aR,4S,7R,7aS)-2-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione",7.52,uM,=,0.8762178405916422,1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1CCCCN1CCN(c2cccc3sccc23)CC1
3594,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2ncc(F)c([C@@H](O)CC[C@@H]3CCN(C4CC(c5cccc(F)c5F)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-1-(3-(2,3-difluorophenyl)cyclobutyl)-4-((S)-3-(3-fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl)piperidine-3-carboxylic acid",25.0,uM,=,1.3979400086720375,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
3595,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(O)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-hydroxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00483,uM,=,-2.316052869248488,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3596,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(F)ccc1Oc1ccc(F)c(Cl)c1,1-(2-(3-chloro-4-fluorophenoxy)-5-fluorophenyl)-N-methylmethanamine,8.29,uM,=,0.9185545305502736,1,c1ccc(Oc2ccccc2)cc1
3597,2133680,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG expressed in CHO by QPatch assay,CC[C@@H](NC(=O)c1ccc(C#N)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-cyano-N-((R)-1-((1R,3S,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",1.4,uM,=,0.1461280356782379,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
3598,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)NC3CCC3)cc2)cc1,(4'-[2-((R)-2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic Acid Cyclobutylamide,0.75,uM,=,-0.1249387366082999,0,O=S(=O)(NC1CCC1)c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
3599,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,O=C(CNc1ncnc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@](O)(c3ccns3)CC2)C1,Cis-N-(1-(4-hydroxy-4-(isothiazol-5-yl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,28.4,uM,=,1.4533183400470375,1,O=C(CNc1ncnc2ccccc12)NC1CN(C2CCC(c3ccns3)CC2)C1
3600,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CN(c1ccc(-c2ccc(-c3cn[nH]c3)cc2O)nn1)C1CC(C)(C)NC(C)(C)C1,"2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol",6.0,uM,=,0.7781512503836436,1,c1cc(-c2ccc(NC3CCNCC3)nn2)ccc1-c1cn[nH]c1
3601,2079116,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 10 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),O=C(COc1ccc(C(=O)c2cc(Cl)ccc2Br)cc1)Nc1cccc(C(=O)NCC2CC2)c1,3-(2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)acetamido)-N-(cyclopropylmethyl)benzamide,0.026,uM,=,-1.585026652029182,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1cccc(C(=O)NCC2CC2)c1
3602,612186,10.1016/j.bmcl.2009.12.071,,,,Inhibition of human ERG by patch clamp study,Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@H]2C[C@H]3CNC[C@H]3C2)c1,(exo)-1-methyl-N-(octahydrocyclopenta[c]pyrrol-5-yl)-N-(3-(trifluoromethoxy)benzyl)-1H-imidazole-4-carboxamide,13.2,uM,=,1.1205739312058498,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)[C@H]1C[C@H]2CNC[C@H]2C1
3603,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,Cc1cc(C(N)=O)ccc1O[C@H]1C[C@H]2CC[C@@H](C1)N2Cc1ccccc1,"endo-4-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)-3-methylbenzamide",1.0,uM,=,0.0,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccc2)C3)cc1
3604,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(C(C)C)C1=O,"4-isopropyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",3.9,uM,=,0.5910646070264992,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1
3605,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C)cc(-c2cncc(-c3nc4cc(F)ccc4[nH]3)c2N2CCC(N)CC2)c1,"1-(3-(3,5-dimethylphenyl)-5-(5-fluoro-1H-benzo[d]imidazol-2-yl)pyridin-4-yl)piperidin-4-amine",3.7,uM,=,0.568201724066995,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
3606,948139,10.1016/j.bmcl.2013.01.019,,,,Inhibition of human ERG,COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CC[C@@H](O)C4)nc3n2)cc1CO,"(R)-1-(7-(3-(hydroxymethyl)-4-methoxyphenyl)-4-((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-2-yl)pyrrolidin-3-ol",8.0,uM,=,0.9030899869919436,1,c1ccc(-c2ccc3c(N4CCOCC4)nc(N4CCCC4)nc3n2)cc1
3607,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CCn1cc(C2(c3cccc(-c4cncnc4)c3)N=C(N)c3c(F)cccc32)cc(C)c1=O,5-(3-Amino-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-1-yl)-1-ethyl-3-methylpyridin-2(1H)-one,15.0,uM,=,1.1760912590556811,1,O=c1ccc(C2(c3cccc(-c4cncnc4)c3)N=Cc3ccccc32)c[nH]1
3608,1622890,10.1021/acsmedchemlett.6b00433,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes after 90 mins by scintillation counting,FC(F)Oc1cc(-c2cnn(Cc3cn[nH]c3)c2)ccc1Cl,1-((1H-pyrazol-4-yl)methyl)-4-(4-chloro-3-(difluoromethoxy)phenyl)-1H-pyrazole,52.6,uM,=,1.720985744153739,1,c1ccc(-c2cnn(Cc3cn[nH]c3)c2)cc1
3609,793464,10.1016/j.bmcl.2011.09.114,,,,Inhibition of human ERG by whole cell patch clamp assay,COc1ccc2nccc(NC(=O)[C@H]3CC[C@H](NCc4ccc5c(c4)OCCO5)CC3)c2c1,"4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)-N-(6-methoxyquinolin-4-yl)cyclohexanecarboxamide",25.0,uM,=,1.3979400086720375,1,O=C(Nc1ccnc2ccccc12)[C@H]1CC[C@H](NCc2ccc3c(c2)OCCO3)CC1
3610,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(C)C)C2=O,"2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-6-isopropyl-7,8-dihydro-1,6-naphthyridin-5(6H)-one",4.4,uM,=,0.6434526764861874,1,O=C1NCCc2nc(OCc3conc3-c3ccccc3)ccc21
3611,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,Nc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1,"4-[2-Amino-4-(4-fluorophenyl)-1,3-thiazol-5-yl]-N-[4-(piperazin-1-yl)phenyl]pyrimidin-2-amine",35.5,uM,=,1.5502283530550942,1,c1ccc(-c2ncsc2-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3612,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2cc(C)c(=O)n(C)n2)C3=O)ccc2c1COC2=O,"(R)-2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-3-yl)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one",2.7,uM,=,0.4313637641589873,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccc(=O)[nH]n3)C4=O)ccc21
3613,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(C(F)(F)F)cc1Oc1ccc(Cl)cc1,1-(2-(4-chlorophenoxy)-4-(trifluoromethyl)phenyl)-N-methylmethanamine,5.11,uM,=,0.7084209001347128,1,c1ccc(Oc2ccccc2)cc1
3614,1988642,10.1021/acs.jmedchem.0c00909,,,,Inhibition of human ERG,Cc1noc(N2C[C@H]3CC[C@@H](C2)[C@@H]3Nc2nc3c(OCC(F)(F)F)ccc(C(F)(F)F)n3n2)n1,"N-[(1R,5S,8r)-3-(3-Methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl]-8-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine",8.75,uM,=,0.9420080530223132,1,c1ccn2nc(N[C@@H]3[C@@H]4CC[C@H]3CN(c3ncno3)C4)nc2c1
3615,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1[nH]nc(C(=O)N[C@@H]2CC(C)(C)Oc3nc(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)cc32)c1C,"N-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-4,5-dimethyl-1H-pyrazole-3-carboxamide",8.7,uM,=,0.9395192526186184,1,O=C(N[C@@H]1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)c1cc[nH]n1
3616,1473874,10.1021/jm5018863,,,,Inhibition of human ERG expressed in CHO cells by automated Qpatch clamp assay,NC(=O)c1nnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc(-n2nccn2)c1,"5-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-3-((1R,2S)-2-aminocyclohexylamino)-1,2,4-triazine-6-carboxamide",3.7,uM,=,0.568201724066995,1,c1cc(Nc2cnnc(NC3CCCCC3)n2)cc(-n2nccn2)c1
3617,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,O=C(/C=C/c1ccc(CN2CCCC(c3c[nH]c4ccccc34)C2)cc1)NO,(E)-N-Hydroxy-3-{4-[3-(1H-indol-3-yl)piperidin-1-ylmethyl]-phenyl}acrylamide,29.3,uM,=,1.4668676203541096,1,c1ccc(CN2CCCC(c3c[nH]c4ccccc34)C2)cc1
3618,581929,10.1016/j.bmcl.2009.06.011,,,,Inhibition of human ERG,CS(=O)(=O)c1ccc2c(c1)nc1n2C[C@H](N)[C@@H](c2cc(F)c(F)cc2F)C1.O=C(O)C(F)(F)F,"Trifluoro-acetate(2R,3R)-7-methanesulfonyl-3-(2,4,5-trifluoro-phenyl)-1,2,3,4-tetrahydro-benzo[4,5]imidazo[1,2-a]pyridin-2-yl-ammonium",38.0,uM,=,1.57978359661681,1,c1ccc([C@@H]2CCn3c(nc4ccccc43)C2)cc1
3619,1275662,10.1021/jm400856t,,,,Inhibition of human ERG,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),0.01,uM,=,-2.0,0,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1
3620,1522961,10.1016/j.bmcl.2015.04.057,,,,Inhibition of human ERG,COc1cc2nc([C@@H](CNC(=O)c3c(Cl)cc(-n4cnc(C)n4)cc3Cl)c3cccc(F)c3)[nH]c2cc1Cl,"(R)-2,6-dichloro-N-(2-(6-chloro-5-methoxy-1H-benzo[d]imidazol-2-yl)-2-(3-fluorophenyl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",10.93,uM,=,1.0386201619497029,1,O=C(NC[C@@H](c1ccccc1)c1nc2ccccc2[nH]1)c1ccc(-n2cncn2)cc1
3621,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(CNC(=O)c2cnccn2)c1,N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methyl)pyrazine-2-carboxamide,7.11,uM,=,0.8518696007297664,1,O=C(NCc1cncc(-c2ccccc2)c1)c1cnccn1
3622,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(C3CCCC3)n2)(c2ccc(F)cc2)CC1,2-cyclopentyl-6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,12.0,uM,=,1.0791812460476249,1,c1ccc(C2(COCc3cccc(C4CCCC4)n3)CCNCC2)cc1
3623,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cnc(-c2cnc(O[C@H]3CCN(C(=O)Cc4ccc(OC(F)(F)F)cc4)C[C@H]3F)c(C(N)=O)c2)c1,"2-(((3R,4S)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)-piperidin-4-yl)oxy)-5-(1-methyl-1H-imidazol-4-yl)nicotinamide",14.0,uM,=,1.146128035678238,1,O=C(Cc1ccccc1)N1CCC(Oc2ccc(-c3c[nH]cn3)cn2)CC1
3624,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,CCOc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2F)cc(OCC)n1,"(1S,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-2-(2,6-diethoxypyridin-4-yl)-4-(dimethylamino)-1-(2-fluoro-3-methoxyphenyl)butan-2-ol",10.0,uM,=,1.0,1,c1ccc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)cc1
3625,948139,10.1016/j.bmcl.2013.01.019,,,,Inhibition of human ERG,CNCc1cccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@@H](C)O[C@@H](C)C4)nc3n2)c1,"1-(3-(2-((2R,6S)-2,6-dimethylmorpholino)-4-morpholinopyrido[2,3-d]pyrimidin-7-yl)phenyl)-N-methylmethanamine",17.4,uM,=,1.2405492482825995,1,c1ccc(-c2ccc3c(N4CCOCC4)nc(N4CCOCC4)nc3n2)cc1
3626,1682731,10.1021/acs.jmedchem.7b01135,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cell membranes,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccc(OC(F)F)cc2)n1,"1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-3-(4-(difluoromethoxy)phenylamino)-1H-pyrazole-4-carboxamide",25.0,uM,=,1.3979400086720375,1,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1
3627,1871838,10.1016/j.bmcl.2018.12.015,,,,Inhibition of human ERG,COCCC#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1,"(S)-3,4-dichloro-2-(4-methoxybut-1-ynyl)-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",0.003,uM,=,-2.5228787452803374,0,c1cnc2c(c1)ccn2[C@H]1CCCNC1
3628,2188217,10.1021/acs.jmedchem.2c00981,,,,Inhibition of hERG expressed in HEK293 cells by whole-cell patch clamp technique,O=C1NCCCCn2cc(cn2)-c2cnc3ccc(cc3c2)CCn2nc(ccc2=O)-c2ccc1c(C(F)(F)F)c2,"6(3)-(trifluoromethyl)-5(1),5(6)-dihydro-1(1)H-8-aza-2(3,6)-quinolina-5(1,3)-pyridazina-1(4,1)-pyrazola-6(1,4)-benzenacyclododecaphane-5(6),7-dione",27.72,uM,=,1.442793225939769,1,O=C1NCCCCn2cc(cn2)-c2cnc3ccc(cc3c2)CCn2nc(ccc2=O)-c2ccc1cc2
3629,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc(Br)cc1)Cc1ccc2c(c1)OCCC2.Cl,(E)-N-(Chroman-7-methyl)-N-methyl-3-(4-bromorphenyl)prop-2-en-1-amine Hydrochloride,1.9,uM,=,0.2787536009528289,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)OCCC2
3630,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H](C3CNC3)O2)cc1,"(5R)-5-(azetidin-3-yl)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-4,5-dihydrooxazole",6.2,uM,=,0.7923916894982539,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H](C3CNC3)O2)cc1
3631,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)CN3C(=O)Cc4ccccc43)[C@H](C)C2)cn1,"1-(2-{(R)-4-(4-(2-Ethoxy-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-2-oxo-ethyl)-1,3-dihydro-indol-2-one",3.0,uM,=,0.4771212547196624,1,O=C(CN1C(=O)Cc2ccccc21)N1CCN(c2scnc2-c2cncnc2)CC1
3632,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,O=C1CN(CCc2ccc(F)cc2)CCN1[C@H]1CCc2cc(CN3CCC(C(F)(F)F)CC3)ccc2C1,"(S)-4-(4-fluorophenethyl)-1-(6-((4-(trifluoromethyl)piperidin-1-yl)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)piperazin-2-one",2.0,uM,=,0.3010299956639812,1,O=C1CN(CCc2ccccc2)CCN1[C@H]1CCc2cc(CN3CCCCC3)ccc2C1
3633,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,Nc1cccnc1[C@H]1CC[C@@H](N2CC(NC(=O)CNc3ncnc4ccc(C(F)(F)F)cc34)C2)CC1,Cis-N-(1-(4-(3-aminopyridin-2-yl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,8.3,uM,=,0.919078092376074,1,O=C(CNc1ncnc2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccccn3)CC2)C1
3634,762537,10.1016/j.bmcl.2011.06.017,,,,Inhibition of human ERG expressed in HEK293 cells assessed as inhibition of potassium channel current after 5 mins by patch clamp assay,CCc1c(C(=O)NC(C)(C)c2nnnn2C)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Br)cc1,"5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(2-(1-methyl-1H-tetrazol-5-yl)propan-2-yl)-1H-pyrazole-3-carboxamide",22.7,uM,=,1.3560258571931227,1,O=C(NCc1nnn[nH]1)c1cc(-c2ccccc2)n(-c2ccccc2)n1
3635,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CN(CCC(=O)N1CCCC1)C(=O)CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,N-methyl-N-(3-oxo-3-(pyrrolidin-1-yl)propyl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,28.0,uM,=,1.4471580313422192,1,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NCCC(=O)N1CCCC1
3636,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,COc1nc2ccc(Cl)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,1-(6-chloro-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol,6.9,uM,=,0.8388490907372553,1,c1ccc(C(Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
3637,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CC1(C)CC(Nc2ccc(-c3cc4ccccc4s3)nn2)CC(C)(C)N1,"6-(benzo[b]thiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine",0.6,uM,=,-0.2218487496163563,0,c1ccc2sc(-c3ccc(NC4CCNCC4)nn3)cc2c1
3638,513541,10.1016/j.bmcl.2008.06.078,,,,Inhibition of human ERG potassium channel,CC(C)C(=O)N(Cc1ccc(Cl)cc1Cl)[C@H]1CCNC1,"(S)-N-(2,4-dichlorobenzyl)-N-(pyrrolidin-3-yl)isobutyramide",40.2,uM,=,1.60422605308447,1,c1ccc(CN[C@H]2CCNC2)cc1
3639,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,C[C@@H]1CCCN1C(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1,"6-(4-{[(2R)-2-Methylpyrrolidin-1-yl]carbonyl}phenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one",10.5,uM,=,1.021189299069938,1,O=C(c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1)N1CCCC1
3640,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2cnsn2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(1,2,5-thiadiazol-3-yl)-2,8-diazaspiro[4.5]decan-1-one",6.1,uM,=,0.785329835010767,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cnsn3)C4=O)ccc21
3641,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,Nc1ccncc1,Pyridin-4-ylamine,4400.0,uM,=,3.643452676486187,1,c1ccncc1
3642,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3C2(c3ccccc3)CC2)c1,endo-3-(8-(1-phenylcyclopropyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0048,uM,=,-2.318758762624413,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3C2(c3ccccc3)CC2)cc1
3643,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(F)cc2)CC1,"US9145392, 68",1.2,uM,=,0.0791812460476248,1,c1ccc(-c2c[nH]c(C3CCN(c4ncncc4-c4ccccc4)CC3)n2)cc1
3644,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4c(ccc(Br)c4F)N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"7-bromo-6-fluoro-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",0.53,uM,=,-0.2757241303992109,0,O=C1Nc2ccccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
3645,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,CC(=O)c1nn(-c2ccc(C)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1,"2-((5-Acetyl-3-(p-tolyl)-1,3,4-thiadiazol-2(3H)-ylidene)amino)-4,6-diphenylnicotinonitrile",28.7,uM,=,1.4578818967339924,1,c1ccc(-c2cc(/N=c3\scnn3-c3ccccc3)nc(-c3ccccc3)c2)cc1
3646,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,C[C@H](Nc1c(C(N)=O)cnc2ccc(-c3cccnc3)cc12)C1CCOCC1,6-(3-Pyridinyl)-4-{[(1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide,3.6,uM,=,0.5563025007672873,1,c1cncc(-c2ccc3nccc(NCC4CCOCC4)c3c2)c1
3647,945538,10.1016/j.bmcl.2012.10.140,,,,Inhibition of human ERG expressed in CHO cells by IONWORKS assay,CC(C)(C)NC(=O)NCCN1CCC(NC(=O)c2cc(Cl)cc(Cl)c2)C1,"N-(1-(2-(3-tert-butylureido)ethyl)pyrrolidin-3-yl)-3,5-dichlorobenzamide",6.6,uM,=,0.8195439355418687,1,O=C(NC1CCNC1)c1ccccc1
3648,487847,10.1021/jm800386y,,,,Displacement of [35S]MK499 from human ERG expressed in HEL cells,CN1CC[C@H](N(C)C(=O)N2CC(c3cc(F)ccc3F)=C[C@@]2(CO)c2ccccc2)[C@@H](F)C1,"(S)-4-(2,5-difluorophenyl)-N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)-2-(hydroxymethyl)-N-methyl-2-phenyl-2H-pyrrole-1(5H)-carboxamide",36.9,uM,=,1.5670263661590604,1,O=C(NC1CCNCC1)N1CC(c2ccccc2)=CC1c1ccccc1
3649,378763,10.1016/j.bmcl.2006.05.058,,,,Inhibition of hERG potassium channel expressed in CHO cells by whole cell patch clamp method,O=C1NC[C@@H](c2ccccc2)C12CCN(C1CCCCC1c1ccccc1)CC2,"4-phenyl-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one",1.4,uM,=,0.1461280356782379,1,O=C1NC[C@@H](c2ccccc2)C12CCN(C1CCCCC1c1ccccc1)CC2
3650,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1c(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)sc2ncnn12,"(R)-6-methyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)thiazolo[3,2-b][1,2,4]triazole",2.8,uM,=,0.4471580313422192,1,c1nc2sc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cn2n1
3651,2153540,10.1021/acs.jmedchem.1c01586,,,,Inhibition of human ERG by thallium flux assay,CNC(=O)c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CCC3)c12,4-(azetidin-1-ylmethyl)-5-hydroxy-2-(4-hydroxyphenyl)-N-methylbenzofuran-3-carboxamide,11.0,uM,=,1.0413926851582251,1,c1ccc(-c2cc3c(CN4CCC4)cccc3o2)cc1
3652,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cnc(-c2cnc(O[C@@H]3CCN(C(=O)Cc4ccc(OC(F)(F)F)cc4)C[C@H]3F)c(C(N)=O)c2)c1,"2-(((3R,4R)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)-piperidin-4-yl)oxy)-5-(1-methyl-1H-imidazol-4-yl)nicotinamide",7.0,uM,=,0.8450980400142568,1,O=C(Cc1ccccc1)N1CCC(Oc2ccc(-c3c[nH]cn3)cn2)CC1
3653,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)CCN1CCC(CNC(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1,"N-{[1-(3,3-dimethylbutyl)piperidin-4-yl]methyl}-3,5-bis(trifluoromethyl)benzamide",1.799,uM,=,0.2550311633455513,1,O=C(NCC1CCNCC1)c1ccccc1
3654,2079116,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 10 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),N#Cc1cc(NC(=O)COc2ccc(C(=O)c3cc(Cl)ccc3Br)cc2)ccc1F,2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)-N-(3-cyano-4-fluorophenyl)acetamide,0.0695,uM,=,-1.158015195409886,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1ccccc1
3655,501618,10.1021/jm8016199,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,COc1cc(-n2ccnc(CCCc3ccccc3)c2=O)ccc1OCCN1CCCC1,1-[3-Methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-3-(3-phenylpropyl)-1H-pyrazin-2-one,7.3,uM,=,0.8633228601204559,1,O=c1c(CCCc2ccccc2)nccn1-c1ccc(OCCN2CCCC2)cc1
3656,1973422,10.1021/acs.jmedchem.0c00168,,,,Inhibition of human ERG,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",0.4,uM,=,-0.3979400086720376,0,c1ccc(CCCCNCCc2ccccc2)cc1
3657,1788652,10.1021/acs.jmedchem.8b00794,,,,Inhibition of human ERG expressed in HEK293 cells by manual patch clamp assay,Cc1cc(-c2ccc3c(c2)CC[C@H]3N2CCC(N(C)C(=O)N[C@@H](C)c3ccc(C#CC4CC4)c(Cl)c3Cl)CC2)ncn1,"3-((S)-1-(2,3-dichloro-4-(cyclopropylethynyl)phenyl)ethyl)-1-methyl-1-(1-((R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)piperidin-4-yl)urea",3.16,uM,=,0.4996870826184038,1,O=C(NCc1ccc(C#CC2CC2)cc1)NC1CCN([C@@H]2CCc3cc(-c4ccncn4)ccc32)CC1
3658,1455475,10.1016/j.bmcl.2014.06.026,,,,Inhibition of human ERG expressed in CHO-K1 cells by patch-clamp electrophysiology method,Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl,3-(2-(4-chloro-3-fluorophenyl)-2-(2-fluorophenoxy)ethyl)azetidine,1.41,uM,=,0.1492191126553798,1,c1ccc(OC(CC2CNC2)c2ccccc2)cc1
3659,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CCCC1,"US9452986, 10",30.0,uM,=,1.4771212547196624,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCCC1
3660,345010,10.1016/j.bmcl.2005.12.094,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CN(C(=O)N1CC(c2cc(F)ccc2F)=CC1c1cccc(O)c1)C1CCNCC1,"rac-4-(2,5-difluorophenyl)-2-(3-hydroxyphenyl)-N-methyl-N-(piperidin-4-yl)-2H-pyrrole-1(5H)-carboxamide",6.6,uM,=,0.8195439355418687,1,O=C(NC1CCNCC1)N1CC(c2ccccc2)=CC1c1ccccc1
3661,1463729,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG by MK499 binding assay,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"6-((1-((3-fluoro-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",12.3,uM,=,1.089905111439398,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
3662,990152,10.1016/j.bmc.2013.08.041,,,,Inhibition of human ERG channel expressed in CHO cells by whole cell patch clamp technique,COC(=O)C(Cc1c[nH]c2ccccc12)NS(=O)(=O)c1ccc(OC2CCCC2)cc1,Methyl 2-(4-(cyclopentyloxy)phenylsulfonamido)-3-(1Hindol-3-yl)propanoate,9.56,uM,=,0.9804578922761,1,O=S(=O)(NCCc1c[nH]c2ccccc12)c1ccc(OC2CCCC2)cc1
3663,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,CC(=O)c1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1,N-[1-{4-[(4-aminopiperidin-1-yl)methyl]phenyl}ethanonyl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide,0.0203,uM,=,-1.692503962086787,0,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
3664,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cnc2ccc(-c3cccnc3)cc2c1NCC1CCOCC1,6-(3-Pyridinyl)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3-quinolinecarboxamide,2.3,uM,=,0.3617278360175928,1,c1cncc(-c2ccc3nccc(NCC4CCOCC4)c3c2)c1
3665,1558443,10.1016/j.bmc.2016.02.030,,,,Inhibition of human ERG channel tail current,CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,Eltrombopag,0.69,uM,=,-0.1611509092627447,0,O=C1/C(=N\Nc2cccc(-c3ccccc3)c2)C=NN1c1ccccc1
3666,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5Cl)OCC(=O)N6)(CC3)CO4)c2n1,"7-chloro-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",5.8,uM,=,0.7634279935629373,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3667,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@H]1CN(C)C[C@@H]1c1ccc(-c2ccc(F)nc2)cc1,"N-((3R,4R)-4-(4-(6-fluoropyridin-3-yl)phenyl)-1-methylpyrrolidin-3-yl)propane-2-sulfonamide",1.0,uM,=,0.0,0,c1cncc(-c2ccc([C@@H]3CCNC3)cc2)c1
3668,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCc3ccccc32)c1,"endo-3-(8-(1,2,3,4-tetrahydronaphthalen-1-yl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide",0.00095,uM,=,-3.0222763947111524,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCc3ccccc32)cc1
3669,611802,10.1021/jm9015075,,,,Inhibition of human ERG,Clc1cnc2oc(N3CCN4CCC3CC4)nc2c1,"2-(6-Chlorooxazolo[5,4-b]pyridin-2-yl)-2,5-diazabicyclo[3.2.2]-nonane",2.2,uM,=,0.3424226808222063,1,c1cnc2oc(N3CCN4CCC3CC4)nc2c1
3670,989740,10.1021/jm4010829,,,,Inhibition of human ERG channel expressed in HEK293 cells by whole-cell patch clamp technique,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1,[(3-Methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine,6.2,uM,=,0.7923916894982539,1,c1ccc([C@]2(CCNCc3cccs3)CCOC3(CCCC3)C2)nc1
3671,1471694,10.1016/j.ejmech.2015.03.054,,,,Inhibition of human ERG by patch clamp technique,C[C@H](COc1ccc(C2=NNC(=O)C3CC23)cc1)CN1CCC[C@H]1C,"(+/-)5-{4-[(S)-2-Methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one",8.0,uM,=,0.9030899869919436,1,O=C1NN=C(c2ccc(OCCCN3CCCC3)cc2)C2CC12
3672,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,COc1ccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)nc1,cis-N-({1-[4-Hydroxy-4-(5-methoxy-pyridin-2-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,25.0,uM,=,1.3979400086720375,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccccn3)CC2)C1
3673,2260412,10.1021/acs.jmedchem.0c01744,,,,Inhibition of hERG by fluorescence polarization assay,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,"3-Dibutylamino-1-(1,3-dichloro-6-trifluoromethyl-phenanthren-9-yl)-propan-1-ol",0.16,uM,=,-0.7958800173440752,0,c1ccc2c(c1)ccc1ccccc12
3674,2154547,10.1021/acs.jmedchem.0c02081,,,,Inhibition of human ERG,CC(=O)N1C=Cc2nc(N3CCC(Oc4ccc(F)cc4F)CC3)c(NC(C)C)nc2C1,"1-(2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-(isopropylamino)pyrido[3,4-b]pyrazin-6(5H)-yl)ethanone",6.2,uM,=,0.7923916894982539,1,C1=Cc2nc(N3CCC(Oc4ccccc4)CC3)cnc2CN1
3675,2159402,10.1021/acs.jmedchem.1c01968,,,,Inhibition of human ERG by voltage clamp assay,Clc1cc2cnc(Nc3cnn(C4CC4)c3Cl)nc2cc1C1CCN(C2COC2)CC1,6-chloro-N-(5-chloro-1-cyclopropyl-1H-pyrazol-4-yl)-7-(1-(oxetan-3-yl)piperidin-4-yl)quinazolin-2-amine,4.6,uM,=,0.6627578316815741,1,c1nn(C2CC2)cc1Nc1ncc2ccc(C3CCN(C4COC4)CC3)cc2n1
3676,2051795,10.1021/acs.jmedchem.6b00275,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1cc(NC2CCc3ccc(Br)cc3C2)n2nc(C(C)(F)F)nc2n1,"2-(1,1-Difluoroethyl)-N-(7-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",1.1,uM,=,0.041392685158225,1,c1ccc2c(c1)CCC(Nc1ccnc3ncnn13)C2
3677,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Nc1cnc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cn1,"5-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridin-6-yl)pyrazin-2-amine",40.0,uM,=,1.6020599913279625,1,c1cnc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cn1
3678,2120447,10.1016/j.ejmech.2021.113718,,,,Inhibition of human ERG,COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2,VALBENAZINE,1.7,uM,=,0.2304489213782739,1,c1ccc2c(c1)CCN1CCCC[C@H]21
3679,2129860,10.1021/acsmedchemlett.1c00328,,,,Inhibition of human ERG stably expressed in CHO-K1 cells at -90 mV holding potential by automated Q-patch clamp method,COc1ccc(CCNCCCNc2nc3ccccc3n2Cc2ccc(F)cc2)cc1,"N1-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)-N3-(4-methoxyphenethyl)propane-1,3-diamine",0.41,uM,=,-0.3872161432802645,0,c1ccc(CCNCCCNc2nc3ccccc3n2Cc2ccccc2)cc1
3680,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)c(Cl)c2)[C@@H]3C)n1,"US9422299, 6",45.0,uM,=,1.6532125137753435,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
3681,1663976,10.1021/acs.jmedchem.7b00140,,,,Inhibition of human ERG by fluorescence polarization assay,N/C(CC(O)c1cc2c(F)cc(F)cc2c2cc(C(F)(F)F)ccc12)=N\N=C\c1ccc(F)cc1,"(Z)-3-(1,3-Difluoro-6-(trifluoromethyl)phenanthren-9-yl)-N'-((E)-4-fluorobenzylidene)-3-hydroxypropanehydrazonamide",0.067,uM,=,-1.1739251972991736,0,C(CCc1cc2ccccc2c2ccccc12)=N/N=C/c1ccccc1
3682,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CCC(O)(CN)CC3)nn12,"4-(Aminomethyl)-1-(5-(4-fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-ol",18.5,uM,=,1.2671717284030135,1,c1ccc(-c2cnc3sc(N4CCCCC4)nn23)cc1
3683,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,CO[C@H]1CN(CCn2c(=O)ccc3ccc(C#N)cc32)CC[C@@H]1NCc1cc2c(cn1)OCCO2,"trans-1-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]-3-methoxypiperidin-1-yl}ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",176.0,uM,=,2.24551266781415,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
3684,726964,10.1016/j.bmcl.2011.01.019,,,,Inhibition of human ERG,CNC(C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1,"(+/-)-1-(1-(3,4-dichlorophenyl)cyclohexyl)-N-methylethanamine",23.0,uM,=,1.3617278360175928,1,c1ccc(C2CCCCC2)cc1
3685,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3cccc(C(F)(F)F)n3)ccc2n1)N1CCNCC1,"US9452986, 153",12.8,uM,=,1.1072099696478683,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
3686,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CCC(O)c1cn(-c2ccc(F)cc2)c2ccc(Cl)cc12,1-[5-Chloro-1-(4-fluoro-phenyl)-1H-indol-3-yl]-propan-1-ol,2.2,uM,=,0.3424226808222063,1,c1ccc(-n2ccc3ccccc32)cc1
3687,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ccc(Cl)cc3C2)C1,"(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)((2R,3aR,6aR)-2-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)methanone",42.4,uM,=,1.6273658565927327,1,O=C(N1CCc2ccccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
3688,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)CC3)ccc2c1COC2=O,"6-(9-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-3,9-diazaspiro[5.5]undecan-3-yl)-2-methylpyridazin-3(2H)-one",45.0,uM,=,1.6532125137753435,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccc(=O)[nH]n3)CC4)ccc21
3689,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(O)ncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1,"4-{5-[1-(6-Hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-pyridin-2-yl}-3-methyl-benzoic acid",20.0,uM,=,1.3010299956639813,1,O=C1N(c2ccc(-c3ccccc3)nc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
3690,748939,10.1016/j.bmcl.2011.04.034,,,,Inhibition of human ERG by voltage-clamp electrophysiology,CCN1C(=O)c2nc(Cc3ccccc3)n(Cc3ccccc3)c2N2CC3(CCc4ccccc43)N=C12,"1,2-dibenzyl-5-ethyl-2',3',5,8-tetrahydrospiro[imidazo[2,1-b]purine-7,1'-inden]-4(1H)-one",2.3,uM,=,0.3617278360175928,1,O=C1NC2=NC3(CCc4ccccc43)CN2c2c1nc(Cc1ccccc1)n2Cc1ccccc1
3691,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C(NC(c1ccc(Cl)cc1)c1ccnc(F)c1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1,"(1R,2R,4R)-2-(4-bromophenyl)-N-((4-chlorophenyl)(2-fluoropyridin-4-yl)methyl)-4-morpholinocyclohexanecarboxamide",0.59,uM,=,-0.2291479883578558,0,O=C(NC(c1ccccc1)c1ccncc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
3692,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CC[C@H]3OC[C@H](NCc4cc5c(cn4)OCCO5)CO3)c2c1,"N-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methyl)-2-(2-(6-methoxyquinolin-4-yl)ethyl)-trans-1,3-dioxan-5-amine",9.5,uM,=,0.9777236052888478,1,c1ccc2c(CC[C@H]3OC[C@H](NCc4cc5c(cn4)OCCO5)CO3)ccnc2c1
3693,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)C1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1,9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecane-3-carboxylic Acid,14.7,uM,=,1.167317334748176,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCCO5)CC4)nc3)nc2c1
3694,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2ccc(-c3cccnc3)cc2)o1,(S)-6-methyl-N-((S)-7-oxo-1-(5-(4-(pyridin-3-yl)phenyl)oxazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide,4.1,uM,=,0.6127838567197355,1,O=C(NCc1ncc(-c2ccc(-c3cccnc3)cc2)o1)[C@H]1CC12CCNCC2
3695,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCNC(=O)c5ccccc5)c4)n[nH]c2-3)CC1,"N-(3-(4-(6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno-[1,2-c]pyrazol-3-yl)thiophen-2-yl)prop-2-ynyl)benzamide",7.46,uM,=,0.8727388274726688,1,O=C(NCC#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)c1ccccc1
3696,1765499,10.1021/acs.jmedchem.8b01040,,,,Displacement of [3H]dofetilide from human ERG by high throughput assay,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cncnc2)c1,"US9278981, 170",3.6,uM,=,0.5563025007672873,1,O=C(Nc1ccccc1)c1cnc(N2CCCC2)c(-c2cncnc2)c1
3697,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)C1CCN(Cc2nc3c(s2)CCCC3)CC1,"2-(4-(1H-tetrazol-1-yl)phenyl)-N-methyl-N-(1-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)methyl)piperidin-4-yl)acetamide",7.6,uM,=,0.8808135922807914,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2nc3c(s2)CCCC3)CC1
3698,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CC(C)C1OC2(CCN(CCc3ccccc3)CC2)CN(C)C1=O,"2-isopropyl-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",6.2,uM,=,0.7923916894982539,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1
3699,540677,10.1016/j.bmcl.2008.12.083,,,,Inhibition of human ERG,Nc1ccc(-c2cccc(F)c2)cc1NC(=O)c1ccc(CN2CCC3(CCCN3)CC2)cc1,"4-(1,8-diazaspiro[4.5]decan-8-ylmethyl)-N-(4-amino-3'-fluorobiphenyl-3-yl)benzamide",0.167,uM,=,-0.7772835288524167,0,O=C(Nc1cccc(-c2ccccc2)c1)c1ccc(CN2CCC3(CCCN3)CC2)cc1
3700,1978265,10.1016/j.bmcl.2019.126928,,,,Inhibition of human ERG expressed in HEK293 cells by semi-automatic patch clamp assay,Cc1cnc(-c2ccc(OC(F)(F)F)cc2)n1Cc1ccccc1OCCC[C@@H](C)CC(=O)O,(R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid,10.0,uM,=,1.0,1,c1ccc(Cn2ccnc2-c2ccccc2)cc1
3701,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CC[C@@H](NC(=O)c1ccc(C#N)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4ccc(Cl)cc43)C[C@@H]21,"N-((R)-1-((1R,3S,5S,6r)-3-(6-chloro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)-4-cyanobenzamide",0.5,uM,=,-0.3010299956639812,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
3702,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N3CCCC[C@@H]3Cc3ccc(Cl)cc3)CC2)n1,"(R)-5-(2-(4-Chlorobenzyl)-[1,4'-bipiperidin]-1'-yl)-1H-1,2,4-triazol-3-amine",8.3,uM,=,0.919078092376074,1,c1ccc(C[C@H]2CCCCN2C2CCN(c3ncn[nH]3)CC2)cc1
3703,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7cc[n+]([O-])cc7)[nH]6)CC5)cc4)nc3n2)CC1,"2-(4-Methyl-piperazin-1-yl)-7-(4-{4-[5-(1-oxy-pyridin-4-yl)-4H-[1,2,4]triazol-3-yl]-piperidin-1-ylmethyl}-phenyl)-6-phenyl-pyrido[2,3-d]pyrimidine",9.8,uM,=,0.9912260756924948,1,c1ccc(-c2cc3cnc(N4CCNCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5cc[nH+]cc5)[nH]4)CC3)cc2)cc1
3704,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(N3CCC(C#N)CC3)n2)(c2ccc(F)cc2)CC1,1-(6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)piperidine-4-carbonitrile,7.7,uM,=,0.8864907251724818,1,c1ccc(C2(COCc3cccc(N4CCCCC4)n3)CCNCC2)cc1
3705,1616176,10.1021/acs.jmedchem.6b00487,,,,Inhibition of human ERG,COc1c(Nc2ncc(Cl)c(Nc3ccccc3N3CCCS3(=O)=O)n2)ccc2c1CCCC(N1CCN(CCO)CC1)C2,"rac-2-[4-[2-[[5-Chloro-4-[2-(1,1-dioxo-1,2-thiazolidin-2-yl)-anilino]pyrimidin-2-yl]amino]-1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl]piperazin-1-yl]ethanol",2.7,uM,=,0.4313637641589873,1,O=S1(=O)CCCN1c1ccccc1Nc1ccnc(Nc2ccc3c(c2)CCCC(N2CCNCC2)C3)n1
3706,939638,10.1016/j.bmcl.2012.11.023,,,,Inhibition of human ERG,Nc1nc2cc3c(cc2s1)CCN(Cc1cscn1)CC3,"7-Thiazol-4-ylmethyl-6,7,8,9-tetrahydro-5H-1-thia-3,7-diaza-cyclohepta[f]inden-2-ylamine",15.0,uM,=,1.1760912590556811,1,c1nc(CN2CCc3cc4ncsc4cc3CC2)cs1
3707,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ccc(=O)n(CCN3CCC(C4C(=O)Nc5ccc(Cl)cc54)CC3)c2c1,"1-(2-(4-(5-chloro-2-oxoindolin-3-yl)piperidin-1-yl)ethyl)-7-methoxy-1,5-naphthyridin-2(1H)-one",4.8,uM,=,0.6812412373755872,1,O=C1Nc2ccccc2C1C1CCN(CCn2c(=O)ccc3ncccc32)CC1
3708,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@H]3CO2)ccc2nonc12,"2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)-1-((3S,9aS)-3-(4-methylbenzo[c][1,2,5]oxadiazol-5-yl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)ethanone",10.0,uM,=,1.0,1,O=C(Cc1ccc(-n2cnnn2)nc1)N1CCN2C[C@H](c3ccc4nonc4c3)OC[C@@H]2C1
3709,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,O=C(NC1CC1c1ccccc1)N1CCC(c2nnco2)CC1,"4-(1,3,4-oxadiazol-2-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide",27.0,uM,=,1.4313637641589874,1,O=C(NC1CC1c1ccccc1)N1CCC(c2nnco2)CC1
3710,825853,10.1021/ml100095k,,,,Inhibition of human ERG,N#Cc1ccc(N2CCN(Cc3cc(C(=O)O)c(=O)n4ccccc34)CC2)cc1,1-((4-(4-cyanophenyl)piperazin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid,7.4,uM,=,0.8692317197309762,1,O=c1ccc(CN2CCN(c3ccccc3)CC2)c2ccccn12
3711,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(CC(OCCO)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(rac)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-(2-hydroxyethoxy)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.4,uM,=,0.1461280356782379,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3712,499728,10.1016/j.bmcl.2009.02.111,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp method,COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2F)c(C(=O)Nc2ccc(Cl)cn2)c1,"N-(2-(5-chloropyridin-2-ylcarbamoyl)-4-methoxyphenyl)-4-(N,N-dimethylcarbamimidoyl)-2-fluorobenzamide",4.2,uM,=,0.6232492903979004,1,O=C(Nc1ccccc1C(=O)Nc1ccccn1)c1ccccc1
3713,357755,10.1021/jm0508641,,,,Inhibition of hERG potassium channel in HEK293 cells by patch clamp assay,CC(=O)Nc1cccc(N2CCN(CCCCN(C)S(=O)(=O)CC3CCCCC3)CC2)c1,N-(3-{4-[4-(cyclohexylmethanesulfonyl-methyl-amino)-butyl]-piperazin-1-yl}-phenyl)-acetamide,4.0,uM,=,0.6020599913279624,1,O=S(=O)(CC1CCCCC1)NCCCCN1CCN(c2ccccc2)CC1
3714,1789491,10.1021/acs.jmedchem.8b01533,,,,Inhibition of human ERG expressed in CHO-S1 cells by automated planar chip-based electrophysiology,CC(C)(C)c1ccc(CN2CCC3(CCCCO3)CC2)cc1,9-(4-tert-butylbenzyl)-1-oxa-9-azaspiro[5.5]undecane,15.8,uM,=,1.1986570869544226,1,c1ccc(CN2CCC3(CCCCO3)CC2)cc1
3715,1545989,10.1021/acs.jmedchem.5b01227,,,,Inhibition of human ERG channel by automated Q-patch assay,CNCc1cc(Oc2ccc3c(ccn3C(=O)Nc3ccc(F)c(C(F)(F)F)c3)c2)ncn1,5-(6-Methylaminomethyl-pyrimidin-4-yloxy)-indole-1-carboxylic Acid (4-Fluoro-3-trifluoromethyl-phenyl)-amide,5.8,uM,=,0.7634279935629373,1,O=C(Nc1ccccc1)n1ccc2cc(Oc3ccncn3)ccc21
3716,938758,10.1016/j.bmcl.2013.01.033,,,,Inhibition of human hERG by automated patch clamp assay,N#CC=C1CCN(c2ccc(N3C[C@H](Cn4cc(F)nn4)OC3=O)cc2F)CC1,"(R)-2-(1-(2-fluoro-4-(5-((4-fluoro-1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)phenyl)piperidin-4-ylidene)acetonitrile",2.37,uM,=,0.3747483460101038,1,C=C1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2)CC1
3717,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNC(C)c1cc(F)ccc1Oc1ccc(Cl)cc1,1-(2-(4-chlorophenoxy)-5-fluorophenyl)-N-methylethanamine,5.23,uM,=,0.7185016888672743,1,c1ccc(Oc2ccccc2)cc1
3718,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide,0.0040999999999999,uM,=,-2.3872161432802645,0,c1ccc(CCNCCOc2ccccc2)cc1
3719,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,C[C@@H](C(=O)N1CCC(Oc2ccc(-c3cn(C)cn3)cc2C(N)=O)CC1)c1ccc(OC(F)(F)F)cc1,(R)-5-(1-Methyl-1H-imidazol-4-yl)-2-((1-(2-(4-(trifluoromethoxy)-phenyl)propanoyl)piperidin-4-yl)oxy)benzamide,4.2,uM,=,0.6232492903979004,1,O=C(Cc1ccccc1)N1CCC(Oc2ccc(-c3c[nH]cn3)cc2)CC1
3720,649965,10.1021/jm100505n,,,,Displacement of [3H]dofetilide from human ERG at 10 uM,CN(C)CCN(C)C(=O)c1ccc(C2=NN(c3ccc(C#N)cc3)C(c3ccc(F)cc3)C2)cc1,"(+/-)-4-[1-(4-Cyanophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1Hpyrazol-3-yl]-N-[2-(dimethylamino)ethyl]-N-methylbenzamideTrifluoroacetate",0.17,uM,=,-0.7695510786217261,0,c1ccc(C2=NN(c3ccccc3)C(c3ccccc3)C2)cc1
3721,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CCNc1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCN(C)CC2)n1,N-ethyl-6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridin-2-amine,80.0,uM,=,1.9030899869919435,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
3722,1515505,10.1021/ml500440u,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,Cc1nc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-2-methylnicotinonitrile",14.0,uM,=,1.146128035678238,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
3723,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide,0.03,uM,=,-1.5228787452803376,0,c1ccc(CCNCCOc2ccccc2)cc1
3724,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2c1ccncn1,"(R)-4-fluoro-N-(1-(5-(pyrimidin-4-yl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)benzamide",20.0,uM,=,1.3010299956639813,1,O=C(NCc1ccc2c(n1)CCCN2c1ccncn1)c1ccccc1
3725,1655139,10.1016/j.bmcl.2016.12.054,,,,Displacement of [3H]-MK499 from human ERG IKr channel expressed in HEK293 cell membranes,c1cncc(C(Cc2ccccc2-c2cncc3ccccc23)c2cccnc2)c1,"4-(2-(2,2-di(pyridin-3-yl)ethyl)phenyl)isoquinoline",12.0,uM,=,1.0791812460476249,1,c1cncc(C(Cc2ccccc2-c2cncc3ccccc23)c2cccnc2)c1
3726,1679756,10.1016/j.bmcl.2017.03.086,,,,Inhibition of human ERG by Qpatch electrophysiology method,Cc1nsc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)n1,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(3-methyl-1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",9.0,uM,=,0.9542425094393248,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ncns3)C4=O)ccc21
3727,1327812,10.1039/C1MD00116G,,,,Inhibition of dofetilide binding to human ERG,Cc1cnc(NC(=O)c2cc(Oc3ccc(C(=O)N(C)C)cc3)c3cc(C)oc3c2)cn1,4-(4-(Dimethylcarbamoyl)phenoxy)-2-methyl-N-(5-methylpyrazin-2-yl)benzofuran-6-carboxamide,59.0,uM,=,1.7708520116421442,1,O=C(Nc1cnccn1)c1cc(Oc2ccccc2)c2ccoc2c1
3728,1475693,10.1016/j.bmcl.2015.04.002,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.6,uM,=,-0.2218487496163563,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3729,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=NC(c2ccncc2)(c2cccc(-c3cncc(F)c3)c2)c2cccc(F)c21,4-Fluoro-1-(3-(5-fluoropyridin-3-yl)phenyl)-1-(pyridin-4-yl)-1H-isoindol-3-amine,1.6,uM,=,0.2041199826559248,1,C1=NC(c2ccncc2)(c2cccc(-c3cccnc3)c2)c2ccccc21
3730,762093,10.1021/jm200018k,,,,Inhibition of human Erg expressed in human HEK293 cells by patch-clamp electrophysiological assay,CC(=O)Nc1cccc(Nc2ncnc(N3CCC(OCc4ccc(C(C)C)cc4)CC3)n2)c1C,"N-(3-(4-(4-(4-Isopropylbenzyloxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)-2-methylphenyl)acetamide",0.44,uM,=,-0.3565473235138126,0,c1ccc(COC2CCN(c3ncnc(Nc4ccccc4)n3)CC2)cc1
3731,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,FC(F)(F)c1cc(Cl)cc(COCC2(c3ccccc3)CCNCC2)c1,4-((3-chloro-5-(trifluoromethyl)benzyloxy)methyl)-4-phenylpiperidine,7.2,uM,=,0.8573324964312685,1,c1ccc(COCC2(c3ccccc3)CCNCC2)cc1
3732,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)[C@@H]1CCN(Cc2ccc(C(F)(F)F)cn2)C[C@@H]1F,"2-(4-(1H-tetrazol-1-yl)phenyl)-N-((3S,4R)-3-fluoro-1-((5-(trifluoromethyl)pyridin-2-yl)methyl)piperidin-4-yl)-N-methylacetamide",10.0,uM,=,1.0,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2ccccn2)CC1
3733,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,Cc1nccc(N2CCCc3nc([C@@H](C)NC(=O)c4ccc(F)cc4)ccc32)n1,"(R)-4-fluoro-N-(1-(5-(2-methylpyrimidin-4-yl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)benzamide",18.0,uM,=,1.255272505103306,1,O=C(NCc1ccc2c(n1)CCCN2c1ccncn1)c1ccccc1
3734,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,C[C@H](N)C(=O)N1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc([N+](=O)[O-])c4)c3c2)CC1,(S)-2-amino-1-(4-(5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinolin-3-yl)piperazin-1-yl)propan-1-one,1.28,uM,=,0.1072099696478683,1,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
3735,487847,10.1021/jm800386y,,,,Displacement of [35S]MK499 from human ERG expressed in HEL cells,CN(C(=O)N1CC(c2cc(F)ccc2F)=C[C@@]1(CO)c1ccccc1)C1CCN(CCF)CC1,"(2S)-4-(2,5-difluorophenyl)-N-(1-(2-fluoroethyl)piperidin-4-yl)-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide",13.8,uM,=,1.1398790864012365,1,O=C(NC1CCNCC1)N1CC(c2ccccc2)=CC1c1ccccc1
3736,2153149,10.1016/j.ejmech.2021.113827,,,,Inhibition of hERG expressed in CHO-K1 cells assessed as reduction in thallium influx incubated for 30 minutes by FLIPR,O=c1ccc2c([nH]1)CCC(NCCCCCCCNc1c3c(nc4cc(Cl)ccc14)CCCC3)C2,"6-(7-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)heptylamino)-5,6,7,8-tetrahydroquinolin-2(1H)-one",6.357,uM,=,0.803252211430457,1,O=c1ccc2c([nH]1)CCC(NCCCCCCCNc1c3c(nc4ccccc14)CCCC3)C2
3737,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(n2cncn2)=NC1c1ccc(F)cc1Br,"Ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholinomethyl)-2-(1H-1,2,4-triazol-1-yl)-1,4-dihydropyrimidine-5-carboxylate",0.7,uM,=,-0.1549019599857432,0,C1=C(CN2CCOCC2)NC(n2cncn2)=NC1c1ccccc1
3738,788296,10.1021/jm201108k,,,,Inhibition of human ERG expressed in Chinese hamster CHL cells by perforated patch clamp assay,CC(C)(C)c1cc(C(=O)Nc2nc(CN)cs2)n(Cc2ccccc2)n1,3-tert-Butyl-N-(4-(aminomethyl)thiazol-2-yl)-1-benzyl-1Hpyrazole-5-carboxamide,3.7,uM,=,0.568201724066995,1,O=C(Nc1nccs1)c1ccnn1Cc1ccccc1
3739,2025950,10.1021/acsmedchemlett.0c00575,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,CCS(=O)(=O)c1ccc(CNc2nc3cnc(-c4c(C)ncnc4C4CC4)nc3n([C@@H](C)C3CC3)c2=O)cn1,(S)-2-(4-cyclopropyl-6-methylpyrimidin-5-yl)-8-(1-cyclopropylethyl)-6-((6-(ethylsulfonyl)pyridin-3-yl)methylamino)pteridin-7(8H)-one,22.0,uM,=,1.3424226808222062,1,O=c1c(NCc2cccnc2)nc2cnc(-c3cncnc3C3CC3)nc2n1CC1CC1
3740,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCCOCCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1,N-((4-(4-(2-propoxyethyl)piperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)propionamide,3.4,uM,=,0.5314789170422551,1,c1ccc(NCC2(N3CCNCC3)CCOCC2)nc1
3741,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CC1(Cn2nc(-c3ccc4cc(OC5CC5)ccc4c3)c3c(N)ncnc32)COC1,"3-(6-Cyclopropoxynaphthalen-2-yl)-1-((3-methyloxetan-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",1.9,uM,=,0.2787536009528289,1,c1ncc2c(-c3ccc4cc(OC5CC5)ccc4c3)nn(CC3COC3)c2n1
3742,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccccc4C(=O)O)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-2-carboxylic acid",2.4,uM,=,0.380211241711606,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
3743,1804296,10.1021/acs.jmedchem.8b01096,,,,Inhibition of human ERG expressed in HEK293 cells at -50 mV holding potential by patch clamp assay,O=C(CCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2c3c(c1)CCN3C(=O)CC2,"8-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butanoyl)-5,6-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-4(2H)-one",0.8237000000000001,uM,=,-0.0842309340163158,0,O=C(CCCN1CCC(c2noc3ccccc23)CC1)c1cc2c3c(c1)CCN3C(=O)CC2
3744,1515505,10.1021/ml500440u,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,Cc1c([C@@H](O)CN2CCN(CC(O)c3cc(C4CC4)c(C#N)cn3)CC2)ccc2c1COC2=O,"4-cyclopropyl-6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)nicotinonitrile",14.0,uM,=,1.146128035678238,1,O=C1OCc2cc(CCN3CCN(CCc4cc(C5CC5)ccn4)CC3)ccc21
3745,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(c(C)c5F)OCC(=O)N6)(CC3)CO4)c2n1,"7-fluoro-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-8-methyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.9,uM,=,-0.0457574905606751,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3746,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1,"3-(5-(3-(2-methoxyethoxy)prop-1-ynyl)thiophen-3-yl)-6-((4-methylpiperazin-1-yl)methyl)indeno[1,2-c]pyrazol-4(1H)-one",9.4,uM,=,0.9731278535996988,1,O=C1c2cc(CN3CCNCC3)ccc2-c2[nH]nc(-c3ccsc3)c21
3747,1436764,10.1021/ml500187a,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated whole-cell patch-clamp electrophysiology method,Clc1cccc(CN(CC2CNC2)c2ccccc2)c1Cl.O=C(O)C(F)(F)F,"N-(azetidin-3-ylmethyl)-N-(2,3-dichlorobenzyl)aniline 2,2,2-trifluoroacetate",1.88,uM,=,0.2741578492636798,1,c1ccc(CN(CC2CNC2)c2ccccc2)cc1
3748,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)CCN1CC[C@H](CNC(=O)c2cc(Cl)cc(Cl)c2)[C@H](F)C1,"3,5-Dichloro-N-{[(3S,4R)-1-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}benzamide",4.114,uM,=,0.6142642873587052,1,O=C(NCC1CCNCC1)c1ccccc1
3749,1713882,10.1016/j.bmcl.2018.05.030,,,,Inhibition of human ERG expressed in CHO-K1 cells at -90 mV holding potential by Qpatch clamp assay,CN(CCC1CCN(C(=O)OCc2cc(Cl)cc(Cl)c2)CC1)C(=O)c1c[nH]c(=O)o1,"US9409895, 32",7.3,uM,=,0.8633228601204559,1,O=C(NCCC1CCN(C(=O)OCc2ccccc2)CC1)c1c[nH]c(=O)o1
3750,1473398,10.1021/jm501920g,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,Fc1ccc(-n2cc(NCCN3CCCCC3)nn2)cc1F,"1-(3,4-difluorophenyl)-N-(2-(piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-amine",2.2,uM,=,0.3424226808222063,1,c1ccc(-n2cc(NCCN3CCCCC3)nn2)cc1
3751,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COCCNS(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1,4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic Acid(2-Methoxy-ethyl)-amide,7.344827586,uM,=,0.865981605527548,1,c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
3752,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1nnn(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)C1CCOC1)C2,"(2-((1-(4-fluorophenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)(tetrahydrofuran-3-yl)methanone",30.0,uM,=,1.4771212547196624,1,O=C(C1CCOC1)N1CCc2nc(OCc3cnnn3-c3ccccc3)ccc2C1
3753,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,CC(=O)N1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc([N+](=O)[O-])c4)c3c2)CC1,3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinoline,0.46,uM,=,-0.3372421683184259,0,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
3754,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,COC(C)(C)CCOc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1,N-(1-(4-(3-methoxy-3-methylbutoxy)benzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,4.3,uM,=,0.6334684555795865,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
3755,43805,10.1021/jm0208875,,,,K+ channel blocking activity in COS-7 African green monkey kidney derived cells expressing HERG Kv11.1,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",1.43,uM,=,0.1553360374650617,1,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
3756,460777,10.1021/jm070637u,,,,Inhibition of hERG potassium channel expressed in CHO cells by isotope efflux assay,CN1CCCc2cc(NC(=O)c3ccc(-c4ccc(Cl)cc4)o3)ccc21,"5-(4-chlorophenyl)-N-[(1-methyl-1,2,3,4-tetrahydroquinolin)-6-yl]furan-2-carboxamide",5.3,uM,=,0.724275869600789,1,O=C(Nc1ccc2c(c1)CCCN2)c1ccc(-c2ccccc2)o1
3757,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4cccc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-3-carboxylic acid",7.0,uM,=,0.8450980400142568,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
3758,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cnc2ccc(-c3cccnc3)cc2c1NCC1CCCCC1,4-[(Cyclohexylmethyl)amino]-6-(3-pyridinyl)-3-quinolinecarboxamide,0.83,uM,=,-0.0809219076239261,0,c1cncc(-c2ccc3nccc(NCC4CCCCC4)c3c2)c1
3759,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(CC(O)(C(F)(F)F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(rac)-6-((1-(1,1,1-trifluoro-3-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-2-hydroxypropan-2-yl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.4,uM,=,0.380211241711606,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3760,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ccc(C(F)(F)F)cc3C2)C1,"((2R,3aR,6aR)-2-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)(7-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone",27.6,uM,=,1.4409090820652175,1,O=C(N1CCc2ccccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
3761,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)-N-(2-methoxy-4-morpholinophenyl)pyrimidin-2-amine",3.2,uM,=,0.505149978319906,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCOCC5)cc4)n3)cnc2c1
3762,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CCCc2ccccc2)c1,endo-3-(8-(3-phenylpropyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.00025,uM,=,-3.6020599913279625,0,c1ccc(CCCN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
3763,2286786,10.1021/acs.jmedchem.1c00790,,,,Inhibition of hERG,O=C(O)c1cccc(CN2CN(C3CCCCC3)C3(CCN(CCCC(=O)c4ccccc4)CC3)C2O)c1,Trazpiroben,15.6,uM,=,1.1931245983544616,1,O=C(CCCN1CCC2(CC1)CN(Cc1ccccc1)CN2C1CCCCC1)c1ccccc1
3764,811343,10.1016/j.bmcl.2012.01.095,,,,Inhibition of human ERG by fluorescence polarization assay,CCC(NCCCC[C@@H](Cc1cc(C)c(F)c(C)c1)C(=O)NO)c1ccc(F)cc1,"rac-(2S)-2-(4-fluoro-3,5-dimethylbenzyl)-6-(1-(4-fluorophenyl)propylamino)-N-hydroxyhexanamide",13.3,uM,=,1.1238516409670858,1,c1ccc(CCCCCCNCc2ccccc2)cc1
3765,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(C#N)cc2cc1[C@@H](c1cccc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc2c1CCC2,"7-((1S,2S)-2-(2,3-dihydro-1H-inden-4-yl)-1-(2,3-dimethoxyphenyl)-4-(dimethylamino)-2-hydroxybutyl)-6-methoxy-2-naphthonitrile",1.0,uM,=,0.0,0,c1ccc([C@@H](Cc2cccc3c2CCC3)c2ccc3ccccc3c2)cc1
3766,494878,10.1021/jm8012618,,,,Inhibition of human cloned ERG,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,4-(7-Chloro-quinolin-4-ylamino)-2-ethylaminomethyl-phenol,9.5,uM,=,0.9777236052888478,1,c1ccc(Nc2ccnc3ccccc23)cc1
3767,1886560,10.1021/acs.jmedchem.8b02021,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc2ccc(SC(F)(F)F)cc2s1,6-Trifluoromethylsulfanyl-benzothiazol-2-ylamine,10.0,uM,=,1.0,1,c1ccc2scnc2c1
3768,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2F)cc(S(C)(=O)=O)n1,"Rac-(1S,2S)1-(6-Bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-1-(2-fluoro-3-methoxyphenyl)-2-(2-methoxy-6-methylsulfonylpyridine-4-yl)butan-2-ol",1.8,uM,=,0.255272505103306,1,c1ccc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)cc1
3769,1924902,10.1016/j.bmcl.2016.07.048,,,,Inhibition of MK499 binding to human ERG,CN1CCCC(CNC(=O)c2nn(C)cc2NC(=O)c2cccc(-c3ccnc(NCC4CC4)c3)n2)C1,"2'-(cyclopropylmethylamino)-N-(1-methyl-3-((1-methylpiperidin-3-yl)methylcarbamoyl)-1H-pyrazol-4-yl)-2,4'-bipyridine-6-carboxamide",12.0,uM,=,1.0791812460476249,1,O=C(Nc1c[nH]nc1C(=O)NCC1CCCNC1)c1cccc(-c2ccnc(NCC3CC3)c2)n1
3770,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3ccc(N4CCCCC4)cc3)ccc2c1,(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)-2-(4-(piperidin-1-yl)phenyl)quinoline,2.8,uM,=,0.4471580313422192,1,c1cc2nc(-c3ccc(N4CCCCC4)cc3)ccc2cc1CCN1CCCC1
3771,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CNS(=O)(=O)CCN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"2-((1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)(4-chlorophenethyl)amino)-N-methylethane-1-sulfonamide",16.0,uM,=,1.2041199826559248,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
3772,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)C1CCN(Cc2ccc(C(F)(F)F)c(F)c2)CC1,2-(4-(1H-tetrazol-1-yl)phenyl)-N-(1-(3-fluoro-4-(trifluoromethyl)benzyl)piperidin-4-yl)-N-methylacetamide,2.8,uM,=,0.4471580313422192,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2ccccc2)CC1
3773,1898259,10.1016/j.bmcl.2019.126643,,,,Inhibition of human ERG,C[C@]12CC[C@@H]3c4ccc(OCCCN5CCCC5)cc4CC[C@H]3[C@@H]1CC[C@@H]2N1CCCC1,"1-(3-((8R,9S,13S,14S,17S)-13-methyl-17-(pyrrolidin-1-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yloxy)propyl)pyrrolidine",7.5,uM,=,0.8750612633917001,1,c1cc2c(cc1OCCCN1CCCC1)CC[C@@H]1[C@@H]2CCC2[C@H]1CC[C@@H]2N1CCCC1
3774,611802,10.1021/jm9015075,,,,Inhibition of human ERG,Fc1ccccc1-c1ccc2oc(N3CCN4CCC3CC4)nc2n1,"2-(5-(2-Fluorophenyl)oxazolo[4,5-b]pyridin-2-yl)-2,5-diazabicyclo[3.2.2]nonane",2.8,uM,=,0.4471580313422192,1,c1ccc(-c2ccc3oc(N4CCN5CCC4CC5)nc3n2)cc1
3775,1926457,10.1016/j.bmc.2016.08.007,,,,Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assay,N#Cc1ccc(N2CCC(Nc3cc(Nc4ccccn4)ncc3C(N)=O)CC2)nc1,4-{[1-(5-Cyanopyridin-2-yl)piperidin-4-yl]amino}-6-(pyridin-2-ylamino)nicotinamide,0.36,uM,=,-0.4436974992327127,0,c1ccc(Nc2cc(NC3CCN(c4ccccn4)CC3)ccn2)nc1
3776,2113604,10.1016/j.bmc.2021.116163,,,,Inhibition of human ERG,CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1,"6-cyclopropyl-8-fluoro-2-(2-(hydroxymethyl)-3-(1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isoquinolin-1(2H)-one",1.4,uM,=,0.1461280356782379,1,O=c1[nH]cc(-c2cccc(-n3ccc4cc(C5CC5)ccc4c3=O)c2)cc1Nc1ccc(N2CCNCC2)cn1
3777,1327425,10.1039/C2MD20054F,,,,Inhibition of human ERG,CC(C)c1noc(N2CCN(c3ncc(OCc4ccncc4C#N)cn3)[C@H](C)C2)n1,"4-{[(2-{(2R)-2-Methyl-4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]piperazin-1-yl}pyrimidin-5-yl)oxy]methyl}pyridine-3-carbonitrile",11.6,uM,=,1.0644579892269186,1,c1cc(COc2cnc(N3CCN(c4ncno4)CC3)nc2)ccn1
3778,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CC(C)[C@]1(C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)CC[C@@H](N2CCC3COCCC32)C1,"cis-((1S,3R)-3-(hexahydropyrano[4,3-b]pyrrol-1(6H)-yl)-1-isopropylcyclopentyl)(4-(4-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methanone",1.1,uM,=,0.041392685158225,1,O=C(C1CC[C@@H](N2CCC3COCCC32)C1)N1CCN(c2ccccn2)CC1
3779,1288300,10.1016/j.bmcl.2013.12.078,,,,Inhibition of human ERG by whole-cell patch clamp method,COC(=O)C(CCCN1CCC(c2ccccc2OC)CC1)(c1ccc(Br)cc1)C(C)C,methyl 2-(4-bromophenyl)-2-isopropyl-5-(4-(2-methoxyphenyl)piperidin-1-yl)pentanoate,0.78,uM,=,-0.1079053973095195,0,c1ccc(CCCCN2CCC(c3ccccc3)CC2)cc1
3780,1702620,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human ERG expressed in HEK293 cells by lonWorks Quattro analysis,C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",8.46,uM,=,0.9273703630390236,1,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
3781,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2cc3c(N[C@@H](C)c4ccn(C)n4)c(C(N)=O)cnc3cc2F)c(F)n1,7-Fluoro-6-[2-fluoro-6-(methoxymethyl)-3-pyridinyl]-4-{[(1S)-1-(1-methyl-1H-pyrazol-3-yl)ethyl]amino}-3-quinolinecarboxamide,24.0,uM,=,1.380211241711606,1,c1cncc(-c2ccc3nccc(NCc4cc[nH]n4)c3c2)c1
3782,826732,10.1021/jm201194q,,,,Inhibition of human ERG expressed in HEK cells by patch clamp assay,c1ccc(CCCNCCC(c2ccccc2)c2ccccc2)cc1,"3,3-diphenyl-N-(3-phenylpropyl)propan-1-amine",0.017,uM,=,-1.769551078621726,0,c1ccc(CCCNCCC(c2ccccc2)c2ccccc2)cc1
3783,1908637,10.1021/acsmedchemlett.9b00430,,,,Inhibition of human ERG stably expressed in HEK293 cells measured at holding potential of -90 mV by manual patch clamp assay,O=C1CN(c2cn[nH]c(=O)c2Cl)CCN1Cc1ccccc1C(F)(F)F,"4-chloro-5-(3-oxo-4-[[2-(trifluoromethyl)phenyl]methyl]piperazin-1-yl)-2,3-dihydropyridazin-3-one",8.7,uM,=,0.9395192526186184,1,O=C1CN(c2cn[nH]c(=O)c2)CCN1Cc1ccccc1
3784,1635871,10.1016/j.ejmech.2016.11.017,,,,Inhibition of human ERG expressed in CHOK1 cells by automated patch clamp method,COc1ccc(OC)c(Cc2nc3ccccc3n2CC(=O)Nc2cc(C(C)(C)C)cc(C(C)(C)C)c2)c1,"N-(3,5-Di-tert-butylphenyl)-2-(2-(2,5-dimethoxybenzyl)-1H-benzo[d]imidazol-1-yl)acetamide",0.02,uM,=,-1.6989700043360187,0,O=C(Cn1c(Cc2ccccc2)nc2ccccc21)Nc1ccccc1
3785,716794,10.1016/j.bmcl.2010.12.123,,,,Inhibition of human ERG expressed in CHO cells,O=C(N[C@H]1CC[C@H](O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,"trans-(S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexyl-N-(4-hydroxycyclohexyl)acetamide",7.3,uM,=,0.8633228601204559,1,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
3786,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1c(C(O)CN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O,(rac)-5-(2-(4-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperazin-1-yl)-1-hydroxyethyl)-4-methoxyisobenzofuran-1(3H)-one,19.0,uM,=,1.2787536009528289,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
3787,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)[C@@H]1CCN(Cc2ccc(C(F)(F)F)cc2)C[C@@H]1F,"N-((3S,4R)-3-fluoro-1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)-N-methyl-2-(4-(methylsulfonyl)phenyl)acetamide",4.2,uM,=,0.6232492903979004,1,O=C(Cc1ccccc1)NC1CCN(Cc2ccccc2)CC1
3788,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,COCCC(=O)N1CCSC(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1,"4-(8-amino-3-(4-(3-methoxypropanoyl)thiomorpholin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",1.8,uM,=,0.255272505103306,1,O=C(Nc1ccccn1)c1ccc(-c2nc(C3CNCCS3)n3ccncc23)cc1
3789,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3cc(F)ccc32)CC1,"4-{3-[4-(5-Fluoro-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-4H-benzo[1,4]oxazin-3-one",1.9,uM,=,0.2787536009528289,1,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
3790,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,Cc1cnc(COc2nc(N)nc3ccn(Cc4ccccn4)c23)s1,"4-((5-Methylthiazol-2-yl)methoxy)-5-(pyridin-2-ylmethyl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine",44.7,uM,=,1.6503075231319366,1,c1ccc(Cn2ccc3ncnc(OCc4nccs4)c32)nc1
3791,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(C#N)cn2)C3)ccc2c1COC2=O,"(R)-6-(8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-2-yl)nicotinonitrile",2.4,uM,=,0.380211241711606,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccccn3)C4)ccc21
3792,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(CCc2ccccc2)C1=O,"2-methyl-4,9-diphenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.2,uM,=,-0.6989700043360187,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1CCc1ccccc1
3793,2084867,10.1021/acs.jmedchem.6b00943,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated Qpatch electrophysiological assay,Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C#Cc1nn(C2CCN(C)CC2)c2ncnc(N)c12,"N-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1H-pyrazolo-[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)-benzamide",0.6,uM,=,-0.2218487496163563,0,O=C(Nc1cccc(C#Cc2nn(C3CCNCC3)c3ncncc23)c1)c1ccccc1
3794,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)nc(C)c1C#N,"6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-methoxy-2-methylnicotinonitrile",5.7,uM,=,0.7558748556724915,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
3795,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,FC(F)(F)Oc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1,"(1R,3R)-1-(tetrahydro-2H-pyran-4-yl)-3-(4-(4-(trifluoromethoxy)phenyl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.13,uM,=,-0.8860566476931633,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
3796,2133680,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG expressed in CHO by QPatch assay,C[C@@H](NC(=O)c1ccc(C#N)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-cyano-N-((R)-1-((1R,3S,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)ethyl)benzamide",0.74,uM,=,-0.1307682802690238,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
3797,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(CN1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cn3)c2)CC1)NC(c1ccc(F)cc1)c1ccc(F)cc1,N-(bis(4-fluorophenyl)methyl)-2-(4-((1-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrol-3-yl)methyl)piperazin-1-yl)acetamide,0.8,uM,=,-0.0969100130080563,0,O=C(CN1CCN(Cc2ccn(-c3ccccn3)c2)CC1)NC(c1ccccc1)c1ccccc1
3798,1567467,10.1039/C5MD00479A,,,,Inhibition of human ERG,CCCCC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1,"(1R)-2-[(5S)-5-{[5-Chloro-2-(1H-tetrazol-1-yl)benzyl]carbamoyl}-4,5-dihydro-1H-pyrazol-1-yl]-1-(4-fluorophenyl)-2-oxoethyl pentanoate",14.0,uM,=,1.146128035678238,1,O=C(NCc1ccccc1-n1cnnn1)[C@@H]1CC=NN1C(=O)Cc1ccccc1
3799,2241386,10.1016/j.ejmech.2021.113981,,,,Inhibition of hERG channel expressed in CHO cells at holding potential of -80 mV by whole cell patch clamp method,CCCCCCCNC[C@@H](O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12,"(1S)-1-[2,8-bis(trifluoromethyl)-4-quinolyl]-2-(heptylamino)ethanol",7.0,uM,=,0.8450980400142568,1,c1ccc2ncccc2c1
3800,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,O=c1n(Cc2ccc(Cl)cc2)c2sc3c(c2c2ncnn12)CCN(C1COC1)C3,"6-(4-Chlorobenzyl)-9-(oxetan-3-yl)-8,9,10,11-tetrahydropyrido-[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one",0.98,uM,=,-0.0087739243075051,0,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCN(C1COC1)C3
3801,635425,10.1016/j.bmcl.2010.04.071,,,,Inhibition of human ERG,C[C@H](O)C(=O)NC1CC(C)(C)Oc2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc21,"(2R)-N-[6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-2-hydroxypropanamide",0.34,uM,=,-0.4685210829577448,0,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
3802,463271,10.1016/j.bmcl.2007.11.052,,,,Inhibition of human ERG,C[C@H](Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12)C(=O)N(C)CCO,(S)-2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)-N-(2-hydroxyethyl)-N-methylpropanamide,11.0,uM,=,1.0413926851582251,1,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
3803,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,Cc1ccccc1[C@H]1C[C@@H](NCc2ccc(Cl)cc2)CC[C@@H]1C(=O)N1CC(c2ccccc2)(c2ccccc2)C1,"((1S,2S,4S)-4-(4-chlorobenzylamino)-2-o-tolylcyclohexyl)(3,3-diphenylazetidin-1-yl)methanone",0.003,uM,=,-2.5228787452803374,0,O=C([C@H]1CC[C@H](NCc2ccccc2)C[C@@H]1c1ccccc1)N1CC(c2ccccc2)(c2ccccc2)C1
3804,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=N[C@](c2ccncc2)(c2cccc(-c3cncnc3)c2)c2cccc(F)c21,(S)-4-Fluoro-1-(pyridin-4-yl)-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine,3.1,uM,=,0.4913616938342727,1,C1=N[C@](c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
3805,1452204,10.1021/ml500137b,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes incubated for 90 mins by beta-counting method,CCOC[C@@H](CC(C)C)NC(=O)[C@@H]1CNC[C@H](C(=O)N(c2ccc(C(C)C)cn2)C2CC2)C1.Cl,"(3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(5-isopropylpyridin-2-yl)piperidine-3,5-dicarboxamide hydrochloride",7.0,uM,=,0.8450980400142568,1,O=C([C@@H]1CCCNC1)N(c1ccccn1)C1CC1
3806,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,Cn1cccc1CNC(=O)CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,N-((1-methyl-1H-pyrrol-2-yl)methyl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,2.4,uM,=,0.380211241711606,1,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NCc1ccc[nH]1
3807,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H](C3CN4CCC3CC4)O2)cc1,"(5R)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-5-quinuclidin-3-yl-4,5-dihydrooxazole",0.69,uM,=,-0.1611509092627447,0,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H](C3CN4CCC3CC4)O2)cc1
3808,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,CC(C)Oc1ccccc1CC(c1ccccc1)N1CCNCC1,1-(2-(2-isopropoxyphenyl)-1-phenylethyl)piperazine,6.37,uM,=,0.8041394323353505,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
3809,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,Cc1nc(NCC(=O)NC2CN([C@H]3CC[C@@](O)(c4cncs4)CC3)C2)c2cc(C(F)(F)F)ccc2n1,Cis-N-(1-(4-hydroxy-4-(thiazol-5-yl)cyclohexyl)azetidin-3-yl)-2-(2-methyl-6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,25.7,uM,=,1.4099331233312946,1,O=C(CNc1ncnc2ccccc12)NC1CN(C2CCC(c3cncs3)CC2)C1
3810,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(CC(=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)acetyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",9.4,uM,=,0.9731278535996988,1,O=C1COc2ccc(CNC34CCC(C(=O)Cc5ccnc6cccnc56)(CC3)OC4)nc2N1
3811,1890282,10.1021/acs.jmedchem.8b01972,,,,Inhibition of Tracer Red binding to human ERG expressed in membranes by fluorescence polarization assay,CN(C)c1ccc(CNC(=O)[C@H]2CNC[C@@H]2c2ccc(C(F)(F)F)cc2)cc1,"(+/-)-(3R,4S)-N-{[4-(dimethylamino)phenyl]methyl}-4-[4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide",9.41,uM,=,0.973589623427257,1,O=C(NCc1ccccc1)[C@H]1CNC[C@@H]1c1ccccc1
3812,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CC1(C)CC(NC(=O)C(C)(O)C(F)(F)F)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1,"N-[6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide",0.6,uM,=,-0.2218487496163563,0,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
3813,674336,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human ERG expressed in HEK cells by patch clamp technique,Nc1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cc(Cl)cc2o1,(S)-2-amino-6-chloro-N-(quinuclidin-3-yl)benzo[d]oxazole-4-carboxamide,4.8,uM,=,0.6812412373755872,1,O=C(N[C@@H]1CN2CCC1CC2)c1cccc2ocnc12
3814,676113,10.1016/j.bmcl.2010.09.089,,,,Inhibition of human ERG,Cc1nc2ccccc2n1C1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCSCC1)c1cccc(F)c1,"N-((1S)-1-(3-fluorophenyl)-3-((1R,5S)-3-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)propyl)tetrahydro-2H-thiopyran-4-carboxamide",0.74,uM,=,-0.1307682802690238,0,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1CC(n1cnc3ccccc31)C2)c1ccccc1)C1CCSCC1
3815,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,COc1ccccc1N1CCN(CCCCNS(=O)(=O)c2ccc(C)cc2)CC1,N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methylbenzenesulfonamide,5.0,uM,=,0.6989700043360189,1,O=S(=O)(NCCCCN1CCN(c2ccccc2)CC1)c1ccccc1
3816,2159402,10.1021/acs.jmedchem.1c01968,,,,Inhibition of human ERG by voltage clamp assay,CC(C)(O)Cn1ncc(Nc2ncc3cc(Cl)c(C4CCN(C5COC5)CC4)cc3n2)c1Cl,1-(5-chloro-4-(6-chloro-7-(1-(oxetan-3-yl)piperidin-4-yl)quinazolin-2-ylamino)-1H-pyrazol-1-yl)-2-methylpropan-2-ol,23.0,uM,=,1.3617278360175928,1,c1n[nH]cc1Nc1ncc2ccc(C3CCN(C4COC4)CC3)cc2n1
3817,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,COc1cc2oc(C(=O)NC3CCN(Cc4ccc5c(c4)OCO5)CC3)cc(=O)c2cc1F,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-6-fluoro-7-methoxy-4-oxo-4H-chromene-2-carboxamide",0.0159,uM,=,-1.7986028756795485,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
3818,627338,10.1016/j.bmcl.2010.03.005,,,,Inhibition of human ERG,OC(c1cccnc1)(c1cccnc1)C(c1ccccc1)N1CCNCC1,"2-phenyl-2-(piperazin-1-yl)-1,1-di(pyridin-3-yl)ethanol",2.3,uM,=,0.3617278360175928,1,c1ccc(C(C(c2cccnc2)c2cccnc2)N2CCNCC2)cc1
3819,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,COc1ccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,cis-N-({1-[4-Hydroxy-4-(6-methoxy-pyridin-3-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,37.0,uM,=,1.568201724066995,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccnc3)CC2)C1
3820,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,C1=CCC(c2cc3ccccc3o2)CNC1,"3-(Benzofuran-2-yl)-2,3,4,7-tetrahydro-1H-azepine",19.0,uM,=,1.2787536009528289,1,C1=CCC(c2cc3ccccc3o2)CNC1
3821,1496337,10.1021/ml500505q,,,,Inhibition of human ERG expressed in HEK293 cells by FLIPR based flux assay,CCCC[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1NC(=O)CNC(=O)c1cccc(C(F)(F)F)c1,"N-(2-((1S,2R,4R)-2-butyl-4-(isopropyl(methyl)amino)cyclohexylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide",0.36,uM,=,-0.4436974992327127,0,O=C(CNC(=O)c1ccccc1)NC1CCCCC1
3822,501217,10.1016/j.bmcl.2009.02.099,,,,Inhibition of human ERG by patch-clamp assay,Cc1nccnc1C(=O)N1CCC([C@H](N)Cc2cc(F)c(F)cc2F)CC1,"(R)-(4-(1-amino-2-(2,4,5-trifluorophenyl)ethyl)piperidin-1-yl)(3-methylpyrazin-2-yl)methanone",55.0,uM,=,1.740362689494244,1,O=C(c1cnccn1)N1CCC(CCc2ccccc2)CC1
3823,1930034,10.1016/j.bmc.2017.07.058,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by patch clamp method,Clc1ccc(CCCOCCCN2CCCCC2)cc1,1-(3-(3-(4-chlorophenyl)propoxy)propyl)piperidine,1.7,uM,=,0.2304489213782739,1,c1ccc(CCCOCCCN2CCCCC2)cc1
3824,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COC(=O)N(Cc1ccc2c(n1)NC(=O)CO2)C12CCC(CCc3c(F)cnc4ccc(OC)nc34)(CC1)OC2,"methyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-yl((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl)carbamate",6.1,uM,=,0.785329835010767,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3825,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](C4CCCCC4)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-N-(1-(bi(cyclohexan)-4-yl)azetidin-3-yl)-2-(1-methyl-5-(trifluoromethyl)-1H-indazol-3-ylamino)acetamide,3.1,uM,=,0.4913616938342727,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](C3CCCCC3)CC2)C1
3826,2204956,10.1016/j.ejmech.2022.114581,,,,Inhibition of human ERG potassium channel expressed in CHO cells by automated patch clamp electrophysiological assay,Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O,DORAVIRINE,88.0,uM,=,1.944482672150169,1,O=c1[nH]nc(Cn2cccc(Oc3ccccc3)c2=O)[nH]1
3827,857606,10.1021/ml2002604,,,,Inhibition of human recombinant hERG expressed in CHO cells by automated patch clamp assay,COCC(=O)N(Cc1ccsc1)C1CCN([C@H](C)CCNC(=O)c2c(C)cc(Cl)nc2C)CC1,"(R)-6-Chloro-N-(3-(4-(2-methoxy-N-(thiophen-3-ylmethyl)acetamido)piperidin-1-yl)butyl)-2,4-dimethylnicotinamide",8.4,uM,=,0.9242792860618816,1,O=C(NCCCN1CCC(NCc2ccsc2)CC1)c1cccnc1
3828,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(C(=O)N2CCN(C(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)[C@@H](C)C2)cc1C(C)(C)C,"(S)-1-(4-(3,5-di-tert-butyl-4-methoxybenzoyl)-2-methylpiperazin-1-yl)-6,6-bis(4-fluorophenyl)hexan-1-one",0.9,uM,=,-0.0457574905606751,0,O=C(CCCCC(c1ccccc1)c1ccccc1)N1CCN(C(=O)c2ccccc2)CC1
3829,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,N#CC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1,"1-((7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)methyl)cyclopropanecarbonitrile",5.5,uM,=,0.7403626894942439,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7CC7)nc56)(CC3)OC4)nc2N1
3830,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,C[C@@H]1CN(c2nnc(C(F)(F)F)o2)CCN1c1ncc(OCc2ccc(C#N)cc2F)cn1,"3-fluoro-4-{[(2-{(2R)-2-methyl-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]piperazin-1-yl}pyrimidin-5-yl)oxy]methyl}benzonitrile",11.0,uM,=,1.0413926851582251,1,c1ccc(COc2cnc(N3CCN(c4nnco4)CC3)nc2)cc1
3831,430246,10.1021/jm0491750,,,,Inhibition of hERG receptor,CCN(CC)c1ccc(NC(=O)C2(N(C)C(=O)OCC(C)C)CCc3cccc(OC)c3C2)cc1,"[2-(4-Diethylamino-phenylcarbamoyl)-8-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl]-methyl-carbamic acid isobutyl ester",6.1,uM,=,0.785329835010767,1,O=C(Nc1ccccc1)C1CCc2ccccc2C1
3832,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O,"R,R-A-29-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.5.2.12,5.114,18.08,12.023,26]nonacosa-8,10,14(28),15,17,20(27),21,23(26)-octaen-17-yl cyanide",0.08,uM,=,-1.0969100130080565,0,O=C1[C@H]2CCN1[C@@H]1CCc3ccc(cc31)Oc1cccc(c1)Cn1cncc1CN2
3833,1869078,10.1021/acs.jmedchem.8b01656,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual patch clamp assay,Cc1cc(C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(C(N)=O)cc3)CC2)nc2c1COC2,"4-((4-((4-(4-Cyano-2,6-dimethylphenoxy)-5,7-dihydrofuro-[3,4-d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzamide",0.83,uM,=,-0.0809219076239261,0,c1ccc(CN2CCC(Nc3nc4c(c(Oc5ccccc5)n3)COC4)CC2)cc1
3834,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,COc1cnc2ccc(=O)n(CCN3CC[C@@H](NCc4cnc(C)c(C#N)c4)[C@@H](F)C3)c2c1,"5-(((3S,4R)-3-Fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile",90.0,uM,=,1.954242509439325,1,O=c1ccc2ncccc2n1CCN1CCC(NCc2cccnc2)CC1
3835,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CC6(CCOC6)C5)cc4)C3)o2)cc1,"(3-(4-(6-oxa-2-azaspiro[3.4]octan-2-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone",16.0,uM,=,1.2041199826559248,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CC4(CCOC4)C3)cc2)C1
3836,613538,10.1021/jm901781q,,,,Inhibition of human ERG by patch-clamp method,CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21,"3-(4-(2-hydroxyethyl)piperazin-1-yl)-1-(2-propoxyethyl)-7-(6-methoxypyridin-3-yl)pyrido[3,4-b]pyrazin-2(1H)-one",1.79,uM,=,0.2528530309798932,1,O=c1[nH]c2cc(-c3cccnc3)ncc2nc1N1CCNCC1
3837,687332,10.1016/j.bmcl.2010.10.042,,,,Displacement of [3H]-dofetilide from human ERG,N#Cc1ccc(CNC(=O)N(c2cccc(F)c2)C2CCN(CCC3(c4cccc(F)c4)CCN(C(=O)c4ccc(F)cc4O)CC3)CC2)cc1,3-(4-cyanobenzyl)-1-(1-(2-(1-(4-fluoro-2-hydroxybenzoyl)-4-(3-fluorophenyl)piperidin-4-yl)ethyl)piperidin-4-yl)-1-(3-fluorophenyl)urea,0.8,uM,=,-0.0969100130080563,0,O=C(c1ccccc1)N1CCC(CCN2CCC(N(C(=O)NCc3ccccc3)c3ccccc3)CC2)(c2ccccc2)CC1
3838,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nnc(O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,3,4-oxadiazol-2-ol",22.4,uM,=,1.3502480183341627,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4nnco4)N3)n2)nc1
3839,795379,10.1016/j.bmcl.2011.10.111,,,,Inhibition of human ERG,CC(=O)Nc1cccc(C2CCN(CCCn3nc(-c4ccc(F)c(F)c4)c4ccccc4c3=O)CC2)c1,"4-(3,4-difluorophenyl)-2-[3-[4-[3-(acetylamino)phenyl]piperidin-1-yl]propyl]phthalazin-1(2H)-one",16.0,uM,=,1.2041199826559248,1,O=c1c2ccccc2c(-c2ccccc2)nn1CCCN1CCC(c2ccccc2)CC1
3840,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,CCN(CC)CC(=O)N[C@@H]1CC[C@@H](C(=O)NC(c2ccc(F)cc2)c2ccc(F)cc2)[C@H](c2ccc(Br)cc2)C1,"(1R,2R,4R)-N-(bis(4-fluorophenyl)methyl)-2-(4-bromophenyl)-4-(2-(diethylamino)acetamido)cyclohexanecarboxamide",0.78,uM,=,-0.1079053973095195,0,O=C(NC(c1ccccc1)c1ccccc1)[C@@H]1CCCC[C@H]1c1ccccc1
3841,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(S(C)(=O)=O)cc1F)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1,2-(2-fluoro-4-(methylsulfonyl)phenyl)-N-methyl-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)acetamide,2.6,uM,=,0.414973347970818,1,O=C(Cc1ccccc1)NC1CCN(Cc2ccccc2)CC1
3842,1904027,10.1021/acs.jmedchem.9b01392,,,,Inhibition of human ERG,COc1nn(C)cc1Nc1ncc(Cl)c(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1,(2R)-N-(3-(5-chloro-2-(3-methoxy-1-methyl-1H-pyrazol-4-ylamino)pyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide,22.0,uM,=,1.3424226808222062,1,O=C(CN1CCNCC1)Nc1cccc2c(-c3ccnc(Nc4cn[nH]c4)n3)c[nH]c12
3843,1665800,10.1021/acs.jmedchem.7b00328,,,,Inhibition of human ERG by thallium flux assay,CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ccccn5)CC4)ccc3C)cc12,2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyridin-2-yl)-cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide,5.8,uM,=,0.7634279935629373,1,O=C(NC1(c2ccccn2)CC1)c1cccc(-c2ccc3oc(-c4ccccc4)cc3c2)c1
3844,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3cnc4c(c3)OCO4)ccc2c1,"(R)-6-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-[1,3]dioxolo[4,5-b]pyridine",40.0,uM,=,1.6020599913279625,1,c1cc2nc(-c3cnc4c(c3)OCO4)ccc2cc1CCN1CCCC1
3845,597420,10.1016/j.bmcl.2009.08.080,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,CCc1n[nH]c(CC)c1Oc1cc(C#N)cc(C#N)c1,"5-(3,5-diethyl-1H-pyrazol-4-yloxy)isophthalonitrile",9.8,uM,=,0.9912260756924948,1,c1ccc(Oc2cn[nH]c2)cc1
3846,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,Clc1ccc([C@@H]2CC=CCNC2)cc1Cl,"(S)-3-(3,4-dichlorophenyl)-2,3,4,7-tetrahydro-1H-azepine",13.7,uM,=,1.136720567156407,1,C1=CC[C@@H](c2ccccc2)CNC1
3847,1475773,10.1021/jm5017413,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch-clamp assay,Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",5.1,uM,=,0.7075701760979364,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2ncno2)C1
3848,1640440,,,,,"hERG Patch Clamp Assay: All testing was carried out in CHO cells transfected with the hERG gene purchased from Millipore (PrecisION hERG-CHO Recombinant Cell Line CYL3038). The cell line was grown in DMEM/F-12, GlutaMAX with 10% fetal bovine serum, 1% Penicillin-Streptomycin, 1% Geneticin and 1% of 1M HEPES buffer solution, and maintained at approximately 37 °C. in a humidified atmosphere containing 5% carbon dioxide. The cells were passaged every 3-5 days based on confluency. On the day of the experiment, 50%-80% confluent cells were harvested from a 175 cm2 culture flask using Detachin. After 10 minutes of exposure to Detachin at 37 °C., the cells were centrifuged for 1 minute at 1000 RPM. The supernatant was removed and the cell pellet was reconstituted in 5-8 mL of serum free media with 2.5% of 1M HEPES, placed on the Qstirrer, and allowed to recover. After a 30 minute recovery period, experiments were initiated.",C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2cc(NC(=O)c3ccc(C#N)cn3)cs2)CO1,"US9315520, Comparator 5",1.8,uM,=,0.255272505103306,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)c1)c1ccccn1
3849,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,CN1CCC[C@H]1c1cccnc1,3-((S)-1-Methyl-pyrrolidin-2-yl)-pyridine,244.3,uM,=,2.3879234669734366,1,c1cncc([C@@H]2CCCN2)c1
3850,1973040,10.1021/acsmedchemlett.0c00015,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,COC(=O)N1CCN(C(=O)c2ccc(-c3cnn4c(N)c(-c5ccccc5)c(NC5CC(C)(C)N(C)C(C)(C)C5)nc34)cc2)CC1,"methyl 4-(4-(7-amino-5-((1,2,2,6,6-pentamethylpiperidin-4-yl)amino)-6-phenylpyrazolo[1,5-a]pyrimidin-3-yl)benzoyl)piperazine-1-carboxylate",7.5,uM,=,0.8750612633917001,1,O=C(c1ccc(-c2cnn3cc(-c4ccccc4)c(NC4CCNCC4)nc23)cc1)N1CCNCC1
3851,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3cccc(C(=O)O)c3)CC2)C1,"3-(1-((1R,3S)-3-((3,5-bis(trifluoromethyl)benzyl)carbamoyl)-3-isopropylcyclopentyl)piperidin-4-yl)benzoic acid",0.6,uM,=,-0.2218487496163563,0,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3ccccc3)CC2)C1
3852,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,O=C1CN(CCc2ccc(F)cc2)CCN1[C@H]1CCc2cc(CN3CCOCC3)ccc2C1,"(S)-4-(4-fluorophenethyl)-1-(6-(morpholinomethyl)-1,2,3,4-tetrahydronaphthalen-2-yl)piperazin-2-one",11.0,uM,=,1.0413926851582251,1,O=C1CN(CCc2ccccc2)CCN1[C@H]1CCc2cc(CN3CCOCC3)ccc2C1
3853,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCC3CCOCC3)C[C@@H]2CNC(=O)c2cccc(Cl)c2)cc1,"rac-3-chloro-N-(((3S,4S)-4-(4-methoxyphenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)pyrrolidin-3-yl)methyl)benzamide",1.96,uM,=,0.292256071356476,1,O=C(NC[C@H]1CN(CCC2CCOCC2)C[C@@H]1c1ccccc1)c1ccccc1
3854,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)N(C)C)C2,"2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-N,N-dimethyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxamide",8.3,uM,=,0.919078092376074,1,c1ccc(-c2nocc2COc2ccc3c(n2)CCNC3)cc1
3855,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,COc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1,"2-(4-((4-(5-(6-methoxypyridin-3-yl)-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-3-phenyl-1,6-naphthyridin-5(6H)-one",1.22,uM,=,0.0863598306747482,1,O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6cccnc6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12
3856,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2,1-Methyl-1H-indazole-3-carboxylic acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide,3.73,uM,=,0.5717088318086876,1,O=C(NC1CC2CCCC(C1)N2)c1n[nH]c2ccccc12
3857,622012,10.1021/jm901319p,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1ncoc1-c1nnc(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3)C2)n1C,"(1S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane",0.2,uM,=,-0.6989700043360187,0,c1ccc([C@]23C[C@H]2CN(CCCSc2nnc(-c4cnco4)[nH]2)C3)cc1
3858,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(OC)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3,6-dimethoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",4.26,uM,=,0.6294095991027189,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3859,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1cccn1)c1ccccc1,1-(1-phenyl-2-(1H-pyrazol-1-yl)ethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,4.04,uM,=,0.6063813651106049,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(Cn1cccn1)c1ccccc1
3860,1616176,10.1021/acs.jmedchem.6b00487,,,,Inhibition of human ERG,COc1c(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)ccc2c1CCCC(N1CCN(CCO)CC1)C2,"rac-2-[[5-Chloro-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]amino]-pyrimidin-4-yl]amino]-N,N-dimethylbenzenesulfonamide",0.24,uM,=,-0.619788758288394,0,c1ccc(Nc2ccnc(Nc3ccc4c(c3)CCCC(N3CCNCC3)C4)n2)cc1
3861,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CCC(NCc4ccc5c(n4)NC(=O)CO5)CC3)c2c1,"6-[({1-[2-(7-Methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]-piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",35.0,uM,=,1.5440680443502757,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)cnc5ccccc54)CC3)nc2N1
3862,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),0.032,uM,=,-1.494850021680094,0,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1
3863,1973041,10.1021/acsmedchemlett.0c00015,,,,Inhibition of human ERG expressed in human embryonic kidney cells by manual patch clamp assay,CN1C(C)(C)CC(Nc2nc3c(-c4ccc(C(=O)N5C[C@@H]6C[C@H]5CO6)cc4)cnn3c(N)c2-c2ccccc2)CC1(C)C,"(4-(7-amino-5-((1,2,2,6,6-pentamethylpiperidin-4-yl)amino)-6-phenylpyrazolo[1,5-a]pyrimidin-3-yl)phenyl)((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methanone",2.8,uM,=,0.4471580313422192,1,O=C(c1ccc(-c2cnn3cc(-c4ccccc4)c(NC4CCNCC4)nc23)cc1)N1C[C@@H]2C[C@H]1CO2
3864,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Cc1nc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"5-methyl-3-((1R,3R)-1-(1-methyl-1H-pyrazol-4-yl)-3-(4-(pyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,2,4-oxadiazole",5.503,uM,=,0.7405995128111565,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)nc1
3865,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(6-(((1s,3R,4S)-3,4-dihydroxycyclopentyl)methoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.1,uM,=,0.4913616938342727,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7CCCC7)nc56)(CC3)OC4)nc2N1
3866,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCN(CC(O)c3ncc(C#N)cc3Cl)CC2)ccc2c1COC2=O,"5-chloro-6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)nicotinonitrile",16.0,uM,=,1.2041199826559248,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
3867,1447392,10.1016/j.bmcl.2014.04.085,,,,Inhibition of human ERG channel,CCOC(=O)N1CCC(CN2CCC3(CC2)CC(=O)N(CC)c2ncccc23)CC1,"ethyl 4-((1-ethyl-2-oxo-2,3-dihydro-1H-spiro[[1,8]naphthyridine-4,4'-piperidine]-1'-yl)methyl)piperidine-1-carboxylate",2.89,uM,=,0.4608978427565479,1,O=C1CC2(CCN(CC3CCNCC3)CC2)c2cccnc2N1
3868,1789492,10.1021/acs.jmedchem.8b01533,,,,Inhibition of human ERG expressed in CHO-S1 cells by Qpatch clamp assay,CC(C)(C)c1ccc(CN2CCC3(CCCCO3)CC2)cc1,9-(4-tert-butylbenzyl)-1-oxa-9-azaspiro[5.5]undecane,8.1,uM,=,0.9084850188786496,1,c1ccc(CN2CCC3(CCCCO3)CC2)cc1
3869,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,CCCCCc1nn(-c2nc(N)c3c(n2)NC(=O)C3(C)C)c2ccc(Cl)cc12,"4-amino-2-(5-chloro-3-pentyl-indazol-1-yl)-5,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-6-one",9.0,uM,=,0.9542425094393248,1,O=C1Cc2cnc(-n3ncc4ccccc43)nc2N1
3870,493421,10.1016/j.bmcl.2008.10.025,,,,Inhibition of human ERG expressed in CHO cells,CCCCC1(c2ccc3[nH]ccc3c2)CCNC1,5-(3-butylpyrrolidin-3-yl)-1H-indole,4.4,uM,=,0.6434526764861874,1,c1cc2cc(C3CCNC3)ccc2[nH]1
3871,1972831,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(CCO)CC3)c(Cl)c2)cc1C#Cc1cnc2cccnn12,"N-[3-chloro-4-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]phenyl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",0.1,uM,=,-1.0,0,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(C#Cc2cnc3cccnn23)c1
3872,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1,N-methyl-2-(4-(methylsulfonyl)phenyl)-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)acetamide,3.0,uM,=,0.4771212547196624,1,O=C(Cc1ccccc1)NC1CCN(Cc2ccccc2)CC1
3873,803124,10.1016/j.bmcl.2011.12.117,,,,Inhibition of human ERG by electrophysiological assay,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@H](c2ccc(S(C)(=O)=O)cc2)c2cc(F)cc(F)c2)CC1,"(R)-N-(1-(3-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide",1.9,uM,=,0.2787536009528289,1,O=C(Cc1ccccc1)NC1CCN(CCC(c2ccccc2)c2ccccc2)CC1
3874,1677359,10.1021/acs.jmedchem.7b01454,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK cells after 180 mins by scintillation counting method,CC(C)[C@@H](N)CN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2,(R)-1-{3-[Bis-(4-fluoro-phenyl)-methoxy]-8-aza-bicyclo[3.2.1]oct-8-ylmethyl}-2-methyl-propylamine,4.36,uM,=,0.6394864892685861,1,c1ccc(C(OC2CC3CCC(C2)N3)c2ccccc2)cc1
3875,49081,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,C[C@@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@H](C)N1,"5-Amino-1-cyclopropyl-7-(3,5-dimethyl-piperazin-1-yl)-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid",34.4,uM,=,1.5365584425715302,1,O=c1ccn(C2CC2)c2cc(N3CCNCC3)ccc12
3876,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,Fc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCCCC4)N3)n2)nc1,"(3R)-1-cyclohexyl-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.17,uM,=,-0.7695510786217261,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCCCC4)N3)n2)nc1
3877,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1ccc2nc(-c3ccc(OC4CCN(C5CCC5)CC4)cc3)n(C)c(=O)c2c1,2-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-6-methoxy-3-methylquinazolin-4(3H)-one,3.8,uM,=,0.5797835966168101,1,O=c1[nH]c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2ccccc12
3878,460777,10.1021/jm070637u,,,,Inhibition of hERG potassium channel expressed in CHO cells by isotope efflux assay,C[C@@H](NC(=O)c1ccc(-c2ccc(Cl)cc2)o1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1,(R)-5-(4-chlorophenyl)-N-(1-(4-(3-(4-(cyclopropanecarbonyl)phenoxy)propyl)piperazin-1-yl)-1-oxopropan-2-yl)furan-2-carboxamide,0.8,uM,=,-0.0969100130080563,0,O=C(NCC(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1)c1ccc(-c2ccccc2)o1
3879,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NCc3c(Cl)cc4c(c3Cl)OCCO4)(CC1)CO2,"(R)-4-((4-((5,7-dichloro-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",30.4,uM,=,1.4828735836087537,1,O=c1ccc2nccc3c2n1CC3CC12CCC(NCc3ccc4c(c3)OCCO4)(CC1)CO2
3880,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCNCC4)N3)n2)cc1,"(3R)-3-(4-phenyl-1H-imidazol-2-yl)-1-(piperidin-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",5.1,uM,=,0.7075701760979364,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCNCC4)N3)n2)cc1
3881,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,Cn1c(=O)n([C@H]2CCCOC2)c2c3cc(-c4ccc(OCCCN5CCCCC5)nc4)c(F)cc3ncc21,"US9428503, 47",18.0,uM,=,1.255272505103306,1,O=c1[nH]c2cnc3ccc(-c4ccc(OCCCN5CCCCC5)nc4)cc3c2n1[C@H]1CCCOC1
3882,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2ccc3ncc(C(N)=O)c(N[C@@H](C)C4CCOCC4)c3c2)cn1,(S)-6-(6-(methoxymethyl)pyridin-3-yl)-4-(1-(tetrahydro-2H-pyran-4-yl)ethylamino)quinoline-3-carboxamide,4.5,uM,=,0.6532125137753437,1,c1cncc(-c2ccc3nccc(NCC4CCOCC4)c3c2)c1
3883,945538,10.1016/j.bmcl.2012.10.140,,,,Inhibition of human ERG expressed in CHO cells by IONWORKS assay,CC(C)(C)NC(=O)NCCN1CC(NC(=O)c2cc(Cl)cc(Cl)c2)C1,"N-(1-(2-(3-tert-butylureido)ethyl)azetidin-3-yl)-3,5-dichlorobenzamide",13.0,uM,=,1.1139433523068367,1,O=C(NC1CNC1)c1ccccc1
3884,1755294,10.1021/acs.jmedchem.8b00270,,,,Inhibition of human ERG,CS(=O)(=O)N1CCN(C(=O)c2cnc3ccc(F)cc3c2N2CCC(C#N)(c3ccccc3)CC2)CC1,1-(6-Fluoro-3-(4-(methylsulfonyl)piperazine-1-carbonyl)-quinolin-4-yl)-4-phenylpiperidine-4-carbonitrile,5.46,uM,=,0.7371926427047373,1,O=C(c1cnc2ccccc2c1N1CCC(c2ccccc2)CC1)N1CCNCC1
3885,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CCC1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)(C(C)C)C1,"cis-((1S,3R)-3-((4S)-3-ethyltetrahydro-2H-pyran-4-ylamino)-1-isopropylcyclopentyl)(4-(4-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methanone",1.2,uM,=,0.0791812460476248,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2ccccn2)CC1
3886,1667873,10.1016/j.bmcl.2017.03.043,,,,Inhibition of human ERG,O=S(=O)(Nc1cscn1)c1cc(Cl)c(OCC2NCCC=C2c2ccc(F)cc2)cc1F,"5-chloro-2-fluoro-4-((3-(4-fluorophenyl)-1,2,5,6-tetrahydropyridin-2-yl)methoxy)-N-(thiazol-4-yl)benzenesulfonamide",10.3,uM,=,1.0128372247051722,1,O=S(=O)(Nc1cscn1)c1ccc(OCC2NCCC=C2c2ccccc2)cc1
3887,598542,10.1016/j.bmcl.2009.07.023,,,,Inhibition of human ERG potassium channel 1,CCCNCc1ccc(CCn2ccc(OCc3ccc(F)cc3)cc2=O)nc1,4-(4-fluorobenzyloxy)-1-(2-(5-((propylamino)methyl)pyridin-2-yl)ethyl)pyridin-2(1H)-one,5.1,uM,=,0.7075701760979364,1,O=c1cc(OCc2ccccc2)ccn1CCc1ccccn1
3888,1804296,10.1021/acs.jmedchem.8b01096,,,,Inhibition of human ERG expressed in HEK293 cells at -50 mV holding potential by patch clamp assay,O=C1CCc2cc(C(O)CCCN3CCC(c4noc5cc(F)ccc45)CC3)cc3c2N1CC3,"8-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)-1-hydroxybutyl)-5,6-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-4(2H)-one",1.8996,uM,=,0.2786621609099807,1,O=C1CCc2cc(CCCCN3CCC(c4noc5ccccc45)CC3)cc3c2N1CC3
3889,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2nc(C)n(-c3ccc(OCCCN4CCCC4)cc3)c(=O)c12,5-Methoxy-2-methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,10.0,uM,=,1.0,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
3890,1440048,10.1021/jm500887k,,,,Inhibition of human ERG channel by patch clamp technique,C[S+]([O-])c1ccc(-c2cnc3ccc(-c4cccc([S+](C)[O-])c4)nn23)cc1,"6-(3-(methylsulfinyl)phenyl)-3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine",12.0,uM,=,1.0791812460476249,1,c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1
3891,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,CC(C)(N)CNc1nn2c(-c3ccc(F)cc3F)cnc2s1,"N1-[5-(2,4-difluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-2-methylpropane-1,2-diamine",22.0,uM,=,1.3424226808222062,1,c1ccc(-c2cnc3scnn23)cc1
3892,1988418,10.1021/acsmedchemlett.0c00239,,,,Inhibition of human ERG,CNC(=O)[C@H](C)Cn1cnc2ccc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4Cl)c3)cc2c1=O,"(R)-3-(6-(5-(2-chloro-4-fluorophenylsulfonamido)-6-methoxypyridin-3-yl)-4-oxoquinazolin-3(4H)-yl)-N,2-dimethylpropanamide",27.5,uM,=,1.4393326938302626,1,O=c1[nH]cnc2ccc(-c3cncc(NS(=O)(=O)c4ccccc4)c3)cc12
3893,984415,10.1021/jm400314m,,,,Binding affinity to human ERG channel,CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(Cl)cc3)n2CCN1C(=O)CN,"2-amino-1-(3-(4-chlorophenylamino)-2-(4-fluorophenyl)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone",7.2,uM,=,0.8573324964312685,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
3894,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,Cc1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2C)n1,"2-(3-Methyl-[1,2,4]triazol-1-yl)-1-((R)-2-methyl-4-(2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl)-piperazin-1-yl)-ethanone",0.017,uM,=,-1.769551078621726,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
3895,808069,10.1016/j.bmcl.2012.01.080,,,,Inhibition of human ERG by patch-clamp assay,O=C(c1cccn2ccnc12)N1CCN(CCc2ccc(F)cc2F)CC1,"(4-(2,4-difluorophenethyl)piperazin-1-yl)(imidazo[1,2-a]pyridin-8-yl)methanone",1.9,uM,=,0.2787536009528289,1,O=C(c1cccn2ccnc12)N1CCN(CCc2ccccc2)CC1
3896,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C1CCOC1)C2=O,"2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-6-(tetrahydrofuran-3-yl)-7,8-dihydro-1,6-naphthyridin-5(6H)-one",3.2,uM,=,0.505149978319906,1,O=C1c2ccc(OCc3conc3-c3ccccc3)nc2CCN1C1CCOC1
3897,1522961,10.1016/j.bmcl.2015.04.057,,,,Inhibition of human ERG,Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4ccc(Cl)cc4[nH]3)c(Cl)c2)n1,"(R)-2,6-dichloro-N-(2-(6-chloro-1H-benzo[d]imidazol-2-yl)-2-(3-fluorophenyl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",5.351,uM,=,0.7284349509742548,1,O=C(NC[C@@H](c1ccccc1)c1nc2ccccc2[nH]1)c1ccc(-n2cncn2)cc1
3898,467875,10.1016/j.bmcl.2008.04.074,,,,Inhibition of human ERG,O=C1N=CC=C2N=C(c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)C(c3ccccc3)=CC12,"3-phenyl-2-(4-((4-(5-(pyridin-2-yl)-1H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-1,6-naphthyridin-5(4aH)-one",5.61,uM,=,0.7489628612561614,1,O=C1N=CC=C2N=C(c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)C(c3ccccc3)=CC12
3899,1496337,10.1021/ml500505q,,,,Inhibition of human ERG expressed in HEK293 cells by FLIPR based flux assay,CC(C)CC[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1NC(=O)CNC(=O)c1cccc(C(F)(F)F)c1,"N-(2-((1S,2R,4R)-2-isopentyl-4-(isopropyl(methyl)amino)cyclohexylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide",2.7,uM,=,0.4313637641589873,1,O=C(CNC(=O)c1ccccc1)NC1CCCCC1
3900,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CC[C@H](O)[C@@H](N)C3)nn12,"(3S,4S)-3-Amino-1-(5-(4-fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-ol",28.5,uM,=,1.4548448600085102,1,c1ccc(-c2cnc3sc(N4CCCCC4)nn23)cc1
3901,580799,10.1016/j.bmcl.2009.06.095,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells overexpressing Ikr channel protein,Cc1ccc(-n2c(-c3ncccc3Cl)nc(CN[C@H]3CC[C@@H](F)C3)c2C)cn1,"(1S,3R)-N-((2-(3-chloropyridin-2-yl)-5-methyl-1-(6-methylpyridin-3-yl)-1H-imidazol-4-yl)methyl)-3-fluorocyclopentanamine",31.0,uM,=,1.4913616938342726,1,c1ccc(-c2nc(CNC3CCCC3)cn2-c2cccnc2)nc1
3902,1473398,10.1021/jm501920g,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,Clc1ccc(-n2cc(NCCN3CCCCC3)nn2)cc1Cl,"1-(3,4-dichlorophenyl)-N-(2-(piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-amine",1.7,uM,=,0.2304489213782739,1,c1ccc(-n2cc(NCCN3CCCCC3)nn2)cc1
3903,1637594,,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in outward tail current after 5 mins at -80 mV holding potential by patch clamp assay,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1.Cl.Cl,N-(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide dihydrochloride,0.5,uM,=,-0.3010299956639812,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
3904,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CN1CCC(Cn2nc(-c3ccc4cc(OC5CCC5)ccc4c3)c3c(N)ncnc32)CC1,"3-(6-Cyclobutoxynaphthalen-2-yl)-1-((1-methylpiperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.2,uM,=,-0.6989700043360187,0,c1ncc2c(-c3ccc4cc(OC5CCC5)ccc4c3)nn(CC3CCNCC3)c2n1
3905,886196,10.1016/j.bmcl.2012.10.036,,,,Inhibition of dofetilide binding to human ERG by patch clamp assay,CC(=O)NC1CC2CCC(C1)N2CCc1ccc(Oc2nc3ncccc3s2)cc1,"N-(8-(4-(thiazolo[4,5-b]pyridin-2-yloxy)phenethyl)-8-azabicyclo[3.2.1]octan-3-yl)acetamide",8.3,uM,=,0.919078092376074,1,c1cnc2nc(Oc3ccc(CCN4C5CCCC4CC5)cc3)sc2c1
3906,1518195,10.1016/j.bmcl.2015.09.018,,,,Inhibition of human ERG by flux assay,O=c1c2cc(-c3ccc(Cl)cc3)cn2ncn1-c1ccc(N2CC(O)C2)nc1,"6-(4-chlorophenyl)-3-(6-(3-hydroxyazetidin-1-yl)pyridin-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one",3.3,uM,=,0.5185139398778875,1,O=c1c2cc(-c3ccccc3)cn2ncn1-c1ccc(N2CCC2)nc1
3907,1628654,10.1021/acsmedchemlett.6b00471,,,,Inhibition of human ERG by patch clamp assay,Brc1ccc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncnn12,"(2R)-N-{7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-yl}-3'H-4-azaspiro[bicyclo[2.2.2]octane-2,2'-[1,4]oxazole]-5'-amine",2.5,uM,=,0.3979400086720376,1,c1cc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncnn2c1
3908,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)s1,3-Endo-(8-((5-methylthiophen-2-yl)methyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.00026,uM,=,-3.585026652029182,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccs2)cc1
3909,675101,10.1016/j.bmcl.2010.08.121,,,,Inhibition of human ERG by Isotopic flux assay,O=C(NCc1cccnc1OCC(F)(F)F)c1cncc(-c2ccc(Cl)cc2)c1,"5-(4-chlorophenyl)-N-((2-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)nicotinamide",19.0,uM,=,1.2787536009528289,1,O=C(NCc1cccnc1)c1cncc(-c2ccccc2)c1
3910,1475693,10.1016/j.bmcl.2015.04.002,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,COc1ccc2ncc(C(F)F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-(difluoromethyl)-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.75,uM,=,0.2430380486862944,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3911,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,COc1cc(Nc2cnc(C#N)c(O[C@H](C)CN(C)C)n2)ncc1-c1cnn(C)c1,(R)-3-((1-(Dimethylamino)propan-2-yl)oxy)-5-((4-methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)pyrazine-2-carbonitrile,5.0,uM,=,0.6989700043360189,1,c1cnc(Nc2ccc(-c3cn[nH]c3)cn2)cn1
3912,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cnccc3CO)cc12,5-(4-(Hydroxymethyl)pyridin-3-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-3-carboxamide,41.3,uM,=,1.615950051656401,1,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cccnc3)cc12
3913,463271,10.1016/j.bmcl.2007.11.052,,,,Inhibition of human ERG,C[C@@H](Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12)C(=O)N(C)CCO,(R)-2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)-N-(2-hydroxyethyl)-N-methylpropanamide,12.0,uM,=,1.0791812460476249,1,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
3914,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide,0.02,uM,=,-1.6989700043360187,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
3915,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(CNC(=O)c2ccccc2)c1,N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methyl)benzamide,18.8,uM,=,1.2741578492636798,1,O=C(NCc1cncc(-c2ccccc2)c1)c1ccccc1
3916,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@@]3(O)CO[C@@H]4[C@@H](NCc5cc6c(cn5)OCCO6)CO[C@@H]43)c2n1,"(3R,3aS,6S,6aR)-6-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-3-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)hexahydrofuro[3,2-b]furan-3-ol",66.0,uM,=,1.8195439355418688,1,c1cnc2c(CCC3CO[C@@H]4[C@@H](NCc5cc6c(cn5)OCCO6)CO[C@H]34)ccnc2c1
3917,1879326,10.1021/acs.jmedchem.9b01172,,,,Inhibition of human ERG assessed as reduction in channel tail current by plate-based planar patch clamp assay,CN(C)C(=O)CNCCc1cccc(OCCCCC(F)(F)F)c1.Cl,"2-((3-(5,5,5-Trifluoropentoxy)phenethyl)amino)-N,N,-dimethylacetamide Hydrochloride",9.6,uM,=,0.9822712330395684,1,c1ccccc1
3918,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,CCCCCCC#Cc1cccc(C#CCCCCCC)[n+]1C,"1-methyl-2,6-di(oct-1-ynyl)pyridinium",1.992,uM,=,0.2992893340876799,1,c1cc[nH+]cc1
3919,611802,10.1021/jm9015075,,,,Inhibition of human ERG,Cc1nc2nc(N3CCN4CCC3CC4)oc2cc1Cl,"4-(6-Chloro-5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo-[3.2.2]nonane",16.2,uM,=,1.209515014542631,1,c1cnc2nc(N3CCN4CCC3CC4)oc2c1
3920,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CS(=O)(=O)Nc1ccc(OC[C@@H](O)CNCCc2ccc(F)c(F)c2)cc1,"(S)-1-(4-Methanesulfonamidophenoxy)-3-(3,4-difluorophenylethylamino)-2-propanol",1.63,uM,=,0.2121876044039577,1,c1ccc(CCNCCCOc2ccccc2)cc1
3921,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc2ncccc2cc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,"2-methyl-3-{6-[2-([2R]-2-methylpyrrolidin-1-yl)-ethyl]quinolin-2-yl}-[1,8]naphthyridine",40.0,uM,=,1.6020599913279625,1,c1cnc2ncc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cc2c1
3922,1436764,10.1021/ml500187a,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated whole-cell patch-clamp electrophysiology method,Clc1ccc(CN(C2CC2)C2CNC2)cc1Cl,"N-cyclopropyl-N-(3,4-dichlorobenzyl)azetidin-3-amine",4.71,uM,=,0.6730209071288962,1,c1ccc(CN(C2CC2)C2CNC2)cc1
3923,2264097,10.1021/acs.jmedchem.1c00703,,,,Inhibition of hERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp assay,COCCCN1CCC(O)(NC(=O)c2nn(C(C)C)c3ccccc23)CC1.O=C(O)C(=O)O,1-Isopropyl-1H-indazole-3-carboxylic Acid[4-Hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide Oxalate,1.5,uM,=,0.1760912590556812,1,O=C(NC1CCNCC1)c1n[nH]c2ccccc12
3924,1288300,10.1016/j.bmcl.2013.12.078,,,,Inhibition of human ERG by whole-cell patch clamp method,COc1ccccc1N1CCN(CCCC(C(=O)O)(c2ccc(Br)cc2)C(C)C)CC1,2-(4-bromophenyl)-2-isopropyl-5-(4-(2-methoxyphenyl)piperazin-1-yl)pentanoic acid,3.96,uM,=,0.5976951859255123,1,c1ccc(CCCCN2CCN(c3ccccc3)CC2)cc1
3925,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COc1ccc(CN2CCC(C#N)(CNC(=O)c3cc(CC(C)C)n(-c4ccccc4)n3)CC2)cc1,N-((4-cyano-1-(4-methoxybenzyl)piperidin-4-yl)methyl)-5-isobutyl-1-phenyl-1H-pyrazole-3-carboxamide,3.21,uM,=,0.5065050324048721,1,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccn(-c2ccccc2)n1
3926,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,O=C(CNc1ncnc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3ccccc3)CC2)C1,cis-N-(1-(4-phenylcyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,5.2,uM,=,0.7160033436347992,1,O=C(CNc1ncnc2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccccc3)CC2)C1
3927,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccccc1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1,N-methyl-2-phenyl-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)acetamide,1.6,uM,=,0.2041199826559248,1,O=C(Cc1ccccc1)NC1CCN(Cc2ccccc2)CC1
3928,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,N[C@@H]1CC[C@@]2(CN=C(N3CCc4ccccc4[C@@H]3c3ccc(F)cc3)O2)C1,"(5S,8R)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-1-oxa-3-azaspiro[4.4]non-2-en-8-amine",8.8,uM,=,0.9444826721501688,1,c1ccc([C@H]2c3ccccc3CCN2C2=NCC3(CCCC3)O2)cc1
3929,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,COc1c(C)cc(C2(c3cccc(-c4cncnc4)c3)N=C(N)c3c(F)cccc32)nc1C,"4-Fluoro-1-(5-methoxy-4,6-dimethylpyridin-2-yl)-1-(3-(pyrimidin-5-yl)phenyl)-1Hisoindol-3-amine",3.8,uM,=,0.5797835966168101,1,C1=NC(c2cccc(-c3cncnc3)c2)(c2ccccn2)c2ccccc21
3930,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,COc1nsc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)n1,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(3-methoxy-1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",9.6,uM,=,0.9822712330395684,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ncns3)C4=O)ccc21
3931,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",O=c1cc(OCc2ccc3ccccc3c2)ccn1-c1ccc(OCCN2CCCC2)cc1,4-(Naphthalen-2-ylmethoxy)-1-{4-[2-(pyrrolidin-1-yl)-ethoxy]phenyl}pyridin-2(1H)-one,0.00067,uM,=,-3.1739251972991736,0,O=c1cc(OCc2ccc3ccccc3c2)ccn1-c1ccc(OCCN2CCCC2)cc1
3932,2229351,10.1021/acsmedchemlett.2c00172,,,,Inhibition of hERG expressed in CHO cells by electrophysiological assay based automated patch clamp method,Cc1cc2ncccc2cc1Nc1ncc2c(n1)n([C@@H]1CCN(C)C1)c(=O)n2C,(R)-7-methyl-9-(1-methylpyrrolidin-3-yl)-2-(7-methylquinolin-6-ylamino)-7H-purin-8(9H)-one,9.6,uM,=,0.9822712330395684,1,O=c1[nH]c2cnc(Nc3ccc4ncccc4c3)nc2n1[C@@H]1CCNC1
3933,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-(2-hydroxyethoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",25.0,uM,=,1.3979400086720375,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3934,1435893,10.1016/j.bmc.2014.10.020,,,,Inhibition of human ERG expressed in CHO cells by Rb efflux assay,O=C(CNCC1(O)CCCC1)N1CCc2ccccc2C1C1CCCCC1,"1-(1-Cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-{[(1-hydroxycyclopentyl)methyl]amino}ethanone",78.6,uM,=,1.895422546039408,1,O=C(CNCC1CCCC1)N1CCc2ccccc2C1C1CCCCC1
3935,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1c(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)sc2nc3ccccc3n12,"(R)-3-methyl-2-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)benzo[d]thiazolo[3,2-a]imidazole",1.72,uM,=,0.2355284469075489,1,c1ccc2c(c1)nc1sc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cn12
3936,304899,10.1016/j.bmcl.2005.03.055,,,,Inhibitory concentration against Potassium channel HERG was determined,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)[C@H](N)C(=O)N1CC[C@H](F)C1.O=C(O)C(F)(F)F,"Trifluoro-acetate(1S,2S)-2-(4'-fluoro-biphenyl-4-yl)-1-((S)-3-fluoro-pyrrolidine-1-carbonyl)-propyl-ammonium",1.1,uM,=,0.041392685158225,1,O=C(CCc1ccc(-c2ccccc2)cc1)N1CCCC1
3937,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,CCc1nc2cc(CN3CCC(NC(=O)c4cc(=O)c5ccc(F)cc5o4)CC3)ccc2o1,N-(1-((2-ethylbenzo[d]oxazol-5-yl)methyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,20.0,uM,=,1.3010299956639813,1,O=C(NC1CCN(Cc2ccc3ocnc3c2)CC1)c1cc(=O)c2ccccc2o1
3938,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2nccc([C@@H](O)CC[C@@H]3CCN(CCSc4cccs4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-4-((S)-3-hydroxy-3-(6-methoxyquinolin-4-yl)propyl)-1-(2-(thiophen-2-ylthio)ethyl)piperidine-3-carboxylic acid",19.7,uM,=,1.294466226161593,1,c1csc(SCCN2CCC(CCCc3ccnc4ccccc34)CC2)c1
3939,1447392,10.1016/j.bmcl.2014.04.085,,,,Inhibition of human ERG channel,CCOC(=O)N1CCC(CN2CCC3(CC2)CN(S(C)(=O)=O)c2ncccc23)CC1,"ethyl 4-((1'-(methylsulfonyl)-1',2'-dihydrospiro[piperidine-4,3'-pyrrolo[2,3-b]pyridine]-1-yl)methyl)piperidine-1-carboxylate",1.9,uM,=,0.2787536009528289,1,c1cnc2c(c1)C1(CCN(CC3CCNCC3)CC1)CN2
3940,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Fc1ccc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)cn1,"2-(1,4'-bipiperidin-1'-yl)-6-(6-fluoropyridin-3-yl)thiazolo[4,5-c]pyridine",9.607843137,uM,=,0.9826259039190552,1,c1cncc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)c1
3941,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,CC(C)(C)c1cc(C(=O)NC[C@@H]2CCN(C(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc(C(C)(C)C)c1,"(S)-N-((1-(6,6-bis(4-fluorophenyl)hexanoyl)pyrrolidin-3-yl)methyl)-3,5-di-tert-butylbenzamide",2.0,uM,=,0.3010299956639812,1,O=C(NC[C@@H]1CCN(C(=O)CCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
3942,1691759,10.1016/j.ejmech.2016.11.014,,,,Inhibition of human ERG,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(C#CCCCC(=O)N3CCOCC3)c2c(=O)n1-c1ccccc1,"(S)-4-Amino-6-(2-(5-(6-morpholino-6-oxohex-1-ynyl)-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)pyrrolidin-1-yl)pyrimidine-5-carbonitrile",31.7,uM,=,1.5010592622177514,1,O=C(CCCC#Cc1cccc2nc([C@@H]3CCCN3c3ccncn3)n(-c3ccccc3)c(=O)c12)N1CCOCC1
3943,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(C3CC(C)(C)CCNC3=O)nn2)ccc1-n1cnc(C)c1,"rac-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-5,5-dimethylazepan-2-one",20.8,uM,=,1.3180633349627615,1,O=C1NCCCCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
3944,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,CCCOc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2ccnc(OC)c2OC)cc(OC)n1,"Rac-(1R,2S)-1-(6-bromo-2-methoxy-3-quinolyl)-1-(2,3-dimethoxy-4-pyridyl)-4-(dimethylamino)-2-(2-methoxy-6-propoxy-4-pyridyl)butan-2-ol",7.8,uM,=,0.8920946026904804,1,c1ccc2ncc([C@H](Cc3ccncc3)c3ccncc3)cc2c1
3945,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(NCc1ccccc1)N(c1ccc(Br)cc1)C1CCN(C2CCCC2)CC1,3-benzyl-1-(4-bromophenyl)-1-(1-cyclopentylpiperidin-4-yl)urea,0.178,uM,=,-0.7495799976911061,0,O=C(NCc1ccccc1)N(c1ccccc1)C1CCN(C2CCCC2)CC1
3946,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,CC(C)(C)c1cc(CN2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc(C(C)(C)C)c1O,"4-((4-(6,6-bis(4-fluorophenyl)hexyl)piperazin-1-yl)methyl)-2,6-di-tert-butylphenol",0.1,uM,=,-1.0,0,c1ccc(CN2CCN(CCCCCC(c3ccccc3)c3ccccc3)CC2)cc1
3947,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Cl)cc1Oc1ccc(C)cc1,1-(4-chloro-2-(p-tolyloxy)phenyl)-N-methylmethanamine,1.64,uM,=,0.2148438480476978,1,c1ccc(Oc2ccccc2)cc1
3948,627036,10.1021/jm100095x,,,,Inhibition of human ERG by electrophysiology assay,Cc1ccc(C(=O)NC2CC2)cc1-c1cc2cnn(-c3c(F)cccc3F)c2n(C)c1=O,"N-Cyclopropyl-3-(1-(2,6-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-5-yl)-4-methylbenzamide",36.0,uM,=,1.5563025007672873,1,O=C(NC1CC1)c1cccc(-c2cc3cnn(-c4ccccc4)c3[nH]c2=O)c1
3949,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,O=C(c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1)N1Cc2ccccc2C1,"Isoindolin-2-yl(4-(spiro[chromene-2,4'-piperidine]-4-yl)phenyl)methanone",3.501,uM,=,0.5441921107650326,1,O=C(c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1)N1Cc2ccccc2C1
3950,2246303,10.1021/acs.jmedchem.1c01670,,,,Inhibition of MK-499 binding to hERG,Cc1cc(C(F)(F)F)ncc1-c1ccc(C2(C(=O)Nc3ccc(F)cc3)COC2)cc1,N-(4-Fluorophenyl)-3-(4-(4-methyl-6-(trifluoromethyl)pyridin-3-yl)phenyl)oxetane-3-carboxamide,2228.0,uM,=,3.3479151865016914,1,O=C(Nc1ccccc1)C1(c2ccc(-c3cccnc3)cc2)COC1
3951,2048454,10.1016/j.bmc.2020.115734,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,COc1nc(-c2csc(Nc3c4c(nn3CCF)CCCC4)n2)ccc1-n1cnc(C)c1,"N-(2-(2-fluoroethyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",11.4,uM,=,1.0569048513364727,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCC5)n3)nc2)cn1
3952,580515,10.1016/j.bmcl.2009.06.050,,,,Displacement of [35S]MK499 from human ERG potassium channel expressed in HEK293 cells,COc1ccc([C@@H](C)N[C@@H]2CC[C@@H](C(=O)N3CCC(c4ccccc4)(c4ccc(Cl)nc4)CC3)C(C)(C)C2)cc1,"(4-(6-chloropyridin-3-yl)-4-phenylpiperidin-1-yl)((1R,4R)-4-((R)-1-(4-methoxyphenyl)ethylamino)-2,2-dimethylcyclohexyl)methanone",2.1,uM,=,0.3222192947339193,1,O=C([C@H]1CC[C@H](NCc2ccccc2)CC1)N1CCC(c2ccccc2)(c2cccnc2)CC1
3953,2222127,10.1016/j.ejmech.2022.114246,,,,Inhibition of hERG potassium channel expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,PIMAVANSERIN,0.41,uM,=,-0.3872161432802645,0,O=C(NCc1ccccc1)N(Cc1ccccc1)C1CCNCC1
3954,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,CNC(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCC[C@H]2C)C3=O)cc1,"N-Methyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydro-isoquinolin-6-yl)benzamide",17.0,uM,=,1.230448921378274,1,O=C1c2ccc(-c3ccccc3)cc2CCN1CCN1CCCC1
3955,1813578,10.1021/acs.jmedchem.9b00510,,,,Inhibition of human ERG by patch-clamp method,Cc1ccc2oc(C(=O)CC#N)c(C)c2c1,"3-(3,5-Dimethylbenzofuran-2-yl)-3-oxopropanenitrile",0.03,uM,=,-1.5228787452803376,0,c1ccc2occc2c1
3956,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cnc(-c2cnc(O[C@@H]3CCN(C(=O)Cc4ccc(OC(F)(F)F)cc4)C[C@@H]3F)c(C(N)=O)c2)c1,"2-(((3S,4R)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)-piperidin-4-yl)oxy)-5-(1-methyl-1H-imidazol-4-yl)nicotinamide",9.0,uM,=,0.9542425094393248,1,O=C(Cc1ccccc1)N1CCC(Oc2ccc(-c3c[nH]cn3)cn2)CC1
3957,687332,10.1016/j.bmcl.2010.10.042,,,,Displacement of [3H]-dofetilide from human ERG,N#Cc1ccc(CNC(=O)N(c2cccc(F)c2)C2CCN(CCC3(c4cccc(F)c4)CCN(C(=O)c4ccc(C#N)cc4)CC3)CC2)cc1,1-(1-(2-(1-(4-cyanobenzoyl)-4-(3-fluorophenyl)piperidin-4-yl)ethyl)piperidin-4-yl)-3-(4-cyanobenzyl)-1-(3-fluorophenyl)urea,0.4,uM,=,-0.3979400086720376,0,O=C(c1ccccc1)N1CCC(CCN2CCC(N(C(=O)NCc3ccccc3)c3ccccc3)CC2)(c2ccccc2)CC1
3958,1642194,,,,,Fast Patch Assay: Representative compounds were tested for hERG activity using the Fast Patch assay available from WuXiApptec (Shanghai China).,C[C@]1(O)CC[C@H](Nc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,"US9416132, 8-9",26.0,uM,=,1.414973347970818,1,c1ccc(-c2cnc3ccc(NC4CCCCC4)nn23)cc1
3959,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CN(c1ccc(-c2ccc(-n3cc(CO)cn3)cc2O)nn1)C1CC(C)(C)NC(C)(C)C1,"5-(4-(hydroxymethyl)-1H-pyrazol-1-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenol",16.0,uM,=,1.2041199826559248,1,c1cnn(-c2ccc(-c3ccc(NC4CCNCC4)nn3)cc2)c1
3960,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CC[C@@H](N)[C@@H](F)C3)nn12,"(3S,4R)-3-Fluoro-1-(5-(4-fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-amine",13.9,uM,=,1.1430148002540952,1,c1ccc(-c2cnc3sc(N4CCCCC4)nn23)cc1
3961,539843,10.1021/jm8005405,,,,Inhibition of human ERG by manual electrophysiology,CNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(C)ccc12,"N,6-Dimethyl-7-(1-((S)-3-methylmorpholino)phthalazin-6-yl)-benzo[d]isoxazol-3-amine",13.0,uM,=,1.1139433523068367,1,c1cc(-c2ccc3c(N4CCOCC4)nncc3c2)c2oncc2c1
3962,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,Cc1c(N2CC[C@@H]([C@H](C)N)C2)c(F)cc2cc(O)c(=O)n(C3CC3)c12,7-((R)-3-((S)-1-aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-8-methylquinolin-2(1H)-one,25.0,uM,=,1.3979400086720375,1,O=c1ccc2ccc(N3CCCC3)cc2n1C1CC1
3963,807853,10.1016/j.bmcl.2012.01.074,,,,Displacement of [3H]-astemizole from human ERG expressed in CHO-K1 cells membrane,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,"2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine",64.0,uM,=,1.806179973983887,1,c1cc(-c2nc(N3CCOCC3)c3sc(CN4CCNCC4)cc3n2)c2cn[nH]c2c1
3964,2238137,10.1021/acs.jmedchem.1c01012,,,,Inhibition of human ERG,Cc1cnc(N2CCN(Cc3ccc4c(c3)[nH]c(=O)c3ccccc34)CC2)n1C,"3-((4-(1,5-dimethyl-1H-imidazol-2-yl)piperazin-1-yl)methyl)phenanthridin-6(5H)-one",3.9,uM,=,0.5910646070264992,1,O=c1[nH]c2cc(CN3CCN(c4ncc[nH]4)CC3)ccc2c2ccccc12
3965,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4ccccc4N(C)C3=O)nn2)ccc1-n1cnc(C)c1,"3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-methyl-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",4.06,uM,=,0.608526033577194,1,O=C1Nc2ccccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
3966,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCN(CC)C(=O)c1ccc([C@H](c2cccc(NC(=O)OC)c2)N2CCN(Cc3cccnc3)CC2)cc1,(R)-methyl 3-((4-(diethylcarbamoyl)phenyl)(4-(pyridin-3-ylmethyl)piperazin-1-yl)methyl)phenylcarbamate,11.0,uM,=,1.0413926851582251,1,c1ccc(C(c2ccccc2)N2CCN(Cc3cccnc3)CC2)cc1
3967,1446841,10.1021/jm500715u,,,,Inhibition of human ERG,CN1CCC(c2ccc3nc(Nc4ccc(C(F)(F)F)cn4)[nH]c3c2)CC1,6-(1-Methylpiperidin-4-yl)-N-(5-(trifluoromethyl)pyridin-2-yl)-1H-benzo[d]imidazol-2-amine,4.3,uM,=,0.6334684555795865,1,c1ccc(Nc2nc3ccc(C4CCNCC4)cc3[nH]2)nc1
3968,1435893,10.1016/j.bmc.2014.10.020,,,,Inhibition of human ERG expressed in CHO cells by Rb efflux assay,O=C(CNCC1CCCCC1)N1CCc2ccccc2C1C1CCCCC1,"1-(1-Cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-[(cyclohexylmethyl)amino]ethanone",26.0,uM,=,1.414973347970818,1,O=C(CNCC1CCCCC1)N1CCc2ccccc2C1C1CCCCC1
3969,1779901,10.1021/acs.jmedchem.8b00884,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1ccc2nn(C)cc2c1NS(=O)(=O)c1ccc(CCCO[C@@H]2C[C@H]3CC[C@@H](C2)N3C)cc1,"N-(5-isobutyl-2-methyl-2H-indazol-4-yl)-4-(3-(((1R,3s,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)oxy)propyl)benzenesulfonamide",3.3,uM,=,0.5185139398778875,1,O=S(=O)(Nc1cccc2n[nH]cc12)c1ccc(CCCO[C@@H]2C[C@H]3CC[C@@H](C2)N3)cc1
3970,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,COc1cnc2ccc(=O)n(CCN3CCC(NCc4cnc(C)c(C#N)c4)CC3)c2c1,"5-((1-(2-(7-Methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)-piperidin-4-ylamino)methyl)-2-methylnicotinonitrile",50.6,uM,=,1.7041505168397992,1,O=c1ccc2ncccc2n1CCN1CCC(NCc2cccnc2)CC1
3971,585577,10.1016/j.bmcl.2009.06.081,,,,Inhibition of human ERG by whole cell patch clamp assay,CN1C[C@@H](N(Cc2ccccc2F)c2ccc(C#N)c(Cl)c2)CC1=O,(S)-2-chloro-4-((2-fluorobenzyl)(1-methyl-5-oxopyrrolidin-3-yl)amino)benzonitrile,6.5,uM,=,0.8129133566428556,1,O=C1C[C@H](N(Cc2ccccc2)c2ccccc2)CN1
3972,1435055,10.1021/jm500809c,,,,Inhibition of human ERG,Cc1nn(C)c(C)c1NS(=O)(=O)c1c(Cl)cc(-c2ccnc(N3CCNCC3)c2)cc1Cl,"2,6-Dichloro-4-(2-piperazin-1-yl-pyridin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide",28.0,uM,=,1.4471580313422192,1,O=S(=O)(Nc1cn[nH]c1)c1ccc(-c2ccnc(N3CCNCC3)c2)cc1
3973,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@H]1CN(C)C[C@@H]1c1ccc(-c2ccc(C#N)cc2)cc1,"N-((3R,4R)-4-(4'-cyanobiphenyl-4-yl)-1-methylpyrrolidin-3-yl)propane-2-sulfonamide",2.0,uM,=,0.3010299956639812,1,c1ccc(-c2ccc([C@@H]3CCNC3)cc2)cc1
3974,2287590,10.1021/acsmedchemlett.8b00517,,,,Inhibition of hERG by patch clamp assay,CCC(=O)CCCCC[C@H](NC(=O)C1CN(C)C1)c1ncc(-c2cc3ccccc3nc2OC)o1,(S)-N-(1-(5-(2-methoxyquinolin-3-yl)oxazol-2-yl)-7-oxononyl)-1-methylazetidine-3-carboxamide,10.0,uM,=,1.0,1,O=C(NCc1ncc(-c2cnc3ccccc3c2)o1)C1CNC1
3975,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,C[S+]([O-])c1ccc(-c2cnc3ccc(Nc4ccc(S(C)(=O)=O)cc4)nn23)cc1,"3-(4-(methylsulfinyl)phenyl)-N-(4-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazin-6-amine",26.1,uM,=,1.416640507338281,1,c1ccc(Nc2ccc3ncc(-c4ccccc4)n3n2)cc1
3976,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(C(F)(F)F)ncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-(6-trifluoromethyl-pyrimidin-4-yl)-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",21.0,uM,=,1.3222192947339193,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
3977,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5C)OCC(=O)N6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-7-methyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.0,uM,=,0.0,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3978,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,CCOC(=O)c1ccnc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)c1,"Ethyl 2-((1S,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)isonicotinate",1.42,uM,=,0.1522883443830564,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ccccn4)N3)n2)cc1
3979,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCSCC4)N3)n2)cc1,"(3R)-3-(4-phenyl-1H-imidazol-2-yl)-1-(tetrahydro-2H-thiopyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.12,uM,=,-0.9208187539523752,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCSCC4)N3)n2)cc1
3980,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,Cc1[nH]c2ccccc2c1CC1CCCCN1Cc1ccc(/C=C/C(=O)NO)cc1,(E)-N-Hydroxy-3-{4-[2-(2-methyl-1H-indol-3-ylmethyl)piperidin-1-ylmethyl]phenyl}acrylamide,9.1,uM,=,0.9590413923210936,1,c1ccc(CN2CCCCC2Cc2c[nH]c3ccccc23)cc1
3981,1911678,10.1021/acs.jmedchem.8b01725,,,,Inhibition of human ERG by Q-patch assay,C[C@@H]1OCC2(CCN(c3cnc4c(-c5cccc(Cl)c5Cl)n[nH]c4n3)CC2)[C@@H]1N,"(3S,4S)-8-(3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine",0.004,uM,=,-2.397940008672037,0,c1ccc(-c2n[nH]c3nc(N4CCC5(CCOC5)CC4)cnc23)cc1
3982,793275,10.1016/j.bmcl.2011.09.117,,,,Displacement of [3H]dofetilide from human ERG by liquid scintillation counting,COc1ccc2nccc([C@@H](O)CN3CCC(NCc4ccc5c(c4)OCCO5)CC3)c2c1,"(R)-2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)piperidin-1-yl)-1-(6-methoxyquinolin-4-yl)ethanol",39.8,uM,=,1.599883072073688,1,c1ccc2c(CCN3CCC(NCc4ccc5c(c4)OCCO5)CC3)ccnc2c1
3983,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C#N)cc(C3CC3)n2)(c2ccc(F)cc2)CC1,2-cyclopropyl-6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)isonicotinonitrile,17.0,uM,=,1.230448921378274,1,c1ccc(C2(COCc3cccc(C4CC4)n3)CCNCC2)cc1
3984,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,C[C@H]1COc2c(N3CC[C@@H](C4(N)CC4)C3)cc(F)c3cc(C(=O)O)c(=O)n1c23,"(S)-10-((R)-3-(1-aminocyclopropyl)pyrrolidin-1-yl)-8-fluoro-3-methyl-5-oxo-3,5-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid",126.0,uM,=,2.100370545117563,1,O=c1ccc2ccc(N3CC[C@@H](C4CC4)C3)c3c2n1CCO3
3985,1543580,10.1016/j.bmcl.2015.11.030,,,,Inhibition of human ERG by IKr binding assay,CCOC(=O)C1CCN(C(=O)c2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)CC1,"ethyl 1-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)benzoyl)piperidine-4-carboxylate",8.3,uM,=,0.919078092376074,1,O=C(c1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)N1CCCCC1
3986,1676692,10.1021/acs.jmedchem.7b01039,,,,Inhibition of human ERG by fluorescently labeled tracer binding method,Oc1ccc(Oc2ccnc3cc(-c4cnn(C5CCNCC5)c4)ccc23)cc1,4-((7-(1-(Piperidin-4-yl)-1H-pyrazol-4-yl)quinolin-4-yl)oxy)phenol,2.76,uM,=,0.4409090820652177,1,c1ccc(Oc2ccnc3cc(-c4cnn(C5CCNCC5)c4)ccc23)cc1
3987,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3cc(Br)cc(Br)c3)nn2)ccc1-n1cnc(C)c1,"1-(3,5-dibromobenzyl)-4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazole",0.1,uM,=,-1.0,0,c1ccc(Cn2cc(-c3ccc(-n4ccnc4)cc3)nn2)cc1
3988,2079116,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 10 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),CNC(=O)c1cccc(NC(=O)COc2ccc(C(=O)c3cc(Cl)ccc3Br)cc2)c1,3-(2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)acetamido)-N-methylbenzamide,0.022,uM,=,-1.6575773191777938,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1ccccc1
3989,766531,10.1016/j.bmcl.2011.06.126,,,,Inhibition of human ERG by electrophysiological assay,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccc(F)cc54)CC3)nc2N1,"6-((1-(2-(6-fluoro-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",8.5,uM,=,0.9294189257142929,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccccc54)CC3)nc2N1
3990,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)CC1CCC2(CC1)CCN(c1ccc(-c3nc4cc(C(F)(F)F)ccc4[nH]3)cn1)CC2,2-(3-(5-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-3-azaspiro[5.5]undecan-9-yl)acetic acid,5.4,uM,=,0.7323937598229685,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCCC5)CC4)nc3)nc2c1
3991,1802839,10.1016/j.ejmech.2018.08.020,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current at -80 holding potential after 100 to 200 secs by whole cell automated patch-clamp electrophysiology assay,O=C1S/C(=C\c2ccc(Oc3ccc(Br)cc3)cc2)C(=O)N1c1ccc(OCCCCN2CCN(CC3CC3)CC2)cc1,"(Z)-5-(4-(4-Bromophenoxy)benzylidene)-3-(4-(4-(4-(cyclopropylmethyl)piperazin-1-yl)butoxy)phenyl)thiazolidine-2,4-dione",27.5,uM,=,1.4393326938302626,1,O=C1S/C(=C\c2ccc(Oc3ccccc3)cc2)C(=O)N1c1ccc(OCCCCN2CCN(CC3CC3)CC2)cc1
3992,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CC(C)=Cc1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCN(C)CC2)n1,2-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-6-(2-methylprop-1-enyl)-4-(trifluoromethyl)pyridine,18.0,uM,=,1.255272505103306,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
3993,1911678,10.1021/acs.jmedchem.8b01725,,,,Inhibition of human ERG by Q-patch assay,Cc1nc(N)ccc1-c1n[nH]c2nc(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)n(C)c(=O)c12,"3-(6-amino-2-methylpyridin-3-yl)-6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-methyl-2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one",6.6,uM,=,0.8195439355418687,1,O=c1[nH]c(N2CCC3(CCOC3)CC2)nc2[nH]nc(-c3cccnc3)c12
3994,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc(C(NC(=O)CC2CC2)C(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)nc1,"2-[(Cyclopropylacetyl)amino]-2-[5-(ethylsulfonyl)pyridin-2-yl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]acetamide",34.0,uM,=,1.5314789170422551,1,O=C(CC1CC1)NC(C(=O)Nc1ccccc1)c1ccccn1
3995,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,CCC(CC)N(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1,"(S)-2,3-dichloro-N-(pentan-3-yl)-N-(pyrrolidin-3-yl)benzamide",7.74,uM,=,0.8887409606828927,1,O=C(N[C@H]1CCNC1)c1ccccc1
3996,1655139,10.1016/j.bmcl.2016.12.054,,,,Displacement of [3H]-MK499 from human ERG IKr channel expressed in HEK293 cell membranes,CN(C)C(=O)c1cccc(-c2ccc(F)cc2CC(c2cccnc2)c2cccnc2)c1,"2'-(2,2-di(pyridin-3-yl)ethyl)-4'-fluoro-N,N-dimethylbiphenyl-3-carboxamide",26.4,uM,=,1.421603926869831,1,c1ccc(-c2ccccc2CC(c2cccnc2)c2cccnc2)cc1
3997,1517213,10.1021/acs.jmedchem.5b01156,,,,Inhibition of human ERG expressed in CHO cells by patch clamp electrophysiology assay,Nc1nc(NC2CCNC2)c2sc(-c3ccc(C(F)(F)F)cc3)cc2n1,"N4-(pyrrolidin-3-yl)-6-(4-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine",2.4,uM,=,0.380211241711606,1,c1ccc(-c2cc3ncnc(NC4CCNC4)c3s2)cc1
3998,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,Nc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-amino-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00321,uM,=,-2.493494967595128,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
3999,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc2ccccn2c1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,"(R)-2-(2-methylimidazo[1,2-a]pyridin-3-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline",8.0,uM,=,0.9030899869919436,1,c1ccn2c(-c3ccc4cc(CCN5CCCC5)ccc4n3)cnc2c1
4000,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,O=C(NC1CCS(=O)(=O)CC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,"5-(2,3-Difluorophenyl)-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-indazole-3-carboxamide",2.1,uM,=,0.3222192947339193,1,O=C(NC1CCS(=O)(=O)CC1)c1n[nH]c2ccc(-c3ccccc3)cc12
4001,1654955,10.1016/j.bmcl.2016.10.032,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2cnc(S(C)(=O)=O)cn2)C3)ccc2c1COC2=O,"(R)-5-(1-hydroxy-2-(2-(5-(methylsulfonyl)pyrazin-2-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",22.7,uM,=,1.3560258571931227,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cnccn3)C4)ccc21
4002,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3cn4c(n3)SCC4)ccc2c1,"(R)-6-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-2,3-dihydroimidazo[2,1-b]thiazole",40.0,uM,=,1.6020599913279625,1,c1cc2nc(-c3cn4c(n3)SCC4)ccc2cc1CCN1CCCC1
4003,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1,"4-{3-[4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-4H-benzo[1,4]oxazin-3-one",6.6,uM,=,0.8195439355418687,1,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
4004,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(C)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-3-methyl-biphenyl-4-carboxylic acid",23.0,uM,=,1.3617278360175928,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
4005,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CC(=O)N(c2cncc(C#N)c2)C3)ccc2c1COC2=O,"(R)-5-(8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-3-oxo-2,8-diazaspiro[4.5]decan-2-yl)nicotinonitrile",1.8,uM,=,0.255272505103306,1,O=C1OCc2cc(CCN3CCC4(CC3)CC(=O)N(c3cccnc3)C4)ccc21
4006,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(CN2CCC(CNCCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc1C(C)(C)C,"N-((1-(3,5-di-tert-butyl-4-methoxybenzyl)pyrrolidin-3-yl)methyl)-6,6-bis(4-fluorophenyl)hexan-1-amine",0.11,uM,=,-0.958607314841775,0,c1ccc(CN2CCC(CNCCCCCC(c3ccccc3)c3ccccc3)C2)cc1
4007,1478753,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,C1CCC2(C1)[C@H]1CN(CC3CC3)C[C@@H]2CN(CC2CC2)C1,"3,7-di(cyclopropylmethyl)spiro[3,7-diazabicyclo[3.3.1]nonane-9,1'-cyclopentane]",2.5,uM,=,0.3979400086720376,1,C1CCC2(C1)[C@H]1CN(CC3CC3)C[C@@H]2CN(CC2CC2)C1
4008,1779901,10.1021/acs.jmedchem.8b00884,,,,Inhibition of human ERG by patch clamp assay,CC(C)Cc1ccc2nn(C)cc2c1NS(=O)(=O)c1ccc(CCCCC2CCN(C)CC2)cc1,N-(5-isobutyl-2-methyl-2H-indazol-4-yl)-4-(4-(1-methylpiperidin-4-yl)butyl)benzenesulfonamide,3.7,uM,=,0.568201724066995,1,O=S(=O)(Nc1cccc2n[nH]cc12)c1ccc(CCCCC2CCNCC2)cc1
4009,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,COCC(=O)N1Cc2cc(S(=O)(=O)CC3CC3)ccc2C1C(=O)Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,"5-(cyclopropylmethylsulfonyl)-2-(2-methoxyacetyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]isoindoline-1-carboxamide",18.0,uM,=,1.255272505103306,1,O=C(Nc1ccccc1)C1NCc2cc(S(=O)(=O)CC3CC3)ccc21
4010,1521346,10.1016/j.bmcl.2015.09.011,,,,Inhibition of human ERG by manual patch clamp assay,Cc1nn(-c2ccnc(Nc3ccc4c(c3)c(Cl)c(C)n4C)n2)cc1CN1CC(O)C1,"1-((1-(2-(3-chloro-1,2-dimethyl-1H-indol-5-ylamino)pyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methyl)azetidin-3-ol",24.2,uM,=,1.383815365980431,1,c1cc(-n2cc(CN3CCC3)cn2)nc(Nc2ccc3[nH]ccc3c2)n1
4011,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,O=C(N[C@H]1CCN(CC2CC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccc(F)cc2F)on1,"(3S,4S)-1-Cyclopropylmethyl-4-([5-(2,4-difluoro-phenyl)isoxazole-3-carbonyl]-amino)-piperidine-3-carboxylic acid (1-Pyrimidin-2-yl-cyclopropyl)-amide",5.7,uM,=,0.7558748556724915,1,O=C(N[C@H]1CCN(CC2CC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccccc2)on1
4012,1648277,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG,COCc1cnc(N2CCC([C@H]3C[C@H]3CCOc3ccc(CC(=O)N4CCC4)c(F)c3)CC2)nc1,"(cis)-1-(azetidin-1-yl)-2-(2-fluoro-4-(2-((1S,2R)-2-(1-(5-(methoxymethyl)pyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)phenyl)ethanone",19.0,uM,=,1.2787536009528289,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)cc1)N1CCC1
4013,1640014,,,,,Inhibition of human ERG expressed in CHO cells using voltage step to -50 mV for 300 ms from -80 mV holding potential by automated patch clamp assay,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,"N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide",13.4,uM,=,1.1271047983648077,1,O=C(CN1CCN(CCCOc2ccccc2)CC1)Nc1ccccc1
4014,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,CO[C@H]1CCN(CCn2ncc3cc(-n4ccc(OCc5ccccc5)cc4=O)ccc32)C1,(S)-4-(benzyloxy)-1-(1-(2-(3-methoxypyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,1.8,uM,=,0.255272505103306,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
4015,2049320,10.1021/acs.jmedchem.0c01179,,,,Inhibition of tracer red binding to human ERG expressed in HEK293 cell membranes measured after 2 to 6 hrs by fluorescence polarization assay,CC(C)CN1C[C@H](Cc2ccc(Cl)cc2)N(C2CCN(c3n[nH]c(N)n3)CC2)C[C@@H]1C,"5-(4-((2S,5S)-2-(4-chlorobenzyl)-4-isobutyl-5-methylpiperazin-1-yl)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",2.4,uM,=,0.380211241711606,1,c1ccc(C[C@H]2CNCCN2C2CCN(c3nc[nH]n3)CC2)cc1
4016,990657,10.1016/j.bmcl.2013.08.104,,,,Inhibition of human ERG by electrophysiology assay,O=C1OCCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21,6-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isochroman-1-one,18.0,uM,=,1.255272505103306,1,O=C1OCCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
4017,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,N#Cc1ccc2ccc(=O)n(CCN3CC[C@@H](NCc4ccc5c(n4)NC(=O)CO5)[C@@H](F)C3)c2c1,"cis-1-[2-((3S,4R)-3-Fluoro-4-{[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino}piperidin-1-yl)ethyl]-2-oxo-1,2-dihydroquinoline-7-carbonitrile",168.0,uM,=,2.225309281725863,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)ccc5ccccc54)CC3)nc2N1
4018,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ncc2ccc(=O)n(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"8-(2-(4-((2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)-methylamino)piperidin-1-yl)ethyl)-2-methoxypyrido[2,3-d]-pyrimidin-7(8H)-one",206.0,uM,=,2.3138672203691533,1,O=c1ccc2cncnc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
4019,579539,10.1016/j.bmcl.2009.05.101,,,,Inhibition of [35S]MK499 binding to human ERG transfected in HEK293 cells by microscintillation counting,CC1C(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc2S1(=O)=O,"(+/-)-1-{3-[4-(3-Methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",1.3,uM,=,0.1139433523068367,1,O=S1(=O)CC(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
4020,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,Cc1ccc(C(C)N2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)s1,endo-3-(8-(1-(5-methylthiophen-2-yl)ethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0016,uM,=,-2.7958800173440754,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccs2)cc1
4021,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,O=C1OCc2cc(/C=C/C3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21,(E)-5-(2-(1-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperidin-4-yl)vinyl)isobenzofuran-1(3H)-one,1.8,uM,=,0.255272505103306,1,O=C1OCc2cc(/C=C/C3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
4022,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(F)cc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide",15.1,uM,=,1.1789769472931697,1,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
4023,1760517,10.1021/acs.jmedchem.8b00372,,,,Inhibition of human ERG expressed in CHO cells at 10 nM to 10 uM at holding potential of -80 mV measured after 5 mins by QPatch automated patch clamp electrophysiology method,CS(=O)(=O)c1ccc(-c2cccc(F)c2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1,"2-(2-Fluorophenyl)-5-[2-(3-fluorophenyl)-5-methanesulfonylbenzoyl]-2H,4H,5H,6H-pyrrolo[3,4-c]-pyrazole",4.5,uM,=,0.6532125137753437,1,O=C(c1ccccc1-c1ccccc1)N1Cc2cn(-c3ccccc3)nc2C1
4024,2129860,10.1021/acsmedchemlett.1c00328,,,,Inhibition of human ERG stably expressed in CHO-K1 cells at -90 mV holding potential by automated Q-patch clamp method,N#Cc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(C(F)(F)F)nc3)CC2)cc1,4-(2-(4-((1-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1H-benzo[d]imidazol-2-yl)amino)piperidin-1-yl)ethyl)benzonitrile,0.97,uM,=,-0.0132282657337551,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3cccnc3)CC2)cc1
4025,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,CNc1cc(Nc2cnc(C#N)c(O[C@H]3CCN(C)C3)n2)ncc1-c1cnn(C)c1,(S)-5-((5-(1-Methyl-1H-pyrazol-4-yl)-4-(methylamino)pyridin-2-yl)amino)-3-((1-methylpyrrolidin-3-yl)oxy)pyrazine-2-carbonitrile,19.0,uM,=,1.2787536009528289,1,c1cc(Nc2cncc(O[C@H]3CCNC3)n2)ncc1-c1cn[nH]c1
4026,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3cc(Cl)cn3)[C@H](C)C2)cn1,2-(4-Chloro-pyrazol-1-yl)-1-{(R)-4-[4-(2-ethoxy-primidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-ethanone,2.8,uM,=,0.4471580313422192,1,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
4027,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CCN1CC2(CCN(CCc3ccc(F)cc3)CC2)O[C@H](C)C1=O,"(R)-4-ethyl-9-(4-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",1.5,uM,=,0.1760912590556812,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1
4028,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CCC(C)(O)C5)cc4)C3)o2)cc1,"(3-(4-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone",26.0,uM,=,1.414973347970818,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CCCC3)cc2)C1
4029,761736,10.1021/jm200401v,,,,Inhibition of recombinant human ERG channel expressed in human HEK 293 cells by patch clamp assay,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1,6-{4-[3-(R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one,13.8,uM,=,1.1398790864012365,1,O=c1ccc(-c2ccc(OCCCN3CCCC3)cc2)n[nH]1
4030,2054254,10.1016/j.ejmech.2020.112501,,,,Inhibition of human ERG by fluorescence polarization assay,CC(C)N1CCC(c2ccc(/C(=C(/CCCO)c3ccccc3)c3ccc(O)cc3)cc2)CC1.Cl,4-(5-hydroxy-1-(4-(1-isopropylpiperidin-4-yl)phenyl)-2-phenylpent-1-enyl)phenol hydrochloride,22.0,uM,=,1.3424226808222062,1,C(=C(c1ccccc1)c1ccc(C2CCNCC2)cc1)c1ccccc1
4031,1464376,10.1016/j.bmc.2014.12.060,,,,Inhibition of human ERG channel,COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol",0.3609086226107887,uM,=,-0.4426027419151365,0,c1ccc([C@@H](Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
4032,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,NCC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-(3-amino-2-hydroxypropoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.3,uM,=,0.5185139398778875,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4033,699583,10.1016/j.bmcl.2010.10.086,,,,Inhibition of human ERG,N[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21,"(R)-1-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroquinolin-4-amine",3.5,uM,=,0.5440680443502757,1,c1ccc(N2CCCc3ccccc32)cc1
4034,1924853,10.1016/j.bmcl.2016.07.029,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells measured after 90 mins by scintillation proximity assay,COc1cc(C(=O)N2C[C@@H](n3cc(C4CC4)nn3)C[C@H]2C(=O)N[C@H]2CCCC[C@@H]2c2ccccc2)ccc1CN,"(2S,4S)-1-(4-(aminomethyl)-3-methoxybenzoyl)-4-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)-N-((1S,2R)-2-phenylcyclohexyl)pyrrolidine-2-carboxamide",12.0,uM,=,1.0791812460476249,1,O=C(N[C@H]1CCCC[C@@H]1c1ccccc1)[C@@H]1C[C@H](n2cc(C3CC3)nn2)CN1C(=O)c1ccccc1
4035,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CC(O)CC(O)C7)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(6-(3,5-dihydroxycyclohexyloxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",6.3,uM,=,0.7993405494535817,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OC7CCCCC7)nc56)(CC3)OC4)nc2N1
4036,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3cn[nH]c3)ccc2c1,(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)-2-(1H-pyrazol-4-yl)quinoline,40.0,uM,=,1.6020599913279625,1,c1cc2nc(-c3cn[nH]c3)ccc2cc1CCN1CCCC1
4037,640506,10.1016/j.bmcl.2010.05.031,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,Cl.Nc1ncc(-c2cnn(C3CCNCC3)c2)cc1-c1nc2ccccc2o1,3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine tetrahydrochloride,0.75,uM,=,-0.1249387366082999,0,c1ccc2oc(-c3cncc(-c4cnn(C5CCNCC5)c4)c3)nc2c1
4038,834187,10.1021/jm2013248,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,C[C@@H](Oc1nnc(-c2ccncc2)n1C)c1noc(-c2cccc(Cl)c2)n1,"(R)-5-(3-chlorophenyl)-3-(1-(4-methyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yloxy)ethyl)-1,2,4-oxadiazole",11.6,uM,=,1.0644579892269186,1,c1ccc(-c2nc(COc3nnc(-c4ccncc4)[nH]3)no2)cc1
4039,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2c1O[C@H](c1ccc(OCCCN3CCCC3)cc1)[C@@H](C)S2(=O)=O,"1-{3-[4-((2R,3R)-8-Methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",6.2,uM,=,0.7923916894982539,1,O=S1(=O)C[C@@H](c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
4040,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(C)N1CCN(C(=O)N2CCC(C(=O)N3CC4CCC(CC4)C3)CC2)CC1,[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-piperidin-1-yl]-(4-isopropyl-piperazin-1-yl)-methanone,115.0,uM,=,2.060697840353612,1,O=C(C1CCN(C(=O)N2CCNCC2)CC1)N1CC2CCC(CC2)C1
4041,566263,10.1016/j.bmcl.2009.01.073,,,,Inhibition of human ERG by patch-clamp technique,CN1C(=O)[C@@H](CN2CCCCC2)C[C@H]1C#Cc1ccccc1,cis-1-methyl-5-(phenylethynyl)-3-(piperidin-1-ylmethyl)pyrrolidin-2-one,6.85,uM,=,0.8356905714924255,1,O=C1N[C@H](C#Cc2ccccc2)C[C@@H]1CN1CCCCC1
4042,1667858,10.1016/j.bmcl.2017.03.030,,,,Inhibition of human ERG,N=C(NCCCOc1ccc(F)cc1)Nc1ccc(I)cc1,1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine,0.1090999999999999,uM,=,-0.9621752494116582,0,N=C(NCCCOc1ccccc1)Nc1ccccc1
4043,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CC[C@@H]4CCCC[C@H]4N(Cc4ccccc4)C3=O)nn2)ccc1-n1cnc(C)c1,"(5aS,9aR)-1-benzyl-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)octahydro-1H-benzo[b]azepin-2(3H)-one",9.0,uM,=,0.9542425094393248,1,O=C1C(n2cc(-c3ccc(-n4ccnc4)cc3)nn2)CC[C@@H]2CCCC[C@H]2N1Cc1ccccc1
4044,1913293,10.1021/acs.jmedchem.9b01032,,,,Inhibition of human ERG expressed in HEK293 cells by IonWorks barracuda patch clamp method,CC1(C)CCN1Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1,"4-((2-((2,2-Dimethylazetidin-1-yl)methyl)-6-fluorobenzyl)-amino)-2,6-difluoro-N-(thiazol-4-yl)benzenesulfonamide",22.2,uM,=,1.3463529744506386,1,O=S(=O)(Nc1cscn1)c1ccc(NCc2ccccc2CN2CCC2)cc1
4045,2015639,10.1016/j.bmcl.2020.127393,,,,Inhibition of human ERG,CN(C)Cc1cc(-c2ccnc3[nH]c(-c4cccc5c4ccn5C)nc23)nn1C,"N,N-dimethyl-1-(1-methyl-3-(2-(1-methyl-1H-indol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-5-yl)methanamine",13.0,uM,=,1.1139433523068367,1,c1cc(-c2nc3c(-c4cc[nH]n4)ccnc3[nH]2)c2cc[nH]c2c1
4046,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2c1OC(c1ccc(OCCCN3CCC[C@H](C)C3)cc1)C(C)S2(=O)=O,"(+/-)-(S)-1-{3-[4-(8-Methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-3-methyl-piperidine",2.5,uM,=,0.3979400086720376,1,O=S1(=O)CC(c2ccc(OCCCN3CCCCC3)cc2)Oc2ccccc21
4047,487847,10.1021/jm800386y,,,,Displacement of [35S]MK499 from human ERG expressed in HEL cells,CN(C(=O)N1CC(c2cc(F)ccc2F)=C[C@@]1(CO)c1ccccc1)C1CCN(C2CC2)CC1,"(2S)-N-(1-cyclopropylpiperidin-4-yl)-4-(2,5-difluorophenyl)-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide",15.2,uM,=,1.1818435879447726,1,O=C(NC1CCN(C2CC2)CC1)N1CC(c2ccccc2)=CC1c1ccccc1
4048,793274,10.1016/j.bmcl.2011.09.117,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp electrophysiology,COc1ccc2ncc(F)c(CCN3CC[C@H](NCc4cc5c(cn4)OCCO5)[C@H](O)C3)c2n1,"(3R,4S)-4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)piperidin-3-ol",3.0,uM,=,0.4771212547196624,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
4049,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1cc2cc(-c3ccc(C#N)cc3)ccc2o1,4-{2-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-benzofuran-5-yl}-benzonitrile,1.6,uM,=,0.2041199826559248,1,c1ccc(-c2ccc3oc(CCN4CCCC4)cc3c2)cc1
4050,1838868,10.1021/acsmedchemlett.9b00550,,,,Inhibition of human ERG by competitive fluorescence polarization assay,Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1cc(F)c(F)c(F)c1,"2-amino-4-fluoro-5-((4-hydroxypiperidin-1-yl)sulfonyl)-N-(3,4,5-trifluorophenyl)benzamide",10.9,uM,=,1.0374264979406236,1,O=C(Nc1ccccc1)c1cccc(S(=O)(=O)N2CCCCC2)c1
4051,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1ccc2c(=O)n(C)c(-c3ccc(OC4CCN(C5CCC5)CC4)cc3)nc2c1,2-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-7-methoxy-3-methylquinazolin-4(3H)-one,4.3,uM,=,0.6334684555795865,1,O=c1[nH]c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2ccccc12
4052,2054254,10.1016/j.ejmech.2020.112501,,,,Inhibition of human ERG by fluorescence polarization assay,CC(C)N1CC=C(c2ccc(/C(=C(/CCCO)c3ccccc3)c3cccc(O)c3)cc2)CC1.Cl,"3-(5-hydroxy-1-(4-(1-isopropyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-2-phenylpent-1-enyl)phenol hydrochloride",10.3,uM,=,1.0128372247051722,1,C1=C(c2ccc(C(=Cc3ccccc3)c3ccccc3)cc2)CCNC1
4053,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(OC2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"1-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenoxy)piperidin-1-yl)ethanone",10.0,uM,=,1.0,1,c1ccn2c(-c3ccnc(Nc4ccc(OC5CCNCC5)cc4)n3)cnc2c1
4054,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCCCCCCN(CC)CCCCc1ccc([N+](=O)[O-])cc1,Ethyl-heptyl-[4-(4-nitro-phenyl)-butyl]-amine,0.01,uM,=,-2.0,0,c1ccccc1
4055,652287,10.1016/j.bmcl.2010.07.020,,,,Inhibition of human ERG,CCCC1(C(=O)c2ccc(Cl)c(Cl)c2)CCCN1,"(3,4-dichloro phenyl)(2-propylpyrrolidin-2-yl)methanone",3.1,uM,=,0.4913616938342727,1,O=C(c1ccccc1)C1CCCN1
4056,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CC[C@H](O)C2)c1,(S)-4-(benzyloxy)-1-(1-(2-(3-hydroxypyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,9.0,uM,=,0.9542425094393248,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
4057,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CCCC5)cc4)C3)o2)cc1,"(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)(3-(4-(pyrrolidin-1-ylmethyl)phenoxy)azetidin-1-yl)methanone",5.5,uM,=,0.7403626894942439,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CCCC3)cc2)C1
4058,2238137,10.1021/acs.jmedchem.1c01012,,,,Inhibition of human ERG,CCc1cc2ccc(CN3CCN(c4ccc(C(=O)NC)cc4)CC3)cc2[nH]c1=O,"4-(4-((3-ethyl-2-oxo-1,2-dihydroquinolin-7-yl)methyl)piperazin-1-yl)-N-methylbenzamide",8.3,uM,=,0.919078092376074,1,O=c1ccc2ccc(CN3CCN(c4ccccc4)CC3)cc2[nH]1
4059,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,O=C(c1ccccc1C1CCCC1)N(CC1CCC1)[C@H]1CCNC1,(S)-N-(cyclobutylmethyl)-2-cyclopentyl-N-(pyrrolidin-3-yl)benzamide,2.21,uM,=,0.3443922736851107,1,O=C(c1ccccc1C1CCCC1)N(CC1CCC1)[C@H]1CCNC1
4060,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1cc(-c2ccccc2)on1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1,(5-phenylisoxazol-3-yl)(4-(4-(pyrrolidin-1-ylmethyl)phenoxy)piperidin-1-yl)methanone,3.3,uM,=,0.5185139398778875,1,O=C(c1cc(-c2ccccc2)on1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
4061,2021700,10.1021/acs.jmedchem.9b00069,,,,Inhibition of human ERG by thallium flux assay,CC(C)(CCO)n1nc(-c2ccc3nc(OC4CC4)ccc3c2)c(C(N)=O)c1N,5-Amino-3-(2-cyclopropoxyquinolin-6-yl)-1-(4-hydroxy-2-methylbutan-2-yl)-1H-pyrazole-4-carboxamide,30.0,uM,=,1.4771212547196624,1,c1cc(-c2ccc3nc(OC4CC4)ccc3c2)n[nH]1
4062,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(C[C@H](O)C3CCC(NCc4nc5c(cc4F)OCC(=O)N5)CO3)c2n1,"7-fluoro-6-((6-((S)-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)tetrahydro-2H-pyran-3-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.4,uM,=,0.380211241711606,1,O=C1COc2ccc(CNC3CCC(CCc4ccnc5cccnc45)OC3)nc2N1
4063,1643768,10.1039/C6MD00281A,,,,Inhibition of Cy3B-labeled ligand binding to recombinant human ERG expressed in HEK293 cells by fluorescence polarization method,CC(C)(N)c1nc(-c2ccc(OC(F)(F)F)cc2)c[nH]1,2-(4-(4-(Trifluoromethoxy)phenyl)-1H-imidazol-2-yl)propan-2-amine,1.8,uM,=,0.255272505103306,1,c1ccc(-c2c[nH]cn2)cc1
4064,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COc1cccc(-n2cc3nc(-c4cccnc4C)n(C[C@H]4CCCN(C(C)C)C4)c(=O)c3n2)c1,"(S)-6-((1-Isopropylpiperidin-3-yl)methyl)-2-(3-methoxyphenyl)-5-(2-methylpyridin-3-yl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",47.0,uM,=,1.6720978579357175,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2cccnc2)n1C[C@H]1CCCNC1
4065,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,Fc1ccc(C(Cc2ccccc2OC(F)(F)F)N2CCNCC2)cc1,1-(1-(4-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine,8.05,uM,=,0.9057958803678684,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
4066,2157699,10.1021/acsmedchemlett.1c00549,,,,Inhibition of human ERG,COc1cnc2ccc(=O)n(CCN3CCC(NCc4ccc(Cl)c(Cl)c4)CC3)c2c1,"1-(2-(4-(3,4-dichlorobenzylamino)piperidin-1-yl)ethyl)-7-methoxy-1,5-naphthyridin-2(1H)-one",1.32,uM,=,0.1205739312058498,1,O=c1ccc2ncccc2n1CCN1CCC(NCc2ccccc2)CC1
4067,499505,10.1016/j.bmcl.2009.01.110,,,,Inhibition of human ERG,CC(C)(C)CNc1nc(C#N)nc(N2CCOCC2)c1N,5-amino-4-morpholino-6-(neopentylamino)pyrimidine-2-carbonitrile,70.0,uM,=,1.845098040014257,1,c1cc(N2CCOCC2)ncn1
4068,2049320,10.1021/acs.jmedchem.0c01179,,,,Inhibition of tracer red binding to human ERG expressed in HEK293 cell membranes measured after 2 to 6 hrs by fluorescence polarization assay,CC[C@H]1CN(C2CCN(c3nc(N)n[nH]3)CC2)[C@@H](Cc2ccc(Cl)cc2)CO1,"5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-ethylmorpholino)-piperidin-1-yl)-4H-1,2,4-triazol-3-amine",33.0,uM,=,1.5185139398778875,1,c1ccc(C[C@H]2COCCN2C2CCN(c3ncn[nH]3)CC2)cc1
4069,1706671,10.1016/j.bmc.2017.07.008,,,,Inhibition of human ERG expressed in CHOK1 cells by whole cell patch clamp method,CC(C)c1cc(CN2Cc3ccccc3S2(=O)=O)nn1-c1ccc(F)cc1,"2-[(1-4-fluorophenyl)-5-isobutyl-1H-pyrazol-3-yl)methyl]-2,3-dihydrobenzo[d]isothiazole1,1-dioxide",14.7,uM,=,1.167317334748176,1,O=S1(=O)c2ccccc2CN1Cc1ccn(-c2ccccc2)n1
4070,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C)cc(-c2cncc(-c3nc4cc(C)ccc4[nH]3)c2N2CCC(N)CC2)c1,"1-(3-(3,5-dimethylphenyl)-5-(5-methyl-1H-benzo[d]imidazol-2-yl)pyridin-4-yl)piperidin-4-amine",1.0,uM,=,0.0,0,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
4071,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(C(F)(F)F)cc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-4-(trifluoromethyl)phenyl)-N-methylmethanamine",1.19,uM,=,0.0755469613925307,1,c1ccc(Oc2ccccc2)cc1
4072,1765743,10.1021/acs.jmedchem.8b00913,,,,Inhibition of human ERG,COc1cncc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)c1,1-(1H-indol-3-yl)-2-(5-methoxypyridin-3-ylamino)-2-phenylethanone,3.5,uM,=,0.5440680443502757,1,O=C(c1c[nH]c2ccccc12)C(Nc1cccnc1)c1ccccc1
4073,306290,10.1016/j.bmcl.2005.02.093,,,,In vivo inhibitory concentration against displacement of 35[S] MK-499 binding to hERG channel expressed in HEK293 cells,O=C(c1ccccc1OCc1csc(-c2ccc(Cl)cc2)n1)N1CCCC1,{2-[2-(4-Chloro-phenyl)-thiazol-4-ylmethoxy]-phenyl}-pyrrolidin-1-yl-methanone,9.8,uM,=,0.9912260756924948,1,O=C(c1ccccc1OCc1csc(-c2ccccc2)n1)N1CCCC1
4074,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(F)cc(-c2cncc(-c3nc4cc(F)ccc4[nH]3)c2N2CCC(N)CC2)c1,1-(3-(5-fluoro-1H-benzo[d]imidazol-2-yl)-5-(3-fluoro-5-methylphenyl)pyridin-4-yl)piperidin-4-amine,5.7,uM,=,0.7558748556724915,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
4075,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4ccccc4N(Cc4ccccc4)C3=O)nn2)ccc1-n1cnc(C)c1,"rac-1-benzyl-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",1.01,uM,=,0.0043213737826425,1,O=C1C(n2cc(-c3ccc(-n4ccnc4)cc3)nn2)CCc2ccccc2N1Cc1ccccc1
4076,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,Cn1cc(-c2cnc(Nc3cnc(C#N)cn3)cc2NC[C@@H]2CNCCO2)cn1,(S)-5-((5-(1-Methyl-1H-pyrazol-4-yl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,22.0,uM,=,1.3424226808222062,1,c1cnc(Nc2cc(NC[C@@H]3CNCCO3)c(-c3cn[nH]c3)cn2)cn1
4077,2024431,10.1021/acs.jmedchem.0c01245,,,,Inhibition of human ERG,COc1ncc(NC(=O)Nc2cnc3ccc(F)cc3c2N(C)C2CCCN(C)C2)cc1Cl,1-(5-chloro-6-methoxy-3-pyridyl)-3-[6-fluoro-4-[methyl-(1-methyl-3-piperidyl)amino]-3-quinolyl]urea,9.0,uM,=,0.9542425094393248,1,O=C(Nc1cccnc1)Nc1cnc2ccccc2c1NC1CCCNC1
4078,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,C[C@H]1OC2(CCN(CCc3ccccc3F)CC2)CN(c2ncccc2C(F)(F)F)C1=O,"(2R)-9-[2-(2-fluorophenyl)ethyl]-2-methyl-4-[3-(trifluoromethyl)-2-pyridyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",6.6,uM,=,0.8195439355418687,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccn1
4079,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,Cc1cc(C2(c3cccc(-c4cncnc4)c3)N=C(N)c3c(F)cccc32)cc(C)n1,"1-(2,6-Dimethylpyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine",6.4,uM,=,0.8061799739838872,1,C1=NC(c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
4080,635425,10.1016/j.bmcl.2010.04.071,,,,Inhibition of human ERG,C[C@@H](O)C(=O)NC1CC(C)(C)Oc2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc21,"(2R)-N-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl)-2-hydroxypropanamide",0.12,uM,=,-0.9208187539523752,0,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
4081,1463729,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG by MK499 binding assay,O=C1COc2ccc(CNC34CCC(CC5(F)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"rac-6-((1-((3,4-difluoro-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",13.8,uM,=,1.1398790864012365,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
4082,1655139,10.1016/j.bmcl.2016.12.054,,,,Displacement of [3H]-MK499 from human ERG IKr channel expressed in HEK293 cell membranes,CS(=O)(=O)Nc1cccc(-c2cc(F)ccc2CC(c2cccnc2)c2cccnc2)c1,"N-(2'-(2,2-di(pyridin-3-yl)ethyl)-5'-fluorobiphenyl-3-yl)methanesulfonamide",1.9,uM,=,0.2787536009528289,1,c1ccc(-c2ccccc2CC(c2cccnc2)c2cccnc2)cc1
4083,1616176,10.1021/acs.jmedchem.6b00487,,,,Inhibition of human ERG,COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CCC[C@H](N1CCN(C)CC1)C2,"(1S,2S,3R,4R)-3-[[5-Chloro-2-[[(6S)-1-methoxy-6-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]bicyclo-[2.2.1]hept-5-ene-2-carboxamide",9.1,uM,=,0.9590413923210936,1,C1=C[C@H]2C[C@@H]1C[C@@H]2Nc1ccnc(Nc2ccc3c(c2)CCC[C@H](N2CCNCC2)C3)n1
4084,1879326,10.1021/acs.jmedchem.9b01172,,,,Inhibition of human ERG assessed as reduction in channel tail current by plate-based planar patch clamp assay,CN(C)C(=O)CNCCc1cccc(OCCCC(F)(F)F)c1.Cl,"2-((3-(4,4,4-Trifluorobutoxy)phenethyl)amino)-N,N-dimethylacetamide Hydrochloride",18.0,uM,=,1.255272505103306,1,c1ccccc1
4085,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(CNC2CCCC2)n1,N-((6-(4-fluoro-2-methoxyphenyl)pyrazin-2-yl)methyl)cyclopentanamine,16.0,uM,=,1.2041199826559248,1,c1ccc(-c2cncc(CNC3CCCC3)n2)cc1
4086,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCc3ccc(OC)c(OC)c3)C[C@@H]2CCc2cc3ccc(Cl)cc3[nH]2)cc1,"rac-6-chloro-2-(2-((3R,4S)-1-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)ethyl)-1H-indole",0.045,uM,=,-1.3467874862246565,0,c1ccc(CCN2C[C@H](CCc3cc4ccccc4[nH]3)[C@@H](c3ccccc3)C2)cc1
4087,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,CC(C)C(=O)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1,"(S)-N-(2,3-dichlorobenzyl)-N-(pyrrolidin-3-yl)isobutyramide",24.7,uM,=,1.3926969532596658,1,c1ccc(CN[C@H]2CCNC2)cc1
4088,949743,10.1021/jm301720p,,,,Inhibition of human ERG channel,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCCN4CCOCC4)c4ccc(OC(F)F)cc34)nc12,"N-tert-butyl-2-(5-(difluoromethoxy)-1-(3-morpholinopropyl)-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",1.44,uM,=,0.1583624920952496,1,c1ccc2c(c1)c(-c1cnc3[nH]ccc3n1)nn2CCCN1CCOCC1
4089,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cccc(S[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"endo-3-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-ylthio)benzamide",1.1,uM,=,0.041392685158225,1,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Sc2ccccc2)C3)cc1
4090,1906723,10.1016/j.ejmech.2019.111674,,,,Inhibition of human ERG expressed in HEK293 cells incubated for 72 hrs by patch clamp assay,NC(=O)c1ccn(-c2cccc(OC(=O)NCCN3CCN(c4ccccc4)CC3)c2)c1,3-(3-Carbamoyl-1H-pyrrol-1-yl)phenyl (2-(4-phenylpiperazin-1-yl)ethyl)carbamate,5.3,uM,=,0.724275869600789,1,O=C(NCCN1CCN(c2ccccc2)CC1)Oc1cccc(-n2cccc2)c1
4091,1327425,10.1039/C2MD20054F,,,,Inhibition of human ERG,C[C@@H]1CN(c2noc(C(F)(F)F)n2)CCN1c1ncc(OCc2ccncc2C#N)cn1,"4-{[(2-{(2R)-2-Methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]piperazin-1-yl}pyrimidin-5-yl)oxy]methyl}pyridine-3-carbonitrile",7.6,uM,=,0.8808135922807914,1,c1cc(COc2cnc(N3CCN(c4ncon4)CC3)nc2)ccn1
4092,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,Cc1cc(CNc2nc(N)nc3ccn(Cc4ccc(C(F)(F)F)cn4)c23)no1,"N4-((5-Methylisoxazol-3-yl)methyl)-5-((5-(trifluoromethyl)-pyridin-2-yl)methyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine",0.5,uM,=,-0.3010299956639812,0,c1ccc(Cn2ccc3ncnc(NCc4ccon4)c32)nc1
4093,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,COCCOc1cc(NC(=O)N2CCCc3cc(CN(C)C(=O)CN(C)C)c(C=O)nc32)ncc1C#N,"N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-6-((2-(dimethylamino)-N-methylacetamido)methyl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide",6.8,uM,=,0.8325089127062363,1,O=C(Nc1ccccn1)N1CCCc2cccnc21
4094,1654955,10.1016/j.bmcl.2016.10.032,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@@H](O)CN2CCC3(CC2)CC(=O)N(c2ccc(S(C)(=O)=O)cn2)C3)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(5-(methylsulfonyl)pyridin-2-yl)-2,8-diazaspiro[4.5]decan-3-one",24.0,uM,=,1.380211241711606,1,O=C1OCc2cc(CCN3CCC4(CC3)CC(=O)N(c3ccccn3)C4)ccc21
4095,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2ncc(F)c([C@@H](O)CC[C@@H]3CCN(C4CC(c5cc(F)cc(F)c5)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-1-(3-(3,5-difluorophenyl)cyclobutyl)-4-((S)-3-(3-fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl)piperidine-3-carboxylic acid",14.1,uM,=,1.14921911265538,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
4096,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,CO[C@H]1CN(CCn2c(=O)ccc3ccc(C#N)cc32)CC[C@H]1NCc1cc2c(cn1)OCCO2,"cis-1-(2-{(3S,4R)-4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-3-methoxypiperidin-1-yl}ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",174.0,uM,=,2.2405492482826,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
4097,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ncc(=O)n(CCN3CCC(c4nc5cc(Cl)c(C)cc5[nH]4)CC3)c2c1,"1-(2-(4-(5-chloro-6-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)-7-methoxypyrido[2,3-b]pyrazin-2(1H)-one",10.0,uM,=,1.0,1,O=c1cnc2ncccc2n1CCN1CCC(c2nc3ccccc3[nH]2)CC1
4098,611200,10.1021/jm901200t,,,,Inhibition of human ERG,COc1cc2c(c(N3CCN(C)CC3)c1)O[C@@H](C(=O)Nc1ccc(N3CCOCC3)cc1)CC2,(R)-6-methoxy-8-(4-methylpiperazin-1-yl)-N-(4-morpholinophenyl)chroman-2-carboxamide,19.0,uM,=,1.2787536009528289,1,O=C(Nc1ccc(N2CCOCC2)cc1)[C@H]1CCc2cccc(N3CCNCC3)c2O1
4099,1744232,10.1021/acs.jmedchem.6b01703,,,,Displacement of [3H]dofetilide from recombinant human ERG expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting method,CCc1nn2c(C)cc(C)nc2c1Cc1ccc(-c2nnc(C3CCNCC3)o2)cc1,"US8748435, 35",19.0,uM,=,1.2787536009528289,1,c1cnc2c(Cc3ccc(-c4nnc(C5CCNCC5)o4)cc3)cnn2c1
4100,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,Cc1ccn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@@H]2CCO)n1,1-((S)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-methylpyrazol-1-yl)-ethanone,0.012,uM,=,-1.9208187539523751,0,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
4101,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOCC7)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-morpholino-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.01146,uM,=,-1.9408153823686287,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(N7CCOCC7)nc56)(CC3)OC4)nc2N1
4102,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1cnc3ccccc3n1)c(=O)n2C,"(S)-6-(3-aminopiperidin-1-yl)-1-methyl-5-(3-methylbut-2-enyl)-2,4-dioxo-3-(quinoxalin-2-ylmethyl)-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",5.0,uM,=,0.6989700043360189,1,O=c1[nH]c2cc(N3CCCCC3)[nH]c2c(=O)n1Cc1cnc2ccccc2n1
4103,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,O=C(O)c1ccc(-n2cc(C3CCN(CCN4CCNC4=O)CC3)c3cc(Cl)ccc32)cc1,4-(5-Chloro-3-{1-[2-(2-oxo-imidazolidin-1-yl)-ethyl]-piperidin-4-yl}-indol-1-yl)-benzoic acid,75.0,uM,=,1.8750612633917,1,O=C1NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccccc23)CC1
4104,1578394,10.1021/acsmedchemlett.5b00450,,,,Inhibition of human ERG by patch clamp method,O=C1N[C@H](c2cncc(C#Cc3ccccc3)c2)[C@@H](c2cc(F)ccc2F)O1,"(4R,5R)-5-(2,5-Difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one",3.6,uM,=,0.5563025007672873,1,O=C1N[C@H](c2cncc(C#Cc3ccccc3)c2)[C@@H](c2ccccc2)O1
4105,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCCC[C@@H](CCO)Nc1nc(N)nc2ccc(F)cc12,(S)-3-((2-Amino-6-fluoroquinazolin-4-yl)amino)heptan-1-ol,5.8,uM,=,0.7634279935629373,1,c1ccc2ncncc2c1
4106,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCC3(O)CCOCC3)C[C@@H]2CC(=O)Nc2cccc(Cl)c2)cc1,"N-(3-chlorophenyl)-2-((3R,4S)-1-(2-(4-hydroxytetrahydro-2H-pyran-4-yl)ethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)acetamide",8.24,uM,=,0.9159272116971158,1,O=C(C[C@H]1CN(CCC2CCOCC2)C[C@@H]1c1ccccc1)Nc1ccccc1
4107,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=N[C@H]1c1ccc(F)cc1Br,"(R)-ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholinomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",4.5,uM,=,0.6532125137753437,1,C1=C(CN2CCOCC2)NC(c2nccs2)=N[C@H]1c1ccccc1
4108,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,O=C1CCc2cc(C(O)CN3CCC(O)(c4cccc(F)c4)CC3)ccc2N1,"6-(2-(4-(3-fluorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxyethyl)-3,4-dihydroquinolin-2(1H)-one",9.8,uM,=,0.9912260756924948,1,O=C1CCc2cc(CCN3CCC(c4ccccc4)CC3)ccc2N1
4109,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,CCNC(=O)N1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc([N+](=O)[O-])c4)c3c2)CC1,N-ethyl-4-(5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinolin-3-yl)piperazine-1-carboxamide,0.21,uM,=,-0.6777807052660807,0,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
4110,877724,10.1021/jm300831b,,,,Inhibition of human ERG expressed in rat after 2 to 3 days by patch clamp assay,CCCN1CNc2cc(Nc3ccnc4cc(Cl)ccc34)ccc2C1,"N-(3-Propyl-1,2,3,4-tetrahydroquinazolin-7-yl)-7-chloro-4-aminoquinoline",0.022,uM,=,-1.6575773191777938,0,c1ccc2c(Nc3ccc4c(c3)NCNC4)ccnc2c1
4111,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(N1Cc2ccccc2C1)N1CCC[C@H]1CN1CCCC1,(S)-isoindolin-2-yl(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone,28.46153846,uM,=,1.4542583717366828,1,O=C(N1Cc2ccccc2C1)N1CCC[C@H]1CN1CCCC1
4112,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,COc1cc(C2(c3cccc(-c4cncnc4)c3)N=C(N)c3c(F)cccc32)ccn1,4-Fluoro-1-(2-methoxypyridin-4-yl)-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine,2.2,uM,=,0.3424226808222063,1,C1=NC(c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
4113,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,Cn1c(NCCN(CCO)CCCc2ccc([N+](=O)[O-])cc2)cc(=O)n(C)c1=O,"6-(2-{(2-Hydroxy-ethyl)-[3-(4-nitro-phenyl)-propyl]-amino}-ethylamino)-1,3-dimethyl-1H-pyrimidine-2,4-dione",10.0,uM,=,1.0,1,O=c1cc(NCCNCCCc2ccccc2)[nH]c(=O)[nH]1
4114,821302,10.1021/jm201454n,,,,Displacement of dofetilide from human ERG,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccnc(c2)OCC/1,"11-(2-(Pyrrolidin-1-yl)ethoxy)-14,20-dioxa-5,7,22,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8-(27),9,11,16,21,23-decaene",2.4,uM,=,0.380211241711606,1,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccnc(c2)OCC/1
4115,2286826,10.1016/j.bmc.2021.116354,,,,Inhibition of hERG by thallium flux assay,N#C[C@@H]1C[C@H](F)CN1C(=O)[C@@H](N)Cc1cc(Cl)c(Cl)cc1Cl,"(2S,4S)-1-((S)-2-amino-3-(2,4,5-trichlorophenyl)propanoyl)-4-fluoropyrrolidine-2-carbonitrile",97.7,uM,=,1.989894563718773,1,O=C(CCc1ccccc1)N1CCCC1
4116,761292,10.1021/jm101312a,,,,Inhibition of human ERG expressed in CHO cells by high throughput single cell planar patch clamp method,CN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1,"cis-(3aS,7aR)-3a-(3,4-dichlorophenyl)-2-methyloctahydro-1H-isoindole",2.32,uM,=,0.3654879848908996,1,c1ccc([C@]23CCCC[C@H]2CNC3)cc1
4117,465697,10.1021/jm701187w,,,,Inhibition of human ERG potassium current expressed in HEK293 cells by patch-clamp technique,Cc1cc(C)n(-c2cc(NC(=O)CN3CC[C@@H](CN(C)C)C3)nc(-c3ccc(C)o3)n2)n1,"2-((S)-3-dimethylaminomethylpyrrolidin-1-yl)-N-[6-(3,5-di methylpyrazol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl]acetamide",1.01,uM,=,0.0043213737826425,1,O=C(CN1CCCC1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
4118,851153,10.1021/jm2007672,,,,Inhibition of human ERG,c1cc(-c2cnc3c(c2)C[C@@]2(CN4CCC2CC4)O3)co1,"(2'R)-3-(furan-3-yl)spiro-[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo-[2,3-b]pyridine]",1.6,uM,=,0.2041199826559248,1,c1cc(-c2cnc3c(c2)C[C@@]2(CN4CCC2CC4)O3)co1
4119,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCS(=O)(=O)CC2)NC(c2nccs2)=NC1c1ccc(F)cc1Br,"Ethyl 4-(2-Bromo-4-fluorophenyl)-6-((1,1-dioxidothiomorpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",1.07,uM,=,0.0293837776852096,1,O=S1(=O)CCN(CC2=CC(c3ccccc3)N=C(c3nccs3)N2)CC1
4120,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,O=C(NCC1CCN(C(=O)CCCCC(c2ccc(F)cc2)c2ccc(F)cc2)C1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"N-((1-(6,6-bis(4-fluorophenyl)hexanoyl)pyrrolidin-3-yl)methyl)-3,5-bis(trifluoromethyl)benzamide",0.7,uM,=,-0.1549019599857432,0,O=C(NCC1CCN(C(=O)CCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
4121,2133680,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG expressed in CHO by QPatch assay,CC[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4ccc(F)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(6-fluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",9.9,uM,=,0.99563519459755,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
4122,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cc(-c2ccc(OC3CCN(C(=O)Nc4ccc(OC(F)(F)F)cc4)CC3)c(C(N)=O)c2)cn1,4-(2-carbamoyl-4-(1-methyl-1H-pyrazol-4-yl)phenoxy)-N-(4-(trifluoromethoxy)phenyl)piperidine-1-carboxamide,3.8,uM,=,0.5797835966168101,1,O=C(Nc1ccccc1)N1CCC(Oc2ccc(-c3cn[nH]c3)cc2)CC1
4123,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1cc(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)nc(-c2ccccc2)n1,(R)-2-(6-methyl-2-phenylpyrimidin-4-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,0.12,uM,=,-0.9208187539523752,0,c1ccc(-c2nccc(-c3ccc4cc(CCN5CCCC5)ccc4n3)n2)cc1
4124,726964,10.1016/j.bmcl.2011.01.019,,,,Inhibition of human ERG,CNC(C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1.Cl,"1-(1-(3,4-dichlorophenyl)cyclohexyl)-N-methylethanamine hydrochloride",23.0,uM,=,1.3617278360175928,1,c1ccc(C2CCCCC2)cc1
4125,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cn4)CC3)ccc21,5-(2-(4-(2-(5-(1H-tetrazol-1-yl)pyridin-2-yl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,46.0,uM,=,1.662757831681574,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cn4)CC3)ccc21
4126,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,COC(=O)N(C)c1c(N)nc(-n2nc(Cc3c(F)ccc(F)c3F)c3cc(Cl)ccc32)nc1N,"methyl N-[4,6-diamino-2-[5-chloro-3-[(2,3,6-trifluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methyl-carbamate",3.9,uM,=,0.5910646070264992,1,c1ccc(Cc2nn(-c3ncccn3)c3ccccc23)cc1
4127,1935939,10.1016/j.bmc.2019.02.025,,,,Inhibition of human ERG by manual patch clamp electrophysiology assay,COc1nc2ccc(C#N)cc2cc1C(c1cccc(C)c1)C(O)(CCN(C)C)c1cccnc1OC,rac-3-(4-(dimethylamino)-2-hydroxy-2-(2-methoxypyridin-3-yl)-1-m-tolylbutyl)-2-methoxyquinoline-6-carbonitrile,0.3,uM,=,-0.5228787452803376,0,c1ccc(C(Cc2cccnc2)c2cnc3ccccc3c2)cc1
4128,621608,10.1016/j.bmcl.2009.09.024,,,,Inhibition of human ERG expressed in CHO cells by patch clamp technique,CCOc1cc(CN2CCC(Nc3nc4cc(C(N)=O)ccc4o3)CC2)cc(OCC)c1F,"2-(1-(3,5-diethoxy-4-fluorobenzyl)piperidin-4-ylamino)benzo[d]oxazole-5-carboxamide",0.43,uM,=,-0.3665315444204134,0,c1ccc(CN2CCC(Nc3nc4ccccc4o3)CC2)cc1
4129,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1cc2c(cc1OC)C1Cc3ccc(OC)c(OC)c3C(Cc3ccccc3)N1CC2,"8-Benzyl-2,3,9,10-tetramethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinoline",14.0,uM,=,1.146128035678238,1,c1ccc(CC2c3ccccc3CC3c4ccccc4CCN23)cc1
4130,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,N#Cc1ccc(Oc2ccc3nc(OCC(=O)N4CCCCC4)ccc3c2)cc1,4-[[2-[2-oxo-2-(1-piperidyl)ethoxy]-6-quinolyl]oxy]benzonitrile,6.4,uM,=,0.8061799739838872,1,O=C(COc1ccc2cc(Oc3ccccc3)ccc2n1)N1CCCCC1
4131,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,Cc1cc(C)nc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)cnc2C(N)=O)c1,"5-{[(1R,2S)-2-aminocyclohexyl]amino}-3-[(4,6-dimethylpyridin-2-yl)amino]pyridine-2-carboxamide",1.6,uM,=,0.2041199826559248,1,c1ccc(Nc2cncc(NC3CCCCC3)c2)nc1
4132,1515505,10.1021/ml500440u,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,COc1cc([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N,"6-((S)-1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-methoxynicotinonitrile",33.0,uM,=,1.5185139398778875,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
4133,772749,10.1016/j.bmcl.2011.08.038,,,,Displacement of [3H]dofetilide from human ERG transfected in HEK293 cells by fluorescence polarization binding assay,CS(=O)(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1,"8-chloro-5-(methylsulfonyl)-1-(1-(pyridin-2-yl)piperidin-4-yl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine",30.7,uM,=,1.4871383754771863,1,c1ccc(N2CCC(c3nnc4n3-c3ccccc3CNC4)CC2)nc1
4134,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,NC(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1,"4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide",11.589,uM,=,1.0640459628644827,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
4135,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CC[C@@H](NCc4ccc5c(n4)NC(=O)CO5)[C@@H](F)C3)c2c1,"cis-6-[({(3S,4R)-3-Fluoro-1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)-ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]-oxazin-3(4H)-one",32.0,uM,=,1.505149978319906,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)cnc5ccccc54)CC3)nc2N1
4136,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1ccc(CCNCCCNC(=O)c2ccc([N+](=O)[O-])cc2)cc1OC,"N-{3-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-propyl}-4-nitro-benzamide",0.42,uM,=,-0.3767507096020995,0,O=C(NCCCNCCc1ccccc1)c1ccccc1
4137,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCCC1c1cccnc1,2-(pyridin-3-yl)-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)pyrrolidine-1-carboxamide,3.08,uM,=,0.4885507165004443,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCCC1c1cccnc1
4138,1680139,10.1021/acs.jmedchem.6b01647,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,{4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-phenyl-amine,2.76,uM,=,0.4409090820652177,1,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
4139,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,O=C(NC[C@@H]1CCN(C(=O)CCCCC(c2ccc(F)cc2)c2ccc(F)cc2)C1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"(S)-N-((1-(6,6-bis(4-fluorophenyl)hexanoyl)pyrrolidin-3-yl)methyl)-3,5-bis(trifluoromethyl)benzamide",0.8,uM,=,-0.0969100130080563,0,O=C(NC[C@@H]1CCN(C(=O)CCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
4140,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-3-yl)acetic Acid,7.8,uM,=,0.8920946026904804,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCCO5)CC4)nc3)nc2c1
4141,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Fc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)c(F)c1,"(1R,3R)-3-(4-(2,4-difluorophenyl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.634,uM,=,-0.1979107421182673,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
4142,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,C[C@H](c1ccccc1)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,endo-3-(8-((R)-1-phenylethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.013,uM,=,-1.8860566476931635,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
4143,462997,10.1016/j.bmcl.2008.02.035,,,,Inhibition of human ERG,C[C@@H](Oc1cccc2ncnc(Nc3ccc4c(cnn4Cc4ccccn4)c3)c12)C(=O)N(C)C,"(R)-N,N-dimethyl-2-(4-(1-(pyridin-2-ylmethyl)-1H-indazol-5-ylamino)quinazolin-5-yloxy)propanamide",25.0,uM,=,1.3979400086720375,1,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)nc1
4144,1824040,10.1021/acs.jmedchem.9b01382,,,,Inhibition of human ERG expressed in HEK293 cells at holding potential -80 mV by whole-cell voltage-clamp method,O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1,"(5S)-N-[2-(4-Fluorophenoxy)pyrimidin-5-yl]-5-(4-fluorophenyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxamide",10.6,uM,=,1.0253058652647702,1,O=C(Nc1cnc(Oc2ccccc2)nc1)N1CCc2ncccc2[C@@H]1c1ccccc1
4145,945538,10.1016/j.bmcl.2012.10.140,,,,Inhibition of human ERG expressed in CHO cells by IONWORKS assay,CC(C)(C)NC(=O)NCCN1CCN(CC(=O)Nc2cc(Cl)cc(Cl)c2)CC1,"2-(4-(2-(3-tert-butylureido)ethyl)piperazin-1-yl)-N-(3,5-dichlorophenyl)acetamide",1.6,uM,=,0.2041199826559248,1,O=C(CN1CCNCC1)Nc1ccccc1
4146,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C1COc2ccc(CN3CCC(NC(=O)c4cc(=O)c5ccc(F)cc5o4)CC3)cc2N1,"7-fluoro-4-oxo-N-(1-((3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methyl)piperidin-4-yl)-4H-chromene-2-carboxamide",5.79,uM,=,0.7626785637274363,1,O=C1COc2ccc(CN3CCC(NC(=O)c4cc(=O)c5ccccc5o4)CC3)cc2N1
4147,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc2ccccc2c1)Cc1ccc2c(c1)CCO2.Cl,(E)-N-(Coumaran-5-methyl)-N-methyl-3-(naphthalen-2-yl)prop-2-en-1-amine Hydrochloride,6.7,uM,=,0.8260748027008264,1,C(=C/c1ccc2ccccc2c1)\CNCc1ccc2c(c1)CCO2
4148,1747135,10.1016/j.bmcl.2017.10.042,,,,Inhibition of human ERG,COc1nc2ccc(Br)cc2cc1[C@@H](c1ccc(N(C)C)nc1)[C@@](O)(CCN(C)C)c1cccc(F)c1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-1-(6-(dimethylamino)pyridin-3-yl)-2-(3-fluorophenyl)butan-2-ol",0.89,uM,=,-0.0506099933550872,0,c1ccc(C[C@H](c2cccnc2)c2cnc3ccccc3c2)cc1
4149,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,CCOc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-ethoxy-3-fluoro-8-methyl-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.0011899999999999,uM,=,-2.9244530386074694,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4150,1329251,10.1039/C1MD00164G,,,,Inhibition of human ERG by [3H]dofetilide binding assay,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21,"N-(3-((1R,5S)-6-ethyl-3-((2-hydroxy-2,3-dihydro-1H-inden-2-yl)methyl)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)methanesulfonamide",1.6,uM,=,0.2041199826559248,1,c1ccc(C2[C@H]3CN(CC4Cc5ccccc5C4)C[C@@H]23)cc1
4151,75160,10.1021/jm00014a008,,,,Blockade of the delayed rectifier K+ current (IKr) of guinea pig myocytes,CN1Cc2ccccc2[C@H](c2ccccc2)N=C1OCc1ccc(NS(C)(=O)=O)cc1.O=C(O)/C=C/C(=O)O,"N-[4-(2-Methyl-5-phenyl-2,5-dihydro-1H-benzo[e][1,3]diazepin-3-yloxymethyl)-phenyl]-methanesulfonamide; compound with (E)-but-2-enedioic acid",29.0,uM,=,1.462397997898956,1,c1ccc(COC2=N[C@@H](c3ccccc3)c3ccccc3CN2)cc1
4152,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(C(F)(F)F)c3n2CCN1CC1CC2CCC1C2,"2-[(Bicyclo[2.2.1]heptan-2-yl)methyl]-6-(trifluoromethyl)-3,4-dihydropyrazino[1,2-a]benzimidazol-1(2H)-one",3.0,uM,=,0.4771212547196624,1,O=C1c2nc3ccccc3n2CCN1CC1CC2CCC1C2
4153,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,O=C(CNc1noc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3nccs3)CC2)C1,cis-N-[1-(4-Hydroxy-4-thiazol-2-yl-cyclohexyl)-azetidin-3-yl]-2-(5-trifluoromethyl-benzo[d]isoxazol-3-ylamino)-acetamide,0.011,uM,=,-1.958607314841775,0,O=C(CNc1noc2ccccc12)NC1CN([C@H]2CC[C@@H](c3nccs3)CC2)C1
4154,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCNCC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)-N-(2-methoxy-4-(piperazin-1-yl)phenyl)pyrimidin-2-amine",4.6,uM,=,0.6627578316815741,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
4155,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(COCc2cccc(COCc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis((4-methylbenzyloxy)methyl)pyridinium",0.107,uM,=,-0.9706162223147904,0,c1ccc(COCc2cccc(COCc3ccccc3)[nH+]2)cc1
4156,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(-c2cccnc2)sc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-4-methyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-2-(pyridin-3-yl)thiazole,6.0,uM,=,0.7781512503836436,1,c1cncc(-c2ncc(-c3ccc4cc(CCN5CCCC5)ccc4n3)s2)c1
4157,2024332,10.1016/j.bmcl.2020.127710,,,,Inhibition of human ERG,NC(=O)c1cc(Cl)c2cc(-c3cc4c(s3)CCNC4)cnn12,"5-chloro-3-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)pyrrolo[1,2-b]pyridazine-7-carboxamide",1.31,uM,=,0.1172712956557642,1,c1cc2cc(-c3cc4c(s3)CCNC4)cnn2c1
4158,439396,10.1016/j.bmcl.2007.05.087,,,,Inhibition of human ERG potassium channel,N[C@H]1CN(c2ccc3nc(C(F)(F)F)nn3n2)CC[C@@H]1c1cc(F)c(F)cc1F.O=C(O)C(F)(F)F,"(3R,4R)-1-(2-(trifluoromethyl)-[1,2,4]triazolo[1,5-b]pyridazin-6-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium 2,2,2-trifluoroacetate",8.1,uM,=,0.9084850188786496,1,c1ccc(C2CCN(c3ccc4ncnn4n3)CC2)cc1
4159,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(F)cnc56)(CC3)OC4)nc2N1,"6-((1-(2-(7-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.01675,uM,=,-1.775985188627136,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4160,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(CCN(C)CCOc2ccc(C)cc2)cc1,N-methyl-N-(4-methylphenethyl)-2-(p-tolyloxy)ethanamine,0.0050999999999999,uM,=,-2.292429823902064,0,c1ccc(CCNCCOc2ccccc2)cc1
4161,499833,10.1016/j.bmcl.2009.04.022,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(S[C@]4(C)CC[C@@H](c5nc(C)no5)CC4)nc3cc2Cl)CC1,"trans-5-(4-(5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazol-2-ylthio)-4-methylcyclohexyl)-3-methyl-1,2,4-oxadiazole",0.38,uM,=,-0.4202164033831898,0,c1noc(C2CCC(Sc3nc4ccc(N5CCNCC5)cc4[nH]3)CC2)n1
4162,959401,10.1016/j.bmcl.2013.04.006,,,,Inhibition of human ERG by IonWorks assay,N#Cc1cnccc1COc1cnc(N2CC3CCC(C2)N3C(=O)OCC(F)(F)F)nc1,"2,2,2-trifluoroethyl 3-(5-((3-cyanopyridin-4-yl)methoxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate",13.0,uM,=,1.1139433523068367,1,c1cc(COc2cnc(N3CC4CCC(C3)N4)nc2)ccn1
4163,1871838,10.1016/j.bmcl.2018.12.015,,,,Inhibition of human ERG,NC(=O)c1cc(Cl)c2c(Cl)c(C#CC3COCCO3)n([C@H]3CCCNC3)c2n1,"2-((1,4-dioxan-2-yl)ethynyl)-3,4-dichloro-1-((S)-piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",0.0014,uM,=,-2.853871964321762,0,C(#CC1COCCO1)c1cc2cccnc2n1[C@H]1CCCNC1
4164,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,CCSc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2ccnc(OC)c2OC)cc(SCC)n1,"Rac-3-[(1R,2S)-2-[2,6-bis(ethylsulfanyl)-4-pyridyl]-1-(2,3-dimethoxy-4-pyridyl)-4-(dimethylamino)-2-hydroxy-butyl]-2-methoxy-quinoline-6-carbonitrile",1.5,uM,=,0.1760912590556812,1,c1ccc2ncc([C@H](Cc3ccncc3)c3ccncc3)cc2c1
4165,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=N[C@@H]1c1ccc(F)cc1Br,"(S)-ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholinomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",4.88,uM,=,0.6884198220027107,1,C1=C(CN2CCOCC2)NC(c2nccs2)=N[C@@H]1c1ccccc1
4166,2153149,10.1016/j.ejmech.2021.113827,,,,Inhibition of hERG expressed in CHO-K1 cells assessed as reduction in thallium influx incubated for 30 minutes by FLIPR,O=c1ccc2c([nH]1)CCC(NCCNc1c3c(nc4cc(Cl)ccc14)CCCC3)C2,"6-(2-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)ethylamino)-5,6,7,8-tetrahydroquinolin-2(1H)-one",2.408,uM,=,0.3816564825857869,1,O=c1ccc2c([nH]1)CCC(NCCNc1c3c(nc4ccccc14)CCCC3)C2
4167,1667859,10.1016/j.bmcl.2017.03.030,,,,Inhibition of human ERG expressed in CHOK1 cells by Qpatch clamp method,N=C(Nc1ccc(I)cc1)NC12CC3CC(CC(C3)C1)C2,N-Adamantan-1-yl-N'-(4-iodo-phenyl)-guanidine,2.6,uM,=,0.414973347970818,1,N=C(Nc1ccccc1)NC12CC3CC(CC(C3)C1)C2
4168,2192070,10.1016/j.ejmech.2020.112955,,,,Inhibition of human ERG,COc1ccc(NC(=O)N2CCCCN3[C@H](CN(C)C)[C@H](c4ccc(C#Cc5ccccc5)cc4)[C@@H]3C2)cc1,"(8R,9S,10S)-10-((dimethylamino)methyl)-N-(4-methoxyphenyl)-9-(4-(phenylethynyl)phenyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide",2.1,uM,=,0.3222192947339193,1,O=C(Nc1ccccc1)N1CCCCN2C[C@H](c3ccc(C#Cc4ccccc4)cc3)[C@@H]2C1
4169,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(C(F)F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-(difluoromethyl)-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",5.85,uM,=,0.7671558660821804,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4170,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2cccc(F)c2)CC1)c1cc(=O)c2ccc(F)cc2o1,N-[1-[(3-fluorobenzyl)methyl]piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide,0.0212,uM,=,-1.6736641390712486,0,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
4171,1329251,10.1039/C1MD00164G,,,,Inhibition of human ERG by [3H]dofetilide binding assay,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3Cc4ccccc4C3)C[C@@H]21,"trans-N-(3-((1R,5S)-3-((2,3-dihydro-1H-inden-2-yl)methyl)-6-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)methanesulfonamide",0.326,uM,=,-0.4867823999320609,0,c1ccc(C2[C@H]3CN(CC4Cc5ccccc5C4)C[C@@H]23)cc1
4172,834187,10.1021/jm2013248,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,c1ccc(CN2CCN(Cc3nc(-c4ccccc4)no3)CC2)cc1,"5-((4-benzylpiperazin-1-yl)methyl)-3-phenyl-1,2,4-oxadiazole",12.7,uM,=,1.1038037209559568,1,c1ccc(CN2CCN(Cc3nc(-c4ccccc4)no3)CC2)cc1
4173,1474497,10.1021/acs.jmedchem.5b00191,,,,Inhibition of human ERG expressed in CHO cells,Cc1cc([C@H]2C[C@H]3[C@@H](C)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1,"(4R,4aR,6R,8aS)-8a-(2,4-difluorophenyl)-4-methyl-6-(3-methylisoxazol-5-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine",2.1,uM,=,0.3222192947339193,1,C1=N[C@@]2(c3ccccc3)CO[C@@H](c3ccno3)C[C@H]2CS1
4174,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=NC(c2cccc(-c3cncnc3)c2)(c2ccnc(C(F)(F)F)c2)c2cccc(F)c21,4-Fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1-(2-(trifluoromethyl)pyridin-4-yl)-1H-isoindol-3-amine,11.0,uM,=,1.0413926851582251,1,C1=NC(c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
4175,2045776,10.1039/d0md00174k,,,,Inhibition of human ERG,Cc1c(-c2ccc3[nH]ncc3c2)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12,"2-(aminomethyl)-5-cyclopropyl-7-(1H-indazol-5-yl)-6-methyloxazolo[4,5-c]quinolin-4(5H)-one",6.2,uM,=,0.7923916894982539,1,O=c1c2ncoc2c2ccc(-c3ccc4[nH]ncc4c3)cc2n1C1CC1
4176,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CCO[C@H]1COCC[C@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)(C(C)C)C1,"cis-((1S,3R)-3-((3R,4R)-3-ethoxytetrahydro-2H-pyran-4-ylamino)-1-isopropylcyclopentyl)(4-(4-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methanone",6.5,uM,=,0.8129133566428556,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2ccccn2)CC1
4177,501618,10.1021/jm8016199,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,COc1cc(-n2cnc3cc(-c4ccc(Cl)cc4)sc3c2=O)ccc1OCCN1CCCC1,"6-(4-chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-4(3H)-one",1.17,uM,=,0.0681858617461616,1,O=c1c2sc(-c3ccccc3)cc2ncn1-c1ccc(OCCN2CCCC2)cc1
4178,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,O=C(c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1)N1CCCCC1,"Piperidin-1-yl(4-(spiro[chromene-2,4'-piperidine]-4-yl)phenyl)methanone",3.027,uM,=,0.481012420956573,1,O=C(c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1)N1CCCCC1
4179,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CO[C@H]1CN(C2CCN(c3nc(N)n[nH]3)CC2)[C@H]1Cc1ccc(Cl)cc1,"5-(4-((2S,3S)-2-(4-Chlorobenzyl)-3-methoxyazetidin-1-yl)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",0.34,uM,=,-0.4685210829577448,0,c1ccc(C[C@H]2CCN2C2CCN(c3ncn[nH]3)CC2)cc1
4180,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C,"N-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)-1,2-dimethyl-5-phenyl-1H-pyrrole-3-carboxamide hydrchloride",0.14,uM,=,-0.8538719643217619,0,O=C(NCCCN1CCN(c2ccccc2)CC1)c1c[nH]c(-c2ccccc2)c1
4181,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCCC[C@@H](CCO)Nc1nc(N)nc2cccc(C)c12,(S)-3-((2-Amino-5-methylquinazolin-4-yl)amino)heptan-1-ol,0.6,uM,=,-0.2218487496163563,0,c1ccc2ncncc2c1
4182,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,0.213,uM,=,-0.6716203965612623,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
4183,408766,10.1021/jm060683e,,,,Activity at hERG expressed in HEK293 cells assessed as blockade of current at -50 mV by voltage clamp assay,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(F)cc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
4184,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(C2=CC3SC=NC3C=C2)[nH]1,"(S)-N-[(1S)-1-[5-(3a,7a-dihydro-1,3-benzothiazol-6-yl)-1H-imidazol-2-yl]-7-oxo-nonyl]-6-methyl-6-azaspiro[2.5]octane-2-carboxamide",40.0,uM,=,1.6020599913279625,1,O=C(NCc1ncc(C2=CC3SC=NC3C=C2)[nH]1)[C@H]1CC12CCNCC2
4185,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,C[C@@H]1CN(c2sc(C(F)(F)F)nc2-c2cnc(C(F)(F)F)nc2)CCN1C(=O)Cn1cnc(C(C)(C)C)n1,"2-(3-tert-Butyl-[1,2,4]triazol-1-yl)-1-((R)-2-methyl-4-(2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl)-piperazin-1-yl)ethanone",0.0075,uM,=,-2.1249387366083,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
4186,1665270,10.1016/j.bmcl.2017.03.027,,,,Inhibition of human ERG,O=C(c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1,"(R)-8-(1-(3,5-difluorophenyl)pyrrolidin-2-yl)-6-(morpholine-4-carbonyl)-2-morpholino-4H-chromen-4-one",45.0,uM,=,1.6532125137753435,1,O=C(c1cc([C@H]2CCCN2c2ccccc2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1
4187,701537,10.1021/jm101075v,,,,Displacement of [3H]astemizole from human ERG by whole cell patch-clamp technique,FC(F)(F)c1ccccc1-c1cc(C(F)(F)F)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1,3-[7-Trifluoromethyl-5-(2-trifluoromethyl-phenyl)-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene,16.0,uM,=,1.2041199826559248,1,c1ccc(-c2ccc3[nH]c(C4=NOC5(CCCCC5)C4)nc3c2)cc1
4188,606908,10.1016/j.bmcl.2009.10.092,,,,Inhibition of human ERG by patch clamp technique,Cc1ccccc1CN(c1ccc(C#N)c(Cl)c1)[C@H]1CCN(S(C)(=O)=O)C1,(S)-2-chloro-4-((2-methylbenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)benzonitrile,2.8,uM,=,0.4471580313422192,1,c1ccc(CN(c2ccccc2)[C@H]2CCNC2)cc1
4189,537242,10.1021/jm800569w,,,,"Antagonist activity at human ERG in HEK293 cells assessed as inhibition of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide binding",Cc1nc2ccccc2c(=O)n1-c1ccc(OC2CCCN(C3CCC3)CC2)cc1,3-(4-[(1-Cyclobutyl-4-azepanyl)oxy]phenyl)-2-methyl-4(3H)-quinazolinone,7.3,uM,=,0.8633228601204559,1,O=c1c2ccccc2ncn1-c1ccc(OC2CCCN(C3CCC3)CC2)cc1
4190,2129931,10.1021/acsmedchemlett.1c00363,,,,Inhibition of human ERG by patch clamp assay,Fc1cc(F)c(F)c(-c2ccc(N[C@H]3C[C@@H]4CN(CC5CCOCC5)C[C@@H]4C3)nn2)c1,"(3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)-N-(6-(2,3,5-trifluorophenyl)pyridazin-3-yl)octahydrocyclopenta[c]pyrrol-5-amine",0.431,uM,=,-0.3655227298392684,0,c1ccc(-c2ccc(N[C@H]3C[C@@H]4CN(CC5CCOCC5)C[C@@H]4C3)nn2)cc1
4191,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(C(C)(O)CC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(rac)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-2-hydroxypropyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",6.5,uM,=,0.8129133566428556,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4192,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C(NC(c1ccncc1)c1ccc(F)cc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1,"(1R,2R,4R)-2-(4-bromophenyl)-N-((4-fluorophenyl)(pyridin-4-yl)methyl)-4-morpholinocyclohexanecarboxamide",8.4,uM,=,0.9242792860618816,1,O=C(NC(c1ccccc1)c1ccncc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
4193,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,CC(C)(C)c1cc(CNCC2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc(C(C)(C)C)c1,"1-(1-(6,6-bis(4-fluorophenyl)hexyl)pyrrolidin-3-yl)-N-(3,5-di-tert-butylbenzyl)methanamine",0.46,uM,=,-0.3372421683184259,0,c1ccc(CNCC2CCN(CCCCCC(c3ccccc3)c3ccccc3)C2)cc1
4194,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,COc1ccc2c(c1)C(C1=C[C@H](C)N(C)CC1)=Nc1cc(Cl)ccc1N2,"(S)-8-chloro-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-methoxy-5H-dibenzo[b,e][1,4]diazepine",1.5,uM,=,0.1760912590556812,1,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
4195,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc([C@@H]2CC3(CCNCC3)Oc3ccccc32)cc1,"(S)-N,N-diethyl-4-(spiro[chroman-2,4'-piperidine]-4-yl)benzamide",18.471,uM,=,1.266490408311144,1,c1ccc([C@@H]2CC3(CCNCC3)Oc3ccccc32)cc1
4196,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC#CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C,"(S)-6-(3-aminopiperidin-1-yl)-5-(but-2-ynyl)-3-(isoquinolin-1-ylmethyl)-1-methyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",28.2,uM,=,1.4502491083193612,1,O=c1[nH]c2cc(N3CCCCC3)[nH]c2c(=O)n1Cc1nccc2ccccc12
4197,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,Clc1ccc([C@H]2CC=CCNC2)cc1Cl,"(R)-3-(3,4-dichlorophenyl)-2,3,4,7-tetrahydro-1H-azepine",21.0,uM,=,1.3222192947339193,1,C1=CC[C@H](c2ccccc2)CNC1
4198,990657,10.1016/j.bmcl.2013.08.104,,,,Inhibition of human ERG by electrophysiology assay,O=C1OCc2c1ccc(CCN1CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC1)c2F,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-4-fluoroisobenzofuran-1(3H)-one,12.0,uM,=,1.0791812460476249,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
4199,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,COc1cc(C)nc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)cnc2C(N)=O)c1,"5-(((1R,2S)-2-aminocyclohexyl)amino)-3-((4-methoxy-6-methylpyridin-2-yl)amino)picolinamide",1.7,uM,=,0.2304489213782739,1,c1ccc(Nc2cncc(NC3CCCCC3)c2)nc1
4200,1288300,10.1016/j.bmcl.2013.12.078,,,,Inhibition of human ERG by whole-cell patch clamp method,COC(=O)C(CCC(=O)N(C)CCCc1nc2ccccc2[nH]1)(c1ccc(Br)cc1)C(C)C,methyl 5-((3-(1H-benzo[d]imidazol-2-yl)propyl)(methyl)amino)-2-(4-bromophenyl)-2-isopropyl-5-oxopentanoate,12.5,uM,=,1.0969100130080565,1,O=C(CCCc1ccccc1)NCCCc1nc2ccccc2[nH]1
4201,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,CCOC(=O)c1cncc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)c1,"Ethyl5-((1R,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)nicotinate",2.257,uM,=,0.353531559077762,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@](c4cccnc4)(c4cn[nH]c4)N3)n2)cc1
4202,850453,10.1021/ml300146q,,,,Inhibition of recombinant human ERG channel IKr expressed in CHO cells by patch clamp assay,Cc1cc(C#N)ccc1-c1ccnc(NCc2n[nH]c3ncccc23)c1,"4-(2-((1H-Pyrazolo[3,4-b]pyridin-3-yl)methylamino)pyridin-4-yl)-3-methylbenzonitrile",1.9,uM,=,0.2787536009528289,1,c1ccc(-c2ccnc(NCc3n[nH]c4ncccc34)c2)cc1
4203,2204561,10.1016/j.bmcl.2022.128871,,,,Inhibition of human ERG,C[C@]1(CN2Cc3nc(-c4ccc(F)cc4)sc3C2)Cn2cc([N+](=O)[O-])nc2O1,"(S)-2-((2-(4-fluorophenyl)-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)methyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole",1.69,uM,=,0.2278867046136735,1,c1ccc(-c2nc3c(s2)CN(CC2Cn4ccnc4O2)C3)cc1
4204,541589,10.1021/jm801236n,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp method,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,2-(4-{1-Hydroxy-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butyl}-phenyl)-2-methyl-propionic acid,65.0,uM,=,1.812913356642856,1,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
4205,1433959,10.1021/jm5010682,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by scintillation counting method,OC(c1ccccc1)(c1ccccc1)C1CCN(Cc2ccc(-c3ccccc3)cc2)CC1,"(1-([1,1'-Biphenyl]-4-ylmethyl)piperidin-4-yl)-diphenylmethanol",0.21,uM,=,-0.6777807052660807,0,c1ccc(-c2ccc(CN3CCC(C(c4ccccc4)c4ccccc4)CC3)cc2)cc1
4206,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2ccsc2)CO1,"(4aR,6S,8aS)-6-Methyl-8a-(thiophen-3-yl)-4,4a,5,6,8,8ahexahydropyrano[3,4-d][1,3]thiazin-2-amine",39.9,uM,=,1.6009728956867482,1,C1=N[C@@]2(c3ccsc3)COCC[C@H]2CS1
4207,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)ncn3)CC2)(C(C)C)C1,"cis-((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxytetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)methanone",42.6,uM,=,1.6294095991027189,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2ccncn2)CC1
4208,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,CC(=O)Nc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1,N-[1-N-[1-{4-[(4-aminopiperidin-1-yl)methyl]phenyl}ethanonyl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide,47.7,uM,=,1.678518379040114,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
4209,405656,10.1016/j.bmcl.2006.06.045,,,,Inhibition of HERG potassium channel expressed in HEK cells by whole cell patch clamp method,CN(C(=O)c1ccc(-c2ccc(C(F)(F)F)cc2)cc1)[C@H]1CCN(C(=O)N(C)[C@@H]2CCN(CCCc3ccc(Cl)cc3)C2)C1,(S)-3-[methyl-(4'-trifluoromethyl-biphenyl-4-carbonyl)-amino]-pyrrolidine-1-carboxylic acid {(R)-1-[3-(4-chloro-phenyl)-propyl]-pyrrolidin-3-yl}-methyl-amide,0.17,uM,=,-0.7695510786217261,0,O=C(N[C@H]1CCN(C(=O)N[C@@H]2CCN(CCCc3ccccc3)C2)C1)c1ccc(-c2ccccc2)cc1
4210,2155012,10.1021/acs.jmedchem.1c00082,,,,Inhibition of hERG,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,"3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide",8.0,uM,=,0.9030899869919436,1,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(C#Cc2cnc3cccnn23)c1
4211,1700805,10.1021/acs.jmedchem.6b01831,,,,Inhibition of human ERG assessed as reduction of K+ current,COc1ccc2ccc(=O)n(C[C@H](N)[C@@H]3CC[C@@H](NCc4ccc5c(n4)NC(=O)CO5)CO3)c2n1,"6-((((3R,6S)-6-((1S)-1-Amino-2-(7-methoxy-2-oxo-1,8-naphthyridin-1(2H)-yl)ethyl)tetrahydro-2H-pyran-3-yl)amino)methyl)-2Hpyrido[3,2-b][1,4]oxazin-3(4H)-one",52.0,uM,=,1.7160033436347992,1,O=C1COc2ccc(CN[C@@H]3CC[C@@H](CCn4c(=O)ccc5cccnc54)OC3)nc2N1
4212,1809217,10.1021/acsmedchemlett.9b00204,,,,Inhibition of human ERG,COC1CCN(Cc2cc(-c3ccc(C(C)C)cc3)n(-c3ccc(F)cc3)n2)CC1,1-((1-(4-Fluorophenyl)-5-(4-isopropylphenyl)-1H-pyrazol-3-yl)methyl)-4-methoxypiperidine,6.31,uM,=,0.8000293592441343,1,c1ccc(-c2cc(CN3CCCCC3)nn2-c2ccccc2)cc1
4213,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,CCCn1c(-c2ccccn2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C.Cl.Cl.Cl.Cl,"N-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propyl)-2-methyl-1-propyl-5-(pyridin-2-yl)-1H-pyrrole-3-carboxamide dihydrochloride",1.0,uM,=,0.0,0,O=C(NCCCN1CCN(c2ccccc2)CC1)c1c[nH]c(-c2ccccn2)c1
4214,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"4-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-2-methoxybenzonitrile",1.7,uM,=,0.2304489213782739,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
4215,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,O=C(c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)c(F)c1)N1CCCC1,"6-[2-Fluoro-4-(pyrrolidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one",11.3,uM,=,1.0530784434834195,1,O=C(c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1)N1CCCC1
4216,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,CNc1cc(Nc2cnc(C#N)c(O[C@@H]3CCN(C)C3)n2)ncc1-c1cnn(C)c1,(R)-5-((5-(1-Methyl-1H-pyrazol-4-yl)-4-(methylamino)pyridin-2-yl)amino)-3-((1-methylpyrrolidin-3-yl)oxy)pyrazine-2-carbonitrile,24.0,uM,=,1.380211241711606,1,c1cc(Nc2cncc(O[C@@H]3CCNC3)n2)ncc1-c1cn[nH]c1
4217,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,CNc1cc(Nc2cnc(C#N)c(O[C@H](C)CN(C)C)n2)ncc1-c1cnn(C)c1,(R)-3-((1-(Dimethylamino)propan-2-yl)oxy)-5-((5-(1-methyl-1Hpyrazol-4-yl)-4-(methylamino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,12.0,uM,=,1.0791812460476249,1,c1cnc(Nc2ccc(-c3cn[nH]c3)cn2)cn1
4218,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCC[C@@H]2CO)c1,(R)-4-(benzyloxy)-1-(1-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,2.3,uM,=,0.3617278360175928,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
4219,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1Cl,"6-((1-(2-(7-chloro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.0042,uM,=,-2.3767507096021,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4220,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3ccncc3nc2OC)[nH]1,"(S)-N-((S)-1-(5-(2-methoxy-1,7-naphthyridin-3-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide",26.0,uM,=,1.414973347970818,1,O=C(NCc1ncc(-c2cnc3cnccc3c2)[nH]1)[C@H]1CC12CCNCC2
4221,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,CC(=O)c1ccc(Oc2ccc3nc(C(=O)N4CCNCC4)ccc3c2)cc1,"US9452986, 7",23.6,uM,=,1.3729120029701067,1,O=C(c1ccc2cc(Oc3ccccc3)ccc2n1)N1CCNCC1
4222,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N,"6-((S)-1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-methoxynicotinonitrile",17.0,uM,=,1.230448921378274,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
4223,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Cc1nc([C@@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccccc4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"5-methyl-3-((1S,3R)-1-(1-methyl-1H-pyrazol-4-yl)-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,2,4-oxadiazole",1.753,uM,=,0.2437819160937949,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@](c4cn[nH]c4)(c4ncon4)N3)n2)cc1
4224,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(Cl)cc(Cl)c2)CCN(CC2=Cc3ccccc3OC2(C)C)CC1,"methyl 4-((3,5-dichlorobenzamido)methyl)-1-((2,2-dimethyl-2H-chromen-3-yl)methyl)piperidine-4-carboxylate",13.83,uM,=,1.1408221801093106,1,O=C(NCC1CCN(CC2=Cc3ccccc3OC2)CC1)c1ccccc1
4225,622012,10.1021/jm901319p,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cn1c(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccnnc1,"(1S,5R)-3-(3-{[4-Methyl-5-(4-pyridazinyl)-4H-1,2,4-triazol-3-yl]-thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane",0.47,uM,=,-0.3279021420642826,0,c1ccc([C@]23C[C@H]2CN(CCCSc2nnc(-c4ccnnc4)[nH]2)C3)cc1
4226,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,COc1cc2nnc(C(N)=O)c(Nc3ccc(C)cc3F)c2cc1N1CCCN(C)CC1,"4-(2-fluoro-4-methylphenylamino)-7-methoxy-6-(4-methyl-1,4-diazepan-1-yl)cinnoline-3-carboxamide",6.0,uM,=,0.7781512503836436,1,c1ccc(Nc2cnnc3ccc(N4CCCNCC4)cc23)cc1
4227,793464,10.1016/j.bmcl.2011.09.114,,,,Inhibition of human ERG by whole cell patch clamp assay,COc1cc(F)c2nccc(NC(=O)[C@]3(O)CC[C@@H](NCc4cc5c(cn4)OCCO5)CC3)c2c1,"4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-N-(8-fluoro-6-methoxyquinolin-4-yl)-1-hydroxycyclohexanecarboxamide",113.0,uM,=,2.05307844348342,1,O=C(Nc1ccnc2ccccc12)C1CCC(NCc2cc3c(cn2)OCCO3)CC1
4228,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CC(=O)N[C@@H]1CC(C)(C)Oc2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc21,"N-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]acetamide",0.54,uM,=,-0.2676062401770315,0,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
4229,464747,10.1016/j.bmcl.2008.01.126,,,,Inhibition of human ERG by FLIPR assay,COc1ccc(N2C(=O)[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@H]2C(=O)O)cc1,"(2S,3S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid",54.0,uM,=,1.7323937598229686,1,O=C1[C@@H](Cc2ccc(OCCc3coc(-c4ccccc4)n3)cc2)CN1c1ccccc1
4230,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-4-yl)acetic Acid,4.3,uM,=,0.6334684555795865,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCCO5)CC4)nc3)nc2c1
4231,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2ncc(=O)n(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"4-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]piperidin-1-yl}ethyl)-6-methoxypyrido[2,3-b]pyrazin-3(4H)-one",31.0,uM,=,1.4913616938342726,1,O=c1cnc2cccnc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
4232,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,COCCOCC#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCN(C)CC4)ccc2-3)cs1,"3-(5-(3-(2-methoxyethoxy)prop-1-ynyl)thiophen-3-yl)-6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno[1,2-c]pyrazole",9.19,uM,=,0.9633155113861112,1,c1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1
4233,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,COc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1F,N-[1-[(3-fluoro-4-methoxybenzyl)methyl]piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide,0.0085,uM,=,-2.070581074285707,0,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
4234,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@H]3CO2)ccc(F)c1C#N,"3-((3R,9aS)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-6-fluoro-2-methylbenzonitrile",10.0,uM,=,1.0,1,O=C(Cc1ccc(-n2cnnn2)nc1)N1CCN2C[C@@H](c3ccccc3)OC[C@@H]2C1
4235,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N(CCc3ccc(Cl)cc3)C3COC3)CC2)n1,"1-(3-Amino-1H-1,2,4-triazol-5-yl)-N-(4-chlorophenethyl)-N-(oxetan-3-yl)piperidin-4-amine",4.4,uM,=,0.6434526764861874,1,c1ccc(CCN(C2CCN(c3ncn[nH]3)CC2)C2COC2)cc1
4236,819957,10.1021/ml200199c,,,,Displacement of [3H]dofetilide from human ERG,Cc1ccc([C@]2(O)CC[C@H](N[C@H]3CCN(C(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)nc1,(S)-N-(2-{3-[trans-4-Hydroxy-4-(5-methylpyridin-2-yl)cyclohexylamino]pyrrolidin-1-yl}-2-oxoethyl)-3-(trifluoromethyl)benzamide,24.0,uM,=,1.380211241711606,1,O=C(NCC(=O)N1CC[C@H](NC2CCC(c3ccccn3)CC2)C1)c1ccccc1
4237,2287586,10.1021/acsmedchemlett.8b00517,,,,Inhibition of hERG potassium channel incubated for 4 hrs by fluorescence polarization assay,CCC(=O)CCCCC[C@H](NC(=O)C1CN(C)C1)c1ncc(-c2cc3ccccc3nc2OC)[nH]1,(S)-N-(1-(5-(2-methoxyquinolin-3-yl)-1H-imidazol-2-yl)-7-oxooctyl)-1-methylazetidine-3-carboxamide,3.0,uM,=,0.4771212547196624,1,O=C(NCc1ncc(-c2cnc3ccccc3c2)[nH]1)C1CNC1
4238,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(Cl)c(F)cc5[nH]4)CC3)c2c1,"1-(2-(4-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)-7-methoxy-1,5-naphthyridin-2(1H)-one",1.2,uM,=,0.0791812460476248,1,O=c1ccc2ncccc2n1CCN1CCC(c2nc3ccccc3[nH]2)CC1
4239,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(C#N)cc1Oc1ccc(Cl)c(Cl)c1,"3-(3,4-dichlorophenoxy)-4-((methylamino)methyl)benzonitrile",1.31,uM,=,0.1172712956557642,1,c1ccc(Oc2ccccc2)cc1
4240,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,Oc1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"endo-3-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)phenol",1.6,uM,=,0.2041199826559248,1,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccc2)C3)cc1
4241,2157068,10.1021/acsmedchemlett.1c00445,,,,Inhibition of hERG expressed in HEK293 cells at -80 mV holding potential by automated patch-clamp method,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)Cn2ccnc2C(N)=N1,"(R)-N-(3-(8-amino-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-6-yl)-4-fluorophenyl)-5-cyanopicolinamide",4.2,uM,=,0.6232492903979004,1,O=C(Nc1cccc(C2Cn3ccnc3C=N2)c1)c1ccccn1
4242,1926979,10.1021/acsmedchemlett.6b00119,,,,Displacement of [3H]dofetilide from recombinant human ERG transfected in HEK293 cell membranes after 60 mins by scintillation counting,COc1ccc(-c2ccc3ncnc(-c4cncc(C(=O)N5CCN(C)CC5)c4)c3c2)cn1,(5-(6-(6-methoxypyridin-3-yl)quinazolin-4-yl)pyridin-3-yl)(4-methylpiperazin-1-yl)methanone,26.0,uM,=,1.414973347970818,1,O=C(c1cncc(-c2ncnc3ccc(-c4cccnc4)cc23)c1)N1CCNCC1
4243,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CCC(CC)Nc1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCN(C)CC2)n1,6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-N-(pentan-3-yl)-4-(trifluoromethyl)pyridin-2-amine,7.1,uM,=,0.8512583487190752,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
4244,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,Cc1cc(C#N)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12,"4-methyl-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridine-2-carbonitrile",0.00208,uM,=,-2.6819366650372385,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4245,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2c1,"N-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methyl)-1-(2-(6-methoxyquinolin-4-yl)ethyl)piperidin-4-amine",1.9,uM,=,0.2787536009528289,1,c1ccc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
4246,857606,10.1021/ml2002604,,,,Inhibition of human recombinant hERG expressed in CHO cells by automated patch clamp assay,CONC(=O)N(Cc1ccsc1)C1CCN([C@H](C)CCNC(=O)c2c(C)cc(C#N)nc2Cl)CC1,(R)-2-Chloro-6-cyano-N-(3-(4-(3-methoxy-1-(thiophen-3-ylmethyl)ureido)piperidin-1-yl)butyl)-4-methylnicotinamide,10.8,uM,=,1.0334237554869496,1,O=C(NCCCN1CCC(NCc2ccsc2)CC1)c1cccnc1
4247,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,Cc1ccc(C2(O)CCN(C(C)C(O)c3ccc4c(c3)CCC(=O)N4)CC2)cc1,"6-(1-hydroxy-2-(4-hydroxy-4-p-tolylpiperidin-1-yl)propyl)-3,4-dihydroquinolin-2(1H)-one",3.3,uM,=,0.5185139398778875,1,O=C1CCc2cc(CCN3CCC(c4ccccc4)CC3)ccc2N1
4248,575209,10.1016/j.bmcl.2009.03.090,,,,Inhibition of human ERG channel,Clc1cccc(OC(c2cccnc2)[C@@H]2CCCNC2)c1Cl,"3-((2,3-dichlorophenoxy)((R)-piperidin-3-yl)methyl)pyridine",6.61,uM,=,0.8202014594856403,1,c1ccc(OC(c2cccnc2)[C@@H]2CCCNC2)cc1
4249,541742,10.1016/j.bmc.2009.01.061,,,,Inhibition of human ERG,CC(c1nc(-c2ccc(S(C)(=O)=O)cc2Cl)no1)[C@H](N)C(F)=C1CCCC1.O=C(O)C(F)(F)F,"(2S)-3-(3-(2-chloro-4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-cyclopentylidene-1-fluorobutan-2-aminium 2,2,2-trifluoroacetate",19.0,uM,=,1.2787536009528289,1,C(CCc1nc(-c2ccccc2)no1)=C1CCCC1
4250,675131,10.1016/j.bmcl.2010.08.118,,,,Inhibition of human ERG,Cc1ncnc(C)c1C(=O)N1C[C@H]2CN(CCC(c3cccc(F)c3)C3CCN(S(C)(=O)=O)CC3)C[C@H]2C1,"(4,6-dimethylpyrimidin-5-yl)((3aR,6aS)-5-(3-(3-fluorophenyl)-3-(1-(methylsulfonyl)piperidin-4-yl)propyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methanone",15.4,uM,=,1.187520720836463,1,O=C(c1cncnc1)N1C[C@H]2CN(CCC(c3ccccc3)C3CCNCC3)C[C@H]2C1
4251,1766690,10.1021/acs.jmedchem.8b01147,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method,CC(C)n1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N,"4-({4-Amino-6-[3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1H)-yl)-2-(hydroxymethyl)phenyl]-1,3,5-triazin-2-yl}amino)-1-isopropyl-1H-pyrrole-2-carbonitrile",30.0,uM,=,1.4771212547196624,1,O=c1c2ccc(C3CC3)cc2ccn1-c1cccc(-c2ncnc(Nc3cc[nH]c3)n2)c1
4252,624297,10.1016/j.bmcl.2010.01.134,,,,Inhibition of human ERG expressed in HEK cells assessed as blockade of potassium tail current by standard patch clamp analysis,C[C@@H](c1cscn1)c1c(CCN(C)C)sc2ccccc12,"(-)-(R)-N,N-dimethyl-2-(3-(1-(thiazol-4-yl)ethyl)benzo[b]thiophen-2-yl)ethanamine",1.7,uM,=,0.2304489213782739,1,c1ccc2c(Cc3cscn3)csc2c1
4253,964986,10.1016/j.bmcl.2013.04.047,,,,Inhibition of human ERG expressed in HEK cells by ion flux electrophysiology method,O=C(NC1CC1)c1ccc(O)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2,"(S)-2-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-N-cyclopropyl-4-hydroxybenzamide",0.3,uM,=,-0.5228787452803376,0,O=C(NC1CC1)c1ccccc1OCCCN1CCC2(CC1)Cc1ccccc1O2
4254,699583,10.1016/j.bmcl.2010.10.086,,,,Inhibition of human ERG,CN[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21,"(R)-1-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydroquinolin-4-amine",3.25,uM,=,0.5118833609788744,1,c1ccc(N2CCCc3ccccc32)cc1
4255,1437941,10.1021/jm5016022,,,,Inhibition of human ERG channel by patch-clamp assay,CC(C)n1ncc2c1C(=O)CC1(CCN(C(=O)c3ccc4[nH]ncc4c3)CC1)C2,"1'-(1H-Indazole-5-carbonyl)-1-isopropyl-1,4-dihydrospiro-[indazole-5,4'-piperidin]-7(6H)-one",23.0,uM,=,1.3617278360175928,1,O=C1CC2(CCN(C(=O)c3ccc4[nH]ncc4c3)CC2)Cc2cn[nH]c21
4256,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CCCc1nc2ccccc2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,2-Propyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,2.8,uM,=,0.4471580313422192,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
4257,793464,10.1016/j.bmcl.2011.09.114,,,,Inhibition of human ERG by whole cell patch clamp assay,COc1ccc2nccc(NC(=O)[C@]3(O)CC[C@@H](NCc4ccc5c(c4)OCCO5)CC3)c2n1,"4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)-1-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)cyclohexanecarboxamide",25.0,uM,=,1.3979400086720375,1,O=C(Nc1ccnc2cccnc12)C1CCC(NCc2ccc3c(c2)OCCO3)CC1
4258,802976,10.1021/ml200030q,,,,Inhibition of human Erg by patch clamp assay,COc1ccc([C@]2(O)CC[C@H](N3CC[C@@H](NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1.CS(=O)(=O)O,N-(2-((R)-1-(trans-4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide bismethanesulfonate,84.0,uM,=,1.9242792860618816,1,O=C(CNC(=O)c1ccccc1)N[C@@H]1CCN(C2CCC(c3cccnc3)CC2)C1
4259,2022324,10.1021/acs.jmedchem.0c01163,,,,Inhibition of human ERG by plate-based planar patch clamp technique,COc1cc(NC2CN(CCCF)C2)ccc1[C@@H]1c2ccc3[nH]ncc3c2C[C@@H](C)N1CC1(F)CC1,"N-(4-((6S,8R)-7-((1-Fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)-3-methoxyphenyl)-1-(3-fluoropropyl)azetidin-3-amine",9.1,uM,=,0.9590413923210936,1,c1cc([C@@H]2c3ccc4[nH]ncc4c3CCN2CC2CC2)ccc1NC1CNC1
4260,1972207,10.1021/acs.jmedchem.9b01624,,,,Inhibition of human ERG by Qpatch S8 assay,O=C(Nc1cc(-c2cn(C3CCOCC3)c3cnccc23)ccn1)N1CCOCC1,"N-(4-(1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)morpholine-4-carboxamide",24.1,uM,=,1.3820170425748683,1,O=C(Nc1cc(-c2cn(C3CCOCC3)c3cnccc23)ccn1)N1CCOCC1
4261,1456349,10.1021/jm401951t,,,,Inhibition of human ERG expressed in CHO cells by electrophysiology assay,CN(C)Cc1ccc2c(c1)CCN(C(=O)c1cc3cc(Cl)ccc3n1C)C2,"(5-chloro-1-methyl-1H-indol-2-yl)(6-((dimethylamino)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone",4.9,uM,=,0.6901960800285137,1,O=C(c1cc2ccccc2[nH]1)N1CCc2ccccc2C1
4262,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCC(O)(Cc2ccccc2)CC1,4-benzyl-4-hydroxy-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)piperidine-1-carboxamide,7.93,uM,=,0.8992731873176038,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCC(Cc2ccccc2)CC1
4263,1698436,10.1021/acs.jmedchem.8b00190,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,CCc1ccn2ccnc2c1N1CCCN([C@@H](CC(N)=O)C2CCN(C(=O)[C@H]3C[C@@H]4CC[C@H]3O4)CC2)CC1,"(S)-3-(1-((1R,2R,4S)-7-Oxabicyclo[2.2.1]heptane-2-carbonyl)-piperidin-4-yl)-3-(4-(7-ethylimidazo[1,2-a]pyridin-8-yl)-1,4-diazepan-1-yl)propanamide",8.3,uM,=,0.919078092376074,1,O=C([C@H]1C[C@@H]2CC[C@H]1O2)N1CCC(CN2CCCN(c3cccn4ccnc34)CC2)CC1
4264,698202,10.1016/j.bmcl.2010.11.033,,,,Inhibition of human hERG,COc1ccc(C(CC(=O)N2CCN(Cc3nc4ccc(C)cc4o3)CC2)c2ccccc2)cc1,3-(4-methoxyphenyl)-1-(4-((6-methylbenzo[d]oxazol-2-yl)methyl)piperazin-1-yl)-3-phenylpropan-1-one,1.16,uM,=,0.0644579892269184,1,O=C(CC(c1ccccc1)c1ccccc1)N1CCN(Cc2nc3ccccc3o2)CC1
4265,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CC(C)c1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@@H]2CCO)n1,"1-((S)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-isopropyl-[1,2,4]triazol-1-yl)-ethanone",0.019,uM,=,-1.7212463990471711,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
4266,766531,10.1016/j.bmcl.2011.06.126,,,,Inhibition of human ERG by electrophysiological assay,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccc(-c6ccco6)cc54)CC3)nc2N1,"6-((1-(2-(6-(furan-2-yl)-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.3,uM,=,0.1139433523068367,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccc(-c6ccco6)cc54)CC3)nc2N1
4267,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"1-(2,2-difluoroethyl)-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",8.96,uM,=,0.9523080096621253,1,O=C1Nc2ccccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
4268,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3ccc(C)nc3cc2Cl)[nH]1,(S)-N-((S)-1-(5-(7-chloro-2-methylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,10.0,uM,=,1.0,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)[nH]1)[C@H]1CC12CCNCC2
4269,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4cncnc4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(pyrimidin-5-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide",8.5,uM,=,0.9294189257142929,1,c1ncc(-c2cc3c(NC4CCCC4)ccnn3c2)cn1
4270,762093,10.1021/jm200018k,,,,Inhibition of human Erg expressed in human HEK293 cells by patch-clamp electrophysiological assay,CC(=O)Nc1cccc(Nc2ncnc(N3CCC(Oc4ccc(C(F)(F)F)cc4)CC3)n2)c1C,"N-(2-Methyl-3-(4-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide",4.1,uM,=,0.6127838567197355,1,c1ccc(Nc2ncnc(N3CCC(Oc4ccccc4)CC3)n2)cc1
4271,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,Cc1cccc(N2CCN(CCNC(=O)c3cc(C(C)(C)C)n(C)c3C)CC2)c1C,"5-tert-Butyl-N-(2-(4-(2,3-dimethylphenyl)piperazin-1-yl)ethyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide",11.8,uM,=,1.0718820073061257,1,O=C(NCCN1CCN(c2ccccc2)CC1)c1cc[nH]c1
4272,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1cc(C)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-methoxy-8-methyl-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00522,uM,=,-2.282329496997738,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4273,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=N[C@H]3CNC[C@H]3CO2)cc1,"(4aR,7aR)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-4,4a,5,6,7,7a-hexahydropyrrolo[3,4-d][1,3]oxazine",3.3,uM,=,0.5185139398778875,1,c1ccc([C@H]2c3ccccc3CCN2C2=N[C@H]3CNC[C@H]3CO2)cc1
4274,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7cc[n+]([O-])cc7)[nH]6)CC5)cc4)nc3n2)CC1,"Dimethyl-(2-{4-[7-(4-{4-[5-(1-oxy-pyridin-4-yl)-4H-[1,2,4]triazol-3-yl]-piperidin-1-ylmethyl}-phenyl)-6-phenyl-pyrido[2,3-d]pyrimidin-2-yl]-piperazin-1-yl}-ethyl)-amine",7.9,uM,=,0.8976270912904415,1,c1ccc(-c2cc3cnc(N4CCNCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5cc[nH+]cc5)[nH]4)CC3)cc2)cc1
4275,1664072,10.1021/acs.jmedchem.7b00584,,,,Inhibition of human ERG expressed in CHO cells by automated patch-clamp assay,COc1ccccc1CNC[C@H]1C[C@@H]1c1cc(F)ccc1OC.Cl,"(+)-1-[(1S,2S)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-(2-methoxybenzyl)methanamine Hydrochloride",1.4,uM,=,0.1461280356782379,1,c1ccc(CNC[C@H]2C[C@@H]2c2ccccc2)cc1
4276,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1cc(CN2CCC(CNCCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc(OC)c1OC,"6,6-bis(4-fluorophenyl)-N-((1-(3,4,5-trimethoxybenzyl)pyrrolidin-3-yl)methyl)hexan-1-amine",0.1,uM,=,-1.0,0,c1ccc(CN2CCC(CNCCCCCC(c3ccccc3)c3ccccc3)C2)cc1
4277,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,Cc1cc(Nc2nccc(-c3sc(C4CCNCC4)nc3-c3ccc(F)cc3)n2)cc(C)n1,"N-(2,6-Dimethylpyridin-4-yl)-4-(4-(4-fluorophenyl)-2-(piperidin-4-yl)thiazol-5-yl)pyrimidin-2-amine",1.5,uM,=,0.1760912590556812,1,c1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(Nc3ccncc3)n2)cc1
4278,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",O=c1cc(OCc2ccccc2F)ccn1-c1ccc(OCCN2CCCC2)cc1,4-[(2-Fluorobenzyl)oxy]-1-{4-[2-(pyrrolidin-1-yl)ethoxy]-phenyl}pyridin-2(1H)-one,0.0043,uM,=,-2.3665315444204134,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCN2CCCC2)cc1
4279,745085,10.1016/j.bmcl.2011.02.049,,,,Displacement of [35S]MK499 from human ERG expressed in HEK cells,CC(C)c1cc(C#N)cc2nc(-c3ccc(C(=O)NCC4CN(c5ccc(-c6ccccc6C#N)cn5)C(=O)O4)cc3)oc12,rac-4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((3-(5-(2-cyanophenyl)pyridin-2-yl)-2-oxooxazolidin-5-yl)methyl)benzamide,1.188,uM,=,0.0748164406451747,1,O=C(NCC1CN(c2ccc(-c3ccccc3)cn2)C(=O)O1)c1ccc(-c2nc3ccccc3o2)cc1
4280,2050721,10.1021/acs.jmedchem.0c01544,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp assay,CC[C@@H](c1nc2cccc(F)c2c(=O)n1C1CC1)n1nc(-c2ccc(OC)c(F)c2)c2c(N)ncnc21,"(S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo-[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one",13.8,uM,=,1.1398790864012365,1,O=c1c2ccccc2nc(Cn2nc(-c3ccccc3)c3cncnc32)n1C1CC1
4281,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1cc(-n2cnnn2)cnc1CC(=O)N1CCN(CCc2ccc3c(c2C)COC3=O)CC1,4-methyl-5-(2-(4-(2-(3-methyl-5-(1H-tetrazol-1-yl)pyridin-2-yl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,52.0,uM,=,1.7160033436347992,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cn4)CC3)ccc21
4282,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,Fc1ccccc1C(Cc1ccccc1OC(F)(F)F)N1CCNCC1,1-(1-(2-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine,0.76,uM,=,-0.1191864077192086,0,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
4283,1700906,10.1021/acs.jmedchem.7b00032,,,,Inhibition of human ERG by automated patch clamp assay,CCc1nc2c(C)cc(N3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)c(C#N)s1,"2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile",15.0,uM,=,1.1760912590556811,1,O=C(CN1CCN(c2ccc3ncc(Nc4nc(-c5ccccc5)cs4)n3c2)CC1)N1CCC1
4284,2047203,10.1021/acs.jmedchem.0c01170,,,,Inhibition of human ERG by Q-patch assay,CC1(N)CCN(c2cnc(Sc3ccccc3Cl)c(N)n2)CC1,6-(4-amino-4-methylpiperidin-1-yl)-3-(2-chlorophenylthio)pyrazin-2-amine,6.1,uM,=,0.785329835010767,1,c1ccc(Sc2cnc(N3CCCCC3)cn2)cc1
4285,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,Fc1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(Nc3ccncn3)n2)cc1,4-(4-(4-Fluorophenyl)-2-(piperidin-4-yl)thiazol-5-yl)-N-(pyrimidin-4-yl)pyrimidin-2-amine,0.6,uM,=,-0.2218487496163563,0,c1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(Nc3ccncn3)n2)cc1
4286,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCC(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOc5ccccc5)c4)n[nH]c2-3)CC1,"6-((1-methylpiperidin-4-yl)methyl)-3-(5-(3-phenoxyprop-1-ynyl)thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole",2.1,uM,=,0.3222192947339193,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CC4CCNCC4)ccc2-3)cs1)COc1ccccc1
4287,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,CNC(=O)c1ccc(Nc2ncc(F)c(-c3cnc(C)n3C(C)C)n2)cc1,4-(5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)-N-methylbenzamide,12.0,uM,=,1.0791812460476249,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
4288,2153149,10.1016/j.ejmech.2021.113827,,,,Inhibition of hERG expressed in CHO-K1 cells assessed as reduction in thallium influx incubated for 30 minutes by FLIPR,O=c1ccc2c([nH]1)CCC(NCCCCCCCCCNc1c3c(nc4cc(Cl)ccc14)CCCC3)C2,"6-(9-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)nonylamino)-5,6,7,8-tetrahydroquinolin-2(1H)-one",2.755,uM,=,0.4401216031878038,1,O=c1ccc2c([nH]1)CCC(NCCCCCCCCCNc1c3c(nc4ccccc14)CCCC3)C2
4289,793464,10.1016/j.bmcl.2011.09.114,,,,Inhibition of human ERG by whole cell patch clamp assay,COc1ccc2nccc(NC(=O)[C@]3(O)CC[C@@H](NCc4cc5c(cn4)OCCO5)CC3)c2n1,"4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-1-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)cyclohexanecarboxamide",24.0,uM,=,1.380211241711606,1,O=C(Nc1ccnc2cccnc12)C1CCC(NCc2cc3c(cn2)OCCO3)CC1
4290,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,N#CC1(CNC(=O)c2cc(Cl)cc(Cl)c2)CCN(CCc2ccccc2)CC1,"3,5-dichloro-N-((4-cyano-1-phenethylpiperidin-4-yl)methyl)benzamide",0.36,uM,=,-0.4436974992327127,0,O=C(NCC1CCN(CCc2ccccc2)CC1)c1ccccc1
4291,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,C=CCn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](C(=O)OCC)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-4-{3-[2-(1-Allyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetylamino]-azetidin-1-yl}-cyclohexanecarboxylic acid ethyl ester,3.7,uM,=,0.568201724066995,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
4292,541583,10.1021/jm801236n,,,,Inhibition of wild-type human ERG expressed in HEK293 cells by whole cell patch clamp method,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,0.03,uM,=,-1.5228787452803376,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
4293,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1c(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)nnn1-c1ccc(F)cc1F,"2-(1-(2,4-difluorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)-6-(2-((R)-2-methylpyrrolidin-1-yl)ethyl)quinoline",2.8,uM,=,0.4471580313422192,1,c1ccc(-n2cc(-c3ccc4cc(CCN5CCCC5)ccc4n3)nn2)cc1
4294,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCOC(=O)[C@H]1CC[C@@H](N2CC(NC(=O)CNC3=NC(Cc4ccccc4)c4ccc(C(F)(F)F)cc43)C2)CC1,cis-4-{3-[2-(1-Benzyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetylamino]-azetidin-1-yl}-cyclohexane carboxylic acid ethyl ester,1.4,uM,=,0.1461280356782379,1,O=C(CNC1=NC(Cc2ccccc2)c2ccccc21)NC1CN(C2CCCCC2)C1
4295,345010,10.1016/j.bmcl.2005.12.094,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CN(CCO)C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1cccc(O)c1,"(S)-4-(2,5-difluorophenyl)-N-(2-hydroxyethyl)-2-(3-hydroxyphenyl)-N-methyl-2H-pyrrole-1(5H)-carboxamide",15.0,uM,=,1.1760912590556811,1,C1=C(c2ccccc2)CN[C@@H]1c1ccccc1
4296,2266525,10.1021/acsmedchemlett.2c00454,,,,Displacement of E-4031 from hERG by fluorescence polarization assay,N[C@@H]1c2ccccc2CC12CCN(c1nc3nc(Sc4ccncc4Cl)cnc3[nH]1)CC2,"(S)-1'-(5-((3-chloropyridin-4-yl)thio)-1H-imidazo[4,5-b]pyrazin-2-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine",3.1,uM,=,0.4913616938342727,1,c1ccc2c(c1)CC1(CCN(c3nc4nc(Sc5ccncc5)cnc4[nH]3)CC1)C2
4297,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,C[C@H]1COc2c(N3CC[C@@H](C4(N)CC4)C3)c(F)c(F)c3cc(C(=O)O)c(=O)n1c23,"(S)-10-((R)-3-(1-aminocyclopropyl)pyrrolidin-1-yl)-8,9-difluoro-3-methyl-5-oxo-3,5-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid",211.0,uM,=,2.3242824552976926,1,O=c1ccc2ccc(N3CC[C@@H](C4CC4)C3)c3c2n1CCO3
4298,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6cnccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12,"3-phenyl-2-(4-((4-(5-(pyrazin-2-yl)-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-1,6-naphthyridin-5(6H)-one",8.428,uM,=,0.9257245269360628,1,O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6cnccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12
4299,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(F)c(OC)cc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxyphenyl)-N-methylmethanamine",2.15,uM,=,0.3324384599156053,1,c1ccc(Oc2ccccc2)cc1
4300,1672277,10.1016/j.bmcl.2017.05.026,,,,Inhibition of recombinant human ERG expressed in HEK293 cells after 9 mins by patch clamp method,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,Chidamide,32.0,uM,=,1.505149978319906,1,O=C(/C=C/c1cccnc1)NCc1ccc(C(=O)Nc2ccccc2)cc1
4301,1515505,10.1021/ml500440u,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,CCOc1cc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N,"4-ethoxy-6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)nicotinonitrile",12.0,uM,=,1.0791812460476249,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
4302,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,Oc1cc(-c2cn[nH]c2)ccc1-c1ccc(N2C[C@H]3CNC[C@H]3C2)nn1,"2-(6-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol",2.5,uM,=,0.3979400086720376,1,c1cc(-c2ccc(N3C[C@H]4CNC[C@H]4C3)nn2)ccc1-c1cn[nH]c1
4303,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,O=C(CNc1cc(C(F)(F)F)nc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1,"Cis-2-(2,6-bis(trifluoromethyl)quinolin-4-ylamino)-N-(1-(4-hydroxy-4-(thiazol-5-yl)cyclohexyl)azetidin-3-yl)acetamide",36.1,uM,=,1.557507201905658,1,O=C(CNc1ccnc2ccccc12)NC1CN(C2CCC(c3cncs3)CC2)C1
4304,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CN(c1ccc(-c2cc3ccccc3s2)nn1)C1CC(C)(C)NC(C)(C)C1,"6-(benzo[b]thiophen-2-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine",0.11,uM,=,-0.958607314841775,0,c1ccc2sc(-c3ccc(NC4CCNCC4)nn3)cc2c1
4305,2133680,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG expressed in CHO by QPatch assay,CC[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3c(C)nc4ccc(F)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(6-fluoro-2-methyl-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",21.0,uM,=,1.3222192947339193,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
4306,652287,10.1016/j.bmcl.2010.07.020,,,,Inhibition of human ERG,CCCC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCCN1,(7-fluoro-1H-indol-5-yl)(2-propylpyrrolidin-2-yl)methanone,5.9,uM,=,0.7708520116421442,1,O=C(c1ccc2[nH]ccc2c1)C1CCCN1
4307,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCN(CC)C(=O)c1ccc([C@H](c2cccc(NC(=O)C3CC3)c2)N2CCN(Cc3ccccn3)CC2)cc1,"(R)-4-((3-(cyclopropanecarboxamido)phenyl)(4-(pyridin-2-ylmethyl)piperazin-1-yl)methyl)-N,N-diethylbenzamide",20.0,uM,=,1.3010299956639813,1,O=C(Nc1cccc([C@@H](c2ccccc2)N2CCN(Cc3ccccn3)CC2)c1)C1CC1
4308,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3ccc4cccnc43)[C@H](C)C2)cn1,"1-{(R)-4-[4-(2-Ethoxy-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-2-pyrrolo[2,3-b]pyridin-1-yl-ethanone",4.2,uM,=,0.6232492903979004,1,O=C(Cn1ccc2cccnc21)N1CCN(c2scnc2-c2cncnc2)CC1
4309,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1,5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol,0.23,uM,=,-0.6382721639824072,0,c1ccc(/N=N/c2ccccn2)cc1
4310,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C)C2=O,"2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-6-methyl-7,8-dihydro-1,6-naphthyridin-5(6H)-one",3.8,uM,=,0.5797835966168101,1,O=C1NCCc2nc(OCc3conc3-c3ccccc3)ccc21
4311,1435893,10.1016/j.bmc.2014.10.020,,,,Inhibition of human ERG expressed in CHO cells by Rb efflux assay,O=C(CNCC1(O)CCCCC1)N1CCc2ccccc2[C@H]1C1CCCCC1,"(1R)-(1-Cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-{[(1-hydroxycyclohexyl)methyl]amino}ethanone",76.0,uM,=,1.880813592280792,1,O=C(CNCC1CCCCC1)N1CCc2ccccc2[C@H]1C1CCCCC1
4312,1706834,10.1016/j.bmcl.2017.07.031,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp method,CC(C)Cc1cc(CNS(=O)(=O)c2cccc3cccnc23)nn1-c1ccc(F)cc1,N-((1-(4-fluorophenyl)-5-isobutyl-1H-pyrazol-3-yl)methyl)quinoline-8-sulfonamide,1.6,uM,=,0.2041199826559248,1,O=S(=O)(NCc1ccn(-c2ccccc2)n1)c1cccc2cccnc12
4313,2212585,10.1021/acsmedchemlett.2c00081,,,,Inhibition of human ERG potassium channel by fluorescence polarization assay,CC(c1ccccc1)N1CCN(Cc2ccc(C(=O)NO)cc2)CC1,N-Hydroxy-4-((4-(1-phenylethyl)piperazin-1-yl)methyl)benzamide,106.0,uM,=,2.0253058652647704,1,c1ccc(CN2CCN(Cc3ccccc3)CC2)cc1
4314,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN1CCc2cc(C3=CC4(CCNCC4)Oc4ccccc43)ccc2C1=O,"2-Ethyl-6-(spiro[chromene-2,4'-piperidine]-4-yl)-3,4-dihydroisoquinolin-1(2H)-one",13.5,uM,=,1.130333768495006,1,O=C1NCCc2cc(C3=CC4(CCNCC4)Oc4ccccc43)ccc21
4315,793275,10.1016/j.bmcl.2011.09.117,,,,Displacement of [3H]dofetilide from human ERG by liquid scintillation counting,COc1ccc2ncc(C#N)c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"4-(2-(4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)ethyl)-6-methoxy-1,5-naphthyridine-3-carbonitrile",7.9,uM,=,0.8976270912904415,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
4316,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,Brc1cncc(COCC2(c3ccccc3)CCNCC2)c1,3-bromo-5-(((4-phenylpiperidin-4-yl)methoxy)methyl)pyridine,15.0,uM,=,1.1760912590556811,1,c1ccc(C2(COCc3cccnc3)CCNCC2)cc1
4317,2194946,10.1021/acs.jmedchem.2c01064,,,,Inhibition of hERG expressed in CHO cells Qpatch-clamp electrophysiology assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,25.0,uM,=,1.3979400086720375,1,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
4318,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CNC(Cc2ccccc2)C(=O)O)NC(c2nccs2)=NC1c1ccc(F)cc1Br,"2-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)amino)-3-phenylpropanoic Acid",8.68,uM,=,0.9385197251764918,1,C1=C(CNCCc2ccccc2)NC(c2nccs2)=NC1c1ccccc1
4319,876021,10.1021/jm3011838,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,Nc1ccccc1NC(=O)/C=C/c1ccc([C@H]2CN(CCO)C[C@@H]2C(=O)Nc2ccc(Cl)cc2)cc1,"rac-(trans-3,4)-4-{4-[(E)-2-(2-Amino-phenylcarbamoyl)-vinyl]-phenyl}-1-(2-hydroxy-ethyl)-pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-amide",15.0,uM,=,1.1760912590556811,1,O=C(/C=C/c1ccc([C@H]2CNC[C@@H]2C(=O)Nc2ccccc2)cc1)Nc1ccccc1
4320,624297,10.1016/j.bmcl.2010.01.134,,,,Inhibition of human ERG expressed in HEK cells assessed as blockade of potassium tail current by standard patch clamp analysis,COc1ncccc1[C@@H](C)c1c(CCN(C)C)sc2ccccc12,"(-)-(R)-2-(3-(1-(2-methoxypyridin-3-yl)ethyl)benzo[b]thiophen-2-yl)-N,N-dimethylethanamine",1.8,uM,=,0.255272505103306,1,c1cncc(Cc2csc3ccccc23)c1
4321,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nnc(S)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,3,4-oxadiazole-2-thiol",10.4,uM,=,1.0170333392987805,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4nnco4)N3)n2)nc1
4322,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,CC(=O)c1cccc(CNc2cc(C(F)(F)F)cc3ncc(N4CCN(C)CC4)cc23)c1,1-(3-((3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinolin-5-ylamino)methyl)phenyl)ethanone,93.6,uM,=,1.9712758487381048,1,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
4323,863322,10.1021/jm3008294,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp technique,Cl.Clc1ccc(OC(c2ccc3ccccc3c2)C2CNC2)cc1Cl,"3-((3,4-Dichlorophenoxy)(naphthalen-2-yl)methyl)azetidine hydrochloride",0.18,uM,=,-0.744727494896694,0,c1ccc(OC(c2ccc3ccccc3c2)C2CNC2)cc1
4324,570979,10.1016/j.bmcl.2009.04.035,,,,Inhibition human ERG expressed in HEK293 cells assessed as blockade of membrane current by patch clamp method,CCN1C[C@@H]2[C@H](C1)[C@H]2CN(Cc1cccc(OC(F)(F)F)c1)C(=O)c1cn(C)cn1,1-Methyl-1H-imidazole-4-carboxylic acid(3-ethyl-3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-(3-trifluoromethoxy-benzyl)-amide,2.2,uM,=,0.3424226808222063,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)C[C@H]1[C@@H]2CNC[C@@H]21
4325,801352,10.1016/j.bmcl.2011.12.016,,,,Inhibition of human ERG channel by patch clamp assay,C[N+](C)(CCCCNC(=O)Cc1ccc(OCc2ccccc2)cc1)CCNC(=O)c1nc(Cl)c(N)nc1N.[Br-],"4-(2-(4-(benzyloxy)phenyl)acetamido)-N-(2-(3,5-diamino-6-chloropyrazine-2-carboxamido)ethyl)-N,N-dimethylbutan-1-aminium bromide",10.8,uM,=,1.0334237554869496,1,O=C(Cc1ccc(OCc2ccccc2)cc1)NCCCC[NH2+]CCNC(=O)c1cnccn1
4326,1996654,10.1021/acs.jmedchem.0c00446,,,,Inhibition of MK499 binding to human ERG,COc1cc(C2=CC3=NOC[C@H](c4cc(F)c(F)c(F)c4)N3CCC2)ccc1-n1cnc(C)c1,"(S)-9-(3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-4-(3,4,5-trifluorophenyl)-3,4,7,8-tetrahydro-6H-[1,2,4]oxadiazino[4,3-a]azepine",2.608,uM,=,0.4163075870598826,1,C1=C(c2ccc(-n3ccnc3)cc2)CCCN2C1=NOC[C@@H]2c1ccccc1
4327,1744232,10.1021/acs.jmedchem.6b01703,,,,Displacement of [3H]dofetilide from recombinant human ERG expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting method,CCc1nn2c(C)cc(C)nc2c1Cc1ccc(CCCC2(O)CCNCC2)cc1,"4-(3-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)propyl)piperidin-4-ol",24.0,uM,=,1.380211241711606,1,c1cnc2c(Cc3ccc(CCCC4CCNCC4)cc3)cnn2c1
4328,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1,Oxiperomide,2.1,uM,=,0.3222192947339193,1,O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1
4329,498774,10.1021/jm900110t,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",CC[C@@H]1NC(c2cc(C#N)ccn2)=NC1(c1ccc(F)cc1)c1ccc(F)cc1,"2-[(5S)-5-Ethyl-4,4-bis(4-fluorophenyl)-4,5-dihydro-1H-imidazol-2-yl]-4-pyridinecarbonitrile",0.49,uM,=,-0.3098039199714864,0,c1ccc(C2(c3ccccc3)CNC(c3ccccn3)=N2)cc1
4330,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,O=C1CN(CCc2ccc(F)cc2)CCN1[C@H]1CCc2cc(CN3CCS(=O)(=O)CC3)ccc2C1,"4-{[(6S)-6-{4-[2-(4-fluorophenyl)ethyl]-2-oxopiperazin-1-yl}-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1,4-thiomorpholine-1,1-dione",24.0,uM,=,1.380211241711606,1,O=C1CN(CCc2ccccc2)CCN1[C@H]1CCc2cc(CN3CCS(=O)(=O)CC3)ccc2C1
4331,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)cc(F)c21,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-7-fluoroisobenzofuran-1(3H)-one,13.0,uM,=,1.1139433523068367,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
4332,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)cn4)C[C@H]3CO2)ccc(F)c1C#N,"3-((3S,9aS)-8-(2-(5-(1H-tetrazol-1-yl)pyridin-2-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-6-fluoro-2-methylbenzonitrile",19.9,uM,=,1.2988530764097066,1,O=C(Cc1ccc(-n2cnnn2)cn1)N1CCN2C[C@H](c3ccccc3)OC[C@@H]2C1
4333,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1ccc2nc(C)n(-c3ccc(OCCCN4CCCC4)cc3)c(=O)c2c1,6-Methoxy-2-methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,10.0,uM,=,1.0,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
4334,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(C(C)CN2CCN(CCc3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"2-methoxy-4-(1-(4-(2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)propan-2-yl)benzonitrile",1.1,uM,=,0.041392685158225,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
4335,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3ccccc3F)nn2)ccc1-n1cnc(C)c1,"1-(2-fluorobenzyl)-4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazole",2.49,uM,=,0.3961993470957364,1,c1ccc(Cn2cc(-c3ccc(-n4ccnc4)cc3)nn2)cc1
4336,762093,10.1021/jm200018k,,,,Inhibition of human Erg expressed in human HEK293 cells by patch-clamp electrophysiological assay,CC(=O)Nc1cccc(Nc2ncnc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)n2)c1C,"N-(2-Methyl-3-(4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide",2.6,uM,=,0.414973347970818,1,c1ccc(Nc2ncnc(N3CCC(Oc4ccccc4)CC3)n2)cc1
4337,1637594,,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in outward tail current after 5 mins at -80 mV holding potential by patch clamp assay,COc1ccc2c(c1)CN(C(=O)N1CCN(Cc3ccc4c(c3)OCO4)CC1)CCS2,"(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)(7-methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methanone",2.496,uM,=,0.3972445810103864,1,O=C(N1CCN(Cc2ccc3c(c2)OCO3)CC1)N1CCSc2ccccc2C1
4338,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,COc1ccncc1-c1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,(E)-N-Hydroxy-3-[4-({2-[2-(4-methoxy-pyridin-3-yl)-1H-indol-3-yl]-ethylamino}-methyl)-phenyl]-acrylamide,8.48,uM,=,0.9283958522567138,1,c1ccc(CNCCc2c(-c3cccnc3)[nH]c3ccccc23)cc1
4339,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3ccc4cnccc43)[C@H](C)C2)cn1,"1-{(R)-4-[4-(2-Ethoxy-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-2-pyrrolo[2,3-c]pyridin-1-yl-ethanone",0.57,uM,=,-0.2441251443275086,0,O=C(Cn1ccc2cnccc21)N1CCN(c2scnc2-c2cncnc2)CC1
4340,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"1-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)-1,4-diazepan-1-yl)ethanone",11.0,uM,=,1.0413926851582251,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCCNCC5)cc4)n3)cnc2c1
4341,1783291,10.1016/j.ejmech.2017.12.099,,,,Inhibition of human ERG by auomated patch clamp assay,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2cccc3sccc23)CC1,"8-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-8-azaspiro[4.5]decane-7,9-dione",2.63,uM,=,0.4199557484897578,1,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2cccc3sccc23)CC1
4342,499833,10.1016/j.bmcl.2009.04.022,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(S[C@]4(C)CC[C@@H](c5nnn(C)n5)CC4)nc3cc2Cl)CC1,"trans-5-chloro-6-(4-ethylpiperazin-1-yl)-2-((1r,4r)-1-methyl-4-(2-methyl-2H-tetrazol-5-yl)cyclohexylthio)-1H-benzo[d]imidazole",4.4,uM,=,0.6434526764861874,1,c1cc2nc(SC3CCC(c4nn[nH]n4)CC3)[nH]c2cc1N1CCNCC1
4343,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CCc1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2CO)n1,"2-(3-Ethyl-[1,2,4]triazol-1-yl)-1-((S)-2-hydroxymethyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-ethanone",0.052,uM,=,-1.2839966563652008,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
4344,1665841,10.1021/acs.jmedchem.7b00328,,,,Inhibition of human ERG by patch clamp assay,CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ncccn5)CC4)ccc3C)c(F)c12,4-Fluoro-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide,18.0,uM,=,1.255272505103306,1,O=C(NC1(c2ncccn2)CC1)c1cccc(-c2ccc3oc(-c4ccccc4)cc3c2)c1
4345,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,COCCOc1cc(NC(=O)N2CCCc3cc(CN4C[C@@H](C)N[C@@H](C)C4)c(C=O)nc32)ncc1C#N,"N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-6-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide",13.0,uM,=,1.1139433523068367,1,O=C(Nc1ccccn1)N1CCCc2cc(CN3CCNCC3)cnc21
4346,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1ncc(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)cn1,(R)-2-(2-methoxypyrimidin-5-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,22.4,uM,=,1.3502480183341627,1,c1ncc(-c2ccc3cc(CCN4CCCC4)ccc3n2)cn1
4347,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(C#CC2CCCCC2)cccc1C#CC1CCCCC1,"2,6-bis(cyclohexylethynyl)-1-methylpyridinium",4.34,uM,=,0.6374897295125107,1,C(#CC1CCCCC1)c1cccc(C#CC2CCCCC2)[nH+]1
4348,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@H]1CN(C)C[C@@H]1c1ccc(-c2cccnc2F)cc1,"N-((3R,4R)-4-(4-(2-fluoropyridin-3-yl)phenyl)-1-methylpyrrolidin-3-yl)propane-2-sulfonamide",6.3,uM,=,0.7993405494535817,1,c1cncc(-c2ccc([C@@H]3CCNC3)cc2)c1
4349,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,CN(C)CC(C)(C)COc1cc(NC(=O)N2CCCc3cc(C(F)F)c(C=O)nc32)ncc1C#N,"N-(5-cyano-4-(3-(dimethylamino)-2,2-dimethylpropoxy)pyridin-2-yl)-6-(difluoromethyl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide",12.0,uM,=,1.0791812460476249,1,O=C(Nc1ccccn1)N1CCCc2cccnc21
4350,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,Cc1ccccc1C1CCN(C[C@H]2CCc3cccnc3[C@@H](O)C2)CC1,"cis-(+)-7-((4-o-tolylpiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",0.22,uM,=,-0.6575773191777937,0,c1ccc(C2CCN(C[C@H]3CCc4cccnc4CC3)CC2)cc1
4351,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNC(C)c1cc(F)ccc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-5-fluorophenyl)-N-methylethanamine",6.83,uM,=,0.8344207036815325,1,c1ccc(Oc2ccccc2)cc1
4352,454299,10.1016/j.bmcl.2007.01.020,,,,Inhibition of hERG,FC(F)(F)c1ccccc1CN(C1CCOCC1)[C@H]1CCNC1,(S)-pyrrolidin-3-yl-(tetrahydro-pyran-4-yl)-(2-trifluoromethyl-benzyl)-amine,1.1,uM,=,0.041392685158225,1,c1ccc(CN(C2CCOCC2)[C@H]2CCNC2)cc1
4353,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,Cc1nc(CNC2CCN(CCn3c(=O)ccc4ccc(C#N)cc43)CC2)ccc1C#N,"1-(2-(4-((5-Cyano-6-methylpyridin-2-yl)methylamino)-piperidin-1-yl)ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",5.3,uM,=,0.724275869600789,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2ccccn2)CC1
4354,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,Cc1ccccc1C1CCN(C[C@@H]2CCc3cccnc3[C@@H](O)C2)CC1,"trans-(+)-7-((4-o-tolylpiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",1.5,uM,=,0.1760912590556812,1,c1ccc(C2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
4355,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CC6(CCCO6)C5)cc4)C3)o2)cc1,"US8685958, 4::US8685958, 5",13.0,uM,=,1.1139433523068367,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CC4(CCCO4)C3)cc2)C1
4356,1679756,10.1016/j.bmcl.2017.03.086,,,,Inhibition of human ERG by Qpatch electrophysiology method,Cc1cc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)sn1,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(3-methylisothiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",6.6,uM,=,0.8195439355418687,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccns3)C4=O)ccc21
4357,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(Cl)n2)(c2ccc(F)cc2)CC1,2-chloro-6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,6.0,uM,=,0.7781512503836436,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
4358,1327812,10.1039/C1MD00116G,,,,Inhibition of dofetilide binding to human ERG,Cc1cnc(NC(=O)c2cc(Oc3ccc(S(C)(=O)=O)cc3)c3cc(C)oc3c2)cn1,2-Methyl-N-(5-methylpyrazin-2-yl)-4-(4-(methylsulfonyl)phenoxy)benzofuran-6-carboxamide,22.0,uM,=,1.3424226808222062,1,O=C(Nc1cnccn1)c1cc(Oc2ccccc2)c2ccoc2c1
4359,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1,"2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol",8.1,uM,=,0.9084850188786496,1,C(=C1c2ccccc2-c2ccccc21)c1ccccc1
4360,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,COc1ccc2c(c1)C(=O)N(Cc1ccccc1-c1ccccc1)C2C(=O)NC(C)(C)C,(rac)-2-(biphenyl-2-ylmethyl)-N-tert-butyl-5-methoxy-3-oxoisoindoline-1-carboxamide,30.0,uM,=,1.4771212547196624,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
4361,2133643,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG by manual patch clamp method,CC[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-chloro-N-((R)-1-((1R,3S,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",0.79,uM,=,-0.1023729087095585,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
4362,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1ccc(C2CCN(CC[C@H]3CCOc4ccccc43)CC2)cc1OC,"1-((S)-2-Chroman-4-yl-ethyl)-4-(3,4-dimethoxy-phenyl)-piperidine",0.03,uM,=,-1.5228787452803376,0,c1ccc(C2CCN(CC[C@H]3CCOc4ccccc43)CC2)cc1
4363,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3c(F)cccc32)CC1,"4-{3-[4-(4-Fluoro-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-4H-benzo[1,4]oxazin-3-one",3.4,uM,=,0.5314789170422551,1,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
4364,2157068,10.1021/acsmedchemlett.1c00445,,,,Inhibition of hERG expressed in HEK293 cells at -80 mV holding potential by automated patch-clamp method,C[C@@]1(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)Cn2nc(C#N)cc2C(N)=N1,"(R)-N-(3-(4-amino-2-cyano-6-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-6-yl)-4-fluorophenyl)-5-fluoropicolinamide",3.3,uM,=,0.5185139398778875,1,O=C(Nc1cccc(C2Cn3nccc3C=N2)c1)c1ccccn1
4365,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cncc(F)c2)C1=O,"4-(5-fluoro-3-pyridyl)-2-methyl-9-(2-phenylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",1.1,uM,=,0.041392685158225,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1cccnc1
4366,1436636,10.1021/jm501045e,,,,Inhibition of human ERG by patch clamp assay,O=C(NC[C@@H]1OC(=O)N2c3ccc(N4CCOCC4=O)cc3OC[C@@H]12)c1ccc(Cl)s1,"5-Chloro-N-(((3S,3aS)-1-oxo-7-(3-oxomorpholino)-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl)methyl)-thiophene-2-carboxamide",79.75,uM,=,1.9017306917292187,1,O=C(NC[C@@H]1OC(=O)N2c3ccc(N4CCOCC4=O)cc3OC[C@@H]12)c1cccs1
4367,1328170,10.1039/C3MD20368A,,,,Inhibition of human ERG by electrophysiological analysis,O=C(Nc1ccc(F)cn1)[C@H](CN1CC(O)C1)Oc1ncnc2c1cnn2-c1ccccc1Cl,"(2S)-2-(1-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)-N-(5-fluoropyridin-2-yl)-3-(3-hydroxyazetidin-1-yl)propanamide",36.0,uM,=,1.5563025007672873,1,O=C(Nc1ccccn1)[C@H](CN1CCC1)Oc1ncnc2c1cnn2-c1ccccc1
4368,499833,10.1016/j.bmcl.2009.04.022,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(S[C@]4(C)CC[C@H](NC(=O)OC)CC4)nc3cc2Cl)CC1,cis-methyl 4-(5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazol-2-ylthio)-4-methylcyclohexylcarbamate,1.5,uM,=,0.1760912590556812,1,c1cc2nc(SC3CCCCC3)[nH]c2cc1N1CCNCC1
4369,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CC[C@H]3CC[C@H](NCc4ccc(Cl)c(Cl)c4)CC3)c2c1,"trans-N-(3,4-dichlorobenzyl)-4-(2-(6-methoxyquinolin-4-yl)ethyl)cyclohexan-1-amine",2.3,uM,=,0.3617278360175928,1,c1ccc(CN[C@H]2CC[C@H](CCc3ccnc4ccccc34)CC2)cc1
4370,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cccc(OC)c2)C2CCN(S(C)(=O)=O)CC2)CC1,(R)-N-ethyl-N-(1-(3-(3-methoxyphenyl)-3-(1-(methylsulfonyl)piperidin-4-yl)propyl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)acetamide,32.0,uM,=,1.505149978319906,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
4371,501217,10.1016/j.bmcl.2009.02.099,,,,Inhibition of human ERG by patch-clamp assay,Cc1ncc(C)c(C(=O)N2CCC([C@H](N)Cc3cc(F)c(F)cc3F)CC2)n1,"(R)-(4-(1-amino-2-(2,4,5-trifluorophenyl)ethyl)piperidin-1-yl)(2,5-dimethylpyrimidin-4-yl)methanone",85.0,uM,=,1.9294189257142929,1,O=C(c1ccncn1)N1CCC(CCc2ccccc2)CC1
4372,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1Cl,"US9145392, 218",1.9,uM,=,0.2787536009528289,1,c1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ccncn4)CC3)n2)cc1
4373,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CC(C)CN(CC(C)C)c1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCN(C)CC2)n1,"6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-N,N-diisobutyl-4-(trifluoromethyl)pyridin-2-amine",9.5,uM,=,0.9777236052888478,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
4374,1641577,,,,,"In Vitro Assay: The in vitro effects of the selected compounds on the hERG (human ether-á-go-go-related gene) potassium channel current (a surrogate for IKr, the rapidly activating, delayed rectifier cardiac potassium current) expressed in mammalian cells were evaluated at room temperature using the PatchXpress 7000A (Molecular Devices), an automatic parallel patch clamp system. Each compound was evaluated at varying concentrations in duplicate up to 10 μM, and the duration of exposure to each test article concentration was 5 minutes.",NCCCCN(Cc1nccc2c3ccccc3n(CCCN3CCNCC3)c12)[C@H]1CCCc2cccnc21,"US9314468, Table 7, Compound 70::US9314468, Table 9, Compound 4",4.1,uM,=,0.6127838567197355,1,c1cnc2c(c1)CCC[C@@H]2NCc1nccc2c3ccccc3n(CCCN3CCNCC3)c12
4375,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c(n1c1ccccc41)[C@@H]32,"(11aS,11bS)-11a-Ethyl-2,3,4,5,11a,11b-hexahydro-1H-3a,9b-diaza-benzo[cd]fluoranthene-10-carboxylic acid ethyl ester",0.039,uM,=,-1.408935392973501,0,C1=Cn2c3c(c4ccccc42)CCN2CCCC1[C@@H]32
4376,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(c1ccccc1)c1ccccn1,N-(phenyl(pyridin-2-yl)methyl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,2.3,uM,=,0.3617278360175928,1,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(c1ccccc1)c1ccccn1
4377,1496337,10.1021/ml500505q,,,,Inhibition of human ERG expressed in HEK293 cells by FLIPR based flux assay,CC(C)N(C)[C@@H]1CC[C@H](NC(=O)CNC(=O)c2cccc(C(F)(F)F)c2)[C@H](COc2ccccc2)C1,"N-(2-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenoxymethyl)cyclohexylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide",5.3,uM,=,0.724275869600789,1,O=C(CNC(=O)c1ccccc1)N[C@H]1CCCC[C@H]1COc1ccccc1
4378,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)[C@@H]1CCN(Cc2nc3ccccc3s2)C[C@@H]1F,"N-((3S,4R)-1-(benzo[d]thiazol-2-ylmethyl)-3-fluoropiperidin-4-yl)-N-methyl-2-(4-(methylsulfonyl)phenyl)acetamide",16.0,uM,=,1.2041199826559248,1,O=C(Cc1ccccc1)NC1CCN(Cc2nc3ccccc3s2)CC1
4379,747985,10.1016/j.bmcl.2011.03.112,,,,Inhibition of human ERG by patch clamp method,Cc1c2c(n3c1CCCN[C@H](C)CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,"(15R)-5,5,9,15-tetramethyl-7-oxo-2,14,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",3.2,uM,=,0.505149978319906,1,O=C1CCCc2c1cc1n2-c2cccc(c2)NCCNCCC1
4380,1702620,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human ERG expressed in HEK293 cells by lonWorks Quattro analysis,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.57,uM,=,-0.2441251443275086,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4381,2059992,10.1021/acsmedchemlett.0c00679,,,,Inhibition of human ERG expressed in HEK293 cells measured by whole cell patch clamp method,Cn1cc(-c2nc3c(-c4ccnc(OC5CC5)c4)cnn3cc2OCCC(C)(C)O)cn1,"4-((3-(2-Cyclopropoxypyridin-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)oxy)-2-methylbutan-2-ol",22.8,uM,=,1.3579348470004535,1,c1cc(-c2cnn3ccc(-c4cn[nH]c4)nc23)cc(OC2CC2)n1
4382,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1ccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c(F)c1,"endo-4-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)-3-fluorobenzamide",1.4,uM,=,0.1461280356782379,1,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccc2)C3)cc1
4383,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,Cn1ccnc1[C@]1(O)CC[C@H](N2CC(NC(=O)CNC(=O)c3cccc(C(F)(F)F)c3)C2)CC1,cis-N-({1-[4-Hydroxy-4-(1-methyl-1H-imidazol-2-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,15.0,uM,=,1.1760912590556811,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ncc[nH]3)CC2)C1
4384,726745,10.1016/j.bmcl.2011.01.036,,,,Inhibition of human ERG,C[C@@H](C[C@@](C)(CS(=O)(=O)N1CCC(OCc2ccc(Cl)cc2Cl)CC1)N(O)C=O)c1ncc(F)cn1,"N-((2S,4S)-1-(4-(2,4-dichlorobenzyloxy)piperidin-1-ylsulfonyl)-4-(5-fluoropyrimidin-2-yl)-2-methylpentan-2-yl)-N-hydroxyformamide",8.0,uM,=,0.9030899869919436,1,O=S(=O)(CCCCc1ncccn1)N1CCC(OCc2ccccc2)CC1
4385,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,O=C(CNc1ncnc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3ccccn3)CC2)C1,Cis-N-(1-(4-(pyridin-2-yl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,7.5,uM,=,0.8750612633917001,1,O=C(CNc1ncnc2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccccn3)CC2)C1
4386,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)ccn1,"endo-4-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)picolinamide",1.6,uM,=,0.2041199826559248,1,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccncc2)C3)cc1
4387,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(NCc1ccc(F)cc1)N(c1ccc(Cl)cc1)C1CCN(Cc2ccncc2)CC1,1-(4-chlorophenyl)-3-(4-fluorobenzyl)-1-(1-(pyridin-4-ylmethyl)piperidin-4-yl)urea,3.81,uM,=,0.5809249756756193,1,O=C(NCc1ccccc1)N(c1ccccc1)C1CCN(Cc2ccncc2)CC1
4388,611200,10.1021/jm901200t,,,,Inhibition of human ERG,COC1(c2ccc(NC(=O)c3cc(=O)c4cc(F)cc(-c5c(C)nn(C)c5C)c4o3)cn2)CCOCC1,"6-Fluoro-N-(6-(4-methoxytetrahydro-2H-pyran-4-yl)pyridin-3-yl)-4-oxo-8-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4H-chromene-2-carboxamide",95.0,uM,=,1.977723605288848,1,O=C(Nc1ccc(C2CCOCC2)nc1)c1cc(=O)c2cccc(-c3cn[nH]c3)c2o1
4389,540677,10.1016/j.bmcl.2008.12.083,,,,Inhibition of human ERG,Nc1ccc(-c2cccs2)cc1N,"4-(2-thienyl)benzene-1,2-diamine",1.6,uM,=,0.2041199826559248,1,c1ccc(-c2cccs2)cc1
4390,585577,10.1016/j.bmcl.2009.06.081,,,,Inhibition of human ERG by whole cell patch clamp assay,CCN1C[C@@H](N(Cc2cc(F)ccc2Cl)c2ccc(C#N)c(Cl)c2)CC1=O,(S)-2-chloro-4-((2-chloro-5-fluorobenzyl)(1-ethyl-5-oxopyrrolidin-3-yl)amino)benzonitrile,3.1,uM,=,0.4913616938342727,1,O=C1C[C@H](N(Cc2ccccc2)c2ccccc2)CN1
4391,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(C3(F)CC3)n2)(c2ccc(F)cc2)CC1,2-(1-fluorocyclopropyl)-6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,4.3,uM,=,0.6334684555795865,1,c1ccc(C2(COCc3cccc(C4CC4)n3)CCNCC2)cc1
4392,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COC1CCN(S(=O)(=O)c2ccc(-c3ccc(CCN4CCC[C@H]4C)cc3)cc2)CC1,4-Methoxy-1-{4'-[2-((R)-2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine,2.0,uM,=,0.3010299956639812,1,O=S(=O)(c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1)N1CCCCC1
4393,452350,10.1021/jm701144e,,,,Binding affinity to human ERG channel,CCOc1cc(CN2CCC(NC(=O)c3cccc(S(C)(=O)=O)c3)CC2)ccc1Cl,N-(1-(4-chloro-3-ethoxybenzyl)piperidin-4-yl)-3-(methylsulfonyl)benzamide,1.3,uM,=,0.1139433523068367,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1ccccc1
4394,939638,10.1016/j.bmcl.2012.11.023,,,,Inhibition of human ERG,Nc1nc2cc3c(cc2s1)CCN(Cc1ccc(F)cc1)CC3,"7-(4-Fluoro-benzyl)-6,7,8,9-tetrahydro-5H-1-thia-3,7-diaza-cyclohepta[f]inden-2-ylamine",3.6,uM,=,0.5563025007672873,1,c1ccc(CN2CCc3cc4ncsc4cc3CC2)cc1
4395,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cnc2ccc(-c3cccnc3)cc2c1NC1CCOCC1,6-(pyridin-3-yl)-4-(tetrahydro-2H-pyran-4-ylamino)quinoline-3-carboxamide,2.1,uM,=,0.3222192947339193,1,c1cncc(-c2ccc3nccc(NC4CCOCC4)c3c2)c1
4396,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(CC(NS(C)(=O)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(rac)-N-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)methanesulfonamide",3.3,uM,=,0.5185139398778875,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4397,1329649,10.1039/C1MD00015B,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch clamp assay,CC(=O)Nc1cccc(C2CCN(Cc3ccc(C(=O)c4nc5ccccc5n4C4CCOCC4)cc3)CC2)c1,N-(3-(1-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazole-2-carbonyl)benzyl)piperidin-4-yl)phenyl)acetamide,1.2,uM,=,0.0791812460476248,1,O=C(c1ccc(CN2CCC(c3ccccc3)CC2)cc1)c1nc2ccccc2n1C1CCOCC1
4398,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,Cn1cc([C@@]2(c3noc(CN)n3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"(3-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,2,4-oxadiazol-5-yl)methanamine",3.7,uM,=,0.568201724066995,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)nc1
4399,809877,10.1021/ml200143c,,,,Inhibition of human ERG expressed in CHOK1 cells by whole cell voltage clamp assay,Cc1nc2c(C#N)cccc2n1-c1ccc(C(=O)NC2CC2)s1,N-Cyclopropyl-5-(4-cyano-2-methyl-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,53.0,uM,=,1.7242758696007892,1,O=C(NC1CC1)c1ccc(-n2cnc3ccccc32)s1
4400,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,C[C@H]1C=C(C2=Nc3cc(Cl)ccc3Nc3ccc(OC(F)(F)F)cc32)CCN1C,"(S)-8-chloro-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(trifluoromethoxy)-5H-dibenzo[b,e][1,4]diazepine",1.9,uM,=,0.2787536009528289,1,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
4401,2046076,10.1021/acsmedchemlett.8b00541,,,,Inhibition of human ERG by patch clamp method,CNc1nc(Nc2ccc(-n3cnc(Cl)c3)c(OC)c2)nc2c1CC[C@H]2c1ccccc1,"(S)-N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine",0.2,uM,=,-0.6989700043360187,0,c1ccc([C@@H]2CCc3cnc(Nc4ccc(-n5ccnc5)cc4)nc32)cc1
4402,2212585,10.1021/acsmedchemlett.2c00081,,,,Inhibition of human ERG potassium channel by fluorescence polarization assay,O=C(NO)c1ccc(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1,4-((4-Benzhydrylpiperazin-1-yl)methyl)-N-hydroxybenzamide,0.66,uM,=,-0.1804560644581313,0,c1ccc(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
4403,2249200,10.1021/acs.jmedchem.2c00008,,,,Inhibition of human ERG potassium channel expressed in CHO cells by patch-clamp assay,COc1cc(Oc2c(-c3cc(F)c(F)cc3C(C)(F)F)sc3c2ccc2[nH]ncc23)ccc1NC1CN(CCCF)C1,"N-[4-[[2-[2-(1,1-difluoroethyl)-4,5-difluoro-phenyl]-6H-thieno[2,3-e]indazol-3-yl]oxy]-2-methoxy-phenyl]-1-(3-fluoropropyl)azetidin-3-amine",15.6,uM,=,1.1931245983544616,1,c1ccc(-c2sc3c(ccc4[nH]ncc43)c2Oc2ccc(NC3CNC3)cc2)cc1
4404,885330,10.1016/j.bmcl.2012.10.090,,,,Inhibition of human ERG,COCC[C@H](Oc1ncnc2c1cnn2-c1ccccc1Cl)C(=O)Nc1ccc(C)cn1,"(2S)-2-(1-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)-4-methoxy-N-(5-methylpyridin-2-yl)butanamide",22.0,uM,=,1.3424226808222062,1,O=C(COc1ncnc2c1cnn2-c1ccccc1)Nc1ccccn1
4405,630101,10.1016/j.bmcl.2010.03.027,,,,Inhibition of human ERG channel by patch clamp assay,CCOCCn1c([C@@H]2CCCN(C3CCOCC3)C2)nc2ccccc21,(R)-1-(2-ethoxyethyl)-2-(1-(tetrahydro-2H-pyran-4-yl)piperidin-3-yl)-1H-benzo[d]imidazole,2.1,uM,=,0.3222192947339193,1,c1ccc2[nH]c([C@@H]3CCCN(C4CCOCC4)C3)nc2c1
4406,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,CC(=O)N1Cc2ccc(OCc3c(C)nnn3-c3ccc(F)cc3)nc2C1,"1-(2-((1-(4-fluorophenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethanone",30.0,uM,=,1.4771212547196624,1,c1ccc(-n2nncc2COc2ccc3c(n2)CNC3)cc1
4407,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4cccc(Cl)c4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(3-chlorophenyl)pyrrolo[1,2-b]pyridazine-3-carboxamide",6.0,uM,=,0.7781512503836436,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
4408,815278,10.1016/j.ejmech.2012.02.049,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cells after 45 mins by scintillation counting method,CCOC(=O)C1CCN(CCOc2ccc(S(N)(=O)=O)cc2)CC1,4-{2-[(4-ethoxycarbonyl)piperidin-1-yl]ethoxy}benzenesulfonamide,22.9,uM,=,1.359835482339888,1,c1ccc(OCCN2CCCCC2)cc1
4409,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cn1nc(N2CCC3(CCN(C[C@H](O)c4ccc(-n5cnnn5)nn4)CC3)C2=O)ccc1=O,"(S)-8-(2-(6-(1H-tetrazol-1-yl)pyridazin-3-yl)-2-hydroxyethyl)-2-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one",3.1,uM,=,0.4913616938342727,1,O=C1N(c2ccc(=O)[nH]n2)CCC12CCN(CCc1ccc(-n3cnnn3)nn1)CC2
4410,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCc3ccc(OC)c(OC)c3)C[C@@H]2CC(=O)N(C)c2cccc(Cl)c2)cc1,"rac-N-(3-chlorophenyl)-2-((3R,4S)-1-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)-N-methylacetamide",0.029,uM,=,-1.537602002101044,0,O=C(C[C@H]1CN(CCc2ccccc2)C[C@@H]1c1ccccc1)Nc1ccccc1
4411,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3ccc(OCC(F)(F)F)nc3)CC2)C1,"cis-N-[(1-{4-Hydroxy-4-[6-(2,2,2-trifluoro-ethoxy)-pyridin-3-yl]-cyclohexyl}-azetidin-3-ylcarbamoyl)-methyl]-3-trifluoromethyl-benzamide",7.0,uM,=,0.8450980400142568,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccnc3)CC2)C1
4412,599953,10.1016/j.bmcl.2009.07.047,,,,Inhibition of human ERG in L929 cells by whole cell patch-clamp assay,Cc1ccc(CCCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,"1-[4-(4-methylphenyl)butyl]-alpha,alpha-diphenyl-4-piperdine-methanol",0.396,uM,=,-0.4023048140744877,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
4413,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,CC(C)C(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1,"4-(8-amino-3-((R)-4-isobutyrylmorpholin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-3-fluoro-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",15.0,uM,=,1.1760912590556811,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@H]3CNCCO3)n3ccncc23)cc1
4414,464747,10.1016/j.bmcl.2008.01.126,,,,Inhibition of human ERG by FLIPR assay,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)cc1,"(2S,3S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",18.1,uM,=,1.2576785748691846,1,O=C1[C@@H](Cc2ccc(OCCc3coc(-c4ccccc4)n3)cc2)CN1c1ccccc1
4415,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N(C)C)nc1CN1C(=O)O[C@H](c2cc(F)cc(F)c2)[C@@H]1C,"3'-(4-(((4S,5R)-5-(3,5-Difluorophenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-2-(dimethylamino)pyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic Acid",11.0,uM,=,1.0413926851582251,1,O=C1O[C@H](c2ccccc2)CN1Cc1ncncc1-c1cccc(-c2ccccc2)c1
4416,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=c1c2ccccc2nc(-c2ccc(OCCCN3CCCCC3)cc2)n1-c1ccccc1,3-phenyl-2-(4-(3-(piperidin-1-yl)propoxy)phenyl)quinazolin-4(3H)-one,0.46,uM,=,-0.3372421683184259,0,O=c1c2ccccc2nc(-c2ccc(OCCCN3CCCCC3)cc2)n1-c1ccccc1
4417,624297,10.1016/j.bmcl.2010.01.134,,,,Inhibition of human ERG expressed in HEK cells assessed as blockade of potassium tail current by standard patch clamp analysis,Cc1cccnc1[C@H](C)c1c(CCN(C)C)sc2ccccc12,"(-)-(R)-N,N-dimethyl-2-(3-(1-(3-methylpyridin-2-yl)ethyl)benzo[b]thiophen-2-yl)ethanamine",0.91,uM,=,-0.0409586076789063,0,c1ccc(Cc2csc3ccccc23)nc1
4418,634714,10.1021/jm901692q,,,,Binding affinity to human ERG expressed in CHO cells,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccc(F)cc2)nc1,1-[6-(4-Fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl)urea,1.3,uM,=,0.1139433523068367,1,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccc2)nc1
4419,699709,10.1016/j.bmcl.2010.11.111,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells,COc1cc(/C=C/c2nc3ccccc3c(=O)n2C)ccc1-n1cnc(C)c1,2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)styryl)-3-methylquinazolin-4(3H)-one,0.31,uM,=,-0.5086383061657274,0,O=c1[nH]c(/C=C/c2ccc(-n3ccnc3)cc2)nc2ccccc12
4420,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,[O-][S+]1CCC(C2N[C@@H](c3nc(-c4ccccc4)c[nH]3)Cc3c2[nH]c2ccccc32)CC1,"(R)-1-(1-Oxo-hexahydro-1lambda*4*-thiopyran-4-yl)-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-beta-carboline",0.1,uM,=,-1.0,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CC[SH+]CC4)N3)n2)cc1
4421,541084,10.1016/j.bmcl.2009.01.009,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,Cc1nnc(C(C)C)n1C1CCN(C(C)C[C@H](NC(=O)C2CCC2)c2ccccc2)CC1,"N-((1S)-3-(4-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl)-1-phenylbutyl)cyclobutanecarboxamide",4.0,uM,=,0.6020599913279624,1,O=C(N[C@@H](CCN1CCC(n2cnnc2)CC1)c1ccccc1)C1CCC1
4422,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CCC(N)(CO)CC3)nn12,"(4-Amino-1-(5-(4-fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-yl)methanol",17.7,uM,=,1.2479732663618066,1,c1ccc(-c2cnc3sc(N4CCCCC4)nn23)cc1
4423,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,Cc1ncc(CNC2CCN(CCn3c(=O)ccc4ccc(C#N)cc43)CC2)cc1C#N,"1-(2-(4-((5-Cyano-6-methylpyridin-3-yl)methylamino)-piperidin-1-yl)ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",26.0,uM,=,1.414973347970818,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cccnc2)CC1
4424,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(NCc1ccc(F)cc1)N(c1ccc(Br)cc1)C1CCN(CCO)CC1,1-(4-bromophenyl)-3-(4-fluorobenzyl)-1-(1-(2-hydroxyethyl)piperidin-4-yl)urea,7.88,uM,=,0.8965262174895553,1,O=C(NCc1ccccc1)N(c1ccccc1)C1CCNCC1
4425,2100968,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch clamp method,Cc1c(N2CCC(C3(N)CC3)C2)c(F)cc2c(CC(=O)N(C)C)cc(=O)n(C3CC3)c12,"2-(7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-4-yl)-N,N-dimethylacetamide",293.0,uM,=,2.4668676203541096,1,O=c1ccc2ccc(N3CCC(C4CC4)C3)cc2n1C1CC1
4426,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2ccc3nc(OC)ccc3c2)[nH]1,(S)-N-((S)-1-(5-(2-methoxyquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,3.3,uM,=,0.5185139398778875,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)[nH]1)[C@H]1CC12CCNCC2
4427,1655139,10.1016/j.bmcl.2016.12.054,,,,Displacement of [3H]-MK499 from human ERG IKr channel expressed in HEK293 cell membranes,Fc1ccc(CC(c2cccnc2)c2cccnc2)c(-c2cccc(C(F)(F)F)c2)c1,"3,3'-(2-(5-fluoro-3'-(trifluoromethyl)biphenyl-2-yl)ethane-1,1-diyl)dipyridine",2.23,uM,=,0.3483048630481606,1,c1ccc(-c2ccccc2CC(c2cccnc2)c2cccnc2)cc1
4428,2165730,10.1021/acsmedchemlett.1c00696,,,,Inhibition of human ERG,Cc1nccc(-c2cc3[nH]nc(N[C@H]4CCNC[C@@H]4F)c3cc2C2CC2)c1F,"5-cyclopropyl-6-(3-fluoro-2-methylpyridin-4-yl)-N-((3S,4S)-3-fluoropiperidin-4-yl)-1H-indazol-3-amine",19.0,uM,=,1.2787536009528289,1,c1cc(-c2cc3[nH]nc(NC4CCNCC4)c3cc2C2CC2)ccn1
4429,1512965,10.1021/acsmedchemlett.5b00117,,,,Inhibition of human ERG,C[C@@H]1c2nnc(-c3nc(C(F)(F)F)ns3)n2CCN1C(=O)c1ccc(F)cc1,"(R)-(4-Fluorophenyl)(8-methyl-3-(3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",39.0,uM,=,1.591064607026499,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
4430,2222743,10.1021/acs.jmedchem.2c00468,,,,Inhibition of human ERG potassium channel transfected in CHO cells by automated patch clamp assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.002,uM,=,-2.6989700043360187,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
4431,2063573,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by IonWorks patch-clamp electrophysiology assay,OCC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1,"(R)-3-Phenyl-3-((6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)propan-1-ol",22.0,uM,=,1.3424226808222062,1,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
4432,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,O=C1NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccc(Cl)cc23)CC1,1-{2-[4-(5-Chloro-1-phenyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-imidazolidin-2-one,0.088,uM,=,-1.055517327849831,0,O=C1NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccccc23)CC1
4433,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cccc(C(F)(F)F)n3)CC2)(C(C)C)C1,"((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(6-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methanone",3.9,uM,=,0.5910646070264992,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2ccccn2)CC1
4434,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCCc3ccc(OC)c(OC)c3)C[C@@H]2CNC(=O)c2cccc(Cl)c2)cc1,"rac-3-chloro-N-(((3S,4S)-1-(3-(3,4-dimethoxyphenyl)propyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)methyl)benzamide",0.2,uM,=,-0.6989700043360187,0,O=C(NC[C@H]1CN(CCCc2ccccc2)C[C@@H]1c1ccccc1)c1ccccc1
4435,458756,10.1016/j.bmcl.2007.10.063,,,,Inhibition of hERG by patch clamp assay,Cc1cc(CN2C[C@H](N)[C@H](C(=O)C3CCC[C@H]3C#N)C2)ccc1C#N,"4-(((3R,4R)-3-amino-4-((2R)-2-cyanocyclopentanecarbonyl)pyrrolidin-1-yl)methyl)-2-methylbenzonitrile",19.6,uM,=,1.292256071356476,1,O=C(C1CCCC1)[C@H]1CCN(Cc2ccccc2)C1
4436,1810686,10.1021/acs.jmedchem.8b01333,,,,Inhibition of human ERG by patch clamp electrophysiology,C[C@@H]1CN(C(=O)c2ccnc(Nc3nc4cnc(Nc5ccc(F)c(C(F)(F)F)c5)cc4[nH]3)c2)C[C@H](C)O1,"(2,6-Dimethylmorpholino)(2-((2-(4-fluoro-3-(trifluoromethyl)-phenyl)-1H-imidazo[4,5-c]pyridin-6-yl)amino)pyridin-4-yl)-methanone",5.3,uM,=,0.724275869600789,1,O=C(c1ccnc(Nc2nc3cnc(Nc4ccccc4)cc3[nH]2)c1)N1CCOCC1
4437,726745,10.1016/j.bmcl.2011.01.036,,,,Inhibition of human ERG,C[C@@H](C[C@@H](CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O)c1ncc(F)cn1,"N-((2S,4S)-1-(4-(4-fluorophenyl)piperazin-1-ylsulfonyl)-4-(5-fluoropyrimidin-2-yl)pentan-2-yl)-N-hydroxyformamide",26.0,uM,=,1.414973347970818,1,O=S(=O)(CCCCc1ncccn1)N1CCN(c2ccccc2)CC1
4438,1435893,10.1016/j.bmc.2014.10.020,,,,Inhibition of human ERG expressed in CHO cells by Rb efflux assay,O=C(CNCC1(O)CCCCCC1)N1CCc2ccccc2C1C1CCCCC1,"1-(1-Cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-{[(1-hydroxycycloheptyl)methyl]amino}ethanone",50.1,uM,=,1.6998377258672457,1,O=C(CNCC1CCCCCC1)N1CCc2ccccc2C1C1CCCCC1
4439,740926,10.1016/j.bmcl.2011.02.099,,,,Inhibition hERG by patch clamp method,CC(=O)Nc1cccc(C2CCN(CCCn3c(-c4ccc(Cl)cc4)nc4ccccc43)CC2)c1,2-(4-chlorophenyl)-1-{3-[4-(3-acetylaminophenyl)piperidin-1-yl]propyl}-1H-benzimidazole,0.003,uM,=,-2.5228787452803374,0,c1ccc(-c2nc3ccccc3n2CCCN2CCC(c3ccccc3)CC2)cc1
4440,1642335,,,,,"Cell-Based Electrophysiology Assays: All hERG percentage inhibitions at 10 uM compound concentration were determined by Millipore in a high-throughput cell-based electrophysiology assay for inhibition of hERG tail current41, and values are reported as a mean of multiple determinations. 0.3% DMSO aqueous vehicle negative control gave 7-16% inhibition. Cisapride (1 uM) positive control gave 96-104% inhibition. All hERG IC50 values were determined by Millipore,41 and the hERG IC50 for Example 1 was also determined by Cyprotex plc measuring hERG tail-currents by whole-cell voltage-clamping.",Cc1nn(C)c(C)c1-c1nc2c(N3CCN(Cc4cccnc4)CC3)c(Br)cnc2[nH]1,"US9447092, Comparator 2, Example 57",10.8,uM,=,1.0334237554869496,1,c1cncc(CN2CCN(c3ccnc4[nH]c(-c5cn[nH]c5)nc34)CC2)c1
4441,1832209,10.1016/j.bmcl.2018.12.024,,,,Inhibition of human ERG by patch clamp method,CS(=O)(=O)c1cc(CNC(=O)c2cncc3c2cnn3-c2ccc(F)cc2)ccn1,"1-(4-fluorophenyl)-N-((2-(methylsulfonyl)pyridin-4-yl)methyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxamide",30.0,uM,=,1.4771212547196624,1,O=C(NCc1ccncc1)c1cncc2c1cnn2-c1ccccc1
4442,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,Cc1oc(-c2ccccc2)nc1C(=O)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1,(5-methyl-2-phenyloxazol-4-yl)(4-(4-(pyrrolidin-1-ylmethyl)phenoxy)piperidin-1-yl)methanone,3.0,uM,=,0.4771212547196624,1,O=C(c1coc(-c2ccccc2)n1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
4443,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,O=C(c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1F)N1CCCC1,"6-[3-Fluoro-4-(pyrrolidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one",8.8,uM,=,0.9444826721501688,1,O=C(c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1)N1CCCC1
4444,580799,10.1016/j.bmcl.2009.06.095,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells overexpressing Ikr channel protein,Cc1nc(CN[C@H]2CC[C@@H](F)C2)c(C(C)C)n1-c1cc(F)cc(F)c1,"(1S,3R)-N-((1-(3,5-difluorophenyl)-5-isopropyl-2-methyl-1H-imidazol-4-yl)methyl)-3-fluorocyclopentanamine",34.0,uM,=,1.5314789170422551,1,c1ccc(-n2cnc(CNC3CCCC3)c2)cc1
4445,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-(3-hydroxypropoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.4,uM,=,0.380211241711606,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4446,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)O6)(CC3)CO4)c2n1,"(+)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2-methyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.8,uM,=,0.255272505103306,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4447,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(C#N)nc2)C3)ccc2c1COC2=O,"(R)-5-(8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-2-yl)picolinonitrile",1.2,uM,=,0.0791812460476248,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cccnc3)C4)ccc21
4448,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,"1-{1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one",0.0546,uM,=,-1.2628073572952627,0,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccccc2)c2ccccc2)CC1
4449,2129591,10.1021/acs.jmedchem.1c00459,,,,Inhibition of human ERG by patch-clamp assay,CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1,"N-(3-(2-((4-(4-Ethylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide",2.7,uM,=,0.4313637641589873,1,c1ccc(-c2csc3cnc(Nc4ccc(N5CCNCC5)cc4)nc23)cc1
4450,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCCN2C(=O)N(NS(C)(=O)=O)C[C@H]2c2ccc(OC)cc2)cc1,(R)-1-(Methylsulfonylamino)-3-[3-(4-methoxyphenyl)propyl]-4-[(4-methoxy)-phenyl]-2-imidazolidinone,14.3,uM,=,1.155336037465062,1,O=C1NC[C@@H](c2ccccc2)N1CCCc1ccccc1
4451,1445162,10.1021/ml500300c,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp method,CN1CCC(CNc2ccn3ncc(-c4cccc(OC(F)(F)F)c4)c3n2)CC1,"N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-5-amine",1.9,uM,=,0.2787536009528289,1,c1ccc(-c2cnn3ccc(NCC4CCNCC4)nc23)cc1
4452,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(C(=O)c2ccc3c(c2)Cc2c(-c4csc(C#CCOc5ccccc5)c4)n[nH]c2-3)CC1,"(4-methylpiperazin-1-yl)(3-(5-(3-phenoxyprop-1-ynyl)thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)methanone",1.72,uM,=,0.2355284469075489,1,O=C(c1ccc2c(c1)Cc1c(-c3csc(C#CCOc4ccccc4)c3)n[nH]c1-2)N1CCNCC1
4453,633190,10.1021/jm100262j,,,,Inhibition of human ERG,Cc1cc(CN2CCN(c3c(Br)cnc4[nH]c(N5CCN(C)CC5)nc34)CC2)no1,"3-((4-(6-Bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo-[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole",3.0,uM,=,0.4771212547196624,1,c1cc(N2CCN(Cc3ccon3)CC2)c2nc(N3CCNCC3)[nH]c2n1
4454,581929,10.1016/j.bmcl.2009.06.011,,,,Inhibition of human ERG,N[C@H]1Cn2c(nc3cc(C(F)(F)F)ccc32)C[C@@H]1c1cc(F)c(F)cc1F.O=C(O)C(F)(F)F,"Trifluoro-acetate(2R,3R)-7-trifluoromethyl-3-(2,4,5-trifluoro-phenyl)-1,2,3,4-tetrahydro-benzo[4,5]imidazo[1,2-a]pyridin-2-yl-ammonium",7.5,uM,=,0.8750612633917001,1,c1ccc([C@@H]2CCn3c(nc4ccccc43)C2)cc1
4455,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3cc(Br)no3)ccc2c1,(R)-3-bromo-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)isoxazole,0.88,uM,=,-0.0555173278498313,0,c1cc(-c2ccc3cc(CCN4CCCC4)ccc3n2)on1
4456,1469860,10.1021/jm501921k,,,,Inhibition of human ERG,O=c1cc(-c2ccnc(NC3CCOCC3)n2)ccn1[C@H](CO)c1ccc(Cl)c(F)c1,(S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2H-pyran-4-ylamino))pyrimidin-4-yl)pyridin-2(1H)-one,14.5,uM,=,1.1613680022349748,1,O=c1cc(-c2ccnc(NC3CCOCC3)n2)ccn1Cc1ccccc1
4457,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Cl)cc1Oc1ccc(F)c(C)c1,1-(4-chloro-2-(4-fluoro-3-methylphenoxy)phenyl)-N-methylmethanamine,3.04,uM,=,0.4828735836087537,1,c1ccc(Oc2ccccc2)cc1
4458,751126,10.1016/j.bmcl.2011.04.028,,,,Inhibition of human ERG,Cc1noc(C)c1CCC1CCN(S(=O)(=O)C[C@](C)(C[C@H](C)c2ncc(F)cn2)N(O)C=O)CC1,"N-[(2S,4S)-1-({4-[2-(3,5-dimethyl-1,2-oxazol-4-yl)ethyl]piperidin-1-yl}sulfonyl)-4-(5-fluoropyrimidin-2-yl)-2-methylpentan-2-yl]-N-hydroxyformamide",65.0,uM,=,1.812913356642856,1,O=S(=O)(CCCCc1ncccn1)N1CCC(CCc2cnoc2)CC1
4459,1576909,10.1021/acs.jmedchem.5b01416,,,,Inhibition of human ERG expressed in HEK293 cells assessed as tail current at -50 mV holding potential by whole-cell patch clamp method,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccc(Cl)c(Cl)c1,"2-(3,4-Dichlorophenyl)-6-(3-(piperidin-1-yl)propoxy)-pyridazin-3(2H)-one",6.34,uM,=,0.8020892578817327,1,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccccc1
4460,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCN(CC)C(=O)c1ccc([C@H](c2cccc(NC(=O)OC)c2)N2CCN(Cc3cncs3)CC2)cc1,(R)-methyl 3-((4-(diethylcarbamoyl)phenyl)(4-(thiazol-5-ylmethyl)piperazin-1-yl)methyl)phenylcarbamate,14.0,uM,=,1.146128035678238,1,c1ccc(C(c2ccccc2)N2CCN(Cc3cncs3)CC2)cc1
4461,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1nsc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)n1,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(3-methyl-1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",14.5,uM,=,1.1613680022349748,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ncns3)C4=O)ccc21
4462,2153149,10.1016/j.ejmech.2021.113827,,,,Inhibition of hERG expressed in CHO-K1 cells assessed as reduction in thallium influx incubated for 30 minutes by FLIPR,O=c1ccc2c([nH]1)CCC(NCCCCCCCCCCNc1c3c(nc4cc(Cl)ccc14)CCCC3)C2,"6-(10-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)decylamino)-5,6,7,8-tetrahydroquinolin-2(1H)-one",2.768,uM,=,0.4421660857847201,1,O=c1ccc2c([nH]1)CCC(NCCCCCCCCCCNc1c3c(nc4ccccc14)CCCC3)C2
4463,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(OC)c(OC)cc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-4,5-dimethoxyphenyl)-N-methylmethanamine",10.1,uM,=,1.0043213737826426,1,c1ccc(Oc2ccccc2)cc1
4464,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cc(-c2ccc(OC3CCN(C(=O)Cc4ccc(OC(F)(F)F)cc4)CC3)c(C(N)=O)c2)cn1,5-(1-methyl-1H-pyrazol-4-yl)-2-(1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yloxy)benzamide,4.5,uM,=,0.6532125137753437,1,O=C(Cc1ccccc1)N1CCC(Oc2ccc(-c3cn[nH]c3)cc2)CC1
4465,582246,10.1016/j.bmcl.2009.06.051,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells overexpressing Ikr channel protein,Cc1c(CN[C@H]2CC[C@@H](F)C2)nn(CCC#N)c1-c1cc(F)cc(F)c1,"3-[5-(3,5-difluorophenyl)-3-({[(1S,3R)-3-fluorocyclopentyl]amino}-methyl)-4-methyl-1H-pyrazol-1-yl]propanenitrile",9.5,uM,=,0.9777236052888478,1,c1ccc(-c2cc(CNC3CCCC3)n[nH]2)cc1
4466,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cncc(C(F)(F)F)c2)C1=O,"2-methyl-9-(2-phenylethyl)-4-[5-(trifluoromethyl)-3-pyridyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.5,uM,=,-0.3010299956639812,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1cccnc1
4467,1734340,10.1021/acsmedchemlett.8b00080,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in peak tail current after 2 to 5 mins by patch clamp based electrophysiology assay,O=C1[C@H](N2CCC(c3ccc(O)cc3)CC2)CCN1Cc1ccc(F)cc1,"US9221796, 2b",0.62,uM,=,-0.2076083105017461,0,O=C1[C@H](N2CCC(c3ccccc3)CC2)CCN1Cc1ccccc1
4468,632181,10.1016/j.bmcl.2010.03.106,,,,Inhibition of human ERG expressed by patch clam electrophysiology assay,Cc1cccc(Nc2nc(N3CCNCC3)nc3c(C)nn(CCOCC(F)(F)F)c23)n1,"3-methyl-N-(6-methylpyridin-2-yl)-5-(piperazin-1-yl)-1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine",0.56,uM,=,-0.2518119729937995,0,c1ccc(Nc2nc(N3CCNCC3)nc3cn[nH]c23)nc1
4469,1509543,10.1021/acs.jmedchem.5b00810,,,,Inhibition of human ERG by radioligand binding assay,CC[C@@H](C)Oc1cc2c(cc1OC)CC(=O)N(c1ccc(N(C)C[C@H]3CC[C@H](N(C)C)CC3)cc1)[C@H]2c1ccc(Cl)cc1,"(trans)-(S)-7-((R)-sec-Butoxy)-1-(4-chloro-phenyl)-2-{4-[(4-dimethylamino-cyclohexylmethyl)-methyl-amino]-phenyl}-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one",1.3,uM,=,0.1139433523068367,1,O=C1Cc2ccccc2[C@H](c2ccccc2)N1c1ccc(NCC2CCCCC2)cc1
4470,1926401,10.1021/acs.jmedchem.6b00722,,,,Inhibition of human ERG by patch clamp assay,Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O,7-(2-hydroxypropan-2-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-9H-carbazole-1-carboxamide,10.0,uM,=,1.0,1,O=c1c2ccccc2ncn1-c1cccc(-c2cccc3[nH]c4ccccc4c23)c1
4471,1336040,10.1021/jm500118j,,,,Binding affinity to human ERG,Clc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12,"8-Chloro-9-cyclopentyl-N-(5-(1-piperazinyl)-2-pyridinyl)-9Hpyrido[4',3':4,5]-pyrrolo[2,3-d]pyrimidin-2-amine",2.0,uM,=,0.3010299956639812,1,c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2cn1
4472,1990748,10.1016/j.bmcl.2020.127214,,,,Inhibition of human ERG expressed in CHO cells by electrophysiology QPatch assay,C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CC(c2ccc(C(F)(F)F)cc2)C1)C(F)(F)F,"(S)-(5-(methylsulfonyl)-2-(1,1,1-trifluoropropan-2-yloxy)phenyl)(3-(4-(trifluoromethyl)phenyl)azetidin-1-yl)methanone",5.9,uM,=,0.7708520116421442,1,O=C(c1ccccc1)N1CC(c2ccccc2)C1
4473,1630280,10.1016/j.ejmech.2016.07.032,,,,Inhibition of human ERG expressed in CHOK1 cells by whole-cell patch clamp method,CC(C)Cc1cc(CNS(=O)(=O)c2cccc(F)c2)nn1-c1ccccc1,N-[(5-Isobutyl-1-phenyl-1H-pyrazol-3-yl)methyl]-3-fluorobenzenesulfonamide,14.5,uM,=,1.1613680022349748,1,O=S(=O)(NCc1ccn(-c2ccccc2)n1)c1ccccc1
4474,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,COCCOc1cc(NC(=O)N2CCCc3cc(C4CCN(CC(F)(F)F)CC4)c(C=O)nc32)ncc1C#N,"N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide",0.5,uM,=,-0.3010299956639812,0,O=C(Nc1ccccn1)N1CCCc2cc(C3CCNCC3)cnc21
4475,1865114,10.1021/acsmedchemlett.9b00086,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp method,CN(C)C(C(=O)N[C@](Cc1ccccc1)(c1ccc(F)cc1)c1cc(F)cc(C(F)(F)F)c1)C(O)(C(F)(F)F)C(F)(F)F,"2-(dimethylamino)-4,4,4-trifluoro-N-((R)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-hydroxy-3-(trifluoromethyl)butanamide",16.0,uM,=,1.2041199826559248,1,c1ccc(CC(c2ccccc2)c2ccccc2)cc1
4476,2153986,10.1021/acsmedchemlett.1c00660,,,,Inhibition on hERG expressed in HEK293 cells by Qpatch method,CN(C)CCCNC(=O)c1cccn2c(=O)c3ccc4ccccc4c3nc12,"N-(3-(dimethylamino)propyl)-7-oxo-7H-benzo[h]pyrido[2,1-b]quinazoline-12-carboxamide",5.57,uM,=,0.7458551951737289,1,O=c1c2ccc3ccccc3c2nc2ccccn12
4477,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,CCN(CC)Cc1ccc2c(c1)CC[C@H](N1CCN(CCc3ccc(F)cc3)CC1=O)C2,"(S)-1-(6-((diethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-4-(4-fluorophenethyl)piperazin-2-one",8.1,uM,=,0.9084850188786496,1,O=C1CN(CCc2ccccc2)CCN1[C@H]1CCc2ccccc2C1
4478,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CN(c2ccns2)C3)ccc2c1COC2=O,"5-((1R)-1-hydroxy-2-(2-(isothiazol-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",4.5,uM,=,0.6532125137753437,1,O=C1OCc2cc(CCN3CCC4(CC3)CN(c3ccns3)C4)ccc21
4479,949743,10.1021/jm301720p,,,,Inhibition of human ERG channel,NC(=O)c1cnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc(-n2nccn2)c1,"4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide",9.1,uM,=,0.9590413923210936,1,c1cc(Nc2ccnc(NC3CCCCC3)n2)cc(-n2nccn2)c1
4480,826732,10.1021/jm201194q,,,,Inhibition of human ERG expressed in HEK cells by patch clamp assay,Fc1ccc(N(CCNCCc2ccccc2)c2ccc(F)cc2)cc1,"N1,N1-bis(4-fluorophenyl)-N2-phenetylethane-1,2-diamine",0.044,uM,=,-1.3565473235138126,0,c1ccc(CCNCCN(c2ccccc2)c2ccccc2)cc1
4481,2241386,10.1016/j.ejmech.2021.113981,,,,Inhibition of hERG channel expressed in CHO cells at holding potential of -80 mV by whole cell patch clamp method,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,"(S)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((R)-piperidin-2-yl)methanol",15.0,uM,=,1.1760912590556811,1,c1ccc2c(C[C@H]3CCCCN3)ccnc2c1
4482,2047203,10.1021/acs.jmedchem.0c01170,,,,Inhibition of human ERG by Q-patch assay,CC1(N)CCN(c2cnc(Sc3cccc(Cl)c3Cl)c(N)n2)CC1,"6-(4-amino-4-methylpiperidin-1-yl)-3-((2,3-dichlorophenyl)thio)pyrazin-2-amine",2.8,uM,=,0.4471580313422192,1,c1ccc(Sc2cnc(N3CCCCC3)cn2)cc1
4483,882788,10.1016/j.ejmech.2012.07.006,,,,Inhibition of human recombinant ERG expressed in HEK293 cells after 5 to 10 mins by conventional whole-cell patch clamp assay,N=C(Nc1ccc2c(c1)CCN2C1CCNCC1)c1cccs1,N-(1-(Piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide,13.0,uM,=,1.1139433523068367,1,N=C(Nc1ccc2c(c1)CCN2C1CCNCC1)c1cccs1
4484,2035346,10.1021/acsmedchemlett.0c00660,,,,Inhibition of human ERG,CN1CCC(c2noc(-c3cnc(Nc4ccc5c(c4)C(C)(C)OC5=O)nc3N[C@H](CO)c3ccccc3)n2)CC1,"(S)-5-((4-((2-Hydroxy-1-phenylethyl)amino)-5-(3-(1-methylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)pyrimidin-2-yl)amino)-3,3-dimethylisobenzofuran-1(3H)-one",2.5,uM,=,0.3979400086720376,1,O=C1OCc2cc(Nc3ncc(-c4nc(C5CCNCC5)no4)c(NCc4ccccc4)n3)ccc21
4485,1760801,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by patch express assay,Cn1cnc(-c2ccc(OC3CCN(C(=O)Cc4ccc(OC(F)(F)F)cc4)CC3)c(C(N)=O)c2)c1,5-(1-methyl-1H-imidazol-4-yl)-2-(1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yloxy)benzamide,9.5,uM,=,0.9777236052888478,1,O=C(Cc1ccccc1)N1CCC(Oc2ccc(-c3c[nH]cn3)cc2)CC1
4486,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2ncn(Cc3ccnc4ccccc34)c(=O)c21,"(S)-6-(3-aminopiperidin-1-yl)-5-(3-methylbut-2-enyl)-4-oxo-3-(quinolin-4-ylmethyl)-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",4.2,uM,=,0.6232492903979004,1,O=c1c2[nH]c(N3CCCCC3)cc2ncn1Cc1ccnc2ccccc12
4487,820025,10.1016/j.bmcl.2012.04.128,,,,Inhibition of human ERG,CNC(=O)CCCN(C)C(=O)c1ccc2c(c1)c1c(n2C)CC[C@@H](C2CCOCC2)C1,"(R)-N,9-dimethyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide",105.0,uM,=,2.0211892990699383,1,c1ccc2c3c([nH]c2c1)CC[C@@H](C1CCOCC1)C3
4488,2155012,10.1021/acs.jmedchem.1c00082,,,,Inhibition of hERG,Cc1ccc(C(=O)Nc2ccc3c(c2)C(F)(F)C[C@@H]3N2CCN(C)CC2)cc1C#Cc1cnc2cccnn12,"(S)-N-(3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1Hinden-5-yl)-3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",11.1,uM,=,1.0453229787866574,1,O=C(Nc1ccc2c(c1)CC[C@@H]2N1CCNCC1)c1cccc(C#Cc2cnc3cccnn23)c1
4489,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,NCC(O)COc1ccccc1C(=O)CCc1ccccc1,1-[2-(3-Amino-2-hydroxy-propoxy)-phenyl]-3-phenyl-propan-1-one,44.0,uM,=,1.6434526764861874,1,O=C(CCc1ccccc1)c1ccccc1
4490,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3ccc4nccnc4c3)ccc2c1,(R)-6-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)quinoxaline,8.4,uM,=,0.9242792860618816,1,c1cnc2cc(-c3ccc4cc(CCN5CCCC5)ccc4n3)ccc2n1
4491,2054254,10.1016/j.ejmech.2020.112501,,,,Inhibition of human ERG by fluorescence polarization assay,Cl.OCCC/C(=C(\c1ccc(O)cc1)c1ccc(C2CCNCC2)cc1)c1ccccc1,4-(5-hydroxy-2-phenyl-1-(4-(piperidin-4-yl)phenyl)pent-1-enyl)phenol hydrochloride,12.7,uM,=,1.1038037209559568,1,C(=C(c1ccccc1)c1ccc(C2CCNCC2)cc1)c1ccccc1
4492,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,NCC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1,"6-((1-(2-(6-((1-(aminomethyl)cyclopropyl)methoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",7.6,uM,=,0.8808135922807914,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7CC7)nc56)(CC3)OC4)nc2N1
4493,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1cccc(C)c1)[C@@](O)(CCN(C)C)c1cccc2c1OCO2,"(1R,2S)-2-(benzo[d][1,3]dioxol-4-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-4-(dimethylamino)-1-m-tolylbutan-2-ol",0.5,uM,=,-0.3010299956639812,0,c1ccc([C@@H](Cc2cccc3c2OCO3)c2ccc3ccccc3c2)cc1
4494,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2c(c1)N(CCN1CCC(NCc3ccc4c(n3)NC(=O)CO4)CC1)C(=O)OC2,"6-[({1-[2-(7-Methoxy-2-oxo-2H-3,1-benzoxazin-1(4H)-yl)-ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]-oxazin-3(4H)-one",42.0,uM,=,1.6232492903979006,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)OCc5ccccc54)CC3)nc2N1
4495,1475693,10.1016/j.bmcl.2015.04.002,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(S)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.018,uM,=,-1.744727494896694,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4496,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3csc(-c4ccccc4)n3)ccc2c1,(R)-4-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-2-phenylthiazole,1.6,uM,=,0.2041199826559248,1,c1ccc(-c2nc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cs2)cc1
4497,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,CC(C)(C)c1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,(E)-3-(4-((2-(2-tert-butyl-1H-indol-3-yl)ethylamino)methyl)phenyl)-N-hydroxyacrylamide,7.45,uM,=,0.8721562727482929,1,c1ccc(CNCCc2c[nH]c3ccccc23)cc1
4498,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3ccc(C(F)(F)F)cn3)cs2)CO1,"US9315520, 17",11.7,uM,=,1.0681858617461617,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccn1
4499,582986,10.1021/jm900933k,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp technique,C[C@@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12,(-)-Dimethyl-{2-[3-((R)-1-pyridin-2-yl-ethyl)-benzo[b]thiophen-2-yl]-ethyl}-amine,1.4,uM,=,0.1461280356782379,1,c1ccc(Cc2csc3ccccc23)nc1
4500,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,CNCC(=O)N1CCN(c2ccc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)c(OC)c2)CC1,"1-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)piperazin-1-yl)-2-(methylamino)ethanone",9.5,uM,=,0.9777236052888478,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
4501,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CC(c1ccccc1Oc1ccc(Cl)c(Cl)c1)N(C)C,"1-(2-(3,4-dichlorophenoxy)phenyl)-N,N-dimethylethanamine",0.9,uM,=,-0.0457574905606751,0,c1ccc(Oc2ccccc2)cc1
4502,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(Cl)cc(Cl)c2)CCN(Cc2ccccc2C(F)(F)F)CC1,"methyl 4-((3,5-dichlorobenzamido)methyl)-1-(2-(trifluoromethyl)benzyl)piperidine-4-carboxylate",0.46,uM,=,-0.3372421683184259,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
4503,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,COc1cnc2ccc(=O)n(CCN3CC[C@@H](NCc4cnc(C)c(C#N)c4)[C@@H](OC)C3)c2c1,"5-(((3S,4R)-3-Methoxy-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile",151.0,uM,=,2.1789769472931693,1,O=c1ccc2ncccc2n1CCN1CCC(NCc2cccnc2)CC1
4504,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(C3CCCCNC3=O)nn2)ccc1-n1cnc(C)c1,"rac-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)azepan-2-one",43.9,uM,=,1.6424645202421213,1,O=C1NCCCCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
4505,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)n1,"endo-6-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)picolinamide",1.0,uM,=,0.0,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccn2)C3)cc1
4506,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,C[C@H](O)C(=O)NC1CC(C)(C)Oc2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc21,"(2R)-N-[6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-2-hydroxypropanamide",0.12,uM,=,-0.9208187539523752,0,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
4507,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC([C@@H](O)Cc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1,"(S)-6-((1-(2-(3-fluoro-6-(2-hydroxyethoxy)-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",29.7,uM,=,1.4727564493172125,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4508,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,C[C@@H]1CN(c2sc(C3COC3)nc2-c2nc3ccccc3[nH]2)CCN1C(=O)Cn1cnc2cccnc21,"US9266876, 113",4.4,uM,=,0.6434526764861874,1,O=C(Cn1cnc2cccnc21)N1CCN(c2sc(C3COC3)nc2-c2nc3ccccc3[nH]2)CC1
4509,1871838,10.1016/j.bmcl.2018.12.015,,,,Inhibition of human ERG,NC(=O)c1cc(Cl)c2c(Cl)c(C#CC3CCOCC3)n([C@H]3CCCNC3)c2n1,"(S)-3,4-dichloro-1-(piperidin-3-yl)-2-((tetrahydro-2H-pyran-4-yl)ethynyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",0.0017,uM,=,-2.7695510786217263,0,C(#CC1CCOCC1)c1cc2cccnc2n1[C@H]1CCCNC1
4510,597420,10.1016/j.bmcl.2009.08.080,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,CCc1n[nH]c(CC)c1Oc1cc(Cl)cc(C#N)c1,"3-(3,5-diethyl-1H-pyrazol-4-yloxy)-5-chlorobenzonitrile",39.0,uM,=,1.591064607026499,1,c1ccc(Oc2cn[nH]c2)cc1
4511,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCCO)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-(5-hydroxypentyloxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.7,uM,=,-0.1549019599857432,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4512,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4cccnc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"7-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-9-(2,2,2-trifluoroethyl)-6,7-dihydro-5H-pyrido[2,3-b]azepin-8(9H)-one",8.74,uM,=,0.9415114326344032,1,O=C1Nc2ncccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
4513,1736165,10.1021/acs.jmedchem.8b00300,,,,Inhibition of human ERG,O=S(=O)(CC1CC1)NC1CN(c2ccc3c(c2)[C@@H](Cc2ccccc2)[C@@H](N2CCC2)CC3)C1,"N-(1-((7S,8R)-7-(Azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)azetidin-3-yl)-1-cyclopropylmethanesulfonamide",4.4,uM,=,0.6434526764861874,1,O=S(=O)(CC1CC1)NC1CN(c2ccc3c(c2)[C@@H](Cc2ccccc2)[C@@H](N2CCC2)CC3)C1
4514,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCCNCC4)n3CC=C(C)C)n(C)c2=O)c1,"6-(1,4-diazepan-1-yl)-3-(2-(3-methoxyphenyl)-2-oxoethyl)-1-methyl-5-(3-methylbut-2-enyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",1.1,uM,=,0.041392685158225,1,O=C(Cn1c(=O)[nH]c2cc(N3CCCNCC3)[nH]c2c1=O)c1ccccc1
4515,2025950,10.1021/acsmedchemlett.0c00575,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,CCS(=O)(=O)c1ccc(CNc2nc3cnc(-c4c(OC)ncnc4C4CC4)nc3n([C@H](C)C3CC3)c2=O)nc1,(R)-2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-8-(1-cyclopropylethyl)-6-((5-(ethylsulfonyl)pyridin-2-yl)methylamino)pteridin-7(8H)-one,5.6,uM,=,0.7481880270062004,1,O=c1c(NCc2ccccn2)nc2cnc(-c3cncnc3C3CC3)nc2n1CC1CC1
4516,793275,10.1016/j.bmcl.2011.09.117,,,,Displacement of [3H]dofetilide from human ERG by liquid scintillation counting,COc1ccc2ncc(F)c([C@@H](O)CN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"(R)-2-(4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)-1-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethanol",79.4,uM,=,1.899820502427096,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
4517,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",17.3,uM,=,1.2380461031287957,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
4518,1629116,10.1016/j.bmc.2016.10.009,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes,Cl.N=C(N)N/N=C/c1ccc(-c2ccc(/C=N/Nc3ccccc3Br)cc2)cc1,2-((4'-((2-(2-bromophenyl)hydrazono)methyl)biphenyl-4-yl)methylene)hydrazinecarboximidamide hydrochloride,0.44,uM,=,-0.3565473235138126,0,C(=N/Nc1ccccc1)\c1ccc(-c2ccccc2)cc1
4519,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21,6-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isochroman-1-one,43.0,uM,=,1.6334684555795866,1,O=C1OCCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
4520,1892808,10.1016/j.ejmech.2019.03.062,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated patch clamp assay,Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1,RABUSERTIB,28.1,uM,=,1.44870631990508,1,O=C(Nc1cnccn1)Nc1ccccc1OC[C@@H]1CNCCO1
4521,570979,10.1016/j.bmcl.2009.04.035,,,,Inhibition human ERG expressed in HEK293 cells assessed as blockade of membrane current by patch clamp method,CN1C[C@@H]2[C@H](C1)[C@H]2CN(Cc1ccc(F)c(Cl)c1)C(=O)c1cn(C)cn1,1-Methyl-1H-imidazole-4-carboxylic acid(3-chloro-4-fluoro-benzyl)-(3-methyl-3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-amide,8.5,uM,=,0.9294189257142929,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)C[C@H]1[C@@H]2CNC[C@@H]21
4522,591827,10.1021/jm900729s,,,,Inhibition of human ERG by patch-clamp assay,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(C3CN(Cc4ccnc5ncccc45)C3)C(=O)O[C@]12C,"3-Descladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl-(1-(([1,8]naphthyridin-4-yl)methyl)azetidin-3-yl)imino)-erythromycin A",80.0,uM,=,1.9030899869919435,1,O=C1CC(=O)OCC2OC(=O)N(C3CN(Cc4ccnc5ncccc45)C3)[C@@H]2CC(=O)CCC[C@H](O[C@H]2CCCCO2)C1
4523,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,c1ccc([C@@H]2Sc3ccccc3O[C@@H]2c2ccc(OCCCN3CCCC3)cc2)cc1,"cis-1-(3-(4-(3-phenyl-2,3-dihydrobenzo[b][1,4]oxathiin-2-yl)phenoxy)propyl)pyrrolidine",0.012,uM,=,-1.9208187539523751,0,c1ccc([C@@H]2Sc3ccccc3O[C@@H]2c2ccc(OCCCN3CCCC3)cc2)cc1
4524,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,N#Cc1cncc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)c1,"5-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridin-6-yl)nicotinonitrile",6.666666667,uM,=,0.8239087409660335,1,c1cncc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)c1
4525,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,O=C(c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1)N1CCCC1,"6-[4-(Pyrrolidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroiso-quinolin-1(2H)-one",8.8,uM,=,0.9444826721501688,1,O=C(c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1)N1CCCC1
4526,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,c1ccc(-c2ccc(OCCCN3CCCCC3)cc2)cc1,1-(3-(biphenyl-4-yloxy)propyl)piperidine,0.42,uM,=,-0.3767507096020995,0,c1ccc(-c2ccc(OCCCN3CCCCC3)cc2)cc1
4527,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N(CCc3ccc(Cl)cc3)CC(=O)O)CC2)n1,"N-(1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)-N-(4-chlorophenethyl)glycine",8.0,uM,=,0.9030899869919436,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
4528,1554472,10.1021/acs.jmedchem.5b01372,,,,Binding affinity to human ERG channel,O=C(Cn1cnc2ccccc2c1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1,"N-(4-(((2S,5R)-5-((R)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)-methyl)phenyl)-2-(4-oxoquinazolin-3(4H)-yl)acetamide",2.0,uM,=,0.3010299956639812,1,O=C(Cn1cnc2ccccc2c1=O)Nc1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1
4529,1573848,10.1016/j.ejmech.2016.02.039,,,,Inhibition of human ERG assessed as reduction in channel current by automated patch-clamp electrophysiology assay,CNC(=O)c1cc(Oc2ccc3nc(NC(=O)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)sc3c2)ccn1,"4-((2-(3,5-Bis(trifluoromethyl)benzamido)benzo[d]thiazol-6-yl)oxy)-N-methylpicolinamide",48.38,uM,=,1.684665864025861,1,O=C(Nc1nc2ccc(Oc3ccncc3)cc2s1)c1ccccc1
4530,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@]3(O)CC[C@@H](NCc4ccc5c(c4)OCCO5)CC3)c2n1,"(1s,4r)-4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)-1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)cyclohexanol",2.2,uM,=,0.3424226808222063,1,c1cnc2c(CCC3CCC(NCc4ccc5c(c4)OCCO5)CC3)ccnc2c1
4531,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COCCN1CCC[C@H](Cn2c(-c3cccnc3C)nc3cn(-c4cccc(OC)c4)nc3c2=O)C1,"(S)-6-((1-(2-Methoxyethyl)piperidin-3-yl)methyl)-2-(3-methoxyphenyl)-5-(2-methylpyridin-3-yl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",43.0,uM,=,1.6334684555795866,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2cccnc2)n1C[C@H]1CCCNC1
4532,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCc1nnc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1,"2-ethyl-5-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,3,4-oxadiazole",4.3,uM,=,0.6334684555795865,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4nnco4)N3)n2)nc1
4533,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,COc1ccc([C@H]2CC[C@@H](N3CC(NC(=O)CNc4noc5ccc(C(F)(F)F)cc45)C3)CC2)cn1,cis-N-{1-[4-Hydroxy-4-(6-methoxy-pyridin-3-yl)-cyclohexyl]-azetidin-3-yl}-2-(5-trifluoromethyl-benzo[d]isoxazol-3-ylamino)-acetamide,0.0087,uM,=,-2.0604807473813813,0,O=C(CNc1noc2ccccc12)NC1CN([C@H]2CC[C@@H](c3cccnc3)CC2)C1
4534,1783529,10.1016/j.ejmech.2017.12.075,,,,Inhibition of human ERG by [3H]dofetilide binding displacement assay,Cc1c(CN2CCOCC2)cc(-c2ccc(C(C)C)cc2)n1C1CCCOC1,4-((5-(4-Isopropylphenyl)-2-methyl-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrrol-3-yl)methyl)morpholine,10.0,uM,=,1.0,1,c1ccc(-c2cc(CN3CCOCC3)cn2C2CCCOC2)cc1
4535,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H](C3(F)CNC3)O2)cc1,"(5R)-5-(3-fluoroazetidin-3-yl)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-4,5-dihydrooxazole",11.0,uM,=,1.0413926851582251,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H](C3CNC3)O2)cc1
4536,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,N#Cc1cnc(Nc2cc(NC[C@H]3CNCCO3)c(-c3cccc(F)c3)cn2)cn1,(R)-5-((5-(3-Fluorophenyl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,8.8,uM,=,0.9444826721501688,1,c1ccc(-c2cnc(Nc3cnccn3)cc2NC[C@H]2CNCCO2)cc1
4537,1349505,10.1021/jm500115w,,,,Inhibition of human ERG channel expressed in HEK293 cells after 3 to 5.7 mins by whole-cell patch clamp technique,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1,"N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline",31.04,uM,=,1.4919217125861508,1,c1ccc(NCc2nc(-c3ccc4ncnn4c3)c(-c3ccccn3)[nH]2)cc1
4538,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(CCCOCc2cccc(COCCCc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis((3-p-tolylpropoxy)methyl)pyridinium",0.024,uM,=,-1.619788758288394,0,c1ccc(CCCOCc2cccc(COCCCc3ccccc3)[nH+]2)cc1
4539,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1F,"N,N-Diethyl-2-fluoro-4-(spiro[chromene-2,4'-piperidine]-4-yl)-benzamide",3.794,uM,=,0.5790973265526438,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
4540,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,C[C@@H]1CN(c2scnc2-c2nc3ccccc3[nH]2)CCN1C(=O)Cn1cnc2cccnc21,"US9266876, 17",2.2,uM,=,0.3424226808222063,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2nc3ccccc3[nH]2)CC1
4541,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,CNC(=O)c1cnc(N)c(O[C@H]2CN(C(=O)Cc3ccc(OC(F)(F)F)cc3)CC2(F)F)c1,"(S)-6-amino-5-(4,4-difluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)pyrrolidin-3-yloxy)-N-methylnicotinamide",79.0,uM,=,1.8976270912904407,1,O=C(Cc1ccccc1)N1CC[C@@H](Oc2cccnc2)C1
4542,1906723,10.1016/j.ejmech.2019.111674,,,,Inhibition of human ERG expressed in HEK293 cells incubated for 72 hrs by patch clamp assay,Cc1cc(C(N)=O)c(-c2cccc(OC(=O)NCCCN3CCN(c4ccccc4)CC3)c2)o1,3-(3-Carbamoyl-5-methylfuran-2-yl)phenyl (3-(4-phenylpiperazin-1-yl)propyl)carbamate,1.1,uM,=,0.041392685158225,1,O=C(NCCCN1CCN(c2ccccc2)CC1)Oc1cccc(-c2ccco2)c1
4543,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(Cl)cc2)[C@@H]3C)n1,"(R)-(4-Chlorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",66.0,uM,=,1.8195439355418688,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
4544,2064218,10.1021/acs.jmedchem.6b01265,,,,Inhibition of human ERG by IonWorks patch clamp electrophysiology method,Nc1ncc(-c2ccc(C(=O)N3CCNCC3)cc2)nc1-c1ccc(C(F)(F)F)cc1,(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(piperazin-1-yl)methanone,10.0,uM,=,1.0,1,O=C(c1ccc(-c2cncc(-c3ccccc3)n2)cc1)N1CCNCC1
4545,1783529,10.1016/j.ejmech.2017.12.075,,,,Inhibition of human ERG by [3H]dofetilide binding displacement assay,Cc1c(CN2CCOCC2)cc(-c2ccc(C(C)C)cc2)n1C(C)C,4-((1-Isopropyl-5-(4-isopropylphenyl)-2-methyl-1H-pyrrol-3-yl)methyl)morpholine,16.0,uM,=,1.2041199826559248,1,c1ccc(-c2cc(CN3CCOCC3)c[nH]2)cc1
4546,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,Cc1cc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)cnc2C(N)=O)nc(C)c1-c1cnn(C)c1,"5-(((1R,2S)-2-aminocyclohexyl)amino)-3-((4,6-dimethyl-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)picolinamide",1.0,uM,=,0.0,0,c1ncc(NC2CCCCC2)cc1Nc1ccc(-c2cn[nH]c2)cn1
4547,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NC4CC4)cc3)n2)n1C(C)C,N-cyclopropyl-4-(4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)benzamide,7.0,uM,=,0.8450980400142568,1,O=C(NC1CC1)c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
4548,1676692,10.1021/acs.jmedchem.7b01039,,,,Inhibition of human ERG by fluorescently labeled tracer binding method,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide,0.0012,uM,=,-2.920818753952376,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
4549,744146,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG,O=C(NC1CC1)c1ccc(OCC2CC2C2CCN(c3ncc(Cl)cn3)CC2)cc1F,(rac)-cis-4-((2-(1-(5-chloropyrimidin-2-yl)piperidin-4-yl)cyclopropyl)methoxy)-N-cyclopropyl-2-fluorobenzamide,1.5,uM,=,0.1760912590556812,1,O=C(NC1CC1)c1ccc(OCC2CC2C2CCN(c3ncccn3)CC2)cc1
4550,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4c(F)cc(F)cc43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(4,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",1.9,uM,=,0.2787536009528289,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
4551,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(NCCN(C)C)nc5)cc4c32)C1,"8-(6-[[2-(Dimethylamino)ethyl]amino]pyridin-3-yl)-7-fluoro-3-methyl-1-[cis-3-methoxycyclobutyl]-1H,2H,3H-imidazo[4,5-c]quinolin-2-one",24.0,uM,=,1.380211241711606,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCC1
4552,2185846,10.1021/acs.jmedchem.1c00621,,,,Inhibition of hERG potassium channel assessed as maximum inhibition rate at -80 mV holding potential incubated for 120 seconds by whole cell-automated voltage clamp analysis assay,CNc1cc(F)cc2c1[nH]c1nc(Oc3cnc(C)nc3)nc(N3CCC(=C(F)CN)CC3)c12,"4-(4-(2-Amino-1-fluoroethylidene)piperidin-1-yl)-6-fluoro-N-methyl-2-((2-methylpyrimidin-5-yl)oxy)-9H-pyrimido[4,5-b]indol-8-amine",18.4,uM,=,1.2648178230095364,1,C=C1CCN(c2nc(Oc3cncnc3)nc3[nH]c4ccccc4c23)CC1
4553,443485,10.1016/j.bmcl.2007.03.006,,,,Inhibition of hERG expressed in CHO cells by cell voltage clamp assay,CN(C)C(=O)N1CC(c2cc(F)ccc2F)=C[C@@]1(CC[C@H](N)C(F)F)c1ccccc1,"(S)-2-((S)-3-amino-4,4-difluorobutyl)-4-(2,5-difluorophenyl)-N,N-dimethyl-2-phenyl-2H-pyrrole-1(5H)-carboxamide",15.9,uM,=,1.2013971243204515,1,C1=C(c2ccccc2)CNC1c1ccccc1
4554,632181,10.1016/j.bmcl.2010.03.106,,,,Inhibition of human ERG expressed by patch clam electrophysiology assay,Cc1nn(CCOCC(F)(F)F)c2c(Nc3ccncn3)nc(N3CCN[C@H](C)C3)nc12,"(R)-3-methyl-5-(3-methylpiperazin-1-yl)-N-(pyrimidin-4-yl)-1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine",0.9,uM,=,-0.0457574905606751,0,c1cc(Nc2nc(N3CCNCC3)nc3cn[nH]c23)ncn1
4555,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,O=C(/C=C/c1ccc(CNCCc2c(-c3ccccc3)[nH]c3ccccc23)cc1)NO,(E)-N-hydroxy-3-(4-((2-(2-phenyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide,1.48,uM,=,0.1702617153949573,1,c1ccc(CNCCc2c(-c3ccccc3)[nH]c3ccccc23)cc1
4556,2298656,10.1016/j.bmcl.2023.129280,,,,Inhibition of hERG,CCCOc1c(CCC)cc(-c2ccccc2-c2nn[nH]n2)cc1NC(=O)Nc1ccc(C)cc1,"1-(4-propoxy-5-propyl-2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-3-yl)-3-(p-tolyl)urea",40.0,uM,=,1.6020599913279625,1,O=C(Nc1ccccc1)Nc1cccc(-c2ccccc2-c2nn[nH]n2)c1
4557,2208843,10.1016/j.bmc.2022.116657,,,,Inhibition of hERG channel expressed in CHO cells at -80 mV holding potential by Qpatch clamp method,COc1cc(OC)c(F)c(COc2cnc(Nc3cnc(N4CCC(N5CCN(C)CC5)CC4)nc3)nc2)c1F,"5-[(2,6-Difluoro-3,5-dimethoxyphenyl)methoxy]-N-{2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidin-5-yl}pyrimidin-2-amine",14.0,uM,=,1.146128035678238,1,c1ccc(COc2cnc(Nc3cnc(N4CCC(N5CCNCC5)CC4)nc3)nc2)cc1
4558,1768711,10.1016/j.bmc.2018.01.021,,,,Inhibition of human ERG expressed in HEK293 cells by automated patch clamp method,CN(c1ncnc2[nH]ccc12)[C@@H]1CCN(C(=O)CC#N)C1,"(R)-3-(3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile",93.0,uM,=,1.9684829485539352,1,c1nc(N[C@@H]2CCNC2)c2cc[nH]c2n1
4559,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,N[C@H](COc1cccc2ccc(=O)[nH]c12)CN1CCC2(CC1)Cc1cc(F)ccc1O2,"(S)-8-(2-amino-3-(5-fluoro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)propoxy)quinolin-2(1H)-one",1.2,uM,=,0.0791812460476248,1,O=c1ccc2cccc(OCCCN3CCC4(CC3)Cc3ccccc3O4)c2[nH]1
4560,434542,10.1021/jm061223o,,,,Inhibition of hERG expressed in HEK293 cells assessed as effect on ionic current by patch clamp assay,COCCOCC#Cc1cc(-c2n[nH]c3c2Cc2ccc(Cn4cncn4)cc2-3)cs1,"7-((1H-1,2,4-triazol-1-yl)methyl)-3-(5-(3-(2-methoxyethoxy)-prop-1-ynyl)thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole",11.6,uM,=,1.0644579892269186,1,c1ncn(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)n1
4561,520038,10.1021/jm900364m,,,,Binding affinity to human ERG,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N.Cl,"2-Chloro-6-[((2R)-3-([1,1-dimethyl-2-(2-naphthalenyl)ethyl]-amino)-2-hydroxypropyl)oxy]benzonitrile hydrochloride",3.0,uM,=,0.4771212547196624,1,c1ccc(OCCCNCCc2ccc3ccccc3c2)cc1
4562,1677014,10.1021/acs.jmedchem.7b01537,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp method,CN(Cc1ccccn1)Cc1ccccc1CNc1ccnc2cc(Cl)ccc12,7-Chloro-N-(2-((methyl(pyridin-2-ylmethyl)amino)methyl)-benzyl)quinolin-4-amine,0.87,uM,=,-0.0604807473813814,0,c1ccc(CNCc2ccccc2CNc2ccnc3ccccc23)nc1
4563,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,CC(=O)c1nn(-c2ccccc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1,"2-((5-Acetyl-3-phenyl-1,3,4-thiadiazol-2(3H)-ylidene)amino)-4,6-diphenylnicotinonitrile",32.6,uM,=,1.513217600067939,1,c1ccc(-c2cc(/N=c3\scnn3-c3ccccc3)nc(-c3ccccc3)c2)cc1
4564,1348027,10.1021/jm5004599,,,,Inhibition of human ERG by whole-cell voltage clamp assay,Cl.c1cncc(OC[C@H]2CNCCN2c2nc3ncccc3o2)c1,"(R)-2-(2-((Pyridin-3-yloxy)methyl)piperazin-1-yl)oxazolo[4,5-b]-pyridine Hydrochloride",72.0,uM,=,1.8573324964312683,1,c1cncc(OC[C@H]2CNCCN2c2nc3ncccc3o2)c1
4565,1924853,10.1016/j.bmcl.2016.07.029,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells measured after 90 mins by scintillation proximity assay,COc1cc(C(=O)N2C[C@@H](n3cc(C4CC4)nn3)C[C@H]2C(=O)N[C@@H]2C[C@H]2c2ccccc2)ccc1CN,"(2S,4S)-1-(4-(aminomethyl)-3-methoxybenzoyl)-4-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)-N-((1R,2S)-2-phenylcyclopropyl)pyrrolidine-2-carboxamide",22.0,uM,=,1.3424226808222062,1,O=C(N[C@@H]1C[C@H]1c1ccccc1)[C@@H]1C[C@H](n2cc(C3CC3)nn2)CN1C(=O)c1ccccc1
4566,2051795,10.1021/acs.jmedchem.6b00275,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1cc(Nc2ccc(S(F)(F)(F)(F)F)cc2)n2nc(C(C)(F)F)nc2n1,"2-(1,1-Difluoroethyl)-5-methyl-N-[4-(pentafluoro-lambda6-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",1.6,uM,=,0.2041199826559248,1,c1ccc(Nc2ccnc3ncnn23)cc1
4567,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CC3CN(Cc4ccccc4)CC3C2)CCOCC1)c1cccc(C(F)(F)F)n1,"N-((4-(5-benzylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)tetrahydro-2H-pyran-4-yl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)propionamide",3.4,uM,=,0.5314789170422551,1,c1ccc(CN2CC3CN(C4(CNc5ccccn5)CCOCC4)CC3C2)cc1
4568,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc(CCN2C[C@H](CNC(=O)c3cccc(Cl)c3)[C@@H](c3ccc(OC)cc3)C2)cc1,"rac-3-chloro-N-(((3S,4S)-1-(4-methoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)methyl)benzamide",0.028,uM,=,-1.5528419686577808,0,O=C(NC[C@H]1CN(CCc2ccccc2)C[C@@H]1c1ccccc1)c1ccccc1
4569,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2ccc3nc(C)ccc3c2)[nH]1,(S)-6-methyl-N-((S)-1-(5-(2-methylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide,43.0,uM,=,1.6334684555795866,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)[nH]1)[C@H]1CC12CCNCC2
4570,1447392,10.1016/j.bmcl.2014.04.085,,,,Inhibition of human ERG channel,CCNC(=O)N1CC2(CCN(CC3CCN(C(=O)OCC)CC3)CC2)c2cccnc21,"ethyl 4-((1'-(ethylcarbamoyl)-1',2'-dihydrospiro[piperidine-4,3'-pyrrolo[2,3-b]pyridine]-1-yl)methyl)piperidine-1-carboxylate",0.23,uM,=,-0.6382721639824072,0,c1cnc2c(c1)C1(CCN(CC3CCNCC3)CC1)CN2
4571,1882359,10.1016/j.ejmech.2018.10.057,,,,Inhibition of red tracer binding to human ERG expressed in membranes preincubated for 10 to 15 mins followed by tracer addition measured after 3 hrs by fluorescence polarization assay,COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)nc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1,"3,5-Dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide",17.1,uM,=,1.2329961103921538,1,O=C(Nc1cnc(Nc2ccc(N3CCOCC3)nc2)nc1Oc1ccccc1)c1ccccc1
4572,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(N)nc7)[nH]6)CC5)cc4)nc3n2)CC1,"5-(5-(1-((4-(6-(4-methylpiperazin-1-yl)-2-phenylpyrido[3,2-b]pyrazin-3-yl)phenyl)methyl)piperidin-4-yl)-4H-1,2,4-triazol-3-yl)pyridin-2-amine",4.7,uM,=,0.6720978579357175,1,c1ccc(-c2nc3ccc(N4CCNCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5cccnc5)[nH]4)CC3)cc2)cc1
4573,1700921,10.1021/acs.jmedchem.7b00032,,,,Inhibition of human ERG by manual patch clamp assay,CCc1nc2ccc(C3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)cs1,"2-[4-(2-Ethyl-3-{[4-(4-fluoro-phenyl)-thiazol-2-yl]-methylamino}-imidazo[1,2-a]pyridin-6-yl)-piperidin-1-yl]-1-(3-hydroxy-azetidin-1-yl)-ethanone",5.6,uM,=,0.7481880270062004,1,O=C(CN1CCC(c2ccc3ncc(Nc4nc(-c5ccccc5)cs4)n3c2)CC1)N1CCC1
4574,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,"N*4*-(7-Chloro-quinolin-4-yl)-N*1*,N*1*-diethyl-pentane-1,4-diamine (Chloroquine)",2.5,uM,=,0.3979400086720376,1,c1ccc2ncccc2c1
4575,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,CNc1cc(Nc2cnc(C#N)c(O[C@H](C)CN(C)C)n2)ncc1C(=O)OC,(R)-Methyl 6-((5-cyano-6-((1-(dimethylamino)propan-2-yl)oxy)pyrazin-2-yl)amino)-4-(methylamino)nicotinate,5.0,uM,=,0.6989700043360189,1,c1ccc(Nc2cnccn2)nc1
4576,499332,10.1016/j.bmcl.2009.04.023,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(C(=O)[C@]4(C)CC[C@](C)(O)CC4)nc3cc2Cl)CC1,"cis-(5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)(4-hydroxy-1,4-dimethylcyclohexyl)methanone",3.1,uM,=,0.4913616938342727,1,O=C(c1nc2ccc(N3CCNCC3)cc2[nH]1)C1CCCCC1
4577,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,CCOC(=O)c1cccc([C@@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)n1,"Ethyl6-((1R,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)picolinate",0.625,uM,=,-0.2041199826559248,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@](c4cn[nH]c4)(c4ccccn4)N3)n2)cc1
4578,2153986,10.1021/acsmedchemlett.1c00660,,,,Inhibition on hERG expressed in HEK293 cells by Qpatch method,O=C(NC1CNC1)c1cccn2c(=O)c3ccc4ccccc4c3nc12,"N-(azetidin-3-yl)-7-oxo-7H-benzo[h]pyrido[2,1-b]quinazoline-12-carboxamide",3.97,uM,=,0.5987905067631151,1,O=C(NC1CNC1)c1cccn2c(=O)c3ccc4ccccc4c3nc12
4579,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,FC(F)(F)c1noc(-c2ccc(CCN3CCC(Nc4nc5ccccc5[nH]4)CC3)cc2)n1,"N-(1-(4-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)phenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine",0.63,uM,=,-0.2006594505464183,0,c1ccc2[nH]c(NC3CCN(CCc4ccc(-c5ncno5)cc4)CC3)nc2c1
4580,2163947,10.1021/acs.jmedchem.1c01564,,,,Inhibition of human ERG by [3H]]Astemizole binding assay,CN(CCCCN(C[C@H]1Cc2ncccc2CN1)[C@H]1CCCc2cccnc21)C1CCC(F)(F)CC1,"N1-(4,4-difluorocyclohexyl)-N1-methyl-N4-(((R)-5,6,7,8-tetrahydro-1,6-naphthyridin-7-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",17.0,uM,=,1.230448921378274,1,c1cnc2c(c1)CN[C@@H](CN(CCCCNC1CCCCC1)[C@H]1CCCc3cccnc31)C2
4581,1475693,10.1016/j.bmcl.2015.04.002,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,COc1ccc2ncc(CO)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-(hydroxymethyl)-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",5.9,uM,=,0.7708520116421442,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4582,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,CC(C)(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-(3-hydroxy-3-methylbutoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",7.0,uM,=,0.8450980400142568,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4583,1912248,10.1021/acs.jmedchem.9b00443,,,,Inhibition of human ERG by fluorescence polarization assay,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccccc1S(C)(=O)=O,6-((5-Fluoropyridin-2-yl)amino)-N-methyl-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide,25.0,uM,=,1.3979400086720375,1,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1
4584,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)(O)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3cncnc3)CC2)C1,"(1S,3R)-N-(3,5-bis(trifluoromethyl)benzyl)-1-(2-hydroxypropan-2-yl)-3-(4-(pyrimidin-5-yl)piperidin-1-yl)cyclopentanecarboxamide",0.844,uM,=,-0.0736575533743449,0,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3cncnc3)CC2)C1
4585,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(F)ccc1Oc1ccc(Cl)cc1,1-(2-(4-chlorophenoxy)-5-fluorophenyl)-N-methylmethanamine,7.39,uM,=,0.8686444383948257,1,c1ccc(Oc2ccccc2)cc1
4586,936798,10.1021/jm301511h,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,C[S+]([O-])Cc1ccc(C(=O)Nc2nccnc2C(=O)NCC2CCC2)c2ccccc12,N-(Cyclobutylmethyl)-3-({4-[(methylsulfinyl)methyl]-1-naphthoyl}amino)pyrazine-2-carboxamide,17.0,uM,=,1.230448921378274,1,O=C(NCC1CCC1)c1nccnc1NC(=O)c1cccc2ccccc12
4587,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2ccccn2)=NC1c1ccc(F)cc1Br,"Ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholinomethyl)-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate",3.8,uM,=,0.5797835966168101,1,C1=C(CN2CCOCC2)NC(c2ccccn2)=NC1c1ccccc1
4588,1672389,10.1016/j.bmcl.2017.05.018,,,,Inhibition of human ERG by patch clamp assay,CCc1cc(COc2cc(C(=O)N3CCC[C@@H](N)C3)nn2-c2ccc(C#N)cc2)on1,4-[3-[(3R)-3-Aminopiperidine-1-carbonyl]-5-[(3-ethylisoxazol-5-yl)methoxy]pyrazol-1-yl]benzonitrile,5.0,uM,=,0.6989700043360189,1,O=C(c1cc(OCc2ccno2)n(-c2ccccc2)n1)N1CCCCC1
4589,876604,10.1021/jm301476b,,,,Inhibition of human ERG expressed in chinese hamster lung cells by IonWorks patch clamp electrophysiology assay,Nc1ncc(-c2ccc(C(=O)N3CCNCC3)cc2)cc1-c1ccc(C(F)(F)F)nc1,(4-(6-Amino-5-(6-(trifluoromethyl)pyridin-3-yl)pyridin-3-yl)phenyl)(piperazin-1-yl)methanone,19.7,uM,=,1.294466226161593,1,O=C(c1ccc(-c2cncc(-c3cccnc3)c2)cc1)N1CCNCC1
4590,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(C(=O)NC[C@@H]2CCN(C(=O)CCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc1C(C)(C)C,"(S)-N-((1-(6,6-bis(4-fluorophenyl)hexanoyl)pyrrolidin-3-yl)methyl)-3,5-di-tert-butyl-4-methoxybenzamide",2.0,uM,=,0.3010299956639812,1,O=C(NC[C@@H]1CCN(C(=O)CCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
4591,2249200,10.1021/acs.jmedchem.2c00008,,,,Inhibition of human ERG potassium channel expressed in CHO cells by patch-clamp assay,CC(F)(F)c1cc(F)ccc1-c1sc2c(ccc3[nH]ncc32)c1Oc1ccc(NC2CN(CCCF)C2)c(F)c1,"N-[4-[[2-[2-(1,1-difluoroethyl)-4-fluoro-phenyl]-6H-thieno[2,3-e]indazol-3-yl]oxy]-2-fluoro-phenyl]-1-(3-fluoropropyl)azetidin-3-amine",27.5,uM,=,1.4393326938302626,1,c1ccc(-c2sc3c(ccc4[nH]ncc43)c2Oc2ccc(NC3CNC3)cc2)cc1
4592,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CC[C@H]3OC[C@H](NCc4cc5c(cn4)OCCC5)CO3)c2c1,"N-((3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-2-(2-(6-methoxyquinolin-4-yl)ethyl)-trans-1,3-dioxan-5-amine",12.0,uM,=,1.0791812460476249,1,c1ccc2c(CC[C@H]3OC[C@H](NCc4cc5c(cn4)OCCC5)CO3)ccnc2c1
4593,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3ccncc3)cc12,4-[(2-Ethylbutyl)amino]-6-(4-pyridinyl)-3-quinolinecarboxamide,0.62,uM,=,-0.2076083105017461,0,c1cnc2ccc(-c3ccncc3)cc2c1
4594,421810,10.1016/j.bmcl.2006.10.053,,,,Inhibition of binding to hERG,CN(C)Cc1ccc2c(c1)CC[C@H](N(C)C(=O)c1ccc(-c3ccc(F)cc3)cc1)C2,"(S)-N-(6-((dimethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-4'-fluoro-N-methylbiphenyl-4-carboxamide",1.8,uM,=,0.255272505103306,1,O=C(N[C@H]1CCc2ccccc2C1)c1ccc(-c2ccccc2)cc1
4595,1648277,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG,CCc1cnc(N2CCC([C@H]3C[C@H]3CCOc3ccc(CC(=O)N4CCC4)c(F)c3)CC2)nc1,"(cis)-1-(azetidin-1-yl)-2-(4-(2-((1S,2R)-2-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)-2-fluorophenyl)ethanone",3.2,uM,=,0.505149978319906,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)cc1)N1CCC1
4596,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCNc5ccccc5)c4)n[nH]c2-3)CC1,"N-(3-(4-(6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno-[1,2-c]pyrazol-3-yl)thiophen-2-yl)prop-2-ynyl)aniline",1.75,uM,=,0.2430380486862944,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)CNc1ccccc1
4597,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1CCc2cccnc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1,"1-{3-[4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-3,4-dihydro-1H-[1,8]naphthyridin-2-one",6.3,uM,=,0.7993405494535817,1,O=C1CCc2cccnc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
4598,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,O=C(c1cccc(Cl)c1Cl)N(C1CCCC1)[C@H]1CCNC1,"(S)-2,3-dichloro-N-cyclopentyl-N-(pyrrolidin-3-yl)benzamide",10.3,uM,=,1.0128372247051722,1,O=C(c1ccccc1)N(C1CCCC1)[C@H]1CCNC1
4599,980797,10.1021/jm4006324,,,,Inhibition of human ERG channel by electrophysiological method,Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCCCC2)n1,4-(1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyrimidin-2-amine,27.0,uM,=,1.4313637641589874,1,c1ccc(-c2ncn(C3CCCCC3)c2-c2ccncn2)cc1
4600,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CC[C@@H](O)[C@@H](N)C3)nn12,"(3S,4R)-3-Amino-1-(5-(4-fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-o",14.4,uM,=,1.1583624920952498,1,c1ccc(-c2cnc3sc(N4CCCCC4)nn23)cc1
4601,1934362,10.1016/j.bmcl.2016.07.061,,,,Inhibition of human ERG channel by automated patch clamp assay,CCc1c(-c2ccc(N3CCC(N(C)C)C3)cc2)[nH]c(=O)c2c(=O)[nH]sc12,"rac-6-(4-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)-7-ethylisothiazolo[4,5-c]pyridine-3,4(2H,5H)-dione",20.0,uM,=,1.3010299956639813,1,O=c1[nH]sc2cc(-c3ccc(N4CCCC4)cc3)[nH]c(=O)c12
4602,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CC1(C)CC(Nc2ccc(-c3ccc4ccccc4c3)nn2)CC(C)(C)N1,"6-(naphthalen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine",1.5,uM,=,0.1760912590556812,1,c1ccc2cc(-c3ccc(NC4CCNCC4)nn3)ccc2c1
4603,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3ccn(C(F)F)n3)cs2)CO1,"N-(2-((4aR,6S,8aR)-2-amino-6-methyl-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-8a-yl)thiazol-4-yl)-1-(difluoromethyl)-1H-pyrazole-3-carboxamide",9.3,uM,=,0.9684829485539352,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1cc[nH]n1
4604,699317,10.1016/j.bmc.2010.10.034,,,,Inhibition of human ERG,NCC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1,"Cis-2-((2S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine",13.1,uM,=,1.1172712956557642,1,c1ccc([C@@H]2CCCc3ccccc32)cc1
4605,755804,10.1021/jm2003359,,,,Inhibition of human ERG expressed in CHO cells by Q-patch assay,NCC(=O)N1CCn2c(nc(-c3ccccc3)c2Nc2ccc3c(c2)OCO3)C1,GNF-Pf-5069,19.0,uM,=,1.2787536009528289,1,c1ccc(-c2nc3n(c2Nc2ccc4c(c2)OCO4)CCNC3)cc1
4606,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,CCOc1cccc(-n2cc3nc(-c4cccnc4C)n(C[C@H]4CCCN(C[C@H]5CCCO5)C4)c(=O)c3n2)c1,"2-(3-ethoxyphenyl)-5-(2-methylpyridin-3-yl)-6-(((S)-1-(((R)-tetrahydrofuran-2-yl)methyl)piperidin-3-yl)methyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",14.0,uM,=,1.146128035678238,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2cccnc2)n1C[C@H]1CCCN(C[C@H]2CCCO2)C1
4607,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,Cc1ccccc1-c1nc2ccc(-c3ccc(Cl)cc3)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,(S)-6-(4-chlorophenyl)-3-((1-isopropylpiperidin-3-yl)methyl)-2-o-tolylquinazolin-4(3H)-one,8.7,uM,=,0.9395192526186184,1,O=c1c2cc(-c3ccccc3)ccc2nc(-c2ccccc2)n1C[C@H]1CCCNC1
4608,1617630,10.1021/acs.jmedchem.6b01217,,,,Inhibition of human ERG,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide,0.2,uM,=,-0.6989700043360187,0,c1ccc(CCNCCOc2ccccc2)cc1
4609,1442903,10.1016/j.bmcl.2014.08.008,,,,Inhibition of human ERG by patch clamp assay,C[C@H](CO)CONC(=O)c1ncc2cncn2c1Nc1ccc(I)cc1F,"(R)-5-(2-fluoro-4-iodophenylamino)-N-(3-hydroxy-2-methylpropoxy)imidazo[1,5-a]pyrazine-6-carboxamide",14.0,uM,=,1.146128035678238,1,c1ccc(Nc2cncc3cncn23)cc1
4610,1792104,10.1016/j.bmcl.2018.09.018,,,,Inhibition of human ERG,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,1.1,uM,=,0.041392685158225,1,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
4611,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,O=C1NCCN1CCN1CC=C(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,"1-(2-{4-[5-Chloro-1-(4-fluoro-phenyl)-1H-indol-3-yl]-3,6-dihydro-2H-pyridin-1-yl}-ethyl)-imidazolidin-2-one",0.01,uM,=,-2.0,0,O=C1NCCN1CCN1CC=C(c2cn(-c3ccccc3)c3ccccc23)CC1
4612,1926979,10.1021/acsmedchemlett.6b00119,,,,Displacement of [3H]dofetilide from recombinant human ERG transfected in HEK293 cell membranes after 60 mins by scintillation counting,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cc1C(F)(F)F,(3-(6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)quinazolin-4-yl)phenyl)(4-methylpiperazin-1-yl)methanone,1.6,uM,=,0.2041199826559248,1,O=C(c1cccc(-c2ncnc3ccc(-c4cccnc4)cc23)c1)N1CCNCC1
4613,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccccc3)cc1)C(=O)N2c1cc(O)ncn1,"3-(Biphenyl-4-yl)-8-[(3-methylpyridin-2-yl)methyl]-1-(6-hydroxypyrimidin-4-yl)-1,3,8-triazaspiro[4.5]decane-2,4-dione",0.22,uM,=,-0.6575773191777937,0,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
4614,1277482,10.1016/j.bmcl.2013.10.009,,,,Inhibition of human ERG flux,CN1Cc2cccc(Oc3ncccc3NC(=O)Nc3ccc(OC(F)(F)F)cc3)c2C1C(C)(C)C,1-(2-(3-tert-butyl-2-methylisoindolin-4-yloxy)pyridin-3-yl)-3-(4-(trifluoromethoxy)phenyl)urea,7.2,uM,=,0.8573324964312685,1,O=C(Nc1ccccc1)Nc1cccnc1Oc1cccc2c1CNC2
4615,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C,"tert-Butyl-(1-methyl-3,3-diphenyl-propyl)-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc(Cc2ccccc2)cc1
4616,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CCN1C[C@H](NS(=O)(=O)C(C)C)[C@@H](c2ccc(-c3cccc(NS(C)(=O)=O)c3)cc2)C1,"N-((3R,4R)-1-ethyl-4-(3'-(methylsulfonamido)biphenyl-4-yl)pyrrolidin-3-yl)propane-2-sulfonamide",2.5,uM,=,0.3979400086720376,1,c1ccc(-c2ccc([C@@H]3CCNC3)cc2)cc1
4617,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OCCO3)CC1)c1cc(=O)c2ccc(F)cc2o1,"N-[1-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide",0.0121999999999999,uM,=,-1.913640169325252,0,O=C(NC1CCN(Cc2ccc3c(c2)OCCO3)CC1)c1cc(=O)c2ccccc2o1
4618,796063,10.1016/j.bmcl.2011.11.050,,,,Inhibition of human ERG by patch express assay,O=S(=O)(c1cccc(F)c1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3,"(+/-)-7-(3-fluorophenylsulfonyl)-2',3,4,4',5',6'-hexahydro-2H-spiro[benzofuro[2,3-c]pyridine-1,3'-pyran]",12.0,uM,=,1.0791812460476249,1,O=S(=O)(c1ccccc1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3
4619,651377,10.1016/j.bmcl.2010.06.126,,,,Inhibition of human ERG,CC(C)N1C[C@H](C(=O)Nc2ccc(Cl)cn2)[C@@H](C(=O)Nc2ccc(-n3ccccc3=O)cc2F)C1,"(3R,4R)-N3-(5-chloropyridin-2-yl)-N4-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-1-isopropylpyrrolidine-3,4-dicarboxamide",12.0,uM,=,1.0791812460476249,1,O=C(Nc1ccc(-n2ccccc2=O)cc1)[C@H]1CNC[C@@H]1C(=O)Nc1ccccn1
4620,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,COc1ccc(Cn2ccc3nc(N)nc(NCc4cc(C)on4)c32)nc1OC,"5-((5,6-Dimethoxypyridin-2-yl)methyl)-N4-((5-methylisoxazol-3-yl)methyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine",0.7,uM,=,-0.1549019599857432,0,c1ccc(Cn2ccc3ncnc(NCc4ccon4)c32)nc1
4621,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,CCOc1cc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N,"4-ethoxy-6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)nicotinonitrile",11.0,uM,=,1.0413926851582251,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
4622,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,NC(=O)n1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4nccs4)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-3-(2-oxo-2-(1-(4-(thiazol-2-yl)cyclohexyl)azetidin-3-ylamino)ethylamino)-5-(trifluoromethyl)-1H-indazole-1-carboxamide,31.0,uM,=,1.4913616938342726,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3nccs3)CC2)C1
4623,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,N#Cc1ccc(Oc2ccc3nc(OCC(=O)N4CCNCC4)ccc3c2)cc1,4-[[2-(2-oxo-2-piperazin-1-yl-ethoxy)-6-quinolyl]oxy]benzonitrile,1.8,uM,=,0.255272505103306,1,O=C(COc1ccc2cc(Oc3ccccc3)ccc2n1)N1CCNCC1
4624,520038,10.1021/jm900364m,,,,Binding affinity to human ERG,COc1ccc(CC(C)(C)NC[C@H](O)COc2cccc3[nH]c(=O)[nH]c23)cc1,(S)-4-(2-hydroxy-3-(1-(4-methoxyphenyl)-2-methylpropan-2-ylamino)propoxy)-1H-benzo[d]imidazol-2(3H)-one,11.8,uM,=,1.0718820073061257,1,O=c1[nH]c2cccc(OCCCNCCc3ccccc3)c2[nH]1
4625,1622890,10.1021/acsmedchemlett.6b00433,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes after 90 mins by scintillation counting,FC(F)Oc1cc(-c2cnn(Cc3cc[nH]n3)c2)ccc1Cl,1-((1H-pyrazol-3-yl)methyl)-4-(4-chloro-3-(difluoromethoxy)phenyl)-1H-pyrazole,9.56,uM,=,0.9804578922761,1,c1ccc(-c2cnn(Cc3cc[nH]n3)c2)cc1
4626,1554580,10.1016/j.ejmech.2016.01.043,,,,Inhibition of human ERG expressed in CHO-K1 cells by patch clamp method,COc1ccccc1N1CCN(CCCCCC(=O)n2c3ccccc3c3ccccc32)CC1.Cl,1-(9H-carbazol-9-yl)-6-(4-(2-methoxyphenyl)piperazin-1-yl)hexan-1-one hydrochloride,2.83,uM,=,0.4517864355242902,1,O=C(CCCCCN1CCN(c2ccccc2)CC1)n1c2ccccc2c2ccccc21
4627,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,CCCCOc1cc(Cl)c(/N=N/c2c(O)ccc3ccccc23)c(OCCCC)c1,"1-((2,4-dibutoxy-6-chlorophenyl)diazenyl)naphthalen-2-ol",0.4,uM,=,-0.3979400086720376,0,c1ccc(/N=N/c2cccc3ccccc23)cc1
4628,1648279,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG by PatchXpress method,CC1(OC(=O)N2CCC([C@H]3C[C@H]3CCOc3ccc(CC(=O)N4CCC4)c(F)c3)CC2)CC1,"(cis)-1-methylcyclopropyl 4-((1R,2S)-2-(2-(4-(2-(azetidin-1-yl)-2-oxoethyl)-3-fluorophenoxy)ethyl)cyclopropyl)piperidine-1-carboxylate",8.6,uM,=,0.9344984512435676,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(C(=O)OC3CC3)CC2)cc1)N1CCC1
4629,1460449,10.1016/j.bmcl.2014.06.083,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by patch clamp method,CC(C(=O)O)c1ccc(CN2CCC(COC(=O)c3c4n(c5ccccc35)CCCO4)CC2)cc1,"2-[4-[[4-(3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyloxymethyl)-1-piperidinyl]methyl]phenyl]propanoic acid",25.0,uM,=,1.3979400086720375,1,O=C(OCC1CCN(Cc2ccccc2)CC1)c1c2n(c3ccccc13)CCCO2
4630,1875991,10.1021/acs.jmedchem.9b00444,,,,Inhibition of human ERG by in vitro patch clamp method,CNC(=O)c1cnc(Nc2ccc(C(F)(F)F)cn2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,"4-((2-Methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-methyl-6-((5-(trifluoromethyl)pyridin-2-yl)amino)nicotinamide",16.0,uM,=,1.2041199826559248,1,c1ccc(Nc2cc(Nc3cccc(-c4nc[nH]n4)c3)ccn2)nc1
4631,2027247,10.1021/acs.jmedchem.6b00850,,,,Inhibition of human ERG by electrophysiology assay,CC(C)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cc3)c2)c2c(N)ncnc21,"N-(5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)pyridin-3-yl)-2-(4-chlorophenyl)acetamide",7.8,uM,=,0.8920946026904804,1,O=C(Cc1ccccc1)Nc1cncc(C(=O)c2c[nH]c3ncncc23)c1
4632,803864,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by Qpatch assay,CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C,"5-(but-2-ynyl)-6-(1,4-diazepan-1-yl)-3-(isoquinolin-1-ylmethyl)-1-methyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",10.0,uM,=,1.0,1,O=c1[nH]c2cc(N3CCCNCC3)[nH]c2c(=O)n1Cc1nccc2ccccc12
4633,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(OC(F)(F)F)cn3)ccc2n1)N1CCNCC1,"US9452986, 431",12.8,uM,=,1.1072099696478683,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
4634,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@@]3(O)CO[C@@H]4[C@@H](NCc5ccc(C)cc5)CO[C@@H]43)c2n1,"(3R,3aS,6S,6aR)-3-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-6-(4-methylbenzylamino)hexahydrofuro[3,2-b]furan-3-ol",4.2,uM,=,0.6232492903979004,1,c1ccc(CN[C@H]2CO[C@@H]3C(CCc4ccnc5cccnc45)CO[C@H]23)cc1
4635,820094,10.1021/ml200199c,,,,Inhibition of human ERG by patch clamp assay,O=C(NCC(=O)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ncccn4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1,(S)-N-[2-(3-{trans-4-Hydroxy-4-[5-(pyrimidin-2-yl)pyridin-2-yl]cyclohexylamino}pyrrolidin-1-yl)-2-oxoethyl]-3-(trifluoromethyl)benzamide,20.0,uM,=,1.3010299956639813,1,O=C(NCC(=O)N1CC[C@H](NC2CCC(c3ccc(-c4ncccn4)cn3)CC2)C1)c1ccccc1
4636,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1nnc(-c2ccccc2Cl)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1,"(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)(4-(4-(pyrrolidin-1-ylmethyl)phenoxy)piperidin-1-yl)methanone",5.3,uM,=,0.724275869600789,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
4637,1545989,10.1021/acs.jmedchem.5b01227,,,,Inhibition of human ERG channel by automated Q-patch assay,CC(C)(C)c1cc(NC(=O)n2ccc3cc(Oc4ncnc5c4CCNC5)ccc32)no1,"5-(5,6,7,8-Tetrahydro-pyrido[3,4-d]pyrimidin-4-yloxy)-indole-1-carboxylic Acid (5-tert-Butyl-isoxazol-3-yl)-amide",7.0,uM,=,0.8450980400142568,1,O=C(Nc1ccon1)n1ccc2cc(Oc3ncnc4c3CCNC4)ccc21
4638,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccc(Cl)cc1Cl,"Ethyl 4-(2,4-dichlorophenyl)-6-(morpholinomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",0.3,uM,=,-0.5228787452803376,0,C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccccc1
4639,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCC[C@@H](CCO)Nc1nc(N)nc2ccccc12,(S)-3-((2-Aminoquinazolin-4-yl)amino)hexan-1-ol,6.8,uM,=,0.8325089127062363,1,c1ccc2ncncc2c1
4640,2264097,10.1021/acs.jmedchem.1c00703,,,,Inhibition of hERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp assay,COCCCN1CCC(c2nnc(-c3nn(C(C)C)c4ccccc34)o2)CC1.O=C(O)C(=O)O,"1-lsopropyl-3-[5-(1-(3-methoxypropyl)-piperidin-4-yl]-[1,3,4]-oxadiazol-2-yl]-1H-indazole oxalate",3.0,uM,=,0.4771212547196624,1,c1ccc2c(-c3nnc(C4CCNCC4)o3)n[nH]c2c1
4641,1935939,10.1016/j.bmc.2019.02.025,,,,Inhibition of human ERG by manual patch clamp electrophysiology assay,COc1cc(C(O)(CCN(C)C)C(c2cc3cc(Br)ccc3nc2OC)c2ccnc(OC)c2OC)cnc1OC,"rac-1-(6-bromo-2-methoxyquinolin-3-yl)-2-(5,6-dimethoxypyridin-3-yl)-1-(2,3-dimethoxypyridin-4-yl)-4-(dimethylamino)butan-2-ol",3.6,uM,=,0.5563025007672873,1,c1cncc(CC(c2ccncc2)c2cnc3ccccc3c2)c1
4642,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,CN(C)CCC1=C(Cc2cccnn2)c2ccc(Cl)cc2C1,"2-(6-chloro-3-(pyridazin-3-ylmethyl)-1H-inden-2-yl)-N,N-dimethylethanamine",0.22,uM,=,-0.6575773191777937,0,C1=C(Cc2cccnn2)c2ccccc2C1
4643,761736,10.1021/jm200401v,,,,Inhibition of recombinant human ERG channel expressed in human HEK 293 cells by patch clamp assay,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)n2)cc1,2-Methyl-6-[4-[3-((R)-2-methylpyrrolidin-1-yl)propoxy]-phenyl]-2H-pyridazin-3-one,13.0,uM,=,1.1139433523068367,1,O=c1ccc(-c2ccc(OCCCN3CCCC3)cc2)n[nH]1
4644,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(Cc2ccc3ccc(=O)oc3c2)CC1)c1cc(=O)c2ccc(F)cc2o1,7-fluoro-4-oxo-N-(1-((2-oxo-2H-chromen-7-yl)methyl)piperidin-4-yl)-4H-chromene-2-carboxamide,51.1,uM,=,1.7084209001347128,1,O=C(NC1CCN(Cc2ccc3ccc(=O)oc3c2)CC1)c1cc(=O)c2ccccc2o1
4645,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN(C)C)cc4)C3)o2)cc1,"(3-(4-((dimethylamino)methyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone",21.0,uM,=,1.3222192947339193,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccccc2)C1
4646,1366626,10.1021/jm500535j,,,,Inhibition of human ERG,Nc1nccn1CC(O)c1cccc(Cl)c1Cl,"rac-2-(2-Amino-1H-imidazol-1-yl)-1-(2,3-dichlorophenyl)ethanol",22.0,uM,=,1.3424226808222062,1,c1ccc(CCn2ccnc2)cc1
4647,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=NC(c2ccnc(C(F)(F)F)c2)(c2ccc(F)c(-c3cncnc3)c2)c2cccc(F)c21,rac-4-Fluoro-1-(4-fluoro-3-(pyrimidin-5-yl)phenyl)-1-(2-(trifluoromethyl)pyridin-4-yl)-1H-isoindol-3-amine,16.0,uM,=,1.2041199826559248,1,C1=NC(c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
4648,1554472,10.1021/acs.jmedchem.5b01372,,,,Binding affinity to human ERG channel,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1,N-{4-[2-((R)-2-Hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenyl}-4-[4-(4-trifluoromethyl-phenyl)-thiazol-2-yl]-benzenesulfonamide,0.22,uM,=,-0.6575773191777937,0,O=S(=O)(Nc1ccc(CCNCCc2cccnc2)cc1)c1ccc(-c2nc(-c3ccccc3)cs2)cc1
4649,534565,10.1016/j.bmc.2008.01.017,,,,Inhibition of human ERG potassium channel,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,"2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene",0.181,uM,=,-0.7423214251308154,0,c1ccc2c(c1)N=C(N1CCNCC1)c1ccsc1N2
4650,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cc(-c2ccc(O[C@@H]3CCN(C(=O)Cc4ccc(OC(F)(F)F)cc4)C3)c(C(N)=O)n2)cn1,(R)-6-(1-methyl-1H-pyrazol-4-yl)-3-(1-(2-(4-(trifluoromethoxy)phenyl)acetyl)pyrrolidin-3-yloxy)picolinamide,6.8,uM,=,0.8325089127062363,1,O=C(Cc1ccccc1)N1CC[C@@H](Oc2ccc(-c3cn[nH]c3)nc2)C1
4651,629418,10.1016/j.bmcl.2010.03.071,,,,Displacement of labeled dofetilide human ERG,O=C([C@H]1C[C@H](Oc2cccc(Cl)c2)CN1)N1CCCN(C2CCC2)CC1,"((2R,4S)-4-(3-chlorophenoxy)pyrrolidin-2-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methanone",7.2,uM,=,0.8573324964312685,1,O=C([C@H]1C[C@H](Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
4652,463271,10.1016/j.bmcl.2007.11.052,,,,Inhibition of human ERG,C[C@@H](Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12)C(=O)N1CCOCC1,(R)-2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)-1-morpholinopropan-1-one,10.0,uM,=,1.0,1,O=C(COc1cccc2ncnc(Nc3ccc(OCc4ccccn4)cc3)c12)N1CCOCC1
4653,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,O=C(CNc1ccnc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1,Cis-N-(1-(4-hydroxy-4-(thiazol-5-yl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinolin-4-ylamino)acetamide,11.2,uM,=,1.0492180226701815,1,O=C(CNc1ccnc2ccccc12)NC1CN(C2CCC(c3cncs3)CC2)C1
4654,1502030,10.1021/acs.jmedchem.5b00217,,,,Inhibition of human ERG,Cc1ncc(OC[C@@]2(c3ccccc3F)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1,"(1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(2-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide",5.9,uM,=,0.7708520116421442,1,O=C(Nc1ccccn1)[C@@H]1C[C@@]1(COc1cncnc1)c1ccccc1
4655,1617630,10.1021/acs.jmedchem.6b01217,,,,Inhibition of human ERG,COc1ccc2[nH]c3c(c2c1)C[C@H]1c2cc4c(cc2CCN1C3)OCO4,"(S)-2,3-Methylenedioxy-12-methoxy-5,8,14,14a-tetrahydro-6H-benzo[a]indolo[2,3-g]quinolizine",13.2,uM,=,1.1205739312058498,1,c1ccc2c3c([nH]c2c1)CN1CCc2cc4c(cc2[C@@H]1C3)OCO4
4656,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CCC(C)(N)CC3)nn12,"1-(5-(4-Fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-4-methylpiperidin-4-amine",2.4,uM,=,0.380211241711606,1,c1ccc(-c2cnc3sc(N4CCCCC4)nn23)cc1
4657,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ncns2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",12.3,uM,=,1.089905111439398,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ncns3)C4=O)ccc21
4658,1655138,10.1016/j.bmcl.2016.12.054,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in rapidly activating delayed rectifier cardiac potassium current by whole-cell voltage-patch clamp assay,O[C@@H](c1cccnc1-c1cc(Cl)cc(Cl)c1)C(c1cccnc1)c1cccnc1,"(R)-1-(2-(3,5-dichlorophenyl)pyridin-3-yl)-2,2-di(pyridin-3-yl)ethanol",128.0,uM,=,2.1072099696478683,1,c1ccc(-c2ncccc2CC(c2cccnc2)c2cccnc2)cc1
4659,499833,10.1016/j.bmcl.2009.04.022,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,C[C@@H]1CN(CCO)CCN1c1cc2[nH]c(SC(C)(C)C)nc2cc1Cl,(R)-2-(4-(2-(tert-butylthio)-5-chloro-1H-benzo[d]imidazol-6-yl)-3-methylpiperazin-1-yl)ethanol,1.6,uM,=,0.2041199826559248,1,c1nc2ccc(N3CCNCC3)cc2[nH]1
4660,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,N[C@@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-(((2S,3R)-3-aminooxetan-2-yl)methoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.3,uM,=,0.5185139398778875,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OC[C@@H]7CCO7)nc56)(CC3)OC4)nc2N1
4661,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)CCS(C)(=O)=O)C2,"1-(2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-3-(methylsulfonyl)propan-1-one",4.2,uM,=,0.6232492903979004,1,c1ccc(-c2nocc2COc2ccc3c(n2)CCNC3)cc1
4662,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Cc1nc([C@@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"3-((1S,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,2,4-oxadiazole",6.481,uM,=,0.811642021453151,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@](c4cn[nH]c4)(c4ncon4)N3)n2)nc1
4663,611894,10.1021/jm901650u,,,,Inhibition of human ERG,CC(C)OC(=O)C1=CN(C(=O)c2ccc(OCCCN3CCOCC3)cc2)CC(C)(C)c2c1[nH]c1ccccc21,"Isopropyl 1,1-Dimethyl-3-[4-(3-morpholin-4-ylpropoxy)benzoyl]-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate",5.74,uM,=,0.7589118923979735,1,O=C(c1ccc(OCCCN2CCOCC2)cc1)N1C=Cc2[nH]c3ccccc3c2CC1
4664,1680139,10.1021/acs.jmedchem.6b01647,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,Cn1c([S+](C)[O-])nc(-c2ccc(F)cc2)c1-c1ccnc(N)c1,4-(4-(4-fluorophenyl)-1-methyl-2-(methylsulfinyl)-1H-imidazol-5-yl)pyridin-2-amine,83.0,uM,=,1.919078092376074,1,c1ccc(-c2nc[nH]c2-c2ccncc2)cc1
4665,1886560,10.1021/acs.jmedchem.8b02021,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,4-[(5-{4-[(Z)-amino(imino)methyl]phenoxy}pentyl)oxy]benzenecarboximidamide,10.0,uM,=,1.0,1,c1ccc(OCCCCCOc2ccccc2)cc1
4666,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ccncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrimidin-4-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",22.0,uM,=,1.3424226808222062,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
4667,2024431,10.1021/acs.jmedchem.0c01245,,,,Inhibition of human ERG,C[C@H]1COCCN1c1c(NC(=O)Nc2cnc(OC3CCN(C)CC3)c(Cl)c2)cnc2ccc(F)cc12,(S)-1-(5-Chloro-6-((1-methylpiperidin-4-yl)oxy)pyridin-3-yl)-3-(6-fluoro-4-(3-methylmorpholino)quinolin-3-yl)urea,16.0,uM,=,1.2041199826559248,1,O=C(Nc1ccc(OC2CCNCC2)nc1)Nc1cnc2ccccc2c1N1CCOCC1
4668,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,CC(C)(C)c1cc(CN2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc(C(C)(C)C)c1,"1-(6,6-bis(4-fluorophenyl)hexyl)-4-(3,5-di-tert-butylbenzyl)piperazine",0.1,uM,=,-1.0,0,c1ccc(CN2CCN(CCCCCC(c3ccccc3)c3ccccc3)CC2)cc1
4669,1570617,10.1016/j.bmcl.2016.03.106,,,,Inhibition of human ERG,O=c1cnc2ccc(F)c3c2n1C[C@H]3CN1CCC(NCc2cc3c(nn2)OCCO3)CC1,"(R)-6-((4-((6,7-dihydro-[1,4]dioxino[2,3-c]pyridazin-3-yl)methylamino)piperidin-1-yl)methyl)-7-fluoro-5,6-dihydro-3H-pyrrolo[1,2,3-de]quinoxalin-3-one",42.0,uM,=,1.6232492903979006,1,O=c1cnc2cccc3c2n1C[C@H]3CN1CCC(NCc2cc3c(nn2)OCCO3)CC1
4670,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(C1CC(Oc2ccc(Cl)cc2)CN1)N1CCCN(C2CCC2)CC1,"(4-(4-chlorophenoxy)pyrrolidin-2-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methanone",2.0,uM,=,0.3010299956639812,1,O=C(C1CC(Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
4671,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,O=C(CNc1nn(CCO)c2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3ccc4c(c3)OCO4)CC2)C1,"cis-N-[1-(4-Benzo[1,3]dioxol-5-yl-cyclohexyl)-azetidin-3-yl]-2-[1-(2-hydroxy-ethyl)-5-trifluoromethyl-1H-indazol-3-ylamino]-acetamide",7.6,uM,=,0.8808135922807914,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccc4c(c3)OCO4)CC2)C1
4672,439396,10.1016/j.bmcl.2007.05.087,,,,Inhibition of human ERG potassium channel,N[C@H]1CN(c2ccc3nc(=O)ccn3n2)CC[C@@H]1c1cc(F)c(F)cc1F.O=C(O)C(F)(F)F,"(3R,4R)-1-(2-oxo-2H-pyrimido[1,2-b]pyridazin-7-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium 2,2,2-trifluoroacetate",100.0,uM,=,2.0,1,O=c1ccn2nc(N3CCC(c4ccccc4)CC3)ccc2n1
4673,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,Cn1c(NC2CCN(CCc3ccc(-c4nc(C(F)(F)F)no4)cc3)CC2)nc2ccccc21,"1-methyl-N-(1-(4-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)phenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine",0.86,uM,=,-0.0655015487564322,0,c1ccc2[nH]c(NC3CCN(CCc4ccc(-c5ncno5)cc4)CC3)nc2c1
4674,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,COc1ccc2c(c1C)C(=O)N(Cc1ccccc1-c1ccccc1)C2C(=O)NC(C)(C)C,(rac)-2-(biphenyl-2-ylmethyl)-N-tert-butyl-5-methoxy-4-methyl-3-oxoisoindoline-1-carboxamide,24.0,uM,=,1.380211241711606,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
4675,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,COCCN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"1-(3-Amino-1H-1,2,4-triazol-5-yl)-N-(4-chlorophenethyl)-N-(2-methoxyethyl)piperidin-4-amine",2.8,uM,=,0.4471580313422192,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
4676,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cncc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)n1,"endo-6-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)pyrazine-2-carboxamide",15.0,uM,=,1.1760912590556811,1,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2cnccn2)C3)cc1
4677,1348051,10.1016/j.bmcl.2014.03.075,,,,Inhibition of human ERG by Q-patch assay,N[C@H]1COCC[C@H]1Nc1cc2cc[nH]c(=O)c2c(Nc2cccc3cc[nH]c23)n1,"8-(1H-indol-7-ylamino)-6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-2,7-naphthyridin-1(2H)-one",24.9,uM,=,1.3961993470957363,1,O=c1[nH]ccc2cc(NC3CCOCC3)nc(Nc3cccc4cc[nH]c34)c12
4678,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1ncccc1C#N)c(=O)n2C,"(S)-6-(3-aminopiperidin-1-yl)-3-((3-cyanopyridin-2-yl)methyl)-1-methyl-5-(3-methylbut-2-enyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",16.9,uM,=,1.2278867046136734,1,O=c1[nH]c2cc(N3CCCCC3)[nH]c2c(=O)n1Cc1ccccn1
4679,421810,10.1016/j.bmcl.2006.10.053,,,,Inhibition of binding to hERG,CN(C)Cc1ccc2c(c1)CC[C@H](N(C)C(=O)c1ccc(-c3ccc(Cl)cn3)cc1)C2,"(S)-4-(5-chloropyridin-2-yl)-N-(6-((dimethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylbenzamide",14.0,uM,=,1.146128035678238,1,O=C(N[C@H]1CCc2ccccc2C1)c1ccc(-c2ccccn2)cc1
4680,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)COc1c(C(N)=O)cnc2ccc(-c3cccnc3)cc12,4-(2-Ethylbutoxy)-6-(3-pyridinyl)-3-quinolinecarboxamide,2.1,uM,=,0.3222192947339193,1,c1cncc(-c2ccc3ncccc3c2)c1
4681,2021863,10.1016/j.bmcl.2020.127433,,,,Inhibition of human ERG by plate-based planar patch clamp method,CNC(=O)c1nc(C)n2ccc(Nc3nccc(-n4cc([C@@H]5C[C@@H](F)CN5C)cn4)n3)cc12,"7-(4-(4-((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-N,3-dimethylimidazo[1,5-a]pyridine-1-carboxamide",10.0,uM,=,1.0,1,c1cc(-n2cc([C@@H]3CCCN3)cn2)nc(Nc2ccn3cncc3c2)n1
4682,554780,10.1016/j.bmcl.2008.05.036,,,,Displacement of [35S]MK499 from human ERG in HEK293 cell membrane,Cc1cccnc1-n1cc(CN2CCC3(CC2)OCc2ccccc23)c(C)n1,"1'-{[3-methyl-1-(3-methylpyridin-2-yl)-1H-pyrazol-4-yl]methyl}-3H-spiro[2-benzofuran-1,4'-piperidine]",13.0,uM,=,1.1139433523068367,1,c1ccc(-n2cc(CN3CCC4(CC3)OCc3ccccc34)cn2)nc1
4683,1648279,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG by PatchXpress method,COCc1cnc(N2CCC([C@H]3C[C@H]3CCOc3cc(F)c(CC(=O)N4CCC4)c(F)c3)CC2)nc1,"(cis)-1-(azetidin-1-yl)-2-(2,6-difluoro-4-(2-((1S,2R)-2-(1-(5-(methoxymethyl)pyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)phenyl)ethanone",12.0,uM,=,1.0791812460476249,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)cc1)N1CCC1
4684,2026007,10.1021/acsmedchemlett.0c00626,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,N#Cc1ccc(N2C3CCC2CN(C(=O)CCS(=O)(=O)c2cccc4ncsc24)C3)nc1,"6-(3-(3-(benzo[d]thiazol-7-ylsulfonyl)propanoyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)nicotinonitrile",5.6,uM,=,0.7481880270062004,1,O=C(CCS(=O)(=O)c1cccc2ncsc12)N1CC2CCC(C1)N2c1ccccn1
4685,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@H]1CN(C)C[C@@H]1c1ccc(-c2cccc(C(F)(F)F)c2)cc1,"N-((3R,4R)-1-methyl-4-(3'-(trifluoromethyl)biphenyl-4-yl)pyrrolidin-3-yl)propane-2-sulfonamide",4.0,uM,=,0.6020599913279624,1,c1ccc(-c2ccc([C@@H]3CCNC3)cc2)cc1
4686,819957,10.1021/ml200199c,,,,Displacement of [3H]dofetilide from human ERG,O=C(NCC(=O)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ccncc4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1,"(S)-N-(2-{3-[trans-4-(3,4'-Bipyridin-6-yl)-4-hydroxycyclohexylamino]pyrrolidin-1-yl}-2-oxoethyl)-3-(trifluoromethyl)benzamide",13.0,uM,=,1.1139433523068367,1,O=C(NCC(=O)N1CC[C@H](NC2CCC(c3ccc(-c4ccncc4)cn3)CC2)C1)c1ccccc1
4687,2048454,10.1016/j.bmc.2020.115734,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,COc1nc(-c2csc(Nc3c4c(nn3C(C)(C)C)CCCC4)n2)ccc1-n1cnc(C)c1,"N-(2-(tert-butyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",7.18,uM,=,0.8561244442423004,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCC5)n3)nc2)cn1
4688,745085,10.1016/j.bmcl.2011.02.049,,,,Displacement of [35S]MK499 from human ERG expressed in HEK cells,Cc1cccc([C@H]2CC[C@@H](CNC(=O)c3ccc(-c4nc5cc(C#N)cc(C(C)C)c5o4)cc3)CC2)c1,cis-4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((4-m-tolylcyclohexyl)methyl)benzamide,11.33,uM,=,1.0542299098633974,1,O=C(NC[C@H]1CC[C@@H](c2ccccc2)CC1)c1ccc(-c2nc3ccccc3o2)cc1
4689,2122463,10.1021/acs.jmedchem.1c00263,,,,Inhibition of human ERG,CCOC(=O)NC(=O)c1ccsc1NC(=O)c1ccc(C(=O)N2CCCCC2)cc1,Ethyl (2-(4-(Piperidine-1-carbonyl)benzamido)thiophene-3-carbonyl)carbamate,55.22726766098757,uM,=,1.74215355727203,1,O=C(Nc1cccs1)c1ccc(C(=O)N2CCCCC2)cc1
4690,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,O=C(NC1CCN(Cc2ccc(OCCCN3CCOCC3)c(F)c2)CC1)c1cc(=O)c2ccc(F)cc2o1,N-(1-(3-fluoro-4-(3-morpholinopropoxy)benzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,34.0,uM,=,1.5314789170422551,1,O=C(NC1CCN(Cc2ccc(OCCCN3CCOCC3)cc2)CC1)c1cc(=O)c2ccccc2o1
4691,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,O=C(Nc1ccc(C(F)(F)F)cc1)N1CCC(c2nc(-c3ccccn3)no2)CC1,"4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-N-(4-(trifluoromethyl)phenyl)piperidine-1-carboxamide",8.0,uM,=,0.9030899869919436,1,O=C(Nc1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1
4692,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCC2)c1,endo-3-(8-cyclohexyl-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.015,uM,=,-1.8239087409443189,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCC2)cc1
4693,1658369,10.1016/j.ejmech.2016.12.038,,,,Inhibition of human ERG expressed in CHO cells by Qpatch assay,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-2-methoxy-piperidin-4-yl}-2-methoxy-benzamide,0.15,uM,=,-0.8239087409443188,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
4694,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(CC)CC2)c1ncc(-c2cc3ccncc3nc2OC)o1,"(S)-6-ethyl-N-((S)-1-(5-(2-methoxy-1,7-naphthyridin-3-yl)oxazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide",40.0,uM,=,1.6020599913279625,1,O=C(NCc1ncc(-c2cnc3cnccc3c2)o1)[C@H]1CC12CCNCC2
4695,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@@H]2CN3CCN(C(=O)Cc4cnc(-n5cnnn5)cn4)C[C@H]3CO2)ccc(F)c1C#N,"3-((3R,9aS)-8-(2-(5-(1H-tetrazol-1-yl)pyrazin-2-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-6-fluoro-2-methylbenzonitrile",10.0,uM,=,1.0,1,O=C(Cc1cnc(-n2cnnn2)cn1)N1CCN2C[C@@H](c3ccccc3)OC[C@@H]2C1
4696,1988642,10.1021/acs.jmedchem.0c00909,,,,Inhibition of human ERG,Cc1cc(N2C[C@H]3CC[C@@H](C2)[C@@H]3Nc2nc3c(OCC(F)(F)F)cccn3n2)sn1,"N-((1R,5S,8r)-3-(3-Methylisothiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl)-8-(2,2,2-trifluoroethoxy)-[1,2,4]triazolo[1,5-a]pyridin-2-amine",2.9,uM,=,0.4623979978989561,1,c1ccn2nc(N[C@@H]3[C@@H]4CC[C@H]3CN(c3ccns3)C4)nc2c1
4697,816614,10.1016/j.bmcl.2012.03.032,,,,Inhibition of human ERG by electrophysiology assay,c1ccc(-n2cc(-c3ccnc4ccccc34)cn2)cc1,4-(1-phenyl-1H-pyrazol-4-yl)quinoline,2.5,uM,=,0.3979400086720376,1,c1ccc(-n2cc(-c3ccnc4ccccc34)cn2)cc1
4698,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CCc1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@@H]2CCO)n1,"2-(3-Ethyl-[1,2,4]triazol-1-yl)-1-((S)-2-(2-hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-ethanone",0.027,uM,=,-1.5686362358410126,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
4699,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CCC(Oc4ccc(CN5CCCC5)cc4)CC3)o2)cc1,"(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)(4-(4-(pyrrolidin-1-ylmethyl)phenoxy)piperidin-1-yl)methanone",11.0,uM,=,1.0413926851582251,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
4700,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2cc3c(cc2F)ncc2c3n(C3CCOCC3)c(=O)n2C)cn1,"7-Fluoro-8-(6-(methoxymethyl)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",27.0,uM,=,1.4313637641589874,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCOCC1
4701,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,Cn1c(=O)n(C2CCOCC2)c2c3cc(-c4cccnc4)ccc3ncc21,"3-Methyl-8-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",11.0,uM,=,1.0413926851582251,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCOCC1
4702,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1ncc3ccccc3c1C#N)c(=O)n2C,"3-((5-(but-2-ynyl)-7-cyano-6-(1,4-diazepan-1-yl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)methyl)isoquinoline-4-carbonitrile",12.0,uM,=,1.0791812460476249,1,O=c1[nH]c2cc(N3CCCNCC3)[nH]c2c(=O)n1Cc1cc2ccccc2cn1
4703,465697,10.1021/jm701187w,,,,Inhibition of human ERG potassium current expressed in HEK293 cells by patch-clamp technique,Cc1cc(C)n(-c2cc(NC(=O)CCN(C)C)nc(-c3ccc(C)o3)n2)n1,"3-dimethylamino-N-[6-(3,5-dimethylpyrazol-1-yl)-2-(5-meth ylfuran-2-yl)pyrimidin-4-yl]propionamide",0.65,uM,=,-0.1870866433571444,0,c1coc(-c2nccc(-n3cccn3)n2)c1
4704,1545989,10.1021/acs.jmedchem.5b01227,,,,Inhibition of human ERG channel by automated Q-patch assay,C[C@H]1Cc2c(ncnc2Oc2ccc3c(ccn3C(=O)Nc3cccc(C(F)(F)F)c3)c2)CN1,"(S)-5-((6-Methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-oxy)-N-(3-(trifluoromethyl)phenyl)-1H-indole-1-carboxamide",10.7,uM,=,1.0293837776852095,1,O=C(Nc1ccccc1)n1ccc2cc(Oc3ncnc4c3CCNC4)ccc21
4705,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3ccc(C4CC4)nc3cc2OC)[nH]1,(S)-N-((S)-1-(5-(2-cyclopropyl-7-methoxyquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,11.0,uM,=,1.0413926851582251,1,O=C(NCc1ncc(-c2ccc3nc(C4CC4)ccc3c2)[nH]1)[C@H]1CC12CCNCC2
4706,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,CC(c1ccccc1)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,endo-3-(8-(1-phenylethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.006,uM,=,-2.2218487496163566,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
4707,304964,10.1016/j.bmcl.2004.09.065,,,,Inhibitory activity against human Potassium channel HERG,NCc1ccc(F)c(C2CCN(C(=O)c3cc(C(N)=O)cc(-c4nc(-c5cccs5)no4)c3)CC2)c1,"3-[4-(5-Aminomethyl-2-fluoro-phenyl)-piperidine-1-carbonyl]-5-(3-thiophen-2-yl-[1,2,4]oxadiazol-5-yl)-benzamide",17.1,uM,=,1.2329961103921538,1,O=C(c1cccc(-c2nc(-c3cccs3)no2)c1)N1CCC(c2ccccc2)CC1
4708,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCN(CC(O)c3cc(C(F)(F)F)c(C#N)cn3)CC2)ccc2c1COC2=O,"6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-(trifluoromethyl)nicotinonitrile",4.8,uM,=,0.6812412373755872,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
4709,1292641,10.1021/jm401760c,,,,Binding affinity to full length human ERG expressed in CHO cells after 6 to 7 mins by IonWorks assay,CNc1nc(NCCCN(C)C)c2sc(-c3ccc(OC)nc3)cc2n1,"N4-(3-(dimethylamino)propyl)-6-(6-methoxypyridin-3-yl)-N2-methylthieno[3,2-d]pyrimidine-2,4-diamine",6.8,uM,=,0.8325089127062363,1,c1cncc(-c2cc3ncncc3s2)c1
4710,1744232,10.1021/acs.jmedchem.6b01703,,,,Displacement of [3H]dofetilide from recombinant human ERG expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting method,CCc1nn2c(C)cc(C)nc2c1Cc1ccc(CCC(=O)N2CCNCC2)cc1,"3-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-1-(piperazin-1-yl)propan-1-one",23.0,uM,=,1.3617278360175928,1,O=C(CCc1ccc(Cc2cnn3cccnc23)cc1)N1CCNCC1
4711,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N3CCOC[C@@H]3Cc3ccc(Cl)cc3)CC2)n1,"(S)-5-(4-(3-(4-Chlorobenzyl)morpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",39.0,uM,=,1.591064607026499,1,c1ccc(C[C@H]2COCCN2C2CCN(c3ncn[nH]3)CC2)cc1
4712,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCN(C(=O)[C@H](C)N)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"(2S)-2-amino-1-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)piperazin-1-yl)propan-1-one",9.4,uM,=,0.9731278535996988,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
4713,2057776,10.1016/j.ejmech.2020.113103,,,,Inhibition of fluorescence tracer red binding to human ERG measured after 4 hrs by fluorescence polarization assay,Cl.O=S(=O)(/C=C/c1ncccc1F)c1ccc(OCCCN2CCOCC2)cc1,(E)-4-(3-(4-(2-(3'-fluoropyridin-2'-yl)vinylsulfonyl)phenoxy)propyl)morpholine Hydrochloride,112.0,uM,=,2.049218022670181,1,O=S(=O)(/C=C/c1ccccn1)c1ccc(OCCCN2CCOCC2)cc1
4714,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COC(=O)c1c(C)noc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-methyl 3-methyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)isoxazole-4-carboxylate,6.0,uM,=,0.7781512503836436,1,c1cc(-c2ccc3cc(CCN4CCCC4)ccc3n2)on1
4715,2084867,10.1021/acs.jmedchem.6b00943,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated Qpatch electrophysiological assay,Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C#Cc1nn([C@@H]2CCN(C)C2)c2ncnc(N)c12,"(R)-N-(3-((4-amino-1-(1-methylpyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide",0.68,uM,=,-0.1674910872937636,0,O=C(Nc1cccc(C#Cc2nn([C@@H]3CCNC3)c3ncncc23)c1)c1ccccc1
4716,1517213,10.1021/acs.jmedchem.5b01156,,,,Inhibition of human ERG expressed in CHO cells by patch clamp electrophysiology assay,Nc1nc(N2CCC(N)CC2)c2sc(-c3ccc(C(F)(F)F)cc3)cc2n1,"4-(4-aminopiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidin-2-amine",6.1,uM,=,0.785329835010767,1,c1ccc(-c2cc3ncnc(N4CCCCC4)c3s2)cc1
4717,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CC(C)CNC(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1,"N-Isobutyl-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide",3.19,uM,=,0.5037906830571811,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
4718,2217382,10.1021/acs.jmedchem.1c02141,,,,Inhibition of hERG,C[C@@H](N)c1cc(Cl)ccc1Cn1c(=S)[nH]c(=O)c2[nH]ccc21,MITIPERSTAT,21.0,uM,=,1.3222192947339193,1,O=c1[nH]c(=S)n(Cc2ccccc2)c2cc[nH]c12
4719,1435893,10.1016/j.bmc.2014.10.020,,,,Inhibition of human ERG expressed in CHO cells by Rb efflux assay,O=C(CNCC1(O)CCCCC1)N1CCc2ccccc2[C@@H]1C1CCCCC1,"(1S)-(1-Cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-{[(1-hydroxycyclohexyl)methyl]amino}ethanone",98.0,uM,=,1.9912260756924949,1,O=C(CNCC1CCCCC1)N1CCc2ccccc2[C@@H]1C1CCCCC1
4720,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-n3cccn3)cc1)C(=O)N2c1cc(O)ncn1,"1-(6-Hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-3-(4-pyrazol-1-yl-phenyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",9.0,uM,=,0.9542425094393248,1,O=C1N(c2ccc(-n3cccn3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
4721,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1CCc2ccccc2N1OCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1,"1-{2-[4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-ethoxy}-3,4-dihydro-1H-quinolin-2-one",9.3,uM,=,0.9684829485539352,1,O=C1CCc2ccccc2N1OCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
4722,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3csc4ccccc34)nn2)ccc1-n1cnc(C)c1,"1-(benzo[b]thiophen-3-ylmethyl)-4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazole",2.15,uM,=,0.3324384599156053,1,c1ccc2c(Cn3cc(-c4ccc(-n5ccnc5)cc4)nn3)csc2c1
4723,726964,10.1016/j.bmcl.2011.01.019,,,,Inhibition of human ERG,CC(N(C)C)C1(c2ccc3ccccc3c2)CCCCC1,"(+/-)-N,N-dimethyl-1-(1-(naphthalen-2-yl)cyclohexyl)ethanamine",4.3,uM,=,0.6334684555795865,1,c1ccc2cc(C3CCCCC3)ccc2c1
4724,804476,10.1016/j.bmcl.2012.01.026,,,,Inhibition of human Erg by patch clamp assay,O=c1ccc(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)n[nH]1,6-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)pyridazin-3(2H)-one,8.0,uM,=,0.9030899869919436,1,O=c1ccc(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)n[nH]1
4725,2246303,10.1021/acs.jmedchem.1c01670,,,,Inhibition of MK-499 binding to hERG,O=C(Nc1ccc(C2(C(=O)Nc3ccc(F)cc3)COC2)cc1)c1cccc(Cl)c1,3-(4-(3-chlorobenzamido)phenyl)-N-(4-fluorophenyl)oxetane-3-carboxamide,9094.0,uM,=,3.9587549498690895,1,O=C(Nc1ccc(C2(C(=O)Nc3ccccc3)COC2)cc1)c1ccccc1
4726,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,Cc1nc(C)n(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C4CC4)nc3)C[C@H]2C)n1,"1-{(R)-4-[4-(2-Cyclopropyl-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-2-(3,5-dimethyl-[1,2,4]-triazol-1-yl)-ethanone",13.0,uM,=,1.1139433523068367,1,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cnc(C3CC3)nc2)CC1
4727,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CCO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)(C(C)C)C1,"cis-((1S,3R)-3-((3S,4S)-3-ethoxytetrahydro-2H-pyran-4-ylamino)-1-isopropylcyclopentyl)(4-(4-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methanone",8.6,uM,=,0.9344984512435676,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2ccccn2)CC1
4728,2278023,10.1021/acs.jmedchem.2c01517,,,,Inhibition of human ERG channel expressed in HEK293 cells clamped at -80 mV stimulated +20 mV for 2 sec followed by repolarized to -50 mV for 5 secs by electrophysiological analysis,COc1cc2nc(C)nc(N[C@H](C)c3cc(N)cc(C(F)(F)F)c3)c2cc1O[C@H]1CCOC1,N-((R)-1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)-7-methoxy-2-methyl-6-((S)-tetrahydrofuran-3-yloxy)quinazolin-4-amine,1.4,uM,=,0.1461280356782379,1,c1ccc(CNc2ncnc3ccc(O[C@H]4CCOC4)cc23)cc1
4729,819957,10.1021/ml200199c,,,,Displacement of [3H]dofetilide from human ERG,O=C(C1CCN(c2cccc(C(F)(F)F)c2)CC1)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ncccn4)cn3)CC2)C1,(S)-(3-{trans-4-Hydroxy-4-[5-(pyrimidin-2-yl)pyridin-2-yl]cyclohexylamino}pyrrolidin-1-yl){1-[3-(trifluoromethyl)phenyl]piperidin-4-yl}methanone,9.0,uM,=,0.9542425094393248,1,O=C(C1CCN(c2ccccc2)CC1)N1CC[C@H](NC2CCC(c3ccc(-c4ncccn4)cn3)CC2)C1
4730,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(CCS(C)(=O)=O)C2=O,"2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-6-(2-(methylsulfonyl)ethyl)-7,8-dihydro-1,6-naphthyridin-5(6H)-one",1.1,uM,=,0.041392685158225,1,O=C1NCCc2nc(OCc3conc3-c3ccccc3)ccc21
4731,1898259,10.1016/j.bmcl.2019.126643,,,,Inhibition of human ERG,CCNC(=O)[C@H]1C[C@H](OC)[C@@]2(C)CC[C@@H]3c4ccc(OCCCN5CCC[C@H]5C)cc4CC[C@H]3[C@H]12,"(8R,9S,13S,14R,15S,17S)-N-ethyl-17-methoxy-13-methyl-3-(3-((R)-2-methylpyrrolidin-1-yl)propoxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-15-carboxamide",11.4,uM,=,1.0569048513364727,1,c1cc2c(cc1OCCCN1CCCC1)CC[C@@H]1[C@@H]2CCC2CCC[C@H]21
4732,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2c1ccnc(C(F)(F)F)n1,"(R)-4-fluoro-N-(1-(5-(2-(trifluoromethyl)pyrimidin-4-yl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)benzamide",25.0,uM,=,1.3979400086720375,1,O=C(NCc1ccc2c(n1)CCCN2c1ccncn1)c1ccccc1
4733,1452362,10.1016/j.ejmech.2014.08.027,,,,Inhibition of human ERG expressed in CHO-K1 cells by whole cell patch-clamp assay,COc1ccc(-n2cnc3c(-c4ccccc4)csc3c2=O)cc1,"3-(4-Methoxyphenyl)-7-phenylthieno[3,2-d]pyrimidin-4(3H)-one",10.8,uM,=,1.0334237554869496,1,O=c1c2scc(-c3ccccc3)c2ncn1-c1ccccc1
4734,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CCN(CC(F)(F)F)CC1,"US9452986, 181",18.9,uM,=,1.276461804173244,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
4735,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)C1CCS(=O)(=O)CC1)C2,"4-(2-((3-(4-Fluorophenyl)-5-methyl-1,2-oxazol-4-yl)methoxy)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)-1,6-thiane-1,1-dione",2.9,uM,=,0.4623979978989561,1,O=C(C1CCS(=O)(=O)CC1)N1CCc2nc(OCc3conc3-c3ccccc3)ccc2C1
4736,1833863,10.1021/acsmedchemlett.8b00414,,,,Inhibition of human ERG by patch clamp method,CC1=C(c2cccc(O)c2)[C@H](c2ccc(OCCN3CC(CF)C3)cc2)Oc2ccc(O)cc21,(S)-2-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-chromen-6-ol,4.6,uM,=,0.6627578316815741,1,C1=C(c2ccccc2)[C@H](c2ccc(OCCN3CCC3)cc2)Oc2ccccc21
4737,460777,10.1021/jm070637u,,,,Inhibition of hERG potassium channel expressed in CHO cells by isotope efflux assay,Cc1cccc(NC(=N)c2ccc(-c3ccc(Cl)cc3)o2)c1.Cl,5-(4-chlorophenyl)-N-(3-methylphenyl)furan-2-carboxamidine hydrochloride,2.1,uM,=,0.3222192947339193,1,N=C(Nc1ccccc1)c1ccc(-c2ccccc2)o1
4738,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,COCc1cncc(-c2ccc3[nH]nc(C(=O)NCC4CCOCC4)c3c2)c1,5-(5-(Methoxymethyl)pyridin-3-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-3-carboxamide,5.7,uM,=,0.7558748556724915,1,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cccnc3)cc12
4739,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(F)ccc3OC[C@H]2[C@@]1(CCCN1CCOCC1)c1ccccc1,"1-[(3R,3aR)-8-fluoro-3-(3-morpholin-4-yl-propyl)-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-2-yl]-ethanone",6.1,uM,=,0.785329835010767,1,C1=NN2c3ccccc3OC[C@H]2[C@@]1(CCCN1CCOCC1)c1ccccc1
4740,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,CN(C)C/C=C/C(=O)N1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc([N+](=O)[O-])c4)c3c2)CC1,4-(dimethylamino)-1-(4-(5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinolin-3-yl)piperazin-1-yl)but-2-en-1-one,92.1,uM,=,1.964259630196849,1,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
4741,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1,[4-(4-Chloro-phenyl)-butyl]-diethyl-heptyl-ammonium,0.15,uM,=,-0.8239087409443188,0,c1ccccc1
4742,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2c1OC(c1ccc(OCCCN3CCC[C@H]3C)cc1)C(C)S2(=O)=O,"(+/-)-(R)-1-{3-[4-(8-Methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-2-methyl-pyrrolidine",2.9,uM,=,0.4623979978989561,1,O=S1(=O)CC(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
4743,1648277,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncc(Cl)cn3)CC2)cc1F)N1CCCCC1,"(cis)-2-(4-(2-((1S,2R)-2-(1-(5-chloropyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)-2-fluorophenyl)-1-(piperidin-1-yl)ethanone",3.3,uM,=,0.5185139398778875,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)cc1)N1CCCCC1
4744,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CC(C)c1ncc([C@H]2CC[C@@H](N3CC(NC(=O)CNc4nn(C)c5ccc(C(F)(F)F)cc45)C3)CC2)s1,cis-N-{1-[4-Hydroxy-4-(2-isopropyl-thiazol-5-yl)-cyclohexyl]-azetidin-3-yl}-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,17.0,uM,=,1.230448921378274,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3cncs3)CC2)C1
4745,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2cc(CC(=O)N3CCN(CCc4ccc([N+](=O)[O-])cc4)CC3)ccc21,5-(2-(4-(4-nitrophenethyl)piperazin-1-yl)-2-oxoethyl)isobenzofuran-1(3H)-one,1.3,uM,=,0.1139433523068367,1,O=C1OCc2cc(CC(=O)N3CCN(CCc4ccccc4)CC3)ccc21
4746,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,FC(F)Oc1ccccc1CC(c1ccccc1)N1CCNCC1,1-(2-(2-(difluoromethoxy)phenyl)-1-phenylethyl)piperazine,12.7,uM,=,1.1038037209559568,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
4747,1765499,10.1021/acs.jmedchem.8b01040,,,,Displacement of [3H]dofetilide from human ERG by high throughput assay,O=C(Nc1ccc(OC(F)(F)F)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cncnc2)c1,"US9278981, 35",17.0,uM,=,1.230448921378274,1,O=C(Nc1ccccc1)c1cnc(N2CCCC2)c(-c2cncnc2)c1
4748,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,C[C@H]1C=C(C2=Nc3cc(Cl)ccc3Nc3ccc(Cl)cc32)CCN1C,"(S)-2,8-dichloro-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepine",0.9,uM,=,-0.0457574905606751,0,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
4749,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COCCN1CCC[C@@H](Cn2c(-c3ccccc3C)nc3cc(-c4ccc(Cl)cc4)sc3c2=O)C1,"6-(4-Chlorophenyl)-3-{[(3R)-1-(2-methoxyethyl)piperidin-3-yl]methyl}-2-(2-methylphenyl)thieno[3,2-d]pyrimidin-4(3H)-one",2.1,uM,=,0.3222192947339193,1,O=c1c2sc(-c3ccccc3)cc2nc(-c2ccccc2)n1C[C@@H]1CCCNC1
4750,499526,10.1016/j.bmcl.2009.02.041,,,,Inhibition of human ERG by patch-clamp technique,O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1,"cis-(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone",126.0,uM,=,2.100370545117563,1,O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCCC1
4751,1541589,10.1039/C4MD00578C,,,,Inhibition of human ERG,O=S(=O)(c1ccc(C(F)(F)F)cc1)N1CCC(CN2CCC(c3noc4cc(F)ccc34)CC2)CC1,6-Fluoro-3-(1-((1-((4-(trifluoromethyl)phenyl)sulfonyl)piperidin-4-yl)methyl)piperidin-4-yl)benzo[d]isoxazole,1.3901,uM,=,0.1430460433375877,1,O=S(=O)(c1ccccc1)N1CCC(CN2CCC(c3noc4ccccc34)CC2)CC1
4752,647318,10.1016/j.bmcl.2010.06.069,,,,Inhibition of human hERG,NC(=O)c1cnc(-c2cnc3c(Nc4ccc(C(F)(F)F)cn4)ccnc3n2)c(C(F)(F)F)c1,"5-(trifluoromethyl)-6-(8-(5-(trifluoromethyl)pyridin-2-ylamino)pyrido[2,3-b]pyrazin-3-yl)nicotinamide",5.9,uM,=,0.7708520116421442,1,c1ccc(Nc2ccnc3nc(-c4ccccn4)cnc23)nc1
4753,2247004,10.1021/acs.jmedchem.1c02132,,,,Inhibition of human ERG by patch clamp assay,CC(C)C[C@](C)(N)COc1cnc(-c2ccnc(C(F)F)c2)cc1C(F)F,"(S)-1-((2',4-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine",1.3,uM,=,0.1139433523068367,1,c1ccc(-c2ccncc2)nc1
4754,2079118,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 1 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),O=C(COc1ccc(C(=O)c2cc(Cl)ccc2Br)cc1)Nc1cncc(C(=O)NCC2CC2)c1,5-(2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)acetamido)-N-(cyclopropylmethyl)nicotinamide,0.0195,uM,=,-1.709965388637482,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1cncc(C(=O)NCC2CC2)c1
4755,1573848,10.1016/j.ejmech.2016.02.039,,,,Inhibition of human ERG assessed as reduction in channel current by automated patch-clamp electrophysiology assay,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,0.00331,uM,=,-2.480172006224281,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
4756,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,O=C(N[C@H]1CCN(C2CCCCC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccc(F)cc2F)on1,"(3S,4S)-1-Cyclohexyl-4-([5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino)piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide",2.6,uM,=,0.414973347970818,1,O=C(N[C@H]1CCN(C2CCCCC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccccc2)on1
4757,699709,10.1016/j.bmcl.2010.11.111,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells,COc1cc(/C=C/c2nc3ccccc3c(=O)n2-c2ccccc2)ccc1-n1cnc(C)c1,2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)styryl)-3-phenylquinazolin-4(3H)-one,0.99,uM,=,-0.00436480540245,0,O=c1c2ccccc2nc(/C=C/c2ccc(-n3ccnc3)cc2)n1-c1ccccc1
4758,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1nc(-c2ccccc2)no1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1,"(3-phenyl-1,2,4-oxadiazol-5-yl)(4-(4-(pyrrolidin-1-ylmethyl)phenoxy)piperidin-1-yl)methanone",1.8,uM,=,0.255272505103306,1,O=C(c1nc(-c2ccccc2)no1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
4759,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2c1OC(c1ccc(OCCCN3CCC[C@@H]3C)cc1)C(C)S2(=O)=O,"(+/-)-(S)-1-{3-[4-(8-Methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-2-methyl-pyrrolidine",3.8,uM,=,0.5797835966168101,1,O=S1(=O)CC(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
4760,538846,10.1021/jm800830n,,,,Inhibition of human ERG,O=C(NCC1CCN(Cc2cccc(C(F)(F)F)c2)CC1)c1cc(Cl)cc(Cl)c1,"3,5-dichloro-N-({1-[3-(trifluoromethyl)benzyl]piperidin-4-yl}methyl)benzamide",0.483,uM,=,-0.3160528692484878,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
4761,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,CCN(c1ncc(C(N)=O)c2sc(-c3ccccc3)cc12)[C@H]1CCCNC1,"4-{Ethyl[(3S)-piperidin-3-yl]amino}-2-phenylthieno[3,2-c]-pyridine-7-carboxamide",2.4,uM,=,0.380211241711606,1,c1ccc(-c2cc3c(N[C@H]4CCCNC4)nccc3s2)cc1
4762,627338,10.1016/j.bmcl.2010.03.005,,,,Inhibition of human ERG,COCCN(C)C(c1ccccc1)C(O)(c1cccnc1)c1cccnc1,"2-((2-methoxyethyl)(methyl)amino)-2-phenyl-1,1-di(pyridin-3-yl)ethanol",3.45,uM,=,0.5378190950732742,1,c1ccc(CC(c2cccnc2)c2cccnc2)cc1
4763,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CCN1CCO[C@@H](CN2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"(S)-N-(3,4-dichlorophenyl)-4-((4-ethylmorpholin-2-yl)methyl)piperazine-1-carboxamide",7.9,uM,=,0.8976270912904415,1,O=C(Nc1ccccc1)N1CCN(C[C@H]2CNCCO2)CC1
4764,857606,10.1021/ml2002604,,,,Inhibition of human recombinant hERG expressed in CHO cells by automated patch clamp assay,Cc1cc(Cl)nc(C)c1C(=O)NCC[C@@H](C)N1CCC(N(Cc2ccsc2)C(=O)CC#N)CC1,"(R)-6-Chloro-N-(3-(4-(2-cyano-N-(thiophen-3-ylmethyl)acetamido)piperidin-1-yl)butyl)-2,4-dimethylnicotinamide",16.0,uM,=,1.2041199826559248,1,O=C(NCCCN1CCC(NCc2ccsc2)CC1)c1cccnc1
4765,1365780,10.1021/jm5005978,,,,Inhibition of human ERG by medium-throughput electrophysiology,Cc1onc(C(=O)N2[C@@H]3CC[C@H]2C[C@@H](Nc2cc(=O)n(C)c4cc(F)c(F)cc24)C3)c1C,"4-((3-endo-8-((4,5-Dimethyl-1,2-oxazol-3-yl)carbonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)-6,7-difluoro-1-methylquinolin-2(1H)-one",16.0,uM,=,1.2041199826559248,1,O=C(c1ccon1)N1[C@@H]2CC[C@H]1C[C@@H](Nc1cc(=O)[nH]c3ccccc13)C2
4766,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCN(C(=O)[C@@H](C)O)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"(2R)-1-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)piperazin-1-yl)-2-hydroxypropan-1-one",15.0,uM,=,1.1760912590556811,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
4767,1789491,10.1021/acs.jmedchem.8b01533,,,,Inhibition of human ERG expressed in CHO-S1 cells by automated planar chip-based electrophysiology,FC(F)(F)Oc1ccc(Oc2ccc(N3CCC4(CC3)OCCc3sccc34)cc2)cc1,"1-(4-(4-(Trifluoromethoxy)phenoxy)phenyl)-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran]",10.0,uM,=,1.0,1,c1ccc(Oc2ccc(N3CCC4(CC3)OCCc3sccc34)cc2)cc1
4768,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,CC(=O)c1nn(-c2ccc(Cl)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1,"2-((5-Acetyl-3-(4-chlorophenyl)-1,3,4-thiadiazol-2(3H)-ylidene)amino)-4,6-diphenylnicotinonitrile",11.5,uM,=,1.0606978403536118,1,c1ccc(-c2cc(/N=c3\scnn3-c3ccccc3)nc(-c3ccccc3)c2)cc1
4769,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3ccc(COC)cc3)cc12,4-[(2-Ethylbutyl)amino]-6-[4-(methoxymethyl)phenyl]-3-quinolinecarboxamide,18.0,uM,=,1.255272505103306,1,c1ccc(-c2ccc3ncccc3c2)cc1
4770,1475773,10.1021/jm5017413,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch-clamp assay,Cc1csc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(4-methylthiazol-2-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",17.0,uM,=,1.230448921378274,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2nccs2)C1
4771,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C(NC(c1ccc(F)cc1)c1ccc(F)cc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1,"(1R,2R,4R)-N-(bis(4-fluorophenyl)methyl)-2-(4-bromophenyl)-4-morpholinocyclohexanecarboxamide",0.1,uM,=,-1.0,0,O=C(NC(c1ccccc1)c1ccccc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
4772,811343,10.1016/j.bmcl.2012.01.095,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1cc(N[C@H](CCCCNCc2ccc(F)cc2)C(=O)NO)cc(C)c1F,"(R)-2-(4-fluoro-3,5-dimethylphenylamino)-6-(4-fluorobenzylamino)-N-hydroxyhexanamide",1.23,uM,=,0.0899051114393979,1,c1ccc(CNCCCCCNc2ccccc2)cc1
4773,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nc(CC(=O)OC)cs2)=NC1c1ccc(F)cc1Br,"Ethyl 4-(2-bromo-4-fluorophenyl)-2-(4-(2-methoxy-2-oxoethyl)thiazol-2-yl)-6-(morpholinomethyl)-1,4-dihydropyrimidine-5-carboxylate",1.64,uM,=,0.2148438480476978,1,C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccccc1
4774,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=c1\sc(-c2ccccc2)nn1-c1ccccc1,"2-((3,5-Diphenyl-1,3,4-thiadiazol-2(3H)-ylidene)amino)-4,6-diphenylnicotinonitrile",7.6,uM,=,0.8808135922807914,1,c1ccc(-c2cc(/N=c3\sc(-c4ccccc4)nn3-c3ccccc3)nc(-c3ccccc3)c2)cc1
4775,629699,10.1016/j.bmcl.2010.03.084,,,,Inhibition of human ERG,O=C(CNc1ccccc1C(F)(F)F)N1CCCN(Cc2nc3ccccc3[nH]2)CC1,"1-(4-((1H-benzo[d]imidazol-2-yl)methyl)-1,4-diazepan-1-yl)-2-(2-(trifluoromethyl)phenylamino)ethanone",1.32,uM,=,0.1205739312058498,1,O=C(CNc1ccccc1)N1CCCN(Cc2nc3ccccc3[nH]2)CC1
4776,949743,10.1021/jm301720p,,,,Inhibition of human ERG channel,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCCS(C)(=O)=O)c4ccc(OC(F)F)cc34)nc12,"N-tert-butyl-2-(5-(difluoromethoxy)-1-(3-(methylsulfonyl)propyl)-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",0.429,uM,=,-0.3675427078152757,0,c1ccc2c(-c3cnc4[nH]ccc4n3)n[nH]c2c1
4777,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cnccn3)no2)CC1,"N-(2-phenylcyclopropyl)-4-(3-(pyrazin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",27.0,uM,=,1.4313637641589874,1,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cnccn3)no2)CC1
4778,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4c(F)cccc43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(4-fluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",1.0,uM,=,0.0,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
4779,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H](C3(F)CNC3)O2)cc1,"(5S)-5-(3-fluoroazetidin-3-yl)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-4,5-dihydrooxazole",3.6,uM,=,0.5563025007672873,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H](C3CNC3)O2)cc1
4780,803124,10.1016/j.bmcl.2011.12.117,,,,Inhibition of human ERG by electrophysiological assay,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1,"(R)-N-(1-(3-(3,5-difluorophenyl)-3-(1-(methylsulfonyl)piperidin-4-yl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide",11.0,uM,=,1.0413926851582251,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
4781,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,COCCOc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)C(=O)C4)c(C=O)nc32)ncc1C#N,"N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-3-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide",22.0,uM,=,1.3424226808222062,1,O=C1CN(Cc2cnc3c(c2)CCCN3C(=O)Nc2ccccn2)CCN1
4782,457440,10.1016/j.bmcl.2007.07.051,,,,Binding affinity at hERG expressed in human embryonic kidney cells,Cc1[nH]nc2c1c(=O)n(C[C@H](F)CN)c1cc(C3CCCCC3)c(C3CCCCC3)cc21,"(R)-5-(3-amino-2-fluoropropyl)-7,8-dicyclohexyl-3-methyl-2H-pyrazolo[4,3-c]quinolin-4(5H)-one",13.2,uM,=,1.1205739312058498,1,O=c1[nH]c2cc(C3CCCCC3)c(C3CCCCC3)cc2c2n[nH]cc12
4783,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)C1CCN(Cc2nc3cc(F)ccc3s2)CC1,2-(4-(1H-tetrazol-1-yl)phenyl)-N-(1-((5-fluorobenzo[d]thiazol-2-yl)methyl)piperidin-4-yl)-N-methylacetamide,1.3,uM,=,0.1139433523068367,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2nc3ccccc3s2)CC1
4784,2100973,10.1021/acs.jmedchem.1c00375,,,,Displacement of [3H]-dofetilide from human ERG after 60 mins by scintillation counting method,Cc1c(N2CCC(C3(N)CC3)C2)c(F)cc2c(-c3cc(O)no3)cc(=O)n(C3CC3)c12,7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-(3-hydroxyisoxazol-5-yl)-8-methylquinolin-2(1H)-one,17.0,uM,=,1.230448921378274,1,O=c1cc(-c2ccno2)c2ccc(N3CCC(C4CC4)C3)cc2n1C1CC1
4785,1351560,10.1016/j.bmcl.2014.03.036,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells,O=C(N1CCc2ncc(C(F)(F)F)cc2C1)[C@@]12CCO[C@@H]1C[C@@H](NC1CCOCC1)C2,"((3aS,5S,6aR)-5-(tetrahydro-2H-pyran-4-ylamino)hexahydro-2H-cyclopenta[b]furan-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",43.0,uM,=,1.6334684555795866,1,O=C(N1CCc2ncccc2C1)[C@@]12CCO[C@@H]1C[C@@H](NC1CCOCC1)C2
4786,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,NC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"2,2-difluoro-4-(7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)butanamide",9.2,uM,=,0.9637878273455552,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4787,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CN(c1ccc(-c2ccc(C#N)cc2O)nn1)C1CC(C)(C)NC(C)(C)C1,"3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)benzonitrile",0.3,uM,=,-0.5228787452803376,0,c1ccc(-c2ccc(NC3CCNCC3)nn2)cc1
4788,490606,10.1016/j.bmcl.2008.06.027,,,,Inhibition of human ERG,Cc1ncc(-c2nc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3)ncc2F)n1C(C)C,1-(4-(4-(5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)-2-hydroxyethanone,18.0,uM,=,1.255272505103306,1,c1cc(-c2cnc[nH]2)nc(Nc2ccc(N3CCNCC3)cc2)n1
4789,2196932,10.1016/j.bmcl.2022.128911,,,,Inhibition of hERG,C=C(c1ccc(N2CC[C@H](N(C)C)C2)cc1)c1ccc2c(c1)Nc1ccccc1S2,"(S)-1-(4-(1-(10H-phenothiazin-2-yl)vinyl)phenyl)-N,N-dimethylpyrrolidin-3-amine",5.06,uM,=,0.7041505168397991,1,C=C(c1ccc(N2CCCC2)cc1)c1ccc2c(c1)Nc1ccccc1S2
4790,219494,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one",0.163,uM,=,-0.7878123955960422,0,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2
4791,455097,10.1016/j.bmcl.2007.02.066,,,,Inhibition of cardiac hERG,C[C@@H](C1CCC(N(C)C(=O)C2CC2)CC1)[C@H](N)C(=O)N1CC[C@H](F)C1.Cl,"(2S,3S)-1-((S)-3-fluoropyrrolidin-1-yl)-3-(4-(N-methylcyclopropanecarboxamido)cyclohexyl)-1-oxobutan-2-aminium chloride",39.0,uM,=,1.591064607026499,1,O=C(NC1CCC(CCC(=O)N2CCCC2)CC1)C1CC1
4792,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,O=C(N1CCc2ncc(C(F)(F)F)cc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCSCC1)C2,"((2R,3aR,6aR)-2-(tetrahydro-2H-thiopyran-4-ylamino)octahydropentalen-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",23.1,uM,=,1.3636119798921444,1,O=C(N1CCc2ncccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCSCC1)C2
4793,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,CC1(c2nc(-c3ccccc3)c[nH]2)Cc2c([nH]c3ccccc23)C(C2CCOCC2)N1,"3-methyl-3-(4-phenyl-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",2.946,uM,=,0.4692327425066121,1,c1ccc(-c2c[nH]c(C3Cc4c([nH]c5ccccc45)C(C4CCOCC4)N3)n2)cc1
4794,2049320,10.1021/acs.jmedchem.0c01179,,,,Inhibition of tracer red binding to human ERG expressed in HEK293 cell membranes measured after 2 to 6 hrs by fluorescence polarization assay,CC(C)[C@H]1CN(C2CCN(c3nc(N)n[nH]3)CC2)[C@@H](Cc2ccc(Cl)cc2)CO1,"5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-isopropylmorpholino)-piperidin-1-yl)-4H-1,2,4-triazol-3-amine",34.0,uM,=,1.5314789170422551,1,c1ccc(C[C@H]2COCCN2C2CCN(c3ncn[nH]3)CC2)cc1
4795,1475773,10.1021/jm5017413,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch-clamp assay,Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(6-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",7.3,uM,=,0.8633228601204559,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2ccccn2)C1
4796,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,CCNC(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1,"N-Ethyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide",16.0,uM,=,1.2041199826559248,1,O=C1c2ccc(-c3ccccc3)cc2CCN1CCN1CCCC1
4797,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CS(=O)(=O)Nc1ccc(OC[C@@H](O)CN(CCc2ccc(Cl)c(Cl)c2)Cc2ccccc2)cc1,"(S)-1-(4-Methanesulfonamidophenoxy)-3-(N-benzyl-3,4-dichlorophenylethylamino)-2-propanol",0.43,uM,=,-0.3665315444204134,0,c1ccc(CCN(CCCOc2ccccc2)Cc2ccccc2)cc1
4798,674336,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human ERG expressed in HEK cells by patch clamp technique,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,"9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one (GR 38032F)",0.4,uM,=,-0.3979400086720376,0,O=C1c2c([nH]c3ccccc23)CCC1Cn1ccnc1
4799,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,C[C@H]1OC2(CCN(CCc3ccccc3)CC2)CN(C2CC2)C1=O,"(R)-4-cyclopropyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",4.5,uM,=,0.6532125137753437,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1C1CC1
4800,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=NC(c2ccncc2)(c2cccc(-c3cncnc3)c2)c2cccc(F)c21,rac-4-Fluoro-1-(pyridin-4-yl)-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine,5.7,uM,=,0.7558748556724915,1,C1=NC(c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
4801,1789230,10.1021/acs.jmedchem.8b01622,,,,Inhibition of human ERG,Cc1cc(Oc2nccc3occc23)ccc1-c1c(C)ncc2nccn12,"4-(3-Methyl-4-(6-methylimidazo[1,2-a]pyrazin-5-yl)-phenoxy)furo[3,2-c]pyridine",12.0,uM,=,1.0791812460476249,1,c1cc2occc2c(Oc2ccc(-c3cncc4nccn34)cc2)n1
4802,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(C2CCN(Cc3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,N-((4-(1-benzylpiperidin-4-yl)tetrahydro-2H-pyran-4-yl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)propionamide,4.8,uM,=,0.6812412373755872,1,c1ccc(CN2CCC(C3(CNc4ccccn4)CCOCC3)CC2)cc1
4803,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COc1ccc(-n2cc3nc(-c4ccccc4C)n(CC4CCCN(C(C)C)C4)c(=O)c3n2)cc1,"rac-6-((1-Isopropylpiperidin-3-yl)methyl)-2-(4-methoxyphenyl)-5-o-tolyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",11.0,uM,=,1.0413926851582251,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2ccccc2)n1CC1CCCNC1
4804,2254299,10.1021/acs.jmedchem.1c01856,,,,Inhibition of hERG ion channel by patch-clamp method,N#Cc1ccc(COc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)n2)c(F)c1,2-[[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridyl]-1-piperidyl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid,4.3,uM,=,0.6334684555795865,1,c1ccc(COc2cccc(C3CCN(Cc4nc5ccccc5n4C[C@@H]4CCO4)CC3)n2)cc1
4805,2104164,10.1021/acs.jmedchem.1c00173,,,,Inhibition of human ERG by QPatch assay,Cc1c(C2(c3ccc(C(F)(F)F)c(C#N)c3)CC2)c[nH]c1C(=O)NC(C)c1nc[nH]n1,"rac-N-(1-(1H-1,2,4-triazol-3-yl)ethyl)-4-(1-(3-cyano-4-(trifluoromethyl)phenyl)cyclopropyl)-3-methyl-1H-pyrrole-2-carboxamide",20.4,uM,=,1.3096301674258988,1,O=C(NCc1nc[nH]n1)c1cc(C2(c3ccccc3)CC2)c[nH]1
4806,2185846,10.1021/acs.jmedchem.1c00621,,,,Inhibition of hERG potassium channel assessed as maximum inhibition rate at -80 mV holding potential incubated for 120 seconds by whole cell-automated voltage clamp analysis assay,CCCC(CN)=C1CN(c2nc(Oc3cnc(C)nc3)nc3[nH]c4c(NC)cc(F)cc4c23)C1,"4-(3-(1-Aminopentan-2-ylidene)azetidin-1-yl)-6-fluoro-N-methyl-2-((2-methylpyrimidin-5-yl)oxy)-9H-pyrimido[4,5-b]indol-8-amine",51.5,uM,=,1.711807229041191,1,C=C1CN(c2nc(Oc3cncnc3)nc3[nH]c4ccccc4c23)C1
4807,971921,10.1016/j.bmcl.2013.05.037,,,,Inhibition of human ERG,Cc1ccc(Cn2cnc(=O)c3cc(Oc4ncccc4C(F)(F)F)ccc32)c(F)c1,1-(2-fluoro-4-methylbenzyl)-6-(3-(trifluoromethyl)pyridin-2-yloxy)quinazolin-4(1H)-one,14.0,uM,=,1.146128035678238,1,O=c1ncn(Cc2ccccc2)c2ccc(Oc3ccccn3)cc12
4808,1278259,10.1021/jm4010434,,,,Inhibition of human ERG channel expressed in HEK293 cells after 15 mins by whole-cell patch clamp technique,CCCCCCCN(CC)CC#CCOc1ccc(Cl)cc1,N-(4-(4-Chlorophenoxy)but-2-yn-1-yl)-N-ethylheptan-1-amine,0.058,uM,=,-1.2365720064370629,0,c1ccccc1
4809,1789492,10.1021/acs.jmedchem.8b01533,,,,Inhibition of human ERG expressed in CHO-S1 cells by Qpatch clamp assay,FC(F)(F)Oc1ccc(Oc2ccc(N3CCC4(CC3)OCCc3sccc34)cc2)cc1,"1-(4-(4-(Trifluoromethoxy)phenoxy)phenyl)-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran]",1.5,uM,=,0.1760912590556812,1,c1ccc(Oc2ccc(N3CCC4(CC3)OCCc3sccc34)cc2)cc1
4810,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,Cn1c(=O)ccc2ccc(CN3CCC(NC(=O)c4cc(=O)c5ccc(F)cc5o4)CC3)cc21,"7-fluoro-N-(1-((1-methyl-2-oxo-1,2-dihydroquinolin-7-yl)methyl)piperidin-4-yl)-4-oxo-4H-chromene-2-carboxamide",47.4,uM,=,1.675778341674085,1,O=C(NC1CCN(Cc2ccc3ccc(=O)[nH]c3c2)CC1)c1cc(=O)c2ccccc2o1
4811,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(Cl)cc(Cl)c2)CCN(Cc2ccc(OC)cc2)CC1,"methyl 4-((3,5-dichlorobenzamido)methyl)-1-(4-methoxybenzyl)piperidine-4-carboxylate",0.13,uM,=,-0.8860566476931633,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
4812,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CC(C)(C)NC(=O)n1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4ccc5c(c4)OCO5)CC3)C2)c2cc(C(F)(F)F)ccc21,"cis-3-((2-((1-(4-(benzo[d][1,3]dioxol-5-yl)cyclohexyl)azetidin-3-yl)amino)-2-oxoethyl)-amino)-N-(tert-butyl)-5-(trifluoromethyl)-1H-indazole-1-carboxamide",4.7,uM,=,0.6720978579357175,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccc4c(c3)OCO4)CC2)C1
4813,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2nccc([C@@H](O)CC[C@@H]3CCN(C4CC(c5ccccc5)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-4-((S)-3-hydroxy-3-(6-methoxyquinolin-4-yl)propyl)-1-(3-phenylcyclobutyl)piperidine-3-carboxylic acid",24.9,uM,=,1.3961993470957363,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
4814,2048454,10.1016/j.bmc.2020.115734,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,COc1nc(-c2csc(Nc3c4c(nn3CC(F)(F)F)CCC4)n2)ccc1-n1cnc(C)c1,"4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-N-(2-(2,2,2-trifluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)thiazol-2-amine",0.92,uM,=,-0.0362121726544447,0,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCC5)n3)nc2)cn1
4815,861902,10.1021/jm3007323,,,,Inhibition of human ERG transfected in HEK293 cell membranes by whole cell patch clamp assay,Cc1cc(OCCN2C[C@@H](C)O[C@@H](C)C2)nn1-c1ccc2ccccc2c1,"(2R,6S)-2,6-dimethyl-4-(2-(5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy)ethyl)morpholine",7.4,uM,=,0.8692317197309762,1,c1ccc2cc(-n3ccc(OCCN4CCOCC4)n3)ccc2c1
4816,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,CN1CC=CCC(c2ccc(Cl)c(Cl)c2)C1,"rac-3-(3,4-Dichloro-phenyl)-1-methyl-2,3,4,7-tetrahydro-1H-azepine",7.6,uM,=,0.8808135922807914,1,C1=CCC(c2ccccc2)CNC1
4817,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(S(C)(=O)=O)cn2)C3)ccc2c1COC2=O,"(R)-5-(1-hydroxy-2-(2-(5-(methylsulfonyl)pyridin-2-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",14.4,uM,=,1.1583624920952498,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccccn3)C4)ccc21
4818,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCOC(=O)Nc1ccccc1[C@@H](c1ccc(C(=O)N(CC)CC)cc1)N1CCN(Cc2cscn2)CC1,(R)-ethyl 2-((4-(diethylcarbamoyl)phenyl)(4-(thiazol-4-ylmethyl)piperazin-1-yl)methyl)phenylcarbamate,8.7,uM,=,0.9395192526186184,1,c1ccc(C(c2ccccc2)N2CCN(Cc3cscn3)CC2)cc1
4819,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,O=C(/C=C/c1ccc(CNCCc2c[nH]c3ccccc23)cc1)NO,(E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide,27.46,uM,=,1.4387005329007363,1,c1ccc(CNCCc2c[nH]c3ccccc23)cc1
4820,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CC(C)(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-chloro-N-(2-((1R,3s,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propan-2-yl)benzamide",1.6,uM,=,0.2041199826559248,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
4821,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,COc1nc2ccccc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,4-(dimethylamino)-1-(2-methoxyquinolin-3-yl)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol,1.6,uM,=,0.2041199826559248,1,c1ccc(C(Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
4822,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc4scnc4c3)cc1)C(=O)N2c1cc(O)ncn1,"3-(4-Benzothiazol-5-yl-phenyl)-1-(6-hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",1.5,uM,=,0.1760912590556812,1,O=C1N(c2ccc(-c3ccc4scnc4c3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
4823,438926,10.1021/jm0701019,,,,Inhibition of hERG by patch clamp assay,Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12,(2S)-1-(5-(3-methyl-1H-indazol-5-yl)pyridin-3-yloxy)-3-phenylpropan-2-amine,13.4,uM,=,1.1271047983648077,1,c1ccc(CCCOc2cncc(-c3ccc4[nH]ncc4c3)c2)cc1
4824,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(Cl)ccc1Oc1ccc(Cl)cc1,1-(5-chloro-2-(4-chlorophenoxy)phenyl)-N-methylmethanamine,4.79,uM,=,0.6803355134145632,1,c1ccc(Oc2ccccc2)cc1
4825,2100973,10.1021/acs.jmedchem.1c00375,,,,Displacement of [3H]-dofetilide from human ERG after 60 mins by scintillation counting method,Cc1c(N2CCC(C3(N)CC3)C2)c(F)cc2c(-c3n[nH]c(=O)o3)cc(=O)n(C3CC3)c12,"5-(7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-4-yl)-1,3,4-oxadiazol-2(3H)-one",13.0,uM,=,1.1139433523068367,1,O=c1[nH]nc(-c2cc(=O)n(C3CC3)c3cc(N4CCC(C5CC5)C4)ccc23)o1
4826,1908563,10.1021/acsmedchemlett.9b00334,,,,Inhibition of human ERG expressed in HEK293 cells by voltage patch clamp assay,CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,PARSACLISIB,75.0,uM,=,1.8750612633917,1,O=C1C[C@H](c2cccc(Cn3ncc4cncnc43)c2)CN1
4827,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,COc1cccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)c1,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(3-methoxyphenyl)pyrrolo[1,2-b]pyridazine-3-carboxamide",7.2,uM,=,0.8573324964312685,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
4828,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nn4)C[C@H]3CO2)ccc(F)c1C#N,"3-((3S,9aS)-8-(2-(6-(1H-tetrazol-1-yl)pyridazin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-6-fluoro-2-methylbenzonitrile",33.7,uM,=,1.5276299008713388,1,O=C(Cc1ccc(-n2cnnn2)nn1)N1CCN2C[C@H](c3ccccc3)OC[C@@H]2C1
4829,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,CC1(C(=O)N2CC(c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1,"4-(8-amino-3-(1-(3-methyloxetane-3-carbonyl)azetidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",0.4,uM,=,-0.3979400086720376,0,O=C(Nc1ccccn1)c1ccc(-c2nc(C3CN(C(=O)C4COC4)C3)n3ccncc23)cc1
4830,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,c1ccc2c3c([nH]c2c1)C(C1CCOCC1)NC(c1nc(C2CCCCC2)c[nH]1)C3,"3-(4-cyclohexyl-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.136,uM,=,-0.8664610916297825,0,c1ccc2c3c([nH]c2c1)C(C1CCOCC1)NC(c1nc(C2CCCCC2)c[nH]1)C3
4831,1996654,10.1021/acs.jmedchem.0c00446,,,,Inhibition of MK499 binding to human ERG,COc1cc(/C=C2\CCCN3C2=NO[C@H](c2cc(F)c(F)c(F)c2)[C@@H]3C)ccc1-n1cnc(C)c1,"(3R,4S)-9-((E)-3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)-benzylidene)-4-methyl-3-(3,4,5-trifluorophenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]oxadiazine",1.607,uM,=,0.2060158767633445,1,C(=C1\CCCN2C[C@@H](c3ccccc3)ON=C12)\c1ccc(-n2ccnc2)cc1
4832,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2ccccc2)N2CCN(S(=O)(=O)CC(F)(F)F)CC2)CC1,"(S)-N-ethyl-2-(4-(methylsulfonyl)phenyl)-N-(1-(3-phenyl-3-(4-(2,2,2-trifluoroethylsulfonyl)piperazin-1-yl)propyl)piperidin-4-yl)acetamide",5.8,uM,=,0.7634279935629373,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)N2CCNCC2)CC1
4833,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,,0.012,uM,=,-1.9208187539523751,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
4834,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,Cc1ccc(N(C)C(=O)c2ccc3c(c2)CC(c2ccc(Cl)cc2)OC3=O)cc1C,"3-(4-chlorophenyl)-N-(3,4-dimethylphenyl)-N-methyl-1-oxoisochromane-6-carboxamide",2.92,uM,=,0.4653828514484183,1,O=C(Nc1ccccc1)c1ccc2c(c1)CC(c1ccccc1)OC2=O
4835,1911678,10.1021/acs.jmedchem.8b01725,,,,Inhibition of human ERG by Q-patch assay,C[C@@H]1OCC2(CCN(c3nc4[nH]nc(-c5ccnc(NC6CC6)c5Cl)c4c(=O)n3C)CC2)[C@@H]1N,"6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(3-chloro-2-(cyclopropylamino)pyridin-4-yl)-5-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one",17.0,uM,=,1.230448921378274,1,O=c1[nH]c(N2CCC3(CCOC3)CC2)nc2[nH]nc(-c3ccnc(NC4CC4)c3)c12
4836,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(Br)c3n2CCN1Cc1ccccc1,"2-Benzyl-6-bromo-3,4-dihydropyrazino[1,2-a]benzimidazol-1(2H)-one",15.0,uM,=,1.1760912590556811,1,O=C1c2nc3ccccc3n2CCN1Cc1ccccc1
4837,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3cccc(C#N)c3)CC2)CN(c2ccccc2)C1=O,"3-[2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl]benzonitrile",0.6,uM,=,-0.2218487496163563,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
4838,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CC[C@H]3CC[C@H](NCc4ccc5c(c4)OCCO5)CC3)c2c1,"trans-N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-(2-(6-methoxyquinolin-4-yl)ethyl)cyclohexanamine",0.26,uM,=,-0.585026652029182,0,c1ccc2c(CC[C@H]3CC[C@H](NCc4ccc5c(c4)OCCO5)CC3)ccnc2c1
4839,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(C#N)ccc43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(5-cyano-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",0.15,uM,=,-0.8239087409443188,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
4840,75160,10.1021/jm00014a008,,,,Blockade of the delayed rectifier K+ current (IKr) of guinea pig myocytes,CN1Cc2ccccc2[C@@H](c2ccc(F)cc2F)N=C1CCc1ccc(NS(C)(=O)=O)cc1.Cl,"N-(4-{2-[5-(2,4-Difluoro-phenyl)-2-methyl-2,5-dihydro-1H-benzo[e][1,3]diazepin-3-yl]-ethyl}-phenyl)-methanesulfonamide hydrochloride",38.0,uM,=,1.57978359661681,1,c1ccc(CCC2=N[C@H](c3ccccc3)c3ccccc3CN2)cc1
4841,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,CCOC(=O)c1cccc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)n1,"Ethyl6-((1S,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)picolinate",0.707,uM,=,-0.1505805862031006,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ccccn4)N3)n2)cc1
4842,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,CC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)c(C)c1,"N-(2-(4'-((1R,3'S)-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-yl)-3'-methylbiphenyl-2-yl)ethyl)acetamide",5.1,uM,=,0.7075701760979364,1,c1ccc(-c2ccc([C@H]3CNCC[C@@]34OCc3ccccc34)cc2)cc1
4843,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2ncc(F)c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"N-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methyl)-1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)piperidin-4-amine",3.0,uM,=,0.4771212547196624,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
4844,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CCC7)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(6-cyclobutoxy-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.5,uM,=,-0.3010299956639812,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OC7CCC7)nc56)(CC3)OC4)nc2N1
4845,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccncc2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",10.4,uM,=,1.0170333392987805,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccncc3)C4=O)ccc21
4846,1935939,10.1016/j.bmc.2019.02.025,,,,Inhibition of human ERG by manual patch clamp electrophysiology assay,COc1nc2ccc(Br)cc2cc1C(c1cccc(C)c1)C(O)(CCN(C)C)c1cccnc1OC,rac-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(2-methoxypyridin-3-yl)-1-m-tolylbutan-2-ol,0.45,uM,=,-0.3467874862246563,0,c1ccc(C(Cc2cccnc2)c2cnc3ccccc3c2)cc1
4847,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1cc2nc(CC3CC4CCC(C3)N4)n(Cc3ccc(Cl)cc3)c2cc1C,"US8975247, EBP882",4.3,uM,=,0.6334684555795865,1,c1ccc(Cn2c(CC3CC4CCC(C3)N4)nc3ccccc32)cc1
4848,973417,10.1016/j.bmcl.2013.05.089,,,,Inhibition of human ERG channel by electrophysiological assay,C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(OC(F)(F)C(F)F)cc3)CC2)NC(=O)NC1=O,"5S-methyl-5-[({4-[4-(1,1,2,2-tetrafluoroethoxy)phenoxy]piperidin-yl}sulfonyl)methyl]imidazolidine-2,4-dione",40.0,uM,=,1.6020599913279625,1,O=C1NC(=O)C(CS(=O)(=O)N2CCC(Oc3ccccc3)CC2)N1
4849,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,CC(C(O)c1ccc2c(c1)CCC(=O)N2)N1CCC(O)(c2ccc(F)cc2)CC1,"6-(2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxypropyl)-3,4-dihydroquinolin-2(1H)-one",8.6,uM,=,0.9344984512435676,1,O=C1CCc2cc(CCN3CCC(c4ccccc4)CC3)ccc2N1
4850,886194,10.1016/j.bmcl.2012.10.036,,,,Inhibition of human ERG by patch clamp assay,O=C1CCCN1C1CCN(CCc2ccc(Oc3nc4ncccc4s3)cc2)CC1,"1-(1-(4-(thiazolo[4,5-b]pyridin-2-yloxy)phenethyl)piperidin-4-yl)pyrrolidin-2-one",2.8,uM,=,0.4471580313422192,1,O=C1CCCN1C1CCN(CCc2ccc(Oc3nc4ncccc4s3)cc2)CC1
4851,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCC3CCOCC3)C[C@@H]2CC(=O)Nc2cccc(Cl)c2)cc1,"N-(3-chlorophenyl)-2-((3R,4S)-4-(4-methoxyphenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)pyrrolidin-3-yl)acetamide",0.12,uM,=,-0.9208187539523752,0,O=C(C[C@H]1CN(CCC2CCOCC2)C[C@@H]1c1ccccc1)Nc1ccccc1
4852,1525287,10.1016/j.bmcl.2015.09.045,,,,Inhibition of human ERG expressed in HEK293 cells by whole-cell patch clamp method,Fc1ccc2c(C3CCN(CCCOc4ccc(-c5nc6ccccc6o5)cc4)CC3)noc2c1,3-(1-(3-(4-(benzo[d]oxazol-2-yl)phenoxy)propyl)piperidin-4-yl)-6-fluorobenzo[d]isoxazole,3.76,uM,=,0.5751878449276611,1,c1ccc2oc(-c3ccc(OCCCN4CCC(c5noc6ccccc56)CC4)cc3)nc2c1
4853,597420,10.1016/j.bmcl.2009.08.080,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,CCc1n[nH]c(CC)c1Oc1cc(C)cc(C#N)c1,"3-(3,5-diethyl-1H-pyrazol-4-yloxy)-5-methylbenzonitrile",100.0,uM,=,2.0,1,c1ccc(Oc2cn[nH]c2)cc1
4854,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccnc(F)c4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(2-fluoropyridin-4-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide",41.0,uM,=,1.6127838567197357,1,c1cc(-c2cc3c(NC4CCCC4)ccnn3c2)ccn1
4855,1865114,10.1021/acsmedchemlett.9b00086,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp method,CC(C)Oc1cc([C@@](Cc2ccccc2)(NC(=O)C(N)C(O)(C(F)(F)F)C(F)(F)F)c2cc(F)cc(OC(F)(F)C(F)F)c2)ccc1F,"2-amino-4,4,4-trifluoro-N-((R)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-hydroxy-3-(trifluoromethyl)butanamide",44.0,uM,=,1.6434526764861874,1,c1ccc(CC(c2ccccc2)c2ccccc2)cc1
4856,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(CCN2CCN(CC(F)c3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"4-(2-(4-(2-fluoro-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-2-methoxybenzonitrile",2.4,uM,=,0.380211241711606,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
4857,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,CCc1nc2ccc(CN3CCC(NC(=O)c4cc(=O)c5ccc(F)cc5o4)CC3)cc2o1,N-(1-((2-ethylbenzo[d]oxazol-6-yl)methyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,26.7,uM,=,1.4265112613645752,1,O=C(NC1CCN(Cc2ccc3ncoc3c2)CC1)c1cc(=O)c2ccccc2o1
4858,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,c1ccc2c3c([nH]c2c1)[C@@H](C1CCOCC1)N[C@@H](c1nc(-c2ccsc2)c[nH]1)C3,"(1R,3R)-1-(tetrahydro-2H-pyran-4-yl)-3-(4-(thiophen-3-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.146,uM,=,-0.835647144215563,0,c1ccc2c3c([nH]c2c1)[C@@H](C1CCOCC1)N[C@@H](c1nc(-c2ccsc2)c[nH]1)C3
4859,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N(Cc3ccccc3)Cc3ccccc3)nn2)ccc1-n1cnc(C)c1,"N,N-dibenzyl-2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)acetamide",0.87,uM,=,-0.0604807473813814,0,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)N(Cc1ccccc1)Cc1ccccc1
4860,1853420,10.1016/j.ejmech.2019.06.037,,,,Inhibition of human ERG,COCCN1CCN(CCNc2nonc2/C(=N/O)Nc2ccc(F)c(Br)c2)S1(=O)=O,"N-(3-Bromo-4-fluorophenyl)-N'-hydroxy-4-((2-(5-(2-methoxyethyl)-1,1-dioxido-1,2,5-thiadiazolidin-2-yl)ethyl)amino)-1,2,5-oxadiazole-3-carboximidamide",16.63,uM,=,1.220892249219519,1,N=C(Nc1ccccc1)c1nonc1NCCN1CCNS1(=O)=O
4861,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,O=C(NC1CCCOC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,"5-(2,3-Difluorophenyl)-N-(tetrahydro-2H-pyran-3-yl)-1H-indazole-3-carboxamide",6.6,uM,=,0.8195439355418687,1,O=C(NC1CCCOC1)c1n[nH]c2ccc(-c3ccccc3)cc12
4862,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,COc1nc2ccc(CC(C)=O)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,1-(3-(4-(dimethylamino)-2-hydroxy-2-(naphthalen-1-yl)-1-phenylbutyl)-2-methoxyquinolin-6-yl)propan-2-one,10.0,uM,=,1.0,1,c1ccc(C(Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
4863,489010,10.1021/jm8003834,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide from human ERG in HEK293 cells",Cc1nc2ccccc2c(=O)n1-c1ccc(OCCCN2CCC[C@H](C)C2)cc1,2-Methyl-3-[4-({3-[(3S)-3-methyl-1-piperidinyl]propyl}oxy)phenyl]-4(3H)-quinazolinone,5.3,uM,=,0.724275869600789,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCCC2)cc1
4864,1362933,10.1016/j.bmcl.2014.04.083,,,,Inhibition of human ERG tail current after 5 mins by patch-clamp method,CCOC(=O)N1CCC(C)(CN2CCC3(CC2)CN(S(C)(=O)=O)c2ncccc23)CC1,"ethyl 4-methyl-4-((1'-(methylsulfonyl)-1',2'-dihydrospiro[piperidine-4,3'-pyrrolo[2,3-b]pyridine]-1-yl)methyl)piperidine-1-carboxylate",3.63,uM,=,0.5599066250361125,1,c1cnc2c(c1)C1(CCN(CC3CCNCC3)CC1)CN2
4865,2156392,10.1016/j.ejmech.2021.114040,,,,Inhibition of human ERG,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1ccc2c(c1)OC1(CCOCC1)CC(=O)N2,"N-(4-Methyl-3-(4-oxo-2',3',4,5,5',6'-hexahydro-3H-spiro[benzo[b][1,4]oxazepine-2,4'-pyran]-8-yl)phenyl)-2-(trifluoromethyl)isonicotinamide",3.0,uM,=,0.4771212547196624,1,O=C1CC2(CCOCC2)Oc2cc(-c3cccc(NC(=O)c4ccncc4)c3)ccc2N1
4866,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(O)c1,"N,N-Diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide",56.7,uM,=,1.7535830588929069,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
4867,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,Cn1cc([C@@]2(c3cccc(C(=O)O)n3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"6-((1S,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)picolinicacid",8.703,uM,=,0.9396689835223264,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ccccn4)N3)n2)cc1
4868,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,COc1ccccc1CC(c1ccccc1)N1CCNCC1,1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine,39.0,uM,=,1.591064607026499,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
4869,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,O=C(NC1CCc2ccccc2C1)N1CCC(c2nc(-c3ccccn3)no2)CC1,"4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-N-(1,2,3,4-tetrahydronaphthalen-2-yl)piperidine-1-carboxamide",6.0,uM,=,0.7781512503836436,1,O=C(NC1CCc2ccccc2C1)N1CCC(c2nc(-c3ccccn3)no2)CC1
4870,886196,10.1016/j.bmcl.2012.10.036,,,,Inhibition of dofetilide binding to human ERG by patch clamp assay,NC(=O)C1CCN(Cc2ccc(Oc3nc4ccccc4s3)cc2)CC1,1-[4-(Benzothiazol-2-yloxy)benzyl]piperidine-4-carboxylic AcidAmide,1.5,uM,=,0.1760912590556812,1,c1ccc2sc(Oc3ccc(CN4CCCCC4)cc3)nc2c1
4871,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCc3ccc(OC)c(OC)c3)C[C@@H]2Cc2nc3ccc(Cl)cc3[nH]2)cc1,"rac-6-chloro-2-(((3R,4S)-1-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)methyl)-1H-benzo[d]imidazole",0.028,uM,=,-1.5528419686577808,0,c1ccc(CCN2C[C@H](Cc3nc4ccccc4[nH]3)[C@@H](c3ccccc3)C2)cc1
4872,632181,10.1016/j.bmcl.2010.03.106,,,,Inhibition of human ERG expressed by patch clam electrophysiology assay,CCc1nn(CCOCC(F)(F)F)c2c(Nc3ccncn3)nc(N3CCN[C@H](C)C3)nc12,"(R)-3-ethyl-5-(3-methylpiperazin-1-yl)-N-(pyrimidin-4-yl)-1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine",1.4,uM,=,0.1461280356782379,1,c1cc(Nc2nc(N3CCNCC3)nc3cn[nH]c23)ncn1
4873,863322,10.1021/jm3008294,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp technique,Cl.Fc1cc(C(Oc2ccccc2)C2CNC2)ccc1Cl,3-((4-Chloro-3-fluorophenyl)(phenoxy)methyl)azetidine hydrochloride,1.56,uM,=,0.1931245983544616,1,c1ccc(OC(c2ccccc2)C2CNC2)cc1
4874,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,CC(=O)Nc1cccc(N2CCN(CCCCNS(=O)(=O)CC3CCCCC3)CC2)c1,N-{3-[4-(4-cyclohexylmethanesulfonylamino-butyl)-piperazin-1-yl]-phenyl}-acetamide,3.8,uM,=,0.5797835966168101,1,O=S(=O)(CC1CCCCC1)NCCCCN1CCN(c2ccccc2)CC1
4875,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",CC(C)N(CCOc1ccc(-n2ccc(OCc3ccccc3)cc2=O)cc1)C(C)C,4-(Benzyloxy)-1-{4-[2-(diisopropylamino)ethoxy]-phenyl}pyridin-2(1H)-one,0.0043,uM,=,-2.3665315444204134,0,O=c1cc(OCc2ccccc2)ccn1-c1ccccc1
4876,1714647,10.1021/acs.jmedchem.8b00650,,,,Inhibition of human ERG by patch clamp method,Cc1cncc(-c2ccc(C(=O)N(c3ncccc3Cl)[C@@H]3CCCNC3)cc2)n1,(R)-N-(3-Chloropyridin-2-yl)-4-(6-methylpyrazin-2-yl)-N-(piperidin-3-yl)benzamide,59.8,uM,=,1.7767011839884108,1,O=C(c1ccc(-c2cnccn2)cc1)N(c1ccccn1)[C@@H]1CCCNC1
4877,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CC(C)Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ccc(C#N)cc2F)CC1,3-Fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-1-yl]-benzonitrile,3.3,uM,=,0.5185139398778875,1,O=C(c1ccccc1)N1CCN(c2ccccc2)CC1
4878,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H]([C@@H]3CCNC3)O2)cc1,"(5R)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-5-[(3R)-pyrrolidin-3-yl]-4,5-dihydrooxazole",5.4,uM,=,0.7323937598229685,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@H]([C@@H]3CCNC3)O2)cc1
4879,795488,10.1016/j.bmcl.2011.11.037,,,,Inhibition of human ERG by patch-express assay,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)C(C)(C)C2)cc1,"(R)-4,4-dimethyl-6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-4,5-dihydropyridazin-3(2H)-one",20.0,uM,=,1.3010299956639813,1,O=C1CCC(c2ccc(OCCCN3CCCC3)cc2)=NN1
4880,1520089,10.1021/acsmedchemlett.5b00207,,,,Inhibition of human ERG by by patchXpress method,COCc1cnc(N2CCC([C@H]3C[C@H]3COCc3ccc(S(C)(=O)=O)cc3F)CC2)nc1,"2-(4-((1R,2R)-2-((2-fluoro-4-(methylsulfonyl)benzyloxy)methyl)cyclopropyl)piperidin-1-yl)-5-(methoxymethyl)pyrimidine",13.0,uM,=,1.1139433523068367,1,c1ccc(COC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)cc1
4881,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,Cc1cc(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC2)cc2c1C(=O)OC2,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-7-methylisobenzofuran-1(3H)-one,10.0,uM,=,1.0,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
4882,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,CC(c1ccncc1)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,endo-3-(8-(1-(pyridin-4-yl)ethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0037,uM,=,-2.431798275933005,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccncc2)cc1
4883,499833,10.1016/j.bmcl.2009.04.022,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(S[C@]4(C)CC[C@@H](c5nnnn5C)CC4)nc3cc2Cl)CC1,trans-5-chloro-6-(4-ethylpiperazin-1-yl)-2-(1-methyl-4-(1-methyl-1H-tetrazol-5-yl)cyclohexylthio)-1H-benzo[d]imidazole,6.3,uM,=,0.7993405494535817,1,c1cc2nc(SC3CCC(c4nnn[nH]4)CC3)[nH]c2cc1N1CCNCC1
4884,2130695,10.1021/acsmedchemlett.1c00334,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated Qpatch electrophysiological method,Cc1nc2c(cnn2-c2csc(C(=O)NC3COC3)c2)cc1Nc1c(F)cccc1Cl,"4-(5-((2-chloro-6-fluorophenyl)amino)-6-methyl-1H-pyrazolo[3,4-b]pyridin-1-yl)-N-(oxetan-3-yl)thiophene-2-carboxamide",10.0,uM,=,1.0,1,O=C(NC1COC1)c1cc(-n2ncc3cc(Nc4ccccc4)cnc32)cs1
4885,1765499,10.1021/acs.jmedchem.8b01040,,,,Displacement of [3H]dofetilide from human ERG by high throughput assay,O=C(Nc1ccc(OC(F)(F)F)cc1)c1cnc(N2CC[C@H](O)C2)c(-c2cncnc2)c1,"US9278981, 33",9.6,uM,=,0.9822712330395684,1,O=C(Nc1ccccc1)c1cnc(N2CCCC2)c(-c2cncnc2)c1
4886,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-2-methyl-biphenyl-4-carboxylic acid",13.0,uM,=,1.1139433523068367,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
4887,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1cc(-n2cnnn2)ncc1C(C)C(=O)N1CCN(CCc2ccc3c(c2C)COC3=O)CC1,4-methyl-5-(2-(4-(2-(4-methyl-6-(1H-tetrazol-1-yl)pyridin-3-yl)propanoyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,42.0,uM,=,1.6232492903979006,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
4888,1884876,10.1021/acs.jmedchem.9b00336,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current amplitude by automated patch-clamp method,CCC#CC[C@H](C)[C@H](O)/C=C/[C@H]1CCC(=O)N1CCCCCCC(=O)O,"7-((R)-2-((3S,4S,E)-3-Hydroxy-4-methylnon-1-en-6-yn-1-yl)-5-oxopyrrolidin-1-yl)heptanoic Acid",29.0,uM,=,1.462397997898956,1,O=C1CCCN1
4889,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCN(C(=O)CO)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"1-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)piperazin-1-yl)-2-hydroxyethanone",14.0,uM,=,1.146128035678238,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
4890,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,c1ncc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cn1,"2-(1,4'-bipiperidin-1'-yl)-6-(pyrimidin-5-yl)thiazolo[4,5-b]pyridine",23.33333333,uM,=,1.3679767852325524,1,c1ncc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cn1
4891,1753764,10.1016/j.bmcl.2017.12.068,,,,Inhibition of human ERG,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc6n(c5c4)C(C)(C)CC6)n3)nc2)CC1,"N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(5-fluoro-1,1-dimethyl-2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)pyrimidin-2-amine",6.38,uM,=,0.8048206787211624,1,c1cc(-c2ccc3nc4n(c3c2)CCC4)nc(Nc2ccc(CN3CCNCC3)cn2)n1
4892,971488,10.1016/j.bmcl.2013.05.017,,,,Inhibition of human ERG channel by patch clamp technique,Cc1nc2cc(F)ccc2n1[C@H]1CC[C@@H](NC[C@H]2Cc3ccc(C#N)cc3C2)CC1,"cis-(S)-2-((-4-(5-fluoro-2-methyl-1H-benzo[d]imidazol-1-yl)cyclohexylamino)methyl)-2,3-dihydro-1H-indene-5-carbonitrile",0.03,uM,=,-1.5228787452803376,0,c1ccc2c(c1)CC(CN[C@H]1CC[C@@H](n3cnc4ccccc43)CC1)C2
4893,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,CC(C)(C)c1cc(C(=O)N2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc(C(C)(C)C)c1O,"(4-(6,6-bis(4-fluorophenyl)hexyl)piperazin-1-yl)(3,5-di-tert-butyl-4-hydroxyphenyl)methanone",0.25,uM,=,-0.6020599913279624,0,O=C(c1ccccc1)N1CCN(CCCCCC(c2ccccc2)c2ccccc2)CC1
4894,1689488,10.1021/acs.jmedchem.7b00662,,,,Inhibition of human ERG by patch clamp assay,O=C(CN1CCCC2=C1C(=O)N(C1CC1)C2=O)Nc1ccc(-c2cccnc2)nn1,"2-(6-Cyclopropyl-5,7-dioxo-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-b]pyridin-1-yl)-N-(6-(pyridin-3-yl)pyridazin-3-yl)-acetamide",48.0,uM,=,1.6812412373755872,1,O=C(CN1CCCC2=C1C(=O)N(C1CC1)C2=O)Nc1ccc(-c2cccnc2)nn1
4895,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,COCC#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCN(C)CC4)ccc2-3)cs1,"3-(5-(3-methoxyprop-1-ynyl)thiophen-3-yl)-6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno[1,2-c]pyrazole",5.19,uM,=,0.7151673578484579,1,c1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1
4896,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,FC(F)Oc1ccccc1CC(c1ccccc1)N1CCNCC1,1-(2-(2-(difluoromethoxy)phenyl)-1-phenylethyl)piperazine,10.7,uM,=,1.0293837776852095,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
4897,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,COc1cc2nnc(C(N)=O)c(Nc3ccc(C)cc3F)c2cc1N1CCN(C(C)C)CC1,4-(2-fluoro-4-methylphenylamino)-6-(4-isopropylpiperazin-1-yl)-7-methoxycinnoline-3-carboxamide,17.0,uM,=,1.230448921378274,1,c1ccc(Nc2cnnc3ccc(N4CCNCC4)cc23)cc1
4898,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,N#Cc1ccc(OC2CNC(C(=O)N3CCCN(C4CCCC4)CC3)C2)cc1,"4-(5-(4-cyclopentyl-1,4-diazepane-1-carbonyl)pyrrolidin-3-yloxy)benzonitrile",2.9,uM,=,0.4623979978989561,1,O=C(C1CC(Oc2ccccc2)CN1)N1CCCN(C2CCCC2)CC1
4899,963062,10.1021/jm400408r,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,Cc1cc(=O)oc2c(C)c(OCCCCN3CCC(c4noc5cc(F)ccc45)CC3)ccc12,"7-(4-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-4,8-dimethyl-2H-chromen-2-one",0.226,uM,=,-0.645891560852599,0,O=c1ccc2ccc(OCCCCN3CCC(c4noc5ccccc45)CC3)cc2o1
4900,1290262,10.1016/j.bmcl.2013.05.024,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CN(c3ccccc3)C[C@@]2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1,"((3aR,5R,6aR)-5-(3-methoxytetrahydro-2H-pyran-4-ylamino)-2-phenyloctahydrocyclopenta[c]pyrrol-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",22.9,uM,=,1.359835482339888,1,O=C(N1CCc2ncccc2C1)[C@]12C[C@H](NC3CCOCC3)C[C@H]1CN(c1ccccc1)C2
4901,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,O=C(/C=C/[C@@H]1CCCN1)N1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc([N+](=O)[O-])c4)c3c2)CC1,(S)-1-(4-(5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinolin-3-yl)piperazin-1-yl)-3-(pyrrolidin-2-yl)prop-2-en-1-one,86.2,uM,=,1.9355072658247128,1,O=C(/C=C/[C@@H]1CCCN1)N1CCN(c2cnc3cccc(NCc4ccccc4)c3c2)CC1
4902,1462544,10.1016/j.bmcl.2015.01.035,,,,Inhibition of human ERG,CC(C)N1Cc2cc(-c3cc(-c4ccc(Cl)nc4)no3)ccc2C1=O,5-(3-(6-chloropyridin-3-yl)isoxazol-5-yl)-2-isopropylisoindolin-1-one,40.0,uM,=,1.6020599913279625,1,O=C1NCc2cc(-c3cc(-c4cccnc4)no3)ccc21
4903,948139,10.1016/j.bmcl.2013.01.019,,,,Inhibition of human ERG,COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@@H](C)O[C@@H](C)C4)nc3n2)cc1CO,"(5-(2-((2R,6S)-2,6-dimethylmorpholino)-4-morpholinopyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol",8.3,uM,=,0.919078092376074,1,c1ccc(-c2ccc3c(N4CCOCC4)nc(N4CCOCC4)nc3n2)cc1
4904,498774,10.1021/jm900110t,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",COc1ccnc(C2=N[C@@](c3ccc(F)cc3)(c3ccc(F)nc3)[C@H](C)N2)c1,"2-[(4S,5S)-4-(4-Fluorophenyl)-4-(6-fluoro-3-pyridyl)-5-methyl-4,5-dihydro-1H-imidazol-2-yl]-4-(methyloxy)pyridine",6.33,uM,=,0.8014037100173551,1,c1ccc([C@]2(c3cccnc3)CNC(c3ccccn3)=N2)cc1
4905,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,C[C@@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(C)(C)C,"(R)-4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl]methanone",28.0,uM,=,1.4471580313422192,1,O=C(c1ccccc1)N1CCN(c2ccccn2)CC1
4906,1736165,10.1021/acs.jmedchem.8b00300,,,,Inhibition of human ERG,CCCS(=O)(=O)NC1CN(c2ccc3c(c2)[C@@H](Cc2ccccc2)[C@@H](N2CCC2)CC3)C1,"N-(1-((7S,8R)-7-(Azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)azetidin-3-yl)propane-1-sulfonamide",6.8,uM,=,0.8325089127062363,1,c1ccc(C[C@@H]2c3cc(N4CCC4)ccc3CC[C@@H]2N2CCC2)cc1
4907,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,Cn1cc([C@@]2(c3noc(O)n3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"3-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,2,4-oxadiazol-5-ol",1.2,uM,=,0.0791812460476248,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)nc1
4908,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,Cc1ncc(-c2nc(Nc3ccc(C(=O)N(C)C)cc3)ncc2F)n1C(C)C,"4-(5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)-N,N-dimethylbenzamide",11.0,uM,=,1.0413926851582251,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
4909,2157068,10.1021/acsmedchemlett.1c00445,,,,Inhibition of hERG expressed in HEK293 cells at -80 mV holding potential by automated patch-clamp method,C[C@@]1(c2cccc(NC(=O)c3ccc(C#N)cn3)c2)Cn2nccc2C(N)=N1,"(R)-N-(3-(4-amino-6-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-6-yl)phenyl)-5-cyanopicolinamide",1.8,uM,=,0.255272505103306,1,O=C(Nc1cccc(C2Cn3nccc3C=N2)c1)c1ccccn1
4910,1540690,10.1016/j.ejmech.2015.08.051,,,,Inhibition of human ERG channel expressed in HEK293 cells after 5 mins by patch clamp assay,COCCCN1C[C@@H]2[C@@H](CNC(=O)c3nc(C(C)C)n4ccccc34)[C@@H]2C1,"N-[N-(3-methoxy propyl)-3-azabicyclo[3.1.0]hexane-6-yl methyl]-3-isopropylimidazo[1,5-a]pyridine-1-carboxamide",5.1,uM,=,0.7075701760979364,1,O=C(NC[C@H]1[C@@H]2CNC[C@@H]21)c1ncn2ccccc12
4911,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,CNc1cc(Nc2cnc(C#N)c(O[C@H](C)CN(C)C)n2)ncc1Cl,(R)-5-((5-Chloro-4-(methylamino)pyridin-2-yl)amino)-3-((1-(dimethylamino)propan-2-yl)oxy)pyrazine-2-carbonitrile,1.0,uM,=,0.0,0,c1ccc(Nc2cnccn2)nc1
4912,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)cnn3)CC2)(C(C)C)C1,"cis-(((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone)",31.3,uM,=,1.4955443375464486,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2cccnn2)CC1
4913,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,[2H]C(Nc1cc(C(F)(F)F)cc2ncc(N3CCN(C)CC3)cc12)c1cccc([N+](=O)[O-])c1,3-(4-methylpiperazin-1-yl)-N-([2H]-3-nitrobenzyl)-7-(trifluoromethyl)quinolin-5-amine,1.27,uM,=,0.1038037209559568,1,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
4914,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CNc1nccc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)n1,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(2-(methylamino)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",9.4,uM,=,0.9731278535996988,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccncn3)C4=O)ccc21
4915,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,Clc1cc(COCC2(c3ccccc3)CCNCC2)cc(Cl)n1,"2,6-dichloro-4-(((4-phenylpiperidin-4-yl)methoxy)methyl)pyridine",33.0,uM,=,1.5185139398778875,1,c1ccc(C2(COCc3ccncc3)CCNCC2)cc1
4916,457440,10.1016/j.bmcl.2007.07.051,,,,Binding affinity at hERG expressed in human embryonic kidney cells,Cc1[nH]nc2c1c(=O)n(CCCN)c1cc(C3CCCCC3)c(C3CCCCC3)cc21,"5-(3-aminopropyl)-7,8-dicyclohexyl-3-methyl-2H-pyrazolo[4,3-c]quinolin-4(5H)-one",5.3,uM,=,0.724275869600789,1,O=c1[nH]c2cc(C3CCCCC3)c(C3CCCCC3)cc2c2n[nH]cc12
4917,886194,10.1016/j.bmcl.2012.10.036,,,,Inhibition of human ERG by patch clamp assay,O=C1CCCN1C1CCN(CCOc2ccc(Oc3nc4ncccc4s3)cc2)CC1,"1-(1-(2-(4-(thiazolo[4,5-b]pyridin-2-yloxy)phenoxy)ethyl)piperidin-4-yl)pyrrolidin-2-one",2.5,uM,=,0.3979400086720376,1,O=C1CCCN1C1CCN(CCOc2ccc(Oc3nc4ncccc4s3)cc2)CC1
4918,1879326,10.1021/acs.jmedchem.9b01172,,,,Inhibition of human ERG assessed as reduction in channel tail current by plate-based planar patch clamp assay,CN(C)C(=O)CNCCc1cccc(OCCCC(C)(F)F)c1.Cl,"2-(3-(4,4-difluoropentyloxy)phenethylamino)-N,N-dimethylacetamide Hydrochloride",7.6,uM,=,0.8808135922807914,1,c1ccccc1
4919,1912248,10.1021/acs.jmedchem.9b00443,,,,Inhibition of human ERG by fluorescence polarization assay,CNC(=O)c1cnc(Nc2ccc(C)nn2)cc1Nc1ccccc1S(C)(=O)=O,N-Methyl-6-((6-methylpyridazin-3-yl)amino)-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide,43.0,uM,=,1.6334684555795866,1,c1ccc(Nc2ccnc(Nc3cccnn3)c2)cc1
4920,1572821,10.1016/j.bmcl.2016.04.024,,,,Inhibition of human ERG1 expressed in CHO cells by whole cell patch clamp electrophysiology method,CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCN(C)CC3)nc21,"1-methyl-4-[1-(2-methylpropanesulfonyl)-4-[4-(trifluoromethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-6-yl]piperazine",2.1,uM,=,0.3222192947339193,1,c1ccc(-c2cc(N3CCNCC3)nc3[nH]ccc23)cc1
4921,1658369,10.1016/j.ejmech.2016.12.038,,,,Inhibition of human ERG expressed in CHO cells by Qpatch assay,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)[C@H]1CCCN1.Cl,"(R,Z)-N-(5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)pyrrolidine-2-carboxamide hydrochloride",6.73,uM,=,0.8280150642239769,1,O=C1Nc2ccccc2/C1=C/c1cc(NC(=O)[C@H]2CCCN2)c[nH]1
4922,1446841,10.1021/jm500715u,,,,Inhibition of human ERG,Cc1nc(Nc2nc3cnc(N4CCN(C)CC4)cc3[nH]2)cc(C2CC2)c1F,"N-(4-Cyclopropyl-5-fluoro-6-methylpyridin-2-yl)-6-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-amine",8.8,uM,=,0.9444826721501688,1,c1cc(C2CC2)cc(Nc2nc3cnc(N4CCNCC4)cc3[nH]2)n1
4923,575209,10.1016/j.bmcl.2009.03.090,,,,Inhibition of human ERG channel,Clc1cccc(OC(c2ccccc2)C2CCNCC2)c1Cl,"rac-4-((2,3-dichlorophenoxy)(phenyl)methyl)piperidine",0.95,uM,=,-0.0222763947111522,0,c1ccc(OC(c2ccccc2)C2CCNCC2)cc1
4924,1875991,10.1021/acs.jmedchem.9b00444,,,,Inhibition of human ERG by in vitro patch clamp method,CNC(=O)c1cnc(Nc2ccc(C#N)cn2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,"6-((5-Cyanopyridin-2-yl)amino)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-methylnicotinamide",6.7,uM,=,0.8260748027008264,1,c1ccc(Nc2cc(Nc3cccc(-c4nc[nH]n4)c3)ccn2)nc1
4925,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-1-(6-methyl-pyrimidin-4-yl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",38.0,uM,=,1.57978359661681,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
4926,1523405,10.1016/j.bmcl.2015.10.031,,,,Inhibition of human ERG by thallium flux assay,N/C1=N\C(=O)[C@@H]2CCCN2c2ccc(cc2)OCCCCCCNCC(=O)Nc2c(Cl)cc(cc2Cl)CN1,,32.0,uM,=,1.505149978319906,1,O=C1CNCCCCCCOc2ccc(cc2)N2CCC[C@H]2C(=O)N=CNCc2ccc(cc2)N1
4927,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)NC3C4CC5CC(C4)CC3C5)nn2)ccc1-n1cnc(C)c1,"N-Adamantan-2-yl-2-{4-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[1,2,3]triazol-1-yl}-acetamide",4.03,uM,=,0.6053050461411095,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)NC1C2CC3CC(C2)CC1C3
4928,1682731,10.1021/acs.jmedchem.7b01135,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cell membranes,N#Cc1ccc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)cc1,"US9394282, 9-35",40.0,uM,=,1.6020599913279625,1,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1
4929,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,N#Cc1ccc2ccc(=O)n(CCN3CC[C@@H](NCc4cc5c(cn4)OCCO5)[C@@H](O)C3)c2c1,"cis-1-(2-{(3S,4R)-4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-3-hydroxypiperidin-1-yl}ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",117.0,uM,=,2.0681858617461617,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
4930,1924512,10.1021/acsmedchemlett.6b00122,,,,Displacement of [35S]MK-499 from human ERG,O=[N+]([O-])c1ccc(CCN2CCN(CCc3ccc([N+](=O)[O-])cc3)CC2)cc1,"1,4-bis(4-nitrophenethyl)piperazine",0.007,uM,=,-2.154901959985743,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
4931,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-phenylpyrrolo[1,2-b]pyridazine-3-carboxamide",3.8,uM,=,0.5797835966168101,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
4932,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccccc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(phenyl)methanone",50.0,uM,=,1.6989700043360187,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
4933,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cccnc3)no2)CC1,"N-(2-phenylcyclopropyl)-4-(3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",2.0,uM,=,0.3010299956639812,1,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cccnc3)no2)CC1
4934,591458,10.1021/jm900563e,,,,Inhibition of human ERG,COc1ccc(CC(C)(C)NC[C@H](O)COc2cccc3[nH]c(=O)[nH]c23)cc1,(S)-4-(2-hydroxy-3-(1-(4-methoxyphenyl)-2-methylpropan-2-ylamino)propoxy)-1H-benzo[d]imidazol-2(3H)-one,0.0118,uM,=,-1.9281179926938743,0,O=c1[nH]c2cccc(OCCCNCCc3ccccc3)c2[nH]1
4935,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Clc1ccc(Cn2c(/C=C/C3CCN(CC4CCCCC4)C3)nc3cc(Br)ccc32)cc1,"US8975247, EBP933",1.1,uM,=,0.041392685158225,1,C(=C/C1CCN(CC2CCCCC2)C1)\c1nc2ccccc2n1Cc1ccccc1
4936,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(C(C)(C)CN2CCN(CCc3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"2-methoxy-4-(2-methyl-1-(4-(2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)propan-2-yl)benzonitrile",1.2,uM,=,0.0791812460476248,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
4937,699583,10.1016/j.bmcl.2010.10.086,,,,Inhibition of human ERG,CNC1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21,"1-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydroquinolin-4-amine",7.8,uM,=,0.8920946026904804,1,c1ccc(N2CCCc3ccccc32)cc1
4938,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4C4CC4)CC3)ccc21,5-(2-(4-(2-(2-cyclopropyl-4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,3.0,uM,=,0.4771212547196624,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4C4CC4)CC3)ccc21
4939,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,CC(C(O)c1ccc2c(c1)CCC(=O)N2)N1CCC(O)(c2cccc(F)c2)CC1,"6-(2-(4-(3-fluorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxypropyl)-3,4-dihydroquinolin-2(1H)-one",10.0,uM,=,1.0,1,O=C1CCc2cc(CCN3CCC(c4ccccc4)CC3)ccc2N1
4940,518708,10.1016/j.bmcl.2008.12.017,,,,Inhibition of human ERG expressed in HEK cells by competitive radioligand binding assay,Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12,"9-phenyl-8-(4-((4-(5-(pyridin-2-yl)-1H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-amine",5.319,uM,=,0.7258299903205803,1,c1ccc(-c2cc3c(ccn4cnnc34)nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1
4941,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cccc(F)c43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(7-fluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",2.1,uM,=,0.3222192947339193,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
4942,1438341,10.1016/j.ejmech.2014.09.010,,,,Inhibition of human ERG,O=C1NC(=O)/C(=C\c2ccccc2OCc2nnc(OCc3c(Cl)cccc3Cl)o2)S1,"(E)-5-(2-((5-(2,6-dichlorobenzyloxy)-1,3,4-oxadiazol-2-yl)methoxy)benzylidene)thiazolidine-2,4-dione",29.0,uM,=,1.462397997898956,1,O=C1NC(=O)/C(=C\c2ccccc2OCc2nnc(OCc3ccccc3)o2)S1
4943,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"4-{5-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-pyridin-2-yl}-3-methyl-benzoic acid",7.1,uM,=,0.8512583487190752,1,O=C1N(c2ccc(-c3ccccc3)nc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
4944,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C1CCC1)CC2)c1ncc(-c2cc3ccc(C)nc3cc2OC)[nH]1,(S)-6-cyclobutyl-N-((S)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide,8.9,uM,=,0.9493900066449128,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)[nH]1)[C@H]1CC12CCN(C1CCC1)CC2
4945,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H]([C@H]3CCNC3)O2)cc1,"(5S)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-5-[(3S)-pyrrolidin-3-yl]-4,5-dihydrooxazole",2.3,uM,=,0.3617278360175928,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H]([C@H]3CCNC3)O2)cc1
4946,1764419,10.1021/acsmedchemlett.8b00095,,,,Inhibition of human ERG,O=c1c2cc(Cc3cccnc3)c3ccccc3c2ncn1[C@H]1CCCC[C@@H]1O,3-(trans-2-hydroxycyclohexyl)-6-(pyridin-3-ylmethyl)benzo[h]quinazolin-4(3H)-one,12.0,uM,=,1.0791812460476249,1,O=c1c2cc(Cc3cccnc3)c3ccccc3c2ncn1C1CCCCC1
4947,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,c1ncc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)cn1,"2-(1,4'-bipiperidin-1'-yl)-6-(pyrimidin-5-yl)thiazolo[4,5-c]pyridine",6.393442623,uM,=,0.805734772019073,1,c1ncc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)cn1
4948,1472977,10.1021/jm5019274,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp method,C=C(F)COc1ccc(Cl)cc1[C@H]1C[C@@H]1CN.Cl,"(+)-((1S,2S)-2-(5-chloro-2-(2-fluoroallyloxy)phenyl)cyclopropyl)methanamine hydrochloride",3.98,uM,=,0.5998830720736879,1,c1ccc(C2CC2)cc1
4949,766531,10.1016/j.bmcl.2011.06.126,,,,Inhibition of human ERG by electrophysiological assay,CC(=O)c1ccc2c(c1)N(CCN1CCC(NCc3ccc4c(n3)NC(=O)CO4)CC1)C(=O)CO2,"6-((1-(2-(6-acetyl-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",49.1,uM,=,1.6910814921229684,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccccc54)CC3)nc2N1
4950,1822313,10.1021/acs.jmedchem.8b01891,,,,Inhibition of human ERG,O=C1OCCc2cc([C@@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)cc5)C[C@H]4CO3)ccc21,"6-((3R,9aS)-8-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)isochroman-1-one",75.9,uM,=,1.8802417758954804,1,O=C1OCCc2cc([C@@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)cc5)C[C@H]4CO3)ccc21
4951,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,c1ccc(C2(c3ccccc3)CC2C2=NCCN2)cc1,"2-(2,2-Diphenyl-cyclopropyl)-4,5-dihydro-1H-imidazole",8.8,uM,=,0.9444826721501688,1,c1ccc(C2(c3ccccc3)CC2C2=NCCN2)cc1
4952,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2ccc(NC(=O)OC)cc2)cc1,methyl 4-((4-(diethylcarbamoyl)phenyl)(1-(4-fluorobenzyl)piperidin-4-ylidene)methyl)phenylcarbamate,0.9,uM,=,-0.0457574905606751,0,c1ccc(CN2CCC(=C(c3ccccc3)c3ccccc3)CC2)cc1
4953,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,O=C1OCc2cc(CCC3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21,5-(2-(1-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperidin-4-yl)ethyl)isobenzofuran-1(3H)-one,6.4,uM,=,0.8061799739838872,1,O=C1OCc2cc(CCC3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
4954,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1c(-c2ccc(Cl)cc2)noc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-3-(4-chlorophenyl)-4-methyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)isoxazole,2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cc(-c3ccc4cc(CCN5CCCC5)ccc4n3)on2)cc1
4955,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,CNCc1cnc(C)cc1Oc1ccccc1Oc1ccccc1,N-methyl(6-methyl-4-(2-phenoxyphenoxy)pyridin-3-yl)methanamine,11.2,uM,=,1.0492180226701815,1,c1ccc(Oc2ccccc2Oc2ccncc2)cc1
4956,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N,"2-methoxy-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridine-3-carbonitrile",0.0016,uM,=,-2.7958800173440754,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4957,613538,10.1021/jm901781q,,,,Inhibition of human ERG by patch-clamp method,CCCOCCn1c(=O)c(N2CCN([C@@H](C)[C@@H](C)O)CC2)nc2cnc(-c3ccc(OC)nc3)cc21,"(+/-)-3-(4-((2S,3R)-3-hydroxybutan-2-yl)piperazin-1-yl)-1-(2-isopropoxyethyl)-7-(6-methoxypyridin-3-yl)pyrido[3,4-b]pyrazin-2(1H)-one",0.054,uM,=,-1.2676062401770316,0,O=c1[nH]c2cc(-c3cccnc3)ncc2nc1N1CCNCC1
4958,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cn1c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2c(Cl)cccc2c1=O,8-chloro-2-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-3-methylquinazolin-4(3H)-one,1.1,uM,=,0.041392685158225,1,O=c1[nH]c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2ccccc12
4959,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,O=C(Cc1ccc(C(F)(F)F)cc1C(F)(F)F)N[C@@H]1N=C(c2ccccc2)c2ccccc2N(CC(F)(F)F)C1=O,"2-(2,4-Bis-trifluoromethyl-phenyl)-N-[(R)-2-oxo-5-phenyl-1-(2,2,2-trifluoro-ethyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-acetamide",6.0,uM,=,0.7781512503836436,1,O=C(Cc1ccccc1)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O
4960,761292,10.1021/jm101312a,,,,Inhibition of human ERG expressed in CHO cells by high throughput single cell planar patch clamp method,CN1C[C@H]2CCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1,"(3aR,6aS)-3a-(3,4-dichlorophenyl)-2-methyloctahydrocyclopenta[c]pyrrole",5.43,uM,=,0.7347998295888469,1,c1ccc([C@@]23CCC[C@@H]2CNC3)cc1
4961,811343,10.1016/j.bmcl.2012.01.095,,,,Inhibition of human ERG by fluorescence polarization assay,CCC(NCCCC[C@@H](Nc1cc(C)c(F)c(C)c1)C(=O)NO)c1ccc(F)cc1,"rac-(2R)-2-(4-fluoro-3,5-dimethylphenylamino)-6-(1-(4-fluorophenyl)propylamino)-N-hydroxyhexanamide",0.95,uM,=,-0.0222763947111522,0,c1ccc(CNCCCCCNc2ccccc2)cc1
4962,1859473,10.1021/acs.jmedchem.9b00362,,,,Inhibition of human ERG by patch clamp method,COc1nc(N[C@@H](C)c2cc3cc(Cl)ccc3[nH]c2=O)ncc1C#N,"(S)-2-((1-(6-Chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-4-methoxypyrimidine-5-carbonitrile",3.2,uM,=,0.505149978319906,1,O=c1[nH]c2ccccc2cc1CNc1ncccn1
4963,2298656,10.1016/j.bmcl.2023.129280,,,,Inhibition of hERG,Cc1ccc(NC(=O)Nc2cc(-c3ccccc3-c3nn[nH]n3)cc3c2OCC=CC3c2ccccc2)cc1,"(+/-)-1-(7-(2-(2H-tetrazol-5-yl)phenyl)-5-phenyl-2,5-dihydrobenzo[b]oxepin-9-yl)-3-(p-tolyl)urea",69.0,uM,=,1.8388490907372552,1,O=C(Nc1ccccc1)Nc1cc(-c2ccccc2-c2nn[nH]n2)cc2c1OCC=CC2c1ccccc1
4964,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(Cc3ccc(OC)c(OC)c3)C[C@@H]2CNC(=O)c2cccc(Cl)c2)cc1,"rac-3-chloro-N-(((3S,4S)-1-(3,4-dimethoxybenzyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)methyl)benzamide",0.6,uM,=,-0.2218487496163563,0,O=C(NC[C@H]1CN(Cc2ccccc2)C[C@@H]1c1ccccc1)c1ccccc1
4965,1576971,10.1016/j.bmcl.2016.04.087,,,,Inhibition of human ERG after 10 mins,CNC(=O)c1cc(OCCCCN2CCC(c3noc4cc(F)ccc34)CC2)ccc1F,2-Fluoro-5-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-N-methylbenzamide,0.998,uM,=,-0.0008694587126288,0,c1ccc(OCCCCN2CCC(c3noc4ccccc34)CC2)cc1
4966,971477,10.1021/jm400402q,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)Oc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,"5-Chloro-N2-(2-isopropoxy-4-(piperidin-4-yl)-phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine",5.3,uM,=,0.724275869600789,1,c1ccc(Nc2ccnc(Nc3ccc(C4CCNCC4)cc3)n2)cc1
4967,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1ccccc1O[C@H]1C[C@H]2CC[C@@H](C1)N2Cc1ccccc1,"endo-2-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide",0.34,uM,=,-0.4685210829577448,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccc2)C3)cc1
4968,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(CC(N)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(+)-6-((1-(1-amino-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.2,uM,=,0.0791812460476248,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4969,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN1CCN(c2ccc3nc(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)c(-c4ccccc4)nc3n2)CC1,"6-(4-methylpiperazin-1-yl)-3-phenyl-2-(4-((4-(5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)pyrido[2,3-b]pyrazine",2.143,uM,=,0.3310221710418286,1,c1ccc(-c2nc3nc(N4CCNCC4)ccc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1
4970,1478746,10.1093/cvr/cvr044,,,,Inhibition of potassium current (Ikr) measured using whole-cell patch clamp experiments in HEK-293 cells stable transfected with hERG cDNA,CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1,"(3,3-Diphenyl-propyl)-(1-methyl-2-phenyl-ethyl)-amine",0.065,uM,=,-1.1870866433571443,0,c1ccc(CCNCCC(c2ccccc2)c2ccccc2)cc1
4971,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,N#CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"4-(7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)butanenitrile",8.9,uM,=,0.9493900066449128,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4972,1911375,10.1021/acs.jmedchem.8b01296,,,,Inhibition of human ERG after 4 hrs by fluorescence polarization assay,CCN1CCN(c2ccc(/C(=C(/CCCO)c3ccccc3)c3ccc(C)cc3)cc2)CC1.Cl.Cl,(Z)-5-(4-(4-ethylpiperazin-1-yl)phenyl)-4-phenyl-5-p-tolylpent-4-en-1-ol dihydrochloride,17.0,uM,=,1.230448921378274,1,C(=C(c1ccccc1)c1ccc(N2CCNCC2)cc1)c1ccccc1
4973,1665706,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by flux assay,NS(=O)(=O)c1ccc(CCNc2nc(Cl)nc3cccc(-c4ccccc4)c23)cc1,4-(2-((2-chloro-5-phenylquinazolin-4-yl)amino)ethyl)benzenesulfonamide,24.0,uM,=,1.380211241711606,1,c1ccc(CCNc2ncnc3cccc(-c4ccccc4)c23)cc1
4974,820025,10.1016/j.bmcl.2012.04.128,,,,Inhibition of human ERG,CCS(=O)(=O)n1c2c(c3cc(C(=O)N4CCC(C)CC4)ccc31)CN(C1CCOCC1)CC2,"(5-(ethylsulfonyl)-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)(4-methylpiperidin-1-yl)methanone",3.1,uM,=,0.4913616938342727,1,O=C(c1ccc2[nH]c3c(c2c1)CN(C1CCOCC1)CC3)N1CCCCC1
4975,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC1CCCN1CCc1ccc2nc(-c3ccsc3)ccc2c1,6-(2-(2-methylpyrrolidin-1-yl)ethyl)-2-(thiophen-3-yl)quinoline,4.8,uM,=,0.6812412373755872,1,c1cc(-c2ccc3cc(CCN4CCCC4)ccc3n2)cs1
4976,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1ccc(CCNC(C)COc2c(C)cccc2C)cc1OC,"[2-(3,4-Dimethoxy-phenyl)-ethyl]-[2-(2,6-dimethyl-phenoxy)-1-methyl-ethyl]-amine",6.1,uM,=,0.785329835010767,1,c1ccc(CCNCCOc2ccccc2)cc1
4977,936798,10.1021/jm301511h,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,COc1ccc(NC(=O)c2ccc(Cn3ccnn3)c3ccccc23)c(C(=O)NCC2CCOCC2)n1,"6-Methoxy-N-(tetrahydro-2H-pyran-4-ylmethyl)-3-{[4-(1H-1,2,3-triazol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C(NCC1CCOCC1)c1ncccc1NC(=O)c1ccc(Cn2ccnn2)c2ccccc12
4978,1473874,10.1021/jm5018863,,,,Inhibition of human ERG expressed in CHO cells by automated Qpatch clamp assay,NC(=O)c1ccc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc(-n2nccn2)c1,"2-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-6-((1R,2S)-2-aminocyclohexylamino)nicotinamide",8.5,uM,=,0.9294189257142929,1,c1cc(Nc2cccc(NC3CCCCC3)n2)cc(-n2nccn2)c1
4979,1540295,10.1016/j.bmcl.2015.10.097,,,,Inhibition of human ERG by patch clamp technique,O=C(c1ccccn1)[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCN(S(=O)(=O)c1ccc(C(F)(F)F)cc1)C2,"(R)-(1-(4-fluorophenyl)-6-(4-(trifluoromethyl)phenylsulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone",5.0,uM,=,0.6989700043360189,1,O=C(c1ccccn1)[C@]12Cc3cnn(-c4ccccc4)c3C=C1CCN(S(=O)(=O)c1ccccc1)C2
4980,945538,10.1016/j.bmcl.2012.10.140,,,,Inhibition of human ERG expressed in CHO cells by IONWORKS assay,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",3.3,uM,=,0.5185139398778875,1,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
4981,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)c(F)cc21,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-6-fluoroisobenzofuran-1(3H)-one,26.0,uM,=,1.414973347970818,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
4982,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,[2H]C([2H])(O)CN1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc([N+](=O)[O-])c4)c3c2)CC1,[2H]-2-(4-(5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinolin-3-yl)piperazin-1-yl)ethanol,0.16,uM,=,-0.7958800173440752,0,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
4983,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(C)ccc3OC[C@H]2[C@@]1(CCCN(C)C)c1ccccc1,"1-[(3R,3aR)-3-(3-dimethylamino-propyl)-8-methyl-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-2-yl]-ethanone",2.4,uM,=,0.380211241711606,1,C1=NN2c3ccccc3OC[C@H]2C1c1ccccc1
4984,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CCCN(CCc1ccc(Cl)c(Cl)c1)C[C@H](O)COc1ccc(NS(C)(=O)=O)cc1,"(S)-1-(4-Methanesulfonamidophenoxy)3-(N-propyl-3,4-dichlorophenylethylamino)-2-propanol",0.13,uM,=,-0.8860566476931633,0,c1ccc(CCNCCCOc2ccccc2)cc1
4985,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1cc2nc(CC3CCNC(C)C3)n(Cc3ccc(Cl)cc3)c2cc1C,"US8975247, EBP881",0.58,uM,=,-0.2365720064370627,0,c1ccc(Cn2c(CC3CCNCC3)nc3ccccc32)cc1
4986,887723,10.1021/np300232b,,,,Inhibition of human ERG tail current expressed in HEK293 cells at + 60 mV holding potential by patch clamp assay,COc1cc2c(cc1O)[C@@H](Cc1ccc(O)c(Oc3ccc(C[C@@H]4c5cc(OC)c(OC)cc5CCN4C)cc3)c1)N(C)CC2,Daruisoline,9.6,uM,=,0.9822712330395684,1,c1cc(C[C@H]2NCCc3ccccc32)cc(Oc2ccc(C[C@H]3NCCc4ccccc43)cc2)c1
4987,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,COc1nccnc1CC1=C(CCN(C)C)Cc2cc(Cl)ccc21,"2-(6-chloro-3-((3-methoxypyrazin-2-yl)methyl)-1H-inden-2-yl)-N,N-dimethylethanamine",0.23,uM,=,-0.6382721639824072,0,C1=C(Cc2cnccn2)c2ccccc2C1
4988,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc(-c2ccccc2)cc1)Cc1ccc2c(c1)CCO2.Cl,(E)-N-(Coumaran-5-methyl)-N-methyl-3-(4-biphenyl)prop-2-en-1-amine Hydrochloride,11.3,uM,=,1.0530784434834195,1,C(=C/c1ccc(-c2ccccc2)cc1)\CNCc1ccc2c(c1)CCO2
4989,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cnccc2C(F)(F)F)C1=O,"2-methyl-9-(2-phenylethyl)-4-[4-(trifluoromethyl)-3-pyridyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",3.3,uM,=,0.5185139398778875,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1cccnc1
4990,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-(2-(5-hydroxy-4-oxo-1,4-dihydropyridin-2-yl)ethoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.9,uM,=,-0.0457574905606751,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCCc7cc(=O)cc[nH]7)nc56)(CC3)OC4)nc2N1
4991,1650772,10.1016/j.bmcl.2016.11.079,,,,Inhibition of human ERG,CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc(C23CCC(C(=O)O)(CC2)CC3)n2ccnc(N)c12,"4-(8-amino-1-(2-ethoxy-4-(4-(trifluoromethyl)pyridin-2-ylcarbamoyl)phenyl)imidazo[1,5-a]pyrazin-3-yl)bicyclo[2.2.2]octane-1-carboxylic acid",26.0,uM,=,1.414973347970818,1,O=C(Nc1ccccn1)c1ccc(-c2nc(C34CCC(CC3)CC4)n3ccncc23)cc1
4992,591408,10.1021/jm9010065,,,,Inhibition of human ERG expressed in HEK cells,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"[4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid,(3S)-3-morpholinylmethyl ester",4.0,uM,=,0.6020599913279624,1,O=C(Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnn2c1)OC[C@@H]1COCCN1
4993,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,N#Cc1ccc(COc2ccc3nc(C(=O)N4CCNCC4)ccc3c2)cc1,4-[[2-(piperazine-1-carbonyl)-6-quinolyl]oxymethyl]benzonitrile,5.61,uM,=,0.7489628612561614,1,O=C(c1ccc2cc(OCc3ccccc3)ccc2n1)N1CCNCC1
4994,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N(C)C)nc1CN1C(=O)O[C@H](c2cccc(C(F)(F)F)c2)[C@@H]1C,"3'-(2-(Dimethylamino)-4-(((4S,5R)-4-methyl-2-oxo-5-(3-(trifluoromethyl)phenyl)oxazolidin-3-yl)methyl)pyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic Acid",9.6,uM,=,0.9822712330395684,1,O=C1O[C@H](c2ccccc2)CN1Cc1ncncc1-c1cccc(-c2ccccc2)c1
4995,2166403,,,,,Inhibition of hERG (unknown origin) expressed in CHO-K1 cells measured by PatchXpress higher-throughput assay,CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1,"(R)-2-(4-isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide",8.7,uM,=,0.9395192526186184,1,O=C(Cc1ccccc1)NCc1ccccn1
4996,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,CN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1,Dimethyl-[2-(3-pyrazin-2ylmethyl-1H-inden-2-yl)-ethyl]-amine,5.4,uM,=,0.7323937598229685,1,C1=C(Cc2cnccn2)c2ccccc2C1
4997,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1ccc2occc2c1,"(1R,2S)-2-(benzofuran-5-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-4-(dimethylamino)-1-phenylbutan-2-ol",0.4,uM,=,-0.3979400086720376,0,c1ccc([C@@H](Cc2ccc3occc3c2)c2ccc3ccccc3c2)cc1
4998,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(C(F)(F)F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-methoxy-3-(trifluoromethyl)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.13,uM,=,-0.8860566476931633,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
4999,624297,10.1016/j.bmcl.2010.01.134,,,,Inhibition of human ERG expressed in HEK cells assessed as blockade of potassium tail current by standard patch clamp analysis,COc1cccnc1[C@H](C)c1c(CCN(C)C)sc2ccccc12,"(+)-(R)-2-(3-(1-(3-methoxypyridin-2-yl)ethyl)benzo[b]thiophen-2-yl)-N,N-dimethylethanamine",3.0,uM,=,0.4771212547196624,1,c1ccc(Cc2csc3ccccc23)nc1
5000,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N(C)C)nc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C,"3'-(4-(((4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-2-(dimethylamino)pyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic Acid",16.0,uM,=,1.2041199826559248,1,O=C1O[C@H](c2ccccc2)CN1Cc1ncncc1-c1cccc(-c2ccccc2)c1
5001,757144,10.1016/j.bmcl.2011.05.063,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc2c(c1)nc(C(C)(C)C)n2CC1CC1,2-tert-butyl-1-(cyclopropylmethyl)-5-(ethylsulfonyl)-1H-benzo[d]imidazole,2.6,uM,=,0.414973347970818,1,c1ccc2c(c1)ncn2CC1CC1
5002,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)O1,2-(8-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-8-azaspiro[4.5]decan-2-yl)acetic Acid,17.4,uM,=,1.2405492482825995,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCO5)CC4)nc3)nc2c1
5003,2076406,10.1021/acsmedchemlett.0c00462,,,,Inhibition of human ERG,COc1nc2ccccc2cc1-c1cnc([C@H](CCCCNC(=O)c2ccccc2SC)NC(=O)c2cncs2)[nH]1,(S)-N-(1-(5-(2-methoxyquinolin-3-yl)-1H-imidazol-2-yl)-5-(2-(methylthio)benzamido)pentyl)thiazole-5-carboxamide,1.329,uM,=,0.1235249809427319,1,O=C(NCCCC[C@H](NC(=O)c1cncs1)c1ncc(-c2cnc3ccccc3c2)[nH]1)c1ccccc1
5004,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cncc(Br)c2)(c2ccccc2)CC1,3-bromo-5-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)pyridine,13.0,uM,=,1.1139433523068367,1,c1ccc(C2(COCc3cccnc3)CCNCC2)cc1
5005,1478751,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one",0.15,uM,=,-0.8239087409443188,0,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2
5006,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COCCN1CCCC(Cn2c(-c3cccnc3C)nc3cn(-c4ccc(C#N)cc4)nc3c2=O)C1,"rac-4-[6-{[1-(2-Methoxyethyl)piperidin-3-yl]methyl}-5-(2-methylpyridin-3-yl)-7-oxo-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-2-yl]benzonitrile",21.0,uM,=,1.3222192947339193,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2cccnc2)n1CC1CCCNC1
5007,2287586,10.1021/acsmedchemlett.8b00517,,,,Inhibition of hERG potassium channel incubated for 4 hrs by fluorescence polarization assay,CCC(=O)CCCCC[C@H](NC(=O)C1(F)CN(C)C1)c1ncc(-c2cc3ccccc3nc2OC)o1,(S)-3-fluoro-N-(1-(5-(2-methoxyquinolin-3-yl)oxazol-2-yl)-7-oxononyl)-1-methylazetidine-3-carboxamide,13.6,uM,=,1.1335389083702174,1,O=C(NCc1ncc(-c2cnc3ccccc3c2)o1)C1CNC1
5008,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2cc(F)c(F)c(F)c2F)[C@@H]3C)n1,"US9422299, 10",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
5009,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,CCOc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc3c2OCCO3)cc(OCC)n1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-2-(2,6-diethoxypyridin-4-yl)-1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-4-(dimethylamino)butan-2-ol",13.3,uM,=,1.1238516409670858,1,c1cc2c(c([C@@H](Cc3ccncc3)c3cnc4ccccc4c3)c1)OCCO2
5010,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21,5-(2-(4-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,9.3,uM,=,0.9684829485539352,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
5011,1329251,10.1039/C1MD00164G,,,,Inhibition of human ERG by [3H]dofetilide binding assay,CC[C@]1(c2cccc(C(N)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21,"3-((1R,5S)-6-ethyl-3-((2-hydroxy-2,3-dihydro-1H-inden-2-yl)methyl)-3-azabicyclo[3.1.0]hexan-6-yl)benzamide",2.2,uM,=,0.3424226808222063,1,c1ccc(C2[C@H]3CN(CC4Cc5ccccc5C4)C[C@@H]23)cc1
5012,1450434,10.1021/ml500053b,,,,Inhibition of human ERG by patch-clamp assay,CN1Cc2cc(N3CCOCC3)ccc2[C@@H](c2ccc3sccc3c2)C1,"(+)-4-(4-(benzo[b]thiophen-5-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)morpholine",1.0,uM,=,0.0,0,c1cc2cc([C@H]3CNCc4cc(N5CCOCC5)ccc43)ccc2s1
5013,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)Nc3ccccc3)cc2)cc1,4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic Acid Phenylamide,0.2967032967,uM,=,-0.5276776281669318,0,O=S(=O)(Nc1ccccc1)c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
5014,948139,10.1016/j.bmcl.2013.01.019,,,,Inhibition of human ERG,CNC(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1OC(F)F,"5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-(difluoromethoxy)-N-methylbenzamide",24.2,uM,=,1.383815365980431,1,c1ccc(-c2ccc3c(N4CCOCC4)nc(N4CCOCC4)nc3n2)cc1
5015,1289670,10.1016/j.bmcl.2013.12.118,,,,Inhibition of human ERG by dofetilide binding assay,NC[C@]1(c2cccc(Cl)c2)CC[C@H](n2nc(-c3cccnc3)ccc2=O)CC1,2-(syn-4-(aminomethyl)-4-(3-chlorophenyl)cyclohexyl)-6-(pyridin-3-yl)pyridazin-3(2H)-one,4.4,uM,=,0.6434526764861874,1,O=c1ccc(-c2cccnc2)nn1C1CCC(c2ccccc2)CC1
5016,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,COc1cc(F)ccc1-c1cnc2sc(N3CCC(N)(CO)C3)nn12,"(3-Amino-1-(5-(4-fluoro-2-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)pyrrolidin-3-yl)methanol",28.3,uM,=,1.4517864355242902,1,c1ccc(-c2cnc3sc(N4CCCC4)nn23)cc1
5017,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,Cc1cnc([C@]2(O)CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)s1,cis-N-({1-[4-Hydroxy-4-(5-methyl-thiazol-2-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,28.0,uM,=,1.4471580313422192,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3nccs3)CC2)C1
5018,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3ccc(-n4ccc(=O)cc4)cc3)ccc2c1,(R)-1-(4-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)phenyl)pyridin-4(1H)-one,20.0,uM,=,1.3010299956639813,1,O=c1ccn(-c2ccc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cc2)cc1
5019,1512965,10.1021/acsmedchemlett.5b00117,,,,Inhibition of human ERG,CC(C)c1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1,"(R)-(4-Fluorophenyl)(3-(3-isopropyl-1,2,4-oxadiazol-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",1.6,uM,=,0.2041199826559248,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncno2)C1
5020,1890282,10.1021/acs.jmedchem.8b01972,,,,Inhibition of Tracer Red binding to human ERG expressed in membranes by fluorescence polarization assay,C[C@H](NC(=O)[C@H]1CNC[C@@H]1c1ccc(C(F)(F)F)cc1)c1ccc(N(C)C)cc1,"(+)-(3R,4S)-N-[(1S)-1-[4-(Dimethylamino)phenyl]ethyl]-4-[4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide",32.0,uM,=,1.505149978319906,1,O=C(NCc1ccccc1)[C@H]1CNC[C@@H]1c1ccccc1
5021,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,O=C(N[C@H]1CCN(C2CCCC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccc(F)cc2F)on1,"(3S,4S)-1-Cyclopentyl-4-([5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino)piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide",9.6,uM,=,0.9822712330395684,1,O=C(N[C@H]1CCN(C2CCCC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccccc2)on1
5022,556966,10.1021/jm801065q,,,,Displacement of [3H]dofetilide from human recombinant ERG expressed in HEK293 cells,C1=C(CS/C(=N\C2CCCCC2)NC2CCCCC2)N2CCN=C2S1,"1,3-dicyclohexyl-2-((5,6-dihydroimidazo[2,1-b]thiazol-3-yl)methyl)isothiourea",8.5,uM,=,0.9294189257142929,1,C1=C(CS/C(=N\C2CCCCC2)NC2CCCCC2)N2CCN=C2S1
5023,699709,10.1016/j.bmcl.2010.11.111,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells,COc1cc(/C=C/c2nc(N)c3ccccc3n2)ccc1-n1cnc(C)c1,2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)styryl)quinazolin-4-amine,0.14,uM,=,-0.8538719643217619,0,C(=C/c1ncc2ccccc2n1)\c1ccc(-n2ccnc2)cc1
5024,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cn1c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2c(F)cccc2c1=O,2-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-8-fluoro-3-methylquinazolin-4(3H)-one,7.9,uM,=,0.8976270912904415,1,O=c1[nH]c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2ccccc12
5025,626176,10.1016/j.bmcl.2010.02.046,,,,Inhibition of human recombinant ERG by patch clamp assay,CSc1nn2c3c(c(C)nc2c1S(=O)(=O)c1ccccc1)CCCC3,"5-methyl-2-(methylthio)-3-(phenylsulfonyl)-6,7,8,9-tetrahydropyrazolo[1,5-a]quinazoline",8.4,uM,=,0.9242792860618816,1,O=S(=O)(c1ccccc1)c1cnn2c3c(cnc12)CCCC3
5026,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,COc1ccc([C@H]2CC[C@@H](N3CC(NC(=O)CNc4nn(C)c5ccc(C(F)(F)F)cc45)C3)CC2)cn1,cis-N-{1-[4-Hydroxy-4-(6-methoxy-pyridin-3-yl)-cyclohexyl]-azetidin-3-yl}-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,12.0,uM,=,1.0791812460476249,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3cccnc3)CC2)C1
5027,1447392,10.1016/j.bmcl.2014.04.085,,,,Inhibition of human ERG channel,CCOC(=O)N1CCC(CN2CCC3(CC2)CN(C(=O)N(CC)CC)c2ncccc23)CC1,"ethyl 4-((1'-(diethylcarbamoyl)-1',2'-dihydrospiro[piperidine-4,3'-pyrrolo[2,3-b]pyridine]-1-yl)methyl)piperidine-1-carboxylate",2.54,uM,=,0.404833716619938,1,c1cnc2c(c1)C1(CCN(CC3CCNCC3)CC1)CN2
5028,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(=O)Nc1ccc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cn1,"N-(5-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridin-6-yl)pyridin-2-yl)acetamide",40.0,uM,=,1.6020599913279625,1,c1cncc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)c1
5029,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,CCCNC(=O)N1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc([N+](=O)[O-])c4)c3c2)CC1,4-(5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinolin-3-yl)-N-propylpiperazine-1-carboxamide,1.28,uM,=,0.1072099696478683,1,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
5030,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCC3CCS(=O)(=O)CC3)C[C@@H]2CC(=O)Nc2cccc(Cl)c2)cc1,"N-(3-Chloro-phenyl)-2-[(3R,4S)-1-[2-(1,1-dioxo-hexahydro-1lambda6-thiopyran-4-yl)-ethyl]-4-(4-methoxy-phenyl)-pyrrolidin-3-yl]-acetamide",0.29,uM,=,-0.5376020021010439,0,O=C(C[C@H]1CN(CCC2CCS(=O)(=O)CC2)C[C@@H]1c1ccccc1)Nc1ccccc1
5031,77051,10.1021/jm970517u,,,,Inhibition of Ikr current in isolated guinea pig myocytes during a 0.5 s voltage clamp step from -50 to -10 mV.,CN1C(=O)[C@H](NC(=O)/C=C/c2ccc(Cl)cc2Cl)N=C(c2ccccc2)c2ccccc21,"3-(2,4-Dichloro-phenyl)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acrylamide",1.5,uM,=,0.1760912590556812,1,O=C(/C=C/c1ccccc1)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O
5032,420606,10.1016/j.bmcl.2006.11.061,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,CC(=O)Nc1ccc2c(c1)C(N1CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC1)CC2,"N-(1-(6-acetamido-2,3-dihydro-1H-inden-1-yl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide",27.2,uM,=,1.434568904034199,1,O=C(NC1CCN(C2CCc3ccccc32)CC1)c1cc(=O)c2ccccc2o1
5033,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,Cc1nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"3-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,2,4-oxadiazole",4.2,uM,=,0.6232492903979004,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)nc1
5034,499332,10.1016/j.bmcl.2009.04.023,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(C(=O)[C@]4(C)CC[C@@H](NC(=O)OC)CC4)nc3cc2Cl)CC1,trans-methyl-4-(5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazole-2-carbonyl)-4-methylcyclohexylcarbamate,4.9,uM,=,0.6901960800285137,1,O=C(c1nc2ccc(N3CCNCC3)cc2[nH]1)C1CCCCC1
5035,964986,10.1016/j.bmcl.2013.04.047,,,,Inhibition of human ERG expressed in HEK cells by ion flux electrophysiology method,O=C(NC1CC1)c1ccc(F)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2,"(S)-2-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-N-cyclopropyl-4-fluorobenzamide",0.038,uM,=,-1.42021640338319,0,O=C(NC1CC1)c1ccccc1OCCCN1CCC2(CC1)Cc1ccccc1O2
5036,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,Fc1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(NCc3ccncc3)n2)cc1,"4-[4-(4-Fluorophenyl)-2-(piperidin-4-yl)-1,3-thiazol-5-yl]-N-(pyridin-4-ylmethyl)pyrimidin-2-amine",1.5,uM,=,0.1760912590556812,1,c1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(NCc3ccncc3)n2)cc1
5037,699583,10.1016/j.bmcl.2010.10.086,,,,Inhibition of human ERG,CN(C)[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21,"(R)-1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine",8.6,uM,=,0.9344984512435676,1,c1ccc(N2CCCc3ccccc32)cc1
5038,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,O=C(CNc1n[nH]c2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](n3ccccc3=O)CC2)C1,cis-N-(1-(4-(2-oxopyridin-1(2H)-yl)cyclohexyl)azetidin-3-yl)-2-(5-(trifluoromethyl)-1H-indazol-3-ylamino)acetamide,34.0,uM,=,1.5314789170422551,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](n3ccccc3=O)CC2)C1
5039,850453,10.1021/ml300146q,,,,Inhibition of recombinant human ERG channel IKr expressed in CHO cells by patch clamp assay,Cc1cc(C#N)ccc1-c1ccnc(NCc2n[nH]c3nc(N)ccc23)c1,"4-(2-((6-Amino-1H-pyrazolo[3,4-b]pyridin-3-yl)methylamino)pyridin-4-yl)-3-methylbenzonitrile",4.3,uM,=,0.6334684555795865,1,c1ccc(-c2ccnc(NCc3n[nH]c4ncccc34)c2)cc1
5040,1478727,10.1093/cvr/cvr044,,,,Inhibition of potassium current (Ikr) measured using whole-cell patch clamp experiments in HEK-293 cells stable transfected with hERG cDNA,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,"(2-Butyl-benzofuran-3-yl)-[4-(2-diethylamino-ethoxy)-3,5-diiodo-phenyl]-methanone",0.03,uM,=,-1.5228787452803376,0,O=C(c1ccccc1)c1coc2ccccc12
5041,2133640,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG by fluorescence polarization assay,C[C@H](C(=O)Nc1ccc(Cl)cc1)[C@H]1CC[C@@H](c2ccnc3ccc(F)cc32)CC1,"(S)-N-(4-chlorophenyl)-2-((1s,4R)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide",4.2,uM,=,0.6232492903979004,1,O=C(C[C@H]1CC[C@@H](c2ccnc3ccccc32)CC1)Nc1ccccc1
5042,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@]3(O)CC[C@H](NCc4ccc(Cl)c(Cl)c4)CC3)c2n1,"(1r,4s)-4-(3,4-dichlorobenzylamino)-1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)cyclohexanol",3.8,uM,=,0.5797835966168101,1,c1ccc(CNC2CCC(CCc3ccnc4cccnc34)CC2)cc1
5043,1655139,10.1016/j.bmcl.2016.12.054,,,,Displacement of [3H]-MK499 from human ERG IKr channel expressed in HEK293 cell membranes,N#Cc1cccc(-c2cc(F)ccc2CC(c2cccnc2)c2cccnc2)c1,"2'-(2,2-di(pyridin-3-yl)ethyl)-5'-fluorobiphenyl-3-carbonitrile",10.2,uM,=,1.0086001717619175,1,c1ccc(-c2ccccc2CC(c2cccnc2)c2cccnc2)cc1
5044,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(C(O)CC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(+)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-2-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",4.0,uM,=,0.6020599913279624,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5045,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(C)c1nc2ccccc2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,2-Isopropyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,3.9,uM,=,0.5910646070264992,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
5046,2216859,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG by manual patch clamp method,Cc1nc(C)n(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2C)n1,"2-(3,5-Dimethyl-[1,2,4]triazol-1-yl)-1-{(R)-2-methyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-ethanone",18.0,uM,=,1.255272505103306,1,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
5047,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nnc(SC)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"2-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-(methylthio)-1,3,4-oxadiazole",1.6,uM,=,0.2041199826559248,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4nnco4)N3)n2)nc1
5048,1463730,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"6-((1-((3-fluoro-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",21.6,uM,=,1.334453751150931,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
5049,629418,10.1016/j.bmcl.2010.03.071,,,,Displacement of labeled dofetilide human ERG,O=C([C@H]1C[C@H](Oc2ccc(Cl)cc2)CN1)N1CCCN(C2CCC2)CC1,"((2R,4S)-4-(4-chlorophenoxy)pyrrolidin-2-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methanone",2.0,uM,=,0.3010299956639812,1,O=C([C@H]1C[C@H](Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
5050,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,CC(C)(C)NC(=O)C1c2ccc(O)cc2C(=O)N1Cc1ccccc1-c1ccccc1,(rac)-2-(biphenyl-2-ylmethyl)-N-tert-butyl-5-hydroxy-3-oxoisoindoline-1-carboxamide,45.0,uM,=,1.6532125137753435,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
5051,825853,10.1021/ml100095k,,,,Inhibition of human ERG,O=C(O)c1cc(CN2CCN(c3ccc(Br)cc3)CC2)c2ccccn2c1=O,1-((4-(4-bromophenyl)piperazin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid,2.1,uM,=,0.3222192947339193,1,O=c1ccc(CN2CCN(c3ccccc3)CC2)c2ccccn12
5052,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,O=C1OCc2cc(CCC3(O)CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21,5-(2-(1-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)-4-hydroxypiperidin-4-yl)ethyl)isobenzofuran-1(3H)-one,6.5,uM,=,0.8129133566428556,1,O=C1OCc2cc(CCC3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
5053,1497730,10.1021/jm5020023,,,,Inhibition of human ERG expressed in CHO cells assessed as whole cell current by patch clamp assay,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-2-methoxy-piperidin-4-yl}-2-methoxy-benzamide,0.04,uM,=,-1.3979400086720375,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
5054,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,[2H]C([2H])([2H])Oc1cc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N,"6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-(methoxy-d3)nicotinonitrile",20.0,uM,=,1.3010299956639813,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
5055,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CCC(C)C(C)CN1CCC(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1,"3,5-dichloro-N-{[1-(2,3-dimethylpentyl)piperidin-4-yl]methyl}benzamide",0.883,uM,=,-0.0540392964224314,0,O=C(NCC1CCNCC1)c1ccccc1
5056,1898259,10.1016/j.bmcl.2019.126643,,,,Inhibition of human ERG,CCNC(=O)[C@H]1CC(=O)[C@@]2(C)CC[C@@H]3c4ccc(OCCCN5CCC[C@H]5C)cc4CC[C@H]3[C@H]12,"(15alpha)-N-ethyl-3-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}-17-oxoestra-1,3,5(10)-triene-15-carboxamide",17.5,uM,=,1.2430380486862944,1,O=C1CC[C@@H]2C1CC[C@@H]1c3ccc(OCCCN4CCCC4)cc3CC[C@H]12
5057,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2c1ccc(CCN1CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC1)c2Cl,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-4-chloroisobenzofuran-1(3H)-one,17.0,uM,=,1.230448921378274,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
5058,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3cnccn3)ccc2c1,(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)-2-(pyrazin-2-yl)quinoline,24.8,uM,=,1.3944516808262164,1,c1cnc(-c2ccc3cc(CCN4CCCC4)ccc3n2)cn1
5059,2106897,10.1021/acs.jmedchem.0c01863,,,,Inhibition of human ERG,COc1cc2c(cc1OC)C(=O)C(CC1(F)CCN(Cc3ccccc3F)CC1)C2,"2-((4-fluoro-1-(2-fluorobenzyl)piperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one",9.23,uM,=,0.965201701025912,1,O=C1c2ccccc2CC1CC1CCN(Cc2ccccc2)CC1
5060,2061618,10.1016/j.bmcl.2015.11.049,,,,Inhibition of human ERG by dofetilide binding assay,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3c(C)[nH]nc3n2)c(OC(C)C)cc1C1CCN(C)CC1,"US8592432, 34",20.8,uM,=,1.3180633349627615,1,c1ccc(Nc2nc(Nc3ccc(C4CCNCC4)cc3)nc3n[nH]cc23)cc1
5061,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,Cc1ncc(CNC2CCN(CCn3c(=O)ccc4ncc(F)cc43)CC2)cc1C#N,"5-((1-(2-(7-Fluoro-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)-piperidin-4-ylamino)methyl)-2-methylnicotinonitrile",69.0,uM,=,1.8388490907372552,1,O=c1ccc2ncccc2n1CCN1CCC(NCc2cccnc2)CC1
5062,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,COc1nc2ccc(C(=O)N(C)C)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,"3-(4-(dimethylamino)-2-hydroxy-2-(naphthalen-1-yl)-1-phenylbutyl)-2-methoxy-N,N-dimethylquinoline-6-carboxamide",6.3,uM,=,0.7993405494535817,1,c1ccc(C(Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
5063,1749583,10.1016/j.bmcl.2017.10.040,,,,Inhibition of human ERG,CCN(CC)CCNC(=O)c1ccnc(-c2cnn3ccc(-c4cccs4)nc23)c1,"N-(2-(diethylamino)ethyl)-2-(5-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)isonicotinamide",1.17,uM,=,0.0681858617461616,1,c1ccc(-c2cnn3ccc(-c4cccs4)nc23)nc1
5064,984415,10.1021/jm400314m,,,,Binding affinity to human ERG channel,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)cc2)C1,"2-amino-1-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one",3.95,uM,=,0.5965970956264602,1,c1ccc(Nc2c(-c3ccccc3)nc3n2CCNC3)cc1
5065,612186,10.1016/j.bmcl.2009.12.071,,,,Inhibition of human ERG by patch clamp study,Cn1cnc(C(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)[C@H]2C[C@H]3CNC[C@H]3C2)c1,"(exo)-1-Methyl-1H-imidazole-4-carboxylic acid(3-trifluoromethyl, 4-fluorobenzyl)-(octahydro-cyclopenta[c]pyrrol-5-yl)-amide",4.33,uM,=,0.6364878963533654,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)[C@H]1C[C@H]2CNC[C@H]2C1
5066,2014372,10.1021/acsmedchemlett.9b00123,,,,Displacement of Tracer Red from human ERG incubated for 2 hrs by fluorescence polarization assay,CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(S(F)(F)(F)(F)F)cc2)cc1,"(-)-2-[4-(dimethylamino)phenyl]-N-[(3S,4R)-4-[4-(pentafluoro-lambda6-sulfanyl)phenyl]pyrrolidin-3-yl]acetamide",2.572,uM,=,0.4102709642521844,1,O=C(Cc1ccccc1)N[C@@H]1CNC[C@H]1c1ccccc1
5067,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cc1ncc([C@H]2CC[C@@H](N3CC(NC(=O)CNc4nn(C)c5ccc(C(F)(F)F)cc45)C3)CC2)s1,cis-N-{1-[4-Hydroxy-4-(2-methyl-thiazol-5-yl)-cyclohexyl]-azetidin-3-yl}-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,25.0,uM,=,1.3979400086720375,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3cncs3)CC2)C1
5068,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CCO3)N1CC[C@@H](NCc3cncn3C2)C1=O,"R,R-30-oxo-19,24-dioxa-2,6,10,12-tetraazahexacyclo[18.6.2.12,5.114,18.08,12.023,27]triaconta-8,10,14(29),15,17,20(28),21,23(27)-octaen-17-yl cyanide",0.15,uM,=,-0.8239087409443188,0,O=C1[C@H]2CCN1[C@@H]1CCOc3ccc(cc31)Oc1cccc(c1)Cn1cncc1CN2
5069,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,O=C(CNc1ncnc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3ccc(O)cn3)CC2)C1,Cis-N-(1-(4-(5-hydroxypyridin-2-yl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,12.9,uM,=,1.110589710299249,1,O=C(CNc1ncnc2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccccn3)CC2)C1
5070,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2cc3c(N[C@@H](C)C4CCOCC4)c(C(N)=O)cnc3cc2F)cn1,7-Fluoro-6-[6-(methoxymethyl)-3-pyridinyl]-4-{[(1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide,8.9,uM,=,0.9493900066449128,1,c1cncc(-c2ccc3nccc(NCC4CCOCC4)c3c2)c1
5071,2157068,10.1021/acsmedchemlett.1c00445,,,,Inhibition of hERG expressed in HEK293 cells at -80 mV holding potential by automated patch-clamp method,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)Cn2cc(C#N)nc2C(N)=N1,"(R)-N-(3-(8-amino-2-cyano-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-6-yl)-4-fluorophenyl)-5-cyanopicolinamide",6.6,uM,=,0.8195439355418687,1,O=C(Nc1cccc(C2Cn3ccnc3C=N2)c1)c1ccccn1
5072,1829675,10.1016/j.ejmech.2018.10.006,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",29.5,uM,=,1.469822015978163,1,O=C1NC(=O)C(Cc2ccc(OCCNc3ccccn3)cc2)S1
5073,938040,10.1016/j.bmcl.2012.11.013,,,,Inhibition of human ERG by patch clamp assay,COc1cc(Nc2cc(-c3cccc(C#N)c3)ccn2)ccc1N1CCOCC1,3-(2-(3-methoxy-4-morpholinophenylamino)pyridin-4-yl)benzonitrile,7.7,uM,=,0.8864907251724818,1,c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)c2)cc1
5074,2079118,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 1 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),N#Cc1cccc(NC(=O)COc2ccc(C(=O)c3cc(Cl)ccc3Br)cc2)c1,2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)-N-(3-cyanophenyl)acetamide,0.0283,uM,=,-1.5482135644757098,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1ccccc1
5075,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,COC(=O)N(C)c1c(N)nc(-n2nc(Cc3ccccc3F)c3cc(F)ccc32)nc1N,"methyl N-[4,6-diamino-2-[5-fluoro-3-[(2-fluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methyl-carbamate",15.1,uM,=,1.1789769472931697,1,c1ccc(Cc2nn(-c3ncccn3)c3ccccc23)cc1
5076,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",O=c1cc(OCc2cccc(Cl)c2)ccn1-c1ccc(OCCN2CCCC2)cc1,4-[(3-Chlorobenzyl)oxy]-1-{4-[2-(pyrrolidin-1-yl)ethoxy]-phenyl}pyridin-2(1H)-one,0.0019,uM,=,-2.721246399047171,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCN2CCCC2)cc1
5077,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c([C@@H]2CN3CCN(C(=O)Cc4cnc(-n5cnnn5)nc4)C[C@H]3CO2)ccc(F)c1C#N,"3-((3R,9aS)-8-(2-(2-(1H-tetrazol-1-yl)pyrimidin-5-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-6-fluoro-2-methylbenzonitrile",5.9,uM,=,0.7708520116421442,1,O=C(Cc1cnc(-n2cnnn2)nc1)N1CCN2C[C@@H](c3ccccc3)OC[C@@H]2C1
5078,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,COc1ccc([C@H]2CC[C@@H](N3CC(NC(=O)CNc4n[nH]c5ccc(C(F)(F)F)cc45)C3)CC2)cn1,cis-N-{1-[4-(6-Methoxy-pyridin-3-yl)-cyclohexyl]-azetidin-3-yl}-2-(5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,2.5,uM,=,0.3979400086720376,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3cccnc3)CC2)C1
5079,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCOC4)N3)n2)cc1,"(3R)-3-(4-phenyl-1H-imidazol-2-yl)-1-(tetrahydrofuran-3-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.064,uM,=,-1.193820026016113,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)C(C4CCOC4)N3)n2)cc1
5080,811343,10.1016/j.bmcl.2012.01.095,,,,Inhibition of human ERG by fluorescence polarization assay,CCC(NCCCC[C@@H](Oc1cc(C)c(F)c(C)c1)C(=O)NO)c1ccc(F)cc1,"rac-(2R)-2-(4-fluoro-3,5-dimethylphenoxy)-6-(1-(4-fluorophenyl)propylamino)-N-hydroxyhexanamide",2.7,uM,=,0.4313637641589873,1,c1ccc(CNCCCCCOc2ccccc2)cc1
5081,883359,10.1021/jm300952s,,,,Inhibition of human ERG by cell-based electrophysiology assay,Cc1nn(C)cc1-c1nc2c(N3CCN(Cc4ncon4)CC3)c(Cl)cnc2[nH]1,"3-((4-(6-Chloro-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-1,2,4-oxadiazole",11.0,uM,=,1.0413926851582251,1,c1cc(N2CCN(Cc3ncon3)CC2)c2nc(-c3cn[nH]c3)[nH]c2n1
5082,2064218,10.1021/acs.jmedchem.6b01265,,,,Inhibition of human ERG by IonWorks patch clamp electrophysiology method,CC(C)(C)N1CCN(C(=O)c2ccc(-c3cnc(N)c(-c4ccc(C(F)(F)F)cc4)n3)cc2)CC1,(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-(tertbutyl)piperazin-1-yl)methanone,2.0,uM,=,0.3010299956639812,1,O=C(c1ccc(-c2cncc(-c3ccccc3)n2)cc1)N1CCNCC1
5083,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,CN(C)CCC1=C(Cc2cccnn2)c2ccc(F)cc2C1,"2-(6-fluoro-3-(pyridazin-3-ylmethyl)-1H-inden-2-yl)-N,N-dimethylethanamine",0.89,uM,=,-0.0506099933550872,0,C1=C(Cc2cccnn2)c2ccccc2C1
5084,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCc1nc(-c2nc3ccccc3[nH]2)c(N2CCN(C(=O)Cn3cnc4cccnc43)[C@H](C)C2)s1,"US9266876, 146",0.96,uM,=,-0.0177287669604316,0,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2nc3ccccc3[nH]2)CC1
5085,1972831,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,COCCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5cccnn45)c3)cc2C2CC2)CC1,"N-[3-cyclopropyl-4-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]phenyl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",0.08,uM,=,-1.0969100130080565,0,O=C(Nc1ccc(CN2CCNCC2)c(C2CC2)c1)c1cccc(C#Cc2cnc3cccnn23)c1
5086,2219922,10.1016/j.bmcl.2021.128463,,,,Inhibition of human ERG expressed in HEK cells by voltage clamp assay,Cc1cc(C#N)cnc1C(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)[C@@](C)(C(F)F)C(=N)N2)n1,"5-cyano-N-(6-((3R,6R)-6-(difluoromethyl)-5-imino-3,6-dimethyl-1,1-dioxidothiomorpholin-3-yl)-5-fluoropyridin-2-yl)-3-methylpicolinamide",44.0,uM,=,1.6434526764861874,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3ccccn3)n2)N1
5087,2287586,10.1021/acsmedchemlett.8b00517,,,,Inhibition of hERG potassium channel incubated for 4 hrs by fluorescence polarization assay,CCC(=O)CCCCC[C@H](NC(=O)C12CCN(CC1)CC2)c1ncc(-c2cc3ccccc3nc2OC)o1,(S)-N-(1-(5-(2-methoxyquinolin-3-yl)oxazol-2-yl)-7-oxononyl)quinuclidine-4-carboxamide,0.19,uM,=,-0.721246399047171,0,O=C(NCc1ncc(-c2cnc3ccccc3c2)o1)C12CCN(CC1)CC2
5088,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Oc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1,"4-(2-((1R,3R)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl)-1H-imidazol-4-yl)phenol",0.467,uM,=,-0.3306831194338878,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
5089,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(CN1CCOCC1)c1ccccc1,1-(2-morpholino-1-phenylethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,6.9,uM,=,0.8388490907372553,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(CN1CCOCC1)c1ccccc1
5090,1472762,10.1021/jm501940y,,,,Inhibition of human ERG channel after 2 hrs by fluorescence polarization assay,O=C(NO)C1(S(=O)(=O)c2ccc(OCc3ccc(OC(F)(F)F)cc3)cc2)CCC2(CCNCC2)C1,3-[4-[[4-(Trifluoromethoxy)phenyl]methoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid,50.3,uM,=,1.701567985055927,1,O=S(=O)(c1ccc(OCc2ccccc2)cc1)C1CCC2(CCNCC2)C1
5091,1713882,10.1016/j.bmcl.2018.05.030,,,,Inhibition of human ERG expressed in CHO-K1 cells at -90 mV holding potential by Qpatch clamp assay,CN(CCC1CCN(C(=O)OCc2cc(Cl)cc(Cl)c2)CC1)C(=O)c1c[nH]nn1,"US9409895, 35",8.6,uM,=,0.9344984512435676,1,O=C(NCCC1CCN(C(=O)OCc2ccccc2)CC1)c1c[nH]nn1
5092,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4ccc(F)cc43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(6-fluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",5.4,uM,=,0.7323937598229685,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
5093,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)C(=O)CN1CCC(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1,"3,5-dichloro-N-{[1-(3,3-dimethyl-2-oxobutyl)piperidin-4-yl]methyl}benzamide",2.047,uM,=,0.3111178426625057,1,O=C(NCC1CCNCC1)c1ccccc1
5094,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn([C@H]3CCCCN(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"(S)-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)azepan-2-one",21.9,uM,=,1.3404441148401185,1,O=C1NCCCC[C@@H]1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
5095,1911678,10.1021/acs.jmedchem.8b01725,,,,Inhibition of human ERG by Q-patch assay,C[C@@H]1OCC2(CCN(c3nc4[nH]nc(-c5cccc(Cl)c5Cl)c4c(=O)n3C)CC2)[C@@H]1N,"6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-5-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one",0.29,uM,=,-0.5376020021010439,0,O=c1[nH]c(N2CCC3(CCOC3)CC2)nc2[nH]nc(-c3ccccc3)c12
5096,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(CC(C)(C)C)N1CCC(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1,"3,5-dichloro-N-{[1-(1,3,3-trimethylbutyl)piperidin-4-yl]methyl}benzamide",2.208,uM,=,0.3439990690571613,1,O=C(NCC1CCNCC1)c1ccccc1
5097,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cc(-c2ccc(OC3CCN(C(=O)Cc4ccc(OC(F)(F)F)cc4)CC3)c(C(N)=O)n2)cn1,6-(1-methyl-1H-pyrazol-4-yl)-3-(1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yloxy)picolinamide,5.3,uM,=,0.724275869600789,1,O=C(Cc1ccccc1)N1CCC(Oc2ccc(-c3cn[nH]c3)nc2)CC1
5098,833999,10.1016/j.bmcl.2012.06.094,,,,Inhibition of human ERG by patch clamp assay,Cc1cccc(-c2noc(C3CC(=O)N(c4ccc(F)cc4)C3)n2)c1,"(-)-1-(4-fluorophenyl)-4-(3-m-tolyl-1,2,4-oxadiazol-5-yl)pyrrolidin-2-one",8.0,uM,=,0.9030899869919436,1,O=C1CC(c2nc(-c3ccccc3)no2)CN1c1ccccc1
5099,964237,10.1016/j.ejmech.2013.03.061,,,,Displacement of [3H]astemizole from human ERG channel transfected in HEK293 cells after 60 mins by liquid scintillation counting analysis,O=C(/C=C/c1ccc2c(c1)C(=O)CC1(CCN(Cc3ccc(F)cc3)CC1)O2)NO,"3-(1'-(4-fluorobenzyl)-4-oxospiro[chroman-2,4'-piperidine]-6-yl)-N-hydroxyacrylamide",2.38,uM,=,0.3765769570565119,1,O=C1CC2(CCN(Cc3ccccc3)CC2)Oc2ccccc21
5100,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cc2c(cc1OC)CN(C(=O)N1CCN(C(C)C)CC1)CC2,"(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)(4-isopropylpiperazin-1-yl)methanone",115.0,uM,=,2.060697840353612,1,O=C(N1CCNCC1)N1CCc2ccccc2C1
5101,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2c(=O)n(C)c(-c3ccc(OC4CCN(C5CCC5)CC4)cc3)nc12,2-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-8-methoxy-3-methylquinazolin-4(3H)-one,10.0,uM,=,1.0,1,O=c1[nH]c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2ccccc12
5102,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N(CC(F)(F)F)c3ccc4ccccc4c3)nn2)ccc1-n1cnc(C)c1,"2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-N-(naphthalen-2-yl)-N-(2,2,2-trifluoroethyl)acetamide",0.63,uM,=,-0.2006594505464183,0,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)Nc1ccc2ccccc2c1
5103,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNC(C)c1ccccc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)phenyl)-N-methylethanamine",3.85,uM,=,0.5854607295085007,1,c1ccc(Oc2ccccc2)cc1
5104,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(-c4ccc(F)cc4)c3n2CCN1CC1CC1,"2-(Cyclopropylmethyl)-6-(4-fluorophenyl)-3,4-dihydropyrazino-(1,2-a)bendmidazol-1(2H)-one",9.6,uM,=,0.9822712330395684,1,O=C1c2nc3cccc(-c4ccccc4)c3n2CCN1CC1CC1
5105,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cccc(C(F)(F)F)c2)C2CCN(S(C)(=O)=O)CC2)CC1,(R)-N-ethyl-2-(4-(methylsulfonyl)phenyl)-N-(1-(3-(1-(methylsulfonyl)piperidin-4-yl)-3-(3-(trifluoromethyl)phenyl)propyl)piperidin-4-yl)acetamide,7.9,uM,=,0.8976270912904415,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
5106,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,COc1cccc([C@]2(O)CC[C@H](N3CC(NC(=O)CNc4ncnc5ccc(C(F)(F)F)cc45)C3)CC2)n1,Cis-N-(1-(4-hydroxy-4-(6-methoxypyridin-2-yl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,13.4,uM,=,1.1271047983648077,1,O=C(CNc1ncnc2ccccc12)NC1CN(C2CCC(c3ccccn3)CC2)C1
5107,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-((5-hydroxy-4-oxo-1,4-dihydropyridin-2-yl)methoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",5.3,uM,=,0.724275869600789,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCc7cc(=O)cc[nH]7)nc56)(CC3)OC4)nc2N1
5108,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn([C@H]3C[C@@H]([Si](C)(C)C)CCN(Cc4ccccc4)C3=O)nn2)ccc1-n1cnc(C)c1,"(3S,5S)-1-benzyl-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-5-(trimethylsilyl)azepan-2-one",40.8,uM,=,1.61066016308988,1,O=C1[C@@H](n2cc(-c3ccc(-n4ccnc4)cc3)nn2)CCCCN1Cc1ccccc1
5109,499332,10.1016/j.bmcl.2009.04.023,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(C(=O)[C@]4(C)CC[C@@H](NC(=O)OC)CC4)nc3cc2C)CC1,trans-methyl-4-(6-(4-ethylpiperazin-1-yl)-5-methyl-1H-benzo[d]imidazole-2-carbonyl)-4-methylcyclohexylcarbamate,3.0,uM,=,0.4771212547196624,1,O=C(c1nc2ccc(N3CCNCC3)cc2[nH]1)C1CCCCC1
5110,798813,10.1016/j.bmcl.2011.11.019,,,,Inhibition of human ERG,COc1cc2ncnc(Oc3ccc(CC(=O)Nc4cnn(C(C)C)c4)cc3)c2cc1OC,"2-(4-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-N-(1-isopropyl-1H-pyrazol-4-yl)acetamide",137.0,uM,=,2.1367205671564067,1,O=C(Cc1ccc(Oc2ncnc3ccccc23)cc1)Nc1cn[nH]c1
5111,501217,10.1016/j.bmcl.2009.02.099,,,,Inhibition of human ERG by patch-clamp assay,Cc1cc2ncc(C(=O)N3CCC([C@H](N)Cc4cc(F)c(F)cc4F)CC3)c(C)n2n1,"(R)-(4-(1-amino-2-(2,4,5-trifluorophenyl)ethyl)piperidin-1-yl)(2,7-dimethylpyrazolo[1,5-a]pyrimidin-6-yl)methanone",18.0,uM,=,1.255272505103306,1,O=C(c1cnc2ccnn2c1)N1CCC(CCc2ccccc2)CC1
5112,2196932,10.1016/j.bmcl.2022.128911,,,,Inhibition of hERG,C=C(c1ccc(N2C[C@@H]3C[C@H]2CN3C)cc1)c1ccc2c(c1)Nc1ccccc1S2,"2-(1-(4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)vinyl)-10H-phenothiazine",12.0,uM,=,1.0791812460476249,1,C=C(c1ccc(N2C[C@@H]3C[C@H]2CN3)cc1)c1ccc2c(c1)Nc1ccccc1S2
5113,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,Clc1ccc(C2CC=CCNC2)cc1Cl,"rac-3-(3,4-Dichloro-phenyl)-2,3,4,7-tetrahydro-1H-azepine",11.0,uM,=,1.0413926851582251,1,C1=CCC(c2ccccc2)CNC1
5114,1472762,10.1021/jm501940y,,,,Inhibition of human ERG channel after 2 hrs by fluorescence polarization assay,COc1ccc(Oc2ccc(S(=O)(=O)C3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1,3-[4-(4-Methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid,37.0,uM,=,1.568201724066995,1,O=S(=O)(c1ccc(Oc2ccccc2)cc1)C1CCC2(CCNCC2)C1
5115,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(C(F)(F)F)cc2)[C@@H]3C)n1,"US9422299, 21",45.0,uM,=,1.6532125137753435,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
5116,2021700,10.1021/acs.jmedchem.9b00069,,,,Inhibition of human ERG by thallium flux assay,CC(C)(CO)Cn1nc(-c2ccc3cc(OC4CC4)ccc3c2)c(C(N)=O)c1N,"5-Amino-3-(6-cyclopropoxynaphthalen-2-yl)-1-(3-hydroxy-2,2-dimethylpropyl)-1H-pyrazole-4-carboxamide",13.0,uM,=,1.1139433523068367,1,c1cc(-c2ccc3cc(OC4CC4)ccc3c2)n[nH]1
5117,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,C1=CCC(c2ccc3ccccc3c2)CNC1,"3-Naphthalen-2-yl-2,3,4,7-tetrahydro-1H-azepine",15.4,uM,=,1.187520720836463,1,C1=CCC(c2ccc3ccccc3c2)CNC1
5118,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(-c2cnccn2)sc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1,(R)-4-methyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-2-(pyrazin-2-yl)thiazole,32.0,uM,=,1.505149978319906,1,c1cnc(-c2ncc(-c3ccc4cc(CCN5CCCC5)ccc4n3)s2)cn1
5119,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,CCN1CCCC(CN2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"rac-N-(3,4-dichlorophenyl)-4-((1-ethylpiperidin-3-yl)methyl)piperazine-1-carboxamide",4.3,uM,=,0.6334684555795865,1,O=C(Nc1ccccc1)N1CCN(CC2CCCNC2)CC1
5120,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2CC3(CCNCC3)Oc3ccccc32)cc1,"(+/-)-N,N-Diethyl-4-(spiro[chroman-2,4'-piperidine]-4-yl)benzamide",5.094,uM,=,0.7070589406275963,1,c1ccc(C2CC3(CCNCC3)Oc3ccccc32)cc1
5121,2100973,10.1021/acs.jmedchem.1c00375,,,,Displacement of [3H]-dofetilide from human ERG after 60 mins by scintillation counting method,Cc1c(N2CC[C@@H](C3(N)CC3)C2)c(F)cc2cc(C(N)=O)c(=O)n(C3CC3)c12,"(R)-7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide",10.0,uM,=,1.0,1,O=c1ccc2ccc(N3CC[C@@H](C4CC4)C3)cc2n1C1CC1
5122,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,Cn1cc([C@@]2(c3cc(C(=O)O)ccn3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"2-((1S,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)isonicotinicacid",19.56,uM,=,1.2913688504515826,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ccccn4)N3)n2)cc1
5123,1352925,10.1016/j.bmcl.2014.03.040,,,,Inhibition of human ERG channel,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1,2-Methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine,2.4,uM,=,0.380211241711606,1,O=S(=O)(c1ccccc1-c1ccccc1)N1CCCC1
5124,1676692,10.1021/acs.jmedchem.7b01039,,,,Inhibition of human ERG by fluorescently labeled tracer binding method,COc1ccc(Oc2ccnc3cc(-c4cnn(C5CCNCC5)c4)ccc23)cc1,4-(4-Methoxyphenoxy)-7-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-quinoline,2.46,uM,=,0.3909351071033791,1,c1ccc(Oc2ccnc3cc(-c4cnn(C5CCNCC5)c4)ccc23)cc1
5125,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(F)ccc3OC[C@H]2[C@@]1(CCCO)c1ccccc1,"1-[(3R,3aR)-8-fluoro-3-(3-hydroxy-propyl)-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-2-yl]-ethanone",18.0,uM,=,1.255272505103306,1,C1=NN2c3ccccc3OC[C@H]2C1c1ccccc1
5126,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,CCOC(=O)N1CCCc2nc([C@@H](C)NC(=O)c3ccc(F)cc3)ccc21,"(R)-ethyl 6-(1-(4-fluorobenzamido)ethyl)-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate",60.0,uM,=,1.7781512503836436,1,O=C(NCc1ccc2c(n1)CCCN2)c1ccccc1
5127,2093710,10.1016/j.ejmech.2020.112710,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,Nc1n[nH]c2cccc(C#Cc3cccc(NC(=O)c4ccc(N5CCOCC5)c(C(F)(F)F)c4)c3)c12,N-[3-(3-Amino-1H-indazol-4-ylethynyl)-phenyl]-4-morpholin-4-yl-3-trifluoromethyl-benzamide,3.405,uM,=,0.532117116248804,1,O=C(Nc1cccc(C#Cc2cccc3[nH]ncc23)c1)c1ccc(N2CCOCC2)cc1
5128,466094,10.1016/j.bmcl.2008.02.012,,,,Inhibition of human ERG,CN(C)C(=O)C(N)c1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1,4-(amino-dimethylcarbamoyl-methyl)-N-(2-amino-5-thiophen-2-yl-phenyl)-benzamide,6.8,uM,=,0.8325089127062363,1,O=C(Nc1cccc(-c2cccs2)c1)c1ccccc1
5129,1622890,10.1021/acsmedchemlett.6b00433,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes after 90 mins by scintillation counting,Cn1ccc(Cn2cc(-c3ccc(Cl)c(OC(F)F)c3)cn2)n1,4-(4-chloro-3-(difluoromethoxy)phenyl)-1-((1-methyl-1H-pyrazol-3-yl)methyl)-1H-pyrazole,8.08,uM,=,0.9074113607745862,1,c1ccc(-c2cnn(Cc3cc[nH]n3)c2)cc1
5130,1743006,10.1021/acs.jmedchem.8b01183,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp assay,O[C@H]1Cc2ccccc2C2(CCC(N3CCN(C4CCCCC4)CC3)CC2)O1,"cis-4'-(4-cyclohexylpiperazin-1-yl)-3,4-dihydrospiro[[2]benzopyran-1,1'-cyclohexan]-3-ol",3.207,uM,=,0.5060989599284405,1,c1ccc2c(c1)CCOC21CCC(N2CCN(C3CCCCC3)CC2)CC1
5131,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,C[C@@H]1CN(c2sc(CO)nc2-c2nc3ccccc3[nH]2)CCN1C(=O)Cn1cnc2cccnc21,"US9266876, 225",19.0,uM,=,1.2787536009528289,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2nc3ccccc3[nH]2)CC1
5132,1686959,10.1021/acs.jmedchem.7b01490,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by patch clamp assay,CN(c1ncc(C(N)=O)c2sc(-c3ccccc3)cc12)[C@H]1CCCNC1,"4-{Methyl[(3S)-piperidin-3-yl]amino}-2-phenylthieno[3,2-c]-pyridine-7-carboxamide",2.7,uM,=,0.4313637641589873,1,c1ccc(-c2cc3c(N[C@H]4CCCNC4)nccc3s2)cc1
5133,461764,10.1016/j.bmcl.2007.11.047,,,,Displacement of [35S]MK-499 from ERG expressed in HEK293 cells,Nc1ccc(-c2ccccc2)cc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,[4-(4-amino-biphenyl-3-ylcarbamoyl)-benzyl]-carbamic acid pyridin-3-ylmethyl ester,3.0,uM,=,0.4771212547196624,1,O=C(NCc1ccc(C(=O)Nc2cccc(-c3ccccc3)c2)cc1)OCc1cccnc1
5134,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)C[C@H]2c2ccc(OC)cc2)cc1,(R)-1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxy-phenyl)-2-imidazolidinone,15.1,uM,=,1.1789769472931697,1,O=C1NC[C@@H](c2ccccc2)N1CCc1ccccc1
5135,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,Fc1ccc(C2(COCc3cc(C(F)(F)F)cc(Cl)n3)CCNCC2)cc1,2-chloro-6-(((4-(4-fluorophenyl)piperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,20.0,uM,=,1.3010299956639813,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
5136,2048454,10.1016/j.bmc.2020.115734,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,CCn1nc(C2(C)CC2)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(OC)n2)cs1,N-(1-ethyl-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine,12.3,uM,=,1.089905111439398,1,c1cn(-c2ccc(-c3csc(Nc4cc(C5CC5)n[nH]4)n3)nc2)cn1
5137,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(OC)cc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-4-methoxyphenyl)-N-methylmethanamine",0.692,uM,=,-0.1598939055432422,0,c1ccc(Oc2ccccc2)cc1
5138,1840679,10.1016/j.ejmech.2019.02.022,,,,Inhibition of human ERG incubated for 1 hr by Fluorescence polarization binding assay,CN1CCOc2c1cnn1c(-c3ccc4cccc(NC5CCCCC5)c4c3)nnc21,"N-cyclohexyl-7-(7-methyl-8,9-dihydro-7H-[1,4]oxazino[2,3-d][1,2,4]triazolo[4,3-b]pyridazin-3-yl)naphthalen-1-amine",6.06,uM,=,0.7824726241662862,1,c1cc(NC2CCCCC2)c2cc(-c3nnc4c5c(cnn34)NCCO5)ccc2c1
5139,1459712,10.1016/j.ejmech.2014.08.059,,,,Inhibition of human ERG expressed in CHO cells after 20 mins by thallium assay,N#C[C@@H]1C[C@H](F)CN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,"(2S,4S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-4-fluoropyrrolidine-2-carbonitrile",97.7,uM,=,1.989894563718773,1,O=C(CCCc1ccccc1)N1CCCC1
5140,883359,10.1021/jm300952s,,,,Inhibition of human ERG by cell-based electrophysiology assay,Cc1cc(CN2CCN(c3c(Cl)cnc4[nH]c(-c5cn(C)nc5C5CC5)nc34)CC2)no1,"3-((4-(6-Chloro-2-(3-cyclopropyl-1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole",2.5,uM,=,0.3979400086720376,1,c1cc(N2CCN(Cc3ccon3)CC2)c2nc(-c3c[nH]nc3C3CC3)[nH]c2n1
5141,964986,10.1016/j.bmcl.2013.04.047,,,,Inhibition of human ERG expressed in HEK cells by ion flux electrophysiology method,O=C(c1ccc(O)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2)N1CCC(O)CC1,"(S)-(2-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-hydroxyphenyl)(4-hydroxypiperidin-1-yl)methanone",1.6,uM,=,0.2041199826559248,1,O=C(c1ccccc1OCCCN1CCC2(CC1)Cc1ccccc1O2)N1CCCCC1
5142,1366626,10.1021/jm500535j,,,,Inhibition of human ERG,Nc1nccn1CC(O)c1ccc(Cl)cc1F,rac-2-(2-Amino-1H-imidazol-1-yl)-1-(4-chloro-2-fluorophenyl)ethan-1-ol,60.0,uM,=,1.7781512503836436,1,c1ccc(CCn2ccnc2)cc1
5143,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2cc(F)ccc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-6-fluoro-4-oxo-4H-chromene-2-carboxamide",0.004,uM,=,-2.397940008672037,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
5144,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4c(F)cc(F)cc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"6,8-difluoro-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",1.83,uM,=,0.2624510897304295,1,O=C1Nc2ccccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
5145,2293467,10.1021/acs.jmedchem.7b00463,,,,Inhibition of hERG potassium channel by Q-patch clamp assay,COc1cccc(NC(=O)c2nnn(Cc3ccc(CN4CCOCC4)cc3)c2N)c1,5-amino-N-(3-methoxyphenyl)-1-[[4-(morpholinomethyl)phenyl]methyl]triazole-4-carboxamide,24.0,uM,=,1.380211241711606,1,O=C(Nc1ccccc1)c1cn(Cc2ccc(CN3CCOCC3)cc2)nn1
5146,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3ccc(C(F)(F)F)n3)[C@H](C)C2)cn1,1-{(R)-4-[4-(2-Ethoxy-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-2-(3-trifluoromethyl-pyrazol-1-yl)-ethanone,5.1,uM,=,0.7075701760979364,1,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
5147,1869840,10.1016/j.bmcl.2019.01.024,,,,Inhibition of human ERG,CC(C)(O)c1cccc(-c2ccc3nc(-c4ccc(Cl)cc4)cn3c2)c1,"2-(3-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl)phenyl)propan-2-ol",1.5,uM,=,0.1760912590556812,1,c1ccc(-c2ccc3nc(-c4ccccc4)cn3c2)cc1
5148,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cnc3ccccc3c2)[nH]1,(S)-6-methyl-N-((S)-7-oxo-1-(5-(quinolin-3-yl)-1H-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide,11.0,uM,=,1.0413926851582251,1,O=C(NCc1ncc(-c2cnc3ccccc3c2)[nH]1)[C@H]1CC12CCNCC2
5149,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,C[C@@H]1CN(c2nnc(C(F)(F)F)o2)CCN1c1ncc(OCc2ccc(S(C)(=O)=O)cc2F)cn1,"5-{[2-Fluoro-4-(methylsulfonyl)benzyl]oxy}-2-{(2R)-2-methyl-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]piperazin-1-yl}pyrimidine",6.9,uM,=,0.8388490907372553,1,c1ccc(COc2cnc(N3CCN(c4nnco4)CC3)nc2)cc1
5150,1475693,10.1016/j.bmcl.2015.04.002,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,COc1ccc2ncc(C(F)(F)F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-methoxy-3-(trifluoromethyl)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.73,uM,=,-0.1366771398795441,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5151,880571,10.1021/ml300280g,,,,Binding affinity to human ERG,N#Cc1ccc(N2CCN(Cc3cc(C(=O)N[C@H]4CCCC[C@@H]4O)c(=O)n4ccccc34)CC2)cc1,"1-((4-(4-cyanophenyl)piperazin-1-yl)methyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-oxo-4H-quinolizine-3-carboxamide",0.39,uM,=,-0.4089353929735008,0,O=C(NC1CCCCC1)c1cc(CN2CCN(c3ccccc3)CC2)c2ccccn2c1=O
5152,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(F)ccc3OC[C@H]2[C@@]1(CCCN(C)C)c1ccccc1,"1-[(3R,3aR)-3-(3-dimethylamino-propyl)-8-fluoro-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-2-yl]-ethanone",5.94,uM,=,0.7737864449811935,1,C1=NN2c3ccccc3OC[C@H]2C1c1ccccc1
5153,1986395,10.1016/j.bmcl.2020.127027,,,,Inhibition of human ERG,N#Cc1ccc2nn(CCCCN3CCN(c4cccc5sccc45)CC3)c(=O)n2c1,"2-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridine-6-carbonitrile",1.05,uM,=,0.021189299069938,1,O=c1n(CCCCN2CCN(c3cccc4sccc34)CC2)nc2ccccn12
5154,1682731,10.1021/acs.jmedchem.7b01135,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cell membranes,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccc(C3CC3)cc2)n1,"1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-3-(4-cyclopropylphenylamino)-1H-pyrazole-4-carboxamide",35.0,uM,=,1.5440680443502757,1,c1cc(C2CC2)ccc1Nc1ccn([C@@H]2CCCOC2)n1
5155,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,Fc1cc2ncn([C@H]3C[C@@H]4[C@@H](CNC(c5ccc(Cl)cc5)C(F)(F)F)[C@@H]4C3)c2cc1F,"1-(4-chlorophenyl)-N-(((1R,3s,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)methyl)-2,2,2-trifluoroethanamine",0.46,uM,=,-0.3372421683184259,0,c1ccc(CNC[C@@H]2[C@H]3C[C@H](n4cnc5ccccc54)C[C@@H]23)cc1
5156,77051,10.1021/jm970517u,,,,Inhibition of Ikr current in isolated guinea pig myocytes during a 0.5 s voltage clamp step from -50 to -10 mV.,CN(C)CCN1C(=O)C(NC(=O)CCc2ccc(Cl)cc2Cl)N=C(c2ccccc2)c2ccccc21,"3-(2,4-Dichloro-phenyl)-N-[1-(2-dimethylamino-ethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-propionamide",0.1,uM,=,-1.0,0,O=C(CCc1ccccc1)NC1N=C(c2ccccc2)c2ccccc2NC1=O
5157,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(S(C)(=O)=O)c(F)c1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1,2-(3-fluoro-4-(methylsulfonyl)phenyl)-N-methyl-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)acetamide,2.9,uM,=,0.4623979978989561,1,O=C(Cc1ccccc1)NC1CCN(Cc2ccccc2)CC1
5158,1996017,10.1021/acs.jmedchem.9b01803,,,,Inhibition of human ERG by Ionworks electrophysiology assay,CC(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)C)n1,"(S)-2-(3-Aminopiperidin-1-yl)-4-((2,6-diisopropylpyridin-4-yl)amino)pyrimidine-5-carboxamide",3.7,uM,=,0.568201724066995,1,c1cc(Nc2ccnc(N3CCCCC3)n2)ccn1
5159,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc(C(O)(CCn2ccnc2)C(c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2OC)cc(OC)n1,"1-(6-bromo-2-methoxyquinolin-3-yl)-1-(2,3-dimethoxyphenyl)-2-(2,6-dimethoxypyridin-4-yl)-4-(1H-imidazol-1-yl)butan-2-ol",11.0,uM,=,1.0413926851582251,1,c1ccc(C(c2cnc3ccccc3c2)C(CCn2ccnc2)c2ccncc2)cc1
5160,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,COc1ccccc1[C@]12CO[C@@H](C)C[C@H]1CSC(N)=N2,"(4aR,6S,8aS)-8a-(2-Methoxyphenyl)-6-methyl-4,4a,5,6,8,8ahexahydropyrano[3,4-d][1,3]thiazin-2-amine",85.6,uM,=,1.9324737646771533,1,C1=N[C@@]2(c3ccccc3)COCC[C@H]2CS1
5161,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=N[C@](c2ccnc(C(F)(F)F)c2)(c2ccc(F)c(-c3cncnc3)c2)c2cccc(F)c21,(S)-4-Fluoro-1-(4-fluoro-3-(pyrimidin-5-yl)phenyl)-1-(2-(trifluoromethyl)pyridin-4-yl)-1H-isoindol-3-amine,7.9,uM,=,0.8976270912904415,1,C1=N[C@](c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
5162,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,NCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-(3-aminopropoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",7.9,uM,=,0.8976270912904415,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5163,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N(C)C(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-4-methyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.8,uM,=,-0.0969100130080563,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5164,819957,10.1021/ml200199c,,,,Displacement of [3H]dofetilide from human ERG,O=C(C1CCN(c2nccc(C(F)(F)F)n2)CC1)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ncccn4)cn3)CC2)C1,(S)-(3-{trans-4-Hydroxy-4-[5-(pyrimidin-2-yl)pyridin-2-yl]cyclohexylamino}pyrrolidin-1-yl){1-[4-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanone,26.0,uM,=,1.414973347970818,1,O=C(C1CCN(c2ncccn2)CC1)N1CC[C@H](NC2CCC(c3ccc(-c4ncccn4)cn3)CC2)C1
5165,1437941,10.1021/jm5016022,,,,Inhibition of human ERG channel by patch-clamp assay,CC(C)(C)n1cc2c(n1)C(=O)CC1(CCN(C(=O)c3ccc4[nH]ncc4c3)CC1)O2,"2'-tert-butyl-1-(1H-indazole-5-carbonyl)-2'H-spiro[piperidine-4,5'-pyrano[3,2-c]pyrazol]-7'(6'H)-one",34.0,uM,=,1.5314789170422551,1,O=C1CC2(CCN(C(=O)c3ccc4[nH]ncc4c3)CC2)Oc2c[nH]nc21
5166,1784292,10.1021/acsmedchemlett.7b00501,,,,Inhibition of recombinant human ERG expressed in CHO cells at -80 mV holding potential measured after 3 minutes by automated whole cell patch clamp Qpatch method,CN(C/C=C/C=C/c1ccc(C(F)(F)F)cc1)Cc1ccc2c(c1)OCCO2.Cl,"(2E,4E)-N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-N-methyl-5-(4-(trifluoromethyl)phenyl)penta-2,4-dien-1-amine Hydrochloride",12.1,uM,=,1.08278537031645,1,C(/C=C/c1ccccc1)=C\CNCc1ccc2c(c1)OCCO2
5167,2122463,10.1021/acs.jmedchem.1c00263,,,,Inhibition of human ERG,COC(=O)NC(=O)c1ccsc1NC(=O)c1ccc(C(=O)N2CCCCC2)cc1,Methyl (2-(4-(Piperidine-1-carbonyl)benzamido)thiophene-3-carbonyl)carbamate,54.44206388402516,uM,=,1.7359345808305866,1,O=C(Nc1cccs1)c1ccc(C(=O)N2CCCCC2)cc1
5168,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cnc2c(F)cc(-c3cccnc3)cc2c1NC1CCOCC1,8-Fluoro-6-(pyridin-3-yl)-4-(tetrahydro-2H-pyran-4-ylamino)quinoline-3-carboxamide,10.0,uM,=,1.0,1,c1cncc(-c2ccc3nccc(NC4CCOCC4)c3c2)c1
5169,1894370,10.1016/j.ejmech.2019.05.034,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated patch clamp electrophysiology assay,COc1ccc2c(c1)CCN(CCC(F)Cc1ccccc1)CC2,"3-(3-Fluoro-4-phenylbutyl)-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine",0.553,uM,=,-0.2572748686953017,0,c1ccc(CCCCN2CCc3ccccc3CC2)cc1
5170,2153854,10.1021/acsmedchemlett.1c00663,,,,Inhibition of human ERG expressed in HEK-293 cells by patch clamp method,CNCCNC(=O)c1cc2c([nH]c3c(C)cccc32)c(-c2ccc(Cl)c(Cl)c2)n1.Cl,"1-(3,4-dichlorophenyl)-8-methyl-N-(2-(methylamino)ethyl)-9H-pyrido[3,4-b]indole-3-carboxamide hydrochloride",0.51,uM,=,-0.2924298239020636,0,c1ccc(-c2nccc3c2[nH]c2ccccc23)cc1
5171,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn([C@H]3C[C@@H](C(F)(F)F)CCN(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"(3S,5S)-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)azepan-2-one",31.9,uM,=,1.5037906830571812,1,O=C1NCCCC[C@@H]1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
5172,1972154,10.1021/acs.jmedchem.9b01624,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells incubated for 90 mins by microbeta scintillation counting method,O=C(Nc1cc(-c2cn(-c3ccccc3)c3cnccc23)ccn1)C1CC1,"N-(4-(1-phenyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)cyclopropanecarboxamide",0.13,uM,=,-0.8860566476931633,0,O=C(Nc1cc(-c2cn(-c3ccccc3)c3cnccc23)ccn1)C1CC1
5173,1462544,10.1016/j.bmcl.2015.01.035,,,,Inhibition of human ERG,COc1ccc(-c2cc(-c3ccc4c(c3)CN(C(C)C)C4=O)on2)cn1,2-isopropyl-5-(3-(6-methoxypyridin-3-yl)isoxazol-5-yl)isoindolin-1-one,12.0,uM,=,1.0791812460476249,1,O=C1NCc2cc(-c3cc(-c4cccnc4)no3)ccc21
5174,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3ccc(C#N)cc3)ccc2c1,(R)-4-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)benzonitrile,3.2,uM,=,0.505149978319906,1,c1ccc(-c2ccc3cc(CCN4CCCC4)ccc3n2)cc1
5175,606311,10.1016/j.bmcl.2009.10.133,,,,Inhibition of human ERG channel,Cc1cc(Nc2ccccc2)nc(NCc2ccc3c(c2)OCO3)n1,"N2-(benzo[d][1,3]dioxol-5-ylmethyl)-6-methyl-N4-phenylpyrimidine-2,4-diamine",9.5,uM,=,0.9777236052888478,1,c1ccc(Nc2ccnc(NCc3ccc4c(c3)OCO4)n2)cc1
5176,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,CC(C)CC(=O)N1CCCc2cc(CNC(=O)c3ccsc3)ccc21,"N-((1-(3-methylbutanoyl)-1,2,3,4-tetrahydroquinolin-6-yl)methyl)thiophene-3-carboxamide",24.0,uM,=,1.380211241711606,1,O=C(NCc1ccc2c(c1)CCCN2)c1ccsc1
5177,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1ccc2c(c1)OC(c1ccc(OCCCN3CCCC3)cc1)C(C)S2(=O)=O,"(+/-)-1-{3-[4-(7-Methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",1.7,uM,=,0.2304489213782739,1,O=S1(=O)CC(c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
5178,2021863,10.1016/j.bmcl.2020.127433,,,,Inhibition of human ERG by plate-based planar patch clamp method,Cc1nnc(-c2nn(C)c3ccc(Nc4nccc(-c5cc(CN(C)C)n(C)n5)n4)cc23)o1,"N-(4-(5-((dimethylamino)methyl)-1-methyl-1H-pyrazol-3-yl)pyrimidin-2-yl)-1-methyl-3-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-indazol-5-amine",2.2,uM,=,0.3424226808222063,1,c1cc(-c2cc[nH]n2)nc(Nc2ccc3[nH]nc(-c4nnco4)c3c2)n1
5179,2047203,10.1021/acs.jmedchem.0c01170,,,,Inhibition of human ERG by Q-patch assay,CC1(CN)CCN(c2cnc(Sc3cccnc3C(F)(F)F)c(N)n2)CC1,6-(4-(aminomethyl)-4-methylpiperidin-1-yl)-3-((2-(trifluoromethyl)pyridin-3-yl)thio)pyrazin-2-amine,12.3,uM,=,1.089905111439398,1,c1cncc(Sc2cnc(N3CCCCC3)cn2)c1
5180,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,COC(=O)c1ccc(/C=C/CN(C)Cc2ccc3c(c2)OCCC3)cc1.Cl,(E)-N-(Chroman-7-methyl)-N-methyl-3-(4-formatemethylphenylprop-2-en-1-amine Hydrochloride,6.5,uM,=,0.8129133566428556,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)OCCC2
5181,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,CC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c(C)c1,"N-(2-(4'-((3S,4R)-4-(3,4-difluorophenyl)-4-hydroxypiperidin-3-yl)-3'-methylbiphenyl-2-yl)ethyl)acetamide",4.2,uM,=,0.6232492903979004,1,c1ccc(-c2ccc([C@H]3CNCCC3c3ccccc3)cc2)cc1
5182,1517213,10.1021/acs.jmedchem.5b01156,,,,Inhibition of human ERG expressed in CHO cells by patch clamp electrophysiology assay,CNc1nc(NCCCN(C)C)c2sc(-c3ccc(C(F)(F)F)cc3)cc2n1,"N4-(3-(dimethylamino)propyl)-N2-methyl-6-(4-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine",2.7,uM,=,0.4313637641589873,1,c1ccc(-c2cc3ncncc3s2)cc1
5183,1809217,10.1021/acsmedchemlett.9b00204,,,,Inhibition of human ERG,Cc1c(CN2CCOCC2)cc(-c2ccc(C(C)C)cc2)n1-c1ccc(F)cc1,4-((1-(4-fluorophenyl)-5-(4-isopropylphenyl)-2-methyl-1H-pyrrol-3-yl)methyl)morpholine,10.0,uM,=,1.0,1,c1ccc(-c2cc(CN3CCOCC3)cn2-c2ccccc2)cc1
5184,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)cc(F)c43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(5,7-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",0.57,uM,=,-0.2441251443275086,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
5185,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,CCOCC1(COCC)N[C@@H](c2nc(-c3ccccc3)c[nH]2)Cc2c1[nH]c1ccccc21,"(R)-1,1-bis(ethoxymethyl)-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.176,uM,=,-0.7544873321858502,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)CN3)n2)cc1
5186,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c(CCN2CCN(C(=O)Cc3cncc(-n4cnnn4)c3)CC2)ccc2c1COC2=O,5-(2-(4-(2-(5-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperazin-1-yl)ethyl)-4-methylisobenzofuran-1(3H)-one,21.0,uM,=,1.3222192947339193,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4cncc(-n5cnnn5)c4)CC3)ccc21
5187,357755,10.1021/jm0508641,,,,Inhibition of hERG potassium channel in HEK293 cells by patch clamp assay,CC(=O)Nc1cccc(N2CCN(CC3CCN(S(=O)(=O)CC4CCCCC4)CC3)CC2)c1,N-{3-[4-(1-Cyclohexylmethanesulfonyl-piperidin-4-ylmethyl)-piperizine-1-yl]-phenyl}-acetamide,2.0,uM,=,0.3010299956639812,1,O=S(=O)(CC1CCCCC1)N1CCC(CN2CCN(c3ccccc3)CC2)CC1
5188,1574383,10.1021/acs.jmedchem.6b00089,,,,Inhibition of human ERG by patch clamp method,O=C(O)C1CN(Cc2ccc(-c3noc(-c4onc(-c5ccccc5)c4C(F)(F)F)n3)cc2)C1,"1-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylic acid",18.0,uM,=,1.255272505103306,1,c1ccc(-c2cc(-c3nc(-c4ccc(CN5CCC5)cc4)no3)on2)cc1
5189,2047203,10.1021/acs.jmedchem.0c01170,,,,Inhibition of human ERG by Q-patch assay,CC1(N)CCN(c2cnc(Sc3cccnc3C(F)(F)F)c(N)n2)CC1,6-(4-amino-4-methylpiperidin-1-yl)-3-(2-(trifluoromethyl)pyridin-3-ylthio)pyrazin-2-amine,17.4,uM,=,1.2405492482825995,1,c1cncc(Sc2cnc(N3CCCCC3)cn2)c1
5190,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1cc2nc(/C=C/C3CCCN3C)n(Cc3ccc(Cl)cc3)c2cc1C,"US8975247, EBP470",0.98,uM,=,-0.0087739243075051,0,C(=C/C1CCCN1)\c1nc2ccccc2n1Cc1ccccc1
5191,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CC[C@H]1OC2(CCN(CCc3ccccc3)CC2)CN(C)C1=O,"(R)-2-ethyl-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",6.6,uM,=,0.8195439355418687,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1
5192,2076406,10.1021/acsmedchemlett.0c00462,,,,Inhibition of human ERG,COc1nc2ccccc2cc1-c1nnc([C@H](CCCCNC(=O)c2ccccc2SC)NC(=O)c2cncs2)o1,"(S)-N-(1-(5-(2-methoxyquinolin-3-yl)-1,3,4-oxadiazol-2-yl)-5-(2-(methylthio)benzamido)pentyl)thiazole-5-carboxamide",13.0,uM,=,1.1139433523068367,1,O=C(NCCCC[C@H](NC(=O)c1cncs1)c1nnc(-c2cnc3ccccc3c2)o1)c1ccccc1
5193,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(C3=NCCS3)ccc2c1,"(R)-2-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)-4,5-dihydrothiazole",25.2,uM,=,1.4014005407815442,1,c1cc2nc(C3=NCCS3)ccc2cc1CCN1CCCC1
5194,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,Cc1cc(C)n(CC(NC(=O)NC2CCN(Cc3ccn(-c4ccc(C(F)(F)F)cc4)c3)CC2)c2ccccc2)n1,"1-(2-(3,5-dimethyl-1H-pyrazol-1-yl)-1-phenylethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea",2.84,uM,=,0.4533183400470376,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(Cn1cccn1)c1ccccc1
5195,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,O=C1COc2cccc(OC[C@@H](O)CN3CCC4(CC3)Cc3cc(Cl)ccc3O4)c2N1,"(S)-5-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one",0.6,uM,=,-0.2218487496163563,0,O=C1COc2cccc(OCCCN3CCC4(CC3)Cc3ccccc3O4)c2N1
5196,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,[2H]C([2H])([2H])Oc1cc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N,"6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-(methoxy-d3)nicotinonitrile",21.0,uM,=,1.3222192947339193,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
5197,2021863,10.1016/j.bmcl.2020.127433,,,,Inhibition of human ERG by plate-based planar patch clamp method,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(CN(C)C)cn4)n3)cc12,"5-(4-(4-((dimethylamino)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-N,1-dimethyl-1H-indazole-3-carboxamide",4.5,uM,=,0.6532125137753437,1,c1cnn(-c2ccnc(Nc3ccc4[nH]ncc4c3)n2)c1
5198,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCS(=O)(=O)c1cnc(N2CC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)CC2=O)cn1,"(R)-2-(5-(ethylsulfonyl)pyrazin-2-yl)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-3-one",6.1,uM,=,0.785329835010767,1,O=C1OCc2cc(CCN3CCC4(CC3)CC(=O)N(c3cnccn3)C4)ccc21
5199,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc(C(NC(=O)Cc2ccccc2)C(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)nc1,"2-(5-ethylsulfonyl-2-pyridyl)-2-[(2-phenylacetyl)amino]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide",16.0,uM,=,1.2041199826559248,1,O=C(Cc1ccccc1)NC(C(=O)Nc1ccccc1)c1ccccn1
5200,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,CCCN(CCc1c[nH]c2ccccc12)Cc1ccc(/C=C/C(=O)NO)cc1,(E)-3-(4-(((2-(1H-indol-3-yl)ethyl)(propyl)amino)methyl)phenyl)-N-hydroxyacrylamide,6.68,uM,=,0.8247764624755457,1,c1ccc(CNCCc2c[nH]c3ccccc23)cc1
5201,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,COc1cc(Nc2cnc(C#N)c(O[C@@H]3CCN(C)C3)n2)ncc1-c1cnn(C)c1,(R)-5-((4-Methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)-3-((1-methylpyrrolidin-3-yl)oxy)pyrazine-2-carbonitrile,16.0,uM,=,1.2041199826559248,1,c1cc(Nc2cncc(O[C@@H]3CCNC3)n2)ncc1-c1cn[nH]c1
5202,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CN(c2ccc(=O)n(C)n2)C(=O)CO3)ccc2c1COC2=O,"(R)-9-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-4-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",46.0,uM,=,1.662757831681574,1,O=C1OCc2cc(CCN3CCC4(CC3)CN(c3ccc(=O)[nH]n3)C(=O)CO4)ccc21
5203,1804296,10.1021/acs.jmedchem.8b01096,,,,Inhibition of human ERG expressed in HEK293 cells at -50 mV holding potential by patch clamp assay,O=C(CCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2c3c(c1)CCN3C(=O)CC2,"8-(5-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)pentanoyl)-5,6-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-4(2H)-one",2.9054,uM,=,0.4632059321941437,1,O=C(CCCCN1CCC(c2noc3ccccc23)CC1)c1cc2c3c(c1)CCN3C(=O)CC2
5204,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2ccc3ncc(C(N)=O)c(N[C@@H](C)c4ccn(C)n4)c3c2)c(F)n1,6-[2-Fluoro-6-(methoxymethyl)-3-pyridinyl]-4-{[(1S)-1-(1-methyl-1H-pyrazol-3-yl)ethyl]amino}-3-quinolinecarboxamide,14.0,uM,=,1.146128035678238,1,c1cncc(-c2ccc3nccc(NCc4cc[nH]n4)c3c2)c1
5205,1472762,10.1021/jm501940y,,,,Inhibition of human ERG channel after 2 hrs by fluorescence polarization assay,COc1ccc(C(=O)Oc2ccc(S(=O)(=O)C3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1,[4-[[3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenyl]-4-methoxybenzoate,63.4,uM,=,1.802089257881733,1,O=C(Oc1ccc(S(=O)(=O)C2CCC3(CCNCC3)C2)cc1)c1ccccc1
5206,699709,10.1016/j.bmcl.2010.11.111,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells,COc1cc(/C=C/c2nc(NCc3ccccc3)c3c4c(sc3n2)CCC4)ccc1-n1cnc(C)c1,"Benzyl-(2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-vinyl}-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine",1.12,uM,=,0.0492180226701816,1,C(=C/c1nc(NCc2ccccc2)c2c3c(sc2n1)CCC3)\c1ccc(-n2ccnc2)cc1
5207,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(C#N)cnc43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",0.69,uM,=,-0.1611509092627447,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4cccnc43)C[C@@H]12)c1ccccc1
5208,1734340,10.1021/acsmedchemlett.8b00080,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in peak tail current after 2 to 5 mins by patch clamp based electrophysiology assay,Cc1ccc(CN2CC[C@@H](N3CC[C@@H](c4ccc(O)cc4)[C@H](F)C3)C2=O)cc1,"US9221796, 46, P-4",28.0,uM,=,1.4471580313422192,1,O=C1[C@H](N2CCC(c3ccccc3)CC2)CCN1Cc1ccccc1
5209,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1ccc(N2CCOCC2)cc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)-N-(2-methoxy-5-morpholinophenyl)pyrimidin-2-amine",5.1,uM,=,0.7075701760979364,1,c1cc(Nc2nccc(-c3cnc4ccccn34)n2)cc(N2CCOCC2)c1
5210,1292641,10.1021/jm401760c,,,,Binding affinity to full length human ERG expressed in CHO cells after 6 to 7 mins by IonWorks assay,CNc1nc(NCCCN(C)C)c2sc(-c3ccc(N4CCOCC4)cc3)cc2n1,"N4-(3-(dimethylamino)propyl)-N2-methyl-6-(4-morpholinophenyl)thieno[3,2-d]pyrimidine-2,4-diamine",1.8,uM,=,0.255272505103306,1,c1ncc2sc(-c3ccc(N4CCOCC4)cc3)cc2n1
5211,1806513,10.1016/j.ejmech.2019.06.005,,,,Inhibition of human ERG expressed in CHO cells at - 80 mV holding potential by Q-patch clamp electrophysiology assay,Cc1nc2c(F)cc(-c3nc(Nc4ccc5c(n4)CCN(CCN(C)C)C5)ncc3F)cc2n1C(C)C,"6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine",10.0,uM,=,1.0,1,c1cc(-c2ccc3nc[nH]c3c2)nc(Nc2ccc3c(n2)CCNC3)n1
5212,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,N#Cc1cnc(Nc2cc(NC[C@@H]3CNCCO3)c(-c3cccc(F)c3)cn2)cn1,(S)-5-((5-(3-Fluorophenyl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,8.1,uM,=,0.9084850188786496,1,c1ccc(-c2cnc(Nc3cnccn3)cc2NC[C@@H]2CNCCO2)cc1
5213,1577772,10.1021/acsmedchemlett.5b00360,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cell membranes incubated for 2 hrs by scintillation counting analysis,O=[N+]([O-])c1ccc(NCCCCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c2nonc12,"N-(4-(4-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-ylamino)piperidin-1-yl)butyl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine",0.025,uM,=,-1.6020599913279625,0,c1ccc(Cn2c(NC3CCN(CCCCNc4cccc5nonc45)CC3)nc3ccccc32)cc1
5214,887718,10.1021/np300232b,,,,Inhibition of human ERG stepped current expressed in HEK293 cells at + 20 mV holding potential by patch clamp assay,COc1cc2c(cc1O)[C@@H](Cc1ccc(O)c(Oc3ccc(C[C@@H]4c5cc(OC)c(OC)cc5CCN4C)cc3)c1)N(C)CC2,Daruisoline,9.1,uM,=,0.9590413923210936,1,c1cc(C[C@H]2NCCc3ccccc32)cc(Oc2ccc(C[C@H]3NCCc4ccccc43)cc2)c1
5215,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,Cn1cc([C@@]2(c3nn(C)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"5-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one",25.8,uM,=,1.4116197059632305,1,O=c1[nH]nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
5216,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3cnccc32)CC1,"4-{3-[4-(2-Oxo-2,3-dihydro-imidazo[4,5-c]pyridin-1-yl)-piperidin-1-yl]-propyl}-4H-benzo[1,4]oxazin-3-one",46.0,uM,=,1.662757831681574,1,O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3cnccc32)CC1
5217,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CC2=NCCN2)c1,"4-(benzyloxy)-1-(1-((4,5-dihydro-1H-imidazol-2-yl)methyl)-1H-indazol-5-yl)pyridin-2(1H)-one",8.5,uM,=,0.9294189257142929,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CC2=NCCN2)c1
5218,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,Cc1c(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(C(C)(C)C)n1C.Cl,"5-tert-Butyl-N-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride",6.9,uM,=,0.8388490907372553,1,O=C(NCCN1CCN(c2ccccc2)CC1)c1cc[nH]c1
5219,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(C(O)CN2CCN(CCc3ccc4c(c3C)COC4=O)CC2)ncc1C#N,"6-(1-hydroxy-2-(4-(2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-methoxynicotinonitrile",6.4,uM,=,0.8061799739838872,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
5220,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNC(C)c1ccc(Cl)cc1Oc1ccc(C)c(C)c1,"1-(4-chloro-2-(3,4-dimethylphenoxy)phenyl)-N-methylethanamine",2.47,uM,=,0.3926969532596658,1,c1ccc(Oc2ccccc2)cc1
5221,1583749,10.1016/j.bmcl.2016.05.058,,,,Inhibition of recombinant human ERG flux expressed in HEK293 cells by patch clamp assay,CC(C)Oc1cc([C@@](Cc2ccccc2)(NC[C@H](O)C(F)(F)F)c2cc(F)cc(OC(F)(F)C(F)F)c2)ccc1F,"(S)-1,1,1-trifluoro-3-((R)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethylamino)propan-2-ol",12.0,uM,=,1.0791812460476249,1,c1ccc(CC(c2ccccc2)c2ccccc2)cc1
5222,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3F)CC2)CN(c2ccccc2)C1=O,"9-(2-Fluorophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.8,uM,=,-0.0969100130080563,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
5223,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(COc1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CCNCC1,1-piperazin-1-yl-2-[[6-[[5-(trifluoromethyl)-2-pyridyl]oxy]-2-quinolyl]oxy]ethanone,12.3,uM,=,1.089905111439398,1,O=C(COc1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
5224,726964,10.1016/j.bmcl.2011.01.019,,,,Inhibition of human ERG,CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1,"(+/-)-1-(1-(3,4-dichlorophenyl)cyclohexyl)-N,N-dimethylethanamine",40.0,uM,=,1.6020599913279625,1,c1ccc(C2CCCCC2)cc1
5225,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCN(C)C(=O)c1ccc([C@H](c2cccnc2)N2CCN(Cc3cscn3)CC2)cc1,(R)-N-ethyl-N-methyl-4-(pyridin-3-yl(4-(thiazol-4-ylmethyl)piperazin-1-yl)methyl)benzamide,15.0,uM,=,1.1760912590556811,1,c1ccc([C@H](c2cccnc2)N2CCN(Cc3cscn3)CC2)cc1
5226,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c([C@H](O)[C@@H](O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-((1R,2S)-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1,2-dihydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",36.1,uM,=,1.557507201905658,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5227,2212585,10.1021/acsmedchemlett.2c00081,,,,Inhibition of human ERG potassium channel by fluorescence polarization assay,O=C(NO)c1ccc(CN2CCN(Cc3ccccc3)CC2)cc1,4-((4-Benzylpiperazin-1-yl)methyl)-N-hydroxybenzamide,73.1,uM,=,1.8639173769578603,1,c1ccc(CN2CCN(Cc3ccccc3)CC2)cc1
5228,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Nc1ccc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cn1,"5-(2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridin-6-yl)pyridin-2-amine",19.41176471,uM,=,1.2880650185917366,1,c1cncc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)c1
5229,2133680,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG expressed in CHO by QPatch assay,CC(C)(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-chloro-N-(2-((1R,3s,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propan-2-yl)benzamide",12.0,uM,=,1.0791812460476249,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
5230,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1cc(Cl)ccc1-c1nc2c(cc1-c1ccc(Cl)cc1)C(NC(=O)C(O)C(F)(F)F)CC(C)(C)O2,"N-[6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-3,3,3-trifluoro-2-hydroxypropanamide",0.41,uM,=,-0.3872161432802645,0,c1ccc(-c2cc3c(nc2-c2ccccc2)OCCC3)cc1
5231,834187,10.1021/jm2013248,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,c1ccc(-c2noc(CN3CCN(Cc4nc5ccccc5s4)CC3)n2)cc1,"5-((4-(benzo[d]thiazol-2-ylmethyl)piperazin-1-yl)methyl)-3-phenyl-1,2,4-oxadiazole",13.0,uM,=,1.1139433523068367,1,c1ccc(-c2noc(CN3CCN(Cc4nc5ccccc5s4)CC3)n2)cc1
5232,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(N1CCN(C2CCCC2)CC1)N1Cc2ccccc2C1,(4-cyclopentylpiperazin-1-yl)(isoindolin-2-yl)methanone,12.22222222,uM,=,1.0871501756399375,1,O=C(N1CCN(C2CCCC2)CC1)N1Cc2ccccc2C1
5233,1694220,10.1016/j.bmc.2017.07.040,,,,Inhibition of human ERG,Cc1nc2n(c(=O)c1CCN1CCN(c3cccc4sccc34)CC1)CCCC2O,"3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one",4.05,uM,=,0.6074550232146685,1,O=c1c(CCN2CCN(c3cccc4sccc34)CC2)cnc2n1CCCC2
5234,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCOCC1)c1ccccc1,N-((4-(4-benzylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-N-phenylpropionamide,2.3,uM,=,0.3617278360175928,1,c1ccc(CN2CCN(C3(CNc4ccccc4)CCOCC3)CC2)cc1
5235,1889161,10.1021/acs.jmedchem.8b01719,,,,Inhibition of human ERG by patch clamp electrophysiology method,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3cc(Cl)c4c(c3)COB4O)S(C)(=O)=O)c(C3CC3)cc12,"6-(N-(7-Chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide",16.0,uM,=,1.2041199826559248,1,B1OCc2cc(Nc3cc4oc(-c5ccccc5)cc4cc3C3CC3)ccc21
5236,2074272,10.1016/j.bmcl.2020.127506,,,,Inhibition of human ERG by patch-clamp method,CC(=O)Nc1ccc(OCCCCN2CCC(c3noc4cc(F)ccc34)CC2)cc1,N-(4-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)phenyl)acetamide,0.3691,uM,=,-0.4328559548043428,0,c1ccc(OCCCCN2CCC(c3noc4ccccc34)CC2)cc1
5237,971477,10.1021/jm400402q,,,,Inhibition of human ERG by dofetilide binding assay,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(CCO)CC1,2-[4-(4-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]pyrimidin-2-ylamino}-5-isopropoxy-2-methylphenyl)-piperidin-1-yl]ethanol,2.64,uM,=,0.421603926869831,1,c1ccc(Nc2ccnc(Nc3ccc(C4CCNCC4)cc3)n2)cc1
5238,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,CN(C)c1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2c1,"6-((1-(2-(7-(dimethylamino)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.01837,uM,=,-1.7358908436941918,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5239,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@H]3OC[C@H](NCc4ccc(Cl)c(Cl)c4)CO3)c2n1,"(2r,5r)-N-(3,4-dichlorobenzyl)-2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-1,3-dioxan-5-amine",7.9,uM,=,0.8976270912904415,1,c1ccc(CN[C@H]2CO[C@H](CCc3ccnc4cccnc34)OC2)cc1
5240,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,COc1cccc(C2CCN([C@@H]3CC[C@@](C(=O)NCc4cc(C(F)(F)F)cc(C(F)(F)F)c4)(C(C)C)C3)CC2)c1,"N-(3,5-bis(trifluoromethyl)benzyl)-1-isopropyl-3-(4-(3-methoxyphenyl)piperidin-1-yl)cyclopentanecarboxamide",0.217,uM,=,-0.6635402661514705,0,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3ccccc3)CC2)C1
5241,461764,10.1016/j.bmcl.2007.11.047,,,,Displacement of [35S]MK-499 from ERG expressed in HEK293 cells,Nc1ccc(-c2ccccc2)cc1NC(=O)c1ccc(CNC(=O)CCc2cccnc2)cc1,N-(4-amino-biphenyl-3-yl)-4-[(3-pyridin-3-yl-propionylamino)-methyl]-benzamide,3.7,uM,=,0.568201724066995,1,O=C(CCc1cccnc1)NCc1ccc(C(=O)Nc2cccc(-c3ccccc3)c2)cc1
5242,1871838,10.1016/j.bmcl.2018.12.015,,,,Inhibition of human ERG,NC(=O)c1cc(Cl)c2c(Cl)c(C#CC3CCCO3)n([C@H]3CCCNC3)c2n1,"3,4-dichloro-1-((S)-piperidin-3-yl)-2-((tetrahydrofuran-2-yl)ethynyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",0.005,uM,=,-2.3010299956639813,0,C(#CC1CCCO1)c1cc2cccnc2n1[C@H]1CCCNC1
5243,1926457,10.1016/j.bmc.2016.08.007,,,,Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assay,N#Cc1ccc(N2CCC(Nc3cc(Nc4cnccn4)ncc3C(N)=O)CC2)nc1,4-{[1-(5-Cyanopyridin-2-yl)piperidin-4-yl]amino}-6-(pyrazin-2-ylamino)nicotinamide,7.7,uM,=,0.8864907251724818,1,c1ccc(N2CCC(Nc3ccnc(Nc4cnccn4)c3)CC2)nc1
5244,1642442,,,,,"Binding Assay: Predictor hERG Assay test kits were obtained from Invitrogen (Carlsbad, Calif.). The binding assay was carried out according to the kit instructions. Fluorescence polarization measurements were made using EnVision Microplate Reader from Perkin-Elmer Instruments.",CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCOCC1,"US9453031, 3",6000.0,uM,=,3.778151250383644,1,c1cc(-c2nc(C3CCOCC3)c3c(n2)N2CCOC[C@H]2CO3)c2cc[nH]c2c1
5245,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,FC(F)(F)c1cc(Cl)cc(COCC2(c3ccccc3)CCNCC2)n1,4-chloro-2-(((4-phenylpiperidin-4-yl)methoxy)methyl)-6-(trifluoromethyl)pyridine,25.0,uM,=,1.3979400086720375,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
5246,1282069,10.1021/ml4003315,,,,Inhibition of human ERG,CC1(C)OC(=O)N([C@H]2CC[C@H](c3cnc(N)c(-c4ncccn4)c3)CC2)[C@H]1c1ccccc1,"trans-(S)-3-(-4-(6-amino-5-(pyrimidin-2-yl)pyridin-3-yl)cyclohexyl)-5,5-dimethyl-4-phenyloxazolidin-2-one",10.9,uM,=,1.0374264979406236,1,O=C1OC[C@H](c2ccccc2)N1[C@H]1CC[C@H](c2cncc(-c3ncccn3)c2)CC1
5247,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,CC1(C)C(=O)Nc2nc(-n3nc(Cc4ccccc4F)c4ccccc43)nc(N)c21,"4-amino-2-[3-[(2-fluorophenyl)methyl]indazol-1-yl]-5,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-6-one",4.9,uM,=,0.6901960800285137,1,O=C1Cc2cnc(-n3nc(Cc4ccccc4)c4ccccc43)nc2N1
5248,1572821,10.1016/j.bmcl.2016.04.024,,,,Inhibition of human ERG1 expressed in CHO cells by whole cell patch clamp electrophysiology method,CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCNCC3)nc21,"1-[1-(2-methylpropanesulfonyl)-4-[4-(trifluoromethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-6-yl]piperazine",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2cc(N3CCNCC3)nc3[nH]ccc23)cc1
5249,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)c1c[nH]c(=O)c(Cl)c1,"5-chloro-6-oxo-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)-1,6-dihydropyridine-3-carboxamide",19.6,uM,=,1.292256071356476,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)c1ccc(=O)[nH]c1
5250,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,O=C1OCCc2cc([C@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@@H]4CO3)ccc21,"6-((3S,9aR)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)isochroman-1-one",41.5,uM,=,1.6180480967120927,1,O=C1OCCc2cc([C@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@@H]4CO3)ccc21
5251,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,CCSc1ccccc1C(=O)N(CC1CCC1)[C@H]1CCNC1,(S)-N-(cyclobutylmethyl)-2-(ethylthio)-N-(pyrrolidin-3-yl)benzamide,7.57,uM,=,0.8790958795000727,1,O=C(c1ccccc1)N(CC1CCC1)[C@H]1CCNC1
5252,815278,10.1016/j.ejmech.2012.02.049,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cells after 45 mins by scintillation counting method,CCOC(=O)C1CCN(CCCCOc2ccc(S(N)(=O)=O)cc2)CC1,4-{4-[4-(ethoxycarbonyl)piperidin-1-yl]butoxy}benzenesulfonamide,18.8,uM,=,1.2741578492636798,1,c1ccc(OCCCCN2CCCCC2)cc1
5253,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N(c3ccccc3)c3ccccc3)nn2)ccc1-n1cnc(C)c1,"2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-N,N-diphenylacetamide",3.05,uM,=,0.4842998393467858,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)N(c1ccccc1)c1ccccc1
5254,1473874,10.1021/jm5018863,,,,Inhibition of human ERG expressed in CHO cells by automated Qpatch clamp assay,NC(=O)c1nnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc2cc[nH]c12,"5-(1H-indol-7-ylamino)-3-((1R,2S)-2-aminocyclohexylamino)-1,2,4-triazine-6-carboxamide",25.9,uM,=,1.413299764081252,1,c1cc(Nc2cnnc(NC3CCCCC3)n2)c2[nH]ccc2c1
5255,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,C[C@H](c1ccc(Cl)nc1)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,endo-3-(8-((R)-1-(6-chloropyridin-3-yl)ethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0033,uM,=,-2.4814860601221125,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccnc2)cc1
5256,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,O=C(NC1CCC1)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1,"N-Cyclobutyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide",2.5,uM,=,0.3979400086720376,1,O=C(NC1CCC1)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1
5257,971477,10.1021/jm400402q,,,,Inhibition of human ERG by dofetilide binding assay,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC2CCC2)cc1C1CCNCC1,"5-Chloro-N2-(2-cyclobutoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine",3.02,uM,=,0.4800069429571506,1,c1ccc(Nc2ccnc(Nc3ccc(C4CCNCC4)cc3OC3CCC3)n2)cc1
5258,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)c1ccno1)C2,"(2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)(isoxazol-5-yl)methanone",6.4,uM,=,0.8061799739838872,1,O=C(c1ccno1)N1CCc2nc(OCc3conc3-c3ccccc3)ccc2C1
5259,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCN2CCCC2)cc1,4-(Benzyloxy)-1-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-pyridin-2(1H)-one,0.0081,uM,=,-2.0915149811213505,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCN2CCCC2)cc1
5260,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2ncc(F)c([C@@H](O)CC[C@@H]3CCN(C4CC(c5ccccc5)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-4-((S)-3-(3-fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl)-1-(3-phenylcyclobutyl)piperidine-3-carboxylic acid",22.3,uM,=,1.3483048630481609,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)cc1
5261,1986395,10.1016/j.bmcl.2020.127027,,,,Inhibition of human ERG,O=c1n(CCCCN2CCN(c3cccc4sccc34)CC2)nc2c(F)cccn12,"2-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-8-fluoro-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one",2.2,uM,=,0.3424226808222063,1,O=c1n(CCCCN2CCN(c3cccc4sccc34)CC2)nc2ccccn12
5262,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,CC(C)(C)NC(=O)C1c2c(O)cccc2C(=O)N1Cc1ccccc1-c1ccccc1,(rac)-2-(biphenyl-2-ylmethyl)-N-tert-butyl-7-hydroxy-3-oxoisoindoline-1-carboxamide,28.0,uM,=,1.4471580313422192,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
5263,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"6-fluoro-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",2.61,uM,=,0.4166405073382809,1,O=C1Nc2ccccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
5264,606908,10.1016/j.bmcl.2009.10.092,,,,Inhibition of human ERG by patch clamp technique,C[C@H](O)C(=O)N1CC[C@H](N(Cc2cc(Cl)ccc2Cl)c2ccc(C#N)c(Cl)c2)C1,"2-chloro-4-((2,5-dichlorobenzyl)((S)-1-((S)-2-hydroxypropanoyl)pyrrolidin-3-yl)amino)benzonitrile",2.2,uM,=,0.3424226808222063,1,c1ccc(CN(c2ccccc2)[C@H]2CCNC2)cc1
5265,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(F)ccc3OC[C@H]2[C@@]1(CCCN1CCNCC1)c1ccccc1,"1-[(3R,3aR)-8-fluoro-3-phenyl-3-(3-piperazin-1-yl-propyl)-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-2-yl]-ethanone",4.6,uM,=,0.6627578316815741,1,C1=NN2c3ccccc3OC[C@H]2[C@@]1(CCCN1CCNCC1)c1ccccc1
5266,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCO[C@H]1CC[C@@H](N2CC(NC(=O)CNc3n[nH]c4ccc(C(F)(F)F)cc34)C2)CC1,cis-N-[1-(4-Ethoxy-cyclohexyl)-azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,4.5,uM,=,0.6532125137753437,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
5267,1871838,10.1016/j.bmcl.2018.12.015,,,,Inhibition of human ERG,CC1(C#Cc2c(Cl)c3c(Cl)cc(C(N)=O)nc3n2[C@H]2CCCNC2)COC1,"(S)-3,4-dichloro-2-((3-methyloxetan-3-yl)ethynyl)-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",0.003,uM,=,-2.5228787452803374,0,C(#CC1COC1)c1cc2cccnc2n1[C@H]1CCCNC1
5268,1566421,10.1016/j.bmcl.2016.02.081,,,,Inhibition of human ERG,CC(C)(C)NC(=O)C1c2ccccc2C(=O)N1Cc1ccccc1-c1ccc(F)cc1,N-tert-butyl-2-((4'-fluorobiphenyl-2-yl)methyl)-3-oxoisoindoline-1-carboxamide,56.0,uM,=,1.7481880270062005,1,O=C1c2ccccc2CN1Cc1ccccc1-c1ccccc1
5269,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,CC(C(O)c1ccc2c(c1)COC(=O)N2)N1CCC(O)(c2ccc(F)cc2)CC1,"6-(2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxypropyl)-1H-benzo[d][1,3]oxazin-2(4H)-one",2.4,uM,=,0.380211241711606,1,O=C1Nc2ccc(CCN3CCC(c4ccccc4)CC3)cc2CO1
5270,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,C[C@H](c1ccnc(Cl)c1)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,endo-3-(8-((R)-1-(2-chloropyridin-4-yl)ethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.013,uM,=,-1.8860566476931635,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccncc2)cc1
5271,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,Cc1cc(CNc2nc(N)nc3ccn(Cc4ccc(F)cn4)c23)no1,"5-((5-Fluoropyridin-2-yl)methyl)-N4-((5-methylisoxazol-3-yl)-methyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine",2.0,uM,=,0.3010299956639812,1,c1ccc(Cn2ccc3ncnc(NCc4ccon4)c32)nc1
5272,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,O=C(NC1CC1)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1,"N-Cyclopropyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide",11.0,uM,=,1.0413926851582251,1,O=C(NC1CC1)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1
5273,2025950,10.1021/acsmedchemlett.0c00575,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,CCS(=O)(=O)c1ccc(CNc2nc3cnc(-c4c(OC)ncnc4C4CC4)nc3n(C(C)C)c2=O)nc1,2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-6-((5-(ethylsulfonyl)pyridin-2-yl)methylamino)-8-isopropylpteridin-7(8H)-one,13.0,uM,=,1.1139433523068367,1,O=c1[nH]c2nc(-c3cncnc3C3CC3)ncc2nc1NCc1ccccn1
5274,761292,10.1021/jm101312a,,,,Inhibition of human ERG expressed in CHO cells by high throughput single cell planar patch clamp method,Clc1ccc([C@@]23CCC[C@@H]2CNC3)cc1Cl,"(3aR,6aS)-3a-(3,4-dichlorophenyl)octahydrocyclopenta[c]pyrrole",5.28,uM,=,0.7226339225338123,1,c1ccc([C@@]23CCC[C@@H]2CNC3)cc1
5275,1858719,10.1021/acs.jmedchem.0c00117,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell electrophysiology assay,Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2sccc12,"(E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[2,3-d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenesulfonamide",0.979,uM,=,-0.0092173081968621,0,c1ccc(CN2CCC(Nc3nc(Oc4ccccc4)c4ccsc4n3)CC2)cc1
5276,540677,10.1016/j.bmcl.2008.12.083,,,,Inhibition of human ERG,Nc1ccc(-c2ccc(F)cc2)cc1NC(=O)c1ccc(CN2CCC3(CCNC3)CC2)cc1,"4-(2,8-diazaspiro[4.5]decan-8-ylmethyl)-N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide",0.237,uM,=,-0.6252516539898961,0,O=C(Nc1cccc(-c2ccccc2)c1)c1ccc(CN2CCC3(CCNC3)CC2)cc1
5277,699709,10.1016/j.bmcl.2010.11.111,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells,COc1cc(/C=C/c2nc3sc4c(c3c(=O)[nH]2)CCC4)ccc1-n1cnc(C)c1,"2-{(E)-2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-vinyl}-3,5,6,7-tetrahydro-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one",4.73,uM,=,0.6748611407378116,1,O=c1[nH]c(/C=C/c2ccc(-n3ccnc3)cc2)nc2sc3c(c12)CCC3
5278,857606,10.1021/ml2002604,,,,Inhibition of human recombinant hERG expressed in CHO cells by automated patch clamp assay,CONC(=O)N(Cc1ccsc1)C1CCN([C@H](C)CCNC(=O)c2c(C)cc(C(=O)NC(C)C)nc2C)CC1,"(R)-N2-Isopropyl-N5-(3-(4-(3-methoxy-1-(thiophen-3-ylmethyl)ureido)piperidin-1-yl)butyl)-4,6-dimethylpyridine-2,5-dicarboxamide",33.0,uM,=,1.5185139398778875,1,O=C(NCCCN1CCC(NCc2ccsc2)CC1)c1cccnc1
5279,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,COc1ccc(C(=O)Nc2csc([C@]34CO[C@@H](C)C[C@H]3CSC(N)=N4)n2)cc1,"N-(2-((4aR,6S,8aR)-2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)thiazol-4-yl)-4-methoxybenzamide",18.4,uM,=,1.2648178230095364,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccc1
5280,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn([C@H]3C[C@@H](C(F)(F)F)CN(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"(3S,5R)-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)piperidin-2-one",13.1,uM,=,1.1172712956557642,1,O=C1NCCC[C@@H]1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
5281,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=NC(c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21,3-Pyridin-4-yl-3-(3-pyrimidin-5-yl-phenyl)-3H-isoindol-1-ylamine,16.0,uM,=,1.2041199826559248,1,C1=NC(c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
5282,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CN1Cc2ccccc2[C@@H](c2ccccc2)N=C1CCc1ccccc1,"(R)-2-Methyl-3-phenethyl-5-phenyl-2,5-dihydro-1H-benzo[e][1,3]diazepine",0.09,uM,=,-1.0457574905606752,0,c1ccc(CCC2=N[C@H](c3ccccc3)c3ccccc3CN2)cc1
5283,357755,10.1021/jm0508641,,,,Inhibition of hERG potassium channel in HEK293 cells by patch clamp assay,CC(=O)Nc1cccc(N2CCN(CCCCN(C)S(=O)(=O)CC(C)C)CC2)c1,N-[3-(4-{4-[methyl-(2-methyl-propane-1-sulfonyl)-amino]-butyl}-piperazin-1-yl)-phenyl]-acetamide,2.2,uM,=,0.3424226808222063,1,c1ccc(N2CCNCC2)cc1
5284,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1ccc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)cn1,"2-(1,4'-bipiperidin-1'-yl)-6-(6-methoxypyridin-3-yl)thiazolo[4,5-c]pyridine",1.111111111,uM,=,0.0457574905172456,1,c1cncc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)c1
5285,806244,10.1016/j.bmcl.2012.01.078,,,,Inhibition of human Erg by patch clamp assay,Cc1nc2ncc(Oc3ccc(F)cc3)nc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,6-(4-Fluoro-phenoxy)-3-((S)-1-isopropyl-piperidin-3-ylmethyl)-2-methyl-3H-pteridin-4-one,16.1,uM,=,1.2068258760318498,1,O=c1c2nc(Oc3ccccc3)cnc2ncn1C[C@H]1CCCNC1
5286,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2c1O[C@@H](c1ccc(OCCCN3CCCC3)cc1)[C@H](C)S2(=O)=O,"1-{3-[4-((2S,3S)-8-Methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",4.9,uM,=,0.6901960800285137,1,O=S1(=O)C[C@H](c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
5287,1328170,10.1039/C3MD20368A,,,,Inhibition of human ERG by electrophysiological analysis,O=C(Nc1ccc(F)cn1)[C@H](CN1CC(O)C1)Oc1ncnc2c1cnn2-c1c(Cl)cccc1Cl,"(S)-2-(1-(2,6-dichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)-N-(5-fluoropyridin-2-yl)-3-(3-hydroxyazetidin-1-yl)propanamide",19.0,uM,=,1.2787536009528289,1,O=C(Nc1ccccn1)[C@H](CN1CCC1)Oc1ncnc2c1cnn2-c1ccccc1
5288,344973,10.1016/j.bmcl.2006.01.030,,,,Inhibitory activity against human hERG receptor expressed in CHO cells by whole cell voltage clamp assay,N[C@H](C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1ccccc1)C1CC1,"(S)-2-amino-2-cyclopropyl-1-((S)-4-(2,5-difluorophenyl)-2-phenyl-2H-pyrrol-1(5H)-yl)ethanone",6.5,uM,=,0.8129133566428556,1,O=C(CC1CC1)N1CC(c2ccccc2)=C[C@H]1c1ccccc1
5289,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,CCCCCCCCc1cccc(CCCCCCCC)[n+]1C,"1-methyl-2,6-dioctylpyridinium",0.015,uM,=,-1.8239087409443189,0,c1cc[nH+]cc1
5290,2133643,10.1021/acs.jmedchem.1c00679,,,,Inhibition of human ERG by manual patch clamp method,CC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"N-(4-Chlorophenyl)-2-((1R,3s,5S,6r)-3-(5,6-difluoro-1H-benzo[d]-imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propanamide",1.0,uM,=,0.0,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
5291,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cnc2c(Cl)cc(-c3cccnc3)cc2c1NC1CCOCC1,8-Chloro-6-(pyridin-3-yl)-4-(tetrahydro-2H-pyran-4-ylamino)quinoline-3-carboxamide,1.1,uM,=,0.041392685158225,1,c1cncc(-c2ccc3nccc(NC4CCOCC4)c3c2)c1
5292,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,CC1(C(=O)N2CCO[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1,"(R)-4-(8-amino-3-(4-(3-methyloxetane-3-carbonyl)morpholin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",14.4,uM,=,1.1583624920952498,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@H]3CN(C(=O)C4COC4)CCO3)n3ccncc23)cc1
5293,1768711,10.1016/j.bmc.2018.01.021,,,,Inhibition of human ERG expressed in HEK293 cells by automated patch clamp method,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,SID174006711,85.0,uM,=,1.9294189257142929,1,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
5294,2149702,10.1021/acs.jmedchem.1c00563,,,,Inhibition of human ERG by patch clamp electrophysiology assay,O=C1c2nc3cccc(-c4ccccc4)c3n2CCN1CC1CC1,"2-(Cyclopropylmethyl)-6-phenyl-3,4-dihydropyrazino-(1,2-a)benzimidazol-1(2H)-one",14.0,uM,=,1.146128035678238,1,O=C1c2nc3cccc(-c4ccccc4)c3n2CCN1CC1CC1
5295,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(C3CC3)n2)(c2ccccc2)CC1,2-cyclopropyl-6-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,9.0,uM,=,0.9542425094393248,1,c1ccc(C2(COCc3cccc(C4CC4)n3)CCNCC2)cc1
5296,2084867,10.1021/acs.jmedchem.6b00943,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated Qpatch electrophysiological assay,Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C#Cc1nn(CC2CCN(C)CC2)c2ncnc(N)c12,"N-(3-((4-Amino-1-((1-methylpiperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide",5.62,uM,=,0.7497363155690611,1,O=C(Nc1cccc(C#Cc2nn(CC3CCNCC3)c3ncncc23)c1)c1ccccc1
5297,2022324,10.1021/acs.jmedchem.0c01163,,,,Inhibition of human ERG by plate-based planar patch clamp technique,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@](C)(c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)F,"6-((6S,8R)-7-(2,2-Difluoroethyl)-6,8-dimethyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)-N-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine",13.0,uM,=,1.1139433523068367,1,c1cc(C2NCCc3c2ccc2[nH]ncc32)ncc1NC1CNC1
5298,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(COc1ccc2cc(Oc3ccccn3)ccc2n1)N1CCCCC1,1-(1-piperidyl)-2-[[6-(2-pyridyloxy)-2-quinolyl]oxy]ethanone,30.0,uM,=,1.4771212547196624,1,O=C(COc1ccc2cc(Oc3ccccn3)ccc2n1)N1CCCCC1
5299,443485,10.1016/j.bmcl.2007.03.006,,,,Inhibition of hERG expressed in CHO cells by cell voltage clamp assay,CN(C)C(=O)N1N=C(c2cc(F)ccc2F)C[C@@]1(CCCN)c1ccccc1,"(S)-5-(3-aminopropyl)-3-(2,5-difluorophenyl)-N,N-dimethyl-5-phenyl-4,5-dihydropyrazole-1-carboxamide",19.3,uM,=,1.285557309007774,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
5300,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CN1CCC(Cn2nc(-c3ccc4cc(OC5CC5)ccc4c3)c3c(N)ncnc32)CC1,"3-(6-Cyclopropoxynaphthalen-2-yl)-1-((1-methylpiperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.37,uM,=,-0.431798275933005,0,c1ncc2c(-c3ccc4cc(OC5CC5)ccc4c3)nn(CC3CCNCC3)c2n1
5301,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,CC(C)NC(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1,"N-Isopropyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide",6.2,uM,=,0.7923916894982539,1,O=C1c2ccc(-c3ccccc3)cc2CCN1CCN1CCCC1
5302,2021863,10.1016/j.bmcl.2020.127433,,,,Inhibition of human ERG by plate-based planar patch clamp method,CNC(=O)c1nn(C)c2c(C)cc(Nc3nccc(-n4cc(CN(C)C)cn4)n3)cc12,"5-(4-(4-((dimethylamino)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-N,1,7-trimethyl-1H-indazole-3-carboxamide",4.9,uM,=,0.6901960800285137,1,c1cnn(-c2ccnc(Nc3ccc4[nH]ncc4c3)n2)c1
5303,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(CCCOc2cccc(Cl)c2)cccc1CCCOc1cccc(Cl)c1,"2,6-bis(3-(3-chlorophenoxy)propyl)-1-methylpyridinium",0.06,uM,=,-1.2218487496163564,0,c1ccc(OCCCc2cccc(CCCOc3ccccc3)[nH+]2)cc1
5304,2264097,10.1021/acs.jmedchem.1c00703,,,,Inhibition of hERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp assay,CC(C)n1nc(-c2nnc(C3CCN(CC4(O)CCCC4)CC3)o2)c2ccccc21.O=C(O)C(=O)O,"1-{4-[5-(1-Isopropyl-1H-indazol-3-yl)-[1,3,4]oxadiazol-2-yl]-piperidin-1-ylmethyl}-cyclopentanol oxalate",1.1,uM,=,0.041392685158225,1,c1ccc2c(-c3nnc(C4CCN(CC5CCCC5)CC4)o3)n[nH]c2c1
5305,1823180,10.1021/acs.jmedchem.9b01247,,,,Inhibition of human ERG by electrophysiology,N#Cc1ccc(O[C@H]2CN(S(=O)(=O)c3ccc(Cl)cn3)C[C@@]2(O)CN)cc1F,"4-(((3S,4S)-4-(Aminomethyl)-1-((5-chloropyridin-2-yl)-sulfonyl)-4-hydroxypyrrolidin-3-yl)oxy)-2-fluorobenzonitrile",20.0,uM,=,1.3010299956639813,1,O=S(=O)(c1ccccn1)N1CC[C@@H](Oc2ccccc2)C1
5306,2015654,10.1016/j.bmcl.2020.127417,,,,Inhibition of human ERG by QPatch HTX automated patch clamp system,Cc1cc([C@H]2CC[C@H](c3nnc4n3-c3ccc(Cl)cc3CC4)CC2)no1,"3-((1r,4r)-4-(7-chloro-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolin-1-yl)cyclohexyl)-5-methylisoxazole",7.6,uM,=,0.8808135922807914,1,c1ccc2c(c1)CCc1nnc([C@H]3CC[C@H](c4ccon4)CC3)n1-2
5307,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CCC(c2ccccc2)N2CCN(c3cccc(F)c3)CC2)CC1,rac-N-ethyl-N-(1-(3-(4-(3-fluorophenyl)piperazin-1-yl)-3-phenylpropyl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)acetamide,3.2,uM,=,0.505149978319906,1,O=C(Cc1ccccc1)NC1CCN(CCC(c2ccccc2)N2CCN(c3ccccc3)CC2)CC1
5308,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1ccc(-c2ccc(-c3ccc4cc(CCN5CCC[C@H]5C)ccc4n3)s2)s1,"(R)-2-(5'-methyl-2,2'-bithiophen-5-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline",2.0,uM,=,0.3010299956639812,1,c1csc(-c2ccc(-c3ccc4cc(CCN5CCCC5)ccc4n3)s2)c1
5309,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-4-oxo-4H-chromene-2-carboxamide",0.0067,uM,=,-2.1739251972991736,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
5310,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(c2ccc3c(c2)Cc2c(-c4csc(C#CCOc5ccccc5)c4)n[nH]c2-3)CC1,"6-(4-methylpiperazin-1-yl)-3-(5-(3-phenoxyprop-1-ynyl)-thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole",1.74,uM,=,0.2405492482825997,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(N4CCNCC4)ccc2-3)cs1)COc1ccccc1
5311,2048454,10.1016/j.bmc.2020.115734,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCCC2,"N-(2-ethyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",8.6,uM,=,0.9344984512435676,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCC5)n3)nc2)cn1
5312,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc(C(NC(=O)Cc2ccccn2)C(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)nc1,"2-(5-ethylsulfonyl-2-pyridyl)-2-[[2-(2-pyridyl)acetyl]amino]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide",4.1,uM,=,0.6127838567197355,1,O=C(Cc1ccccn1)NC(C(=O)Nc1ccccc1)c1ccccn1
5313,2194946,10.1021/acs.jmedchem.2c01064,,,,Inhibition of hERG expressed in CHO cells Qpatch-clamp electrophysiology assay,CNC(=O)c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CCCCC3)c12,5-hydroxy-2-(4-hydroxyphenyl)-N-methyl-4-(1-piperidylmethyl)benzofuran-3-carboxamide,0.038,uM,=,-1.42021640338319,0,c1ccc(-c2cc3c(CN4CCCCC4)cccc3o2)cc1
5314,535682,10.1016/j.bmcl.2008.08.067,,,,Displacement of [3H]dofetilide from human ERG in HEK293 cells,CNC(=O)c1c(NCC2CCC3(CCCC3)CC2)nc(C#N)nc1OCC1CCN(C)CC1,2-cyano-N-methyl-4-((1-methylpiperidin-4-yl)methoxy)-6-(spiro[4.5]decan-8-ylmethylamino)pyrimidine-5-carboxamide,1.455,uM,=,0.1628629933219261,1,c1nc(NCC2CCC3(CCCC3)CC2)cc(OCC2CCNCC2)n1
5315,651867,10.1016/j.bmc.2010.07.013,,,,Inhibition of human ERG at holding potential of -80 mV to +40 mV,CC(C)(C)c1nnc(-c2nn(-c3ccccc3Cl)c(-c3ccc(Br)cc3)c2Cn2cncn2)s1,"2-(4-((1H-1,2,4-Triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole",10.5,uM,=,1.021189299069938,1,c1ccc(-c2c(Cn3cncn3)c(-c3nncs3)nn2-c2ccccc2)cc1
5316,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CCc1nc2ccccc2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,2-Ethyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,5.0,uM,=,0.6989700043360189,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
5317,617393,10.1016/j.bmcl.2010.01.100,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,CCC(CC)NCCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1,4-(3-(pentan-3-ylamino)propyl)-6-(3-(trifluoromethyl)phenyl)pyrimidine-2-carbonitrile,0.32,uM,=,-0.494850021680094,0,c1ccc(-c2ccncn2)cc1
5318,1627127,10.1016/j.bmcl.2016.10.064,,,,Displacement of 35S-MK499 from human ERG expressed in HEK293 cell membranes,Cc1c([C@@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@@H]3CO2)ccc2c1COC2=O,"5-((3R,9aR)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-4-methylisobenzofuran-1(3H)-one",59.4,uM,=,1.7737864449811935,1,O=C1OCc2cc([C@@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@@H]4CO3)ccc21
5319,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,Cc1ccc([C@@H](C)N2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)cn1,endo-3-(8-((R)-1-(6-methylpyridin-3-yl)ethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.003,uM,=,-2.5228787452803374,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccnc2)cc1
5320,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C)cc(-c2cncc(-c3nc4cc(C(F)(F)F)ccc4[nH]3)c2N2CCC(N)CC2)c1,"1-(3-(3,5-dimethylphenyl)-5-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-4-yl)piperidin-4-amine",0.6,uM,=,-0.2218487496163563,0,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
5321,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(Cc2ccc3ccc(=O)[nH]c3c2)CC1)c1cc(=O)c2ccc(F)cc2o1,"7-fluoro-4-oxo-N-(1-((2-oxo-1,2-dihydroquinolin-7-yl)methyl)piperidin-4-yl)-4H-chromene-2-carboxamide",85.5,uM,=,1.9319661147281728,1,O=C(NC1CCN(Cc2ccc3ccc(=O)[nH]c3c2)CC1)c1cc(=O)c2ccccc2o1
5322,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N(C)C)c(F)c3)n2)n1C(C)C,"2-fluoro-4-(4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)-N,N-dimethylbenzamide",3.0,uM,=,0.4771212547196624,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
5323,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(C(=O)NCC2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc1C(C)(C)C,"N-((1-(6,6-bis(4-fluorophenyl)hexyl)pyrrolidin-3-yl)methyl)-3,5-di-tert-butyl-4-methoxybenzamide",0.1,uM,=,-1.0,0,O=C(NCC1CCN(CCCCCC(c2ccccc2)c2ccccc2)C1)c1ccccc1
5324,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,O=C(CNc1n[nH]c2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3ccc4c(c3)OCO4)CC2)C1,"cis-N-[1-(4-Benzo[1,3]dioxol-5-yl-cyclohexyl)-azetidin-3-yl]-2-(5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide",1.1,uM,=,0.041392685158225,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccc4c(c3)OCO4)CC2)C1
5325,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)C[C@H]1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,(S)-2-(8-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-8-azaspiro[4.5]decan-3-yl)acetic Acid,4.9,uM,=,0.6901960800285137,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCO5)CC4)nc3)nc2c1
5326,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CCC(c2ccccc2)N2CCN(c3ccccc3)CC2)CC1,rac-N-ethyl-2-(4-(methylsulfonyl)phenyl)-N-(1-(3-phenyl-3-(4-phenylpiperazin-1-yl)propyl)piperidin-4-yl)acetamide,13.0,uM,=,1.1139433523068367,1,O=C(Cc1ccccc1)NC1CCN(CCC(c2ccccc2)N2CCN(c3ccccc3)CC2)CC1
5327,1795017,10.1016/j.bmcl.2018.08.036,,,,Inhibition of human ERG,CCCCc1nc(C(C)C)c(CC(=S)N2CCCC2)c(=O)n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,"3-(4'-((2-butyl-4-isopropyl-6-oxo-5-(2-(pyrrolidin-1-yl)-2-thioxoethyl)pyrimidin-1(6H)-yl)methyl)biphenyl-2-yl)-1,2,4-oxadiazol-5(4H)-one",7.0,uM,=,0.8450980400142568,1,O=c1[nH]c(-c2ccccc2-c2ccc(Cn3cncc(CC(=S)N4CCCC4)c3=O)cc2)no1
5328,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1,"6-((1-(2-(7-(trifluoromethyl)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00039,uM,=,-3.408935392973501,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5329,2264097,10.1021/acs.jmedchem.1c00703,,,,Inhibition of hERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp assay,COCCCN1CCC(c2nc(-c3nn(C(C)C)c4ccccc34)no2)CC1,"1-isopropyl-3-[3-(1-(3-methoxy-propyl)-piperidin-4-yl]-[1,2,4]-oxadiazol-5-yl]-1H-indazole",2.8,uM,=,0.4471580313422192,1,c1ccc2c(-c3noc(C4CCNCC4)n3)n[nH]c2c1
5330,559360,10.1021/jm8012932,,,,Inhibition of human ERG,CN1CCN(c2ncnc3c2nc(-c2ccc(Cl)cc2Cl)n3-c2ccc(Cl)cc2)CC1,"9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(4-methylpiperazin-1-yl)-9H-purine",0.35,uM,=,-0.4559319556497244,0,c1ccc(-c2nc3c(N4CCNCC4)ncnc3n2-c2ccccc2)cc1
5331,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc(C(F)(F)F)cc1)Cc1ccc2c(c1)OCCC2.Cl,(E)-N-(Chroman-7-methyl)-N-methyl-3-(4-trifluoromethylphenyl)prop-2-en-1-amine Hydrochloride,2.9,uM,=,0.4623979978989561,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)OCCC2
5332,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(OCCCc2cccc(CCCOc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis(3-(p-tolyloxy)propyl)pyridinium",0.086,uM,=,-1.0655015487564323,0,c1ccc(OCCCc2cccc(CCCOc3ccccc3)[nH+]2)cc1
5333,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccc(F)cc1Cl,"Ethyl 4-(2-chloro-4-fluorophenyl)-6-(morpholinomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",2.31,uM,=,0.3636119798921443,1,C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccccc1
5334,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cc1,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(4-methoxyphenyl)pyrrolo[1,2-b]pyridazine-3-carboxamide",13.8,uM,=,1.1398790864012365,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
5335,1904027,10.1021/acs.jmedchem.9b01392,,,,Inhibition of human ERG,Cc1cnc(Nc2cccnc2F)nc1-c1c[nH]c2c(NC(=O)[C@@H](C)N3CCN(C)CC3)cccc12,(R)-N-(3-(2-((2-fluoropyridin-3-yl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide,10.0,uM,=,1.0,1,O=C(CN1CCNCC1)Nc1cccc2c(-c3ccnc(Nc4cccnc4)n3)c[nH]c12
5336,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N(CC(F)(F)F)c3cccc4ccccc34)nn2)ccc1-n1cnc(C)c1,"2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-N-(naphthalen-1-yl)-N-(2,2,2-trifluoroethyl)acetamide",0.8,uM,=,-0.0969100130080563,0,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)Nc1cccc2ccccc12
5337,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,N#Cc1ccc(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC2)cc1,4-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)benzonitrile,0.42,uM,=,-0.3767507096020995,0,O=C(Cc1ccc(-n2cnnn2)cc1)N1CCN(CCc2ccccc2)CC1
5338,498774,10.1021/jm900110t,,,,"Displacement of [35S]N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",C[C@@H]1NC(c2cccc(C#N)c2)=N[C@@]1(c1ccc(F)cc1)c1ccc(F)nc1,"3-[(4S,5S)-4-(4-Fluorophenyl)-4-(6-fluoro-3-pyridyl)-5-methyl-4,5-dihydro-1H-imidazol-2-yl]benzonitrile",4.33,uM,=,0.6364878963533654,1,c1ccc(C2=N[C@@](c3ccccc3)(c3cccnc3)CN2)cc1
5339,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1cc2nc(CCC3CCCN3C)n(Cc3ccc(Cl)cc3)c2cc1C,"US8975247, EBP661",0.26,uM,=,-0.585026652029182,0,c1ccc(Cn2c(CCC3CCCN3)nc3ccccc32)cc1
5340,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N(c3ccccc3)C3CCCCC3)nn2)ccc1-n1cnc(C)c1,"N-cyclohexyl-2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-N-phenylacetamide",0.8,uM,=,-0.0969100130080563,0,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)N(c1ccccc1)C1CCCCC1
5341,1792104,10.1016/j.bmcl.2018.09.018,,,,Inhibition of human ERG,C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4C[C@@H](C)O[C@@H](C)C4)nc3)n2)C1,"6-((S)-3-acrylamidopyrrolidin-1-yl)-2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-ylamino)nicotinamide",10.0,uM,=,1.0,1,c1cc(Nc2ccc(N3CCOCC3)nc2)nc(N2CCCC2)c1
5342,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,0.056,uM,=,-1.2518119729937995,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
5343,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Cl)cc1Oc1ccc(Cl)c(Cl)c1,"1-(4-chloro-2-(3,4-dichlorophenoxy)phenyl)-N-methylmethanamine",1.24,uM,=,0.093421685162235,1,c1ccc(Oc2ccccc2)cc1
5344,1875991,10.1021/acs.jmedchem.9b00444,,,,Inhibition of human ERG by in vitro patch clamp method,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,"6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-methylnicotinamide",38.0,uM,=,1.57978359661681,1,c1ccc(Nc2cc(Nc3cccc(-c4nc[nH]n4)c3)ccn2)nc1
5345,1641577,,,,,"In Vitro Assay: The in vitro effects of the selected compounds on the hERG (human ether-á-go-go-related gene) potassium channel current (a surrogate for IKr, the rapidly activating, delayed rectifier cardiac potassium current) expressed in mammalian cells were evaluated at room temperature using the PatchXpress 7000A (Molecular Devices), an automatic parallel patch clamp system. Each compound was evaluated at varying concentrations in duplicate up to 10 μM, and the duration of exposure to each test article concentration was 5 minutes.",c1cnc2c(c1)CCCC2N(CCCN1CCNCC1)Cc1nccc2c3ccccc3n(CCN3CCOCC3)c12,"US9314468, Table 8, Compound 9::US9314468, Table 9, Compound 12",3.1,uM,=,0.4913616938342727,1,c1cnc2c(c1)CCCC2N(CCCN1CCNCC1)Cc1nccc2c3ccccc3n(CCN3CCOCC3)c12
5346,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,O=C(NCCN1CCCCC1)c1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1,N-(1-(4-((2-(piperidin-1-yl)ethyl)carbamoyl)benzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,66.0,uM,=,1.8195439355418688,1,O=C(NCCN1CCCCC1)c1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccccc4o3)CC2)cc1
5347,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,Cc1ncccc1-c1nc2cn(-c3cccc(OC(F)F)c3)nc2c(=O)n1C[C@H]1CCCN(C[C@H]2CCCO2)C1,"2-(3-(Difluoromethoxy)phenyl)-5-(2-methylpyridin-3-yl)-6-(((S)-1-(((R)-tetrahydrofuran-2-yl)methyl)piperidin-3-yl)methyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",8.4,uM,=,0.9242792860618816,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2cccnc2)n1C[C@H]1CCCN(C[C@H]2CCCO2)C1
5348,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3ccc(F)cn3)cs2)CO1,"US9315520, 9",10.7,uM,=,1.0293837776852095,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccn1
5349,1831774,10.1016/j.bmc.2018.12.002,,,,Inhibition of human ERG,CC(C)(C)c1ccc2[nH]c(C(C)(C)N)nc2c1,2-(5-(tert-Butyl)-1H-benzo[d]imidazol-2-yl)propan-2-amine,41.0,uM,=,1.6127838567197357,1,c1ccc2[nH]cnc2c1
5350,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O,"5-Methyl-2-(5-methyl-1H-imidazol-4-ylmethyl)-2,3,4,5-tetrahydro-pyrido[4,3-b]indol-1-one",3.2,uM,=,0.505149978319906,1,O=C1c2c([nH]c3ccccc23)CCN1Cc1c[nH]cn1
5351,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,COC(=O)N(C)c1c(N)nc(-n2nc(Cc3cc(F)cc(F)c3F)c3ccccc32)nc1N,"methyl N-[4,6-diamino-2-[3-[(2,3,5-trifluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methyl-carbamate",28.0,uM,=,1.4471580313422192,1,c1ccc(Cc2nn(-c3ncccn3)c3ccccc23)cc1
5352,2287586,10.1021/acsmedchemlett.8b00517,,,,Inhibition of hERG potassium channel incubated for 4 hrs by fluorescence polarization assay,CCC(=O)CCCCC[C@H](NC(=O)C1CN(C)C1)c1ncc(-c2cc3ccccc3nc2OC)o1,(S)-N-(1-(5-(2-methoxyquinolin-3-yl)oxazol-2-yl)-7-oxononyl)-1-methylazetidine-3-carboxamide,3.6,uM,=,0.5563025007672873,1,O=C(NCc1ncc(-c2cnc3ccccc3c2)o1)C1CNC1
5353,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@H](c2cc(OC)c(OC)nc2OC)c2cc3cc(Br)ccc3nc2OC)cc(OC)n1,"(1S,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)-1-(2,5,6-trimethoxypyridin-3-yl)butan-2-ol",5.9,uM,=,0.7708520116421442,1,c1cncc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)c1
5354,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3ccc(OC4CCC4)nc3)CC2)C1,cis-N-({1-[4-(6-Cyclobutoxy-pyridin-3-yl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,9.8,uM,=,0.9912260756924948,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccc(OC4CCC4)nc3)CC2)C1
5355,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2F)[C@@H]3C)n1,"US9422299, 18",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
5356,2125318,10.1021/acs.jmedchem.0c01955,,,,Displacement of [3H]dofetilide from recombinant human ERG stably expressed in HEK293 cell membranes measured after 90 mins by microbeta liquid scintillation counting method,NCCn1nnc(-c2ccc(Oc3ccc(Cl)cc3)cc2)n1,2-(5-(4-(4-Chlorophenoxy)phenyl)-2H-tetrazol-2-yl)ethan-1-amine,8.5,uM,=,0.9294189257142929,1,c1ccc(Oc2ccc(-c3nn[nH]n3)cc2)cc1
5357,687332,10.1016/j.bmcl.2010.10.042,,,,Displacement of [3H]-dofetilide from human ERG,CC(C)(O)C(=O)N1CCC(CCN2CCC(N(C(=O)NCc3ccc(C#N)cc3)c3cccc(F)c3)CC2)(c2cccc(F)c2)CC1,3-(4-cyanobenzyl)-1-(3-fluorophenyl)-1-(1-(2-(4-(3-fluorophenyl)-1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl)ethyl)piperidin-4-yl)urea,10.0,uM,=,1.0,1,O=C(NCc1ccccc1)N(c1ccccc1)C1CCN(CCC2(c3ccccc3)CCNCC2)CC1
5358,872803,10.1021/jm300991n,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,COc1cccc(-c2cccc(C3(C)N=C(C)C(N)=N3)c2)c1,"2-(3'-Methoxybiphenyl-3-yl)-2,5-dimethyl-2H-imidazol-4-amine",16.7,uM,=,1.2227164711475833,1,C1=NC(c2cccc(-c3ccccc3)c2)N=C1
5359,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1nc(C(=O)N[C@@H]2CC(C)(C)Oc3nc(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)cc32)n[nH]1,"N-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-5-methyl-1H-1,2,4-triazole-3-carboxamide",2.0,uM,=,0.3010299956639812,1,O=C(N[C@@H]1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)c1nc[nH]n1
5360,948139,10.1016/j.bmcl.2013.01.019,,,,Inhibition of human ERG,COCC(C)Nc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1,"(2-methoxy-5-(2-(1-methoxypropan-2-ylamino)-4-((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)phenyl)methanol",17.0,uM,=,1.230448921378274,1,c1ccc(-c2ccc3c(N4CCOCC4)ncnc3n2)cc1
5361,1765499,10.1021/acs.jmedchem.8b01040,,,,Displacement of [3H]dofetilide from human ERG by high throughput assay,CN1CCN(c2ncc(C(=O)Nc3ccc(OC(F)(F)F)cc3)cc2-c2cncnc2)CC1,"US9278981, 26",0.31,uM,=,-0.5086383061657274,0,O=C(Nc1ccccc1)c1cnc(N2CCNCC2)c(-c2cncnc2)c1
5362,699709,10.1016/j.bmcl.2010.11.111,,,,Displacement of radiolabeled MK-499 from human ERG expressed in HEK293 cells,COc1cc(/C=C/c2nc(N)c3c(n2)oc2ccccc23)ccc1-n1cnc(C)c1,"2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)styryl)benzofuro[2,3-d]pyrimidin-4-amine",0.51,uM,=,-0.2924298239020636,0,C(=C/c1ncc2c(n1)oc1ccccc12)\c1ccc(-n2ccnc2)cc1
5363,1630280,10.1016/j.ejmech.2016.07.032,,,,Inhibition of human ERG expressed in CHOK1 cells by whole-cell patch clamp method,CC(C)Cc1cc(CNS(=O)(=O)c2ccc(Cc3ccccc3)cc2)nn1-c1ccccc1,N-[(5-Isobutyl-1-phenyl-1H-pyrazol-3-yl)methyl]benzylsulfonamide,6.55,uM,=,0.8162412999917831,1,O=S(=O)(NCc1ccn(-c2ccccc2)n1)c1ccc(Cc2ccccc2)cc1
5364,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(C#N)ccc5[nH]4)CC3)c2c1,"2-(1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazole-5-carbonitrile",4.5,uM,=,0.6532125137753437,1,O=c1ccc2ncccc2n1CCN1CCC(c2nc3ccccc3[nH]2)CC1
5365,770623,10.1016/j.bmcl.2011.07.061,,,,Inhibition of human ERG,Cc1nc2ccccc2n1-c1ccc(C(=O)N(C)[C@@H]2CCN(C3CCCCC3)C2)cc1,(R)-N-(1-cyclohexylpyrrolidin-3-yl)-N-methyl-4-(2-methyl-1H-benzo[d]imidazol-1-yl)benzamide,2.8,uM,=,0.4471580313422192,1,O=C(N[C@@H]1CCN(C2CCCCC2)C1)c1ccc(-n2cnc3ccccc32)cc1
5366,2047203,10.1021/acs.jmedchem.0c01170,,,,Inhibition of human ERG by Q-patch assay,Nc1nccc(Sc2cnc(N3CCC4(CCC[C@H]4N)CC3)cn2)c1Cl,(R)-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-1-amine,11.9,uM,=,1.0755469613925308,1,c1cc(Sc2cnc(N3CCC4(CCCC4)CC3)cn2)ccn1
5367,2084088,,,,,Inhibition of human ERG,CC(=O)N1CCc2nc(N3CCC(Oc4ccc(F)cc4F)CC3)c(N[C@H]3CCOC3)nc2C1,"US9181249, 149",0.505,uM,=,-0.2967086218813386,0,c1ccc(OC2CCN(c3nc4c(nc3N[C@H]3CCOC3)CNCC4)CC2)cc1
5368,2046362,10.1021/acs.jmedchem.0c00746,,,,Inhibition of human ERG,FC(F)Oc1ccc(-c2nnc3cncc(OCCc4ccccc4)n23)cc1,"3-(4-(Difluoromethoxy)phenyl)-5-phenethoxy-[1,2,4]triazolo[4,3-a]pyrazine",7.41,uM,=,0.8698182079793282,1,c1ccc(CCOc2cncc3nnc(-c4ccccc4)n23)cc1
5369,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,CCOc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3Cl)c2cc1C1CCN(C)CC1,"4-(2,3-dichlorophenylamino)-7-ethoxy-6-(1-methylpiperidin-4-yl)quinoline-3-carboxamide",4.0,uM,=,0.6020599913279624,1,c1ccc(Nc2ccnc3ccc(C4CCNCC4)cc23)cc1
5370,1686117,10.1016/j.bmcl.2017.06.009,,,,Inhibition of human ERG,COc1ccc2ncc(F)c([C@@H](O)CC[C@@H]3CCN(C4CC(c5ncccc5F)C4)C[C@@H]3C(=O)O)c2c1,"(3R,4R)-4-((S)-3-(3-fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl)-1-(3-(3-fluoropyridin-2-yl)cyclobutyl)piperidine-3-carboxylic acid",10.7,uM,=,1.0293837776852095,1,c1ccc(C2CC(N3CCC(CCCc4ccnc5ccccc45)CC3)C2)nc1
5371,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,COc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2C)CC1,"US9145392, 9",670.0,uM,=,2.8260748027008264,1,c1ccc(-c2c[nH]c(C3CCN(c4ccncn4)CC3)n2)cc1
5372,462016,10.1016/j.bmcl.2007.12.029,,,,Displacement of [33S]MK499 from human ERG expressed in HEK cells,CC(C)[C@]1(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H](N2CCC(c3cncnc3)CC2)C1,"N-(3,5-bis(trifluoromethyl)benzyl)-1-isopropyl-3-(4-(pyrimidin-5-yl)piperidin-1-yl)cyclopentanecarboxamide",1.8,uM,=,0.255272505103306,1,O=C(NCc1ccccc1)C1CC[C@@H](N2CCC(c3cncnc3)CC2)C1
5373,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ccncn1,"4'-[8-(3-Methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrimidin-4-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",31.0,uM,=,1.4913616938342726,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
5374,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,Cc1ccc(Oc2ccc(Cl)c(Cl)c2)c(CN(C)C)c1,"1-(2-(3,4-dichlorophenoxy)-5-methylphenyl)-N,N-dimethylmethanamine",3.39,uM,=,0.5301996982030822,1,c1ccc(Oc2ccccc2)cc1
5375,520038,10.1021/jm900364m,,,,Binding affinity to human ERG,COc1ccc(CC(C)(C)NCC(O)COc2cccc(Cl)c2C#N)cc1,"(+/-)-2-Chloro-6-([3-((1,1-dimethyl-2-[4-(methyloxy)phenyl]ethyl)-amino)-2-hydroxypropyl]oxy)benzonitrile",3.6,uM,=,0.5563025007672873,1,c1ccc(CCNCCCOc2ccccc2)cc1
5376,949743,10.1021/jm301720p,,,,Inhibition of human ERG channel,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCCN4CC(C#N)C4)c4ccc(OC(F)F)cc34)nc12,"N-tert-butyl-2-(1-(3-(3-cyanoazetidin-1-yl)propyl)-5-(difluoromethoxy)-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",0.414,uM,=,-0.3829996588791011,0,c1ccc2c(c1)c(-c1cnc3[nH]ccc3n1)nn2CCCN1CCC1
5377,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,O=C(/C=C/c1ccc(CNCCc2c(-c3ccccc3)nn3ccccc23)cc1)NO,"(E)-N-Hydroxy-3-(4-{[2-(2-phenyl-pyrazolo[1,5-a]pyridin-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide",10.4,uM,=,1.0170333392987805,1,c1ccc(CNCCc2c(-c3ccccc3)nn3ccccc23)cc1
5378,1473546,10.1021/jm5018169,,,,Displacement of radio-labeled MK-499 from ERG channel in human embryonic kidney cells,Cc1cc(C)nc(Nc2cc(NC[C@@H](N)C(F)(F)F)cnc2C(N)=O)c1,"(R)-5-((2-amino-3,3,3-trifluoropropyl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide",42.0,uM,=,1.6232492903979006,1,c1ccc(Nc2cccnc2)nc1
5379,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccccc3)CC2)CN(Cc2ccccc2)C1=O,"4-benzyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.1,uM,=,-1.0,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1Cc1ccccc1
5380,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ncccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrimidin-2-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",23.0,uM,=,1.3617278360175928,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ncccn1
5381,726745,10.1016/j.bmcl.2011.01.036,,,,Inhibition of human ERG,C[C@@H](C[C@@](C)(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O)c1ncc(F)cn1,"N-((2S,4S)-1-(4-(4-fluorophenyl)piperazin-1-ylsulfonyl)-4-(5-fluoropyrimidin-2-yl)-2-methylpentan-2-yl)-N-hydroxyformamide",21.0,uM,=,1.3222192947339193,1,O=S(=O)(CCCCc1ncccn1)N1CCN(c2ccccc2)CC1
5382,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F,"6-((1-(2-(7-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00249,uM,=,-2.603800652904264,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5383,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(NC1CC(F)C1)c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1,"US9452986, 604",30.0,uM,=,1.4771212547196624,1,O=C(NC1CCC1)c1ccc2cc(Oc3ccccn3)ccc2n1
5384,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(CC)CC2)c1ncc(-c2cc3ccc(C)nc3cc2OC)o1,(S)-6-ethyl-N-((S)-1-(5-(7-methoxy-2-methylquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide,51.0,uM,=,1.7075701760979365,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)o1)[C@H]1CC12CCNCC2
5385,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)N3CCS(=O)(=O)CC3)cc2)cc1,"4-{4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl4-sulfonyl}-thiomorpholine 1,1-Dioxide",9.5,uM,=,0.9777236052888478,1,O=S1(=O)CCN(S(=O)(=O)c2ccc(-c3ccc(CCN4CCCC4)cc3)cc2)CC1
5386,2208843,10.1016/j.bmc.2022.116657,,,,Inhibition of hERG channel expressed in CHO cells at -80 mV holding potential by Qpatch clamp method,COc1cc(OC)c(F)c(COc2cnc(Nc3cnn(CCN4CCNCC4)c3)nc2)c1F.Cl.Cl.Cl,"5-[(2,6-Difluoro-3,5-dimethoxyphenyl)methoxy]-N-{1-[2-(piperazin-1-yl)ethyl]-1H-pyrazol-4-yl}pyrimidin-2-amine trihydrochloride",89.0,uM,=,1.9493900066449128,1,c1ccc(COc2cnc(Nc3cnn(CCN4CCNCC4)c3)nc2)cc1
5387,2069167,10.1016/j.bmcl.2020.127763,,,,Inhibition of human ERG,O=C(NO)c1ccc(CCCN2CCC(CN[C@H]3C[C@@H]3c3ccccc3)CC2)cc1,rac-N-hydroxy-4-(3-(4-((2-phenylcyclopropylamino)methyl)piperidin-1-yl)propyl)benzamide,5.6,uM,=,0.7481880270062004,1,c1ccc(CCCN2CCC(CN[C@H]3C[C@@H]3c3ccccc3)CC2)cc1
5388,828054,10.1016/j.bmcl.2012.05.098,,,,Inhibition of human ERG,CC(C)COc1cccc(/C=C2\SC(=O)NC2=O)c1N1CCC[C@@H](N)C1,"(R,Z)-5-(2-(3-aminopiperidin-1-yl)-3-isobutoxybenzylidene)thiazolidine-2,4-dione",23.0,uM,=,1.3617278360175928,1,O=C1NC(=O)/C(=C/c2ccccc2N2CCCCC2)S1
5389,1669768,10.1021/acs.jmedchem.7b00949,,,,Inhibition of human ERG expressed in CHO cells after 3 mins at -80 mV holding potential by automated patch clamp method,CN(C/C=C/c1ccc(C(F)(F)F)cc1)Cc1ccc2c(c1)CCCC2.Cl,"(E)-N-Methyl-N-((5,6,7,8-tetrahydronaphthalen-2-yl)methyl)-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-amine Hydrochloride",1.4,uM,=,0.1461280356782379,1,C(=C/c1ccccc1)\CNCc1ccc2c(c1)CCCC2
5390,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c(CCN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)C3=O)ccc2c1COC2=O,"8-(2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one",4.7,uM,=,0.6720978579357175,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccc(=O)[nH]n3)C4=O)ccc21
5391,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCCC(C(=O)N2CCCC2)C1,3-(pyrrolidine-1-carbonyl)-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)piperidine-1-carboxamide,11.7,uM,=,1.0681858617461617,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCCC(C(=O)N2CCCC2)C1
5392,1554472,10.1021/acs.jmedchem.5b01372,,,,Binding affinity to human ERG channel,Nc1nc(CC(=O)Nc2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)cs1,"2-(2-aminothiazol-4-yl)-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)acetamide",19.0,uM,=,1.2787536009528289,1,O=C(Cc1cscn1)Nc1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1
5393,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ncc(Cl)cc3C2)C1,"(3-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)((2R,3aR,6aR)-2-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)methanone",33.3,uM,=,1.5224442335063195,1,O=C(N1CCc2ncccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
5394,826732,10.1021/jm201194q,,,,Inhibition of human ERG expressed in HEK cells by patch clamp assay,O=C(CCc1ccccc1)NCCN(c1ccc(F)cc1)c1ccc(F)cc1,N-(2-(bis(4-fluorophenyl)amino)ethyl)-3-phenylpropanamide,0.192,uM,=,-0.7166987712964504,0,O=C(CCc1ccccc1)NCCN(c1ccccc1)c1ccccc1
5395,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2C(=O)OC1CCC1,"(R)-cyclobutyl 6-(1-(4-fluorobenzamido)ethyl)-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate",60.0,uM,=,1.7781512503836436,1,O=C(NCc1ccc2c(n1)CCCN2C(=O)OC1CCC1)c1ccccc1
5396,2201879,10.1016/j.ejmech.2022.114402,,,,Inhibition of hERG by automated patch clamp analysis,COc1cccc(CNCc2c(C(=O)O)n(Cc3ccc(C)cc3)c3cc(C(C)C)ccc23)c1,6-isopropyl-3-(((3-methoxybenzyl)amino)methyl)-1-(4-methylbenzyl)-1H-indole-2-carboxylic acid,34.59,uM,=,1.5389505620143615,1,c1ccc(CNCc2cn(Cc3ccccc3)c3ccccc23)cc1
5397,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(F)ccc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-5-fluorophenyl)-N-methylmethanamine",5.57,uM,=,0.7458551951737289,1,c1ccc(Oc2ccccc2)cc1
5398,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(N)nc7)[nH]6)CC5)cc4)nc3n2)CC1,"5-(5-(1-((4-(2-(4-(2-(dimethylamino)ethyl)piperazin-1-yl)-6-phenylpyrido[2,3-d]pyrimidin-7-yl)phenyl)methyl)piperidin-4-yl)-4H-1,2,4-triazol-3-yl)pyridin-2-amine",3.5,uM,=,0.5440680443502757,1,c1ccc(-c2cc3cnc(N4CCNCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5cccnc5)[nH]4)CC3)cc2)cc1
5399,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(OCc2cccc(COc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis(p-tolyloxymethyl)pyridinium",0.053,uM,=,-1.275724130399211,0,c1ccc(OCc2cccc(COc3ccccc3)[nH+]2)cc1
5400,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(C3CC3(C)C)n2)(c2ccc(F)cc2)CC1,"2-(2,2-dimethylcyclopropyl)-6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine",9.0,uM,=,0.9542425094393248,1,c1ccc(C2(COCc3cccc(C4CC4)n3)CCNCC2)cc1
5401,963961,10.1016/j.bmcl.2013.03.019,,,,Inhibition of human ERG,COc1cccc(COC(=O)c2c(-c3ccc(OC)c(OC)c3)csc2N)c1,"3-methoxybenzyl 2-amino-4-(3,4-dimethoxyphenyl)thiophene-3-carboxylate",1.0,uM,=,0.0,0,O=C(OCc1ccccc1)c1cscc1-c1ccccc1
5402,219494,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,"2-(2,2-Dicyclohexyl-ethyl)-piperidine",7.8,uM,=,0.8920946026904804,1,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
5403,2089285,10.1016/j.ejmech.2020.112395,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,COc1ccc(-c2ccccc2N2CCN(C[C@@H](O)COc3ccc(-c4cn5ccccc5n4)cc3)CC2)cc1,"(R)-1-[4-(Imidazo[1,2-a]pyridin-2-yl)phenoxy]-3-{4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl}propan-2-ol",1.907,uM,=,0.2803506930460056,1,c1ccc(-c2ccccc2N2CCN(CCCOc3ccc(-c4cn5ccccc5n4)cc3)CC2)cc1
5404,2238137,10.1021/acs.jmedchem.1c01012,,,,Inhibition of human ERG,Cc1cnc(N2CCN(Cc3ccc4c(c3)[nH]c(=O)c3cccnc34)CC2)n1C,"8-((4-(1,5-dimethyl-1H-imidazol-2-yl)piperazin-1-yl)methyl)benzo[h][1,6]naphthyridin-5(6H)-one",11.0,uM,=,1.0413926851582251,1,O=c1[nH]c2cc(CN3CCN(c4ncc[nH]4)CC3)ccc2c2ncccc12
5405,2067975,10.1021/acs.jmedchem.0c01019,,,,Inhibition of human ERG channel in presence of dofetilide by competition binding assay,COCCOc1cc(NC(=O)N2CCCc3cc(CN(CCN(C)C)C(C)=O)c(C=O)nc32)ncc1C#N,"N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-6-((N-(2-(dimethylamino)ethyl)acetamido)methyl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C(Nc1ccccn1)N1CCCc2cccnc21
5406,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NCc1cccc(F)c1)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,1-(3-fluorobenzyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,1.2,uM,=,0.0791812460476248,1,O=C(NCc1ccccc1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
5407,1703610,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by patch clamp method,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-phenylpyrrolo[1,2-b]pyridazine-3-carboxamide",0.3,uM,=,-0.5228787452803376,0,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
5408,540677,10.1016/j.bmcl.2008.12.083,,,,Inhibition of human ERG,Nc1ccc(-c2ccccc2)cc1NC(=O)c1ccc(C(=O)N2CCC3(CCCN3)CC2)cc1,"N-(4-aminobiphenyl-3-yl)-4-(1,8-diazaspiro[4.5]decane-8-carbonyl)benzamide",12.39,uM,=,1.0930713063760635,1,O=C(Nc1cccc(-c2ccccc2)c1)c1ccc(C(=O)N2CCC3(CCCN3)CC2)cc1
5409,876604,10.1021/jm301476b,,,,Inhibition of human ERG expressed in chinese hamster lung cells by IonWorks patch clamp electrophysiology assay,Nc1ncc(-c2ccc(C(=O)N3CCOCC3)cc2)cc1-c1ccc(C(F)(F)F)cc1,(4-(6-amino-5-(4-(trifluoromethyl)phenyl)pyridin-3-yl)phenyl)(morpholino)methanone,3.0,uM,=,0.4771212547196624,1,O=C(c1ccc(-c2cncc(-c3ccccc3)c2)cc1)N1CCOCC1
5410,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O,"5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione",3000.0,uM,=,3.4771212547196626,1,O=C1NC(=O)C(c2ccccc2)C(=O)N1
5411,651867,10.1016/j.bmc.2010.07.013,,,,Inhibition of human ERG at holding potential of -80 mV to +40 mV,Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,"5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide",4.8,uM,=,0.6812412373755872,1,O=C(NN1CCCCC1)c1cc(-c2ccccc2)n(-c2ccccc2)n1
5412,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CCc1nc(C)n(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2C)n1,"(R)-2-(3-Ethyl-5-methyl-1H-1,2,4-triazol-1-yl)-1-(2-methyl-4-(2-(trifluoromethyl)-4-(2-(trifluoromethyl)pyrimidin-5-yl)thiazol-5-yl)piperazin-1-yl)ethan-1-one",0.0087,uM,=,-2.0604807473813813,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
5413,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCCN3CCCC3=O)C[C@@H]2CC(=O)Nc2cccc(Cl)c2)cc1,"N-(3-chlorophenyl)-2-((3R,4S)-4-(4-methoxyphenyl)-1-(3-(2-oxopyrrolidin-1-yl)propyl)pyrrolidin-3-yl)acetamide",1.26,uM,=,0.1003705451175629,1,O=C(C[C@H]1CN(CCCN2CCCC2=O)C[C@@H]1c1ccccc1)Nc1ccccc1
5414,1911678,10.1021/acs.jmedchem.8b01725,,,,Inhibition of human ERG by Q-patch assay,Cn1c(N2CCC(C)(CN)CC2)nc2[nH]nc(-c3cccc(Cl)c3Cl)c2c1=O,"6-(4-(aminomethyl)-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)-5-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one",0.98,uM,=,-0.0087739243075051,0,O=c1[nH]c(N2CCCCC2)nc2[nH]nc(-c3ccccc3)c12
5415,861902,10.1021/jm3007323,,,,Inhibition of human ERG transfected in HEK293 cell membranes by whole cell patch clamp assay,CC(=O)C1CCN(CCOc2ccn(-c3ccc(Cl)c(Cl)c3)n2)CC1,"1-(1-(2-(1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy)ethyl)piperidin-4-yl)ethanone",4.5,uM,=,0.6532125137753437,1,c1ccc(-n2ccc(OCCN3CCCCC3)n2)cc1
5416,2203568,10.1016/j.bmcl.2022.128824,,,,Inhibition of human ERG,CNCC[C@@](O)(c1cccc2ccccc12)[C@H](c1ccccc1)c1cc2cc(Br)ccc2nc1OC,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(methylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol",1.73,uM,=,0.2380461031287954,1,c1ccc([C@@H](Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
5417,1895899,10.1021/acs.jmedchem.9b00518,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential measured after 3 mins by QPatch automated patch-clamp assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.07,uM,=,-1.154901959985743,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
5418,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,COCCOc1cc2ncc(C(N)=O)c(Nc3ccc(C)cc3F)c2cc1N1CCOCC1,4-(2-fluoro-4-methylphenylamino)-7-(2-methoxyethoxy)-6-morpholinoquinoline-3-carboxamide,9.0,uM,=,0.9542425094393248,1,c1ccc(Nc2ccnc3ccc(N4CCOCC4)cc23)cc1
5419,499505,10.1016/j.bmcl.2009.01.110,,,,Inhibition of human ERG,CC(C)CNc1nc(C#N)nc(N2CCNCC2)c1N,5-amino-4-(isobutylamino)-6-(piperazin-1-yl)pyrimidine-2-carbonitrile,52.0,uM,=,1.7160033436347992,1,c1cc(N2CCNCC2)ncn1
5420,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,Cc1ccn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2CO)n1,1-((S)-2-Hydroxymethyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-methyl-pyrazol-1-yl)-ethanone,0.013,uM,=,-1.8860566476931635,0,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
5421,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CN(c1ccc(-c2ccc(-n3cccn3)cc2O)nn1)C1CC(C)(C)NC(C)(C)C1,"2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol",0.3,uM,=,-0.5228787452803376,0,c1cnn(-c2ccc(-c3ccc(NC4CCNCC4)nn3)cc2)c1
5422,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,CCN(CC)Cc1cc(Nc2ccc3ncc(-c4ccc([S+](C)[O-])cc4)n3n2)ccc1O,"2-((diethylamino)methyl)-4-(3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-ylamino)phenol",7.83,uM,=,0.8937617620579434,1,c1ccc(Nc2ccc3ncc(-c4ccccc4)n3n2)cc1
5423,944980,10.1021/ml3003132,,,,Inhibition of human ERG by patch clamp assay,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C(C)C)C3)cc1,"(S)-1-ethyl-3-(4-(7-isopropyl-4-(3-methylmorpholino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea",8.5,uM,=,0.9294189257142929,1,c1ccc(-c2nc3c(c(N4CCOCC4)n2)CCNC3)cc1
5424,1620545,10.1021/acs.jmedchem.6b00821,,,,Inhibition of human ERG by patch clamp assay,COc1cnc(O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3C3CC3)N(C(=O)[C@@H](NC(=O)O[C@H](C)C(F)(F)F)C3CCCCC3)C2)c2cc(Cl)ccc12,"(R)-1,1,1-Trifluoropropan-2-yl ((S)-2-((2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1S,2R)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1'-bi(cyclopropan)]-2-yl)-carbamoyl)pyrrolidin-1-yl)-1-cyclohexyl-2-oxoethyl)-carbamate",12.5,uM,=,1.0969100130080565,1,O=C(N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C1CC1)[C@@H]1C[C@@H](Oc2nccc3ccccc23)CN1C(=O)CC1CCCCC1
5425,971488,10.1016/j.bmcl.2013.05.017,,,,Inhibition of human ERG channel by patch clamp technique,CC(C)(O)c1nc2cc(Cl)ccc2n1[C@H]1CC[C@@H](NC[C@H]2Cc3ccc(C#N)cc3C2)CC1,"cis-(S)-2-((-4-(5-chloro-2-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-1-yl)cyclohexylamino)methyl)-2,3-dihydro-1H-indene-5-carbonitrile",0.06,uM,=,-1.2218487496163564,0,c1ccc2c(c1)CC(CN[C@H]1CC[C@@H](n3cnc4ccccc43)CC1)C2
5426,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CC[C@H](NCc4ccc5c(n4)NC(=O)CO5)[C@H](F)C3)c2c1,"cis-6-[({(3R,4S)-3-Fluoro-1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b]-[1,4]oxazin-3(4H)-one",25.0,uM,=,1.3979400086720375,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)cnc5ccccc54)CC3)nc2N1
5427,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COC(=O)C1(CNC(=O)c2cc(Cl)cc(Cl)c2)CCN(Cc2cccc(C(F)(F)F)c2)CC1,"methyl 4-((3,5-dichlorobenzamido)methyl)-1-(3-(trifluoromethyl)benzyl)piperidine-4-carboxylate",0.89,uM,=,-0.0506099933550872,0,O=C(NCC1CCN(Cc2ccccc2)CC1)c1ccccc1
5428,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCCNCC3)Oc3ccccc32)cc1,"N,N-Diethyl-4-(spiro[azepane-4,2'-chromene]-4'-yl)benzamide",11.784,uM,=,1.0712927338345746,1,C1=C(c2ccccc2)c2ccccc2OC12CCCNCC2
5429,1701460,10.1021/acs.jmedchem.7b00332,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,0.022,uM,=,-1.6575773191777938,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
5430,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCn2cccc2C1c1ccccc1,"1-phenyl-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazine-2(1H)-carboxamide",1.3,uM,=,0.1139433523068367,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCn2cccc2C1c1ccccc1
5431,1578296,10.1016/j.bmcl.2016.04.020,,,,Inhibition of human ERG,Cc1cc2ncc3c(n2n1)CN([C@H]1CC[C@H](c2cc(F)c(F)cc2F)[C@@H](N)C1)C3,"(1S,2R,5S)-5-(2-methyl-6H-pyrazolo[1,5-a]pyrrolo[3,4-e]pyrimidin-7(8H)-yl)-2-(2,4,5-trifluorophenyl)cyclohexanamine",0.6,uM,=,-0.2218487496163563,0,c1ccc([C@H]2CC[C@H](N3Cc4cnc5ccnn5c4C3)CC2)cc1
5432,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1n[nH]cc1C(=O)N[C@@H]1CC(C)(C)Oc2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc21,"N-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-3-methyl-1H-pyrazole-4-carboxamide",1.1,uM,=,0.041392685158225,1,O=C(N[C@@H]1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)c1cn[nH]c1
5433,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,Cc1nc(-c2ccc(CN3CCC(N(C)C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)cc2)no1,"2-(4-(1H-tetrazol-1-yl)phenyl)-N-methyl-N-(1-(4-(5-methyl-1,2,4-oxadiazol-3-yl)benzyl)piperidin-4-yl)acetamide",6.5,uM,=,0.8129133566428556,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2ccc(-c3ncon3)cc2)CC1
5434,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CC(=O)N(c2ccc(C#N)cn2)C3)ccc2c1COC2=O,"(R)-6-(8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-3-oxo-2,8-diazaspiro[4.5]decan-2-yl)nicotinonitrile",1.8,uM,=,0.255272505103306,1,O=C1OCc2cc(CCN3CCC4(CC3)CC(=O)N(c3ccccn3)C4)ccc21
5435,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,CC1(C(=O)N2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1,"(R)-4-(8-amino-3-(1-(3-methyloxetane-3-carbonyl)pyrrolidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",2.5,uM,=,0.3979400086720376,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@@H]3CCN(C(=O)C4COC4)C3)n3ccncc23)cc1
5436,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,CCOC(=O)c1nn(-c2ccc(Cl)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1,"Ethyl 4-(4-chlorophenyl)-5-((3-cyano-4,6-diphenylpyridin-2-yl)imino)-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate",8.4,uM,=,0.9242792860618816,1,c1ccc(-c2cc(/N=c3\scnn3-c3ccccc3)nc(-c3ccccc3)c2)cc1
5437,1473398,10.1021/jm501920g,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,Clc1ccc(Cn2cc(NCCN3CCCCCC3)nn2)cc1Cl,"N-(2-(azepan-1-yl)ethyl)-1-(3,4-dichlorobenzyl)-1H-1,2,3-triazol-4-amine",3.9,uM,=,0.5910646070264992,1,c1ccc(Cn2cc(NCCN3CCCCCC3)nn2)cc1
5438,2117635,10.1016/j.ejmech.2021.113560,,,,Inhibition of human ERG channel expressed in CHO cells measured after 7 to 10 mins at -80 mV holding potential by whole cell patch clamp assay,O=C(NCc1ccc2[nH]ccc2c1)N1CC(COc2ccc(C(F)(F)F)cc2)C1,N-[(1H-indol-5-yl)methyl]-3-([4-(trifluoromethyl)phenoxy]methyl)azetidine-1-carboxamide,4.6,uM,=,0.6627578316815741,1,O=C(NCc1ccc2[nH]ccc2c1)N1CC(COc2ccccc2)C1
5439,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",1.9,uM,=,0.2787536009528289,1,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
5440,1499195,10.1021/acsmedchemlett.5b00070,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,Cc1cn(-c2ccc3n(c2=O)CCN([C@@H](C)COc2ccc(F)cc2[C@@H](C)C(F)(F)F)C3=O)cn1,"2-((S)-1-(4-fluoro-2-((R)-1,1,1-trifluoropropan-2-yl)phenoxy)propan-2-yl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-1H-pyrido[1,2-a]pyrazine-1,6(2H)-dione",9.2,uM,=,0.9637878273455552,1,O=C1c2ccc(-n3ccnc3)c(=O)n2CCN1CCOc1ccccc1
5441,609460,10.1016/j.bmcl.2009.12.026,,,,Inhibition of human ERG,O=C(c1cc(Cc2c[nH]c(=O)c3cc(Cl)c(Cl)n23)ccc1F)N1CCC2(CCCN2)CC1,"6,7-dichloro-4-(4-fluoro-3-(1,8-diazaspiro[4.5]decane-8-carbonyl)benzyl)pyrrolo[1,2-a]pyrazin-1(2H)-one",12.0,uM,=,1.0791812460476249,1,O=C(c1cccc(Cc2c[nH]c(=O)c3cccn23)c1)N1CCC2(CCCN2)CC1
5442,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ccccc1F,N-((1-(4-benzylpiperazin-1-yl)cyclopropyl)methyl)-N-(2-fluorophenyl)propionamide,2.6,uM,=,0.414973347970818,1,c1ccc(CN2CCN(C3(CNc4ccccc4)CC3)CC2)cc1
5443,1911298,10.1021/acs.jmedchem.8b01300,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole-cell patch clamp assay,CN(C)CCC=C1c2ccccc2CCc2ccccc21,"[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine",3.0,uM,=,0.4771212547196624,1,C=C1c2ccccc2CCc2ccccc21
5444,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc5cn[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"3-[4-(1H-Indazol-6-yl)-phenyl]-1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",0.72,uM,=,-0.1426675035687315,0,O=C1N(c2ccc(-c3ccc4cn[nH]c4c3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
5445,1577772,10.1021/acsmedchemlett.5b00360,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cell membranes incubated for 2 hrs by scintillation counting analysis,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,0.023,uM,=,-1.6382721639824072,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
5446,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,CN(C(=O)c1ccccc1Oc1ccccc1)[C@H]1CCNC1,(S)-N-methyl-2-phenoxy-N-(pyrrolidin-3-yl)benzamide,9.21,uM,=,0.964259630196849,1,O=C(N[C@H]1CCNC1)c1ccccc1Oc1ccccc1
5447,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCN(CC(O)c3cc(C4CC4)c(C#N)cn3)CC2)ccc2c1COC2=O,"4-cyclopropyl-6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)nicotinonitrile",11.0,uM,=,1.0413926851582251,1,O=C1OCc2cc(CCN3CCN(CCc4cc(C5CC5)ccn4)CC3)ccc21
5448,1898259,10.1016/j.bmcl.2019.126643,,,,Inhibition of human ERG,CCNC(=O)[C@H]1CC[C@@]2(C)CC[C@@H]3c4ccc(OCCCN5CCC[C@H]5C)cc4CC[C@H]3[C@H]12,"(8R,9S,13R,14R,15S)-N-ethyl-13-methyl-3-(3-((R)-2-methylpyrrolidin-1-yl)propoxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-15-carboxamide",4.1,uM,=,0.6127838567197355,1,c1cc2c(cc1OCCCN1CCCC1)CC[C@@H]1[C@@H]2CCC2CCC[C@H]21
5449,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2nc(-c3ccc(OC4CCN(C5CCC5)CC4)cc3)n(C)c(=O)c12,2-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-5-methoxy-3-methylquinazolin-4(3H)-one,10.0,uM,=,1.0,1,O=c1[nH]c(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)nc2ccccc12
5450,1824533,10.1021/acs.jmedchem.9b01295,,,,Inhibition of human ERG,Cc1cnc(Nc2ccnn2C)nc1-c1cn2c(n1)C(=O)N(Cc1ccc(F)c(F)c1)[C@@H](C)C2,"(6S)-7-[(3,4-difluorophenyl)methyl]-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one",23.0,uM,=,1.3617278360175928,1,O=C1c2nc(-c3ccnc(Nc4ccn[nH]4)n3)cn2CCN1Cc1ccccc1
5451,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(Cl)ccc1Oc1ccc(C)c(C)c1,"1-(5-chloro-2-(3,4-dimethylphenoxy)phenyl)-N-methylmethanamine",5.23,uM,=,0.7185016888672743,1,c1ccc(Oc2ccccc2)cc1
5452,766531,10.1016/j.bmcl.2011.06.126,,,,Inhibition of human ERG by electrophysiological assay,CS(=O)(=O)c1ccc2c(c1)N(CCN1CCC(NCc3ccc4c(n3)NC(=O)CO4)CC1)C(=O)CO2,"6-((1-(2-(6-(methylsulfonyl)-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",50.7,uM,=,1.705007959333336,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccccc54)CC3)nc2N1
5453,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,O=C(Nc1ccc(O)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(Cl)ccc1O2)NC1CC1,"(S)-1-(2-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-hydroxyphenyl)-3-cyclopropylurea",2.4,uM,=,0.380211241711606,1,O=C(Nc1ccccc1OCCCN1CCC2(CC1)Cc1ccccc1O2)NC1CC1
5454,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3ccnc(C(F)(F)F)n3)CC2)(C(C)C)C1,"cis-((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxytetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(2-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)methanone",35.9,uM,=,1.5550944485783191,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2ccncn2)CC1
5455,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CC(N2CCC(C(F)(F)F)CC2)C1,N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)-3-(4-(trifluoromethyl)piperidin-1-yl)azetidine-1-carboxamide,3.87,uM,=,0.5877109650189114,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CC(N2CCCCC2)C1
5456,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,FC(F)(F)c1cc(COCC2(c3ccccc3)CCNCC2)nc(C2CC2)c1,2-cyclopropyl-6-(((4-phenylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,5.5,uM,=,0.7403626894942439,1,c1ccc(C2(COCc3cccc(C4CC4)n3)CCNCC2)cc1
5457,938571,10.1021/jm3014597,,,,Inhibition of human ERG channel expressed in CHO cells by Ionworks HT assay,Cc1ccc(C(=O)N(CCCN)[C@@H](c2oc3cc(Cl)ccc3c(=O)c2Cc2ccccc2)C(C)C)cc1,(R)-N-(3-aminopropyl)-N-(1-(3-benzyl-7-chloro-4-oxo-4H-chromen-2-yl)-2-methylpropyl)-4-methylbenzamide,1.6,uM,=,0.2041199826559248,1,O=C(NCc1oc2ccccc2c(=O)c1Cc1ccccc1)c1ccccc1
5458,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,C[C@@H](NC(=O)c1ccc(C#N)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)c(F)cc43)C[C@@H]21,"4-cyano-N-((R)-1-((1R,3S,5S,6r)-3-(5,6-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)ethyl)benzamide",1.3,uM,=,0.1139433523068367,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
5459,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one",21.6,uM,=,1.334453751150931,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccc(=O)[nH]n3)C4=O)ccc21
5460,345010,10.1016/j.bmcl.2005.12.094,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CC(C)[C@H](N)C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1cccc(O)c1,"(S)-2-amino-1-((S)-4-(2,5-difluorophenyl)-2-(3-hydroxyphenyl)-2H-pyrrol-1(5H)-yl)-3-methylbutan-1-one",8.5,uM,=,0.9294189257142929,1,C1=C(c2ccccc2)CN[C@@H]1c1ccccc1
5461,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccno3)cc1)C(=O)N2c1cc(O)ncn1,"1-(6-Hydroxy-pyrimidin-4-yl)-3-(4-isoxazol-5-yl-phenyl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",22.0,uM,=,1.3424226808222062,1,O=C1N(c2ccc(-c3ccno3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
5462,1890282,10.1021/acs.jmedchem.8b01972,,,,Inhibition of Tracer Red binding to human ERG expressed in membranes by fluorescence polarization assay,CN(C)c1ccc(CNC(=O)[C@@H]2CNC[C@H]2c2ccc(C(F)(F)F)c(F)c2)cc1,"(+/-)-(3S,4R)-N-{[4-(dimethylamino)phenyl]methyl}-4-[3-fluoro-4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide",8.54,uM,=,0.931457870689005,1,O=C(NCc1ccccc1)[C@@H]1CNC[C@H]1c1ccccc1
5463,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c(C(O)CN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O,(rac)-5-(2-(4-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperazin-1-yl)-1-hydroxyethyl)-4-methylisobenzofuran-1(3H)-one,33.0,uM,=,1.5185139398778875,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
5464,2049587,10.1016/j.bmcl.2020.127625,,,,Inhibition of human ERG by patch clamp assay,Cc1cn([C@@H](C)[C@@H]2CCNC[C@@H]2F)c2nc(C(N)=O)cc(Cl)c12,"Rac-4-chloro-1-[(1S)-1-[(3R,4S)-3-fluoro-4-piperidyl]ethyl]-3-methyl-pyrrolo[2,3-b]pyridine-6-carboxamide",10.0,uM,=,1.0,1,c1cnc2c(c1)ccn2CC1CCNCC1
5465,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC(C)N1CCN(C(=O)N2CCC(C(=O)OC(C)(C)C)CC2)CC1,tert-butyl 1-(1-isopropylpiperazine-4-carbonyl)piperidine-4-carboxylate,101.1111111,uM,=,2.004798882834044,1,O=C(N1CCCCC1)N1CCNCC1
5466,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nn(CC)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"3-ethyl-5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-1,3,4-oxadiazol-2(3H)-one",7.7,uM,=,0.8864907251724818,1,O=c1[nH]nc([C@]2(c3cn[nH]c3)N[C@@H](c3nc(-c4ccccn4)c[nH]3)Cc3c2[nH]c2ccccc32)o1
5467,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCCN(C)S(C)(=O)=O)C[C@@H]2CC(=O)Nc2cccc(Cl)c2)cc1,"N-(3-chlorophenyl)-2-((3R,4S)-4-(4-methoxyphenyl)-1-(3-(N-methylmethylsulfonamido)propyl)pyrrolidin-3-yl)acetamide",4.62,uM,=,0.6646419755561255,1,O=C(C[C@H]1CNC[C@@H]1c1ccccc1)Nc1ccccc1
5468,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(c(C)c5C(C)C)OCC(=O)N6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-7-isopropyl-8-methyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.2,uM,=,0.0791812460476248,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5469,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,Cc1ccc([C@@H](C)N2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)s1,endo-3-(8-((R)-1-(5-methylthiophen-2-yl)ethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0028,uM,=,-2.552841968657781,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccs2)cc1
5470,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,C[C@@H]1CN(c2nnc(C(F)(F)F)o2)CCN1c1ncc(OCc2ccc(OS(C)(=O)=O)cc2F)cn1,"(R)-3-fluoro-4-((2-(2-methyl-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)piperazin-1-yl)pyrimidin-5-yloxy)methyl)phenyl methanesulfonate",17.0,uM,=,1.230448921378274,1,c1ccc(COc2cnc(N3CCN(c4nnco4)CC3)nc2)cc1
5471,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,CC1(C)C(=O)Nc2nc(-n3nc(Cc4c(F)ccc(F)c4F)c4ccccc43)nc(N)c21,"4-amino-5,5-dimethyl-2-[3-[(2,3,6-trifluorophenyl)methyl]indazol-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-6-one",2.2,uM,=,0.3424226808222063,1,O=C1Cc2cnc(-n3nc(Cc4ccccc4)c4ccccc43)nc2N1
5472,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,CCNC(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCC[C@H]2C)C3=O)cc1,"N-Ethyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydro-isoquinolin-6-yl)benzamide",7.4,uM,=,0.8692317197309762,1,O=C1c2ccc(-c3ccccc3)cc2CCN1CCN1CCCC1
5473,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cnc(-c2cnc(N)c(O[C@@H]3CN(C(=O)Cc4ccc(OC(F)(F)F)cc4)CC3(F)F)c2)c1,"(R)-1-(4-((2-Amino-5-(1-methyl-1H-imidazol-4-yl)pyridin-3-yl)-oxy)-3,3-difluoropyrrolidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)-ethan-1-one",21.0,uM,=,1.3222192947339193,1,O=C(Cc1ccccc1)N1CC[C@H](Oc2cncc(-c3c[nH]cn3)c2)C1
5474,421371,10.1016/j.bmcl.2006.10.052,,,,Inhibition of binding to hERG,CCN(CC)Cc1ccc2c(c1)CC[C@H](N1CCN(CCc3cccc(C(F)(F)F)c3)CC1=O)C2,"(S)-1-(6-((diethylamino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-4-(3-(trifluoromethyl)phenethyl)piperazin-2-one",1.7,uM,=,0.2304489213782739,1,O=C1CN(CCc2ccccc2)CCN1[C@H]1CCc2ccccc2C1
5475,535682,10.1016/j.bmcl.2008.08.067,,,,Displacement of [3H]dofetilide from human ERG in HEK293 cells,CNC(=O)c1c(NCC2CCC3(CCC3)CC2)nc(C#N)nc1OCC1CCNCC1,2-cyano-N-methyl-4-(piperidin-4-ylmethoxy)-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide,2.34,uM,=,0.3692158574101428,1,c1nc(NCC2CCC3(CCC3)CC2)cc(OCC2CCNCC2)n1
5476,434542,10.1021/jm061223o,,,,Inhibition of hERG expressed in HEK293 cells assessed as effect on ionic current by patch clamp assay,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOc5ccccc5)c4)n[nH]c2-3)C(=O)C1,"4-methyl-1-((3-(5-(3-phenoxyprop-1-ynyl)thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)methyl)piperazin-2-one",53.0,uM,=,1.7242758696007892,1,O=C1CNCCN1Cc1ccc2c(c1)Cc1c(-c3csc(C#CCOc4ccccc4)c3)n[nH]c1-2
5477,616809,10.1016/j.bmcl.2010.01.091,,,,Inhibition of human ERG,Cc1cnc(Nc2cc(N3CCOCC3)nc(N[C@@H](C)c3ccc(F)cn3)n2)s1,"(S)-N2-(1-(5-fluoropyridin-2-yl)ethyl)-N4-(5-methylthiazol-2-yl)-6-morpholinopyrimidine-2,4-diamine",12.0,uM,=,1.0791812460476249,1,c1ccc(CNc2nc(Nc3nccs3)cc(N3CCOCC3)n2)nc1
5478,2025950,10.1021/acsmedchemlett.0c00575,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,CCS(=O)(=O)c1cnc(CNc2nc3cnc(-c4c(C)ncnc4C4CC4)nc3n([C@@H](C)C3CC3)c2=O)nc1,(S)-2-(4-cyclopropyl-6-methylpyrimidin-5-yl)-8-(1-cyclopropylethyl)-6-((5-(ethylsulfonyl)pyrimidin-2-yl)methylamino)pteridin-7(8H)-one,8.8,uM,=,0.9444826721501688,1,O=c1c(NCc2ncccn2)nc2cnc(-c3cncnc3C3CC3)nc2n1CC1CC1
5479,581596,10.1016/j.bmcl.2009.06.096,,,,Displacement of [3H]dofetilide from human ERG,CCN(C(=O)c1ccccc1Oc1ccccc1)[C@H]1CCNC1,(S)-N-ethyl-2-phenoxy-N-(pyrrolidin-3-yl)benzamide,5.03,uM,=,0.7015679850559274,1,O=C(N[C@H]1CCNC1)c1ccccc1Oc1ccccc1
5480,1728697,10.1021/acsmedchemlett.7b00312,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,O=C(NC[C@@H]1[C@H]2CN(C(=O)C3CC3c3cc(Cl)cc(Cl)c3)C[C@@H]12)c1ccc2[nH]c(=O)oc2c1,"N-(((1R,5S,6s)-3-(2-(3,5-dichlorophenyl)cyclopropanecarbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxamide",4.7,uM,=,0.6720978579357175,1,O=C(NC[C@@H]1[C@H]2CN(C(=O)C3CC3c3ccccc3)C[C@@H]12)c1ccc2[nH]c(=O)oc2c1
5481,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,N#Cc1ccc2ccc(=O)n(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2c1,"1-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]piperidin-1-yl}ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",44.0,uM,=,1.6434526764861874,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
5482,573789,10.1021/np800729q,,,,Inhibition of human ERG channel,CC[C@H]1CN2CC[C@]3(C(=O)Nc4ccccc43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,rhynchophylline,773.0,uM,=,2.888179493918325,1,O=C1Nc2ccccc2[C@@]12CCN1CCCC[C@H]12
5483,1576909,10.1021/acs.jmedchem.5b01416,,,,Inhibition of human ERG expressed in HEK293 cells assessed as tail current at -50 mV holding potential by whole-cell patch clamp method,CC1CCN(CCCOc2ccc(=O)n(-c3ccc(Cl)cc3)n2)CC1,2-(4-Chlorophenyl)-6-(3-(4-methylpiperidin-1-yl)propoxy)-pyridazin-3(2H)-one,1.61,uM,=,0.2068258760318497,1,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccccc1
5484,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(Cl)n2)(c2ccccc2)CC1,2-chloro-6-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,25.0,uM,=,1.3979400086720375,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
5485,853148,10.1021/ml300074j,,,,Inhibition of human ERG,CC(C)Oc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cn3)ncc2Cl)n[nH]1,"5-Chloro-N2-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]-N4-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine",5.2,uM,=,0.7160033436347992,1,c1ccc(CNc2nccc(Nc3cc[nH]n3)n2)nc1
5486,1540295,10.1016/j.bmcl.2015.10.097,,,,Inhibition of human ERG by patch clamp technique,O=C(c1ccccn1)[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCN(S(=O)(=O)c1ccc(F)cc1)C2,"(R)-(1-(4-fluorophenyl)-6-(4-fluorophenylsulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone",0.98,uM,=,-0.0087739243075051,0,O=C(c1ccccn1)[C@]12Cc3cnn(-c4ccccc4)c3C=C1CCN(S(=O)(=O)c1ccccc1)C2
5487,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1,"(2,8-Bis-trifluoromethyl-quinolin-4-yl)-piperidin-2-yl-methanol",2.6,uM,=,0.414973347970818,1,c1ccc2c(CC3CCCCN3)ccnc2c1
5488,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,0.05,uM,=,-1.3010299956639813,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
5489,2125084,10.1021/acsmedchemlett.1c00450,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell after 90 mins by microbeta liquid scintillation counting method,COC(=O)N[C@H]1CC[C@@H](n2cc(-c3ccc(Cl)c(N)c3)c3c(N)ncnc32)CC1,"methyl ((cis)-4-(4-amino-5-(3-amino-4-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)carbamate",25.0,uM,=,1.3979400086720375,1,c1ccc(-c2cn(C3CCCCC3)c3ncncc23)cc1
5490,1889161,10.1021/acs.jmedchem.8b01719,,,,Inhibition of human ERG by patch clamp electrophysiology method,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(C3CC3)cc12,(2-Chloro-4-(N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)phenyl)boronic acid,1.6,uM,=,0.2041199826559248,1,c1ccc(Nc2cc3oc(-c4ccccc4)cc3cc2C2CC2)cc1
5491,1990506,10.1016/j.bmc.2020.115548,,,,Inhibition of human ERG,NCCCCn1cc(-c2ccc3cc[nH]c3c2)c(C(F)(F)F)n1,4-[4-(1H-indol-6-yl)-3-(trifluoromethyl)pyrazol-1-yl]butan-1-amine,1.9,uM,=,0.2787536009528289,1,c1cc2ccc(-c3cn[nH]c3)cc2[nH]1
5492,591458,10.1021/jm900563e,,,,Inhibition of human ERG,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1ccc(CCC(=O)O)cc1,"3-{4-[((2R)-3-{[1,1-Dimethyl-2-(2-naphthalenyl)ethyl]amino}-2-hydroxypropyl)oxy]phenyl}propanoic Acid",0.0385,uM,=,-1.4145392704914994,0,c1ccc(OCCCNCCc2ccc3ccccc3c2)cc1
5493,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,CC(C(O)c1ccc2c(c1)CNC(=O)N2)N1CCC(O)(c2ccc(F)cc2)CC1,"6-(2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxypropyl)-3,4-dihydroquinazolin-2(1H)-one",7.4,uM,=,0.8692317197309762,1,O=C1NCc2cc(CCN3CCC(c4ccccc4)CC3)ccc2N1
5494,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,CCOc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1N1CCC(O)CC1,"4-(2,4-difluorophenylamino)-7-ethoxy-6-(4-hydroxypiperidin-1-yl)quinoline-3-carboxamide",17.0,uM,=,1.230448921378274,1,c1ccc(Nc2ccnc3ccc(N4CCCCC4)cc23)cc1
5495,823109,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG by electrophysiology assay,CC(C)N1CCN[C@@H](C(=O)N2CCN(C(=O)Nc3ccc(Cl)c(Cl)c3)CC2)C1,"(R)-N-(3,4-dichlorophenyl)-4-(4-isopropylpiperazine-2-carbonyl)piperazine-1-carboxamide",60.0,uM,=,1.7781512503836436,1,O=C(Nc1ccccc1)N1CCN(C(=O)[C@H]2CNCCN2)CC1
5496,499833,10.1016/j.bmcl.2009.04.022,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(S[C@]4(C)CC[C@@H](NC(=O)OC)CC4)nc3cc2Cl)CC1,trans-methyl 4-(5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazol-2-ylthio)-4-methylcyclohexylcarbamate,3.5,uM,=,0.5440680443502757,1,c1cc2nc(SC3CCCCC3)[nH]c2cc1N1CCNCC1
5497,627338,10.1016/j.bmcl.2010.03.005,,,,Inhibition of human ERG,CCCCC(N1CCOCC1)C(O)(c1cccnc1)c1cccnc1,"2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol",36.0,uM,=,1.5563025007672873,1,c1cncc(C(CN2CCOCC2)c2cccnc2)c1
5498,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,COc1cc2nnc(C(N)=O)c(Nc3ccc(C)cc3F)c2cc1N1C[C@@H](C)N[C@@H](C)C1,"6-((3S,5R)-3,5-dimethylpiperazin-1-yl)-4-(2-fluoro-4-methylphenylamino)-7-methoxycinnoline-3-carboxamide",20.0,uM,=,1.3010299956639813,1,c1ccc(Nc2cnnc3ccc(N4CCNCC4)cc23)cc1
5499,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,CN1CCN(C(=O)COc2ccc3cc(Oc4ccc(C(F)(F)F)cn4)ccc3n2)CC1,1-(4-methylpiperazin-1-yl)-2-[[6-[[5-(trifluoromethyl)-2-pyridyl]oxy]-2-quinolyl]oxy]ethanone,19.6,uM,=,1.292256071356476,1,O=C(COc1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1
5500,1627129,10.1016/j.bmcl.2016.10.064,,,,Inhibition of human ERG by electrophysiology method,Cc1c(C#N)cccc1[C@H]1CN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)C[C@H]2CO1,"3-((3S,9aS)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-2-methylbenzonitrile",17.6,uM,=,1.24551266781415,1,O=C(Cc1ccc(-n2cnnn2)nc1)N1CCN2C[C@H](c3ccccc3)OC[C@@H]2C1
5501,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,CC1(CN2CC[C@H](NC(=O)c3cc(-c4ccc(F)cc4F)on3)[C@@H](C(=O)NC3(c4ncccn4)CC3)C2)CC1,"(3S,4S)-4-([5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]-amino)-1-(1-methylcyclopropylmethyl)-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide",11.0,uM,=,1.0413926851582251,1,O=C(N[C@H]1CCN(CC2CC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccccc2)on1
5502,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CS(=O)(=O)Nc1ccc(OC[C@@H](O)CN(CCc2ccc(Cl)c(Cl)c2)Cc2ccccc2O)cc1,"(S)-1-(4-Methanesulfonamidophenoxy)-3-(N-(2-hydroxybenzyl)-3,4-dichlorophenylethylamino)-2-propanol",0.83,uM,=,-0.0809219076239261,0,c1ccc(CCN(CCCOc2ccccc2)Cc2ccccc2)cc1
5503,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",O=c1cc(OCc2cccc(F)c2)ccn1-c1ccc(OCCN2CCCC2)cc1,4-[(3-Fluorobenzyl)oxy]-1-{4-[2-(pyrrolidin-1-yl)ethoxy]-phenyl}pyridin-2(1H)-one,0.0029,uM,=,-2.537602002101044,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCN2CCCC2)cc1
5504,613538,10.1021/jm901781q,,,,Inhibition of human ERG by patch-clamp method,CCCOCCn1c(=O)c(N2CCN(CC)CC2)nc2cnc(-c3ccc(OC)nc3)cc21,"3-(4-ethylpiperazin-1-yl)-1-(2-propoxyethyl)-7-(6-methoxypyridin-3-yl)pyrido[3,4-b]pyrazin-2(1H)-one",0.32,uM,=,-0.494850021680094,0,O=c1[nH]c2cc(-c3cccnc3)ncc2nc1N1CCNCC1
5505,2061618,10.1016/j.bmcl.2015.11.049,,,,Inhibition of human ERG by dofetilide binding assay,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(C)CC1,"N2-(2-isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",1.7,uM,=,0.2304489213782739,1,c1ccc(Nc2nc(Nc3ccc(C4CCNCC4)cc3)nc3[nH]ccc23)cc1
5506,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccnc2)c1,endo-3-(8-(pyridin-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0035,uM,=,-2.4559319556497243,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccnc2)cc1
5507,834187,10.1021/jm2013248,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,CN(Cc1nc2ccccc2c(=O)[nH]1)Cc1nc(-c2ccccc2)no1,"2-((methyl((3-phenyl-1,2,4-oxadiazol-5-yl)methyl)amino)methyl)quinazolin-4(3H)-one",26.2,uM,=,1.4183012913197457,1,O=c1[nH]c(CNCc2nc(-c3ccccc3)no2)nc2ccccc12
5508,762093,10.1021/jm200018k,,,,Inhibition of human Erg expressed in human HEK293 cells by patch-clamp electrophysiological assay,CC(=O)Nc1cccc(Nc2ncnc(N3CCc4ccccc4C3)n2)c1,"N-(3-(4-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide",3.8,uM,=,0.5797835966168101,1,c1ccc(Nc2ncnc(N3CCc4ccccc4C3)n2)cc1
5509,2054254,10.1016/j.ejmech.2020.112501,,,,Inhibition of human ERG by fluorescence polarization assay,CC(C)N1CCN(c2ccc(/C(=C(/CCCO)c3ccccc3)c3cccc(O)c3)cc2)CC1,3-(5-hydroxy-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylpent-1-enyl)phenol,24.6,uM,=,1.390935107103379,1,C(=C(c1ccccc1)c1ccc(N2CCNCC2)cc1)c1ccccc1
5510,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,c1ccc2c3c([nH]c2c1)C(C1CCCCC1)N[C@@H](c1nc(-c2ccncc2)c[nH]1)C3,"(3R)-1-cyclohexyl-3-(4-(pyridin-4-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.09,uM,=,-1.0457574905606752,0,c1ccc2c3c([nH]c2c1)C(C1CCCCC1)N[C@@H](c1nc(-c2ccncc2)c[nH]1)C3
5511,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,C[C@@H]1CN(c2nc(C(F)(F)F)no2)CCN1c1ncc(OCc2ccc(S(C)(=O)=O)cc2F)cn1,"5-{[2-Fluoro-4-(methylsulfonyl)benzyl]oxy}-2-{(2R)-2-methyl-4-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]piperazin-1-yl}pyrimidine",3.6,uM,=,0.5563025007672873,1,c1ccc(COc2cnc(N3CCN(c4ncno4)CC3)nc2)cc1
5512,1682731,10.1021/acs.jmedchem.7b01135,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cell membranes,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccc(Cl)cc2)n1,"US9394282, 9-4",40.0,uM,=,1.6020599913279625,1,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1
5513,1928615,10.1021/acs.jmedchem.6b00760,,,,Inhibition of human ERG,CCOc1ccc2cc(-c3nn(CC4CCN(C)CC4)c4ncnc(N)c34)ccc2n1,"3-(2-Ethoxyquinolin-6-yl)-1-((1-methylpiperidin-4-yl)-methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",10.0,uM,=,1.0,1,c1cnc2ccc(-c3nn(CC4CCNCC4)c4ncncc34)cc2c1
5514,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCC(O)C3)cc2)CC1,"(4-(4-((3-hydroxypyrrolidin-1-yl)methyl)phenoxy)piperidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone",31.0,uM,=,1.4913616938342726,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
5515,2051658,10.1021/acs.jmedchem.0c01588,,,,Inhibition of human ERG expressed in CHO cells at -40 mV holding potential by Q-patch clamp assay,C[C@@H](NC(=O)[C@H]1CN(C2CCCCC2)CC[C@@H]1NC(=O)c1cc(-c2ccc(F)cc2F)on1)c1ccccn1,"(trans,rac)-(3S*,4S*)-1-Cyclohexyl-4-([5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino)-piperidine-3-carboxylic acid ((R*)-1-pyridin-2-yl-ethyl)-amide",3.4,uM,=,0.5314789170422551,1,O=C(N[C@H]1CCN(C2CCCCC2)C[C@@H]1C(=O)NCc1ccccn1)c1cc(-c2ccccc2)on1
5516,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)ccn1,"2-(1,4'-bipiperidin-1'-yl)-6-(2-methoxypyridin-4-yl)thiazolo[4,5-c]pyridine",0.989010989,uM,=,-0.0047988828865942,0,c1cc(-c2cc3sc(N4CCC(N5CCCCC5)CC4)nc3cn2)ccn1
5517,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C(NC(c1ccc(Cl)cc1)c1ncccn1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1,"(1R,2R,4R)-2-(4-bromophenyl)-N-((4-chlorophenyl)(pyrimidin-2-yl)methyl)-4-morpholinocyclohexanecarboxamide",1.2,uM,=,0.0791812460476248,1,O=C(NC(c1ccccc1)c1ncccn1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
5518,1852155,10.1021/acs.jmedchem.9b00426,,,,Inhibition of human ERG,CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1,BERZOSERTIB,3.0,uM,=,0.4771212547196624,1,c1ccc(-c2cc(-c3cncc(-c4ccccc4)n3)on2)cc1
5519,611802,10.1021/jm9015075,,,,Inhibition of human ERG,CCc1ccc2oc(N3CCN4CCC3CC4)nc2n1,"2-(5-Ethyloxazolo[4,5-b]pyridin-2-yl)-2,5-diazabicyclo[3.2.2]-nonane",27.7,uM,=,1.4424797690644486,1,c1cnc2nc(N3CCN4CCC3CC4)oc2c1
5520,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(C3CC(C4CCCCC4)CCNC3=O)nn2)ccc1-n1cnc(C)c1,"rac-5-cyclohexyl-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)azepan-2-one",3.68,uM,=,0.5658478186735176,1,O=C1NCCC(C2CCCCC2)CC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
5521,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Cl)cc1Oc1ccc(Cl)c(C)c1,1-(4-chloro-2-(4-chloro-3-methylphenoxy)phenyl)-N-methylmethanamine,1.78,uM,=,0.250420002308894,1,c1ccc(Oc2ccccc2)cc1
5522,850453,10.1021/ml300146q,,,,Inhibition of recombinant human ERG channel IKr expressed in CHO cells by patch clamp assay,Cc1cc(C#N)ccc1-c1ccnc(NCc2n[nH]c(-c3ccccc3)c2Cl)c1,4-(2-((4-Chloro-5-phenyl-1H-pyrazol-3-yl)methylamino)pyridin-4-yl)-3-methylbenzonitrile,30.0,uM,=,1.4771212547196624,1,c1ccc(-c2ccnc(NCc3cc(-c4ccccc4)[nH]n3)c2)cc1
5523,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)N1CCCCC1)C2,"(2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)(piperidin-1-yl)methanone",10.0,uM,=,1.0,1,O=C(N1CCCCC1)N1CCc2nc(OCc3conc3-c3ccccc3)ccc2C1
5524,935892,10.1016/j.bmcl.2012.10.069,,,,Binding affinity to human ERG,COC1COCCC1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ccc(C#N)cc3C2)C1,"2-((2R,3aR,6aR)-2-(3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalene-3a-carbonyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile",33.7,uM,=,1.5276299008713388,1,O=C(N1CCc2ccccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
5525,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(CO)nc5)cc4c32)C1,"7-Fluoro-8-[6-(hydroxymethyl)pyridin-3-yl]-3-methyl-1-[cis-3-methoxycyclobutyl]-1H,2H,3H-imidazo[4,5-c]quinolin-2-one",23.0,uM,=,1.3617278360175928,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCC1
5526,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccc(C#N)nc4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(6-cyanopyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide",4.1,uM,=,0.6127838567197355,1,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1
5527,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,N[C@@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-(((2R,3R)-3-aminooxetan-2-yl)methoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",17.7,uM,=,1.2479732663618066,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OC[C@H]7CCO7)nc56)(CC3)OC4)nc2N1
5528,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,Cc1ccc2c(c1)C(C1=C[C@H](C)N(C)CC1)=Nc1cc(Cl)ccc1N2,"(S)-8-chloro-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-methyl-5H-dibenzo[b,e][1,4]diazepine",0.8,uM,=,-0.0969100130080563,0,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
5529,806244,10.1016/j.bmcl.2012.01.078,,,,Inhibition of human Erg by patch clamp assay,Cc1nc2ncc(Oc3ccc(F)cc3)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,"(S)-6-(4-fluorophenoxy)-3-((1-isopropylpiperidin-3-yl)methyl)-2-methylpyrido[2,3-d]pyrimidin-4(3H)-one",3.1,uM,=,0.4913616938342727,1,O=c1c2cc(Oc3ccccc3)cnc2ncn1C[C@H]1CCCNC1
5530,624440,10.1016/j.bmcl.2010.02.072,,,,Displacement of [3H]astemizole from human ERG,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3cc(F)ccc3F)CC2)C1,"(R)-N-(2-(1-(2-(1-(2,5-difluorobenzoyl)piperidin-4-yl)ethyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide",10.0,uM,=,1.0,1,O=C(CNC(=O)c1ccccc1)N[C@@H]1CCN(CCC2CCN(C(=O)c3ccccc3)CC2)C1
5531,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,CC(=O)Nc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1,"N-[4-(4-Fluorophenyl)-5-{2-[4-(piperazin-1-yl)anilino]pyrimidin-4-yl}-1,3-thiazol-2-yl]acetamide",38.0,uM,=,1.57978359661681,1,c1ccc(-c2ncsc2-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5532,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C#N)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carbonitrile",0.37,uM,=,-0.431798275933005,0,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
5533,493421,10.1016/j.bmcl.2008.10.025,,,,Inhibition of human ERG expressed in CHO cells,CNCCC(c1ccccc1)c1c[nH]c2ccccc12,3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine,1.0,uM,=,0.0,0,c1ccc(Cc2c[nH]c3ccccc23)cc1
5534,1554472,10.1021/acs.jmedchem.5b01372,,,,Binding affinity to human ERG channel,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2scnc21,"(R)-N-(4-(((2S,5R)-5-((R)-Hydroxy(pyridin-3-yl)methyl)-pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]-thiazole-4-carboxamide",6.1,uM,=,0.785329835010767,1,O=C(Nc1ccc(C[C@@H]2CC[C@H](Cc3cccnc3)N2)cc1)[C@@H]1CCc2scnc21
5535,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1nccnc1N1C(=O)N(c2ccc(-c3ccc(C(=O)O)cc3C)cc2)C(=O)C12CCN(Cc1ncccc1C)CC2,"4'-[1-(3-Methoxy-pyrazin-2-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-2-methyl-biphenyl-4-carboxylic acid",1.4,uM,=,0.1461280356782379,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1cnccn1
5536,2266240,10.1021/acsmedchemlett.2c00441,,,,Inhibition of human ERG,Cl.O=C(N1CCN2CCC1CC2)n1nc(-n2cc(C(F)(F)F)cn2)c2c1COCC2,"(1,4-diazabicyclo[3.2.2]nonan-4-yl)(3-(4-(trifluoromethyl)-1H-pyrazol-1-yl)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)methanone Hydrochloride",4.1,uM,=,0.6127838567197355,1,O=C(N1CCN2CCC1CC2)n1nc(-n2cccn2)c2c1COCC2
5537,1478754,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,0.0089,uM,=,-2.050609993355087,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
5538,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2cccc(NC(=O)OC)c2)cc1,methyl 3-((4-(diethylcarbamoyl)phenyl)(1-(4-fluorobenzyl)piperidin-4-ylidene)methyl)phenylcarbamate,1.1,uM,=,0.041392685158225,1,c1ccc(CN2CCC(=C(c3ccccc3)c3ccccc3)CC2)cc1
5539,1813224,10.1021/acs.jmedchem.9b00681,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Patch Clamp method,Nc1n[nH]c(N2CCC(N3CCOC[C@@H]3Cc3ccc(Cl)cc3)CC2)n1,"(S)-5-(4-(3-(4-Chlorobenzyl)morpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",12.0,uM,=,1.0791812460476249,1,c1ccc(C[C@H]2COCCN2C2CCN(c3ncn[nH]3)CC2)cc1
5540,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(-c3cnn(C)c3)cc12,4-[(2-Ethylbutyl)amino]-6-(1-methyl-1H-pyrazol-4-yl)-3-quinolinecarboxamide,1.2,uM,=,0.0791812460476248,1,c1cnc2ccc(-c3cn[nH]c3)cc2c1
5541,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.56,uM,=,-0.2518119729937995,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5542,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(CC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(c1ccc(F)cc1)c1cccnc1,N-((4-fluorophenyl)(pyridin-3-yl)methyl)-2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetamide,2.17,uM,=,0.3364597338485295,1,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(c1ccccc1)c1cccnc1
5543,1720532,10.1021/acsmedchemlett.7b00196,,,,Inhibition of human ERG,COc1nc2ccc(C)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,4-(dimethylamino)-1-(2-methoxy-6-methylquinolin-3-yl)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol,4.3,uM,=,0.6334684555795865,1,c1ccc(C(Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
5544,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,Cc1ccccc1-c1cc2c(N[C@@H]3CC[C@](C)(N)C3(C)C)c(C(N)=O)cnn2c1,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-o-tolylpyrrolo[1,2-b]pyridazine-3-carboxamide",4.9,uM,=,0.6901960800285137,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
5545,1985700,10.1021/acsmedchemlett.0c00109,,,,Inhibition of human ERG,Cc1cc(N2C[C@H]3CC[C@@H](C2)[C@@H]3Nc2nc3n(n2)CCCN3c2cc(F)cc(F)c2)ncn1,"4-(3,5-difluorophenyl)-N-[(1R,5S,8S)-3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5H-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine",0.7,uM,=,-0.1549019599857432,0,c1ccc(N2CCCn3nc(N[C@@H]4[C@@H]5CC[C@H]4CN(c4ccncn4)C5)nc32)cc1
5546,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1cc(C(=O)N[C@@H]2CC(C)(C)Oc3nc(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)cc32)n[nH]1,"N-((4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl)-5-methyl-1H-pyrazole-3-carboxamide",1.0,uM,=,0.0,0,O=C(N[C@@H]1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)c1cc[nH]n1
5547,772749,10.1016/j.bmcl.2011.08.038,,,,Displacement of [3H]dofetilide from human ERG transfected in HEK293 cells by fluorescence polarization binding assay,COC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1,"methyl 8-chloro-1-(1-(pyridin-2-yl)piperidin-4-yl)-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine-5(6H)-carboxylate",47.3,uM,=,1.6748611407378116,1,c1ccc(N2CCC(c3nnc4n3-c3ccccc3CNC4)CC2)nc1
5548,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,C[C@@H]1CN(c2sc(CN(C)C)nc2-c2nc3ccccc3[nH]2)CCN1C(=O)Cn1cnc2cccnc21,"US9266876, 223",20.0,uM,=,1.3010299956639813,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2nc3ccccc3[nH]2)CC1
5549,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CC1(C)C[C@@H](NC(=O)c2cn[nH]c2)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1,"N-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-1H-pyrazole-4-carboxamide",0.38,uM,=,-0.4202164033831898,0,O=C(N[C@@H]1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)c1cn[nH]c1
5550,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1cc2c(cc1OC)[C@@H](Cc1ccc(Oc3cc(C[C@@H]4c5cc(OC)c(OC)cc5CCN4C)ccc3O)cc1)N(C)CC2,"4-((S)-6,7-Dimethoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-2-[4-((R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-phenoxy]-phenol",16.0,uM,=,1.2041199826559248,1,c1cc(C[C@H]2NCCc3ccccc32)cc(Oc2ccc(C[C@H]3NCCc4ccccc43)cc2)c1
5551,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,COC(C)(C)CN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"1-(3-Amino-1H-1,2,4-triazol-5-yl)-N-(4-chlorophenethyl)-N-(2-methoxy-2-methylpropyl)piperidin-4-amine",3.5,uM,=,0.5440680443502757,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
5552,1294681,10.1021/jm4016894,,,,Inhibition of human ERG by fluorescence-based thallium flux assay,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,"(8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-({3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl}carbonyl)-12-azapentacyclo[10.7.0.0^{2,7}.0^{8,10}.0^{13,18}]nonadeca-1(19),2(7),3,5,13,15,17-heptaene-15-carboxamide",24.5,uM,=,1.3891660843645326,1,O=C(N1C2CCC1CNC2)[C@]12C[C@H]1c1ccccc1-c1c(C3CCCCC3)c3ccccc3n1C2
5553,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,CCNC(=O)Nc1cccc(CNc2cc(C(F)(F)F)cc3ncc(N4CCN(C)CC4)cc23)c1,1-ethyl-3-(3-((3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinolin-5-ylamino)methyl)phenyl)urea,81.7,uM,=,1.9122220565324155,1,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
5554,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3c(=O)oc4ccccc43)[C@H](C)C2)cn1,3-(2-{(R)-4-(4-(2-Ethoxy-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-2-oxo-ethyl)-3H-benzooxazol-2-one,2.2,uM,=,0.3424226808222063,1,O=C(Cn1c(=O)oc2ccccc21)N1CCN(c2scnc2-c2cncnc2)CC1
5555,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,FC(F)(F)c1cc(COCC2(c3ccccc3)CCNCC2)nc(N2CCCC2)c1,2-(((4-phenylpiperidin-4-yl)methoxy)methyl)-6-(pyrrolidin-1-yl)-4-(trifluoromethyl)pyridine,2.3,uM,=,0.3617278360175928,1,c1ccc(C2(COCc3cccc(N4CCCC4)n3)CCNCC2)cc1
5556,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1cccc(C(F)(F)F)c1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1,(S)-4-((1-cyclopropylpiperidin-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamide,13.0,uM,=,1.1139433523068367,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
5557,499526,10.1016/j.bmcl.2009.02.041,,,,Inhibition of human ERG by patch-clamp technique,O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1C[C@@H](F)[C@@H](F)C1,"cis-((3S,4R)-3,4-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone",54.0,uM,=,1.7323937598229686,1,O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCCC1
5558,624297,10.1016/j.bmcl.2010.01.134,,,,Inhibition of human ERG expressed in HEK cells assessed as blockade of potassium tail current by standard patch clamp analysis,C[C@H](c1cccnc1)c1c(CCN(C)C)sc2ccccc12,"(-)-(R)-N,N-dimethyl-2-(3-(1-(pyridin-3-yl)ethyl)benzo[b]thiophen-2-yl)ethanamine",0.49,uM,=,-0.3098039199714864,0,c1cncc(Cc2csc3ccccc23)c1
5559,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,[2H]C(Nc1cc(C(F)(F)F)cc2ncc(N3CCN(CC([2H])([2H])O)CC3)cc12)c1cccc([N+](=O)[O-])c1,[2H]-2-(4-(5-([2H]-3-nitrobenzylamino)-7-(trifluoromethyl)quinolin-3-yl)piperazin-1-yl)ethanol,0.48,uM,=,-0.3187587626244128,0,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
5560,75160,10.1021/jm00014a008,,,,Blockade of the delayed rectifier K+ current (IKr) of guinea pig myocytes,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide,44.0,uM,=,1.6434526764861874,1,c1ccc(CCNCCOc2ccccc2)cc1
5561,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,CCOc1cc([C@](O)(CCN(C)C)[C@H](c2ccc(N(CC)CC)nc2)c2cc3cc(Br)ccc3nc2OC)cc(OCC)n1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-2-(2,6-diethoxypyridin-4-yl)-1-(6-(diethylamino)pyridin-3-yl)-4-(dimethylamino)butan-2-ol",9.9,uM,=,0.99563519459755,1,c1cncc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)c1
5562,651537,10.1016/j.bmcl.2010.06.089,,,,Inhibition of human ERG,CC[C@@H](CC(=O)NCC1CCCCC1)n1c(N)nc2cc(Cl)ccc21,(S)-3-(2-amino-5-chloro-1H-benzo[d]imidazol-1-yl)-N-(cyclohexylmethyl)pentanamide,7.5,uM,=,0.8750612633917001,1,O=C(CCn1cnc2ccccc21)NCC1CCCCC1
5563,219494,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1,"3-(4-Fluoro-benzyl)-2-(piperidin-4-ylamino)-3a,4,5,6,7,7a-hexahydro-3H-benzoimidazol-5-ol",0.028,uM,=,-1.5528419686577808,0,c1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1
5564,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CCc2ccccc2)c1,endo-3-(8-phenethyl-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.00038,uM,=,-3.42021640338319,0,c1ccc(CCN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
5565,939638,10.1016/j.bmcl.2012.11.023,,,,Inhibition of human ERG,COc1ccc(CN2CCc3cc4nc(N)sc4cc3CC2)cc1,"7-(4-Methoxy-benzyl)-6,7,8,9-tetrahydro-5H-1-thia-3,7-diaza-cyclohepta[f]inden-2-ylamine",3.3,uM,=,0.5185139398778875,1,c1ccc(CN2CCc3cc4ncsc4cc3CC2)cc1
5566,606354,10.1016/j.bmcl.2009.11.061,,,,Inhibition of human ERG,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1,"3-((S)-2-amino-3-(1H-indol-3-yl)propoxy)-5-(3-methyl-1H-pyrazolo[4,3-b]pyrazin-5-yl)-6-(2-methylfuran-3-yl)pyridin-2-amine",10.4,uM,=,1.0170333392987805,1,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cnc5[nH]ncc5n4)c3)c[nH]c2c1
5567,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1OC,"6-((1-(2-(6,7-dimethoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.0014299999999999,uM,=,-2.844663962534938,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5568,458756,10.1016/j.bmcl.2007.10.063,,,,Inhibition of hERG by patch clamp assay,Cc1nnc(-c2ccc(CN3C[C@H](N)[C@H](C(=O)N4CCC[C@H]4C#N)C3)cc2)o1,"(S)-1-((3R,4R)-1-(4-(5-methyl-1,3,4-oxadiazol-2-yl)benzyl)-3-aminopyrrolidine-4-carbonyl)pyrrolidine-2-carbonitrile",165.0,uM,=,2.2174839442139063,1,O=C([C@H]1CCN(Cc2ccc(-c3nnco3)cc2)C1)N1CCCC1
5569,2208843,10.1016/j.bmc.2022.116657,,,,Inhibition of hERG channel expressed in CHO cells at -80 mV holding potential by Qpatch clamp method,COc1cc(OC)c(F)c(COc2cnc(Nc3cnn(CCNC4CCN(C)CC4)c3)nc2)c1F.Cl.Cl.Cl,"5-[(2,6-Difluoro-3,5-dimethoxyphenyl)methoxy]-N-(1-{2-[(1-methylpiperidin-4-yl)amino]ethyl}-1H-pyrazol-4-yl)pyrimidin-2-amine trihydrochloride",83.0,uM,=,1.919078092376074,1,c1ccc(COc2cnc(Nc3cnn(CCNC4CCNCC4)c3)nc2)cc1
5570,772749,10.1016/j.bmcl.2011.08.038,,,,Displacement of [3H]dofetilide from human ERG transfected in HEK293 cells by fluorescence polarization binding assay,CC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1,"1-(8-chloro-1-(1-(pyridin-2-yl)piperidin-4-yl)-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-5(6H)-yl)ethanone",35.2,uM,=,1.546542663478131,1,c1ccc(N2CCC(c3nnc4n3-c3ccccc3CNC4)CC2)nc1
5571,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccc(Cl)cc1Oc1ccc(F)c(Cl)c1,1-(4-chloro-2-(3-chloro-4-fluorophenoxy)phenyl)-N-methylmethanamine,2.11,uM,=,0.3242824552976926,1,c1ccc(Oc2ccccc2)cc1
5572,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(C#N)cc2cc1[C@@H](c1cccc(C)c1)[C@@](O)(CCN(C)C)c1cccc2c1OCO2,"7-((1R,2S)-2-(benzo[d][1,3]dioxol-4-yl)-4-(dimethylamino)-2-hydroxy-1-m-tolylbutyl)-6-methoxy-2-naphthonitrile",0.3,uM,=,-0.5228787452803376,0,c1ccc([C@@H](Cc2cccc3c2OCO3)c2ccc3ccccc3c2)cc1
5573,1924902,10.1016/j.bmcl.2016.07.048,,,,Inhibition of MK499 binding to human ERG,Cn1cc(NC(=O)c2cccc(-c3ccnc(NCC4CC4)c3)n2)c(C(=O)N2CC(CN)C2)n1,"N-(3-(3-(aminomethyl)azetidine-1-carbonyl)-1-methyl-1H-pyrazol-4-yl)-2'-(cyclopropylmethylamino)-2,4'-bipyridine-6-carboxamide",40.0,uM,=,1.6020599913279625,1,O=C(Nc1c[nH]nc1C(=O)N1CCC1)c1cccc(-c2ccnc(NCC3CC3)c2)n1
5574,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4cccc(F)c4F)cc23)CC1,"5-(2,3-Difluorophenyl)-N-{[1-(2-methoxyethyl)piperidin-4-yl]-methyl}-1H-indazole-3-carboxamide",0.044,uM,=,-1.3565473235138126,0,O=C(NCC1CCNCC1)c1n[nH]c2ccc(-c3ccccc3)cc12
5575,1747135,10.1016/j.bmcl.2017.10.042,,,,Inhibition of human ERG,COc1cc([C@H](c2cc3cc(Br)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cccc(F)c2)cnc1OC,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-1-(5,6-dimethoxypyridin-3-yl)-4-(dimethylamino)-2-(3-fluorophenyl)butan-2-ol",1.9,uM,=,0.2787536009528289,1,c1ccc(C[C@H](c2cccnc2)c2cnc3ccccc3c2)cc1
5576,465697,10.1021/jm701187w,,,,Inhibition of human ERG potassium current expressed in HEK293 cells by patch-clamp technique,Cc1cc(C)n(-c2cc(NC(=O)CN3CC[C@H](N(C)C)C3)nc(-c3ccc(C)o3)n2)n1,"2-((S)-3-dimethylaminopyrrolidin-1-yl)-N-[6-(3,5-dimethylpyra zol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl]acetamide",0.6,uM,=,-0.2218487496163563,0,O=C(CN1CCCC1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
5577,833911,10.1021/ml200272z,,,,Displacement of [35S]MK499 from human Erg expressed in HEK293 cells after 60 mins by scintillation counting,CCCCC1(CCCC)N[C@@H](c2nc(-c3ccccc3)c[nH]2)Cc2c1[nH]c1ccccc21,"1,1-Dibutyl-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-beta-carboline",0.15,uM,=,-0.8239087409443188,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)CN3)n2)cc1
5578,939638,10.1016/j.bmcl.2012.11.023,,,,Inhibition of human ERG,CCN1CCc2cc3nc(N)sc3cc2CC1,"7-Ethyl-6,7,8,9-tetrahydro-5H-1-thia-3,7-diaza-cyclohepta[f]inden-2-ylamine",29.0,uM,=,1.462397997898956,1,c1nc2cc3c(cc2s1)CCNCC3
5579,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1,"(5-phenyl-1,3,4-oxadiazol-2-yl)(4-(4-(pyrrolidin-1-ylmethyl)phenoxy)piperidin-1-yl)methanone",11.0,uM,=,1.0413926851582251,1,O=C(c1nnc(-c2ccccc2)o1)N1CCC(Oc2ccc(CN3CCCC3)cc2)CC1
5580,2161353,10.1021/acs.jmedchem.1c02048,,,,Inhibition of [35S]MK-499 binding to hERG expressed in HEK293 cells at 60 uM,CCNC(=O)N1C[C@H]2[C@H](C)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@]32C1,"(3R,3aS,4S,5R,6R,6aS,9aR)-4-[(E)-2-[5-(2-cyanophenyl)-2-pyridyl]vinyl]-N-ethyl-3,5,6-trimethyl-1-oxo-3,3a,4,5,6,6a,7,9-octahydrofuro[3,4-d]isoindole-8-carboxamide",9.0,uM,=,0.9542425094393248,1,O=C1OC[C@H]2[C@@H](/C=C/c3ccc(-c4ccccc4)cn3)CC[C@@H]3CNC[C@@]132
5581,1857806,10.1021/acs.jmedchem.9b01916,,,,Inhibition of human ERG by Qpatch clamp method,CCC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C,N-(3-(6-Amino-5-(2-(N-methylpropionamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide,2.9,uM,=,0.4623979978989561,1,O=C(Nc1cccc(-c2ccncn2)c1)c1ccc(C2CC2)cc1
5582,1667859,10.1016/j.bmcl.2017.03.030,,,,Inhibition of human ERG expressed in CHOK1 cells by Qpatch clamp method,N=C(NCCCOc1ccc(F)cc1)Nc1ccc(Cl)cc1,1-(4-chlorophenyl)-3-(3-(4-fluorophenoxy)propyl)guanidine,0.43,uM,=,-0.3665315444204134,0,N=C(NCCCOc1ccccc1)Nc1ccccc1
5583,1617630,10.1021/acs.jmedchem.6b01217,,,,Inhibition of human ERG,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,"1-(3-Hydroxy-propyl)-5-((R)-2-{2-[2-(2,2,2-trifluoro-ethoxy)-phenoxy]-ethylamino}-propyl)-2,3-dihydro-1H-indole-7-carboxylic acid amide",8.2,uM,=,0.9138138523837168,1,c1ccc(OCCNCCc2ccc3c(c2)CCN3)cc1
5584,971477,10.1021/jm400402q,,,,Inhibition of human ERG by dofetilide binding assay,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine",1.25,uM,=,0.0969100130080564,1,c1ccc(Nc2ccnc(Nc3ccc(C4CCNCC4)cc3)n2)cc1
5585,1444863,10.1021/ml500353p,,,,Inhibition of human ERG by automated whole cell electrophysiology,C[C@@H]1Cn2ncc(-c3ccc(S(C)(=O)=O)cc3)c2CN1c1ccnc2[nH]ccc12,"(R)-6-methyl-3-(4-(methylsulfonyl)phenyl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine",1.5,uM,=,0.1760912590556812,1,c1ccc(-c2cnn3c2CN(c2ccnc4[nH]ccc24)CC3)cc1
5586,2051938,10.1021/acs.jmedchem.5b01938,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by radioligand binding assay,N#Cc1cnc(Nc2cc(NC[C@@H]3CNCCO3)c(C#CC3(O)CCCC3)cn2)cn1,(S)-5-((5-((1-Hydroxycyclopentyl)ethynyl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,16.0,uM,=,1.2041199826559248,1,C(#CC1CCCC1)c1cnc(Nc2cnccn2)cc1NC[C@@H]1CNCCO1
5587,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)O6)(CC3)CO4)c2n1,"(+)-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2-methyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.8,uM,=,-0.0969100130080563,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5588,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,O=C1CCc2cccc(OC[C@@H](O)CN3CCC4(CC3)Cc3cc(Cl)ccc3O4)c2N1,"(S)-8-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-3,4-dihydroquinolin-2(1H)-one",0.5,uM,=,-0.3010299956639812,0,O=C1CCc2cccc(OCCCN3CCC4(CC3)Cc3ccccc3O4)c2N1
5589,806244,10.1016/j.bmcl.2012.01.078,,,,Inhibition of human Erg by patch clamp assay,Cc1nc2cnc(Oc3ccc4ncsc4c3)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,"(S)-6-(benzo[d]thiazol-6-yloxy)-3-((1-isopropylpiperidin-3-yl)methyl)-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one",2.4,uM,=,0.380211241711606,1,O=c1c2cc(Oc3ccc4ncsc4c3)ncc2ncn1C[C@H]1CCCNC1
5590,570979,10.1016/j.bmcl.2009.04.035,,,,Inhibition human ERG expressed in HEK293 cells assessed as blockade of membrane current by patch clamp method,Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)C[C@H]2[C@@H]3CN(CC4CCCC4)C[C@@H]32)c1,1-Methyl-1H-imidazole-4-carboxylic acid(3-cyclopentylmethyl-3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-(3-trifluoromethoxy-benzyl)-amide,0.46,uM,=,-0.3372421683184259,0,O=C(c1c[nH]cn1)N(Cc1ccccc1)C[C@H]1[C@@H]2CN(CC3CCCC3)C[C@@H]21
5591,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1c(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)cnn1-c1ccccn1,2-(5-methyl-1-pyridin-2-yl-1H-pyrazol-4-yl)-6-[2-(2-(R)-methylpyrrolidin-1-yl)ethyl]quinoline,20.0,uM,=,1.3010299956639813,1,c1ccc(-n2cc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cn2)nc1
5592,2021863,10.1016/j.bmcl.2020.127433,,,,Inhibition of human ERG by plate-based planar patch clamp method,COC(=O)c1nn(C)c2c(C)cc(Nc3nccc(-c4cc(CN(C)C)n(C)n4)n3)cc12,"Methyl 5-(4-(5-((dimethylamino)methyl)-1-methyl-1H-pyrazol-3-yl)pyrimidin-2-ylamino)-1,7-dimethyl-1H-indazole-3-carboxylate",23.0,uM,=,1.3617278360175928,1,c1cc(-c2cc[nH]n2)nc(Nc2ccc3[nH]ncc3c2)n1
5593,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C4CCCC4)n2)C3=O)ccc2c1COC2=O,"(R)-2-(1-cyclopentyl-6-oxo-1,6-dihydropyridazin-3-yl)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one",13.5,uM,=,1.130333768495006,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccc(=O)n(C5CCCC5)n3)C4=O)ccc21
5594,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(N2CCN(C(=O)[C@@H](C)N)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"(2R)-2-amino-1-(4-(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)piperazin-1-yl)propan-1-one",14.0,uM,=,1.146128035678238,1,c1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cnc2c1
5595,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C,4-Diisopropylamino-2-phenyl-2-pyridin-2-yl-butyramide,12.0,uM,=,1.0791812460476249,1,c1ccc(Cc2ccccn2)cc1
5596,744146,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG,Cc1cnc(N2CCC(C3CCN(c4cc(C#N)nc(C)n4)CC3)CC2)cn1,"2-methyl-6-(1'-(5-methylpyrazin-2-yl)-4,4'-bipiperidin-1-yl)pyrimidine-4-carbonitrile",5.4,uM,=,0.7323937598229685,1,c1cc(N2CCC(C3CCN(c4cnccn4)CC3)CC2)ncn1
5597,643226,10.1021/jm100210p,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(C)(C)C,"(S)-4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl]-methanone",17.0,uM,=,1.230448921378274,1,O=C(c1ccccc1)N1CCN(c2ccccn2)CC1
5598,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C(NC(c1ccc(Cl)cc1)c1cnccn1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1,"(1R,2R,4R)-2-(4-bromophenyl)-N-((4-chlorophenyl)(pyrazin-2-yl)methyl)-4-morpholinocyclohexanecarboxamide",1.0,uM,=,0.0,0,O=C(NC(c1ccccc1)c1cnccn1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
5599,1576909,10.1021/acs.jmedchem.5b01416,,,,Inhibition of human ERG expressed in HEK293 cells assessed as tail current at -50 mV holding potential by whole-cell patch clamp method,CC1CCN(CCCOc2ccc(=O)n(-c3ccc(Cl)c(Cl)c3)n2)CC1,"2-(3,4-Dichlorophenyl)-6-(3-(4-methylpiperidin-1-yl)-propoxy)pyridazin-3(2H)-one",1.46,uM,=,0.1643528557844371,1,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccccc1
5600,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C(F)F)n2)C3=O)ccc2c1COC2=O,"(R)-2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridazin-3-yl)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one",19.1,uM,=,1.2810333672477277,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccc(=O)[nH]n3)C4=O)ccc21
5601,457338,10.1016/j.bmcl.2007.08.014,,,,Displacement of [3H]bufuralol from hERG channel expressed in HEK293 cells,O=C1CCc2cc(C(O)CN3CCC(O)(c4cccc(F)c4)CC3)ccc2N1,"6-(2-(4-(3-fluorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxyethyl)-3,4-dihydroquinolin-2(1H)-one",21.0,uM,=,1.3222192947339193,1,O=C1CCc2cc(CCN3CCC(c4ccccc4)CC3)ccc2N1
5602,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1cc2ncc(-c3ccc4cc(CCN5CCC[C@H]5C)ccc4n3)c(C)n2n1,"2-(2,7-dimethylpyrazolo[1,5-a]pyrimidin-6-yl)-6-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}quinoline",8.8,uM,=,0.9444826721501688,1,c1cc2ncc(-c3ccc4cc(CCN5CCCC5)ccc4n3)cn2n1
5603,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(c1ccccc1)c1ccccc1,1-benzhydryl-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,3.8,uM,=,0.5797835966168101,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(c1ccccc1)c1ccccc1
5604,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1c(CCC2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC2)ccc2c1COC2=O,5-(2-(1-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperidin-4-yl)ethyl)-4-methylisobenzofuran-1(3H)-one,5.9,uM,=,0.7708520116421442,1,O=C1OCc2cc(CCC3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
5605,2166402,,,,,Inhibition of hERG (unknown origin) expressed in CHO-K1 cells measured by whole-cell voltage-clamp assay,CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1,"(R)-2-(4-isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide",4.0,uM,=,0.6020599913279624,1,O=C(Cc1ccccc1)NCc1ccccn1
5606,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,C[C@@H]1CN(C(=O)OC2(C(F)(F)F)COC2)CCN1c1ncc(OCc2ccc(S(C)(=O)=O)cc2F)cn1,(R)-3-(Trifluoromethyl)oxetan-3-yl4-(5-(2-Fluoro-4-(methylsulfonyl)benzyloxy)pyrimidin-2-yl)-3-methylpiperazine-1-carboxylate,11.0,uM,=,1.0413926851582251,1,O=C(OC1COC1)N1CCN(c2ncc(OCc3ccccc3)cn2)CC1
5607,989986,10.1016/j.bmc.2013.09.004,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp technique,COC(=O)c1ccccc1-c1ccc(CN2CCC(COC(=O)c3c4n(c5ccccc35)CCCO4)CC2)cc1.CS(=O)(=O)O,"(1-((2'-(Methoxycarbonyl)-[1,1'-biphenyl]-4-yl)methyl)piperidin-4-yl)methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate methanesulfonate",0.131,uM,=,-0.8827287043442358,0,O=C(OCC1CCN(Cc2ccc(-c3ccccc3)cc2)CC1)c1c2n(c3ccccc13)CCCO2
5608,1987839,10.1021/acs.jmedchem.0c00279,,,,Inhibition of human ERG by Qpatch assay,CC(C)c1cc(COc2ccccc2CC(=O)O)cc(-c2ccc3c(c2)[C@H](N)CO3)c1,"(S)-2-(2-((3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylbenzyl)oxy)phenyl)acetic Acid",24.0,uM,=,1.380211241711606,1,c1ccc(OCc2cccc(-c3ccc4c(c3)CCO4)c2)cc1
5609,1655139,10.1016/j.bmcl.2016.12.054,,,,Displacement of [3H]-MK499 from human ERG IKr channel expressed in HEK293 cell membranes,c1ccc(-c2ccccc2CC(c2cccnc2)c2cccnc2)cc1,"3,3'-(2-(biphenyl-2-yl)ethane-1,1-diyl)dipyridine",7.62,uM,=,0.8819549713396005,1,c1ccc(-c2ccccc2CC(c2cccnc2)c2cccnc2)cc1
5610,2159402,10.1021/acs.jmedchem.1c01968,,,,Inhibition of human ERG by voltage clamp assay,F[C@@H]1CNCC[C@H]1c1cc2nc(Nc3cnn([C@@H]4CC4(F)F)c3Cl)ncc2cc1Cl,"6-chloro-N-(5-chloro-1-((R)-2,2-difluorocyclopropyl)-1H-pyrazol-4-yl)-7-((3S,4S)-3-fluoropiperidin-4-yl)quinazolin-2-amine",0.57,uM,=,-0.2441251443275086,0,c1nn(C2CC2)cc1Nc1ncc2ccc(C3CCNCC3)cc2n1
5611,1973585,10.1021/acs.jmedchem.9b02016,,,,Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,2.6,uM,=,0.414973347970818,1,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
5612,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)cc(N3CCC4CC43)n2)(c2ccc(F)cc2)CC1,2-(6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane,12.0,uM,=,1.0791812460476249,1,c1ccc(C2(COCc3cccc(N4CCC5CC54)n3)CCNCC2)cc1
5613,630798,10.1021/jm100023j,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CC1(C)C[C@@H](NC(=O)c2n[nH]c3ccccc23)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1,"N-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-1H-indazole-3-carboxamide",4.6,uM,=,0.6627578316815741,1,O=C(N[C@@H]1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)c1n[nH]c2ccccc12
5614,1748610,10.1021/acs.jmedchem.8b00246,,,,Inhibition of human ERG expressed in CHOK1 cells for 5 mins at -80 mV holding potential by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3ccc(C#N)cn3)cs2)CO1,"N-{2-[(4aR,6S,8aR)-2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl]-1,3-thiazol-4-yl}-5-cyanopyridine-2-carboxamide",12.1,uM,=,1.08278537031645,1,O=C(Nc1csc([C@]23COCC[C@H]2CSC=N3)n1)c1ccccn1
5615,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(N)(=O)=O)cc2)cc1,4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic Acid Amide,7.714285714,uM,=,0.8872957197926267,1,c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
5616,2246303,10.1021/acs.jmedchem.1c01670,,,,Inhibition of MK-499 binding to hERG,O=C(Nc1ccc(F)cc1)C1(c2ccc(-c3cnc(C(F)(F)F)cc3CO)cc2)COC1,4-Fluoro-N-(3-(4-(4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-3-yl)phenyl)oxetan-3-yl)benzamide,22840.0,uM,=,4.358696099573811,1,O=C(Nc1ccccc1)C1(c2ccc(-c3cccnc3)cc2)COC1
5617,1822313,10.1021/acs.jmedchem.8b01891,,,,Inhibition of human ERG,Cc1c(C#N)cccc1[C@@H]1CN2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)C[C@H]2CO1,"3-((3R,9aS)-8-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-2-methylbenzonitrile",14.8,uM,=,1.1702617153949575,1,O=C(Cc1ccc(-n2cnnn2)cc1)N1CCN2C[C@@H](c3ccccc3)OC[C@@H]2C1
5618,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1ccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)cc1,"endo-4-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide",0.68,uM,=,-0.1674910872937636,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccc2)C3)cc1
5619,971488,10.1016/j.bmcl.2013.05.017,,,,Inhibition of human ERG channel by patch clamp technique,CC(C)(O)c1nc2cc(Cl)ccc2n1[C@H]1CC[C@@H](NCC2Cc3ccc(Cl)cc3C2)CC1,"cis-2-(5-chloro-1-(-4-((5-chloro-2,3-dihydro-1H-inden-2-yl)methylamino)cyclohexyl)-1H-benzo[d]imidazol-2-yl)propan-2-ol",0.42,uM,=,-0.3767507096020995,0,c1ccc2c(c1)CC(CN[C@H]1CC[C@@H](n3cnc4ccccc43)CC1)C2
5620,1894370,10.1016/j.ejmech.2019.05.034,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated patch clamp electrophysiology assay,FC(CCN1CCc2ccccc2CC1)Cc1ccccc1,"3-(3-Fluoro-4-phenylbutyl)-2,3,4,5-tetrahydro-1H-3-benzazepine",1.183,uM,=,0.0729847446279303,1,c1ccc(CCCCN2CCc3ccccc3CC2)cc1
5621,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,N#Cc1ccc(Oc2ccc3nc(OCC(=O)N4CCNC(=O)C4)ccc3c2)cc1,4-[[2-[2-oxo-2-(3-oxopiperazin-1-yl)ethoxy]-6-quinolyl]oxy]benzonitrile,2.6,uM,=,0.414973347970818,1,O=C1CN(C(=O)COc2ccc3cc(Oc4ccccc4)ccc3n2)CCN1
5622,796063,10.1016/j.bmcl.2011.11.050,,,,Inhibition of human ERG by patch express assay,O=S(=O)(c1cccc(F)c1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3,"(+/-)-7-(3-fluorophenylsulfonyl)-2',3,4,4',5',6'-hexahydro-2H-spiro[benzofuro[2,3-c]pyridine-1,3'-pyran]",13.6,uM,=,1.1335389083702174,1,O=S(=O)(c1ccccc1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3
5623,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccccc1[N+](=O)[O-],"Ethyl 6-(morpholinomethyl)-4-(2-nitrophenyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",0.26,uM,=,-0.585026652029182,0,C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccccc1
5624,1764419,10.1021/acsmedchemlett.8b00095,,,,Inhibition of human ERG,CSc1ccc(Cc2cc3c(=O)n([C@H]4CCCC[C@@H]4O)cnc3c3ccccc23)cn1,"3-((1S,2S)-2-Hydroxycyclohexyl)-6-((6-(methylthio)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one",7.5,uM,=,0.8750612633917001,1,O=c1c2cc(Cc3cccnc3)c3ccccc3c2ncn1C1CCCCC1
5625,2204561,10.1016/j.bmcl.2022.128871,,,,Inhibition of human ERG,C[C@]1(COc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)CN=C(N)O1,(5R)-5-methyl-5-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidyl]phenoxy]methyl]-4H-oxazol-2-amine,0.0819999999999999,uM,=,-1.0861861476162833,0,C1=NCC(COc2ccc(N3CCC(Oc4ccccc4)CC3)cc2)O1
5626,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C)cc(OCc2cncc(-c3cc(C)cc(C)c3)c2N2CCC(N)CC2)c1,"1-(3-((3,5-dimethylphenoxy)methyl)-5-(3,5-dimethylphenyl)pyridin-4-yl)piperidin-4-amine",1.7,uM,=,0.2304489213782739,1,c1ccc(OCc2cncc(-c3ccccc3)c2N2CCCCC2)cc1
5627,2123853,10.1021/acs.jmedchem.1c01197,,,,Inhibition of human ERG,CCS(=O)(=O)c1ccc(C(Cn2cccn2)C(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)cc1,"2-(4-ethylsulfonylphenyl)-3-pyrazol-1-yl-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]propanamide",2.4,uM,=,0.380211241711606,1,O=C(Nc1ccccc1)C(Cn1cccn1)c1ccccc1
5628,635425,10.1016/j.bmcl.2010.04.071,,,,Inhibition of human ERG,CN1c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc2C(C(=O)NCO)CC1(C)C,"6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-N-(hydroxymethyl)-1,2,2-trimethyl-1,2,3,4-tetrahydro-1,8-naphthyridine-4-carboxamide",0.04,uM,=,-1.3979400086720375,0,c1ccc(-c2cc3c(nc2-c2ccccc2)NCCC3)cc1
5629,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(=O)c1cccc(-c2ccc([C@H]3CN(C)C[C@@H]3NS(=O)(=O)C(C)C)cc2)c1,"N-((3R,4R)-4-(3'-acetylbiphenyl-4-yl)-1-methylpyrrolidin-3-yl)propane-2-sulfonamide",7.9,uM,=,0.8976270912904415,1,c1ccc(-c2ccc([C@@H]3CCNC3)cc2)cc1
5630,787991,10.1021/jm2005546,,,,Inhibition of human cloned ERG channel expressed in chinese hamster CHO cells after 5 mins by patch clamp assay,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,1-[2-(2-Hydroxy-3-propylamino-propoxy)-phenyl]-3-phenyl-propan-1-one,2.88,uM,=,0.4593924877592308,1,O=C(CCc1ccccc1)c1ccccc1
5631,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,N#Cc1ccc2[nH]c(C3CCN(CCn4c(=O)ccc5ncc(Oc6cccnc6)cc54)CC3)nc2c1,"2-(1-(2-(2-oxo-7-(pyridin-3-yloxy)-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazole-5-carbonitrile",1.4,uM,=,0.1461280356782379,1,O=c1ccc2ncc(Oc3cccnc3)cc2n1CCN1CCC(c2nc3ccccc3[nH]2)CC1
5632,1990087,10.1021/acs.jmedchem.0c00259,,,,Inhibition of human ERG by Ionworks high-throughput electrophysiology method,Cc1cc(S(=O)(=O)Nc2ccncn2)c(F)cc1O[C@H]1CCCC[C@@H]1c1ccnn1C,"rac-2-Fluoro-5-methyl-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",90.0,uM,=,1.954242509439325,1,O=S(=O)(Nc1ccncn1)c1ccc(O[C@H]2CCCC[C@@H]2c2ccn[nH]2)cc1
5633,1447392,10.1016/j.bmcl.2014.04.085,,,,Inhibition of human ERG channel,CCOC(=O)N1CCC(CN2CCC3(CC2)CN(C(N)=O)c2ncccc23)CC1,"ethyl 4-((1'-carbamoyl-1',2'-dihydrospiro[piperidine-4,3'-pyrrolo[2,3-b]pyridine]-1-yl)methyl)piperidine-1-carboxylate",0.19,uM,=,-0.721246399047171,0,c1cnc2c(c1)C1(CCN(CC3CCNCC3)CC1)CN2
5634,793464,10.1016/j.bmcl.2011.09.114,,,,Inhibition of human ERG by whole cell patch clamp assay,Cc1ccc2cccc(NC(=O)[C@]3(O)CC[C@@H](NCc4cc5c(cn4)OCCO5)CC3)c2n1,"4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-1-hydroxy-N-(2-methylquinolin-8-yl)cyclohexanecarboxamide",2.0,uM,=,0.3010299956639812,1,O=C(Nc1cccc2cccnc12)C1CCC(NCc2cc3c(cn2)OCCO3)CC1
5635,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC[C@@H]1Sc2ccccc2O[C@@H]1c1ccc(OCCCN2CCCC2)cc1,"cis-1-(3-(4-(3-ethyl-2,3-dihydrobenzo[b][1,4]oxathiin-2-yl)phenoxy)propyl)pyrrolidine",0.011,uM,=,-1.958607314841775,0,c1ccc2c(c1)O[C@H](c1ccc(OCCCN3CCCC3)cc1)CS2
5636,834187,10.1021/jm2013248,,,,Inhibition of human ERG channel expressed in CHO cells by patch clamp assay,c1cncc(-c2ccc(-c3noc(C4CN5CCC4CC5)n3)o2)c1,"3-(5-(pyridin-3-yl)furan-2-yl)-5-(quinuclidin-3-yl)-1,2,4-oxadiazole",6.4,uM,=,0.8061799739838872,1,c1cncc(-c2ccc(-c3noc(C4CN5CCC4CC5)n3)o2)c1
5637,1459712,10.1016/j.ejmech.2014.08.059,,,,Inhibition of human ERG expressed in CHO cells after 20 mins by thallium assay,N#C[C@@H]1C[C@@H]2CCC[C@@H]2N1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,"(2S,3aS,6aS)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]octahydrocyclopenta[b]pyrrole-2-carbonitrile",55.3,uM,=,1.7427251313046983,1,O=C(CCCc1ccccc1)N1CC[C@@H]2CCC[C@@H]21
5638,940270,10.1016/j.bmcl.2013.01.005,,,,Binding affinity to human ERG by patch clamp assay,COc1cc(N2CCN(C(=O)Cn3nc(C(F)(F)F)c(Cl)c3C)CC2)ccc1Cl,1-(4-(4-chloro-3-methoxyphenyl)piperazin-1-yl)-2-(4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)ethanone,16.0,uM,=,1.2041199826559248,1,O=C(Cn1cccn1)N1CCN(c2ccccc2)CC1
5639,2076406,10.1021/acsmedchemlett.0c00462,,,,Inhibition of human ERG,CSc1ccccc1C(=O)NCCCC[C@H](NC(=O)c1cncs1)c1ncc(-c2ccc3ccccc3c2)[nH]1,(S)-N-(5-(2-(methylthio)benzamido)-1-(5-(naphthalen-2-yl)-1H-imidazol-2-yl)pentyl)thiazole-5-carboxamide,0.016,uM,=,-1.7958800173440752,0,O=C(NCCCC[C@H](NC(=O)c1cncs1)c1ncc(-c2ccc3ccccc3c2)[nH]1)c1ccccc1
5640,741328,10.1016/j.bmcl.2011.02.046,,,,Displacement of [3H]-dofetilide from human ERG expressed in human HEK293 cells after 90 mins by scintillation counting,COc1ccc([C@H]2CN(CCc3ccc(OC)c(OC)c3)C[C@@H]2CCc2nc3ccc(Cl)cc3[nH]2)cc1,"rac-6-chloro-2-(2-((3R,4S)-1-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)ethyl)-1H-benzo[d]imidazole",0.016,uM,=,-1.7958800173440752,0,c1ccc(CCN2C[C@H](CCc3nc4ccccc4[nH]3)[C@@H](c3ccccc3)C2)cc1
5641,1512245,10.1016/j.bmcl.2015.07.003,,,,Binding affinity to human ERG expressed in HEK cells by MK-499 radioligand displacement assay,COc1cc(-c2cn(C3CCc4ccccc4NC3=O)nn2)ccc1-n1cnc(C)c1,"3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",17.6,uM,=,1.24551266781415,1,O=C1Nc2ccccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
5642,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F,"6-((1-(2-(6-(dimethylamino)-7-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00121,uM,=,-2.91721462968355,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5643,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COc1cccc(-n2cc3nc(CC(C)C)n(C[C@H]4CCCN(C[C@H]5CCCO5)C4)c(=O)c3n2)c1,"5-Isobutyl-2-(3-methoxyphenyl)-6-(((S)-1-(((R)-tetrahydrofuran-2-yl)methyl)piperidin-3-yl)methyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",3.2,uM,=,0.505149978319906,1,O=c1c2nn(-c3ccccc3)cc2ncn1C[C@H]1CCCN(C[C@H]2CCCO2)C1
5644,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,CS(=O)(=O)Nc1ccc2c(c1)C(O)CC1(CCN(C3CCc4cc(C#N)ccc4C3)CC1)O2,"N-[1'-(6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl)-4-hydroxyspiro[3,4-dihydro-2H-chromene-2,4'-(hexahydropyridine)]-6-yl]methanesulfonamide",0.034,uM,=,-1.4685210829577449,0,c1ccc2c(c1)CCC(N1CCC3(CCc4ccccc4O3)CC1)C2
5645,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,COc1ccc(C#Cc2cccc(C#Cc3ccc(OC)cc3)[n+]2C)cc1,"2,6-bis((4-methoxyphenyl)ethynyl)-1-methylpyridinium",0.377,uM,=,-0.4236586497942071,0,C(#Cc1cccc(C#Cc2ccccc2)[nH+]1)c1ccccc1
5646,1926979,10.1021/acsmedchemlett.6b00119,,,,Displacement of [3H]dofetilide from recombinant human ERG transfected in HEK293 cell membranes after 60 mins by scintillation counting,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cn1,(3-(6-(6-methoxypyridin-3-yl)quinazolin-4-yl)phenyl)(4-methylpiperazin-1-yl)methanone,12.0,uM,=,1.0791812460476249,1,O=C(c1cccc(-c2ncnc3ccc(-c4cccnc4)cc23)c1)N1CCNCC1
5647,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNC(C)c1ccc(OC)cc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)-4-methoxyphenyl)-N-methylethanamine",0.785,uM,=,-0.1051303432547474,0,c1ccc(Oc2ccccc2)cc1
5648,793275,10.1016/j.bmcl.2011.09.117,,,,Displacement of [3H]dofetilide from human ERG by liquid scintillation counting,COc1ccc2ncc(F)c([C@H](O)CN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2n1,"(S)-2-(4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)piperidin-1-yl)-1-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethanol",63.1,uM,=,1.8000293592441343,1,c1cnc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
5649,534565,10.1016/j.bmc.2008.01.017,,,,Inhibition of human ERG potassium channel,CCC[S+]([O-])CCCN(CC)CC(O)COc1ccc(C#N)cc1,4-(3-{Ethyl-[3-(propane-1-sulfinyl)-propyl]-amino}-2-hydroxy-propoxy)-benzonitrile,0.005,uM,=,-2.3010299956639813,0,c1ccccc1
5650,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1ccccc1Oc1ccc(Cl)c(Cl)c1,"1-(2-(3,4-dichlorophenoxy)phenyl)-N-methylmethanamine",3.88,uM,=,0.5888317255942073,1,c1ccc(Oc2ccccc2)cc1
5651,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,C[C@@H](N)C(=O)N1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc([N+](=O)[O-])c4)c3c2)CC1,(R)-2-amino-1-(4-(5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinolin-3-yl)piperazin-1-yl)propan-1-one,4.92,uM,=,0.6919651027673603,1,c1ccc(CNc2cccc3ncc(N4CCNCC4)cc23)cc1
5652,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,O=c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCN(CCO)CC7)ncc6cc5-c5ccccc5)cc4)CC3)[nH]2)c[nH]1,"5-(5-(1-((4-(2-(4-(2-hydroxyethyl)piperazin-1-yl)-6-phenylpyrido[2,3-d]pyrimidin-7-yl)phenyl)methyl)piperidin-4-yl)-4H-1,2,4-triazol-3-yl)pyridin-2(1H)-one",6.8,uM,=,0.8325089127062363,1,O=c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCNCC7)ncc6cc5-c5ccccc5)cc4)CC3)[nH]2)c[nH]1
5653,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CNC(=O)CN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"2-((1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)(4-chlorophenethyl)amino)-N-methylacetamide",2.6,uM,=,0.414973347970818,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
5654,463271,10.1016/j.bmcl.2007.11.052,,,,Inhibition of human ERG,Cc1ccc(Oc2ccc(Nc3ncnc4cccc(O[C@H](C)C(=O)N(C)CCO)c34)cc2C)cn1,(R)-N-(2-hydroxyethyl)-N-methyl-2-(4-(3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino)quinazolin-5-yloxy)propanamide,12.0,uM,=,1.0791812460476249,1,c1cncc(Oc2ccc(Nc3ncnc4ccccc34)cc2)c1
5655,2017994,10.1016/j.bmcl.2020.127563,,,,Inhibition of human ERG,C[C@H]1C=C(C2=Nc3ccccc3Nc3ccc(Cl)cc32)CCN1C,"(S)-2-chloro-11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepine",0.6,uM,=,-0.2218487496163563,0,C1=C(C2=Nc3ccccc3Nc3ccccc32)CCNC1
5656,1765499,10.1021/acs.jmedchem.8b01040,,,,Displacement of [3H]dofetilide from human ERG by high throughput assay,O=C(Nc1ccc(OC(F)(F)F)cc1)c1cnc(NCCCO)c(-c2cncnc2)c1,"US9278981, 161",1.5,uM,=,0.1760912590556812,1,O=C(Nc1ccccc1)c1cncc(-c2cncnc2)c1
5657,1682333,10.1021/acs.jmedchem.7b01347,,,,Inhibition of full length human ERG expressed in CHO cells at -70 mV holding potential by patch clamp assay,CN1CCN(c2ccc(NC(=O)c3cc(N(C)Cc4ccc(C(F)(F)F)cc4)ncn3)cc2)CC1,6-(Methyl(4-(trifluoromethyl)benzyl)amino)-N-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-4-carboxamide,0.9,uM,=,-0.0457574905606751,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1cc(NCc2ccccc2)ncn1
5658,1339285,10.1016/j.bmcl.2014.02.013,,,,Inhibition of human ERG by FLIPR assay,CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](NC(=O)c3cccc(C(C)(C)C)c3)C2=O)[C@H](CS(=O)(=O)C(C)C)C1,"3-tert-butyl-N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(isopropylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)benzamide",77.0,uM,=,1.8864907251724816,1,O=C(N[C@H]1CCN(C2CCCCC2)C1=O)c1ccccc1
5659,1769256,10.1016/j.bmc.2018.02.026,,,,Inhibition of human ERG by patch clamp assay,COc1cc2ccc(C#N)cc2cc1[C@@H](c1cccc(F)c1)[C@@](O)(CCN(C)C)c1cccc2ccoc12,"7-((1R,2S)-2-(benzofuran-7-yl)-4-(dimethylamino)-1-(3-fluorophenyl)-2-hydroxybutyl)-6-methoxy-2-naphthonitrile",0.6,uM,=,-0.2218487496163563,0,c1ccc([C@@H](Cc2cccc3ccoc23)c2ccc3ccccc3c2)cc1
5660,1643779,10.1039/C6MD00281A,,,,Inhibition of recombinant human ERG expressed in HEK293 cells at holding potential of -120 mV by PatchXpress automated electrophysiology method,NC1(Cc2nc(-c3ccc(OC(F)(F)F)cc3)c[nH]2)COC1,3-((5-(4-(Trifluoromethoxy)phenyl)-1H-imidazol-2-yl)methyl)oxetan-3-amine,10.0,uM,=,1.0,1,c1ccc(-c2c[nH]c(CC3COC3)n2)cc1
5661,2049587,10.1016/j.bmcl.2020.127625,,,,Inhibition of human ERG by patch clamp assay,Cc1cn([C@@H](C)[C@H]2CCNC[C@H]2F)c2nc(C(N)=O)cc(Cl)c12,"Rac-4-chloro-1-[(1S)-1-[(3S,4R)-3-fluoro-4-piperidyl]ethyl]-3-methyl-pyrrolo[2,3-b]pyridine-6-carboxamide",10.0,uM,=,1.0,1,c1cnc2c(c1)ccn2CC1CCNCC1
5662,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CCN3CCC(NCc4ccc5c(n4)NC(=O)CO5)CC3)c2c1,"6-(((1-(2-(6-methoxyquinolin-4-yl)ethyl)piperidin-4-yl)amino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.8,uM,=,0.5797835966168101,1,O=C1COc2ccc(CNC3CCN(CCc4ccnc5ccccc45)CC3)nc2N1
5663,2116620,10.1021/acsmedchemlett.1c00308,,,,Inhibition of ERG in human VCaP cells after 48 hrs by Western blotting analysis,CN(C)c1ccc(/N=N/c2ccccn2)c(O)c1.O=C(O)/C=C\C(=O)O,5-(dimethylamino)-2-(pyridin-2-yldiazenyl)phenol maleate,0.26,uM,=,-0.585026652029182,0,c1ccc(/N=N/c2ccccn2)cc1
5664,1552682,10.1016/j.bmcl.2015.12.058,,,,Inhibition of human ERG by FLIPR assay,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)C(C)C)cc21,,40.9,uM,=,1.611723308007342,1,O=C(N1C2CCC1CNC2)[C@]12C[C@H]1c1ccccc1-c1c(C3CCCCC3)c3ccccc3n1C2
5665,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,CCOC(=O)CCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"ethyl 4-(7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)butanoate",1.0,uM,=,0.0,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5666,816515,10.1021/jm201195m,,,,Inhibition of human ERG,Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1,"(R)-N-(3-aminopropyl)-N-(1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl)-4-methylbenzamide",4.81,uM,=,0.6821450763738317,1,O=C(NCc1nc2ccccc2c(=O)n1Cc1ccccc1)c1ccccc1
5667,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.0,uM,=,0.3010299956639812,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5668,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,C[S+]([O-])c1cccc(-c2ccc3ncc(-c4cccc([S+](C)[O-])c4)n3n2)c1,"3,6-bis(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine",8.45,uM,=,0.9268567089496924,1,c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1
5669,640798,10.1016/j.bmcl.2010.05.041,,,,Inhibition of human ERG by patch clamp technique,O=C(c1ccc(Oc2cccc(Cl)c2)nc1)N1CCCN(C2CCC2)CC1,"(6-(3-chlorophenoxy)pyridin-3-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methanone",1.6,uM,=,0.2041199826559248,1,O=C(c1ccc(Oc2ccccc2)nc1)N1CCCN(C2CCC2)CC1
5670,1625797,10.1016/j.bmcl.2016.10.054,,,,Inhibition of human ERG,Cc1cc(-c2cc(OC(F)(F)F)ccc2Cl)cc(C)c1OCCCC(=O)O,"4-(2'-chloro-3,5-dimethyl-5'-(trifluoromethoxy)biphenyl-4-yloxy)butanoic acid",54.57,uM,=,1.736953953783146,1,c1ccc(-c2ccccc2)cc1
5671,1682724,10.1021/acs.jmedchem.7b01135,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,CN(C)[C@H]1CC[C@H](n2cc(C(N)=O)c(Nc3ccc(Cl)cc3)n2)[C@@H](C#N)C1,"US8962608, 28-117",3.0,uM,=,0.4771212547196624,1,c1ccc(Nc2ccn(C3CCCCC3)n2)cc1
5672,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",3.1,uM,=,0.4913616938342727,1,c1ccc(CCCCNCCc2ccccc2)cc1
5673,2169625,10.1021/acs.jmedchem.1c01300,,,,Binding affinity to human ERG,C[C@@]1(c2nc(NC(=O)c3ncc(C(F)(F)F)cc3Cl)ccc2F)CO[C@@](C)(C(F)(F)F)C(N)=N1,"US8637508, 34",3.2,uM,=,0.505149978319906,1,O=C(Nc1cccc(C2COCC=N2)n1)c1ccccn1
5674,499833,10.1016/j.bmcl.2009.04.022,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCOC(=O)N1CCC(C)(Sc2nc3cc(Cl)c(N4CCN(CC)CC4)cc3[nH]2)CC1,ethyl 4-(5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazol-2-ylthio)-4-methylpiperidine-1-carboxylate,3.9,uM,=,0.5910646070264992,1,c1cc2nc(SC3CCNCC3)[nH]c2cc1N1CCNCC1
5675,2015639,10.1016/j.bmcl.2020.127393,,,,Inhibition of human ERG,Cc1nn(-c2ccnc3[nH]c(-c4cccc5c4ccn5C)nc23)cc1CN1CC[C@@H](O)C1,"(R)-1-((3-methyl-1-(2-(1-methyl-1H-indol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-4-yl)methyl)pyrrolidin-3-ol",31.0,uM,=,1.4913616938342726,1,c1cc(-c2nc3c(-n4cc(CN5CCCC5)cn4)ccnc3[nH]2)c2cc[nH]c2c1
5676,1910901,10.1016/j.ejmech.2018.12.042,,,,Inhibition of [3H]-dofetilide binding to human ERG expressed in HEK293 cell membranes measured after 1 hr by liquid scintillation counting method,N=C(N)N/N=C/c1ccc(-c2cccc(/C=N/NC(=N)N)c2)cc1,"2,2'-(biphenyl-3,4'-diylbis(methan-1-yl-1-ylidene))bis(hydrazinecarboximidamide)",4.66,uM,=,0.6683859166900001,1,c1ccc(-c2ccccc2)cc1
5677,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1,"6-(4-methylpiperazin-1-yl)-2-phenyl-3-(4-((4-(5-(pyrimidin-2-yl)-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)pyrido[3,2-b]pyrazine",8.3,uM,=,0.919078092376074,1,c1ccc(-c2nc3ccc(N4CCNCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ncccn5)[nH]4)CC3)cc2)cc1
5678,1699176,10.1021/acs.jmedchem.6b01543,,,,Inhibition of MK499 binding to human ERG,O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-3-yl)acetic Acid,0.8,uM,=,-0.0969100130080563,0,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCCO5)CC4)nc3)nc2c1
5679,2150697,10.1021/acs.jmedchem.1c00712,,,,Inhibition of human ERG,O=C1NC2(CC2)COc2ncc(F)cc2[C@H]2CNCCN2c2ccn3ncc1c3n2,,6.7,uM,=,0.8260748027008264,1,O=C1NC2(CC2)COc2ncccc2[C@H]2CNCCN2c2ccn3ncc1c3n2
5680,2298259,10.1016/j.bmc.2023.117276,,,,Inhibition of hERG expressed in CHO cells by automated patch clamp method,Cn1cc(C(=O)NCc2ccc(Cl)cc2)c(=O)c2cc(CN3CCOCC3)sc21,"7-Methyl-2-morpholin-4-ylmethyl-4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxylic acid 4-chloro-benzylamide",9.4,uM,=,0.9731278535996988,1,O=C(NCc1ccccc1)c1c[nH]c2sc(CN3CCOCC3)cc2c1=O
5681,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,O=C(N1CCOCC1)N1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc([N+](=O)[O-])c4)c3c2)CC1,morpholino(4-(5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinolin-3-yl)piperazin-1-yl)methanone,0.39,uM,=,-0.4089353929735008,0,O=C(N1CCOCC1)N1CCN(c2cnc3cccc(NCc4ccccc4)c3c2)CC1
5682,2153986,10.1021/acsmedchemlett.1c00660,,,,Inhibition on hERG expressed in HEK293 cells by Qpatch method,CN(C)CCNC(=O)c1cccn2c(=O)c3ccc4ccccc4c3nc12,"N-(2-(dimethylamino)ethyl)-7-oxo-7H-benzo[h]pyrido[2,1-b]quinazoline-12-carboxamide",4.53,uM,=,0.6560982020128319,1,O=c1c2ccc3ccccc3c2nc2ccccn12
5683,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(F)cc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide",0.0150999999999999,uM,=,-1.8210230527068303,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
5684,883359,10.1021/jm300952s,,,,Inhibition of human ERG by cell-based electrophysiology assay,Cc1cc(CN2CCN(c3c(Br)cnc4nc(-c5ccc(N6CCN(C)CC6)cc5)[nH]c34)CC2)no1,"3-((4-(6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole",3.0,uM,=,0.4771212547196624,1,c1cc(N2CCN(Cc3ccon3)CC2)c2[nH]c(-c3ccc(N4CCNCC4)cc3)nc2n1
5685,1706716,10.1016/j.bmcl.2017.03.040,,,,Inhibition of human ERG by [35S]-MK499 displacement or iKr channel assay,CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1,"(R)-4-(8-amino-3-(1-(3-methyloxetane-3-carbonyl)piperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",3.5,uM,=,0.5440680443502757,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@@H]3CCCN(C(=O)C4COC4)C3)n3ccncc23)cc1
5686,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,CC1(c2nc(-c3ccccc3)c[nH]2)Cc2c([nH]c3ccccc23)C(C2CCOCC2)N1,"3-methyl-3-(4-phenyl-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",1.634,uM,=,0.2132520521963966,1,c1ccc(-c2c[nH]c(C3Cc4c([nH]c5ccccc45)C(C4CCOCC4)N3)n2)cc1
5687,492219,10.1021/jm800419w,,,,Antagonist activity at human ERG by voltage-clamp electrophysiology assay,CC1(C)C[C@@H](CN2CCC(F)(CNC(=O)c3cc(Cl)cc(Cl)c3)CC2)CCO1,"(S)-3,5-Dichloro-N-[1-(2,2-dimethyl-tetrahydro-pyran-4-ylmethyl)-4-fluoro-piperidin-4-ylmethyl]-benzamide",2.9,uM,=,0.4623979978989561,1,O=C(NCC1CCN(CC2CCOCC2)CC1)c1ccccc1
5688,1330254,10.1039/C2MD20010D,,,,Inhibition of human ERG channel expressed in CHO cells by IonWorks assay,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CC[C@H](NCCc3cncn3C2)C1=O,"31-oxo-(5S)-20-oxa-2,6,11,13-tetraazahexacyclo[19.6.2.12,5.115,19.09,13.024,28]hentriaconta-1(27),9,11,15,17,19(30),21(29),22,24(28),25-decaen-18-yl cyanide",8.1,uM,=,0.9084850188786496,1,O=C1[C@@H]2CCN1c1cccc3ccc(cc13)Oc1cccc(c1)Cn1cncc1CCN2
5689,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,Cc1ncc(-c2ccnc(Nc3ccc(C(N)=O)cc3)n2)n1C(C)C,4-(4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)benzamide,17.0,uM,=,1.230448921378274,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
5690,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(N3CCC3=O)cc1)C(=O)N2c1cc(O)ncn1,"1-(6-Hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-3-[4-(2-oxo-azetidin-1-yl)-phenyl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione",27.0,uM,=,1.4313637641589874,1,O=C1CCN1c1ccc(N2C(=O)N(c3ccncn3)C3(CCN(Cc4ccccn4)CC3)C2=O)cc1
5691,1475692,10.1016/j.bmcl.2015.04.002,,,,Inhibition of MK499 binding to human ERG,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12,"6-((1-(2-(8-methyl-6-(methylsulfonyl)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.00671,uM,=,-2.173277479831008,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5692,501217,10.1016/j.bmcl.2009.02.099,,,,Inhibition of human ERG by patch-clamp assay,N[C@H](Cc1cc(F)c(F)cc1F)C1CCN(C(=O)c2cnc3ncccn23)CC1,"(R)-(4-(1-amino-2-(2,4,5-trifluorophenyl)ethyl)piperidin-1-yl)(imidazo[1,2-a]pyrimidin-3-yl)methanone",59.0,uM,=,1.7708520116421442,1,O=C(c1cnc2ncccn12)N1CCC(CCc2ccccc2)CC1
5693,304886,10.1016/j.bmcl.2004.07.056,,,,Inhibition of human Potassium channel HERG,CC(C)[C@@H](Oc1ccc(CNC(=O)[C@@H]2CCCN2C(=O)CC(N)Cc2cc(F)ccc2F)cc1)C(=O)O.O=C(O)C(F)(F)F,"Trifluoro-acetate3-{(S)-2-[4-((R)-1-carboxy-2-methyl-propoxy)-benzylcarbamoyl]-pyrrolidin-1-yl}-1-(2,5-difluoro-benzyl)-3-oxo-propyl-ammonium",76.0,uM,=,1.880813592280792,1,O=C(NCc1ccccc1)[C@@H]1CCCN1C(=O)CCCc1ccccc1
5694,2093710,10.1016/j.ejmech.2020.112710,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1.Cl.Cl,N-(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide dihydrochloride,0.011,uM,=,-1.9586073148417749,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
5695,1577079,10.1016/j.bmc.2016.04.065,,,,Inhibition of human ERG expressed in cell membranes after 4 hrs by fluorescence polarization assay,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide,0.07,uM,=,-1.154901959985743,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
5696,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc2nc(-c3ccncc3)ccc2c1,(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)-2-(pyridin-4-yl)quinoline,28.0,uM,=,1.4471580313422192,1,c1cc(-c2ccc3cc(CCN4CCCC4)ccc3n2)ccn1
5697,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,Cc1nc([C@]2(c3cnn(CC4CC4)c3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"3-((1R,3R)-1-(1-(cyclopropylmethyl)-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,2,4-oxadiazole",3.2,uM,=,0.505149978319906,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cnn(CC5CC5)c4)(c4ncon4)N3)n2)nc1
5698,810825,10.1021/jm201449n,,,,Inhibition of human Erg expressed CHO cells,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3,"11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one",20.0,uM,=,1.3010299956639813,1,O=C1NCc2c1c1c(c3[nH]c4ccc(Nc5ncccn5)cc4c23)CCc2n[nH]cc2-1
5699,876604,10.1021/jm301476b,,,,Inhibition of human ERG expressed in chinese hamster lung cells by IonWorks patch clamp electrophysiology assay,COc1ccc(-c2cc(-c3ccc(C(=O)N4CCN(C)CC4)cc3)cnc2N)cn1,(4-(6-amino-5-(6-methoxypyridin-3-yl)pyridin-3-yl)phenyl)(4-methylpiperazin-1-yl)methanone,20.5,uM,=,1.3117538610557542,1,O=C(c1ccc(-c2cncc(-c3cccnc3)c2)cc1)N1CCNCC1
5700,1642016,,,,,"Inhibition Assay: Briefly, the experiments were performed on an IonWorks™ HT instrument (Molecular Devices Corporation), which automatically performs electrophysiology measurements in 48 single cells simultaneously in a specialised 384-well plate (PatchPlate™). The cells used were Chinese hamster ovary (CHO) cells stably transfected with hERG. A single-cell suspension is prepared in extracellular solution (Dulbecco's phosphate buffered saline with calcium and magnesium pH 7-7.2) and aliquots added automatically to each well of a PatchPlate™. The cells were then positioned over a small hole at the bottom of each well by applying a vacuum beneath the plate to form an electrical seal. The vacuum was applied through a single compartment common to all wells which is filled with intracellular solution (buffered to pH 7.2 with HEPES). The resistance of each seal was measured via a common ground-electrode in the intracellular compartment and individual electrodes placed into each of the upper wells. Electrical access to the cell was achieved by circulating a perforating agent, amphotericin, underneath the PatchPlate™ and then measuring the pre-compound hERG current. An electrode was positioned in the extracellular compartment and a holding potential of −80 mV applied for 15 sec. The hERG channels were then activated by applying a depolarising step to +40 mV for 5 sec and then clamped at −50 mV for 4 sec to elicit the hERG tail current, before returning to −80 mV for 0.3 s. The test compound was then added at various concentrations (0.008, 0.04, 0.2, 1, 5 and 25 μM) to the upper wells of the PatchPlate™. The test compound was left in contact with the cells for 300 sec before recording currents using the same voltage-step protocol as in the pre-compound scan. Quinidine, an established hERG inhibitor, was included as a positive control.",C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,(6-Methoxy-quinolin-4-yl)-(5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol,1.44,uM,=,0.1583624920952496,1,c1ccc2c(C[C@H]3CC4CCN3CC4)ccnc2c1
5701,1682333,10.1021/acs.jmedchem.7b01347,,,,Inhibition of full length human ERG expressed in CHO cells at -70 mV holding potential by patch clamp assay,CN(Cc1ccc(F)cc1)c1cc(C(=O)Nc2nncs2)ncn1,"6-((4-Fluorobenzyl)(methyl)amino)-N-(1,3,4-thiadiazol-2-yl)pyrimidine-4-carboxamide",4.2,uM,=,0.6232492903979004,1,O=C(Nc1nncs1)c1cc(NCc2ccccc2)ncn1
5702,75160,10.1021/jm00014a008,,,,Blockade of the delayed rectifier K+ current (IKr) of guinea pig myocytes,CN1Cc2ccccc2[C@H](c2ccc(F)cc2F)N=C1CCc1ccc(NS(C)(=O)=O)cc1.Cl,"N-(4-{2-[5-(2,4-Difluoro-phenyl)-2-methyl-2,5-dihydro-1H-benzo[e][1,3]diazepin-3-yl]-ethyl}-phenyl)-methanesulfonamide hydrochloride",85.0,uM,=,1.9294189257142929,1,c1ccc(CCC2=N[C@@H](c3ccccc3)c3ccccc3CN2)cc1
5703,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OC(F)(F)O3)CC1)c1cc(=O)c2ccc(F)cc2o1,"N-[1-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide",0.0056,uM,=,-2.2518119729938,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
5704,1760800,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by fluorescence polarization assay,CC(C)(O)COc1ccc(C(N)=O)c(O[C@H]2CCN(C(=O)Cc3ccc(OC(F)(F)F)cc3)C[C@@H]2F)c1,"2-(((3S,4S)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)-piperidin-4-yl)oxy)-4-(2-hydroxy-2-methylpropoxy)benzamide",38.0,uM,=,1.57978359661681,1,O=C(Cc1ccccc1)N1CCC(Oc2ccccc2)CC1
5705,1904547,10.1021/acs.jmedchem.0c00395,,,,Inhibition of human ERG expressed in HEK293 cells measured after 5 mins by whole cell patch clamp method,COc1cc(-c2cncc(-c3ccc(N4C[C@@H](C)N(C)[C@@H](C)C4)cc3)c2C)cc(F)c1C(N)=O,"2-Fluoro-6-methoxy-4-(4-methyl-5-(4-((3R,5S)-3,4,5-trimethylpiperazin-1-yl)phenyl)pyridin-3-yl)benzamide",19.0,uM,=,1.2787536009528289,1,c1ccc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2)cc1
5706,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccc(F)cc1,"[(3R)-quinuclidin-3-yl] (1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate",0.34,uM,=,-0.4685210829577448,0,O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1
5707,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,Cc1nc(C)n(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3ccc(C(F)(F)F)nc3)C[C@H]2C)n1,"2-(3,5-Dimethyl-[1,2,4]triazol-1-yl)-1-{(R)-2-methyl-4-[2-trifluoromethyl-4-(6-trifluoromethyl-pyridin-3-yl)-thiazol-5-yl]-piperazin-1-yl}-ethanone",5.2,uM,=,0.7160033436347992,1,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cccnc2)CC1
5708,796211,10.1016/j.bmcl.2011.11.038,,,,Inhibition of human Erg,O=S1(=O)CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1,"4-{1'-cyclobutyl-3,4-dihydrospiro[1-benzopyran- 2,4'-piperidine]oxy}-1{6}-thiane-1,1-dione",7.0,uM,=,0.8450980400142568,1,O=S1(=O)CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
5709,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,O=C(Nc1ccc(O)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(F)ccc1O2)NC1CC1,"(S)-1-cyclopropyl-3-(2-(3-(5-fluoro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-hydroxyphenyl)urea",3.8,uM,=,0.5797835966168101,1,O=C(Nc1ccccc1OCCCN1CCC2(CC1)Cc1ccccc1O2)NC1CC1
5710,2159402,10.1021/acs.jmedchem.1c01968,,,,Inhibition of human ERG by voltage clamp assay,FC1CN(C2COC2)CCC1c1cc2nc(Nc3cnn(C4CC4(F)F)c3Cl)ncc2cc1Cl,"6-chloro-N-(5-chloro-1-(2,2-difluorocyclopropyl)-1H-pyrazol-4-yl)-7-(3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)quinazolin-2-amine",18.3,uM,=,1.2624510897304295,1,c1nn(C2CC2)cc1Nc1ncc2ccc(C3CCN(C4COC4)CC3)cc2n1
5711,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3nccc3C)[C@H](C)C2)cn1,1-{(R)-4-[4-(2-Ethoxy-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-2-(5-methyl-pyrazol-1-yl)-ethanone,5.6,uM,=,0.7481880270062004,1,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
5712,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,CC1(C)C(=O)Nc2nc(-n3nc(Cc4ccccc4F)c4cc(Cl)ccc43)nc(N)c21,"4-amino-2-[5-chloro-3-[(2-fluorophenyl)methyl]indazol-1-yl]-5,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-6-one",1.5,uM,=,0.1760912590556812,1,O=C1Cc2cnc(-n3nc(Cc4ccccc4)c4ccccc43)nc2N1
5713,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,C[C@@H]1CCCN1CCN1CCc2cc(-c3ccc(C(=O)N4CCCC4)cc3)ccc2C1=O,"2-{2-[(2R)-2-Methylpyrrolidin-1-yl]ethyl}-6-[4-(pyrrolidin-1-ylcarbonyl)phenyl]-3,4-dihydroisoquinolin-1(2H)-one",9.6,uM,=,0.9822712330395684,1,O=C(c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1)N1CCCC1
5714,2246303,10.1021/acs.jmedchem.1c01670,,,,Inhibition of MK-499 binding to hERG,O=C(Nc1ccc(F)cc1)C1(c2ccc(-c3nc(C4CC4)no3)cc2)COC1,"3-(4-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl)-N-(4-fluorophenyl)oxetane-3-carboxamide",13830.0,uM,=,4.140822180109311,1,O=C(Nc1ccccc1)C1(c2ccc(-c3nc(C4CC4)no3)cc2)COC1
5715,541084,10.1016/j.bmcl.2009.01.009,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,CCN(C(=O)Cc1ccc(OC)cc1)[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC1)c1ccccc1,"N-((S)-3-((1R,3S,5S)-3-(N-ethyl-2-(4-methoxyphenyl)acetamido)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclobutanecarboxamide",0.248,uM,=,-0.6055483191737837,0,O=C(Cc1ccccc1)N[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC1)c1ccccc1
5716,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,CS(=O)(=O)Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)cc1,endo-3-(8-(4-(methylsulfonylmethyl)benzyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0066,uM,=,-2.1804560644581312,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
5717,438968,10.1021/jm0700565,,,,Blockade of hERG expressed in HEK293 cells by whole-cell patch clamp method,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide,0.0092,uM,=,-2.036212172654445,0,c1ccc(CCNCCOc2ccccc2)cc1
5718,1879326,10.1021/acs.jmedchem.9b01172,,,,Inhibition of human ERG assessed as reduction in channel tail current by plate-based planar patch clamp assay,CN(C)C(=O)CNCCc1cccc(OCCCC(F)(F)CF)c1.Cl,"2-((3-(4,4,5-Trifluoropentoxy)phenethyl)amino)-N,N-dimethylacetamide Hydrochloride",15.0,uM,=,1.1760912590556811,1,c1ccccc1
5719,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Clc1ccc(OCCCc2cccc(CCCOc3ccc(Cl)cc3)n2)cc1,"2,6-bis(3-(4-chlorophenoxy)propyl)pyridine",0.0099,uM,=,-2.00436480540245,0,c1ccc(OCCCc2cccc(CCCOc3ccccc3)n2)cc1
5720,599953,10.1016/j.bmcl.2009.07.047,,,,Inhibition of human ERG in L929 cells by whole cell patch-clamp assay,O=C(O)c1ccc(CCCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,4-[4-[4-[hydroxy(diphenyl)methyl]-1-piperidinyl]butyl]benzoic acid,11.0,uM,=,1.0413926851582251,1,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
5721,984173,10.1021/jm400279y,,,,Inhibition of human ERG channel expressed in Chinese hamster lung cells after 6 to 7 mins by patch clamp assay,COc1ccc(-c2cc(-c3ccc(S(C)(=O)=O)cc3)cnc2N)cn1,TCMDC-133351,3.5,uM,=,0.5440680443502757,1,c1ccc(-c2cncc(-c3cccnc3)c2)cc1
5722,750496,10.1016/j.bmcl.2011.01.034,,,,Displacement of labeled dofetilide from human ERG,CO[C@@H]1COCC[C@@H]1N(C)[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)(C(C)C)C1,"cis-((1S,3R)-1-isopropyl-3-(((3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl)(methyl)amino)cyclopentyl)(4-(4-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methanone",17.0,uM,=,1.230448921378274,1,O=C(C1CC[C@@H](NC2CCOCC2)C1)N1CCN(c2ccccn2)CC1
5723,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2cc(F)c(F)cc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-6,7-difluoro-4-oxo-4H-chromene-2-carboxamide",0.0062,uM,=,-2.207608310501746,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
5724,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(F)c(Cl)c1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1,(S)-N-(3-chloro-4-fluorophenyl)-4-((1-cyclopropylpiperidin-3-yl)methyl)piperazine-1-carboxamide,14.0,uM,=,1.146128035678238,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
5725,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ccc(=O)n(CCN3CCN(c4nc5cc(C(F)(F)F)ccc5[nH]4)CC3)c2c1,"7-methoxy-1-(2-(4-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)piperazin-1-yl)ethyl)-1,5-naphthyridin-2(1H)-one",10.0,uM,=,1.0,1,O=c1ccc2ncccc2n1CCN1CCN(c2nc3ccccc3[nH]2)CC1
5726,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(CC)CC2)c1ncc(-c2cc3ccc(C)nc3cc2OC)[nH]1,(S)-6-ethyl-N-((S)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide,42.0,uM,=,1.6232492903979006,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)[nH]1)[C@H]1CC12CCNCC2
5727,1544456,10.1021/acs.jmedchem.5b01275,,,,Inhibition of human ERG by patch clamp assay,C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1,LGH-447,12.0,uM,=,1.0791812460476249,1,O=C(Nc1cnccc1C1CCCCC1)c1cccc(-c2ccccc2)n1
5728,75160,10.1021/jm00014a008,,,,Blockade of the delayed rectifier K+ current (IKr) of guinea pig myocytes,CSc1ccc([C@@H]2N=C(OCc3ccc(NS(C)(=O)=O)cc3)N(C)Cc3ccccc32)cc1.Cl,"N-{4-[2-Methyl-5-(4-methylsulfanyl-phenyl)-2,5-dihydro-1H-benzo[e][1,3]diazepin-3-yloxymethyl]-phenyl}-methanesulfonamide hydrochloride",56.0,uM,=,1.7481880270062005,1,c1ccc(COC2=N[C@@H](c3ccccc3)c3ccccc3CN2)cc1
5729,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,C[C@@H](O)CN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"(R)-1-((1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)(4-chlorophenethyl)amino)propan-2-ol",6.1,uM,=,0.785329835010767,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
5730,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,CC(C)(C)c1[nH]c2ccccc2c1C1CCCN(Cc2ccc(/C=C/C(=O)NO)cc2)C1,(E)-3-{4-[3-(2-tert-Butyl-1H-indol-3-yl)piperidin-1-ylmethyl]-phenyl}-N-hydroxyacrylamide,13.5,uM,=,1.130333768495006,1,c1ccc(CN2CCCC(c3c[nH]c4ccccc34)C2)cc1
5731,77051,10.1021/jm970517u,,,,Inhibition of Ikr current in isolated guinea pig myocytes during a 0.5 s voltage clamp step from -50 to -10 mV.,O=C(Cc1ccc(Cl)cc1Cl)N[C@@H]1N=C(c2ccccc2)c2ccccc2N(CC(F)(F)F)C1=O,"2-(2,4-Dichloro-phenyl)-N-[(R)-2-oxo-5-phenyl-1-(2,2,2-trifluoro-ethyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-acetamide",2.4,uM,=,0.380211241711606,1,O=C(Cc1ccccc1)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O
5732,2156141,10.1021/acsmedchemlett.1c00272,,,,Inhibition of hERG (unknown origin),Cc1ccc(F)c2cc(C(=O)N[C@@H]3CCC[C@H](N4CC[C@H](N(C)S(C)(=O)=O)C4)C3)[nH]c12,"4-fluoro-7-methyl-N-((1R,3S)-3-((S)-3-(N-methylmethylsulfonamido)pyrrolidin-1-yl)cyclohexyl)-1H-indole-2-carboxamide",4.5,uM,=,0.6532125137753437,1,O=C(N[C@@H]1CCC[C@H](N2CCCC2)C1)c1cc2ccccc2[nH]1
5733,1332040,10.1039/C1MD00092F,,,,Inhibition of human ERG,COC[C@H](C)Oc1cc(Oc2ccc(S(C)(=O)=O)cc2)cc(C(=O)Nc2nc(C)ns2)c1,"3-[(1S)-2-methoxy-1-methyl-ethoxy]-5-(4-methylsulfonylphenoxy)-N-(3-methyl-1,2,4-thiadiazol-5-yl)benzamide",7.5,uM,=,0.8750612633917001,1,O=C(Nc1ncns1)c1cccc(Oc2ccccc2)c1
5734,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,O=C1OCc2cc(CCN3CCN(CCc4ccc([N+](=O)[O-])cc4)CC3)ccc21,5-(2-(4-(4-nitrophenethyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,0.15,uM,=,-0.8239087409443188,0,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
5735,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(CCc2ccc3c(c2)Cc2c(-c4csc(C#CCOc5ccccc5)c4)n[nH]c2-3)CC1,"6-(2-(4-methylpiperazin-1-yl)ethyl)-3-(5-(3-phenoxyprop-1-ynyl)thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole",5.87,uM,=,0.7686381012476144,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CCN4CCNCC4)ccc2-3)cs1)COc1ccccc1
5736,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CC1CCN(c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)CC1,(R)-2-(4-methylpiperidin-1-yl)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline,22.4,uM,=,1.3502480183341627,1,c1cc2nc(N3CCCCC3)ccc2cc1CCN1CCCC1
5737,1502030,10.1021/acs.jmedchem.5b00217,,,,Inhibition of human ERG,Cc1ncc(OC[C@@]2(c3cc(F)cc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1,"(1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,5-difluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide",4.8,uM,=,0.6812412373755872,1,O=C(Nc1ccccn1)[C@@H]1C[C@@]1(COc1cncnc1)c1ccccc1
5738,1755185,10.1021/acs.jmedchem.8b00457,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,COCCCN1CCC(c2nnc(-c3cccc4cc(C(C)C)nn34)o2)CC1,"2-Isopropyl-7-{5-[1-(3-methoxypropyl)-piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-pyrazolo[1,5-a]pyridine",2.3,uM,=,0.3617278360175928,1,c1cc(-c2nnc(C3CCNCC3)o2)n2nccc2c1
5739,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,CC1(C)CC(Oc2ccc(-c3ccc(-n4cccn4)cc3O)nn2)CC(C)(C)N1,"5-(1H-pyrazol-1-yl)-2-(6-(2,2,6,6-tetramethylpiperidin-4-yloxy)pyridazin-3-yl)phenol",0.23,uM,=,-0.6382721639824072,0,c1cnn(-c2ccc(-c3ccc(OC4CCNCC4)nn3)cc2)c1
5740,793464,10.1016/j.bmcl.2011.09.114,,,,Inhibition of human ERG by whole cell patch clamp assay,COc1ccc2nccc(NC(=O)[C@]3(O)CC[C@@H](NCc4cnc5c(c4)OCCO5)CC3)c2n1,"4-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)methylamino)-1-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)cyclohexanecarboxamide",52.0,uM,=,1.7160033436347992,1,O=C(Nc1ccnc2cccnc12)C1CCC(NCc2cnc3c(c2)OCCO3)CC1
5741,1473874,10.1021/jm5018863,,,,Inhibition of human ERG expressed in CHO cells by automated Qpatch clamp assay,NC(=O)c1nnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc2[nH]ccc12,"5-(1H-indol-4-ylamino)-3-((1R,2S)-2-aminocyclohexylamino)-1,2,4-triazine-6-carboxamide",3.7,uM,=,0.568201724066995,1,c1cc(Nc2cnnc(NC3CCCCC3)n2)c2cc[nH]c2c1
5742,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn([C@H]3C[C@@H](C(C)(C)C)CCN(CC45CC6CC(CC(C6)C4)C5)C3=O)nn2)ccc1-n1cnc(C)c1,"(3S,5S)-1-Adamantan-1-ylmethyl-5-tert-butyl-3-{4-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[1,2,3]triazol-1-yl}-azepan-2-one",0.87,uM,=,-0.0604807473813814,0,O=C1[C@@H](n2cc(-c3ccc(-n4ccnc4)cc3)nn2)CCCCN1CC12CC3CC(CC(C3)C1)C2
5743,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2cccc(C(N)=O)c2)C3)s1,8-azabicyclo[3.2.1]octan-3-yloxy-benzamide,0.26,uM,=,-0.585026652029182,0,c1ccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccs2)cc1
5744,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,COc1ccc(-n2cc3nc(-c4cccnc4C)n(C[C@H]4CCCN(C[C@H]5CCCO5)C4)c(=O)c3n2)cc1,"2-(4-Methoxyphenyl)-5-(2-methylpyridin-3-yl)-6-(((S)-1-(((R)-tetrahydrofuran-2-yl)methyl)piperidin-3-yl)methyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one",4.1,uM,=,0.6127838567197355,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2cccnc2)n1C[C@H]1CCCN(C[C@H]2CCCO2)C1
5745,408752,10.1021/jm060683e,,,,Displacement of [3H]dofetilide from hERG,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2cc(Cl)c(Cl)cc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-6,7-dichloro-4-oxo-4H-chromene-2-carboxamide",0.0014,uM,=,-2.853871964321762,0,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
5746,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CC(=O)N(c2cnc(S(C)(=O)=O)cn2)C3)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(5-(methylsulfonyl)pyrazin-2-yl)-2,8-diazaspiro[4.5]decan-3-one",16.1,uM,=,1.2068258760318498,1,O=C1OCc2cc(CCN3CCC4(CC3)CC(=O)N(c3cnccn3)C4)ccc21
5747,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2c(c1)N(CCN1CCC(NCc3ccc4c(n3)NC(=O)CO4)CC1)C(=O)CC2,"6-[({1-[2-(7-Methoxy-2-oxo-3,4-dihydroquinolin-1(2H)-yl)-ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]-oxazin-3(4H)-one",29.0,uM,=,1.462397997898956,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)CCc5ccccc54)CC3)nc2N1
5748,625165,10.1016/j.bmcl.2010.02.055,,,,Inhibition of human ERG by patch clamp assay,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2ccccc21,"(R)-2-(3-(1-(3-methoxypyrazin-2-yl)ethyl)-1H-inden-2-yl)-N,N-dimethylethanamine",7.6,uM,=,0.8808135922807914,1,C1=C(Cc2cnccn2)c2ccccc2C1
5749,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)C(O)CN1CCC(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1,"3,5-dichloro-N-{[1-(2-hydroxy-3,3-dimethylbutyl)piperidin-4-yl]methyl}benzamide",4.81,uM,=,0.6821450763738317,1,O=C(NCC1CCNCC1)c1ccccc1
5750,2264097,10.1021/acs.jmedchem.1c00703,,,,Inhibition of hERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp assay,CC(C)n1c(=O)c(C(=O)NCCCN2CCCCC2)c(O)c2ccsc21,"4-hydroxy-7-isopropyl-6-oxo-N-(3-(piperidin-1-yl)propyl)-6,7-dihydrothieno[2,3-b]pyridine-5-carboxamide",1.3,uM,=,0.1139433523068367,1,O=C(NCCCN1CCCCC1)c1cc2ccsc2[nH]c1=O
5751,763307,10.1021/jm200388e,,,,Inhibition of human ERG by radioligand binding assay,CCc1nn2ccccc2c1CCN(Cc1ccc(/C=C/C(=O)NO)cc1)C(C)C,"(E)-3-[4-({[2-(2-Ethyl-pyrazolo[1,5-a]pyridin-3-yl)-ethyl]-isopropylamino}-methyl)-phenyl]-N-hydroxy-acrylamide",7.52,uM,=,0.8762178405916422,1,c1ccc(CNCCc2cnn3ccccc23)cc1
5752,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3cccc(C(F)(F)F)c3)nn2)ccc1-n1cnc(C)c1,"4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1-(3-(trifluoromethyl)benzyl)-1H-1,2,3-triazole",1.25,uM,=,0.0969100130080564,1,c1ccc(Cn2cc(-c3ccc(-n4ccnc4)cc3)nn2)cc1
5753,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,N[C@H]1COC[C@@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-((3R,4S)-4-aminotetrahydrofuran-3-yloxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",2.8,uM,=,0.4471580313422192,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(O[C@@H]7CCOC7)nc56)(CC3)OC4)nc2N1
5754,1570047,10.1016/j.bmcl.2016.02.074,,,,Inhibition of human ERG by dofetilide binding assay,Nc1ncnc2c1c(-c1cccc(OC[C@@H]3CCCO3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,"7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(((S)-tetrahydrofuran-2-yl)methoxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",3.6,uM,=,0.5563025007672873,1,c1cc(OC[C@@H]2CCCO2)cc(-c2cn([C@H]3C[C@@H](CN4CCC4)C3)c3ncncc23)c1
5755,804280,10.1016/j.bmcl.2011.12.124,,,,Inhibition of human Erg by voltage ion flux electrophysiological assay,CCCS(=O)(=O)n1c2c(c3cc(C(=O)N4CCC(C)CC4)ccc31)CN(C1CCOCC1)CC2,"(4-methylpiperidin-1-yl)(5-(propylsulfonyl)-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)methanone",2.0,uM,=,0.3010299956639812,1,O=C(c1ccc2[nH]c3c(c2c1)CN(C1CCOCC1)CC3)N1CCCCC1
5756,1663976,10.1021/acs.jmedchem.7b00140,,,,Inhibition of human ERG by fluorescence polarization assay,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,"3-Dibutylamino-1-(1,3-dichloro-6-trifluoromethyl-phenanthren-9-yl)-propan-1-ol",0.156,uM,=,-0.8068754016455384,0,c1ccc2c(c1)ccc1ccccc12
5757,1281525,10.1016/j.bmcl.2013.11.062,,,,Inhibition of human ERG expressed in HEK cells after 3 hrs by ion flux electrophysiology,CNC(=O)Nc1ccc(O)cc1OC[C@@H](O)CN1CCC2(CC1)Cc1cc(F)ccc1O2,"(S)-1-(2-(3-(5-fluoro-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy)-4-hydroxyphenyl)-3-methylurea",13.1,uM,=,1.1172712956557642,1,c1ccc(OCCCN2CCC3(CC2)Cc2ccccc2O3)cc1
5758,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,O=C(C1CC(Oc2ccc(F)cc2)CN1)N1CCCN(C2CCC2)CC1,"(4-cyclobutyl-1,4-diazepan-1-yl)(4-(4-fluorophenoxy)pyrrolidin-2-yl)methanone",10.0,uM,=,1.0,1,O=C(C1CC(Oc2ccccc2)CN1)N1CCCN(C2CCC2)CC1
5759,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,O=C(CCCC(=O)c1cccc([N+](=O)[O-])c1)NC1CCCC1,N-cyclopentyl-5-(3-nitrophenyl)-5-oxopentanamide,20.38,uM,=,1.3092041796704077,1,O=C(CCCC(=O)c1ccccc1)NC1CCCC1
5760,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",COc1ccc(COc2ccn(-c3ccc(OCCN4CCCC4)cc3)c(=O)c2)cc1,4-[(4-Methoxybenzyl)oxy]-1-{4-[2-(pyrrolidin-1-yl)-ethoxy]phenyl}pyridin-2(1H)-one,0.0012,uM,=,-2.920818753952376,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCCN2CCCC2)cc1
5761,2163947,10.1021/acs.jmedchem.1c01564,,,,Inhibition of human ERG by [3H]]Astemizole binding assay,c1cnc2c(c1)CN[C@@H](CN(CCCC1CCNCC1)[C@H]1CCCc3cccnc31)C2,"(S)-N-(3-(piperidin-4-yl)propyl)-N-(((R)-5,6,7,8-tetrahydro-1,6-naphthyridin-7-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",9.3,uM,=,0.9684829485539352,1,c1cnc2c(c1)CN[C@@H](CN(CCCC1CCNCC1)[C@H]1CCCc3cccnc31)C2
5762,2092876,10.1016/j.ejmech.2020.112677,,,,Inhibition of human ERG,CN(C)CCOc1ccc(-c2cc(=O)c3c(O)cc(OCCCCCC(=O)NO)cc3o2)cc1.Cl,6-((2-(4-(2-(Dimethylamino)ethoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)-N-hydroxyhexanamide hydrochloride,1.2009999999999998,uM,=,0.079543007402906,1,O=c1cc(-c2ccccc2)oc2ccccc12
5763,2051310,10.1021/acs.jmedchem.0c01575,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,Cc1cc(COCCN2CCCC2)nn1-c1ccc(Cl)c(Cl)c1,"1-(3,4-dichlorophenyl)-5-methyl-3-(2-pyrrolidin-1-ylethoxymethyl)pyrazole",5.123,uM,=,0.7095243558763411,1,c1ccc(-n2ccc(COCCN3CCCC3)n2)cc1
5764,591458,10.1021/jm900563e,,,,Inhibition of human ERG,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1ccc(CCC(=O)O)cc1C#N,"3-{3-Cyano-4-[((2R)-3-{[1,1-dimethyl-2-(2-naphthalenyl)ethyl]-amino}-2-hydroxypropyl)oxy]phenyl}propanoic Acid",0.0327,uM,=,-1.485452247339714,0,c1ccc(OCCCNCCc2ccc3ccccc3c2)cc1
5765,421696,10.1016/j.bmcl.2006.11.065,,,,Displacement of 3H-dofetilide from hERG-expressing HEK membrane homogenates,O=C(NC1CCN(Cc2ccc3oc(=O)oc3c2)CC1)c1cc(=O)c2ccc(F)cc2o1,"7-fluoro-4-oxo-N-(1-((2-oxobenzo[d][1,3]dioxol-5-yl)methyl)piperidin-4-yl)-4H-chromene-2-carboxamide",85.2,uM,=,1.9304395947667,1,O=C(NC1CCN(Cc2ccc3oc(=O)oc3c2)CC1)c1cc(=O)c2ccccc2o1
5766,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CN1CC2(CCN(CCc3ccccc3)CC2)OC2(CC2)C1=O,"12-Methyl-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]-tridecan-13-one",3.6,uM,=,0.5563025007672873,1,O=C1NCC2(CCN(CCc3ccccc3)CC2)OC12CC2
5767,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,Cc1cc(C(C)(C)O)cc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)cnc2C(N)=O)n1,"5-(((1R,2S)-2-aminocyclohexyl)amino)-3-((4-(2-hydroxypropan-2-yl)-6-methylpyridin-2-yl)amino)picolinamide",6.5,uM,=,0.8129133566428556,1,c1ccc(Nc2cncc(NC3CCCCC3)c2)nc1
5768,1543580,10.1016/j.bmcl.2015.11.030,,,,Inhibition of human ERG by IKr binding assay,CCc1nnc([C@H]2[C@@H]3CN(C(=O)c4ccc(C[C@@H]5CC[C@H]([C@H](O)c6ccccc6)N5)cc4)C[C@@H]32)o1,"((1R,5S,6S)-6-(5-ethyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.1.0]hexan-3-yl)(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)methanone",36.0,uM,=,1.5563025007672873,1,O=C(c1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)N1C[C@@H]2[C@H](C1)[C@H]2c1nnco1
5769,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,O=C(CCNC(=O)c1cccc([N+](=O)[O-])c1)NC1CCOC1=O,3-nitro-N-(3-oxo-3-((2-oxotetrahydrofuran-3-yl)amino)propyl)benzamide,904.35,uM,=,2.9563365429210338,1,O=C(CCNC(=O)c1ccccc1)NC1CCOC1=O
5770,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,N#Cc1ccc(Cn2cncc2CN[C@H]2CCN(C(=O)c3cccc(Cl)c3)C2)cc1,4-(5-{[1-(3-Chloro-benzoyl)-pyrrolidin-3-ylamino]-methyl}-imidazol-1-ylmethyl)-benzonitrile,5.8,uM,=,0.7634279935629373,1,O=C(c1ccccc1)N1CC[C@H](NCc2cncn2Cc2ccccc2)C1
5771,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,CCOc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2ccnc(OC)c2OC)cc(OC)n1,"Rac-(1R,2S)-1-(6-bromo-2-methoxy-3-quinolyl)-1-(2,3-dimethoxy-4-pyridyl)-4-(dimethylamino)-2-(2-ethoxy-6-methoxy-4-pyridyl)butan-2-ol",3.3,uM,=,0.5185139398778875,1,c1ccc2ncc([C@H](Cc3ccncc3)c3ccncc3)cc2c1
5772,2204956,10.1016/j.ejmech.2022.114581,,,,Inhibition of human ERG potassium channel expressed in CHO cells by automated patch clamp electrophysiological assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.022,uM,=,-1.6575773191777938,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
5773,2153986,10.1021/acsmedchemlett.1c00660,,,,Inhibition on hERG expressed in HEK293 cells by Qpatch method,O=C(NCCN1CC[C@@H](F)C1)c1cccn2c(=O)c3ccc4ccccc4c3nc12,"(R)-N-(2-(3-fluoropyrrolidin-1-yl)ethyl)-7-oxo-7H-benzo[h]pyrido[2,1-b]quinazoline-12-carboxamide",8.26,uM,=,0.9169800473203822,1,O=C(NCCN1CCCC1)c1cccn2c(=O)c3ccc4ccccc4c3nc12
5774,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc([C@H]2CC3(CCNCC3)Oc3ccccc32)cc1,"(R)-N,N-diethyl-4-(spiro[chroman-2,4'-piperidine]-4-yl)benzamide",2.543,uM,=,0.4053463601757089,1,c1ccc([C@H]2CC3(CCNCC3)Oc3ccccc32)cc1
5775,616809,10.1016/j.bmcl.2010.01.091,,,,Inhibition of human ERG,Cc1cnc(Nc2cc(N3CCN(C)CC3)nc(N[C@@H](C)c3ccc(F)cn3)n2)s1,"(S)-N2-(1-(5-fluoropyridin-2-yl)ethyl)-6-(4-methylpiperazin-1-yl)-N4-(5-methylthiazol-2-yl)pyrimidine-2,4-diamine",13.0,uM,=,1.1139433523068367,1,c1ccc(CNc2nc(Nc3nccs3)cc(N3CCNCC3)n2)nc1
5776,2116382,10.1016/j.bmcl.2021.128352,,,,Inhibition of human ERG by patch clamp assay,NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1,"US9145392, 78",17.4,uM,=,1.2405492482825995,1,c1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ccncn4)CC3)n2)cc1
5777,1665706,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by flux assay,NS(=O)(=O)c1ccc(CCNc2nc(-c3cncnc3)nc3cccc(-c4ccccc4)c23)cc1,4-(2-((5-phenyl-2-(pyrimidin-5-yl)quinazolin-4-yl)amino)ethyl)benzenesulfonamide,5.6,uM,=,0.7481880270062004,1,c1ccc(CCNc2nc(-c3cncnc3)nc3cccc(-c4ccccc4)c23)cc1
5778,1854518,10.1021/acs.jmedchem.9b00224,,,,Inhibition of human ERG expressd in CHO-hERG cells after 2.5 hrs by Rb+ efflux assay,Cc1ccc2c(c1)nc(CCN1C(=O)c3cccc4cccc(c34)C1=O)n2-c1ccncc1,"2-(2-(5-methyl-1-(pyridin-4-yl)-1H-benzo[d]imidazol-2-yl)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione",4.7,uM,=,0.6720978579357175,1,O=C1c2cccc3cccc(c23)C(=O)N1CCc1nc2ccccc2n1-c1ccncc1
5779,305857,10.1016/j.bmcl.2004.11.071,,,,Inhibitory concentration against human Kv11.1 ERG potassium channel,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N,"2-Chloro-6-[(R)-3-(1,1-dimethyl-2-naphthalen-2-yl-ethylamino)-2-hydroxy-propoxy]-benzonitrile",0.194,uM,=,-0.712198270069774,0,c1ccc(OCCCNCCc2ccc3ccccc3c2)cc1
5780,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,C[C@@H]1CN(c2nnc(C(F)(F)F)o2)CCN1c1ncc(OCc2ccncc2C#N)cn1,"(R)-4-((2-(2-methyl-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)piperazin-1-yl)pyrimidin-5-yloxy)methyl)nicotinonitrile",18.0,uM,=,1.255272505103306,1,c1cc(COc2cnc(N3CCN(c4nnco4)CC3)nc2)ccn1
5781,887296,10.1021/jm3012933,,,,Inhibition of human ERG overexpressed in HEK cells,COC(=O)c1cnc(Nc2cnc(C#N)c(O[C@@H]3CCNC3)n2)cc1N(C)C,(R)-Methyl 6-((5-cyano-6-(pyrrolidin-3-yloxy)pyrazin-2-yl)amino)-4-(dimethylamino)-nicotinate,30.0,uM,=,1.4771212547196624,1,c1ccc(Nc2cncc(O[C@@H]3CCNC3)n2)nc1
5782,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N3CCC(c4nc5ccccc5o4)CC3)nn2)ccc1-n1cnc(C)c1,"1-(4-(benzo[d]oxazol-2-yl)piperidin-1-yl)-2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)ethanone",10.3,uM,=,1.0128372247051722,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)N1CCC(c2nc3ccccc3o2)CC1
5783,1502030,10.1021/acs.jmedchem.5b00217,,,,Inhibition of human ERG,Cc1ncc(OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1,LEMBOREXANT,6.1,uM,=,0.785329835010767,1,O=C(Nc1ccccn1)[C@@H]1C[C@@]1(COc1cncnc1)c1ccccc1
5784,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,C[C@@H]1CN(c2sc(C(F)(F)F)nc2-c2cnc(C(F)(F)F)nc2)CCN1C(=O)Cn1cnc(C(F)(F)F)n1,"1-((R)-2-Methyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-trifluoromethyl-[1,2,4]-triazol-1-yl)ethanone",0.0039,uM,=,-2.408935392973501,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
5785,1935999,10.1016/j.bmc.2019.02.026,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@H](c2cccnc2OC)c2cc3cc(Br)ccc3nc2OC)cc(OC)n1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-2-(2,6-dimethoxypyridin-4-yl)-4-(dimethylamino)-1-(2-methoxypyridin-3-yl)butan-2-ol",1.7,uM,=,0.2304489213782739,1,c1cncc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)c1
5786,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CC(C)Cc1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCN(C)CC2)n1,2-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-6-isobutyl-4-(trifluoromethyl)pyridine,12.0,uM,=,1.0791812460476249,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
5787,745085,10.1016/j.bmcl.2011.02.049,,,,Displacement of [35S]MK499 from human ERG expressed in HEK cells,CC(C)Oc1ccc(F)cc1-c1ccc(N2CCC(CNC(=O)c3ccc(-c4nc5cc(C#N)cc(C(C)C)c5o4)cc3)CC2)nc1,4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((1-(5-(5-fluoro-2-isopropoxyphenyl)pyridin-2-yl)piperidin-4-yl)methyl)benzamide,0.056,uM,=,-1.2518119729937995,0,O=C(NCC1CCN(c2ccc(-c3ccccc3)cn2)CC1)c1ccc(-c2nc3ccccc3o2)cc1
5788,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,O=C(NC1CCS(=O)(=O)C1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,"5-(2,3-Difluorophenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1H-indazole-3-carboxamide",14.5,uM,=,1.1613680022349748,1,O=C(NC1CCS(=O)(=O)C1)c1n[nH]c2ccc(-c3ccccc3)cc12
5789,1721264,10.1021/acsmedchemlett.7b00164,,,,Inhibition of human ERG,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N2C(=O)CC[C@H]2CN2CCN(C)CC2)cc1)c1ccccc1,"(S,Z)-3-((4-(2-((4-methylpiperazine-1-yl)methyl)-5-carbonylpyrrolidine-1-yl)(phenyl)amide)methylene)-2-carbonylindole-6-carboxylate",0.00095,uM,=,-3.0222763947111524,0,O=C1Nc2ccccc2/C1=C(/Nc1ccc(N2C(=O)CC[C@H]2CN2CCNCC2)cc1)c1ccccc1
5790,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5cc(=O)[nH][nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-3-[4'-(5-oxo-2,5-dihydro-1H-pyrazol-3-yl)-biphenyl-4-yl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione",17.0,uM,=,1.230448921378274,1,O=C1N(c2ccc(-c3ccc(-c4cc(=O)[nH][nH]4)cc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
5791,1550041,10.1039/C5MD00297D,,,,Displacement of MK499 from human ERG,COc1ccc2ncc(F)c(CC(C)(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(rac)-6-((1-(1-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-2-hydroxypropan-2-yl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",6.1,uM,=,0.785329835010767,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5792,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2cccc(OC)c2F)cc(OC(F)F)n1,"Rac-3-[(1S,2S)-2-[2-(difluoromethoxy)-6-methoxy-4-pyridyl]-4-(dimethylamino)-1-(2-fluoro-3-methoxy-phenyl)-2-hydroxy-butyl]-2-methoxy-quinoline-6-carbonitrile",5.3,uM,=,0.724275869600789,1,c1ccc([C@@H](Cc2ccncc2)c2cnc3ccccc3c2)cc1
5793,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,COC(=O)C1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1,"methyl 1-((7-fluoro-8-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)ethyl)-1,5-naphthyridin-2-yloxy)methyl)cyclopropanecarboxylate",1.6,uM,=,0.2041199826559248,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCC7CC7)nc56)(CC3)OC4)nc2N1
5794,1522961,10.1016/j.bmcl.2015.04.057,,,,Inhibition of human ERG,Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3ccc4[nH]c(C)nc4c3)c(Cl)c2)n1,"(R)-2,6-dichloro-N-(2-(3-fluorophenyl)-2-(2-methyl-1H-benzo[d]imidazol-5-yl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",19.9,uM,=,1.2988530764097066,1,O=C(NC[C@@H](c1ccccc1)c1ccc2[nH]cnc2c1)c1ccc(-n2cncn2)cc1
5795,806244,10.1016/j.bmcl.2012.01.078,,,,Inhibition of human Erg by patch clamp assay,Cc1nc2ccc(Oc3ccc(F)cc3)nc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,"6-(4-Fluorophenoxy)-3-((S)-1-isopropylpiperidin-3-ylmethyl)-2-methyl-3H-pyrido[3,2-d]pyrimidin-4-one",3.2,uM,=,0.505149978319906,1,O=c1c2nc(Oc3ccccc3)ccc2ncn1C[C@H]1CCCNC1
5796,1641577,,,,,"In Vitro Assay: The in vitro effects of the selected compounds on the hERG (human ether-á-go-go-related gene) potassium channel current (a surrogate for IKr, the rapidly activating, delayed rectifier cardiac potassium current) expressed in mammalian cells were evaluated at room temperature using the PatchXpress 7000A (Molecular Devices), an automatic parallel patch clamp system. Each compound was evaluated at varying concentrations in duplicate up to 10 μM, and the duration of exposure to each test article concentration was 5 minutes.",NCCCCN(Cc1nccc2c3ccccc3n(CC(N)=O)c12)[C@H]1CCCc2cccnc21,"US9314468, Table 7, Compound 112::US9314468, Table 9, Compound 14",1.8,uM,=,0.255272505103306,1,c1cnc2c(c1)CCC[C@@H]2NCc1nccc2c1[nH]c1ccccc12
5797,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CCN(CCOCC(C)C)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,N-((4-(4-(2-isobutoxyethyl)piperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)propionamide,9.5,uM,=,0.9777236052888478,1,c1ccc(NCC2(N3CCNCC3)CCOCC2)nc1
5798,640798,10.1016/j.bmcl.2010.05.041,,,,Inhibition of human ERG by patch clamp technique,O=C(c1ccc(Oc2cccc(F)c2)nc1)N1CCCN(C2CCC2)CC1,"(4-cyclobutyl-1,4-diazepan-1-yl)(6-(3-fluorophenoxy)pyridin-3-yl)methanone",3.5,uM,=,0.5440680443502757,1,O=C(c1ccc(Oc2ccccc2)nc1)N1CCCN(C2CCC2)CC1
5799,1824040,10.1021/acs.jmedchem.9b01382,,,,Inhibition of human ERG expressed in HEK293 cells at holding potential -80 mV by whole-cell voltage-clamp method,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@@H]1c1ccc(Cl)cc1,"(5S)-5-(4-Chlorophenyl)-N-[4-(4-fluorophenoxy)phenyl]-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxamide",3.0,uM,=,0.4771212547196624,1,O=C(Nc1ccc(Oc2ccccc2)cc1)N1CCc2ncccc2[C@@H]1c1ccccc1
5800,580515,10.1016/j.bmcl.2009.06.050,,,,Displacement of [35S]MK499 from human ERG potassium channel expressed in HEK293 cells,COc1ccc([C@@H](C)N[C@@H]2CC[C@@H](C(=O)N3CCC(C(=O)N4CCCCC4)(c4ccccc4)CC3)C(C)(C)C2)cc1,"(1-((1R,4R)-4-((R)-1-(4-methoxyphenyl)ethylamino)-2,2-dimethylcyclohexanecarbonyl)-4-phenylpiperidin-4-yl)(piperidin-1-yl)methanone",9.0,uM,=,0.9542425094393248,1,O=C(N1CCCCC1)C1(c2ccccc2)CCN(C(=O)[C@H]2CC[C@H](NCc3ccccc3)CC2)CC1
5801,1502030,10.1021/acs.jmedchem.5b00217,,,,Inhibition of human ERG,Cc1ncc(OC[C@@]2(c3ccccc3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1,"(1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-N-(5-fluoropyridin-2-yl)-2-phenylcyclopropanecarboxamide",7.7,uM,=,0.8864907251724818,1,O=C(Nc1ccccn1)[C@@H]1C[C@@]1(COc1cncnc1)c1ccccc1
5802,1528325,,,,,"Potassium Channel Assay: Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This current is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue.",Cc1cc2nc(CC3CCNCC3)n(Cc3ccc(Cl)cc3)c2cc1C,"US8975247, EBP467",1.1,uM,=,0.041392685158225,1,c1ccc(Cn2c(CC3CCNCC3)nc3ccccc32)cc1
5803,675101,10.1016/j.bmcl.2010.08.121,,,,Inhibition of human ERG by Isotopic flux assay,Cc1cc(C)cc(NC(=O)c2cncc(-c3ccc(C#N)cc3)c2)c1,"5-(4-cyanophenyl)-N-(3,5-dimethylphenyl)nicotinamide",16.0,uM,=,1.2041199826559248,1,O=C(Nc1ccccc1)c1cncc(-c2ccccc2)c1
5804,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,C[C@@H]1CN(c2sc(C(F)(F)F)nc2-c2nc3ccccc3[nH]2)CCN1C(=O)Cn1cnc2cccnc21,"US9266876, 51",1.75,uM,=,0.2430380486862944,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2nc3ccccc3[nH]2)CC1
5805,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)CS(C)(=O)=O)C2,"1-(2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-(methylsulfonyl)ethanone",6.2,uM,=,0.7923916894982539,1,c1ccc(-c2nocc2COc2ccc3c(n2)CCNC3)cc1
5806,989986,10.1016/j.bmc.2013.09.004,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp technique,CS(=O)(=O)O.O=C(O)c1ccccc1-c1ccc(CN2CCC(COC(=O)c3c4n(c5ccccc35)CCCO4)CC2)cc1,"4'-((4-(((3,4-Dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyl)oxy)methyl)piperidin-1-yl)methyl)[1,1'-biphenyl]-2-carboxylic acid methanesulfonate",47.5,uM,=,1.6766936096248666,1,O=C(OCC1CCN(Cc2ccc(-c3ccccc3)cc2)CC1)c1c2n(c3ccccc13)CCCO2
5807,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,O=C(/C=C/c1ccc(CN(CCO)CCc2c[nH]c3ccccc23)cc1)NO,(E)-N-Hydroxy-3-[4-({(2-hydroxy-ethyl)-[2-(1H-indol-3-yl)-ethyl]-amino}-methyl)-phenyl]-acrylamide,12.2,uM,=,1.0863598306747482,1,c1ccc(CNCCc2c[nH]c3ccccc23)cc1
5808,1570074,10.1016/j.bmcl.2016.02.075,,,,Displacement of [3H]-dofetilide from human ERG channel expressed in HEK293 cells,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,"7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.13,uM,=,-0.8860566476931633,0,c1ccc(COc2cccc(-c3cn([C@H]4C[C@@H](CN5CCC5)C4)c4ncncc34)c2)cc1
5809,580515,10.1016/j.bmcl.2009.06.050,,,,Displacement of [35S]MK499 from human ERG potassium channel expressed in HEK293 cells,C[C@@H](N[C@@H]1CC[C@@H](C(=O)N2CCC(C(=O)N3CCCC3)(c3ccccc3)CC2)C(C)(C)C1)c1ccc(Cl)cc1,"(1-((1R,4R)-4-((R)-1-(4-chlorophenyl)ethylamino)-2,2-dimethylcyclohexanecarbonyl)-4-phenylpiperidin-4-yl)(pyrrolidin-1-yl)methanone",1.3,uM,=,0.1139433523068367,1,O=C(N1CCCC1)C1(c2ccccc2)CCN(C(=O)[C@H]2CC[C@H](NCc3ccccc3)CC2)CC1
5810,1661931,10.1021/acs.jmedchem.7b00302,,,,Inhibition of human ERG,O=c1n(Cc2ccc(Cl)cc2)c2sc3c(c2c2ncnn12)CCN(Cc1ccccc1)C3,"9-Benzyl-6-(4-chlorobenzyl)-8,9,10,11-tetrahydropyrido-[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one",0.49,uM,=,-0.3098039199714864,0,O=c1n(Cc2ccccc2)c2sc3c(c2c2ncnn12)CCN(Cc1ccccc1)C3
5811,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,NC1=NC(c2cccc(-c3cncnc3)c2)(c2ccnc(C(F)(F)F)c2)c2ccccc21,1-(3-(Pyrimidin-5-yl)phenyl)-1-(2-(trifluoromethyl)pyridin-4-yl)-1H-isoindol-3-amine,5.5,uM,=,0.7403626894942439,1,C1=NC(c2ccncc2)(c2cccc(-c3cncnc3)c2)c2ccccc21
5812,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,N[C@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-(((2S,3S)-3-aminooxetan-2-yl)methoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",24.4,uM,=,1.3873898263387294,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OC[C@@H]7CCO7)nc56)(CC3)OC4)nc2N1
5813,647229,10.1016/j.bmc.2010.06.037,,,,Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccn2)n1C.Cl.Cl.Cl.Cl,"N-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propyl)-1,2-dimethyl-5-(pyridin-2-yl)-1H-pyrrole-3-carboxamide dihydrochloride",1.7,uM,=,0.2304489213782739,1,O=C(NCCCN1CCN(c2ccccc2)CC1)c1c[nH]c(-c2ccccn2)c1
5814,880322,10.1021/ml300260s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 1 hr by scintillation counting analysis,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3ccc(F)nc3)CC2)C1,cis-N-({1-[4-(6-Fluoro-pyridin-3-yl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,10.0,uM,=,1.0,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccnc3)CC2)C1
5815,1667858,10.1016/j.bmcl.2017.03.030,,,,Inhibition of human ERG,COc1ccc(NC(=N)NCCCOc2ccc(F)cc2)cc1,1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine,0.4168,uM,=,-0.3800722897085319,0,N=C(NCCCOc1ccccc1)Nc1ccccc1
5816,2025950,10.1021/acsmedchemlett.0c00575,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay,CCS(=O)(=O)c1ccc(CNc2nc3cnc(-c4c(C)ncnc4C4CC4)nc3n(C(C)C)c2=O)nc1,2-(4-cyclopropyl-6-methylpyrimidin-5-yl)-6-((5-(ethylsulfonyl)pyridin-2-yl)methylamino)-8-isopropylpteridin-7(8H)-one,11.0,uM,=,1.0413926851582251,1,O=c1[nH]c2nc(-c3cncnc3C3CC3)ncc2nc1NCc1ccccn1
5817,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,Cc1ccc(OCC#Cc2cc(-c3n[nH]c4c3Cc3cc(CN5CCN(C)CC5)ccc3-4)cs2)cc1C,"3-(5-(3-(3,4-dimethylphenoxy)prop-1-ynyl)thiophen-3-yl)-6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno[1,2-c]pyrazole",2.5,uM,=,0.3979400086720376,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)COc1ccccc1
5818,814585,10.1016/j.bmcl.2012.03.054,,,,Inhibition of human ERG,COc1cc(-c2cn(CC(=O)N([C@H](C)c3ccccc3)[C@H](C)c3ccccc3)nn2)ccc1-n1cnc(C)c1,"2-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-N,N-bis((R)-1-phenylethyl)acetamide",0.84,uM,=,-0.0757207139381183,0,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)N(Cc1ccccc1)Cc1ccccc1
5819,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,C[n+]1c(C#Cc2ccc(-c3ccccc3)cc2)cccc1C#Cc1ccc(-c2ccccc2)cc1,"2,6-bis(biphenyl-4-ylethynyl)-1-methylpyridinium",0.294,uM,=,-0.5316526695878427,0,C(#Cc1cccc(C#Cc2ccc(-c3ccccc3)cc2)[nH+]1)c1ccc(-c2ccccc2)cc1
5820,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2cc3ccc(C)nc3cc2OC)o1,(S)-N-((S)-1-(5-(7-methoxy-2-methylquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide,34.0,uM,=,1.5314789170422551,1,O=C(NCc1ncc(-c2ccc3ncccc3c2)o1)[C@H]1CC12CCNCC2
5821,2064218,10.1021/acs.jmedchem.6b01265,,,,Inhibition of human ERG by IonWorks patch clamp electrophysiology method,CN1CCCN(C(=O)c2ccc(-c3cnc(N)c(-c4ccc(C(F)(F)F)cc4)n3)cc2)CC1,"(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-methyl-1,4-diazepan-1-yl)methanone",5.0,uM,=,0.6989700043360189,1,O=C(c1ccc(-c2cncc(-c3ccccc3)n2)cc1)N1CCCNCC1
5822,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1cc(C(=O)N2CCOCC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"(4-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-3-methoxyphenyl)(morpholino)methanone",2.7,uM,=,0.4313637641589873,1,O=C(c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1)N1CCOCC1
5823,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,C[C@H](O)CN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"(S)-1-((1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)(4-chlorophenethyl)amino)propan-2-ol",14.0,uM,=,1.146128035678238,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
5824,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,CNC(=O)c1ccc(Nc2ncc(F)c(-c3cnc(C)n3C(C)C)n2)cc1F,2-fluoro-4-(5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)-N-methylbenzamide,19.0,uM,=,1.2787536009528289,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
5825,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCSCC1)c1cccc(C(F)(F)F)n1,N-((4-(4-benzylpiperazin-1-yl)tetrahydro-2H-thiopyran-4-yl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)propionamide,3.6,uM,=,0.5563025007672873,1,c1ccc(CN2CCN(C3(CNc4ccccn4)CCSCC3)CC2)cc1
5826,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3ccc(-c4noc(C)n4)cc3)nn2)ccc1-n1cnc(C)c1,"3-(4-((4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)-5-methyl-1,2,4-oxadiazole",8.1,uM,=,0.9084850188786496,1,c1cn(-c2ccc(-c3cn(Cc4ccc(-c5ncon5)cc4)nn3)cc2)cn1
5827,1747335,10.1021/acs.jmedchem.7b01236,,,,Inhibition of human ERG,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",0.58,uM,=,-0.2365720064370627,0,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
5828,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@H]1CN(c2ccccc2)C[C@@H]1c1ccc(-c2ccc(F)nc2)cc1,"N-((3R,4R)-4-(4-(6-fluoropyridin-3-yl)phenyl)-1-phenylpyrrolidin-3-yl)propane-2-sulfonamide",0.08,uM,=,-1.0969100130080565,0,c1ccc(N2CC[C@@H](c3ccc(-c4cccnc4)cc3)C2)cc1
5829,499833,10.1016/j.bmcl.2009.04.022,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(S[C@]4(C)CC[C@@H](c5nnco5)CC4)nc3cc2Cl)CC1,"trans-2-(4-(5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazol-2-ylthio)-4-methylcyclohexyl)-1,3,4-oxadiazole",3.4,uM,=,0.5314789170422551,1,c1nnc(C2CCC(Sc3nc4ccc(N5CCNCC5)cc4[nH]3)CC2)o1
5830,1278259,10.1021/jm4010434,,,,Inhibition of human ERG channel expressed in HEK293 cells after 15 mins by whole-cell patch clamp technique,CCCCCCCN(CC)CCCCc1ccc(Cl)cc1,N-(4-(4-Chlorophenyl)butyl)-N-ethylheptan-1-amine,0.0043,uM,=,-2.3665315444204134,0,c1ccccc1
5831,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4F)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"2-Fluoro-4'-[1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",54.0,uM,=,1.7323937598229686,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
5832,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)C(F)CN1CCC(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1,"3,5-dichloro-N-{[1-(2-fluoro-3,3-dimethylbutyl)piperidin-4-yl]methyl}benzamide",4.731,uM,=,0.6749529480485653,1,O=C(NCC1CCNCC1)c1ccccc1
5833,823014,10.1016/j.bmcl.2012.04.118,,,,Inhibition of human ERG,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(C[C@H]2CN(C3CC3)CCO2)CC1,"(S)-4-((4-cyclopropylmorpholin-2-yl)methyl)-N-(3,4-dichlorophenyl)piperazine-1-carboxamide",16.0,uM,=,1.2041199826559248,1,O=C(Nc1ccccc1)N1CCN(C[C@H]2CN(C3CC3)CCO2)CC1
5834,1813578,10.1021/acs.jmedchem.9b00510,,,,Inhibition of human ERG by patch-clamp method,Cc1c(C(=O)CC#N)oc2ccccc12,3-(3-Methylbenzofuran-2-yl)-3-oxopropanenitrile,0.03,uM,=,-1.5228787452803376,0,c1ccc2occc2c1
5835,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)CCN1CCC(CNC(=O)c2ccc(Cl)c(Cl)c2)CC1,"3,4-dichloro-N-{[1-(3,3-dimethylbutyl)piperidin-4-yl]methyl}benzamide",1.047,uM,=,0.0199466816788423,1,O=C(NCC1CCNCC1)c1ccccc1
5836,593052,10.1021/jm901042m,,,,Inhibition of human ERG by patch-clamp technique,CCOc1ccc(CCN2C(=O)N(NS(C)(=O)=O)C[C@@H]2c2ccc(OC)cc2)cc1,1-(Methylsulfonylamino)-3-[2-(4-ethoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone,12.2,uM,=,1.0863598306747482,1,O=C1NC[C@H](c2ccccc2)N1CCc1ccccc1
5837,2253956,10.1021/acs.jmedchem.1c01977,,,,Inhibition of hERG channel assessed as prolongation of QT interval by patch clamp method,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.17,uM,=,-0.7695510786217261,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
5838,539362,10.1021/jm8002153,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,CS(=O)(=O)Nc1ccc(OC[C@@H](O)CN(CCc2ccc(Cl)c(Cl)c2)Cc2ccc(F)c(F)c2F)cc1,"(S)-1-(4-Methanesulfonamidophenoxy)-3-(N-(2,3,4-trifluorobenzyl)-3,4-dichlorophenylethylamino)-2-propanol",1.7,uM,=,0.2304489213782739,1,c1ccc(CCN(CCCOc2ccccc2)Cc2ccccc2)cc1
5839,761292,10.1021/jm101312a,,,,Inhibition of human ERG expressed in CHO cells by high throughput single cell planar patch clamp method,Clc1ccc([C@]23CCC[C@H]2CNC3)cc1Cl,"cis-3a-(3,4-dichlorophenyl)octahydrocyclopenta[c]pyrrole",6.4,uM,=,0.8061799739838872,1,c1ccc([C@]23CCC[C@H]2CNC3)cc1
5840,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1cnc(N2CC(F)C2)nc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C,"3'-(4-(((4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-2-(3-fluoroazetidin-1-yl)pyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic Acid",19.0,uM,=,1.2787536009528289,1,O=C1O[C@H](c2ccccc2)CN1Cc1nc(N2CCC2)ncc1-c1cccc(-c2ccccc2)c1
5841,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,CCc1c(CNC23CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC2)OC3)nc2c(c1C)OCC(=O)N2,"7-ethyl-6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-8-methyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.7,uM,=,-0.1549019599857432,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5842,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,Fc1ccc(-n2cc(C3CCN(CCN4CCN=C4S)CC3)c3ccccc32)cc1,1-(2-{4-[1-(4-Fluoro-phenyl)-1H-indol-3-yl]-piperidin-1-yl}-ethyl)-imidazolidine-2-thione,0.0062,uM,=,-2.207608310501746,0,C1=NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccccc23)CC1
5843,958105,10.1016/j.bmcl.2013.03.125,,,,Inhibition of human ERG by patch clamp assay,CN(C)Cc1ccccc1-c1ccc(NC(=O)Nc2cccnc2Oc2ccccc2C(C)(C)C)c(F)c1,1-(2-(2-tert-butylphenoxy)pyridin-3-yl)-3-(2'-((dimethylamino)methyl)-3-fluorobiphenyl-4-yl)urea,5.4,uM,=,0.7323937598229685,1,O=C(Nc1ccc(-c2ccccc2)cc1)Nc1cccnc1Oc1ccccc1
5844,2054254,10.1016/j.ejmech.2020.112501,,,,Inhibition of human ERG by fluorescence polarization assay,CC(C)N1CCC(c2ccc(/C(=C(/CCCO)c3ccc(F)cc3F)c3ccc(O)cc3)cc2)CC1.Cl,"4-(2-(2,4-difluorophenyl)-5-hydroxy-1-(4-(1-isopropylpiperidin-4-yl)phenyl)pent-1-enyl)phenol hydrochloride",20.2,uM,=,1.305351369446624,1,C(=C(c1ccccc1)c1ccc(C2CCNCC2)cc1)c1ccccc1
5845,583695,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(c1ccccc1)c1ncc[nH]1,1-((1H-imidazol-2-yl)(phenyl)methyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,12.7,uM,=,1.1038037209559568,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(c1ccccc1)c1ncc[nH]1
5846,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,COC(=O)N(C)c1c(N)nc(-n2nc(Cc3ccccc3F)c3cc(Cl)ccc32)nc1N,"methyl N-[4,6-diamino-2-[5-chloro-3-[(2-fluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methyl-carbamate",6.3,uM,=,0.7993405494535817,1,c1ccc(Cc2nn(-c3ncccn3)c3ccccc23)cc1
5847,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(CCOCCCc2cccc(CCCOCCc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis(3-(4-methylphenethoxy)propyl)pyridinium",0.371,uM,=,-0.4306260903849541,0,c1ccc(CCOCCCc2cccc(CCCOCCc3ccccc3)[nH+]2)cc1
5848,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,CCOC(=O)c1nn(-c2ccccc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1,"Ethyl 5-((3-cyano-4,6-diphenylpyridin-2-yl)imino)-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate",10.4,uM,=,1.0170333392987805,1,c1ccc(-c2cc(/N=c3\scnn3-c3ccccc3)nc(-c3ccccc3)c2)cc1
5849,1890282,10.1021/acs.jmedchem.8b01972,,,,Inhibition of Tracer Red binding to human ERG expressed in membranes by fluorescence polarization assay,CN(C)c1ccc(CNC(=O)[C@H]2CNC[C@@H]2c2ccc(C(F)(F)F)nc2)cc1,(+/-)-N-{[4-(dimethylamino)phenyl]methyl}-4-[6-(trifluoromethyl)pyridin-3-yl]pyrrolidine-3-carboxamide,21.7,uM,=,1.3364597338485296,1,O=C(NCc1ccccc1)[C@H]1CNC[C@@H]1c1cccnc1
5850,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,O=C(NCCN1CCCC1)c1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)c(Cl)c1,N-(1-(2-chloro-4-((2-(pyrrolidin-1-yl)ethyl)carbamoyl)benzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,11.0,uM,=,1.0413926851582251,1,O=C(NCCN1CCCC1)c1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccccc4o3)CC2)cc1
5851,1469544,10.1021/jm501642c,,,,Inhibition of human ERG channel,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1,BASIMGLURANT,7.1,uM,=,0.8512583487190752,1,C(#Cc1cn(-c2ccccc2)cn1)c1ccncc1
5852,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N(CCc3ccc(Cl)cc3)CC3CCCCO3)CC2)n1,"1-(3-Amino-1H-1,2,4-triazol-5-yl)-N-(4-chlorophenethyl)-N-((tetrahydro-2H-pyran-2-yl)methyl)piperidin-4-amine",11.0,uM,=,1.0413926851582251,1,c1ccc(CCN(CC2CCCCO2)C2CCN(c3ncn[nH]3)CC2)cc1
5853,764468,10.1016/j.bmc.2011.07.042,,,,Inhibition of human ERG,Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O,"2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile",30.0,uM,=,1.4771212547196624,1,O=c1[nH]c(=O)c2c(cc(N3CCCCC3)n2Cc2ccccc2)[nH]1
5854,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccncc2)c1,endo-3-(8-(pyridin-4-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.0015,uM,=,-2.8239087409443187,0,c1ccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccncc2)cc1
5855,487380,10.1021/jm800199h,,,,Displacement of MK-499 from human ERG channel in HEK293 cells,O=C(Nc1ccc(S(=O)(=O)Nc2ccccc2C(=O)c2ccccc2)cc1)OCC1CCCO1,Tetrahydrofuran-2-ylmethyl 4-{[(2-benzoylphenyl)amino]sulfonyl}phenylcarbamate,8.2,uM,=,0.9138138523837168,1,O=C(Nc1ccc(S(=O)(=O)Nc2ccccc2C(=O)c2ccccc2)cc1)OCC1CCCO1
5856,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CC(C)c1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2C)n1,"2-(3-Isopropyl-[1,2,4]triazol-1-yl)-1-((R)-2-methyl-4-(2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl)-piperazin-1-yl)ethanone",0.007,uM,=,-2.154901959985743,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
5857,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CC(=O)NCCN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"N-(2-((1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)(4-chlorophenethyl)amino)ethyl)acetamide",3.3,uM,=,0.5185139398778875,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
5858,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CC#Cc1cncc(-c2cccc([C@@]3(c4cc(C)c(=O)n(CC)c4)N=C(N)c4c(F)cccc43)c2)c1,(R)-5-(3-amino-4-fluoro-1-(3-(5-(prop-1-ynyl)pyridin-3-yl)phenyl)-1H-isoindol-1-yl)-1-ethyl-3-methylpyridin-2(1H)-one,2.8,uM,=,0.4471580313422192,1,O=c1ccc([C@]2(c3cccc(-c4cccnc4)c3)N=Cc3ccccc32)c[nH]1
5859,1616176,10.1021/acs.jmedchem.6b00487,,,,Inhibition of human ERG,COc1c(Nc2ncc(Cl)c(Nc3ccccc3-n3cccn3)n2)ccc2c1CCCC(N1CCN(CCO)CC1)C2,"rac-2-[4-[2-[[5-Chloro-4-(2-pyrazol-1-ylanilino)pyrimidin-2-yl]amino]-1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl]piperazin-1-yl]ethanol",3.7,uM,=,0.568201724066995,1,c1ccc(-n2cccn2)c(Nc2ccnc(Nc3ccc4c(c3)CCCC(N3CCNCC3)C4)n2)c1
5860,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,COc1ccc(CCN(C)CCOc2ccc(NS(C)(=O)=O)cc2N)cc1OC,"N-[3-Amino-4-(2-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide",1.0,uM,=,0.0,0,c1ccc(CCNCCOc2ccccc2)cc1
5861,674336,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human ERG expressed in HEK cells by patch clamp technique,O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(C3CC3)nc12,(S)-2-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]oxazole-4-carboxamide,0.7,uM,=,-0.1549019599857432,0,O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(C3CC3)nc12
5862,368899,10.1021/jm051263c,,,,Affinity for human ERG channel by patch clamp assay,CN[C@@H]1CCN(c2ccc(-n3ncc4cc(-c5ccc(C(F)(F)F)cc5)sc4c3=O)cn2)C1,"(R)-6-(6-(3-(methylamino)pyrrolidin-1-yl)pyridin-3-yl)-2-(4-(trifluoromethyl)phenyl)thieno[2,3-d]pyridazin-7(6H)-one",1.8,uM,=,0.255272505103306,1,O=c1c2sc(-c3ccccc3)cc2cnn1-c1ccc(N2CCCC2)nc1
5863,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc2ccc(F)cc2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,6-Fluoro-2-methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone,2.5,uM,=,0.3979400086720376,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
5864,2021863,10.1016/j.bmcl.2020.127433,,,,Inhibition of human ERG by plate-based planar patch clamp method,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(CN5CC(O)C5)c(C)n4)n3)cc12,"5-(4-(4-((3-hydroxyazetidin-1-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-N,1-dimethyl-1H-indazole-3-carboxamide",12.0,uM,=,1.0791812460476249,1,c1cc(-n2cc(CN3CCC3)cn2)nc(Nc2ccc3[nH]ncc3c2)n1
5865,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(F)(F)F)nc56)(CC3)OC4)nc2N1,"6-((1-(2-(3-fluoro-6-(2,2,2-trifluoroethoxy)-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.1,uM,=,0.041392685158225,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5866,1472762,10.1021/jm501940y,,,,Inhibition of human ERG channel after 2 hrs by fluorescence polarization assay,O=C(NO)C1(S(=O)(=O)c2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)CCC2(CCNCC2)C1,3-[4-[4-(Trifluoromethoxy)phenoxy]phenyl]sulfonyl-8-azaspiro-[4.5]decane-3-carbohydroxamic Acid,100.0,uM,=,2.0,1,O=S(=O)(c1ccc(Oc2ccccc2)cc1)C1CCC2(CCNCC2)C1
5867,1913590,10.1021/acs.jmedchem.9b01099,,,,Inhibition of human ERG expressed in CHO cells by Q-patch clamp assay,Cc1cc(Nc2nccc(-c3sc(C4CCNCC4)nc3-c3ccc(F)cc3)n2)ccn1,4-(4-(4-Fluorophenyl)-2-(piperidin-4-yl)thiazol-5-yl)-N-(2-methylpyridin-4-yl)pyrimidin-2-amine,1.0,uM,=,0.0,0,c1ccc(-c2nc(C3CCNCC3)sc2-c2ccnc(Nc3ccncc3)n2)cc1
5868,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,Cc1noc(-c2ccc(CCN3CCC(Nc4nc5ccccc5n4Cc4ccc(C(F)(F)F)nc4)CC3)cc2)n1,"N-(1-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenethyl)piperidin-4-yl)-1-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1H-benzo[d]imidazol-2-amine",0.25,uM,=,-0.6020599913279624,0,c1cncc(Cn2c(NC3CCN(CCc4ccc(-c5ncno5)cc4)CC3)nc3ccccc32)c1
5869,2298656,10.1016/j.bmcl.2023.129280,,,,Inhibition of hERG,Cc1ccc(NC(=O)Nc2cc(-c3ccccc3-c3nn[nH]n3)ccc2OC(C(C)C)C(C)C)cc1,"1-(4-((2,4-dimethylpentan-3-yl)oxy)-2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-3-yl)-3-(p-tolyl)urea",18.0,uM,=,1.255272505103306,1,O=C(Nc1ccccc1)Nc1cccc(-c2ccccc2-c2nn[nH]n2)c1
5870,464747,10.1016/j.bmcl.2008.01.126,,,,Inhibition of human ERG by FLIPR assay,COc1cccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)c1,"(2S,3S)-3-(3-(2-(2-(3-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",2.1,uM,=,0.3222192947339193,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
5871,1648277,10.1016/j.bmcl.2017.01.091,,,,Inhibition of human ERG,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncc(Cl)cn3)CC2)cc1F)N1CC(O)C1,"(cis)-2-(4-(2-((1S,2R)-2-(1-(5-chloropyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)-2-fluorophenyl)-1-(3-hydroxyazetidin-1-yl)ethanone",5.3,uM,=,0.724275869600789,1,O=C(Cc1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)cc1)N1CCC1
5872,939638,10.1016/j.bmcl.2012.11.023,,,,Inhibition of human ERG,Nc1nc2cc3c(cc2s1)CCN(Cc1cccc(F)c1)CC3,"7-(3-Fluoro-benzyl)-6,7,8,9-tetrahydro-5H-1-thia-3,7-diaza-cyclohepta[f]inden-2-ylamine",6.8,uM,=,0.8325089127062363,1,c1ccc(CN2CCc3cc4ncsc4cc3CC2)cc1
5873,2126505,10.1021/acs.jmedchem.1c00076,,,,Inhibition of human ERG,COc1ccc(-c2ccc(CO[C@H]3C[C@@H](N=C=S)C3)nc2)cc1F,"5-(3-Fluoro-4-methoxyphenyl)-2-(((1s,3s)-3-isothiocyanatocyclobutoxy)methyl)pyridine",19.0,uM,=,1.2787536009528289,1,c1ccc(-c2ccc(COC3CCC3)nc2)cc1
5874,1640440,,,,,"hERG Patch Clamp Assay: All testing was carried out in CHO cells transfected with the hERG gene purchased from Millipore (PrecisION hERG-CHO Recombinant Cell Line CYL3038). The cell line was grown in DMEM/F-12, GlutaMAX with 10% fetal bovine serum, 1% Penicillin-Streptomycin, 1% Geneticin and 1% of 1M HEPES buffer solution, and maintained at approximately 37 °C. in a humidified atmosphere containing 5% carbon dioxide. The cells were passaged every 3-5 days based on confluency. On the day of the experiment, 50%-80% confluent cells were harvested from a 175 cm2 culture flask using Detachin. After 10 minutes of exposure to Detachin at 37 °C., the cells were centrifuged for 1 minute at 1000 RPM. The supernatant was removed and the cell pellet was reconstituted in 5-8 mL of serum free media with 2.5% of 1M HEPES, placed on the Qstirrer, and allowed to recover. After a 30 minute recovery period, experiments were initiated.",NC1=N[C@@]2(c3cc(NC(=O)c4ccc(OC(F)F)cn4)ccc3F)COCC[C@H]2CS1,"US9315520, Comparator 4",0.5,uM,=,-0.3010299956639812,0,O=C(Nc1cccc([C@]23COCC[C@H]2CSC=N3)c1)c1ccccn1
5875,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,CCOC(=O)c1ccc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)nc1,"ethyl6-((1S,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)nicotinate",1.611,uM,=,0.207095540419218,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ccccn4)N3)n2)cc1
5876,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Cc1nc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"3-((1R,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,2,4-oxadiazole",1.701,uM,=,0.230704313612569,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)cc1
5877,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C,"5-(but-2-ynyl)-6-(1,4-diazepan-1-yl)-3-(isoquinolin-1-ylmethyl)-1-methyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",3.4,uM,=,0.5314789170422551,1,O=c1[nH]c2cc(N3CCCNCC3)[nH]c2c(=O)n1Cc1nccc2ccccc12
5878,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H](C3CNC3)O2)cc1,"(5S)-5-(azetidin-3-yl)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-4,5-dihydrooxazole",2.2,uM,=,0.3424226808222063,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@H](C3CNC3)O2)cc1
5879,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,O=C(CNc1ncnc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3ccccc3O)CC2)C1,Cis-N-(1-(4-(2-hydroxyphenyl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,6.6,uM,=,0.8195439355418687,1,O=C(CNc1ncnc2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccccc3)CC2)C1
5880,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1cccc(C(F)(F)F)n1,N-((1-(4-benzylpiperazin-1-yl)cyclopropyl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)propionamide,3.5,uM,=,0.5440680443502757,1,c1ccc(CN2CCN(C3(CNc4ccccn4)CC3)CC2)cc1
5881,1545989,10.1021/acs.jmedchem.5b01227,,,,Inhibition of human ERG channel by automated Q-patch assay,C[C@H]1Cc2c(ncnc2Oc2ccc3c(ccn3C(=O)Nc3cc(C(C)(C)C)on3)c2)CN1,"5-((S)-6-Methyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yloxy)-indole-1-carboxylic Acid (5-tert-Butyl-isoxazol-3-yl)-amide",11.1,uM,=,1.0453229787866574,1,O=C(Nc1ccon1)n1ccc2cc(Oc3ncnc4c3CCNC4)ccc21
5882,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CCC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,"2-ethyl-4-phenyl-9-(2-phenylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.4,uM,=,-0.3979400086720376,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
5883,2298259,10.1016/j.bmc.2023.117276,,,,Inhibition of hERG expressed in CHO cells by automated patch clamp method,CS(=O)(=O)NCCc1cc2cc(CN3CCOCC3)cc3c(=O)c(C(=O)NCc4ccc(Cl)cc4)cn1c23,"N-[(4-Chlorophenyl)methyl]-2-(2-[(methanesulfonyl)amino]ethyl)-8-[(morpholin-4-yl)methyl]-6-oxo-6H-pyrrolo[3,2,1-ij]quinoline-5-carboxamide",5.2,uM,=,0.7160033436347992,1,O=C(NCc1ccccc1)c1cn2ccc3cc(CN4CCOCC4)cc(c1=O)c32
5884,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C(Cc1ccccc1)NC1CCN(CCCN2C(=O)COc3ccccc32)CC1,"N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]-piperidin-4-yl}-2-phenylacetamide",20.0,uM,=,1.3010299956639813,1,O=C(Cc1ccccc1)NC1CCN(CCCN2C(=O)COc3ccccc32)CC1
5885,545772,10.1021/jm900002x,,,,Inhibition of human ERG channel,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CCC3)N1CC[C@@H](NCc3cncn3C2)C1=O,"R,R-30-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.6.2.12,5.114,18.08,12.023,27]triaconta-8,10,14(29),15,17,20(28),21,23(27)-octaen-17-yl cyanide",7.0,uM,=,0.8450980400142568,1,O=C1[C@H]2CCN1[C@@H]1CCCc3ccc(cc31)Oc1cccc(c1)Cn1cncc1CN2
5886,2100973,10.1021/acs.jmedchem.1c00375,,,,Displacement of [3H]-dofetilide from human ERG after 60 mins by scintillation counting method,Cc1c(N2CC[C@@H](C3(N)CC3)C2)c(F)cc2cc(-c3n[nH]c(=O)o3)c(=O)n(C3CC3)c12,"(R)-5-(7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-1,3,4-oxadiazol-2(3H)-one",10.0,uM,=,1.0,1,O=c1[nH]nc(-c2cc3ccc(N4CC[C@@H](C5CC5)C4)cc3n(C3CC3)c2=O)o1
5887,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C1CCc2cccc(F)c2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1,"8-Fluoro-1-{3-[4-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-3,4-dihydro-1H-quinolin-2-one",7.9,uM,=,0.8976270912904415,1,O=C1CCc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1
5888,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(C(O)CN2CCN(CCc3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"4-(1-hydroxy-2-(4-(2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-2-methoxybenzonitrile",2.2,uM,=,0.3424226808222063,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
5889,1468656,10.1016/j.ejmech.2015.01.019,,,,Inhibition of human ERG assessed as reduction in channel current expressed in HEK cells by patch clamp assay,N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1NC(=S)Nc1ccccc1,"1-(3-cyano-4,6-diphenylpyridin-2-yl)-3-phenylthiourea",48.4,uM,=,1.6848453616444126,1,S=C(Nc1ccccc1)Nc1cc(-c2ccccc2)cc(-c2ccccc2)n1
5890,454299,10.1016/j.bmcl.2007.01.020,,,,Inhibition of hERG,Cc1ccccc1CN(C1CCOCC1)[C@H]1CCNC1,(2-methyl-benzyl)-(S)-pyrrolidin-3-yl-(tetrahydro-pyran-4-yl)-amine,2.4,uM,=,0.380211241711606,1,c1ccc(CN(C2CCOCC2)[C@H]2CCNC2)cc1
5891,2238137,10.1021/acs.jmedchem.1c01012,,,,Inhibition of human ERG,CCc1cc2ccc(CN3CCN(c4ncc(C)n4C)CC3)cc2[nH]c1=O,"7-((4-(1,5-dimethyl-1H-imidazol-2-yl)piperazin-1-yl)methyl)-3-ethylquinolin-2(1H)-one",12.0,uM,=,1.0791812460476249,1,O=c1ccc2ccc(CN3CCN(c4ncc[nH]4)CC3)cc2[nH]1
5892,1890282,10.1021/acs.jmedchem.8b01972,,,,Inhibition of Tracer Red binding to human ERG expressed in membranes by fluorescence polarization assay,Cc1ccc(CNC(=O)[C@@H]2CNC[C@H]2c2ccc(C(F)(F)F)cc2)cc1,"(+/-)-(3S,4R)-N-[(4-methylphenyl)methyl]-4-[4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide",8.95,uM,=,0.951823035315912,1,O=C(NCc1ccccc1)[C@@H]1CNC[C@H]1c1ccccc1
5893,570979,10.1016/j.bmcl.2009.04.035,,,,Inhibition human ERG expressed in HEK293 cells assessed as blockade of membrane current by patch clamp method,Cn1cnc(C(=O)N(Cc2cccc(Cl)c2)[C@H]2CC[C@@H](N)CC2)c1,Cis-N-(3-Chlorobenzyl)-N-(-4-aminocyclohexyl)-1-methyl-1H-imidazole-4-carboxamide,65.6,uM,=,1.81690383937566,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)C1CCCCC1
5894,612186,10.1016/j.bmcl.2009.12.071,,,,Inhibition of human ERG by patch clamp study,Cl.Cl.Cl.Cn1cnc(C(=O)N(Cc2cccc(Cl)c2)[C@H]2CC[C@@H](N)CC2)c1,N-((cis)-4-aminocyclohexyl)-N-(3-chlorobenzyl)-1-methyl-1H-imidazole-4-carboxamide dihydrochloride,65.6,uM,=,1.81690383937566,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)C1CCCCC1
5895,1366626,10.1021/jm500535j,,,,Inhibition of human ERG,Nc1nc2ccc(NCC(F)(F)F)nc2n1CC(O)c1ccc(Cl)cc1Cl,"rac-2-(2-Amino-5-((2,2,2-trifluoroethyl)amino)-3H-imidazo[4,5-b]-pyridin-3-yl)-1-(2,4-dichlorophenyl)ethanol",3.5,uM,=,0.5440680443502757,1,c1ccc(CCn2cnc3cccnc32)cc1
5896,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCn1nc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)ccc1=O,"(R)-2-(1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one",7.6,uM,=,0.8808135922807914,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccc(=O)[nH]n3)C4=O)ccc21
5897,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(c(C)c5C)OCC(=O)N6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-7,8-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",0.5,uM,=,-0.3010299956639812,0,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5898,158542,10.1016/s0960-894x(03)00196-3,,,,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,COC(=O)Cc1ccc(-n2cc(C3CCN(CCN4CCNC4=O)CC3)c3cc(Cl)ccc32)cc1,[4-(5-Chloro-3-{1-[2-(2-oxo-imidazolidin-1-yl)-ethyl]-piperidin-4-yl}-indol-1-yl)-phenyl]-acetic acid methyl ester,0.131,uM,=,-0.8827287043442358,0,O=C1NCCN1CCN1CCC(c2cn(-c3ccccc3)c3ccccc23)CC1
5899,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,Cc1c(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)cccc1C(N)=O,"endo-3-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)-2-methylbenzamide",1.1,uM,=,0.041392685158225,1,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccc2)C3)cc1
5900,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,Cc1ncn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2CCO)n1,"1-((R)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-methyl-[1,2,4]triazol-1-yl)-ethanone",0.026,uM,=,-1.585026652029182,0,O=C(Cn1cncn1)N1CCN(c2scnc2-c2cncnc2)CC1
5901,1789191,10.1021/acs.jmedchem.8b01291,,,,Displacement of [3H]-dofetilide from human ERG expressed in CHO cell membranes after 90 mins by micro-beta counting,Oc1cc(-c2cn[nH]c2)ccc1-c1ccc(N2CCC3(CCCNC3)C2)nn1,"2-(6-(2,7-diazaspiro[4.5]decan-2-yl)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol",0.27,uM,=,-0.5686362358410126,0,c1cc(-c2ccc(N3CCC4(CCCNC4)C3)nn2)ccc1-c1cn[nH]c1
5902,814499,10.1016/j.bmcl.2012.03.050,,,,Inhibition of human ERG,Cc1nc(N2CCC(N3CCCC3)CC2)nc2ccc(NC(=O)COc3ccc(Cl)cc3)cc12,2-(4-chlorophenoxy)-N-(4-methyl-2-(4-(pyrrolidin-1-yl)piperidin-1-yl)quinazolin-6-yl)acetamide,0.45,uM,=,-0.3467874862246563,0,O=C(COc1ccccc1)Nc1ccc2nc(N3CCC(N4CCCC4)CC3)ncc2c1
5903,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCC(=O)N(CC1(N2CCN(CCOCC(F)(F)F)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,"N-((4-(4-(2-(2,2,2-trifluoroethoxy)ethyl)piperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)propionamide",8.7,uM,=,0.9395192526186184,1,c1ccc(NCC2(N3CCNCC3)CCOCC2)nc1
5904,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CC[C@@H](F)C1,"US9452986, 52",25.5,uM,=,1.4065401804339552,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCCC1
5905,1935939,10.1016/j.bmc.2019.02.025,,,,Inhibition of human ERG by manual patch clamp electrophysiology assay,COc1cccc(C(O)(CCN(C)C)C(c2cc3cc(Br)ccc3nc2OC)c2cccc3c2OCO3)n1,"rac-1-(benzo[d][1,3]dioxol-4-yl)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(6-methoxypyridin-2-yl)butan-2-ol",0.24,uM,=,-0.619788758288394,0,c1ccc(CC(c2cnc3ccccc3c2)c2cccc3c2OCO3)nc1
5906,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,COc1cc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"4-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-2-methoxybenzonitrile",5.1,uM,=,0.7075701760979364,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
5907,823549,10.1021/jm201542d,,,,Binding affinity to human Erg,COc1cc(N2C(=O)N(c3ccc(-c4ccc5nc[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"3-[4-(3H-Benzoimidazol-5-yl)-phenyl]-1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",15.0,uM,=,1.1760912590556811,1,O=C1N(c2ccc(-c3ccc4nc[nH]c4c3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
5908,1840679,10.1016/j.ejmech.2019.02.022,,,,Inhibition of human ERG incubated for 1 hr by Fluorescence polarization binding assay,CN1CCOc2c1cnn1c(-c3ccc4ccc(Cl)c(NCC5(F)CCNCC5)c4n3)nnc21,"[7-Chloro-2-(6-methyl-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalen-3-yl)-quinolin-8-yl]-(4-fluoropiperidin-4-ylmethyl)-amine",2.1,uM,=,0.3222192947339193,1,c1cc(NCC2CCNCC2)c2nc(-c3nnc4c5c(cnn34)NCCO5)ccc2c1
5909,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cnccc43)C[C@@H]21,"N-(1-((1R,3s,5S,6r)-3-(1H-imidazo[4,5-c]pyridin-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)-4-chlorobenzamide",0.059,uM,=,-1.2291479883578558,0,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4cnccc43)C[C@@H]12)c1ccccc1
5910,1655139,10.1016/j.bmcl.2016.12.054,,,,Displacement of [3H]-MK499 from human ERG IKr channel expressed in HEK293 cell membranes,N#Cc1cccc(-c2cccc(Cl)c2CC(c2cccnc2)c2cccnc2)c1,"3'-chloro-2'-(2,2-di(pyridin-3-yl)ethyl)biphenyl-3-carbonitrile",2.56,uM,=,0.4082399653118496,1,c1ccc(-c2ccccc2CC(c2cccnc2)c2cccnc2)cc1
5911,632181,10.1016/j.bmcl.2010.03.106,,,,Inhibition of human ERG expressed by patch clam electrophysiology assay,CCc1nn(CCOCC(F)(F)F)c2c(Nc3ccncn3)nc(N3CCNCC3)nc12,"3-ethyl-5-(piperazin-1-yl)-N-(pyrimidin-4-yl)-1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine",5.1,uM,=,0.7075701760979364,1,c1cc(Nc2nc(N3CCNCC3)nc3cn[nH]c23)ncn1
5912,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2cccs2)=NC1c1ccc(F)cc1Br,"Ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholinomethyl)-2-(thiophen-2-yl)-1,4-dihydropyrimidine-5-carboxylate",0.9,uM,=,-0.0457574905606751,0,C1=C(CN2CCOCC2)NC(c2cccs2)=NC1c1ccccc1
5913,745049,10.1016/j.bmcl.2010.12.054,,,,Inhibition of human ERG,O=C1Nc2ncccc2C2(CCN(C(=O)N[C@@H]3CC[C@@H](c4cccc(F)c4F)Cn4c(CC(F)(F)F)cnc43)CC2)O1,"N-((6S,9R)-6-(2,3-difluorophenyl)-3-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-9-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-carboxamide",3.3,uM,=,0.5185139398778875,1,O=C1Nc2ncccc2C2(CCN(C(=O)N[C@@H]3CC[C@@H](c4ccccc4)Cn4ccnc43)CC2)O1
5914,1746101,10.1016/j.bmcl.2017.09.062,,,,Inhibition of human ERG,CC(C)OCc1ccccc1CNC(=O)c1c2c(c(Cl)n1C)CC(C)(C)CC2,"3-chloro-N-(2-(isopropoxymethyl)benzyl)-2,5,5-trimethyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxamide",16.5,uM,=,1.2174839442139065,1,O=C(NCc1ccccc1)c1[nH]cc2c1CCCC2
5915,580799,10.1016/j.bmcl.2009.06.095,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells overexpressing Ikr channel protein,Cc1ccc(-n2c(-c3ncccc3Cl)nc(CNC3CCCC3)c2C(C)C)cn1,N-((2-(3-chloropyridin-2-yl)-5-isopropyl-1-(6-methylpyridin-3-yl)-1H-imidazol-4-yl)methyl)cyclopentanamine,9.9,uM,=,0.99563519459755,1,c1ccc(-c2nc(CNC3CCCC3)cn2-c2cccnc2)nc1
5916,2199955,10.1021/acs.jmedchem.2c01336,,,,Inhibition of hERG cardiac ion channel by patch clamp assay,C[C@H]1C[C@@H](N2C(=N)N[C@](C)(c3cccc(Nc4ccc(C5CC5)nc4)c3Cl)CC2=O)CCO1,"(6S)-6-[2-Chloro-3-[(6-cyclopropyl-3-pyridyl)amino]phenyl]-2-imino-6-methyl-3-[(2S,4S)-2-methyltetrahydropyran-4-yl]hexahydropyrimidin-4-one",14.0,uM,=,1.146128035678238,1,N=C1NC(c2cccc(Nc3ccc(C4CC4)nc3)c2)CC(=O)N1C1CCOCC1
5917,79533,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,2-(4-{1-Hydroxy-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butyl}-phenyl)-2-methyl-propionic acid,21.57,uM,=,1.333850145102545,1,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
5918,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C(F)(F)F)ccn2)(c2ccc(F)cc2)CC1,2-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridine,29.0,uM,=,1.462397997898956,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
5919,815278,10.1016/j.ejmech.2012.02.049,,,,Displacement of [3H] dofetilide from human ERG channel expressed in HEK293 cells after 45 mins by scintillation counting method,NS(=O)(=O)c1ccc(OCCCCN2CCCCC2)cc1,4-[(4-(piperidin-1-yl)butoxy)]benzenesulfonamide,13.6,uM,=,1.1335389083702174,1,c1ccc(OCCCCN2CCCCC2)cc1
5920,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,C[C@H](NC(=O)c1ccc(Cl)cc1)c1ccc2c(c1)CCCN2C(=O)c1cccc(Cl)c1,"(S)-4-chloro-N-(1-(1-(3-chlorobenzoyl)-1,2,3,4-tetrahydroquinolin-6-yl)ethyl)benzamide",1.0,uM,=,0.0,0,O=C(NCc1ccc2c(c1)CCCN2C(=O)c1ccccc1)c1ccccc1
5921,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COCC1CCCN1S(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1,2-(methoxymethyl)-1-(4'-(2-((R)-2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-ylsulfonyl)pyrrolidine,1.918032787,uM,=,0.282856026761378,1,O=S(=O)(c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1)N1CCCC1
5922,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CS(=O)(=O)NCCN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"N-(2-((1-(3-Amino-1H-1,2,4-triazol-5-yl)piperidin-4-yl)(4-chlorophenethyl)amino)ethyl)methanesulfonamide",7.2,uM,=,0.8573324964312685,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
5923,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,Cn1cc([C@@]2(c3ccc(C(=O)O)cn3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"6-((1S,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)nicotinicacid",95.6,uM,=,1.9804578922761,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ccccn4)N3)n2)cc1
5924,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,O=C(CNc1noc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3cncs3)CC2)C1,cis-N-[1-(4-Hydroxy-4-thiazol-5-yl-cyclohexyl)-azetidin-3-yl]-2-(5-trifluoromethyl-benzo[d]isoxazol-3-ylamino)-acetamide,0.016,uM,=,-1.7958800173440752,0,O=C(CNc1noc2ccccc12)NC1CN([C@H]2CC[C@@H](c3cncs3)CC2)C1
5925,1679735,10.1016/j.bmcl.2017.03.086,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2cc(-c4ccccc4)no2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(3-phenylisoxazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",0.054,uM,=,-1.2676062401770316,0,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cc(-c5ccccc5)no3)C4=O)ccc21
5926,1446331,10.1021/ml500387y,,,,Inhibition of human ERG channel expressed in recombinant HEK293 cells by whole cell patch-clamp technique,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(-c3ccccc3)ncc2[nH]1)C(F)(F)F,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((5-phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",3.8,uM,=,0.5797835966168101,1,c1ccc(CCCCc2cc3cc(-c4ccccc4)ncc3[nH]2)cc1
5927,1627127,10.1016/j.bmcl.2016.10.064,,,,Displacement of 35S-MK499 from human ERG expressed in HEK293 cell membranes,Cc1c([C@@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)C[C@H]3CS2)ccc2c1COC2=O,"5-((3R,9aS)-8-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)octahydropyrazino[2,1-c][1,4]thiazin-3-yl)-4-methylisobenzofuran-1(3H)-one",8.9,uM,=,0.9493900066449128,1,O=C1OCc2cc([C@@H]3CN4CCN(C(=O)Cc5ccc(-n6cnnn6)nc5)C[C@H]4CS3)ccc21
5928,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cccc(N[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"endo-3-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-ylamino)benzamide",1.1,uM,=,0.041392685158225,1,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Nc2ccccc2)C3)cc1
5929,1510551,10.1016/j.bmcl.2015.06.057,,,,Inhibition of MK499 binding to human ERG,CCOC(=O)C1(C)Oc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)nc2NC1=O,"(+)-ethyl 6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2-methyl-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-2-carboxylate",2.4,uM,=,0.380211241711606,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
5930,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1,4-Acetylamino-N-(2-diethylamino-ethyl)-benzamide,100.0,uM,=,2.0,1,c1ccccc1
5931,1288300,10.1016/j.bmcl.2013.12.078,,,,Inhibition of human ERG by whole-cell patch clamp method,COC(=O)C(CCCN(C)CCCc1nc2ccccc2[nH]1)(c1ccc(Br)cc1)C(C)C,methyl 5-((3-(1H-benzo[d]imidazol-2-yl)propyl)(methyl)amino)-2-(4-bromophenyl)-2-isopropylpentanoate,0.178,uM,=,-0.7495799976911061,0,c1ccc(CCCCNCCCc2nc3ccccc3[nH]2)cc1
5932,2156555,10.1021/acs.jmedchem.1c01570,,,,Inhibition of human ERG by PatchXpress assay,CSCC[C@@H]1NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@@H](N)Cc3ccc(O)cc3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H]3CSSC[C@H](NC(=O)[C@H](C(C)C)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(N)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC3=O)C(=O)N2,"3-[(1R,4S,7S,13S,16R,21R,24S,27S,30S,33S,36S,39S,42R,45S,48S,51S,54S,57S,60R,65R,68S,71S,74S)-65-{[(1S)-5-amino-1-{[(1S)-5-amino-1-{[(1S)-5-amino-1-{[(1S)-1-{[(1S)-1-carbamoyl-2-(1H-indol-3-yl)ethyl]carbamoyl}-3-methylbutyl]carbamoyl}pentyl]carbamoyl}pentyl]carbamoyl}pentyl]carbamoyl}-21-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-27,57-bis(4-aminobutyl)-54,74-bis(3-carbamimidamidopropyl)-24-(2-carbamoylethyl)-51-(2-carboxyethyl)-45-(carboxymethyl)-39-[(1R)-1-hydroxyethyl]-48-(hydroxymethyl)-30,36,68-tris(1H-indol-3-ylmethyl)-71-(2-methylpropyl)-7,33-bis[2-(methylsulfanyl)ethyl]-3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,67,70,73,76,81-tricosaoxo-4-(propan-2-yl)-18,19,62,63,78,79-hexathia-2,5,8,11,14,23,26,29,32,35,38,41,44,47,50,53,56,59,66,69,72,75,82-tricosaazatricyclo[40.34.4.2^{16,60}]dooctacontan-13-yl]propanoic acid",0.022,uM,=,-1.6575773191777938,0,O=C(CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CSSC[C@@H]2NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]3CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)CCc4ccccc4)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc4c[nH]c5ccccc45)C(=O)NCC(=O)N[C@@H](Cc4c[nH]c5ccccc45)C(=O)NCC(=O)N3)NC2=O)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1)NCCc1c[nH]c2ccccc12
5933,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3cccc(F)c3)CC2)CN(c2ccccc2)C1=O,"9-[2-(3-fluorophenyl)ethyl]-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.6,uM,=,-0.2218487496163563,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
5934,1921440,10.1021/acs.jmedchem.8b01679,,,,Inhibition of human ERG expressed in HEK293 cells at 10 uM by Qpatch clamp assay,CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1,"1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine",0.001,uM,=,-3.0,0,c1ccc2nc(N3CCC(NC4CCOCC4)CC3)c(-c3ncno3)cc2c1
5935,1755229,10.1021/acs.jmedchem.8b00168,,,,Inhibition of human ERG,CCN(CC)CC.NC(=O)c1ccc(-c2cc(C(=O)O)cc(-n3cc(-c4ccc(C(F)(F)F)cc4)nn3)c2)cc1,"triethylamine 4'-carbamoyl-5-(4-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)biphenyl-3-carboxylate",0.166,uM,=,-0.7798919119599449,0,c1ccc(-c2cccc(-n3cc(-c4ccccc4)nn3)c2)cc1
5936,1622890,10.1021/acsmedchemlett.6b00433,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes after 90 mins by scintillation counting,Fc1ccc(-c2cnn(Cc3cc[nH]n3)c2)cc1OC(F)F,1-((1H-pyrazol-3-yl)methyl)-4-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazole,135.0,uM,=,2.130333768495006,1,c1ccc(-c2cnn(Cc3cc[nH]n3)c2)cc1
5937,850899,10.1021/jm300403a,,,,Inhibition of human Erg expressed in CHO cells after 5 mins,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,"3-Amino-6-(4-chloro-3-(N-(2,3-difluorophenyl)sulfamoyl)-phenyl)-N-methylpyrazine-2-carboxamide",17.318,uM,=,1.2384977353073587,1,O=S(=O)(Nc1ccccc1)c1cccc(-c2cnccn2)c1
5938,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,COc1cnc2ccc(=O)n(CCN3CCC(c4c[nH]c5ccc(C#N)cc45)CC3)c2c1,"3-(1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-yl)-1H-indole-5-carbonitrile",2.0,uM,=,0.3010299956639812,1,O=c1ccc2ncccc2n1CCN1CCC(c2c[nH]c3ccccc23)CC1
5939,1765499,10.1021/acs.jmedchem.8b01040,,,,Displacement of [3H]dofetilide from human ERG by high throughput assay,O=C(Nc1ccc(OC(F)(F)F)cc1)c1ccc(OCCN2CCCC2)c(-c2cncnc2)c1,"US9315489, 40",0.009,uM,=,-2.0457574905606752,0,O=C(Nc1ccccc1)c1ccc(OCCN2CCCC2)c(-c2cncnc2)c1
5940,1576971,10.1016/j.bmcl.2016.04.087,,,,Inhibition of human ERG after 10 mins,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one",1.07,uM,=,0.0293837776852096,1,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2
5941,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,COc1cccc2c(=O)n(-c3ccc(OCCCN4CCCC4)cc3)c(C)nc12,8-Methoxy-2-methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone trifluoroacetate,10.0,uM,=,1.0,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
5942,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,O=C(NCC1CCCOC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,"5-(2,3-Difluorophenyl)-N-((tetrahydro-2H-pyran-3-yl)methyl)-1H-indazole-3-carboxamide",22.3,uM,=,1.3483048630481609,1,O=C(NCC1CCCOC1)c1n[nH]c2ccc(-c3ccccc3)cc12
5943,2291086,10.1021/acs.jmedchem.3c00074,,,,Inhibition of human ERG stably expressed in CHO cells at -80 mV holding voltage by automated QPatch electrophysiological assay,CCc1ccn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2CCO)n1,2-(3-Ethyl-pyrazol-1-yl)-1-((R)-2-(2-hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-ethanone,0.0029,uM,=,-2.537602002101044,0,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
5944,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@@]3(O)CO[C@@H]4[C@@H](NCc5ccc6c(n5)NC(=O)CO6)CO[C@@H]43)c2n1,"6-(((3S,3aR,6R,6aS)-6-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-6-hydroxyhexahydrofuro[3,2-b]furan-3-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",12.0,uM,=,1.0791812460476249,1,O=C1COc2ccc(CN[C@H]3CO[C@@H]4C(CCc5ccnc6cccnc56)CO[C@H]34)nc2N1
5945,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CCCOCC5)cc4)C3)o2)cc1,"(3-(4-((1,4-oxazepan-4-yl)methyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone",25.0,uM,=,1.3979400086720375,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CCCOCC3)cc2)C1
5946,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2ccc(-c3cccnc3)cc2)[nH]1,(S)-6-methyl-N-((S)-7-oxo-1-(5-(4-(pyridin-3-yl)phenyl)-1H-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide,4.0,uM,=,0.6020599913279624,1,O=C(NCc1ncc(-c2ccc(-c3cccnc3)cc2)[nH]1)[C@H]1CC12CCNCC2
5947,1760801,10.1021/acs.jmedchem.8b00633,,,,Inhibition of human ERG by patch express assay,CNC(=O)c1cnc(N)c(O[C@H]2CN(C(=O)Cc3ccc(OC(F)(F)F)cc3)CC2(F)F)c1,"(S)-6-amino-5-(4,4-difluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)pyrrolidin-3-yloxy)-N-methylnicotinamide",88.0,uM,=,1.944482672150169,1,O=C(Cc1ccccc1)N1CC[C@@H](Oc2cccnc2)C1
5948,770623,10.1016/j.bmcl.2011.07.061,,,,Inhibition of human ERG,Cc1nc2ccccc2n1-c1ccc(C(=O)N(C)[C@@H]2CCN(C3CCCC3)C2)cc1,(R)-N-(1-cyclopentylpyrrolidin-3-yl)-N-methyl-4-(2-methyl-1H-benzo[d]imidazol-1-yl)benzamide,2.3,uM,=,0.3617278360175928,1,O=C(N[C@@H]1CCN(C2CCCC2)C1)c1ccc(-n2cnc3ccccc32)cc1
5949,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,O=C(CNc1nc(C(F)(F)F)nc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1,"Cis-2-(2,6-bis(trifluoromethyl)quinazolin-4-ylamino)-N-(1-(4-hydroxy-4-(thiazol-5-yl)cyclohexyl)azetidin-3-yl)acetamide",32.7,uM,=,1.5145477526602862,1,O=C(CNc1ncnc2ccccc12)NC1CN(C2CCC(c3cncs3)CC2)C1
5950,1552682,10.1016/j.bmcl.2015.12.058,,,,Inhibition of human ERG by FLIPR assay,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)C3CCC3)cc21,,38.1,uM,=,1.5809249756756194,1,O=C(NS(=O)(=O)C1CCC1)c1ccc2c(C3CCCCC3)c3n(c2c1)C[C@@]1(C(=O)N2C4CCC2CNC4)C[C@H]1c1ccccc1-3
5951,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CN1CCC(COCc2cc(C3CC3)cc(C3CC3)n2)(c2ccc(F)cc2)CC1,"2,4-dicyclopropyl-6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)pyridine",17.0,uM,=,1.230448921378274,1,c1ccc(C2(COCc3cc(C4CC4)cc(C4CC4)n3)CCNCC2)cc1
5952,2122463,10.1021/acs.jmedchem.1c00263,,,,Inhibition of human ERG,CCOC(=O)NC(=O)c1ccsc1NC(=O)c1nc2ccccc2s1,ethyl 2-(benzo[d]thiazole-2-carboxamido)thiophene-3-carbonylcarbamate,48.79547855942866,uM,=,1.688379581681729,1,O=C(Nc1cccs1)c1nc2ccccc2s1
5953,2113604,10.1016/j.bmc.2021.116163,,,,Inhibition of human ERG,Cn1cc(-c2nc3c(-c4ccc(CN5CCc6cc(C(C)(C)C)ccc6C5=O)c(F)c4)ccnc3[nH]2)cn1,"6-tert-butyl-2-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)benzyl)-3,4-dihydroisoquinolin-1(2H)-one",2.6,uM,=,0.414973347970818,1,O=C1c2ccccc2CCN1Cc1ccc(-c2ccnc3[nH]c(-c4cn[nH]c4)nc23)cc1
5954,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,O=C(NC(c1ccc(Cl)cc1)c1ccc(F)cn1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1,"(1R,2R,4R)-2-(4-bromophenyl)-N-((4-chlorophenyl)(5-fluoropyridin-2-yl)methyl)-4-morpholinocyclohexanecarboxamide",0.18,uM,=,-0.744727494896694,0,O=C(NC(c1ccccc1)c1ccccn1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
5955,583051,10.1021/jm900773n,,,,Inhibition of human ERG channel expressed in HEK293 cells by voltage clamp assay,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)s1,"N,N-Diethyl-5-(spiro[chromene-2,4'-piperidine]-4-yl)thiophene-2-carboxamide",1.261,uM,=,0.1007150865730815,1,C1=C(c2cccs2)c2ccccc2OC12CCNCC2
5956,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,N#Cc1ccc(Cn2c(NC3CCN(CCc4ccc(-c5nc(C(F)(F)F)no5)cc4)CC3)nc3ccccc32)cc1,"4-((2-(1-(4-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)phenethyl)piperidin-4-ylamino)-1H-benzo[d]imidazol-1-yl)methyl)benzonitrile",0.47,uM,=,-0.3279021420642826,0,c1ccc(Cn2c(NC3CCN(CCc4ccc(-c5ncno5)cc4)CC3)nc3ccccc32)cc1
5957,1755185,10.1021/acs.jmedchem.8b00457,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,CC(C)c1cc2cccc(-c3nnc(C4CCN(CC5CCOCC5)CC4)o3)n2n1,"2-Isopropyl-7-{5-[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-pyrazolo[1,5-a]-pyridine",1.9,uM,=,0.2787536009528289,1,c1cc(-c2nnc(C3CCN(CC4CCOCC4)CC3)o2)n2nccc2c1
5958,1911375,10.1021/acs.jmedchem.8b01296,,,,Inhibition of human ERG after 4 hrs by fluorescence polarization assay,Cc1ccc(/C(=C(\CCCO)c2ccccc2)c2ccc(N3CCN(C)CC3)cc2)cc1.Cl.Cl,(Z)-5-(4-(4-methylpiperazin-1-yl)phenyl)-4-phenyl-5-p-tolylpent-4-en-1-ol dihydrochloride,18.9,uM,=,1.276461804173244,1,C(=C(c1ccccc1)c1ccc(N2CCNCC2)cc1)c1ccccc1
5959,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CC(F)(F)C1,"US9452986, 508",30.0,uM,=,1.4771212547196624,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCC1
5960,2027247,10.1021/acs.jmedchem.6b00850,,,,Inhibition of human ERG by electrophysiology assay,CC(C)n1cc(C(=O)c2cncc(NC(=O)Cn3ccc(C(F)(F)F)n3)c2)c2cnccc21,"US9163021, 21",1.6,uM,=,0.2041199826559248,1,O=C(Cn1cccn1)Nc1cncc(C(=O)c2c[nH]c3ccncc23)c1
5961,1329649,10.1039/C1MD00015B,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch clamp assay,CC(=O)Nc1cccc(C2CCN(Cc3ccc(C(=O)c4nc5ccccc5n4-c4ccc(F)cc4)cc3F)CC2)c1,N-(3-(1-(2-fluoro-4-(1-(4-fluorophenyl)-1H-benzo[d]imidazole-2-carbonyl)benzyl)piperidin-4-yl)phenyl)acetamide,1.9,uM,=,0.2787536009528289,1,O=C(c1ccc(CN2CCC(c3ccccc3)CC2)cc1)c1nc2ccccc2n1-c1ccccc1
5962,1477141,10.1016/j.bmcl.2015.04.063,,,,Inhibition of human ERG expressed in CHO cells measured over 5 mins by patch clamp assay,CN1CCN(C)c2nc(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)ccc21,"(R)-4-((4-((1,4-dimethyl-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-6-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",30.6,uM,=,1.48572142648158,1,O=c1ccc2nccc3c2n1CC3CC12CCC(NCc3ccc4c(n3)NCCN4)(CC1)CO2
5963,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,C[C@H]1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,"(2R)-2-Methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",1.2,uM,=,0.0791812460476248,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
5964,1772472,10.1016/j.bmcl.2018.06.003,,,,Inhibition of human ERG expressed in CHOK1 cells by patch clamp assay,COc1ccc2nccc(CC[C@H]3CC[C@H](NCc4cc5c(cn4)OCCO5)CC3)c2c1,"trans-N-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methyl)-4-(2-(6-methoxyquinolin-4-yl)ethyl)cyclohexan-1-amine",0.94,uM,=,-0.0268721464003013,0,c1ccc2c(CC[C@H]3CC[C@H](NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
5965,878181,10.1021/jm301190s,,,,Displacement of dofetilide from human ERG,C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc(C(=O)Nc4ccc(C(C)C)cc4)c3)c3c(N)ncnc32)C1,"(R)-3-(1-(1-Acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)-N-(4-isopropylphenyl)benzamide",1.1,uM,=,0.041392685158225,1,O=C(Nc1ccccc1)c1cccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)c1
5966,1331791,10.1039/C2MD20340E,,,,Inhibition of human ERG,Cc1ccccc1-c1nc2cn(-c3ccc(Cl)cc3)nc2c(=O)n1CC1CCCN(C(C)C)C1,"rac-2-(4-Chlorophenyl)-5-(2-methylphenyl)-6-{[1-(propan-2-yl)piperidin-3-yl]methyl}-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one",3.5,uM,=,0.5440680443502757,1,O=c1c2nn(-c3ccccc3)cc2nc(-c2ccccc2)n1CC1CCCNC1
5967,797690,10.1016/j.bmcl.2011.11.088,,,,Inhibition of human Erg,CCN(C)C(=O)c1ccc([C@H](c2cccc(NC(=O)OC)c2)N2CCN(Cc3cscn3)CC2)cc1,(R)-methyl 3-((4-(ethyl(methyl)carbamoyl)phenyl)(4-(thiazol-4-ylmethyl)piperazin-1-yl)methyl)phenylcarbamate,17.0,uM,=,1.230448921378274,1,c1ccc(C(c2ccccc2)N2CCN(Cc3cscn3)CC2)cc1
5968,1932520,10.1021/acs.jmedchem.6b00519,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cnc2ccc(-c3cccnc3)cc2c1SC1CCCC1,4-(cyclopentylsulfanyl)-6-(3-pyridinyl)-3-quinolinecarboxamide,5.1,uM,=,0.7075701760979364,1,c1cncc(-c2ccc3nccc(SC4CCCC4)c3c2)c1
5969,2149057,10.1021/acs.jmedchem.1c00417,,,,Inhibition of hERG expressed in CHO cells by whole cell patch clamp assay,CCCCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1,N-((4-(4-butylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)propionamide,2.2,uM,=,0.3424226808222063,1,c1ccc(NCC2(N3CCNCC3)CCOCC2)nc1
5970,686871,10.1016/j.bmcl.2010.10.031,,,,Binding affinity to human ERG expressed in HEK cells by radioligand displacement assay,CC(C)[C@@H](Nc1nc2cc[nH]c(=O)c2c2cnccc12)C(F)(F)F,"(R)-6-(1,1,1-trifluoro-3-methylbutan-2-ylamino)pyrido[4,3-c][1,6]naphthyridin-1(2H)-one",1.4,uM,=,0.1461280356782379,1,O=c1[nH]ccc2ncc3ccncc3c12
5971,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(Cl)ccc3OC[C@H]2C1(CCCN1CCOCC1)c1ccccc1,"1-[(R)-8-chloro-3-(3-morpholin-4-yl-propyl)-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-2-yl]-ethanone",3.3,uM,=,0.5185139398778875,1,C1=NN2c3ccccc3OC[C@H]2C1(CCCN1CCOCC1)c1ccccc1
5972,2118310,10.1021/acs.jmedchem.1c00847,,,,Inhibition of human ERG expressed in HEK293 cells incubated for 5 mins by patch clamp assay,C[C@@H]1Cc2c([nH]c3ccc(F)cc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO,"3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol",2.8,uM,=,0.4471580313422192,1,c1ccc2c3c([nH]c2c1)[C@@H](c1ccc(NC2CNC2)cc1)NCC3
5973,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4ccc(F)c(F)c43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(6,7-difluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",5.4,uM,=,0.7323937598229685,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
5974,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-12,13-dihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione",46.0,uM,=,1.662757831681574,1,O=C1CCCCOC(=O)C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CCC1
5975,1629116,10.1016/j.bmc.2016.10.009,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cell membranes,C/C(=N\NC(=N)N)c1ccc2c(c1)Cc1cc(/C(C)=N/NC(=N)N)ccc1-2.Cl.Cl,"2,2'-(1,1'-(9H-fluorene-2,7-diyl)bis(ethan-1-yl-1-ylidene))bis(hydrazinecarboximidamide)dihydrochloride",1.12,uM,=,0.0492180226701816,1,c1ccc2c(c1)Cc1ccccc1-2
5976,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol",1.6,uM,=,0.2041199826559248,1,c1ccc([C@@H](Cc2cccc3ccccc23)c2cnc3ccccc3c2)cc1
5977,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,"3-Dibutylamino-1-(1,3-dichloro-6-trifluoromethyl-phenanthren-9-yl)-propan-1-ol",0.04,uM,=,-1.3979400086720375,0,c1ccc2c(c1)ccc1ccccc12
5978,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CCOCC5)c(OC)c4)C3)o2)cc1,"(3-(3-methoxy-4-(morpholinomethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone",9.8,uM,=,0.9912260756924948,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CCOCC3)cc2)C1
5979,2133671,10.1021/acs.jmedchem.1c00679,,,,Displacement of Tracer Red from human ERG measured after 4 hrs by fluorescence polarization assay,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4ccncc43)C[C@@H]21,"N-(1-((1R,3s,5S,6r)-3-(3H-imidazo[4,5-c]pyridin-3-yl)bicyclo[3.1.0]hexan-6-yl)propyl)-4-chlorobenzamide",1.2,uM,=,0.0791812460476248,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccncc43)C[C@@H]12)c1ccccc1
5980,2134017,10.1021/acs.jmedchem.1c00959,,,,Inhibition of [S35]-MK-0499 binding to human ERG expressed in HEK293 cells,CCc1ncc(-c2cc(-c3ccc(C(=O)O)cc3C)ccc2OC)c(CN2C(=O)O[C@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H]2C)n1,"3'-(4-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-2-ethylpyrimidin-5-yl)-4'-methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic acid",19.0,uM,=,1.2787536009528289,1,O=C1O[C@H](c2ccccc2)CN1Cc1ncncc1-c1cccc(-c2ccccc2)c1
5981,1869078,10.1021/acs.jmedchem.8b01656,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual patch clamp assay,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,0.086,uM,=,-1.0655015487564323,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
5982,1461416,10.1016/j.bmcl.2014.12.068,,,,Inhibition of human ERG,Fc1cccnc1-c1ccc2[nH]nc(-c3cncc(O[C@H]4CNCCC45CC5)n3)c2c1,(R)-3-(6-(6-azaspiro[2.5]octan-4-yloxy)pyrazin-2-yl)-5-(3-fluoropyridin-2-yl)-1H-indazole,3.0,uM,=,0.4771212547196624,1,c1ccc(-c2ccc3[nH]nc(-c4cncc(O[C@H]5CNCCC56CC6)n4)c3c2)nc1
5983,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1cn3ccccc3n1)c(=O)n2C,"6-(1,4-diazepan-1-yl)-3-(imidazo[1,2-a]pyridin-2-ylmethyl)-1-methyl-5-(3-methylbut-2-enyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",1.8,uM,=,0.255272505103306,1,O=c1[nH]c2cc(N3CCCNCC3)[nH]c2c(=O)n1Cc1cn2ccccc2n1
5984,1447890,10.1021/ml500028c,,,,Inhibition of human ERG by MK-499 displacement binding analysis,CCOC(=O)c1ccnc([C@@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)c1,"Ethyl 2-((1R3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)isonicotinate",1.205,uM,=,0.0809870469108872,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@](c4cn[nH]c4)(c4ccccn4)N3)n2)cc1
5985,1541589,10.1039/C4MD00578C,,,,Inhibition of human ERG,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,"8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine",0.901,uM,=,-0.045275209020937,0,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2
5986,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2cccc(F)c2)[C@@H]3C)n1,"US9422299, 15",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
5987,2088630,10.1016/j.ejmech.2020.112324,,,,Inhibition of human ERG,COc1ccc2ncc(F)c(CC[C@@]3(O)CO[C@@H]4[C@@H](NCc5ccc(Cl)c(Cl)c5)CO[C@@H]43)c2n1,"(3R,3aS,6S,6aR)-6-(3,4-dichlorobenzylamino)-3-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)hexahydrofuro[3,2-b]furan-3-ol",6.1,uM,=,0.785329835010767,1,c1ccc(CN[C@H]2CO[C@@H]3C(CCc4ccnc5cccnc45)CO[C@H]23)cc1
5988,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(Br)ccc1Oc1ccc(Cl)c(Cl)c1,"1-(5-bromo-2-(3,4-dichlorophenoxy)phenyl)-N-methylmethanamine",1.62,uM,=,0.2095150145426309,1,c1ccc(Oc2ccccc2)cc1
5989,613538,10.1021/jm901781q,,,,Inhibition of human ERG by patch-clamp method,CCCOCCn1c(=O)c(NCCNCCO)nc2cnc(-c3ccc(OC)nc3)cc21,"3-(2-(2-hydroxyethylamino)ethylamino)-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one",4.5,uM,=,0.6532125137753437,1,O=c1cnc2cnc(-c3cccnc3)cc2[nH]1
5990,434539,10.1021/jm061223o,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOc5ccc(CN6CCOCC6)cc5)c4)n[nH]c2-3)CC1,"4-(4-(3-(4-(6-((4-methylpiperazin-1-yl)methyl)-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)thiophen-2-yl)prop-2-ynyloxy)benzyl)-morpholine",2.56,uM,=,0.4082399653118496,1,C(#Cc1cc(-c2n[nH]c3c2Cc2cc(CN4CCNCC4)ccc2-3)cs1)COc1ccc(CN2CCOCC2)cc1
5991,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,COc1cc(OC)cc(-c2cncc(-c3nc4cc(C)ccc4[nH]3)c2N2CCC(N)CC2)c1,"1-(3-(3,5-dimethoxyphenyl)-5-(5-methyl-1H-benzo[d]imidazol-2-yl)pyridin-4-yl)piperidin-4-amine",8.6,uM,=,0.9344984512435676,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
5992,1437941,10.1021/jm5016022,,,,Inhibition of human ERG channel by patch-clamp assay,CC(C)n1ncc2c1C(=O)CC1(CCN(C(=O)c3cnc4cc[nH]c4c3)CC1)C2,"1-Isopropyl-1'-(1H-pyrrolo[3,2-b]pyridine-6-carbonyl)-1,4-dihydrospiro[indazole-5,4'-piperidin]-7(6H)-one",29.0,uM,=,1.462397997898956,1,O=C1CC2(CCN(C(=O)c3cnc4cc[nH]c4c3)CC2)Cc2cn[nH]c21
5993,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,CCN1CCC(N(C(=O)NCc2ccc(F)cc2)c2ccc(Cl)cn2)CC1,1-(5-chloropyridin-2-yl)-1-(1-ethylpiperidin-4-yl)-3-(4-fluorobenzyl)urea,9.19,uM,=,0.9633155113861112,1,O=C(NCc1ccccc1)N(c1ccccn1)C1CCNCC1
5994,990152,10.1016/j.bmc.2013.08.041,,,,Inhibition of human ERG channel expressed in CHO cells by whole cell patch clamp technique,COC(=O)C(Cc1c[nH]c2ccccc12)NS(=O)(=O)c1ccc(Br)cc1,Methyl 2-(4-bromophenylsulfonamido)-3-(1H-indol-3-yl)propanoate,4.66,uM,=,0.6683859166900001,1,O=S(=O)(NCCc1c[nH]c2ccccc12)c1ccccc1
5995,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,O=C(CNc1nccc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1,Cis-N-(1-(4-hydroxy-4-(thiazol-5-yl)cyclohexyl)azetidin-3-yl)-2-(7-(trifluoromethyl)isoquinolin-1-ylamino)acetamide,32.9,uM,=,1.5171958979499742,1,O=C(CNc1nccc2ccccc12)NC1CN(C2CCC(c3cncs3)CC2)C1
5996,2035523,10.1021/acsmedchemlett.0c00525,,,,Displacement of [35S]-MK499 binding to human ERG expressed in HEK293 cells incubated for 2 hrs by liquid scintillation counting method,O=C(NCc1ccc2c(c1)CCCN2C(=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,"4-chloro-N-((1-(3-chlorobenzoyl)-1,2,3,4-tetrahydroquinolin-6-yl)methyl)benzamide",11.0,uM,=,1.0413926851582251,1,O=C(NCc1ccc2c(c1)CCCN2C(=O)c1ccccc1)c1ccccc1
5997,617393,10.1016/j.bmcl.2010.01.100,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,N#Cc1nc(CCCN2CCCCC2)cc(-c2cccc(C(F)(F)F)c2)n1,4-(3-(piperidin-1-yl)propyl)-6-(3-(trifluoromethyl)phenyl)pyrimidine-2-carbonitrile,0.16,uM,=,-0.7958800173440752,0,c1ccc(-c2cc(CCCN3CCCCC3)ncn2)cc1
5998,558175,10.1016/j.bmcl.2008.10.028,,,,Displacement of [3H]dofetilide from human ERG channel,CNC(C)c1ccc(Cl)cc1Oc1ccc(C)cc1,1-(4-chloro-2-(p-tolyloxy)phenyl)-N-methylethanamine,3.69,uM,=,0.5670263661590603,1,c1ccc(Oc2ccccc2)cc1
5999,787991,10.1021/jm2005546,,,,Inhibition of human cloned ERG channel expressed in chinese hamster CHO cells after 5 mins by patch clamp assay,Cl.O=C(CCc1ccccc1)c1cc(F)ccc1OCC(O)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,rac-1-(2-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy)-5-fluorophenyl)-3-phenylpropan-1-one hydrochloride,4.84,uM,=,0.6848453616444125,1,O=C(CCc1ccccc1)c1ccccc1OCCCN1CCN(C(c2ccccc2)c2ccccc2)CC1
6000,1734340,10.1021/acsmedchemlett.8b00080,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in peak tail current after 2 to 5 mins by patch clamp based electrophysiology assay,Cc1ccc(CN2CC[C@@H](N3CCC(c4ccc(O)cc4)CC3)C2=O)cc1,"US9221796, 23b",0.4,uM,=,-0.3979400086720376,0,O=C1[C@H](N2CCC(c3ccccc3)CC2)CCN1Cc1ccccc1
6001,2079116,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 10 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),O=C(COc1ccc(C(=O)c2cc(Cl)ccc2Br)cc1)Nc1ccnc(F)c1,2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)-N-(2-fluoropyridin-4-yl)acetamide,0.0176,uM,=,-1.75448733218585,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1ccncc1
6002,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,O=C(NCCN1CCC(F)(F)CC1)c1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1,"N-(1-(4-((2-(4,4-difluoropiperidin-1-yl)ethyl)carbamoyl)benzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide",6.3,uM,=,0.7993405494535817,1,O=C(NCCN1CCCCC1)c1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccccc4o3)CC2)cc1
6003,686509,10.1016/j.bmcl.2010.09.039,,,,Inhibition of human ERG expressed in HEK cells by mini-patch clamp assay,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CC3CC2CO3)c1,1-(1-(2-(2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)ethyl)-1H-indazol-5-yl)-4-(benzyloxy)pyridin-2(1H)-one,16.0,uM,=,1.2041199826559248,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CC3CC2CO3)c1
6004,1453951,10.1021/ml5001728,,,,Inhibition of human ERG by electrophysiology assay,O=c1ccc2ncc(F)cc2n1CCN1CCN(c2nc3cc(C(F)(F)F)ccc3[nH]2)CC1,"7-fluoro-1-(2-(4-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)piperazin-1-yl)ethyl)-1,5-naphthyridin-2(1H)-one",1.0,uM,=,0.0,0,O=c1ccc2ncccc2n1CCN1CCN(c2nc3ccccc3[nH]2)CC1
6005,972908,10.1016/j.bmcl.2013.06.031,,,,Inhibition of human ERG,COc1cc2nnc(C(N)=O)c(Nc3ccc(C)cc3F)c2cc1N1CCC(N(C)C)CC1,6-(4-(dimethylamino)piperidin-1-yl)-4-(2-fluoro-4-methylphenylamino)-7-methoxycinnoline-3-carboxamide,21.0,uM,=,1.3222192947339193,1,c1ccc(Nc2cnnc3ccc(N4CCCCC4)cc23)cc1
6006,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,C[C@H]1OC2(CCN(CCc3ccccc3F)CC2)CN(c2cnccc2C(F)(F)F)C1=O,"(R)-9-(2-Fluorophenethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",6.3,uM,=,0.7993405494535817,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1cccnc1
6007,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(Cl)c(F)c2)[C@@H]3C)n1,"US9422299, 4",70.0,uM,=,1.845098040014257,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
6008,826732,10.1021/jm201194q,,,,Inhibition of human ERG expressed in HEK cells by patch clamp assay,Fc1ccc(N(CCNCCCc2ccccc2)c2ccc(F)cc2)cc1,"N1,N1-bis(4-fluorophenyl)-N2-(3-phenylpropyl)ethane-1,2-diamine",0.0024,uM,=,-2.619788758288394,0,c1ccc(CCCNCCN(c2ccccc2)c2ccccc2)cc1
6009,763011,10.1016/j.bmc.2011.04.014,,,,Inhibition of human ERG,CN(C)CCC1CCN(c2cc(C(=O)NC[C@H]3CC[C@H](CNC(=O)OCC(C)(C)C)CC3)c3ccccc3n2)CC1,"2,2-Dimethylpropyl{[trans-4-({[(2-{4-[2-(dimethylamino)ethyl]piperidin-1-yl}quinolin-4-yl)-carbonyl]amino}-methyl)cyclohexyl]methyl}carbamate",14.0,uM,=,1.146128035678238,1,O=C(NCC1CCCCC1)c1cc(N2CCCCC2)nc2ccccc12
6010,2084737,10.1021/acs.jmedchem.6b00939,,,,Inhibition of human ERG expressed stably in CHO cells by manual patch clamp technique,O=C1c2cc(-c3ccc(OC(F)(F)F)cc3)ccc2OCCN1Cc1ncccn1,ELECLAZINE,6.0,uM,=,0.7781512503836436,1,O=C1c2cc(-c3ccccc3)ccc2OCCN1Cc1ncccn1
6011,2245830,10.1021/acs.jmedchem.1c01995,,,,Inhibition of hERG by Qpatch-clamp method,CCOc1nc(C(C)C)ccc1-c1cnc2sc(N3CCC(O)(CN)CC3)nn12,"4-(Aminomethyl)-1-(5-(2-ethoxy-6-isopropylpyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-ol",12.3,uM,=,1.089905111439398,1,c1cncc(-c2cnc3sc(N4CCCCC4)nn23)c1
6012,786825,10.1021/jm2008826,,,,Inhibition of human ERG by ionworks HT assay,COc1ccc2ccc(=O)n(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2c1,"1-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]piperidin-1-yl}ethyl)-7-methoxyquinolin-2(1H)-one",34.0,uM,=,1.5314789170422551,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
6013,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,NC(=O)c1cccc(C[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,"endo-3-(((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)methyl)benzamide",1.5,uM,=,0.1760912590556812,1,c1ccc(C[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)cc1
6014,493016,10.1021/jm800851u,,,,Inhibition of human ERG by electrophysiology assay,CC(=O)Nc1cc(-c2cccc(N3CCN(C)CC3)n2)nc(-n2nc(C)cc2C)n1,"N-{2-(3,5-Dimethyl-pyrazol-1-yl)-6-[6-(4-methyl-piperazin-1-yl)-pyridin-2-yl]-pyrimidin-4-yl}-acetamide",0.54,uM,=,-0.2676062401770315,0,c1cc(-c2ccnc(-n3cccn3)n2)nc(N2CCNCC2)c1
6015,939922,10.1021/ml300262e,,,,Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay,Clc1ccc(C2CCCCNC2)cc1Cl,"rac-3-(3,4-Dichlorophenyl)azepane",6.1,uM,=,0.785329835010767,1,c1ccc(C2CCCCNC2)cc1
6016,538846,10.1021/jm800830n,,,,Inhibition of human ERG,CC(C)(C)CCN1CCC(CNC(=O)C2(c3ccc(F)cc3)CCCCC2)CC1,"N-{[1-(3,3-dimethylbutyl)piperidin-4-yl]methyl}-1-(4-fluorophenyl)cyclohexanecarboxamide",3.674,uM,=,0.5651391519697895,1,O=C(NCC1CCNCC1)C1(c2ccccc2)CCCCC1
6017,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1ccc(N2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"1-(4-(3-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)piperazin-1-yl)ethanone",4.3,uM,=,0.6334684555795865,1,c1cc(Nc2nccc(-c3cnc4ccccn34)n2)cc(N2CCNCC2)c1
6018,1977619,10.1016/j.bmc.2019.115213,,,,Inhibition of human ERG,COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2ccnc(OC)c2OC)cc(N(C)C)n1,"Rac-3-[(1R,2S)-1-(2,3-dimethoxy-4-pyridyl)-4-(dimethylamino)-2-[2-(dimethylamino)-6-methoxy-4-pyridyl]-2-hydroxy-butyl]-2-methoxy-quinoline-6-carbonitrile",3.4,uM,=,0.5314789170422551,1,c1ccc2ncc([C@H](Cc3ccncc3)c3ccncc3)cc2c1
6019,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CCOC(=O)[C@H]1CC[C@@H](N2CC(NC(=O)CNc3nn(CC)c4ccc(C(F)(F)F)cc34)C2)CC1,cis-4-{3-[2-(1-Ethyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetylamino]-azetidin-1-yl}-cyclohexanecarboxylic acid ethyl ester,7.6,uM,=,0.8808135922807914,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
6020,1327499,10.1039/C2MD20192E,,,,Displacement of [3H]dofetilide from human ERG expressed in CHO cells after 30 mins by FluxOR thallium assay,CN1CCN(c2cnc3cc(C(F)(F)F)cc(NCc4cccc5nonc45)c3c2)CC1,"N-(benzo[c][1,2,5]oxadiazol-4-ylmethyl)-3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinolin-5-amine",0.107,uM,=,-0.9706162223147904,0,c1cc(NCc2cccc3nonc23)c2cc(N3CCNCC3)cnc2c1
6021,2051795,10.1021/acs.jmedchem.6b00275,,,,Inhibition of human ERG by patch clamp electrophysiology assay,COc1ccc2c(c1)CC(Nc1cc(C)nc3nc(C(C)(F)F)nn13)CC2,"2-(1,1-Difluoroethyl)-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",1.8,uM,=,0.255272505103306,1,c1ccc2c(c1)CCC(Nc1ccnc3ncnn13)C2
6022,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CCN(CC)CC#CCOC(=O)[C@](O)(c1ccccc1)C1CCCCC1,(R)-Cyclohexyl-hydroxy-phenyl-acetic acid 4-diethylamino-but-2-ynyl ester,12.0,uM,=,1.0791812460476249,1,c1ccc(CC2CCCCC2)cc1
6023,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](CO)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-N-[1-(4-Hydroxymethyl-cyclohexyl)-azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,32.0,uM,=,1.505149978319906,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
6024,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,COc1cnc2ccc(=O)n(CCN3CCC(NC(=O)c4cnc(C)c(C#N)c4)CC3)c2c1,"5-Cyano-N-(1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-yl)-6-methylnicotinamide",74.0,uM,=,1.869231719730976,1,O=C(NC1CCN(CCn2c(=O)ccc3ncccc32)CC1)c1cccnc1
6025,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C,"6-(1,4-diazepan-1-yl)-3-(isoquinolin-1-ylmethyl)-1-methyl-5-(3-methylbut-2-enyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",1.9,uM,=,0.2787536009528289,1,O=c1[nH]c2cc(N3CCCNCC3)[nH]c2c(=O)n1Cc1nccc2ccccc12
6026,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@H]1[C@H](c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc2S1(=O)=O,"1-{3-[4-((2S,3S)-3-Methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",0.44,uM,=,-0.3565473235138126,0,O=S1(=O)C[C@H](c2ccc(OCCCN3CCCC3)cc2)Oc2ccccc21
6027,1823180,10.1021/acs.jmedchem.9b01247,,,,Inhibition of human ERG by electrophysiology,N#Cc1ccc(O[C@H]2CN(S(=O)(=O)c3ccc(Cl)cc3Cl)C[C@@]2(O)CN)cc1F,"(+/-)-trans-4-((-4-(Aminomethyl)-1-((2,4-dichlorophenyl)-sulfonyl)-4-hydroxypyrrolidin-3-yl)oxy)-2-fluorobenzonitrile",3.0,uM,=,0.4771212547196624,1,O=S(=O)(c1ccccc1)N1CC[C@@H](Oc2ccccc2)C1
6028,554780,10.1016/j.bmcl.2008.05.036,,,,Displacement of [35S]MK499 from human ERG in HEK293 cell membrane,Cc1nn(-c2ccccc2)cc1CN1CCC2(CC1)OCc1ccccc12,"1'-[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]-3H-spiro[2-benzofuran-1,4'-piperidine]",0.74,uM,=,-0.1307682802690238,0,c1ccc(-n2cc(CN3CCC4(CC3)OCc3ccccc34)cn2)cc1
6029,1694220,10.1016/j.bmc.2017.07.040,,,,Inhibition of human ERG,Cc1nc2n(c(=O)c1CCN1CCN(c3cccc4sccc34)CC1)CCCC2(F)F.Cl,"3-(2-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-9,9-difluoro-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one hydrochloric acid",5.8,uM,=,0.7634279935629373,1,O=c1c(CCN2CCN(c3cccc4sccc34)CC2)cnc2n1CCCC2
6030,304914,10.1016/j.bmcl.2004.06.070,,,,Inhibitory concentration against IKr potassium channel,CN([C@H]1c2cc(OCCCC(F)(F)F)ccc2OC(C)(C)[C@@H]1O)S(C)(=O)=O,"N-[3-Hydroxy-2,2-dimethyl-6-(4,4,4-trifluoro-butoxy)-chroman-4-yl]-N-methyl-methanesulfonamide",12.6,uM,=,1.100370545117563,1,c1ccc2c(c1)CCCO2
6031,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,O=C(CNc1ncnc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@H](c3cccnc3)CC2)C1,Cis-N-(1-(4-(pyridin-3-yl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,16.0,uM,=,1.2041199826559248,1,O=C(CNc1ncnc2ccccc12)NC1CN([C@H]2CC[C@@H](c3cccnc3)CC2)C1
6032,1985876,10.1021/acsmedchemlett.0c00155,,,,Inhibition of human ERG,C[C@H](CN[C@@H](C(=O)Nc1ccc(-c2cnn(C)c2)cn1)c1ccccc1)c1ccc(C#N)cc1,(R)-2-(((S)-2-(4-cyanophenyl)propyl)amino)-N-(5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-2-phenylacetamide,10.4,uM,=,1.0170333392987805,1,O=C(Nc1ccc(-c2cn[nH]c2)cn1)[C@H](NCCc1ccccc1)c1ccccc1
6033,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(CC1CCCO1)C2=O,"2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-6-((tetrahydrofuran-2-yl)methyl)-7,8-dihydro-1,6-naphthyridin-5(6H)-one",2.9,uM,=,0.4623979978989561,1,O=C1c2ccc(OCc3conc3-c3ccccc3)nc2CCN1CC1CCCO1
6034,1816376,10.1016/j.ejmech.2019.111800,,,,Inhibition of human ERG,CCCCOc1ccc(Cl)c(OCCCC)c1/N=N/c1c(O)ccc2ccccc12,"1-((2,6-dibutoxy-3-chlorophenyl)diazenyl)naphthalen-2-ol",0.38,uM,=,-0.4202164033831898,0,c1ccc(/N=N/c2cccc3ccccc23)cc1
6035,664324,10.1016/j.bmcl.2010.07.113,,,,Inhibition of human ERG,Cc1cccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)c1,endo-3-(8-(3-methylbenzyl)-8-azabicyclo[3.2.1]octan-3-yloxy)benzamide,0.00052,uM,=,-3.283996656365201,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2ccccc2)C3)cc1
6036,1613479,10.1021/acs.jmedchem.6b00972,,,,Inhibition of human ERG transfected in HEK293 cells assessed as reduction in tail current by patch clamp assay,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccccn1,"rac-(1R,3S/1S,3R)-5-(3-{[4-Methyl-5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]-heptane",0.2,uM,=,-0.6989700043360187,0,c1ccc([C@H]2C[C@]23CCN(CCCSc2nnc(-c4ccccn4)[nH]2)C3)cc1
6037,591458,10.1021/jm900563e,,,,Inhibition of human ERG,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1ccccc1C#N,(R)-2-(2-hydroxy-3-(2-methyl-1-(naphthalen-2-yl)propan-2-ylamino)propoxy)benzonitrile,0.0032,uM,=,-2.494850021680094,0,c1ccc(OCCCNCCc2ccc3ccccc3c2)cc1
6038,811343,10.1016/j.bmcl.2012.01.095,,,,Inhibition of human ERG by fluorescence polarization assay,CO[C@H](C[C@H](CCCCNCc1ccc(F)cc1)C(=O)NO)c1ccc(F)cc1,(S)-6-(4-fluorobenzylamino)-2-((R)-2-(4-fluorophenyl)-2-methoxyethyl)-N-hydroxyhexanamide,2.0,uM,=,0.3010299956639812,1,c1ccc(CCCCCCCNCc2ccccc2)cc1
6039,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,"(S)-1-Phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid (R)-(1-aza-bicyclo[2.2.2]oct-3-yl) ester",0.27,uM,=,-0.5686362358410126,0,O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1
6040,2153149,10.1016/j.ejmech.2021.113827,,,,Inhibition of hERG expressed in CHO-K1 cells assessed as reduction in thallium influx incubated for 30 minutes by FLIPR,O=c1ccc2c([nH]1)CCC(NCCCNc1c3c(nc4cc(Cl)ccc14)CCCC3)C2,"6-(3-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)propylamino)-5,6,7,8-tetrahydroquinolin-2(1H)-one",8.975,uM,=,0.9530344572503568,1,O=c1ccc2c([nH]1)CCC(NCCCNc1c3c(nc4ccccc14)CCCC3)C2
6041,763238,10.1016/j.ejmech.2011.05.015,,,,Inhibition of wild-type human ERG channel expressed in CHO cells by whole-cell patch clamp technique,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl,SID26748842,22.0,uM,=,1.3424226808222062,1,O=C(Nc1ccccc1)C1CCCCN1
6042,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)N3CCOCC3)cc2)cc1,4-{4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-morpholine,3.666666667,uM,=,0.564271430478044,1,O=S(=O)(c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1)N1CCOCC1
6043,989740,10.1021/jm4010829,,,,Inhibition of human ERG channel expressed in HEK293 cells by whole-cell patch clamp technique,c1ccc([C@]2(CCNCc3cccs3)CCOC3(CCCC3)C2)nc1,{2-[(9R)-9-(Pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl}-(thiophen-2-ylmethyl)amine,2.3,uM,=,0.3617278360175928,1,c1ccc([C@]2(CCNCc3cccs3)CCOC3(CCCC3)C2)nc1
6044,487847,10.1021/jm800386y,,,,Displacement of [35S]MK499 from human ERG expressed in HEL cells,CN(C(=O)N1CC(c2cc(F)ccc2F)=C[C@@]1(CO)c1ccccc1)C1CCNCC1,"(S)-4-(2,5-difluorophenyl)-2-(hydroxymethyl)-N-methyl-2-phenyl-N-(piperidin-4-yl)-2,5dihydro-1H-pyrrole-1-carboxamide",19.2,uM,=,1.2833012287035497,1,O=C(NC1CCNCC1)N1CC(c2ccccc2)=CC1c1ccccc1
6045,770593,10.1016/j.bmcl.2011.07.087,,,,Inhibition of human ERG by patch clamp assay,COc1cc(OC)cc(C(=O)NCC2(C#N)CCN(CC3=Cc4ccccc4OC3(C)C)CC2)c1,"N-((4-cyano-1-((2,2-dimethyl-2H-chromen-3-yl)methyl)piperidin-4-yl)methyl)-3,5-dimethoxybenzamide",4.73,uM,=,0.6748611407378116,1,O=C(NCC1CCN(CC2=Cc3ccccc3OC2)CC1)c1ccccc1
6046,1809217,10.1021/acsmedchemlett.9b00204,,,,Inhibition of human ERG,COC1CCN(Cc2cc(-c3ccc(C(F)(F)F)cc3)n(-c3ccc(F)cc3)n2)CC1,1-((1-(4-Fluorophenyl)-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl)-4-methoxypiperidine,3.2,uM,=,0.505149978319906,1,c1ccc(-c2cc(CN3CCCCC3)nn2-c2ccccc2)cc1
6047,2263757,10.1016/j.bmc.2020.115797,,,,Inhibition of hERG,O=C(Nc1ccc(-c2ccc(F)cn2)cc1)c1cc2sc(NCCN3CCOCC3)nc2s1,"N-(4-(5-fluoropyridin-2-yl)phenyl)-2-((2-morpholinoethyl)amino)thieno[2,3-d]thiazole-5-carboxamide",27.6,uM,=,1.4409090820652175,1,O=C(Nc1ccc(-c2ccccn2)cc1)c1cc2sc(NCCN3CCOCC3)nc2s1
6048,1576909,10.1021/acs.jmedchem.5b01416,,,,Inhibition of human ERG expressed in HEK293 cells assessed as tail current at -50 mV holding potential by whole-cell patch clamp method,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccc(F)c(Cl)c1,2-(3-Chloro-4-fluorophenyl)-6-(3-(piperidin-1-yl)propoxy)-pyridazin-3(2H)-one,0.98,uM,=,-0.0087739243075051,0,O=c1ccc(OCCCN2CCCCC2)nn1-c1ccccc1
6049,963062,10.1021/jm400408r,,,,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one",0.581,uM,=,-0.2358238676096692,0,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2
6050,1930034,10.1016/j.bmc.2017.07.058,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by patch clamp method,O=C(O)C(=O)O.c1ccc(-c2ccc(OCCCCCN3CCCCCC3)cc2)cc1,1-(5-(biphenyl-4-yloxy)pentyl)azepane oxalate,2.03,uM,=,0.3074960379132129,1,c1ccc(-c2ccc(OCCCCCN3CCCCCC3)cc2)cc1
6051,1616176,10.1021/acs.jmedchem.6b00487,,,,Inhibition of human ERG,COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CCC[C@@H](N1CCN(C)CC1)C2,"(1S,2S,3R,4R)-3-[[5-Chloro-2-[[(6S)-1-methoxy-6-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]-amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide",7.9,uM,=,0.8976270912904415,1,C1=C[C@H]2C[C@@H]1C[C@@H]2Nc1ccnc(Nc2ccc3c(c2)CCC[C@@H](N2CCNCC2)C3)n1
6052,2099367,,,,,Inhibition of human ERG expressed in HEK cells by automated electrophysiology assay,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,"N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide",14.3,uM,=,1.155336037465062,1,O=C(Nc1ccccc1)c1cnc(Nc2cc(N3CCNCC3)ncn2)s1
6053,1927239,10.1016/j.bmc.2016.06.006,,,,Inhibition of human ERG expressed in CHO-K1 cells by whole cell patch clamp method,CC(C)Cc1cc(CNC(=O)C2C3CN(Cc4ccccc4)CC32)nn1-c1ccccc1,3-(3-Benzyl-3-azabicyclo[3.1.0]hexane-6-carboxamido)methyl-5-isobutyl-1-phenyl-1H-pyrazole,1.43,uM,=,0.1553360374650617,1,O=C(NCc1ccn(-c2ccccc2)n1)C1C2CN(Cc3ccccc3)CC21
6054,1498163,10.1021/ml500514w,,,,Inhibition of MK499 binding to human ERG,CCn1cc([C@@]2(c3nnc(NC)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,"5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-N-methyl-1,3,4-oxadiazol-2-amine",1.1,uM,=,0.041392685158225,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4nnco4)N3)n2)nc1
6055,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,"5-(but-2-ynyl)-6-(1,4-diazepan-1-yl)-1-methyl-3-((4-methylquinazolin-2-yl)methyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",12.0,uM,=,1.0791812460476249,1,O=c1[nH]c2cc(N3CCCNCC3)[nH]c2c(=O)n1Cc1ncc2ccccc2n1
6056,1512965,10.1021/acsmedchemlett.5b00117,,,,Inhibition of human ERG,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1,"(R)-(8-Methyl-3-(2-methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)-phenyl)methanone",24.0,uM,=,1.380211241711606,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2cscn2)C1
6057,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,COc1cnccc1[C@H]1CC[C@@H](N2CC(NC(=O)CNc3ncnc4ccc(C(F)(F)F)cc34)C2)CC1,Cis-N-(1-(4-(3-methoxypyridin-4-yl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,20.2,uM,=,1.305351369446624,1,O=C(CNc1ncnc2ccccc12)NC1CN([C@H]2CC[C@@H](c3ccncc3)CC2)C1
6058,622012,10.1021/jm901319p,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1ncccc1-c1nnc(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3)C2)n1C,"(1S,5R)-3-(3-{[4-Methyl-5-(2-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo-[3.1.0]hexane",0.39,uM,=,-0.4089353929735008,0,c1ccc([C@]23C[C@H]2CN(CCCSc2nnc(-c4cccnc4)[nH]2)C3)cc1
6059,2022612,10.1021/acs.jmedchem.0c01127,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay,CCN1CC2(CCN(CCc3ccccc3F)CC2)O[C@H](C)C1=O,"(R)-4-ethyl-9-(2-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",4.0,uM,=,0.6020599913279624,1,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1
6060,876604,10.1021/jm301476b,,,,Inhibition of human ERG expressed in chinese hamster lung cells by IonWorks patch clamp electrophysiology assay,Nc1ncc(-c2ccc(C(=O)N3CCNCC3)cc2)cc1-c1ccc(C(F)(F)F)cc1,(4-(6-amino-5-(4-(trifluoromethyl)phenyl)pyridin-3-yl)phenyl)(piperazin-1-yl)methanone,5.5,uM,=,0.7403626894942439,1,O=C(c1ccc(-c2cncc(-c3ccccc3)c2)cc1)N1CCNCC1
6061,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc([S+](C)[O-])nc2)C3)ccc2c1COC2=O,"5-((1R)-1-hydroxy-2-(2-(6-(methylsulfinyl)pyridin-3-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",3.0,uM,=,0.4771212547196624,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cccnc3)C4)ccc21
6062,491437,10.1021/jm701590h,,,,Displacement of [35S]MK499 from human ERG K+ channel expressed in HEK293 cells,Cc1ccccc1[C@@H]1CCN(C[C@@H]2CCc3cccnc3[C@@H](O)C2)C[C@H]1CO,"(7R,9S)-7-(((3S,4R)-3-(hydroxymethyl)-4-o-tolylpiperidin-1-yl)methyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol",20.0,uM,=,1.3010299956639813,1,c1ccc(C2CCN(C[C@@H]3CCc4cccnc4CC3)CC2)cc1
6063,1678480,10.1021/acs.jmedchem.7b01914,,,,Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual-patch-clamp electrophysiology assay,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccccc1Cl,"Ethyl 4-(2-chlorophenyl)-6-(morpholinomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",4.04,uM,=,0.6063813651106049,1,C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccccc1
6064,2233923,10.1016/j.bmc.2022.116743,,,,Inhibition of hERG channel by electrophysiology,O=C(c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CCC1,"US9452986, 597",26.4,uM,=,1.421603926869831,1,O=C(c1ccc2cc(Oc3ccccn3)ccc2n1)N1CCC1
6065,1927239,10.1016/j.bmc.2016.06.006,,,,Inhibition of human ERG expressed in CHO-K1 cells by whole cell patch clamp method,CC(C)Cc1cc(CNC(=O)C2C3CN(C(=O)c4ccccc4)CC32)nn1-c1ccccc1,3-(3-Benzoyl-3-azabicyclo[3.1.0]hexane-6-carboxamido)methyl-5-isobutyl-1-phenyl-1H-pyrazole,15.0,uM,=,1.1760912590556811,1,O=C(NCc1ccn(-c2ccccc2)n1)C1C2CN(C(=O)c3ccccc3)CC21
6066,1865114,10.1021/acsmedchemlett.9b00086,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp method,O=C(CC(O)(C(F)(F)F)C(F)(F)F)N[C@@](Cc1ccccc1)(c1cc(F)cc(C(F)(F)F)c1)c1ccc(Cl)cn1,"(S)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butanamide",22.0,uM,=,1.3424226808222062,1,c1ccc(CC(c2ccccc2)c2ccccn2)cc1
6067,1460449,10.1016/j.bmcl.2014.06.083,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by patch clamp method,O=C(OCC1CCN(CC2CCC(C(=O)O)C2)CC1)c1c2n(c3ccccc13)CCCO2,"3-[4-(3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyloxymethyl)-1-piperidinyl]cyclopentanecarboxylic acid",209.0,uM,=,2.3201462861110542,1,O=C(OCC1CCN(CC2CCCC2)CC1)c1c2n(c3ccccc13)CCCO2
6068,617393,10.1016/j.bmcl.2010.01.100,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,CC(C)(C)NCCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1,4-(3-(tert-butylamino)propyl)-6-(3-(trifluoromethyl)phenyl)pyrimidine-2-carbonitrile,1.1,uM,=,0.041392685158225,1,c1ccc(-c2ccncn2)cc1
6069,2260545,10.1021/acs.jmedchem.0c02150,,,,Inhibition of human ERG,CCC(=O)CCCCC[C@H](NC(=O)[C@H]1CC12CCN(C)CC2)c1ncc(-c2ccc(-c3cnccn3)cc2)[nH]1,(S)-6-methyl-N-((S)-7-oxo-1-(5-(4-(pyrazin-2-yl)phenyl)-1H-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide,21.0,uM,=,1.3222192947339193,1,O=C(NCc1ncc(-c2ccc(-c3cnccn3)cc2)[nH]1)[C@H]1CC12CCNCC2
6070,1911678,10.1021/acs.jmedchem.8b01725,,,,Inhibition of human ERG by Q-patch assay,Cn1c(N2CCC3(CC2)COC[C@H]3N)nc2[nH]nc(-c3cccc(Cl)c3Cl)c2c1=O,"(S)-6-(4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-5-methyl1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one",0.93,uM,=,-0.0315170514460648,0,O=c1[nH]c(N2CCC3(CCOC3)CC2)nc2[nH]nc(-c3ccccc3)c12
6071,1352646,10.1021/jm4016284,,,,Inhibition of human ERG expressed in CHO cells by whole-cell patch clamp assay,C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,"4-{2-[(1R,2R)-2-(2,4-Difluoro-phenyl)-2-hydroxy-1-methyl-3-[1,2,4]triazol-1-yl-propyl]-thiazol-4-yl}-benzonitrile",10.37,uM,=,1.015778756389041,1,c1ccc(-c2csc(CC(Cn3cncn3)c3ccccc3)n2)cc1
6072,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc(C)c(-c2ccc3cc(CCN4CCC[C@H]4C)ccc3n2)s1,"(R)-2,4-dimethyl-5-(6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinolin-2-yl)thiazole",20.4,uM,=,1.3096301674258988,1,c1ncc(-c2ccc3cc(CCN4CCCC4)ccc3n2)s1
6073,2100973,10.1021/acs.jmedchem.1c00375,,,,Displacement of [3H]-dofetilide from human ERG after 60 mins by scintillation counting method,Cc1c(N2CC[C@@H](C3(N)CC3)C2)c(F)cc2cc(-c3ncon3)c(=O)n(C3CC3)c12,"(R)-7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-3-(1,2,4-oxadiazol-3-yl)quinolin-2(1H)-one",12.0,uM,=,1.0791812460476249,1,O=c1c(-c2ncon2)cc2ccc(N3CC[C@@H](C4CC4)C3)cc2n1C1CC1
6074,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CO[C@@H](C)CN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"(S)-1-(3-Amino-1H-1,2,4-triazol-5-yl)-N-(4-chlorophenethyl)-N-(2-methoxypropyl)piperidin-4-amine",17.6,uM,=,1.24551266781415,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
6075,499833,10.1016/j.bmcl.2009.04.022,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,CCN1CCN(c2cc3[nH]c(SC(C)(C)C)nc3cc2Cl)[C@H](C)C1,(R)-2-(tert-butylthio)-5-chloro-6-(4-ethyl-2-methylpiperazin-1-yl)-1H-benzo[d]imidazole,0.99,uM,=,-0.00436480540245,0,c1nc2ccc(N3CCNCC3)cc2[nH]1
6076,1842230,10.1016/j.bmcl.2018.12.049,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method,C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2ncc(NC(=O)c3ccc(OC(F)F)cn3)s2)CO1,"N-(2-((6S,8aR)-2-amino-6-methyl-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-8a-yl)thiazol-5-yl)-5-(difluoromethoxy)picolinamide",11.97,uM,=,1.0780941504064108,1,O=C(Nc1cnc([C@]23COCC[C@H]2CSC=N3)s1)c1ccccn1
6077,772990,10.1016/j.bmcl.2011.08.074,,,,Displacement of [3H]-astemizole from human ERG in HEK293 cells after 1 hrs by scintillation counting,CC(C)[C@H]1CC[C@@H](N2CC(NC(=O)CNc3n[nH]c4ccc(C(F)(F)F)cc34)C2)CC1,cis-N-[1-(4-Isopropyl-cyclohexyl)-azetidin-3-yl]-2-(5-trifluoromethyl-1H-indazol-3-ylamino)-acetAmide,6.2,uM,=,0.7923916894982539,1,O=C(CNc1n[nH]c2ccccc12)NC1CN(C2CCCCC2)C1
6078,1463730,10.1016/j.bmcl.2015.03.044,,,,Inhibition of human ERG expressed in CHO cells by Patch express assay,O=C1COc2ccc(CNC34CCC(C[C@@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"(S)-6-((1-((3-fluoro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",394.0,uM,=,2.595496221825574,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
6079,1871838,10.1016/j.bmcl.2018.12.015,,,,Inhibition of human ERG,NC(=O)c1cc(Cl)c2c(Cl)c(C#CC3CCCO3)n([C@H]3CCCNC3)c2n1,"3,4-dichloro-1-((S)-piperidin-3-yl)-2-((tetrahydrofuran-2-yl)ethynyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",0.01,uM,=,-2.0,0,C(#CC1CCCO1)c1cc2cccnc2n1[C@H]1CCCNC1
6080,1989034,10.1021/acsmedchemlett.0c00249,,,,Inhibition of human ERG by automated patch clamp assay,Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@@H]2C[C@@H]2F)c1=O,"(1S,2S)-N-[5-[2-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-yl)-3-(hydroxymethyl)-4-pyridyl]-1-methyl-2-oxo-3-pyridyl]-2-fluoro-cyclopropanecarboxamide",1.3,uM,=,0.1139433523068367,1,O=C(Nc1cc(-c2ccnc(-n3ncc4ccccc4c3=O)c2)c[nH]c1=O)C1CC1
6081,745085,10.1016/j.bmcl.2011.02.049,,,,Displacement of [35S]MK499 from human ERG expressed in HEK cells,CC(C)c1cc(C#N)cc2nc(-c3ccc(C(=O)NC[C@H]4CC[C@@H](c5cccc(C(F)(F)F)c5)CC4)cc3)oc12,cis-4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((4-(3-(trifluoromethyl)phenyl)cyclohexyl)methyl)benzamide,2.372,uM,=,0.375114684692225,1,O=C(NC[C@H]1CC[C@@H](c2ccccc2)CC1)c1ccc(-c2nc3ccccc3o2)cc1
6082,744146,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG,Cc1cc(N2CCC(C3CCN(c4ncc(Cl)cn4)CC3)CC2)nc(C#N)n1,"4-(1'-(5-chloropyrimidin-2-yl)-4,4'-bipiperidin-1-yl)-6-methylpyrimidine-2-carbonitrile",0.277,uM,=,-0.5575202309355514,0,c1cnc(N2CCC(C3CCN(c4ccncn4)CC3)CC2)nc1
6083,2049320,10.1021/acs.jmedchem.0c01179,,,,Inhibition of tracer red binding to human ERG expressed in HEK293 cell membranes measured after 2 to 6 hrs by fluorescence polarization assay,CC(C)CN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"1-(3-Amino-1H-1,2,4-triazol-5-yl)-N-(4-chlorophenethyl)-N-isobutylpiperidin-4-amine",4.0,uM,=,0.6020599913279624,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
6084,1679756,10.1016/j.bmcl.2017.03.086,,,,Inhibition of human ERG by Qpatch electrophysiology method,COc1nccc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)n1,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(2-methoxypyrimidin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",8.2,uM,=,0.9138138523837168,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccncn3)C4=O)ccc21
6085,1703612,10.1016/j.bmcl.2017.05.043,,,,Inhibition of human ERG by flux-based assay,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccc(F)nc4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(6-fluoropyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide",35.0,uM,=,1.5440680443502757,1,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1
6086,1765257,10.1021/acsmedchemlett.8b00200,,,,Inhibition of recombinant human ERG expressed in CHOK1 cells at -70 mV holding potential by patch clamp electrophysiology method,C[C@H](Nc1c(C(N)=O)nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc12)C1CCOCC1,6-{6-[3-(Dimethylamino)propoxy]-3-pyridinyl}-4-{[(1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-cinnolinecarboxamide,24.0,uM,=,1.380211241711606,1,c1cncc(-c2ccc3nncc(NCC4CCOCC4)c3c2)c1
6087,810399,10.1016/j.bmcl.2011.10.033,,,,Binding affinity to human ERG,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)[C@@H]1CCN(Cc2nc3cc(F)ccc3s2)C[C@@H]1F,"2-(4-(1H-tetrazol-1-yl)phenyl)-N-((3S,4R)-3-fluoro-1-((5-fluorobenzo[d]thiazol-2-yl)methyl)piperidin-4-yl)-N-methylacetamide",4.7,uM,=,0.6720978579357175,1,O=C(Cc1ccc(-n2cnnn2)cc1)NC1CCN(Cc2nc3ccccc3s2)CC1
6088,1910901,10.1016/j.ejmech.2018.12.042,,,,Inhibition of [3H]-dofetilide binding to human ERG expressed in HEK293 cell membranes measured after 1 hr by liquid scintillation counting method,CN(C)CCC=C1c2ccccc2CCc2ccccc21,"[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine",9.6,uM,=,0.9822712330395684,1,C=C1c2ccccc2CCc2ccccc21
6089,948437,10.1016/j.bmcl.2012.11.094,,,,Inhibition of human ERG,CCN(CC)c1cc(C(F)(F)F)cc(COCC2(c3ccc(F)cc3)CCN(C)CC2)n1,"N,N-diethyl-6-(((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-4-(trifluoromethyl)pyridin-2-amine",14.0,uM,=,1.146128035678238,1,c1ccc(C2(COCc3ccccn3)CCNCC2)cc1
6090,793275,10.1016/j.bmcl.2011.09.117,,,,Displacement of [3H]dofetilide from human ERG by liquid scintillation counting,COc1ccc2ncc(F)c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2c1,"N-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methyl)-1-(2-(3-fluoro-6-methoxyquinolin-4-yl)ethyl)piperidin-4-amine",5.0,uM,=,0.6989700043360189,1,c1ccc2c(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)ccnc2c1
6091,580799,10.1016/j.bmcl.2009.06.095,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells overexpressing Ikr channel protein,Cc1ccc(-n2c(-c3ncccc3Cl)nc(CN[C@H]3CC[C@@H](F)C3)c2C(C)C)cn1,"(1S,3R)-N-((2-(3-chloropyridin-2-yl)-5-isopropyl-1-(6-methylpyridin-3-yl)-1H-imidazol-4-yl)methyl)-3-fluorocyclopentanamine",15.0,uM,=,1.1760912590556811,1,c1ccc(-c2nc(CNC3CCCC3)cn2-c2cccnc2)nc1
6092,1911678,10.1021/acs.jmedchem.8b01725,,,,Inhibition of human ERG by Q-patch assay,Cn1c(N2CCC(C)(N)CC2)nc2[nH]nc(-c3cccc(Cl)c3Cl)c2c1=O,"6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)-5-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one",0.2,uM,=,-0.6989700043360187,0,O=c1[nH]c(N2CCCCC2)nc2[nH]nc(-c3ccccc3)c12
6093,1642207,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG). Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 μM; 3 μM; 10 μM; 30 μM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models. The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from −80 mV to a maximum value of +40 mV, starting with −40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to −55 mV, after each of these incremented steps, for 1 second and finally repolarized to −80 mV for 1 second.",Cc1nsc(-c2nnc3n2CCN(C(=O)c2cc(F)cc(F)c2)[C@@H]3C)n1,"US9422299, 17",46.0,uM,=,1.662757831681574,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
6094,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(CNC2CCCCC2)c1,N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methyl)cyclohexanamine,2.18,uM,=,0.3384564936046048,1,c1ccc(-c2cncc(CNC3CCCCC3)c2)cc1
6095,2100973,10.1021/acs.jmedchem.1c00375,,,,Displacement of [3H]-dofetilide from human ERG after 60 mins by scintillation counting method,Cc1c(N2CC[C@@H](C3(N)CC3)C2)c(F)cc2cc(C#N)c(=O)n(C3CC3)c12,"(R)-7-(3-(1-aminocyclopropyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile",2.7,uM,=,0.4313637641589873,1,O=c1ccc2ccc(N3CC[C@@H](C4CC4)C3)cc2n1C1CC1
6096,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Cc1nc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,"3-((1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,2,4-oxadiazole",8.544,uM,=,0.9316612396844812,1,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@](c4cn[nH]c4)(c4ncon4)N3)n2)nc1
6097,819072,10.1021/jm300011d,,,,Inhibition of human ERG by IonWorks assay,O=C(c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1Cl)N1CCCC1,"6-(3-Chloro-4-(pyrrolidine-1-carbonyl)phenyl)-2-(2-(pyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one",9.3,uM,=,0.9684829485539352,1,O=C(c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1)N1CCCC1
6098,874890,10.1021/jm3009025,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CCn1cc(C2(c3cccc(-c4cncc(F)c4)c3)N=C(N)c3c(F)cccc32)cc(C)c1=O,5-(3-Amino-4-fluoro-1-(3-(5-fluoropyridin-3-yl)phenyl)-1H-isoindol-1-yl)-1-ethyl-3-methylpyridin-2(1H)-one,2.7,uM,=,0.4313637641589873,1,O=c1ccc(C2(c3cccc(-c4cccnc4)c3)N=Cc3ccccc32)c[nH]1
6099,219494,10.1021/jm0208875,,,,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C,3-Benzoyloxy-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester,0.0044,uM,=,-2.356547323513813,0,O=C(O[C@@H]1C[C@H]2CC[C@@H](C1)N2)c1ccccc1
6100,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,N#Cc1cc(NCC(=O)NC2CN([C@H]3CC[C@@](O)(c4cncs4)CC3)C2)c2cc(C(F)(F)F)ccc2n1,Cis-2-(2-cyano-6-(trifluoromethyl)quinolin-4-ylamino)-N-(1-(4-hydroxy-4-(thiazol-5-yl)cyclohexyl)azetidin-3-yl)acetamide,35.1,uM,=,1.545307116465824,1,O=C(CNc1ccnc2ccccc12)NC1CN(C2CCC(c3cncs3)CC2)C1
6101,2018154,10.1016/j.bmcl.2020.127574,,,,Inhibition of human ERG,CCCc1nn(-c2nc(N)c3c(n2)NC(=O)C3(C)C)c2ccc(Cl)cc12,"4-amino-2-(5-chloro-3-propyl-indazol-1-yl)-5,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-6-one",9.6,uM,=,0.9822712330395684,1,O=C1Cc2cnc(-n3ncc4ccccc43)nc2N1
6102,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(F)ccc3OC[C@H]2[C@@]1(CCCN1CCC(=O)N(C)CC1)c1ccccc1,"1-[3-((3R,3aR)-2-acetyl-8-fluoro-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-3-yl)-propyl]-4-methyl-[1,4]diazepan-5-one",9.6,uM,=,0.9822712330395684,1,O=C1CCN(CCC[C@]2(c3ccccc3)C=NN3c4ccccc4OC[C@H]32)CCN1
6103,808018,10.1016/j.bmcl.2012.01.044,,,,Inhibition of human ERG,COC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)c(Cl)c1,"methyl 2-(3'-chloro-4'-((3S,4S)-4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidin-3-yl)biphenyl-2-yl)ethylcarbamate",10.3,uM,=,1.0128372247051722,1,O=c1cc([C@H]2CCNC[C@@H]2c2ccc(-c3ccccc3)cc2)cc[nH]1
6104,1571178,10.1016/j.bmcl.2016.03.035,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1nc(-n2cnnn2)ccc1CC(=O)N1CCN(CCc2ccc3c(c2C)COC3=O)CC1,4-methyl-5-(2-(4-(2-(2-methyl-6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,8.5,uM,=,0.9294189257142929,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
6105,1642194,,,,,Fast Patch Assay: Representative compounds were tested for hERG activity using the Fast Patch assay available from WuXiApptec (Shanghai China).,C[C@]1(O)CC[C@H](Nc2ccc3ncc(-c4cccc(C(F)(F)F)c4)n3n2)CC1,"US9416132, 8-30",12.0,uM,=,1.0791812460476249,1,c1ccc(-c2cnc3ccc(NC4CCCCC4)nn23)cc1
6106,748230,10.1016/j.bmcl.2011.03.117,,,,Inhibition of human ERG expressed in CHOK1 cells electrophysiology study,COc1cc(F)ccc1-c1cncc(NC2CCCOC2)c1,5-(4-fluoro-2-methoxyphenyl)-N-(tetrahydro-2H-pyran-3-yl)pyridin-3-amine,9.4,uM,=,0.9731278535996988,1,c1ccc(-c2cncc(NC3CCCOC3)c2)cc1
6107,763220,10.1016/j.bmcl.2011.04.089,,,,Binding affinity to human ERG by radioligand displacement assay,COc1cc(-c2cn(Cc3cc(C(C)(C)C)cc(C(C)(C)C)c3)nn2)ccc1-n1cnc(C)c1,"1-(3,5-di-tert-butylbenzyl)-4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazole",0.32,uM,=,-0.494850021680094,0,c1ccc(Cn2cc(-c3ccc(-n4ccnc4)cc3)nn2)cc1
6108,1826269,10.1039/C8MD00382C,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by QPatch clamp method,CCN(CC)Cc1cc(-c2ccc3ncc(-c4ccc([S+](C)[O-])cc4)n3n2)ccc1F,"N-ethyl-N-(2-fluoro-5-(3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)benzyl)ethanamine",0.59,uM,=,-0.2291479883578558,0,c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1
6109,767896,10.1021/jm200758k,,,,Inhibition of human ERG channel by patch clamp assay,COc1cc(N2CCN(C[C@H](C)O)CC2)ccc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1,"N-[2-(2-{4-[4-((S)-2-Hydroxy-propyl)-piperazin-1-yl]-2-methoxy-phenylamino}-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-phenyl]-N-methyl-methanesulfonamide",9.1,uM,=,0.9590413923210936,1,c1ccc(-c2ccc3cnc(Nc4ccc(N5CCNCC5)cc4)nn23)cc1
6110,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,CC(C)(C)c1cc(CN2CCC(CNCCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)C2)cc(C(C)(C)C)c1O,"4-((3-((6,6-bis(4-fluorophenyl)hexylamino)methyl)pyrrolidin-1-yl)methyl)-2,6-di-tert-butylphenol",0.01,uM,=,-2.0,0,c1ccc(CN2CCC(CNCCCCCC(c3ccccc3)c3ccccc3)C2)cc1
6111,457444,10.1016/j.bmcl.2007.07.067,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN2c3cc(C)ccc3OC[C@H]2[C@@]1(CCCN1CCOCC1)c1ccccc1,"1-[(3R,3aR)-8-methyl-3-(3-morpholin-4-yl-propyl)-3-phenyl-3a,4-dihydro-3H-5-oxa-1,9b-diaza-cyclopenta[a]naphthalen-2-yl]-ethanone",6.3,uM,=,0.7993405494535817,1,C1=NN2c3ccccc3OC[C@H]2[C@@]1(CCCN1CCOCC1)c1ccccc1
6112,941020,10.1021/jm301564f,,,,Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis,Cc1ccc(C#CCOCc2cccc(COCC#Cc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis((3-p-tolylprop-2-ynyloxy)methyl)pyridinium",0.04,uM,=,-1.3979400086720375,0,C(#Cc1ccccc1)COCc1cccc(COCC#Cc2ccccc2)[nH+]1
6113,819647,10.1016/j.bmcl.2012.04.054,,,,Inhibition of human Erg expressed in HEK293 cells by whole cell patch clamp analysis,COc1c(C(C)(C)C)cc(CN2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1C(C)(C)C,"1-(6,6-bis(4-fluorophenyl)hexyl)-4-(3,5-di-tert-butyl-4-methoxybenzyl)piperazine",0.1,uM,=,-1.0,0,c1ccc(CN2CCN(CCCCCC(c3ccccc3)c3ccccc3)CC2)cc1
6114,1440048,10.1021/jm500887k,,,,Inhibition of human ERG channel by patch clamp technique,C[S+]([O-])c1ccc(-c2cnc3ccc(-c4cccc(S(=O)(=O)C5CC5)c4)nn23)cc1,"6-(3-(Cyclopropylsulfonyl)phenyl)-3-(4-(methylsulfinyl)-phenyl)imidazo[1,2-b]pyridazine",0.4,uM,=,-0.3979400086720376,0,O=S(=O)(c1cccc(-c2ccc3ncc(-c4ccccc4)n3n2)c1)C1CC1
6115,945538,10.1016/j.bmcl.2012.10.140,,,,Inhibition of human ERG expressed in CHO cells by IONWORKS assay,CC(C)(C)NC(=O)NCCN1CCCC(CNC(=O)c2cc(Cl)cc(Cl)c2)C1,"N-((1-(2-(3-tert-butylureido)ethyl)piperidin-3-yl)methyl)-3,5-dichlorobenzamide",5.3,uM,=,0.724275869600789,1,O=C(NCC1CCCNC1)c1ccccc1
6116,883359,10.1021/jm300952s,,,,Inhibition of human ERG by cell-based electrophysiology assay,Cc1cc(CN2CCN(c3c(Cl)cnc4[nH]c(-c5cccc(N6CCN(C)CC6)c5)nc34)CC2)no1,"3-((4-(6-Chloro-2-(3-(4-methylpiperazin-1-yl)phenyl)-3Himidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole",9.5,uM,=,0.9777236052888478,1,c1cc(-c2nc3c(N4CCN(Cc5ccon5)CC4)ccnc3[nH]2)cc(N2CCNCC2)c1
6117,760065,10.1016/j.bmcl.2011.06.090,,,,Inhibition of human ERG by electrophysiology assay,COc1ccc(N2CCNCC2)cc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)-N-(2-methoxy-5-(piperazin-1-yl)phenyl)pyrimidin-2-amine",4.8,uM,=,0.6812412373755872,1,c1cc(Nc2nccc(-c3cnc4ccccn34)n2)cc(N2CCNCC2)c1
6118,1434157,10.1021/jm5011012,,,,Inhibition of human ERG by patch clamp based electrophysiology method,C[C@@H]1CN(c2nnc(C(F)(F)F)o2)CCN1c1ncc(OCc2ccc(S(C)(=O)=O)cc2C#N)cn1,"5-(Methylsulfonyl)-2-{[(2-{(2R)-2-methyl-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]piperazin-1-yl}pyrimidin-5-yl)oxy]methyl}-benzonitrile",6.4,uM,=,0.8061799739838872,1,c1ccc(COc2cnc(N3CCN(c4nnco4)CC3)nc2)cc1
6119,766531,10.1016/j.bmcl.2011.06.126,,,,Inhibition of human ERG by electrophysiological assay,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccc(OC(F)(F)F)cc54)CC3)nc2N1,"6-((1-(2-(3-oxo-6-(trifluoromethoxy)-2H-benzo[b][1,4]oxazin-4(3H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",1.4,uM,=,0.1461280356782379,1,O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccccc54)CC3)nc2N1
6120,674336,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human ERG expressed in HEK cells by patch clamp technique,COc1ccccc1-c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1,"endo-2-(2-methoxyphenyl)-N-((1R,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzo[d]oxazole-4-carboxamide",0.4,uM,=,-0.3979400086720376,0,O=C(N[C@@H]1C[C@H]2CCC[C@@H](C1)N2)c1cccc2oc(-c3ccccc3)nc12
6121,491927,10.1016/j.bmcl.2008.05.084,,,,Inhibition of human ERG in embryonic kidney cells by radioligand-binding competition assay,CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(=O)[nH]c7)[nH]6)CC5)cc4)nc3n2)CC1,"5-(5-(1-((4-(2-(4-(2-(dimethylamino)ethyl)piperazin-1-yl)-6-phenylpyrido[2,3-d]pyrimidin-7-yl)phenyl)methyl)piperidin-4-yl)-4H-1,2,4-triazol-3-yl)pyridin-2(1H)-one",0.8,uM,=,-0.0969100130080563,0,O=c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCNCC7)ncc6cc5-c5ccccc5)cc4)CC3)[nH]2)c[nH]1
6122,959401,10.1016/j.bmcl.2013.04.006,,,,Inhibition of human ERG by IonWorks assay,N#Cc1cnccc1COc1cnc(N2CCN(C(=O)OCC(F)(F)F)CC2)nc1,"2,2,2-trifluoroethyl 4-(5-((3-cyanopyridin-4-yl)methoxy)pyrimidin-2-yl)piperazine-1-carboxylate",10.0,uM,=,1.0,1,c1cc(COc2cnc(N3CCNCC3)nc2)ccn1
6123,1361409,10.1021/jm500432n,,,,Inhibition of human ERG by patch clamp electrophysiological analysis,COc1cc(C#N)c2ccc(=O)n(CCN3CCC(NCc4cnc(C)c(C#N)c4)CC3)c2c1,"1-(2-(4-((5-Cyano-6-methylpyridin-3-yl)methylamino)-piperidin-1-yl)ethyl)-7-methoxy-2-oxo-1,2-dihydroquinoline-5-carbonitrile",2.5,uM,=,0.3979400086720376,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cccnc2)CC1
6124,454875,10.1016/j.bmcl.2006.11.068,,,,Displacement of [3H]dofetilide from hERG expressed in HEK293 cell membrane,CC(C)CO/N=C/COc1ccc(CN2CCC(NC(=O)c3cc(=O)c4ccc(F)cc4o3)CC2)cc1F,N-(1-(3-fluoro-4-(2-(isobutoxyimino)ethoxy)benzyl)piperidin-4-yl)-7-fluoro-4-oxo-4H-chromene-2-carboxamide,0.45,uM,=,-0.3467874862246563,0,O=C(NC1CCN(Cc2ccccc2)CC1)c1cc(=O)c2ccccc2o1
6125,1982667,10.1021/acsmedchemlett.9b00633,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in tail current by measuring tail current amplitude measured after deploarization to +20 mV for 2s followed by 1s pulse to -40 mV by whole cell patch clamp assay,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,"5-(2,3-Difluorophenyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-3-carboxamide",4.1,uM,=,0.6127838567197355,1,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3ccccc3)cc12
6126,1654946,10.1016/j.bmcl.2016.10.032,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,COc1ccc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2)cn1,"(R)-5-(1-hydroxy-2-(2-(6-methoxypyridin-3-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",3.3,uM,=,0.5185139398778875,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3cccnc3)C4)ccc21
6127,2100970,10.1021/acs.jmedchem.1c00375,,,,Inhibition of human ERG expressed in CHO-K1 cells by long incubation protocol based Qpatch clamp method,Cc1c(N2CC3CC3(N)C2)c(F)cc2c(CN)cc(=O)n(C3CC3)c12,7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-cyclopropyl-6-fluoro-8-methylquinolin-2(1H)-one,114.0,uM,=,2.0569048513364727,1,O=c1ccc2ccc(N3CC4CC4C3)cc2n1C1CC1
6128,1865114,10.1021/acsmedchemlett.9b00086,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp method,CC(C)NC(C(=O)N[C@](Cc1ccccc1)(c1ccc(F)cc1)c1cc(F)cc(C(F)(F)F)c1)C(O)(C(F)(F)F)C(F)(F)F,"4,4,4-trifluoro-N-((R)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-hydroxy-2-(isopropylamino)-3-(trifluoromethyl)butanamide",63.0,uM,=,1.7993405494535817,1,c1ccc(CC(c2ccccc2)c2ccccc2)cc1
6129,1275519,10.1016/j.bmcl.2013.09.094,,,,Inhibition of human ERG,C[C@H](NC(=O)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccc(Br)cc1)c1ccc(F)cc1,"(1R,2R,4R)-2-(4-bromophenyl)-N-((S)-1-(4-fluorophenyl)ethyl)-4-morpholinocyclohexanecarboxamide",2.2,uM,=,0.3424226808222063,1,O=C(NCc1ccccc1)[C@@H]1CC[C@@H](N2CCOCC2)C[C@H]1c1ccccc1
6130,949743,10.1021/jm301720p,,,,Inhibition of human ERG channel,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3ncn4c3CCCC4)nc12,"N-tert-butyl-2-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",4.1,uM,=,0.6127838567197355,1,c1cc2nc(-c3ncn4c3CCCC4)cnc2[nH]1
6131,580799,10.1016/j.bmcl.2009.06.095,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells overexpressing Ikr channel protein,Cc1nc(CNC2CCCC2)n(C(C)C)c1-c1ccc(Cl)cc1,N-((5-(4-chlorophenyl)-1-isopropyl-4-methyl-1H-imidazol-2-yl)methyl)cyclopentanamine,3.2,uM,=,0.505149978319906,1,c1ccc(-c2cnc(CNC3CCCC3)[nH]2)cc1
6132,1469544,10.1021/jm501642c,,,,Inhibition of human ERG channel,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1,"2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine",1.0,uM,=,0.0,0,C(#Cc1cn(-c2ccccc2)cn1)c1ccncc1
6133,1935939,10.1016/j.bmc.2019.02.025,,,,Inhibition of human ERG by manual patch clamp electrophysiology assay,COc1cccc(C(c2cc3cc(C#N)ccc3nc2OC)C(O)(CCN(C)C)c2cc(C)nc(C)c2)c1OC,"rac-3-(1-(2,3-dimethoxyphenyl)-4-(dimethylamino)-2-(2,6-dimethylpyridin-4-yl)-2-hydroxybutyl)-2-methoxyquinoline-6-carbonitrile",5.2,uM,=,0.7160033436347992,1,c1ccc(C(Cc2ccncc2)c2cnc3ccccc3c2)cc1
6134,449357,10.1016/j.bmcl.2007.08.039,,,,Displacement of [3H]dofetilide from human HERG expressed in HEK293 cells,O=C1CCc2cc([C@@H](O)CN3CCC(O)(c4cccc(F)c4)CC3)ccc2N1,"(R)-6-(2-(4-(3-fluorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxyethyl)-3,4-dihydroquinolin-2(1H)-one",1.1,uM,=,0.041392685158225,1,O=C1CCc2cc(CCN3CCC(c4ccccc4)CC3)ccc2N1
6135,699317,10.1016/j.bmc.2010.10.034,,,,Inhibition of human ERG,CNC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1,"cis-1-((2S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylmethanamine",2.0,uM,=,0.3010299956639812,1,c1ccc([C@@H]2CCCc3ccccc32)cc1
6136,699750,10.1016/j.bmc.2010.12.002,,,,"Displacement of [35S]N-[(4R)-10-[(2R)-6-cyano-1,2,3,4-tetrahydro-2-naphthyl]-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,40-piperidin]-6-yl]methanesulfonamide from human ERG expressed in HEK293 cells",CN1CCCCC1COc1ccc(-n2ccc(OCc3ccccc3)cc2=O)cc1,4-(Benzyloxy)-1-{4-[(1-methylpiperidin-2-yl)methoxy]-phenyl}pyridin-2(1H)-one,0.0058,uM,=,-2.2365720064370627,0,O=c1cc(OCc2ccccc2)ccn1-c1ccc(OCC2CCCCN2)cc1
6137,1366626,10.1021/jm500535j,,,,Inhibition of human ERG,Nc1nc(-c2ccc(F)cc2)cn1CC(O)c1ccc(C(F)(F)F)cc1Cl,rac-2-(2-Amino-4-(4-fluorophenyl)-1H-imidazol-1-yl)-1-(2-chloro-4-(trifluoromethyl)phenyl)ethanol,25.0,uM,=,1.3979400086720375,1,c1ccc(CCn2cnc(-c3ccccc3)c2)cc1
6138,1560972,10.1016/j.bmcl.2016.02.022,,,,Binding affinity to human ERG,Cc1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1,"(1R,3R)-1-(tetrahydro-2H-pyran-4-yl)-3-(4-p-tolyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole",0.101,uM,=,-0.9956786262173574,0,c1ccc(-c2c[nH]c([C@H]3Cc4c([nH]c5ccccc45)[C@@H](C4CCOCC4)N3)n2)cc1
6139,699317,10.1016/j.bmc.2010.10.034,,,,Inhibition of human ERG,CN[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1,"cis-(2S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",5.27,uM,=,0.7218106152125465,1,c1ccc([C@@H]2CCCc3ccccc32)cc1
6140,1813249,10.1021/acs.jmedchem.9b00681,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CO[C@H](C)CN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"(R)-1-(3-amino-1H-1,2,4-triazol-5-yl)-N-(4-chlorophenethyl)-N-(2-methoxypropyl)piperidin-4-amine",6.4,uM,=,0.8061799739838872,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
6141,1680433,10.1021/acs.jmedchem.7b00365,,,,Displacement of 3H-dofetilide from human ERG,Nc1nc(NCc2cc(C3CC3)on2)c2c(ccn2Cc2ccccn2)n1,"N4-((5-Cyclopropylisoxazol-3-yl)methyl)-5-(pyridin-2-ylmethyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine",0.2,uM,=,-0.6989700043360187,0,c1ccc(Cn2ccc3ncnc(NCc4cc(C5CC5)on4)c32)nc1
6142,990660,10.1016/j.bmcl.2013.08.104,,,,Displacement of [35S]-MK499 from human ERG,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)cc(Cl)c21,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-7-chloroisobenzofuran-1(3H)-one,3.4,uM,=,0.5314789170422551,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
6143,2033688,10.1016/j.bmc.2020.115724,,,,Inhibition of human ERG,CN1CCC(CNC2=NC(=O)/C(=C/c3csc(-c4ccc(OC(F)(F)F)cc4)n3)S2)CC1,2-((1-methylpiperidin-4-yl)methylamino)-5-((2-(4-(trifluoromethoxy)phenyl)thiazol-4-yl)methylene)thiazol-4(5H)-one,4.9,uM,=,0.6901960800285137,1,O=C1N=C(NCC2CCNCC2)S/C1=C\c1csc(-c2ccccc2)n1
6144,1437941,10.1021/jm5016022,,,,Inhibition of human ERG channel by patch-clamp assay,CC(C)(C)n1ncc2c1C(=O)CC1(CCN(C(=O)c3ccc4[nH]ncc4c3)CC1)C2,"1-(tert-Butyl)-1'-(1H-indazole-5-carbonyl)-1,4-dihydrospiro-[indazole-5,4'-piperidin]-7(6H)-one",21.0,uM,=,1.3222192947339193,1,O=C1CC2(CCN(C(=O)c3ccc4[nH]ncc4c3)CC2)Cc2cn[nH]c21
6145,803093,10.1016/j.bmcl.2011.12.117,,,,"Displacement of 3,7-Bis[2-(4-nitro[3,5-3H]phenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane from human ERG expressed in HEK cells after 3 hrs",CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(Cl)cc(Cl)c2)C2CCN(S(C)(=O)=O)CC2)CC1,"(R)-N-(1-(3-(3,5-dichlorophenyl)-3-(1-(methylsulfonyl)piperidin-4-yl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide",6.5,uM,=,0.8129133566428556,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
6146,558914,10.1016/j.bmcl.2008.10.075,,,,Inhibition of human ERG by patch clamp assay,Cc1ncc(-c2nc(Nc3ccc(C(N)=O)c(F)c3)ncc2F)n1C(C)C,2-fluoro-4-(5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)benzamide,20.0,uM,=,1.3010299956639813,1,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1
6147,804476,10.1016/j.bmcl.2012.01.026,,,,Inhibition of human Erg by patch clamp assay,CC1(C)CC(c2ccc(OC3CCN(C4CCC4)CC3)cc2)=NNC1=O,"6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one",21.0,uM,=,1.3222192947339193,1,O=C1CCC(c2ccc(OC3CCN(C4CCC4)CC3)cc2)=NN1
6148,652661,10.1016/j.bmcl.2010.07.112,,,,Inhibition of human ERG by electrophysiology assay,Cc1cc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)cc(C(N)=O)c1,"endo-3-((1R,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)-5-methylbenzamide",0.66,uM,=,-0.1804560644581313,0,c1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2ccccc2)C3)cc1
6149,1766690,10.1021/acs.jmedchem.8b01147,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method,Cn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1,"2-(3-{4-Amino-6-[(1-methyl-1H-pyrazol-4-yl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2H)-one",24.0,uM,=,1.380211241711606,1,O=c1c2ccc(C3CC3)cc2ccn1-c1cccc(-c2ncnc(Nc3cn[nH]c3)n2)c1
6150,1292641,10.1021/jm401760c,,,,Binding affinity to full length human ERG expressed in CHO cells after 6 to 7 mins by IonWorks assay,CNc1nc(NCCCN(C)C)c2sc(-c3ccc4nonc4c3)cc2n1,"6-(benzo[c][1,2,5]oxadiazol-5-yl)-N4-(3-(dimethylamino)propyl)-N2-methylthieno[3,2-d]pyrimidine-2,4-diamine",2.0,uM,=,0.3010299956639812,1,c1ncc2sc(-c3ccc4nonc4c3)cc2n1
6151,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,CCOc1ncc(-c2nc(C(F)(F)F)sc2N2CCN(C(=O)Cn3nc(C)cc3C)[C@H](C)C2)cn1,"2-(3,5-Dimethyl-pyrazol-1-yl)-1-{(R)-4-[4-(7-ethoxy-pyrimidin-5-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl}-ethanone",13.0,uM,=,1.1139433523068367,1,O=C(Cn1cccn1)N1CCN(c2scnc2-c2cncnc2)CC1
6152,1722526,10.1021/acs.jmedchem.8b00643,,,,Inhibition of radioligand binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,CCCC[C@@H](CCO)Nc1nc(N)nc2c(F)cccc12,(S)-3-((2-Amino-8-fluoroquinazolin-4-yl)amino)heptan-1-ol,4.47,uM,=,0.6503075231319364,1,c1ccc2ncncc2c1
6153,2253116,10.1021/acs.jmedchem.2c00414,,,,Inhibition of hERG expressed in CHO cells stably at -80 mV holding potential by automated patch clamp method,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCNC2=O,"2-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)-7,8-dihydro-1,6-naphthyridin-5(6H)-one",10.0,uM,=,1.0,1,O=C1NCCc2nc(OCc3conc3-c3ccccc3)ccc21
6154,1928900,10.1021/acs.jmedchem.6b00475,,,,Inhibition of human ERG channel,CC(C)=CCn1c(N2CCC[C@H](N)C2)nc2c1c(=O)n(CC(=O)c1ccccc1)c(=O)n2C,"8-((S)-3-amino-piperidin-1-yl)-3-methyl-7-(3-methyl-but-2-enyl)-1-(2-oxo-2-phenyl-ethyl)-3,7-dihydro-purine-2,6-dione",0.2,uM,=,-0.6989700043360187,0,O=C(Cn1c(=O)[nH]c2nc(N3CCCCC3)[nH]c2c1=O)c1ccccc1
6155,801328,10.1016/j.bmcl.2011.11.089,,,,Inhibition of human ERG,CCN(C)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2ccccc2NC(C)=O)cc1,4-((2-acetamidophenyl)(1-(4-fluorobenzyl)piperidin-4-ylidene)methyl)-N-ethyl-N-methylbenzamide,12.0,uM,=,1.0791812460476249,1,c1ccc(CN2CCC(=C(c3ccccc3)c3ccccc3)CC2)cc1
6156,2027822,10.1021/acs.jmedchem.8b00152,,,,Inhibition of human ERG expressed in HEK293 cells,CC(C)(Oc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cc1)C(=O)O,2-{4-[6-Amino-5-(4-chlorophenyl)pyridin-3-yl]phenoxy}-2-methylpropanoic Acid,100.0,uM,=,2.0,1,c1ccc(-c2cncc(-c3ccccc3)c2)cc1
6157,2208843,10.1016/j.bmc.2022.116657,,,,Inhibition of hERG channel expressed in CHO cells at -80 mV holding potential by Qpatch clamp method,COc1cc(Nc2ncc(CCc3c(F)c(OC)cc(OC)c3F)cn2)ccc1N1CCC(N2CCN(C)CC2)CC1,"5-[2-(2,6-Difluoro-3,5-dimethoxyphenyl)ethyl]-N-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl}pyrimidin-2-amine",10.0,uM,=,1.0,1,c1ccc(CCc2cnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)nc2)cc1
6158,1351560,10.1016/j.bmcl.2014.03.036,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells,CNC(=O)c1cccc(C2CCN([C@@H]3C[C@H]4OCC[C@@]4(C(=O)N4COc5ccc(C(F)(F)F)cc5C4)C3)CC2)c1,"N-methyl-3-(1-((3aS,5S,6aR)-3a-(6-(trifluoromethyl)-3,4-dihydro-2H-benzo[e][1,3]oxazine-3-carbonyl)hexahydro-2H-cyclopenta[b]furan-5-yl)piperidin-4-yl)benzamide",3.1,uM,=,0.4913616938342727,1,O=C(N1COc2ccccc2C1)[C@@]12CCO[C@@H]1C[C@@H](N1CCC(c3ccccc3)CC1)C2
6159,858025,10.1021/jm300690s,,,,Inhibition of human ERG by Ionworks assay,COc1ccc2ncc(=O)n(CCN3CC[C@@H](NCc4ccc5c(n4)NC(=O)CO5)[C@@H](OC)C3)c2c1,"cis-6-[({(3S,4R)-3-Methoxy-1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b]-[1,4]oxazin-3(4H)-one",88.0,uM,=,1.944482672150169,1,O=C1COc2ccc(CNC3CCN(CCn4c(=O)cnc5ccccc54)CC3)nc2N1
6160,1738026,10.1021/acs.jmedchem.7b01896,,,,Inhibition of human ERG by electrophysiology assay,COCc1ccc(-c2cc3c(cc2F)ncc2c3n([C@H]3C[C@H](OC)C3)c(=O)n2C)cn1,"7-Fluoro-1-(trans-3-methoxycyclobutyl)-8-(6-(methoxymethyl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one",8.9,uM,=,0.9493900066449128,1,O=c1[nH]c2cnc3ccc(-c4cccnc4)cc3c2n1C1CCC1
6161,1766690,10.1021/acs.jmedchem.8b01147,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method,N#Cc1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1C1CC1,"4-({4-Amino-6-[3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1H)-yl)-2-(hydroxymethyl)phenyl]-1,3,5-triazin-2-yl}amino)-1-cyclopropyl-1H-pyrrole-2-carbonitrile",30.0,uM,=,1.4771212547196624,1,O=c1c2ccc(C3CC3)cc2ccn1-c1cccc(-c2ncnc(Nc3ccn(C4CC4)c3)n2)c1
6162,2216807,10.1021/acs.jmedchem.2c00675,,,,Inhibition of hERG expressed in CHO cells by Q patch-clamp method,C[C@@H]1CN(c2sc(Br)nc2-c2nc3ccccc3[nH]2)CCN1C(=O)Cn1cnc2cccnc21,"US9266876, 80",0.34,uM,=,-0.4685210829577448,0,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2nc3ccccc3[nH]2)CC1
6163,939638,10.1016/j.bmcl.2012.11.023,,,,Inhibition of human ERG,COc1cccc(CN2CCc3cc4nc(N)sc4cc3CC2)c1,"7-(3-Methoxy-benzyl)-6,7,8,9-tetrahydro-5H-1-thia-3,7-diaza-cyclohepta[f]inden-2-ylamine4-(2-Amino-5,6,8,9-tetrahydro-1-thia-3,7-diaza-cyclohepta[f]inden-7-ylmethyl)-N,N-dimethyl-benzamide",6.6,uM,=,0.8195439355418687,1,c1ccc(CN2CCc3cc4ncsc4cc3CC2)cc1
6164,620410,10.1016/j.bmcl.2009.07.049,,,,Inhibition of human ERG,O=C(c1cccc(Cl)c1Cl)N(CCC1CC1)[C@H]1CCNC1,"(S)-2,3-dichloro-N-(2-cyclopropylethyl)-N-(pyrrolidin-3-yl)benzamide",7.14,uM,=,0.8536982117761743,1,O=C(c1ccccc1)N(CCC1CC1)[C@H]1CCNC1
6165,1511128,10.1016/j.bmcl.2015.06.061,,,,Inhibition of human ERG assessed as reduction in MK499 competitive binding,NCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(6-(4-aminobutoxy)-3-fluoro-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",8.0,uM,=,0.9030899869919436,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
6166,829290,10.1016/j.bmcl.2012.05.048,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),1.1,uM,=,0.041392685158225,1,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1
6167,1766690,10.1021/acs.jmedchem.8b01147,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method,CC(C1CC1)n1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1,"2-[3-(4-Amino-6-{[1-(1-cyclopropylethyl)-1H-pyrazol-4-yl]-amino}-1,3,5-triazin-2-yl)-2-(hydroxymethyl)phenyl]-6-cyclopropyl-8-fluoroisoquinolin-1(2H)-one",13.5,uM,=,1.130333768495006,1,O=c1c2ccc(C3CC3)cc2ccn1-c1cccc(-c2ncnc(Nc3cnn(CC4CC4)c3)n2)c1
6168,2279747,10.1021/acs.jmedchem.2c01516,,,,Inhibition of human ERG expressed in CHO-K1 cells by Q-patch clamp assay,Cn1c(NC2CCN(CCc3ccc(-c4nc(C(C)(C)C)no4)cc3)CC2)nc2ccccc21,"N-(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenethyl)piperidin-4-yl)-1-methyl-1H-benzo[d]imidazol-2-amine",1.35,uM,=,0.1303337684950061,1,c1ccc2[nH]c(NC3CCN(CCc4ccc(-c5ncno5)cc4)CC3)nc2c1
6169,1855928,10.1021/acs.jmedchem.9b01256,,,,Inhibition of human ERG expressed in CHOK1 cells assessed as reduction in channel current at -80 mV holding potential by whole cell patch clamp assay,CC1OC2(CCN(CCc3ccc(F)cc3)CC2)CN(c2ccccc2)C1=O,"9-[2-(4-fluorophenyl)ethyl]-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",0.1,uM,=,-1.0,0,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
6170,687158,10.1016/j.bmcl.2010.09.062,,,,Displacement of [3H]-dofetilide from human hERG,CC(C)S(=O)(=O)N[C@H]1CN(c2ccccc2)C[C@@H]1c1ccc(-c2ccc(C#N)cc2)cc1,"N-((3R,4R)-4-(4'-cyanobiphenyl-4-yl)-1-phenylpyrrolidin-3-yl)propane-2-sulfonamide",0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2ccc([C@@H]3CCN(c4ccccc4)C3)cc2)cc1
6171,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,CC(C)c1ncc([C@]2(O)CC[C@H](N3CC(NC(=O)CNc4ncnc5ccc(C(F)(F)F)cc45)C3)CC2)s1,Cis-N-(1-(4-hydroxy-4-(2-isopropylthiazol-5-yl)cyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,37.5,uM,=,1.5740312677277188,1,O=C(CNc1ncnc2ccccc12)NC1CN(C2CCC(c3cncs3)CC2)C1
6172,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,Fc1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@]3(CCNC3)O2)cc1,"(5S)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-1-oxa-3,7-diazaspiro[4.4]non-2-ene",4.8,uM,=,0.6812412373755872,1,c1ccc([C@H]2c3ccccc3CCN2C2=NC[C@@]3(CCNC3)O2)cc1
6173,1515502,10.1021/ml500440u,,,,Displacement of [35S]-MK499 from human ERG expressed in HEK293 cells,Cc1nc(C(O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc1C#N,"6-(1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-2-methylnicotinonitrile",17.0,uM,=,1.230448921378274,1,O=C1OCc2cc(CCN3CCN(CCc4ccccn4)CC3)ccc21
6174,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,C[C@@H]1CCCN1CCc1ccc(-c2ccc(S(=O)(=O)NCc3ccncc3)cc2)cc1,4'-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic Acid(Pyridin-4-ylmethyl)-amide,8.111111111,uM,=,0.9090803506751818,1,O=S(=O)(NCc1ccncc1)c1ccc(-c2ccc(CCN3CCCC3)cc2)cc1
6175,971477,10.1021/jm400402q,,,,Inhibition of human ERG by dofetilide binding assay,Cc1cc(Nc2ncc(C)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(C)CC1,"N2-(2-Isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-5-methylpyrimidine-2,4-diamine",1.1,uM,=,0.041392685158225,1,c1ccc(Nc2ccnc(Nc3ccc(C4CCNCC4)cc3)n2)cc1
6176,766668,10.1016/j.bmcl.2011.07.006,,,,Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay,Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,2-Methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-5-(trifluoromethyl)-4(3H)-quinazolinone,10.0,uM,=,1.0,1,O=c1c2ccccc2ncn1-c1ccc(OCCCN2CCCC2)cc1
6177,625337,10.1021/jm100007m,,,,Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay,Cc1[nH]c2ccccc2c1CCN1CCCC1c1ccc(/C=C/C(=O)NO)cc1,(E)-N-Hydroxy-3-(4-{1-[2-(2-methyl-1H-indol-3-yl)ethyl]-pyrrolidin-2-yl}phenyl)acrylamide,19.4,uM,=,1.287801729930226,1,c1ccc(C2CCCN2CCc2c[nH]c3ccccc23)cc1
6178,1473800,10.1021/jm5018169,,,,Inhibition of ERG channel expressed in human embryonic kidney cells assessed as tail current amplitude measured for 3 to 30 mins by PatchXpress electrophysiology assay,Cc1cc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)cnc2C(N)=O)nc(-n2nccn2)n1,"5-(((1R,2S)-2-aminocyclohexyl)amino)-3-((6-methyl-2-(2H-1,2,3-triazol-2-yl)pyrimidin-4-yl)amino)picolinamide",44.0,uM,=,1.6434526764861874,1,c1cc(Nc2cncc(NC3CCCCC3)c2)nc(-n2nccn2)n1
6179,1566578,10.1021/acs.jmedchem.5b01654,,,,Inhibition of human ERG by IonWork assay,COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CC(OC)C5)cc4)C3)o2)cc1,"(3-(4-((3-methoxyazetidin-1-yl)methyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone",8.5,uM,=,0.9294189257142929,1,O=C(c1nnc(-c2ccccc2)o1)N1CC(Oc2ccc(CN3CCC3)cc2)C1
6180,937533,10.1016/j.bmcl.2012.12.017,,,,Inhibition of human ERG assessed as [3H]astemizole binding activity,O=C(CNc1ncnc2ccc(C(F)(F)F)cc12)NC1CN([C@H]2CC[C@@](O)(c3ccccc3)CC2)C1,Cis-N-(1-(4-hydroxy-4-phenylcyclohexyl)azetidin-3-yl)-2-(6-(trifluoromethyl)quinazolin-4-ylamino)acetamide,16.9,uM,=,1.2278867046136734,1,O=C(CNc1ncnc2ccccc12)NC1CN(C2CCC(c3ccccc3)CC2)C1
6181,941017,10.1021/jm301564f,,,,Inhibition of human ERG K+ channel expressed in HEK293 cells after 15 mins by patch clamp assay,Cc1ccc(C#CCOCc2cccc(COCC#Cc3ccc(C)cc3)[n+]2C)cc1,"1-methyl-2,6-bis((3-p-tolylprop-2-ynyloxy)methyl)pyridinium",0.214,uM,=,-0.6695862266508091,0,C(#Cc1ccccc1)COCc1cccc(COCC#Cc2ccccc2)[nH+]1
6182,579349,10.1016/j.bmcl.2009.05.067,,,,Inhibition of human ERG expressed in CHO cells by patch clamp assay,CCN(CC)C(=O)C1CCCN(C(=O)CC2CCN(Cc3ccn(-c4ccc(C(F)(F)F)cc4)c3)CC2)C1,"N,N-diethyl-1-(2-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)acetyl)piperidine-3-carboxamide",16.0,uM,=,1.2041199826559248,1,O=C(CC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCCCC1
6183,1858719,10.1021/acs.jmedchem.0c00117,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell electrophysiology assay,Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2ccsc12,"(E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenesulfonamide",0.186,uM,=,-0.7304870557820837,0,c1ccc(CN2CCC(Nc3nc(Oc4ccccc4)c4sccc4n3)CC2)cc1
6184,634882,10.1016/j.bmcl.2010.04.052,,,,Displacement of [3H]dofetilide from human ERG,COc1ccccc1CC(c1ccccc1)N1CCNCC1,1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine,22.9,uM,=,1.359835482339888,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
6185,518708,10.1016/j.bmcl.2008.12.017,,,,Inhibition of human ERG expressed in HEK cells by competitive radioligand binding assay,Cc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12,"3-methyl-9-phenyl-8-(4-((4-(5-(pyridin-2-yl)-1H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-[1,2,4]triazolo[3,4-f][1,6]naphthyridine",2.778,uM,=,0.4437322414015968,1,c1ccc(-c2cc3c(ccn4cnnc34)nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1
6186,2277957,10.1016/j.bmcl.2022.129048,,,,Inhibition of human ERG,CN(C)[C@H]1CC[C@]2(CN=C(N3CCc4ccccc4[C@@H]3c3ccc(F)cc3)O2)C1,"(5R,8S)-2-[(1S)-1-(4-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N,N-dimethyl-1-oxa-3-azaspiro[4.4]non-2-en-8-amine",7.8,uM,=,0.8920946026904804,1,c1ccc([C@H]2c3ccccc3CCN2C2=NCC3(CCCC3)O2)cc1
6187,1679756,10.1016/j.bmcl.2017.03.086,,,,Inhibition of human ERG by Qpatch electrophysiology method,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccncc2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",19.5,uM,=,1.290034611362518,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccncc3)C4=O)ccc21
6188,2132048,10.1016/j.bmc.2021.116424,,,,Inhibition of human ERG expressed in CHO-K1 cells with holding potential -80 mV incubated for 5 mins by patch-clamp assay,Cc1cc(C)cc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCC(N)CC2)c1,"1-(3-(1H-benzo[d]imidazol-2-yl)-5-(3,5-dimethylphenyl)pyridin-4-yl)piperidin-4-amine",3.0,uM,=,0.4771212547196624,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2N2CCCCC2)cc1
6189,803863,10.1016/j.bmcl.2011.11.054,,,,Inhibition of human ERG by dofetilide binding assay,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,"(S)-6-(3-aminopiperidin-1-yl)-1-methyl-5-(3-methylbut-2-enyl)-3-((4-methylquinazolin-2-yl)methyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",6.7,uM,=,0.8260748027008264,1,O=c1[nH]c2cc(N3CCCCC3)[nH]c2c(=O)n1Cc1ncc2ccccc2n1
6190,2051795,10.1021/acs.jmedchem.6b00275,,,,Inhibition of human ERG by patch clamp electrophysiology assay,Cc1cc(NC2CCc3cc(Br)ccc3C2)n2nc(C(C)(F)F)nc2n1,"2-(1,1-Difluoroethyl)-N-(6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc2c(c1)CCC(Nc1ccnc3ncnn13)C2
6191,580013,10.1021/jm900725r,,,,Inhibition of IKr channel,O=C(NC1CCc2ccccc2CC1)N1CCC(c2nc(-c3ccccn3)no2)CC1,"4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-N-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-yl)piperidine-1-carboxamide",25.0,uM,=,1.3979400086720375,1,O=C(NC1CCc2ccccc2CC1)N1CCC(c2nc(-c3ccccn3)no2)CC1
6192,2164004,10.1021/acs.jmedchem.1c02110,,,,Inhibition of hERG by patch clamp method,CCOP(=O)(Cn1ccc(NC(=O)c2cc(Oc3ccc(S(=O)(=O)N4CCC4)cc3)cc(OC(C)C)c2)n1)OCC,Diethyl ((3-(3-(4-(Azetidin-1-ylsolfonyl)phenoxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate,33.0,uM,=,1.5185139398778875,1,O=C(Nc1cc[nH]n1)c1cccc(Oc2ccc(S(=O)(=O)N3CCC3)cc2)c1
6193,627243,10.1021/jm9016812,,,,Inhibition of human ERG by electrophysiology assay,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4cccc(Cl)c4)oc3C)c2)cc1,2-((3-((2-(3-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,7.3,uM,=,0.8633228601204559,1,O=C(NCc1cccc(OCc2coc(-c3ccccc3)n2)c1)Oc1ccccc1
6194,1794818,10.1016/j.bmcl.2018.08.015,,,,Displacement of 3H-dofetilide from human ERG,CCC[C@@H](CCO)Nc1nc(N)nc2c1CN(C(=O)c1csc(C)n1)CC2,"[2-amino-4-[[(1S)-1-(2-hydroxyethyl)butyl]amino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-(2-methylthiazol-4-yl)methanone",22.0,uM,=,1.3424226808222062,1,O=C(c1cscn1)N1CCc2ncncc2C1
6195,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,O=C1CCCN1C1CCN(Cc2ccc(Oc3nc4ccccc4s3)cc2)CC1,1-{1-[4-(Benzothiazol-2-yloxy)benzyl]piperidin-4-yl}pyrrolidin-2-one,15.0,uM,=,1.1760912590556811,1,O=C1CCCN1C1CCN(Cc2ccc(Oc3nc4ccccc4s3)cc2)CC1
6196,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccc4c(c3)OCO4)CC2)C1,"N-{[1-(4-Benzo[1,3]dioxol-5-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-benzamide",2.8,uM,=,0.4471580313422192,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccc4c(c3)OCO4)CC2)C1
6197,2029491,10.1016/j.ejmech.2019.112017,,,,Inhibition of human ERG expressed in CHO cells by manual patch clamp assay,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(CCCN1CCN(c3nc(-c4ccccc4)no3)CC1)c(=O)n2C.Cl,"(R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-(3-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperazin-1-yl)propyl)-1H-purine-2,6(3H,7H)-dione hydrochloride",4.9,uM,=,0.6901960800285137,1,O=c1[nH]c2nc(N3CCCCC3)[nH]c2c(=O)n1CCCN1CCN(c2nc(-c3ccccc3)no2)CC1
6198,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,Fc1cc2c(cn1)C1(CCN(Cc3ccc(Oc4ccc(F)c(F)c4)cc3)CC1)OC2,"1'-(4-(3,4-difluorophenoxy)benzyl)-6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]",0.024,uM,=,-1.619788758288394,0,c1ccc(Oc2ccc(CN3CCC4(CC3)OCc3ccncc34)cc2)cc1
6199,841532,10.1016/j.bmcl.2012.06.029,,,,Binding affinity to human ERG,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(Cl)cc2)c2ncc[nH]2)C(=O)N3)CC1,(Z)-3-((4-chlorophenyl)(1H-imidazol-2-yl)methylene)-5-(1-ethylpiperidin-4-ylamino)indolin-2-one,3.367,uM,=,0.5272431163880886,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1ncc[nH]1
6200,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)c1,"US8975415, RP111::US8975415, RP52a::US9242973, RP111",1.98,uM,=,0.2966651902615311,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
6201,980788,10.1021/jm4006324,,,,Displacement of [3H]dofetilide from human ERG channel,CNCc1cc(-c2cn(C)nc2-c2ccc(F)cc2)ccn1,1-(4-(3-(4-Fluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine-2-yl)-N-methylmethanamine,38.2,uM,=,1.582063362911709,1,c1ccc(-c2n[nH]cc2-c2ccncc2)cc1
6202,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,O=C(c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CCC4(COC4)C3)c12)N1CCC1,(4-(2-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-5-hydroxy-2-(4-hydroxyphenyl)benzofuran-3-yl)(azetidin-1-yl)methanone,6.9,uM,=,0.8388490907372553,1,O=C(c1c(-c2ccccc2)oc2cccc(CN3CCC4(COC4)C3)c12)N1CCC1
6203,2079117,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 3 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),O=C(COc1ccc(C(=O)c2cc(Cl)ccc2Br)cc1)Nc1cccnc1,2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)-N-(pyridin-3-yl)acetamide,0.0347,uM,=,-1.4596705252091262,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1cccnc1
6204,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2cccc(F)c2C(=O)N1CCc1ccccn1,4-Fluoro-3-oxo-2-(2-(pyridin-2-yl)ethyl)-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,8.2,uM,=,0.9138138523837168,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
6205,2223202,10.1021/acsmedchemlett.2c00111,,,,Inhibition of hERG cardiac ion channel,O=c1ccc2ccc(F)c3c2n1CC3C[C@H]1OC[C@H](NCc2ccc3c(c2)OCCO3)CO1,"1-((5-(((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)amino)-trans-1,3-dioxan-2-yl)methyl)-9-fluoro-1,2-dihydro-4H-pyrrolo[3,2,1-iJ]quinolin-4-one",35.0,uM,=,1.5440680443502757,1,O=c1ccc2cccc3c2n1CC3C[C@H]1OC[C@H](NCc2ccc3c(c2)OCCO3)CO1
6206,976818,10.1016/j.bmcl.2013.06.100,,,,Binding affinity to human ERG,COc1cc(-c2nc3n(n2)CCC[C@H]3c2ccc(F)cc2C)ccc1-n1cnc(C)c1,"(S)-8-(4-fluoro-2-methylphenyl)-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine",7.9,uM,=,0.8976270912904415,1,c1ccc([C@@H]2CCCn3nc(-c4ccc(-n5ccnc5)cc4)nc32)cc1
6207,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,OC1CCN(CCc2ccc(Oc3nc4ccccc4s3)cc2)CC1,1-{2-[4-(Benzothiazol-2-yloxy)phenyl]ethyl}piperidin-4-ol,3.0,uM,=,0.4771212547196624,1,c1ccc2sc(Oc3ccc(CCN4CCCCC4)cc3)nc2c1
6208,1797573,10.1021/acs.jmedchem.8b01187,,,,Inhibition of human ERG by whole cell electrophysiology analysis,C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(-c2cc[nH]c3nccc2-3)n1,CERALASERTIB,166.0,uM,=,2.220108088040055,1,c1cc2c(-c3nc(C4CC4)cc(N4CCOCC4)n3)cc[nH]c-2n1
6209,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN1CCC(Cc2ccccc2)CC1,4-Benzyl-1-heptylpiperidine,0.058,uM,=,-1.2365720064370629,0,c1ccc(CC2CCNCC2)cc1
6210,858750,10.1021/jm3008689,,,,Inhibition of human ERG,CS(=O)(=O)c1ccc(C(CC2CCCC2)C(=O)Nc2nccs2)cc1F,rac-3-Cyclopentyl-2-(3-fluoro-4-methanesulfonyl-phenyl)-N-thiazol-2-yl-propionamide,23.0,uM,=,1.3617278360175928,1,O=C(Nc1nccs1)C(CC1CCCC1)c1ccccc1
6211,1538961,10.1021/acs.jmedchem.5b01345,,,,Displacement of [35S]-MK-0499 from human ERG,Cc1noc([C@H]2C[C@@H]2C(=O)NCc2ccc(-c3cccc(OC(F)(F)F)c3)c3c2CN(C(=O)NC(C)(C)C)CC3)n1,"N-tert-butyl-8-(((trans)-2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropanecarboxamido)methyl)-5-(3-(trifluoromethoxy)phenyl)-3,4-dihydroisoquinoline-2(1H)-carboxamide",2.34,uM,=,0.3692158574101428,1,O=C(NCc1ccc(-c2ccccc2)c2c1CNCC2)[C@H]1C[C@@H]1c1ncno1
6212,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,NC1(C(=O)NC(CCCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,"rac-4-Amino-N-[1-(4-chlorophenyl)-4-hydroxybutyl]-1-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",57.793,uM,=,1.7618752390178485,1,O=C(NCc1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
6213,1927981,10.1021/acsmedchemlett.6b00117,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1,5-phenyl-N-(pyridin-2-ylmethyl)-2-(pyridin-3-yl)quinazolin-4-amine,20.0,uM,=,1.3010299956639813,1,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1
6214,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cc2c(Cl)c(-c3n[nH]c4nc(N5C[C@@H]6[C@H](C5)[C@@]6(CN)c5ccccn5)cnc34)ccc2n1,"((1R,5S,6r)-3-(3-(4-chloro-2-methyl-2H-indazol-5-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-6-(pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methanamine",8.957,uM,=,0.9521625742144626,1,c1ccc(C2[C@H]3CN(c4cnc5c(-c6ccc7n[nH]cc7c6)n[nH]c5n4)C[C@@H]23)nc1
6215,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCc1ncccn1,3-Oxo-2-(2-(pyrimidin-2-yl)ethyl)-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,16.0,uM,=,1.2041199826559248,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ncccn1
6216,943154,10.1016/j.bmcl.2012.12.056,,,,Inhibition of human ERG,C(#Cc1ccc2ccccc2n1)c1ccccn1,2-(Pyridin-2-ylethynyl)quinoline,20.3,uM,=,1.307496037913213,1,C(#Cc1ccc2ccccc2n1)c1ccccn1
6217,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CCCCCc1ccc(Cl)cc1,N-(5-(4-Chlorophenyl)pentyl)-N-ethylheptan-1-amine,0.123,uM,=,-0.910094888560602,0,c1ccccc1
6218,1760898,10.1021/acs.jmedchem.8b00521,,,,Inhibition of human ERG by cell based automated patch clamp method,COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sccc34)[C@@H](C)C2)c(C)c1,"(3S)-4-(2-aminothieno[2,3-d]pyrimidin-4-yl)-N-(4-methoxy-2-methyl-phenyl)-3-methyl-piperazine-1-carboxamide",8.0,uM,=,0.9030899869919436,1,O=C(Nc1ccccc1)N1CCN(c2ncnc3sccc23)CC1
6219,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CC(=O)c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CCC4(COC4)C3)c12,1-(4-(2-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-5-hydroxy-2-(4-hydroxyphenyl)benzofuran-3-yl)ethanone,2.6,uM,=,0.414973347970818,1,c1ccc(-c2cc3c(CN4CCC5(COC5)C4)cccc3o2)cc1
6220,748605,10.1016/j.bmcl.2011.03.114,,,,Inhibition of human ERG,CC#C[C@@H](c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1)[C@H]1OC(=O)NC1=O,"cis-rac-5-(1-(4-(2-(difluoromethoxy)-4-(trifluoromethyl)phenoxy)phenyl)but-2-ynyl)oxazolidine-2,4-dione",3.4,uM,=,0.5314789170422551,1,O=C1NC(=O)[C@@H](Cc2ccc(Oc3ccccc3)cc2)O1
6221,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cnc4[nH]ccc4c3)ccc1OCC21CC1,"US8975415, RP61::US9242973, RP61",9.22,uM,=,0.9647309210536292,1,C1=NC2(CO1)c1cc(-c3cnc4[nH]ccc4c3)ccc1OCC21CC1
6222,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,O=C1CSC(c2cc(C(F)(F)F)cc(S(=O)(=O)N3CCN(C(=O)[C@@H]4C[C@H]4c4ccc(C(F)(F)F)cc4)CC3)c2)=N1,"2-(3-(trifluoromethyl)-5-(4-((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropanecarbonyl)piperazin-1-ylsulfonyl)phenyl)thiazol-4(5H)-one",4.0,uM,=,0.6020599913279624,1,O=C1CSC(c2cccc(S(=O)(=O)N3CCN(C(=O)[C@@H]4C[C@H]4c4ccccc4)CC3)c2)=N1
6223,1552715,10.1016/j.ejmech.2015.12.006,,,,Inhibition of human ERG channel by fluorescence polarization assay,CCC(=S)N1CCC(CN2CC[C@H](NC(=O)c3cc(Cl)c(N)cc3OC)[C@H](OC)C2)CC1,cis-4-Amino-5-chloro-N-(1-((1-propanethioylpiperidin-4-yl)methyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide,2.862,uM,=,0.4566696294237575,1,O=C(NC1CCN(CC2CCNCC2)CC1)c1ccccc1
6224,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,COc1cccc2c1C(C(=O)NCc1ccc(OC(F)(F)F)cc1)N(CCc1ccccn1)C2=O,7-Methoxy-3-oxo-2-(2-(pyridin-2-yl)ethyl)-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,3.6,uM,=,0.5563025007672873,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
6225,1353223,10.1021/jm401705g,,,,Inhibition of human ERG by electrophysiology assay,CSc1cc(-c2ccc(C[C@@H](C#N)NC(=O)[C@@H]3CCCCN3)cc2)ccc1C#N,(S)-N-((S)-1-Cyano-2-(4'-cyano-3'-(methylthio)biphenyl-4-yl)ethyl)piperidine-2-carboxamide,2.7,uM,=,0.4313637641589873,1,O=C(NCCc1ccc(-c2ccccc2)cc1)[C@@H]1CCCCN1
6226,1448459,10.1021/jm5004864,,,,Inhibition of human ERG over-expressed in HEK293 cell membrane by [3H]dofetilide binding assay,CN(C)c1ccc(/C=C/c2c(F)cccc2F)nc1,"(E)-2-(2',6'-Difluorostyryl)-5-(N,N-dimethylamino)pyridine",21.1,uM,=,1.3242824552976926,1,C(=C/c1ccccn1)\c1ccccc1
6227,740013,10.1016/j.bmcl.2011.02.061,,,,Inhibition of human ERG,CNCC[C@@H](Oc1cc(Cl)ccc1C#N)c1ccccc1.Cl,(R)-4-chloro-2-(3-(methylamino)-1-phenylpropoxy)benzonitrile hydrochloride,10.0,uM,=,1.0,1,c1ccc(COc2ccccc2)cc1
6228,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,Cc1nn(C2CCN(C(=O)[C@@H](C)O)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"(2R)-1-[4-(4-{[5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-2-hydroxy-1-propanone",29.0,uM,=,1.462397997898956,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
6229,1295005,10.1021/jm4017224,,,,Inhibition of human ERG,Nc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccc(F)c3)N2)cc1,"(R)-2-Amino-N-(4-(((2S,5R)-5-((R)-(3-fluorophenyl)(hydroxy)-methyl)pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4Hcyclopenta[d]thiazole-4-carboxamide",4.0,uM,=,0.6020599913279624,1,O=C(Nc1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)[C@@H]1CCc2scnc21
6230,2025894,10.1021/acsmedchemlett.0c00573,,,,Inhibition of human ERG by planar patch clamp method,Cc1cncc(C#Cc2sc(NC(=O)NC[C@H](C)OCC3CC3)nc2C)c1,(S)-1-(2-(Cyclopropylmethoxy)propyl)-3-(5-((5-methoxypyridin-3-yl)ethynyl)-4-methylthiazol-2-yl)urea,28.0,uM,=,1.4471580313422192,1,O=C(NCCOCC1CC1)Nc1ncc(C#Cc2cccnc2)s1
6231,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cncc(Cl)c3)ccc1OCC21CC1,"US8975415, RP107::US9242973, RP107",2.91,uM,=,0.4638929889859073,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
6232,1990613,10.1016/j.bmcl.2020.127249,,,,Inhibition of human ERG,CN1CCN(Cc2cnc(NC(=O)/C(=N/N3CCCC3)c3ccc(S(=O)(=O)C4CC4)cc3)s2)CC1,(E)-2-(4-(cyclopropylsulfonyl)phenyl)-N-(5-((4-methylpiperazin-1-yl)methyl)thiazol-2-yl)-2-(pyrrolidin-1-ylimino)acetamide,16.9,uM,=,1.2278867046136734,1,O=C(Nc1ncc(CN2CCNCC2)s1)/C(=N/N1CCCC1)c1ccc(S(=O)(=O)C2CC2)cc1
6233,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,"US9018211, 2A",22.0,uM,=,1.3424226808222062,1,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21
6234,766645,10.1016/j.bmcl.2011.07.030,,,,Inhibition of human ERG,CN(C)C1(CNC(=O)N2CCC(c3nc(-c4ccc5ccccc5n4)no3)CC2)CCCC1,"N-((1-(dimethylamino)cyclopentyl)methyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",38.0,uM,=,1.57978359661681,1,O=C(NCC1CCCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
6235,2084852,10.1021/acs.jmedchem.6b01315,,,,Binding affinity to human ERG,COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12,CPI-1205,21.3,uM,=,1.3283796034387378,1,O=C(NCc1ccc[nH]c1=O)c1cn(CC2CCNCC2)c2ccccc12
6236,1295005,10.1021/jm4017224,,,,Inhibition of human ERG,Nc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1,"(R)-2-Amino-N-(4-(((2S,5R)-5-((R)-hydroxy(pyridin-3-yl)-methyl)pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4Hcyclopenta[d]thiazole-4-carboxamide",23.3,uM,=,1.3673559210260189,1,O=C(Nc1ccc(C[C@@H]2CC[C@H](Cc3cccnc3)N2)cc1)[C@@H]1CCc2scnc21
6237,2049685,10.1021/acs.jmedchem.0c01411,,,,Inhibition of human ERG by patch clamp method,CN1CCCN(c2nccc3[nH]c(-c4ccc(F)c(F)c4)nc23)CC1,"2-(3,4-Difluorophenyl)-4-(4-methyl-1,4-diazepan-1-yl)-1H-imidazo[4,5-c]pyridine",0.4,uM,=,-0.3979400086720376,0,c1ccc(-c2nc3c(N4CCCNCC4)nccc3[nH]2)cc1
6238,2064912,10.1016/j.ejmech.2017.12.079,,,,Inhibition of human ERG expressed in CHO cells by automated Q-patch clamp assay,C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1,"1-(4-((4-Amino-5-(benzo[d][1,3]dioxol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)piperidin-1-yl)prop-2-en-1-one",11.1,uM,=,1.0453229787866574,1,c1ncc2c(-c3ccc4c(c3)OCO4)cn(CC3CCNCC3)c2n1
6239,1650134,10.1021/acs.jmedchem.6b01751,,,,Inhibition of human ERG expressed in HEK293 cells,CN1C(=O)[C@@H](NC(=O)c2n[nH]c(Cc3ccccc3)n2)COc2ccccc21,"(S)-5-Benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide",195.0,uM,=,2.290034611362518,1,O=C(N[C@H]1COc2ccccc2NC1=O)c1n[nH]c(Cc2ccccc2)n1
6240,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1ncc(-c2c(C)c(CN[C@H]3CC[C@@H](F)C3)nn2-c2ncccc2Cl)cc1F,"(1S,3R)-N-((1-(3-chloropyridin-2-yl)-5-(5-fluoro-6-methylpyridin-3-yl)-4-methyl-1H-pyrazol-3-yl)methyl)-3-fluorocyclopentanamine",41.0,uM,=,1.6127838567197357,1,c1ccc(-n2nc(CNC3CCCC3)cc2-c2cccnc2)nc1
6241,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,O=C1CCCCN1C1CCN(CCOc2ccc(Oc3nc4ccccc4s3)cc2)CC1,"1-{2-[4-(Benzothiazol-2-yloxy)phenoxy]ethyl}[1,4]bipiperidinyl-2-one",1.8,uM,=,0.255272505103306,1,O=C1CCCCN1C1CCN(CCOc2ccc(Oc3nc4ccccc4s3)cc2)CC1
6242,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1ccccc1N1CCN(Cc2nc3c4cccc(OC)c4nc(N)n3n2)[C@H](C)C1,"(R)-7-methoxy-2-((4-(2-methoxyphenyl)-2-methylpiperazin-1-yl)methyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",47.6,uM,=,1.677606952720493,1,c1ccc(N2CCN(Cc3nc4c5ccccc5ncn4n3)CC2)cc1
6243,2232362,10.1016/j.bmcl.2022.128648,,,,Inhibition of human ERG by Ionworks electrophysiology assay,N#Cc1ccc2ccc(=O)n(CCCN[C@H]3CC[C@H]4[C@H](C3)OC(=O)N4c3ccc4c(n3)NC(=O)CO4)c2c1,"2-oxo-1-(3-(((3aS,6S,7aS)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)octahydrobenzo[d]oxazol-6-yl)amino)propyl)-1,2-dihydroquinoline-7-carbonitrile",7.0,uM,=,0.8450980400142568,1,O=C1COc2ccc(N3C(=O)O[C@H]4C[C@@H](NCCCn5c(=O)ccc6ccccc65)CC[C@@H]43)nc2N1
6244,945796,10.1016/j.bmcl.2012.12.072,,,,Inhibition of human ERG,COc1ccccc1N1CCN(C[C@@H](O)COc2ccc(C(F)(F)F)cc2)CC1,(R)-1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(4-(trifluoromethyl)phenoxy)propan-2-ol,3.95,uM,=,0.5965970956264602,1,c1ccc(OCCCN2CCN(c3ccccc3)CC2)cc1
6245,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,CC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1,"1-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",23.0,uM,=,1.3617278360175928,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
6246,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,COC[C@H](C)Oc1cc(Oc2ccc(C(=O)N3CCC3)nc2)cc(C(=O)Nc2cnc(C)cn2)c1,(S)-3-(6-(azetidine-1-carbonyl)pyridin-3-yloxy)-5-(1-methoxypropan-2-yloxy)-N-(5-methylpyrazin-2-yl)benzamide,40.0,uM,=,1.6020599913279625,1,O=C(Nc1cnccn1)c1cccc(Oc2ccc(C(=O)N3CCC3)nc2)c1
6247,2094146,10.1021/acs.jmedchem.0c01518,,,,Inhibition of human ERG by patch clamp assay,C[C@H](Oc1cc2cc(F)cc(F)c2nc1N)c1cc(C(=O)O)ccc1-n1cccn1,"(S)-3-(1-((2-Amino-6,8-difluoroquinolin-3-yl)oxy)ethyl)-4-(1H-pyrazol-1-yl)benzoic acid",144.0,uM,=,2.1583624920952498,1,c1ccc(-n2cccn2)c(COc2cnc3ccccc3c2)c1
6248,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,O=C1OCc2cc(CCN3CCN(CCc4ccc5nonc5c4)CC3)ccc21,"5-(2-(4-(2-(benzo[c][1,2,5]oxadiazol-5-yl)ethyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one",0.28,uM,=,-0.5528419686577808,0,O=C1OCc2cc(CCN3CCN(CCc4ccc5nonc5c4)CC3)ccc21
6249,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cncnc3)ccc1OCC21CCC1,"US8975415, RP101::US9242973, RP101",5.28,uM,=,0.7226339225338123,1,C1=NC2(CO1)c1cc(-c3cncnc3)ccc1OCC21CCC1
6250,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,O=[N+]([O-])c1ccc(CCN2CCN(CCc3ccc4nonc4c3)CC2)cc1,"5-(2-(4-(4-nitrophenethyl)piperazin-1-yl)ethyl)benzo[c][1,2,5]oxadiazole",0.025,uM,=,-1.6020599913279625,0,c1ccc(CCN2CCN(CCc3ccc4nonc4c3)CC2)cc1
6251,306311,10.1016/j.bmcl.2005.02.093,,,,In vitro inhibitory concentration against displacement of 35[S] MK-499 binding to hERG channel expressed in HEK293 cells,Clc1ccc(-c2nc(COc3ccccc3CN3CCCCCCC3)cs2)cc1,1-{2-[2-(4-Chloro-phenyl)-thiazol-4-ylmethoxy]-benzyl}-azocane,0.03,uM,=,-1.5228787452803376,0,c1ccc(-c2nc(COc3ccccc3CN3CCCCCCC3)cs2)cc1
6252,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1ccc(-c2c(C)c(CNC3CCCC3)nn2-c2ncc(Cl)cc2Cl)cn1,"N-((1-(3,5-dichloropyridin-2-yl)-4-methyl-5-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)methyl)cyclopentanamine",1.2,uM,=,0.0791812460476248,1,c1ccc(-n2nc(CNC3CCCC3)cc2-c2cccnc2)nc1
6253,1911580,10.1021/acs.jmedchem.8b01726,,,,Inhibition of human ERG,C[C@@H]1OCC2(CCN(c3nc(N)c(Sc4ccnc(C5CC5)c4Cl)c(=O)n3C)CC2)[C@@H]1N,"6-Amino-2-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-((3-chloro-2-cyclopropylpyridin-4-yl)thio)-3-methylpyrimidin-4(3H)-one",9.8,uM,=,0.9912260756924948,1,O=c1[nH]c(N2CCC3(CCOC3)CC2)ncc1Sc1ccnc(C2CC2)c1
6254,1712776,10.1016/j.bmcl.2018.03.056,,,,Inhibition of human ERG expressed in CHOK1 cells at holding potential of -80 mV after 5 mins by patch clamp assay,C[C@]12CCC(F)(F)C[C@H]1C[C@@H](N1CCC[C@@H](N)C1)[C@@H]2Oc1ccc(C#N)cc1,"4-((1R,2R,3aR,7aS)-2-((R)-3-aminopiperidin-1-yl)-5,5-difluoro-7a-methyloctahydro-1H-inden-1-yloxy)benzonitrile",13.0,uM,=,1.1139433523068367,1,c1ccc(O[C@@H]2C3CCCC[C@H]3C[C@H]2N2CCCCC2)cc1
6255,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(C2=CC(=O)OC2)C3)ccc2c1COC2=O,"(R)-5-(1-Hydroxy-2-(2-(5-oxo-2,5-dihydrofuran-3-yl)-2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one",90.0,uM,=,1.954242509439325,1,O=C1C=C(N2CCC3(CCN(CCc4ccc5c(c4)COC5=O)CC3)C2)CO1
6256,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(C(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCc1ccccn1,3-Oxo-2-(2-pyridin-2-ylethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-1H-isoindole-1-carboxamide,8.6,uM,=,0.9344984512435676,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
6257,875038,10.1021/jm300573d,,,,Inhibition of human ERG,Cl.Cn1cc2c(OCC3CCN(CCc4ccc(N)cc4)CC3)nc3ccccc3c2c1,"4-[[1-[2-(4-Aminophenyl)ethyl]-4-piperidinyl]methoxy]-2-methyl-2H-pyrrolo[3,4-c]quinoline hydrochloride",0.05,uM,=,-1.3010299956639813,0,c1ccc(CCN2CCC(COc3nc4ccccc4c4c[nH]cc34)CC2)cc1
6258,1926818,10.1021/acs.jmedchem.6b00914,,,,Inhibition of human ERG channel expressed in HEK293 cells by patch clamp assay,CC(NC(=O)c1ccc(C(F)(F)F)cc1Cl)C1(N2CCN(S(=O)(=O)c3cn(C)nn3)CC2)CCC(F)(F)CC1.Cl,"(+/-)-2-Chloro-N-(1-(4,4-difluoro-1-(4-((1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl)piperazin-1-yl)cyclohexyl)ethyl)-4-(trifluoromethyl)-benzamide Hydrochloride",20.2,uM,=,1.305351369446624,1,O=C(NCC1(N2CCN(S(=O)(=O)c3c[nH]nn3)CC2)CCCCC1)c1ccccc1
6259,2027427,10.1021/acs.jmedchem.6b01204,,,,Inhibition of human ERG measured after 4 hrs by fluorescence polarization assay,CN1CCC[C@H]1COc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(Br)cc2)cc1.Cl,"(S,E)-5-(4-Bromophenyl)-5-(4-((1-methylpyrrolidin-2-yl)-methoxy)phenyl)-4-phenylpent-4-en-1-ol Hydrochloride Salt",4.7,uM,=,0.6720978579357175,1,C(=C(c1ccccc1)c1ccc(OC[C@@H]2CCCN2)cc1)c1ccccc1
6260,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(-c3ccn[nH]3)cc(C(F)(F)F)c2)CC1,"(4-(3-(1H-pyrazol-5-yl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",0.5,uM,=,-0.3010299956639812,0,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2cccc(-c3ccn[nH]3)c2)CC1
6261,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CC(=O)c1cccc(-c2cccc(-n3cc(C(=O)NC(C)C)c(=O)c4cccnc43)c2)c1,"1-(3'-Acetyl-biphenyl-3-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid isopropylamide",6.96,uM,=,0.8426092396105621,1,O=c1ccn(-c2cccc(-c3ccccc3)c2)c2ncccc12
6262,2219924,10.1016/j.bmcl.2021.128463,,,,Displacement of MK499 from human ERG expressed in HEK membrane by radio ligand binding competition assay,CC1(C)C(=N)N[C@](C)(c2nc(NC(=O)c3ccc(C#N)cn3)ccc2F)CS1(=O)=O,"(R)-5-cyano-N-(5-fluoro-6-(5-imino-3,6,6-trimethyl-1,1-dioxidothiomorpholin-3-yl)pyridin-2-yl)picolinamide",15.89,uM,=,1.2011238972073797,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3ccccn3)n2)N1
6263,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)CO3)c1,"US8975415, RP108::US8975415, RP53b::US9242973, RP108",9.4,uM,=,0.9731278535996988,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21COC1
6264,877119,10.1021/jm3013568,,,,Inhibition of human ERG expressed in CHO cells,O=C(CCCN1CCCCC1)Nc1cc(-c2cncc(F)c2)n[nH]1,N-[5-(5-Fluoropyridin-3-yl)-2H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide,15.8,uM,=,1.1986570869544226,1,O=C(CCCN1CCCCC1)Nc1cc(-c2cccnc2)n[nH]1
6265,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc(N2CCN(Cc3nc4c5cccc(OC)c5nc(N)n4n3)[C@H](C)C2)c1,"(R)-7-methoxy-2-((4-(3-methoxyphenyl)-2-methylpiperazin-1-yl)methyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",21.06,uM,=,1.3234583668494675,1,c1ccc(N2CCN(Cc3nc4c5ccccc5ncn4n3)CC2)cc1
6266,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CCO/N=C(/c1ccc(F)c(F)c1)c1ccc(CN2CCC3(CC2)OCc2cc(F)ncc23)cn1,"(Z)-(3,4-difluorophenyl)(5-((6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1'-yl)methyl)pyridin-2-yl)methanone O-ethyl oxime",1.79,uM,=,0.2528530309798932,1,N=C(c1ccccc1)c1ccc(CN2CCC3(CC2)OCc2ccncc23)cn1
6267,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,CC(C)(NCc1cc([C@]2(C)CCSC(N)=N2)c(F)cc1F)C(F)(F)F,"(S)-4-(2,4-Difluoro-5-(((1,1,1-trifluoro-2-methylpropan-2-yl)-amino)methyl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine",11.2,uM,=,1.0492180226701815,1,C1=NC(c2ccccc2)CCS1
6268,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1C1CCC(F)(F)CC1,"2-(4,4-Difluorocyclohexyl)-3-oxo-N-[4-(trifluoromethoxy)benzyl]isoindoline-1-carboxamide",14.0,uM,=,1.146128035678238,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1C1CCCCC1
6269,840300,10.1021/ml300064v,,,,Inhibition of human ERG expressed in HEK293 cells after 240 secs by patch clamp assay,C=CCc1ccccc1OC(C)C1=NCCN1,"2-[1-(2-Allyl-phenoxy)-ethyl]-4,5-dihydro-1H-imidazole",16.9,uM,=,1.2278867046136734,1,c1ccc(OCC2=NCCN2)cc1
6270,462632,10.1016/j.bmcl.2008.01.108,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes,Cc1cc[n+]([O-])c(C)c1C(=O)N1CCC(C)(N2CCC(N(Cc3ccccc3)c3ccccc3)CC2)CC1,"[4-(Benzyl-phenyl-amino)-4'-methyl-[1,4']bipiperidinyl-1'-yl]-(2,4-dimethyl-1-oxy-pyridin-3-yl)-methanone",0.55,uM,=,-0.2596373105057561,0,O=C(c1ccc[nH+]c1)N1CCC(N2CCC(N(Cc3ccccc3)c3ccccc3)CC2)CC1
6271,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,CCOC(=O)c1ccc(CCN2CCN(CCc3ccc([N+](=O)[O-])cc3)CC2)cc1,ethyl 4-(2-(4-(4-nitrophenethyl)piperazin-1-yl)ethyl)benzoate,0.019,uM,=,-1.7212463990471711,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6272,755897,10.1021/jm200112k,,,,Inhibition of Kv11.1 channel,CN(Cc1cnccn1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1,"N-methyl-N'-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyrazin-2-ylmethyl)sulfuric diamide",7.1,uM,=,0.8512583487190752,1,O=c1c2cc(NS(=O)(=O)NCc3cnccn3)ccc2ccc2ncc(-c3cn[nH]c3)cc12
6273,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc2c1nc(N)n1nc(CN3CCN(c4cccc(F)c4)C[C@H]3C)nc21,"(R)-2-((4-(3-fluorophenyl)-2-methylpiperazin-1-yl)methyl)-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",23.83,uM,=,1.377124042346456,1,c1ccc(N2CCN(Cc3nc4c5ccccc5ncn4n3)CC2)cc1
6274,1891417,10.1016/j.bmcl.2019.03.026,,,,Inhibition of human ERG by whole-cell patch clamp method,COC(=O)C1=C(C)NC(C)=C(C(=O)NC[C@H]2CCN(CCc3ccc(C(F)(F)F)cc3)C2)C1c1cccc([N+](=O)[O-])c1,"Methyl 2,6-dimethyl-4-(3-nitrophenyl)-5-((((R)-1-(4-(trifluoromethyl)phenethyl)pyrrolidin-3-yl)methyl)carbamoyl)-1,4-dihydropyridine-3-carboxylate",1.48,uM,=,0.1702617153949573,1,O=C(NC[C@H]1CCN(CCc2ccccc2)C1)C1=CNC=CC1c1ccccc1
6275,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,O=C(Nc1c(Cl)cncc1Cl)c1cn(-c2ccc(Cl)cc2)c2ncccc2c1=O,"1-(4-chlorophenyl)-N-(3,5-dichloropyridin-4-yl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide",0.198,uM,=,-0.7033348097384688,0,O=C(Nc1ccncc1)c1cn(-c2ccccc2)c2ncccc2c1=O
6276,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1cccc(-c2cccc(C3(C)CSCC(N)=N3)c2)c1,"5-(3'-Methoxybiphenyl-3-yl)-5-methyl-5,6-dihydro-2H-1,4-thiazin-3-amine",9.0,uM,=,0.9542425094393248,1,C1=NC(c2cccc(-c3ccccc3)c2)CSC1
6277,462632,10.1016/j.bmcl.2008.01.108,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes,Cc1cc[n+]([O-])c(C)c1C(=O)N1CCC(C)(N2CCC(N(Cc3cccc(C#N)c3)c3ccccc3)CC2)CC1,"3-({[1'-(2,4-Dimethyl-1-oxy-pyridine-3-carbonyl)-4'-methyl-[1,4']bipiperidinyl-4-yl]-phenyl-amino}-methyl)-benzonitrile",1.3,uM,=,0.1139433523068367,1,O=C(c1ccc[nH+]c1)N1CCC(N2CCC(N(Cc3ccccc3)c3ccccc3)CC2)CC1
6278,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(CC)O3)c1,"US8975415, RP86::US9242973, RP86",7.94,uM,=,0.8998205024270963,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21COC1
6279,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,C=CC(=O)Nc1cc(Nc2ncc(C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(5-methyl-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,15.6,uM,=,1.1931245983544616,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6280,2162538,10.1016/j.ejmech.2021.114045,,,,Inhibition of hERG expressed in CHO cells at -80 mV holding potential by automated patch clamp method,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.0559999999999999,uM,=,-1.2518119729937995,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
6281,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CCCCC3)c12,5-hydroxy-2-(4-hydroxyphenyl)-N-methyl-4-(1-piperidylmethyl)benzofuran-3-carboxamide,6.9,uM,=,0.8388490907372553,1,c1ccc(-c2cc3c(CN4CCCCC4)cccc3o2)cc1
6282,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,Cc1n[nH]cc1-c1cc(C(F)(F)F)cc(S(=O)(=O)N2CCN(C(=O)[C@@H]3C[C@H]3c3ccc(C(F)(F)F)cc3)CC2)c1,"(4-(3-(3-methyl-1H-pyrazol-4-yl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",0.04,uM,=,-1.3979400086720375,0,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2cccc(-c3cn[nH]c3)c2)CC1
6283,2223619,10.1021/acsmedchemlett.2c00294,,,,Inhibition of human ERG by fluorescence polarization assay,N[C@@H]1C[C@@H]1c1cc(F)c(Br)cc1F,"(+/-)-cis-2-(4-Bromo-2,5-difluorophenyl)cyclopropylamine",7.3,uM,=,0.8633228601204559,1,c1ccc(C2CC2)cc1
6284,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,Cc1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1,"4-(p-Tolyl)spiro[chromene-2,4'-piperidine]",0.462,uM,=,-0.3353580244438744,0,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
6285,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,COc1ccc(CCN2CCC(CCc3cccc(OCCF)c3)CC2)cc1.Cl,4-(3-(2-Fluoroethoxy)phenethyl)-1-(4-methoxyphenethyl)piperidine hydrochloride,0.28,uM,=,-0.5528419686577808,0,c1ccc(CCC2CCN(CCc3ccccc3)CC2)cc1
6286,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)CC#CCc1ccc(C)cc1,N-Butyl-N-ethyl-4-(p-tolyl)but-2-yn-1-amine,3.47,uM,=,0.5403294747908738,1,c1ccccc1
6287,748773,10.1016/j.bmcl.2011.04.102,,,,Inhibition of human ERG by HT patch clamp assay,Cc1c2c(n3c1CCCN1CC[C@H](CNc4cc-3ccc4C(N)=O)C1)CC(C)(C)CC2=O,"(17R)-5,5,9-trimethyl-7-oxo-2,14,19-triazapentacyclo[18.3.1.1^{14,17}.0^{2,10}.0^{3,8}]pentacosa-1(24),3(8),9,20,22-pentaene-21-carboxamide",0.44,uM,=,-0.3565473235138126,0,O=C1CCCc2c1cc1n2-c2cccc(c2)NC[C@H]2CCN(CCC1)C2
6288,411697,10.1021/jm060927v,,,,Binding affinity to hERG potassium channel,COc1ccc2c(OC[C@H](O)CO)nc(C#N)c(-c3ccccc3)c2c1,"1-{[(2R)-2,3-dihydroxypropyl]oxy}-6-methoxy-4-phenylisoquinoline-3-carbonitrile",20.5,uM,=,1.3117538610557542,1,c1ccc(-c2cncc3ccccc23)cc1
6289,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N3Cc4cc(Cl)cc(Cl)c4OC[C@@H]3Cc3ccc(Cl)cc3)CC2)n[nH]1,"(S)-3-(4-(7,9-dichloro-3-(4-chlorobenzyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-1H-1,2,4-triazol-5-amine",6.0,uM,=,0.7781512503836436,1,c1ccc(C[C@H]2COc3ccccc3CN2C2CCN(c3nc[nH]n3)CC2)cc1
6290,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCNc1cc(N2CCOCC2)cc(CCc2nc(C)c(CC)o2)n1,N-ethyl-6-(2-(5-ethyl-4-methyloxazol-2-yl)ethyl)-4-morpholinopyridin-2-amine,0.4,uM,=,-0.3979400086720376,0,c1cc(N2CCOCC2)cc(CCc2ncco2)n1
6291,640796,10.1016/j.bmcl.2010.05.041,,,,Displacement of radiolabeled astemizole from human ERG,O=C(c1ccc(Oc2ccc(F)cc2)cn1)N1CCCN(C2CCC2)CC1,"(4-cyclobutyl-1,4-diazepan-1-yl)(5-(4-fluorophenoxy)pyridin-2-yl)methanone",8.4,uM,=,0.9242792860618816,1,O=C(c1ccc(Oc2ccccc2)cn1)N1CCCN(C2CCC2)CC1
6292,702661,10.1021/jm100978n,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells,CCC(=O)N1CCc2c(nc(C)n2[C@H]2C[C@H]3CC[C@@H](C2)N3CC[C@H](NC(C)=O)c2cccc(F)c2)C1,"endo-N-((S)-1-(3-fluorophenyl)-3-(3-(2-methyl-5-propionyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)propyl)acetamide",5.0,uM,=,0.6989700043360189,1,c1ccc(CCCN2[C@@H]3CC[C@H]2C[C@@H](n2cnc4c2CCNC4)C3)cc1
6293,1891417,10.1016/j.bmcl.2019.03.026,,,,Inhibition of human ERG by whole-cell patch clamp method,COC(=O)C1=C(C)NC(C)=C(C(=O)NC[C@H]2CCN(CCc3ccc(Cl)c(Cl)c3)C2)C1c1cccc([N+](=O)[O-])c1,"Methyl 5-((((R)-1-(3,4-dichlorophenethyl)pyrrolidin-3-yl)methyl)carbamoyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate",0.65,uM,=,-0.1870866433571444,0,O=C(NC[C@H]1CCN(CCc2ccccc2)C1)C1=CNC=CC1c1ccccc1
6294,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cnc4[nH]cc(Cl)c4c3)ccc1OCC21CC1,"US8975415, RP62::US9242973, RP62",4.43,uM,=,0.6464037262230695,1,C1=NC2(CO1)c1cc(-c3cnc4[nH]ccc4c3)ccc1OCC21CC1
6295,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,CCN1CCC2(C=C(c3ccc(C(=O)N(CC)CC)cc3)c3ccccc3O2)CC1,"N,N-Diethyl-4-(1'-ethylspiro[chromene-2,4'-piperidine]-4-yl)benzamide",1.814,uM,=,0.2586372827240765,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
6296,1697113,10.1021/acs.jmedchem.7b00932,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in peak tail current amplitude by path clamp method,NC(=O)c1c(NC(=O)Nc2ccc(Cl)cc2)sc2c1CC[N+]1(CCOCC1)C2.[I-],"3'-Carbamoyl-2'-[3-(4-chlorophenyl)ureido]-5',7'-dihydro-4'H-spiro[morpholine-4,6'-thieno[2,3-c]pyridin]-4-ium Iodide",12.4,uM,=,1.0934216851622351,1,O=C(Nc1ccccc1)Nc1cc2c(s1)C[N+]1(CCOCC1)CC2
6297,1780154,10.1021/acs.jmedchem.8b01077,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV after 60 secs by patch clamp assay,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCCC1)c1cccs1,"N-((S)-3-(exo-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(thiophen-2-yl)propyl)cyclopentaneCarboxamide",1.52,uM,=,0.1818435879447725,1,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@H](n1cnnc1)C2)c1cccs1)C1CCCC1
6298,1448459,10.1021/jm5004864,,,,Inhibition of human ERG over-expressed in HEK293 cell membrane by [3H]dofetilide binding assay,CN(C)c1ccc(/C=C/c2c(F)cccc2F)cn1,"(E)-5-(2',6'-Difluorostyryl)-2-(N,N-dimethylamino)pyridine",22.0,uM,=,1.3424226808222062,1,C(=C/c1cccnc1)\c1ccccc1
6299,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,Cc1cccc(CCN2C(=O)c3ccccc3C2C(=O)NCc2ccc(OC(F)(F)F)cc2)n1,2-(2-(6-Methylpyridin-2-yl)ethyl)-3-oxo-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,6.6,uM,=,0.8195439355418687,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
6300,1666152,10.1021/acs.jmedchem.7b00231,,,,Inhibition of human ERG,CC(C)Oc1cc2c(OC[C@@H]3CCC(=O)N3)nccc2cc1C(N)=O,(S)-7-Isopropoxy-1-((5-oxopyrrolidin-2-yl)methoxy)isoquinoline-6-carboxamide,30.0,uM,=,1.4771212547196624,1,O=C1CC[C@@H](COc2nccc3ccccc23)N1
6301,2023418,10.1016/j.bmcl.2020.127663,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch clamp assay,Cc1ncn(C2CCN(C(=O)/C=C/c3ccc(C(F)(F)F)cc3Cn3nnc(C)n3)CC2)n1,"(E)-1-(4-(3-methyl-1H-1,2,4-triazol-1-yl)piperidin-1-yl)-3-(2-((5-methyl-2H-tetrazol-2-yl)methyl)-4-(trifluoromethyl)phenyl)prop-2-en-1-one",25.0,uM,=,1.3979400086720375,1,O=C(/C=C/c1ccccc1Cn1ncnn1)N1CCC(n2cncn2)CC1
6302,1665702,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,Oc1ccc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)cn1,5-(5-phenyl-4-((pyridin-2-ylmethyl)amino)quinazolin-2-yl)pyridin-2(1H)-one,0.5,uM,=,-0.3010299956639812,0,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1
6303,1353223,10.1021/jm401705g,,,,Inhibition of human ERG by electrophysiology assay,N#Cc1ccc(-c2ccc(C[C@@H](C#N)NC(=O)C3(N)CCOCC3)cc2)cc1,(S)-4-Amino-N-(1-cyano-2-(4'-cyanobiphenyl-4-yl)ethyl)-tetrahydro-2H-pyran-4-carboxamide,26.0,uM,=,1.414973347970818,1,O=C(NCCc1ccc(-c2ccccc2)cc1)C1CCOCC1
6304,2054470,10.1016/j.ejmech.2020.112517,,,,Inhibition of human ERG,CNC(=O)c1n[nH]c2cc(-c3ccc(-n4cccc(C)c4=O)cc3Cl)ccc12,6-(2-Chloro-4-(3-methyl-2-oxopyridin-1-(2H)-yl)phenyl)-N-methyl-1H-indazole-3-carboxamide,21.0,uM,=,1.3222192947339193,1,O=c1ccccn1-c1ccc(-c2ccc3cn[nH]c3c2)cc1
6305,1552715,10.1016/j.ejmech.2015.12.006,,,,Inhibition of human ERG channel by fluorescence polarization assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CC2CCN(C(=S)C(C)C)CC2)C[C@H]1OC,cis-4-Amino-5-chloro-N-(1-((1-(2-methylpropanethioyl)piperidin-4-yl)methyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide,1.132,uM,=,0.0538464268522525,1,O=C(NC1CCN(CC2CCNCC2)CC1)c1ccccc1
6306,796234,10.1016/j.bmcl.2011.10.115,,,,Inhibition of human Erg by whole cell patch clamp electrophysiology,Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C,"(+)-2-(1-(3,4-dimethylbenzyl)-1H-benzo[d]imidazol-2-yl)morpholine",2.1,uM,=,0.3222192947339193,1,c1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1
6307,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCc1cnccn1,3-Oxo-2-(2-pyrazin-2-ylethyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-1H-isoindole-1-carboxamide,9.2,uM,=,0.9637878273455552,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1cnccn1
6308,2158639,10.1016/j.ejmech.2021.113986,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by whole cell patch clamp assay,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1,[(3-Methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine,5.5,uM,=,0.7403626894942439,1,c1ccc([C@]2(CCNCc3cccs3)CCOC3(CCCC3)C2)nc1
6309,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CC#Cc1cncc(-c2ccc3c(c2)C2(CSC(N)=N2)C2(COC2)CO3)c1,"US8975415, RP68::US9242973, RP68",6.05,uM,=,0.7817553746524689,1,C1=NC2(CS1)c1cc(-c3cccnc3)ccc1OCC21COC1
6310,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,NC1=N[C@@]2(c3cc(CNCC(F)(F)F)c(F)cc3F)CO[C@@H](CF)C[C@H]2CS1,"US9045498, 8",4.3,uM,=,0.6334684555795865,1,C1=N[C@@]2(c3ccccc3)COCC[C@H]2CS1
6311,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(-c3cn[nH]c3)cc(C(F)(F)F)c2)CC1,"(4-(3-(1H-pyrazol-4-yl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",0.5,uM,=,-0.3010299956639812,0,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2cccc(-c3cn[nH]c3)c2)CC1
6312,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,C[C@@]1(c2cc(CNCC(F)F)c(F)cc2F)CCSC(N)=N1,"(S)-4-(5-(((2,2-Difluoroethyl)amino)methyl)-2,4-difluorophenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine",14.7,uM,=,1.167317334748176,1,C1=NC(c2ccccc2)CCS1
6313,748773,10.1016/j.bmcl.2011.04.102,,,,Inhibition of human ERG by HT patch clamp assay,Cc1c2c(n3c1CCCN1CCOC[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,"(19S)-5,5,9-trimethyl-7-oxo-17-oxa-2,14,21-triazapentacyclo[20.3.1.0^{2,10}.0^{3,8}.0^{14,19}]hexacosa-1(26),3(8),9,22,24-pentaene-23-carboxamide",12.5,uM,=,1.0969100130080565,1,O=C1CCCc2c1cc1n2-c2cccc(c2)NC[C@H]2COCCN2CCC1
6314,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1csc([C@]2(CN)[C@@H]3CN(c4cnc5c(-c6cccc(Cl)c6Cl)n[nH]c5n4)CC[C@@H]32)n1,"((1R,6S,7S)-3-(3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-7-(4-methylthiazol-2-yl)-3-azabicyclo[4.1.0]heptan-7-yl)methanamine",0.769,uM,=,-0.1140736601985689,0,c1ccc(-c2n[nH]c3nc(N4CC[C@@H]5C(c6nccs6)[C@@H]5C4)cnc23)cc1
6315,858750,10.1021/jm3008689,,,,Inhibition of human ERG,CS(=O)(=O)c1ccc([C@@H](CC2CCCC2)C(=O)Nc2cnccn2)cc1Cl,2(R)-(3-Chloro-4-methylsulfonyl-phenyl)-3-cyclopentyl-N-pyrazin-2-yl-propionamide,7.3,uM,=,0.8633228601204559,1,O=C(Nc1cnccn1)[C@H](CC1CCCC1)c1ccccc1
6316,1552715,10.1016/j.ejmech.2015.12.006,,,,Inhibition of human ERG channel by fluorescence polarization assay,CCOC(=O)N1CCC(CN2CC[C@H](NC(=O)c3cc(Cl)c(N)cc3OC)[C@H](OC)C2)CC1,Ethyl 4-((cis-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)methyl)piperidine-1-carboxylate,4.58,uM,=,0.6608654780038692,1,O=C(NC1CCN(CC2CCNCC2)CC1)c1ccccc1
6317,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)c1,"US8975415, RP111::US8975415, RP52a::US9242973, RP111",4.83,uM,=,0.6839471307515121,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
6318,2169259,10.1021/acs.jmedchem.1c00625,,,,Inhibition of human ERG by flux assay,Cc1noc(C)c1-c1cnc2c3ccc(C(C)(C)O)cc3n([C@H](c3ccccc3)C3CCOCC3)c2c1,"(S)-2-[3-(Dimethyl-1,2-ozazol-4-yl)-5-[oxan-4-yl(phenyl)-methyl)-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol",51.0,uM,=,1.7075701760979365,1,c1ccc([C@H](C2CCOCC2)n2c3ccccc3c3ncc(-c4cnoc4)cc32)cc1
6319,1841342,10.1016/j.bmcl.2019.03.029,,,,Inhibition of human ERG by QPatch assay,Cc1sc(-c2ccccc2Cl)cc1C(=O)N[C@@H](CN)c1ccccc1,(R)-N-(2-amino-1-phenylethyl)-5-(2-chlorophenyl)-2-methylthiophene-3-carboxamide,6.7,uM,=,0.8260748027008264,1,O=C(NCc1ccccc1)c1csc(-c2ccccc2)c1
6320,1554488,10.1016/j.bmcl.2016.01.049,,,,Inhibition of human ERG using tracer red fluorescent probe,CNCc1cc(C(=O)N[C@@H]2CCc3ccc(Oc4ccnc5c4CCC(=O)N5)cc3C2)cc(C(F)(F)F)c1.Cl.Cl,"3-((methylamino)methyl)-N-{(2R)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide dihydrochloride",10.0,uM,=,1.0,1,O=C1CCc2c(Oc3ccc4c(c3)C[C@H](NC(=O)c3ccccc3)CC4)ccnc2N1
6321,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CCO/N=C(/c1ccc(CN2CCC3(CC2)OCc2cc(F)ncc23)cc1)c1ccc(F)c(F)c1,"(Z)-(3,4-difluorophenyl)(4-((6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1'-yl)methyl)phenyl)methanone O-ethyl oxime",0.14,uM,=,-0.8538719643217619,0,N=C(c1ccccc1)c1ccc(CN2CCC3(CC2)OCc2ccncc23)cc1
6322,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,N[C@]1(c2ccccc2)CC[C@H](N2CC(NC(=O)CNC(=O)c3cccc(C(F)(F)F)c3)C2)CC1,N-{[1-(4-Amino-4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide,6.2,uM,=,0.7923916894982539,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccccc3)CC2)C1
6323,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,FC(F)(F)c1cccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)c1,"10-(pyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",0.557,uM,=,-0.254144804826271,0,c1ccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
6324,1765513,10.1021/acs.jmedchem.8b01040,,,,Inhibition of human ERG by automated patch clamp assay,O=C(Nc1ccc(SC(F)(F)F)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cncnc2)c1,"US9278981, 186",1.5,uM,=,0.1760912590556812,1,O=C(Nc1ccccc1)c1cnc(N2CCCC2)c(-c2cncnc2)c1
6325,858024,10.1021/jm300690s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 60 mins by liquid scintillation counter,N#Cc1ccc2ccc(=O)n(CCN3CC[C@H](NCc4cc5c(cn4)OCCO5)[C@@H](F)C3)c2c1,"trans-1-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]-3-fluoropiperidin-1-yl}ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",57.0,uM,=,1.7558748556724917,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
6326,1554488,10.1016/j.bmcl.2016.01.049,,,,Inhibition of human ERG using tracer red fluorescent probe,Cl.Cl.NCc1cc(C(=O)N[C@@H]2CCc3ccc(Oc4ccnc5c4CCC(=O)N5)cc3C2)cc(C(F)(F)F)c1,"3-(aminomethyl)-N-[(2R)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide dihydrochloride",6.6,uM,=,0.8195439355418687,1,O=C1CCc2c(Oc3ccc4c(c3)C[C@H](NC(=O)c3ccccc3)CC4)ccnc2N1
6327,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(N[C@@H]5CCOC[C@@H]5N)c(C)n4)n3)cc12,"5-[[4-[4-[[(3R,4R)-3-aminotetrahydropyran-4-yl]amino]-3-methyl-pyrazol-1-yl]pyrimidin-2-yl]amino]-N,1-dimethyl-indazole-3-carboxamide",17.0,uM,=,1.230448921378274,1,c1cc(-n2cc(NC3CCOCC3)cn2)nc(Nc2ccc3[nH]ncc3c2)n1
6328,462632,10.1016/j.bmcl.2008.01.108,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes,Cc1cccnc1C(=O)N1CCC(C)(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CC1,(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)(3-methylpyridin-2-yl)methanone,0.41,uM,=,-0.3872161432802645,0,O=C(c1ccccn1)N1CCC(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CC1
6329,627243,10.1021/jm9016812,,,,Inhibition of human ERG by electrophysiology assay,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(F)cc4)oc3C)c2)cc1,2-((3-((2-(4-fluorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,38.0,uM,=,1.57978359661681,1,O=C(NCc1cccc(OCc2coc(-c3ccccc3)n2)c1)Oc1ccccc1
6330,972740,10.1021/ml400197u,,,,Binding affinity to human ERG expressed in CHO cells by IonWorks assay,CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C1CC1,"N-[5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-cyclopropylphenyl]acetamide",19.0,uM,=,1.2787536009528289,1,c1cc2nc(Nc3ccc(C4CC4)cc3)cc(NC3CC3)n2n1
6331,875038,10.1021/jm300573d,,,,Inhibition of human ERG,COCc1ccc(CCN2CCC(COc3nc4ccccc4c4cn(C)cc34)CC2)cc1,"4-[[1-[2-[4-(Methoxymethyl)phenyl]ethyl]-4-piperidinyl]-methoxy]-2-methyl-2H-pyrrolo[3,4-c]quinoline",0.02,uM,=,-1.6989700043360187,0,c1ccc(CCN2CCC(COc3nc4ccccc4c4c[nH]cc34)CC2)cc1
6332,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1C1CC(F)(F)C1,"2-(3,3-Difluorocyclobutyl)-3-oxo-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide",23.0,uM,=,1.3617278360175928,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1C1CCC1
6333,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NC/C=C/c3cc(F)ccc3F)(CC1)CO2,"(R,E)-4-((4-(3-(2,5-difluorophenyl)allylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",0.008,uM,=,-2.096910013008056,0,O=c1ccc2nccc3c2n1CC3CC12CCC(NC/C=C/c3ccccc3)(CC1)CO2
6334,2186534,10.1021/acs.jmedchem.1c01132,,,,Inhibition of hERG ion channel incubated for 3 hrs by fluorescence polarization assay,N[C@@H]1CCCC12CCN(c1cnc3c(-c4cccc(Cl)c4Cl)n[nH]c3n1)CC2,"(R)-8-(3-(2,3-Dichlorophenyl)-1H-pyrazolo[3,4-b]-pyrazin-6-yl)-8-azaspiro[4.5]decan-1-amine",0.06,uM,=,-1.2218487496163564,0,c1ccc(-c2n[nH]c3nc(N4CCC5(CCCC5)CC4)cnc23)cc1
6335,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCc1oc(SCc2cc(N3CCOCC3)cc(NCC#N)n2)nc1C,2-(6-((5-ethyl-4-methyloxazol-2-ylthio)methyl)-4-morpholinopyridin-2-ylamino)acetonitrile,8.3,uM,=,0.919078092376074,1,c1cc(N2CCOCC2)cc(CSc2ncco2)n1
6336,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CC(=O)c1c(-c2cc(C)c(O)cn2)oc2ccc(O)c(CN3CCC3)c12,1-(4-(azetidin-1-ylmethyl)-5-hydroxy-2-(5-hydroxy-4-methylpyridin-2-yl)benzofuran-3-yl)ethanone,12.4,uM,=,1.0934216851622351,1,c1ccc(-c2cc3c(CN4CCC4)cccc3o2)nc1
6337,2073754,10.1021/acs.jmedchem.0c00983,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp electrophysiology method,COc1ccc2c3c([nH]c2c1)[C@@H]1N(CC3)C(=O)c2c(OC)cccc2N1C,"(S)-4,11-Dimethoxy-14-methyl-7,8,13b,14-tetrahydroindolo-[2',3':3,4]pyrido[2,1-b]quinazolin-5(13H)-one",20.0,uM,=,1.3010299956639813,1,O=C1c2ccccc2N[C@@H]2c3[nH]c4ccccc4c3CCN12
6338,1335624,10.1016/j.bmcl.2014.02.064,,,,Inhibition of human ERG,CC(C)(O)COCc1cccc(Nc2sc(-c3c(F)cc(C(C)(C)O)cc3F)cc2C(N)=O)n1,"5-(2,6-difluoro-4-(2-hydroxypropan-2-yl)phenyl)-2-(6-((2-hydroxy-2-methylpropoxy)methyl)pyridin-2-ylamino)thiophene-3-carboxamide",12.0,uM,=,1.0791812460476249,1,c1ccc(-c2ccc(Nc3ccccn3)s2)cc1
6339,1580962,10.1021/acsmedchemlett.6b00018,,,,Binding affinity to human ERG by radioligand binding assay,C[C@H]1Cc2c(ncnc2Oc2ccc3ccn(C(=O)Nc4cc(C5(C(F)(F)F)CC5)on4)c3c2)CN1,"(S)-6-((6-Methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)oxy)-N-(5-(1-(trifluoromethyl)cyclopropyl)isoxazol-3-yl)-1H-indole-1-carboxamide",8.6,uM,=,0.9344984512435676,1,O=C(Nc1cc(C2CC2)on1)n1ccc2ccc(Oc3ncnc4c3CCNC4)cc21
6340,1469020,10.1016/j.bmcl.2014.12.078,,,,Inhibition of human ERG channel,CCOc1nc(NC(=O)C2(NC(=O)c3ccc4c(C5CCCC5)c(-c5ccc(F)cn5)n(C)c4c3)CCC2)ccc1/C=C/C(=O)O,3-(6-(1-(3-cyclopentyl-2-(5-fluoropyridin-2-yl)-1-methyl-1H-indole-6-carboxamido)cyclobutanecarboxamido)-2-ethoxypyridin-3-yl)acrylic acid,2.1,uM,=,0.3222192947339193,1,O=C(NC1(C(=O)Nc2ccccn2)CCC1)c1ccc2c(C3CCCC3)c(-c3ccccn3)[nH]c2c1
6341,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)C/C=C\Cc1ccccc1,(Z)-N-Ethyl-N-(4-phenylbut-2-en-1-yl)heptan-1-amine,1.178,uM,=,0.0711452904510828,1,c1ccccc1
6342,768794,10.1021/jm200290z,,,,Inhibition of human ERG,c1ccc(Nc2nc3c(s2)CCc2n[nH]cc2-3)nc1,"(5,7-Dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-pyridin-2-yl-amine",17.0,uM,=,1.230448921378274,1,c1ccc(Nc2nc3c(s2)CCc2n[nH]cc2-3)nc1
6343,2216976,10.1021/acs.jmedchem.2c00676,,,,Inhibition of hERG by Qpatch-clamp method,Cc1nc(C)n(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3nc4ccc(-c5noc(C)n5)cc4[nH]3)C[C@H]2C)n1,"US9266876, 236",18.0,uM,=,1.255272505103306,1,O=C(Cn1cncn1)N1CCN(c2scnc2-c2nc3ccc(-c4ncon4)cc3[nH]2)CC1
6344,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CC#CCc1ccc(C)cc1,N-Ethyl-N-heptyl-4-(p-tolyl)but-2-yn-1-amine,5.09,uM,=,0.7067177823367587,1,c1ccccc1
6345,2161344,10.1021/acs.jmedchem.1c02048,,,,Inhibition of [35S]MK-499 binding to hERG expressed in HEK293 cells,CCOC(=O)N1C[C@H]2[C@H](C)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@]32C1,"ethyl(3R,3aS,4S,5R,6R,6aS,9aR)-4-[(E)-2-[5-(2-cyanophenyl)-2-pyridyl]vinyl]-3,5,6-trimethyl-1-oxo-3,3a,4,5,6,6a,7,9-octahydrofuro[3,4-d]isoindole-8-carboxylate",1.6,uM,=,0.2041199826559248,1,O=C1OC[C@H]2[C@@H](/C=C/c3ccc(-c4ccccc4)cn3)CC[C@@H]3CNC[C@@]132
6346,1580962,10.1021/acsmedchemlett.6b00018,,,,Binding affinity to human ERG by radioligand binding assay,CC(C)(C)c1cc(NC(=O)n2ncc3cc(Oc4ncnc5c4CNC5)ccc32)no1,"N-(5-(tert-Butyl)isoxazol-3-yl)-5-((6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)oxy)-1H-indazole-1-carboxamide",7.7,uM,=,0.8864907251724818,1,O=C(Nc1ccon1)n1ncc2cc(Oc3ncnc4c3CNC4)ccc21
6347,2223202,10.1021/acsmedchemlett.2c00111,,,,Inhibition of hERG cardiac ion channel,O=C1CSc2ccc(CN[C@H]3CO[C@H](CC4Cn5c(=O)ccc6ncc(F)c4c65)OC3)nc2N1,"6-(((2-((3-fluoro-7-oxo-4,5-dihydro-7H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-trans-1,3-dioxan-5-yl)amino)methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one",55.0,uM,=,1.740362689494244,1,O=C1CSc2ccc(CN[C@H]3CO[C@H](CC4Cn5c(=O)ccc6nccc4c65)OC3)nc2N1
6348,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,CC(=O)N1CCC(n2cc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)c(C)n2)CC1,"1-[4-(4-{[5-Chloro-4-(imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3-methyl-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",5.2,uM,=,0.7160033436347992,1,c1ccn2c(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)cnc2c1
6349,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CC#Cc1ccc(Cl)cc1,N-(3-(4-Chlorophenyl)prop-2-yn-1-yl)-N-ethylheptan-1-amine,4.08,uM,=,0.6106601630898799,1,c1ccccc1
6350,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,N#Cc1ccc(CCN2CCN(CCc3ccc4c(c3)COC4=O)CC2)cc1F,"2-fluoro-4-(2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",0.17,uM,=,-0.7695510786217261,0,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
6351,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(-c3cn[nH]n3)cc(C(F)(F)F)c2)CC1,"(4-(3-(2H-1,2,3-triazol-4-yl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",3.5,uM,=,0.5440680443502757,1,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2cccc(-c3cn[nH]n3)c2)CC1
6352,2148733,10.1021/acs.jmedchem.1c00174,,,,Binding affinity to human ERG,COc1cc(OC)cc(-c2nn(CCCCCN3CCN(C(=O)/C=C/C(F)(F)F)CC3)c3ncnc(N)c23)c1,"(E)-1-(4-(5-(4-amino-3-(3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)-4,4,4-trifluorobut-2-en-1-one",3.211,uM,=,0.5066403055665025,1,c1ccc(-c2nn(CCCCCN3CCNCC3)c3ncncc23)cc1
6353,2023418,10.1016/j.bmcl.2020.127663,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch clamp assay,Cc1nnn(Cc2cc(C(F)(F)F)ccc2/C=C/C(=O)N2CCC(C(F)(F)F)CC2)n1,(E)-3-(2-((5-methyl-2H-tetrazol-2-yl)methyl)-4-(trifluoromethyl)phenyl)-1-(4-(trifluoromethyl)piperidin-1-yl)prop-2-en-1-one,19.0,uM,=,1.2787536009528289,1,O=C(/C=C/c1ccccc1Cn1ncnn1)N1CCCCC1
6354,344972,10.1016/j.bmcl.2006.01.030,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CN(CCCN)C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1ccccc1,"(S)-N-(3-aminopropyl)-4-(2,5-difluorophenyl)-N-methyl-2-phenyl-2H-pyrrole-1(5H)-carboxamide",1.3,uM,=,0.1139433523068367,1,C1=C(c2ccccc2)CN[C@@H]1c1ccccc1
6355,1861615,10.1016/j.ejmech.2019.111595,,,,Inhibition of human ERG transfected in HEK293 cells by whole-cell patch clamp method,CCON=C1CCC(CN2CCN(c3nc(=O)c4cc(C(F)(F)F)cc([N+](=O)[O-])c4s3)CC2)CC1,"2-(4-((4-(ethoxyimino)cyclohexyl)methyl)piperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one",38.92,uM,=,1.5901728315963144,1,N=C1CCC(CN2CCN(c3nc(=O)c4ccccc4s3)CC2)CC1
6356,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4ccccc4OC(F)(F)F)n2CCO3)ccn1,"10-(2-methylpyridin-4-yl)-3-(2-(trifluoromethoxy)phenoxy)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",2.84,uM,=,0.4533183400470376,1,c1ccc(Oc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
6357,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,COC[C@H](C)Oc1cc(Oc2ccc(C(=O)N3CCC3)cc2)cc(C(=O)Nc2ccn(C)n2)c1,(S)-3-(4-(azetidine-1-carbonyl)phenoxy)-5-(1-methoxypropan-2-yloxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide,36.0,uM,=,1.5563025007672873,1,O=C(Nc1cc[nH]n1)c1cccc(Oc2ccc(C(=O)N3CCC3)cc2)c1
6358,1554488,10.1016/j.bmcl.2016.01.049,,,,Inhibition of human ERG using tracer red fluorescent probe,Cl.N[C@H](CO)c1cc(C(=O)N[C@@H]2CCc3ccc(Oc4ccnc5c4CCC(=O)N5)cc3C2)cc(C(F)(F)F)c1,"3-((1S)-1-amino-2-hydroxyethyl)-N-{(2R)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide hydrochloride",13.8,uM,=,1.1398790864012365,1,O=C1CCc2c(Oc3ccc4c(c3)C[C@H](NC(=O)c3ccccc3)CC4)ccnc2N1
6359,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCc1oc(CCc2cc(N3CCOCC3)cc(NC)n2)nc1C,6-(2-(5-ethyl-4-methyloxazol-2-yl)ethyl)-N-methyl-4-morpholinopyridin-2-amine,0.83,uM,=,-0.0809219076239261,0,c1cc(N2CCOCC2)cc(CCc2ncco2)n1
6360,1883248,10.1021/acs.jmedchem.8b01344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch assay,N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cn3)[C@@](O)(CN)C2)c(Cl)c1,"4-(((3R,4S)-3-(Aminomethyl)-4-((5-chloropyridin-2-yl)-sulfonyl)-3-hydroxypyrrolidin-1-yl)sulfonyl)-3-chlorobenzonitrile",8.0,uM,=,0.9030899869919436,1,O=S(=O)(c1ccccn1)[C@@H]1CCN(S(=O)(=O)c2ccccc2)C1
6361,980788,10.1021/jm4006324,,,,Displacement of [3H]dofetilide from human ERG channel,Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCCCC2)n1,4-(1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyrimidin-2-amine,27.7,uM,=,1.4424797690644486,1,c1ccc(-c2ncn(C3CCCCC3)c2-c2ccncn2)cc1
6362,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,CC(=O)OCC(=O)NC1CCN(CCc2ccc(Oc3nc4ccccc4s3)cc2)CC1,Acetic acid(1-{2-[4-(Benzothiazol-2-yloxy)phenyl]ethyl}piperidin-4-ylcarbamoyl)methyl Ester,5.0,uM,=,0.6989700043360189,1,c1ccc2sc(Oc3ccc(CCN4CCCCC4)cc3)nc2c1
6363,2023418,10.1016/j.bmcl.2020.127663,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch clamp assay,Cc1nnn(Cc2cc(Cl)ccc2/C=C/C(=O)N2CCN(Cc3coc(C)n3)CC2)n1,(E)-3-(4-chloro-2-((5-methyl-2H-tetrazol-2-yl)methyl)phenyl)-1-(4-((2-methyloxazol-4-yl)methyl)piperazin-1-yl)prop-2-en-1-one,23.0,uM,=,1.3617278360175928,1,O=C(/C=C/c1ccccc1Cn1ncnn1)N1CCN(Cc2cocn2)CC1
6364,344972,10.1016/j.bmcl.2006.01.030,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CC(C)(C)[C@H](N)C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1ccccc1,"(S)-2-amino-1-((S)-4-(2,5-difluorophenyl)-2-phenyl-2H-pyrrol-1(5H)-yl)-3,3-dimethylbutan-1-one",1.5,uM,=,0.1760912590556812,1,C1=C(c2ccccc2)CN[C@@H]1c1ccccc1
6365,2164528,10.1021/acs.jmedchem.1c02169,,,,Inhibition of hERG,Cc1nc(C)c([C@H](OC(C)(C)C)C(=O)O)c(N2CCC(C)(C)CC2)c1-c1ccc(OCCc2ccc(F)cc2)cc1,"(2S)-2-tert-butoxy-2-[4-(4,4-dimethyl-1-piperidyl)-5-[4-[2-(4-fluorophenyl)ethoxy]phenyl]-2,6-dimethyl-3-pyridyl]acetic acid",0.67,uM,=,-0.1739251972991735,0,c1ccc(CCOc2ccc(-c3cnccc3N3CCCCC3)cc2)cc1
6366,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,CCc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"1-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3-ethyl-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",5.2,uM,=,0.7160033436347992,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
6367,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CCCCc1ccc(Cl)cc1,N-(4-(4-Chlorophenyl)butyl)-N-ethylheptan-1-amine,0.043,uM,=,-1.3665315444204136,0,c1ccccc1
6368,687881,10.1016/j.bmcl.2010.10.020,,,,Inhibition of human ERG,CCO[C@H]1CN([C@H]2CC[C@@](O)(c3ccc(C)cc3)CC2)C[C@@H]1NC(=O)CNC(=O)c1cccc(C(F)(F)F)c1,"N-(2-((3S,4S)-4-ethoxy-1-(cis-4-hydroxy-4-p-tolylcyclohexyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide",11.0,uM,=,1.0413926851582251,1,O=C(CNC(=O)c1ccccc1)N[C@@H]1CCN(C2CCC(c3ccccc3)CC2)C1
6369,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N(CCc3ccc(Cl)cc3)Cc3cccc(Cl)c3)CC2)n[nH]1,"1-(5-amino-1H-1,2,4-triazol-3-yl)-N-(3-chlorobenzyl)-N-(4-chlorophenethyl)piperidin-4-amine",3.7,uM,=,0.568201724066995,1,c1ccc(CCN(Cc2ccccc2)C2CCN(c3nc[nH]n3)CC2)cc1
6370,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,Cc1cnc(NC(=O)c2cc(Oc3ccc(C(=O)N4CCC4)cc3)cc(O[C@@H](C)CO)c2)cn1,(S)-3-(4-(azetidine-1-carbonyl)phenoxy)-5-(1-hydroxypropan-2-yloxy)-N-(5-methylpyrazin-2-yl)benzamide,38.0,uM,=,1.57978359661681,1,O=C(Nc1cnccn1)c1cccc(Oc2ccc(C(=O)N3CCC3)cc2)c1
6371,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccc(O)cc2C)oc2ccc(O)c(CN3CCC4(COC4)C3)c12,4-(2-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-5-hydroxy-2-(4-hydroxy-2-methylphenyl)-N-methylbenzofuran-3-carboxamide,30.0,uM,=,1.4771212547196624,1,c1ccc(-c2cc3c(CN4CCC5(COC5)C4)cccc3o2)cc1
6372,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc2c1nc(N)n1nc(CN3CCN(c4ccc(F)cn4)C[C@H]3C)nc21,"(R)-2-((4-(5-fluoropyridin-2-yl)-2-methylpiperazin-1-yl)methyl)-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",21.87,uM,=,1.339848783037637,1,c1ccc(N2CCN(Cc3nc4c5ccccc5ncn4n3)CC2)nc1
6373,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,CC1(c2cccc(-c3cccc(Cl)c3)c2)N=C(N)CCO1,"2-(3'-Chlorobiphenyl-3-yl)-2-methyl-5,6-dihydro-2H-1,3-oxazin-4-amine",6.15,uM,=,0.7888751157754168,1,C1=NC(c2cccc(-c3ccccc3)c2)OCC1
6374,1666036,10.1021/acs.jmedchem.7b00363,,,,Inhibition of human ERG expressed in CHO cells assessed as reduction in tail current at -40 holding potential by automated patch-clamp assay,O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2N1,"7-{4-[4-(8-Hydroxyquinolin-2(1H)-one-5-yl)-1,4-diazepan-1-yl]-butoxy}-3,4-dihydroquinolin-2(1H)-one",19.7,uM,=,1.294466226161593,1,O=C1CCc2ccc(OCCCCN3CCCN(c4cccc5[nH]c(=O)ccc45)CC3)cc2N1
6375,1469975,10.1021/jm501021n,,,,Inhibition of human ERG by PDSP screening,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccc(Cl)s4)nc31)[C@H](O)[C@@H]2O,"(1S,2R,3S,4R,5S)-4-(2-((5-Chlorothiophen-2-yl)ethynyl)-6-(methylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]-hexane-1-carboxamide",12.9,uM,=,1.110589710299249,1,C(#Cc1cccs1)c1ncc2ncn([C@H]3CCC4C[C@@H]43)c2n1
6376,1571176,10.1016/j.bmcl.2016.03.035,,,,Inhibition of human ERG by electrophysiology analysis,Cc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O,"US9056859, 72",17.0,uM,=,1.230448921378274,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
6377,2151854,10.1016/j.ejmech.2020.112914,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,C[C@]1(COc2ccc(OC(F)(F)F)cc2)Cn2cc([N+](=O)[O-])nc2O1,"(R)-2-methyl-6-nitro-2-(4-trifluoromethoxyphenoxymethyl)-2,3-dihydroimidazo[2,1-b]oxazole",10.5,uM,=,1.021189299069938,1,c1ccc(OCC2Cn3ccnc3O2)cc1
6378,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,CC1(c2cccc(-c3cccnc3)c2)N=C(N)c2ccccc2O1,"2-Methyl-2-(3-(pyridin-3-yl)phenyl)-2H-benzo[e][1,3]oxazin-4-amine",2.8,uM,=,0.4471580313422192,1,C1=NC(c2cccc(-c3cccnc3)c2)Oc2ccccc21
6379,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21,"5,5'-(2,2'-(piperazine-1,4-diyl)bis(ethane-2,1-diyl))diisobenzofuran-1(3H)-one",1.9,uM,=,0.2787536009528289,1,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21
6380,2232362,10.1016/j.bmcl.2022.128648,,,,Inhibition of human ERG by Ionworks electrophysiology assay,COc1ccc2ccc(=O)n(CCN[C@H]3CC[C@H]4[C@@H](C3)OC(=O)N4c3ccc4c(n3)NC(=O)CO4)c2n1,"6-((3aS,6S,7aR)-6-((2-(7-methoxy-2-oxo-1,8-naphthyridin-1(2H)-yl)ethyl)amino)-2-oxohexahydrobenzo[d]oxazol-3(2H)-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.0,uM,=,0.4771212547196624,1,O=C1COc2ccc(N3C(=O)O[C@@H]4C[C@@H](NCCn5c(=O)ccc6cccnc65)CC[C@@H]43)nc2N1
6381,2024260,10.1016/j.bmcl.2020.127686,,,,Inhibition of human ERG,CN(C)CCn1cc2cc(NC(=O)c3cccc(C(F)(F)F)n3)c(C(C)(C)O)cc2n1,N-[2-[2-(dimethylamino)ethyl]-6-(1-hydroxy-1-methylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide,16.5,uM,=,1.2174839442139065,1,O=C(Nc1ccc2n[nH]cc2c1)c1ccccn1
6382,1858736,10.1021/acs.jmedchem.9b01336,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,CC(C)(C)c1cc(NC(=O)Cc2ccc(-n3cnc4cc(-c5ccc(S(C)(=O)=O)cc5)ccc43)cc2)no1,N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(4-(methylsulfonyl)phenyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide,7.57,uM,=,0.8790958795000727,1,O=C(Cc1ccc(-n2cnc3cc(-c4ccccc4)ccc32)cc1)Nc1ccon1
6383,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,O=C(c1c(-c2ccc(O)cn2)oc2ccc(O)c(CN3CCCCC3)c12)N1CCC1,azetidin-1-yl(5-hydroxy-2-(5-hydroxypyridin-2-yl)-4-(piperidin-1-ylmethyl)benzofuran-3-yl)methanone,13.2,uM,=,1.1205739312058498,1,O=C(c1c(-c2ccccn2)oc2cccc(CN3CCCCC3)c12)N1CCC1
6384,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CN(C)C(=O)c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CCC4(COC4)C3)c12,"4-(2-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-5-hydroxy-2-(4-hydroxyphenyl)-N,N-dimethylbenzofuran-3-carboxamide",10.7,uM,=,1.0293837776852095,1,c1ccc(-c2cc3c(CN4CCC5(COC5)C4)cccc3o2)cc1
6385,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCc1sc(CCc2cc(N3CCOCC3)cc(NC(C)c3cc(Cl)cc(NC(=O)OC(C)C)c3)n2)nc1C,isopropyl 3-chloro-5-(1-(6-(2-(5-ethyl-4-methylthiazol-2-yl)ethyl)-4-morpholinopyridin-2-ylamino)ethyl)phenylcarbamate,0.036,uM,=,-1.4436974992327127,0,c1ccc(CNc2cc(N3CCOCC3)cc(CCc3nccs3)n2)cc1
6386,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(C#N)cn2)C3)ccc2c1COC2=O,"(R)-6-(8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-2-yl)nicotinonitrile",96.0,uM,=,1.9822712330395684,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccccn3)C4)ccc21
6387,1794818,10.1016/j.bmcl.2018.08.015,,,,Displacement of 3H-dofetilide from human ERG,CCCCNc1nc(N)nc2c1CN(C(=O)c1cccs1)CC2,"[2-amino-4-(butylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-(2-thienyl)methanone",0.9,uM,=,-0.0457574905606751,0,O=C(c1cccs1)N1CCc2ncncc2C1
6388,1901021,10.1021/acs.jmedchem.9b01112,,,,Inhibition of human ERG expressed in CHOK1 cells by Qpatch electrophysiological assay,NCc1ncc(S(=O)(=O)c2ccc3ccccc3c2)s1,[5-(2-naphthylsulfonyl)thiazol-2-yl]methanamine,51.0,uM,=,1.7075701760979365,1,O=S(=O)(c1ccc2ccccc2c1)c1cncs1
6389,1858736,10.1021/acs.jmedchem.9b01336,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide,0.027,uM,=,-1.5686362358410126,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
6390,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.Cl.FCCOc1ccccc1CCN1CCN(CCc2ccccc2)CC1,1-(2-(2-Fluoroethoxy)phenethyl)-4-phenethylpiperazine dihydrochloride,5.49,uM,=,0.7395723444500919,1,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6391,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,CC(=O)N1CCC(n2cc(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c(C)n2)CC1,"1-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3-methyl-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",7.2,uM,=,0.8573324964312685,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
6392,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,COCCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1,"rac-4-Amino-N-[1-(4-chlorophenyl)-3-methoxypropyl]-1-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",9.369,uM,=,0.971693238949861,1,O=C(NCc1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
6393,634158,10.1021/jm100044a,,,,Inhibition of human ERG by patch clamp assay,Cn1nccc1-c1cc(NC(=O)c2cccc(C(F)(F)F)c2)ccc1OCCN1CCOCC1,N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-3-trifluoromethyl-benzamide,0.9,uM,=,-0.0457574905606751,0,O=C(Nc1ccc(OCCN2CCOCC2)c(-c2ccn[nH]2)c1)c1ccccc1
6394,543016,10.1016/j.bmcl.2008.12.114,,,,Inhibition of human ERG by patch clamp technique,C[C@@H]1CN(CC2(C(N)=O)CCC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1,"1-(((3R)-3-methyl-4-(4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenylsulfonyl)piperazin-1-yl)methyl)cyclobutanecarboxamide",65.0,uM,=,1.812913356642856,1,O=S(=O)(c1ccccc1)N1CCN(CC2CCC2)CC1
6395,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NC/C(F)=C\c3cc(F)ccc3F)(CC1)CO2,"(R,E)-4-((4-(3-(2,5-difluorophenyl)-2-fluoroallylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",0.016,uM,=,-1.7958800173440752,0,O=c1ccc2nccc3c2n1CC3CC12CCC(NC/C=C\c3ccccc3)(CC1)CO2
6396,1503985,10.1021/acsmedchemlett.5b00059,,,,Inhibition of human ERG,CNC(=O)c1ccc(-c2cc(Cl)cc(Cl)c2Cl)c(N)n1,"6-Amino-N-methyl-5-(2,3,5-trichlorophenyl)picolinamide",30.0,uM,=,1.4771212547196624,1,c1ccc(-c2cccnc2)cc1
6397,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,c1ccc2sc(Oc3ccc(CCN4CCCCC4)cc3)nc2c1,2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole,2.0,uM,=,0.3010299956639812,1,c1ccc2sc(Oc3ccc(CCN4CCCCC4)cc3)nc2c1
6398,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,"{2-[4-(1,2-Diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine",0.967,uM,=,-0.0145735259169983,0,C(=C(c1ccccc1)c1ccccc1)c1ccccc1
6399,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)CC#CCOC(c1ccccc1)c1ccccc1,4-(Benzhydryloxy)-N-butyl-N-ethylbut-2-yn-1-amine,4.81,uM,=,0.6821450763738317,1,c1ccc(Cc2ccccc2)cc1
6400,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CC#Cc1cncc(-c2cc3c(cc2F)OCC2(CC2)C32COC(N)=N2)c1,"US8975415, RP112::US9242973, RP112",4.32,uM,=,0.6354837468149122,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
6401,945796,10.1016/j.bmcl.2012.12.072,,,,Inhibition of human ERG,O[C@H](COc1ccc(Cl)cc1)CN1CCN(Cc2ccc(Cl)cc2)CC1,(S)-1-(4-(4-chlorobenzyl)piperazin-1yl)-3-(4-chlorophenoxy)propan-2-ol,0.32,uM,=,-0.494850021680094,0,c1ccc(CN2CCN(CCCOc3ccccc3)CC2)cc1
6402,625756,10.1016/j.bmcl.2010.03.035,,,,Inhibition of human ERG by FLIPR assay,Cc1ccc(S(=O)(=O)C[C@@H]2C[C@H](N(C)C(C)C)CC[C@@H]2N2CC[C@H](NC(=O)c3cccc(C(F)(F)F)c3)C2=O)cc1,"N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(tosylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-3-(trifluoromethyl)benzamide",3.0,uM,=,0.4771212547196624,1,O=C(N[C@H]1CCN([C@H]2CCCC[C@H]2CS(=O)(=O)c2ccccc2)C1=O)c1ccccc1
6403,1927981,10.1021/acsmedchemlett.6b00117,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,Cn1cncc1-c1nc(NCc2ccccn2)c2c(-c3ccccc3)cccc2n1,2-(1-methyl-1H-imidazol-5-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine,2.7,uM,=,0.4313637641589873,1,c1ccc(-c2cccc3nc(-c4cnc[nH]4)nc(NCc4ccccn4)c23)cc1
6404,875038,10.1021/jm300573d,,,,Inhibition of human ERG,CC(C)n1nc(C(=O)NCC2CCN(CCc3ccc(N)cc3)CC2)c2ccccc21.Cl.Cl,N-[[1-[2-(4-Aminophenyl)ethyl]-4-piperidinyl]methyl]-1-isopropyl-1H-indazole-3-carboxamide dihydrochloride,22.6,uM,=,1.354108439147401,1,O=C(NCC1CCN(CCc2ccccc2)CC1)c1n[nH]c2ccccc12
6405,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(Br)cc1)C1c2ccccc2C(=O)N1CCc1ccccn1,N-(4-Bromobenzyl)-3-oxo-2-(2-(pyridin-2-yl)ethyl)isoindoline-1-carboxamide,9.3,uM,=,0.9684829485539352,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
6406,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccc(OC)cc2)oc2ccc(O)c(CN3CCC4(COC4)C3)c12,4-(2-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-5-hydroxy-2-(4-methoxyphenyl)-N-methylbenzofuran-3-carboxamide,1.8,uM,=,0.255272505103306,1,c1ccc(-c2cc3c(CN4CCC5(COC5)C4)cccc3o2)cc1
6407,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,COc1ccc([C@H]2CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,N-({1-[4-(6-Methoxy-pyridin-3-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,2.8,uM,=,0.4471580313422192,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3cccnc3)CC2)C1
6408,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N(CCc3ccc(Cl)cc3)Cc3ccc(F)cc3Cl)CC2)n[nH]1,"1-(5-amino-1H-1,2,4-triazol-3-yl)-N-(2-chloro-4-fluorobenzyl)-N-(4-chlorophenethyl)piperidin-4-amine",4.0,uM,=,0.6020599913279624,1,c1ccc(CCN(Cc2ccccc2)C2CCN(c3nc[nH]n3)CC2)cc1
6409,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCc1oc(CCc2cc(N3CCOCC3)cc(NCCC#N)n2)nc1C,3-(6-(2-(5-ethyl-4-methyloxazol-2-yl)ethyl)-4-morpholinopyridin-2-ylamino)propanenitrile,1.6,uM,=,0.2041199826559248,1,c1cc(N2CCOCC2)cc(CCc2ncco2)n1
6410,1797483,10.1021/acsmedchemlett.8b00344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch clamp assay,CC(C)(C)S(=O)(=O)c1ccc2nccc(Nc3n[nH]c4ccc(F)cc34)c2c1,6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine,7.445,uM,=,0.871864702088195,1,c1ccc2c(Nc3n[nH]c4ccccc34)ccnc2c1
6411,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,CC1=C(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)COC1=O,"US9206198, 7",34.0,uM,=,1.5314789170422551,1,O=C1C=C(N2CCC3(CCN(CCc4ccc5c(c4)COC5=O)CC3)C2=O)CO1
6412,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1n[nH]c(N2CCC(N(CCc3ccc(Cl)cc3)Cc3ccccc3Cl)CC2)n1,"1-(3-Amino-1H-1,2,4-triazol-5-yl)-N-(2-chlorobenzyl)-N-(4-chlorophenethyl)piperidin-4-amine",2.0,uM,=,0.3010299956639812,1,c1ccc(CCN(Cc2ccccc2)C2CCN(c3ncn[nH]3)CC2)cc1
6413,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CC(C)CN(CCc1ccc(Cl)cc1)C1CCN(c2nc(N)n[nH]2)CC1,"1-(3-Amino-1H-1,2,4-triazol-5-yl)-N-(4-chlorophenethyl)-N-isobutylpiperidin-4-amine",8.0,uM,=,0.9030899869919436,1,c1ccc(CCNC2CCN(c3ncn[nH]3)CC2)cc1
6414,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,NC1(C(=O)N[C@@H](CCN2CCCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,"rac-4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-piperidin-1-ylpropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",29.367,uM,=,1.4678595832272,1,O=C(N[C@@H](CCN1CCCCC1)c1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
6415,2026823,10.1021/acs.jmedchem.6b00723,,,,Inhibition of human ERG by IonWorks patch-clamp electrophysiology method,O=C(NCCN1CCCC1)c1cc(-c2ccc(CN3CCOCC3)cc2)nc2ccc(F)cc12,6-fluoro-2-(4-(morpholinomethyl)phenyl)-N-(2-(pyrrolidin-1-yl)ethyl)quinoline-4-carboxamide,16.0,uM,=,1.2041199826559248,1,O=C(NCCN1CCCC1)c1cc(-c2ccc(CN3CCOCC3)cc2)nc2ccccc12
6416,980788,10.1021/jm4006324,,,,Displacement of [3H]dofetilide from human ERG channel,Cn1cc(-c2ccnc(C3COCCN3)c2)c(-c2ccc(F)cc2)n1,(-)3-(4-(3-(4-Fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-pyridin-2-yl)morpholine,25.9,uM,=,1.413299764081252,1,c1ccc(-c2n[nH]cc2-c2ccnc(C3COCCN3)c2)cc1
6417,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,CC(=O)N1CCC(n2cc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)cn2)CC1,"1-[4-(4-{[5-Chloro-4-(imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",5.4,uM,=,0.7323937598229685,1,c1ccn2c(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)cnc2c1
6418,877119,10.1021/jm3013568,,,,Inhibition of human ERG expressed in CHO cells,O=C(CCCN1CCCCC1)Nc1cc(-c2cccc(F)c2)n[nH]1,N-[5-(3-Fluoro-phenyl)-2H-pyrazol-3-yl]-4-piperidin-1-yl-butyramide,1.29,uM,=,0.1105897102992489,1,O=C(CCCN1CCCCC1)Nc1cc(-c2ccccc2)n[nH]1
6419,687881,10.1016/j.bmcl.2010.10.020,,,,Inhibition of human ERG,CCO[C@H]1CN([C@H]2CC[C@@](O)(c3ccccc3)CC2)C[C@@H]1NC(=O)CNC(=O)c1cccc(C(F)(F)F)c1,"N-(2-((3S,4S)-4-ethoxy-1-(cis-4-hydroxy-4-phenylcyclohexyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide",17.0,uM,=,1.230448921378274,1,O=C(CNC(=O)c1ccccc1)N[C@@H]1CCN(C2CCC(c3ccccc3)CC2)C1
6420,1353223,10.1021/jm401705g,,,,Inhibition of human ERG by electrophysiology assay,N#Cc1ccc(-c2ccc(C[C@@H](C#N)NC(=O)C3(N)CCCCC3)cc2)cc1,(S)-1-Amino-N-(1-cyano-2-(4'-cyanobiphenyl-4-yl)ethyl)-cyclohexanecarboxamide,9.0,uM,=,0.9542425094393248,1,O=C(NCCc1ccc(-c2ccccc2)cc1)C1CCCCC1
6421,1911580,10.1021/acs.jmedchem.8b01726,,,,Inhibition of human ERG,Cn1c(N2CCC(C)(CN)CC2)nc(N)c(Sc2cccc(Cl)c2Cl)c1=O,"6-amino-2-(4-(aminomethyl)-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenylthio)-3-methylpyrimidin-4(3H)-one",6.0,uM,=,0.7781512503836436,1,O=c1[nH]c(N2CCCCC2)ncc1Sc1ccccc1
6422,1891417,10.1016/j.bmcl.2019.03.026,,,,Inhibition of human ERG by whole-cell patch clamp method,CC(C)c1cc(C(=O)NC[C@H]2CCN(CCc3ccc(Cl)c(F)c3)C2)on1,(R)-N-((1-(4-chloro-3-fluorophenethyl)pyrrolidin-3-yl)methyl)-3-isopropylisoxazole-5-carboxamide,1.52,uM,=,0.1818435879447725,1,O=C(NC[C@H]1CCN(CCc2ccccc2)C1)c1ccno1
6423,457367,10.1016/j.bmcl.2007.07.074,,,,Inhibition of hERG expressed in HEK cells,CC(=O)C1=NN(c2cc(C)ccc2F)C[C@@]1(CCCN(C)C)c1ccccc1,"(R)-1-(4-(3-(dimethylamino)propyl)-1-(2-fluoro-5-methylphenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-3-yl)ethanone",3.036,uM,=,0.4823017672234427,1,C1=NN(c2ccccc2)CC1c1ccccc1
6424,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,CS(=O)(=O)c1cc(CCN2CCN(CCc3ccc4c(c3)COC4=O)CC2)ccc1C#N,"2-(methylsulfonyl)-4-(2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",4.7,uM,=,0.6720978579357175,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
6425,2023418,10.1016/j.bmcl.2020.127663,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch clamp assay,Cc1nnn(Cc2cc(Cl)ccc2/C=C/C(=O)N2CCN(Cc3cnn(C)c3)CC2)n1,(E)-3-(4-chloro-2-((5-methyl-2H-tetrazol-2-yl)methyl)phenyl)-1-(4-((1-methyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)prop-2-en-1-one,15.0,uM,=,1.1760912590556811,1,O=C(/C=C/c1ccccc1Cn1ncnn1)N1CCN(Cc2cn[nH]c2)CC1
6426,2223619,10.1021/acsmedchemlett.2c00294,,,,Inhibition of human ERG by fluorescence polarization assay,N[C@@H]1C[C@@H]1c1ccc(Br)cc1,(+/-)-cis-4-Bromophenylcyclopropylamine,18.0,uM,=,1.255272505103306,1,c1ccc(C2CC2)cc1
6427,773759,10.1021/jm200909u,,,,Inhibition of human hERG,NC(=O)c1cnc(NC(C2CC2)C2CC2)c2c1[nH]c1cc(-c3cnc(N)cn3)ccc12,"7-(5-Aminopyrazin-2-yl)-1-[(dicyclopropylmethyl)amino]-5H-pyrido[4,3-b]indole-4-carboxamide",0.72,uM,=,-0.1426675035687315,0,c1cnc(-c2ccc3c(c2)[nH]c2ccnc(NC(C4CC4)C4CC4)c23)cn1
6428,702661,10.1021/jm100978n,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(=O)C(C)C)C3)C2)c1cccc(F)c1,"N-{(1S)-3-[3-endo-(5-Isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-(3-fluorophenyl)propyl}acetamide",12.0,uM,=,1.0791812460476249,1,c1ccc(CCCN2[C@@H]3CC[C@H]2C[C@@H](n2cnc4c2CCNC4)C3)cc1
6429,2023418,10.1016/j.bmcl.2020.127663,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch clamp assay,Cc1nnn(Cc2cc(C(F)(F)F)ccc2/C=C/C(=O)N2CCC(c3nnc(C)o3)CC2)n1,"(E)-1-(4-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl)-3-(2-((5-methyl-2H-tetrazol-2-yl)methyl)-4-(trifluoromethyl)phenyl)prop-2-en-1-one",23.0,uM,=,1.3617278360175928,1,O=C(/C=C/c1ccccc1Cn1ncnn1)N1CCC(c2nnco2)CC1
6430,755897,10.1021/jm200112k,,,,Inhibition of Kv11.1 channel,Cn1cc(-c2cnc3ccc4ccc(NS(N)(=O)=O)cc4c(=O)c3c2)cn1,"N-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfuricdiamide",4.3,uM,=,0.6334684555795865,1,O=c1c2ccccc2ccc2ncc(-c3cn[nH]c3)cc12
6431,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(OC(F)(F)F)c4)n2CCO3)ccn1,"10-(2-methylpyridin-4-yl)-3-(3-(trifluoromethoxy)phenoxy)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",0.693,uM,=,-0.1592667653881933,0,c1ccc(Oc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
6432,744151,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG by patch clamp technique,Cc1cnc(N2CCC([C@H]3C[C@H]3CCOc3nc(C)cc(C#N)n3)CC2)nc1,"6-methyl-2-(2-((1S,2R)-2-(1-(5-methylpyrimidin-2-yl)piperidin-4-yl)cyclopropyl)ethoxy)pyrimidine-4-carbonitrile",4.0,uM,=,0.6020599913279624,1,c1cnc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)nc1
6433,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,Cn1ccc(NC(=O)c2cc(Oc3ccc(C(=O)N4CCC4)cc3)cc(OC(CF)CF)c2)n1,"3-(4-(azetidine-1-carbonyl)phenoxy)-5-(1,3-difluoropropan-2-yloxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide",28.0,uM,=,1.4471580313422192,1,O=C(Nc1cc[nH]n1)c1cccc(Oc2ccc(C(=O)N3CCC3)cc2)c1
6434,2054470,10.1016/j.ejmech.2020.112517,,,,Inhibition of human ERG,Cc1cccn(-c2ccc(-c3ccc4c(C(=O)NCC5CC5)n[nH]c4c3)c(Cl)c2)c1=O,6-(2-Chloro-4-(3-methyl-2-oxopyridin-1-(2H)-yl)phenyl)-N-(cyclopropylmethyl)-1H-indazole-3-carboxamide,82.3,uM,=,1.9153998352122696,1,O=C(NCC1CC1)c1n[nH]c2cc(-c3ccc(-n4ccccc4=O)cc3)ccc12
6435,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cncc(OC(F)F)c3)ccc1OCC21CC1,"US8975415, RP60::US9242973, RP60",2.78,uM,=,0.4440447959180762,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
6436,2223202,10.1021/acsmedchemlett.2c00111,,,,Inhibition of hERG cardiac ion channel,O=c1ccc2ncc(F)c3c2n1CC3C[C@H]1OC[C@H](NCc2cc3c(cn2)OCCC3)CO1,"4-((5-(((3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl)methyl)amino)-trans-1,3-dioxan-2-yl)methyl)-3-fluoro-4,5-dihydro-7H-pyrrolo[3,2,1-de][1,5]naphthyridin-7-one",125.0,uM,=,2.096910013008056,1,O=c1ccc2nccc3c2n1CC3C[C@H]1OC[C@H](NCc2cc3c(cn2)OCCC3)CO1
6437,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCC1CCOCC1,3-Oxo-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,22.0,uM,=,1.3424226808222062,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCC1CCOCC1
6438,1798125,10.1021/acsmedchemlett.8b00305,,,,Inhibition of MK-499 binding to human ERG,CCOc1cc(CN2CCC(c3ncc(-c4ccc(F)cc4)[nH]3)CC2)cc(OCC)c1-c1ccc(F)cc1,"1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-4-(5-(4-fluorophenyl)-1H-imidazol-2-yl)piperidine",0.26,uM,=,-0.585026652029182,0,c1ccc(-c2ccc(CN3CCC(c4ncc(-c5ccccc5)[nH]4)CC3)cc2)cc1
6439,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,Cc1nn(-c2ccnc(Nc3ccc4c(c3)c(C(=O)C(F)(F)F)cn4C)n2)cc1N[C@@H]1CCOC[C@@H]1N,"1-[5-[[4-[4-[[(3R,4R)-3-aminotetrahydropyran-4-yl]amino]-3-methyl-pyrazol-1-yl]pyrimidin-2-yl]amino]-1-methyl-indol-3-yl]-2,2,2-trifluoro-ethanone",4.7,uM,=,0.6720978579357175,1,c1cc(-n2cc(NC3CCOCC3)cn2)nc(Nc2ccc3[nH]ccc3c2)n1
6440,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,N#Cc1cccc([C@]2(O)CC[C@@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)c1,N-({1-[4-(3-Cyano-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,1.5,uM,=,0.1760912590556812,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccccc3)CC2)C1
6441,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c(CNC2CCCC2)nn(-c2ncccc2Cl)c1-c1cccnc1,N-((1-(3-chloropyridin-2-yl)-4-methyl-5-(pyridin-3-yl)-1H-pyrazol-3-yl)methyl)cyclopentanamine,23.0,uM,=,1.3617278360175928,1,c1ccc(-n2nc(CNC3CCCC3)cc2-c2cccnc2)nc1
6442,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,FC(F)(F)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1,"4-(4-(Trifluoromethyl)phenyl)spiro [chromene-2,4'-piperidine]",0.379,uM,=,-0.4213607900319276,0,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
6443,1571176,10.1016/j.bmcl.2016.03.035,,,,Inhibition of human ERG by electrophysiology analysis,Cc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)cc3)CC2)ccc2c1COC2=O,5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)-4-methylisobenzofuran-1(3H)-one,13.0,uM,=,1.1139433523068367,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)cc4)CC3)ccc21
6444,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,Cc1nnc(-c2cc(C(F)(F)F)cc(S(=O)(=O)N3CCN(C(=O)[C@@H]4C[C@H]4c4ccc(C(F)(F)F)cc4)CC3)c2)[nH]1,"(4-(3-(5-methyl-4H-1,2,4-triazol-3-yl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",1.3,uM,=,0.1139433523068367,1,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2cccc(-c3nnc[nH]3)c2)CC1
6445,1797483,10.1021/acsmedchemlett.8b00344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch clamp assay,COCCOc1cc2nccc(Nc3n[nH]c(C)c3C)c2cc1S(=O)(=O)C(C)(C)C,"6-(tert-butylsulfonyl)-N-(4,5-dimethyl-1H-pyrazol-3-yl)-7-(2-methoxyethoxy)quinolin-4-amine",30.0,uM,=,1.4771212547196624,1,c1ccc2c(Nc3cc[nH]n3)ccnc2c1
6446,2069799,10.1021/acsmedchemlett.0c00606,,,,Inhibition of human ERG by fluorescence polarization assay,Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1ccc(F)c(F)c1,"2-amino-N-(3,4-difluorophenyl)-4-fluoro-5-((4-hydroxypiperidin-1-yl)sulfonyl)benzamide",50.0,uM,=,1.6989700043360187,1,O=C(Nc1ccccc1)c1cccc(S(=O)(=O)N2CCCCC2)c1
6447,1823215,10.1021/acs.jmedchem.9b01140,,,,Inhibition of human ERG at -80 mV holding potential by automated Qpatch clamp assay,C[C@H]1SC(N)=N[C@](C)(c2cc(NC(=O)c3cnc(OCF)cn3)ccc2F)[C@H]1F,"N-(3-((4R,5R,6R)-2-Amino-5-fluoro-4,6-dimethyl-5,6-dihydro-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide",5.1,uM,=,0.7075701760979364,1,O=C(Nc1cccc(C2CCSC=N2)c1)c1cnccn1
6448,862394,10.1021/jm300601d,,,,Inhibition of human ERG expressed in HEK 293 cells by PatchXpress assay,N#Cc1ccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)cc1,N-{4-[1-(4-Cyano-benzoyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,4.0,uM,=,0.6020599913279624,1,O=C(c1ccccc1)N1CCC(c2ccccc2)CC1
6449,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,C[C@@H](NCc1cc([C@]2(C)CCSC(N)=N2)c(F)cc1F)C(F)(F)F,"(S)-4-(2,4-Difluoro-5-((((R)-1,1,1-trifluoropropan-2-yl)amino)-methyl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine",13.9,uM,=,1.1430148002540952,1,C1=NC(c2ccccc2)CCS1
6450,1665702,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,COc1ncc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)cn1,2-(2-methoxypyrimidin-5-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine,66.0,uM,=,1.8195439355418688,1,c1ccc(-c2cccc3nc(-c4cncnc4)nc(NCc4ccccn4)c23)cc1
6451,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine,12.2864,uM,=,1.0894246502448928,1,c1ccc(COc2ccccc2)cc1
6452,2027427,10.1021/acs.jmedchem.6b01204,,,,Inhibition of human ERG measured after 4 hrs by fluorescence polarization assay,CN1CCCC1CCOc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(Br)cc2)cc1.Cl,(E)-5-(4-Bromophenyl)-5-(4-(2-(1-methylpyrrolidin-2-yl)-ethoxy)phenyl)-4-phenylpent-4-en-1-ol Hydrochloride Salt,1.7,uM,=,0.2304489213782739,1,C(=C(c1ccccc1)c1ccc(OCCC2CCCN2)cc1)c1ccccc1
6453,1745661,10.1016/j.bmcl.2017.10.010,,,,Inhibition of human ERG by Qpatch clamp assay,CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl.Cl,(+/-)-5-chloro-4-((6-(ethylamino)-2-(4-fluorophenyl)cyclohex-2-enyl)methoxy)-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide hydrochloride,4.4,uM,=,0.6434526764861874,1,O=S(=O)(Nc1cscn1)c1ccc(OC[C@H]2CCCC=C2c2ccccc2)cc1
6454,773759,10.1021/jm200909u,,,,Inhibition of human hERG,NC(=O)c1cnc(N[C@H](C2CC2)C(F)(F)F)c2c1[nH]c1cc(-c3ccc(N)nc3)ccc12,"7-(6-Aminopyridin-3-yl)-1-{[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b]indole-4-carboxamide",0.75,uM,=,-0.1249387366082999,0,c1cncc(-c2ccc3c(c2)[nH]c2ccnc(NCC4CC4)c23)c1
6455,1988796,10.1021/acs.jmedchem.0c00745,,,,Inhibition of human ERG,O=C(O)c1cc(-c2ccc(C34CCN(CC3)CC4)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1,4-(4-(Quinuclidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoic Acid,16.4,uM,=,1.214843848047698,1,c1ccc(-c2ccc3c(-c4ccc(C56CCN(CC5)CC6)cc4)cccc3c2)cc1
6456,425254,10.1021/jm060983w,,,,Displacement of [35S]MK-499 from hERG potassium channel expressed in HEK293 cells,c1ccc(COc2ccc(CCNc3ccncc3)cc2)cc1,[2-(4-Benzyloxy-phenyl)-ethyl]-pyridin-4-yl-amine,0.13,uM,=,-0.8860566476931633,0,c1ccc(COc2ccc(CCNc3ccncc3)cc2)cc1
6457,2223619,10.1021/acsmedchemlett.2c00294,,,,Inhibition of human ERG by fluorescence polarization assay,N[C@H]1C[C@@H]1c1ccc(Br)c(F)c1,(+/-)-trans-2-(4-Bromo-3-fluorophenyl)cyclopropylamine,16.0,uM,=,1.2041199826559248,1,c1ccc(C2CC2)cc1
6458,973733,10.1016/j.bmcl.2013.06.013,,,,Inhibition of human ERG by automated planar patch-clamp system,CCOC(=O)N1CCC(CN2CCC3(CC2)CC(=O)N(C)c2ncccc23)CC1,"ethyl 4-((1-methyl-2-oxo-2,3-dihydro-1H-spiro[[1,8]naphthyridine-4,4'-piperidine]-1'-yl)methyl)piperidine-1-carboxylate",2.54,uM,=,0.404833716619938,1,O=C1CC2(CCN(CC3CCNCC3)CC2)c2cccnc2N1
6459,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@H](c3ccc(O)cn3)CC2)C1,N-({1-[4-(5-Hydroxy-pyridin-2-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,10.0,uM,=,1.0,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccccn3)CC2)C1
6460,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3c(O)cccc32)cc1,"N,N-Diethyl-4-(8-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide",18.31,uM,=,1.2626883443016963,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
6461,766645,10.1016/j.bmcl.2011.07.030,,,,Inhibition of human ERG,CC(C)(CNC(=O)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1)N1CCOCC1,"N-(2-methyl-2-morpholinopropyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",28.0,uM,=,1.4471580313422192,1,O=C(NCCN1CCOCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
6462,1760898,10.1021/acs.jmedchem.8b00521,,,,Inhibition of human ERG by cell based automated patch clamp method,COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sc(-c5cccnc5)nc34)CC2)cc1,"4-(5-amino-2-(pyridin-3-yl)thiazolo[5,4-d]pyrimidin-7-yl)-N-(4-methoxyphenyl)piperazine-1-carboxamide",2.2,uM,=,0.3424226808222063,1,O=C(Nc1ccccc1)N1CCN(c2ncnc3sc(-c4cccnc4)nc23)CC1
6463,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,C[C@@H](CO)Oc1cc(Oc2ccc(C(=O)N3CCC3)cc2)cc(C(=O)Nc2ccn(C)n2)c1,(S)-3-(4-(azetidine-1-carbonyl)phenoxy)-5-(1-hydroxypropan-2-yloxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide,70.0,uM,=,1.845098040014257,1,O=C(Nc1cc[nH]n1)c1cccc(Oc2ccc(C(=O)N3CCC3)cc2)c1
6464,748773,10.1016/j.bmcl.2011.04.102,,,,Inhibition of human ERG by HT patch clamp assay,CC(=O)N1CCN2CCCc3c(C)c4c(n3-c3ccc(C(N)=O)c(c3)NC[C@H]2C1)CC(C)(C)CC4=O,"(19S)-17-acetyl-5,5,9-trimethyl-7-oxo-2,14,17,21-tetraazapentacyclo[20.3.1.0^{2,10}.0^{3,8}.0^{14,19}]hexacosa-1(26),3(8),9,22,24-pentaene-23-carboxamide",24.4,uM,=,1.3873898263387294,1,O=C1CCCc2c1cc1n2-c2cccc(c2)NC[C@H]2CNCCN2CCC1
6465,2223619,10.1021/acsmedchemlett.2c00294,,,,Inhibition of human ERG by fluorescence polarization assay,N[C@@H]1C[C@@H]1c1ccc(Br)c(F)c1,(+/-)-cis-2-(4-Bromo-3-fluorophenyl)cyclopropylamine,44.0,uM,=,1.6434526764861874,1,c1ccc(C2CC2)cc1
6466,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CC#CCCc1ccccc1,N-Ethyl-N-(5-phenylpent-2-yn-1-yl)heptan-1-amine,4.394,uM,=,0.6428600525844915,1,c1ccccc1
6467,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,COc1cc([C@H]2CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)ccn1,N-({1-[4-(2-Methoxy-pyridin-4-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,6.2,uM,=,0.7923916894982539,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccncc3)CC2)C1
6468,462632,10.1016/j.bmcl.2008.01.108,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes,Cc1cccc(C)c1C(=O)N1CCC(C)(N2CCC(N(c3ccccc3)c3ccccc3)CC2)CC1,"(2,6-Dimethyl-phenyl)-(4-diphenylamino-4'-methyl-[1,4']bipiperidinyl-1'-yl)-methanone",0.15,uM,=,-0.8239087409443188,0,O=C(c1ccccc1)N1CCC(N2CCC(N(c3ccccc3)c3ccccc3)CC2)CC1
6469,1677519,10.1021/acs.jmedchem.7b01300,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 3 mins by QPatch test,CN(C/C=C/c1ccc(-c2ccccc2)cc1)Cc1coc2ccccc12.Cl,"(E)-3-([1,1'-Biphenyl]-4-yl)-N-(benzofuran-3-ylmethyl)-N-methylprop-2-en-1-amine Hydrochloride",34.8,uM,=,1.541579243946581,1,C(=C/c1ccc(-c2ccccc2)cc1)\CNCc1coc2ccccc12
6470,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CC(C)NC(=O)c1cn(-c2ccccc2)c2ncccc2c1=O,"N-isopropyl-4-oxo-1-phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide",71.5,uM,=,1.8543060418010808,1,O=c1ccn(-c2ccccc2)c2ncccc12
6471,2226898,10.1016/j.ejmech.2022.114512,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated patch clamp method,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.032,uM,=,-1.494850021680094,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
6472,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,"2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene",100.0,uM,=,2.0,1,c1ccc2c(c1)N=C(N1CCNCC1)c1ccsc1N2
6473,1550040,10.1039/C5MD00297D,,,,Inhibition of human ERG expressed in CHO cells by patch express assay,COc1ccc2ncc(F)c(CC(N)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"(+)-6-((1-(1-amino-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",14.0,uM,=,1.146128035678238,1,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cccnc56)(CC3)OC4)nc2N1
6474,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1.[Cl-],benzethonium hydrochloride,0.1085,uM,=,-0.9645702618154516,0,c1ccc(C[NH2+]CCOCCOc2ccccc2)cc1
6475,766645,10.1016/j.bmcl.2011.07.030,,,,Inhibition of human ERG,O=C(NCC1(N2CCCCC2)CCCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1,"N-((1-(piperidin-1-yl)cyclopentyl)methyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",5.8,uM,=,0.7634279935629373,1,O=C(NCC1(N2CCCCC2)CCCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
6476,449746,10.1016/j.bmcl.2007.08.049,,,,Inhibition of human ERG,CN(C)C(=O)[C@@H](c1ccc(-c2ccc3ncnn3c2)cc1)[C@H](N)C(=O)N1CC[C@H](F)C1,"(2S,3S)-2-(4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl)-3-amino-4-((S)-3-fluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxobutanamide",86.0,uM,=,1.934498451243568,1,O=C(CCc1ccc(-c2ccc3ncnn3c2)cc1)N1CCCC1
6477,1927981,10.1021/acsmedchemlett.6b00117,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,c1ccc(-c2cccc3nc(-c4ccncc4)nc(NCc4ccccn4)c23)cc1,5-phenyl-N-(pyridin-2-ylmethyl)-2-(pyridin-4-yl)quinazolin-4-amine,6.7,uM,=,0.8260748027008264,1,c1ccc(-c2cccc3nc(-c4ccncc4)nc(NCc4ccccn4)c23)cc1
6478,2290572,10.1021/acs.jmedchem.2c01507,,,,Inhibition of hERG expressed in CHO cells at -80 mV holding potential by automated patch clamp method,C=CC(=O)N1CCC(n2nc3c(=O)[nH]nc(N)c3c2-c2oc3ccc(C)cc3c2C)CC1,"2-(1-acryloylpiperidin-4-yl)-4-amino-3-(3,5-dimethylbenzofuran-2-yl)-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one",1.13,uM,=,0.0530784434834196,1,O=c1[nH]ncc2c(-c3cc4ccccc4o3)n(C3CCNCC3)nc12
6479,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CC#CCc1ccc(Cl)cc1,N-Ethyl-4-(4-chlorophenyl)-N-heptylbut-2-yn-1-amine,0.865,uM,=,-0.0629838925351857,0,c1ccccc1
6480,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1.Cc1ccc(S(=O)(=O)[O-])cc1,GNF-Pf-3889,0.002,uM,=,-2.6989700043360187,0,c1ccccc1.c1ccccc1
6481,1648659,10.1021/acsmedchemlett.7b00094,,,,Inhibition of human ERG by patchXpress electrophysiology assay,C[C@H](NC(=O)c1c(CN2CCC(N3CCCCC3)CC2)c(-c2cccc(C(F)(F)F)c2)nc2ccccc12)c1ccccc1,"3-(1,4'-Bipiperidin-1'-ylmethyl)-N-[(1S)-1-phenylethyl]-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide",1.2,uM,=,0.0791812460476248,1,O=C(NCc1ccccc1)c1c(CN2CCC(N3CCCCC3)CC2)c(-c2ccccc2)nc2ccccc12
6482,1712776,10.1016/j.bmcl.2018.03.056,,,,Inhibition of human ERG expressed in CHOK1 cells at holding potential of -80 mV after 5 mins by patch clamp assay,CO/N=C1\CC[C@@]2(C)[C@@H](C1)C[C@@H](N1CCC[C@@H](N)C1)[C@@H]2Oc1ccc(C#N)cc1,"4-((1R,2R,3aR,7aS)-2-((R)-3-aminopiperidin-1-yl)-5-(methoxyimino)-7a-methyloctahydro-1H-inden-1-yloxy)benzonitrile",25.0,uM,=,1.3979400086720375,1,N=C1CCC2[C@@H](C1)C[C@@H](N1CCCCC1)[C@@H]2Oc1ccccc1
6483,2023418,10.1016/j.bmcl.2020.127663,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch clamp assay,Cc1nnn(Cc2cc(Cl)ccc2/C=C/C(=O)N2CCC(Cc3ncc(C)o3)CC2)n1,(E)-3-(4-chloro-2-((5-methyl-2H-tetrazol-2-yl)methyl)phenyl)-1-(4-((5-methyloxazol-2-yl)methyl)piperidin-1-yl)prop-2-en-1-one,5.2,uM,=,0.7160033436347992,1,O=C(/C=C/c1ccccc1Cn1ncnn1)N1CCC(Cc2ncco2)CC1
6484,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(OC(F)(F)F)c4)n2CCO3)ccn1,"10-(2-methylpyridin-4-yl)-N-(3-(trifluoromethoxy)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",0.236,uM,=,-0.6270879970298934,0,c1ccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
6485,755897,10.1021/jm200112k,,,,Inhibition of Kv11.1 channel,Cn1cc(-c2cnc3ccc4ccc(NS(C)(=O)=O)cc4c(=O)c3c2)cn1,"N-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]methanesulfonamide",10.1,uM,=,1.0043213737826426,1,O=c1c2ccccc2ccc2ncc(-c3cn[nH]c3)cc12
6486,824043,10.1021/jm3001373,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,CS(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc(C(F)(F)F)nc3)c2)cc1,3-[2-(trifluoromethyl)pyridin-5-yl]-5-[4-(methylsulfonyl)phenyl]pyridin-2-amine,4.7,uM,=,0.6720978579357175,1,c1ccc(-c2cncc(-c3cccnc3)c2)cc1
6487,440069,10.1021/jm070299x,,,,Inhibition of hERG by patch clamp method,CCN1CCN(c2ccc(C(C)(C)NC(=O)c3cc4[nH]c5ccccc5c(=O)c4cc3F)cn2)CC1,"N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide",25.0,uM,=,1.3979400086720375,1,O=C(NCc1ccc(N2CCNCC2)nc1)c1ccc2c(=O)c3ccccc3[nH]c2c1
6488,1901021,10.1021/acs.jmedchem.9b01112,,,,Inhibition of human ERG expressed in CHOK1 cells by Qpatch electrophysiological assay,CCc1cc(-c2ccccc2)cc(S(=O)(=O)c2cnc(CN)s2)c1,"(5-((5-Ethyl-[1,1'-biphenyl]-3-yl)sulfonyl)thiazol-2-yl)methanamine",36.0,uM,=,1.5563025007672873,1,O=S(=O)(c1cccc(-c2ccccc2)c1)c1cncs1
6489,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(c3cc(-c4cncnc4)ccc3OCC23CC3)c2cccc(F)c21,"US8975415, RP199::US9242973, RP199",4.25,uM,=,0.6283889300503115,1,C1=NC2(c3ccccc31)c1cc(-c3cncnc3)ccc1OCC21CC1
6490,306311,10.1016/j.bmcl.2005.02.093,,,,In vitro inhibitory concentration against displacement of 35[S] MK-499 binding to hERG channel expressed in HEK293 cells,COc1cccc(CN2CCCCCCC2)c1OCc1csc(-c2ccccc2)n1,1-[3-Methoxy-2-(2-phenyl-thiazol-4-ylmethoxy)-benzyl]-azocane,0.18,uM,=,-0.744727494896694,0,c1ccc(-c2nc(COc3ccccc3CN3CCCCCCC3)cs2)cc1
6491,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CC(C)(O)c1ccc(-c2cccc(-n3cc(C(=O)NC4CC4)c(=O)c4cccnc43)c2)cn1,"N-cyclopropyl-1-(3-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)phenyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide",36.6,uM,=,1.5634810853944108,1,O=C(NC1CC1)c1cn(-c2cccc(-c3cccnc3)c2)c2ncccc2c1=O
6492,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,COc1ccccc1CCN1CCC(CCc2cccc(OCCF)c2)CC1.Cl,4-(3-(2-Fluoroethoxy)phenethyl)-1-(2-methoxyphenethyl)piperidine hydrochloride,0.8,uM,=,-0.0969100130080563,0,c1ccc(CCC2CCN(CCc3ccccc3)CC2)cc1
6493,540897,10.1016/j.bmcl.2009.01.012,,,,Displacement of [3H]dofetilide form human ERG expressed in HEK239 cells,Cc1cccc(C)c1C(=O)N1CCC(N2CC[C@@H](N(Cc3ccccc3)C(=O)C3CC3)C2)CC1,"(R)-N-benzyl-N-(1-(1-(2,6-dimethylbenzoyl)piperidin-4-yl)pyrrolidin-3-yl)cyclopropanecarboxamide",9.8,uM,=,0.9912260756924948,1,O=C(c1ccccc1)N1CCC(N2CC[C@@H](N(Cc3ccccc3)C(=O)C3CC3)C2)CC1
6494,877119,10.1021/jm3013568,,,,Inhibition of human ERG expressed in CHO cells,COc1ccc(-c2cc(NC(=O)CCCN3CCCCC3)[nH]n2)cc1,N-[5-(4-Methoxy-phenyl)-2H-pyrazol-3-yl]-4-piperidin-1-yl-butyramide,4.61,uM,=,0.6637009253896482,1,O=C(CCCN1CCCCC1)Nc1cc(-c2ccccc2)n[nH]1
6495,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",COc1ccnc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(C)(C)O3)c1,"US8975415, RP65::US9242973, RP65",9.77,uM,=,0.989894563718773,1,C1=NC2(CO1)c1cc(-c3ccccn3)ccc1OCC21COC1
6496,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N(CCc3ccc(Cl)cc3)Cc3ccccc3O)CC2)n[nH]1,"2-(((1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl)(4-chlorophenethyl)amino)methyl)phenol",0.1,uM,=,-1.0,0,c1ccc(CCN(Cc2ccccc2)C2CCN(c3nc[nH]n3)CC2)cc1
6497,2161344,10.1021/acs.jmedchem.1c02048,,,,Inhibition of [35S]MK-499 binding to hERG expressed in HEK293 cells,C[C@H]1NC(=O)[C@]2(N)CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@H]12,"2-[6-[(E)-2-[(3R,3aR,4R,5S,7aS)-7a-amino-6,6-difluoro-3,5-dimethyl-1-oxo-2,3,3a,4,5,7-hexahydroisoindol-4-yl]vinyl]-3-pyridyl]benzonitrile",33.0,uM,=,1.5185139398778875,1,O=C1NC[C@@H]2C1CCC[C@@H]2/C=C/c1ccc(-c2ccccc2)cn1
6498,1457497,10.1016/j.bmcl.2014.06.032,,,,Inhibition of human ERG,Cc1cccc(C(=O)Nc2cccc(NC(=O)c3cccc(C)c3)c2)c1,SID110923096,12.4,uM,=,1.0934216851622351,1,O=C(Nc1cccc(NC(=O)c2ccccc2)c1)c1ccccc1
6499,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cncc(OCC(F)F)c3)ccc1OCC21CC1,"US8975415, RP59::US9242973, RP59",6.9,uM,=,0.8388490907372553,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
6500,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,O=C(Nc1cccc(Cl)c1)N1CCOc2ccc(-c3ccncc3)cc2C1,"N-(3-chlorophenyl)-7-(pyridin-4-yl)-2,3-dihydrobenzo[f][1,4]oxazepine-4(5H)-carboxamide",8340.0,uM,=,3.921166050637739,1,O=C(Nc1ccccc1)N1CCOc2ccc(-c3ccncc3)cc2C1
6501,856088,10.1016/j.bmc.2012.08.050,,,,Displacement of [3H]-dofetilide from human ERG,CCN(CC)CCOc1cc(-c2nc(SC)nc3[nH]cc(C#N)c23)c(Cl)cc1Cl,"4-[2,4-Dichloro-5-(2-diethylamino-ethoxy)-phenyl]-2-methylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile",1.71,uM,=,0.2329961103921538,1,c1ccc(-c2ncnc3[nH]ccc23)cc1
6502,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(-c3ncon3)cc(C(F)(F)F)c2)CC1,"(4-(3-(1,2,4-oxadiazol-3-yl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",1.2,uM,=,0.0791812460476248,1,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2cccc(-c3ncon3)c2)CC1
6503,306311,10.1016/j.bmcl.2005.02.093,,,,In vitro inhibitory concentration against displacement of 35[S] MK-499 binding to hERG channel expressed in HEK293 cells,COc1cccc(CN2CCCCCCC2)c1OCc1csc(-c2ccc(Cl)cc2)n1,1-{2-[2-(4-Chloro-phenyl)-thiazol-4-ylmethoxy]-3-methoxy-benzyl}-azocane,0.04,uM,=,-1.3979400086720375,0,c1ccc(-c2nc(COc3ccccc3CN3CCCCCCC3)cs2)cc1
6504,675987,10.1016/j.bmcl.2010.09.081,,,,Inhibition of human ERG channel,Cc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cc(C(C)(C)C)n1.Cl,"6-tert-butyl-N-(3-(4-(2,3-dimethylphenyl)piperazin-1-yl)propyl)-2-methylpyrimidine-4-carboxamide Hydrochloride",5.9,uM,=,0.7708520116421442,1,O=C(NCCCN1CCN(c2ccccc2)CC1)c1ccncn1
6505,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N3Cc4cc(F)ccc4OC[C@@H]3Cc3ccc(Cl)cc3)CC2)n[nH]1,"(S)-3-(4-(3-(4-chlorobenzyl)-7-fluoro-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-1H-1,2,4-triazol-5-amine",6.7,uM,=,0.8260748027008264,1,c1ccc(C[C@H]2COc3ccccc3CN2C2CCN(c3nc[nH]n3)CC2)cc1
6506,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CC#CCOCc1ccc(Cl)cc1,N-(4-((4-Chlorobenzyl)oxy)but-2-yn-1-yl)-N-ethylheptan-1-amine,0.834,uM,=,-0.0788339493622613,0,c1ccccc1
6507,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1ccc(C2(c3cccc(-c4cccnc4)c3)N=C(N)CS2)cc1,"2-(4-Methoxyphenyl)-2-(3-(pyridin-3-yl)phenyl)-2,5-dihydrothiazol-4-amine",10.0,uM,=,1.0,1,C1=NC(c2ccccc2)(c2cccc(-c3cccnc3)c2)SC1
6508,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(C2=CC(=O)OC2)C3=O)ccc2c1COC2=O,"US9206198, 5",31.0,uM,=,1.4913616938342726,1,O=C1C=C(N2CCC3(CCN(CCc4ccc5c(c4)COC5=O)CC3)C2=O)CO1
6509,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1ccc(-c2c(C)c(CNC3CCCC3F)nn2-c2ncccc2Cl)cn1,N-((1-(3-chloropyridin-2-yl)-4-methyl-5-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)methyl)-2-fluorocyclopentanamine,30.0,uM,=,1.4771212547196624,1,c1ccc(-n2nc(CNC3CCCC3)cc2-c2cccnc2)nc1
6510,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCc1oc(CCc2cc(N3CCOCC3)cc(NC(C)=O)n2)nc1C,N-(6-(2-(5-ethyl-4-methyloxazol-2-yl)ethyl)-4-morpholinopyridin-2-yl)acetamide,7.0,uM,=,0.8450980400142568,1,c1cc(N2CCOCC2)cc(CCc2ncco2)n1
6511,1469975,10.1021/jm501021n,,,,Inhibition of human ERG by PDSP screening,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccc(F)c(F)c4)nc31)[C@H](O)[C@@H]2O,"(1S,2R,3S,4R,5S)-4-(2-((3,4-Difluorophenyl)ethynyl)-6-(methylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide",27.0,uM,=,1.4313637641589874,1,C(#Cc1ncc2ncn([C@H]3CCC4C[C@@H]43)c2n1)c1ccccc1
6512,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,N#Cc1ccc(CCN2CCN(CCc3ccc4nonc4c3)CC2)cc1,"4-(2-(4-(2-(benzo[c][1,2,5]oxadiazol-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",0.042,uM,=,-1.3767507096020994,0,c1ccc(CCN2CCN(CCc3ccc4nonc4c3)CC2)cc1
6513,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CC(C)NC(=O)c1cn(-c2cccc(-c3ccc(S(C)(=O)=O)cc3)c2)c2ncccc2c1=O,"1-(4'-Methanesulfonyl-biphenyl-3-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid isopropylamide",23.0,uM,=,1.3617278360175928,1,O=c1ccn(-c2cccc(-c3ccccc3)c2)c2ncccc12
6514,1760898,10.1021/acs.jmedchem.8b00521,,,,Inhibition of human ERG by cell based automated patch clamp method,COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sc(-c5ccccc5)nc34)CC2)cc1,"4-(5-amino-2-phenylthiazolo[5,4-d]pyrimidin-7-yl)-N-(4-methoxyphenyl)piperazine-1-carboxamide",1.7,uM,=,0.2304489213782739,1,O=C(Nc1ccccc1)N1CCN(c2ncnc3sc(-c4ccccc4)nc23)CC1
6515,1797573,10.1021/acs.jmedchem.8b01187,,,,Inhibition of human ERG by whole cell electrophysiology analysis,CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2(S(C)(=O)=O)CC2)n1,N-Methyl-1-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1Hbenzimidazol-2-amine,4.6,uM,=,0.6627578316815741,1,c1ccc2c(c1)ncn2-c1nc(C2CC2)cc(N2CCOCC2)n1
6516,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cc2c(Cl)c(-c3n[nH]c4nc(N5C[C@@H]6[C@H](C5)[C@@]6(CN)c5ccccc5)cnc34)ccc2n1,"((1R,5S,6s)-3-(3-(4-chloro-2-methyl-2H-indazol-5-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-6-phenyl-3-azabicyclo[3.1.0]hexan-6-yl)methanamine",5.352,uM,=,0.7285161047597667,1,c1ccc(C2[C@H]3CN(c4cnc5c(-c6ccc7n[nH]cc7c6)n[nH]c5n4)C[C@@H]23)cc1
6517,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cncc(C4CC4)c3)ccc1OCC21CC1,"US8975415, RP57::US9242973, RP57",3.48,uM,=,0.541579243946581,1,C1=NC2(CO1)c1cc(-c3cncc(C4CC4)c3)ccc1OCC21CC1
6518,1636046,10.1021/acs.jmedchem.6b01506,,,,Inhibition of human ERG by patch clamp assay,COc1ccc2nc(NC3=NC[C@@]4(CN5CCC4CC5)O3)sc2c1,"(R)-N-(6-Methoxybenzo[d]thiazol-2-yl)-4H-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octan]-2-amine",1.3,uM,=,0.1139433523068367,1,c1ccc2sc(NC3=NC[C@@]4(CN5CCC4CC5)O3)nc2c1
6519,945796,10.1016/j.bmcl.2012.12.072,,,,Inhibition of human ERG,O[C@@H](COc1ccc(C(F)(F)F)cc1)CN1CCN(Cc2ccc(Cl)c(Cl)c2)CC1,"(R)-1-(4-(3,4-dichlorobenzyl)piperazin-1-yl)-3-(4-(trifluoromethyl)phenoxy)propan-2-ol",9.2,uM,=,0.9637878273455552,1,c1ccc(CN2CCN(CCCOc3ccccc3)CC2)cc1
6520,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CC#CCCc1ccc(Cl)cc1,N-(5-(4-Chlorophenyl)pent-2-yn-1-yl)-N-ethylheptan-1-amine,0.765,uM,=,-0.1163385648463823,0,c1ccccc1
6521,2223202,10.1021/acsmedchemlett.2c00111,,,,Inhibition of hERG cardiac ion channel,O=C1COc2ccc(CN[C@H]3CO[C@H](CC4Cn5c(=O)ccc6ccc(F)c4c65)OC3)nc2N1,"7-(((2-((9-fluoro-4-oxo-1,2-dihydro-4H-pyrrolo[3,2,1-iJ]quinolin-1-yl)methyl)-trans-1,3-dioxan-5-yl)amino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",30.0,uM,=,1.4771212547196624,1,O=C1COc2ccc(CN[C@H]3CO[C@H](CC4Cn5c(=O)ccc6cccc4c65)OC3)nc2N1
6522,1567397,10.1016/j.ejmech.2016.02.014,,,,Displacement of [3H]dofetilide from human ERG channel expressed in HEK293 cells after 60 mins by liquid scintillation counting method,Oc1ccc2c(c1)CC(CN1CCC3(CCc4ccccc43)CC1)NC2,"3-{(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)methyl}-1,2,3,4-tetrahydroisoquinolin-6-ol",0.34,uM,=,-0.4685210829577448,0,c1ccc2c(c1)CNC(CN1CCC3(CCc4ccccc43)CC1)C2
6523,1758787,10.1021/acsmedchemlett.7b00188,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch assay,CCO/N=C1\CCc2cc(OCCCCCN3CCN(c4ccnc(N)c4)S3(=O)=O)ccc21,"5-{5-[5-(2-Amino-pyridin-4-yl)-1,1-dioxo-1lambda(6)-[1,2,5]thiadiazolidin-2-yl]-pentyloxy}-indan-1-one O-ethyl-oxime",6.0,uM,=,0.7781512503836436,1,N=C1CCc2cc(OCCCCCN3CCN(c4ccncc4)S3(=O)=O)ccc21
6524,1841342,10.1016/j.bmcl.2019.03.029,,,,Inhibition of human ERG by QPatch assay,N=C(N)NC[C@H](Oc1noc2ccc(-c3ccccc3Cl)cc12)c1ccccc1,(R)-1-(2-(5-(2-chlorophenyl)benzo[d]isoxazol-3-yloxy)-2-phenylethyl)guanidine,9.5,uM,=,0.9777236052888478,1,c1ccc(COc2noc3ccc(-c4ccccc4)cc23)cc1
6525,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,CC1(c2cccc(-c3cncnc3)c2)N=C(N)c2c(F)cccc2O1,"5-Fluoro-2-methyl-2-(3-(pyrimidin-5-yl)phenyl)-2H-benzo-[e][1,3]oxazin-4-amine",9.0,uM,=,0.9542425094393248,1,C1=NC(c2cccc(-c3cncnc3)c2)Oc2ccccc21
6526,1554488,10.1016/j.bmcl.2016.01.049,,,,Inhibition of human ERG using tracer red fluorescent probe,CCNCc1cc(C(=O)N[C@@H]2CCc3ccc(Oc4ccnc5c4CCC(=O)N5)cc3C2)cc(C(F)(F)F)c1.Cl.Cl,"3-((ethylamino)methyl)-N-{(2R)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide dihydrochloride",5.6,uM,=,0.7481880270062004,1,O=C1CCc2c(Oc3ccc4c(c3)C[C@H](NC(=O)c3ccccc3)CC4)ccnc2N1
6527,1447484,10.1016/j.bmcl.2014.05.034,,,,Inhibition of human ERG channel,O=C1NC(=O)C(Cc2coc3ccc(Cl)cc3c2=O)S1,"5[(6-chloro-4-oxo-4H-chromen-3yl)methyl]thiazolidine-2,4-dione",0.135,uM,=,-0.8696662315049939,0,O=C1NC(=O)C(Cc2coc3ccccc3c2=O)S1
6528,2290572,10.1021/acs.jmedchem.2c01507,,,,Inhibition of hERG expressed in CHO cells at -80 mV holding potential by automated patch clamp method,C=CC(=O)N1CCCC(n2nc3c(=O)[nH]nc(N)c3c2-c2oc3ccc(C)cc3c2C)C1,"2-(1-acryloylpiperidin-3-yl)-4-amino-3-(3,5-dimethylbenzofuran-2-yl)-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one",17.17,uM,=,1.2347702951609163,1,O=c1[nH]ncc2c(-c3cc4ccccc4o3)n(C3CCCNC3)nc12
6529,2049685,10.1021/acs.jmedchem.0c01411,,,,Inhibition of human ERG by patch clamp method,CN1CCCN(c2nccc3[nH]c(-c4cc(F)cc(F)c4)nc23)CC1,"2-(3,5-difluorophenyl)-4-(4-methyl-1,4-diazepan-1-yl)-1H-imidazo[4,5-c]pyridine",0.4,uM,=,-0.3979400086720376,0,c1ccc(-c2nc3c(N4CCCNCC4)nccc3[nH]2)cc1
6530,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine,5.8275,uM,=,0.7654822821926143,1,c1ccc2c(c1)Nc1ccccc1S2
6531,1980755,10.1021/acs.jmedchem.9b01188,,,,Inhibition of human ERG,CC(O)CN1[C@H](C)CN(CCSC(c2ccc(F)cc2)c2ccc(F)cc2)C[C@@H]1C,"Rac-1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)-2,6-cis-dimethylpiperazin-1-yl)propan-2-ol",0.635,uM,=,-0.1972262747080243,0,c1ccc(C(SCCN2CCNCC2)c2ccccc2)cc1
6532,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,Fc1cc2c(cn1)C1(CCN(Cc3ccc(Nc4ccc(F)c(F)c4)cc3)CC1)OC2,"3,4-difluoro-N-(4-((6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1'-yl)methyl)phenyl)aniline",0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ccc(CN3CCC4(CC3)OCc3ccncc34)cc2)cc1
6533,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(Cl)c4F)n2CCO3)ccn1,"3-(3-chloro-2-fluorophenoxy)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",2.41,uM,=,0.3820170425748684,1,c1ccc(Oc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
6534,1797483,10.1021/acsmedchemlett.8b00344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch clamp assay,Cc1cc(Nc2ccnc3ccc(S(=O)(=O)C(C)(C)C)cc23)n[nH]1,6-(tert-butylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)quinolin-4-amine,6.371,uM,=,0.8042076050820415,1,c1ccc2c(Nc3cc[nH]n3)ccnc2c1
6535,1797573,10.1021/acs.jmedchem.8b01187,,,,Inhibition of human ERG by whole cell electrophysiology analysis,C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cncc3[nH]ccc23)n1,"4-{4-[1-(Methanesulfonyl)cyclopropyl]-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl}-1H-pyrrolo[2,3-c]pyridine",15.0,uM,=,1.1760912590556811,1,c1cc2c(-c3nc(C4CC4)cc(N4CCOCC4)n3)cncc2[nH]1
6536,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2,"4-Phenylspiro[chromene-2,4'-piperidine]",0.68,uM,=,-0.1674910872937636,0,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
6537,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,COc1cc(CCN2CCN(CCc3ccc4c(c3)COC4=O)CC2)ccc1C#N,"2-methoxy-4-(2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",1.6,uM,=,0.2041199826559248,1,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
6538,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N(CCc3ccc(Cl)cc3)Cc3cccc(O)c3)CC2)n[nH]1,"3-(((1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl)(4-chlorophenethyl)amino)methyl)phenol",0.15,uM,=,-0.8239087409443188,0,c1ccc(CCN(Cc2ccccc2)C2CCN(c3nc[nH]n3)CC2)cc1
6539,2149749,10.1021/acs.jmedchem.1c00489,,,,Inhibition of human ERG,COc1cnc(C(=O)Nc2ccc(F)c([C@]34CN(c5ncc(F)cn5)C[C@H]3CSC(N)=N4)c2)cn1,"N-(3-((4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,6,7,7a-hexahydropyrrolo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-methoxypyrazine-2-carboxamide",2.6,uM,=,0.414973347970818,1,O=C(Nc1cccc([C@]23CN(c4ncccn4)C[C@H]2CSC=N3)c1)c1cnccn1
6540,1891417,10.1016/j.bmcl.2019.03.026,,,,Inhibition of human ERG by whole-cell patch clamp method,CC(C)c1cc(C(=O)NC[C@H]2CCN(CCc3ccc(C(F)(F)F)cc3)C2)on1,(R)-3-Isopropyl-N-((1-(4-(trifluoromethyl)phenethyl)pyrrolidin-3-yl)methyl)isoxazole-5-carboxamide,0.41,uM,=,-0.3872161432802645,0,O=C(NC[C@H]1CCN(CCc2ccccc2)C1)c1ccno1
6541,2161344,10.1021/acs.jmedchem.1c02048,,,,Inhibition of [35S]MK-499 binding to hERG expressed in HEK293 cells,CCNC(=O)N1C[C@H]2[C@H](C)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@]32C1,"(3R,3aS,4S,5R,6R,6aS,9aR)-4-[(E)-2-[5-(2-cyanophenyl)-2-pyridyl]vinyl]-N-ethyl-3,5,6-trimethyl-1-oxo-3,3a,4,5,6,6a,7,9-octahydrofuro[3,4-d]isoindole-8-carboxamide",9.2,uM,=,0.9637878273455552,1,O=C1OC[C@H]2[C@@H](/C=C/c3ccc(-c4ccccc4)cn3)CC[C@@H]3CNC[C@@]132
6542,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,Cc1nn(-c2ccnc3[nH]c(-c4cccc5c4ccn5C)nc23)cc1CN(C)C,"N,N-dimethyl-1-(3-methyl-1-(2-(1-methyl-1H-indol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-4-yl)methanamine",2.6,uM,=,0.414973347970818,1,c1cc(-c2nc3c(-n4cccn4)ccnc3[nH]2)c2cc[nH]c2c1
6543,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN(C2CCC(c3c[nH]c4ccccc34)CC2)C1,cis/trans-N-(2-(1-(4-(1H-indol-3-yl)cyclohexyl)azetidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide,2.4,uM,=,0.380211241711606,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3c[nH]c4ccccc34)CC2)C1
6544,945796,10.1016/j.bmcl.2012.12.072,,,,Inhibition of human ERG,O[C@H](COc1ccc(C(F)(F)F)cc1)CN1CCN(Cc2c(F)cccc2Cl)CC1,(S)-1-(4-(2-chloro-6-fluorobenzyl)piperazin-1-yl)-3-(4-(trifluoromethyl)phenoxy)propan-2-ol,13.97,uM,=,1.145196406114182,1,c1ccc(CN2CCN(CCCOc3ccccc3)CC2)cc1
6545,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,N#Cc1ccc(CCN2CCN(CCc3ccc4c(c3)COC4=O)CC2)cc1Br,"2-bromo-4-(2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",0.56,uM,=,-0.2518119729937995,0,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
6546,966750,10.1016/j.bmcl.2013.04.074,,,,Inhibition of human ERG current by patch clamp assay,CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,"8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid",1420.0,uM,=,3.1522883443830567,1,O=c1ccn2c3c(c(N4CCNCC4)ccc13)OCC2
6547,1813820,10.1016/j.ejmech.2019.111684,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,COc1ccc(-c2nn(-c3cccc(NC(=O)c4cccc(C(F)(F)F)c4)c3)cc2-c2ccncc2)cc1Cl,N-(3-(3-(3-Chloro-4-methoxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)phenyl)-3-(trifluoromethyl)benzamide,13.07,uM,=,1.1162755875805443,1,O=C(Nc1cccc(-n2cc(-c3ccncc3)c(-c3ccccc3)n2)c1)c1ccccc1
6548,1335624,10.1016/j.bmcl.2014.02.064,,,,Inhibition of human ERG,CC(C)(O)c1ccc(-c2cc(C(N)=O)c(Nc3cccc(CN4CCOCC4)n3)s2)cc1,5-(4-(2-hydroxypropan-2-yl)phenyl)-2-(6-(morpholinomethyl)pyridin-2-ylamino)thiophene-3-carboxamide,1.4,uM,=,0.1461280356782379,1,c1ccc(-c2ccc(Nc3cccc(CN4CCOCC4)n3)s2)cc1
6549,945471,10.1021/ml300372f,,,,Inhibition of human ERG assessed as decrease in tail current amplitude measured after 5 mins by whole cell patch clamp technique,CCOC(=O)N1CCC(CN2CC[C@H](N3C(=O)Cc4ccccc43)C2)CC1,(S)-ethyl 4-((3-(2-oxoindolin-1-yl)pyrrolidin-1-yl)methyl)piperidine-1-carboxylate,0.8,uM,=,-0.0969100130080563,0,O=C1Cc2ccccc2N1[C@H]1CCN(CC2CCNCC2)C1
6550,1719825,10.1016/j.ejmech.2017.09.012,,,,Inhibition of human ERG by patch clamp assay,COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2.[Cl-],"9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ylium chloride",3.1,uM,=,0.4913616938342727,1,c1ccc2c[n+]3c(cc2c1)-c1cc2c(cc1CC3)OCO2
6551,1448459,10.1021/jm5004864,,,,Inhibition of human ERG over-expressed in HEK293 cell membrane by [3H]dofetilide binding assay,CN(C)c1ccc(/C=C/c2c(F)cccc2Cl)nc1,"(E)-2-(2'-Chloro-6'-fluorostyryl)-5-(N,N-dimethylamino)-pyridine",20.7,uM,=,1.3159703454569178,1,C(=C/c1ccccn1)\c1ccccc1
6552,1891417,10.1016/j.bmcl.2019.03.026,,,,Inhibition of human ERG by whole-cell patch clamp method,COC(=O)C1=C(C)NC(C)=C(C(=O)NC[C@H]2CCN(CCc3ccc(C)c(C(F)(F)F)c3)C2)C1c1cccc([N+](=O)[O-])c1,"Methyl 2,6-dimethyl-5-((((R)-1-(4-methyl-3-(trifluoromethyl)phenethyl)pyrrolidin-3-yl)methyl)carbamoyl)-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate",2.7,uM,=,0.4313637641589873,1,O=C(NC[C@H]1CCN(CCc2ccccc2)C1)C1=CNC=CC1c1ccccc1
6553,1712776,10.1016/j.bmcl.2018.03.056,,,,Inhibition of human ERG expressed in CHOK1 cells at holding potential of -80 mV after 5 mins by patch clamp assay,C[C@]12CCC(F)=C[C@H]1C[C@@H](N1CCC[C@@H](N)C1)[C@@H]2Oc1ccc(C#N)cc1,"4-((1R,2R,3aR,7aS)-2-((R)-3-aminopiperidin-1-yl)-5-fluoro-7a-methyl-2,3,3a,6,7,7a-hexahydro-1H-inden-1-yloxy)benzonitrile",8.6,uM,=,0.9344984512435676,1,C1=C[C@H]2C[C@@H](N3CCCCC3)[C@H](Oc3ccccc3)C2CC1
6554,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,Cn1ccc(NC(=O)c2cc(Oc3ccc(C(=O)N4CCC4)cc3)cc(O[C@H]3CCOC3)c2)n1,(S)-3-(4-(azetidine-1-carbonyl)phenoxy)-N-(1-methyl-1H-pyrazol-3-yl)-5-(tetrahydrofuran-3-yloxy)benzamide,35.0,uM,=,1.5440680443502757,1,O=C(Nc1cc[nH]n1)c1cc(Oc2ccc(C(=O)N3CCC3)cc2)cc(O[C@H]2CCOC2)c1
6555,2223202,10.1021/acsmedchemlett.2c00111,,,,Inhibition of hERG cardiac ion channel,O=c1ccc2ccc(F)c3c2n1CC3C[C@H]1OC[C@H](NCc2cc3c(nn2)OCCS3)CO1,"1-((5-(((6,7-dihydro-[1,4]oxathiino[2,3-c]pyridazin-3-yl)methyl)amino)-trans-1,3-dioxan-2-yl)methyl)-9-fluoro-1,2-dihydro-4H-pyrrolo[3,2,1-iJ]quinolin-4-one",200.0,uM,=,2.3010299956639813,1,O=c1ccc2cccc3c2n1CC3C[C@H]1OC[C@H](NCc2cc3c(nn2)OCCS3)CO1
6556,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,COCC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1,"1-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-2-methoxyethanone",17.0,uM,=,1.230448921378274,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
6557,627243,10.1021/jm9016812,,,,Inhibition of human ERG by electrophysiology assay,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(C(F)(F)F)cc4)oc3C)c2)cc1,2-((3-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,26.0,uM,=,1.414973347970818,1,O=C(NCc1cccc(OCc2coc(-c3ccccc3)n2)c1)Oc1ccccc1
6558,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,"4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine",17.0491,uM,=,1.231701458088038,1,C1=Cc2ccccc2C(=C2CCNCC2)c2ccccc21
6559,1745714,10.1016/j.bmc.2017.10.004,,,,Inhibition of human ERG expressed in Xenopus laevis oocytes by two-electrode voltage clamp assay,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,0.3046999999999999,uM,=,-0.5161275457773264,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
6560,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,O=[N+]([O-])c1ccc(CCN2CCN(CCc3ccc([N+](=O)[O-])cc3)CC2)cc1,"1,4-bis(4-nitrophenethyl)piperazine",0.005,uM,=,-2.3010299956639813,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6561,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,10-[2-(1-Methyl-piperidin-2-yl)-ethyl]-2-methylsulfanyl-10H-phenothiazine,1.588,uM,=,0.2008504980910774,1,c1ccc2c(c1)Sc1ccccc1N2CCC1CCCCN1
6562,543016,10.1016/j.bmcl.2008.12.114,,,,Inhibition of human ERG by patch clamp technique,C[C@@H]1CN(CC2(c3ccc(C(N)=O)cc3)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1,"4-(1-(((3R)-3-methyl-4-(4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenylsulfonyl)piperazin-1-yl)methyl)cyclopropyl)benzamide",6.4,uM,=,0.8061799739838872,1,O=S(=O)(c1ccccc1)N1CCN(CC2(c3ccccc3)CC2)CC1
6563,857209,10.1021/jm300286a,,,,Inhibition of human ERG by patch clamp assay,Cc1ccc(N2CCN(CC(O)COc3ccccc3C(=O)CCc3ccccc3)CC2)cc1,1-(2-(2-hydroxy-3-(4-p-tolylpiperazin-1-yl)propoxy)phenyl)-3-phenylpropan-1-one,4.31,uM,=,0.6344772701607315,1,O=C(CCc1ccccc1)c1ccccc1OCCCN1CCN(c2ccccc2)CC1
6564,2049685,10.1021/acs.jmedchem.0c01411,,,,Inhibition of human ERG by patch clamp method,Fc1ccc(-c2nc3c(N4CCNCC4)nccc3[nH]2)cc1F,"2-(3,4-Difluorophenyl)-4-(piperazin-1-yl)-1H-imidazo[4,5-c]pyridine",3.4,uM,=,0.5314789170422551,1,c1ccc(-c2nc3c(N4CCNCC4)nccc3[nH]2)cc1
6565,1512782,10.1016/j.bmcl.2015.07.038,,,,Inhibition of human ERG expressed in HEK cells by patch clamp assay,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",1.3,uM,=,0.1139433523068367,1,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
6566,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,Cc1nn(C2CCN(CC(=O)N(C)C)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"2-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-N,N-dimethylacetamide",7.8,uM,=,0.8920946026904804,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
6567,411697,10.1021/jm060927v,,,,Binding affinity to hERG potassium channel,COc1ccc2c(=O)n(CCO)c(C#N)c(-c3cccc(F)c3)c2c1,"4-(3-fluorophenyl)-2-(2-hydroxyethyl)-6-methoxy-1-oxo-1,2-dihydroisoquinoline-3-carbonitrile",62.0,uM,=,1.792391689498254,1,O=c1[nH]cc(-c2ccccc2)c2ccccc12
6568,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,COC[C@H](C)Oc1cc(Oc2ccc(C(=O)N3CCC3)cc2)cc(C(=O)Nc2cnc(C)cn2)c1,3-[4-[(Azetidin-1-yl)carbonyl]phenoxy]-5-[(1S)-2-(methoxy)-1-methylethoxy]-N-(5-methylpyrazin-2-yl)benzamide,18.0,uM,=,1.255272505103306,1,O=C(Nc1cnccn1)c1cccc(Oc2ccc(C(=O)N3CCC3)cc2)c1
6569,1580962,10.1021/acsmedchemlett.6b00018,,,,Binding affinity to human ERG by radioligand binding assay,CC(C)(C)c1cc(NC(=O)n2ccc3ccc(Oc4ncnc5c4CNC5)cc32)no1,"N-(5-(tert-Butyl)isoxazol-3-yl)-6-((6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide",21.0,uM,=,1.3222192947339193,1,O=C(Nc1ccon1)n1ccc2ccc(Oc3ncnc4c3CNC4)cc21
6570,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(C2=CC(=O)CC2)C3=O)ccc2c1COC2=O,"(R)-8-(2-Hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(3-oxocyclopent-1-en-1-yl)-2,8-diazaspiro[4.5]decan-1-one",83.0,uM,=,1.919078092376074,1,O=C1C=C(N2CCC3(CCN(CCc4ccc5c(c4)COC5=O)CC3)C2=O)CC1
6571,943154,10.1016/j.bmcl.2012.12.056,,,,Inhibition of human ERG,COc1cccc2nc(C#Cc3cccnc3)ccc12,5-Methoxy-2-(pyridin-3-ylethynyl)quinoline,65.3,uM,=,1.8149131812750736,1,C(#Cc1ccc2ccccc2n1)c1cccnc1
6572,422225,10.1016/j.bmcl.2006.07.061,,,,Inhibition of hERG potassium channel,C[C@H](c1nc(-c2ccc(Cl)cc2Cl)no1)[C@H](N)C(=O)N1CCCC1.O=C(O)C(F)(F)F,"(2S,3S)-3-(3-(2,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl)-1-oxo-1-(pyrrolidin-1-yl)butan-2-aminium 2,2,2-trifluoroacetate",36.7,uM,=,1.564666064252089,1,O=C(CCc1nc(-c2ccccc2)no1)N1CCCC1
6573,411697,10.1021/jm060927v,,,,Binding affinity to hERG potassium channel,COc1ccc2c(=O)n(C)c(CN(C)C)c(-c3ccccc3)c2c1,3-((dimethylamino)methyl)-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one,5.3,uM,=,0.724275869600789,1,O=c1[nH]cc(-c2ccccc2)c2ccccc12
6574,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,COc1ccc(CCN2CCN(CCc3ccc([N+](=O)[O-])cc3)CC2)cc1,1-(4-methoxyphenethyl)-4-(4-nitrophenethyl)piperazine,0.007,uM,=,-2.154901959985743,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6575,411697,10.1021/jm060927v,,,,Binding affinity to hERG potassium channel,COc1ccc2c(-n3cnc(C)c3)nc(C#N)c(-c3cccc(F)c3)c2c1,4-(3-fluorophenyl)-6-methoxy-1-(4-methyl-1H-imidazol-1-yl)isoquinoline-3-carbonitrile,21.0,uM,=,1.3222192947339193,1,c1ccc(-c2cnc(-n3ccnc3)c3ccccc23)cc1
6576,698980,10.1016/j.bmcl.2010.10.115,,,,Inhibition of human ERG by patch clamp assay,COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccc(N4CCOCC4)cc3OC)n1)CCN(CC(=O)N(C)C)CC2,"2-(7-(5-chloro-4-(2-methoxy-4-morpholinophenylamino)pyrimidin-2-ylamino)-8-methoxy-4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-N,N-dimethylacetamide",3.9,uM,=,0.5910646070264992,1,c1cc(Nc2ccc(N3CCOCC3)cc2)nc(Nc2ccc3c(c2)CCNCC3)n1
6577,766845,10.1021/jm200682b,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2C)CC1.Cl.Cl.Cl,"N-(3-(4-(3-Chloro-2-methylphenyl)piperazin-1-yl)propyl)-5-methyl-1,2-diphenyl-1H-imidazole-4-carboxamide dihydrochloride",1.3,uM,=,0.1139433523068367,1,O=C(NCCCN1CCN(c2ccccc2)CC1)c1cn(-c2ccccc2)c(-c2ccccc2)n1
6578,875038,10.1021/jm300573d,,,,Inhibition of human ERG,Cn1cc2c(OCC3CCN(CCc4ccc(C(=O)O)cc4)CC3)nc3ccccc3c2c1,"4-[2-[4-[[(2-Methyl-2H-pyrrolo[3,4-c]-4-quinolinyl)oxy]methyl]-1-piperidinyl]ethyl]benzoic Acid",9.96,uM,=,0.9982593384236988,1,c1ccc(CCN2CCC(COc3nc4ccccc4c4c[nH]cc34)CC2)cc1
6579,748773,10.1016/j.bmcl.2011.04.102,,,,Inhibition of human ERG by HT patch clamp assay,Cc1c2c(n3c1CCCN1CCC[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,"(18R)-5,5,9-trimethyl-7-oxo-2,14,20-triazapentacyclo[19.3.1.0^{2,10}.0^{3,8}.0^{14,18}]pentacosa-1(25),3(8),9,21,23-pentaene-22-carboxamide",2.6,uM,=,0.414973347970818,1,O=C1CCCc2c1cc1n2-c2cccc(c2)NC[C@H]2CCCN2CCC1
6580,1571176,10.1016/j.bmcl.2016.03.035,,,,Inhibition of human ERG by electrophysiology analysis,Cc1c(C(C)CN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O,(rac)-5-(1-(4-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperazin-1-yl)propan-2-yl)-4-methylisobenzofuran-1(3H)-one,30.0,uM,=,1.4771212547196624,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
6581,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc2c1nc(N)n1nc(CN3CCN(c4ccncc4)C[C@H]3C)nc21,"(R)-7-methoxy-2-((2-methyl-4-(pyridin-4-yl)piperazin-1-yl)methyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",2.184,uM,=,0.3392526340326997,1,c1ccc2c(c1)ncn1nc(CN3CCN(c4ccncc4)CC3)nc21
6582,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc2c1nc(N)n1nc(CN3CCN(c4ccccc4)C[C@H]3C)nc21,"(R)-7-methoxy-2-((2-methyl-4-phenylpiperazin-1-yl)methyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",16.94,uM,=,1.2289134059946882,1,c1ccc(N2CCN(Cc3nc4c5ccccc5ncn4n3)CC2)cc1
6583,1927981,10.1021/acsmedchemlett.6b00117,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,c1ccc(-c2cccc3nc(-c4cncs4)nc(NCc4ccccn4)c23)cc1,5-phenyl-N-(pyridin-2-ylmethyl)-2-(thiazol-5-yl)quinazolin-4-amine,6.2,uM,=,0.7923916894982539,1,c1ccc(-c2cccc3nc(-c4cncs4)nc(NCc4ccccn4)c23)cc1
6584,1970442,10.1016/j.bmcl.2019.126715,,,,Inhibition of human ERG,C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C,"3-(1-methyl-1H-pyrazol-4-yl)-5-((R)-3-methyl-4-((1R,2R)-2-methylcyclopropane-1-carbonyl)piperazin-1-yl)pyrazine-2-carbonitrile",23.0,uM,=,1.3617278360175928,1,O=C(C1CC1)N1CCN(c2cncc(-c3cn[nH]c3)n2)CC1
6585,1891417,10.1016/j.bmcl.2019.03.026,,,,Inhibition of human ERG by whole-cell patch clamp method,CC(C)c1cc(C(=O)NC[C@H]2CCN(CCc3ccc(OC(F)(F)F)c(F)c3)C2)on1,(R)-N-((1-(3-fluoro-4-(trifluoromethoxy)phenethyl)pyrrolidin-3-yl)methyl)-3-isopropylisoxazole-5-carboxamide,0.16,uM,=,-0.7958800173440752,0,O=C(NC[C@H]1CCN(CCc2ccccc2)C1)c1ccno1
6586,1665702,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,NS(=O)(=O)c1cncc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)c1,5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]-pyridine-3-sulfonamide,1.9,uM,=,0.2787536009528289,1,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1
6587,856088,10.1016/j.bmc.2012.08.050,,,,Displacement of [3H]-dofetilide from human ERG,CCN(CC)CCSc1nc(-c2cc(OC)c(C#N)cc2Cl)c2c(C#N)c[nH]c2n1,"4-(2-Chloro-4-cyano-5-methoxy-phenyl)-2-(2-diethylamino-ethylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile",1.07,uM,=,0.0293837776852096,1,c1ccc(-c2ncnc3[nH]ccc23)cc1
6588,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4ccccc4Cl)n2CCO3)ccn1,"3-(2-chlorophenoxy)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",3.51,uM,=,0.5453071164658241,1,c1ccc(Oc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
6589,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)C/C=C/Cc1ccc(Cl)cc1,(E)-N-(4-(4-Chlorophenyl)but-2-en-1-yl)-N-ethylheptan-1-amine,0.049,uM,=,-1.3098039199714864,0,c1ccccc1
6590,411697,10.1021/jm060927v,,,,Binding affinity to hERG potassium channel,COc1ccc2c(=O)n(CC(O)CO)c(C#N)c(-c3cccc(F)c3)c2c1,"2-(2,3-dihydroxypropyl)-4-(3-fluorophenyl)-6-methoxy-1-oxo-1,2-dihydroisoquinoline-3-carbonitrile",33.5,uM,=,1.5250448070368452,1,O=c1[nH]cc(-c2ccccc2)c2ccccc12
6591,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1Cc1ccc(C(F)(F)F)cn1,3-Oxo-N-(4-(trifluoromethoxy)benzyl)-2-((5-(trifluoromethyl)pyridin-2-yl)methyl)isoindoline-1-carboxamide,3.3,uM,=,0.5185139398778875,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1Cc1ccccn1
6592,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(O[C@@H]5CCCNC5)c(C)n4)n3)cc12,"N,1-dimethyl-5-[[4-[3-methyl-4-[[(3R)-3-piperidyl]oxy]pyrazol-1-yl]pyrimidin-2-yl]amino]indazole-3-carboxamide",2.5,uM,=,0.3979400086720376,1,c1cc(-n2cc(O[C@@H]3CCCNC3)cn2)nc(Nc2ccc3[nH]ncc3c2)n1
6593,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,O=C(NC1CC1)c1cn(-c2cccc(-c3cccnc3)c2)c2ncccc2c1=O,"N-cyclopropyl-4-oxo-1-(3-(pyridin-3-yl)phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide",34.0,uM,=,1.5314789170422551,1,O=C(NC1CC1)c1cn(-c2cccc(-c3cccnc3)c2)c2ncccc2c1=O
6594,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.Cl.FCCOc1ccc(CCN2CCN(CCc3ccccc3Cl)CC2)cc1,1-(2-Chlorophenethyl)-4-(4-(2-fluoroethoxy)phenethyl)piperazine dihydrochloride,1.4,uM,=,0.1461280356782379,1,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6595,1891417,10.1016/j.bmcl.2019.03.026,,,,Inhibition of human ERG by whole-cell patch clamp method,COC(=O)C1=C(C)NC(C)=C(C(=O)NC[C@H]2CCN(CCc3ccc(Cl)c(F)c3)C2)C1c1cccc([N+](=O)[O-])c1,"Methyl 5-((((R)-1-(4-chloro-3-fluorophenethyl)pyrrolidin-3-yl)methyl)carbamoyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate",0.33,uM,=,-0.4814860601221125,0,O=C(NC[C@H]1CCN(CCc2ccccc2)C1)C1=CNC=CC1c1ccccc1
6596,1554488,10.1016/j.bmcl.2016.01.049,,,,Inhibition of human ERG using tracer red fluorescent probe,Cl.Cl.NC1(c2cc(C(=O)N[C@@H]3CCc4ccc(Oc5ccnc6c5CCC(=O)N6)cc4C3)cc(C(F)(F)F)c2)CCC1,"3-(1-aminocyclobutyl)-N-{(2R)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide dihydrochloride",3.1,uM,=,0.4913616938342727,1,O=C1CCc2c(Oc3ccc4c(c3)C[C@H](NC(=O)c3cccc(C5CCC5)c3)CC4)ccnc2N1
6597,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,Cc1nn(C2CCN(C(=O)[C@H](C)O)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"(2S)-1-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-2-hydroxy-1-propanone",23.0,uM,=,1.3617278360175928,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
6598,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,CC(C)(Cc1ccccn1)N1C(=O)c2ccccc2C1C(=O)NCc1ccc(OC(F)(F)F)cc1,2-(2-Methyl-1-(pyridin-2-yl)propan-2-yl)-3-oxo-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,4.3,uM,=,0.6334684555795865,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
6599,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N(CCc3ccc(Cl)cc3)Cc3ccc(Cl)cc3)CC2)n[nH]1,"1-(5-amino-1H-1,2,4-triazol-3-yl)-N-(4-chlorobenzyl)-N-(4-chlorophenethyl)piperidin-4-amine",0.4,uM,=,-0.3979400086720376,0,c1ccc(CCN(Cc2ccccc2)C2CCN(c3nc[nH]n3)CC2)cc1
6600,2228478,10.1021/acs.jmedchem.2c00794,,,,Inhibition of human ERK potassium channel by automated patch clamp electrophysiology,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,SID11112860,0.015,uM,=,-1.8239087409443189,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
6601,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,CC1=C(N2C(=O)C3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)CC2C)COC1=O,"US9206198, 29",18.0,uM,=,1.255272505103306,1,O=C1C=C(N2CCC3(CCN(CCc4ccc5c(c4)COC5=O)CC3)C2=O)CO1
6602,2232362,10.1016/j.bmcl.2022.128648,,,,Inhibition of human ERG by Ionworks electrophysiology assay,COc1ccc2ccc(=O)n(CCN[C@@H]3CC[C@@H]4[C@@H](C3)OC(=O)N4c3ccc4c(n3)NC(=O)CO4)c2n1,"6-((3aR,6R,7aR)-6-((2-(7-methoxy-2-oxo-1,8-naphthyridin-1(2H)-yl)ethyl)amino)-2-oxohexahydrobenzo[d]oxazol-3(2H)-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",10.0,uM,=,1.0,1,O=C1COc2ccc(N3C(=O)O[C@@H]4C[C@H](NCCn5c(=O)ccc6cccnc65)CC[C@H]43)nc2N1
6603,1552715,10.1016/j.ejmech.2015.12.006,,,,Inhibition of human ERG channel by fluorescence polarization assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCn2cccc2)C[C@H]1OC,cis-4-Amino-5-chloro-N-[1-(3-(1H-pyrrol-1-yl)propyl)-3-methoxypiperidin-4-yl]-2-methoxybenzamide,6.835,uM,=,0.8347385189038411,1,O=C(NC1CCN(CCCn2cccc2)CC1)c1ccccc1
6604,972740,10.1021/ml400197u,,,,Binding affinity to human ERG expressed in CHO cells by IonWorks assay,CC(=O)Nc1cc(Nc2cc(NC3CCC3)n3ncc(C#N)c3n2)c(F)cc1C,"N-[5-[[3-cyano-7-(cyclobutylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-4-fluoro-2-methylphenyl]acetamide",16.0,uM,=,1.2041199826559248,1,c1ccc(Nc2cc(NC3CCC3)n3nccc3n2)cc1
6605,1448459,10.1021/jm5004864,,,,Inhibition of human ERG over-expressed in HEK293 cell membrane by [3H]dofetilide binding assay,CN(C)c1ccc(/C=C/c2c(F)cccc2F)cc1,"(E)-4-(2,6-Difluorostyryl)-N,N-dimethylaniline",32.1,uM,=,1.506505032404872,1,C(=C/c1ccccc1)\c1ccccc1
6606,1552430,10.1021/acs.jmedchem.5b01249,,,,Inhibition of human ERG,Cc1nc(NC(=O)c2cc(CNC(=O)C(C)C)cnc2C(F)F)[nH]c1-c1ccc(C(F)(F)F)cc1,2-(difluoromethyl)-5-(isobutyramidomethyl)-N-(4-methyl-5-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)nicotinamide,82.6,uM,=,1.9169800473203824,1,O=C(Nc1ncc(-c2ccccc2)[nH]1)c1cccnc1
6607,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.FCCOc1ccccc1CCC1CCN(CCc2ccccc2)CC1,4-(2-(2-Fluoroethoxy)phenethyl)-1-phenethylpiperidine hydrochloride,0.76,uM,=,-0.1191864077192086,0,c1ccc(CCC2CCN(CCc3ccccc3)CC2)cc1
6608,1758787,10.1021/acsmedchemlett.7b00188,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch assay,O=C1CN(c2ccncc2)CCN1CCCCCOc1ccc(-c2ccc(Cl)cc2)cc1,1-(5-(4'-chlorobiphenyl-4-yloxy)pentyl)-4-(pyridin-4-yl)piperazin-2-one,0.37,uM,=,-0.431798275933005,0,O=C1CN(c2ccncc2)CCN1CCCCCOc1ccc(-c2ccccc2)cc1
6609,1927981,10.1021/acsmedchemlett.6b00117,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,CN(C)c1nc(NCc2ccccn2)c2c(-c3ccccc3)cccc2n1,"N2,N2-dimethyl-5-phenyl-N4-(pyridin-2-ylmethyl)quinazoline-2,4-diamine",2.5,uM,=,0.3979400086720376,1,c1ccc(-c2cccc3ncnc(NCc4ccccn4)c23)cc1
6610,875038,10.1021/jm300573d,,,,Inhibition of human ERG,CC(C)n1nc(C(=O)NCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc21.Cl,1-Isopropyl-N-[[1-[2-[(methylsulfonyl)amino]ethyl]-4-piperidinyl]methyl]-1H-indazole-3-carboxamide hydrochloride,2.63,uM,=,0.4199557484897578,1,O=C(NCC1CCNCC1)c1n[nH]c2ccccc12
6611,1697113,10.1021/acs.jmedchem.7b00932,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in peak tail current amplitude by path clamp method,NC(=O)c1c(NC(=O)Nc2ccc(Cl)cc2)sc2c1CC[N+]1(CCCC1)C2.[Br-],"3'-Carbamoyl-2'-[3-(4-chlorophenyl)ureido]-5',7'-dihydro-4'H-spiro[pyrrolidine-1,6'-thieno[2,3-c]pyridin]-1-ium Bromide",3.51,uM,=,0.5453071164658241,1,O=C(Nc1ccccc1)Nc1cc2c(s1)C[N+]1(CCCC1)CC2
6612,1980755,10.1021/acs.jmedchem.9b01188,,,,Inhibition of human ERG,C[C@@H]1CN(CC[S+]([O-])C(c2ccc(F)cc2)c2ccc(F)cc2)C[C@H](C)N1CC(O)Cc1ccccc1,"1-(4-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-2,6-cis-dimethylpiperazin-1-yl)-3-phenylpropan-2-ol",0.0915,uM,=,-1.0385789059335515,0,c1ccc(CCCN2CCN(CC[SH+]C(c3ccccc3)c3ccccc3)CC2)cc1
6613,1296753,10.1021/jm4014828,,,,Inhibition of human ERG expressed in CHOK1 cells by electrophysiological analysis,O=C(C1CC12CCN(C1CCCCC1)CC2)N1CCN(C2CCCCC2)CC1,rac-(6-Cyclohexyl-6-azaspiro[2.5]octan-1-yl)(4-cyclohexylpiperazin-1-yl)methanone,20.8,uM,=,1.3180633349627615,1,O=C(C1CC12CCN(C1CCCCC1)CC2)N1CCN(C2CCCCC2)CC1
6614,1697113,10.1021/acs.jmedchem.7b00932,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in peak tail current amplitude by path clamp method,NC(=O)c1c(NC(=O)Nc2ccc(Cl)cc2)sc2c1CCN(CCCNC(=O)CCc1c[nH]c3ccccc13)C2,"2-{[(4-Chlorophenyl)carbamoyl]amino}-6-{3-[3-(1H-indol-3-yl)propanamido]propyl}-4H,5H,6H,7H-thieno[2,3-c]pyridine-3-carboxamide",20.1,uM,=,1.3031960574204888,1,O=C(CCc1c[nH]c2ccccc12)NCCCN1CCc2cc(NC(=O)Nc3ccccc3)sc2C1
6615,1571176,10.1016/j.bmcl.2016.03.035,,,,Inhibition of human ERG by electrophysiology analysis,O=C1OCc2cc(CCC3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21,5-(2-(1-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperidin-4-yl)ethyl)isobenzofuran-1(3H)-one,2.0,uM,=,0.3010299956639812,1,O=C1OCc2cc(CCC3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
6616,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCC[N+](CC)(CC)CC#Cc1ccc(Cl)cc1.Cc1ccc(S(=O)(=O)[O-])cc1,"N-(3-(4-Chlorophenyl)prop-2-yn-1-yl)-N,N-diethylheptan-1-aminium 4-methylbenzenesulfonate",0.04,uM,=,-1.3979400086720375,0,c1ccccc1.c1ccccc1
6617,1924515,10.1021/acsmedchemlett.6b00122,,,,Inhibition of human ERG after 6 mins by electrophysiological assay,Cc1c(C(O)CN2CCN(CC(O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,"5,5'-(2,2'-(piperazine-1,4-diyl)bis(1-hydroxyethane-2,1-diyl))bis(4-methylisobenzofuran-1(3H)-one)",28.0,uM,=,1.4471580313422192,1,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21
6618,1981486,10.1021/acs.jmedchem.9b01870,,,,Inhibition of human ERG by radioligand binding assay,Cc1cc(Br)c(NC2=NCCN2)c2ccccc12,"N-(2-Bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine",7.1,uM,=,0.8512583487190752,1,c1ccc2c(NC3=NCCN3)cccc2c1
6619,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CC[C@@H](N(C)C)C1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-2-((R)-3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide",5.6,uM,=,0.7481880270062004,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCCC5)cc4)n3)c2c1
6620,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,O=[N+]([O-])c1ccc(CCN2CCN(CCc3ccc(F)cc3)CC2)cc1,1-(4-fluorophenethyl)-4-(4-nitrophenethyl)piperazine,0.023,uM,=,-1.6382721639824072,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6621,2216976,10.1021/acs.jmedchem.2c00676,,,,Inhibition of hERG by Qpatch-clamp method,C[C@@H]1CN(c2sc(C(F)(F)F)nc2-c2nc3ccccc3[nH]2)CCN1C(=O)Cn1cnc2cccnc21,"US9266876, 51",1.4,uM,=,0.1461280356782379,1,O=C(Cn1cnc2cccnc21)N1CCN(c2scnc2-c2nc3ccccc3[nH]2)CC1
6622,1611665,10.1039/C6MD00190D,,,,Inhibition of human ERG by patch clamp method,N#Cc1ccc(Oc2ccc(S(=O)(=O)Nc3ccc(F)cn3)cc2C#N)cc1Cl,"US9067922, 1",67.0,uM,=,1.8260748027008264,1,O=S(=O)(Nc1ccccn1)c1ccc(Oc2ccccc2)cc1
6623,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,CC(CN1CCN(CCc2ccc([N+](=O)[O-])cc2)CC1)c1ccc([N+](=O)[O-])cc1,1-(4-nitrophenethyl)-4-(2-(4-nitrophenyl)propyl)piperazine,0.0031,uM,=,-2.508638306165728,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6624,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,C[C@@]1(c2cc(CNC3CC3)c(F)cc2F)CCSC(N)=N1,"(S)-4-(5-((Cyclopropylamino)methyl)-2,4-difluorophenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine",49.2,uM,=,1.6919651027673603,1,C1=NC(c2cccc(CNC3CC3)c2)CCS1
6625,2207007,10.1021/acs.jmedchem.2c01164,,,,Inhibition of hERG potassium channel at -80 mV holding potential incubated for 3 mins by automated patch clamp method,C[C@]12CC[C@H](NC(=O)c3ccncc3)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3ccnc3)=CC[C@@H]12,"N-((3S,8R,9S,10R,13S,14S)-17-(1H-imidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)isonicotinamide",4.99,uM,=,0.69810054562339,1,O=C(N[C@H]1CCC2C(=CC[C@@H]3[C@@H]2CCC2C(n4ccnc4)=CC[C@H]23)C1)c1ccncc1
6626,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,C[C@@H](CO)Oc1cc(Oc2ccc(C(=O)N3CCC3)cc2)cc(C(=O)Nc2nccs2)c1,"3-[4-(Azetidin-1-ylcarbonyl)phenoxy]-5-[(1S)-2-hydroxy-1-methylethoxy]-N-1,3-thiazol-2-ylbenzamide",9.0,uM,=,0.9542425094393248,1,O=C(Nc1nccs1)c1cccc(Oc2ccc(C(=O)N3CCC3)cc2)c1
6627,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,CC(Cc1ccc([N+](=O)[O-])cc1)N1CCN(CCc2ccc([N+](=O)[O-])cc2)CC1,1-(4-nitrophenethyl)-4-(1-(4-nitrophenyl)propan-2-yl)piperazine,0.0039,uM,=,-2.408935392973501,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6628,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,COc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"1-[4-(4-{[5-Chloro-4-(imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3-methoxy-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",6.6,uM,=,0.8195439355418687,1,c1ccn2c(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)cnc2c1
6629,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-2-methoxy-piperidin-4-yl}-2-methoxy-benzamide,0.1701,uM,=,-0.769295686387431,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
6630,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CC#CCOc1ccc(Cl)cc1,N-(4-(4-Chlorophenoxy)but-2-yn-1-yl)-N-ethylheptan-1-amine,2.473,uM,=,0.3932241163612973,1,c1ccccc1
6631,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,N#Cc1ccc(CCN2CCN(CCc3ccc4c(c3)COC4=O)CC2)cc1OC1CC1,"2-cyclopropoxy-4-(2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",0.47,uM,=,-0.3279021420642826,0,O=C1OCc2cc(CCN3CCN(CCc4cccc(OC5CC5)c4)CC3)ccc21
6632,1498989,10.1021/acs.jmedchem.5b00114,,,,Inhibition of human ERG by IonWorks electrophysiology,O=C(NCCCNc1nc2ccccc2[nH]1)c1ccnc(C(F)(F)F)c1,N-[3-[(1H-Benz[d]imidazol-2-yl)amino]propyl]-2-(trifluoromethyl)isonicotinamide,22.39,uM,=,1.3500540935790304,1,O=C(NCCCNc1nc2ccccc2[nH]1)c1ccncc1
6633,1567397,10.1016/j.ejmech.2016.02.014,,,,Displacement of [3H]dofetilide from human ERG channel expressed in HEK293 cells after 60 mins by liquid scintillation counting method,Oc1ccc(Cl)c2c1CNC(CN1CCC3(CCc4ccccc43)CC1)C2,"5-chloro-3-{(2,3-dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)methyl}-1,2,3,4-tetrahydroisoquinolin-8-ol",1.73,uM,=,0.2380461031287954,1,c1ccc2c(c1)CNC(CN1CCC3(CCc4ccccc43)CC1)C2
6634,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1ccc(C2(c3cccc(-c4cncnc4)c3)CCC(N)=N2)cc1,"2-(4-Methoxyphenyl)-2-(3-(pyrimidin-5-yl)phenyl)-3,4-dihydro-2H-pyrrol-5-amine",23.0,uM,=,1.3617278360175928,1,C1=NC(c2ccccc2)(c2cccc(-c3cncnc3)c2)CC1
6635,462632,10.1016/j.bmcl.2008.01.108,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes,Cc1cccc(C)c1C(=O)N1CCC(C)(N2CCC(N(Cc3ccccc3)c3ccccc3)CC2)CC1,"[4-(Benzyl-phenyl-amino)-4'-methyl-[1,4']bipiperidinyl-1'-yl]-(2,6-dimethyl-phenyl)-methanone",0.67,uM,=,-0.1739251972991735,0,O=C(c1ccccc1)N1CCC(N2CCC(N(Cc3ccccc3)c3ccccc3)CC2)CC1
6636,702661,10.1021/jm100978n,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells,Cc1nc(C(C)C)n([C@H]2C[C@H]3CC[C@@H](C2)N3CC[C@H](NC(=O)C2CCC(F)(F)CC2)c2ccccc2)n1,"endo-4,4-difluoro-N-((S)-3-(3-(5-isopropyl-3-methyl-1H-1,2,4-triazol-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide",4.23,uM,=,0.6263403673750424,1,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1cncn1)C2)c1ccccc1)C1CCCCC1
6637,2223202,10.1021/acsmedchemlett.2c00111,,,,Inhibition of hERG cardiac ion channel,O=c1ccc2ncc(F)c3c2n1CC3C[C@H]1OC[C@H](NCc2ccc3c(c2)OCCO3)CO1,"4-((5-(((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)amino)-trans-1,3-dioxan-2-yl)methyl)-3-fluoro-4,5-dihydro-7H-pyrrolo[3,2,1-de][1,5]naphthyridin-7-one",100.0,uM,=,2.0,1,O=c1ccc2nccc3c2n1CC3C[C@H]1OC[C@H](NCc2ccc3c(c2)OCCO3)CO1
6638,1665702,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,NS(=O)(=O)Nc1cncc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)c1,N-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)sulfamide,0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1
6639,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CC(C)(O)c1ccc(C#Cc2cccc(-n3cc(C(=O)NC4CC4)c(=O)c4cccnc43)c2)c[n+]1[O-],"1-{3-[6-(1-Hydroxy-1-methyl-ethyl)-1-oxy-pyridin-3-ylethynyl]-phenyl}-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid cyclopropylamide",89.4,uM,=,1.9513375187959177,1,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[nH+]c3)c2)c2ncccc2c1=O
6640,976818,10.1016/j.bmcl.2013.06.100,,,,Binding affinity to human ERG,COc1cc(-c2nc3n(n2)CCC[C@@H]3c2ccc(F)cc2C)ccc1-n1cnc(C)c1,"(R)-8-(4-fluoro-2-methylphenyl)-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine",0.794,uM,=,-0.1001794975729037,0,c1ccc([C@H]2CCCn3nc(-c4ccc(-n5ccnc5)cc4)nc32)cc1
6641,766845,10.1021/jm200682b,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1.Cl.Cl.Cl.Cl,"N-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propyl)-2,5-dimethyl-1-phenyl-1H-imidazole-4-carboxamide dihydrochloride",8.11,uM,=,0.909020854211156,1,O=C(NCCCN1CCN(c2ccccc2)CC1)c1cn(-c2ccccc2)cn1
6642,1841342,10.1016/j.bmcl.2019.03.029,,,,Inhibition of human ERG by QPatch assay,NC[C@H](Oc1noc2ccc(-c3ccccc3Cl)nc12)c1ccccc1,"(R)-2-(5-(2-chlorophenyl)isoxazolo[4,5-b]pyridin-3-yloxy)-2-phenylethanamine",3.6,uM,=,0.5563025007672873,1,c1ccc(COc2noc3ccc(-c4ccccc4)nc23)cc1
6643,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CC(F)(F)c1ccccn1,"2-(2,2-Difluoro-2-(pyridin-2-yl)ethyl)-3-oxo-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide",9.7,uM,=,0.9867717342662448,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
6644,748773,10.1016/j.bmcl.2011.04.102,,,,Inhibition of human ERG by HT patch clamp assay,Cc1c2c(n3c1CCCN1CCCC[C@@H]1[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,"(19R,20S)-5,5,9,20-tetramethyl-7-oxo-2,14,21-triazapentacyclo[20.3.1.0^{2,10}.0^{3,8}.0^{14,19}]hexacosa-1(26),3(8),9,22,24-pentaene-23-carboxamide",1.5,uM,=,0.1760912590556812,1,O=C1CCCc2c1cc1n2-c2cccc(c2)NC[C@H]2CCCCN2CCC1
6645,759504,10.1016/j.bmcl.2011.06.015,,,,Inhibition of human ERG by automated patch clamp assay,O=C(/C=C/c1ccc2c(c1)CN(CCc1cnn3ccccc13)C2)NO,"N-hydroxy-3-(2-(2-(pyrazolo[1,5-a]pyridin-3-yl)ethyl)isoindolin-5-yl)acrylamide",5.2,uM,=,0.7160033436347992,1,c1ccc2c(c1)CN(CCc1cnn3ccccc13)C2
6646,856088,10.1016/j.bmc.2012.08.050,,,,Displacement of [3H]-dofetilide from human ERG,CCN(CC)CCOc1cc(-c2nc(SCC(=O)NC)nc3[nH]cc(C#N)c23)c(Cl)cc1Cl,"2-{5-Cyano-4-[2,4-dichloro-5-(2-diethylamino-ethoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-2-ylsulfanyl}-N-methylacetamide",3.14,uM,=,0.4969296480732149,1,c1ccc(-c2ncnc3[nH]ccc23)cc1
6647,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NCCCc3cc(F)ccc3F)(CC1)CO2,"(R)-4-((4-(3-(2,5-difluorophenyl)propylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",0.032,uM,=,-1.494850021680094,0,O=c1ccc2nccc3c2n1CC3CC12CCC(NCCCc3ccccc3)(CC1)CO2
6648,748773,10.1016/j.bmcl.2011.04.102,,,,Inhibition of human ERG by HT patch clamp assay,Cc1c2c(n3c1CCCN1CCC[C@@H](C1)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,"(18S)-5,5,9-trimethyl-7-oxo-2,14,19-triazapentacyclo[18.3.1.1^{14,18}.0^{2,10}.0^{3,8}]pentacosa-1(24),3(8),9,20,22-pentaene-21-carboxamide",3.4,uM,=,0.5314789170422551,1,O=C1CCCc2c1cc1n2-c2cccc(c2)N[C@H]2CCCN(CCC1)C2
6649,945796,10.1016/j.bmcl.2012.12.072,,,,Inhibition of human ERG,O[C@H](COc1ccc(Cl)cc1)CN1CCN(Cc2c(F)cccc2Cl)CC1,(S)-1-(4-(2-chloro-6-fluorobenzyl)piperazin-1-yl)-3-(4-chlorophenoxy)propan-2-ol,2.07,uM,=,0.3159703454569177,1,c1ccc(CN2CCN(CCCOc3ccccc3)CC2)cc1
6650,2025894,10.1021/acsmedchemlett.0c00573,,,,Inhibition of human ERG by planar patch clamp method,Cc1nc(NC(=O)NCCc2cn(CC(F)F)cn2)sc1C#Cc1cccnc1,"1-(2-(1-(2,2-Difluoroethyl)-1H imidazol-4-yl)ethyl)-3-(4-methyl-5-(2-(pyridin-3-yl)ethynyl)thiazol-2-yl)urea",13.0,uM,=,1.1139433523068367,1,O=C(NCCc1c[nH]cn1)Nc1ncc(C#Cc2cccnc2)s1
6651,1760898,10.1021/acs.jmedchem.8b00521,,,,Inhibition of human ERG by cell based automated patch clamp method,COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sncc34)[C@@H](C)C2)c(C)c1,"2-Amino-4-[4-(4-methoxy-2-methylphenylcarbamoyl)-2-(S)-methylpiperazin-1-yl]-isothiazolo[5,4-d]pyrimidine",8.0,uM,=,0.9030899869919436,1,O=C(Nc1ccccc1)N1CCN(c2ncnc3sncc23)CC1
6652,1642460,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKf current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG).Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 uM; 3 uM; 10 uM; 30 uM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models.The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from -80 mV to a maximum value of +40 mV, starting with -40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to -55 mV, after each of these incremented steps, for 1 second and finally repolarized to -80 mV for 1 second.Â  The current density recorded were normalized against the baseline conditions and corrected for solvent effect and time-dependent current run-down using experimental design in test compound free conditions.Â  Inhibition curves were obtained for compounds and the concentrations which decreased 50% of the current density determined in the baseline conditions (IC50) were determined. All compounds for which the IC50 value is above 10 uM are not considered to be potent inhibitors of the hERG channel whereas compounds with IC50 values below 1 uM are considered potent hERG channel inhibitors.",Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)sc1C,"US9475814, 22",12.0,uM,=,1.0791812460476249,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2nccs2)C1
6653,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)CC#CCOCc1ccc(Cl)cc1,N-Butyl-4-((4-chlorobenzyl)oxy)-N-ethylbut-2-yn-1-amine,7.372,uM,=,0.8675853265470362,1,c1ccccc1
6654,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,14.8,uM,=,1.1702617153949575,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6655,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,2-{2-[1-(4-Chloro-phenyl)-1-phenyl-ethoxy]-ethyl}-1-methyl-pyrrolidine,0.3951,uM,=,-0.4032929703185537,0,c1ccc(C(OCC[C@H]2CCCN2)c2ccccc2)cc1
6656,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.FCCOc1ccccc1CCC1CCN(CCc2ccc(F)cc2)CC1,4-(2-(2-Fluoroethoxy)phenethyl)-1-(4-fluorophenethyl)piperidine hydrochloride,0.38,uM,=,-0.4202164033831898,0,c1ccc(CCC2CCN(CCc3ccccc3)CC2)cc1
6657,2054470,10.1016/j.ejmech.2020.112517,,,,Inhibition of human ERG,Cc1cccn(-c2ccc(-c3ccc4c(C(=O)NCc5ccncc5)n[nH]c4c3)c(Cl)c2)c1=O,6-(2-Chloro-4-(3-methyl-2-oxopyridin-1(2H)-yl)phenyl)-N-(pyridin-4-ylmethyl)-1H-indazole-3-carboxamide,41.1,uM,=,1.6138418218760693,1,O=C(NCc1ccncc1)c1n[nH]c2cc(-c3ccc(-n4ccccc4=O)cc3)ccc12
6658,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1csc([C@@]2(CN)[C@@H]3CN(c4cnc5c(-c6ccc7nc(C)sc7c6Cl)n[nH]c5n4)C[C@@H]32)n1,"((1R,5S,6r)-3-(3-(7-chloro-2-methylbenzo[d]thiazol-6-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-6-(4-methylthiazol-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methanamine",1.661,uM,=,0.2203696324513945,1,c1csc(C2[C@H]3CN(c4cnc5c(-c6ccc7ncsc7c6)n[nH]c5n4)C[C@@H]23)n1
6659,2223619,10.1021/acsmedchemlett.2c00294,,,,Inhibition of human ERG by fluorescence polarization assay,N[C@H]1C[C@@H]1c1ccc(Br)c(F)c1F,"(+/-)-trans-2-(4-Bromo-2,3-difluorophenyl)cyclopropylamine",15.0,uM,=,1.1760912590556811,1,c1ccc(C2CC2)cc1
6660,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CSc1ccc(-c2cccc(-n3cc(C(=O)NC(C)C)c(=O)c4cccnc43)c2)cc1,"1-(4'-Methylsulfanyl-biphenyl-3-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid isopropylamide",0.96,uM,=,-0.0177287669604316,0,O=c1ccn(-c2cccc(-c3ccccc3)c2)c2ncccc12
6661,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NC/C(F)=C/c3cc(F)ccc3F)(CC1)CO2,"(R,Z)-4-((4-(3-(2,5-difluorophenyl)-2-fluoroallylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",0.016,uM,=,-1.7958800173440752,0,O=c1ccc2nccc3c2n1CC3CC12CCC(NC/C=C/c3ccccc3)(CC1)CO2
6662,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,FC(F)(F)Oc1cccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)c1,"10-(pyridin-4-yl)-N-(3-(trifluoromethoxy)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",0.605,uM,=,-0.2182446253475311,0,c1ccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
6663,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCc1ccc(F)cn1,2-(2-(5-Fluoropyridin-2-yl)ethyl)-3-oxo-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,5.3,uM,=,0.724275869600789,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
6664,627243,10.1021/jm9016812,,,,Inhibition of human ERG by electrophysiology assay,COc1ccc(-c2nc(COc3cccc(CN(CC(=O)O)C(=O)Oc4ccc(C)cc4)c3)c(C)o2)cc1,2-((3-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,8.6,uM,=,0.9344984512435676,1,O=C(NCc1cccc(OCc2coc(-c3ccccc3)n2)c1)Oc1ccccc1
6665,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,CNc1cc(CCN2CCN(CCc3ccc4c(c3)COC4=O)CC2)ccc1C#N,"2-(methylamino)-4-(2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",0.67,uM,=,-0.1739251972991735,0,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
6666,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccccc2)oc2ccc(O)c(CN3CCC4(COC4)C3)c12,4-(2-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-5-hydroxy-N-methyl-2-phenylbenzofuran-3-carboxamide,3.9,uM,=,0.5910646070264992,1,c1ccc(-c2cc3c(CN4CCC5(COC5)C4)cccc3o2)cc1
6667,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,O/N=C(/c1ccc(CN2CCC3(CC2)OCc2cc(F)ncc23)cc1)c1ccc(F)c(F)c1,"(Z)-(3,4-difluorophenyl)(4-((6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1'-yl)methyl)phenyl)methanone oxime",0.31,uM,=,-0.5086383061657274,0,N=C(c1ccccc1)c1ccc(CN2CCC3(CC2)OCc2ccncc23)cc1
6668,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1ccc(C(F)(F)F)cc1)NC1CN([C@H]2CC[C@H](c3ccc4c(c3)OCO4)CC2)C1,"N-(2-(1-(4-(benzo[d][1,3]dioxol-5-yl)cyclohexyl)azetidin-3-ylamino)-2-oxoethyl)-4-(trifluoromethyl)benzamide",1.5,uM,=,0.1760912590556812,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccc4c(c3)OCO4)CC2)C1
6669,1552715,10.1016/j.ejmech.2015.12.006,,,,Inhibition of human ERG channel by fluorescence polarization assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCn2ccnc2)C[C@H]1OC,cis-4-Amino-5-chloro-N-[1-(3-(1H-imidazol-1-yl)propyl)-3-methoxypiperidin-4-yl]-2-methoxybenzamide,7.261,uM,=,0.8609964367571958,1,O=C(NC1CCN(CCCn2ccnc2)CC1)c1ccccc1
6670,1448459,10.1021/jm5004864,,,,Inhibition of human ERG over-expressed in HEK293 cell membrane by [3H]dofetilide binding assay,CNc1ccc(/C=C/c2c(F)cccc2Cl)cn1,(E)-5-(2-chloro-6-fluorostyryl)-N-methylpyridin-2-amine,19.9,uM,=,1.2988530764097066,1,C(=C/c1cccnc1)\c1ccccc1
6671,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,O=C1OCc2c1cccc2-c1ccc(CCN2CCN(CCc3ccc([N+](=O)[O-])cc3)CC2)cc1,4-(4-(2-(4-(4-nitrophenethyl)piperazin-1-yl)ethyl)phenyl)isobenzofuran-1(3H)-one,0.15,uM,=,-0.8239087409443188,0,O=C1OCc2c1cccc2-c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6672,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,4-(4-Benzhydryloxy-piperidin-1-yl)-1-(4-tert-butyl-phenyl)-butan-1-one,0.1048,uM,=,-0.979638717352292,0,O=C(CCCN1CCC(OC(c2ccccc2)c2ccccc2)CC1)c1ccccc1
6673,1617566,10.1021/acs.jmedchem.6b01127,,,,Inhibition of human ERG,CCn1c(=O)oc2ccc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)cc3)cc21,"(2S)-N-[(1S)-1-Cyano-2-[4-(3-ethyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide",31.0,uM,=,1.4913616938342726,1,O=C(NCCc1ccc(-c2ccc3oc(=O)[nH]c3c2)cc1)[C@@H]1CNCCCO1
6674,796234,10.1016/j.bmcl.2011.10.115,,,,Inhibition of human Erg by whole cell patch clamp electrophysiology,Fc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1,(+)-(R)-2-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)thiomorpholine,0.9,uM,=,-0.0457574905606751,0,c1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1
6675,2023418,10.1016/j.bmcl.2020.127663,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch clamp assay,Cc1cc(CN2CCN(C(=O)/C=C/c3ccc(Cl)cc3Cn3nnc(C)n3)CC2)on1,(E)-3-(4-chloro-2-((5-methyl-2H-tetrazol-2-yl)methyl)phenyl)-1-(4-((3-methylisoxazol-5-yl)methyl)piperazin-1-yl)prop-2-en-1-one,12.0,uM,=,1.0791812460476249,1,O=C(/C=C/c1ccccc1Cn1ncnn1)N1CCN(Cc2ccno2)CC1
6676,862394,10.1021/jm300601d,,,,Inhibition of human ERG expressed in HEK 293 cells by PatchXpress assay,CC(C)(C)C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,"N-{4-[1-(2,2-Dimethyl-propionyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine",27.0,uM,=,1.4313637641589874,1,c1ccc(C2CCNCC2)cc1
6677,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,NC1(C(=O)NC(c2ccccc2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,"rac-4-Amino-N-[(4-chlorophenyl)(phenyl)methyl]-1-(7H-pyrrolo-[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(NC(c1ccccc1)c1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
6678,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(CCC)O3)c1,"US8975415, RP92::US9242973, RP92",5.34,uM,=,0.7275412570285564,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21COC1
6679,625756,10.1016/j.bmcl.2010.03.035,,,,Inhibition of human ERG by FLIPR assay,CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](NC(=O)c3cc(F)cc(C(F)(F)F)c3)C2=O)[C@H](CS(=O)(=O)c2ccccc2)C1,"3-fluoro-N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-5-(trifluoromethyl)benzamide",22.0,uM,=,1.3424226808222062,1,O=C(N[C@H]1CCN([C@H]2CCCC[C@H]2CS(=O)(=O)c2ccccc2)C1=O)c1ccccc1
6680,1765513,10.1021/acs.jmedchem.8b01040,,,,Inhibition of human ERG by automated patch clamp assay,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cncnc2)c1,"US9278981, 170",1.8,uM,=,0.255272505103306,1,O=C(Nc1ccccc1)c1cnc(N2CCCC2)c(-c2cncnc2)c1
6681,1908032,10.1016/j.bmcl.2019.126681,,,,Inhibition of ERG in human HEK293 cells incubated for 1 hr by thallium flux assay,O=C1c2ccccc2C(Cc2c(F)cncc2F)(Cc2c(F)cncc2F)c2ccccc21,"10,10-bis[(3,5-difluoropyridin-4-yl)methyl]-9,10-dihydroanthracen-9-one",12.0,uM,=,1.0791812460476249,1,O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc21
6682,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,"[4-(3,4-Dichloro-phenyl)-1,2,3,4-tetrahydro-naphthalen-1-yl]-methyl-amine (Sertraline)",8.3173,uM,=,0.9199823665062116,1,c1ccc([C@@H]2CCCc3ccccc32)cc1
6683,1972824,10.1021/acsmedchemlett.9b00611,,,,Inhibition of human ERG,COc1nn(C)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1,"N-(6-(4-Isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-3-methoxy-1-methyl-1H-pyrazole-4-carboxamide",30.0,uM,=,1.4771212547196624,1,O=C(Nc1cccc(-c2nnc[nH]2)n1)c1cn[nH]c1
6684,2219924,10.1016/j.bmcl.2021.128463,,,,Displacement of MK499 from human ERG expressed in HEK membrane by radio ligand binding competition assay,Cc1cc(C#N)cnc1C(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)[C@@](C)(CF)C(=N)N2)n1,"5-cyano-N-(5-fluoro-6-((3R,6R)-6-(fluoromethyl)-5-imino-3,6-dimethyl-1,1-dioxidothiomorpholin-3-yl)pyridin-2-yl)-3-methylpicolinamide",26.85,uM,=,1.4289442900355744,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3ccccn3)n2)N1
6685,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(NCC5(N)CC5)c(C)n4)n3)cc12,"5-[[4-[4-[(1-aminocyclopropyl)methylamino]-3-methyl-pyrazol-1-yl]pyrimidin-2-yl]amino]-N,1-dimethyl-indazole-3-carboxamide",11.0,uM,=,1.0413926851582251,1,c1cc(-n2cc(NCC3CC3)cn2)nc(Nc2ccc3[nH]ncc3c2)n1
6686,1665702,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,NC(=O)c1ccc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)cn1,5-(5-phenyl-4-((pyridin-2-ylmethyl)amino)quinazolin-2-yl)picolinamide,4.6,uM,=,0.6627578316815741,1,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1
6687,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,10-[3-(4-Methyl-piperazin-1-yl)-propyl]-2-trifluoromethyl-10H-phenothiazine,6.226,uM,=,0.7942091163464965,1,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1
6688,2207007,10.1021/acs.jmedchem.2c01164,,,,Inhibition of hERG potassium channel at -80 mV holding potential incubated for 3 mins by automated patch clamp method,Cc1cn(C2=CC[C@H]3[C@@H]4CC=C5C[C@@H](NC(=O)c6ccncc6)CC[C@]5(C)[C@H]4CC[C@]23C)cn1,"N-((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(4-methyl-1H-imidazol-1-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)isonicotinamide",6.47,uM,=,0.8109042806687004,1,O=C(N[C@H]1CCC2C(=CC[C@@H]3[C@@H]2CCC2C(n4ccnc4)=CC[C@H]23)C1)c1ccncc1
6689,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,CCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1,"rac-4-Amino-N-[1-(4-chlorophenyl)propyl]-1-(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)piperidine-4-carboxamide",6.495,uM,=,0.8125791554090467,1,O=C(NCc1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
6690,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",COc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)c1,"US8975415, RP105::US9242973, RP105",7.9,uM,=,0.8976270912904415,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
6691,634158,10.1021/jm100044a,,,,Inhibition of human ERG by patch clamp assay,COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1,3-Methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide,11.0,uM,=,1.0413926851582251,1,O=C(Nc1ccc(OCCN2CCOCC2)c(-c2ccn[nH]2)c1)c1ccccc1
6692,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cncc(OCC(F)(F)C(F)F)c3)ccc1OCC21CC1,"US8975415, RP64::US9242973, RP64",1.67,uM,=,0.2227164711475832,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
6693,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,NC[C@]1(c2ccccn2)[C@@H]2CCN(c3cnc4c(-c5cccc(Cl)c5Cl)n[nH]c4n3)C[C@@H]21,"((1S,6R,7S)-3-(3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-7-(pyridin-2-yl)-3-azabicyclo[4.1.0]heptan-7-yl)methanamine",0.042,uM,=,-1.3767507096020994,0,c1ccc(-c2n[nH]c3nc(N4CC[C@H]5C(c6ccccn6)[C@H]5C4)cnc23)cc1
6694,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,C=CC(=O)Nc1cc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(4-(1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,17.5,uM,=,1.2430380486862944,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6695,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c(CNC2CCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,"N-((5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)methyl)cyclopentanamine",0.023,uM,=,-1.6382721639824072,0,c1ccc(-c2cc(CNC3CCCC3)nn2-c2ccccc2)cc1
6696,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1cccc([C@@]2(CN)[C@@H]3CN(c4cnc5c(-c6ccc7nn(C)cc7c6Cl)n[nH]c5n4)C[C@@H]32)n1,"((1R,5S,6r)-3-(3-(4-chloro-2-methyl-2H-indazol-5-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-6-(6-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methanamine",5.875,uM,=,0.7690078709437739,1,c1ccc(C2[C@H]3CN(c4cnc5c(-c6ccc7n[nH]cc7c6)n[nH]c5n4)C[C@@H]23)nc1
6697,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,N#CCCN1C(=O)c2ccccc2C1C(=O)NCc1ccc(OC(F)(F)F)cc1,2-(2-Cyanoethyl)-3-oxo-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,26.0,uM,=,1.414973347970818,1,O=C1NC(C(=O)NCc2ccccc2)c2ccccc21
6698,1464651,10.1016/j.bmcl.2015.02.040,,,,Inhibition of human ERG by dofetilide binding assay,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OC(=O)NCc2ccccc2)C(C)C)ccc1OC,rac-(trans)-4-((N-isopropyl-4-methoxy-3-(3-methoxypropoxy)benzamido)methyl)pyrrolidin-3-yl benzylcarbamate,13.0,uM,=,1.1139433523068367,1,O=C(NCc1ccccc1)O[C@@H]1CNC[C@H]1CNC(=O)c1ccccc1
6699,1927981,10.1021/acsmedchemlett.6b00117,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,FC(F)(F)c1nc(NCc2ccccn2)c2c(-c3ccccc3)cccc2n1,5-phenyl-N-(pyridin-2-ylmethyl)-2-(trifluoromethyl)quinazolin-4-amine,10.0,uM,=,1.0,1,c1ccc(-c2cccc3ncnc(NCc4ccccn4)c23)cc1
6700,1883248,10.1021/acs.jmedchem.8b01344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch assay,N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cc3)[C@](O)(CN)C2)c(Cl)c1,"4-(((3S,4S)-3-(Aminomethyl)-4-((4-chlorophenyl)sulfonyl)-3-hydroxypyrrolidin-1-yl)sulfonyl)-3-chlorobenzonitrile",5.3,uM,=,0.724275869600789,1,O=S(=O)(c1ccccc1)[C@@H]1CCN(S(=O)(=O)c2ccccc2)C1
6701,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,CC1(c2cccc(-c3cncnc3)c2)N=C(N)c2ccccc2O1,"2-Methyl-2-(3-(pyrimidin-5-yl)phenyl)-2H-benzo[e]-[1,3]oxazin-4-amine",5.7,uM,=,0.7558748556724915,1,C1=NC(c2cccc(-c3cncnc3)c2)Oc2ccccc21
6702,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1ccc(C2(c3cccc(-c4cncnc4)c3)N=C(N)c3nc(C)sc32)cc1,"6-(4-Methoxyphenyl)-2-methyl-6-[3-(pyrimidin-5-yl)-phenyl]-6H-pyrrolo[3,4-d][1,3]thiazol-4-amine",1.5,uM,=,0.1760912590556812,1,C1=NC(c2ccccc2)(c2cccc(-c3cncnc3)c2)c2scnc21
6703,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,Cc1nn(C2CCNCC2)cc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,"5-Chloro-4-(imidazo[1,2-a]pyridin-3-yl)-N-[3-methyl-1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyrimidinamine",29.0,uM,=,1.462397997898956,1,c1ccn2c(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)cnc2c1
6704,840300,10.1021/ml300064v,,,,Inhibition of human ERG expressed in HEK293 cells after 240 secs by patch clamp assay,CC(Oc1ccccc1CC1CC1)C1=NCCN1,"2-(1-(2-(Cyclopropylmethyl)phenoxy)ethyl)-4,5-dihydro-1H-imidazole",8.9,uM,=,0.9493900066449128,1,c1ccc(OCC2=NCCN2)c(CC2CC2)c1
6705,1780154,10.1021/acs.jmedchem.8b01077,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV after 60 secs by patch clamp assay,Cc1ccc([C@H](CCN2[C@@H]3CC[C@H]2C[C@H](n2c(C)nnc2C(C)C)C3)NC(=O)C2CCC(F)(F)CC2)s1,"4,4-Difluoro-N-((S)-3-((1R,3R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(5-methylthiophen-2-yl)propyl)cyclohexane-1-carboxamide",3.38,uM,=,0.5289167002776547,1,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@H](n1cnnc1)C2)c1cccs1)C1CCCCC1
6706,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1cccc(-c2cccc(C3(C)COCC(N)=N3)c2)c1,"5-(3'-Methoxybiphenyl-3-yl)-5-methyl-5,6-dihydro-2H-1,4-oxazin-3-amine",8.0,uM,=,0.9030899869919436,1,C1=NC(c2cccc(-c3ccccc3)c2)COC1
6707,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one",4.1901,uM,=,0.6222243878660441,1,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2
6708,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,C[C@@]1(c2cc(CNC3(C(F)(F)F)COC3)c(F)cc2F)CCSC(N)=N1,"(S)-4-(2,4-Difluoro-5-(((3-(trifluoromethyl)oxetan-3-yl)amino)-methyl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine",16.5,uM,=,1.2174839442139065,1,C1=NC(c2cccc(CNC3COC3)c2)CCS1
6709,729875,10.1021/ml1001536,,,,Inhibition of human hERG,CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,"5-[(4-(3S)-4-[(1R,2R)-2-ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl-4-methylpiperidin-1-yl)carbonyl]-4,6-dimethylpyrimidine",4.5,uM,=,0.6532125137753437,1,O=C(c1cncnc1)N1CCC(N2CCN([C@H]3CCc4ccccc43)CC2)CC1
6710,1478744,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,"5,5-Diphenyl-imidazolidine-2,4-dione",100.0,uM,=,2.0,1,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
6711,768794,10.1021/jm200290z,,,,Inhibition of human ERG,c1ccc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)nc1,"Pyridin-2-yl-(4,5,6,8-tetrahydro-3-thia-1,7,8-triaza-cyclopenta-[e]azulen-2-yl)-amine",28.0,uM,=,1.4471580313422192,1,c1ccc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)nc1
6712,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@H](c3ccncc3O)CC2)C1,N-({1-[4-(3-Hydroxy-pyridin-4-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,23.0,uM,=,1.3617278360175928,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccncc3)CC2)C1
6713,2230755,10.1016/j.ejmech.2021.113925,,,,Inhibition of human ERG,FC(F)(F)c1nccc(N[C@H]2CC[C@@H](Nc3ccc4nnc(Cl)n4n3)CC2)n1,"(1s,4s)-N1-(3-Chloro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-N4-(2-(trifluoromethyl)pyrimidin-4-yl)cyclohexane-1,4-diamine",24.0,uM,=,1.380211241711606,1,c1cc(N[C@H]2CC[C@@H](Nc3ccc4nncn4n3)CC2)ncn1
6714,2049685,10.1021/acs.jmedchem.0c01411,,,,Inhibition of human ERG by patch clamp method,CN1CCN(C2CCN(c3nccc4[nH]c(-c5cc(F)cc(F)c5)cc34)CC2)CC1,"2-(3,5-difluorophenyl)-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-1H-pyrrolo[3,2-c]pyridine",4.0,uM,=,0.6020599913279624,1,c1ccc(-c2cc3c(N4CCC(N5CCNCC5)CC4)nccc3[nH]2)cc1
6715,2223202,10.1021/acsmedchemlett.2c00111,,,,Inhibition of hERG cardiac ion channel,O=c1ccc2ccc(F)c3c2n1CC3C[C@H]1OC[C@H](NCc2cc3c(cn2)OCCC3)CO1,"1-((5-(((3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl)methyl)amino)-trans-1,3-dioxan-2-yl)methyl)-9-fluoro-1,2-dihydro-4H-pyrrolo[3,2,1-iJ]quinolin-4-one",53.0,uM,=,1.7242758696007892,1,O=c1ccc2cccc3c2n1CC3C[C@H]1OC[C@H](NCc2cc3c(cn2)OCCC3)CO1
6716,2186534,10.1021/acs.jmedchem.1c01132,,,,Inhibition of hERG ion channel incubated for 3 hrs by fluorescence polarization assay,CCNc1nccc(-c2n[nH]c3nc(N4CCC5(CC4)CO[C@@H](C)[C@H]5N)cnc23)c1Cl,"(3S,4S)-8-(3-(3-Chloro-2-(ethylamino)pyridin-4-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3-methyl-2-oxa-8-azaspiro[4.5]-decan-4-amine",13.0,uM,=,1.1139433523068367,1,c1cc(-c2n[nH]c3nc(N4CCC5(CCOC5)CC4)cnc23)ccn1
6717,1551867,10.1021/acs.jmedchem.5b01374,,,,Inhibition of human ERG expressed in CHO cells by patch plate method,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,(6-Methoxy-quinolin-4-yl)-(5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol,2.67,uM,=,0.4265112613645752,1,c1ccc2c(C[C@H]3CC4CCN3CC4)ccnc2c1
6718,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(C2=CC(=O)OC2C)C3=O)ccc2c1COC2=O,"8-((R)-2-Hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(2-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2,8-diazaspiro[4.5]decan-1-one",19.0,uM,=,1.2787536009528289,1,O=C1C=C(N2CCC3(CCN(CCc4ccc5c(c4)COC5=O)CC3)C2=O)CO1
6719,1617566,10.1021/acs.jmedchem.6b01127,,,,Inhibition of human ERG,Cn1c(=O)sc2ccc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)cc3)cc21,"(2S)-N-[(1S)-1-Cyano-2-[4-(3-methyl-2-oxo-1,3-benzothiazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide",23.0,uM,=,1.3617278360175928,1,O=C(NCCc1ccc(-c2ccc3sc(=O)[nH]c3c2)cc1)[C@@H]1CNCCCO1
6720,1980755,10.1021/acs.jmedchem.9b01188,,,,Inhibition of human ERG,CC(O)CN1[C@H](C)CN(CC[S+]([O-])C(c2ccc(F)cc2)c2ccc(F)cc2)C[C@@H]1C,"1-(4-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-2,6-cis-dimethylpiperazin-1-yl)propan-2-ol",7.3,uM,=,0.8633228601204559,1,c1ccc(C([SH+]CCN2CCNCC2)c2ccccc2)cc1
6721,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1csc([C@@]2(CN)[C@@H]3CCN(c4cnc5c(-c6cccnc6C(F)(F)F)n[nH]c5n4)C[C@@H]32)n1,"((1S,6R,7S)-7-(4-methylthiazol-2-yl)-3-(3-(2-(trifluoromethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3-azabicyclo[4.1.0]heptan-7-yl)methanamine",5.057,uM,=,0.7038929536325446,1,c1cncc(-c2n[nH]c3nc(N4CC[C@H]5C(c6nccs6)[C@H]5C4)cnc23)c1
6722,983480,10.1021/jm400564j,,,,Inhibition of human ERG channel,CCc1nc2c(Cc3ccc(C(=O)NO)cc3)cccc2c(=O)n1CCc1ccccc1,"4-((2-Ethyl-4-oxo-3-phenethyl-3,4-dihydroquinazolin-8-yl)-methyl)-N-hydroxybenzamide",4.7,uM,=,0.6720978579357175,1,O=c1c2cccc(Cc3ccccc3)c2ncn1CCc1ccccc1
6723,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,C=CC(=O)Nc1cc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c(OC)cc1N1CCN(C)CC1,N-(5-(4-(1H-indol-3-yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide,9.1,uM,=,0.9590413923210936,1,c1ccc2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c[nH]c2c1
6724,766645,10.1016/j.bmcl.2011.07.030,,,,Inhibition of human ERG,CCN(CC)C1(CNC(=O)N2CCC(c3nc(-c4ccc5ccccc5n4)no3)CC2)CCCC1,"N-((1-(diethylamino)cyclopentyl)methyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",9.4,uM,=,0.9731278535996988,1,O=C(NCC1CCCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
6725,702661,10.1021/jm100978n,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells,CCCC(=O)N1CCc2c(nc(C)n2[C@H]2C[C@H]3CC[C@@H](C2)N3CC[C@H](NC(C)=O)c2cccc(F)c2)C1,"endo-N-((S)-3-(3-(5-butyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(3-fluorophenyl)propyl)acetamide",6.0,uM,=,0.7781512503836436,1,c1ccc(CCCN2[C@@H]3CC[C@H]2C[C@@H](n2cnc4c2CCNC4)C3)cc1
6726,1622144,10.1021/acs.jmedchem.6b01247,,,,Inhibition of human ERG,C[C@@H]1CC[C@@H]([C@@H](C)C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c2nc(CN3CCOCC3)ccc21,"(R)-N-(4-Chloro-3-(pyridin-2-yl)phenyl)-2-((5R,8S)-5-methyl-2-(morpholinomethyl)-5,6,7,8-tetrahydroquinolin-8-yl)-propanamide",3.31,uM,=,0.5198279937757188,1,O=C(C[C@@H]1CCCc2ccc(CN3CCOCC3)nc21)Nc1cccc(-c2ccccn2)c1
6727,2186534,10.1021/acs.jmedchem.1c01132,,,,Inhibition of hERG ion channel incubated for 3 hrs by fluorescence polarization assay,N[C@@H]1COCC12CCN(c1cnc3c(-c4cccc(Cl)c4Cl)n[nH]c3n1)CC2,"(4S)-8-(3-(2,3-Dichlorophenyl)-1H-pyrazolo[3,4-b]-pyrazin-6-yl-2-oxa-8-azaspiro[4.5]-decan-4-amine",0.1,uM,=,-1.0,0,c1ccc(-c2n[nH]c3nc(N4CCC5(CCOC5)CC4)cnc23)cc1
6728,2162538,10.1016/j.ejmech.2021.114045,,,,Inhibition of hERG expressed in CHO cells at -80 mV holding potential by automated patch clamp method,N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,5-{4-[4-(5-Cyano-1H-indol-3-yl)-butyl]-piperazin-1-yl}-benzofuran-2-carboxylic acid amide,5.55,uM,=,0.7442929831226762,1,c1ccc2c(CCCCN3CCN(c4ccc5occc5c4)CC3)c[nH]c2c1
6729,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CCOc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)c1,"US8975415, RP106::US9242973, RP106",5.75,uM,=,0.7596678446896306,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
6730,1695906,10.1016/j.bmcl.2017.08.030,,,,Inhibition of human ERG,O=C(c1cccc(F)c1)N1CCc2oc(-c3ccc(F)cn3)nc2C1,"(3-Fluorophenyl){2-(5-fluoropyridin-2-yl)-6,7-dihydro[1,3]oxazolo[4,5-c]pyridin-5(4H)-yl}methanone",74.0,uM,=,1.869231719730976,1,O=C(c1ccccc1)N1CCc2oc(-c3ccccn3)nc2C1
6731,1745714,10.1016/j.bmc.2017.10.004,,,,Inhibition of human ERG expressed in Xenopus laevis oocytes by two-electrode voltage clamp assay,CCCCCCCCn1c(NC2CCN(CCc3ccc(OC)cc3)CC2)nc2ccccc21,N-(1-(4-Methoxyphenethyl)piperidin-4-yl)-1-octyl-1H-benzo[d]imidazol-2-amine,3.27,uM,=,0.5145477526602861,1,c1ccc(CCN2CCC(Nc3nc4ccccc4[nH]3)CC2)cc1
6732,1679779,10.1016/j.bmcl.2017.03.086,,,,Inhibition of human ERG by PatchXpress method,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)C3=O)ccc2c1COC2=O,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one",20.0,uM,=,1.3010299956639813,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ccc(=O)[nH]n3)C4=O)ccc21
6733,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,2.7,uM,=,0.4313637641589873,1,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
6734,2241739,10.1016/j.ejmech.2021.113983,,,,Inhibition of human ERG,COc1cc(CCNc2nc(C#Cc3ccccc3)nc3c2ncn3[C@H]2[C@H](O)[C@H](O)[C@@H]3C[C@@H]32)ccc1O,"(1R,2R,3S,4R,5S)-4-(6-((4-Hydroxy-3-methoxyphenethyl)amino)-2-(phenylethynyl)-9H-purin-9-yl)bicyclo[3.1.0]hexane-2,3-diol",5.39,uM,=,0.7315887651867387,1,C(#Cc1nc(NCCc2ccccc2)c2ncn([C@H]3CC[C@@H]4C[C@@H]43)c2n1)c1ccccc1
6735,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(CC2CC2)O3)c1,"US8975415, RP205::US9242973, RP205",5.22,uM,=,0.7176705030022621,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OC(CC1CC1)C21COC1
6736,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,O=C1OCCN1C1CCN(CCOc2ccc(Oc3nc4ccccc4s3)cc2)CC1,3-(1-{2-[4-(Benzothiazol-2-yloxy)phenoxy]ethyl}piperidin-4-yl)oxazolidin-2-one,2.7,uM,=,0.4313637641589873,1,O=C1OCCN1C1CCN(CCOc2ccc(Oc3nc4ccccc4s3)cc2)CC1
6737,858024,10.1021/jm300690s,,,,Displacement of [3H]-astemizole from human ERG expressed in HEK293 cells after 60 mins by liquid scintillation counter,N#Cc1ccc2ccc(=O)n(CCN3CCC(NCc4cc5c(cn4)OCCO5)CC3)c2c1,"1-(2-{4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]piperidin-1-yl}ethyl)-2-oxo-1,2-dihydroquinoline-7-carbonitrile",39.0,uM,=,1.591064607026499,1,O=c1ccc2ccccc2n1CCN1CCC(NCc2cc3c(cn2)OCCO3)CC1
6738,1712776,10.1016/j.bmcl.2018.03.056,,,,Inhibition of human ERG expressed in CHOK1 cells at holding potential of -80 mV after 5 mins by patch clamp assay,C[C@]12CC[C@H](C(F)F)C[C@H]1C[C@@H](N1CCC[C@@H](N)C1)[C@@H]2Oc1ccc(C#N)cc1,"4-((1R,2R,3aS,5S,7aS)-2-((R)-3-aminopiperidin-1-yl)-5-(difluoromethyl)-7a-methyloctahydro-1H-inden-1-yloxy)benzonitrile",15.0,uM,=,1.1760912590556811,1,c1ccc(O[C@@H]2C3CCCC[C@H]3C[C@H]2N2CCCCC2)cc1
6739,1901021,10.1021/acs.jmedchem.9b01112,,,,Inhibition of human ERG expressed in CHOK1 cells by Qpatch electrophysiological assay,Cc1ccc(-c2cc(S(C)(=O)=O)cc(S(=O)(=O)c3cnc(CN)s3)c2)cc1,"(5-((4'-Methyl-5-(methylsulfonyl)-[1,1'-biphenyl]-3-yl)sulfonyl)thiazol-2-yl)methanamine",3.2,uM,=,0.505149978319906,1,O=S(=O)(c1cccc(-c2ccccc2)c1)c1cncs1
6740,2219924,10.1016/j.bmcl.2021.128463,,,,Displacement of MK499 from human ERG expressed in HEK membrane by radio ligand binding competition assay,C[C@@]1(c2nc(NC(=O)c3ccc(C#N)cn3)ccc2F)CS(=O)(=O)[C@](C)(CF)C(=N)N1,"5-cyano-N-(5-fluoro-6-((3R,6S)-6-(fluoromethyl)-5-imino-3,6-dimethyl-1,1-dioxidothiomorpholin-3-yl)pyridin-2-yl)picolinamide",25.56,uM,=,1.4075608494863625,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3ccccn3)n2)N1
6741,2069571,10.1016/j.bmc.2021.116015,,,,Inhibition of human ERG,CCOc1cc(C(=O)N2CCC(N3CCCC3)CC2)ccc1Nc1cc2c(cn1)N(C)C(=O)c1ccccc1N2C,"3-(2-ethoxy-4-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)phenylamino)-6-fluoro-5,11-dimethyl-5H-benzo[e]pyrido[3,4-b][1,4]diazepin-10(11H)-one",0.32,uM,=,-0.494850021680094,0,O=C1Nc2cnc(Nc3ccc(C(=O)N4CCC(N5CCCC5)CC4)cc3)cc2Nc2ccccc21
6742,773759,10.1021/jm200909u,,,,Inhibition of human hERG,Cn1cc(-c2ccc3c(c2)[nH]c2c(C(N)=O)cnc(N[C@H](C4CC4)C(F)(F)F)c23)cn1,"1-{[(1R)-1-Cyclopropyl-2,2,2-trifluoroethyl]amino}-7-(1-methyl-1H-pyrazol-4-yl)-5H-pyrido[4,3-b]indole-4-carboxamide",3.4,uM,=,0.5314789170422551,1,c1cc2[nH]c3cc(-c4cn[nH]c4)ccc3c2c(NCC2CC2)n1
6743,2149749,10.1021/acs.jmedchem.1c00489,,,,Inhibition of human ERG,NC1=N[C@@]2(c3cc(NC(=O)c4ncc(F)cc4F)ccc3F)CN(c3ncc(F)cn3)C[C@H]2CS1,"US8987254, 8",1.1,uM,=,0.041392685158225,1,O=C(Nc1cccc([C@]23CN(c4ncccn4)C[C@H]2CSC=N3)c1)c1ccccn1
6744,702661,10.1021/jm100978n,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(C)=O)C3)C2)c1cccc(F)c1,"endo-N-((S)-3-(3-(5-acetyl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(3-fluorophenyl)propyl)acetamide",5.0,uM,=,0.6989700043360189,1,c1ccc(CCCN2[C@@H]3CC[C@H]2C[C@@H](n2cnc4c2CCNC4)C3)cc1
6745,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,O=C(c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CCC4(COC4)C3)c12)N1CC(F)C1,(4-(2-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-5-hydroxy-2-(4-hydroxyphenyl)benzofuran-3-yl)(3-fluoroazetidin-1-yl)methanone,10.1,uM,=,1.0043213737826426,1,O=C(c1c(-c2ccccc2)oc2cccc(CN3CCC4(COC4)C3)c12)N1CCC1
6746,1715180,10.1021/acs.jmedchem.8b00648,,,,Inhibition of full length human ERG expressed in HEK293 cells assessed as reduction in tail current at holding potential of -70 mV after 6 to 7 mins by IonWork patch clamp method,O=S(=O)(NCc1ccccc1)c1cccc(Nc2ccc3nccc(-c4ccncc4)c3n2)c1,"N-benzyl-3-(8-(pyridin-4-yl)-1,5-naphthyridin-2-yl)benzenesulfonamide",1.2,uM,=,0.0791812460476248,1,O=S(=O)(NCc1ccccc1)c1cccc(Nc2ccc3nccc(-c4ccncc4)c3n2)c1
6747,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)C/C=C/c1ccc(Cl)cc1,(E)-N-(3-(4-Chlorophenyl)allyl)-N-ethylheptan-1-amine,0.243,uM,=,-0.6143937264016879,0,c1ccccc1
6748,1461973,10.1021/ml500414n,,,,Inhibition of human ERG by patch clamp assay,COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5cc(C)ncn5)ccc42)C3)c(C(N)=O)c1,"5-Methoxy-2-(2-{2-[(1R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)benzamide",47.0,uM,=,1.6720978579357175,1,O=C(Cc1ccccc1)N1CCC2(CC1)CN([C@@H]1CCc3cc(-c4ccncn4)ccc31)C2
6749,469563,10.1021/jm701164t,,,,Inhibition of human ERG,CN(C)S(=O)(=O)N(C)[C@@H]1CCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O,"(R)-9-[[(dimethylamino)sulfonyl](methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide",20.0,uM,=,1.3010299956639813,1,O=C(NCc1ccccc1)c1cc(=O)n2c(n1)CCCC2
6750,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O,2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate,24.1069,uM,=,1.3821413663519873,1,O=C(OCCN1CCCCC1)c1cccc2c(=O)cc(-c3ccccc3)oc12
6751,1571176,10.1016/j.bmcl.2016.03.035,,,,Inhibition of human ERG by electrophysiology analysis,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21,5-(2-(4-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one,4.5,uM,=,0.6532125137753437,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
6752,759504,10.1016/j.bmcl.2011.06.015,,,,Inhibition of human ERG by automated patch clamp assay,Cc1[nH]c2ccccc2c1CCN1Cc2ccc(/C=C/C(=O)NO)cc2C1,N-hydroxy-3-(2-(2-(2-methyl-1H-indol-3-yl)ethyl)isoindolin-5-yl)acrylamide,4.8,uM,=,0.6812412373755872,1,c1ccc2c(c1)CN(CCc1c[nH]c3ccccc13)C2
6753,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N3Cc4cnccc4OC[C@@H]3Cc3ccc(Cl)cc3)CC2)n[nH]1,"(S)-3-(4-(3-(4-chlorobenzyl)-2,3-dihydropyrido[3,4-f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-1H-1,2,4-triazol-5-amine",17.0,uM,=,1.230448921378274,1,c1ccc(C[C@H]2COc3ccncc3CN2C2CCN(c3nc[nH]n3)CC2)cc1
6754,702661,10.1021/jm100978n,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells,COC(=O)N1CCc2c(nc(C)n2[C@H]2C[C@H]3CC[C@@H](C2)N3CC[C@H](NC(C)=O)c2cccc(F)c2)C1,"Methyl 1-endo-{8-[(3S)-3-(Acetamido)-3-(3-fluorophenyl)propyl]-8-azabicyclo[3.2.1]oct-3-yl}-2-methyl-4,5,6,7-tetrahydro-1H-imidazo-[4,5-c]pyridine-5-carboxylate",2.0,uM,=,0.3010299956639812,1,c1ccc(CCCN2[C@@H]3CC[C@H]2C[C@@H](n2cnc4c2CCNC4)C3)cc1
6755,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3cc(O)ccc32)cc1,"N,N-Diethyl-4-(7-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide",60.0,uM,=,1.7781512503836436,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
6756,1666649,10.1021/acs.jmedchem.7b00008,,,,Inhibition of human ERG expressed in CHO cells after 30 mins by BTC-AM dye based thallium flux assay,Cc1[nH]nc2c1C(c1cc(-c3cccnc3)cc(C(F)(F)F)c1)(C(C)C)C(C#N)=C(N)O2,"(+/-)-6-Amino-3-methyl-4-isopropyl-4-[3-(pyridin-3-yl)-5-(trifluoromethyl)phenyl]-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile",29.0,uM,=,1.462397997898956,1,C1=CC(c2cccc(-c3cccnc3)c2)c2c[nH]nc2O1
6757,818499,10.1016/j.bmcl.2012.04.006,,,,Inhibition of human Erg expressed in HEK293 cells assessed as rubidium efflux after 4 hrs by atomic absorbance spectrometric analysis,C[C@H]1c2c([nH]c3ccc(C(F)(F)F)cc23)C[C@H]2CCN(CCCC3CCOCC3)C[C@@H]21,"(4aR,11R,11aS)-11-methyl-2-(3-(tetrahydro-2H-pyran-4-yl)propyl)-9-(trifluoromethyl)-2,3,4,4a,5,6,11,11a-octahydro-1H-pyrido[4,3-b]carbazole",0.03,uM,=,-1.5228787452803376,0,c1ccc2c3c([nH]c2c1)C[C@H]1CCN(CCCC2CCOCC2)C[C@@H]1C3
6758,1642460,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKf current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG).Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 uM; 3 uM; 10 uM; 30 uM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models.The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from -80 mV to a maximum value of +40 mV, starting with -40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to -55 mV, after each of these incremented steps, for 1 second and finally repolarized to -80 mV for 1 second.Â  The current density recorded were normalized against the baseline conditions and corrected for solvent effect and time-dependent current run-down using experimental design in test compound free conditions.Â  Inhibition curves were obtained for compounds and the concentrations which decreased 50% of the current density determined in the baseline conditions (IC50) were determined. All compounds for which the IC50 value is above 10 uM are not considered to be potent inhibitors of the hERG channel whereas compounds with IC50 values below 1 uM are considered potent hERG channel inhibitors.",Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(-c4ccccc4)cc2)[C@@H]3C)n1,"US9475814, 29",25.0,uM,=,1.3979400086720375,1,O=C(c1ccc(-c2ccccc2)cc1)N1CCn2c(nnc2-c2ccccn2)C1
6759,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(CN(C)C)c(C)n4)n3)cc12,"5-(4-(4-((dimethylamino)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-N,1-dimethyl-1H-indazole-3-carboxamide",3.0,uM,=,0.4771212547196624,1,c1cnn(-c2ccnc(Nc3ccc4[nH]ncc4c3)n2)c1
6760,1508574,10.1016/j.bmc.2015.06.071,,,,Inhibition of human ERG overexpressed in CHO cells by Qpatch method,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-2-methoxy-piperidin-4-yl}-2-methoxy-benzamide,0.098,uM,=,-1.0087739243075051,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
6761,2054470,10.1016/j.ejmech.2020.112517,,,,Inhibition of human ERG,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,90.4,uM,=,1.956168430475364,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
6762,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)C/C=C/Cc1ccccc1,(E)-N-Ethyl-N-(4-phenylbut-2-en-1-yl)heptan-1-amine,0.176,uM,=,-0.7544873321858502,0,c1ccccc1
6763,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,C[C@@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1,"(R)-4-Amino-N-[1-(4-chlorophenyl)ethyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",9.092,uM,=,0.9586594270529332,1,O=C(NCc1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
6764,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN1CCC(C(=O)c2ccccc2)CC1,(1-Heptylpiperidin-4-yl)(phenyl)methanone,0.124,uM,=,-0.906578314837765,0,O=C(c1ccccc1)C1CCNCC1
6765,1580962,10.1021/acsmedchemlett.6b00018,,,,Binding affinity to human ERG by radioligand binding assay,CC(C)(C)c1cc(NC(=O)n2ccc3nc(Oc4ncnc5c4CNC5)ccc32)no1,"N-(5-(tert-Butyl)isoxazol-3-yl)-5-((6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridine-1-carboxamide",26.0,uM,=,1.414973347970818,1,O=C(Nc1ccon1)n1ccc2nc(Oc3ncnc4c3CNC4)ccc21
6766,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N(CCc3ccc(Cl)cc3)Cc3cccc(C(F)(F)F)c3)CC2)n[nH]1,"1-(5-amino-1H-1,2,4-triazol-3-yl)-N-(4-chlorophenethyl)-N-(3-(trifluoromethyl)benzyl)piperidin-4-amine",2.7,uM,=,0.4313637641589873,1,c1ccc(CCN(Cc2ccccc2)C2CCN(c3nc[nH]n3)CC2)cc1
6767,1794818,10.1016/j.bmcl.2018.08.015,,,,Displacement of 3H-dofetilide from human ERG,CCC[C@@H](CCO)Nc1nc(N)nc2c1CN(C(=O)c1cccs1)CC2,"[2-amino-4-[[(1S)-1-(2-hydroxyethyl)butyl]amino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-(2-thienyl)methanone",7.6,uM,=,0.8808135922807914,1,O=C(c1cccs1)N1CCc2ncncc2C1
6768,1813820,10.1016/j.ejmech.2019.111684,,,,Inhibition of human ERG incubated for 4 hrs by competitive fluorescence tracer binding based assay,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide,0.021,uM,=,-1.6777807052660807,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
6769,2219924,10.1016/j.bmcl.2021.128463,,,,Displacement of MK499 from human ERG expressed in HEK membrane by radio ligand binding competition assay,C[C@@]1(c2nc(NC(=O)c3ccc(C#N)cn3)ccc2F)CS(=O)(=O)[C@@](C)(C(F)F)C(=N)N1,"5-cyano-N-(6-((3R,6R)-6-(difluoromethyl)-5-imino-3,6-dimethyl-1,1-dioxidothiomorpholin-3-yl)-5-fluoropyridin-2-yl)picolinamide",2.424,uM,=,0.3845326154942486,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3ccccn3)n2)N1
6770,687881,10.1016/j.bmcl.2010.10.020,,,,Inhibition of human ERG,CCO[C@H]1CN([C@H]2CC[C@@](O)(c3ccc4c(c3)OCO4)CC2)C[C@@H]1NC(=O)CNC(=O)c1cccc(C(F)(F)F)c1,"N-(2-((3S,4S)-1-(cis-4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide",13.0,uM,=,1.1139433523068367,1,O=C(CNC(=O)c1ccccc1)N[C@@H]1CCN(C2CCC(c3ccc4c(c3)OCO4)CC2)C1
6771,1665702,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,O=C(NCC(F)(F)F)c1ccc(-c2cccc3nc(-c4cncnc4)nc(NCc4ccccn4)c23)cc1,"4-(4-((pyridin-2-ylmethyl)amino)-2-(pyrimidin-5-yl)quinazolin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide",4.9,uM,=,0.6901960800285137,1,c1ccc(-c2cccc3nc(-c4cncnc4)nc(NCc4ccccn4)c23)cc1
6772,1567397,10.1016/j.ejmech.2016.02.014,,,,Displacement of [3H]dofetilide from human ERG channel expressed in HEK293 cells after 60 mins by liquid scintillation counting method,CC(=O)N1Cc2ccccc2CC1CN1CCC2(CCc3ccccc32)CC1,"1'-[(2-acetyl-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl]-2,3-dihydro-1'H-spiro[indene-1,4'-piperidine]",0.5,uM,=,-0.3010299956639812,0,c1ccc2c(c1)CNC(CN1CCC3(CCc4ccccc43)CC1)C2
6773,2219924,10.1016/j.bmcl.2021.128463,,,,Displacement of MK499 from human ERG expressed in HEK membrane by radio ligand binding competition assay,Cc1cc(C#N)cnc1C(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)[C@](C)(C(F)F)C(=N)N2)n1,"5-cyano-N-(6-((3R,6S)-6-(difluoromethyl)-5-imino-3,6-dimethyl-1,1-dioxidothiomorpholin-3-yl)-5-fluoropyridin-2-yl)-3-methylpicolinamide",38.9,uM,=,1.5899496013257075,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3ccccn3)n2)N1
6774,1798125,10.1021/acsmedchemlett.8b00305,,,,Inhibition of MK-499 binding to human ERG,CCOc1cc(CN2CCC3(CC2)NC(=O)NC3=O)cc(OCC)c1-c1ccc(F)cc1,"8-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione",25.0,uM,=,1.3979400086720375,1,O=C1NC(=O)C2(CCN(Cc3ccc(-c4ccccc4)cc3)CC2)N1
6775,972740,10.1021/ml400197u,,,,Binding affinity to human ERG expressed in CHO cells by IonWorks assay,CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ncc1C,"N-[2-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-5-methyl-4-pyridyl]acetamide",19.0,uM,=,1.2787536009528289,1,c1ccc(Nc2cc(NC3CC3)n3nccc3n2)nc1
6776,773759,10.1021/jm200909u,,,,Inhibition of human hERG,Cn1cc(-c2ccc3c(c2)[nH]c2c(C(N)=O)cnc(NC(C4CC4)C4CC4)c23)cn1,"1-[(Dicyclopropylmethyl)amino]-7-(1-methyl-1H-pyrazol-4-yl)-5H-pyrido[4,3-b]indole-4-carboxamide",1.7,uM,=,0.2304489213782739,1,c1cc2[nH]c3cc(-c4cn[nH]c4)ccc3c2c(NC(C2CC2)C2CC2)n1
6777,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(C2=C(Cl)C(=O)OC2)C3=O)ccc2c1COC2=O,"US9206198, 25",33.0,uM,=,1.5185139398778875,1,O=C1C=C(N2CCC3(CCN(CCc4ccc5c(c4)COC5=O)CC3)C2=O)CO1
6778,411697,10.1021/jm060927v,,,,Binding affinity to hERG potassium channel,COc1ccc2c(NC[C@H](O)CO)nc(C#N)c(-c3ccccc3)c2c1,"1-{[(2S)-2,3-dihydroxypropyl]amino}-6-methoxy-4-phenylisoquinoline-3-carbonitrile",15.0,uM,=,1.1760912590556811,1,c1ccc(-c2cncc3ccccc23)cc1
6779,1783037,10.1016/j.ejmech.2017.12.063,,,,Inhibition of human ERG expressed in CHO-K1 cells assessed as reduction in tail current amplitude at -80 mV holding potential after 2 mins by path clamp assay,Fc1ccc(N2CCN(CCCc3c[nH]c4ccc(F)cc34)CC2)c(-c2ccccc2)c1,"5-Fluoro-3-(3-(4-(5-fluoro-[1,1'-biphenyl]-2-yl)piperazin-1-yl)propyl)-1H-indole",16.66,uM,=,1.2216749970707688,1,c1ccc(-c2ccccc2N2CCN(CCCc3c[nH]c4ccccc34)CC2)cc1
6780,1798125,10.1021/acsmedchemlett.8b00305,,,,Inhibition of MK-499 binding to human ERG,CCOc1cc(CN2CC[C@H]3C(Nc4nc5ccc(C(=O)O)cc5o4)CC[C@H]32)cc(OCC)c1-c1ccc(F)cc1,"2-(((3a,6a cis)-1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)octahydrocyclopenta[b]pyrrol-4-yl)amino)benzo[d]oxazole-6-carboxylic acid",15.0,uM,=,1.1760912590556811,1,c1ccc(-c2ccc(CN3CC[C@H]4C(Nc5nc6ccccc6o5)CC[C@H]43)cc2)cc1
6781,945471,10.1021/ml300372f,,,,Inhibition of human ERG assessed as decrease in tail current amplitude measured after 5 mins by whole cell patch clamp technique,CCOC(=O)N1CCC(O)(CN2CC[C@H](N3C(=O)Cc4ccccc43)C2)CC1,(S)-ethyl 4-hydroxy-4-((3-(2-oxoindolin-1-yl)pyrrolidin-1-yl)methyl)piperidine-1-carboxylate,3.9,uM,=,0.5910646070264992,1,O=C1Cc2ccccc2N1[C@H]1CCN(CC2CCNCC2)C1
6782,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@H](c3cnccn3)CC2)C1,N-{[1-(4-Pyrazin-2-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide,12.0,uM,=,1.0791812460476249,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3cnccn3)CC2)C1
6783,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,COC(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1,"Methyl 4-(spiro[chromene-2,4'-piperidine]-4-yl)benzoate",0.663,uM,=,-0.1784864715952268,0,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
6784,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,COC(=O)c1ccc([C@H]2CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cc1,4-(4-{3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-cyclohexyl)-benzoic acid methyl ester,1.3,uM,=,0.1139433523068367,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccccc3)CC2)C1
6785,2223202,10.1021/acsmedchemlett.2c00111,,,,Inhibition of hERG cardiac ion channel,O=C1COc2ccc(CN[C@H]3CO[C@H](CC4Cn5c(=O)ccc6ncc(F)c4c65)OC3)nc2N1,"6-(((2-((3-fluoro-7-oxo-4,5-dihydro-7H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-trans-1,3-dioxan-5-yl)amino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",97.0,uM,=,1.9867717342662448,1,O=C1COc2ccc(CN[C@H]3CO[C@H](CC4Cn5c(=O)ccc6nccc4c65)OC3)nc2N1
6786,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccc(O)cc32)cc1,"N,N-Diethyl-4-(6-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide",19.75,uM,=,1.295567099962479,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
6787,1891417,10.1016/j.bmcl.2019.03.026,,,,Inhibition of human ERG by whole-cell patch clamp method,Cc1ccc(CCN2CC[C@H](CNC(=O)c3cc(C(C)C)no3)C2)cc1C(F)(F)F,(R)-3-Isopropyl-N-((1-(4-methyl-3-(trifluoromethyl)phenethyl)pyrrolidin-3-yl)methyl)isoxazole-5-carboxamide,1.9,uM,=,0.2787536009528289,1,O=C(NC[C@H]1CCN(CCc2ccccc2)C1)c1ccno1
6788,1665702,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,NC(=O)Nc1cncc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)c1,1-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)urea,1.9,uM,=,0.2787536009528289,1,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1
6789,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,CC1CN(CCc2ccc([N+](=O)[O-])cc2)CCN1CCc1ccc([N+](=O)[O-])cc1,"2-methyl-1,4-bis(4-nitrophenethyl)piperazine",0.00076,uM,=,-3.1191864077192086,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6790,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@H](c3ccc(N4CCCC4)cc3)CC2)C1,N-({1-[4-(4-Pyrrolidin-1-yl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,7.9,uM,=,0.8976270912904415,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccc(N4CCCC4)cc3)CC2)C1
6791,1665702,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,NC(=O)Nc1ccc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)cn1,1-(5-(5-phenyl-4-((pyridin-2-ylmethyl)amino)quinazolin-2-yl)pyridin-2-yl)urea,4.8,uM,=,0.6812412373755872,1,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1
6792,2232362,10.1016/j.bmcl.2022.128648,,,,Inhibition of human ERG by Ionworks electrophysiology assay,O=C1COc2ccc(N3C(=O)O[C@H]4C[C@@H](NCCCn5c(=O)cnc6ccc(F)cc65)CC[C@@H]43)nc2N1,"6-((3aS,6S,7aS)-6-((3-(7-fluoro-2-oxoquinoxalin-1(2H)-yl)propyl)amino)-2-oxohexahydrobenzo[d]oxazol-3(2H)-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",13.0,uM,=,1.1139433523068367,1,O=C1COc2ccc(N3C(=O)O[C@H]4C[C@@H](NCCCn5c(=O)cnc6ccccc65)CC[C@@H]43)nc2N1
6793,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,Cc1nnc(-c2nn(C)c3ccc(Nc4nccc(-n5cc(N[C@@H]6CCOC[C@@H]6N)c(C)n5)n4)cc23)o1,"(3R,4R)-N4-[3-methyl-1-[2-[[1-methyl-3-(5-methyl-1,3,4-oxadiazol-2-yl)indazol-5-yl]amino]pyrimidin-4-yl]pyrazol-4-yl]tetrahydropyran-3,4-diamine",11.0,uM,=,1.0413926851582251,1,c1cc(-n2cc(NC3CCOCC3)cn2)nc(Nc2ccc3[nH]nc(-c4nnco4)c3c2)n1
6794,342119,10.1021/jm051106d,,,,Inhibitory activity against hERG by patch-clamp assay,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,"(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol",18.0,uM,=,1.255272505103306,1,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
6795,2079117,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 3 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),O=C(COc1ccc(C(=O)c2cc(Cl)ccc2Br)cc1)Nc1cccc(C(=O)NC2CC2)c1,3-(2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)acetamido)-N-cyclopropylbenzamide,0.0112,uM,=,-1.9507819773298185,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1cccc(C(=O)NC2CC2)c1
6796,1883248,10.1021/acs.jmedchem.8b01344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch assay,N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cn3)[C@](O)(CN)C2)c(Cl)c1,"4-(((3S,4S)-3-(Aminomethyl)-4-((5-chloropyridin-2-yl)-sulfonyl)-3-hydroxypyrrolidin-1-yl)sulfonyl)-3-chlorobenzonitrile",8.0,uM,=,0.9030899869919436,1,O=S(=O)(c1ccccn1)[C@@H]1CCN(S(=O)(=O)c2ccccc2)C1
6797,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,CC(=O)N1CCC(n2ncc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)c2C)CC1,"1-[4-(4-{[5-Chloro-4-(imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}-5-methyl-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",21.0,uM,=,1.3222192947339193,1,c1ccn2c(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)cnc2c1
6798,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCc1ccccn1,3-Oxo-2-(2-pyridin-2-ylethyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-1H-isoindole-1-carboxamide,4.6,uM,=,0.6627578316815741,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
6799,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,CS(=O)(=O)c1ccc(CCN2CCN(CCc3ccc([N+](=O)[O-])cc3)CC2)cc1,1-(4-(methylsulfonyl)phenethyl)-4-(4-nitrophenethyl)piperazine,0.15,uM,=,-0.8239087409443188,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6800,759504,10.1016/j.bmcl.2011.06.015,,,,Inhibition of human ERG by automated patch clamp assay,O=C(/C=C/c1ccc(CN(CCO)CCc2c[nH]c3ccccc23)cc1)NO,(E)-N-Hydroxy-3-[4-({(2-hydroxy-ethyl)-[2-(1H-indol-3-yl)-ethyl]-amino}-methyl)-phenyl]-acrylamide,10.3,uM,=,1.0128372247051722,1,c1ccc(CNCCc2c[nH]c3ccccc23)cc1
6801,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(Br)ccc1OC(Cc1ccccc1)C21COC1,"US8975415, RP15a::US8975415, RP15b::US9242973, RP15b",7.93,uM,=,0.8992731873176038,1,C1=NC2(CO1)c1ccccc1OC(Cc1ccccc1)C21COC1
6802,2219924,10.1016/j.bmcl.2021.128463,,,,Displacement of MK499 from human ERG expressed in HEK membrane by radio ligand binding competition assay,COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)[C@@](C)(CF)C(=N)N3)c2)cn1,"N-[4-fluoro-3-[(3R,6R)-6-(fluoromethyl)-5-imino-3,6-dimethyl-1,1-dioxo-1,4-thiazinan-3-yl]phenyl]-5-methoxy-pyrazine-2-carboxamide",14.67,uM,=,1.1664301138432829,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3cnccn3)c2)N1
6803,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CN(C)CCC=C1c2ccccc2CCc2ccccc21,"[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine",17.5894,uM,=,1.2452510252941065,1,C=C1c2ccccc2CCc2ccccc21
6804,1760898,10.1021/acs.jmedchem.8b00521,,,,Inhibition of human ERG by cell based automated patch clamp method,Cc1ccc(NC(=O)N2CCN(c3nc(N)nc4sc(-c5cccnc5)nc34)CC2)cc1,"4-[5-Amino-2-(3-pyridyl)thiazolo[5,4-d]pyrimidin-7-yl]-N-(ptolyl)piperazine-1-carboxamide",2.0,uM,=,0.3010299956639812,1,O=C(Nc1ccccc1)N1CCN(c2ncnc3sc(-c4cccnc4)nc23)CC1
6805,755897,10.1021/jm200112k,,,,Inhibition of Kv11.1 channel,CS(=O)(=O)Nc1ccc2ccc3ncc(-c4ccccc4)cc3c(=O)c2c1,"N-(5-Oxo-3-phenyl-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)methanesulfonamide",0.29,uM,=,-0.5376020021010439,0,O=c1c2ccccc2ccc2ncc(-c3ccccc3)cc12
6806,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),C[C@@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@H](C)N1,"5-Amino-1-cyclopropyl-7-(3,5-dimethyl-piperazin-1-yl)-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid",47.1384,uM,=,1.673374837353265,1,O=c1ccn(C2CC2)c2cc(N3CCNCC3)ccc12
6807,1571176,10.1016/j.bmcl.2016.03.035,,,,Inhibition of human ERG by electrophysiology analysis,Cc1c(C(F)CN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O,(rac)-5-(2-(4-(2-(6-(1H-tetrazol-1-yl)pyridin-3-yl)acetyl)piperazin-1-yl)-1-fluoroethyl)-4-methylisobenzofuran-1(3H)-one,22.0,uM,=,1.3424226808222062,1,O=C1OCc2cc(CCN3CCN(C(=O)Cc4ccc(-n5cnnn5)nc4)CC3)ccc21
6808,1857771,10.1021/acs.jmedchem.9b01916,,,,Inhibition of dofetilide binding to flag-tagged human ERG,C=CC(=O)N1CCC[C@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C,(S)-N-(3-(5-((1-Acryloylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide,0.049,uM,=,-1.3098039199714864,0,O=C(Nc1cccc(-c2ncncc2OC[C@@H]2CCCN2)c1)c1ccc(C2CC2)cc1
6809,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OCCC(F)(F)F)nc1)C1c2ccccc2C(=O)N1CCc1ccccn1,"3-Oxo-2-(2-pyridin-2-ylethyl)-N-{[6-(3,3,3-trifluoropropoxy)pyridin-3-yl]methyl}-isoindoline-1-carboxamide",20.0,uM,=,1.3010299956639813,1,O=C(NCc1cccnc1)C1c2ccccc2C(=O)N1CCc1ccccn1
6810,744151,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG by patch clamp technique,CS(=O)(=O)c1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncc(Cl)cn3)CC2)nc1,"5-chloro-2-(4-((1R,2S)-2-(2-(5-(methylsulfonyl)pyridin-2-yloxy)ethyl)cyclopropyl)piperidin-1-yl)pyrimidine",19.0,uM,=,1.2787536009528289,1,c1ccc(OCC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)nc1
6811,627243,10.1021/jm9016812,,,,Inhibition of human ERG by electrophysiology assay,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(Cl)cc4)sc3C)c2)cc1,2-((3-((2-(4-chlorophenyl)-5-methylthiazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,10.0,uM,=,1.0,1,O=C(NCc1cccc(OCc2csc(-c3ccccc3)n2)c1)Oc1ccccc1
6812,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(N[C@@H]5CCOC[C@@H]5N)cn4)n3)cc12,"5-[[4-[4-[[(3R,4R)-3-aminotetrahydropyran-4-yl]amino]pyrazol-1-yl]pyrimidin-2-yl]amino]-N,1-dimethyl-indazole-3-carboxamide",15.0,uM,=,1.1760912590556811,1,c1cc(-n2cc(NC3CCOCC3)cn2)nc(Nc2ccc3[nH]ncc3c2)n1
6813,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c(CNC(C)C)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,"N-((5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)methyl)propan-2-amine",0.023,uM,=,-1.6382721639824072,0,c1ccc(-c2ccnn2-c2ccccc2)cc1
6814,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,CC(=O)OCC(=O)NC1CCN(Cc2ccc(Oc3nc4ccccc4s3)cc2)CC1,Acetic Acid {1-[4-(Benzothiazol-2-yloxy)benzyl]piperidin-4-ylcarbamoyl}methyl Ester,30.0,uM,=,1.4771212547196624,1,c1ccc2sc(Oc3ccc(CN4CCCCC4)cc3)nc2c1
6815,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1nc(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)c(CO)nc1-c1cccc(Cl)c1Cl,"(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl)methanol",3.348,uM,=,0.5247854493212224,1,c1ccc(-c2cnc(N3CCC4(CCOC4)CC3)cn2)cc1
6816,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,Cc1nn(C2CCN(C(=O)CO)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"1-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-2-hydroxyethanone",22.0,uM,=,1.3424226808222062,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
6817,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N(CCc3ccc(Cl)cc3)Cc3ccncc3Cl)CC2)n[nH]1,"1-(5-amino-1H-1,2,4-triazol-3-yl)-N-(4-chlorophenethyl)-N-((3-chloropyridin-4-yl)methyl)piperidin-4-amine",6.4,uM,=,0.8061799739838872,1,c1ccc(CCN(Cc2ccncc2)C2CCN(c3nc[nH]n3)CC2)cc1
6818,1797483,10.1021/acsmedchemlett.8b00344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch clamp assay,Cc1[nH]nc(Nc2ccnc3ccc(S(=O)(=O)C(C)(C)C)cc23)c1C,"6-(tert-butylsulfonyl)-N-(4,5-dimethyl-1H-pyrazol-3-yl)quinolin-4-amine",15.5,uM,=,1.1903316981702914,1,c1ccc2c(Nc3cc[nH]n3)ccnc2c1
6819,1616839,10.1021/acs.jmedchem.6b01088,,,,Inhibition of human ERG by patch clamp assay,Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,"6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide",5.5,uM,=,0.7403626894942439,1,O=c1[nH]c2ccccc2c(=O)n1-c1cccc(-c2cccc3[nH]c4c(c23)CCCC4)c1
6820,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(Cl)c4)n2CCO3)ccn1,"N-(3-chlorophenyl)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",0.428,uM,=,-0.368556230986828,0,c1ccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
6821,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,CC(C)(C)OC(=O)N1CCC(N2C(=O)c3ccccc3C2C(=O)NCc2ccc(OC(F)(F)F)cc2)CC1,tert-Butyl 4-(1-oxo-3-(4-(trifluoromethoxy)benzylcarbamoyl)isoindolin-2-yl)piperidine-1-carboxylate,14.0,uM,=,1.146128035678238,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1C1CCNCC1
6822,411697,10.1021/jm060927v,,,,Binding affinity to hERG potassium channel,COc1ccc2c(=O)n(C[C@@H](O)CO)c(C#N)c(-c3ccccc3)c2c1,"2-[(2R)-2,3-dihydroxypropyl]-6-methoxy-1-oxo-4-phenyl-1,2-dihydroisoquinoline-3-carbonitrile",76.0,uM,=,1.880813592280792,1,O=c1[nH]cc(-c2ccccc2)c2ccccc12
6823,2204357,10.1016/j.bmc.2022.116894,,,,Inhibition of hERG measured by fluorescence polarization assay,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,(4-{1-[2-(6-Methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide,0.04268,uM,=,-1.3697755892475678,0,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1
6824,1988796,10.1021/acs.jmedchem.0c00745,,,,Inhibition of human ERG,O=C(O)c1cc(-c2ccc(C34CCN(CC3)CC4)cc2)cc(-n2cc(-c3ccc(C(F)(F)F)cc3)nn2)c1,"4'-(Quinuclidin-4-yl)-5-(4-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)-[1,1'-biphenyl]-3-carboxylic Acid",16.8,uM,=,1.2253092817258628,1,c1ccc(-c2cn(-c3cccc(-c4ccc(C56CCN(CC5)CC6)cc4)c3)nn2)cc1
6825,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,C=CC(=O)Nc1cc(Nc2ncc(C#N)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(5-cyano-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,4.3,uM,=,0.6334684555795865,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6826,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,CS(=O)(=O)NCCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1,"rac-4-Amino-N-[1-(4-chlorophenyl)-3-(methylsulfonamido)-propyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",80.124,uM,=,1.903762622281108,1,O=C(NCc1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
6827,796234,10.1016/j.bmcl.2011.10.115,,,,Inhibition of human Erg by whole cell patch clamp electrophysiology,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1,(+/-)-2-(1-(4-methylbenzyl)-1H-benzo[d]imidazol-2-yl)thiomorpholine,0.93,uM,=,-0.0315170514460648,0,c1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
6828,801100,10.1016/j.bmcl.2011.11.118,,,,Inhibition of human ERG by patch clamp assay,O=c1cc(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)cn[nH]1,5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-pyridazinone,2.0,uM,=,0.3010299956639812,1,O=c1cc(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)cn[nH]1
6829,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.FCCOc1ccc(CCC2CCN(CCc3ccccc3Cl)CC2)cc1,1-(2-Chlorophenethyl)-4-(4-(2-fluoroethoxy)phenethyl)piperidine hydrochloride,2.2,uM,=,0.3424226808222063,1,c1ccc(CCC2CCN(CCc3ccccc3)CC2)cc1
6830,422225,10.1016/j.bmcl.2006.07.061,,,,Inhibition of hERG potassium channel,CS(=O)(=O)c1ccc(-c2noc([C@@H](CC3CC3)[C@H](N)C(=O)N3CC[C@H](F)C3)n2)c(F)c1.O=C(O)C(F)(F)F,"(2S,3S)-4-cyclopropyl-3-(3-(2-fluoro-4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-((S)-3-fluoropyrrolidin-1-yl)-1-oxobutan-2-aminium 2,2,2-trifluoroacetate",58.5,uM,=,1.7671558660821804,1,O=C(C[C@H](CC1CC1)c1nc(-c2ccccc2)no1)N1CCCC1
6831,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1cccc(-c2cccc(C3(C)CCSC(N)=N3)c2)c1,"4-(3'-Methoxybiphenyl-3-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine",7.6,uM,=,0.8808135922807914,1,C1=NC(c2cccc(-c3ccccc3)c2)CCS1
6832,1295005,10.1021/jm4017224,,,,Inhibition of human ERG,Nc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccc(Cl)c3)N2)cc1,"(R)-2-Amino-N-(4-(((2S,5R)-5-((R)-(3-chlorophenyl)(hydroxy)-methyl)pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4Hcyclopenta[d]thiazole-4-carboxamide",1.5,uM,=,0.1760912590556812,1,O=C(Nc1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)[C@@H]1CCc2scnc21
6833,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1ccc(C2(c3cccc(-c4cncnc4)c3)N=C(N)n3nc(C)cc32)cc1,"4-(4-Methoxyphenyl)-2-methyl-4-(3-(pyrimidin-5-yl)-phenyl)-4H-imidazo[1,5-b]pyrazol-6-amine",8.6,uM,=,0.9344984512435676,1,C1=NC(c2ccccc2)(c2cccc(-c3cncnc3)c2)c2ccnn21
6834,1797573,10.1021/acs.jmedchem.8b01187,,,,Inhibition of human ERG by whole cell electrophysiology analysis,CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2([S@](C)(=N)=O)CC2)n1,"US8552004, 2.03",15.0,uM,=,1.1760912590556811,1,c1ccc2c(c1)ncn2-c1nc(C2CC2)cc(N2CCOCC2)n1
6835,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1ccc(C2(c3cccc(-c4cccnc4)c3)CC(OC)C(N)=N2)cc1,"rac-4-Methoxy-2-(4-methoxyphenyl)-2-(3-(pyridin-3-yl)phenyl)-3,4-dihydro-2H-pyrrol-5-amine",1.5,uM,=,0.1760912590556812,1,C1=NC(c2ccccc2)(c2cccc(-c3cccnc3)c2)CC1
6836,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CC(=O)c1c(-c2ccc(O)cn2)oc2ccc(O)c(CN3CCCC3)c12,1-(5-hydroxy-2-(5-hydroxypyridin-2-yl)-4-(pyrrolidin-1-ylmethyl)benzofuran-3-yl)ethanone,20.5,uM,=,1.3117538610557542,1,c1ccc(-c2cc3c(CN4CCCC4)cccc3o2)nc1
6837,1843047,10.1021/acs.jmedchem.9b01034,,,,Inhibition of human ERG,C#CCOc1cnc(C(=O)Nc2cc(F)c(F)c([C@@]3(C)N=C(N)S[C@@]4(COC)C[C@H]43)c2)cn1,"N-(3-((1S,5S,6S)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-(prop-2-yn-1-yloxy)pyrazine-2-carboxamide",6.9,uM,=,0.8388490907372553,1,O=C(Nc1cccc(C2N=CSC3C[C@H]32)c1)c1cnccn1
6838,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1-(9H-Carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol,4.1193,uM,=,0.6148234218666244,1,c1ccc(OCCNCCCOc2cccc3[nH]c4ccccc4c23)cc1
6839,1655356,10.1021/acsmedchemlett.7b00032,,,,Inhibition of human ERG potassium channel by patch clamp assay,c1ccc(-c2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncn2)cc1,"(1'S,3'R,4'S)-N-(6-phenylpyrimidin-4-yl)-4H-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octan]-2-amine",4.0,uM,=,0.6020599913279624,1,c1ccc(-c2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncn2)cc1
6840,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(C(F)(F)F)c4)n2CCO3)ccn1,"10-(2-methylpyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",0.3879999999999999,uM,=,-0.4111682744057928,0,c1ccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
6841,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,C[C@@]1(c2cc(CNC3(C(F)F)CC3)c(F)cc2F)CCSC(N)=N1,"(S)-4-(5-(((1-(Difluoromethyl)cyclopropyl)amino)methyl)-2,4-difluorophenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine",13.7,uM,=,1.136720567156407,1,C1=NC(c2cccc(CNC3CC3)c2)CCS1
6842,1554488,10.1016/j.bmcl.2016.01.049,,,,Inhibition of human ERG using tracer red fluorescent probe,Cl.Cl.O=C1CCc2c(Oc3ccc4c(c3)C[C@H](NC(=O)c3cc(C(F)(F)F)cc(C5(O)CNC5)c3)CC4)ccnc2N1,"3-(3-hydroxyazetidin-3-yl)-N-{(2R)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide dihydrochloride",4.9,uM,=,0.6901960800285137,1,O=C1CCc2c(Oc3ccc4c(c3)C[C@H](NC(=O)c3cccc(C5CNC5)c3)CC4)ccnc2N1
6843,1798125,10.1021/acsmedchemlett.8b00305,,,,Inhibition of MK-499 binding to human ERG,CCOc1cc(CN2CCC(NC(=O)c3cncc(C)c3)CC2)cc(OCC)c1-c1ccc(F)cc1,"N-(1-((2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-methylnicotinamide",1.69,uM,=,0.2278867046136735,1,O=C(NC1CCN(Cc2ccc(-c3ccccc3)cc2)CC1)c1cccnc1
6844,1469975,10.1021/jm501021n,,,,Inhibition of human ERG by PDSP screening,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NCc4cccc(Cl)c4)nc(C#Cc4ccc(F)c(F)c4)nc31)[C@H](O)[C@@H]2O,"(1S,2R,3S,4R,5S)-4-(6-(3-Chlorobenzylamino)-2-((3,4-difluorophenyl)ethynyl)-9H-purin-9-yl)-2,3-dihydroxy-Nmethylbicyclo[3.1.0]hexane-1-carboxamide",12.2,uM,=,1.0863598306747482,1,C(#Cc1nc(NCc2ccccc2)c2ncn([C@H]3CCC4C[C@@H]43)c2n1)c1ccccc1
6845,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@H](c3ccc(C(=O)O)cc3)CC2)C1,4-(4-{3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-cyclohexyl)-benzoic acid,23.0,uM,=,1.3617278360175928,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccccc3)CC2)C1
6846,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CC(C)NC(=O)c1cn(-c2cccc(Br)c2)c2ncccc2c1=O,"1-(3-bromophenyl)-N-isopropyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide",31.6,uM,=,1.499687082618404,1,O=c1ccn(-c2ccccc2)c2ncccc12
6847,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3cccc(O)c32)cc1,"N,N-Diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide",78.0,uM,=,1.8920946026904804,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
6848,1550040,10.1039/C5MD00297D,,,,Inhibition of human ERG expressed in CHO cells by patch express assay,COc1ccc2ncc(F)c(C(=O)CC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1,"6-((1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-2-oxoethyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",3.7,uM,=,0.568201724066995,1,O=C1COc2ccc(CNC34CCC(CC(=O)c5ccnc6cccnc56)(CC3)OC4)nc2N1
6849,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,CCn1ccc(NC(=O)c2cc(Oc3ccc(C(=O)N4CCC4)cc3)cc(O[C@@H](C)CO)c2)n1,3-{[4-(Azetidin-1-ylcarbonyl)-2-chlorophenyl]oxy}-5-{[(1S)-2-hydroxy-1-methylethyl]oxy}-N-(1-methyl-1H-pyrazol-3-yl)benzamide,54.0,uM,=,1.7323937598229686,1,O=C(Nc1cc[nH]n1)c1cccc(Oc2ccc(C(=O)N3CCC3)cc2)c1
6850,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCC[N+](CC)(CC)C/C=C/Cc1ccc(Cl)cc1.[I-],"(E)-N-(4-(4-Chlorophenyl)but-2-en-1-yl)-N,N-diethylheptan-1-aminium Iodide",0.0015,uM,=,-2.8239087409443187,0,c1ccccc1
6851,2232362,10.1016/j.bmcl.2022.128648,,,,Inhibition of human ERG by Ionworks electrophysiology assay,COc1ccc2ccc(=O)n(CCN[C@H]3CC[C@H]4[C@H](C3)OC(=O)N4c3ccc4c(n3)NC(=O)CS4)c2n1,"(3aS,6S,7aS)-6-((2-(7-methoxy-2-oxo-1,8-naphthyridin-1(2H)-yl)ethyl)amino)-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)hexahydrobenzo[d]oxazol-2(3H)-one",4.0,uM,=,0.6020599913279624,1,O=C1CSc2ccc(N3C(=O)O[C@H]4C[C@@H](NCCn5c(=O)ccc6cccnc65)CC[C@@H]43)nc2N1
6852,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NC/C=C/c3c(F)cccc3F)(CC1)CO2,"(R,E)-4-((4-(3-(2,6-difluorophenyl)allylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",0.032,uM,=,-1.494850021680094,0,O=c1ccc2nccc3c2n1CC3CC12CCC(NC/C=C/c3ccccc3)(CC1)CO2
6853,1911580,10.1021/acs.jmedchem.8b01726,,,,Inhibition of human ERG,C[C@@H]1OCC2(CCN(c3nc(N)c(Sc4cccc(Cl)c4Cl)c(=O)n3C)CC2)[C@@H]1N,"6-Amino-2-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-((2,3-dichlorophenyl)thio)-3-methylpyrimidin-4(3H)-one",4.0,uM,=,0.6020599913279624,1,O=c1[nH]c(N2CCC3(CCOC3)CC2)ncc1Sc1ccccc1
6854,306311,10.1016/j.bmcl.2005.02.093,,,,In vitro inhibitory concentration against displacement of 35[S] MK-499 binding to hERG channel expressed in HEK293 cells,COc1cccc(C(=O)N2CCCC2)c1OCc1csc(-c2ccc(Cl)cc2)n1,{2-[2-(4-Chloro-phenyl)-thiazol-4-ylmethoxy]-3-methoxy-phenyl}-pyrrolidin-1-yl-methanone,7.7,uM,=,0.8864907251724818,1,O=C(c1ccccc1OCc1csc(-c2ccccc2)n1)N1CCCC1
6855,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,CC1=C(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)C(C)OC1=O,"2-(2,4-Dimethyl-5-oxo-2,5-dihydrofuran-3-yl)-8-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one",20.0,uM,=,1.3010299956639813,1,O=C1C=C(N2CCC3(CCN(CCc4ccc5c(c4)COC5=O)CC3)C2=O)CO1
6856,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,CNC(=O)c1nc(C)n2ccc(Nc3nccc(-n4cc(CN(C)C)cn4)n3)cc12,"7-[[4-[4-[(dimethylamino)methyl]pyrazol-1-yl]pyrimidin-2-yl]amino]-N,3-dimethyl-imidazo[1,5-a]pyridine-1-carboxamide",7.1,uM,=,0.8512583487190752,1,c1cnn(-c2ccnc(Nc3ccn4cncc4c3)n2)c1
6857,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCc1oc(CCc2cc(N3CCOCC3)cc(NCC(F)(F)F)n2)nc1C,"6-(2-(5-ethyl-4-methyloxazol-2-yl)ethyl)-4-morpholino-N-(2,2,2-trifluoroethyl)pyridin-2-amine",1.6,uM,=,0.2041199826559248,1,c1cc(N2CCOCC2)cc(CCc2ncco2)n1
6858,1990613,10.1016/j.bmcl.2020.127249,,,,Inhibition of human ERG,O=C(Nc1nccs1)/C(=N/N1CCCC1)c1ccc(S(=O)(=O)C2CC2)cc1,(E)-2-(4-(cyclopropylsulfonyl)phenyl)-2-(pyrrolidin-1-ylimino)-N-(thiazol-2-yl)acetamide,17.5,uM,=,1.2430380486862944,1,O=C(Nc1nccs1)/C(=N/N1CCCC1)c1ccc(S(=O)(=O)C2CC2)cc1
6859,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N(Cc3ccccc3)[C@H](CO)Cc3ccc(Cl)cc3)CC2)n[nH]1,"(S)-2-((1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl)(benzyl)amino)-3-(4-chlorophenyl)propan-1-ol",2.9,uM,=,0.4623979978989561,1,c1ccc(CCN(Cc2ccccc2)C2CCN(c3nc[nH]n3)CC2)cc1
6860,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,Nc1cccnc1[C@H]1CC[C@H](N2CC(NC(=O)CNC(=O)c3cccc(C(F)(F)F)c3)C2)CC1,N-({1-[4-(3-Amino-pyridin-2-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,44.0,uM,=,1.6434526764861874,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccccn3)CC2)C1
6861,2186534,10.1021/acs.jmedchem.1c01132,,,,Inhibition of hERG ion channel incubated for 3 hrs by fluorescence polarization assay,CCCNc1nccc(-c2n[nH]c3nc(N4CCC5(CC4)CO[C@@H](C)[C@H]5N)c(CO)nc23)c1Cl,"(6-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(3-chloro-2-(ethylamino)pyridin-4-yl)-1H-pyrazolo[3,4-b]pyrazin-5-yl)methanol",1.6,uM,=,0.2041199826559248,1,c1cc(-c2n[nH]c3nc(N4CCC5(CCOC5)CC4)cnc23)ccn1
6862,945796,10.1016/j.bmcl.2012.12.072,,,,Inhibition of human ERG,O[C@H](COc1ccc(F)cc1)CN1CCN(Cc2ccc(Cl)c(Cl)c2)CC1,"(S)-1-(4-(3,4-dichlorobenzyl)piperazin-1-yl)-3-(4-fluorophenoxy)propan-2-ol",0.29,uM,=,-0.5376020021010439,0,c1ccc(CN2CCN(CCCOc3ccccc3)CC2)cc1
6863,1794818,10.1016/j.bmcl.2018.08.015,,,,Displacement of 3H-dofetilide from human ERG,CCCC[C@@H](CCO)Nc1nc(N)nc2c1CN(C(=O)c1cccs1)CC2,"[2-amino-4-[[(1S)-1-(2-hydroxyethyl)pentyl]amino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-(2-thienyl)methanone",6.9,uM,=,0.8388490907372553,1,O=C(c1cccs1)N1CCc2ncncc2C1
6864,1523572,10.1021/acs.jmedchem.5b01605,,,,Inhibition of human ERG potassium channel by ionworks patch-clamp electrophysiology assay,CS(=O)(=O)c1ccc(-c2cnn3ccc(-c4cccc(S(=O)(=O)C5CC5)c4)nc23)cc1,"5-(3-(Cyclopropylsulfonyl)phenyl)-3-(4-(methylsulfonyl)-phenyl)pyrazolo[1,5-a]pyrimidine",0.5,uM,=,-0.3010299956639812,0,O=S(=O)(c1cccc(-c2ccn3ncc(-c4ccccc4)c3n2)c1)C1CC1
6865,627243,10.1021/jm9016812,,,,Inhibition of human ERG by electrophysiology assay,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3oc(-c4ccc(Cl)cc4)nc3C)c2)cc1,2-((3-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,20.0,uM,=,1.3010299956639813,1,O=C(NCc1cccc(OCc2cnc(-c3ccccc3)o2)c1)Oc1ccccc1
6866,1677519,10.1021/acs.jmedchem.7b01300,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 3 mins by QPatch test,CN(C/C=C/c1ccc(C(F)(F)F)cc1)Cc1cccc2ccoc12.Cl,(E)-N-(Benzofuran-7-ylmethyl)-N-methyl-3-(4-(trifluoromethyl)-phenyl)prop-2-en-1-amine Hydrochloride,3.7,uM,=,0.568201724066995,1,C(=C/c1ccccc1)\CNCc1cccc2ccoc12
6867,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",Cc1cc(Cl)cnc1C(=O)Nc1ccc2c(c1)C1(COC(N)=N1)C1(CC1)CO2,"US8975415, RP194::US9242973, RP194",4.91,uM,=,0.6910814921229685,1,O=C(Nc1ccc2c(c1)C1(COC=N1)C1(CC1)CO2)c1ccccn1
6868,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,Cc1c([C@@H](O)CN2CCC3(CC2)CC(=O)N(C2=CC(=O)OC2)C3)ccc2c1COC2=O,"(R)-8-(2-Hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(5-oxo-2,5-dihydrofuran-3-yl)-2,8-diazaspiro[4.5]-decan-3-one",90.0,uM,=,1.954242509439325,1,O=C1C=C(N2CC3(CCN(CCc4ccc5c(c4)COC5=O)CC3)CC2=O)CO1
6869,470090,10.1016/j.bmcl.2008.02.050,,,,Inhibition of human ERG,CS(=O)(=O)c1ccc(-c2noc([C@@H](CCO)[C@H](N)C(F)=C3CCCC3)n2)c(Cl)c1.O=C(O)C(F)(F)F,"(2S,3S)-3-(3-(2-chloro-4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-cyclopentylidene-1-fluoro-5-hydroxypentan-2-aminium 2,2,2-trifluoroacetate",47.0,uM,=,1.6720978579357175,1,C(CCc1nc(-c2ccccc2)no1)=C1CCCC1
6870,2226228,10.1021/acs.jmedchem.2c00227,,,,Inhibition of hERG expressed in human HEK293 cells by whole-cell patch-clamp method,CCSc1ncc(CN2CCN(c3nc4ccccc4o3)CC2)cn1,,1.2,uM,=,0.0791812460476248,1,c1ccc2oc(N3CCN(Cc4cncnc4)CC3)nc2c1
6871,1617566,10.1021/acs.jmedchem.6b01127,,,,Inhibition of human ERG,N#Cc1ccc(-c2ccc(C[C@@H](C#N)NC(=O)[C@@H]3CNCCCO3)cc2)cc1,"(S)-N-((S)-1-Cyano-2-(4'-cyano[1,1'-biphenyl]-4-yl)ethyl)-1,4-oxazepane-2-carboxamide",17.0,uM,=,1.230448921378274,1,O=C(NCCc1ccc(-c2ccccc2)cc1)[C@@H]1CNCCCO1
6872,1712776,10.1016/j.bmcl.2018.03.056,,,,Inhibition of human ERG expressed in CHOK1 cells at holding potential of -80 mV after 5 mins by patch clamp assay,C[C@]12CCCC[C@H]1C[C@@H](N1CCC[C@@H](N)C1)[C@@H]2Oc1ccc(C#N)cc1,"4-((1R,2R,3aS,7aS)-2-((R)-3-aminopiperidin-1-yl)-7a-methyloctahydro-1H-inden-1-yloxy)benzonitrile",7.7,uM,=,0.8864907251724818,1,c1ccc(O[C@@H]2C3CCCC[C@H]3C[C@H]2N2CCCCC2)cc1
6873,627243,10.1021/jm9016812,,,,Inhibition of human ERG by electrophysiology assay,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(C#N)cc4)oc3C)c2)cc1,2-((3-((2-(4-cyanophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,53.0,uM,=,1.7242758696007892,1,O=C(NCc1cccc(OCc2coc(-c3ccccc3)n2)c1)Oc1ccccc1
6874,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1ccc(C2(c3cccc(-c4cccnc4)c3)CC(OC)C(N)=N2)cc1,"rac-4-Methoxy-2-(4-methoxyphenyl)-2-(3-(pyridin-3-yl)phenyl)-3,4-dihydro-2H-pyrrol-5-amine",3.2,uM,=,0.505149978319906,1,C1=NC(c2ccccc2)(c2cccc(-c3cccnc3)c2)CC1
6875,2049685,10.1021/acs.jmedchem.0c01411,,,,Inhibition of human ERG by patch clamp method,CN1CCN(C(=O)C2CCN(c3nccc4[nH]c(-c5ccc(F)c(F)c5)cc34)CC2)CC1,"(1-(2-(3,4-difluorophenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl)piperidin-4-yl)(4-methylpiperazin-1-yl)methanone",3.0,uM,=,0.4771212547196624,1,O=C(C1CCN(c2nccc3[nH]c(-c4ccccc4)cc23)CC1)N1CCNCC1
6876,2079117,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 3 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),N#Cc1cncc(NC(=O)COc2ccc(C(=O)c3cc(Cl)ccc3Br)cc2)c1,2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)-N-(5-cyanopyridin-3-yl)acetamide,0.0189,uM,=,-1.723538195826756,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1cccnc1
6877,748773,10.1016/j.bmcl.2011.04.102,,,,Inhibition of human ERG by HT patch clamp assay,Cc1c2c(n3c1CCCN1C[C@@H](F)C[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,"(16S,18R)-16-fluoro-5,5,9-trimethyl-7-oxo-2,14,20-triazapentacyclo[19.3.1.0^{2,10}.0^{3,8}.0^{14,18}]pentacosa-1(25),3(8),9,21,23-pentaene-22-carboxamide",16.4,uM,=,1.214843848047698,1,O=C1CCCc2c1cc1n2-c2cccc(c2)NC[C@H]2CCCN2CCC1
6878,1861615,10.1016/j.ejmech.2019.111595,,,,Inhibition of human ERG transfected in HEK293 cells by whole-cell patch clamp method,CON=C1CCC(CN2CCN(c3nc(=O)c4cc(C(F)(F)F)cc([N+](=O)[O-])c4s3)CC2)CC1,"2-(4-((4-(methoxyimino)cyclohexyl)methyl)piperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one",47.98,uM,=,1.6810602436318118,1,N=C1CCC(CN2CCN(c3nc(=O)c4ccccc4s3)CC2)CC1
6879,2125967,10.1021/acs.jmedchem.1c00268,,,,Inhibition of human ERG potassium channel in HEK293 cells by manual patch-clamp electrophysiology,Cc1cc(C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(C(N)=O)cc3)CC2)ncc1-c1ccncc1,"4-((4-(4-(4-cyano-2,6-dimethylphenoxy)-5-(pyridin-4-yl)pyrimidin-2-ylamino)piperidin-1-yl)methyl)benzamide",1.19,uM,=,0.0755469613925307,1,c1ccc(CN2CCC(Nc3ncc(-c4ccncc4)c(Oc4ccccc4)n3)CC2)cc1
6880,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,c1cc2nonc2cc1CCN1CCN(CCc2ccc3nonc3c2)CC1,"1,4-bis(2-(benzo[c][1,2,5]oxadiazol-5-yl)ethyl)piperazine",0.067,uM,=,-1.1739251972991736,0,c1cc2nonc2cc1CCN1CCN(CCc2ccc3nonc3c2)CC1
6881,2054470,10.1016/j.ejmech.2020.112517,,,,Inhibition of human ERG,Cc1nc(Nc2n[nH]c3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1,"(S)-N-(2-(dimethylamino)-1-phenylethyl)-6,6-dimethyl-3-((2-methylthieno[3,2-d]pyrimidin-4-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide",42.1,uM,=,1.6242820958356683,1,O=C(NCc1ccccc1)N1Cc2[nH]nc(Nc3ncnc4ccsc34)c2C1
6882,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(N[C@H]5CNC[C@@H]5F)c(C)n4)n3)cc12,"5-[[4-[4-[[(3S,4S)-4-fluoropyrrolidin-3-yl]amino]-3-methyl-pyrazol-1-yl]pyrimidin-2-yl]amino]-N,1-dimethyl-indazole-3-carboxamide",19.0,uM,=,1.2787536009528289,1,c1cc(-n2cc(N[C@@H]3CCNC3)cn2)nc(Nc2ccc3[nH]ncc3c2)n1
6883,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,O=[N+]([O-])c1ccc(CCN2CCNCC2)cc1,1-(4-nitrophenethyl)piperazine,0.19,uM,=,-0.721246399047171,0,c1ccc(CCN2CCNCC2)cc1
6884,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",COc1cnc(C(=O)Nc2ccc3c(c2)[C@@]2(COC(N)=N2)C2(CC2)C(C)(C)O3)cn1,"US8975415, 223::US9242973, 223",20.77,uM,=,1.317436496535099,1,O=C(Nc1ccc2c(c1)[C@@]1(COC=N1)C1(CC1)CO2)c1cnccn1
6885,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,C[C@@]1(c2cc(CNCC(F)(F)F)c(F)cc2F)CCSC(N)=N1,"(S)-4-(2,4-Difluoro-5-(((2,2,2-trifluoroethyl)amino)methyl)-phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine",6.1,uM,=,0.785329835010767,1,C1=NC(c2ccccc2)CCS1
6886,1649450,10.1016/j.ejmech.2016.12.017,,,,Inhibition of human ERG by Tracer Red dye based fluorescence polarization assay,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,4-[(5-{4-[(Z)-amino(imino)methyl]phenoxy}pentyl)oxy]benzenecarboximidamide,18.8,uM,=,1.2741578492636798,1,c1ccc(OCCCCCOc2ccccc2)cc1
6887,773759,10.1021/jm200909u,,,,Inhibition of human hERG,NC(=O)c1cnc(NC(C2CC2)C2CC2)c2c1[nH]c1cc(-c3cnc(N)nc3)ccc12,"7-(2-Aminopyrimidin-5-yl)-1-[(dicyclopropylmethyl)amino]-5H-pyrido[4,3-b]indole-4-carboxamide",8.2,uM,=,0.9138138523837168,1,c1ncc(-c2ccc3c(c2)[nH]c2ccnc(NC(C4CC4)C4CC4)c23)cn1
6888,1731353,10.1016/j.ejmech.2017.12.090,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by whole cell Qpatch assay,CN(C/C=C/C=C/c1ccc(C(F)(F)F)cc1F)Cc1ccc2c(c1)OCO2.Cl,"(2E,4E)-N-(benzo[d][1,3]dioxol-5-ylmethyl)-5-(2-fluoro-4-(trifluoromethyl)phenyl)-N-methylpenta-2,4-dien-1-amine hydrochloride",0.014,uM,=,-1.853871964321762,0,C(/C=C/c1ccccc1)=C\CNCc1ccc2c(c1)OCO2
6889,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,16.2,uM,=,1.209515014542631,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6890,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,Cc1cccc2c1C(C(=O)NCc1ccc(OC(F)(F)F)cc1)N(CCc1ccccn1)C2=O,7-Methyl-3-oxo-2-(2-(pyridin-2-yl)ethyl)-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,5.6,uM,=,0.7481880270062004,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
6891,2145487,10.1021/acs.jmedchem.1c00935,,,,Inhibition of human ERG expressed in CHO cells by patch-clamp assay,CCS(=O)(=O)[C@]1(C)CC[C@@](CF)(c2cc(NC(=O)c3cc4c(cn3)OC(F)(F)O4)ccc2F)N=C1N,"N-(3-((2S,5R)-6-Amino-5-(ethylsulfonyl)-2-(fluoromethyl)-5-methyl-2,3,4,5-tetrahydropyridin-2-yl)-4-fluorophenyl)-2,2-difluoro[1,3]dioxolo[4,5-c]pyridine-6-carboxamide",8.3,uM,=,0.919078092376074,1,O=C(Nc1cccc(C2CCCC=N2)c1)c1cc2c(cn1)OCO2
6892,1695906,10.1016/j.bmcl.2017.08.030,,,,Inhibition of human ERG,O=C(c1cc(F)cc(Cl)c1)N1CCc2oc(-c3ccc(F)cn3)nc2C1,"(3-Chloro-5-fluorophenyl){2-(5-fluoropyridin-2-yl)-6,7-dihydro[1,3]oxazolo[4,5-c]pyridin-5(4H)-yl}methanone",19.0,uM,=,1.2787536009528289,1,O=C(c1ccccc1)N1CCc2oc(-c3ccccn3)nc2C1
6893,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,NC1(C(=O)N[C@@H](CCN2CCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,"rac-4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-pyrrolidin-1-ylpropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",21.03,uM,=,1.3228392726863212,1,O=C(N[C@@H](CCN1CCCC1)c1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
6894,2232362,10.1016/j.bmcl.2022.128648,,,,Inhibition of human ERG by Ionworks electrophysiology assay,COc1ccc2ccc(=O)n(CCN[C@@H]3CC[C@@H]4[C@H](C3)OC(=O)N4c3ccc4c(n3)NC(=O)CO4)c2n1,"6-((3aR,6R,7aS)-6-((2-(7-methoxy-2-oxo-1,8-naphthyridin-1(2H)-yl)ethyl)amino)-2-oxohexahydrobenzo[d]oxazol-3(2H)-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",5.0,uM,=,0.6989700043360189,1,O=C1COc2ccc(N3C(=O)O[C@H]4C[C@H](NCCn5c(=O)ccc6cccnc65)CC[C@H]43)nc2N1
6895,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)CC#CCCc1ccc(Cl)cc1,N-Butyl-5-(4-chlorophenyl)-N-ethylpent-2-yn-1-amine,6.007,uM,=,0.7786576319473553,1,c1ccccc1
6896,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,CNC(=O)CN1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1,"2-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-N-methylacetamide",12.0,uM,=,1.0791812460476249,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
6897,2219924,10.1016/j.bmcl.2021.128463,,,,Displacement of MK499 from human ERG expressed in HEK membrane by radio ligand binding competition assay,C[C@@]1(C(F)F)C(=N)N[C@](C)(c2nc(NC(=O)c3ccc(C#N)cn3)ccc2F)CS1(=O)=O,"5-cyano-N-(6-((3R,6S)-6-(difluoromethyl)-5-imino-3,6-dimethyl-1,1-dioxidothiomorpholin-3-yl)-5-fluoropyridin-2-yl)picolinamide",24.24,uM,=,1.3845326154942486,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3ccccn3)n2)N1
6898,2161344,10.1021/acs.jmedchem.1c02048,,,,Inhibition of [35S]MK-499 binding to hERG expressed in HEK293 cells,C[C@@H]1[C@@H](C)[C@@H]2CN(C)C[C@@]23C(=O)O[C@H](C)[C@H]3[C@H]1/C=C/c1ccc(-c2ccccc2C#N)cn1,"2-[6-[(E)-2-[(3R,3aS,4S,5R,6R,6aS,9aR)-3,5,6,8-tetramethyl-1-oxo-3,3a,4,5,6,6a,7,9-octahydrofuro[3,4-d]isoindol-4-yl]vinyl]-3-pyridyl]benzonitrile",14.8,uM,=,1.1702617153949575,1,O=C1OC[C@H]2[C@@H](/C=C/c3ccc(-c4ccccc4)cn3)CC[C@@H]3CNC[C@@]132
6899,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,COc1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1,"4-(4-Methoxyphenyl)spiro[chromene-2,4'-piperidine]",0.585,uM,=,-0.2328441339178195,0,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
6900,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,O=C(NC1CC1)c1cn(-c2cccc(-c3ccncc3)c2)c2ncccc2c1=O,"N-cyclopropyl-4-oxo-1-(3-(pyridin-4-yl)phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide",18.6,uM,=,1.2695129442179165,1,O=C(NC1CC1)c1cn(-c2cccc(-c3ccncc3)c2)c2ncccc2c1=O
6901,748773,10.1016/j.bmcl.2011.04.102,,,,Inhibition of human ERG by HT patch clamp assay,Cc1c2c(n3c1CCCN1CCCC[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,"(19R)-5,5,9-trimethyl-7-oxo-2,14,21-triazapentacyclo[20.3.1.0^{2,10}.0^{3,8}.0^{14,19}]hexacosa-1(26),3(8),9,22,24-pentaene-23-carboxamide",0.9,uM,=,-0.0457574905606751,0,O=C1CCCc2c1cc1n2-c2cccc(c2)NC[C@H]2CCCCN2CCC1
6902,1448459,10.1021/jm5004864,,,,Inhibition of human ERG over-expressed in HEK293 cell membrane by [3H]dofetilide binding assay,CN(C)c1ncc(/C=C/c2c(F)cccc2F)cn1,"(E)-5-(2',6'-Difluorostyryl)-2-(N,N-dimethylamino)pyrimidine",40.5,uM,=,1.6074550232146685,1,C(=C/c1cncnc1)\c1ccccc1
6903,744151,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG by patch clamp technique,Clc1cnc(N2CCC([C@H]3C[C@H]3CCOc3ccc(-n4ccnn4)cc3)CC2)nc1,"2-(4-((1R,2S)-2-(2-(4-(1H-1,2,3-triazol-1-yl)phenoxy)ethyl)cyclopropyl)piperidin-1-yl)-5-chloropyrimidine",19.0,uM,=,1.2787536009528289,1,c1cnc(N2CCC([C@H]3C[C@H]3CCOc3ccc(-n4ccnn4)cc3)CC2)nc1
6904,2023418,10.1016/j.bmcl.2020.127663,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch clamp assay,COc1ccc(CN2CCN(C(=O)/C=C/c3ccc(Cl)cc3Cn3nnc(C)n3)CC2)nc1,(E)-3-(4-chloro-2-((5-methyl-2H-tetrazol-2-yl)methyl)phenyl)-1-(4-((5-methoxypyridin-2-yl)methyl)piperazin-1-yl)prop-2-en-1-one,1.9,uM,=,0.2787536009528289,1,O=C(/C=C/c1ccccc1Cn1ncnn1)N1CCN(Cc2ccccn2)CC1
6905,543516,10.1016/j.bmcl.2009.01.008,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,Cc1nnc(C(C)C)n1C1CCN(C(C)C[C@H](NC(=O)C2CC(F)(F)C2)c2ccccc2)CC1.Cl,"3,3-difluoro-N-((1S)-3-(4-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl)-1-phenylbutyl)cyclobutanecarboxamide",2.3,uM,=,0.3617278360175928,1,O=C(N[C@@H](CCN1CCC(n2cnnc2)CC1)c1ccccc1)C1CCC1
6906,2149749,10.1021/acs.jmedchem.1c00489,,,,Inhibition of human ERG,NC1=N[C@@]2(c3cc(NC(=O)c4ccc(F)cn4)ccc3F)CN(c3ncc(F)cn3)C[C@H]2CS1,"US8987254, 3",0.18,uM,=,-0.744727494896694,0,O=C(Nc1cccc([C@]23CN(c4ncccn4)C[C@H]2CSC=N3)c1)c1ccccn1
6907,2226898,10.1016/j.ejmech.2022.114512,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by automated patch clamp method,Cc1c(C(C#N)c2c(F)cccc2F)nc(SC(C)C)[nH]c1=O,"2-(2,6-difluorophenyl)-2-(2-(isopropylthio)-5-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)acetonitrile",2687.1,uM,=,3.429283828934125,1,O=c1cc(Cc2ccccc2)nc[nH]1
6908,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)CC#CCc1ccccc1,N-Butyl-N-ethyl-4-phenylbut-2-yn-1-amine,7.82,uM,=,0.893206753059848,1,c1ccccc1
6909,1745714,10.1016/j.bmc.2017.10.004,,,,Inhibition of human ERG expressed in Xenopus laevis oocytes by two-electrode voltage clamp assay,CCCCCCn1c(NC2CCN(CCc3ccc(OC)cc3)CC2)nc2ccccc21,1-Hexyl-N-(1-(4-methoxyphenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine,0.02996,uM,=,-1.523458190972571,0,c1ccc(CCN2CCC(Nc3nc4ccccc4[nH]3)CC2)cc1
6910,1567397,10.1016/j.ejmech.2016.02.014,,,,Displacement of [3H]dofetilide from human ERG channel expressed in HEK293 cells after 60 mins by liquid scintillation counting method,c1ccc2c(c1)CC(CN1CCC3(CCc4ccccc43)CC1)CO2,"1'-{(3,4-dihydro-2H-chromen-3-yl)methyl}-2,3-dihydro-1'H-spiro[indene-1,4'-piperidine]",1.5,uM,=,0.1760912590556812,1,c1ccc2c(c1)CC(CN1CCC3(CCc4ccccc43)CC1)CO2
6911,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CC(C)CNC(=O)c1cn(-c2cccc(Br)c2)c2ncccc2c1=O,"1-(3-bromophenyl)-N-isobutyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide",31.8,uM,=,1.5024271199844328,1,O=c1ccn(-c2ccccc2)c2ncccc12
6912,2079117,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 3 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),Cc1cnccc1NC(=O)COc1ccc(C(=O)c2cc(Cl)ccc2Br)cc1,2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)-N-(3-methylpyridin-4-yl)acetamide,0.0141,uM,=,-1.85078088734462,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1ccncc1
6913,1891417,10.1016/j.bmcl.2019.03.026,,,,Inhibition of human ERG by whole-cell patch clamp method,CC(C)c1cc(C(=O)NC[C@H]2CCN(CCc3ccc(Cl)c(Cl)c3)C2)on1,"(R)-N-((1-(3,4-dichlorophenethyl)pyrrolidin-3-yl)methyl)-3-isopropylisoxazole-5-carboxamide",1.53,uM,=,0.1846914308175988,1,O=C(NC[C@H]1CCN(CCc2ccccc2)C1)c1ccno1
6914,814592,10.1016/j.bmcl.2012.03.049,,,,Inhibition of human ERG expressed in HEK293 cells by voltage clamp electrophysiology assay,Cc1nc(N2CCC(O)(C3CC3)CC2)nc2ccc(NC(=O)/C=C/c3ccc(Cl)cc3)cc12,(E)-3-(4-chlorophenyl)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide,5.6,uM,=,0.7481880270062004,1,O=C(/C=C/c1ccccc1)Nc1ccc2nc(N3CCC(C4CC4)CC3)ncc2c1
6915,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,c1ccc2oc(Oc3ccc(OCCN4CCCCC4)cc3)nc2c1,2-[4-(2-Piperidin-1-ylethoxy)phenoxy]benzooxazole,1.0,uM,=,0.0,0,c1ccc2oc(Oc3ccc(OCCN4CCCCC4)cc3)nc2c1
6916,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,CCN(CC)C(=O)c1ccccc1C1=CC2(CCNCC2)Oc2ccccc21,"N,N-Diethyl-2-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide",6.45,uM,=,0.8095597146352678,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
6917,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cc2c(Cl)c(-c3n[nH]c4nc(N5C[C@@H]6[C@H](C5)[C@@]6(CN)c5nccs5)cnc34)ccc2n1,"((1R,5S,6r)-3-(3-(4-chloro-2-methyl-2H-indazol-5-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-6-(thiazol-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methanamine",13.493,uM,=,1.1301085203609365,1,c1csc(C2[C@H]3CN(c4cnc5c(-c6ccc7n[nH]cc7c6)n[nH]c5n4)C[C@@H]23)n1
6918,1797483,10.1021/acsmedchemlett.8b00344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch clamp assay,CCc1cc2nccc(Nc3n[nH]c(C)c3C)c2cc1S(=O)(=O)C(C)(C)C,"6-(tert-butylsulfonyl)-N-(4,5-dimethyl-1H-pyrazol-3-yl)-7-ethylquinolin-4-amine",23.99,uM,=,1.3800302479678306,1,c1ccc2c(Nc3cc[nH]n3)ccnc2c1
6919,1901021,10.1021/acs.jmedchem.9b01112,,,,Inhibition of human ERG expressed in CHOK1 cells by Qpatch electrophysiological assay,CCc1cc(-c2cnn(C)c2)cc(S(=O)(=O)c2csc(CN)n2)c1,(4-((3-Ethyl-5-(1-methyl-1H-pyrazol-4-yl)phenyl)sulfonyl)thiazol-2-yl)methanamine,29.0,uM,=,1.462397997898956,1,O=S(=O)(c1cccc(-c2cn[nH]c2)c1)c1cscn1
6920,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,CN(C)c1cccc([C@]2(O)CC[C@@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)c1,N-({1-[4-(3-Dimethylamino-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,25.0,uM,=,1.3979400086720375,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccccc3)CC2)C1
6921,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,C[C@@H]1C[C@@](C)(c2cc(CNC3(C(F)(F)F)CC3)c(F)cc2F)N=C(N)S1,"(4S,6R)-4-(2,4-Difluoro-5-(((1-(trifluoromethyl)cyclopropyl)-amino)methyl)phenyl)-4,6-dimethyl-5,6-dihydro-4H-1,3-thiazin-2-amine",2.6,uM,=,0.414973347970818,1,C1=NC(c2cccc(CNC3CC3)c2)CCS1
6922,766645,10.1016/j.bmcl.2011.07.030,,,,Inhibition of human ERG,CC(C)N1CCCC1CNC(=O)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1,"N-((1-isopropylpyrrolidin-2-yl)methyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",17.0,uM,=,1.230448921378274,1,O=C(NCC1CCCN1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
6923,1908032,10.1016/j.bmcl.2019.126681,,,,Inhibition of ERG in human HEK293 cells incubated for 1 hr by thallium flux assay,O=C1c2ccccc2C(Cc2ccnc(F)c2)(Cc2ccnc(F)c2)c2ccccc21,"10,10-Bis-(2-fluoro-pyridin-4-ylmethyl)-10H-anthracen-9-one",32.0,uM,=,1.505149978319906,1,O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc21
6924,759504,10.1016/j.bmcl.2011.06.015,,,,Inhibition of human ERG by automated patch clamp assay,O=C(/C=C/c1ccc2c(c1)CN(Cc1ccccc1)C2)NO,3-(2-benzylisoindolin-5-yl)-N-hydroxyacrylamide,27.5,uM,=,1.4393326938302626,1,c1ccc(CN2Cc3ccccc3C2)cc1
6925,1642460,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKf current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG).Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 uM; 3 uM; 10 uM; 30 uM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models.The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from -80 mV to a maximum value of +40 mV, starting with -40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to -55 mV, after each of these incremented steps, for 1 second and finally repolarized to -80 mV for 1 second.Â  The current density recorded were normalized against the baseline conditions and corrected for solvent effect and time-dependent current run-down using experimental design in test compound free conditions.Â  Inhibition curves were obtained for compounds and the concentrations which decreased 50% of the current density determined in the baseline conditions (IC50) were determined. All compounds for which the IC50 value is above 10 uM are not considered to be potent inhibitors of the hERG channel whereas compounds with IC50 values below 1 uM are considered potent hERG channel inhibitors.",C[C@@H]1c2nnc(-c3cccc(O)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1,"US9475814, 31",20.0,uM,=,1.3010299956639813,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2ccccn2)C1
6926,1798125,10.1021/acsmedchemlett.8b00305,,,,Inhibition of MK-499 binding to human ERG,CCOc1cc(CN2CCC3(CC2)CC(Cc2ccc(F)cc2)C(=O)O3)cc(OCC)c1-c1ccc(F)cc1,"(+/-)-8-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-3-(4-fluorobenzyl)-1-oxa-8-azaspiro[4.5]decan-2-one",0.95,uM,=,-0.0222763947111522,0,O=C1OC2(CCN(Cc3ccc(-c4ccccc4)cc3)CC2)CC1Cc1ccccc1
6927,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CC(C)(O)c1ccc(-c2cccc(-n3cc(C(=O)NC4CC4)c(=O)c4cccnc43)c2)c[n+]1[O-],"1-{3-[6-(1-Hydroxy-1-methyl-ethyl)-1-oxy-pyridin-3-yl]-phenyl}-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid cyclopropylamide",50.1,uM,=,1.6998377258672457,1,O=C(NC1CC1)c1cn(-c2cccc(-c3ccc[nH+]c3)c2)c2ncccc2c1=O
6928,1758787,10.1021/acsmedchemlett.7b00188,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch assay,O=C1N(CCCCC2CCc3cc(-c4ccc(Cl)cc4)ccc3O2)CCN1c1ccncc1,1-(4-(6-(4-chlorophenyl)chroman-2-yl)butyl)-3-(pyridin-4-yl)imidazolidin-2-one,1.75,uM,=,0.2430380486862944,1,O=C1N(CCCCC2CCc3cc(-c4ccccc4)ccc3O2)CCN1c1ccncc1
6929,1780154,10.1021/acs.jmedchem.8b01077,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV after 60 secs by patch clamp assay,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCCCC1)c1cccs1,"N-((S)-3-(exo-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(thiophen-2-yl)propyl)cyclohexane Carboxamide",2.06,uM,=,0.3138672203691534,1,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@H](n1cnnc1)C2)c1cccs1)C1CCCCC1
6930,973733,10.1016/j.bmcl.2013.06.013,,,,Inhibition of human ERG by automated planar patch-clamp system,CCOC(=O)N1CCC(CN2CCC3(CC2)OC(=O)Nc2ncccc23)CC1,"ethyl 4-((2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-yl)methyl)piperidine-1-carboxylate",0.92,uM,=,-0.0362121726544447,0,O=C1Nc2ncccc2C2(CCN(CC3CCNCC3)CC2)O1
6931,1328603,10.1039/C3MD00234A,,,,Inhibition of human ERG,COc1ccc(N2C(=O)C(C)(C)C2c2ccccc2OC)cc1,"4-(2-methoxyphenyl)-1-(4-methoxyphenyl)-3,3-dimethylazetidin-2-one",13.0,uM,=,1.1139433523068367,1,O=C1CC(c2ccccc2)N1c1ccccc1
6932,966750,10.1016/j.bmcl.2013.04.074,,,,Inhibition of human ERG current by patch clamp assay,COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,"1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid",130.0,uM,=,2.113943352306837,1,O=c1ccn(C2CC2)c2cc(N3CCNCC3)ccc12
6933,2186534,10.1021/acs.jmedchem.1c01132,,,,Inhibition of hERG ion channel incubated for 3 hrs by fluorescence polarization assay,C[C@@H]1OCC2(CCN(c3nc4[nH]nc(-c5cccc(Cl)c5Cl)c4nc3CO)CC2)[C@@H]1N,"(6-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-5-yl)methanol",0.23,uM,=,-0.6382721639824072,0,c1ccc(-c2n[nH]c3nc(N4CCC5(CCOC5)CC4)cnc23)cc1
6934,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)C/C=C/c1ccc(Cl)cc1,(E)-N-(3-(4-Chlorophenyl)allyl)-N-ethylbutan-1-amine,1.05,uM,=,0.021189299069938,1,c1ccccc1
6935,796234,10.1016/j.bmcl.2011.10.115,,,,Inhibition of human Erg by whole cell patch clamp electrophysiology,Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1,1-(4-fluorobenzyl)-2-(4-(4-methyl-1H-pyrazol-1-yl)piperidin-1-yl)-1H-benzo[d]imidazole,0.809,uM,=,-0.0920514783877276,0,c1ccc(Cn2c(N3CCC(n4cccn4)CC3)nc3ccccc32)cc1
6936,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(CCO)cc(C(F)(F)F)c2)CC1,"(4-(3-(2-hydroxyethyl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",0.9,uM,=,-0.0457574905606751,0,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2ccccc2)CC1
6937,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(NC(=O)c3ccc(Cl)cn3)ccc1OCC21CC1,"US8975415, RP32::US9242973, RP32",2.17,uM,=,0.3364597338485295,1,O=C(Nc1ccc2c(c1)C1(COC=N1)C1(CC1)CO2)c1ccccn1
6938,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,O=C1OCCN1C1CCN(CCc2ccc(Oc3nc4ccccc4s3)cc2)CC1,3-(1-{2-[4-(Benzothiazol-2-yloxy)phenyl]ethyl}piperidin-4-yl)oxazolidin-2-one,0.5,uM,=,-0.3010299956639812,0,O=C1OCCN1C1CCN(CCc2ccc(Oc3nc4ccccc4s3)cc2)CC1
6939,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@H](c3ccc4[nH]cnc4c3)CC2)C1,N-({1-[4-(3H-Benzoimidazol-5-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,2.5,uM,=,0.3979400086720376,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccc4[nH]cnc4c3)CC2)C1
6940,945796,10.1016/j.bmcl.2012.12.072,,,,Inhibition of human ERG,COc1cccc(N2CCN(C[C@H](O)COc3ccc(C(F)(F)F)cc3)CC2)c1,(S)-1-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(4-(trifluoromethyl)phenoxy)propan-2-ol,4.08,uM,=,0.6106601630898799,1,c1ccc(OCCCN2CCN(c3ccccc3)CC2)cc1
6941,2158639,10.1016/j.ejmech.2021.113986,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by whole cell patch clamp assay,Fc1ccc([C@]2(CCNCc3cccc(Cl)c3)CCO[C@]3(CCOC3)C2)nc1,"N-(3-chlorobenzyl)-2-((5S,9R)-9-(5-fluoropyridin-2-yl)-2,6-dioxaspiro[4.5]decan-9-yl)ethan-1-amine",22.8,uM,=,1.3579348470004535,1,c1ccc(CNCC[C@@]2(c3ccccn3)CCO[C@]3(CCOC3)C2)cc1
6942,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,CC1=C(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)CCC1=O,"(R)-2-(4-Methyl-5-oxo-2,5-dihydrofuran-3-yl)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro-[4.5]decan-1-one",22.0,uM,=,1.3424226808222062,1,O=C1C=C(N2CCC3(CCN(CCc4ccc5c(c4)COC5=O)CC3)C2=O)CC1
6943,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,NC1(C(=O)NC(CCCN2CCOCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,"rac-4-Amino-N-[1-(4-chlorophenyl)-4-morpholin-4-ylbutyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",74.807,uM,=,1.8739422384945863,1,O=C(NC(CCCN1CCOCC1)c1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
6944,1697113,10.1021/acs.jmedchem.7b00932,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in peak tail current amplitude by path clamp method,CN1[C@@H]2CC[C@H]1c1c(sc(NC(=O)Nc3ccc(Cl)cc3)c1C(N)=O)C2.Cl,"(+)-2-[3-(4-Chlorophenyl)ureido]-9-methyl-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[b]thiophene-3-carboxamide Hydrochloride",5.6,uM,=,0.7481880270062004,1,O=C(Nc1ccccc1)Nc1cc2c(s1)C[C@H]1CC[C@@H]2N1
6945,2149816,10.1021/acs.jmedchem.1c00327,,,,Inhibition of human ERG by fluorescence polarization assay,CO[C@]1(C)C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3O)[C@](C)(O)C[C@@H](C)CN(C)C(=O)C[C@@H](Cc3ccc(NC(=O)[C@H](Cc4ccccc4Cl)NC(=O)Nc4ccccc4)cc3)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1O,"(2S)-3-(2-Chlorophenyl)-N-[4-[[(2S,5R,10R,12R,13R,14S,15S,16R)-13-(beta-D-desosaminyl)oxy-12-hydroxy-15-(alpha-L-cladinosyl)oxy-2-isopropyl-8,10,12,14,16-pentamethyl-3,7,17-trioxo-1,4,8-triazacycloheptadec-5-yl]methyl]phenyl]-2-(phenylcarbamoylamino)propanamide",10.0,uM,=,1.0,1,O=C1C[C@@H](Cc2ccc(NC(=O)[C@H](Cc3ccccc3)NC(=O)Nc3ccccc3)cc2)NC(=O)CNC(=O)C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CCCCN1
6946,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CC1(C)Oc2ccc(NC(=O)c3ccc(Cl)cn3)cc2[C@@]2(COC(N)=N2)C12COC2,"US8975415, 218::US9242973, 218",20.67,uM,=,1.3153404766272885,1,O=C(Nc1ccc2c(c1)[C@@]1(COC=N1)C1(COC1)CO2)c1ccccn1
6947,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,CCn1cc(N2CCN(Cc3nc4c5cccc(OC)c5nc(N)n4n3)[C@H](C)C2)cn1,"(R)-2-((4-(1-ethyl-1H-pyrazol-4-yl)-2-methylpiperazin-1-yl)methyl)-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",39.19,uM,=,1.593175263478103,1,c1ccc2c(c1)ncn1nc(CN3CCN(c4cn[nH]c4)CC3)nc21
6948,1861615,10.1016/j.ejmech.2019.111595,,,,Inhibition of human ERG transfected in HEK293 cells by whole-cell patch clamp method,O=c1nc(N2CCN(CC3CCCCC3)CC2)sc2c([N+](=O)[O-])cc(C(F)(F)F)cc12,"2-(4-(cyclohexylmethyl)piperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one",101.7,uM,=,2.0073209529227447,1,O=c1nc(N2CCN(CC3CCCCC3)CC2)sc2ccccc12
6949,1745714,10.1016/j.bmc.2017.10.004,,,,Inhibition of human ERG expressed in Xenopus laevis oocytes by two-electrode voltage clamp assay,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3F)CC2)cc1,"1-(2,4-Difluorobenzyl)-N-(1-(4-methoxyphenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine",0.178,uM,=,-0.7495799976911061,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
6950,875038,10.1021/jm300573d,,,,Inhibition of human ERG,Cl.Cn1cc2c(OCC3CCN(CCN4CCOCC4)CC3)nc3ccccc3c2c1,"2-Methyl-4-[[1-(2-morpholin-4-ylethyl)-4-piperidinyl]methoxy]-2H-pyrrolo[3,4-c]quinoline hydrochloride",1.22,uM,=,0.0863598306747482,1,c1ccc2c(c1)nc(OCC1CCN(CCN3CCOCC3)CC1)c1c[nH]cc12
6951,2109357,10.1016/j.bmcl.2021.127992,,,,Binding affinity to human ERG,O=C(Oc1ccc(OCc2ccccc2)cc1)N(Nc1ccccc1)S(=O)(=O)c1ccc(Cl)cc1,4-(benzyloxy)phenyl 1-(4-chlorophenylsulfonyl)-2-phenylhydrazinecarboxylate,9.6,uM,=,0.9822712330395684,1,O=C(Oc1ccc(OCc2ccccc2)cc1)N(Nc1ccccc1)S(=O)(=O)c1ccccc1
6952,973733,10.1016/j.bmcl.2013.06.013,,,,Inhibition of human ERG by automated planar patch-clamp system,CCCN1C(=O)CC2(CCN(CC3CCN(C(=O)OCC)CC3)CC2)c2cccnc21,"ethyl 4-((2-oxo-1-propyl-2,3-dihydro-1H-spiro[[1,8]naphthyridine-4,4'-piperidine]-1'-yl)methyl)piperidine-1-carboxylate",0.67,uM,=,-0.1739251972991735,0,O=C1CC2(CCN(CC3CCNCC3)CC2)c2cccnc2N1
6953,411697,10.1021/jm060927v,,,,Binding affinity to hERG potassium channel,COCCN(C)CCn1c(C#N)c(-c2cccc(F)c2)c2cc(OC)ccc2c1=O,"4-(3-fluorophenyl)-6-methoxy-2-{2-[(2-methoxyethyl)(methyl)amino]ethyl}-1-oxo-1,2-dihydroisoquinoline-3-carbonitrile",1.65,uM,=,0.2174839442139062,1,O=c1[nH]cc(-c2ccccc2)c2ccccc12
6954,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.FCCOc1ccc(CCN2CCC(CCc3ccccc3)CC2)cc1,1-(4-(2-Fluoroethoxy)phenethyl)-4-phenethylpiperidine hydrochloride,0.35,uM,=,-0.4559319556497244,0,c1ccc(CCC2CCN(CCc3ccccc3)CC2)cc1
6955,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,N#Cc1ccc(CCN2CCN(CCc3ccc4c(c3)COC4=O)CC2)cc1,"4-(2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",0.43,uM,=,-0.3665315444204134,0,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
6956,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,Oc1ccc(-c2cc3c(CN4CCC5(COC5)C4)c(O)ccc3o2)cc1,4-(2-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-2-(4-hydroxyphenyl)benzofuran-5-ol,4.32,uM,=,0.6354837468149122,1,c1ccc(-c2cc3c(CN4CCC5(COC5)C4)cccc3o2)cc1
6957,1760898,10.1021/acs.jmedchem.8b00521,,,,Inhibition of human ERG by cell based automated patch clamp method,COc1ccc(NC(=O)N2CCN(c3nc(N)nc4scnc34)CC2)cc1,"4-(5-Aminothiazolo[5,4-d]pyrimidin-7-yl)-N-(4-methoxyphenyl)-piperazine-1-carboxamide",28.0,uM,=,1.4471580313422192,1,O=C(Nc1ccccc1)N1CCN(c2ncnc3scnc23)CC1
6958,862394,10.1021/jm300601d,,,,Inhibition of human ERG expressed in HEK 293 cells by PatchXpress assay,CC(=O)N1CCC(c2cc(C)c(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,N-[4-(1-Acetyl-piperidin-4-yl)-2-methyl-5-trifluoromethyl-benzoyl]-guanidine,7.0,uM,=,0.8450980400142568,1,c1ccc(C2CCNCC2)cc1
6959,1901021,10.1021/acs.jmedchem.9b01112,,,,Inhibition of human ERG expressed in CHOK1 cells by Qpatch electrophysiological assay,Cn1cc(-c2cc(F)cc(S(=O)(=O)c3cnc(CN)s3)c2)cn1,(5-((3-Fluoro-5-(1-methyl-1H-pyrazol-4-yl)phenyl)sulfonyl)thiazol-2-yl)methanamine,66.0,uM,=,1.8195439355418688,1,O=S(=O)(c1cccc(-c2cn[nH]c2)c1)c1cncs1
6960,748605,10.1016/j.bmcl.2011.03.114,,,,Inhibition of human ERG,CC#CC(CC(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1F,rac-3-(4-(2-(difluoromethoxy)-4-(trifluoromethyl)phenoxy)-2-fluorophenyl)hex-4-ynoic acid,25.0,uM,=,1.3979400086720375,1,c1ccc(Oc2ccccc2)cc1
6961,824043,10.1021/jm3001373,,,,Inhibition of human ERG expressed in CHO cells by IonWorks assay,COc1ccc(-c2cc(-c3ccc(S(C)(=O)=O)cc3)cnc2N)cn1,TCMDC-133351,3.0,uM,=,0.4771212547196624,1,c1ccc(-c2cncc(-c3cccnc3)c2)cc1
6962,966750,10.1016/j.bmcl.2013.04.074,,,,Inhibition of human ERG current by patch clamp assay,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,"1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid",966.0,uM,=,2.9849771264154934,1,O=c1ccn(C2CC2)c2cc(N3CCNCC3)ccc12
6963,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CC4(CCOC4)C3)c12,4-(6-oxa-2-azaspiro[3.4]octan-2-ylmethyl)-5-hydroxy-2-(4-hydroxyphenyl)-N-methylbenzofuran-3-carboxamide,23.5,uM,=,1.3710678622717365,1,c1ccc(-c2cc3c(CN4CC5(CCOC5)C4)cccc3o2)cc1
6964,1642460,,,,,"Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKf current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG).Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 uM; 3 uM; 10 uM; 30 uM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models.The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from -80 mV to a maximum value of +40 mV, starting with -40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to -55 mV, after each of these incremented steps, for 1 second and finally repolarized to -80 mV for 1 second.Â  The current density recorded were normalized against the baseline conditions and corrected for solvent effect and time-dependent current run-down using experimental design in test compound free conditions.Â  Inhibition curves were obtained for compounds and the concentrations which decreased 50% of the current density determined in the baseline conditions (IC50) were determined. All compounds for which the IC50 value is above 10 uM are not considered to be potent inhibitors of the hERG channel whereas compounds with IC50 values below 1 uM are considered potent hERG channel inhibitors.",Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3)cs1,"(3-(2-Methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]-pyrazin-7(8H)-yl)(4-(thiophen-2yl)phenyl)methanone",26.0,uM,=,1.414973347970818,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2cscn2)C1
6965,458983,10.1016/j.bmcl.2007.03.065,,,,Inhibition of hERG,CC(=O)c1cccc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)c1,"1-(3-Acetyl-phenyl)-3-{(1R,2S)-2-[3-(4-fluoro-benzyl)-piperidin-1-ylmethyl]-cyclohexyl}-urea",0.4,uM,=,-0.3979400086720376,0,O=C(Nc1ccccc1)N[C@@H]1CCCC[C@H]1CN1CCC[C@@H](Cc2ccccc2)C1
6966,702661,10.1021/jm100978n,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(c1ccncn1)C3)C2)c1cccc(F)c1,"endo-N-((S)-1-(3-fluorophenyl)-3-(3-(2-methyl-5-(pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)propyl)acetamide",0.01,uM,=,-2.0,0,c1ccc(CCCN2[C@@H]3CC[C@H]2C[C@@H](n2cnc4c2CCN(c2ccncn2)C4)C3)cc1
6967,1697453,10.1021/acs.jmedchem.7b01765,,,,Inhibition of [3H]-astemizole binding to human ERG expressed in HEK293 cell membranes by scintillation counting method,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,0.014,uM,=,-1.853871964321762,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
6968,1745714,10.1016/j.bmc.2017.10.004,,,,Inhibition of human ERG expressed in Xenopus laevis oocytes by two-electrode voltage clamp assay,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3CCC(C)C)CC2)cc1,1-Isopentyl-N-(1-(4-methoxyphenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine,0.2117,uM,=,-0.674279141980588,0,c1ccc(CCN2CCC(Nc3nc4ccccc4[nH]3)CC2)cc1
6969,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1C[C@@H]1CCCO1,3-Oxo-2-[[(2S)-oxolan-2-yl]methyl]-N-[[4-(trifluoromethoxy)phenyl]methyl]-1H-isoindole-1-carboxamide,17.0,uM,=,1.230448921378274,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1C[C@@H]1CCCO1
6970,1498131,10.1021/ml5004876,,,,Inhibition of human ERG channel,CNC(=O)c1ccc(-c2cc(F)c3ncc(Cc4ccc5ncccc5c4)n3c2)cc1F,"2-Fluoro-4-(8-fluoro-3-(quinolin-6-ylmethyl)imidazo[1,2-a]pyridin-6-yl)-N-methylbenzamide",93.56,uM,=,1.9710902131371155,1,c1ccc(-c2ccc3ncc(Cc4ccc5ncccc5c4)n3c2)cc1
6971,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,CC(C)(O)c1cc(C(F)(F)F)cc(S(=O)(=O)N2CCN(C(=O)[C@@H]3C[C@H]3c3ccc(C(F)(F)F)cc3)CC2)c1,"(4-(3-(2-hydroxypropan-2-yl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",1.2,uM,=,0.0791812460476248,1,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2ccccc2)CC1
6972,1780154,10.1021/acs.jmedchem.8b01077,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV after 60 secs by patch clamp assay,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1cccs1,"4,4-Difluoro-N-((S)-3-((1R,3R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(thiophen-2-yl)-propyl)cyclohexane-1-carboxamide",3.5,uM,=,0.5440680443502757,1,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@H](n1cnnc1)C2)c1cccs1)C1CCCCC1
6973,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc2c1nc(N)n1nc(CN3CCN(c4ccc(F)cc4)C[C@H]3C)nc21,"(R)-2-((4-(4-fluorophenyl)-2-methylpiperazin-1-yl)methyl)-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",1.551,uM,=,0.1906117978136049,1,c1ccc(N2CCN(Cc3nc4c5ccccc5ncn4n3)CC2)cc1
6974,2241739,10.1016/j.ejmech.2021.113983,,,,Inhibition of human ERG,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NCCc4ccc(OC)c(OC)c4)nc(C#Cc4ccc(Cl)s4)nc31)[C@H](O)[C@@H]2O,"(1S,2R,3S,4R,5S)-4-[2-[2-(5-chloro-2-thienyl)ethynyl]-6-[2-(3,4-dimethoxyphenyl)ethylamino]purin-9-yl]-2,3-dihydroxy-N-methyl-bicyclo[3.1.0]hexane-1-carboxamide",3.65,uM,=,0.5622928644564748,1,C(#Cc1cccs1)c1nc(NCCc2ccccc2)c2ncn([C@H]3CCC4C[C@@H]43)c2n1
6975,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,N#Cc1ccc(CCN2CCN(CCc3ccc([N+](=O)[O-])cc3)CC2)cc1,4-(2-(4-(4-nitrophenethyl)piperazin-1-yl)ethyl)benzonitrile,0.009,uM,=,-2.0457574905606752,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
6976,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.FCCOc1cccc(CCC2CCN(CCc3ccccc3)CC2)c1,4-(3-(2-Fluoroethoxy)phenethyl)-1-phenethylpiperidine hydrochloride,0.75,uM,=,-0.1249387366082999,0,c1ccc(CCC2CCN(CCc3ccccc3)CC2)cc1
6977,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1ccc(-c2c(C)c(CNC3CCCC3)nn2-c2ncccc2Cl)cn1,N-((1-(3-chloropyridin-2-yl)-4-methyl-5-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)methyl)cyclopentanamine,16.0,uM,=,1.2041199826559248,1,c1ccc(-n2nc(CNC3CCCC3)cc2-c2cccnc2)nc1
6978,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,CCc1c(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)cnn1C1CCN(C(C)=O)CC1,"1-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-5-ethyl-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",17.0,uM,=,1.230448921378274,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
6979,2027427,10.1021/acs.jmedchem.6b01204,,,,Inhibition of human ERG measured after 4 hrs by fluorescence polarization assay,CN1CCC[C@H]1COc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(O)cc2)cc1.Cl,"(S,Z)-4-(5-Hydroxy-1-(4-((1-methylpyrrolidin-2-yl)methoxy)-phenyl)-2-phenylpent-1-en-1-yl)phenol Hydrochloride Salt",18.0,uM,=,1.255272505103306,1,C(=C(c1ccccc1)c1ccc(OC[C@@H]2CCCN2)cc1)c1ccccc1
6980,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,CC(C)(C)OC(=O)N1CC(N2C(=O)c3ccccc3C2C(=O)NCc2ccc(OC(F)(F)F)cc2)C1,"tert-Butyl 3-(1-oxo-3-{[4-(trifluoromethoxy)benzyl]carbamoyl}-1,3-dihydro-2H-isoindol-2-yl)azetidine-1-carboxylate",11.0,uM,=,1.0413926851582251,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1C1CNC1
6981,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,COc1ccc(NC(=O)/C=C/CN(C)C)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"(E)-N-(3-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)-4-(dimethylamino)but-2-enamide",4.2,uM,=,0.6232492903979004,1,c1ccc(Nc2nccc(-c3cnn4ccccc34)n2)cc1
6982,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,"1-{1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one",0.9272,uM,=,-0.0328265770444604,0,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccccc1
6983,2232362,10.1016/j.bmcl.2022.128648,,,,Inhibition of human ERG by Ionworks electrophysiology assay,COc1cnc2ccc(=O)n(CCN[C@H]3CC[C@H]4[C@H](C3)OC(=O)N4c3ccc4c(n3)NC(=O)CO4)c2c1,"6-((3aS,6S,7aS)-6-((2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)amino)-2-oxohexahydrobenzo[d]oxazol-3(2H)-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",32.0,uM,=,1.505149978319906,1,O=C1COc2ccc(N3C(=O)O[C@H]4C[C@@H](NCCn5c(=O)ccc6ncccc65)CC[C@@H]43)nc2N1
6984,2047144,10.1016/j.bmcl.2020.127536,,,,Inhibition of human ERG,Cc1c(F)c(Nc2ccc(-c3cn(C)cn3)cn2)cc2c1ncn2CC1CC1,1-(cyclopropylmethyl)-5-fluoro-4-methyl-N-(5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl)-1H-benzo[d]imidazol-6-amine,11.0,uM,=,1.0413926851582251,1,c1nc(-c2ccc(Nc3ccc4ncn(CC5CC5)c4c3)nc2)c[nH]1
6985,1353223,10.1021/jm401705g,,,,Inhibition of human ERG by electrophysiology assay,N#Cc1ccc(-c2ccc(C[C@@H](C#N)NC(=O)[C@@H]3CCCCN3)cc2)cc1,(S)-N-((S)-1-Cyano-2-(4'-cyanobiphenyl-4-yl)ethyl)-piperidine-2-carboxamide,1.4,uM,=,0.1461280356782379,1,O=C(NCCc1ccc(-c2ccccc2)cc1)[C@@H]1CCCCN1
6986,857209,10.1021/jm300286a,,,,Inhibition of human ERG by patch clamp assay,O=C(CCc1ccccc1)c1ccccc1OCC(O)CN1CCC(c2ccccc2)CC1,1-(2-(2-hydroxy-3-(4-phenylpiperidin-1-yl)propoxy)phenyl)-3-phenylpropan-1-one,3.46,uM,=,0.5390760987927766,1,O=C(CCc1ccccc1)c1ccccc1OCCCN1CCC(c2ccccc2)CC1
6987,973733,10.1016/j.bmcl.2013.06.013,,,,Inhibition of human ERG by automated planar patch-clamp system,CCOC(=O)N1CCC(CN2CCC3(CC2)OC(=O)N(C)c2ncccc23)CC1,"ethyl 4-((1'-methyl-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-yl)methyl)piperidine-1-carboxylate",1.48,uM,=,0.1702617153949573,1,O=C1Nc2ncccc2C2(CCN(CC3CCNCC3)CC2)O1
6988,856088,10.1016/j.bmc.2012.08.050,,,,Displacement of [3H]-dofetilide from human ERG,CSc1nc(-c2cc(OCCN3CCCC3)c(Cl)cc2Cl)c2c(C#N)c[nH]c2n1,"4-[2,4-Dichloro-5-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile",3.64,uM,=,0.561101383649056,1,c1cc(OCCN2CCCC2)cc(-c2ncnc3[nH]ccc23)c1
6989,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)C/C=C/Cc1ccc(Cl)cc1,(E)-N-Butyl-4-(4-chlorophenyl)-N-ethylbut-2-en-1-amine,1.127,uM,=,0.0519239160461065,1,c1ccccc1
6990,796234,10.1016/j.bmcl.2011.10.115,,,,Inhibition of human Erg by whole cell patch clamp electrophysiology,CN1CCC[C@@H](c2nc3ccccc3n2Cc2ccc(F)cc2)C1,(R)-1-(4-fluorobenzyl)-2-(1-methylpiperidin-3-yl)-1H-benzo[d]imidazole,0.72,uM,=,-0.1426675035687315,0,c1ccc(Cn2c([C@@H]3CCCNC3)nc3ccccc32)cc1
6991,2161344,10.1021/acs.jmedchem.1c02048,,,,Inhibition of [35S]MK-499 binding to hERG expressed in HEK293 cells,Cc1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@]4(O)CC(F)(F)[C@H]3C)nc2)c1C#N,"2-[6-[(E)-2-[(3R,3aR,4R,5S,7aS)-6,6-difluoro-7a-hydroxy-3,5-dimethyl-1-oxo-3a,4,5,7-tetrahydro-3H-isobenzofuran-4-yl]vinyl]-3-pyridyl]-6-methyl-benzonitrile",9.0,uM,=,0.9542425094393248,1,O=C1OC[C@@H]2C1CCC[C@@H]2/C=C/c1ccc(-c2ccccc2)cn1
6992,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,"N-(4-Methoxy-benzyl)-N',N'-dimethyl-N-pyridin-2-yl-ethane-1,2-diamine (mepyramine)",12.6182,uM,=,1.1009974067447164,1,c1ccc(CNc2ccccn2)cc1
6993,1552715,10.1016/j.ejmech.2015.12.006,,,,Inhibition of human ERG channel by fluorescence polarization assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCn2cncn2)C[C@H]1OC,"cis-4-Amino-5-chloro-N-[1-(3-(1H-1,2,4-triazol-1-yl)propyl)-3-methoxypiperidin-4-yl]-2-methoxybenzamide",7.711,uM,=,0.8871107031248837,1,O=C(NC1CCN(CCCn2cncn2)CC1)c1ccccc1
6994,1712776,10.1016/j.bmcl.2018.03.056,,,,Inhibition of human ERG expressed in CHOK1 cells at holding potential of -80 mV after 5 mins by patch clamp assay,N#Cc1ccc(O[C@@H]2[C@@H]3[C@H](C[C@H]2N2CCC[C@@H](N)C2)[C@@H]2CC(=O)[C@H]3C2)cc1,"4-[(1R,2R,3aR,4S,7S,7aR)-2-((R)-3-Amino-piperidin-1-yl)-6-oxo-octahydro-4,7-methano-inden-1-yloxy]-benzonitrile",17.0,uM,=,1.230448921378274,1,O=C1C[C@@H]2C[C@H]1[C@H]1[C@@H]2C[C@@H](N2CCCCC2)[C@@H]1Oc1ccccc1
6995,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,COc1nsc(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)n1,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(3-methoxy-1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one",10.3,uM,=,1.0128372247051722,1,O=C1OCc2cc(CCN3CCC4(CC3)CCN(c3ncns3)C4=O)ccc21
6996,1554488,10.1016/j.bmcl.2016.01.049,,,,Inhibition of human ERG using tracer red fluorescent probe,CN(C)Cc1cc(C(=O)N[C@@H]2CCc3ccc(Oc4ccnc5c4CCC(=O)N5)cc3C2)cc(C(F)(F)F)c1.Cl.Cl,"3-((dimethylamino)methyl)-N-{(2R)-[7-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide dihydrochloride",6.3,uM,=,0.7993405494535817,1,O=C1CCc2c(Oc3ccc4c(c3)C[C@H](NC(=O)c3ccccc3)CC4)ccnc2N1
6997,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,OC(c1ccc(CN2CCC3(CC2)OCc2cc(F)ncc23)cc1)c1ccc(F)c(F)c1,"rac-(3,4-difluorophenyl)(4-((6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1'-yl)methyl)phenyl)methanol",0.52,uM,=,-0.2839966563652008,0,c1ccc(Cc2ccc(CN3CCC4(CC3)OCc3ccncc34)cc2)cc1
6998,1568375,10.1016/j.bmcl.2016.02.052,,,,Inhibition of human ERG by patch clamp method,COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCC(N)C2(C)C,"N2-(6-amino-3-methoxy-5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-5-chloro-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine",44.0,uM,=,1.6434526764861874,1,c1ccc(Nc2ccnc(Nc3ccc4c(c3)CCCC4)n2)cc1
6999,943154,10.1016/j.bmcl.2012.12.056,,,,Inhibition of human ERG,COc1cccc2nc(C#Cc3ccccc3)ccc12,5-Methoxy-2-(phenylethynyl)quinoline,61.7,uM,=,1.7902851640332418,1,C(#Cc1ccc2ccccc2n1)c1ccccc1
7000,801100,10.1016/j.bmcl.2011.11.118,,,,Inhibition of human ERG by patch clamp assay,Cc1n[nH]c(=O)cc1-c1ccc(OC2CCN(C3CCC3)CC2)cc1,5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2H-pyridazin-3-one,7.0,uM,=,0.8450980400142568,1,O=c1cc(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)cn[nH]1
7001,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,Cc1nn(C2CCNCC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"5-Chloro-N-[3,5-dimethyl-1-(piperidin-4-yl)-1H-pyrazol-4-yl]-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine",24.0,uM,=,1.380211241711606,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
7002,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CC1(C)Oc2ccc(NC(=O)c3ccc(Cl)cn3)cc2[C@@]2(COC(N)=N2)C12CC2,"US8975415, 221::US9242973, 221",3.25,uM,=,0.5118833609788744,1,O=C(Nc1ccc2c(c1)[C@@]1(COC=N1)C1(CC1)CO2)c1ccccn1
7003,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1csc([C@@]2(CN)[C@@H]3CCN(c4cnc5c(-c6cccc(Cl)c6Cl)n[nH]c5n4)C[C@@H]32)n1,"rac-((1S,6R,7S)-3-(3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-7-(4-methylthiazol-2-yl)-3-azabicyclo[4.1.0]heptan-7-yl)methanamine",0.25,uM,=,-0.6020599913279624,0,c1ccc(-c2n[nH]c3nc(N4CC[C@H]5C(c6nccs6)[C@H]5C4)cnc23)cc1
7004,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,O=[N+]([O-])c1ccc(CCN2CCN(CCc3ccc(-c4ncco4)cc3)CC2)cc1,2-(4-(2-(4-(4-nitrophenethyl)piperazin-1-yl)ethyl)phenyl)oxazole,0.047,uM,=,-1.3279021420642825,0,c1ccc(CCN2CCN(CCc3ccc(-c4ncco4)cc3)CC2)cc1
7005,982810,10.1016/j.ejmech.2013.08.010,,,,Inhibition of human ERG,CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccc(Cl)cc3n2)c1=O,"(R)-6-(3-Aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((7-chloroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione",100.0,uM,=,2.0,1,O=c1cc(N2CCCCC2)[nH]c(=O)n1Cc1ccc2ccccc2n1
7006,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1csc([C@]2(CN)[C@@H]3CCN(c4cnc5c(-c6cccc(Cl)c6Cl)n[nH]c5n4)C[C@@H]32)n1,"((1S,6R,7R)-3-(3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-7-(4-methylthiazol-2-yl)-3-azabicyclo[4.1.0]heptan-7-yl)methanamine",0.058,uM,=,-1.2365720064370629,0,c1ccc(-c2n[nH]c3nc(N4CC[C@H]5C(c6nccs6)[C@H]5C4)cnc23)cc1
7007,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,O=C1OCCN1C1CCN(Cc2ccc(Oc3nc4ccccc4s3)cc2)CC1,3-{1-[4-(Benzothiazol-2-yloxy)benzyl]piperidin-4-yl}oxazolidin-2-one,24.0,uM,=,1.380211241711606,1,O=C1OCCN1C1CCN(Cc2ccc(Oc3nc4ccccc4s3)cc2)CC1
7008,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,O/N=C(\c1ccc(CN2CCC3(CC2)OCc2cc(F)ncc23)cc1)c1ccc(F)c(F)c1,"(E)-(3,4-difluorophenyl)(4-((6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1'-yl)methyl)phenyl)methanone oxime",0.28,uM,=,-0.5528419686577808,0,N=C(c1ccccc1)c1ccc(CN2CCC3(CC2)OCc2ccncc23)cc1
7009,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,"1-(3-Dimethylamino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile",16.6754,uM,=,1.222076260322273,1,c1ccc(C2OCc3ccccc32)cc1
7010,1469020,10.1016/j.bmcl.2014.12.078,,,,Inhibition of human ERG channel,CCOc1nc(NC(=O)C2(NC(=O)c3ccc4c(c3)c(C)c(-c3ccc(F)cn3)n4C3CCCCC3)CCC2)ccc1/C=C/C(=O)O,3-(6-(1-(1-cyclohexyl-2-(5-fluoropyridin-2-yl)-3-methyl-1H-indole-5-carboxamido)cyclobutanecarboxamido)-2-ethoxypyridin-3-yl)acrylic acid,1.4,uM,=,0.1461280356782379,1,O=C(NC1(C(=O)Nc2ccccn2)CCC1)c1ccc2c(c1)cc(-c1ccccn1)n2C1CCCCC1
7011,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CS(=O)(=O)c1ccc(-c2cccc(-n3cc(C(=O)NC4CC4)c(=O)c4cccnc43)c2)cn1,"N-cyclopropyl-1-(3-(6-(methylsulfonyl)pyridin-3-yl)phenyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide",13.6,uM,=,1.1335389083702174,1,O=C(NC1CC1)c1cn(-c2cccc(-c3cccnc3)c2)c2ncccc2c1=O
7012,342119,10.1021/jm051106d,,,,Inhibitory activity against hERG by patch-clamp assay,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCS(C)(=O)=O)c(C)c34)ccc2[nH]1,"4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-6-(3-(methylsulfonyl)propoxy)pyrrolo[2,1-f][1,2,4]triazine",20.0,uM,=,1.3010299956639813,1,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
7013,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N3Cc4ccccc4OC[C@@H]3Cc3ccc(Cl)cc3)CC2)n[nH]1,"(S)-3-(4-(3-(4-chlorobenzyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-1H-1,2,4-triazol-5-amine",22.0,uM,=,1.3424226808222062,1,c1ccc(C[C@H]2COc3ccccc3CN2C2CCN(c3nc[nH]n3)CC2)cc1
7014,2223619,10.1021/acsmedchemlett.2c00294,,,,Inhibition of human ERG by fluorescence polarization assay,N[C@H]1C[C@@H]1c1ccc(Br)cc1,"(1S,2R)-2-(4-bromophenyl)cyclopropanamine",13.0,uM,=,1.1139433523068367,1,c1ccc(C2CC2)cc1
7015,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)CCCCCc1ccc(Cl)cc1,N-Butyl-5-(4-chlorophenyl)-N-ethylpentan-1-amine,2.5,uM,=,0.3979400086720376,1,c1ccccc1
7016,802791,10.1021/ml200030q,,,,Displacement of dofetidine from human Erg,Cc1ccc([C@]2(O)CC[C@H](N3CC[C@@H](NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cc1,N-(2-((R)-1-(trans-4-Hydroxy-4-p-tolylcyclohexyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide,13.2,uM,=,1.1205739312058498,1,O=C(CNC(=O)c1ccccc1)N[C@@H]1CCN(C2CCC(c3ccccc3)CC2)C1
7017,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@](O)(c3ccccc3)CC2)C1,N-{[1-(4-Hydroxy-4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide,10.0,uM,=,1.0,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccccc3)CC2)C1
7018,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)C/C=C/CCc1ccc(Cl)cc1,(E)-N-Butyl-5-(4-chlorophenyl)-N-ethylpent-2-en-1-amine,1.868,uM,=,0.2713768718940745,1,c1ccccc1
7019,773759,10.1021/jm200909u,,,,Inhibition of human hERG,NC(=O)c1cnc(N[C@H](C2CC2)C(F)(F)F)c2c1[nH]c1cc(-c3cnc(N)nc3)ccc12,"7-(2-Aminopyrimidin-5-yl)-1-{[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b]indole-4-carboxamide",22.0,uM,=,1.3424226808222062,1,c1ncc(-c2ccc3c(c2)[nH]c2ccnc(NCC4CC4)c23)cn1
7020,814592,10.1016/j.bmcl.2012.03.049,,,,Inhibition of human ERG expressed in HEK293 cells by voltage clamp electrophysiology assay,Cc1nc(N2CCC(O)CC2)nc2ccc(NC(=O)/C=C/c3ccc(OC(F)(F)F)cc3)cc12,(E)-N-(2-(4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide,3.3,uM,=,0.5185139398778875,1,O=C(/C=C/c1ccccc1)Nc1ccc2nc(N3CCCCC3)ncc2c1
7021,943154,10.1016/j.bmcl.2012.12.056,,,,Inhibition of human ERG,Brc1cccc2nc(C#Cc3ccccn3)ccc12,5-Bromo-2-(pyridin-2-ylethynyl)quinoline,22.7,uM,=,1.3560258571931227,1,C(#Cc1ccc2ccccc2n1)c1ccccn1
7022,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,COc1ccc([C@]2(O)CC[C@@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cc1,N-({1-[4-Hydroxy-4-(4-methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,8.9,uM,=,0.9493900066449128,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccccc3)CC2)C1
7023,2049685,10.1021/acs.jmedchem.0c01411,,,,Inhibition of human ERG by patch clamp method,CN1CCN(C(=O)C2CCN(c3nccc4[nH]c(-c5ccc(F)c(F)c5)nc34)CC2)CC1,"(1-(2-(3,4-Difluorophenyl)-1H-imidazo[4,5-c]pyridin-4-yl)piperidin-4-yl)(4-methylpiperazin-1-yl)methanone",12.0,uM,=,1.0791812460476249,1,O=C(C1CCN(c2nccc3[nH]c(-c4ccccc4)nc23)CC1)N1CCNCC1
7024,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,NC[C@]1(c2ccsc2)[C@@H]2CCN(c3cnc4c(-c5cccnc5C(F)(F)F)n[nH]c4n3)C[C@@H]21,"((1S,6R,7R)-7-(thiophen-3-yl)-3-(3-(2-(trifluoromethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3-azabicyclo[4.1.0]heptan-7-yl)methanamine",5.561,uM,=,0.7451528950769003,1,c1cncc(-c2n[nH]c3nc(N4CC[C@H]5C(c6ccsc6)[C@H]5C4)cnc23)c1
7025,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",N#Cc1ccc(C(=O)Nc2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)nc1,"US8975415, RP196::US9242973, RP196",3.65,uM,=,0.5622928644564748,1,O=C(Nc1ccc2c(c1)C1(COC=N1)C1(CC1)CO2)c1ccccn1
7026,876902,10.1021/jm300896d,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in peak tail current by whole cell patch clamp assay,CC(C)[C@@H](NC(=O)c1ccccc1)C(=O)N1CCC(c2ccc(Cl)cc2)CC1,(R)-N-(1-(4-(4-Chlorophenyl)piperidin-1-yl)-3-methyl-1-oxobutan-2-yl)benzamide,7.0,uM,=,0.8450980400142568,1,O=C(NCC(=O)N1CCC(c2ccccc2)CC1)c1ccccc1
7027,857209,10.1021/jm300286a,,,,Inhibition of human ERG by patch clamp assay,O=C(CCc1ccccc1)c1cc(F)ccc1OCC(O)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,1-(2-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy)-5-fluorophenyl)-3-phenylpropan-1-one,4.84,uM,=,0.6848453616444125,1,O=C(CCc1ccccc1)c1ccccc1OCCCN1CCN(C(c2ccccc2)c2ccccc2)CC1
7028,701983,10.1021/ml100227q,,,,Inhibition of human ERG by patch-clamp method,O=C(O)C1CN(Cc2ccc(-c3cc4cc(Cc5ccccc5)ccc4o3)c(F)c2)C1,1-(4-(5-benzylbenzofuran-2-yl)-3-fluorobenzyl)azetidine-3-carboxylic acid,17.0,uM,=,1.230448921378274,1,c1ccc(Cc2ccc3oc(-c4ccc(CN5CCC5)cc4)cc3c2)cc1
7029,1523572,10.1021/acs.jmedchem.5b01605,,,,Inhibition of human ERG potassium channel by ionworks patch-clamp electrophysiology assay,CS(=O)(=O)c1ccc(-c2cnc3ccc(-c4cccc(S(C)(=O)=O)c4)nn23)cc1,"6-(3-(Methylsulfonyl)phenyl)-3-(4-(methylsulfonyl)phenyl)-imidazo[1,2-b]pyridazine",0.9,uM,=,-0.0457574905606751,0,c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1
7030,1469975,10.1021/jm501021n,,,,Inhibition of human ERG by PDSP screening,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4cccs4)nc31)[C@H](O)[C@@H]2O,"(1S,2R,3S,4R,5S)-2,3-Dihydroxy-N-methyl-4-(6-(methylamino)-2-(thiophen-2-ylethynyl)-9H-purin-9-l)bicyclo[3.1.0]hexane-1-carboxamide",11.5,uM,=,1.0606978403536118,1,C(#Cc1cccs1)c1ncc2ncn([C@H]3CCC4C[C@@H]43)c2n1
7031,1841342,10.1016/j.bmcl.2019.03.029,,,,Inhibition of human ERG by QPatch assay,NC[C@H](Oc1noc2ccc(-c3ccccc3Cl)cc12)c1ccccc1,(R)-2-(5-(2-chlorophenyl)benzo[d]isoxazol-3-yloxy)-2-phenylethanamine,23.0,uM,=,1.3617278360175928,1,c1ccc(COc2noc3ccc(-c4ccccc4)cc23)cc1
7032,1496339,10.1021/ml500505q,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in peak tail current at holding potential of 80 mV to +20 mV by whole cell patch clamp assay,CCC[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1CC[C@H](NC(=O)c2cc(C(F)(F)F)ccc2NC(=O)NCC)C1=O,"2-(3-ethylureido)-N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-propylcyclohexyl)-2-oxopyrrolidin-3-yl)-5-(trifluoromethyl)benzamide",14.0,uM,=,1.146128035678238,1,O=C(N[C@H]1CCN(C2CCCCC2)C1=O)c1ccccc1
7033,2054470,10.1016/j.ejmech.2020.112517,,,,Inhibition of human ERG,CCNC(=O)c1n[nH]c2cc(-c3ccc(-n4cccc(C)c4=O)cc3Cl)ccc12,6-(2-Chloro-4-(3-methyl-2-oxopyridin-1-(2H)-yl)phenyl)-N-ethyl-1H-indazole-3-carboxamide,16.0,uM,=,1.2041199826559248,1,O=c1ccccn1-c1ccc(-c2ccc3cn[nH]c3c2)cc1
7034,462632,10.1016/j.bmcl.2008.01.108,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes,Cc1nc(CN(c2ccccc2)C2CCN(C3(C)CCN(C(=O)c4c(C)cc[n+]([O-])c4C)CC3)CC2)cs1,"2,4-dimethyl-1-oxy-pyridin-3-yl)-{4'-methyl-4-[(2-methyl-thiazol-4-ylmethyl)-phenyl-amino]-[1,4']bipiperidinyl-1'-yl}-methanone",12.2,uM,=,1.0863598306747482,1,O=C(c1ccc[nH+]c1)N1CCC(N2CCC(N(Cc3cscn3)c3ccccc3)CC2)CC1
7035,2151854,10.1016/j.ejmech.2020.112914,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,C[C@]1(COc2ccc(OC(F)(F)F)cc2)CCn2cc([N+](=O)[O-])nc2O1,"(7R)-7-Methyl-2-nitro-7-([4-(trifluoromethoxy)phenoxy]methyl)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine",2.6,uM,=,0.414973347970818,1,c1ccc(OCC2CCn3ccnc3O2)cc1
7036,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1cccc(-c2cccc(C3(C)N=C(N)CCS3)c2)c1,"2-(3'-Methoxybiphenyl-3-yl)-2-methyl-5,6-dihydro-2H-1,3-thiazin-4-amine",11.0,uM,=,1.0413926851582251,1,C1=NC(c2cccc(-c3ccccc3)c2)SCC1
7037,2027427,10.1021/acs.jmedchem.6b01204,,,,Inhibition of human ERG measured after 4 hrs by fluorescence polarization assay,CN1CCCC1CCOc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(O)cc2)cc1.Cl,(Z)-4-(5-Hydroxy-1-(4-(2-(1-methylpyrrolidin-2-yl)ethoxy)-phenyl)-2-phenylpent-1-en-1-yl)phenol Hydrochloride Salt,5.4,uM,=,0.7323937598229685,1,C(=C(c1ccccc1)c1ccc(OCCC2CCCN2)cc1)c1ccccc1
7038,776118,10.1016/j.bmcl.2011.09.074,,,,Inhibition of human ERG by flux assay,Cc1nc2cn(Cc3ccccc3)cc2c(-c2ccc(Cl)cc2Cl)c1CN,"(6-benzyl-4-(2,4-dichlorophenyl)-2-methyl-6H-pyrrolo[3,4-b]pyridin-3-yl)methanamine",14.0,uM,=,1.146128035678238,1,c1ccc(Cn2cc3nccc(-c4ccccc4)c3c2)cc1
7039,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CC(=O)c1ccc(-c2cccc(-n3cc(C(=O)NC(C)C)c(=O)c4cccnc43)c2)cc1,"1-(4'-Acetyl-biphenyl-3-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid isopropylamide",8.95,uM,=,0.951823035315912,1,O=c1ccn(-c2cccc(-c3ccccc3)c2)c2ncccc12
7040,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CC#CCOC(c1ccccc1)c1ccccc1,N-(4-(Benzhydryloxy)but-2-yn-1-yl)-N-ethylheptan-1-amine,0.97,uM,=,-0.0132282657337551,0,c1ccc(Cc2ccccc2)cc1
7041,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccc3[nH]ccc3c2)oc2ccc(O)c(CN3CCC4(COC4)C3)c12,4-(2-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-5-hydroxy-2-(1H-indol-5-yl)-N-methylbenzofuran-3-carboxamide,9.1,uM,=,0.9590413923210936,1,c1cc(CN2CCC3(COC3)C2)c2cc(-c3ccc4[nH]ccc4c3)oc2c1
7042,1985628,10.1021/acsmedchemlett.0c00092,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch-clamp assay,Nc1nc(N2CCC(N3Cc4ccccc4OC[C@@H]3Cc3ccc(Cl)cc3)CC2)n[nH]1,"(S)-3-(4-(3-(4-chlorobenzyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-1H-1,2,4-triazol-5-amine",23.0,uM,=,1.3617278360175928,1,c1ccc(C[C@H]2COc3ccccc3CN2C2CCN(c3nc[nH]n3)CC2)cc1
7043,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(O[C@@H]5CCNC5)c(C)n4)n3)cc12,"N,1-dimethyl-5-[[4-[3-methyl-4-[(3R)-pyrrolidin-3-yl]oxy-pyrazol-1-yl]pyrimidin-2-yl]amino]indazole-3-carboxamide",5.2,uM,=,0.7160033436347992,1,c1cc(-n2cc(O[C@@H]3CCNC3)cn2)nc(Nc2ccc3[nH]ncc3c2)n1
7044,1448459,10.1021/jm5004864,,,,Inhibition of human ERG over-expressed in HEK293 cell membrane by [3H]dofetilide binding assay,CN(C)c1ccc(/C=C/c2c(F)cccc2Cl)cn1,"(E)-5-(2'-Chloro-6'-fluorostyryl)-2-(N,N-dimethylamino)-pyridine",59.5,uM,=,1.7745169657285496,1,C(=C/c1cccnc1)\c1ccccc1
7045,877119,10.1021/jm3013568,,,,Inhibition of human ERG expressed in CHO cells,COc1cccc(-c2cc(NC(=O)CCCN3CCCCC3)[nH]n2)c1,N-[5-(3-Methoxy-phenyl)-2H-pyrazol-3-yl]-4-piperidin-1-yl-butyramide,3.08,uM,=,0.4885507165004443,1,O=C(CCCN1CCCCC1)Nc1cc(-c2ccccc2)n[nH]1
7046,627243,10.1021/jm9016812,,,,Inhibition of human ERG by electrophysiology assay,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(C)cc4)oc3C)c2)cc1,2-((3-((5-methyl-2-p-tolyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,25.9,uM,=,1.413299764081252,1,O=C(NCc1cccc(OCc2coc(-c3ccccc3)n2)c1)Oc1ccccc1
7047,1295005,10.1021/jm4017224,,,,Inhibition of human ERG,Cc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1,"(R)-N-(4-(((2S,5R)-5-((R)-Hydroxy(pyridin-3-yl)methyl)-pyrrolidin-2-yl)methyl)phenyl)-2-methyl-5,6-dihydro-4Hcyclopenta[d]thiazole-4-carboxamide",12.0,uM,=,1.0791812460476249,1,O=C(Nc1ccc(C[C@@H]2CC[C@H](Cc3cccnc3)N2)cc1)[C@@H]1CCc2scnc21
7048,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1,"rac-4-Amino-N-[1-(4-chlorophenyl)ethyl]-1-(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)piperidine-4-carboxamide",7.2,uM,=,0.8573324964312685,1,O=C(NCc1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
7049,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1cccc(OC(F)(F)F)c1)C1c2ccccc2C(=O)N1CCc1ncc(F)cn1,2-(2-(5-Fluoropyrimidin-2-yl)ethyl)-3-oxo-N-(3-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,24.0,uM,=,1.380211241711606,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ncccn1
7050,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,4-[(5-{4-[(Z)-amino(imino)methyl]phenoxy}pentyl)oxy]benzenecarboximidamide,15.7215,uM,=,1.196493980039559,1,c1ccc(OCCCCCOc2ccccc2)cc1
7051,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1ccc(N2CCN(Cc3nc4c5cccc(OC)c5nc(N)n4n3)[C@H](C)C2)cc1,"(R)-7-methoxy-2-((4-(4-methoxyphenyl)-2-methylpiperazin-1-yl)methyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",20.75,uM,=,1.3170181010481117,1,c1ccc(N2CCN(Cc3nc4c5ccccc5ncn4n3)CC2)cc1
7052,2109357,10.1016/j.bmcl.2021.127992,,,,Binding affinity to human ERG,O=C(Oc1ccc(OCc2ccccc2)cc1)N(Cc1ccccc1)S(=O)(=O)c1ccc(Cl)cc1,4-(benzyloxy)phenyl benzyl(4-chlorophenylsulfonyl)carbamate,5.2,uM,=,0.7160033436347992,1,O=C(Oc1ccc(OCc2ccccc2)cc1)N(Cc1ccccc1)S(=O)(=O)c1ccccc1
7053,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,C[C@@]1(c2cc(CNC3(C(F)(F)F)CC3)c(F)cc2F)CCSC(N)=N1,"(S)-4-(2,4-Difluoro-5-(((1-(trifluoromethyl)cyclopropyl)amino)-methyl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine",3.5,uM,=,0.5440680443502757,1,C1=NC(c2cccc(CNC3CC3)c2)CCS1
7054,759504,10.1016/j.bmcl.2011.06.015,,,,Inhibition of human ERG by automated patch clamp assay,O=C(/C=C/c1ccc2c(c1)CN(CCC1CCCCC1)C2)NO,3-(2-(2-cyclohexylethyl)isoindolin-5-yl)-N-hydroxyacrylamide,22.0,uM,=,1.3424226808222062,1,c1ccc2c(c1)CN(CCC1CCCCC1)C2
7055,337984,10.1016/j.bmcl.2005.11.052,,,,Binding to human ERG potassium channel,C[C@@H](c1ccc(-c2ccc(O)nc2)cc1)[C@H](N)C(=O)N1CC[C@H](F)C1.O=C(O)C(F)(F)F,"(2S,3S)-1-((S)-3-fluoropyrrolidin-1-yl)-1-oxo-3-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)butan-2-aminium 2,2,2-trifluoroacetate",8.3,uM,=,0.919078092376074,1,O=C(CCc1ccc(-c2cccnc2)cc1)N1CCCC1
7056,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)CC#CCc1ccc(Cl)cc1,N-Butyl-4-(4-chlorophenyl)-N-ethylbut-2-yn-1-amine,2.654,uM,=,0.4239009185284167,1,c1ccccc1
7057,470090,10.1016/j.bmcl.2008.02.050,,,,Inhibition of human ERG,CS(=O)(=O)c1ccc(-c2noc([C@@H](CC3CC3)[C@H](N)C(F)=C3CCCC3)n2)c(Cl)c1.O=C(O)C(F)(F)F,"(2S,3S)-3-(3-(2-chloro-4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-aminium 2,2,2-trifluoroacetate",7.1,uM,=,0.8512583487190752,1,C(C[C@H](CC1CC1)c1nc(-c2ccccc2)no1)=C1CCCC1
7058,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,Oc1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1,"4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol",0.643,uM,=,-0.1917890270757779,0,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
7059,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c(CNC2CCCC2)nn(-c2ncccc2Cl)c1-c1ccc(Cl)nc1,N-((1-(3-chloropyridin-2-yl)-5-(6-chloropyridin-3-yl)-4-methyl-1H-pyrazol-3-yl)methyl)cyclopentanamine,2.7,uM,=,0.4313637641589873,1,c1ccc(-n2nc(CNC3CCCC3)cc2-c2cccnc2)nc1
7060,1697113,10.1021/acs.jmedchem.7b00932,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in peak tail current amplitude by path clamp method,CC[N+]1(C)CCc2c(sc(NC(=O)Nc3ccc(Cl)cc3)c2C(N)=O)C1.[I-],"3-Carbamoyl-2-[3-(4-chlorophenyl)ureido]-6-ethyl-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-ium Iodide",3.38,uM,=,0.5289167002776547,1,O=C(Nc1ccccc1)Nc1cc2c(s1)C[NH2+]CC2
7061,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,Cc1nn(C2CCN(CCO)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"2-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]ethanol",9.3,uM,=,0.9684829485539352,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
7062,344972,10.1016/j.bmcl.2006.01.030,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,N[C@H](C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1ccccc1)C1CC1,"(S)-2-amino-2-cyclopropyl-1-((S)-4-(2,5-difluorophenyl)-2-phenyl-2H-pyrrol-1(5H)-yl)ethanone",3.5,uM,=,0.5440680443502757,1,O=C(CC1CC1)N1CC(c2ccccc2)=C[C@H]1c1ccccc1
7063,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(Cl)c4)n2CCO3)ccn1,"3-(3-chlorophenoxy)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",0.931,uM,=,-0.0310503190186574,0,c1ccc(Oc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
7064,2165889,10.1021/acsmedchemlett.2c00029,,,,Inhibition of human ERG,Cc1cnc(Nc2ccnn2C)nc1-c1cc2n(c1)C(=O)N([C@H](CO)c1cccc(Cl)c1)C2,"(S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-6-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one",0.014,uM,=,-1.853871964321762,0,O=C1N(Cc2ccccc2)Cc2cc(-c3ccnc(Nc4ccn[nH]4)n3)cn21
7065,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)CC#CC#Cc1ccc(Cl)cc1,"N-Butyl-5-(4-chlorophenyl)-N-ethylpenta-2,4-diyn-1-amine",9.929,uM,=,0.996905510695666,1,c1ccccc1
7066,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@H](c3cccnc3)CC2)C1,N-(2-oxo-2-(1-(4-(pyridin-3-yl)cyclohexyl)azetidin-3-ylamino)ethyl)-3-(trifluoromethyl)benzamide,3.8,uM,=,0.5797835966168101,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3cccnc3)CC2)C1
7067,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,2-Chloro-10-[3-(4-methyl-piperazin-1-yl)-propyl]-10H-phenothiazine (Prochlorperazine),1.8481,uM,=,0.2667254670319199,1,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1
7068,625756,10.1016/j.bmcl.2010.03.035,,,,Inhibition of human ERG by FLIPR assay,CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](NC(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2=O)[C@H](CS(=O)(=O)c2ccccc2)C1,"N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-3,5-bis(trifluoromethyl)benzamide",4.0,uM,=,0.6020599913279624,1,O=C(N[C@H]1CCN([C@H]2CCCC[C@H]2CS(=O)(=O)c2ccccc2)C1=O)c1ccccc1
7069,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CN1C[C@H](Cc2ccc(Cl)cc2)N(C2CCN(c3n[nH]c(N)n3)CC2)Cc2cc(Cl)ccc21,"(S)-3-(4-(7-chloro-3-(4-chlorobenzyl)-1-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-4(5H)-yl)piperidin-1-yl)-1H-1,2,4-triazol-5-amine",0.8,uM,=,-0.0969100130080563,0,c1ccc(C[C@H]2CNc3ccccc3CN2C2CCN(c3nc[nH]n3)CC2)cc1
7070,2027391,10.1021/acs.jmedchem.6b01122,,,,Inhibition of human ERG expressed in CHO cells by whole-cell patch clamp assay,C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2F)CCN1c1nccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1,"2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide",8.0,uM,=,0.9030899869919436,1,O=C(NC1C2CC3CC(C2)CC1C3)c1ccnc(N2CCN(c3ccccc3)CC2)n1
7071,966750,10.1016/j.bmcl.2013.04.074,,,,Inhibition of human ERG current by patch clamp assay,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,"1-Cyclopropyl-6-fluoro-8-methoxy-7-(4aS,7aS)-octahydro-pyrrolo[3,4-b]pyridin-6-yl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid",129.0,uM,=,2.110589710299249,1,O=c1ccn(C2CC2)c2cc(N3C[C@@H]4CCCN[C@@H]4C3)ccc12
7072,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NC/C=C/c3ccccn3)(CC1)CO2,"(R,E)-3-fluoro-4-hydroxy-4-((4-(3-(pyridin-2-yl)allylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",0.064,uM,=,-1.193820026016113,0,O=c1ccc2nccc3c2n1CC3CC12CCC(NC/C=C/c3ccccn3)(CC1)CO2
7073,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(O[C@H]5CNC[C@H]5F)c(C)n4)n3)cc12,"5-[[4-[4-[(3S,4R)-4-fluoropyrrolidin-3-yl]oxy-3-methyl-pyrazol-1-yl]pyrimidin-2-yl]amino]-N,1-dimethyl-indazole-3-carboxamide",3.7,uM,=,0.568201724066995,1,c1cc(-n2cc(O[C@@H]3CCNC3)cn2)nc(Nc2ccc3[nH]ncc3c2)n1
7074,1894872,10.1016/j.bmc.2019.07.044,,,,Inhibition of human ERG in HEK293 cells assessed as effect on QT interval,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Carfilzomib,92.1,uM,=,1.964259630196849,1,O=C(CN1CCOCC1)N[C@@H](CCc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)C1CO1
7075,945471,10.1021/ml300372f,,,,Inhibition of human ERG assessed as decrease in tail current amplitude measured after 5 mins by whole cell patch clamp technique,CCOC(=O)N1CCC(C)(CN2CC[C@H](N3C(=O)Cc4ccccc43)C2)CC1,(S)-ethyl 4-methyl-4-((3-(2-oxoindolin-1-yl)pyrrolidin-1-yl)methyl)piperidine-1-carboxylate,3.5,uM,=,0.5440680443502757,1,O=C1Cc2ccccc2N1[C@H]1CCN(CC2CCNCC2)C1
7076,972740,10.1021/ml400197u,,,,Binding affinity to human ERG expressed in CHO cells by IonWorks assay,CC(=O)Nc1cc(Nc2cc(NC3CCC3)n3ncc(C#N)c3n2)ccc1C,"N-[5-[[3-cyano-7-(cyclobutylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-methyl-phenyl]acetamide",11.0,uM,=,1.0413926851582251,1,c1ccc(Nc2cc(NC3CCC3)n3nccc3n2)cc1
7077,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.FCCOc1cccc(CCN2CCC(CCc3ccccc3)CC2)c1,1-(3-(2-Fluoroethoxy)phenethyl)-4-phenethylpiperidine hydrochloride,0.41,uM,=,-0.3872161432802645,0,c1ccc(CCC2CCN(CCc3ccccc3)CC2)cc1
7078,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,N#Cc1ccc2c(c1)CN(C1CCN(c3n[nH]c(N)n3)CC1)[C@@H](Cc1ccc(Cl)cc1)CO2,"(S)-4-(1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl)-3-(4-chlorobenzyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-7-carbonitrile",23.0,uM,=,1.3617278360175928,1,c1ccc(C[C@H]2COc3ccccc3CN2C2CCN(c3nc[nH]n3)CC2)cc1
7079,875038,10.1021/jm300573d,,,,Inhibition of human ERG,CC(=O)Nc1ccc(CCN2CCC(COc3nc4ccccc4c4cn(C)cc34)CC2)cc1,"N-(4-(2-(4-((2-methyl-2H-pyrrolo[3,4-c]quinolin-4-yloxy)methyl)piperidin-1-yl)ethyl)phenyl)acetamide",0.02,uM,=,-1.6989700043360187,0,c1ccc(CCN2CCC(COc3nc4ccccc4c4c[nH]cc34)CC2)cc1
7080,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCc1oc(CCc2cc(N3CCOCC3)cc(NCC#N)n2)nc1C,2-(6-(2-(5-ethyl-4-methyloxazol-2-yl)ethyl)-4-morpholinopyridin-2-ylamino)acetonitrile,4.3,uM,=,0.6334684555795865,1,c1cc(N2CCOCC2)cc(CCc2ncco2)n1
7081,1745661,10.1016/j.bmcl.2017.10.010,,,,Inhibition of human ERG by Qpatch clamp assay,Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,(-)-4-((6-amino-2-(4-fluorophenyl)cyclohex-2-enyl)methylamino)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide hydrochloride,4.6,uM,=,0.6627578316815741,1,O=S(=O)(Nc1cscn1)c1ccc(NC[C@H]2CCCC=C2c2ccccc2)cc1
7082,1758787,10.1021/acsmedchemlett.7b00188,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch assay,CCO/N=C/c1ccc(OCCCCCN2CCN(c3ccnc(N)c3)S2(=O)=O)cc1,"4-{5-[5-(2-Amino-pyridin-4-yl)-1,1-dioxo-1lambda(6)-[1,2,5]thiadiazolidin-2-yl]-pentyloxy}-benzaldehyde-ethyl-oxime",9.0,uM,=,0.9542425094393248,1,O=S1(=O)N(CCCCCOc2ccccc2)CCN1c1ccncc1
7083,746192,10.1016/j.bmcl.2011.03.007,,,,Inhibition of human ERG by patch clamp assay,CC(C)OC(=O)N1CCC(Oc2ncnc3c2cnn3-c2ccc(S(C)(=O)=O)cc2F)CC1,"isopropyl 4-(1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)piperidine-1-carboxylate",3.0,uM,=,0.4771212547196624,1,c1ccc(-n2ncc3c(OC4CCNCC4)ncnc32)cc1
7084,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(C(O)C(F)(F)F)cc(C(F)(F)F)c2)CC1,"(4-(3-(2,2,2-trifluoro-1-hydroxyethyl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",0.06,uM,=,-1.2218487496163564,0,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2ccccc2)CC1
7085,1448459,10.1021/jm5004864,,,,Inhibition of human ERG over-expressed in HEK293 cell membrane by [3H]dofetilide binding assay,CNc1ccc(/C=C/c2c(F)cccc2F)cc1,"(E)-4-(2',6'-difluorostyryl)-N-methylaniline",49.1,uM,=,1.6910814921229684,1,C(=C/c1ccccc1)\c1ccccc1
7086,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CO/N=C(/c1ccc(CN2CCC3(CC2)OCc2cc(F)ncc23)cc1)c1ccc(F)c(F)c1,"(Z)-(3,4-difluorophenyl)(4-((6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1'-yl)methyl)phenyl)methanone O-methyl oxime",0.25,uM,=,-0.6020599913279624,0,N=C(c1ccccc1)c1ccc(CN2CCC3(CC2)OCc2ccncc23)cc1
7087,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,C[C@@]1(c2cc(CNCC3CC3)c(F)cc2F)CCSC(N)=N1,"(S)-4-(5-(((Cyclopropylmethyl)amino)methyl)-2,4-difluorophenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine",33.0,uM,=,1.5185139398778875,1,C1=NC(c2cccc(CNCC3CC3)c2)CCS1
7088,857323,10.1021/jm200900q,,,,Displacement of [3H]astemizole from human ERG potassium channel,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(Cc4ccccn4)CC3)cc2C2=CCCCC2)n1,4-Cyano-1H-imidazole-2-carboxylic Acid[2-Cyclohex-1-enyl-4-(1-pyridin-2-ylmethyl-piperidin-4-yl)-phenyl]-amide,7.7,uM,=,0.8864907251724818,1,O=C(Nc1ccc(C2CCN(Cc3ccccn3)CC2)cc1C1=CCCCC1)c1ncc[nH]1
7089,543516,10.1016/j.bmcl.2009.01.008,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells,Cc1nnc(C(C)C)n1C1CCN(C(C)C[C@H](NC(=O)C2CCC(F)(F)CC2)c2ccccc2)CC1.Cl,"4,4-difluoro-N-((1S)-3-(4-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl)-1-phenylbutyl)cyclohexanecarboxamide",2.1,uM,=,0.3222192947339193,1,O=C(N[C@@H](CCN1CCC(n2cnnc2)CC1)c1ccccc1)C1CCCCC1
7090,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N3Cc4cc(Cl)ccc4OC[C@@H]3Cc3ccc(Cl)cc3)CC2)n[nH]1,"(S)-3-(4-(7-chloro-3-(4-chlorobenzyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-1H-1,2,4-triazol-5-amine",6.7,uM,=,0.8260748027008264,1,c1ccc(C[C@H]2COc3ccccc3CN2C2CCN(c3nc[nH]n3)CC2)cc1
7091,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc2c1nc(N)n1nc(CN3CCN(c4cnc(C)s4)C[C@H]3C)nc21,"(R)-7-methoxy-2-((2-methyl-4-(2-methylthiazol-5-yl)piperazin-1-yl)methyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",17.88,uM,=,1.252367514459899,1,c1ccc2c(c1)ncn1nc(CN3CCN(c4cncs4)CC3)nc21
7092,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc2c1nc(N)n1nc(CN3CCN(c4nsnc4Cl)C[C@H]3C)nc21,"(R)-2-((4-(4-chloro-1,2,5-thiadiazol-3-yl)-2-methylpiperazin-1-yl)methyl)-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",24.33,uM,=,1.3861421089308186,1,c1ccc2c(c1)ncn1nc(CN3CCN(c4cnsn4)CC3)nc21
7093,1927981,10.1021/acsmedchemlett.6b00117,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,Cc1noc(C)c1-c1nc(NCc2ccccn2)c2c(-c3ccccc3)cccc2n1,"2-(3,5-dimethylisoxazol-4-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine",3.1,uM,=,0.4913616938342727,1,c1ccc(-c2cccc3nc(-c4cnoc4)nc(NCc4ccccn4)c23)cc1
7094,634158,10.1021/jm100044a,,,,Inhibition of human ERG by patch clamp assay,Cn1nccc1-c1cc(NC(=O)c2ccc(F)cc2F)ccc1OCCN1CCOCC1,"2,4-Difluoro-N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide",4.1,uM,=,0.6127838567197355,1,O=C(Nc1ccc(OCCN2CCOCC2)c(-c2ccn[nH]2)c1)c1ccccc1
7095,1891116,10.1016/j.bmcl.2019.03.006,,,,Inhibition of human ERG,CCCN(CCC)[C@H](c1ccccn1)[C@@H](c1ccccn1)N(CCC)CCC,"(1S,2S)-N1,N1,N2,N2-tetrapropyl-1,2-di(pyridin-2-yl)ethane-1,2-diamine",6.3,uM,=,0.7993405494535817,1,c1ccc(CCc2ccccn2)nc1
7096,1765513,10.1021/acs.jmedchem.8b01040,,,,Inhibition of human ERG by automated patch clamp assay,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,ASCIMINIB,26.0,uM,=,1.414973347970818,1,O=C(Nc1ccccc1)c1cnc(N2CCCC2)c(-c2cc[nH]n2)c1
7097,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccc(O)c(F)c2)oc2ccc(O)c(CN3CCC4(COC4)C3)c12,4-(2-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-2-(3-fluoro-4-hydroxyphenyl)-5-hydroxy-N-methylbenzofuran-3-carboxamide,2.7,uM,=,0.4313637641589873,1,c1ccc(-c2cc3c(CN4CCC5(COC5)C4)cccc3o2)cc1
7098,2228478,10.1021/acs.jmedchem.2c00794,,,,Inhibition of human ERK potassium channel by automated patch clamp electrophysiology,CCCCNC(=O)c1c(O)c2sccc2n(Cc2ccccc2)c1=O,"4-benzyl-N-butyl-7-hydroxy-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-6-carboxamide",23.45,uM,=,1.370142847051102,1,O=c1ccc2sccc2n1Cc1ccccc1
7099,1567397,10.1016/j.ejmech.2016.02.014,,,,Displacement of [3H]dofetilide from human ERG channel expressed in HEK293 cells after 60 mins by liquid scintillation counting method,Oc1cccc2c1CNC(CN1CCC3(CCc4ccccc43)CC1)C2,"3-{(2,3-dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)methyl}-1,2,3,4-tetrahydroisoquinolin-8-ol",0.94,uM,=,-0.0268721464003013,0,c1ccc2c(c1)CNC(CN1CCC3(CCc4ccccc43)CC1)C2
7100,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,CC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)c2C)CC1,"1-[4-(4-{[5-Chloro-4-(imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",27.0,uM,=,1.4313637641589874,1,c1ccn2c(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)cnc2c1
7101,449746,10.1016/j.bmcl.2007.08.049,,,,Inhibition of human ERG,CN(C)C(=O)[C@@H](c1ccc(-c2ccc(F)cc2)cc1)[C@H](N)C(=O)N1CC[C@H](F)C1,"(2S,3S)-3-amino-2-(4'-fluoro-biphenyl-4-yl)-4-((S)-3-fluoro-pyrrolidin-1-yl)-N,N-dimethyl-4-oxo-butyramide",4.6,uM,=,0.6627578316815741,1,O=C(CCc1ccc(-c2ccccc2)cc1)N1CCCC1
7102,2024260,10.1016/j.bmcl.2020.127686,,,,Inhibition of human ERG,COc1cc(NC(=O)c2cccc(C(F)(F)F)n2)cc2cn(C3CCN(C)CC3)nc12,N-[7-methoxy-2-(1-methyl-4-piperidyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide,6.9,uM,=,0.8388490907372553,1,O=C(Nc1ccc2nn(C3CCNCC3)cc2c1)c1ccccn1
7103,1630057,10.1016/j.ejmech.2016.07.038,,,,Inhibition of recombinant human ERG expressed in CHOK1 cells at -80 mV holding potential after 2 mins by patch clamp assay,O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1ccco1,N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)furan-2-carboxamide,2.11,uM,=,0.3242824552976926,1,O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1ccco1
7104,2161344,10.1021/acs.jmedchem.1c02048,,,,Inhibition of [35S]MK-499 binding to hERG expressed in HEK293 cells,CC[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(O)CC1(F)F,"2-[6-[(E)-2-[(3R,3aR,4R,5S,7aS)-5-ethyl-6,6-difluoro-7a-hydroxy-3-methyl-1-oxo-3a,4,5,7-tetrahydro-3H-isobenzofuran-4-yl]vinyl]-3-pyridyl]benzonitrile",17.0,uM,=,1.230448921378274,1,O=C1OC[C@@H]2C1CCC[C@@H]2/C=C/c1ccc(-c2ccccc2)cn1
7105,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1cccc(-c2cccc(C3(C)N=C(N)CS3)c2)c1,"2-(3'-Methoxybiphenyl-3-yl)-2-methyl-2,5-dihydrothiazol-4-amine",9.2,uM,=,0.9637878273455552,1,C1=NC(c2cccc(-c3ccccc3)c2)SC1
7106,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCOc2ccc(-c3ccncc3)cc2C1,"N-(3,4-dichlorophenyl)-7-(pyridin-4-yl)-2,3-dihydrobenzo[f][1,4]oxazepine-4(5H)-carboxamide",2030.0,uM,=,3.307496037913213,1,O=C(Nc1ccccc1)N1CCOc2ccc(-c3ccncc3)cc2C1
7107,1695906,10.1016/j.bmcl.2017.08.030,,,,Inhibition of human ERG,O=C(c1ccccc1)N1CCc2oc(-c3ccc(F)cn3)nc2C1,"{2-(5-Fluoropyridin-2-yl)-6,7-dihydro[1,3]oxazolo[4,5-c]pyridin-5(4H)-yl}(phenyl)methanone",64.0,uM,=,1.806179973983887,1,O=C(c1ccccc1)N1CCc2oc(-c3ccccn3)nc2C1
7108,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1ccc(C2(c3cccc(-c4cccnc4)c3)CC(OC)C(N)=N2)cc1,"rac-4-Methoxy-2-(4-methoxyphenyl)-2-(3-(pyridin-3-yl)phenyl)-3,4-dihydro-2H-pyrrol-5-amine",2.4,uM,=,0.380211241711606,1,C1=NC(c2ccccc2)(c2cccc(-c3cccnc3)c2)CC1
7109,1622549,10.1016/j.bmcl.2016.10.039,,,,Inhibition of human ERG,CC1(C)c2cc(C3CCN(CC4CCOCC4)CC3)ccc2C(=O)c2c1[nH]c1cc(C#N)ccc21,"6,6-Dimethyl-11-oxo-8-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile",2.65,uM,=,0.4232458739368078,1,O=C1c2ccc(C3CCN(CC4CCOCC4)CC3)cc2Cc2[nH]c3ccccc3c21
7110,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1ccc(C2(c3cccc(-c4cccnc4)c3)CC(OC)C(N)=N2)cc1,"rac-4-Methoxy-2-(4-methoxyphenyl)-2-(3-(pyridin-3-yl)phenyl)-3,4-dihydro-2H-pyrrol-5-amine",2.5,uM,=,0.3979400086720376,1,C1=NC(c2ccccc2)(c2cccc(-c3cccnc3)c2)CC1
7111,2186534,10.1021/acs.jmedchem.1c01132,,,,Inhibition of hERG ion channel incubated for 3 hrs by fluorescence polarization assay,CC1(N)CCN(c2cnc3c(-c4cccc(Cl)c4Cl)n[nH]c3n2)CC1,"1-(3-(2,3-Dichlorophenyl)-1H-pyrazolo[3,4-b]-pyrazin-6-yl)-4-methylpiperidin-4-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc(-c2n[nH]c3nc(N4CCCCC4)cnc23)cc1
7112,1927981,10.1021/acsmedchemlett.6b00117,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,COc1ncc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)cn1,2-(2-methoxypyrimidin-5-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine,1.9,uM,=,0.2787536009528289,1,c1ccc(-c2cccc3nc(-c4cncnc4)nc(NCc4ccccn4)c23)cc1
7113,849439,10.1016/j.bmc.2012.07.046,,,,Inhibition of human ERG,Cn1c(=O)c2c(nc(N3CCC[C@@H](N)C3)n2Cc2ccccc2Cl)c2ccc(C#N)cc21,"2-[(3R)-3-Aminopiperidin-1-yl]-3-(2-chlorobenzyl)-5-methyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]quinoline-7-carbonitrile",1.2,uM,=,0.0791812460476248,1,O=c1[nH]c2ccccc2c2nc(N3CCCCC3)n(Cc3ccccc3)c12
7114,2161344,10.1021/acs.jmedchem.1c02048,,,,Inhibition of [35S]MK-499 binding to hERG expressed in HEK293 cells,C[C@@H]1[C@@H](C)[C@@H]2CNC[C@@]23C(=O)O[C@H](C)[C@H]3[C@H]1/C=C/c1ccc(-c2ccccc2C#N)cn1,"2-[6-[(E)-2-[(3R,3aS,4S,5R,6R,6aS,9aR)-3,5,6-trimethyl-1-oxo-3a,4,5,6,6a,7,8,9-octahydro-3H-furo[3,4-d]isoindol-4-yl]vinyl]-3-pyridyl]benzonitrile",1.3,uM,=,0.1139433523068367,1,O=C1OC[C@H]2[C@@H](/C=C/c3ccc(-c4ccccc4)cn3)CC[C@@H]3CNC[C@@]132
7115,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,CCOc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"1-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3-ethoxy-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",6.4,uM,=,0.8061799739838872,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
7116,796234,10.1016/j.bmcl.2011.10.115,,,,Inhibition of human Erg by whole cell patch clamp electrophysiology,CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,1-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)-N-methyl-N-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-amine,0.029,uM,=,-1.537602002101044,0,c1ccc(Cn2c(N3CCC(NCC4CCOCC4)CC3)nc3ccccc32)cc1
7117,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CC4(CCO4)C3)c12,4-((1-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)-5-hydroxy-2-(4-hydroxyphenyl)-N-methylbenzofuran-3-carboxamide Formate,21.6,uM,=,1.334453751150931,1,c1ccc(-c2cc3c(CN4CC5(CCO5)C4)cccc3o2)cc1
7118,2223619,10.1021/acsmedchemlett.2c00294,,,,Inhibition of human ERG by fluorescence polarization assay,N[C@H]1C[C@@H]1c1cc(F)c(Br)cc1F,"(+/-)-trans-2-(4-Bromo-2,5-difluorophenyl)cyclopropylamine",7.7,uM,=,0.8864907251724818,1,c1ccc(C2CC2)cc1
7119,1817367,10.1021/acs.jmedchem.8b01857,,,,Inhibition of human ERG expressed in HEK293 cells after 5 mins by patch clamp assay,Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)[C@H](F)CC1,"US8614206, 139",2.7,uM,=,0.4313637641589873,1,O=C(Nc1cn[nH]c1N1CCCCCC1)c1csc(-c2ccccc2)n1
7120,744151,10.1016/j.bmcl.2010.12.086,,,,Inhibition of human ERG by patch clamp technique,Clc1cnc(N2CCC([C@H]3C[C@H]3CCOc3ccc(-n4ccnn4)cn3)CC2)nc1,"2-(4-((1R,2S)-2-(2-(5-(1H-1,2,3-triazol-1-yl)pyridin-2-yloxy)ethyl)cyclopropyl)piperidin-1-yl)-5-chloropyrimidine",44.0,uM,=,1.6434526764861874,1,c1cnc(N2CCC([C@H]3C[C@H]3CCOc3ccc(-n4ccnn4)cn3)CC2)nc1
7121,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,COC[C@H](C)Oc1cc(Oc2ncc(C(=O)N3CCC3)cc2Cl)cc(C(=O)Nc2cnc(C)cn2)c1,(S)-3-(5-(azetidine-1-carbonyl)-3-chloropyridin-2-yloxy)-5-(1-methoxypropan-2-yloxy)-N-(5-methylpyrazin-2-yl)benzamide,18.0,uM,=,1.255272505103306,1,O=C(Nc1cnccn1)c1cccc(Oc2ccc(C(=O)N3CCC3)cn2)c1
7122,2151854,10.1016/j.ejmech.2020.112914,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,CC1(COc2ccc(OC(F)(F)F)cc2)CCn2cc([N+](=O)[O-])nc2O1,"7-Methyl-2-nitro-7-{[4-(trifluoromethoxy)phenoxy]methyl}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine",3.8,uM,=,0.5797835966168101,1,c1ccc(OCC2CCn3ccnc3O2)cc1
7123,766845,10.1021/jm200682b,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccc5c(c4)OCCO5)c3C)CC2)c1C.Cl.Cl,"1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-1-yl)propyl)-2,5-dimethyl-1H-imidazole-4-carboxamide dihydrochloride",8.7,uM,=,0.9395192526186184,1,O=C(NCCCN1CCN(c2ccccc2)CC1)c1cn(-c2ccc3c(c2)OCCO3)cn1
7124,1990613,10.1016/j.bmcl.2020.127249,,,,Inhibition of human ERG,O=C(Nc1ncc(Cl)s1)/C(=N/N1CCCC1)c1ccc(S(=O)(=O)C2CC2)cc1,(E)-N-(5-chlorothiazol-2-yl)-2-(4-(cyclopropylsulfonyl)phenyl)-2-(pyrrolidin-1-ylimino)acetamide,16.7,uM,=,1.2227164711475833,1,O=C(Nc1nccs1)/C(=N/N1CCCC1)c1ccc(S(=O)(=O)C2CC2)cc1
7125,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,COc1ccc([C@H]2CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cc1,N-({1-[4-(4-Methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,3.0,uM,=,0.4771212547196624,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccccc3)CC2)C1
7126,2023418,10.1016/j.bmcl.2020.127663,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch clamp assay,Cc1nnn(Cc2cc(C(F)(F)F)ccc2/C=C/C(=O)N2CCC(C#N)CC2)n1,(E)-1-(3-(2-((5-methyl-2H-tetrazol-2-yl)methyl)-4-(trifluoromethyl)phenyl)acryloyl)piperidine-4-carbonitrile,25.0,uM,=,1.3979400086720375,1,O=C(/C=C/c1ccccc1Cn1ncnn1)N1CCCCC1
7127,1496339,10.1021/ml500505q,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in peak tail current at holding potential of 80 mV to +20 mV by whole cell patch clamp assay,CCC[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3ccc(C(F)(F)F)cc23)C1=O,"(S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-propylcyclohexyl)-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-2-one",1.8,uM,=,0.255272505103306,1,O=C1[C@@H](Nc2ncnc3ccccc23)CCN1C1CCCCC1
7128,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@](F)(c3ccccc3)CC2)C1,cis-N-{[1-(4-Fluoro-4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide,3.3,uM,=,0.5185139398778875,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccccc3)CC2)C1
7129,2115956,10.1021/acsmedchemlett.1c00236,,,,Inhibition of hERG (unknown origin),CC[C@@H](NC(=O)c1ccc(OC)nc1)[C@H]1CC[C@@H](c2ccnc(OC)c2C(F)F)CC1,"N-((R)-1-((1s,4S)-4-(3-(difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide",17.4,uM,=,1.2405492482825995,1,O=C(NC[C@H]1CC[C@@H](c2ccncc2)CC1)c1cccnc1
7130,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCOc1ccccn1,3-Oxo-2-(2-(pyridin-2-yloxy)ethyl)-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,4.9,uM,=,0.6901960800285137,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCOc1ccccn1
7131,1498989,10.1021/acs.jmedchem.5b00114,,,,Inhibition of human ERG by IonWorks electrophysiology,O=C(NCCCNc1nc2ccccc2[nH]1)c1cc(Cl)cc(Cl)c1,"N-[3-[(1H-Benz[d]imidazol-2-yl)amino]propyl]-3,5-dichlorobenzamide",1.17,uM,=,0.0681858617461616,1,O=C(NCCCNc1nc2ccccc2[nH]1)c1ccccc1
7132,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NC/C=C/c3ccc(F)cc3)(CC1)CO2,"(R,E)-3-fluoro-4-((4-(3-(4-fluorophenyl)allylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",0.064,uM,=,-1.193820026016113,0,O=c1ccc2nccc3c2n1CC3CC12CCC(NC/C=C/c3ccccc3)(CC1)CO2
7133,2232362,10.1016/j.bmcl.2022.128648,,,,Inhibition of human ERG by Ionworks electrophysiology assay,COc1ccc2ncc(=O)n(CCN[C@H]3CC[C@H]4[C@H](C3)OC(=O)N4c3ccc4c(n3)NC(=O)CO4)c2n1,"6-((3aS,6S,7aS)-6-((2-(6-methoxy-3-oxopyrido[2,3-b]pyrazin-4(3H)-yl)ethyl)amino)-2-oxohexahydrobenzo[d]oxazol-3(2H)-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",7.0,uM,=,0.8450980400142568,1,O=C1COc2ccc(N3C(=O)O[C@H]4C[C@@H](NCCn5c(=O)cnc6cccnc65)CC[C@@H]43)nc2N1
7134,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,COc1ccccc1CCN1CCC(CCc2ccccc2OCCF)CC1.Cl,4-(2-(2-Fluoroethoxy)phenethyl)-1-(2-methoxyphenethyl)piperidine hydrochloride,0.43,uM,=,-0.3665315444204134,0,c1ccc(CCC2CCN(CCc3ccccc3)CC2)cc1
7135,1580962,10.1021/acsmedchemlett.6b00018,,,,Binding affinity to human ERG by radioligand binding assay,CC(C)(C)c1cc(NC(=O)c2cnc3cc(Oc4ncnc5c4CNC5)ccn23)no1,"N-(5-(tert-butyl)isoxazol-3-yl)-7-((6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)oxy)imidazo[1,2-a]pyridine-3-carboxamide",9.2,uM,=,0.9637878273455552,1,O=C(Nc1ccon1)c1cnc2cc(Oc3ncnc4c3CNC4)ccn12
7136,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CC1(C)Oc2ccc(NC(=O)c3cnc(C(F)F)cn3)cc2[C@@]2(COC(N)=N2)C12CC2,"US8975415, 224::US9242973, 224",15.1,uM,=,1.1789769472931697,1,O=C(Nc1ccc2c(c1)[C@@]1(COC=N1)C1(CC1)CO2)c1cnccn1
7137,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@](O)(c3ccc(F)cc3)CC2)C1,N-({1-[4-(4-Fluoro-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,2.8,uM,=,0.4471580313422192,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccccc3)CC2)C1
7138,945471,10.1021/ml300372f,,,,Inhibition of human ERG assessed as decrease in tail current amplitude measured after 5 mins by whole cell patch clamp technique,CCOC(=O)N1[C@@H]2CC[C@H]1C[C@H](CN1CC[C@H](N3C(=O)Cc4ccccc43)C1)C2,Exo-ethyl 3-(((S)-3-(2-oxoindolin-1-yl)pyrrolidin-1-yl)methyl)-8-azabicyclo[3.2.1]octane-8-carboxylate,2.4,uM,=,0.380211241711606,1,O=C1Cc2ccccc2N1[C@H]1CCN(C[C@@H]2C[C@H]3CC[C@@H](C2)N3)C1
7139,1295005,10.1021/jm4017224,,,,Inhibition of human ERG,Nc1nc(CC(=O)Nc2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)cs1,"2-(2-aminothiazol-4-yl)-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)acetamide",11.2,uM,=,1.0492180226701815,1,O=C(Cc1cscn1)Nc1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1
7140,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCOC(=O)CNc1cc(N2CCOCC2)cc(CCc2nc(C)c(CC)o2)n1,ethyl 2-(6-(2-(5-ethyl-4-methyloxazol-2-yl)ethyl)-4-morpholinopyridin-2-ylamino)acetate,0.91,uM,=,-0.0409586076789063,0,c1cc(N2CCOCC2)cc(CCc2ncco2)n1
7141,875038,10.1021/jm300573d,,,,Inhibition of human ERG,Cn1cc2c(OCC3CCN(CCc4ccc(CO)cc4)CC3)nc3ccccc3c2c1,"4-[2-[4-[[(2-Methyl-2H-pyrrolo[3,4-c]-4-quinolinyl)oxy]methyl]-1-piperidinyl]ethyl]benzenemethanol",0.01,uM,=,-2.0,0,c1ccc(CCN2CCC(COc3nc4ccccc4c4c[nH]cc34)CC2)cc1
7142,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc2c1nc(N)n1nc(CN3CCN(c4ccccn4)C[C@H]3C)nc21,"(R)-7-methoxy-2-((2-methyl-4-(pyridin-2-yl)piperazin-1-yl)methyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",25.46,uM,=,1.4058583993176366,1,c1ccc(N2CCN(Cc3nc4c5ccccc5ncn4n3)CC2)nc1
7143,1552715,10.1016/j.ejmech.2015.12.006,,,,Inhibition of human ERG channel by fluorescence polarization assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCC(=O)N2CCC(Cc3ccccc3)CC2)C[C@H]1OC,cis-4-Amino-5-chloro-N-[1-(3-(4-benzylpiperidin-1-yl)-3-oxopropyl)-3-methoxypiperidin-4-yl]-2-methoxybenzamide,3.701,uM,=,0.5683190850951118,1,O=C(NC1CCN(CCC(=O)N2CCC(Cc3ccccc3)CC2)CC1)c1ccccc1
7144,2046794,10.1016/j.bmcl.2020.127523,,,,Inhibition of human ERG assessed as tail current by plate-based planar patch clamp assay,Cn1ccc2c(-c3nc4c(-n5cc(N[C@@H]6CCOC[C@@H]6N)cn5)ccnc4[nH]3)cccc21,"(3R,4R)-N4-(1-(2-(1-methyl-1H-indol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-4-yl)tetrahydro-2H-pyran-3,4-diamine",9.2,uM,=,0.9637878273455552,1,c1cc(-c2nc3c(-n4cc(NC5CCOCC5)cn4)ccnc3[nH]2)c2cc[nH]c2c1
7145,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CNCCCN1c2ccccc2CCc2ccccc21,"[3-(10,11-Dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-methyl-amine",27.8497,uM,=,1.4448205212675105,1,c1ccc2c(c1)CCc1ccccc1N2
7146,675987,10.1016/j.bmcl.2010.09.081,,,,Inhibition of human ERG channel,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(C(C)C)n1.Cl,"N-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)-6-isopropyl-2-methylpyrimidine-4-carboxamide Hydrochloride",5.4,uM,=,0.7323937598229685,1,O=C(NCCCN1CCN(c2ccccc2)CC1)c1ccncn1
7147,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCc1oc(CCc2cc(N3CCOCC3)cc(NC(C)C)n2)nc1C,6-(2-(5-ethyl-4-methyloxazol-2-yl)ethyl)-N-isopropyl-4-morpholinopyridin-2-amine,0.54,uM,=,-0.2676062401770315,0,c1cc(N2CCOCC2)cc(CCc2ncco2)n1
7148,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3cccnc3)c2)c2ncccc2c1=O,"N-cyclopropyl-4-oxo-1-(3-(2-(pyridin-3-yl)ethynyl)phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide",16.7,uM,=,1.2227164711475833,1,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3cccnc3)c2)c2ncccc2c1=O
7149,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NCc3cc4c(cn3)OCCO4)(CC1)CO2,"(R)-4-((4-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",2.6,uM,=,0.414973347970818,1,O=c1ccc2nccc3c2n1CC3CC12CCC(NCc3cc4c(cn3)OCCO4)(CC1)CO2
7150,814592,10.1016/j.bmcl.2012.03.049,,,,Inhibition of human ERG expressed in HEK293 cells by voltage clamp electrophysiology assay,COCC(=O)NC1CCN(c2nc(C)c3cc(NC(=O)/C=C/c4ccc(Cl)cc4)ccc3n2)CC1,(E)-3-(4-chlorophenyl)-N-(2-(4-(2-methoxyacetamido)piperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide,1.2,uM,=,0.0791812460476248,1,O=C(/C=C/c1ccccc1)Nc1ccc2nc(N3CCCCC3)ncc2c1
7151,1478742,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],"2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester",275.0,uM,=,2.439332693830263,1,C1=CC(c2ccccc2)C=CN1
7152,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,CC(Cc1ccccn1)N1C(=O)c2ccccc2C1C(=O)NCc1ccc(OC(F)(F)F)cc1,2-(1-Methyl-2-pyridin-2-ylethyl)-3-oxo-N-[4-(trifluoromethoxy)benzyl]isoindoline-1-carboxamide,8.6,uM,=,0.9344984512435676,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
7153,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCc1ccncc1,3-Oxo-2-(2-pyridin-4-ylethyl)-N-[4-(trifluoromethoxy)benzyl]isoindoline-1-carboxamide,5.1,uM,=,0.7075701760979364,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccncc1
7154,1797483,10.1021/acsmedchemlett.8b00344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch clamp assay,CC(C)(C)S(=O)(=O)c1ccc2nccc(Nc3n[nH]c4c3CCCC4)c2c1,"6-(tert-butylsulfonyl)-N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)quinolin-4-amine",8.635,uM,=,0.9362623419034776,1,c1ccc2c(Nc3n[nH]c4c3CCCC4)ccnc2c1
7155,1758787,10.1021/acsmedchemlett.7b00188,,,,Inhibition of human ERG expressed in CHO-K1 cells by Qpatch assay,CCO/N=C/c1ccc(OCCC(C)CCN2CCN(c3ccnc(N)c3)C2=O)cc1,(E)-4-(5-(3-(2-aminopyridin-4-yl)-2-oxoimidazolidin-1-yl)-3-methylpentyloxy)benzaldehyde O-ethyl oxime,0.8,uM,=,-0.0969100130080563,0,O=C1N(CCCCCOc2ccccc2)CCN1c1ccncc1
7156,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.Cl.FCCOc1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1,1-(4-(2-Fluoroethoxy)phenethyl)-4-phenethylpiperazine dihydrochloride,3.05,uM,=,0.4842998393467858,1,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
7157,2161344,10.1021/acs.jmedchem.1c02048,,,,Inhibition of [35S]MK-499 binding to hERG expressed in HEK293 cells,C[C@H]1OC(=O)[C@]2(O)CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12,"(3R,3aR,4R,5S,7aS)-5-methyl-6,6-difluoro-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-7a-hydroxy-3-methyl-3a,4,5,7-tetrahydro-3H-isobenzofuran-1-one",29.0,uM,=,1.462397997898956,1,O=C1OC[C@@H]2C1CCC[C@@H]2/C=C/c1ccc(-c2ccccc2)cn1
7158,773759,10.1021/jm200909u,,,,Inhibition of human hERG,C[C@H](Nc1ccc(C(N)=O)c2[nH]c3cc(-c4cnn(C)c4)ccc3c12)C(C)(C)C,"1-{[(2S)-3,3-Dimethylbutan-2-yl]amino}-7-(1-methyl-1Hpyrazol-4-yl)-5H-pyrido[4,3-b]indole-4-carboxamide",29.0,uM,=,1.462397997898956,1,c1ccc2c(c1)[nH]c1cc(-c3cn[nH]c3)ccc12
7159,1731353,10.1016/j.ejmech.2017.12.090,,,,Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by whole cell Qpatch assay,CN(C/C=C/c1ccc(F)cc1C(F)(F)F)Cc1ccc2c(c1)OCO2.Cl,"(E)-N-(benzo[d][1,3]dioxol-5-ylmethyl)-3-(2-fluoro-4-(trifluoromethyl)phenyl)-N-methylprop-2-en-1-amine hydrochloride",0.00422,uM,=,-2.374687549038326,0,C(=C/c1ccccc1)\CNCc1ccc2c(c1)OCO2
7160,702661,10.1021/jm100978n,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(=O)C(C)(C)C)C3)C2)c1cccc(F)c1,"endo-N-((S)-1-(3-fluorophenyl)-3-(3-(2-methyl-5-pivaloyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)propyl)acetamide",5.0,uM,=,0.6989700043360189,1,c1ccc(CCCN2[C@@H]3CC[C@H]2C[C@@H](n2cnc4c2CCNC4)C3)cc1
7161,1617566,10.1021/acs.jmedchem.6b01127,,,,Inhibition of human ERG,N#Cc1ccc(-c2ccc(C[C@@H](C#N)NC(=O)[C@@H]3CCCCC[C@@H]3N)cc2)cc1,"(1R,2S)-2-Amino-N-((S)-1-cyano-2-(4'-cyano[1,1'-biphenyl]-4-yl)ethyl)cycloheptanecarboxamide",3.6,uM,=,0.5563025007672873,1,O=C(NCCc1ccc(-c2ccccc2)cc1)C1CCCCCC1
7162,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,CC(=O)NC1CCN(Cc2ccc(Oc3nc4ccccc4s3)cc2)CC1,N-{1-[4-(Benzothiazol-2-yloxy)benzyl]piperidin-4-yl}acetamide,20.0,uM,=,1.3010299956639813,1,c1ccc2sc(Oc3ccc(CN4CCCCC4)cc3)nc2c1
7163,462632,10.1016/j.bmcl.2008.01.108,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes,CC1(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CCN(C(=O)c2c(Cl)cncc2Cl)CC1,"(3,5-dichloropyridin-4-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone",2.0,uM,=,0.3010299956639812,1,O=C(c1ccncc1)N1CCC(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CC1
7164,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(CC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCc1ccccn1,"3-Oxo-2-(2-(pyridin-2-yl)ethyl)-N-(4-(2,2,2-trifluoroethyl)benzyl)isoindoline-1-carboxamide",14.0,uM,=,1.146128035678238,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
7165,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N(CCc3ccc(Cl)cc3)Cc3cc(F)ccc3F)CC2)n[nH]1,"1-(5-amino-1H-1,2,4-triazol-3-yl)-N-(4-chlorophenethyl)-N-(2,5-difluorobenzyl)piperidin-4-amine",3.4,uM,=,0.5314789170422551,1,c1ccc(CCN(Cc2ccccc2)C2CCN(c3nc[nH]n3)CC2)cc1
7166,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,2-{4-[3-(2-Trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol (Fluphenazine),5.7058,uM,=,0.7563165446749562,1,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1
7167,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,CC(C)n1ccc(NC(=O)c2cc(Oc3ccc(C(=O)N4CCC4)cc3)cc(O[C@@H](C)CO)c2)n1,3-[4-(Azetidin-1-ylcarbonyl)phenoxy]-5-[(1S)-2-hydroxy-1-methylethoxy]-N-(1-isopropyl-1H-pyrazol-3-yl)benzamide,31.0,uM,=,1.4913616938342726,1,O=C(Nc1cc[nH]n1)c1cccc(Oc2ccc(C(=O)N3CCC3)cc2)c1
7168,1765513,10.1021/acs.jmedchem.8b01040,,,,Inhibition of human ERG by automated patch clamp assay,O=C(Nc1ccc(OC(F)(F)F)cc1)c1cnc(N2CC[C@H](O)C2)c(-c2cncnc2)c1,"US9278981, 33",4.2,uM,=,0.6232492903979004,1,O=C(Nc1ccccc1)c1cnc(N2CCCC2)c(-c2cncnc2)c1
7169,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cncc(OCC(F)(F)F)c3)ccc1OCC21CC1,"US8975415, RP58::US9242973, RP58",5.81,uM,=,0.7641761323903307,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
7170,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,Cc1noc(/C(=C/c2cccc(-c3cc(C(C)(C)S(C)(=O)=O)cc4cccnc34)c2)c2ccc(S(C)(=O)=O)cc2)n1,"(E)-8-(3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline",49.9,uM,=,1.69810054562339,1,C(=C(\c1ccccc1)c1ncno1)\c1cccc(-c2cccc3cccnc23)c1
7171,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cc(Cl)cnc3F)ccc1OCC21CC1,"US8975415, RP104::US9242973, RP104",3.25,uM,=,0.5118833609788744,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
7172,1617566,10.1021/acs.jmedchem.6b01127,,,,Inhibition of human ERG,N#Cc1ccc(-c2ccc(C[C@@H](C#N)NC(=O)[C@@H]3CCCC[C@@H]3N)cc2)cc1,"(1R,2S)-2-Amino-N-((S)-1-cyano-2-(4'-cyano[1,1'-biphenyl]-4-yl)ethyl)-cyclohexanecarboxamide",5.4,uM,=,0.7323937598229685,1,O=C(NCCc1ccc(-c2ccccc2)cc1)C1CCCCC1
7173,806502,10.1021/jm201564u,,,,Inhibition of human Erg expressed in HEK293 cells by patch clamp assay,CN[C@H]1CC[C@@H](N2CCc3ccc(NC(=N)c4cccs4)cc32)CC1,cis-N-(1-(4-(Methylamino)cyclohexyl)indolin-6-yl)thiophene-2-carboximidamide,13.0,uM,=,1.1139433523068367,1,N=C(Nc1ccc2c(c1)N(C1CCCCC1)CC2)c1cccs1
7174,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CC(N(C)C)C1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-2-(3-(dimethylamino)azetidin-1-yl)-4-methoxyphenyl)acrylamide",4.0,uM,=,0.6020599913279624,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCC5)cc4)n3)c2c1
7175,702661,10.1021/jm100978n,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3ccccc31)C2)c1ccccc1,endo-N-((S)-3-(3-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)acetamide,1.5,uM,=,0.1760912590556812,1,c1ccc(CCCN2[C@@H]3CC[C@H]2C[C@@H](n2cnc4ccccc42)C3)cc1
7176,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.Cl.FCCOc1cccc(CCN2CCN(CCc3ccccc3)CC2)c1,1-(3-(2-Fluoroethoxy)phenethyl)-4-phenethylpiperazine dihydrochloride,4.31,uM,=,0.6344772701607315,1,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
7177,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol,4.216,uM,=,0.6249006022044902,1,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1
7178,1745714,10.1016/j.bmc.2017.10.004,,,,Inhibition of human ERG expressed in Xenopus laevis oocytes by two-electrode voltage clamp assay,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3CC3CCCCC3)CC2)cc1,1-(Cyclohexylmethyl)-N-(1-(4-methoxyphenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine,0.00327,uM,=,-2.485452247339714,0,c1ccc(CCN2CCC(Nc3nc4ccccc4n3CC3CCCCC3)CC2)cc1
7179,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CCCCc1ccccc1,N-Ethyl-N-(4-phenylbutyl)heptan-1-amine,0.506,uM,=,-0.2958494831602009,0,c1ccccc1
7180,1990613,10.1016/j.bmcl.2020.127249,,,,Inhibition of human ERG,O=C(Nc1ncns1)/C(=N/N1CCCC1)c1ccc(S(=O)(=O)C2CC2)cc1,"(E)-2-(4-(cyclopropylsulfonyl)phenyl)-2-(pyrrolidin-1-ylimino)-N-(1,2,4-thiadiazol-5-yl)acetamide",5.3,uM,=,0.724275869600789,1,O=C(Nc1ncns1)/C(=N/N1CCCC1)c1ccc(S(=O)(=O)C2CC2)cc1
7181,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,"[4-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperazin-1-yl]-furan-2-yl-methanone",24.2778,uM,=,1.385209329390487,1,O=C(c1ccco1)N1CCN(c2ncc3ccccc3n2)CC1
7182,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CC(=O)c1cccc(-c2cccc(-n3cc(C(=O)Nc4nccc(Cl)c4Cl)c(=O)c4cccnc43)c2)c1,"1-(3'-Acetyl-biphenyl-3-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid (3,4-dichloro-pyridin-2-yl)-amide",0.74,uM,=,-0.1307682802690238,0,O=C(Nc1ccccn1)c1cn(-c2cccc(-c3ccccc3)c2)c2ncccc2c1=O
7183,2079119,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 0.5 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),O=C(COc1ccc(C(=O)c2cc(Cl)ccc2Br)cc1)Nc1ccnc(C(=O)NCC2CC2)c1,4-(2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)acetamido)-N-(cyclopropylmethyl)picolinamide,0.0175,uM,=,-1.7569619513137056,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1ccnc(C(=O)NCC2CC2)c1
7184,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CCO/N=C(/c1ccc(F)c(F)c1)c1ccc(CN2CCC3(CC2)OCc2cn(C)c(=O)cc23)cn1,"(Z)-1'-((6-((3,4-difluorophenyl)(ethoxyimino)methyl)pyridin-3-yl)methyl)-5-methyl-3H-spiro[furo[3,4-c]pyridine-1,4'-piperidin]-6(5H)-one",3.67,uM,=,0.5646660642520893,1,N=C(c1ccccc1)c1ccc(CN2CCC3(CC2)OCc2c[nH]c(=O)cc23)cn1
7185,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,"1,4-Dihydroxy-5,8-bis-[2-(2-hydroxy-ethylamino)-ethylamino]-anthraquinone",3.5849,uM,=,0.5544770456233693,1,O=C1c2ccccc2C(=O)c2ccccc21
7186,2048851,10.1021/acs.jmedchem.0c00978,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp assay,COc1ccc(-c2c(-c3ccc(C#N)c(F)c3)nc(N3CCC(N)CC3)n(C)c2=O)cc1F.O=S(=O)(O)c1ccccc1,PULRODEMSTAT BESILATE,3.4,uM,=,0.5314789170422551,1,O=c1[nH]c(N2CCCCC2)nc(-c2ccccc2)c1-c1ccccc1.c1ccccc1
7187,2151854,10.1016/j.ejmech.2020.112914,,,,Inhibition of human ERG expressed in CHO cells by patch clamp method,C[C@@]1(COc2ccc(OC(F)(F)F)cc2)CCn2cc([N+](=O)[O-])nc2O1,"(7S)-7-Methyl-2-nitro-7-([4-(trifluoromethoxy)phenoxy]methyl)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine",1.4,uM,=,0.1461280356782379,1,c1ccc(OCC2CCn3ccnc3O2)cc1
7188,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CCN(CC)CCOCCC1=CCC2CC1C2(C)C,Myrtecaine,5.9024,uM,=,0.7710286378827282,1,C1=CC2CC(C1)C2
7189,2188396,10.1021/acs.jmedchem.2c01170,,,,Inhibition of human ERG stably transfected in HEK293 cells incubated for 2 hrs by TAMRA fluorescence polarization assay,Clc1ccc(Nc2nc3ccccc3c3[nH]c(C4CCC=CCC4)nc23)cc1Cl,"2-(cyclohept-4-en-1-yl)-N-(3,4-dichlorophenyl)-1H-imidazo[4,5-c]quinolin-4-amine",6.06,uM,=,0.7824726241662862,1,C1=CCCC(c2nc3c(Nc4ccccc4)nc4ccccc4c3[nH]2)CC1
7190,462632,10.1016/j.bmcl.2008.01.108,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes,Cc1ccnc(C)c1C(=O)N1CCC(C)(N2CCC(N(c3ccccc3)c3ccccc3)CC2)CC1,"(2,4-Dimethyl-pyridin-3-yl)-(4-diphenylamino-4'-methyl-[1,4']bipiperidinyl-1'-yl)-methanone",0.57,uM,=,-0.2441251443275086,0,O=C(c1cccnc1)N1CCC(N2CCC(N(c3ccccc3)c3ccccc3)CC2)CC1
7191,766645,10.1016/j.bmcl.2011.07.030,,,,Inhibition of human ERG,O=C(NCC1(N2CCCC2)CCCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1,"N-((1-(pyrrolidin-1-yl)cyclopentyl)methyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",7.1,uM,=,0.8512583487190752,1,O=C(NCC1(N2CCCC2)CCCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
7192,1665702,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,Nc1ncc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)cn1,2-(2-aminopyrimidin-5-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine,80.0,uM,=,1.9030899869919435,1,c1ccc(-c2cccc3nc(-c4cncnc4)nc(NCc4ccccn4)c23)cc1
7193,1798125,10.1021/acsmedchemlett.8b00305,,,,Inhibition of MK-499 binding to human ERG,CCOc1cc(CN2CCC3(CC2)CC(=O)N(c2ccc(C(=O)O)cc2)C3)cc(OCC)c1-c1ccc(F)cc1.O=C(O)C(F)(F)F,"4-{8-[(2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid trifluoromethyl acetate",45.0,uM,=,1.6532125137753435,1,O=C1CC2(CCN(Cc3ccc(-c4ccccc4)cc3)CC2)CN1c1ccccc1
7194,1745661,10.1016/j.bmcl.2017.10.010,,,,Inhibition of human ERG by Qpatch clamp assay,N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,"4-(((1R,6R)-6-amino-2-(4-fluorophenyl)cyclohex-2-enyl)methoxy)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide",10.3,uM,=,1.0128372247051722,1,O=S(=O)(Nc1cscn1)c1ccc(OC[C@H]2CCCC=C2c2ccccc2)cc1
7195,493255,10.1021/jm8009537,,,,Inhibition of human ERG expressed in HEK293 cells by patch-clamp method,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,Methyl-((R)-3-phenyl-3-o-tolyloxy-propyl)-amine,2.1,uM,=,0.3222192947339193,1,c1ccc(COc2ccccc2)cc1
7196,2059788,10.1021/acsmedchemlett.0c00675,,,,Inhibition of human ERG by patch clamp analysis,C[C@H](NC(=O)c1cc(C(F)(F)F)nn1C)c1nc(-c2ccnc(C(F)(F)F)c2)no1,"(S)-1-methyl-3-(trifluoromethyl)-N-(1-(3-(2-(trifluoromethyl)pyridin-4-yl)-1,2,4-oxadiazol-5-yl)ethyl)-1H-pyrazole-5-carboxamide",11.9,uM,=,1.0755469613925308,1,O=C(NCc1nc(-c2ccncc2)no1)c1ccn[nH]1
7197,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1,Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester,20.5909,uM,=,1.3136753294490902,1,C1CCC(C2CCCCC2)CC1
7198,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,NC1(C(=O)NC(c2ccc(Cl)cc2)C2CC2)CCN(c2ncnc3[nH]ccc23)CC1,"rac-4-Amino-N-[(4-chlorophenyl)(cyclopropyl)methyl]-1-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",2.6,uM,=,0.414973347970818,1,O=C(NC(c1ccccc1)C1CC1)C1CCN(c2ncnc3[nH]ccc23)CC1
7199,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,"4-(8-Chloro-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-piperidine-1-carboxylic acid ethyl ester",39.0866,uM,=,1.592027894390838,1,c1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
7200,321190,10.1016/j.bmcl.2005.06.101,,,,Inhibitory concentration against Potassium channel hERG,CC(C)(C)C1CCC2(CC1)CCN(c1ccc(OC(F)(F)F)cc1)C(=O)N2Cc1ccc(C(=O)Nc2nn[nH]n2)cc1,"4-[9-tert-Butyl-2-oxo-3-(4-trifluoromethoxy-phenyl)-1,3-diaza-spiro[5.5]undec-1-ylmethyl]-N-(1H-tetrazol-5-yl)-benzamide",5.4,uM,=,0.7323937598229685,1,O=C(Nc1nn[nH]n1)c1ccc(CN2C(=O)N(c3ccccc3)CCC23CCCCC3)cc1
7201,1745714,10.1016/j.bmc.2017.10.004,,,,Inhibition of human ERG expressed in Xenopus laevis oocytes by two-electrode voltage clamp assay,COc1ccc(CCN2CCC(Nc3nc4ccccc4[nH]3)CC2)cc1,N-(1-(4-methoxyphenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine,0.1639,uM,=,-0.7854210464295008,0,c1ccc(CCN2CCC(Nc3nc4ccccc4[nH]3)CC2)cc1
7202,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,Cc1nsc(NC(=O)c2cc(Oc3ccc(C(=O)N4CCC4)cc3)cc(O[C@@H](C)CO)c2)n1,"3-[4-(Azetidin-1-ylcarbonyl)phenoxy]-5-[(1S)-2-hydroxy-1-methylethoxy]-N-(3-methyl-1,2,4-thiadiazol-5-yl)benzamide",11.0,uM,=,1.0413926851582251,1,O=C(Nc1ncns1)c1cccc(Oc2ccc(C(=O)N3CCC3)cc2)c1
7203,945796,10.1016/j.bmcl.2012.12.072,,,,Inhibition of human ERG,O[C@H](COc1ccc(F)cc1)CN1CCN(Cc2ccc(Cl)cc2)CC1,(S)-1-(4-(4-chlorobenzyl)piperazin-1-yl)-3-(4-fluorophenoxy)propan-2-ol,1.35,uM,=,0.1303337684950061,1,c1ccc(CN2CCN(CCCOc3ccccc3)CC2)cc1
7204,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1csc([C@@]2(CN)[C@@H]3CCN(c4cnc5c(-c6ccc7nc(C)sc7c6Cl)n[nH]c5n4)C[C@@H]32)n1,"((1S,6R,7S)-3-(3-(7-chloro-2-methylbenzo[d]thiazol-6-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-7-(4-methylthiazol-2-yl)-3-azabicyclo[4.1.0]heptan-7-yl)methanamine",0.024,uM,=,-1.619788758288394,0,c1csc(C2[C@H]3CN(c4cnc5c(-c6ccc7ncsc7c6)n[nH]c5n4)CC[C@@H]23)n1
7205,849439,10.1016/j.bmc.2012.07.046,,,,Inhibition of human ERG,COCc1ccc2c3nc(N4CCC[C@@H](N)C4)n(Cc4ccccc4Cl)c3c(=O)n(C)c2c1.Cl,"2-[(3R)-3-aminopiperidin-1-yl]-3-(2-chlorobenzyl)-7-(methoxymethyl)-5-methyl-3,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one hydrochloride",1.81,uM,=,0.2576785748691845,1,O=c1[nH]c2ccccc2c2nc(N3CCCCC3)n(Cc3ccccc3)c12
7206,2219924,10.1016/j.bmcl.2021.128463,,,,Displacement of MK499 from human ERG expressed in HEK membrane by radio ligand binding competition assay,C[C@]1(CF)C(=N)N[C@](C)(c2nc(NC(=O)c3ccc(C#N)cn3)ccc2F)CS1(=O)=O,"5-cyano-N-(5-fluoro-6-((3R,6R)-6-(fluoromethyl)-5-imino-3,6-dimethyl-1,1-dioxidothiomorpholin-3-yl)pyridin-2-yl)picolinamide",54.23,uM,=,1.734239604435455,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3ccccn3)n2)N1
7207,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,CC1(C(=O)NCc2ccc(OC(F)(F)F)cc2)c2ccccc2C(=O)N1CCc1ccccn1,rac-1-Methyl-3-oxo-2-(2-(pyridin-2-yl)ethyl)-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,11.0,uM,=,1.0413926851582251,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
7208,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,"4-Amino-N-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",5.235,uM,=,0.7189166860148611,1,O=C(NCc1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
7209,2186534,10.1021/acs.jmedchem.1c01132,,,,Inhibition of hERG ion channel incubated for 3 hrs by fluorescence polarization assay,C[C@@H]1OCC2(CCN(c3cnc4c(-c5cccc(Cl)c5Cl)n[nH]c4n3)CC2)[C@@H]1N,"(3S,4S)-8-(3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine",0.1,uM,=,-1.0,0,c1ccc(-c2n[nH]c3nc(N4CCC5(CCOC5)CC4)cnc23)cc1
7210,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CCC4(CCO4)C3)c12,4-(1-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-5-hydroxy-2-(4-hydroxyphenyl)-N-methylbenzofuran-3-carboxamide,19.4,uM,=,1.287801729930226,1,c1ccc(-c2cc3c(CN4CCC5(CCO5)C4)cccc3o2)cc1
7211,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=C1COc2cc(Cl)c(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)nc2N1,"(R)-7-chloro-6-((1-((3-fluoro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",27.7,uM,=,1.4424797690644486,1,O=C1COc2ccc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)nc2N1
7212,1523572,10.1021/acs.jmedchem.5b01605,,,,Inhibition of human ERG potassium channel by ionworks patch-clamp electrophysiology assay,CS(=O)(=O)c1ccc(-c2cnn3ccc(-c4cccc(S(=O)(=O)C5CC5)c4)cc23)cc1,"5-(3-(Cyclopropylsulfonyl)phenyl)-3-(4-(methylsulfonyl)-phenyl)pyrazolo[1,5-a]pyridine",1.4,uM,=,0.1461280356782379,1,O=S(=O)(c1cccc(-c2ccn3ncc(-c4ccccc4)c3c2)c1)C1CC1
7213,1512238,10.1016/j.bmcl.2015.07.003,,,,Inhibition of human ERG expressed in HEK cells assessed as reduction in IKr current by patchXpress assay,COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,"6-fluoro-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",12.9,uM,=,1.110589710299249,1,O=C1Nc2ccccc2CCC1n1cc(-c2ccc(-n3ccnc3)cc2)nn1
7214,773759,10.1021/jm200909u,,,,Inhibition of human hERG,Cn1cc(-c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(NC4CCCCC4)c23)cn1,"1-(Cyclohexylamino)-7-(1-methyl-1H-pyrazol-4-yl)-5H-pyrido[4,3-b]indole-4-carboxamide",0.62,uM,=,-0.2076083105017461,0,c1cc(NC2CCCCC2)c2c(c1)[nH]c1cc(-c3cn[nH]c3)ccc12
7215,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(-c3nnc[nH]3)cc(C(F)(F)F)c2)CC1,"(4-(3-(4H-1,2,4-triazol-3-yl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",1.0,uM,=,0.0,0,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2cccc(-c3nnc[nH]3)c2)CC1
7216,740013,10.1016/j.bmcl.2011.02.061,,,,Inhibition of human ERG,N#Cc1ccc(C(=O)N2CCC3(CC2)N=C(N)c2c(F)ccc(F)c2N3)cn1,"5-[(4'-amino-5',8'-difluoro-1H,1'H-spiro[piperidine-4,2'-quinazolin]-1-yl)carbonyl]pyridine-2-carbonitrile",0.1,uM,=,-1.0,0,O=C(c1cccnc1)N1CCC2(CC1)N=Cc1ccccc1N2
7217,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CN(c1ccc(CN2CCC3(CC2)OCc2cc(F)ncc23)cc1)c1ccc(F)c(F)c1,"3,4-difluoro-N-(4-((6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1'-yl)methyl)phenyl)-N-methylaniline",0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ccc(CN3CCC4(CC3)OCc3ccncc34)cc2)cc1
7218,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CCCC3)c12,5-hydroxy-2-(4-hydroxyphenyl)-N-methyl-4-(pyrrolidin-1-ylmethyl)benzofuran-3-carboxamide,15.0,uM,=,1.1760912590556811,1,c1ccc(-c2cc3c(CN4CCCC4)cccc3o2)cc1
7219,941692,10.1021/jm3017078,,,,Inhibition of human ERG by dofetilide binding assay,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2Cc2ccccc2)C(C)C)ccc1OC.Cl,"N-((3S,4S)-4-Benzylpyrrolidin-3-ylmethyl)-N-isopropyl-4-methoxy-3-(3-methoxypropoxy)benzamide Hydrochloride Salt",14.5,uM,=,1.1613680022349748,1,O=C(NC[C@@H]1CNC[C@H]1Cc1ccccc1)c1ccccc1
7220,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,"[4-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperazin-1-yl]-(2,3-dihydro-benzo[1,4]dioxin-2-yl)-methanone",2.2155,uM,=,0.3454717543676307,1,O=C(C1COc2ccccc2O1)N1CCN(c2ncc3ccccc3n2)CC1
7221,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1csc([C@@]2(CN)[C@@H]3CN(c4cnc5c(-c6ccn7nccc7c6Cl)n[nH]c5n4)C[C@@H]32)n1,"((1R,5S,6r)-3-(3-(4-chloropyrazolo[1,5-a]pyridin-5-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-6-(4-methylthiazol-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methanamine",0.235,uM,=,-0.6289321377282637,0,c1csc(C2[C@H]3CN(c4cnc5c(-c6ccn7nccc7c6)n[nH]c5n4)C[C@@H]23)n1
7222,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,C[C@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1,"(S)-4-Amino-N-[1-(4-chlorophenyl)ethyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",6.747,uM,=,0.8291107101552946,1,O=C(NCc1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
7223,342119,10.1021/jm051106d,,,,Inhibitory activity against hERG by patch-clamp assay,COC[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C,"(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)-3-methoxypropan-2-ol",18.0,uM,=,1.255272505103306,1,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
7224,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,CCN(CC)C(=O)c1ccc(C2=CC3(CCN(C)CC3)Oc3ccccc32)cc1,"N,N-Diethyl-4-(1'-methylspiro[chromene-2,4'-piperidine]-4-yl)benzamide",0.766,uM,=,-0.115771230367396,0,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
7225,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCc1oc(CCc2cc(N3CCOCC3)cc(NCCOC)n2)nc1C,6-(2-(5-ethyl-4-methyloxazol-2-yl)ethyl)-N-(2-methoxyethyl)-4-morpholinopyridin-2-amine,0.9,uM,=,-0.0457574905606751,0,c1cc(N2CCOCC2)cc(CCc2ncco2)n1
7226,2079117,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 3 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),Cc1cc(NC(=O)COc2ccc(C(=O)c3cc(Cl)ccc3Br)cc2)ccn1,2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)-N-(2-methylpyridin-4-yl)acetamide,0.0597,uM,=,-1.2240256688706308,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1ccncc1
7227,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.FCCOc1ccccc1CCC1CCN(CCc2ccccc2Cl)CC1,1-(2-Chlorophenethyl)-4-(2-(2-fluoroethoxy)phenethyl)piperidine hydrochloride,0.69,uM,=,-0.1611509092627447,0,c1ccc(CCC2CCN(CCc3ccccc3)CC2)cc1
7228,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,"3-[(4,5-Dihydro-1H-imidazol-2-ylmethyl)-p-tolyl-amino]-phenol",20.0763,uM,=,1.302683676717686,1,c1ccc(N(CC2=NCCN2)c2ccccc2)cc1
7229,1465923,10.1016/j.bmcl.2015.02.003,,,,Inhibition of human ERG by voltage clamp method,CC(C)[C@]1(C)CC(=O)N(Cc2cc(F)cc(C(=O)N[C@@H](C)c3ccccc3)c2)C(=N)N1,3-fluoro-5-(((S)-2-imino-4-isopropyl-4-methyl-6-oxotetrahydropyrimidin-1(2H)-yl)methyl)-N-((S)-1-phenylethyl)benzamide,9.0,uM,=,0.9542425094393248,1,N=C1NCCC(=O)N1Cc1cccc(C(=O)NCc2ccccc2)c1
7230,1760898,10.1021/acs.jmedchem.8b00521,,,,Inhibition of human ERG by cell based automated patch clamp method,COc1ccc(NC(=O)N2CCN(c3nc(N)nc4scnc34)[C@@H](C)C2)cc1,"(3S)-4-(5-Aminothiazolo[5,4-d]pyrimidin-7-yl)-N-(4-methoxyphenyl)-3-methyl-piperazine-1-carboxamide",17.0,uM,=,1.230448921378274,1,O=C(Nc1ccccc1)N1CCN(c2ncnc3scnc23)CC1
7231,1630057,10.1016/j.ejmech.2016.07.038,,,,Inhibition of recombinant human ERG expressed in CHOK1 cells at -80 mV holding potential after 2 mins by patch clamp assay,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,CARIPRAZINE,20.72,uM,=,1.3163897510731954,1,c1ccc(N2CCN(CCC3CCCCC3)CC2)cc1
7232,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@H](c3ccccc3)CC2)C1,N-{[1-(4-Phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide,4.0,uM,=,0.6020599913279624,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccccc3)CC2)C1
7233,1665702,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,NC(=O)c1ccc(-c2cccc3nc(-c4cncnc4)nc(NCc4ccccn4)c23)cc1,4-(4-((pyridin-2-ylmethyl)amino)-2-(pyrimidin-5-yl)quinazolin-5-yl)benzamide,1.3,uM,=,0.1139433523068367,1,c1ccc(-c2cccc3nc(-c4cncnc4)nc(NCc4ccccn4)c23)cc1
7234,2079117,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 3 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),Cc1ccc(C#N)cc1NC(=O)COc1ccc(C(=O)c2cc(Cl)ccc2Br)cc1,2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)-N-(5-cyano-2-methylphenyl)acetamide,0.0128,uM,=,-1.892790030352132,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1ccccc1
7235,449746,10.1016/j.bmcl.2007.08.049,,,,Inhibition of human ERG,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)[C@H](N)C(=O)N1CC[C@H](F)C1,"(2S,3S)-2-amino-3-(4'-fluoro-biphenyl-4-yl)-1-((S)-3-fluoro-pyrrolidin-1-yl)-butan-1-one",1.1,uM,=,0.041392685158225,1,O=C(CCc1ccc(-c2ccccc2)cc1)N1CCCC1
7236,2223619,10.1021/acsmedchemlett.2c00294,,,,Inhibition of human ERG by fluorescence polarization assay,N[C@@H]1C[C@@H]1c1ccc(Br)c(F)c1F,"(+/-)-cis-2-(4-Bromo-2,3-difluorophenyl)cyclopropylamine",35.0,uM,=,1.5440680443502757,1,c1ccc(C2CC2)cc1
7237,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,COc1cccc(-c2cccc(C3(c4ccncc4)N=C(N)CS3)c2)c1,"2-(3'-Methoxybiphenyl-3-yl)-2-(pyridin-4-yl)-2,5-dihydrothiazol-4-amine",12.0,uM,=,1.0791812460476249,1,C1=NC(c2ccncc2)(c2cccc(-c3ccccc3)c2)SC1
7238,462632,10.1016/j.bmcl.2008.01.108,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes,CC1(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CCN(C(=O)c2c(Cl)c[n+]([O-])cc2Cl)CC1,"(3,5-dichloro-1-oxy-pyridin-4-yl)-[4'-methyl-4-(phenyl-pyridin-3-yl-amino)-[1,4']bipiperidinyl-1'-yl]-methanone",4.4,uM,=,0.6434526764861874,1,O=C(c1cc[nH+]cc1)N1CCC(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CC1
7239,1568375,10.1016/j.bmcl.2016.02.052,,,,Inhibition of human ERG by patch clamp method,COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CC/C(=N\N1CCN(C)CC1)C2(C)C,"(E)-5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(3-methoxy-5,5-dimethyl-6-((4-methylpiperazin-1-yl)imino)-5,6,7,8-tetrahydronaphthalen-2-yl)pyrimidine-2,4-diamine",24.0,uM,=,1.380211241711606,1,c1ccc(Nc2ccnc(Nc3ccc4c(c3)CC/C(=N\N3CCNCC3)C4)n2)cc1
7240,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,N#Cc1cccc(CCN2CCN(CCc3ccc([N+](=O)[O-])cc3)CC2)c1,3-(2-(4-(4-nitrophenethyl)piperazin-1-yl)ethyl)benzonitrile,0.022,uM,=,-1.6575773191777938,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
7241,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCc1ccccn1,3-Oxo-2-(2-pyridin-2-ylethyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-1H-isoindole-1-carboxamide,7.8,uM,=,0.8920946026904804,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
7242,2079117,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 3 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),O=C(COc1ccc(C(=O)c2cc(Cl)ccc2Br)cc1)Nc1ccc(Cl)c(C(=O)NCC2CC2)c1,5-(2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)acetamido)-2-chloro-N-(cyclopropylmethyl)benzamide,0.0178,uM,=,-1.749579997691106,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1cccc(C(=O)NCC2CC2)c1
7243,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,CC(NC(=O)C1c2ccccc2C(=O)N1CCc1ccccn1)c1ccc(OCC(F)(F)F)cc1,"3-Oxo-2-(2-pyridin-2-ylethyl)-N-[1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl]-1H-isoindole-1-carboxamide",7.3,uM,=,0.8633228601204559,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
7244,2162538,10.1016/j.ejmech.2021.114045,,,,Inhibition of hERG expressed in CHO cells at -80 mV holding potential by automated patch clamp method,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,"2-(1-Benzyl-piperidin-4-ylmethyl)-5,6-dimethoxy-indan-1-one",0.64,uM,=,-0.1938200260161128,0,O=C1c2ccccc2CC1CC1CCN(Cc2ccccc2)CC1
7245,1719825,10.1016/j.ejmech.2017.09.012,,,,Inhibition of human ERG by patch clamp assay,c1ccc(Cc2cc3c(s2)CCN2Cc4ccccc4CC32)cc1,"2-Benzyl-8,11-dimethoxy-4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]-isoquinoline",21.3,uM,=,1.3283796034387378,1,c1ccc(Cc2cc3c(s2)CCN2Cc4ccccc4CC32)cc1
7246,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1ccc(-c2c(C)c(CNC3CCC(F)(F)C3)nn2-c2ncccc2Cl)cn1,"N-((1-(3-chloropyridin-2-yl)-4-methyl-5-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)methyl)-3,3-difluorocyclopentanamine",21.0,uM,=,1.3222192947339193,1,c1ccc(-n2nc(CNC3CCCC3)cc2-c2cccnc2)nc1
7247,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,N#Cc1ccc(CCN2CCN(CCc3ccc4c(c3)COC4=O)CC2)cc1Cl,"2-chloro-4-(2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",0.12,uM,=,-0.9208187539523752,0,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
7248,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CN(C)CCOC(c1ccccc1)c1ccccc1,(2-Benzhydryloxy-ethyl)-dimethyl-amine,31.859,uM,=,1.503232139911512,1,c1ccc(Cc2ccccc2)cc1
7249,945796,10.1016/j.bmcl.2012.12.072,,,,Inhibition of human ERG,O[C@@H](COc1ccc(F)cc1)CN1CCN(Cc2ccc(Cl)c(Cl)c2)CC1,"(R)-1-(4-(3,4-dichlorobenzyl)piperazin-1-yl)-3-(4-fluorophenoxy)propan-2-ol",0.87,uM,=,-0.0604807473813814,0,c1ccc(CN2CCN(CCCOc3ccccc3)CC2)cc1
7250,1981486,10.1021/acs.jmedchem.9b01870,,,,Inhibition of human ERG by radioligand binding assay,CO[C@H]1CCN(Cc2c(C)cc(C)c3[nH]ccc23)[C@H](CO)C1,"((2S,4S)-1-((5,7-Dimethyl-1H-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)methanol",14.0,uM,=,1.146128035678238,1,c1cc(CN2CCCCC2)c2cc[nH]c2c1
7251,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",CCc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)c1,"US8975415, RP63::US9242973, RP63",4.48,uM,=,0.651278013998144,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OCC21CC1
7252,2161344,10.1021/acs.jmedchem.1c02048,,,,Inhibition of [35S]MK-499 binding to hERG expressed in HEK293 cells,CNC(=O)N1C[C@H]2[C@H](C)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@]32C1,"(3R,3aS,4S,5R,6R,6aS,9aR)-4-[(E)-2-[5-(2-cyanophenyl)-2-pyridyl]vinyl]-N,3,5,6-tetramethyl-1-oxo-3,3a,4,5,6,6a,7,9-octahydrofuro[3,4-d]isoindole-8-carboxamide",50.0,uM,=,1.6989700043360187,1,O=C1OC[C@H]2[C@@H](/C=C/c3ccc(-c4ccccc4)cn3)CC[C@@H]3CNC[C@@]132
7253,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,Cc1noc(/C(=C/c2cccc(-n3cc(C(=O)Nc4c(Cl)cncc4Cl)c(=O)c4cccnc43)c2)c2ccc(S(C)(=O)=O)cc2)n1,"N-(3,5-dichloropyridin-4-yl)-1-(3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)phenyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide",0.68,uM,=,-0.1674910872937636,0,O=C(Nc1ccncc1)c1cn(-c2cccc(/C=C(\c3ccccc3)c3ncno3)c2)c2ncccc2c1=O
7254,2023418,10.1016/j.bmcl.2020.127663,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch clamp assay,Cc1noc(C2CCN(C(=O)/C=C/c3ccc(C(F)(F)F)cc3Cn3nnc(C)n3)CC2)n1,"(E)-1-(4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-3-(2-((5-methyl-2H-tetrazol-2-yl)methyl)-4-(trifluoromethyl)phenyl)prop-2-en-1-one",14.0,uM,=,1.146128035678238,1,O=C(/C=C/c1ccccc1Cn1ncnn1)N1CCC(c2ncno2)CC1
7255,2219924,10.1016/j.bmcl.2021.128463,,,,Displacement of MK499 from human ERG expressed in HEK membrane by radio ligand binding competition assay,Cc1cc(C#N)cnc1C(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)[C@@](C)(C(F)F)C(=N)N2)n1,"5-cyano-N-(6-((3R,6R)-6-(difluoromethyl)-5-imino-3,6-dimethyl-1,1-dioxidothiomorpholin-3-yl)-5-fluoropyridin-2-yl)-3-methylpicolinamide",48.15,uM,=,1.6825962914605532,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3ccccn3)n2)N1
7256,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@](O)(c3ccc4c(c3)OCO4)CC2)C1,"N-{[1-(4-Benzo[1,3]dioxol-5-yl-4-hydroxy-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide",13.5,uM,=,1.130333768495006,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccc4c(c3)OCO4)CC2)C1
7257,1580962,10.1021/acsmedchemlett.6b00018,,,,Binding affinity to human ERG by radioligand binding assay,C[C@H]1Cc2c(ncnc2Oc2ccc3c(ccn3C(=O)Nc3cc(C4(C(F)(F)F)CC4)on3)c2)CN1,"(S)-5-(6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)-N-(5-(1-(trifluoromethyl)cyclopropyl)isoxazol-3-yl)-1H-indole-1-carboxamide",7.4,uM,=,0.8692317197309762,1,O=C(Nc1cc(C2CC2)on1)n1ccc2cc(Oc3ncnc4c3CCNC4)ccc21
7258,1924515,10.1021/acsmedchemlett.6b00122,,,,Inhibition of human ERG after 6 mins by electrophysiological assay,Cc1c([C@H](O)CN2CCN(C[C@@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,"US9018211, 2B",22.0,uM,=,1.3424226808222062,1,O=C1OCc2cc(CCN3CCN(CCc4ccc5c(c4)COC5=O)CC3)ccc21
7259,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@](O)(c3cccnc3)CC2)C1,N-{[1-(4-Hydroxy-4-pyridin-3-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide,35.0,uM,=,1.5440680443502757,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3cccnc3)CC2)C1
7260,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,CCc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(C(F)(F)F)c4)n2CCO3)ccn1,"10-(2-ethylpyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",0.3339999999999999,uM,=,-0.4762535331884355,0,c1ccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
7261,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",COc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C2(CCC2)O3)c1,"US8975415, RP72::US9242973, RP72",8.22,uM,=,0.9148718175400504,1,C1=NC2(CO1)c1cc(-c3cccnc3)ccc1OC1(CCC1)C21COC1
7262,2023418,10.1016/j.bmcl.2020.127663,,,,Inhibition of human ERG expressed in CHO-K1 cells by automated Qpatch clamp assay,Cc1cc(CN2CCN(C(=O)/C=C/c3ccc(Cl)cc3Cn3nnc(C)n3)CC2=O)on1,(E)-4-(3-(4-chloro-2-((5-methyl-2H-tetrazol-2-yl)methyl)phenyl)acryloyl)-1-((3-methylisoxazol-5-yl)methyl)piperazin-2-one,17.0,uM,=,1.230448921378274,1,O=C(/C=C/c1ccccc1Cn1ncnn1)N1CCN(Cc2ccno2)C(=O)C1
7263,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,"(3S,4R)-3-(Benzo[1,3]dioxol-5-yloxymethyl)-4-(4-fluoro-phenyl)-piperidine",10.4293,uM,=,1.018255160167726,1,c1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
7264,634158,10.1021/jm100044a,,,,Inhibition of human ERG by patch clamp assay,CC(=O)N1CCN(CCOc2ccc(NC(=O)c3cccc(F)c3)cc2-c2ccnn2C)CC1,N-{4-[2-(4-Acetylpiperazin-1-yl)ethoxy]-3-(1-methyl-1H-pyrazol-5-yl)phenyl}-3-fluorobenzamide,4.1,uM,=,0.6127838567197355,1,O=C(Nc1ccc(OCCN2CCNCC2)c(-c2ccn[nH]2)c1)c1ccccc1
7265,1567397,10.1016/j.ejmech.2016.02.014,,,,Displacement of [3H]dofetilide from human ERG channel expressed in HEK293 cells after 60 mins by liquid scintillation counting method,Cc1cc(F)ccc1C1CCN(CC2Cc3ccccc3CN2)CC1,"3-{[4-(4-Fluoro-2-methylphenyl)piperidin-1-yl]methyl}-1,2,3,4-tetrahydroisoquinoline",0.2,uM,=,-0.6989700043360187,0,c1ccc(C2CCN(CC3Cc4ccccc4CN3)CC2)cc1
7266,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1c(CNC2CCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1cccnc1,"N-((1-(2,4-dichlorophenyl)-4-methyl-5-(pyridin-3-yl)-1H-pyrazol-3-yl)methyl)cyclopentanamine",2.9,uM,=,0.4623979978989561,1,c1ccc(-n2nc(CNC3CCCC3)cc2-c2cccnc2)cc1
7267,1552715,10.1016/j.ejmech.2015.12.006,,,,Inhibition of human ERG channel by fluorescence polarization assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CC2CCN(C(=O)NC(C)C)CC2)C[C@H]1OC,4-((cis-4-(4-Amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)methyl)-N-isopropylpiperidine-1-carboxamide,7.551,uM,=,0.8780044702680252,1,O=C(NC1CCN(CC2CCNCC2)CC1)c1ccccc1
7268,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,CSc1cc(CCN2CCN(CCc3ccc4c(c3)COC4=O)CC2)ccc1C#N,"2-(methylthio)-4-(2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",0.46,uM,=,-0.3372421683184259,0,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
7269,411697,10.1021/jm060927v,,,,Binding affinity to hERG potassium channel,COc1ccc2c(=O)n(C[C@H](O)CO)c(C#N)c(-c3ccccc3)c2c1,"2-[(2S)-2,3-dihydroxypropyl]-6-methoxy-1-oxo-4-phenyl-1,2-dihydroisoquinoline-3-carbonitrile",135.0,uM,=,2.130333768495006,1,O=c1[nH]cc(-c2ccccc2)c2ccccc12
7270,768794,10.1021/jm200290z,,,,Inhibition of human ERG,c1cnc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)nc1,"Pyrimidin-2-yl-(4,5,6,8-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine",30.0,uM,=,1.4771212547196624,1,c1cnc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)nc1
7271,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CC#CC(c1ccccc1)c1ccccc1,"N-(4,4-Diphenylbut-2-yn-1-yl)-N-ethylheptan-1-amine",0.238,uM,=,-0.623423042943488,0,c1ccc(Cc2ccccc2)cc1
7272,857209,10.1021/jm300286a,,,,Inhibition of human ERG by patch clamp assay,O=C(CCc1ccccc1)c1ccccc1OCC(O)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,1-(2-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy)phenyl)-3-phenylpropan-1-one,2.6,uM,=,0.414973347970818,1,O=C(CCc1ccccc1)c1ccccc1OCCCN1CCN(C(c2ccccc2)c2ccccc2)CC1
7273,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1csc([C@@]2(CN)[C@@H]3CCN(c4cnc5c(-c6ccc7nn(C)cc7c6Cl)n[nH]c5n4)C[C@@H]32)n1,"((1S,6R,7S)-3-(3-(4-chloro-2-methyl-2H-indazol-5-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-7-(4-methylthiazol-2-yl)-3-azabicyclo[4.1.0]heptan-7-yl)methanamine",0.107,uM,=,-0.9706162223147904,0,c1csc(C2[C@H]3CN(c4cnc5c(-c6ccc7n[nH]cc7c6)n[nH]c5n4)CC[C@@H]23)n1
7274,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CCOc1cccc(-c2cccc(-n3cc(C(=O)NC(C)C)c(=O)c4cccnc43)c2)c1,"1-(3'-Ethoxy-biphenyl-3-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid isopropylamide",2.7,uM,=,0.4313637641589873,1,O=c1ccn(-c2cccc(-c3ccccc3)c2)c2ncccc12
7275,470090,10.1016/j.bmcl.2008.02.050,,,,Inhibition of human ERG,C[C@H](c1nc(-c2ccc(S(C)(=O)=O)cc2Cl)no1)[C@H](N)C(=O)N1CCCC1.O=C(O)C(F)(F)F,"(2S,3S)-3-(3-(2-chloro-4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-oxo-1-(pyrrolidin-1-yl)butan-2-aminium 2,2,2-trifluoroacetate",37.0,uM,=,1.568201724066995,1,O=C(CCc1nc(-c2ccccc2)no1)N1CCCC1
7276,2049685,10.1021/acs.jmedchem.0c01411,,,,Inhibition of human ERG by patch clamp method,CN1CCN(CC2CCN(c3nccc4[nH]c(-c5cc(F)cc(F)c5)cc34)CC2)CC1,"2-(3,5-difluorophenyl)-4-(4-((4-methylpiperazin-1-yl)methyl)piperidin-1-yl)-1H-pyrrolo[3,2-c]pyridine",5.0,uM,=,0.6989700043360189,1,c1ccc(-c2cc3c(N4CCC(CN5CCNCC5)CC4)nccc3[nH]2)cc1
7277,2186534,10.1021/acs.jmedchem.1c01132,,,,Inhibition of hERG ion channel incubated for 3 hrs by fluorescence polarization assay,CNc1nccc(-c2n[nH]c3nc(N4CCC(C)(N)CC4)cnc23)c1Cl,"4-(6-(4-Amino-4-methylpiperidin-1-yl)-1H-pyrazolo[3,4-b]pyrazin-3-yl)-3-chloro-N-methylpyridin-2-amine",3.5,uM,=,0.5440680443502757,1,c1cc(-c2n[nH]c3nc(N4CCCCC4)cnc23)ccn1
7278,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,1-[Bis-(4-fluoro-phenyl)-methyl]-4-(3-phenyl-allyl)-piperazine (Flunarizine),0.6058,uM,=,-0.217670731003163,0,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
7279,462632,10.1016/j.bmcl.2008.01.108,,,,Displacement of [3H]dofetilide from human ERG expressed in HEK293 cell membranes,Cc1nc[n+]([O-])c(C)c1C(=O)N1CCC(C)(N2CCC(N(c3ccccc3)c3ccccc3)CC2)CC1,"(4,6-Dimethyl-1-oxy-pyrimidin-5-yl)-(4-diphenylamino-4'-methyl-[1,4']bipiperidinyl-1'-yl)-methanone",1.2,uM,=,0.0791812460476248,1,O=C(c1cnc[nH+]c1)N1CCC(N2CCC(N(c3ccccc3)c3ccccc3)CC2)CC1
7280,2219924,10.1016/j.bmcl.2021.128463,,,,Displacement of MK499 from human ERG expressed in HEK membrane by radio ligand binding competition assay,COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C(C)(C)C(N)=N3)c2)cn1,"US9273042, 7",7.464,uM,=,0.8729716307384435,1,O=C(Nc1cccc(C2CS(=O)(=O)CC=N2)c1)c1cnccn1
7281,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1ncc(-c2c(C)c(CNC3CCCC3)nn2-c2ncccc2Cl)cc1F,N-((1-(3-chloropyridin-2-yl)-5-(5-fluoro-6-methylpyridin-3-yl)-4-methyl-1H-pyrazol-3-yl)methyl)cyclopentanamine,23.0,uM,=,1.3617278360175928,1,c1ccc(-n2nc(CNC3CCCC3)cc2-c2cccnc2)nc1
7282,2062193,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human ERG expressed in HEK293 cells assessed as reduction in S35-MK-0499 binding,Cc1cc(-c2ccc3c(c2)-c2nnc(Cc4cccc(Cl)c4)n2CCO3)ccn1,"3-(3-chlorobenzyl)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",3.86,uM,=,0.5865873046717549,1,c1ccc(Cc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
7283,2026823,10.1021/acs.jmedchem.6b00723,,,,Inhibition of human ERG by IonWorks patch-clamp electrophysiology method,O=C(NCCN1CCCC1)c1cc(-c2ccc(S(=O)(=O)N3CCOCC3)cc2)nc2ccc(F)cc12,6-Fluoro-2-(4-(morpholinosulfonyl)phenyl)-N-(2-(pyrrolidin-1-yl)ethyl)quinoline-4-carboxamide,11.0,uM,=,1.0413926851582251,1,O=C(NCCN1CCCC1)c1cc(-c2ccc(S(=O)(=O)N3CCOCC3)cc2)nc2ccccc12
7284,972740,10.1021/ml400197u,,,,Binding affinity to human ERG expressed in CHO cells by IonWorks assay,CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C,"N-(5-(3-Cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-ylamino)-2-methylphenyl)acetamide",21.0,uM,=,1.3222192947339193,1,c1ccc(Nc2cc(NC3CC3)n3nccc3n2)cc1
7285,702661,10.1021/jm100978n,,,,Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(c1cnccn1)C3)C2)c1cccc(F)c1,"endo-N-((S)-1-(3-fluorophenyl)-3-(3-(2-methyl-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)propyl)acetamide",1.0,uM,=,0.0,0,c1ccc(CCCN2[C@@H]3CC[C@H]2C[C@@H](n2cnc4c2CCN(c2cnccn2)C4)C3)cc1
7286,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCc1ncc(F)cn1,2-(2-(5-Fluoropyrimidin-2-yl)ethyl)-3-oxo-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,5.5,uM,=,0.7403626894942439,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ncccn1
7287,818499,10.1016/j.bmcl.2012.04.006,,,,Inhibition of human Erg expressed in HEK293 cells assessed as rubidium efflux after 4 hrs by atomic absorbance spectrometric analysis,C[C@H]1c2c([nH]c3ccc(C(F)(F)F)cc23)C[C@H]2CCN(CCCC3(C(=O)O)CCOCC3)C[C@@H]21,"4-(3-((4aR,11R,11aS)-11-methyl-9-(trifluoromethyl)-3,4,4a,5-tetrahydro-1H-pyrido[4,3-b]carbazol-2(6H,11H,11aH)-yl)propyl)tetrahydro-2H-pyran-4-carboxylic acid",0.3,uM,=,-0.5228787452803376,0,c1ccc2c3c([nH]c2c1)C[C@H]1CCN(CCCC2CCOCC2)C[C@@H]1C3
7288,796234,10.1016/j.bmcl.2011.10.115,,,,Inhibition of human Erg by whole cell patch clamp electrophysiology,CN(C)C(=O)CN1CCCC(c2nc3ccccc3n2CCOc2ccccc2)C1,"(+/-)-N,N-dimethyl-2-(3-(1-(2-phenoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)acetamide",0.45,uM,=,-0.3467874862246563,0,c1ccc(OCCn2c(C3CCCNC3)nc3ccccc32)cc1
7289,1478737,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,5-Methoxy-1-(4-trifluoromethyl-phenyl)-pentan-1-one O-(2-amino-ethyl)-oxime (Fluvoxamine),3.1,uM,=,0.4913616938342727,1,c1ccccc1
7290,676320,10.1021/jm100677s,,,,Inhibition of human ERG,CSc1nn(-c2ccccc2)c2cc(NC(=O)C3CCNCC3)ccc12,N-(3-(methylthio)-1-phenyl-1H-indazol-6-yl)piperidine-4-carboxamide,8.13,uM,=,0.9100905455940682,1,O=C(Nc1ccc2cnn(-c3ccccc3)c2c1)C1CCNCC1
7291,875038,10.1021/jm300573d,,,,Inhibition of human ERG,CC(C)n1nc(C(=O)NCC2CCN(CCN3CCOCC3)CC2)c2ccccc21.Cl.Cl,1-Isopropyl-N-[[1-[2-morpholin-4-ylethyl]-4-piperidinyl]methyl]-1H-indazole-3-carboxamide dihydrochloride,32.5,uM,=,1.5118833609788744,1,O=C(NCC1CCN(CCN2CCOCC2)CC1)c1n[nH]c2ccccc12
7292,766845,10.1021/jm200682b,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2Cn2cncn2)CC1.Cl.Cl.Cl,"5-((1H-1,2,4-Triazol-1-yl)methyl)-N-(3-(4-(3-chloro-2-methylphenyl)piperazin-1-yl)propyl)-1,2-diphenyl-1H-imidazole-4-carboxamide dihydrochloride",9.8,uM,=,0.9912260756924948,1,O=C(NCCCN1CCN(c2ccccc2)CC1)c1nc(-c2ccccc2)n(-c2ccccc2)c1Cn1cncn1
7293,1794818,10.1016/j.bmcl.2018.08.015,,,,Displacement of 3H-dofetilide from human ERG,CCCCNc1nc(N)nc2c1CN(C(=O)c1csc(C)n1)CC2,"(2-amino-4-(butylamino)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)(2-methylthiazol-4-yl)methanone",1.3,uM,=,0.1139433523068367,1,O=C(c1cscn1)N1CCc2ncncc2C1
7294,344972,10.1016/j.bmcl.2006.01.030,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,O=C([C@@H](O)C1CC1)N1CC(c2cc(F)ccc2F)=C[C@H]1c1ccccc1,"(S)-2-cyclopropyl-1-((S)-4-(2,5-difluorophenyl)-2-phenyl-2H-pyrrol-1(5H)-yl)-2-hydroxyethanone",11.0,uM,=,1.0413926851582251,1,O=C(CC1CC1)N1CC(c2ccccc2)=C[C@H]1c1ccccc1
7295,1552715,10.1016/j.ejmech.2015.12.006,,,,Inhibition of human ERG channel by fluorescence polarization assay,COC(=O)N1CCC(CN2CC[C@H](NC(=O)c3cc(Cl)c(N)cc3OC)[C@H](OC)C2)CC1,Methyl 4-((cis-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)methyl)piperidine-1-carboxylate,10.0,uM,=,1.0,1,O=C(NC1CCN(CC2CCNCC2)CC1)c1ccccc1
7296,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.Cl.FCCOc1ccccc1CCN1CCN(CCc2ccc(F)cc2)CC1,1-(2-(2-Fluoroethoxy)phenethyl)-4-(4-fluorophenethyl)piperazine dihydrochloride,1.12,uM,=,0.0492180226701816,1,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
7297,1697113,10.1021/acs.jmedchem.7b00932,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in peak tail current amplitude by path clamp method,CCN1CCc2c(sc(NC(=O)Nc3ccc(Cl)cc3)c2C(N)=O)C1.Cl,"2-[3-(4-Chlorophenyl)ureido]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide Hydrochloride",3.26,uM,=,0.5132176000679389,1,O=C(Nc1ccccc1)Nc1cc2c(s1)CNCC2
7298,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,Cc1cccc(C)c1[C@]1(O)CC[C@@H](N2CC(NC(=O)CNC(=O)c3cccc(C(F)(F)F)c3)C2)CC1,"N-({1-[4-(2,6-Dimethyl-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide",7.6,uM,=,0.8808135922807914,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccccc3)CC2)C1
7299,563071,10.1021/jm900063x,,,,Inhibition of human ERG by MK-0499 binding assay,O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(C(F)(F)F)cc(C(F)(F)CO)c2)CC1,"(4-(3-(1,1-difluoro-2-hydroxyethyl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",2.5,uM,=,0.3979400086720376,1,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2ccccc2)CC1
7300,1719825,10.1016/j.ejmech.2017.09.012,,,,Inhibition of human ERG by patch clamp assay,CCc1cc2c(s1)CCN1Cc3ccccc3CC21,"2-Ethyl-8,11-dimethoxy-4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinoline",10.5,uM,=,1.021189299069938,1,c1ccc2c(c1)CC1c3ccsc3CCN1C2
7301,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,COc1ccc(CCN2CCC(CCc3ccccc3OCCF)CC2)cc1.Cl,4-(2-(2-Fluoroethoxy)phenethyl)-1-(4-methoxyphenethyl)piperidine hydrochloride,0.35,uM,=,-0.4559319556497244,0,c1ccc(CCC2CCN(CCc3ccccc3)CC2)cc1
7302,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(F)cc1,"rac-4-Amino-N-[1-(4-fluorophenyl)ethyl]-1-(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)piperidine-4-carboxamide",26.957,uM,=,1.430671558636988,1,O=C(NCc1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
7303,1797483,10.1021/acsmedchemlett.8b00344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch clamp assay,CC(C)(C)S(=O)(=O)c1ccc2nccc(Nc3n[nH]c4ncc(F)cc34)c2c1,"6-(tert-butylsulfonyl)-N-(5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)quinolin-4-amine",12.14,uM,=,1.0842186867392387,1,c1ccc2c(Nc3n[nH]c4ncccc34)ccnc2c1
7304,1335624,10.1016/j.bmcl.2014.02.064,,,,Inhibition of human ERG,NC(=O)c1cc(-c2ccccc2F)sc1Nc1cccc(CN2CCOCC2)n1,5-(2-fluorophenyl)-2-(6-(morpholinomethyl)pyridin-2-ylamino)thiophene-3-carboxamide,0.161,uM,=,-0.7931741239681502,0,c1ccc(-c2ccc(Nc3cccc(CN4CCOCC4)n3)s2)cc1
7305,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,7.4,uM,=,0.8692317197309762,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7306,1798125,10.1021/acsmedchemlett.8b00305,,,,Inhibition of MK-499 binding to human ERG,CCOc1cc(CN2CCC3(CC2)CCN(S(=O)(=O)c2cccnc2)CC3)cc(OCC)c1-c1ccc(F)cc1,"3-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-9-(pyridin-3-ylsulfonyl)-3,9-diazaspiro[5.5]undecane",0.21,uM,=,-0.6777807052660807,0,O=S(=O)(c1cccnc1)N1CCC2(CCN(Cc3ccc(-c4ccccc4)cc3)CC2)CC1
7307,344972,10.1016/j.bmcl.2006.01.030,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CC(C)(C)[C@H](NC(=O)OCCO)C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1ccccc1,"2-hydroxyethyl (S)-1-((S)-4-(2,5-difluorophenyl)-2-phenyl-2H-pyrrol-1(5H)-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate",25.0,uM,=,1.3979400086720375,1,C1=C(c2ccccc2)CN[C@@H]1c1ccccc1
7308,1580962,10.1021/acsmedchemlett.6b00018,,,,Binding affinity to human ERG by radioligand binding assay,CC(C)(C)c1cc(NC(=O)n2ccc3cc(Oc4ncnc5c4CNC5)cnc32)no1,"N-(5-(tert-Butyl)isoxazol-3-yl)-5-((6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)oxy)-1H-pyrrolo[2,3-b]pyridine-1-carboxamide",5.7,uM,=,0.7558748556724915,1,O=C(Nc1ccon1)n1ccc2cc(Oc3ncnc4c3CNC4)cnc21
7309,1798125,10.1021/acsmedchemlett.8b00305,,,,Inhibition of MK-499 binding to human ERG,CCOc1cc(CN2CCC(C3CCN(S(=O)(=O)c4ccccc4)CC3)CC2)cc(OCC)c1-c1ccc(F)cc1,"1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-1'-(phenylsulfonyl)-4,4'-bipiperidine",0.22,uM,=,-0.6575773191777937,0,O=S(=O)(c1ccccc1)N1CCC(C2CCN(Cc3ccc(-c4ccccc4)cc3)CC2)CC1
7310,2093276,10.1016/j.ejmech.2020.112538,,,,Inhibition of human ERG stably expressed in HEK293 cells by whole-cell manual patch clamp method,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide,0.013,uM,=,-1.8860566476931635,0,c1ccc(CCNCCOc2ccccc2)cc1
7311,2232362,10.1016/j.bmcl.2022.128648,,,,Inhibition of human ERG by Ionworks electrophysiology assay,N#Cc1cnc2ccc(=O)n(CCN[C@H]3CC[C@H]4[C@H](C3)OC(=O)N4c3ccc4c(n3)NC(=O)CS4)c2c1,"6-oxo-5-(2-(((3aS,6S,7aS)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)octahydrobenzo[d]oxazol-6-yl)amino)ethyl)-5,6-dihydro-1,5-naphthyridine-3-carbonitrile",20.0,uM,=,1.3010299956639813,1,O=C1CSc2ccc(N3C(=O)O[C@H]4C[C@@H](NCCn5c(=O)ccc6ncccc65)CC[C@@H]43)nc2N1
7312,1523572,10.1021/acs.jmedchem.5b01605,,,,Inhibition of human ERG potassium channel by ionworks patch-clamp electrophysiology assay,CS(=O)(=O)c1ccc(-c2cnc3ccc(-c4cccc(S(C)(=O)=O)c4)cn23)cc1,"6-(3-(methylsulfonyl)phenyl)-3-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine",4.8,uM,=,0.6812412373755872,1,c1ccc(-c2ccc3ncc(-c4ccccc4)n3c2)cc1
7313,856088,10.1016/j.bmc.2012.08.050,,,,Displacement of [3H]-dofetilide from human ERG,CCN(CC)CCSc1nc(-c2cc(OC)c(Cl)cc2Cl)c2c(C#N)c[nH]c2n1,"4-(2,4-Dichloro-5-methoxy-phenyl)-2-(2-diethylaminoethylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2ncnc3[nH]ccc23)cc1
7314,579203,10.1016/j.bmcl.2009.05.069,,,,Displacement of [35S]MK499 from human ERG channel in HEK293 cells,CCCNc1cc(N2CCOCC2)cc(CCc2nc(C)c(CC)o2)n1,6-(2-(5-ethyl-4-methyloxazol-2-yl)ethyl)-4-morpholino-N-propylpyridin-2-amine,0.48,uM,=,-0.3187587626244128,0,c1cc(N2CCOCC2)cc(CCc2ncco2)n1
7315,1901021,10.1021/acs.jmedchem.9b01112,,,,Inhibition of human ERG expressed in CHOK1 cells by Qpatch electrophysiological assay,CS(=O)(=O)c1cc(-c2ccccc2)cc(S(=O)(=O)c2cnc(CN)s2)c1,"(5-((5-(Methylsulfonyl)-[1,1'-biphenyl]-3-yl)sulfonyl)thiazol-2-yl)methanamine",10.0,uM,=,1.0,1,O=S(=O)(c1cccc(-c2ccccc2)c1)c1cncs1
7316,796234,10.1016/j.bmcl.2011.10.115,,,,Inhibition of human Erg by whole cell patch clamp electrophysiology,COc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1,(+)-(R)-2-(1-(4-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)thiomorpholine,1.5,uM,=,0.1760912590556812,1,c1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1
7317,1901021,10.1021/acs.jmedchem.9b01112,,,,Inhibition of human ERG expressed in CHOK1 cells by Qpatch electrophysiological assay,CCc1cc(-c2cnn(C)c2)cc(S(=O)(=O)c2cnc(CN)s2)c1,(5-((3-Ethyl-5-(1-methyl-1H-pyrazol-4-yl)phenyl)sulfonyl)thiazol-2-yl)methanamine,47.0,uM,=,1.6720978579357175,1,O=S(=O)(c1cccc(-c2cn[nH]c2)c1)c1cncs1
7318,2155248,10.1021/acs.jmedchem.1c00406,,,,Inhibition of human ERG expressed in HEK-293 cells by voltage clamp electrophysiology assay,CCC1=C(N2CCC3(CCN(C[C@H](O)c4ccc5c(c4C)COC5=O)CC3)C2=O)COC1=O,"(R)-2-(4-Ethyl-5-oxo-2,5-dihydrofuran-3-yl)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2,8-diazaspiro-[4.5]decan-1-one",23.0,uM,=,1.3617278360175928,1,O=C1C=C(N2CCC3(CCN(CCc4ccc5c(c4)COC5=O)CC3)C2=O)CO1
7319,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cncc4ccccc34)ccc1OC1(CCC1)C21COC1,"US8975415, RP210::US9242973, RP210",3.7,uM,=,0.568201724066995,1,C1=NC2(CO1)c1cc(-c3cncc4ccccc34)ccc1OC1(CCC1)C21COC1
7320,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CC#CCc1ccccc1,N-Ethyl-N-heptyl-4-phenylbut-2-yn-1-amine,3.543,uM,=,0.5493711523331772,1,c1ccccc1
7321,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@H](c3ccc(O)cc3)CC2)C1,N-({1-[4-(4-Hydroxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,4.1,uM,=,0.6127838567197355,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccccc3)CC2)C1
7322,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,NC[C@]1(c2ccccc2)[C@@H]2CCN(c3cnc4c(-c5cccc(Cl)c5Cl)n[nH]c4n3)C[C@@H]21,"((1S,6R,7R)-3-(3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-7-phenyl-3-azabicyclo[4.1.0]heptan-7-yl)methanamine",0.389,uM,=,-0.4100503986742922,0,c1ccc(-c2n[nH]c3nc(N4CC[C@H]5C(c6ccccc6)[C@H]5C4)cnc23)cc1
7323,1478741,10.1093/cvr/cvr044,,,,Inhibition of hERG K channel,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",1.8,uM,=,0.255272505103306,1,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
7324,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)CC#CCCc1ccc(C)cc1,N-Butyl-N-ethyl-5-(p-tolyl)pent-2-yn-1-amine,5.59,uM,=,0.7474118078864233,1,c1ccccc1
7325,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)C/C=C/CCc1ccc(Cl)cc1,(E)-N-(5-(4-Chlorophenyl)pent-2-en-1-yl)-N-ethylheptan-1-amine,0.238,uM,=,-0.623423042943488,0,c1ccccc1
7326,627243,10.1021/jm9016812,,,,Inhibition of human ERG by electrophysiology assay,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(Cl)cc4)oc3C)c2)cc1,2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,29.3,uM,=,1.4668676203541096,1,O=C(NCc1cccc(OCc2coc(-c3ccccc3)n2)c1)Oc1ccccc1
7327,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C)CC1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide",7.1,uM,=,0.8512583487190752,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c2c1
7328,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,CC(O)(c1ccc(CN2CCC3(CC2)OCc2cc(F)ncc23)cc1)c1ccc(F)c(F)c1,"rac-1-(3,4-difluorophenyl)-1-(4-((6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1'-yl)methyl)phenyl)ethanol",0.53,uM,=,-0.2757241303992109,0,c1ccc(Cc2ccc(CN3CCC4(CC3)OCc3ccncc34)cc2)cc1
7329,2094146,10.1021/acs.jmedchem.0c01518,,,,Inhibition of human ERG by patch clamp assay,C[C@H](Oc1cc2cc(F)ccc2nc1N)c1[nH]c(=O)ccc1-n1cccn1,PF-07059013,43.0,uM,=,1.6334684555795866,1,O=c1ccc(-n2cccn2)c(COc2cnc3ccccc3c2)[nH]1
7330,1448459,10.1021/jm5004864,,,,Inhibition of human ERG over-expressed in HEK293 cell membrane by [3H]dofetilide binding assay,CNc1ccc(/C=C/c2c(F)cccc2Cl)cc1,(E)-4-(2'-chloro-6'-fluorostyryl)-N-methylaniline,49.8,uM,=,1.6972293427597176,1,C(=C/c1ccccc1)\c1ccccc1
7331,1745714,10.1016/j.bmc.2017.10.004,,,,Inhibition of human ERG expressed in Xenopus laevis oocytes by two-electrode voltage clamp assay,CCCCCCCCCCn1c(NC2CCN(CCc3ccc(OC)cc3)CC2)nc2ccccc21,1-Decyl-N-(1-(4-methoxyphenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine,2.069,uM,=,0.3157604906657346,1,c1ccc(CCN2CCC(Nc3nc4ccccc4[nH]3)CC2)cc1
7332,2079711,10.1016/j.ejmech.2020.113054,,,,Inhibition of human ERG,NC(=O)c1cccc2cc(C(=O)N3CCN(c4nc(-c5cnc(NC(=O)CN6CCOCC6)cc5C(F)(F)F)nc(N5CCOCC5)n4)CC3)oc12,"2-(4-(4-morpholino-6-(6-(2-morpholinoacetamido)-4-(trifluoromethyl)pyridin-3-yl)-1,3,5-triazin-2-yl)piperazine-1-carbonyl)benzofuran-7-carboxamide",29.4,uM,=,1.4683473304121573,1,O=C(CN1CCOCC1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCN(C(=O)c4cc5ccccc5o4)CC3)n2)cn1
7333,1695906,10.1016/j.bmcl.2017.08.030,,,,Inhibition of human ERG,O=C(c1cc(F)cc(Cl)c1)N1CCn2nc(-c3ccc(F)cn3)cc2C1,"(3-chloro-5-fluorophenyl)(2-(5-fluoropyridin-2-yl)-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)methanone",15.0,uM,=,1.1760912590556811,1,O=C(c1ccccc1)N1CCn2nc(-c3ccccn3)cc2C1
7334,796234,10.1016/j.bmcl.2011.10.115,,,,Inhibition of human Erg by whole cell patch clamp electrophysiology,Fc1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1,(+/-)-(R)-2-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)morpholine,3.4,uM,=,0.5314789170422551,1,c1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1
7335,1927981,10.1021/acsmedchemlett.6b00117,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,Cc1nc(NCc2ccccn2)c2c(-c3ccccc3)cccc2n1,2-methyl-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine,4.6,uM,=,0.6627578316815741,1,c1ccc(-c2cccc3ncnc(NCc4ccccn4)c23)cc1
7336,1586953,10.1021/acs.jmedchem.6b00203,,,,Inhibition of human ERG expressed in CHOK1 cells after 6 mins by electrophysiology assay,COc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"1-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3-methoxy-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",10.0,uM,=,1.0,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
7337,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1cccc(OC(F)(F)F)c1)C1c2ccccc2C(=O)N1CCc1ccccn1,3-Oxo-2-(2-(pyridin-2-yl)ethyl)-N-(3-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,21.0,uM,=,1.3222192947339193,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
7338,1751570,10.1016/j.bmcl.2017.10.039,,,,Displacement of [3H]Dofetilide from human ERG expressed in HEK293 cells after 60 mins by scintillation spectrometry,Cl.Cl.FCCOc1ccccc1CCN1CCN(CCc2ccccc2Cl)CC1,1-(2-Chlorophenethyl)-4-(2-(2-fluoroethoxy)phenethyl)piperazine dihydrochloride,0.85,uM,=,-0.0705810742857072,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
7339,774669,,,,,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,"8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine",10.571,uM,=,1.0241160728267704,1,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2
7340,368633,10.1021/jm060347y,,,,Inhibition of human ERG expressed in HEK293 cells,O=C(NC1CC1)c1cc(NCc2cnc(Nc3ccccn3)s2)c(F)cc1F,"N-cyclopropyl-2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-yl)methylamino)benzamide",16.6,uM,=,1.2201080880400552,1,O=C(NC1CC1)c1cccc(NCc2cnc(Nc3ccccn3)s2)c1
7341,2128264,10.1021/acs.jmedchem.0c02153,,,,Inhibition of human ERG expressed in HEK293 cells by whole cell manual patch clamp assay,CC(=O)NC[C@@H]1OC(=O)N2Cc3cc(-c4ccc(C#N)nc4)c(F)cc3O[C@@H]12,"N-(((3S,3aS)-7-(6-Cyanopyridin-3-yl)-6-fluoro-1-oxo-3,3a-dihydro-1H,9H-benzo[e]oxazolo[4,3-b][1,3]oxazin-3-yl)methyl)acetamide",17.82,uM,=,1.250907699700856,1,O=C1OC[C@@H]2Oc3ccc(-c4cccnc4)cc3CN12
7342,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,CC(CC#N)N1C(=O)c2ccccc2C1C(=O)NCc1ccc(OC(F)(F)F)cc1,2-(1-Cyanopropan-2-yl)-3-oxo-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,31.0,uM,=,1.4913616938342726,1,O=C1NC(C(=O)NCc2ccccc2)c2ccccc21
7343,1697113,10.1021/acs.jmedchem.7b00932,,,,Inhibition of human ERG expressed in HEK293 cells assessed as decrease in peak tail current amplitude by path clamp method,CC[N+]1(C)Cc2sc(NC(=O)Nc3ccc(Cl)cc3)c(C(N)=O)c2C1.[I-],"3-Carbamoyl-2-[3-(4-chlorophenyl)ureido]-5-ethyl-5-methyl-5,6-dihydro-4H-thieno[2,3-c]pyrrol-5-ium Iodide",3.29,uM,=,0.5171958979499743,1,O=C(Nc1ccccc1)Nc1cc2c(s1)C[NH2+]C2
7344,2161899,10.1021/acs.jmedchem.1c01066,,,,Inhibition of human ERG by patch clamp method,C[C@H](C(=O)O)n1nc(Cn2cc3cc(OCC4CC4)c(Cl)cc3n2)c2ccccc2c1=O,(R)-2-(4-((6-chloro-5-(cyclopropylmethoxy)-2H-indazol-2-yl)methyl)-1-oxophthalazin-2(1H)-yl)propanoic acid,35.8,uM,=,1.5538830266438743,1,O=c1[nH]nc(Cn2cc3cc(OCC4CC4)ccc3n2)c2ccccc12
7345,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,O=C1CCCN1C1CCN(CCc2ccc(Oc3nc4ccccc4s3)cc2)CC1,1-(1-{2-[4-(Benzothiazol-2-yloxy)phenyl]ethyl}piperidin-4-yl)pyrrolidin-2-one,1.0,uM,=,0.0,0,O=C1CCCN1C1CCN(CCc2ccc(Oc3nc4ccccc4s3)cc2)CC1
7346,773759,10.1021/jm200909u,,,,Inhibition of human hERG,NC(=O)c1cnc(NC(C2CC2)C2CC2)c2c1[nH]c1cc(-c3cn[nH]c3)ccc12,"1-[(Dicyclopropylmethyl)amino]-7-(1H-pyrazol-4-yl)-5H-pyrido[4,3-b]indole-4-carboxamide",0.99,uM,=,-0.00436480540245,0,c1cc2[nH]c3cc(-c4cn[nH]c4)ccc3c2c(NC(C2CC2)C2CC2)n1
7347,1295005,10.1021/jm4017224,,,,Inhibition of human ERG,Nc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1,"(R)-2-Amino-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)-pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]-thiazole-4-carboxamide",12.7,uM,=,1.1038037209559568,1,O=C(Nc1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)[C@@H]1CCc2scnc21
7348,2079117,10.1016/j.ejmech.2020.113033,,,,Displacement of [3H]dofetilide from human ERG stably expressed in HEK293 cell membranes assessed as unlabelled dofetilide IC50 at 3 uM measured after 60 mins by microbeta liquid scintillation counting method (Rvb = 9.1 to 11.7 nM),N#Cc1cccc(NC(=O)COc2ccc(C(=O)c3cc(Cl)ccc3Br)cc2)c1F,2-(4-(2-bromo-5-chlorobenzoyl)phenoxy)-N-(3-cyano-2-fluorophenyl)acetamide,0.0127,uM,=,-1.8961962790440432,0,O=C(COc1ccc(C(=O)c2ccccc2)cc1)Nc1ccccc1
7349,814592,10.1016/j.bmcl.2012.03.049,,,,Inhibition of human ERG expressed in HEK293 cells by voltage clamp electrophysiology assay,Cc1nc(N2CCC(O)(C3CC3)CC2)nc2ccc(NC(=O)/C=C/c3ccc(C(F)F)cc3)cc12,(E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(difluoromethyl)phenyl)acrylamide,2.5,uM,=,0.3979400086720376,1,O=C(/C=C/c1ccccc1)Nc1ccc2nc(N3CCC(C4CC4)CC3)ncc2c1
7350,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc2c1nc(N)n1nc(CN3CCN(c4ncc(C)s4)C[C@H]3C)nc21,"(R)-7-methoxy-2-((2-methyl-4-(5-methylthiazol-2-yl)piperazin-1-yl)methyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",47.03,uM,=,1.6723749787460795,1,c1ccc2c(c1)ncn1nc(CN3CCN(c4nccs4)CC3)nc21
7351,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,CN1C[C@H](Cc2ccc(Cl)cc2)N(C2CCN(c3n[nH]c(N)n3)CC2)Cc2ccccc21,"(S)-3-(4-(3-(4-chlorobenzyl)-1-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-4(5H)-yl)piperidin-1-yl)-1H-1,2,4-triazol-5-amine",3.2,uM,=,0.505149978319906,1,c1ccc(C[C@H]2CNc3ccccc3CN2C2CCN(c3nc[nH]n3)CC2)cc1
7352,801351,10.1016/j.bmcl.2011.12.016,,,,Binding affinity to human ERG channel,C[N+](C)(CCCCNC(=O)Cc1ccc(OCc2ccccc2)cc1)CCNC(=O)c1nc(Cl)c(N)nc1N.[Br-],"4-(2-(4-(benzyloxy)phenyl)acetamido)-N-(2-(3,5-diamino-6-chloropyrazine-2-carboxamido)ethyl)-N,N-dimethylbutan-1-aminium bromide",0.33,uM,=,-0.4814860601221125,0,O=C(Cc1ccc(OCc2ccccc2)cc1)NCCCC[NH2+]CCNC(=O)c1cnccn1
7353,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,CN(C)c1ncc([C@H]2CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,N-({1-[4-(2-Dimethylamino-pyrimidin-5-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,9.8,uM,=,0.9912260756924948,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3cncnc3)CC2)C1
7354,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,NC[C@]1(c2ccsc2)[C@@H]2CCN(c3cnc4c(-c5cccc(Cl)c5Cl)n[nH]c4n3)C[C@@H]21,"((1S,6R,7R)-3-(3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-7-(thiophen-3-yl)-3-azabicyclo[4.1.0]heptan-7-yl)methanamine",0.109,uM,=,-0.9625735020593764,0,c1ccc(-c2n[nH]c3nc(N4CC[C@H]5C(c6ccsc6)[C@H]5C4)cnc23)cc1
7355,1567397,10.1016/j.ejmech.2016.02.014,,,,Displacement of [3H]dofetilide from human ERG channel expressed in HEK293 cells after 60 mins by liquid scintillation counting method,CN1C(=O)c2ccccc2CC1CN1CCC2(CCc3ccccc32)CC1,"3-{(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)methyl}-2-methyl-3,4-dihydroisoquinolin-1(2H)-one",6.96,uM,=,0.8426092396105621,1,O=C1NC(CN2CCC3(CCc4ccccc43)CC2)Cc2ccccc21
7356,536741,10.1016/j.bmcl.2008.09.009,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O,"4-Oxo-1-[3-(1-oxy-pyridin-3-ylethynyl)-phenyl]-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid cyclopropylamide",65.7,uM,=,1.8175653695597809,1,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[nH+]c3)c2)c2ncccc2c1=O
7357,2241739,10.1016/j.ejmech.2021.113983,,,,Inhibition of human ERG,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NCCc4ccc(OC)c(O)c4)nc(OCC(C)C)nc31)[C@H](O)[C@@H]2O,"(1S,2R,3S,4R,5S)-2,3-dihydroxy-4-[6-[2-(3-hydroxy-4-methoxy-phenyl)ethylamino]-2-isobutoxy-purin-9-yl]-N-methyl-bicyclo[3.1.0]hexane-1-carboxamide",16.5,uM,=,1.2174839442139065,1,c1ccc(CCNc2ncnc3c2ncn3[C@H]2CCC3C[C@@H]32)cc1
7358,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,Nc1ccc([C@H]2CC[C@H](N3CC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)nc1,N-({1-[4-(5-Amino-pyridin-2-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,37.0,uM,=,1.568201724066995,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccccn3)CC2)C1
7359,766645,10.1016/j.bmcl.2011.07.030,,,,Inhibition of human ERG,O=C(NCC1(N2CCOCC2)CCCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1,"N-((1-morpholinocyclopentyl)methyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",10.0,uM,=,1.0,1,O=C(NCC1(N2CCOCC2)CCCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
7360,973733,10.1016/j.bmcl.2013.06.013,,,,Inhibition of human ERG by automated planar patch-clamp system,CCOC(=O)N1CCC(CN2CCC3(CC2)CC(=O)Nc2ncccc23)CC1,"ethyl 4-((2-oxo-2,3-dihydro-1H-spiro[[1,8]naphthyridine-4,4'-piperidine]-1'-yl)methyl)piperidine-1-carboxylate",2.8,uM,=,0.4471580313422192,1,O=C1CC2(CCN(CC3CCNCC3)CC2)c2cccnc2N1
7361,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NCOc3cc(F)ccc3F)(CC1)CO2,"(R)-4-((4-((2,5-difluorophenoxy)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",0.064,uM,=,-1.193820026016113,0,O=c1ccc2nccc3c2n1CC3CC12CCC(NCOc3ccccc3)(CC1)CO2
7362,1329886,10.1039/C2MD20259J,,,,Inhibition of dofetilide binding to human ERG,N#Cc1ccc(OCC2(O)CN(S(=O)(=O)c3ccc(Cl)cc3Cl)C2)cc1F,"4-[1-(2,4-Dichloro-benzenesulfonyl)-3-hydroxy-azetidin-3-ylmethoxy]-2-fuoro-benzonitrile",9.67,uM,=,0.9854264740830015,1,O=S(=O)(c1ccccc1)N1CC(COc2ccccc2)C1
7363,1436969,10.1021/jm500973a,,,,Inhibition of human ERG,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",6.7,uM,=,0.8260748027008264,1,c1ccc(Nc2nccc(-c3cnn4ccccc34)n2)cc1
7364,966750,10.1016/j.bmcl.2013.04.074,,,,Inhibition of human ERG current by patch clamp assay,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23.C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23.O,"(S)-8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid",915.0,uM,=,2.9614210940664485,1,O=c1ccn2c3c(c(N4CCNCC4)ccc13)OCC2.O=c1ccn2c3c(c(N4CCNCC4)ccc13)OCC2
7365,1567397,10.1016/j.ejmech.2016.02.014,,,,Displacement of [3H]dofetilide from human ERG channel expressed in HEK293 cells after 60 mins by liquid scintillation counting method,Oc1ccc(Br)c2c1CNC(CN1CCC3(CCc4ccccc43)CC1)C2,"5-bromo-3-{(2,3-dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)methyl}-1,2,3,4-tetrahydroisoquinolin-8-ol",1.0,uM,=,0.0,0,c1ccc2c(c1)CNC(CN1CCC3(CCc4ccccc43)CC1)C2
7366,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,CC1(c2cccc(-c3cncnc3)c2)N=C(N)c2ccccc2S1,"2-Methyl-2-(3-(pyrimidin-5-yl)phenyl)-2H-benzo[e][1,3]-thiazin-4-amine",6.0,uM,=,0.7781512503836436,1,C1=NC(c2cccc(-c3cncnc3)c2)Sc2ccccc21
7367,458983,10.1016/j.bmcl.2007.03.065,,,,Inhibition of hERG,CC(=O)c1sc(NC(=O)N[C@@H]2CN(C(C)=O)CC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)nc1C,"1-((3S,4S)-4-(((S)-3-(4-fluorobenzyl)piperidin-1-yl)methyl)-1-acetylpiperidin-3-yl)-3-(5-acetyl-4-methylthiazol-2-yl)urea",6.0,uM,=,0.7781512503836436,1,O=C(Nc1nccs1)N[C@@H]1CNCC[C@H]1CN1CCC[C@@H](Cc2ccccc2)C1
7368,1328433,10.1039/C2MD20077E,,,,Inhibition of human ERG,CC(C)Oc1cc(Oc2ccc(C(=O)N3CCC3)cc2)cc(C(=O)Nc2ccn(C)n2)c1,3-(4-(azetidine-1-carbonyl)phenoxy)-5-isopropoxy-N-(1-methyl-1H-pyrazol-3-yl)benzamide,27.0,uM,=,1.4313637641589874,1,O=C(Nc1cc[nH]n1)c1cccc(Oc2ccc(C(=O)N3CCC3)cc2)c1
7369,773759,10.1021/jm200909u,,,,Inhibition of human hERG,NC(=O)c1cnc(N[C@H](C2CC2)C(F)(F)F)c2c1[nH]c1cc(-c3cn[nH]c3)ccc12,"1-{[(1R)-1-Cyclopropyl-2,2,2-trifluoroethyl]amino}-7-(1H-pyrazol-4-yl)-5H-pyrido[4,3-b]indole-4-carboxamide",3.0,uM,=,0.4771212547196624,1,c1cc2[nH]c3cc(-c4cn[nH]c4)ccc3c2c(NCC2CC2)n1
7370,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccc(O)c(C)c2)oc2ccc(O)c(CN3CCC4(COC4)C3)c12,4-(2-oxa-6-azaspiro[3.4]octan-6-ylmethyl)-5-hydroxy-2-(4-hydroxy-3-methylphenyl)-N-methylbenzofuran-3-carboxamide,16.6,uM,=,1.2201080880400552,1,c1ccc(-c2cc3c(CN4CCC5(COC5)C4)cccc3o2)cc1
7371,1797483,10.1021/acsmedchemlett.8b00344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch clamp assay,COc1cc2nccc(Nc3n[nH]c(C)c3C)c2cc1S(=O)(=O)C(C)(C)C,"6-(tert-butylsulfonyl)-N-(4,5-dimethyl-1H-pyrazol-3-yl)-7-methoxyquinolin-4-amine",14.5,uM,=,1.1613680022349748,1,c1ccc2c(Nc3cc[nH]n3)ccnc2c1
7372,540897,10.1016/j.bmcl.2009.01.012,,,,Displacement of [3H]dofetilide form human ERG expressed in HEK239 cells,Cc1cccc(C)c1C(=O)N1CCC(N2CCC(N(Cc3ccccc3)C(=O)C3CCC3)CC2)CC1,"N-benzyl-N-(1'-(2,6-dimethylbenzoyl)-1,4'-bipiperidin-4-yl)cyclobutanecarboxamide",3.41,uM,=,0.5327543789924978,1,O=C(c1ccccc1)N1CCC(N2CCC(N(Cc3ccccc3)C(=O)C3CCC3)CC2)CC1
7373,796234,10.1016/j.bmcl.2011.10.115,,,,Inhibition of human Erg by whole cell patch clamp electrophysiology,Cc1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1,(+/-)-(R)-2-(1-(4-methylbenzyl)-1H-benzo[d]imidazol-2-yl)morpholine,2.3,uM,=,0.3617278360175928,1,c1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1
7374,966750,10.1016/j.bmcl.2013.04.074,,,,Inhibition of human ERG current by patch clamp assay,C[C@@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@H](C)N1,"5-Amino-1-cyclopropyl-7-(3,5-dimethyl-piperazin-1-yl)-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid",18.0,uM,=,1.255272505103306,1,O=c1ccn(C2CC2)c2cc(N3CCNCC3)ccc12
7375,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2c(F)cccc2C(=O)N1CCc1ccccn1,7-Fluoro-3-oxo-2-(2-(pyridin-2-yl)ethyl)-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide,5.6,uM,=,0.7481880270062004,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
7376,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,N#Cc1ccc(CCN2CCN(CCc3ccc(C#N)cc3)CC2)cc1,"4,4'-(2,2'-(piperazine-1,4-diyl)bis(ethane-2,1-diyl))dibenzonitrile",0.012,uM,=,-1.9208187539523751,0,c1ccc(CCN2CCN(CCc3ccccc3)CC2)cc1
7377,1641174,,,,,"Inhibition Assay: Test Example 5: The hERG potassium current was measured in a hERG-stably-expressing Chinese hamster ovary K1 (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HTX (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. The test solution includes:Extracellular solution: 2 mM of CaCl2, 1 mM of MgCl2, 10 mM of HEPES, 4 mM of KCl, 145 mM of NaCl, and 10 mM of glucose; and pH adjusted to 7.4 with NaOH,Intracellular solution: 5.374 mM of CaCl2, 1.75 mM of MgCl2, 10 mM of HEPES, 10 mM of EGTA, 120 mM of KCl, and 4 mM of ATP, and pH adjusted to 7.2 with KOH.",NC1=NC2(CO1)c1cc(-c3cncnc3)ccc1OC(Cc1ccccc1)C21COC1,"US8975415, RP200::US8975415, RP202::US9242973, RP202",7.73,uM,=,0.888179493918325,1,C1=NC2(CO1)c1cc(-c3cncnc3)ccc1OC(Cc1ccccc1)C21COC1
7378,1985611,10.1021/acsmedchemlett.0c00092,,,,Displacement of Tracer Red from human ERG by fluorescence polarization assay,Nc1nc(N2CCC(N3Cc4ccncc4OC[C@@H]3Cc3ccc(Cl)cc3)CC2)n[nH]1,"(S)-3-(4-(3-(4-chlorobenzyl)-2,3-dihydropyrido[4,3-f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-1H-1,2,4-triazol-5-amine",50.0,uM,=,1.6989700043360187,1,c1ccc(C[C@H]2COc3cnccc3CN2C2CCN(c3nc[nH]n3)CC2)cc1
7379,1891417,10.1016/j.bmcl.2019.03.026,,,,Inhibition of human ERG by whole-cell patch clamp method,COC(=O)C1=C(C)NC(C)=C(C(=O)NC[C@H]2CCN(CCc3ccc(OC(F)(F)F)c(F)c3)C2)C1c1cccc([N+](=O)[O-])c1,"Methyl 5-(((R)-1-(3-fluoro-4-(trifluoromethoxy)phenethyl)pyrrolidin-3-yl)methylcarbamoyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate",1.47,uM,=,0.1673173347481761,1,O=C(NC[C@H]1CCN(CCc2ccccc2)C1)C1=CNC=CC1c1ccccc1
7380,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc2c1nc(N)n1nc(CN3CCN(c4ccccc4F)C[C@H]3C)nc21,"(R)-2-((4-(2-fluorophenyl)-2-methylpiperazin-1-yl)methyl)-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",49.97,uM,=,1.698709349442587,1,c1ccc(N2CCN(Cc3nc4c5ccccc5ncn4n3)CC2)cc1
7381,1295005,10.1021/jm4017224,,,,Inhibition of human ERG,Nc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccc(F)cc3)N2)cc1,"(R)-2-Amino-N-(4-(((2S,5R)-5-((R)-(4-fluorophenyl)(hydroxy)-methyl)pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4Hcyclopenta[d]thiazole-4-carboxamide",5.6,uM,=,0.7481880270062004,1,O=C(Nc1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)[C@@H]1CCc2scnc21
7382,768794,10.1021/jm200290z,,,,Inhibition of human ERG,c1ccc(Nc2nc(-c3cn[nH]c3)cs2)nc1,4-(1H-Pyrazol-4-yl)-N-(pyridin-2-yl)thiazol-2-amine,33.0,uM,=,1.5185139398778875,1,c1ccc(Nc2nc(-c3cn[nH]c3)cs2)nc1
7383,1798125,10.1021/acsmedchemlett.8b00305,,,,Inhibition of MK-499 binding to human ERG,CCOc1cc(CN2CCC(COc3cccc4cccnc34)CC2)cc(OCC)c1-c1ccc(F)cc1,"8-((1-((2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)methoxy)quinoline",0.21,uM,=,-0.6777807052660807,0,c1ccc(-c2ccc(CN3CCC(COc4cccc5cccnc45)CC3)cc2)cc1
7384,1972824,10.1021/acsmedchemlett.9b00611,,,,Inhibition of human ERG,COc1nn(C)cc1C(=O)Nc1cccc(-c2cncn2C(C)C)n1,N-(6-(1-Isopropyl-1H-imidazol-5-yl)pyridin-2-yl)-3-methoxy-1-methyl-1H-pyrazole-4-carboxamide,15.0,uM,=,1.1760912590556811,1,O=C(Nc1cccc(-c2cnc[nH]2)n1)c1cn[nH]c1
7385,960200,10.1021/jm3011349,,,,Inhibition of human ERG expressed in CHO cells,CCC1(c2cccc(-c3cncnc3)c2)N=C(N)c2ccccc2O1,"2-Ethyl-2-(3-(pyrimidin-5-yl)phenyl)-2H-benzo[e][1,3]-oxazin-4-amine",1.6,uM,=,0.2041199826559248,1,C1=NC(c2cccc(-c3cncnc3)c2)Oc2ccccc21
7386,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OCC(F)(F)F)nc1)C1c2ccccc2C(=O)N1CCc1ccccn1,"3-Oxo-2-(2-pyridin-2-ylethyl)-N-[[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]methyl]-1H-isoindole-1-carboxamide",16.0,uM,=,1.2041199826559248,1,O=C(NCc1cccnc1)C1c2ccccc2C(=O)N1CCc1ccccn1
7387,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1cncc(-c2c(C)c(CNC3CCCC3)nn2-c2ncccc2Cl)c1,N-((1-(3-chloropyridin-2-yl)-4-methyl-5-(5-methylpyridin-3-yl)-1H-pyrazol-3-yl)methyl)cyclopentanamine,9.0,uM,=,0.9542425094393248,1,c1ccc(-n2nc(CNC3CCCC3)cc2-c2cccnc2)nc1
7388,1797483,10.1021/acsmedchemlett.8b00344,,,,Inhibition of human ERG expressed in CHO cells by Qpatch clamp assay,CC(C)(C)S(=O)(=O)c1ccc2nccc(Nc3cc[nH]n3)c2c1,6-(tert-butylsulfonyl)-N-(1H-pyrazol-3-yl)quinolin-4-amine,8.305,uM,=,0.9193396367874132,1,c1ccc2c(Nc3cc[nH]n3)ccnc2c1
7389,766645,10.1016/j.bmcl.2011.07.030,,,,Inhibition of human ERG,CCNC1(CNC(=O)N2CCC(c3nc(-c4ccc5ccccc5n4)no3)CC2)CCCC1,"N-((1-(ethylamino)cyclopentyl)methyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",24.0,uM,=,1.380211241711606,1,O=C(NCC1CCCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
7390,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=C1COc2cnc(CNC34CCC(C[C@]5(O)Cn6c(=O)ccc7ncc(F)c5c76)(CC3)OC4)cc2N1,"(R)-7-((1-((3-fluoro-4-hydroxy-7-oxo-5,7-dihydro-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-ylamino)methyl)-1H-pyrido[3,4-b][1,4]oxazin-2(3H)-one",11.7,uM,=,1.0681858617461617,1,O=C1COc2cnc(CNC34CCC(CC5Cn6c(=O)ccc7nccc5c76)(CC3)OC4)cc2N1
7391,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NCc3cc(-c4cccs4)on3)(CC1)CO2,"(R)-3-fluoro-4-hydroxy-4-((4-((5-(thiophen-2-yl)isoxazol-3-yl)methylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",0.016,uM,=,-1.7958800173440752,0,O=c1ccc2nccc3c2n1CC3CC12CCC(NCc3cc(-c4cccs4)on3)(CC1)CO2
7392,1554488,10.1016/j.bmcl.2016.01.049,,,,Inhibition of human ERG using tracer red fluorescent probe,CC(C)(N)c1cc(C(=O)N[C@@H]2CCc3ccc(Oc4ccnc5c4CCC(=O)N5)cc3C2)cc(C(F)(F)F)c1.Cl.Cl,"3-(2-aminopropan-2-yl)-N-{(2R)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide dihydrochloride",7.4,uM,=,0.8692317197309762,1,O=C1CCc2c(Oc3ccc4c(c3)C[C@H](NC(=O)c3ccccc3)CC4)ccnc2N1
7393,597859,10.1016/j.bmcl.2009.07.132,,,,Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells,O=C(c1ccc(CN2CCC3(CC2)OCc2cc(F)ncc23)cc1)c1ccc(F)c(F)c1,"(3,4-difluorophenyl)(4-((6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1'-yl)methyl)phenyl)methanone",0.017,uM,=,-1.769551078621726,0,O=C(c1ccccc1)c1ccc(CN2CCC3(CC2)OCc2ccncc23)cc1
7394,1660007,10.1021/acs.jmedchem.6b01620,,,,Inhibition of human ERG by patch clamp assay,COc1nc(C2=NOC[C@H](c3cc4ccccc4o3)N2)ccc1-n1cnc(C)c1,"(R)-5-(Benzofuran-2-yl)-3-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-5,6-dihydro-4H-1,2,4-oxadiazine",15.0,uM,=,1.1760912590556811,1,c1ccc2oc([C@H]3CON=C(c4ccc(-n5ccnc5)cn4)N3)cc2c1
7395,344972,10.1016/j.bmcl.2006.01.030,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CC(C)(CN)C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1ccccc1,"(S)-3-amino-1-(4-(2,5-difluorophenyl)-2-phenyl-2H-pyrrol-1(5H)-yl)-2,2-dimethylpropan-1-one",2.2,uM,=,0.3424226808222063,1,C1=C(c2ccccc2)CN[C@@H]1c1ccccc1
7396,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCc1cccnc1,3-Oxo-2-(2-pyridin-3-ylethyl)-N-[4-(trifluoromethoxy)benzyl]isoindoline-1-carboxamide,5.5,uM,=,0.7403626894942439,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1cccnc1
7397,411697,10.1021/jm060927v,,,,Binding affinity to hERG potassium channel,COc1ccc2c(=O)n(CC(CO)NCc3cccnc3)c(C#N)c(-c3ccccc3)c2c1,"2-{3-hydroxy-2-[(pyridin-3-ylmethyl)amino]propyl}-6-methoxy-1-oxo-4-phenyl-1,2-dihydroisoquinoline-3-carbonitrile",10.0,uM,=,1.0,1,O=c1c2ccccc2c(-c2ccccc2)cn1CCNCc1cccnc1
7398,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@H](c3ccc4c(c3)OCO4)CC2)C1,"cis-N-{[1-(4-Benzo[1,3]dioxol-5-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide",2.8,uM,=,0.4471580313422192,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@@H](c3ccc4c(c3)OCO4)CC2)C1
7399,2169168,10.1021/acs.jmedchem.1c01279,,,,Inhibition of human ERG,Nc1nc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)c2cc(C3=CCN(C4COC4)CC3)[nH]c2n1,"2-(3-(2-Amino-6-(1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2H)-one",8.54,uM,=,0.931457870689005,1,O=c1c2ccc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1
7400,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,CCN(CC)C(=O)c1ccc(C2=CC3(CCN(C(C)=O)CC3)Oc3ccccc32)cc1,"4-(1'-Acetylspiro[chromene-2,4'-piperidine]-4-yl)-N,Ndiethylbenzamide",47.44,uM,=,1.676144680356206,1,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
7401,2232362,10.1016/j.bmcl.2022.128648,,,,Inhibition of human ERG by Ionworks electrophysiology assay,COc1ccc2ccc(=O)n(CCN[C@H]3CC[C@H]4[C@H](C3)OC(=O)N4c3ccc4c(n3)NC(=O)CO4)c2n1,"6-((3aS,6S,7aS)-6-((2-(7-methoxy-2-oxo-1,8-naphthyridin-1(2H)-yl)ethyl)amino)-2-oxohexahydrobenzo[d]oxazol-3(2H)-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",5.0,uM,=,0.6989700043360189,1,O=C1COc2ccc(N3C(=O)O[C@H]4C[C@@H](NCCn5c(=O)ccc6cccnc65)CC[C@@H]43)nc2N1
7402,941768,10.1021/jm4000598,,,,Inhibition of human ERG,N#Cc1ccc(-c2ccc3c(c2)OC[C@H]2[C@H](CO)OC(=O)N32)cn1,"5-((3R,3aS)-3-(hydroxymethyl)-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-7-yl)picolinonitrile",18.35,uM,=,1.2636360685881085,1,O=C1OC[C@@H]2COc3cc(-c4cccnc4)ccc3N12
7403,1506711,10.1016/j.bmcl.2015.05.036,,,,Inhibition of [35S]MK499 binding to human ERG channel,COc1cccc2c1nc(N)n1nc(CN3CCN(c4cccnc4)C[C@H]3C)nc21,"(R)-7-methoxy-2-((2-methyl-4-(pyridin-3-yl)piperazin-1-yl)methyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine",22.29,uM,=,1.3481100684802376,1,c1cncc(N2CCN(Cc3nc4c5ccccc5ncn4n3)CC2)c1
7404,972740,10.1021/ml400197u,,,,Binding affinity to human ERG expressed in CHO cells by IonWorks assay,CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)c(F)cc1C,"N-(5-(3-Cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-ylamino)-4-fluoro-2-methylphenyl)acetamide",16.0,uM,=,1.2041199826559248,1,c1ccc(Nc2cc(NC3CC3)n3nccc3n2)cc1
7405,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,N#Cc1ccc(CCN2CCN(CCc3ccc4c(c3)COC4=O)CC2)cc1OC(F)(F)F,"4-(2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-2-(trifluoromethoxy)benzonitrile",0.11,uM,=,-0.958607314841775,0,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
7406,79531,10.1021/jm0208875,,,,K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.1,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,"3-Dibutylamino-1-(1,3-dichloro-6-trifluoromethyl-phenanthren-9-yl)-propan-1-ol",0.196,uM,=,-0.707743928643524,0,c1ccc2c(c1)ccc1ccccc12
7407,344972,10.1016/j.bmcl.2006.01.030,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CC(C)[C@H](N)C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1ccccc1,"(S)-2-amino-1-((S)-4-(2,5-difluorophenyl)-2-phenyl-2H-pyrrol-1(5H)-yl)-3-methylbutan-1-one",2.4,uM,=,0.380211241711606,1,C1=C(c2ccccc2)CN[C@@H]1c1ccccc1
7408,822408,10.1016/j.bmc.2012.04.028,,,,Inhibition of human ERG by patch clamp assay,C[C@@H]1CCCN1CCCOc1ccc(-c2cn[nH]c(=O)c2)cc1,5-[4-[3-((R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-2Hpyridazin-3-one,10.0,uM,=,1.0,1,O=c1cc(-c2ccc(OCCCN3CCCC3)cc2)cn[nH]1
7409,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cn1cc2c(Cl)c(-c3n[nH]c4nc(N5C[C@@H]6[C@H](C5)[C@@]6(CN)c5nc(Cl)cs5)cnc34)ccc2n1,"((1R,5S,6r)-3-(3-(4-chloro-2-methyl-2H-indazol-5-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-6-(4-chlorothiazol-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methanamine",12.322,uM,=,1.0906812044573908,1,c1csc(C2[C@H]3CN(c4cnc5c(-c6ccc7n[nH]cc7c6)n[nH]c5n4)C[C@@H]23)n1
7410,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,CNC(=O)c1c(-c2ccc(O)cc2)oc2ccc(O)c(CN3CCC(F)CC3)c12,4-((4-fluoropiperidin-1-yl)methyl)-5-hydroxy-2-(4-hydroxyphenyl)-N-methylbenzofuran-3-carboxamide,6.9,uM,=,0.8388490907372553,1,c1ccc(-c2cc3c(CN4CCCCC4)cccc3o2)cc1
7411,523112,10.1016/j.bmcl.2009.04.116,,,,Displacement of [35S]MK499 from human ERG expressed in HEK293 cells,Cc1ccc(-c2c(C)c(CN[C@H]3CC[C@@H](F)C3)nn2-c2ncccc2Cl)cn1,"(1S,3R)-N-((1-(3-chloropyridin-2-yl)-4-methyl-5-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)methyl)-3-fluorocyclopentanamine",29.0,uM,=,1.462397997898956,1,c1ccc(-n2nc(CNC3CCCC3)cc2-c2cccnc2)nc1
7412,43830,10.1021/jm0208875,,,,K+ channel blocking activity in COS-7 African green monkey kidney derived cells expressing HERG Kv11.1,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,Benzyl-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)-phenyl-amine,0.55,uM,=,-0.2596373105057561,0,c1ccc(CN(CCN2CCCC2)c2ccccc2)cc1
7413,806502,10.1021/jm201564u,,,,Inhibition of human Erg expressed in HEK293 cells by patch clamp assay,CN1CCC[C@H]1CCN1CCCc2cc(NC(=N)c3cccs3)ccc21,"(S)-N-(1-(2-(1-methylpyrrolidin-2-yl)ethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide",4.7,uM,=,0.6720978579357175,1,N=C(Nc1ccc2c(c1)CCCN2CC[C@@H]1CCCN1)c1cccs1
7414,860769,10.1021/jm300623u,,,,Binding affinity to human ERG expressed in CHOK1 cells by IonWorks HT assay,O=C(NCc1ccc(OCC(F)(F)F)cc1)C1c2ccccc2C(=O)N1CCc1ccccn1,"3-Oxo-2-(2-pyridin-2-ylethyl)-N-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]-1H-isoindole-1-carboxamide",8.9,uM,=,0.9493900066449128,1,O=C(NCc1ccccc1)C1c2ccccc2C(=O)N1CCc1ccccn1
7415,344972,10.1016/j.bmcl.2006.01.030,,,,Inhibitory activity against human hERG receptor expressed in HEK cells,CN(C(=O)N1CC(c2cc(F)ccc2F)=C[C@H]1c1ccccc1)C1CCNCC1,"(S)-4-(2,5-difluorophenyl)-N-methyl-2-phenyl-N-(piperidin-4-yl)-2H-pyrrole-1(5H)-carboxamide",1.3,uM,=,0.1139433523068367,1,O=C(NC1CCNCC1)N1CC(c2ccccc2)=C[C@H]1c1ccccc1
7416,2299544,10.1021/acsmedchemlett.3c00059,,,,Inhibition of human ERG by fluorescence polarization assay,Cc1csc([C@@]2(CN)[C@@H]3CCN(c4cnc5c(-c6ccn7nccc7c6Cl)n[nH]c5n4)C[C@@H]32)n1,"((1S,6R,7S)-3-(3-(4-chloropyrazolo[1,5-a]pyridin-5-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-7-(4-methylthiazol-2-yl)-3-azabicyclo[4.1.0]heptan-7-yl)methanamine",0.012,uM,=,-1.9208187539523751,0,c1csc(C2[C@H]3CN(c4cnc5c(-c6ccn7nccc7c6)n[nH]c5n4)CC[C@@H]23)n1
7417,849882,10.1021/ml3000066,,,,Displacement of [35S]MK499 from human ERG,CCOc1cc(CCN2CCN(CCc3ccc4c(c3)COC4=O)CC2)ccc1C#N,"2-ethoxy-4-(2-(4-(2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)benzonitrile",0.67,uM,=,-0.1739251972991735,0,O=C1OCc2cc(CCN3CCN(CCc4ccccc4)CC3)ccc21
7418,543016,10.1016/j.bmcl.2008.12.114,,,,Inhibition of human ERG by patch clamp technique,C[C@@H]1CN(CC2(c3ccncc3)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1,"1,1,1-trifluoro-2-(4-((R)-2-methyl-4-((1-(pyridin-4-yl)cyclopropyl)methyl)piperazin-1-ylsulfonyl)phenyl)propan-2-ol",0.44,uM,=,-0.3565473235138126,0,O=S(=O)(c1ccccc1)N1CCN(CC2(c3ccncc3)CC2)CC1
7419,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCCCCN(CC)CC#CCCc1ccc(C)cc1,N-Ethyl-N-(5-(p-tolyl)pent-2-yn-1-yl)heptan-1-amine,1.89,uM,=,0.2764618041732441,1,c1ccccc1
7420,1665702,10.1021/acs.jmedchem.6b01889,,,,Inhibition of human ERG expressed in HEK293 cells by patch clamp method,CC(=O)Nc1cncc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)c1,N-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)acetamide,2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1
7421,1927981,10.1021/acsmedchemlett.6b00117,,,,Inhibition of human ERG expressed in HEK293 cells by thallium flux assay,COc1cncc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)c1,2-(5-methoxypyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine,8.4,uM,=,0.9242792860618816,1,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1
7422,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@](O)(c3ccc4c(c3)OCC4)CC2)C1,"N-({1-[4-(2,3-Dihydro-benzofuran-6-yl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide",11.7,uM,=,1.0681858617461617,1,O=C(CNC(=O)c1ccccc1)NC1CN(C2CCC(c3ccc4c(c3)OCC4)CC2)C1
7423,718490,10.1021/ml100196d,,,,Inhibition of human ERG,CCC(C)(C)Cc1c[nH]c(CCc2ccc(-c3ccccn3)cc2)n1,"2-(4-(2-(4-(2,2-dimethylbutyl)-1H-imidazol-2-yl)ethyl)phenyl)pyridine",1.2,uM,=,0.0791812460476248,1,c1ccc(-c2ccc(CCc3ncc[nH]3)cc2)nc1
7424,766645,10.1016/j.bmcl.2011.07.030,,,,Inhibition of human ERG,O=C(NCC1(N2CCOCC2)CCCCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1,"N-((1-morpholinocyclohexyl)methyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",4.3,uM,=,0.6334684555795865,1,O=C(NCC1(N2CCOCC2)CCCCC1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
7425,941078,10.1021/jm301762v,,,,Inhibition of human ERG expressed in CHO cells by ionworks assay,NC1(C(=O)NC(Cc2ccccc2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,"rac-4-Amino-N-[1-(4-chlorophenyl)-2-phenylethyl]-1-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",3.5,uM,=,0.5440680443502757,1,O=C(NC(Cc1ccccc1)c1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1
7426,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,C[C@@]1(c2cc(CNCCC(F)(F)F)c(F)cc2F)CCSC(N)=N1,"(S)-4-(2,4-Difluoro-5-(((3,3,3-trifluoropropyl)amino)methyl)-phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine",20.4,uM,=,1.3096301674258988,1,C1=NC(c2ccccc2)CCS1
7427,2232362,10.1016/j.bmcl.2022.128648,,,,Inhibition of human ERG by Ionworks electrophysiology assay,COc1cnc2ccc(=O)n(CCN[C@H]3CC[C@H]4[C@H](C3)OC(=O)N4c3ccc4c(n3)NC(=O)CO4)c2n1,"6-((3aS,6S,7aS)-6-((2-(3-methoxy-6-oxopyrido[2,3-b]pyrazin-5(6H)-yl)ethyl)amino)-2-oxohexahydrobenzo[d]oxazol-3(2H)-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",9.0,uM,=,0.9542425094393248,1,O=C1COc2ccc(N3C(=O)O[C@H]4C[C@@H](NCCn5c(=O)ccc6nccnc65)CC[C@@H]43)nc2N1
7428,1815576,10.1016/j.bmcl.2019.126727,,,,Binding affinity to human ERG,CC(C)C(=O)c1c(Nc2ccc(F)c(F)c2F)[nH]c2c(F)cc(F)cc2c1=O,"6,8-Difluoro-3-isobutyryl-2-((2,3,4-trifluorophenyl)amino)quinolin-4(1H)-one",6.9,uM,=,0.8388490907372553,1,O=c1cc(Nc2ccccc2)[nH]c2ccccc12
7429,1477140,10.1016/j.bmcl.2015.04.063,,,,Displacement of MK499 from human ERG,O=c1ccc2ncc(F)c3c2n1C[C@@]3(O)CC12CCC(NC/C=C/c3ccccc3)(CC1)CO2,"(R,E)-4-((4-(cinnamylamino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-3-fluoro-4-hydroxy-4H-pyrrolo[3,2,1-de][1,5]naphthyridin-7(5H)-one",0.064,uM,=,-1.193820026016113,0,O=c1ccc2nccc3c2n1CC3CC12CCC(NC/C=C/c3ccccc3)(CC1)CO2
7430,1278260,10.1021/jm4010434,,,,Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis,CCCCN(CC)CC#CCOc1ccc(Cl)cc1,N-Butyl-4-(4-chlorophenoxy)-N-ethylbut-2-yn-1-amine,14.443,uM,=,1.1596574112477045,1,c1ccccc1
7431,946889,10.1021/ml400027y,,,,Inhibition of human ERG channel,CS(=O)(=O)c1ccc([C@@H](CC2CCCC2)C(=O)Nc2cnc([C@H](O)CO)cn2)cc1Cl,"2(R)-(3-Chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-[5-(1(S),2-dihydroxyethyl)-pyrazin-2-yl]-propionamide",70.0,uM,=,1.845098040014257,1,O=C(Nc1cnccn1)[C@H](CC1CCCC1)c1ccccc1
7432,1567397,10.1016/j.ejmech.2016.02.014,,,,Displacement of [3H]dofetilide from human ERG channel expressed in HEK293 cells after 60 mins by liquid scintillation counting method,Cc1cc(F)ccc1C1CCN(CC2Cc3c(Cl)ccc(O)c3CN2)CC1,"5-Chloro-3-{[4-(4-fluoro-2-methylphenyl)piperidin-1-yl]methyl}-1,2,3,4-tetrahydroisoquinolin-8-ol",0.97,uM,=,-0.0132282657337551,0,c1ccc(C2CCN(CC3Cc4ccccc4CN3)CC2)cc1
7433,941768,10.1021/jm4000598,,,,Inhibition of human ERG,CC(=O)NC[C@@H]1OC(=O)N2c3ccc(-c4ccc(C#N)nc4)cc3OC[C@@H]12,"N-(((3S,3aS)-7-(6-cyanopyridin-3-yl)-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl)methyl)acetamide",2.78,uM,=,0.4440447959180762,1,O=C1OC[C@@H]2COc3cc(-c4cccnc4)ccc3N12
7434,488207,10.1021/jm701575k,,,,Displacement of [3H]astemizole from human ERG potassium channel expressed in HEK293 cell membrane,CC(=O)NC1CCN(CCc2ccc(Oc3nc4ccccc4s3)cc2)CC1,N-(1-{2-[4-(Benzothiazol-2-yloxy)phenyl]ethyl}piperidin-4-yl)-N-acetamide,9.0,uM,=,0.9542425094393248,1,c1ccc2sc(Oc3ccc(CCN4CCCCC4)cc3)nc2c1
7435,2153514,10.1021/acs.jmedchem.1c01586,,,,Inhibition of hERG ion channel by Q patch-clamp method,O=C(c1c(-c2ccc(O)cn2)oc2ccc(O)c(CN3CCCCC3)c12)N1CC(F)C1,(3-fluoroazetidin-1-yl)(5-hydroxy-2-(5-hydroxypyridin-2-yl)-4-(piperidin-1-ylmethyl)benzofuran-3-yl)methanone,7.4,uM,=,0.8692317197309762,1,O=C(c1c(-c2ccccn2)oc2cccc(CN3CCCCC3)c12)N1CCC1
7436,411697,10.1021/jm060927v,,,,Binding affinity to hERG potassium channel,COc1ccc2c(=O)n(CC(O)CO)c(C#N)c(-c3cccc(C(F)(F)F)c3)c2c1,"2-(2,3-dihydroxypropyl)-6-methoxy-1-oxo-4-[3-(trifluoromethyl)phenyl]-1,2-dihydroisoquinoline-3-carbonitrile",16.0,uM,=,1.2041199826559248,1,O=c1[nH]cc(-c2ccccc2)c2ccccc12
7437,1655356,10.1021/acsmedchemlett.7b00032,,,,Inhibition of human ERG potassium channel by patch clamp assay,c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1,"(2R)-N-(Isoquinolin-3-yl)-3'H-4-azaspiro[bicyclo[2.2.2]octane-2,2'-[1,4]oxazole]-5'-amine",3.2,uM,=,0.505149978319906,1,c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1
7438,768744,10.1016/j.bmcl.2011.06.080,,,,Displacement of [3H]astemizole from human ERG expressed in HEK293 cells after 1 hr,COc1cnccc1[C@H]1CC[C@H](N2CC(NC(=O)CNC(=O)c3cccc(C(F)(F)F)c3)C2)CC1,N-({1-[4-(3-Methoxy-pyridin-4-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide,8.2,uM,=,0.9138138523837168,1,O=C(CNC(=O)c1ccccc1)NC1CN([C@H]2CC[C@H](c3ccncc3)CC2)C1
7439,534605,10.1021/jm8008986,,,,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,CCN(CC)C(=O)c1cccc(C2=CC3(CCNCC3)Oc3ccccc32)c1,"N,N-Diethyl-3-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide",0.303,uM,=,-0.518557371497695,0,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
7440,1552715,10.1016/j.ejmech.2015.12.006,,,,Inhibition of human ERG channel by fluorescence polarization assay,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CC2CCN(C(=O)CC(C)C)CC2)C[C@H]1OC,cis-4-Amino-5-chloro-N-(1-((1-(3-methylbutanoyl)piperidin-4-yl)methyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide,10.0,uM,=,1.0,1,O=C(NC1CCN(CC2CCNCC2)CC1)c1ccccc1
7441,1692061,10.1021/acs.jmedchem.6b01451,,,,Inhibition of human ERG expressed in CHO cells at -80 mV holding potential after 5 mins by patch clamp assay,C[C@@]1(c2cc(CNC3(C#N)CC3)c(F)cc2F)CCSC(N)=N1,"(S)-1-((5-(2-Amino-4-methyl-5,6-dihydro-4H-1,3-thiazin-4-yl)-2,4-difluorobenzyl)amino)cyclopropane-1-carbonitrile",28.4,uM,=,1.4533183400470375,1,C1=NC(c2cccc(CNC3CC3)c2)CCS1
7442,2219924,10.1016/j.bmcl.2021.128463,,,,Displacement of MK499 from human ERG expressed in HEK membrane by radio ligand binding competition assay,Cc1cc(C#N)cnc1C(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)[C@](C)(CF)C(=N)N2)n1,"5-cyano-N-(5-fluoro-6-((3R,6S)-6-(fluoromethyl)-5-imino-3,6-dimethyl-1,1-dioxidothiomorpholin-3-yl)pyridin-2-yl)-3-methylpicolinamide",23.12,uM,=,1.3639878297484915,1,N=C1CS(=O)(=O)CC(c2cccc(NC(=O)c3ccccn3)n2)N1
